ID Species ncRNA ncRNA type Environmental factor (EF) Phenotype Sample Condition of EF Evidence PubMed ID 1 Human hsa-let-2b-5p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 2 Human hsa-let-7 miRNA microsciadia breast cancer MDA-MB-231 cells microsciadia treatment upregulated 32603285 3 Human hsa-let-7 miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 4 Human hsa-let-7 miRNA 3-acetyl-11-keto-¦Â-boswellic acid (AKBA) colorectal cancer (CRC) HCT116 cells£»HT29 cells£»SW480 cells£» SW620 cells 3-acetyl-11-keto-¦Â-boswellic acid (AKBA) upregulated 22983985 5 Human hsa-let-7 miRNA synthetic preimplantation factor (sPIF) duchenne muscular dystrophy (DMD) myoblast Synthetic preimplantation factor (sPIF) treatment downregulated 30692507 6 Human hsa-let-7 miRNA epstein-barr virus EBNA1 protein EBV infection nasopharyngeal carcinoma cell lines EBNA1 treatment downregulated 25031339 7 Human hsa-let-7 miRNA HT-3O sulfate (HT-3Os) epithelial-mesenchymal transition (EMT) IL-1¦Â-treated human umbilical endothelial cells (HUVEC) and human retinal endothelial cells (HREC) HT-3O sulfate (HT-3Os) treatmment upregulated 30725211 8 Human hsa-let-7 miRNA IL-1¦Â epithelial-mesenchymal transition (EMT) human umbilical endothelial cells (HUVEC) and human retinal endothelial cells (HREC) interleukin-1¦Â (IL-1¦Â) treatment downregulated 30725211 9 Human hsa-let-7 miRNA HT-3O sulfate (HT-3Os) epithelial-mesenchymal transition (EMT) human umbilical EC (HUVEC); human retinal EC (HREC) HT-3O sulfate (HT-3Os) treatment Exposure of HUVEC and HREC to IL-1¦Â alone led to a sig- nificant reduction of let-7 miRNA levels which were restored in the presence of HT-3Os. 30725211 10 Human hsa-let-7 miRNA H2O2 gastric cancer (GC) GC cells H2O2 treatment Hsa-let-7 g miRNA increased the sensitivity of GC to oxidative stress by repression activation of DDR indirectly. Let-7 g improved the effects of X-rays on GC cells involving in DDR regulation as well. 25972194 11 Human hsa-let-7 miRNA phenformin glioblastoma multiforme (GBM) glioma stem cells (GSCs) Phenformin treatment upregulated 27486821 12 Human hsa-let-7 miRNA secretin human primary sclerosing cholangitis (PSC) "PSC liver tissue biopsies, serum, and bile" secretin? treatment downregulated 27115285 13 Human hsa-let-7 miRNA heme hepatocellular carcinoma (HCC) Huh?9 cells heme treatment upregulated 23538684 14 Human hsa-let-7 miRNA aspirin lung cancer A549 and H1299 cell lines aspirin treatment upregulated 30756509 15 Human hsa-let-7 miRNA tacrolimus or high glucose new-onset diabetes after liver transplantation (NODALT) human hepatocytes tacrolimus or high glucose treatment dysregulated 27458792 16 Human hsa-let-7 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) human non-small cell lung cancer cells A549 cisplatin treatment downregulated 28235063 17 Human hsa-let-7 miRNA ionizing radiation (IR) non-small cell lung cancer (NSCLC) human non-small cell lung cancer cells A549 2 Gy of irradiation once a week downregulated 28235063 18 Human hsa-let-7 miRNA tankyrase inhibitor JW74 osteosarcoma (OS) "OS cell lines (KPD, U2OS, and SaOS-2)" JW74 treatment upregulated 24403055 19 Human hsa-let-7 miRNA metformin (Met) ovarian cancer (OC) ovarian cancer cells metformin treatment upregulated 27775072 20 Human hsa-let-7 miRNA oxidized low density lipoprotein (ox-LDL) oxidative stress human endometrial cell-lines oxidized low-density lipoprotein (ox-LDL) treatment dysregulated 28499250 21 Human hsa-let-7 miRNA fractionated radiation prostate cancer Human Prostate Cancer Cells radiation treatment Tumor suppressor miR-34a and let-7 miRNAs were upregulated by fractionated radiation in radiosensitive LNCaP (p53 positive) and PC3 (p53-null) cells indicating 22827214 22 Human hsa-let-7 miRNA simvastatin prostate cancer human castration-resistant prostate cancer (CRPC) cells simvastatin treatment upregulated 28910332 23 Human hsa-let-7 miRNA TGF-¦Â1 Pancreatic ductal adenocarcinoma (PDAC) Panc1 cells ?TGF-¦Â1 treatment downregulated 21057545 24 Human hsa-let-7 miRNA metformin (Met) type 2 diabetes mellitus (T2DM) ARK2 and MCF-7 cells metformin treatment upregulated 27775072 25 Human hsa-let-7 miRNA cryptosporidium parvum cryptosporidium parvum infection "C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)" cryptosporidium parvum? infection downregulated 20486857 26 Human hsa-let-7 miRNA cryptosporidium parvum cryptosporidium parvum infection "C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)" cryptosporidium parvum? infection downregulated 20486857 27 Human hsa-let-7 miRNA sorafenib (SOR) human immunodeficiency virus (HIV)-1 infection Huh7 hepatoma cells sorafenib treatment downregulated 20347499 28 Human hsa-let-7a miRNA low-dose ionizing radiation (LDIR) stress response human Epstein-Barr virus-infected B-cells (EBV-B) low-dose ionizing radiation (LDIR) treatment upregulated 26809544 29 Human hsa-let-7a miRNA "sulforaphane, quercetin and GTC" pancreatic ductal adenocarcinoma (PDAC) BxPc-3 and MIA-PaCa2 and human hTERT-HPNE "sulforaphane, quercetin and GTC complement treatment" upregulated 25017900 30 Human hsa-let-7a miRNA antidiabetic glycemic control ment-na?ve diabetic patients with poor metabolic control 12 months of antidiabetic treatment upregulated 24937531 31 Human hsa-let-7a miRNA granulocyte-macrophage colony stimulating factor (GM-CSF) acute myeloid leukemia (AML) "human myeloid leukemic cell line, AML-193" GM-CSF treatment downregulated 22015065 32 Human hsa-let-7a miRNA lipopolysaccharide (LPS) and TGF-¦Â alcoholic liver disease (ALD) human hepatic stellate cells (HSCs) lipopolysaccharide (LPS) and TGF-¦Â treatment downregulated 28536261 33 Human hsa-let-7a miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MCF-7 cells anacardic acid (AnAc) treatment upregulated 28886127 34 Human hsa-let-7a miRNA high glucose-induced endothelial microparticles (EMPs) apoptosis human umbilical vein endothelial cells (HUVECs) high glucose EMPs downregulated 28942148 35 Human hsa-let-7a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "let-7a, which directly targets the 3'-UTR of periostin mRNA. In addition, periostin overexpression partly reversed the biological effects of H19 knockdown in ox-LDL-treated HUVECs, which were almost recapitulated by let-7 overexpression." 31054453 36 Human hsa-let-7a miRNA androgen breast cancer "MCF-7, MDA-MB-453 , MDA-MB-231" androgen treatment upregulated 24172884 37 Human hsa-let-7a miRNA arsenic trioxide (ATO) breast cancer MCF-7 and SK-BR-3 cell lines arsenic trioxide (ATO) treatment upregulated 28980872 38 Human hsa-let-7a miRNA benzo(a)pyrene (BaP) breast cancer MDA-MB-231 cells benzo(a)pyrene (BaP) exposure downregulated 30155724 39 Human hsa-let-7a miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 40 Human hsa-let-7a miRNA metformin (Met) breast cancer MCF-7 cells metformin?treatment upregulated 21368581 41 Human hsa-let-7a miRNA paclitaxel (PTX) breast cancer MCF-7 cells; MDA-MB-231 cells paclitaxel treatment downregulated 30019863 42 Human hsa-let-7a miRNA paclitaxel (PTX) breast cancer BT-474 cells paclitaxel treatment upregulated 30019863 43 Human hsa-let-7a miRNA nanoparticle (NP) colorectal cancer (CRC) Human colon cancer HCT-116 cells Nanoparticle (NP) technology "Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulated of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms," 21929751 44 Human hsa-let-7a miRNA honeysuckle aqueous extract dengue virus (DENV) infection human blood aqueous extract treatment upregulated 28052239 45 Human hsa-let-7a miRNA honeysuckle aqueous extract dengue virus (DENV) infection mouse blood aqueous extract treatment upregulated 28052239 46 Human hsa-let-7a miRNA Rhein-8-O-¦Â-D-glucopyranoside (Rg) diabetic nephropathy (DN) human mesangial cells (HMCs) Rhein-8-O-¦Â-D-glucopyranoside (Rg) treatment Rg attenuated HG-induced apoptosis of HMCs by regulating the lincRNA ANRIL/let-7a/TGF-¦Â1/Smad signaling pathway 32256771 47 Human hsa-let-7a miRNA acrolein environmental pollutants human umbilical vein endothelial cells acrolein treatment upregulated 24812010 48 Human hsa-let-7a miRNA curcumin (Cur) fat esophageal cancer cell lines curcumin treatment downregulated 22363450 49 Human hsa-let-7a miRNA urolithin A (UA) hepatocellular carcinoma (HCC) HepG2.2.15 cells urolithin A treatment upregulated 29742265 50 Human hsa-let-7a miRNA honeysuckle (HS) enterovirus 71 (EV71) infection human muscle rhabdomyosarcoma RD cells Honeysuckle treatment "Moreover, honeysuckle-induced?let-7a?suppression of EV71 RNA and protein expression as well as viral replication were investigated both in vitro and in vivo." 33669264 51 Human hsa-let-7a miRNA estradiol-17¦Â (E2) inflammation human macrophages estradiol-17¦Â (E2) treatment "LPS induces let-7a and inhibits miR-125b expression in human macrophages, and pretreatment with estradiol abrogates these effects" 20351193 52 Human hsa-let-7a miRNA sepsis liver damage liver tissues sepsis induce treatment The expression of let-7a in liver tissue of patients with sepsis-induced liver injury was clearly decreased 31344555 53 Human hsa-let-7a miRNA particulate matter (PM2.5) lung cancer human non-small cell lung cancer cell line A549 chronic (five passages) PM2.5 exposure treatment downregulated 28846189 54 Human hsa-let-7a miRNA ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE) metastasized melanoma A375 melanoma cells SLE treatment upregulated 31514083 55 Human hsa-let-7a miRNA "pan-JAK inhibitor, INC424" myeloproliferative neoplasms Ton.JAK2.V617F cells "pan-JAK inhibitor, INC424 treatment" upregulated 28057739 56 Human hsa-let-7a miRNA pan-HDAC inhibitor ITF2357 non-Hodgkin lymphoma (NHL) human B-cell non-Hodgkin lymphomas (B-NHLs) pan-HDAC inhibitor ITF2357 treatment upregulated 24648290 57 Human hsa-let-7a miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells cisplatin treatment downregulated 31189742 58 Human hsa-let-7a miRNA metformin (Met) pancreatic cancer (PC) Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR Metformin? treatment downregulated 22086681 59 Human hsa-let-7a miRNA XMD8-92 pancreatic ductal adenocarcinoma (PDAC) human pancreatic cancer AsPC-1 cells XMD8-92 treatment upregulated 24880079 60 Human hsa-let-7a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" preeclampsia (PE) JEG-3 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" Let-7a inhibits Bcl-xl and YAP1 expression to induce apoptosis of trophoblast cells in early-onset severe preeclampsia 32721616 61 Human hsa-let-7a miRNA CXCR4 pregnancy disease AML cells CXCR4 treatment downregulated 23676502 62 Human hsa-let-7a miRNA Yangzheng Sanjie decoction (YZSJD) gastric cancer (GC) AGS and HS-746T GC cells YZSJD treatment downregulated 28852313 63 Human hsa-let-7a miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary arterial smooth muscle cells (PASMCs) hypoxia exposure miR-let-7a was downregulated in hypoxic PASMCs. 32803651 64 Human hsa-let-7a miRNA arsenite lung fibrosis THP-1 cells arsenic (As) exposure downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages. 33162208 65 Human hsa-let-7a miRNA arsenite lung fibrosis lung tissues; bone marrow-derived macrophages (BMDMs) arsenite exposure downregulated 33162208 66 Human hsa-let-7a miRNA anti-citrullinated protein antibodies (ACPAs) rheumatoid arthritis (RA) macrophages isolated from patients with RA ACPAs treatment (160IU/mL) downregulated 28802150 67 Human hsa-let-7a miRNA "high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)" skin fibrosis human skin fibroblast HF-LED-RL at 320 and 640?J/cm2 radiation upregulated 30182520 68 Human hsa-let-7a miRNA melatonin subarachnoid hemorrhage (SAH) U87 cells; U251 cells melatonin (MT) treatment downregulated 29367587 69 Human hsa-let-7a miRNA IL-22 systemic sclerosis (SSc) normal human dermal fibroblast IL-22 downregulated 29336866 70 Human hsa-let-7a miRNA IL-22 systemic sclerosis (SSc) Human dermal fibroblasts IL-22 treatment downregulated 29336866 71 Human hsa-let-7a miRNA arsenite tumorigenesis of arsenite human keratinocyte HaCaT cells arsenic exposure downregulated 24704393 72 Human hsa-let-7a1 miRNA listeria monocytogenes (L. monocytogenes) Listeria infection Human epithelial cells (Caco-2) Listeria infection downregulated 22312311 73 Human hsa-let-7a-2 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" muscarinic M(1) receptor dysfunction A549 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 23469214 74 Human hsa-let-7a-3 miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 75 Human hsa-let-7a-5p miRNA paclitaxel (PTX) breast cancer BC tissues; MCF-7 cells MDA-MB-231 Paclitaxel (PTX) treatment downregulated 32273769 76 Human hsa-let-7a-5p miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment downregulated 30503955 77 Human hsa-let-7a-5p miRNA silica pneumoconiosis THP-1 cells silica treatment downregulated 29516679 78 Human hsa-let-7a-5p miRNA TGF-¦Â2 posterior capsular opacification (PCO) human lens epithelial cells (LECs) TGF-¦Â2 treatment TGF-¦Â2 upregulated Smad2 expression and reduced let-7a-5p expression in LECs 32345785 79 Human hsa-let-7a-5p miRNA doxorubicin (DOX) prostate cancer prostate cancer DU-145 cells doxorubicin (DOX) treatment upregulated 31188543 80 Human hsa-let-7a-5p miRNA radiation prostate cancer serum curative radiotherapy (RT) treatment upregulated 30103771 81 Human hsa-let-7b miRNA hypoxia acute myocardial infarction (AMI) AC16 hypoxia treatment downregulated 32922590 82 Human hsa-let-7b miRNA ethanol (EtOH) alcoholic liver disease (ALD) Cryopreserved primary human hepatocytes (cPHH) ethanol (EtOH) exposure upregulated 30103265 83 Human hsa-let-7b miRNA lipopolysaccharide (LPS) and TGF-¦Â alcoholic liver disease (ALD) human hepatic stellate cells (HSCs) lipopolysaccharide (LPS) and TGF-¦Â treatment downregulated 28536261 84 Human hsa-let-7b miRNA curcumin (Cur) breast cancer MCF-10F cells curcumin (Cur) treatment upregulated 31894298 85 Human hsa-let-7b miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 86 Human hsa-let-7b miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 87 Human hsa-let-7b miRNA electrode cervical cancer (CC) HeLa cells electric treatment upregulated 16503596 88 Human hsa-let-7b miRNA adherent-invasive escherichia coli (AIEC) crohn disease (CD) colonic epithelial cells adherent invasive escherichia coli (AIEC) treatment AIEC elicits/exacerbate gut inflammation in WT/IL-10 KO mice that correlates with increased expression of TLR4 and decreased level of let-7b in IECs. 30142321 89 Human hsa-let-7b miRNA mycolactone expression regulation human primary T cells Mycolactone treatment mycolactone-induced suppression of CD62-L expression by human primary T cells was induced rapidly at both the mRNA and protein levels and correlated with the reduced expression of one miRNA: let-7b. 21768364 90 Human hsa-let-7b miRNA preoperative radiotherapy esophageal squamous cell carcinoma (ESCC) ESCC tissues preoperative radiotherapy treatment dysregulated 24576011 91 Human hsa-let-7b miRNA helicobacter pylori (H. pylori) hepatitis B virus (HBV) infection gastric mucosa specimens and two gastric epithelial cell lines Helicobacter pylori infection downregulated 23437218 92 Human hsa-let-7b miRNA oleic acid (OA) inflammation LPS-activated human acute monocytic leukemia cells (THP-1) oleic acid (OA) treatment upregulated 29790117 93 Human hsa-let-7b miRNA palmitic acid (PA) inflammation LPS-activated human acute monocytic leukemia cells (THP-1) palmitic acid (PA) treatment upregulated 29790117 94 Human hsa-let-7b miRNA ursolic acid (UA) malignant pleural mesothelioma (MPM) H2452 cells ursolic acid treatment upregulated 28090191 95 Human hsa-let-7b miRNA "RESMENA (reduction of metabolic syndrome in Navarra, Spain)" metabolic syndrome MetS patients white blood cells (WBC) RESMENA treatment "miR-155-3p was decreased ,miR-Let-7b was strongly upregulated in white blood cells (WBC)" 26421388 96 Human hsa-let-7b miRNA "3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells "3,3'-diindolylmethane (DIM) treatment" upregulated 19654291 97 Human hsa-let-7b miRNA isoflavone pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells isoflavone treatment upregulated 19654291 98 Human hsa-let-7b miRNA metformin (Met) pancreatic cancer (PC) Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR Metformin? treatment downregulated 22086681 99 Human hsa-let-7b miRNA peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) renal fibrosis HK-2 cell lines peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) overexpression treatment upregulated 31614978 100 Human hsa-let-7b miRNA arsenite tumorigenesis of arsenite human keratinocyte HaCaT cells arsenic exposure downregulated 24704393 101 Human hsa-let-7b* miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 102 Human hsa-let-7b-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 103 Human hsa-let-7b-5p miRNA lipopolysaccharide (LPS) chronic obstructive pulmonary disease (COPD) BEAS-2B cells lipopolysaccharide (LPS) treatment "LINC00987 Ameliorates COPD by Regulating LPS-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Autophagy Through Let-7b-5p/SIRT1 Axis." 33311978 104 Human hsa-let-7b-5p miRNA cisplatin (DDP) gastric cancer (GC) SGC 7901cells; AGC cells cisplatin treatment downregulated 33009035 105 Human hsa-let-7b-5p miRNA fibroblast growth factor receptor (FGFR) 1 mitochondrial dynamics normal human dermal microvascular endothelial cells (HMVECs) Fibroblast growth factor receptor (FGFR) 1 treatment downregulated 29269295 106 Human hsa-let-7b-5p miRNA N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) mitochondrial dynamics normal human dermal microvascular endothelial cells (HMVECs) N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) treatment upregulated 29269295 107 Human hsa-let-7b-5p miRNA "triple cytokines (TGF-¦Â2, interleukin-1¦Â, tumor necrosis factor-¦Á)" mitochondrial dynamics normal human dermal microvascular endothelial cells (HMVECs) "triple cytokines (TGF-¦Â2, interleukin-1¦Â, tumor necrosis factor-¦Á) treatment" downregulated 29269295 108 Human hsa-let-7b-5p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 109 Human hsa-let-7b-5p miRNA trichloroethylene (TCE) non-Hodgkin lymphoma (NHL) serum trichloroethylene (TCE) exposure treatment downregulated 31161417 110 Human hsa-let-7b-5p miRNA lipopolysaccharide (LPS) sepsis HK-2 cells lipopolysaccharide (LPS) treatment "NEAT1 regulated TRAF6 expression by sponging let-7b-5p in HK-2 cells, which promotes LPS-induced injury and inflammation in HK-2 cells." 32724027 111 Human hsa-let-7b-5p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) THP-1 human macrophages ?Mycobacterium tuberculosis (Mtb) infection upregulated 29471394 112 Human hsa-let-7c miRNA curcumin (Cur) thyroid cancer (TC) "human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101" curcumin treatment downregulated 28265769 113 Human hsa-let-7c miRNA androgen prostate cancer prostate cancer cells androgen treatment downregulated 23503464 114 Human hsa-let-7c miRNA IFN-¦Ã graft-versus-host disease (GVHD) Cord blood (CB) interferon-¦Ã treatment downregulated 21913990 115 Human hsa-let-7c miRNA all-trans retinoic acid (ATRA) acute myeloid leukemia (AML) "human leukemic cell lines NB4, HEL, HL-60, KG1, K562, SKNO-1, THP-1, and UF-1" all-trans retinoic acid (ATRA) treatment upregulated 24637061 116 Human hsa-let-7c miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 117 Human hsa-let-7c miRNA oxidized low density lipoprotein (ox-LDL) Dendritic cell (DC) maturation Human peripheral blood monocytes differentiated DCs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29617044 118 Human hsa-let-7c miRNA oxidized low density lipoprotein (ox-LDL) apoptosis human umbilical cord vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 22917031 119 Human hsa-let-7c miRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) ARPE-19 cells TGF-¦Â2 treatment The expression of miR-let7c was dramatically reduced after induction by TGF-¦Â2 32420214 120 Human hsa-let-7c miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 121 Human hsa-let-7c miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 122 Human hsa-let-7c miRNA cigarette smoke extract (CSE) lung cancer human bronchial epithelial (HBE) cell cigarette smoke extract (CSE) treatment downregulated 28184029 123 Human hsa-let-7c miRNA fulvestrant non-small cell lung cancer (NSCLC) H1975 NSCLC cells fulvestrant treatment upregulated 24268810 124 Human hsa-let-7c miRNA H2O2 osteoporosis Adipose-derived mesenchymal stem cells (ADMSCs) H2O2 treatment upregulated 30379578 125 Human hsa-let-7c miRNA H2O2 osteoporosis human adipose-derived mesenchymal stem cells (hADMSCs) H2O2 treatment upregulated 30379578 126 Human hsa-let-7c miRNA N-acetyl-L-cysteine (NAC) osteoporosis H2O2-treated human adipose-derived mesenchymal stem cells (hADMSCs) N-acetyl-L-cysteine (NAC) treatment downregulated 30379578 127 Human hsa-let-7c miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment downregulated 32901049 128 Human hsa-let-7c miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 129 Human hsa-let-7c miRNA a moderate-carbohydrate and low glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and low glycemic index diet downregulated 29233588 130 Human hsa-let-7c miRNA "3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells "3,3'-diindolylmethane (DIM) treatment" upregulated 19654291 131 Human hsa-let-7c miRNA isoflavone pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells isoflavone treatment upregulated 19654291 132 Human hsa-let-7c miRNA quercetin pancreatic ductal adenocarcinoma (PDAC) PDA cells quercetin treatment upregulated 27521217 133 Human hsa-let-7c miRNA lipoxins premature ovarian failure (POF) HK-2 cells Lipoxins?treatment upregulated 23520204 134 Human hsa-let-7c miRNA fulvestrant progesterone production in rat granulosa cells H1975 NSCLC cells Fulvestrant treatment let-7c plays an important role in fulvestrant-induced upregulation of gefitinib sensitivity in H1975 cells 24268810 135 Human hsa-let-7c miRNA activin A prostate cancer LNCaP cells activin A treatment upregulated 27018851 136 Human hsa-let-7c miRNA peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) renal fibrosis HK-2 cell lines peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) overexpression treatment upregulated 31614978 137 Human hsa-let-7c miRNA arsenite tumorigenesis of arsenite human keratinocyte HaCaT cells arsenic exposure downregulated 24704393 138 Human hsa-let-7c-3p miRNA H2O2 age-related cataract (ARC) Human lens epithelial cells (LECs) H2O2 treatment the expression of let-7c-3p was also lower under oxidative stress. 32258130 139 Human hsa-let-7c-3p miRNA protein kinase C inhibitor GF109203X wound healing and regeneration of skin tissues. human keratinocytes GF109203X treatment "upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )" 28901412 140 Human hsa-let-7c-5p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 141 Human hsa-let-7c-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HT29 cells 5-fluorouracil (5-FU) treatment upregulated 25526515 142 Human hsa-let-7c-5p miRNA olive oil polyphenol hydroxytyrosol (HT) inflammation TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes olive oil polyphenol hydroxytyrosol (HT) treatment upregulated 31627295 143 Human hsa-let-7c-5p miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 31627295 144 Human hsa-let-7c-5p miRNA honokiol non-small cell lung cancer (NSCLC) NSCLC A549 cells honokiol treatment upregulated 31176168 145 Human hsa-let-7c-5p miRNA oleacein (OA) obesity Simpson-Golabi-Behmel syndrome (SGBS) adipocytes oleacein (OA) treatment upregulated 31766503 146 Human hsa-let-7c-5p miRNA oleocanthal (OC) obesity Simpson-Golabi-Behmel syndrome (SGBS) adipocytes oleocanthal (OC) treatment upregulated 31766503 147 Human hsa-let-7c-5p miRNA tumor necrosis factor alpha (TNF-¦Á) obesity Simpson-Golabi-Behmel syndrome (SGBS) adipocytes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 31766503 148 Human hsa-let-7c-5p miRNA lipopolysaccharide (LPS) pulpitis human dental pulp cells (HDPCs) lipopolysaccharide (LPS) treatment LPS exposure upregulated the expression of NUTM2A-AS1 and High-Mobility Group Box 1 (HMGB1) and downregulated the level of let-7c-5p. 33831808 149 Human hsa-let-7d miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 150 Human hsa-let-7d miRNA soft-shelled turtle peptide gastric cancer (GC) human GC AGS cells soft-shelled turtle peptide treatment differentlly regulated 29435044 151 Human hsa-let-7d miRNA platelet-derived growth factor (PDGF) glioblastoma and ovarian cancer U118-MG cells£»U87-MG glioblastoma cells£» human WI-38 fibroblasts?£» ovarian cells C272/hTert/E7 Platelet derived growth factor (PDGF)? treatment downregulated 21266476 152 Human hsa-let-7d miRNA ficus carica glioblastoma multiforme (GBM) "T98G, U-138 MG, and U-87 MG human GBM cell lines" ficus carica treatment upregulated 25212824 153 Human hsa-let-7d miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 154 Human hsa-let-7d miRNA "3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells "3,3'-diindolylmethane (DIM) treatment" upregulated 19654291 155 Human hsa-let-7d miRNA isoflavone pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells isoflavone treatment upregulated 19654291 156 Human hsa-let-7d miRNA diesel exhaust particle (DEP) pulmonary inflammatory response 16HBE and Beas-2B cells diesel exhaust particle (DEP) exposure downregulated 30172002 157 Human hsa-let-7d miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) T98G cells temozolomide (TMZ) treatment upregulated 22722712 158 Human hsa-let-7d-5p miRNA IL-6 intervertebral disc degeneration (IDD) Primary human chondrocytes IL-6 treatment downregulated 32746985 159 Human hsa-let-7d-5p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 160 Human hsa-let-7d-5p miRNA house dust mite (HDM) lung fibrosis serum dust exposure upregulated 30090591 161 Human hsa-let-7e miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) cancer cell 5-fluorouracil treatment upregulated 23167930 162 Human hsa-let-7e miRNA capecitabine colorectal cancer (CRC) cancer cell capecitabine treatment upregulated 23167930 163 Human hsa-let-7e miRNA olive leaf extract (OLE) atherosclerosis (AS) Serum amyloid A (SAA)-induced human coronary artery endothelial cells (HCAEC) Olive leaf extract (OLE) treatment downregulated 31157238 164 Human hsa-let-7e miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28195197 165 Human hsa-let-7e miRNA serum amyloid A (SAA) atherosclerosis (AS) human coronary artery endothelial cells (HCAEC) Serum amyloid A (SAA) treatment upregulated 31157238 166 Human hsa-let-7e miRNA cisplatin (DDP) breast cancer Human umbilical vein endothelial cells (HUVECs) cisplatin (DPP) treatment downregulated 30670152 167 Human hsa-let-7e miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 168 Human hsa-let-7e miRNA D-glucose epithelial-mesenchymal transition (EMT) peritoneal mesothelial cells (PMCs) D-glucose treatment downregulated 25683944 169 Human hsa-let-7e miRNA IL-1¦Â inflammatory response monocytes IL-1¦Â treatment upregulated 30245693 170 Human hsa-let-7e miRNA lipopolysaccharide (LPS) inflammatory response monocytes lipopolysaccharide (LPS) treatment upregulated 30245693 171 Human hsa-let-7e miRNA TLR2 agonist pam3CSK4 inflammatory response monocytes TLR2 agonist pam3CSK4 treatment upregulated 30245693 172 Human hsa-let-7e miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 173 Human hsa-let-7e miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 174 Human hsa-let-7e miRNA "3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells "3,3'-diindolylmethane (DIM) treatment" upregulated 19654291 175 Human hsa-let-7e miRNA isoflavone pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells isoflavone treatment upregulated 19654291 176 Human hsa-let-7e miRNA intercept (amotosalen+ ultraviolet-A [UVA] light) pathogen reduction platelet gamma irradiation treatment downregulated 24749844 177 Human hsa-let-7e-5p miRNA insulin and high glucose (HG) insulin resistance (IR) HepG2 cells insulin and high glucose treatment upregulated 32710190 178 Human hsa-let-7f miRNA antidiabetic glycemic control ment-na?ve diabetic patients with poor metabolic control 12 months of antidiabetic treatment upregulated 24937531 179 Human hsa-let-7f miRNA ¦Â 2-Adrenergic receptors (¦Â 2ARs) asthma human airway smooth muscle (HASM) cells ¦Â 2-Adrenergic receptors (¦Â 2ARs) treatment "In cultured HASM cells from nonasthmatic and asthmatic lungs, 18 h of ¦Â-agonist exposure increased let-7f by 2-3-fold" 29455573 180 Human hsa-let-7f miRNA aromatase inhibitors (AIs) breast cancer MCF-7; SK-BR-3 cells Aromatase inhibitors (AIs) treatment upregulated 22407818 181 Human hsa-let-7f miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 182 Human hsa-let-7f miRNA lauric acid hepatocellular carcinoma (HCC) HepG2 cells lauric acid treatment upregulated 32156243 183 Human hsa-let-7f miRNA lipopolysaccharide (LPS) inflammation THP1-differentiated macrophages lipopolysaccharide (LPS) treatment downregulated 24062196 184 Human hsa-let-7f miRNA TLR9 and RIG-I immune tolerance Endocervical cells (End1/E6E7) ligands of TLR9 and RIG-I once or after pre-stimulation with same ligand treatment "Stimulation with TLR9 downregulated let-7f , RIG-I stimulation upregulated let-7f" 24405266 185 Human hsa-let-7f miRNA ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE) metastasized melanoma A376 melanoma cells SLE treatment upregulated 31514083 186 Human hsa-let-7f miRNA cigarette smoke extract (CSE) neovascularization HUVECs cigarette smoke extracts (CSE) exposure downregulated 28345812 187 Human hsa-let-7f miRNA hypoxia pulmonary arterial hypertension (PAH) HepG2 cells Hypoxia treatment downregulated 20110569 188 Human hsa-let-7f-1 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 189 Human hsa-let-7f-1 miRNA lycopene prostate cancer Human prostate carcinoma cells PC3 lycopene treatment upregulated 26847233 190 Human hsa-let-7f-1-3p miRNA smoking smoke-induced lung injury (SILI) Human small airway epithelial cells (HSAEC) and human pulmonary alveolar epithelial cells (HPAEpiC) Smoke was generated by heating 500 mg of degreasing cotton at about 400 ¡ãC for 15 min in a tube furnace with air stream of 1L/min for combustion in a non-flaming fashion and 10 L/min for dilution treatment downregulated 31301310 191 Human hsa-let-7f-2 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 192 Human hsa-let-7f-5p miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment downregulated 30503955 193 Human hsa-let-7f-5p miRNA adriamycin (ADR) leukemia K562 cells adriamycin (ADR) treatment downregulated 31793054 194 Human hsa-let-7f-5p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 195 Human hsa-let-7f-5p miRNA lipopolysaccharide (LPS) pneumonia A549 cells; WI-38 cells lipopolysaccharide (LPS) treatment downregulated 33300070 196 Human hsa-let-7f-5p miRNA lipopolysaccharide (LPS) pneumonia A549 cells; WI-38 cells lipopolysaccharide (LPS) treatment let-7f-5p expression levels was significantly decreased in lipopolysaccharide (LPS) induced A549 and WI-38 cells. 33300070 197 Human hsa-let-7g miRNA disulfiram (DSF) atypical teratoid/rhabdoid tumors (AT/RT) human ALDH(+) AT/RT cells DSF treatment upregulated 25378634 198 Human hsa-let-7g miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 199 Human hsa-let-7g miRNA hepatitis B X-interacting protein (HBXIP) breast cancer MCF-7 cells hepatitis B X-interacting protein (HBXIP) treatment downregulated 29174803 200 Human hsa-let-7g miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment upregulated 20346162 201 Human hsa-let-7g miRNA angiotensin II (Ang II) endothelial senescence Human umbilical vein endothelial cells (HUVECs) angiotensin II (Ang II) treatment downregulated 29393358 202 Human hsa-let-7g miRNA aspirin hepatocellular carcinoma (HCC) HepG2 and Huh-7 cell lines aspirin treatment upregulated 31278071 203 Human hsa-let-7g miRNA K. pneumoniae reference strains (K. pneumoniae ATCC 10031) klebsiella pneumoniae infection BEAS 2B cells K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection upregulated 33322147 204 Human hsa-let-7g miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells KPC-producing K. pneumoniae infection upregulated 33322147 205 Human hsa-let-7g miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells MS K. pneumoniae infection upregulated 33322147 206 Human hsa-let-7g miRNA kallistatin oxidative stress human umbilical vein endothelial cells (HUVECs) Kallistatin treatment upregulated 29992759 207 Human hsa-let-7g miRNA intercept (amotosalen+ ultraviolet-A [UVA] light) pathogen reduction platelet gamma irradiation treatment downregulated 24749844 208 Human hsa-let-7g miRNA diesel exhaust particle (DEP) pulmonary inflammatory response 16HBE and Beas-2B cells diesel exhaust particle (DEP) exposure downregulated 30172002 209 Human hsa-let-7g miRNA IFN-¦Á cell senescence HeLa cells 24-h of IFN¦Á treatment downregulated 24942926 210 Human hsa-let-7g miRNA lipopolysaccharide (LPS) sepsis Neonatal Polymorphonuclear Leukocytes lipopolysaccharide (LPS) treatment dysregulated 28655995 211 Human hsa-let-7g-5p miRNA mitogen activated-protein kinase pathway inhibitors (MAPKis) cutaneous malignant melanoma (CMM) extracellular microvesicle in matched plasma Mitogen activated-protein kinase pathway inhibitors (MAPKis) treatment upregulated 30399176 212 Human hsa-let-7g-5p miRNA verbascoside (VB) glioblastoma multiforme (GBM) A172 cells; SHG139 cells; SHG-44 cells; U87 cells; U251 cells verbascoside (VB) treatment let-7g-5p expression was upregulated upon VB treatment 32000296 213 Human hsa-let-7g-5p miRNA IL-6 intervertebral disc degeneration (IDD) Primary human chondrocytes IL-6 treatment downregulated 32746985 214 Human hsa-let-7i miRNA recombinant tissue plasminogen activator (rt-PA) acute ischemic stroke (AIS) AIS patients blood samples rt-PA treatment upregulation of let-7i and downregulated of miR-15a 28892656 215 Human hsa-let-7i miRNA propofol (PPF) anti-cancer therapy human EOC cells expression in OVCAR-3 with or without propofol treatment upregulated 25556276 216 Human hsa-let-7i miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 217 Human hsa-let-7i miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 218 Human hsa-let-7i miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-let-7i was downregulated in resistant patients when compared with sensitive patients 33072545 219 Human hsa-let-7i miRNA propofol (PPF) colorectal cancer (CRC) Colo205; SW620 cells "Propofol (2,6-diisopropylphenol) treatment" Propofol suppresses colorectal cancer tumorigenesis by modulating the HOXA11-AS-let-7i-ABCC10 regulatory network 31013434 220 Human hsa-let-7i miRNA ionizing radiation (IR) anti-cancer therapy SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG ionizing radiation treatment upregulated 21453501 221 Human hsa-let-7i miRNA oxygen glucose deprivation (OGD) inflammation human brain microvascular endothelial cells (HBMECs) oxygen-glucose deprivation (OGD) treatment downregulated 28844675 222 Human hsa-let-7i miRNA cryptosporidium parvum innate immune response H69 cells cryptosporidium parvum? infection downregulated 24862934 223 Human hsa-let-7i miRNA oxygen glucose deprivation (OGD) post-stroke cognitive impairment (PSCI) SH-SY5Y cells oxygen-glucose deprivation (OGD) treatment MicroRNA Let-7i Is a Promising Serum Biomarker for Post-stroke Cognitive Impairment and Alleviated OGD-Induced Cell Damage in vitro by Regulating Bcl-2 32265630 224 Human hsa-let-7i miRNA IFN-¦Á cell senescence HeLa cells 24-h of IFN¦Á treatment downregulated 24942926 225 Human hsa-let-7i-3p miRNA melatonin hepatocellular carcinoma (HCC) Huh7 cells; HepG2 cells melatonin treatment melatonin treatment markedly induced the expression of the miRNA let7i-3p in cells. 30201903 226 Human hsa-let-7i-3p miRNA cyclic mechanical stretch (CMS) osteogenesis human adipose-derived stem cells (hASCs) cyclic strain induce downregulated 31753039 227 Human hsa-let-7i-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1-treatment treatment upregulated 29557526 228 Human hsa-let-7i-5p miRNA hypoxia myocardial ischaemic injury AC16 cells hypoxia treatment downregulated 32926961 229 Human hsa-let-7i-5p miRNA silica pneumoconiosis THP-1 cells silica treatment downregulated 29516679 230 Human hsa-let-7i-5p miRNA activin A prostate cancer LNCaP cells activin A treatment downregulated 27018851 231 Human hsa-miR-1 miRNA coronary artery bypass graft (CABG) acute coronary syndrome (ACS) acute coronary syndrome patients heart CABG treatment upregulated 29506853 232 Human hsa-miR-1 miRNA myocardin andes hantavirus (ANDV) infection human smooth muscle cells (SMCs) myocardin treatment myocardin was reported to induce the expression of microRNA-1 (miR-1) in cardiomyocytes.miR-1 participates in myocardin-dependent of SMC proliferation inhibition. 21051663 233 Human hsa-miR-1 miRNA IL-13 asthma human lung endothelium IL-13 treatment IL-13 stimulation decreased miR-1 levels in human lung endothelium. 32035607 234 Human hsa-miR-1 miRNA IFN-¦Â autophagy HeLa cells IFN-¦Â treatment upregulated 31799933 235 Human hsa-miR-1 miRNA doxorubicin (DOX) "cardiotoxicity,cardiomyopathy and heart failure" female patients from the placebo arm doxorubicin treatment upregulated 28052002 236 Human hsa-miR-1 miRNA angiotensin-converting enzyme 2 (ACE2) inhibitor cardiovascular disease (CVD) H9c2 cardiac myoblast cells ACE2 (angiotensin-converting enzyme 2) treatment upregulated 26400542 237 Human hsa-miR-1 miRNA IFN-¦Á chronic hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) interferon alpha treatment upregulated 21070682 238 Human hsa-miR-1 miRNA bortezomib congenital muscular dystrophy congenital muscular dystrophy type 1A muscle cells bortezomib? treatment downregulated 24631023 239 Human hsa-miR-1 miRNA myocardin contractility of vascular smooth muscle cells human aortic SMCs myocardin treatment upregulated 20458751 240 Human hsa-miR-1 miRNA glucose diabetes mellitus (DM) human retinal microvascular endothelial cells 25mM glucose treatment downregulated 24394957 241 Human hsa-miR-1 miRNA TGF-¦Â glioblastoma multiforme (GBM) "LN15, LN18, LN229, U138, U87, U251 cell lines" TGF-¦Â treatment downregulated 25256711 242 Human hsa-miR-1 miRNA carvedilol heart failure (HF) serum carvedilol treatment upregulated 32943906 243 Human hsa-miR-1 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 cells sorafenib treatment downregulated 32560747 244 Human hsa-miR-1 miRNA oxidized low density lipoprotein (ox-LDL) hyperlipidemia human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 24792518 245 Human hsa-miR-1 miRNA multiwalled carbon nanotubes (MWCNT) liver fibrosis A549 cells MWCNT (20 or 50 ?g/mL) for 6 or 24 h downregulated after 6 or 24 h of treatment regardless of the dose 28128526 246 Human hsa-miR-1 miRNA ionizing radiation (IR) low doses hyper-radiosensitivity (LDHRS) DLD-1 cells ionizing radiation (IR) treatment upregulated 29899866 247 Human hsa-miR-1 miRNA active pterocarpanquinone LQB-118 active pterocarpanquinone LQB-118 cytotoxicity "PC3, LNCaP, and LAPC4 PCa cells" LQB-118 downregulated 29105806 248 Human hsa-miR-1 miRNA carbamate lung cancer Normal human bronchial epithelial (NHBE) cells carbamate treatment downregulated 19748927 249 Human hsa-miR-1 miRNA statins muscle injury plasma statins? treatment upregulated 26472872 250 Human hsa-miR-1 miRNA (-)-epigallocatechin gallate (EGCG) osteosarcoma (OS) MG-63 and U-2OS (-)-Epigallocatechin gallate (EGCG) treatment upregulated 26499783 251 Human hsa-miR-1 miRNA prednisolone polymyositis (PM) serum prednisolone (PSL) treatment the serum miR-1 level is significantly reduced by treatment 31483179 252 Human hsa-miR-1 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (PASMCs) hypoxia induce downregulated 29167124 253 Human hsa-miR-1 miRNA H2O2 sepsis A549 cell line and HKC cell line H2O2 treatment upregulated 28673002 254 Human hsa-miR-1 miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 255 Human hsa-miR-1 miRNA sprint interval training (SIT) training responses skeletal muscle and heart acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment downregulated 29126336 256 Human hsa-miR-100 miRNA "androgen receptor (AR) agonist, CI-4AS-1" breast cancer luminal MCF-7 and T47D cells and the molecular apocrine MDA-MB-453 cells. CI-4AS-1 treatment downregulated 28816390 257 Human hsa-miR-100 miRNA gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor breast cancer BRCA1 wild-type cells (MDA-MB-231) gemcitabine-alone and in combination with PARP1 inhibitor treatment upregulated 25202071 258 Human hsa-miR-100 miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-100 was upregulated in resistant patients when compared with sensitive patients 33072545 259 Human hsa-miR-100 miRNA arsenic trioxide (ATO) epithelial-mesenchymal transition (EMT) BEAS-2B cells arsenic trioxide (As2O3) treatment downregulated 28956730 260 Human hsa-miR-100 miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment upregulated 29435044 261 Human hsa-miR-100 miRNA docetaxel (DTX) head and neck squamous cell carcinoma (HNSCC) UMSCC-1 cells;SQ20B cells docetaxel (DTX) treatment downregulated 21560177 262 Human hsa-miR-100 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 263 Human hsa-miR-100 miRNA cisplatin (DDP) osteosarcoma (OS) MG-63 cells cisplatin (DPP) treatment downregulated 30280766 264 Human hsa-miR-100 miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 265 Human hsa-miR-100 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cell 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 31298038 266 Human hsa-miR-100 miRNA lipopolysaccharide (LPS) pneumonia WI-38?cells lipopolysaccharide (LPS) treatment downregulated 29673591 267 Human hsa-miR-100 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" prostate cancer ?primary prostatic epithelial cells (PrE) "?1,25-dihydroxyvitamin D" downregulated 23503652 268 Human hsa-miR-100 miRNA mifepristone (MIF) prostate cancer prostate cells Mifepristone treatment upregulated 27340920 269 Human hsa-miR-100 miRNA iodine-131 (131I) thyroid cancer (TC) A follicular thyroid carcinoma cell line (FTC-133) I131 treatment downregulated 24785011 270 Human hsa-miR-100* miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 271 Human hsa-miR-100-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 272 Human hsa-miR-100-5p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) SMMC-7721 cells-derived exosomes TGF-¦Â1 treatment downregulated 33194074 273 Human hsa-miR-100-5p miRNA hypoxia hepatocellular carcinoma (HCC) HCCLM3 cells; Huh7 cells; Hep3B cells; HepG2 cells hypoxia treatment The expression of miR-100-5p expression was significantly suppressed in HCC cell lines under 1% O2-induced hypoxia. 32152275 274 Human hsa-miR-100-5p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 275 Human hsa-miR-100-5p miRNA rapamycin osteoarthritis (OA) Chondrocytes Rapamycin treatment upregulated 31358056 276 Human hsa-miR-101 miRNA hypoxia angiogenesis HUVECs 2¡À1% O2 treatment upregulated 24844779 277 Human hsa-miR-101 miRNA hypoxia-inducible factor 1¦Á (HIF-1¦Á) apoptosis breast cancer cells HIF1¦Á treatment upregulated 26841847 278 Human hsa-miR-101 miRNA H2O2 apoptosis human umbilical vein endothelial cells (HUVECs) H2O2 treatment upregulated 33226571 279 Human hsa-miR-101 miRNA melatonin apoptosis H2O2 treated human umbilical vein endothelial cells (HUVECs) melatonin treatment downregulated 33226571 280 Human hsa-miR-101 miRNA lipopolysaccharide (LPS) autophagy intestinal epithelial cell line Caco-2 lipopolysaccharide (LPS) treatment downregulated 31185236 281 Human hsa-miR-101 miRNA octreotide (OCT) autophagy LPS-treated Caco-2 cells Octreotide (OCT) treatment upregulated 31185236 282 Human hsa-miR-101 miRNA gambogic acid (GA) and methyl jasmonate (MJ) bladder cancer human bladder cancer cells GA and MJ treatment upregulated 24490857 283 Human hsa-miR-101 miRNA histone deacetylase inhibitor (HDACi) burkitt lymphoma (BL) Raji B-cell lymphoma HDACi treatment upregulated 24577510 284 Human hsa-miR-101 miRNA cadmium (Cd) cardiovascular disease (CVD) human umbilical vein endothelial cells (HUVECs) cadmium (Cd) treatment CdCl2-induced abnormal angiogenesis is mediated by miR-101/COX-2/VEGF-axis-dependent ER stress. 32783891 285 Human hsa-miR-101 miRNA Sphingosine-1-phosphate (S1P) chondrosarcoma human chondrosarcoma cells S1P treatment downregulated 28672103 286 Human hsa-miR-101 miRNA hypoxia clear cell renal cell carcinoma (ccRCC) ACHN and HK-2 cells hypoxia treatment upregulated 28138701 287 Human hsa-miR-101 miRNA jasmonate colorectal cancer (CRC) SW620 human colorectal cancer cells jasmonate treatment "Compared with control, the anticancer effect of methyl jasmonate inhibited Enhancer of zeste homolog 2 (EZH2) protein expression and activated microRNA (miR)-101 expression in SW620 cells." 28000868 288 Human hsa-miR-101 miRNA methyl jasmonate (MeJA) colorectal cancer (CRC) SW620 human colorectal cancer cells "were treated with 0, 0.5, 0.75, 1.5 and 2.0 mM methyl jasmonate for 12, 24 and 48 h" upregulated 28000868 289 Human hsa-miR-101 miRNA etoposide (VP-16) DNA damage MCF7 cells 1 ?M/5 ?M etoposide treatment upregulated 25353636 290 Human hsa-miR-101 miRNA melatonin apoptosis human umbilical vein endothelial cells (HUVECs) Melatonin treatment Melatonin upregulates DNA-PKcs to suppress apoptosis of human umbilical vein endothelial cells via inhibiting miR-101 under H 2 O 2-induced oxidative stress 33226571 291 Human hsa-miR-101 miRNA nicotine epithelial-mesenchymal transition (EMT) "head and neck squamous cell carcinoma cell lines, UMSCC-10B and HN-1" nicotine treatment downregulated 23300583 292 Human hsa-miR-101 miRNA cyclooxygenase-2 (COX-2) gastric cancer (GC) Human gastric cancer cell lines SGC-7901; BGC-823;matched normal tissue Cyclooxygenase-2 (COX-2)? treatment downregulated 23013439 293 Human hsa-miR-101 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells temozolomide (TMZ) treatment Expression of miR-101 largely decreased in U-251/ TMZ compared with the parental cell 29479863 294 Human hsa-miR-101 miRNA Sinomenine (SIN) glucocorticoids dermatitis HaCaT cells Sinomenine (SIN) treatment downregulated 29501764 295 Human hsa-miR-101 miRNA cigarette smoke extract (CSE) head and neck squamous cell carcinoma (HNSCC) HaCaT cigarette smoke?extract?(CSE) treatment downregulated 28797462 296 Human hsa-miR-101 miRNA apigenin hepatocellular carcinoma (HCC) doxorubicin-resistant hepatocellular carcinoma cell line BEL-7402/ADM apicidin treatment upregulated 29137246 297 Human hsa-miR-101 miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) human liver cancer cells (HepG2) cisplatin (DDP) treatment "Cell proliferation, apoptosis, intracellular reactive oxygen species and comet assay results indicated that the upregulation of miR-101 sensitized HepG2 cells to CDDP, and downregulated of miR-101 reduced chemosensitivity." 31516578 298 Human hsa-miR-101 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) plasma hepatitis B virus (HBV) infection downregulated 22105822 299 Human hsa-miR-101 miRNA lipopolysaccharide (LPS) inflammation pancreatic ¦Â cell Min6 lipopolysaccharide (LPS) treatment upregulated 31213095 300 Human hsa-miR-101 miRNA tetramethylpyrazine (TMP) inflammation LPS-treated pancreatic ¦Â cell Min6 Tetramethylpyrazine (TMP) treatment downregulated 31213095 301 Human hsa-miR-101 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation SH-Sy5y cells tumor necrosis factor alpha (TNF-¦Á) treatment "Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles" 31513985 302 Human hsa-miR-101 miRNA octreotide (OCT) intestinal mucositis Caco-2 cells octreotide (OCT) treatment OCT affected autophagy through up-regulating miR-101 in LPS-treated cells. 30205395 303 Human hsa-miR-101 miRNA carbon tetrachloride (CCl4) liver fibrosis HSCs carbon tetrachloride (CCl4) treatment downregulated 24817606 304 Human hsa-miR-101 miRNA active pterocarpanquinone LQB-118 active pterocarpanquinone LQB-118 cytotoxicity "PC3, LNCaP, and LAPC4 PCa cells" LQB-118 downregulated 29105806 305 Human hsa-miR-101 miRNA IL-1¦Â lung cancer lung IL-1¦Â treatment the interleukin 1 receptor antagonist and interleukin-1¦Â antibody can reduce silica particle-induced downregulated of mir-101 25428391 306 Human hsa-miR-101 miRNA silica particle lung cancer Xuan Wei lung cancer cell line silica particle treatment downregulated 25428391 307 Human hsa-miR-101 miRNA curcumin (Cur) multiple myeloma (MM) MM cell lines RPMI8226 and U266 curcumin treatment upregulated 28322158 308 Human hsa-miR-101 miRNA IL-1¦Â osteoarthritis (OA) primary OA chondrocytes IL-1¦Â treatment "LINC00623/miR-101/HRAS axis modulates OA chondrocyte apoptosis, senescence and ECM degradation through MAPK signaling" 32062610 309 Human hsa-miR-101 miRNA zoledronic acid (ZA) osteoporosis serum ZOL treatment "?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment" 33637048 310 Human hsa-miR-101 miRNA morin oxidative stress A549 cells upon traffic PM2.5 exposure Morin treatment downregulated 31284452 311 Human hsa-miR-101 miRNA particulate matter (PM2.5) oxidative stress A549 cells traffic PM2.5 treatment upregulated 31284452 312 Human hsa-miR-101 miRNA metformin (Met) pancreatic cancer (PC) Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR Metformin? treatment downregulated 22086681 313 Human hsa-miR-101 miRNA tumor necrosis factor alpha (TNF-¦Á) parkinson's disease (PD) SH-Sy5y cells tumor necrosis factor alpha (TNF-¦Á) treatment "Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles" 31513985 314 Human hsa-miR-101 miRNA sunitinib (SU) renal cell carcinoma (RCC) RCC cells sunitinib treatment downregulated 27487138 315 Human hsa-miR-101 miRNA ultraviolet (UV) irradiation skin senescence skin fibroblasts UVB treatment microRNA-mRNA functional interactions in UVB-induced senescence of human diploid fibroblasts 23557329 316 Human hsa-miR-101 miRNA TPA (12-O-tetradecanoylphorbol 13-acetate) hepatocellular carcinoma (HCC) HepG2 cells TPA (12-O-tetradecanoylphorbol 13-acetate) treatment "TPA not only upregulated miR-101 expression, but also reduced protein level of EZH2, EED and H3K27me3 in HepG2 cells" 20444294 317 Human hsa-miR-101-3p miRNA iodine-131 (131I) papillary thyroid cancer (PTC) thyroid papillary cell line TPC-1 (BNCC337912) and B-CPAP (BNCC338685) 131I treatment NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo. 30596336 318 Human hsa-miR-101-3p miRNA titanium dioxide nanoparticles (TiO2 NPs) autophagy human HTR-8/SVneo (HTR) cells Titanium dioxide nanoparticles (TiO2 NPs) treatment upregulated 30345998 319 Human hsa-miR-101-3p miRNA cisplatin (DDP) bladder cancer The 5637 and EJ-M3 cells cisplatin treatment MALAT1 affected the cisplatin resistance of the BC cells via regulating the miR-101-3p/VEGF-C pathway. 31650173 320 Human hsa-miR-101-3p miRNA cocaine drug addiction differentiated SH-SY5Y neuroblastoma cells cocaine treatment downregulated 30166527 321 Human hsa-miR-101-3p miRNA serum deprivation endothelial cell death associated with vascular disorders HUVECs serum deprivation treatment downregulated 28518140 322 Human hsa-miR-101-3p miRNA cigarette smoke extract (CSE) esophageal squamous cell carcinoma (ESCC) human immortalized non-tumorigenic esophageal epithelial cell line (Het-1A) cigarette smoking extract (CSE) treatment downregulated 26530100 323 Human hsa-miR-101-3p miRNA cigarette smoke extract (CSE) esophageal squamous cell carcinoma (ESCC) Eca109 cancer cells cigarette smoking extract (CSE) treatment downregulated 26530100 324 Human hsa-miR-101-3p miRNA bupivacaine neurotoxicity Primary dorsal root ganglion (DRG) neurons bupivacaine treatment miR-101-3p was decreased with increasing concentrations of bupivacaine exposure. 31254586 325 Human hsa-miR-101-3p miRNA ¦Á-synuclein (¦Á-Syn) parkinson's disease (PD) SH-SY5Y cells abnormal accumulation of ¦Á-Syn treatment Overexpressed lncRNA-T199678 significantly downregulated the expression in SH-SY5Y cells 33328976 326 Human hsa-miR-101-3p miRNA docetaxel (DTX) prostate cancer LNCaP and CWR22Rv1 cells docetaxel (DTX) treatment downregulated 30621625 327 Human hsa-miR-101-3p miRNA Treponema pallidum (Tp) treponema pallidum (Tp) infection THP-1 cells Treponema pallidum (Tp) infection treatment Stimulation of THP-1 cells with Tp increased miR-101-3p expression 31930972 328 Human hsa-miR-101a miRNA cyclooxygenase-2 (COX-2) bladder cancer human bladder cancer cells COX-2 treatment downregulated 25109742 329 Human hsa-miR-101a-3p miRNA osthole Alzheimer's disease (AD) SH-SY5Y cells osthole treatment "osthole had a protective effect on APP-SH-SY5Y cells, and it could raise miRNA-101a-3p expression and inhibit APP mRNA/protein expression, the formation of A¦Â protein was inhibited too." 30951743 330 Human hsa-miR-101a-3p miRNA osthole Alzheimer's disease (AD) SH-SY5Y cells osthole treatment Osthole inhibits the expression of APP by up-regulating miR-101a-3p in AD cell model. 30693688 331 Human hsa-miR-103 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cholangiocarcinoma (CCA) Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 19407485 332 Human hsa-miR-103 miRNA adriamycin (ADR) acute myeloid leukemia (AML) K562 cells adriamycin (ADR) treatment upregulated 29058777 333 Human hsa-miR-103 miRNA tetrabromobisphenol-A (TBBPA) adipogenesis human adipose-derived primary MSCs TBBPA treatment upregulated 28329833 334 Human hsa-miR-103 miRNA human immunodeficiency virus (HIV)-1 antiviral immune response monocyte-derived macrophage (MDM) human immunodeficiency virus type 1 (HIV-1) treatment upregulated 32994328 335 Human hsa-miR-103 miRNA IL-1¦Â antiviral immune response monocyte-derived macrophage (MDM) IL-1¦Â treatment Treatment of MDMs with interleukin-1¦Â (IL-1¦Â) enhanced microRNA 103 expression. 32994328 336 Human hsa-miR-103 miRNA glucocorticoid (GC) apoptosis "CEM-C7H2 , CUTLL, MOLT-4, Loucy, BJAB, SUD-H6 , DAUDI cell lines" GC upregulated 27888798 337 Human hsa-miR-103 miRNA H2O2 atherosclerosis (AS) human coronary artery endothelial cells H2O2 treatment "Under the stimulation of H 2O 2, the expression of miR-103 decreased." 32190178 338 Human hsa-miR-103 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31232476 339 Human hsa-miR-103 miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 6¡ã HDT bed rest experiment downregulated 28261104 340 Human hsa-miR-103 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 341 Human hsa-miR-103 miRNA H2O2 cardiovascular disease (CVD) HUVEC H2O2 treatment downregulated 26000071 342 Human hsa-miR-103 miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) The cisplatin-resistant Hep3B (Hep3B-R) and Huh7 (Huh7-R) cells cisplatin treatment "circRNA_101505 could sensitize HCC cells to cisplatin by sponging miR-103, and thereby promoting oxidored-nitro domain-containing protein 1 (NOR1) expression." 31372241 343 Human hsa-miR-103 miRNA lipopolysaccharide (LPS) inflammation HK-2 cells lipopolysaccharide (LPS) treatment upregulated 31284776 344 Human hsa-miR-103 miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) human umbilical vein endothelial cells (HUVECs) oxygen-glucose deprivation (OGD) treatment downregulated 29511499 345 Human hsa-miR-103 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic neuronal injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 30007440 346 Human hsa-miR-103 miRNA morphine morphine tolerance "human embryonic kidney 293 (HEK293) cells, Be(3)C cells" chronic morphine men treatment upregulated 24302561 347 Human hsa-miR-103 miRNA retinoic acid (RA) nervous system cancers SK-N-BE(2)-C £»SH SY5Y??cells?;SH-EP cells£» HEK 293T cells retinoic acid treatment upregulated 22848373 348 Human hsa-miR-103 miRNA IL-1¦Â osteoarthritis (OA) Human primary chondrocyte IL-1¦Â treatment upregulated 31302420 349 Human hsa-miR-103 miRNA iodine-131 (131I) papillary thyroid cancer (PTC) CD4 + cells from PTC patients 131?I treatment downregulated 30267584 350 Human hsa-miR-103 miRNA Shenmai injection (SMI) papillary thyroid cancer (PTC) CD4 + cells from PTC patients 131?I and Shenmai injection (SMI) dual treatment upregulated 30267584 351 Human hsa-miR-103 miRNA hypoxia prostate cancer colorectal cancer (CRC) cells Hypoxia treatment upregulated 22593189 352 Human hsa-miR-103 miRNA hypoxia retinal pigment epithelium (RPE) cells injuries ARPE-19 human RPE cells hypoxia treatment hypoxia downregulated microRNA-103 (miR-103). 30144973 353 Human hsa-miR-103 miRNA lipopolysaccharide (LPS) sepsis Monocytes lipopolysaccharide (LPS) treatment downregulated 32455124 354 Human hsa-miR-103-3p miRNA lipopolysaccharide (LPS) liver fibrosis THP-1 cells lipopolysaccharide (LPS) Exosomal miR-103-3p from LPS-activated THP-1 macrophage contributes to the activation of hepatic stellate cells. 32061112 355 Human hsa-miR-103-3p miRNA salidroside (SAL) non small cell lung cancer (NSCLC) A549 cells; H460 cells salidroside (SAL) treatment "Salidroside could inhibit the proliferation of nonsmall cell lung cancer (NSCLC) cells, and elevated the level of miR-103-3p" 32304408 356 Human hsa-miR-103a-2-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 cells; SKhep1 cells; Huh7 cells; LM3 cells sorafenib treatment downregulated 33222692 357 Human hsa-miR-103a-3p miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 358 Human hsa-miR-103a-3p miRNA physcion 8-O-¦Â-glucopyranoside (PG) gastric cancer (GC) MGC-803 and MKN-45 cells Physcion 8-O-¦Â-Glucopyranoside (PG) treatment downregulated 31606381 359 Human hsa-miR-103a-3p miRNA hyperbaric oxygen (HBO) hepatocellular carcinoma (HCC) Hepatoma cell lines (BEL-7402 and SK-Hep1) HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment downregulated 24956259 360 Human hsa-miR-103a-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 361 Human hsa-miR-103a-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 362 Human hsa-miR-103a-3p miRNA L-dopa parkinson's disease (PD) peripheral blood L-dopa-treated treatment the results suggest a role of L-dopa treatment in miR-103a-3p expression only 25596505 363 Human hsa-miR-103b miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 364 Human hsa-miR-103b miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 365 Human hsa-miR-103b miRNA angiopoietin-2 (Ang-2) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-2 (Ang-2) treatment downregulated 30414893 366 Human hsa-miR-103b miRNA fibroblast growth factor 2 (FGF2) angiogenesis human umbilical vein endothelial cells (HUVECs) fibroblast growth factor 2 (FGF2) treatment downregulated 30414893 367 Human hsa-miR-103b miRNA TGF-¦Â angiogenesis human umbilical vein endothelial cells (HUVECs) TGF-¦Â treatment downregulated 30414893 368 Human hsa-miR-103b miRNA vascular endothelial growth factor (VEGF) angiogenesis human umbilical vein endothelial cells (HUVECs) vascular endothelial cell growth factor (VEGF) treatment downregulated 30414893 369 Human hsa-miR-105 miRNA tumor necrosis factor alpha (TNF-¦Á) colorectal cancer (CRC) "human colon epithelial cell line FHC and CRC cell lines including LS174T, LoVo, HT29, SW620, SW480, HCT116" tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29238068 370 Human hsa-miR-105 miRNA lactobacillus casei (L. casei LC01) irritable bowel syndrome with diarrhea (IBS-D) intestinal epithelial cells (IECs) L. casei LC01 treatment upregulated 32807750 371 Human hsa-miR-105 miRNA fibroblast growth factor 2 (FGF2) osteoarthritis (OA) chondrocytes Fibroblast growth factor 2 (FGF2) treatment downregulated 27998273 372 Human hsa-miR-106 miRNA baicalin (BAI) bladder cancer T24 cells baicalin (BAI) treatment downregulated 30257376 373 Human hsa-miR-106 miRNA diet obesity Plasma diet treatment "Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss." 32439373 374 Human hsa-miR-106 miRNA melatonin osteosarcoma (OS) SaOS2 cells; MG63 cells Melatonin treatment upregulated 32592723 375 Human hsa-miR-106 miRNA cisplatin (DDP) pancreatic cancer (PC) K562 cells cisplatin (DPP) treatment miR-106 and miR-150 were downregulated 20428827 376 Human hsa-miR-106 miRNA high glucose (HG) vascular endothelial dysfunction human umbilical vein endothelial cells (HUVECs) high glucose treatment downregulated 30055307 377 Human hsa-miR-106?b-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 378 Human hsa-miR-106-5p miRNA H2O2 cell senescence multipotent stromal cells H2O2 treatment downregulated 32174776 379 Human hsa-miR-106a miRNA dacarbazine and interferon-alfa-2b breast cancer circulating endothelial cells dacarbazine and interferon-alfa-2b treatment Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a 23217102 380 Human hsa-miR-106a miRNA lipopolysaccharide (LPS) breast cancer HeLa cells lipopolysaccharide (LPS) treatment the expression of miR-17-3p and miR-106a is regulated by LPS in HeLa cells 21370248 381 Human hsa-miR-106a miRNA "anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)" bronchial epithelial cell cancer malignant human bronchial epithelial cells "anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide treatment" upregulated 20889678 382 Human hsa-miR-106a miRNA oxaliplatin colorectal cancer (CRC) HCT116 cells; HT-29 cells oxaliplatin (OXA) treatment upregulated 31897182 383 Human hsa-miR-106a miRNA oxaliplatin colorectal cancer (CRC) HCT116 and HT-29 CELLS oxaliplatin treatment "Elevation of miR-106a and a decrease of FOXQ1 expression levels were detected in tumor tissues from patients with oxaliplatin-sensitive colorectal cancer, compared with patients with oxaliplatin-resistant colorectal cancer" 31897182 384 Human hsa-miR-106a miRNA 5-fluorouracil (5-Fu) diabetic nephropathy (DN) ?plasma 5-fluorouracil (5-FU) treatment upregulated 24119443 385 Human hsa-miR-106a miRNA platelet-derived growth factor-D (PDGF-D) hepatocellular carcinoma (HCC) HepG2 and Huh-7 cells platelet-derived growth factor-D (PDGF-D) treatment downregulated 25760076 386 Human hsa-miR-106a miRNA TGF-¦Â inflammatory bowel disease (IBD) Jurkat T cells TGF-¦Â treatment downregulated 30327532 387 Human hsa-miR-106a miRNA tumor necrosis factor alpha (TNF-¦Á) inflammatory bowel disease (IBD) Jurkat T cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30327532 388 Human hsa-miR-106a miRNA Src-TKIs (saracatinib or dasatinib) lung cancer "A549, H460, and H1299 NSCLC cells" Src-TKIs treatment downregulated 27372519 389 Human hsa-miR-106a miRNA resveratrol lymph node cancer of prostate Lymph node cancer of prostate (LNCaP)£»Du145 cells resveratrol (Res) treatment upregulated 21714127 390 Human hsa-miR-106a miRNA lipopolysaccharide (LPS) macrophage inflammatory response HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells lipopolysaccharide (LPS) treatment upregulated 23562609 391 Human hsa-miR-106a miRNA 5-fluorouracil (5-Fu) metastatic colorectal cancer (mCRC) mCRC patients 5-fluorouracil (5-FU) treatment upregulated 24119443 392 Human hsa-miR-106a miRNA IL-6 ovarian cancer (OC) SKOV3 and OVCAR3 cell lines IL-6 treatment downregulated 275100942 393 Human hsa-miR-106a miRNA radiation prostate cancer PC3 cells; DU145 cells radiation treatment upregulated 29191361 394 Human hsa-miR-106a miRNA Roux-en-Y gastric bypass (RYGB) weight loss obese subjects without exercise program plasma RYGB treatment dysregulatedin plasma 28344345 395 Human hsa-miR-106a-363 miRNA estrogen receptor-¦Á breast cancer breast cancer cells The estrogen receptor-¦Á treatment upregulated 19706389 396 Human hsa-miR-106a-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment miR-106a-3p was increased in exosomes from ox-LDL induced THP-1. 32633398 397 Human hsa-miR-106a-5p miRNA melatonin intervertebral disc degeneration (IDD) human annulus fibrosus (AF) melatonin treatment downregulated 30992660 398 Human hsa-miR-106a-5p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 399 Human hsa-miR-106a-5p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) MGC-803 cells 5-fluorouracil (5-FU) treatment upregulated 31115533 400 Human hsa-miR-106a-5p miRNA cryptotanshinone osteoarthritis (OA) priamry cultured chondrocytes Cryptotanshinone (CTS) treatment upregulated 29858052 401 Human hsa-miR-106a-5p miRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment downregulated 31894109 402 Human hsa-miR-106b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32130290 403 Human hsa-miR-106b miRNA prolactin and estradiol breast cancer "human breast cancer cell lines, T47D and MCF-7, the human prostate cancer cell line, PC3, and human ovarian cancer cell lines, TOV-112D, OV-90 and TOV-21G" prolactin and estradiol treatment upregulated 28422740 404 Human hsa-miR-106b miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells docosahexaenoic acid (DHA) fatty acids treatment MDA-MB-231 cells with DHA caused a decrease in the miR-106b expression. 31713924 405 Human hsa-miR-106b miRNA TGF-¦Â breast cancer "MDA-MB-231, MCF-7 and MCF-10A cell lines" TGF-¦Â treatment upregulated 24292682 406 Human hsa-miR-106b miRNA radiation cervical cancer (CC) SiHa cells radiation treatment miR-106b expression was highly expressed in the radio-resistant SiHa cells 30579899 407 Human hsa-miR-106b miRNA X-rays cervical cancer (CC) CC tissues and cell lines (SiHa and ME180) 6 MV X-ray irradiation upregulated 30579899 408 Human hsa-miR-106b miRNA oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) chronic inflammatory diseases human umbilical vein endothelial cells (HUVECs) exosomes oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment upregulated 29161413 409 Human hsa-miR-106b miRNA butyrate colorectal cancer (CRC) HCT-116 cells butyrate treatment "Butyrate decreased HCT-116 proliferation, an effect reversed with the addition of the miR-106b mimic" 21283757 410 Human hsa-miR-106b miRNA shikonin endometrial cancer (EC) Ishikawa cells Shikonin treatment downregulated 29449346 411 Human hsa-miR-106b miRNA etanercept gastric cancer (GC) ?serum Etanercept treatment downregulated 23600954 412 Human hsa-miR-106b miRNA lipopolysaccharide (LPS) gastric cancer (GC) gastric epithelial cells lipopolysaccharide (LPS) treatment downregulated 25307786 413 Human hsa-miR-106b miRNA lipopolysaccharide (LPS) gastric cancer (GC) "human gastric epithelial cell lines, AGS and MKN45" LPS from H. pylori 26695 treatment downregulated 25307786 414 Human hsa-miR-106b miRNA shikonin hepatocellular carcinoma (HCC) Huh7 cells; HepG2 cells Shikonin treatment Shikonin suppresses cell progression and EMT and accelerates cell death of HCC cells via modulating miR-106b/SMAD7/TGF-¦Â signaling pathway 31617643 415 Human hsa-miR-106b miRNA triptolide (TPL) hepatocellular carcinoma (HCC) HepG2 cells triptolide (TPL) treatment downregulated 29523159 416 Human hsa-miR-106b miRNA TGF-¦Â innate immune response MDA-MB-231 cells; MCF-7 cells; MCF-10A cells TGF-¦Â treatment upregulated 24292682 417 Human hsa-miR-106b miRNA grape seed proanthocyanidins (GSPs) lung cancer "human NSCLC lines, A549 (Adenocarcinoma), H520 (squamous cell carcinoma), H1299 (Metastatic NSCLC), DMS114 (small cell lung cancer), H23 (adenocarcinoma)" grape seed procyanidin extract (GSE) treatment downregulated 29643994 418 Human hsa-miR-106b miRNA leucoselect phytosome (LP) lung cancer human lung tumor xenografts leucoselect phytosome (LP) treatment downregulated 29643994 419 Human hsa-miR-106b miRNA resveratrol lymph node cancer of prostate Lymph node cancer of prostate (LNCaP)£»Du145 cells resveratrol (Res) treatment upregulated 21714127 420 Human hsa-miR-106b miRNA grape seed proanthocyanidins (GSPs) melanoma A375 and Hs294t cells with GSPs treatment downregulated 25361006 421 Human hsa-miR-106b miRNA H2O2 mitophagy HeLa and HEK 293T cells H2O2 treatment "We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions." 33627622 422 Human hsa-miR-106b miRNA berberine (BBR) multiple myeloma (MM) "human multiple myeloma cell, RPMI-8266 and U266" berberine (BBR) treatment downregulated 27647143 423 Human hsa-miR-106b miRNA gemcitabine (GEM) pancreatic cancer (PC) cancer-associated fibroblasts (CAFs) and the exosomes derived from CAFs Gemcitabine (GEM) treatment upregulated 31374207 424 Human hsa-miR-106b miRNA hypoxia prostate cancer PCa cell lines (LNCaP£» PC3)£»neural crest (NC) cells hypoxia treatment downregulated 24135225 425 Human hsa-miR-106b miRNA hypoxia prostate cancer LNCaP cells 5% O2 treatment upregulated 24135225 426 Human hsa-miR-106b miRNA salvianolic acid B (Sal B) renal fibrosis human kidney proximal tubular epithelial cells (HK-2 cells) Sal B treatment upregulated 25094038 427 Human hsa-miR-106b miRNA TGF-¦Â1 renal fibrosis human kidney proximal tubular epithelial cells (HK-2 cells) TGF-¦Â1 treatment downregulated 25094038 428 Human hsa-miR-106b miRNA toxoplasma gondii (T. gondii) toxoplasma gondii infection primary human foreskin fibroblasts (HFFs) toxoplasma gondii (T. gondii) infection treatment upregulated 20090903 429 Human hsa-miR-106b miRNA docosahexaenoic acid (DHA) triple negative breast cancer (TNBC) MDA-MB-231 cells Docosahexaenoic acid (DHA) treatment downregulated 31713924 430 Human hsa-miR-106b miRNA statins unstable angina (UA) plasma statins? treatment downregulated 26474612 431 Human hsa-miR-106b-25 miRNA natalizumab B lymphocytic leukemia whole blood lymphocytes natalizumab treatment downregulated 22659298 432 Human hsa-miR-106b-25 miRNA antrodia cinnamomea hepatocellular carcinoma (HCC) SK-Hep-1 liver cancer cell antrodia cinnamomea treatment "oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated" 24358224 433 Human hsa-miR-106b-3p miRNA matrine acute lymphoblastic leukemia (ALL) CCRF-CEM cells matrine treatment downregulated 29045804 434 Human hsa-miR-106b-3p miRNA BIX01294 lung cancer human NSCLC cells BIX01294 treatment downregulated 24932239 435 Human hsa-miR-106b-5p miRNA TGF-¦Â1 asthma human bronchial epithelial cells BEAS-2B TGF-¦Â1 treatment The present study revealed downregulated miR-106b-5p expression and upregulated SIX1 expression in asthmatic mice and TGF-¦Â1-induced BEAS-2B cells 33495833 436 Human hsa-miR-106b-5p miRNA bone morphogenetic protein 4 (BMP4) breast cancer breast epithelial cell line bone morphogenetic protein 4 (BMP4) treatment upregulated 26684238 437 Human hsa-miR-106b-5p miRNA bone morphogenetic protein 4 (BMP4) breast cancer BT-474 cell bone morphogenetic protein 4 (BMP4) treatment "four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment." 26684238 438 Human hsa-miR-106b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) cardiac dysfunction SH-SY5Y cells; HCN-2 cells MPP+ (1-methyl-4-phenylpyridinium) treatment Inhibition of miR-6862 induces SphK1 elevation and protects neuronal cells from MPP+-induced cell death. 33414358 439 Human hsa-miR-106b-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment MiR-106b-5p expression was increased in OGD/R induced SH-SY5Y cells 32407850 440 Human hsa-miR-106b-5p miRNA radiochemotherapy head and neck squamous cell carcinoma (HNSCC) ?blood plasma radiochemotherapy?treatment treatment "six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)" 24373621 441 Human hsa-miR-106b-5p miRNA magnesium-free extracellular fluid temporal lobe epilepsy (TLE) SK-N-SH cells; IMR-32 cells magnesium-free extracellular solution upregulated 33370579 442 Human hsa-miR-106b-5p miRNA arsenite tumorigenesis human bronchial epithelial (HBE) cells arsenic exposure "upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)" 28972549 443 Human hsa-miR-106b-93-25 miRNA trichostatin A (TSA) inflammation human endometrial cancer (EMC) cells trichostatin (TSA)? treatment downregulated 23028803 444 Human hsa-miR-107 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cholangiocarcinoma (CCA) Two human pancreatic cancer cell lines - MiaPACA-2£» PANC-1 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 19407485 445 Human hsa-miR-107 miRNA hyperbaric oxygen (HBO) intervertebral disc degeneration (IDD) nucleus pulposus cells (NPCs) Hyperbaric oxygen (HBO) treatment upregulated 30704538 446 Human hsa-miR-107 miRNA tetrabromobisphenol-A (TBBPA) adipogenesis human adipose-derived primary MSCs TBBPA treatment upregulated 28329833 447 Human hsa-miR-107 miRNA 6-hydroxydopamine (6-OHDA) Alzheimer's disease (AD) SH-SY5Y cells 6-hydroxydopamine (6-OHDA) treatment downregulated 31778666 448 Human hsa-miR-107 miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y; SK-N-SH cells amyloid ¦Â1-42?(A¦Â) treatment "NEAT1 expression was enhanced in A¦Â-treated SH-SY5Y and SK-N-SH cells, miR-107 abundance was reduced in A¦Â-treated cells, and its overexpression reversed A¦Â-induced injury. Moreover, interference of miR-107 abated silencing of NEAT1-mediated inhibition of neuronal damage in A¦Â-treated SH-SY5Y and SK-N-SH cells." 31250578 449 Human hsa-miR-107 miRNA 6-hydroxydopamine (6-OHDA) Alzheimer's disease (AD) SH-SY5Y Cells 6-hydroxydopamine (6-OHDA) treatment 6-OHDA suppressed miR-107 expression. 31778666 450 Human hsa-miR-107 miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y; SK-N-SH cells amyloid ¦Â1-42?(A¦Â) treatment SOX21-AS1 silencing could attenuate A¦Â1-42-induced neuronal damage by sponging miR-107 32124921 451 Human hsa-miR-107 miRNA metformin (Met) anti-cancer therapy CD8 + T cells Metformin treatment downregulated 32221038 452 Human hsa-miR-107 miRNA human immunodeficiency virus (HIV)-1 antiviral immune response monocyte-derived macrophage (MDM) human immunodeficiency virus type 1 (HIV-1) treatment upregulated 32994328 453 Human hsa-miR-107 miRNA lipopolysaccharide (LPS) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) and human umbilical vein smooth muscle cells (HUVSMCs) lipopolysaccharide (LPS) treatment "The expression of miR-107 was significantly decreased in the blood cells of patients with atherosclerosis compared with the controls. In addition, miR-107 mimics significantly inhibited the proliferation of HUVECs and HUVSMCs, compared with the control groups, at 48 and 72 h, which was in contrast to the observed effects of circRNA-0044073." 30864721 454 Human hsa-miR-107 miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 455 Human hsa-miR-107 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 456 Human hsa-miR-107 miRNA hypoxia colorectal cancer (CRC) Bone marrow mononuclear cells (BMMCs) hypoxia treatment MiR-107 expression were increased in EPCs under hypoxic conditions 22792280 457 Human hsa-miR-107 miRNA dichloroacetate (DCA) and oxaliplatin (L-OHP) colorectal cancer (CRC) HCT-116 cells dichloroacetate (DCA) and oxaliplatin (L-OHP) treatment upregulated 31919406 458 Human hsa-miR-107 miRNA Skullcapflavone I (SF I) colorectal cancer (CRC) HCT116 cells Skullcapflavone I treatment downregulated 30509103 459 Human hsa-miR-107 miRNA doxorubicin (DOX) doxorubicin (DOX)-induced cardiotoxicity plasma extracellular vesicle (EV) doxorubicin (Dox) treatment downregulated 32255536 460 Human hsa-miR-107 miRNA rapamycin endothelial dysfunction human umbilical vein endothelial cells (HUVECs) rapamycin treatment downregulated 29579170 461 Human hsa-miR-107 miRNA extract of Stellerachamaejasme L(ESC) hepatocellular carcinoma (HCC) HepG2 and MHCC97H cells extract of Stellerachamaejasme L(ESC) treatment upregulated 29554896 462 Human hsa-miR-107 miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 463 Human hsa-miR-107 miRNA ischemia/reperfusion (I/R) ischemic stroke (IS) brain tissues ischemia/reperfusion (I/R) treatment upregulated in rat hippocampal cultures 24943094 464 Human hsa-miR-107 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic neuronal injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 30007440 465 Human hsa-miR-107 miRNA cisplatin (DDP) laryngeal squamous cell carcinoma (LSCC) TU-177 cells; AMC-HN-8 cells cisplatin treatment H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo. 33314408 466 Human hsa-miR-107 miRNA morphine morphine tolerance "human embryonic kidney 293 (HEK293) cells, Be(2)C cells" chronic morphine men treatment upregulated 24302561 467 Human hsa-miR-107 miRNA "anthranilamide-pyrazolo[1,5-a]pyrimidine" neuroblastoma (NB) neuronalcancer cells lines MR-32; SK-N-SH "anthranilamide-pyrazolo[1,5-a]pyrimidine treatment" upregulated 23992861 468 Human hsa-miR-107 miRNA hyperbaric oxygen (HBO) osteoarthritis (OA) osteoarthritic (OA) chondrocytes Hyperbaric oxygen (HBO) treatment upregulated 31146014 469 Human hsa-miR-107 miRNA dexamethasone (DEX) oxidative stress OB-6 human osteoblastic cells dexamethasone (DEX) treatment miR-107 inhibition upregulates CAB39 and activates AMPK-Nrf2 signaling to protect osteoblasts from dexamethasone-induced oxidative injury and cytotoxicity 32527986 470 Human hsa-miR-107 miRNA hypoxia prostate cancer colorectal cancer (CRC) cells Hypoxia treatment upregulated 22593189 471 Human hsa-miR-107 miRNA hypoxia tumor angiogenesis HCT116 cells Hypoxia treatment upregulated 20308559 472 Human hsa-miR-10a miRNA alcohol alcohol stress alcohol consumption in heavy drinkers were allowed to drink up to 750 cc of beer? treatment upregulated 25421511 473 Human hsa-miR-10a miRNA tamoxifen (TAM) breast cancer tumour samples of breast cancer tamoxifen treatment upregulated 23968733 474 Human hsa-miR-10a miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury ?SH-SY5Y cell oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 30798122 475 Human hsa-miR-10a miRNA trametenolic acid B (TAB) cerebral ischemia/reperfusion (I/R) injury oxygen glucose deprivation/reoxygenation (OGD/R) induced?SH-SY5Y cell Trametenolic acid B (TAB) treatment downregulated 30798122 476 Human hsa-miR-10a miRNA baicalin (BAI) colorectal cancer (CRC) HT29 cells baicalin (BAI) treatment downregulated 30262902 477 Human hsa-miR-10a miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-10a was upregulated in resistant patients when compared with sensitive patients 33072545 478 Human hsa-miR-10a miRNA hypoxia glioblastoma multiforme (GBM) glioma-derived exosomes (GDEs) hypoxia treatment The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN). 29713056 479 Human hsa-miR-10a miRNA TGF-¦Â glioblastoma multiforme (GBM) human glioma cell transforming growth factor ¦Â (TGF-¦Â) treatment upregulated 24100613 480 Human hsa-miR-10a miRNA H2O2 oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 481 Human hsa-miR-10a miRNA lipopolysaccharide (LPS) oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 482 Human hsa-miR-10a miRNA infliximab inflammatory bowel disease (IBD) IBD patients infliximab treatment downregulated 25281418 483 Human hsa-miR-10a miRNA cisplatin (DDP) lung cancer A549 cells; H1299 cells cisplatin treatment CTCs treated with cisplatin demonstrated higher miR-10a expression and lower PIK3CA expression than that in A549 and H1299 cells. 32186774 484 Human hsa-miR-10a miRNA icariin (ICA) lung cancer A549 cells Icaritin treatment downregulated 31829310 485 Human hsa-miR-10a miRNA retinoic acid (RA) neuroblastoma (NB) SH-SY5Y (ATCC CRL-2266); HeLa (ATCC CCL-2) cells Retinoic acid treatment upregulated 21118818 486 Human hsa-miR-10a miRNA compound C nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) compound C treatment downregulated 32143184 487 Human hsa-miR-10a miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) palmitic acid treatment downregulated 32143184 488 Human hsa-miR-10a miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 489 Human hsa-miR-10a miRNA methotrexate (MTX) rheumatoid arthritis (RA) peripheral blood methotrexate treatment circulating miR-10a was upregulated in RA patients treated with MTX. 29667551 490 Human hsa-miR-10a-3p miRNA respiratory syncytial virus (RSV) respiratory syncytial virus (RSV)-associated pneumonia whole blood respiratory syncytial virus (RSV) infection treatment upregulated 32410870 491 Human hsa-miR-10a-5p miRNA IL-6 intervertebral disc degeneration (IDD) Primary human articular chondrocyte ?IL-6?treatment treatment "?IL-6 downregulated miR-10a-5p, which subsequently derepressed IL-6R expression" 33166496 492 Human hsa-miR-10a-5p miRNA lipopolysaccharide (LPS) apical periodontitis (AP) K-562 cells lipopolysaccharide (LPS) treatment upregulated 33245973 493 Human hsa-miR-10a-5p miRNA S-equol breast cancer MCF-7?cells S-equol treatment upregulated 31390527 494 Human hsa-miR-10a-5p miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment downregulated 26397152 495 Human hsa-miR-10a-5p miRNA aspirin heart repair mesenchymal stem cells (MSCs) aspirin treatment upregulated 32044414 496 Human hsa-miR-10a-5p miRNA IL-6 intervertebral disc degeneration (IDD) Primary human chondrocytes IL-6 treatment downregulated 32746985 497 Human hsa-miR-10a-5p miRNA heparin-binding EGF-like growth factor (HB-EGF) keratinocytes (KCs) diferentiation human primary KCs heparin-binding EGF-like growth factor (HB-EGF) treatment upregulated 31049964 498 Human hsa-miR-10a-5p miRNA bevacizumab and FOLFOX metastatic colorectal cancer (mCRC) mCRC patients tumor tissue bevacizumab/FOLFOX upregulated 28693229 499 Human hsa-miR-10a-5p miRNA azacitidine (AZA) myelodysplastic syndrome (MDS) bone marrow CD34+ cells azacitidine (AZA) treatment downregulated 29630523 500 Human hsa-miR-10a-5p miRNA cyclosporine A (CsA) nephrotoxicity human proximal tubule cells cyclosporine A treatment dysregulated 28925592 501 Human hsa-miR-10a-5p miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment downregulated 26298803 502 Human hsa-miR-10a-5p miRNA IL-1¦Â osteoarthritis (OA) chondrocytes interleukin-1¦Â treatment upregulated 30731321 503 Human hsa-miR-10a-5p miRNA IL-1¦Â osteoarthritis (OA) primary cultured chondrocytes IL-1¦Â treatment upregulated 30731321 504 Human hsa-miR-10a-5p miRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment LncRNA SNHG5 promotes chondrocyte proliferation and inhibits apoptosis in osteoarthritis by regulating miR-10a-5p/H3F3B axis 32967481 505 Human hsa-miR-10a-5p miRNA oleanolic acid (OLA) osteoarthritis (OA) chondrocytes oleanolic acid (OLA) treatment downregulated 32028542 506 Human hsa-miR-10a-5p miRNA tyrosine kinase inhibitors (TKI) renal cell carcinoma (RCC) patients with advanced renal cell carcinoma (RCC) tyrosine kinase inhibitors (TKI) treatment downregulated 28746769 507 Human hsa-miR-10a-5p miRNA IL-1¦Â rheumatoid arthritis (RA) SW982 cells IL-5¦Â treatment downregulated 28782180 508 Human hsa-miR-10a-5p miRNA IL-1¦Â rheumatoid arthritis (RA) human synovial sarcoma cell line SW982 IL-1¦Â treatment downregulated 28782180 509 Human hsa-miR-10a-5p miRNA IL-1¦Â rheumatoid arthritis (RA) SW982 cells IL-1¦Â treatment downregulated 29545315 510 Human hsa-miR-10b miRNA fenretinide angiogenesis human umbilical vein endothelial cells (HUVECs) fenretinide treatment downregulated 31925643 511 Human hsa-miR-10b miRNA propofol (PPF) bladder cancer T24 cells "2,6-diisopropylphenol (propofol) treatment" downregulated 31788099 512 Human hsa-miR-10b miRNA hyperthermia breast cancer BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231 Hyperthermia treatment downregulated 27380148 513 Human hsa-miR-10b miRNA linifanib breast cancer "MCF-7, MM231, MM468, T47D cells" Linifanib treatment downregulated 30166612 514 Human hsa-miR-10b miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 515 Human hsa-miR-10b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)" chondrosarcoma JJ012 and SW1353 chondrosarcoma cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment" upregulated 26549320 516 Human hsa-miR-10b miRNA acidic microenvironment early-stage hepatocellular carcinoma (E-HCC) The human HCC cell lines SMMC-7721 and Hep3B acidic microenvironment treatment upregulated 31037150 517 Human hsa-miR-10b miRNA TGF-¦Â esophageal squamous cell carcinoma (ESCC) "Esophageal cancer cells, TE-1 and EC9706" transforming growth factor-¦Â (TGF-¦Â) treatment upregulated 31602239 518 Human hsa-miR-10b miRNA bisphenol A (BPA) female fertility cumulus oocyte complex (COC) bisphenol A (BPA) treatment downregulated 33285269 519 Human hsa-miR-10b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) GC cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 24481854 520 Human hsa-miR-10b miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 521 Human hsa-miR-10b miRNA lidocaine gastric cancer (GC) MGC-803 cells lidocaine (Lido) treatment Lido declined cisplatin resistance by down-regulating miR-10b. 32892697 522 Human hsa-miR-10b miRNA TGF-¦Â1 glioblastoma multiforme (GBM) human glioma cell lines U87 and U251 5 ng/ml of TGF-¦Â treatment upregulated 28393237 523 Human hsa-miR-10b miRNA neferine (NEF) glioblastoma multiforme (GBM) human glioma cell line U251 neferine (NEF) treatment downregulated 30551353 524 Human hsa-miR-10b miRNA neferine (NEF) glioblastoma multiforme (GBM) human glioma cell line U251 neferine (NEF) treatment downregulated 30551353 525 Human hsa-miR-10b miRNA TGF-¦Â glioblastoma multiforme (GBM) human glioma cell transforming growth factor ¦Â (TGF-¦Â) treatment upregulated 24100613 526 Human hsa-miR-10b miRNA heparin angiogenesis human microvascular endothelial cells (HMEC-1) Heparin treatment downregulated 21642433 527 Human hsa-miR-10b miRNA B cell lymphoma/lewkmia-2 (Bcl2) medulloblastoma medulloblastoma cell B cell lymphoma/lewkmia-2 (Bcl2) treatment high expression of miRNA-10b in medulloblastoma cell lines compared to a normal cerebellar control 26394044 528 Human hsa-miR-10b miRNA retinoic acid (RA) neuroblastoma (NB) SH-SY5Y (ATCC CRL-2266); HeLa (ATCC CCL-2) cells Retinoic acid treatment upregulated 21118818 529 Human hsa-miR-10b miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 530 Human hsa-miR-10b miRNA hyaluronan-CD44 thymic atrophy and alterations in T cell differentiation breast tumor cells (MDA-MB-231 cells) Hyaluronan-CD44? treatment upregulated 20843787 531 Human hsa-miR-10b miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment upregulated 24396484 532 Human hsa-miR-10b miRNA epstein-barr virus (EBV) nasopharyngeal carcinoma (NPC) human nasopharyngeal carcinoma cells Epstein-Barr virus (EBV) infection upregulated 20732742 533 Human hsa-miR-10b-3p miRNA hypoxia esophageal squamous cell carcinoma (ESCC) ECA109 cells; KYSE410 cells hypoxia induce upregulated 31772141 534 Human hsa-miR-10b-3p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) tissues sorafenib treatment dysregulated 28049231 535 Human hsa-miR-10b-3p miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 536 Human hsa-miR-10b-3p miRNA hypoxia preeclampsia (PE) human trophoblast HTR-8/SVneo cells hypoxia induce downregulated 30552989 537 Human hsa-miR-10b-3p miRNA hypoxia preeclampsia (PE) HTR-8/SVneo cells hypoxia treatment Lower levels of miR-10b-3p but higher expression of WDR86-AS1 and LITAF were observed in PE-affected placentas and trophoblast cells under hypoxia. 30552989 538 Human hsa-miR-10b-5p miRNA Kv channel blocker 4-aminopyridine (4-AP) cell proliferation and apoptosis U87-MG cells; U251 cells Kv channel blocker 4-aminopyridine (4-AP) treatment "4-AP altered the miRNA expression in glioma cells, and the downregulated of miR-10b-5p induced by 4-AP was verified by real-time PCR." 29514931 539 Human hsa-miR-10b-5p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment downregulated 25129238 540 Human hsa-miR-10b-5p miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment upregulated 30503955 541 Human hsa-miR-10b-5p miRNA hypoxia ischemic injury endothelial colony-forming cells (ECFCs) exosomes hypoxia induce downregulated 30183690 542 Human hsa-miR-10b-5p miRNA azacitidine (AZA) myelodysplastic syndrome (MDS) bone marrow CD34+ cells azacitidine (AZA) treatment downregulated 29630523 543 Human hsa-miR-1178 miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) human macrophages (HTP-1 and U937 cells) Mycobacterium tuberculosis (M.tb) infection upregulated 29781535 544 Human hsa-miR-1179 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment downregulated 22647265 545 Human hsa-miR-1180 miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 546 Human hsa-miR-1180 miRNA paclitaxel (PTX) triple negative breast cancer (TNBC) HCC38 (paclitaxel-sensitive) and MDA-MB436 (paclitaxel-resistant) TNBC cells paclitaxel treatment downregulated 29416635 547 Human hsa-miR-1181 miRNA platelet derived growth factor-BB (PDGF-BB) pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (PASMCs) Platelet-derived growth factor BB (PDGFBB) treatment downregulated 30211651 548 Human hsa-miR-1181 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 549 Human hsa-miR-1182 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment downregulated 22647265 550 Human hsa-miR-1182 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 551 Human hsa-miR-1182 miRNA hypoxia non-small cell lung cancer (NSCLC) H522; H1975; BEAS-2B hypoxia treatment Circ_0000376 promoted NSCLC progression by regulating the miR-1182/NOVA2 axis 32922073 552 Human hsa-miR-1183 miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 553 Human hsa-miR-1183 miRNA radiation glioblastoma multiforme (GBM) U87 cells; U251 cells radiation treatment miR-1183 expression was significantly upregulated in U87 and U251 cells following irradiation 32080097 554 Human hsa-miR-1183 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 555 Human hsa-miR-1184 miRNA lipopolysaccharide (LPS) neonatal sepsis (NS) serum lipopolysaccharide (LPS) treatment The results indicated that the serum levels of miR-1184 in neonates with sepsis were decreased 33732323 556 Human hsa-miR-1193 miRNA IL-1¦Â rheumatoid arthritis (RA) MH7A cells IL-1¦Â treatment downregulated 32597556 557 Human hsa-miR-12 miRNA cisplatin (DDP) apoptosis K562 cells cisplatin treatment upregulated 20428827 558 Human hsa-miR-1202 miRNA antidepressant major depressive disorder (MDD) cohorts of depressed patients received 8 weeks of antidepressant therapy upregulated 28520926 559 Human hsa-miR-1202 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) neuroinflammation human microglial cells (HM cells) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated of miR-1202 and upregulated of Rab1a were found in OGD/R induced HM cells. 32124161 560 Human hsa-miR-1203 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemia/reperfusion (I/R) injury T-HESC and primary human endometrial cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment miR-1203 targets and silences CypD to protect human endometrial cells from OGDR 32041924 561 Human hsa-miR-1205 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment upregulated 28619522 562 Human hsa-miR-1207-3p miRNA gemcitabine (GEM) advanced pancreatic cancer (PC) BxPC-3 cells; PANC-1 cells Gemcitabine treatment "Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)." 30341811 563 Human hsa-miR-1207-5p miRNA gemcitabine (GEM) advanced pancreatic cancer (PC) BxPC-3 cells; PANC-1 cells Gemcitabine treatment "Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)." 30341811 564 Human hsa-miR-1207-5p miRNA lucidum breast cancer MCF-7 breast cancer cells lucidum treatment upregulated 25954907 565 Human hsa-miR-1207-5p miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) nasopharyngeal carcinoma cell HK-1 TGF-¦Âtreatment upregulated 26032086 566 Human hsa-miR-1207-5p miRNA tanshinol (TAN) melanoma "Human melanoma cell lines (M14, A375)" Tanshinol treatment upregulated 31828417 567 Human hsa-miR-1207-5p miRNA tanshinol (TAN) melanoma A375 cells; M14 cells Tanshinol treatment Tanshinol induced miR-1207-5p expression and suppressed cell growth and mobility of melanoma cells 31828417 568 Human hsa-miR-122 miRNA N-3 polyunsaturated fatty acids (PUFA) nonalcoholic fatty liver disease (NAFLD) blood n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) treatment n-3 PUFA were effective in reducing ALP and liver fibrosis without altering the expression of circulating miR-122 in individuals with NAFLD. 33147705 569 Human hsa-miR-122 miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) primary human hepatocytes (PHH) acetaminophen (APAP) treatment upregulated 32379794 570 Human hsa-miR-122 miRNA high glucose (HG) acute coronary syndrome (ACS) Human Macrophages high glucose treatment upregulated 27519051 571 Human hsa-miR-122 miRNA coptisine (COP) acute liver failure (ALF) HepG2 cells and LO2 cells COP treatment for 7d upregulated 29253766 572 Human hsa-miR-122 miRNA hepatitis C virus (HCV) acute lymphoblastic leukemia (ALL) liver and serum hepatitis C virus (HCV) infection downregulated 23085648 573 Human hsa-miR-122 miRNA H2O2 age-related macular degeneration (AMD) ARPE-19 cells H2O2 treatment downregulated 31784665 574 Human hsa-miR-122 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SK-N-SH cells amyloid-¦Â (A¦Â) 25-35 treatment Both lncRNA Rpph1 and miR-122 were upregulated in AD mouse and Rpph1 activated Wnt/¦Â-catenin signaling to ameliorate amyloid-¦Â induced neuronal apoptosis in SK-N-SH cells via direct targeting miR-122. 31718352 575 Human hsa-miR-122 miRNA amoxicillin or clavulanate amoxicillin/clavulanate-induced liver injury (AC-DILI) healthy subjects liver administered amoxicillin/clavulanate for 14 days upregulated 27785887 576 Human hsa-miR-122 miRNA PAX8/PPAR¦Ã fusion protein (PPFP) anaplastic thyroid carcinoma (ATC) "ATC cell lines: BHT-101; FRO, C-643; KTC-2;KTC-3" PAX8/PPAR¦Ã fusion protein (PPFP) treatment upregulated 23598436 577 Human hsa-miR-122 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 578 Human hsa-miR-122 miRNA rhinoviruses (RVs) asthma human airway epithelial cells rhinoviruses (RVs) infection treatment "Here, we found that RV infection induced the expression of miRNA 122 (miR-122) in mouse lungs and in human airway epithelial cells" 33830082 579 Human hsa-miR-122 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic Endothelial cell (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31228514 580 Human hsa-miR-122 miRNA benzimidazotriazin breast cancer breast cancer (BC) tissues benzimidazotriazin treatment miR-122 was significantly higher in both groups treated with benzimidazotriazine compared to the cisplatin group. 33232730 581 Human hsa-miR-122 miRNA bile duct ligation (BDL) breast cancer serum bile-duct ligation (BDL) treatment Serum miR-122 increased significantly after BDL-induced cholestatic injury 24086271 582 Human hsa-miR-122 miRNA trichostatin A (TSA) cell differentiation hepatocyte-like cells (HLCs) generated from human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) hepatocyte-like cells (HLCs) generated from human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) treatment upregulation 26360933 583 Human hsa-miR-122 miRNA hepatitis B virus (HBV) cell-intrinsic angiogenic activity of ECs liver tissue hepatitis B virus (HBV) infection downregulated 22105316 584 Human hsa-miR-122 miRNA leptin cholangiocarcinoma (CCA) The human cholangiocarcinoma cell lines SK-ChA-1 and TFK-1 Leptin treatment downregulated 31115511 585 Human hsa-miR-122 miRNA hepatitis C virus (HCV) direct-acting antiviral agents (DAAs) chronic hepatitis C virus (HCV) infection Plasma HCV RNA DAAs treatment downregulated 26436610 586 Human hsa-miR-122 miRNA IFN-¦Ã chronic hepatitis C virus (HCV) infection HCV-infected hepatocytes IFN-¦Ë treatment downregulated 24385435 587 Human hsa-miR-122 miRNA transarterial chemoembolization (TACE) chronic hepatitis and hepatocellular carcinoma (HCC) HCC patients plasma TACE treatment upregulated in plasma 27194671 588 Human hsa-miR-122 miRNA PEG-interferon plus ribavirin therapy chronic hepatitis C virus (HCV) infection Blood and plasma PEG-interferon plus ribavirin therapy treatment upregulated 27054010 589 Human hsa-miR-122 miRNA oxaliplatin colorectal cancer (CRC) SW480 cells; HCT116 cells oxaliplatin treatment downregulated 31901148 590 Human hsa-miR-122 miRNA H2O2 crohn disease (CD) HT-29 cells H2O2 treatment downregulated 31019652 591 Human hsa-miR-122 miRNA ionic liquids (ILs) 1-decyl-3-methylimidazolium bromide cytotoxicity HepG2 cells Ionic liquids (ILs) 1-decyl-3-methylimidazolium bromide treatment upregulated 31702098 592 Human hsa-miR-122 miRNA H2O2 deep vein thrombosis (DVT) human umbilical vein endothelial cells (HUVECs) H2O2 treatment downregulated 33195700 593 Human hsa-miR-122 miRNA trichostatin A (TSA) differentiated phenotype in hepatocytes hepatocyte-like cells (HLCs) trichostatin A (TSA) treatment upregulated 26360933 594 Human hsa-miR-122 miRNA acetaminophen (APAP) drug hepatotoxicity healthy men and women acetaminophen (APAP) treatment upregulated 24118944 595 Human hsa-miR-122 miRNA grape pomace extract (GPE) dyslipidemia and insulin resistance rat hepatoma cell line (ECACC); FAO cells grape pomace extract (GPE) treatment GPE reduced miR-122 but increased miR-33a expression. 24165878 596 Human hsa-miR-122 miRNA grape seed proanthocyandin extract (GSPE) dyslipidemia and insulin resistance rat hepatoma cell line (ECACC); FAO cells grape seed proanthocyandin extract (GSPE) treatment GSPE reduced both miR-122 and miR-33a levels. 24165878 597 Human hsa-miR-122 miRNA human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) early non-genotoxic events HepaRG cells human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) treatment downregulated 26609139 598 Human hsa-miR-122 miRNA 2-octynoic acid endometrial cancer (EC) human hepatocytes HepG2.2.15 2-octynoic acid treatment over expression 23741428 599 Human hsa-miR-122 miRNA H2O2 epithelial-mesenchymal transition (EMT) human umbilical vein endothelial cells (HUVECs); human aortic endothelial cells (HAECs) H2O2 treatment miR-122 was markedly upregulated after treatment with H2O2 for 48 h. 33278397 600 Human hsa-miR-122 miRNA cisplatin (DDP) gastric cancer (GC) MKN74 cells cisplatin treatment downregulated 31152437 601 Human hsa-miR-122 miRNA aflatoxin B1 (AFB1) genotoxicity HepaRG cells aflatoxin B1 (AFB1) treatment downregulated 26609139 602 Human hsa-miR-122 miRNA peginterferon alfa-2a (PEG-IFN) HBV/HCV dually infection HBV/HCV patients serum PEG-IFN treatment upregulated 25788377 603 Human hsa-miR-122 miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 cells cisplatin treatment upregulated 27874954 604 Human hsa-miR-122 miRNA FeSO4 hepatic inflammation Huh7 cells 100 ?¦¬ FeSO4 treatment downregulated 29176318 605 Human hsa-miR-122 miRNA holo-transferrin (holo-Tf) hepatic inflammation Huh7 cells holo-transferrin (holo-Tf) treatment downregulated 29176318 606 Human hsa-miR-122 miRNA alcohol liver damage Huh-7.5 cells; Huh-7.5 cells;CYP2E1 expressing cells alcohol exposure upregulated 23126531 607 Human hsa-miR-122 miRNA miravirsen?(SPC3649) hepatitis C virus (HCV) infection HeLa cells; Huh-7 cells Miravirsen (SPC3649) treatment downregulated 24068553 608 Human hsa-miR-122 miRNA miravirsen?(SPC3649) hepatitis C virus (HCV) infection HeLa cells;Huh-7 cells miravircsen?(SPC3649) treatment upregulated 24068553 609 Human hsa-miR-122 miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection ML-1 human thyroid cells hepatitis C virus (HCV) infection upregulated 31784757 610 Human hsa-miR-122 miRNA ribavirin and interferon ¦Â hepatitis C virus (HCV) infection The human hepatoma cell line Huh7 ribavirin and interferon ¦Â treatment downregulated 20428788 611 Human hsa-miR-122 miRNA astragaloside IV (AS-IV) hepatocellular carcinoma (HCC) HepG2 cells astragaloside IV (AS-IV) treatment upregulated 28179291 612 Human hsa-miR-122 miRNA curcumin (Cur) hepatocellular carcinoma (HCC) HepG2 cells curcumin treatment upregulated 28179291 613 Human hsa-miR-122 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Plasma hepatitis B virus (HBV) infection ?upregulated 22105822 614 Human hsa-miR-122 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Huh7 and HepG2 cells hepatitis B virus (HBV) infection downregulated 31485598 615 Human hsa-miR-122 miRNA radiofrequency ablation (RFA) hepatocellular carcinoma (HCC) plasma radiofrequency ablation (RFA) treatment upregulated 26129878 616 Human hsa-miR-122 miRNA TP-1 hepatocellular carcinoma (HCC) SMMC-7721 cells TP-1 treatment upregulated 25787750 617 Human hsa-miR-122 miRNA transarterial chemoembolization (TACE) hepatocellular carcinoma (HCC) HCC patients plasma TACE treatment differently regulated 25275448 618 Human hsa-miR-122 miRNA ochratoxin A (OTA) hepatocyte apoptosis "human hepatoblastoma cell line, HepG2" ochratoxin A treatment inhibited 30090334 619 Human hsa-miR-122 miRNA hepatitis C virus (HCV) liver damage monocytes hepatitis C virus (HCV) infection Serum levels of miR-122 were elevated in cHCV patients and correlated with increased ALT and AST levels and serum miR-155 levels 22846613 620 Human hsa-miR-122 miRNA tolvaptan idiosyncratic drug-induced liver injury (IDILI) primary hepatocytes tolvaptan treatment upregulated 29029277 621 Human hsa-miR-122 miRNA pginterferon (PEG IFN) hepatitis C virus (HCV) infection patients liver IFN treatment upregulated 24612050 622 Human hsa-miR-122 miRNA lipopolysaccharide (LPS) inflammation HaCaT cells lipopolysaccharide (LPS) treatment upregulated 30632205 623 Human hsa-miR-122 miRNA tanshinol (TAN) inflammation LPS-treated HaCaT cells tanshinol (TAN) treatment downregulated 30632205 624 Human hsa-miR-122 miRNA ionic liquids (ILs) Ionic liquids (ILs)-related human health risks HepG2 cells Ionic liquids (ILs) treatment ILs increased the expression of miR-122. 31702098 625 Human hsa-miR-122 miRNA anoxia/reoxygenation (A/R) ischemia/reperfusion (I/R) injury LO2 cell anoxia/reoxygenation (A/R) treatment downregulated 28093198 626 Human hsa-miR-122 miRNA citrus peel flavonoid extracts (CPFE) lipid metabolism HepG2 cells citrus peel flavonoid extracts (CPFE) treatment downregulated 31017523 627 Human hsa-miR-122 miRNA daphnane diterpenoid genkwanine M (GENK) hepatocellular carcinoma (HCC) Huh-7 cells daphnane diterpenoid genkwanine M (GENK) treatment downregulated 22761847 628 Human hsa-miR-122 miRNA heme hepatocellular carcinoma (HCC) Huh?13 cells heme treatment upregulated 23538684 629 Human hsa-miR-122 miRNA IFN-¦Á hepatocellular carcinoma (HCC) ;Huh-7 ; HepG2 Alpha Interferon (IFN-¦Á) treatment downregulated 23055569 630 Human hsa-miR-122 miRNA microcystin-leucine arginine (MC-LR) hepatocellular carcinoma (HCC) WRL-70 cells microcystin-LR treatment downregulated 22265967 631 Human hsa-miR-122 miRNA P body protein LSm1 hepatocellular carcinoma (HCC) Huh7 cells; Huh7.5 cells P body protein LSm1 treatment The P body protein LSm1 contributes to stimulation of hepatitis C virus translation by microRNA-122 24141094 632 Human hsa-miR-122 miRNA sodium selenite hepatocellular carcinoma (HCC) HLF cells sodium selenite treatment upregulated 32656599 633 Human hsa-miR-122 miRNA hepatitis C virus (HCV) liver cirrhosis and hepatocellular carcinoma human hepatocellular carcinoma-derived Huh7; Hep3B; HepG2; embryonic kidney-derived HEK293 ; 293T; lung-derived RERF-LC-AI;NCI-H-2030; A-427; kidney-derived Caki-2 and 769-P; neuron-derived MC-IXC ;SK-PN-DW; uterus-derived Hec1B; ovary-derived SK-OV3; colon-derived SW620; urinary bladder-derived SW780 cells hepatitis C virus (HCV) infection Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus 22593164 634 Human hsa-miR-122 miRNA coptisine (COP) liver damage HepG2 cells; L02 cells coptisine (COP) treatment COP increased the miR-122 level in LPS-treated HepG2 and L02 cells. 29253766 635 Human hsa-miR-122 miRNA hepatitis C virus (HCV) liver fibrosis hepatoma cells hepatitis C virus (HCV) infection upregulated 26157120 636 Human hsa-miR-122 miRNA amoxicillin/clavulanate-induced liver injury (AC-DILI) liver damage Blood and urine amoxicillin/clavulanate-induced liver injury (AC-DILI) treatment upregulated 27785887 637 Human hsa-miR-122 miRNA IFN and ribavirin liver damage HIV-HCV co-infected patients interferon and ribavirin treatment downregulated 24895202 638 Human hsa-miR-122 miRNA paraquat (PQ) liver damage paraquat-exposed individuals liver tissue paraquat (PQ) treatment downregulated 22427142 639 Human hsa-miR-122 miRNA oleanolic acid (OLA) lung cancer "human lung cancer cell lines, A549, NCI-H460, and NCI_x0002_H1299" oleanolic acid (OLA) treatment upregulated 25472877 640 Human hsa-miR-122 miRNA oleanolic acid (OLA) lung cancer lung carcinoma cell lines Oleanolic acid treatment upregulated 25472877 641 Human hsa-miR-122 miRNA ethanol (EtOH) mitochondrial dysfunction human hepatoma cells Ethanol?treatment downregulated 22898980 642 Human hsa-miR-122 miRNA amyloid-¦Â (A¦Â) neuronal cell injury SK-N-SH cells amyloid-¦Â (A¦Â) treatment LncRNA Rpph1 protects amyloid-¦Â induced neuronal injury in SK-N-SH cells via miR-122/Wnt1 axis 31718352 643 Human hsa-miR-122 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 644 Human hsa-miR-122 miRNA compound C nonalcoholic fatty liver disease (NAFLD) HepG2 cells; primary human hepatocytes (HH) compound C treatment downregulated 32143184 645 Human hsa-miR-122 miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) human liver cell line (L02) free fatty acid (FFA) treatment upregulated 31126802 646 Human hsa-miR-122 miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 and Huh-7 cells free fatty acids (FFA) treatment upregulated 31195981 647 Human hsa-miR-122 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) Huh7 cells exosomes palmitic acid (PA) treatment upregulated in exosomes 28623272 648 Human hsa-miR-122 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmitic acid (PA) treatment downregulated 32143184 649 Human hsa-miR-122 miRNA post-bariatric surgery obesity obesity patients serum a 3 months post-bariatric surgery treatment upregulated in serum 29103239 650 Human hsa-miR-122 miRNA propofol (PPF) papillary thyroid cancer (PTC) TPC-1 cells; IHH-4 cells propofol treatment Propofol promoted the expression of miR-122 32432774 651 Human hsa-miR-122 miRNA acetaminophen (APAP) prostate cancer serum acetaminophen (APAP) treatment ?Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients 22045675 652 Human hsa-miR-122 miRNA docetaxel (DTX) prostate cancer LNCaP cells docetaxel (DTX) treatment downregulated 33178345 653 Human hsa-miR-122 miRNA silica lung fibrosis HBE cells silica treatment downregulated 33297121 654 Human hsa-miR-122 miRNA hepatitis C virus (HCV) short bowel syndrome (SBS) human liver hepatitis C virus (HCV) infection downregulated 20625373 655 Human hsa-miR-122 miRNA noncanonical polymerase Gld2 stabilizes specific miRNA populations in human fibroblasts Human primary fibroblasts The noncanonical polymerase Gld2 treatment The noncanonical polymerase Gld2 has been implicated in the stabilization of miR-122 23200856 656 Human hsa-miR-122 miRNA free fatty acids (FFA) steatotic hepatocytes human HCC cell lines HepG2 and Huh7 free fatty acid treatment downregulated 29216638 657 Human hsa-miR-122 miRNA lipopolysaccharide (LPS) triple negative breast cancer (TNBC) HT-29 cells lipopolysaccharide (LPS) treatment downregulated 23872065 658 Human hsa-miR-122 miRNA Roux-en-Y gastric bypass (RYGB) weight loss obese subjects without exercise program plasma RYGB treatment dysregulatedin plasma 28344345 659 Human hsa-miR-122 miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh7.5.1 cells hepatitis C virus (HCV) infection downregulated 23537271 660 Human hsa-miR-122* miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) plasma hepatitis B virus (HBV) infection downregulated 22105822 661 Human hsa-miR-1222-5p miRNA M¦ÂCD-cholesterol nonalcoholic steatohepatitis (NASH) Huh7 cells secreted exosomes M¦ÂCD-cholesterol treatment upregulated 31759057 662 Human hsa-miR-122-3p miRNA glucocorticoid (GC) steroid-induced osteonecrosis of femoral head (ONFH) bone marrow mesenchymal stem cells (BMSCs) glucocorticoid (GC) treatment downregulated 29590087 663 Human hsa-miR-1224 miRNA H2O2 acute liver injury (ALI) L02 cells H2O2 treatment upregulated 30848506 664 Human hsa-miR-1224-3p miRNA bisphenol A (BPA) arterial hypertension urine; whole blood bisphenol A (BPA) treatment upregulated 32438192 665 Human hsa-miR-1224-3p miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 666 Human hsa-miR-1224-3p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 667 Human hsa-miR-1224-3p miRNA proanthocyanidin extract (GSPE) hepatocellular carcinoma (HCC) HepG2 cells proanthocyanidin extract (GSPE) treatment upregulated 21998738 668 Human hsa-miR-1224-5p miRNA radiation chondrosarcoma SW1353 cells radiation treatment upregulated 32362797 669 Human hsa-miR-1224-5p miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 670 Human hsa-miR-1225-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 671 Human hsa-miR-1225-5p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 672 Human hsa-miR-122-5p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment upregulated 28951593 673 Human hsa-miR-122-5p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen (APAP) treatment upregulated 32779042 674 Human hsa-miR-122-5p miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment upregulated 33782973 675 Human hsa-miR-122-5p miRNA resveratrol breast cancer breast cancer cell resveratrol (RS) treatment downregulated 26890143 676 Human hsa-miR-122-5p miRNA resveratrol breast cancer adriamycin-resistant breast cancer cells MCF-7 cells resveratrol (RSV) treatment upregulated 31155753 677 Human hsa-miR-122-5p miRNA chlorpromazine (CHLO) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) treatment downregulated 31198949 678 Human hsa-miR-122-5p miRNA cyclosporine A (CsA) drug-induced liver injury (DILI) upcyte hepatocytes cyclosporine A (CYCA) treatment downregulated 31198949 679 Human hsa-miR-122-5p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 680 Human hsa-miR-122-5p miRNA perfluorooctanoic acid hepatotoxicity occupational workers serum Perfluorooctanoic acid (PFOA) exposure treatment upregulated 24459700 681 Human hsa-miR-122-5p miRNA glucosamine insulin resistance (IR) HepG2 hepatic cells glucosamine treatment upregulated 30958584 682 Human hsa-miR-122-5p miRNA ionizing radiation (IR) low doses hyper-radiosensitivity (LDHRS) DLD-1 cells ionizing radiation (IR) treatment downregulated 29899866 683 Human hsa-miR-122-5p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 684 Human hsa-miR-122-5p miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 29218085 685 Human hsa-miR-122-5p miRNA IFN-¦Ã and lipopolysaccharide (LPS) pancreatic cancer (PC) THP-1 cells lipopolysaccharide; interferon-¦Ã treatment "lncRNA SBF2-AS1 in M2 macrophage-derived exosomes increases miR-122-5p expression to restrain XIAP expression, which further inhibits PC progression." 32301277 686 Human hsa-miR-122-5p miRNA IL-22 psoriatic lesions HaCaT cells IL-22 upregulated 27943426 687 Human hsa-miR-122-5p miRNA radiation rectal injury human intestinal epithelial crypt (HIEC) cells radiation treatment miR-122-5p aggravates radiation-induced rectal injury through targeting CCAR1 32422326 688 Human hsa-miR-122-5p miRNA cadmium (Cd) renal toxic HK-2 cells cadmium (Cd) treatment upregulated 31626960 689 Human hsa-miR-122-5p miRNA curcumin (Cur) schwannoma RT4 schwannoma cells curcumin treatment upregulated 30534000 690 Human hsa-miR-122-5p miRNA coal-burning type fluoride skeletal fluorosis plasma coal-burning type fluoride exposure "In human populations with coal-burning type fluoride exposure, the results showed that miR-122-5p was downregulated" 32572801 691 Human hsa-miR-122-5p miRNA cadmium (Cd) toxic effects of cadmium HK-2 cells cadmium (Cd) treatment upregulated 31626960 692 Human hsa-miR-122-5p miRNA Roux-en-Y gastric bypass (RYGB) type 2 diabetes mellitus (T2DM) patients with T2DM peripheral blood on the peripheral blood microRNAs (miRNAs) of treatment downregulated in the peripheral blood 28273212 693 Human hsa-miR-122-5p miRNA ursolic acid (UA) uric acid nephropathy (UAN) HK-2?cells uric acid treatment miR-122-5p was reduced uric acid-treated HK-2 cells 30347231 694 Human hsa-miR-1228-3p miRNA TGF-¦Â1 chronic kidney disease (CKD) HK-2 cells TGF-¦Â1 treatment Upregulation of miRNA-1228-3p markedly inhibited the progression of renal fibrosis in vitro 32720699 695 Human hsa-miR-1228-5p miRNA particulate matter (PM2.5) non-small cell lung cancer (NSCLC) human A549 cells particulate matter (PM2.5) treatment downregulated 26867688 696 Human hsa-miR-1229 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 697 Human hsa-miR-1229 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 698 Human hsa-miR-1229-5p miRNA occupational noise occupational noise-induced hearing loss (ONIHL) serum occupational noise exposure upregulated 29340520 699 Human hsa-miR-1229-5p miRNA yhexamethylene guanidine phosphate (PHMG-phosphate) lung fibrosis A549 cells yhexamethylene guanidine phosphate (PHMG-phosphate) treatment downregulated 29337256 700 Human hsa-miR-122a miRNA "chenodeoxycholic acid, GW4064" bile acid synthesis human primary hepatocytes "chenodeoxycholic acid, GW4064 treatment" upregulated 20351063 701 Human hsa-miR-122a miRNA fibroblast growth factor ( FGF)19 bile acid synthesis human primary hepatocytes fibroblast growth factor ( FGF)19 treatment upregulated 20351063 702 Human hsa-miR-122a miRNA 5-fluorouracil and ixabepilone breast cancer MDA-MB-453?cells;MDA-kb2 cells 5-FU and ixabepilone treatment upregulated 24396484 703 Human hsa-miR-122a miRNA tumor necrosis factor alpha (TNF-¦Á) intestinal inflammation Caco-2 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 21763238 704 Human hsa-miR-122a miRNA adenovirus (ADV) hepatocellular carcinoma (HCC) Huh7.5 cells; N52.E6 cell line48; CCL-185 cells; CCL 243 cells; CRL 1772 adenovirus vectors treatment miRNA-mediated regulation of antigen expression in the context of adenovirus vectors can significantly improve transgene product-directed immune responses 21556053 705 Human hsa-miR-122a miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment upregulated 24396484 706 Human hsa-miR-1231 miRNA heat stress heat-induced pathophysiology human umbilical vein endothelial cells cultured in the incubator at 43¡ãC for 1 h "downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)" 29039486 707 Human hsa-miR-1234 miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 8¡ã HDT bed rest experiment downregulated 28261104 708 Human hsa-miR-1234 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 709 Human hsa-miR-1236 miRNA "rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" diffuse large B-cell lymphoma (DLBCL) diffuse large B cell lymphoma (DLBCL) patients serum 6 cycles of R-CHOP treatment dysregulated 24858372 710 Human hsa-miR-1236 miRNA hypoxia epithelial-mesenchymal transition (EMT) "Human breast cancer (MCF7), lung cancer (H1299), head and neck cancer (SAS) and embryonic kidney (293T) cell lines" hypoxia treatment downregulated 27177472 711 Human hsa-miR-1236-3p miRNA cisplatin (DDP) lung cancer lung cancer tissues and A549 cell line cisplatin treatment downregulated 30805558 712 Human hsa-miR-1237 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 713 Human hsa-miR-1237-3p miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment miR-1237-3p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs. 33125125 714 Human hsa-miR-1237-3p miRNA vitamin C oxidative stress human umbilical vein endothelial cells (HUVECs) vitamin C treatment miR-1237-3p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2. 33125125 715 Human hsa-miR-1238 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 716 Human hsa-miR-1238 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human thyroid infect with HHV-6A upregulated 28081700 717 Human hsa-miR-1238-2 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 718 Human hsa-miR-1238-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 719 Human hsa-miR-124 miRNA H2O2 acute lung injury (ALI) Beas2B cells H2O2 treatment downregulated 31938089 720 Human hsa-miR-124 miRNA hyperoxia acute lung injury (ALI) Beas2B cells hyperoxia treatment downregulated 31938089 721 Human hsa-miR-124 miRNA Mito-TEMPO acute lung injury (ALI) hyperoxia-/H2O2-treated Beas2B cells Mito-TEMPO treatment upregulated 31938089 722 Human hsa-miR-124 miRNA N-acetyl-L-cysteine (NAC) acute lung injury (ALI) hyperoxia-/H2O2-treated Beas2B cells N-acetyl-L-cysteine (NAC) treatment upregulated 31938089 723 Human hsa-miR-124 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 724 Human hsa-miR-124 miRNA estradiol breast cancer BC cell lines MCF7 and MDA-MB-231 estradiol treatment downregulated 27175587 725 Human hsa-miR-124 miRNA paclitaxel (PTX) breast cancer "Human breast cancer cells, BT474, SKBR3 and MCF7" paclitaxel (PTX) treatment "The miR-124, a tumor suppressive miRNA, was significantly downregulated in Taxol resistant cells." 31367191 726 Human hsa-miR-124 miRNA hepatitis C virus (HCV) chronic hepatitis C virus (HCV) infection Myeloid-derived suppressor cells (MDSCs) chronic hepatitis C virus (HCV) infection downregulated 27753084 727 Human hsa-miR-124 miRNA quercetin chronic kidney disease (CKD) HK-2 cells quercetin (QUE) treatment MyD88 and miR-124 expression was elevated by LPS and alleviated by Quercetin 31804760 728 Human hsa-miR-124 miRNA lipopolysaccharide (LPS) chronic kidney disease (CKD) HK-2 cells lipopolysaccharide (LPS) treatment upregulated 31804760 729 Human hsa-miR-124 miRNA quercetin chronic kidney disease (CKD) LPS-treated HK-2 cells quercetin treatment downregulated 31804760 730 Human hsa-miR-124 miRNA IFN-¦Ã and TNF-¦Á chronic skin inflammation in atopic eczema human keratinocyte IFN-¦Ã and TNF-¦Á downregulated 28847568 731 Human hsa-miR-124 miRNA "2,4,6-trinitrobenzene sulfonic acid (TNBS)" colitis Caco-2 cells and HT-29 cells "2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment" "downregulated or upregulation of miR-124 in TNBS-induced colitic colon alleviated or aggravated experimental colitis, respectively." 26802080 732 Human hsa-miR-124 miRNA 5-aza-2'-deoxycytidine and trichostatin A colonic inflammation Squamous cell carcinoma (SCC) cell line 5-aza-deoxycytidine and trichostatin A treatment downregulated 22828925 733 Human hsa-miR-124 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" colorectal cancer (CRC) Hct-116 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" miR-124 expression was upregulated after 5-AZA-CdR treatment in the Hct-116 cells. 32552060 734 Human hsa-miR-124 miRNA high-intensity focused ultrasound (HIFU) colorectal cancer (CRC) HCT-116 cells High-intensity focused ultrasound (HIFU) induce upregulated 30980700 735 Human hsa-miR-124 miRNA H2O2 cytotoxicity OB-6 cells Hydrogen peroxide (H2O2) treatment upregulated 31955154 736 Human hsa-miR-124 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) "high glucose (25 mmol/L, 1-7 days)" "downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)" 28706953 737 Human hsa-miR-124 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) "Human tongue cancer cell lines, CAL©\27 and SCC©\9" TGF¦Â1 treatment LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling 30635938 738 Human hsa-miR-124 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human RPE cells TGF-¦Â1 treatment downregulated 26746014 739 Human hsa-miR-124 miRNA fluoride fluorosis sodium fluoride (NaF) treated human osteosarcoma (HOS) cells fluoride treatment miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor ¦Ê-B ligand (RANKL) genes 26339601 740 Human hsa-miR-124 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) AGS human gastric cancer cell line "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27041578 741 Human hsa-miR-124 miRNA pemetrexed gastric cancer (GC) Human gastric cancer MGC-803 cells pemetrexed (MTA) treatment "In MGC-803/MTA cells, miR-124 could remarkably increase the resistance of MGC-803/MTA cells to MTA" 31841184 742 Human hsa-miR-124 miRNA phenformin glioblastoma multiforme (GBM) glioma stem cells (GSCs) Phenformin treatment upregulated 27486821 743 Human hsa-miR-124 miRNA H2O2 H2O2-induced apoptosis and oxidative stress human lens epithelial cells (hLEC) H2O2 treatment The H2O2-induced hLEC showed reductions in cell viability with decreased miRNA-124 but increased p-p65 in a dose-/time-dependent manner. 30099456 744 Human hsa-miR-124 miRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) "Hela,HEK293FT,SK-N-SH,SHSY5Y" infect with EV71 upregulated 29120300 745 Human hsa-miR-124 miRNA hepatitis B virus X protein (HBx) HBV-associated hepatocellular carcinoma (HCC) HepG2 cells Hepatitis B virus X protein (HBx) infection HBx upregulated lncRNA-MALAT1 expression while downregulating miR-124 expression in HepG2-X cells. 30500989 746 Human hsa-miR-124 miRNA glucocorticoid (GC) hematological malignancies human embryonic kidney (HEK) 293 and DLBCL cell lines Glucocorticoids (GCs) treatment Our study supports the notion that miR-124 could be an attractive therapeutic target for overcoming GC resistance in DLBCL 25576220 747 Human hsa-miR-124 miRNA citalopram major depressive disorder (MDD) plasma citalopram treatment Plasma miR-124 in the treatment-free MDD and citalopram-treated MDD groups was 1.8-fold and 4-fold that in the control group. 29689690 748 Human hsa-miR-124 miRNA alpinumisoflavone (AIF) melanoma A375 and SK-MEL-1 human melanoma cells alpinumisoflavone (AIF) treatment upregulated 28386327 749 Human hsa-miR-124 miRNA high glucose (HG) diabetes mellitus (DM) human vascular smooth muscle cells (VSMCs) downregulated 29042195 750 Human hsa-miR-124 miRNA mycobacterium bovis bacille Calmette-Gu¨¦rin (BCG) mycobacterium tuberculosis (Mtb) infection A549 alveolar epithelial cells infect with Mycobacterium bovis BCG treatment upregulated 24705038 751 Human hsa-miR-124 miRNA TGF-¦Â nasopharyngeal carcinoma (NPC) 6-10B cells TGF-¦Â treatment TGF-¦Â-induced the suppression of miR-124 in NPC cells 29710466 752 Human hsa-miR-124 miRNA oxygen glucose deprivation (OGD) neonatal hypoxic-ischemic encephalopathy SH-SY5Y Cells oxygen glucose deprivation (OGD) treatment downregulated 31916069 753 Human hsa-miR-124 miRNA niclosamide oral cancer HN6 cells niclosamide treatment upregulated 29251334 754 Human hsa-miR-124 miRNA niclosamide oral cancer WSU-HN6 cells 5 ?M niclosamide upregulated 29251334 755 Human hsa-miR-124 miRNA icariin (ICA) oral squamous cell carcinoma (OSCC) human oral squamous cell carcinoma cells Icaritin?treatment upregulated 27889233 756 Human hsa-miR-124 miRNA dexamethasone (DEX) osteoblast injury OB-6 osteoblastic cells and primary human osteoblasts dexamethasone (DEX) treatment miR-124 accumulated following DEX treatment in OB-6?cells and primary osteoblasts. miR-124 inhibitor attenuated cell death in human osteoblasts. 31242973 757 Human hsa-miR-124 miRNA dihydroartemisinin (DHA) and curcumin (Cur) ovarian cancer (OC) human ovarian cancer SKOV3 cells dihydroartemisinin (DHA) and curcumin (Cur) upregulated 28934730 758 Human hsa-miR-124 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) Human neuroblastoma cell line SH-SY5Y 1-methyl-4-phenylpyridinium (MPP+) treatment miR-124 was a target of NEAT1. Anti-miR-124 could reverse the effects caused by NEAT1 knockdown in MPP+ treated SH-SY5Y cells. 31228597 759 Human hsa-miR-124 miRNA lipopolysaccharide (LPS) parkinson's disease (PD) human neuroblastoma cell lines SH-SY5Y (SH-SY5Y) cells lipopolysaccharide (LPS) treatment downregulated 30995872 760 Human hsa-miR-124 miRNA hypoxia prostate cancer prostate cancer cell lines (DU145 and PC3) hypoxia treatment downregulated 26990493 761 Human hsa-miR-124 miRNA TGF-¦Â prostate cancer "MKN-45, MDA-MB-231, HCT15 and PA1 cell lines" TGF-¦Á treatment downregulated 24969691 762 Human hsa-miR-124 miRNA baicalin (BAI) renal fibrosis HK-2 cells baicalin (BAI) treatment Baicalin prevented renal fibrosis by increasing miR-124 and inactivating downstream TLR4/NF-¦ÊB pathway in DN. 32500512 763 Human hsa-miR-124 miRNA TGF-¦Â1 renal fibrosis HK2 cells TGF-¦Â1 treatment downregulated 29717517 764 Human hsa-miR-124 miRNA ultraviolet (UV) irradiation Skin senescence human epidermal keratinocytes (NHEKs) UVB treatment upregulated 27818465 765 Human hsa-miR-124 miRNA ultraviolet (UV) irradiation skin senescence normal human epidermal keratinocytes (NHEKs) UVB-irradiated treatment upregulated 27818465 766 Human hsa-miR-124 miRNA acute stress stress response mice amygdala acute Stress treatment downregulated 24023867 767 Human hsa-miR-124 miRNA TGF-¦Â1 tongue squamous cell carcinoma (TSCC) "Human tongue cancer cell lines, CAL©\27 and SCC©\9" TGF¦Â1 treatment LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling 30635938 768 Human hsa-miR-124 miRNA nicotine ulcerative colitis (UC) human ulcerative colonic mucosa Nicotine treatment upregulated 27709266 769 Human hsa-miR-124 miRNA high glucose (HG) vascular injury human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 30454897 770 Human hsa-miR-124 miRNA hepatitis B virus X protein (HBx) HBV-associated hepatocellular carcinoma (HCC) HepG2-X cell line was induced by transfect HBx into HepG2 cells. HBx-induce HBx downregulating miR-124 expression in HepG2-X cells. 30500989 771 Human hsa-miR-124-2 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)" bladder cancer BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment" upregulated 23200812 772 Human hsa-miR-1243 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (hRMECs) high glucose treatment circ_0002570 could upregulate angiomotin by targeting miR-1243 to mediate the dysfunction of hRMECs induced by high glucose. 32319024 773 Human hsa-miR-124-3 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)" bladder cancer BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment" upregulated 23200812 774 Human hsa-miR-124-3 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 28958159 775 Human hsa-miR-124-3p miRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment "SNHG14 was boosted in renal tissues of I/R-stimulated rats and H/R-induced HK-2 cells, while miR-124-3p was diminished in H/R-stimulated HK-2 cells." 33490282 776 Human hsa-miR-124-3p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment "LPS induced A549 cells apoptosis and inflammation, wherein SNHG14 was upregulated and miR-124-3p was downregulated." 33652176 777 Human hsa-miR-124-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) "VSMCs were treated with different doses of ox-LDL (0, 25, 50, and 100 mg/L) and for different time points (0, 12, 24, and 48 h) to mimic an in vitro environment of hyperlipidemia." miRNA-124-3p was gradually upregulated in ox-LDL-treated VSMCs. 31696492 778 Human hsa-miR-124-3p miRNA calcium oxalate (CaOx) calcium oxalate (CaOx) nephrolithiasis HK-2 cell calcium oxalate (CaOx) treatment HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis. 31878844 779 Human hsa-miR-124-3p miRNA calcium oxalate monohydrate (COM) calcium oxalate (CaOx) nephrolithiasis calcium oxalate monohydrate (COM)-treated HK-2 cells calcium oxalate monohydrate (COM)-treatment miR©\124©\3p was down©\regulated in calcium oxalate monohydrate (COM)-treated HK-2 cells. 31680444 780 Human hsa-miR-124-3p miRNA cocaine drug addiction differentiated SH-SY5Y neuroblastoma cells cocaine treatment downregulated 30166527 781 Human hsa-miR-124-3p miRNA cisplatin (DDP) gastric cancer (GC) MGC803 cells cisplatin treatment upregulated 33337849 782 Human hsa-miR-124-3p miRNA hydrogen gas (H2) gastric cancer (GC) MGC-803 cells;and BGC-823 cells ?hydrogen treatment "H2?gas significantly inhibited gastric tumor growth in vivo and the proliferation, migration, and lncRNA MALAT1 and EZH2 expression of gastric cancer cells while upregulated miR-124-3p expression" 33482814 783 Human hsa-miR-124-3p miRNA paclitaxel (PTX) gastric cancer (GC) "Human GC tissues and tumor cell lines (MKN-45, HGC-27, MGC-803, and AGS)" paclitaxel (PTX) treatment circ-PVT1 expression was upregulated in PTX-resistant GC tissues and cells. Circ-PVT1 downregulated enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p. 31793989 784 Human hsa-miR-124-3p miRNA amentoflavone (AF) glioblastoma multiforme (GBM) "The glioma cell lines U87, LV229, U251, LN18 and U373" amentoflavone (AF) treatment upregulated 30153494 785 Human hsa-miR-124-3p miRNA sevoflurane (SEV) glioblastoma multiforme (GBM) human glioma cell lines U251 and U87 sevoflurane (SEVO) treatment upregulated 30915607 786 Human hsa-miR-124-3p miRNA hypoxia glioblastoma multiforme (GBM) U251 cells; U87MG cells; A172 cells hypoxia treatment Hypoxia-induced lncRNA PDIA3P1 promotes mesenchymal transition via sponging of miR-124-3p in glioma. 32127518 787 Human hsa-miR-124-3p miRNA midazolam (MDZ) hepatocellular carcinoma (HCC) HepG2 human HCC cells midazolam (MDZ) treatment upregulated 31651086 788 Human hsa-miR-124-3p miRNA suberoylanilide hydroxamic acid (SAHA) hepatocellular carcinoma (HCC) Hep3B and Huh7 HCC cell lines suberanilohydroxamic acid (SAHA) treatment upregulated 31092334 789 Human hsa-miR-124-3p miRNA Japanese encephalitis virus (JEV) Japanese Encephalitis virus (JEV) infection human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses Japanese encephalitis virus (JEV) infection downregulated 31578247 790 Human hsa-miR-124-3p miRNA sevoflurane (SEV) malignant glioma U251 cells; U87 cells sevoflurane treatment Sevoflurane Inhibits Glioma Cells Proliferation and Metastasis through miRNA-124-3p/ROCK1 Axis 30915607 791 Human hsa-miR-124-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) Human-derived cardiomyocytes HCM oxygen-glucose deprivation and reoxygenation (OGD/R) treatment circHIPK3 overexpression reversed the protective effects of miRNA-124-3p on myocardial I/R and cardiomyocyte apoptosis 31799682 792 Human hsa-miR-124-3p miRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) The human cardiac myocyte (HCM) cell line HCMs were exposed to hypoxic conditions for 2?h followed by re-oxygenation (H/R) treatment. "miR-124-3p was significantly downregulated in both MIRI rat model and H/R treated HCMs.?Overexpression of miR-124-3p reversed the H/R-induced cell apoptosis and upregulation of TNF-¦Á, IL-6, and IL-1¦Â." 31768721 793 Human hsa-miR-124-3p miRNA ¦Ã- Mangostin (¦Ã-MS) osteoarthritis (OA) SW984 cells ¦Ã- Mangostin (¦Ã-MS) treatment upregulated 32302289 794 Human hsa-miR-124-3p miRNA 6-hydroxydopamine (6-OHDA) parkinson's disease (PD) SH-SY5Y cells 6-hydroxydopamine (6-OHDA) treatment downregulated 28543594 795 Human hsa-miR-124-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment "We demonstrated that, in SH-SY5Y cells treated with MPP+, NEAT1 and PDE4B expression levels were raised, while miR-124-3p expression was repressed" 33522352 796 Human hsa-miR-124-3p miRNA 6-hydroxydopamine (6-OHDA) parkinson's disease (PD) SH-SY5Y cells 6-hydroxydopamine (6-OHDA) treatment downregulated 28543594 797 Human hsa-miR-124-3p miRNA polystyrene (PSNPs) toxicity of nanoparticles THP-1 cells polystyrene (PSNPs) treatment downregulated 32284792 798 Human hsa-miR-124-3p miRNA Roux-en-Y gastric bypass (RYGB) type 2 diabetes mellitus (T2DM) patients with T2DM peripheral blood on the peripheral blood microRNAs (miRNAs) of treatment downregulated in the peripheral blood 28273212 799 Human hsa-miR-124-3p.1 miRNA propofol (PPF) colorectal cancer (CRC) RKO cell; HCT116 cells Propofol treatment Propofol treatment evidently enhanced the expression of miR- 124-3p1 31894425 800 Human hsa-miR-1244 miRNA statins atherosclerosis (AS) peripheral blood mononuclear cells (PBMCs) statins? treatment upregulated 32885808 801 Human hsa-miR-1244 miRNA estradiol endothelial dysfunction human umbilical vein endothelial cells (HUVEC) estradiol treatment downregulated 29510375 802 Human hsa-miR-1244 miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) HK1 cell line concentration treatment dysregulated 24896104 803 Human hsa-miR-1244 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NSCLC patients NSCLC tissue cisplatin treatment downregulated 28498474 804 Human hsa-miR-124-5p miRNA cocaine drug addiction differentiated SH-SY5Y neuroblastoma cells cocaine treatment downregulated 30166527 805 Human hsa-miR-124-5p miRNA 5-fluorouracil (5-Fu) non-small cell lung cancer (NSCLC) A549 cells 5-fluorouracil (5-FU) treatment A decrease in miR-124-5p expression level was observed in A549/5-FU cells compared with the parental A549 cells. 33240411 806 Human hsa-miR-1246 miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment upregulated 30253370 807 Human hsa-miR-1246 miRNA ultraviolet (UV) irradiation apoptosis HaCaT cells UV irradiation treatment upregulated 24880483 808 Human hsa-miR-1246 miRNA curcumin (Cur) bladder cancer "T24 cells, SV-HUC-1 cells, HT-1376 cells" curcumin treatment downregulated 31236854 809 Human hsa-miR-1246 miRNA curcumin (Cur) corneal neovascularization (CNV) HUVECs curcumin treatment upregulated 27625050 810 Human hsa-miR-1246 miRNA lipopolysaccharide (LPS) corneal neovascularization (CNV) human corneal fibroblasts (HCFs) lipopolysaccharide (LPS) treatment downregulated 30328354 811 Human hsa-miR-1246 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" glioblastoma multiforme (GBM) U87 cells; U118 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" miR-1246 was increased in the glioma cell lines treated with 5-Aza. 33153768 812 Human hsa-miR-1246 miRNA hypoxia glioblastoma multiforme (GBM) The human GBM cell lines U87MG and U251 exosomes hypoxia induce upregulated 31485019 813 Human hsa-miR-1246 miRNA hypoxia glioblastoma multiforme (GBM) U87 cells; U251 cells hypoxia treatment upregulated 31485019 814 Human hsa-miR-1246 miRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) LO2 cells hypoxia induce downregulated 31709894 815 Human hsa-miR-1246 miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 816 Human hsa-miR-1246 miRNA tetrandrine hypertrophic scars (HS) human hypertrophic scar fibroblasts (HSFs) tetrandrine treatment downregulated 26909951 817 Human hsa-miR-1246 miRNA "myclobutanil, propiconazole, and triadimefon" hepatocellular carcinoma (HCC) HepG2 cells "myclobutanil, propiconazole, and triadimefon treatment" downregulated 23159985 818 Human hsa-miR-1246 miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 819 Human hsa-miR-1246 miRNA lipopolysaccharide (LPS) lung injury human PMVECs lipopolysaccharide (LPS) treatment upregulated 28386354 820 Human hsa-miR-1246 miRNA metformin (Met) melanoma "The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951" Metformin treatment upregulated 30754729 821 Human hsa-miR-1246 miRNA radiation non-small cell lung cancer (NSCLC) A549 cells; PC9 cells radiation treatment Both intracellular and extracellular miR-1246 was found to be upregulated after irradiation in a time-dependent pattern 32064170 822 Human hsa-miR-1246 miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human CHON-001 cells lipopolysaccharide (LPS) treatment "CAIF overexpression inhibited the apoptosis of CHON-001 cells under LPS treatment, while miR-1246 overexpression attenuated the effects of CAIF overexpression." 31653823 823 Human hsa-miR-1246 miRNA hypoxia preeclampsia (PE) primary human cytotrophoblasts hypoxia induce downregulated 29546425 824 Human hsa-miR-1246 miRNA photodynamic therapy (PDT) skin cancer ATCC-No. CRL-1555 cells Photodynamic therapy (PDT) treatment upregulated 23466801 825 Human hsa-miR-1246 miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment upregulated 26640557 826 Human hsa-miR-1246 miRNA enterovirus 71 (EV71) viral encephalitis in children human neuroblastoma SH-SY5Y cells HEV71-infected treatment upregulated 24739954 827 Human hsa-miR-1247 miRNA lipopolysaccharide (LPS) acute pneumonia A549 cells lipopolysaccharide (LPS) treatment miR-1247 was decreased expression after LPS treatment. 30378300 828 Human hsa-miR-1247 miRNA curcumin (Cur) prostate cancer DU145 cells; 22Rv1 cells curcumin treatment upregulated 29172709 829 Human hsa-miR-1247 miRNA curcumin (Cur) prostate cancer HuPCaSC lines DU145 and 22Rv1 curcumin treatment dysregulated 29172709 830 Human hsa-miR-1247-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hepatocellular carcinoma (HCC) HepG2 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28586038 831 Human hsa-miR-1247-5p miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 29218085 832 Human hsa-miR-1247-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 833 Human hsa-miR-1248 miRNA lipopolysaccharide (LPS) acute inflammatory response HMEEC lipopolysaccharide (LPS) treatment upregulated 21377743 834 Human hsa-miR-1249 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 835 Human hsa-miR-124a miRNA lipopolysaccharide (LPS) acute-on-chronic liver failure (ACLF) U937 and HepG2 cells lipopolysaccharide (LPS) treatment upregulated 31628069 836 Human hsa-miR-124a miRNA lipopolysaccharide (LPS) acute-on-chronic liver failure (ACLF) U937 cells; HepG2 cells lipopolysaccharide (LPS) treatment upregulated 31628069 837 Human hsa-miR-124a miRNA atorvastatin hypercholesterolemia HepG2 cells atorvastatin treatment downregulated 25926069 838 Human hsa-miR-124a miRNA laquinimod multiple sclerosis (MS) human microglia laquinimod treatment upregulated 25356411 839 Human hsa-miR-124a miRNA glucocorticoid (GC) neuronal development NS1 cells;A549 cells;COS-1cells Glucocorticoids (GCs) treatment upregulated 19131573 840 Human hsa-miR-124a miRNA CoCl2 neuronal differentiation human mesenchymal stem cells CoCl2 treatment upregulated 24491559 841 Human hsa-miR-124a miRNA liraglutide nonalcoholic fatty liver disease (NAFLD) palmitate-treated normal human liver cell line (HL-7702) liraglutide treatment downregulated 30861258 842 Human hsa-miR-124a miRNA palmitate nonalcoholic fatty liver disease (NAFLD) normal human liver cell line (HL-7702) palmitate treatment upregulated 30861258 843 Human hsa-miR-124a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27824863 844 Human hsa-miR-124a miRNA geniposide (GEN) rheumatoid arthritis (RA) MH7A cells geniposide (GE) treatment GE upregulated the expression of miRNA-124a and decreased the expression of Itg¦Â1 at the mRNA and protein levels. 30342345 845 Human hsa-miR-125 miRNA "androgen receptor (AR) agonist, CI-4AS-1" breast cancer luminal MCF-7 and T47D cells and the molecular apocrine MDA-MB-453 cells. CI-4AS-1 treatment downregulated 28816390 846 Human hsa-miR-125 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U-87 cells; A172 cells temozolomide (TMZ) treatment downregulated 32279420 847 Human hsa-miR-1252 miRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3 cells; HeyA-8 cells paclitaxel (PTX) treatment downregulated 31945729 848 Human hsa-miR-1252 miRNA paclitaxel (PTX) ovarian cancer (OC) ovarian cancer cells (SKOV3/PTX and HeyA-8/PTX) paclitaxel (PTX) treatment circCELSR1 acts as a sponge for miR-1252 and verified that forkhead box 2 (FOXR2) is a novel target of miR-1252 31945729 849 Human hsa-miR-125-3p miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 850 Human hsa-miR-125-3p miRNA selenium nanoparticles (SeNPs) prostate cancer LNCaP cells; LNCaP-A cells Selenium nanoparticles (SeNPs) treatment upregulated 33604641 851 Human hsa-miR-1255a miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed upregulated 27915273 852 Human hsa-miR-1255b-5p miRNA hypoxia lung cancer A549 cells hypoxia treatment downregulated 27524914 853 Human hsa-miR-1256 miRNA isoflavone apoptosis PCa cells isoflavone? treatment downregulated 22805767 854 Human hsa-miR-1257 miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MDA-MB-231 cells anacardic acid (AnAc) treatment upregulated 28886127 855 Human hsa-miR-1257 miRNA MLN4924/Pevonedistat breast cancer MCF-7 cells MLN4924/Pevonedistat treatment miR-miR-1257 was significantly decreased after MLN4924 treatment in breast cancer cells. 32360865 856 Human hsa-miR-125a miRNA high glucose (HG) acute coronary syndrome (ACS) Human Macrophages high glucose treatment upregulated 27519051 857 Human hsa-miR-125a miRNA adriamycin (ADR) acute myeloid leukemia (AML) HL60 cells adriamycin (ADR) treatment miR-125a expression was markedly lower in HL60/ADR cells than HL60 cells. 29663500 858 Human hsa-miR-125a miRNA macrophage colony stimulating factor (M-CSF) bone formation CD14+ peripheral blood mononuclear cells (PBMCs) macrophage colony stimulating factor (M-CSF) treatment downregulated 24360988 859 Human hsa-miR-125a miRNA receptor activator of nuclear factor-¦ÊB ligand (RANKL) bone formation CD14+ peripheral blood mononuclear cells (PBMCs) receptor activator of nuclear factor-¦ÊB ligand (RANKL) treatment downregulated 24360988 860 Human hsa-miR-125a miRNA cisplatin (DDP) breast cancer Human umbilical vein endothelial cells (HUVECs) cisplatin (DPP) treatment downregulated 30670152 861 Human hsa-miR-125a miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment downregulated 25120778 862 Human hsa-miR-125a miRNA entinostat breast cancer MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells entinostat treatment downregulated 23519125 863 Human hsa-miR-125a miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment downregulated 20346162 864 Human hsa-miR-125a miRNA paclitaxel (PTX) cervical cancer (CC) CC cell lines paclitaxel treatment downregulated 26878391 865 Human hsa-miR-125a miRNA TGF-¦Â glioblastoma multiforme (GBM) "LN15, LN18, LN229, U138, U87, U251 cell lines" TGF-¦Â treatment downregulated 25256711 866 Human hsa-miR-125a miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HuH-7 and HepG2 HCC cells sorafenib treatment upregulated 27982429 867 Human hsa-miR-125a miRNA hepatitis B virus X protein (HBx) hepatocyte death and liver damage immortalized liver (L-O2) and HepG2 cell lines Hepatitis B virus X protein (HBx) treatment upregulated 25993287 868 Human hsa-miR-125a miRNA "15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2)" angiogenesis human umbilical vein endothelial cells "15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2) treatment" upregulated 27836539 869 Human hsa-miR-125a miRNA IL-1¦Â inflammatory response monocytes IL-1¦Â treatment upregulated 30245693 870 Human hsa-miR-125a miRNA lipopolysaccharide (LPS) inflammatory response monocytes lipopolysaccharide (LPS) treatment upregulated 30245693 871 Human hsa-miR-125a miRNA TLR2 agonist pam3CSK4 inflammatory response monocytes TLR2 agonist pam3CSK4 treatment upregulated 30245693 872 Human hsa-miR-125a miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment upregulated 19022373 873 Human hsa-miR-125a miRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) nasopharyngeal tissues and matched adjacent nasopharyngeal tissues cisplatin treatment upregulated 26017674 874 Human hsa-miR-125a miRNA radiation non-small cell lung cancer (NSCLC) A549; LTEP-a2 cells radiation exposure treatment MicroRNA-125a-5p modulates radioresistance in LTEP-a2 non-small cell lung cancer cells by targeting SIRT7 31683458 875 Human hsa-miR-125a miRNA curcumin (Cur) osteosarcoma (OS) osteosarcoma cell lines U2OS and MG63 curcumin in indicated concentrations upregulated 27231954 876 Human hsa-miR-125a miRNA curcumin (Cur) osteosarcoma (OS) U2OS cells curcumin treatment upregulated 27231954 877 Human hsa-miR-125a miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment H2O2 induced TrxR1 expression partly through downregulated of miR-125a. 30225271 878 Human hsa-miR-125a-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 879 Human hsa-miR-125a-3p miRNA nonylphenol (NP) tumorigenesis Sertoli TM4 cells nonylphenol (NP) treatment upregulated 21914226 880 Human hsa-miR-125a-3p miRNA LukS-PV cell differentiation and apoptosis human monocytic leukaemia cell line THP-1 LukS-PV upregulated 29179212 881 Human hsa-miR-125a-3p miRNA epigallocatechin-3-gallate (EGCG) non-small cell lung cancer (NSCLC) NCI-H460 cells and another kind of NSCLC cells EGCG treatment upregulated 24712372 882 Human hsa-miR-125a-3p miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 883 Human hsa-miR-125a-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 884 Human hsa-miR-125a-3p miRNA hypoxia pancreatic cancer (PC) "pancreatic cancer cell lines SW1990, Capan-1, PANC-1, AsPC-1, CFPAC-1, MIAPaCa-2, and BxPC-3" 1% O2 downregulated 29121972 885 Human hsa-miR-125a-3p miRNA TGF-¦Â1 lung fibrosis MRC-5 cells TGF-¦Â1 treatment downregulated 30658076 886 Human hsa-miR-125a-5p miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 887 Human hsa-miR-125a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (oxLDL) treatment upregulated 30370524 888 Human hsa-miR-125a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 30370524 889 Human hsa-miR-125a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human vascular smooth muscle cells (HVSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31410121 890 Human hsa-miR-125a-5p miRNA p-Coumaric acid (p-CA) autoimmune hepatitis (AIH) SNU-16 cells p-Coumaric acid (p-CA) treatment upregulated 32462517 891 Human hsa-miR-125a-5p miRNA histone deacetylase inhibitor (HDACi) breast cancer human breast cancer cells Histone deacetylase inhibitors (HDACi) treatment downregulated 25531695 892 Human hsa-miR-125a-5p miRNA histone deacetylase inhibitor (HDACi) breast cancer MDA-MB-231 human breast cancer cell line HDACi treatment downregulated 25531695 893 Human hsa-miR-125a-5p miRNA tamoxifen (TAM) breast cancer tamoxifen resistant MCF7 cell lines (MCF7/TAM1 and MCF7/TAM2) tamoxifen treatment downregulated 31894257 894 Human hsa-miR-125a-5p miRNA tamoxifen (TAM) breast cancer MCF7 / TAM2; MCF7 / TAM1 tamoxifen treatment downregulated 31894257 895 Human hsa-miR-125a-5p miRNA propofol (PPF) cervical cancer (CC) A2780 cells; SKOV3 cells propofol treatment Propofol significantly upregulated miR-125a-5p to exert its antitumor activity 32627014 896 Human hsa-miR-125a-5p miRNA schisandrin B (Sch B) glioblastoma multiforme (GBM) U251 and U87 cells Sch B treatment upregulated 27977512 897 Human hsa-miR-125a-5p miRNA oxidized low density lipoprotein (ox-LDL) Marek's disease (MD) primary peripheral blood monocytes oxidized low-density lipoprotein (ox-LDL) treatment upregulated 19377067 898 Human hsa-miR-125a-5p miRNA bevacizumab and FOLFOX metastatic colorectal cancer (mCRC) mCRC patients tumor tissue bevacizumab/FOLFOX upregulated 28693229 899 Human hsa-miR-125a-5p miRNA IFNs monocytic differentiation monocyte IFNs treatment dysregulated 25148686 900 Human hsa-miR-125a-5p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) HK1 cell line concentration treatment dysregulated 24896104 901 Human hsa-miR-125a-5p miRNA gefitinib nasopharyngeal carcinoma (NPC) "HNE-1 cells,HK-1 cells" geftinib treatment upregulated 24602316 902 Human hsa-miR-125a-5p miRNA cisplatin (DDP) osteosarcoma (OS) U2-OS and Saos-2 osteosarcoma cell lines cisplatin (DPP) treatment MiR-125a-5p inhibitor attenuated ANRIL knockdown-induced chemosensitivity to cisplatin. 30777616 903 Human hsa-miR-125a-5p miRNA imiquimod (IMQ) psoriasis HaCaT cells ?imiquimod treatment downregulated 33948156 904 Human hsa-miR-125a-5p miRNA "isoniazid, pyrazinamide and ethambutol" pulmonary tuberculosis (PTB) serum "isoniazid, pyrazinamide and ethambutol treatment" miR-125a-5p was upregulated in treated patients when compared with untreated patients. 29523324 905 Human hsa-miR-125a-5p miRNA cisplatin (DDP) and?thiosemicarbazone compound 4 triple negative breast cancer (TNBC) MDA-MB 231 breast cancer cell line Cisplatin?+?thiosemicarbazone compound 4 treatment upregulated 31541355 906 Human hsa-miR-125a-5p miRNA dioscin type 2 diabetes mellitus (T2DM) insulin-treated HepG2 cells dioscin treatment upregulated 31881477 907 Human hsa-miR-125a-5p miRNA dioscin type 2 diabetes mellitus (T2DM) palmitic acid-treated AML12 cells dioscin treatment upregulated 31881477 908 Human hsa-miR-125a-5p miRNA insulin type 2 diabetes mellitus (T2DM) HepG2 cells insulin treatment downregulated 31881477 909 Human hsa-miR-125a-5p miRNA palmitic acid (PA) type 2 diabetes mellitus (T2DM) AML12 cells palmitic acid treatment downregulated 31881477 910 Human hsa-miR-125a-5p miRNA dioscin type 2 diabetes mellitus (T2DM) HepG2 cells dioscin treatment Dioscin was found to markedly elevate miR-125a-5p level and decrease STAT3 expression. 31881477 911 Human hsa-miR-125a-5p miRNA oxidized low density lipoprotein (ox-LDL) vascular disease human brain microvessel endothelial cells (HBMEC) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 27903586 912 Human hsa-miR-125b miRNA "1,24-dihydroxyvitamin D 3 (tacalcitol)" breast cancer MCF-7 cells "1,24-dihydroxyvitamin D3 (tacalcitol) treatment" downregulated 30503385 913 Human hsa-miR-125b miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" breast cancer MCF-7 cells "1,25-dihydroxyvitamin D3 (calcitriol) treatment" downregulated 30503385 914 Human hsa-miR-125B miRNA transcription factor NRF2 acute myeloid leukemia (AML) peripheral blood Transcription factor NRF2 treatment upregulated 25323587 915 Human hsa-miR-125b miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning downregulated 30602960 916 Human hsa-miR-125b miRNA H2O2 age-related macular degeneration (AMD) human retinal pigment epithelial (RPE) cell H2O2 treatment miR-125b is induced by H2O2 treatments in RPE cells. 29631677 917 Human hsa-miR-125b miRNA lipopolysaccharide (LPS) allergic airway inflammation normal human tracheal epithelial (HTEpC) and A549 cells lipopolysaccharide (LPS) treatment downregulated 27112664 918 Human hsa-miR-125b miRNA epigallocatechin-3-gallate (EGCG) Alzheimer's disease (AD) SH-SY5Y cells 32mol/L EGCG downregulated 28731435 919 Human hsa-miR-125b miRNA metal Alzheimer's disease (AD) human astroglial (HAG) metal sulfate treatment upregulated 22099153 920 Human hsa-miR-125b miRNA metal Alzheimer's disease (AD) human astroglial (HAG) metal sulfate treatment upregulated 22099153 921 Human hsa-miR-125b miRNA platelet derived growth factor-BB (PDGF-BB) arteriosclerosis obliterans (ASO) vascular smooth muscle cells (VSMCs) platelet-derived growth factor (PDGF)-BB treatment downregulated 29689557 922 Human hsa-miR-125b miRNA dexamethasone (DEX) B-cell malignant multiple myeloma£¨MM£© MM cells dexamethasone (DEX) treatment upregulated 23759586 923 Human hsa-miR-125b miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" breast cancer MCF-7 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 30503385 924 Human hsa-miR-125b miRNA aidi injection (ADI) breast cancer MCF-7 cells aidi Injection (ADI) upregulated 21563499 925 Human hsa-miR-125b miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment downregulated 25120778 926 Human hsa-miR-125b miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment upregulated 33159957 927 Human hsa-miR-125b miRNA entinostat breast cancer MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells entinostat treatment downregulated 23519125 928 Human hsa-miR-125b miRNA trastuzumab breast cancer SKBR-3-TR and BT474-TR cell lines Trastuzumab treatment downregulated 30621694 929 Human hsa-miR-125b miRNA proteinase activated receptor 2 (PAR2) tumorigenesis human colorectal carcinoma Proteinase activated-receptor 2 (PAR2) treatment downregulated 26354435 930 Human hsa-miR-125b miRNA camptothecin cancer cell apoptosis PC3 cells; K562 cells; CCRF-CEM cells; NCI-H1299 cells; HCT-15 cells;HBE cells; RBE cells camptothecin treatment downregulated 22252650 931 Human hsa-miR-125b miRNA ultraviolet (UV) irradiation cataract SRA01/04 cell 15W UVB lamps treatment downregulated 25312242 932 Human hsa-miR-125b miRNA ultraviolet (UV) irradiation cell cycle arrest "Human embryonic kidney cell line HEK293, human colon cancer cell line HCT116,human osteosarcoma cell line U2OS and Human keratinocyte cell line HaCaT" ultraviolet radiation (UV) treatment UV radiation induces upregulated of miR-125b 22854965 933 Human hsa-miR-125b miRNA proline-rich polypeptide 1 (PRP-1) chondrosarcoma human JJ012 chondrosarcoma cell line PRP-1 treatment upregulated 24178909 934 Human hsa-miR-125b miRNA hepatitis C virus (HCV) chronic hepatitis C virus (HCV) infection HCV replicon cells Con1 (type 1b) and Huh7/Ava5 (type 1b) and sera from HCV-infected patients hepatitis C virus (HCV) infection upregulated 29541414 935 Human hsa-miR-125b miRNA rituximab (RTX) chronic lymphocytic leukemia (CLL) CD19 cells of CML patients rituximab treatment downregulated 28126961 936 Human hsa-miR-125b miRNA granulocyte-colony stimulating factor (G-CSF) colorectal cancer (CRC) "human CRC cell line HCT-8, SW480, SW620, HCT-116, LOVO" Granulocyte colony-stimulating factor?treatment upregulated 28881590 937 Human hsa-miR-125b miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 renal tubular epithelial cells high glucose treatment upregulated 27775793 938 Human hsa-miR-125b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) "high glucose (25 mmol/L, 1-7 days)" "downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)" 28706953 939 Human hsa-miR-125b miRNA high glucose (HG) diabetic retinopathy (DR) human retina microvascular endothelial cells (hRMECs) high glucose (HG) treatment downregulated 30988072 940 Human hsa-miR-125b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial (RPE) cells high glucose (HG) treatment miR-125b expressions were significantly downregulated by the high glucose treatments. 31938439 941 Human hsa-miR-125b miRNA tumor necrosis factor alpha (TNF-¦Á) encephalitis SH-SY5Y cells tumor necrosis factor alpha (TNF-¦Á) treatment Overexpression of circARF3 mitigates TNF-¦Á-induced inflammatory damage by up-regulating miR-125b. 32329660 942 Human hsa-miR-125b miRNA cocaine viral replication CD4+ T cells Cocaine treatment downregulated 23251514 943 Human hsa-miR-125b miRNA reactive oxygen species (ROS) Epstein-Barr virus (EBV) infection ovarian cancer cells reactive oxygen species (ROS) treatment downregulated 23146892 944 Human hsa-miR-125b miRNA phorbol-12-myristate-13-acetate(PMA) functions of human macrophages U937 cells phorbol 12-myristate 13-acetate (PMA) treatment upregulated 33268675 945 Human hsa-miR-125b miRNA curcumin (Cur) thyroid cancer (TC) "human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101" curcumin treatment downregulated 28265769 946 Human hsa-miR-125b miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" glioblastoma multiforme (GBM) MCF-7 cells "1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))?treatment" upregulated 19437538 947 Human hsa-miR-125b miRNA arsenic trioxide (ATO) glioblastoma multiforme (GBM) human glioma U251 cells arsenic trioxide (As2O3) treatment downregulated 24479808 948 Human hsa-miR-125b miRNA heroin human immunodeficiency virus (HIV)-1 infection Peripheral blood Heroin treatment downregulated 26583016 949 Human hsa-miR-125b miRNA morphine human immunodeficiency virus (HIV)-1 infection peripheral blood mononuclear cells(PBMCs) morphine treatment downregulated 21224041 950 Human hsa-miR-125b miRNA heat shock factor 1 (HSF1) huntington's disease (HD) Blood Heat shock factor 1 (HSF1) treatment downregulated 26634350 951 Human hsa-miR-125b miRNA propranolol (PRO) infantile hemangioma (IH) hemangioma endothelial cells propranolol treatment upregulated 30986805 952 Human hsa-miR-125b miRNA estradiol-17¦Â (E2) inflammation human macrophages estradiol-17¦Â (E2) treatment "LPS induces let-7a and inhibits miR-125b expression in human macrophages, and pretreatment with estradiol abrogates these effects" 20351193 953 Human hsa-miR-125b miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" leukemia U937 and HL60 cells2 "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 28389358 954 Human hsa-miR-125b miRNA daunorubicin leukemia leukemia cell lines on the resistance to the chemotherapeutic agent treatment upregulated 24604579 955 Human hsa-miR-125b miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 956 Human hsa-miR-125b miRNA TGF-¦Â liver fibrosis LX2 cells TGF-¦Â treatment downregulated 31548167 957 Human hsa-miR-125b miRNA 5-fluorouracil/cisplatin (CDDP-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) CDDP-CRTX treatment dysregulated 28347920 958 Human hsa-miR-125b miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 959 Human hsa-miR-125b miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" macrophage polarization LPS-treated THP-1 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 30540970 960 Human hsa-miR-125b miRNA lipopolysaccharide (LPS) macrophage polarization THP-1 cells lipopolysaccharide (LPS) treatment upregulated 30540970 961 Human hsa-miR-125b miRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) nasopharyngeal tissues and matched adjacent nasopharyngeal tissues cisplatin treatment upregulated 26017674 962 Human hsa-miR-125b miRNA tanshinone IIA (Tan IIA) nasopharyngeal carcinoma (NPC) HK1 cells tanshinone IIA treatment the present study demonstrates that tanshinone IIA enhances pyroptosis and inhibits the proliferation of HK1 cells by modulating miR-125b/foxp3/caspase-1/GSDMD signaling 33760137 963 Human hsa-miR-125b miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 964 Human hsa-miR-125b miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 965 Human hsa-miR-125b miRNA osimertinib non-small cell lung cancer (NSCLC) H1975 cells osimertinib treatment The relative expression levels of miR-125b was significantly upregulated after treated with 100 nM osimertinib for 24 h. 32375124 966 Human hsa-miR-125b miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 967 Human hsa-miR-125b miRNA "dexamethasone (DEX), ascorbic acid, and ¦Â-glycerol phosphate" PDLCs osteoblastic differentiation periodontal ligament cells (PDLCS) "dexamethasone, ¦Â-glycerol phosphate and ¦Á-ascorbic acid treatment" miR-125b was downregulated during the process of ostoblast differentiation of PDLCs. 30078007 968 Human hsa-miR-125b miRNA decitabine precursor B-cell acute lymphoblastic leukemia (B-ALL) Nalm6 cell line decitabine treatment downregulated 30912184 969 Human hsa-miR-125b miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" prostate cancer ?primary prostatic epithelial cells (PrE) "?1,25-dihydroxyvitamin D" downregulated 23503652 970 Human hsa-miR-125b miRNA capecitabine rectal cancer rectal cancer tissue capecitabine treatment upregulated 18695884 971 Human hsa-miR-125b miRNA trichostatin A (TSA) systemic sclerosis (SSc) primary dermal fibroblasts trichostatin A treatment downregulated 31309742 972 Human hsa-miR-125b miRNA tubastatin A systemic sclerosis (SSc) primary dermal fibroblasts tubastatin A treatment downregulated 31309742 973 Human hsa-miR-125b miRNA glucosamine type 2 diabetes mellitus (T2DM) HepG2 cells glucosamine treatment upregulated 29319168 974 Human hsa-miR-125b miRNA tumor necrosis factor alpha (TNF-¦Á) type 2 diabetes mellitus (T2DM) HepG2 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29319168 975 Human hsa-miR-125b miRNA phosphorus (Pi) vascular calcification (VC) human aortic vascular smooth muscle cells high levels of phosphate treatment downregulated 28522697 976 Human hsa-miR-125b miRNA lipopolysaccharide (LPS) oral lichen planus (OLP) keratinocytes HaCaT lipopolysaccharide (LPS) treatment downregulated 27133077 977 Human hsa-miR-125b miRNA homocysteine (Hcy) vascular smooth muscle cell proliferation vascular smooth muscle cells homocysteine treatment downregulated 27426728 978 Human hsa-miR-125b-1* miRNA leuprolide endometriosis endometriotic tissues Leuprolide treatment upregulated 27709720 979 Human hsa-miR-125b-1-3p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 980 Human hsa-miR-125b-1-3p miRNA cortisol schizophrenia (SZ) "The immortalized multipotent, human hippocampal progenitor cell line, HPC0A07/03C (propriety of ReNeuron)" HPC0A07/03C cells were treated with the stress hormone cortisol (100 ¦ÌM) or vehicle for 3 days during the proliferation stage (to mimic the early stress exposure) downregulated 30057098 981 Human hsa-miR-125b-2 miRNA androgen prostate cancer prostate cancer cells androgen treatment downregulated 23503464 982 Human hsa-miR-125b-5p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment upregulated 28951593 983 Human hsa-miR-125b-5p miRNA IL-1¦Â arthritis human osteoarthritic (OA) chondrocytes IL-1¦Â treatment downregulated 31053727 984 Human hsa-miR-125b-5p miRNA resveratrol breast cancer breast cancer cell resveratrol (RS) treatment downregulated 26890143 985 Human hsa-miR-125b-5p miRNA brucella.suis brucellosis HEK293T cell lines Brucella infection treatment downregulated 27473222 986 Human hsa-miR-125b-5p miRNA sevoflurane (SEV) cognitive impairment SH-SY5Y cells Sevoflurane treatment upregulated 31490755 987 Human hsa-miR-125b-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT116 cells; HCT8 cells; HT29 cells 5-fluorouracil (5-FU) treatment downregulated 31746054 988 Human hsa-miR-125b-5p miRNA cisplatin (DDP) colorectal cancer (CRC) SW480 cells cisplatin treatment downregulated 32766131 989 Human hsa-miR-125b-5p miRNA oxaliplatin colorectal cancer (CRC) HCT116 cells; HCT8 cells; HT29 cells oxaliplatin treatment downregulated 31746054 990 Human hsa-miR-125b-5p miRNA high glucose (HG) diabetic retinopathy (DR) ARPE©\19 cells high glucose treatment downregulated 31094072 991 Human hsa-miR-125b-5p miRNA oral zinc gluconate esophageal cancer (EC) barrett's esophagus (BE) oral zinc gluconate treatment upregulated 32415564 992 Human hsa-miR-125b-5p miRNA TGF-¦Â1 hepatocarcinogenesis Hep3B cells TGF-¦Â1 treatment upregulated 32269736 993 Human hsa-miR-125b-5p miRNA IL-1¦Â lumbar disc degeneration (LDD) human lumbar degenerative NP specimens and IL-1¦Â-treated NP cells IL-1¦Â? treatment miR-125b-5p was markedly upregulated in both human lumbar degenerative NP specimens and IL-1¦Â-treated NP cells. 33123835 994 Human hsa-miR-125b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY6Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 32057951 995 Human hsa-miR-125b-5p miRNA respiratory syncytial virus (RSV) respiratory syncytial virus (RSV)-associated pneumonia whole blood respiratory syncytial virus (RSV) infection treatment upregulated 32410870 996 Human hsa-miR-125b-5p miRNA infliximab rheumatoid arthritis (RA) serological infliximab treatment upregulated 25860297 997 Human hsa-miR-125b-5p miRNA bortezomib cutaneous T-cell lymphoma (CTCL) MyLa2000 and SeAx ?bortezomib treatment upregulated 23527180 998 Human hsa-miR-126 miRNA arsenic trioxide (ATO) acute promyelocytic leukemia (APL) HUVECs arsenic trioxide (ATO) treatment upregulated 26274316 999 Human hsa-miR-126 miRNA cysteine-rich 61 (CCN1) angiogenesis "human osteoblast-like cell line MG-63, human fetal osteoblastic cell line hFOB" cysteine-rich 61 (CCN1) treatment downregulated 27465842 1000 Human hsa-miR-126 miRNA fenretinide angiogenesis human umbilical vein endothelial cells (HUVECs) fenretinide treatment upregulated 31925643 1001 Human hsa-miR-126 miRNA palmitic acid (PA) antiapoptotic HUVECs palmitic acid (PA) treatment downregulated 25318608 1002 Human hsa-miR-126 miRNA actinomycin X2 (AX2) apoptosis human prostate cancer cells (PC-3) actinomycin X2 (AX2) treatment miR-144 was decreased ; smiR-126 was increased 26645890 1003 Human hsa-miR-126 miRNA palmitate apoptosis HUVECs palmitate treatment downregulated 25318608 1004 Human hsa-miR-126 miRNA resveratrol apoptosis CRL-1730 cells resveratrol (RS) treatment upregulated 24107596 1005 Human hsa-miR-126 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 1006 Human hsa-miR-126 miRNA curcumin (Cur) arteriosclerosis (AS) Human microvascular endothelial HMEC-1 cells curcumin treatment upregulated 31016760 1007 Human hsa-miR-126 miRNA asbestos asbestos-related malignancies serum asbestos treatment upregulated 30257964 1008 Human hsa-miR-126 miRNA inhaled corticosteroids asthma bronchial epidermal cells from asthma patients inhaled corticosteroids treatment downregulated 24995087 1009 Human hsa-miR-126 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment miR-126 level was significantly reduced in ox-LDL-treated HUVECs. 29203244 1010 Human hsa-miR-126 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29203244 1011 Human hsa-miR-126 miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) HUVEC tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 24870014 1012 Human hsa-miR-126 miRNA aidi injection (ADI) breast cancer MCF-7 cells aidi Injection (ADI) upregulated 21563499 1013 Human hsa-miR-126 miRNA arachidonic acid (AA) breast cancer platelet microvesicle (MV) arachidonic acid (AA) treatment upregulated 31665654 1014 Human hsa-miR-126 miRNA dacarbazine and interferon-alfa-2b breast cancer circulating endothelial cells dacarbazine and interferon-alfa-2b treatment Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a 23217102 1015 Human hsa-miR-126 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 1016 Human hsa-miR-126 miRNA tamoxifen (TAM) breast cancer tumour samples of breast cancer tamoxifen treatment upregulated 23968733 1017 Human hsa-miR-126 miRNA hypoxia cardiovascular disease (CVD) human umbilical vein endothelial cells (HUVECs) hypoxia treatment downregulated 22282338 1018 Human hsa-miR-126 miRNA lipopolysaccharide (LPS) cell damage HK-2 cells lipopolysaccharide (LPS) treatment LncRNA?Mirt2 prohibits lipopolysaccharide-evoked HK-2 cell injury via modulation of?microRNA-126. 31889348 1019 Human hsa-miR-126 miRNA benzo(a)pyrene (BaP) cell proliferation primary cell cultures from normal and malignant endometrial tissue benzo(a)pyrene (BaP) exposure downregulated 30811740 1020 Human hsa-miR-126 miRNA high glucose (HG) cell senescence human glomerular mesangial cells (HGMCs) high glucose (HG) treatment downregulated 30717558 1021 Human hsa-miR-126 miRNA tea polyphenols (TP) cell senescence high glucose (HG)-treated human glomerular mesangial cells (HGMCs) tea polyphenols (TP) treatment upregulated 30717558 1022 Human hsa-miR-126 miRNA tumor necrosis factor alpha (TNF-¦Á) cell-to-cell communication human aortic endothelial cells (ECs) and their transfer to recipient cells tumor necrosis factor alpha (TNF-¦Á) treatment differently regulation 25315114 1023 Human hsa-miR-126 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury human umbilical vein endothelial cells (HUVECs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment miR-126 expression was markedly reduced in HUVECs subjected to OGD/R treatment 33355373 1024 Human hsa-miR-126 miRNA naringin chondrosarcoma human chondrosarcoma cell line JJ012 naringin treatment upregulated 24975661 1025 Human hsa-miR-126 miRNA HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA) chronic heart failure (CHF) human aortic endothelial cells HDLNYHA treatment downregulated 24958738 1026 Human hsa-miR-126 miRNA ibrutinib chronic lymphocytic leukemia (CLL) CLL patient cells ibrutinib treatment upregulated 28299881 1027 Human hsa-miR-126 miRNA capecitabine colorectal cancer (CRC) colon cancer cells capecitabine treatment upregulated 22397399 1028 Human hsa-miR-126 miRNA oxaliplatin colorectal cancer (CRC) colon cancer cells oxaliplatin treatment upregulated 22397399 1029 Human hsa-miR-126 miRNA docosahexaenoic acid (DHA) colorectal cancer (CRC) HCT116 and Caco2 cell lines Docosahexaenoic acid (DHA) treatment upregulated 30598703 1030 Human hsa-miR-126 miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 1031 Human hsa-miR-126 miRNA IL-1¦Â and TNF-¦Á cystic fibrosis (CF) cystic fibrosis airway epithelial cells IL-1¦Â and TNF-¦Á treatment downregulated 20083669 1032 Human hsa-miR-126 miRNA glucose plus advanced glycation end product-BSA diabetes mellitus (DM) human cavernous endothelial cells (hCECs) glucose plus advanced glycation end product-BSA treatment downregulated 29942117 1033 Human hsa-miR-126 miRNA icariside II (ICA II) diabetes mellitus (DM) glucose plus advanced glycation end product-BSA-treated human cavernous endothelial cells (hCECs) icariside II (ICA II) treatment upregulated 29942117 1034 Human hsa-miR-126 miRNA hyperglycemia and advanced glycation end products (AGE) diabetic vasculopathy Endothelial Progenitor Cells Hyperglycemia and Advanced Glycation End Products treatment downregulated 27673690 1035 Human hsa-miR-126 miRNA maggot debridement therapy (MDT) diabetic foot ulcer (DFU) patients with DFUs maggot debridement therapy (MDT) treatment upregulated 27623390 1036 Human hsa-miR-126 miRNA high glucose (HG) diabetic nephropathy (DN) human glomerular mesangial cells (HGMCs) high glucose treatment downregulated 30341510 1037 Human hsa-miR-126 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) high glucose treatment downregulated 31608649 1038 Human hsa-miR-126 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) high glucose (HG) treatment miR-126 was downregulated in high-glucose-induced HRECs. 31608649 1039 Human hsa-miR-126 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal capillary endothelial cells (HRCECs) high glucose (HG) treatment downregulated 33416109 1040 Human hsa-miR-126 miRNA streptozocin (STZ) diabetic retinopathy (DR) serum streptozotocin (STZ) treatment downregulated 33416109 1041 Human hsa-miR-126 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal capillary endothelial cells (HRCECs) high glucose (HG) treatment The diabetic rats were found to exhibit downregulated serum and retinal miR-126 levels compared with the non-diabetic rats. 33416109 1042 Human hsa-miR-126 miRNA palmitate endothelial dysfunction human umbilical vein endothelial cells (HUVECs) palmitate treatment MicroRNA-126 Modulates Palmitate-Induced Migration in HUVECs by Downregulating Myosin Light Chain Kinase via the ERK/MAPK Pathway 32850751 1043 Human hsa-miR-126 miRNA aspirin fetal neural stem cells (NSCs)maturation ?plasma aspirin treatment downregulated 23386708 1044 Human hsa-miR-126 miRNA etanercept gastric cancer (GC) ?serum Etanercept treatment downregulated 23600954 1045 Human hsa-miR-126 miRNA Cl-amidine glioblastoma multiforme (GBM) LN18 and LN229 cells Cl-amidine treatment upregulated 30597867 1046 Human hsa-miR-126 miRNA high glucose (HG) hyperglycemia-induced senescence human glomerular mesangial cells (HGMCs) high glucose treatment downregulated 31089945 1047 Human hsa-miR-126 miRNA tea polyphenols (TP) hyperglycemia-induced senescence High glucose-treated human glomerular mesangial cells (HGMCs) tea polyphenols (TPs) treatment upregulated 31089945 1048 Human hsa-miR-126 miRNA training hypertension and skeletal muscle microcirculation rarefaction heart tissues training treatment upregulated 33105326 1049 Human hsa-miR-126 miRNA lipopolysaccharide (LPS) IgA nephropathy (IgAN) HK-2 cells lipopolysaccharide (LPS) treatment upregulated 31889348 1050 Human hsa-miR-126 miRNA polychlorinated biphenyls (PCBs) inflammation HUVECs polychlorinated biphenyls (PCBs) treatment upregulated 27288564 1051 Human hsa-miR-126 miRNA angiopoietin-1 (Ang-1) inflammatory injury HPDE6-C7 treated with LPS (10 ?g/mL) angiopoietin-1 (Ang-1) treatment upregulated 31966500 1052 Human hsa-miR-126 miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) brain microvascular endothelial cells (BMECs) oxygen glucose deprivation (OGD) treatment OGD induced downregulated of miR-126 in HBMECs. 32591985 1053 Human hsa-miR-126 miRNA a?a¨ª (Ac) and red muscadine grape (Gp) lipid accumulation and inflammatory response human vascular endothelial cells (HUVEC) a?a¨ª (Ac) and red muscadine grape (Gp)treatment ?microRNA-126 expression was found to be modulated by Ac and Gp 21682256 1054 Human hsa-miR-126 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 1055 Human hsa-miR-126 miRNA exercise and diet microvascular endothelial dysfunction serum exercise and diet treatment "After 6-weeks intervention, microRNA-126 was significantly decreased." 30472037 1056 Human hsa-miR-126 miRNA exercise and diet microvascular endothelial dysfunction serum from obese adolescents food and exercise treatment downregulated 30472037 1057 Human hsa-miR-126 miRNA natalizumab multiple sclerosis (MS) CD4+T lymphocytes natalizumab treatment downregulated 24598267 1058 Human hsa-miR-126 miRNA dimethyloxalylglycine (DMOG) myocardial angiogenesis human umbilical vein endothelial cells (HUVECs) dimethyloxalylglycine (DMOG) treatment DMOG significantly increased the expression level of HIF-1¦Á and miR-126 in a concentration-dependent manner in normoxia. 32939968 1059 Human hsa-miR-126 miRNA danhong injection (DHI) myocardial infarction (MI) hypoxia-induced human umbilical vein endothelial cells (HUVECs) danhong injection (DHI) treatment upregulated 31629250 1060 Human hsa-miR-126 miRNA hypoxia myocardial infarction (MI) human cardiosphere-derived cells (CDCs) exosomes hypoxia induce upregulated 29243842 1061 Human hsa-miR-126 miRNA hypoxia myocardial infarction (MI) human umbilical vein endothelial cells (HUVECs) hypoxia induce downregulated 31629250 1062 Human hsa-miR-126 miRNA "TNF¦Á , IFN¦Ã" neuroinflammation human brain endothelial cell line "TNF¦Á , IFN¦Ã treatment" downregulated 28358058 1063 Human hsa-miR-126 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 1064 Human hsa-miR-126 miRNA asbestos non-small cell lung cancer (NSCLC) serum asbestos exposure upregulated 30257964 1065 Human hsa-miR-126 miRNA matrine non-small cell lung cancer (NSCLC) A549 NSCLC cell line matrine treatment "matrine induced cell cycle arrest and apoptosis, and recovered the expression of miR-126 in the A549 NSCLC cell line." 27665734 1066 Human hsa-miR-126 miRNA radiation non-small cell lung cancer (NSCLC) non-small cell lung cancer tissue radiation treatment upregulated 20728239 1067 Human hsa-miR-126 miRNA total flavonoids (TFs) non-small cell lung cancer (NSCLC) human lung cancer cell line A549 TFS treatment downregulated 28404902 1068 Human hsa-miR-126 miRNA high glucose (HG) obesity obesity subjects' adipose tissue-derived stem cells (ASCs) high glucose (HG) treatment downregulated in cell-derived extracellular vesicles (EVs) 26122028 1069 Human hsa-miR-126 miRNA palmitic acid (PA) obesity obesity subjects' adipose tissue-derived stem cells (ASCs) palmitic acid (PA) treatment downregulated in cell-derived extracellular vesicles (EVs) 26122028 1070 Human hsa-miR-126 miRNA baicalin (BAI) osteoarthritis (OA) IL-1¦Â-treated CHON-001 cells baicalin (BAI) treatment downregulated 29331857 1071 Human hsa-miR-126 miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment upregulated 29331857 1072 Human hsa-miR-126 miRNA IL-1¦Â osteoarthritis (OA) Human chondrocyte cell line CHON-001 IL-1¦Â treatment upregulated 30034795 1073 Human hsa-miR-126 miRNA ailanthone (AIL) osteosarcoma (OS) MG63 cells ailanthone (AIL) treatment upregulated 31571500 1074 Human hsa-miR-126 miRNA angelica polysaccharide (AP) oxidative stress H2O2-treated HaCaT cells angelica polysaccharide (AP) treatment upregulated 31288012 1075 Human hsa-miR-126 miRNA H2O2 oxidative stress HaCaT cells H2O2 treatment downregulated 31288012 1076 Human hsa-miR-126 miRNA high glucose (HG) periodontitis with diabetes THP-1 cells high glucose (HG) treatment High glucose condition can inhibit the proliferation of THP-1-derived macrophages and increase the expression of miR-126. 33280362 1077 Human hsa-miR-126 miRNA Pomegranate juice (PJ) prostate cancer ?prostate cancer cells Pomegranate juice (PJ) treatment upregulated 21594291 1078 Human hsa-miR-126 miRNA carbon black (CB) particles lung fibrosis human bronchial epithelial cell line (16HBE) carbon black (CB) particles treatment downregulated 31502903 1079 Human hsa-miR-126 miRNA carbon black (CB) particles lung fibrosis 16HBE cells carbon black (CB) particles treatment miR-126 in 16HBE cells after treatment with different concentration of CB was statistically decreased. 31502903 1080 Human hsa-mir-126 miRNA carbon black (CB) particles lung fibrosis 16HBE cells carbon black (CB) particles treatment pri-miR-126 in 16HBE cells after treatment with different concentration of CB was statistically increased. 31502903 1081 Human hsa-miR-126 miRNA oxygen glucose deprivation (OGD) remote ischemic preconditioning (RIPC) SH-SY5Y cells oxygen-glucose deprivation (OGD) treatment upregulated 32380415 1082 Human hsa-miR-126 miRNA lipopolysaccharide (LPS) sepsis-induced severe cardiomyopathy human umbilical vein endothelial cells (HUVECs) lipopolysaccharides (LPS) treatment upregulated 32411123 1083 Human hsa-miR-126 miRNA naringin small-cell lung cancer (SCLC) human small cell lung cancer H69AR cells naringin treatment upregulated 30197681 1084 Human hsa-miR-126 miRNA Buyang Huanwu decoction (BYHWD) stroke mesenchymal stem cell (MSC) Buyang Huanwu decoction (BYHWD) treatment upregulated 25796380 1085 Human hsa-miR-126 miRNA "diet control and exercise in IGT/IFG subjects, insulin plus diet control and exercise" type 2 diabetes mellitus (T2DM) type 2 diabetes mellitus (T2DM) patients six months of treatment upregulated 24927146 1086 Human hsa-miR-126 miRNA lipopolysaccharide (LPS) ulcerative colitis (UC) CCD-18Co cells lipopolysaccharide (LPS) treatment downregulated 27061150 1087 Human hsa-miR-126 miRNA lipopolysaccharide (LPS) ulcerative colitis (UC) CCD-18Co cells lipopolysaccharide (LPS) treatment downregulated 27061150 1088 Human hsa-miR-126 miRNA mango extract ulcerative colitis (UC) CCD-18Co cells mango extract treatment upregulated 27061150 1089 Human hsa-miR-126 miRNA polyphenolics extracted from mango (var. Keitt) ulcerative colitis (UC) LPS-treated CCD-18Co cells polyphenolics extracted from mango (var. Keitt) treatment upregulated 27061150 1090 Human hsa-miR-126 miRNA asbestos asbestos toxicity BEAS-2B cells asbestos exposure upregulated 32006662 1091 Human hsa-miR-126 miRNA red wine polyphenolics chronic intestinal inflammation and colon cancer CCD-18Co myofibroblast cells red wine polyphenolics treatment downregulated 22572890 1092 Human hsa-miR-126* miRNA "TNF¦Á , IFN¦Ã" neuroinflammation human brain endothelial cell line "TNF¦Á , IFN¦Ã treatment" downregulated 28358058 1093 Human hsa-miR-1260 miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 1094 Human hsa-miR-1260 miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 1095 Human hsa-miR-1260b miRNA hypoxia pathological proliferation of VSMCs human primary pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment Hypoxia-induced miR-1260b promotes VSMC proliferation. 31818357 1096 Human hsa-miR-1261 miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine (GEM) treatment upregulated 25722110 1097 Human hsa-miR-126-3p miRNA etanercept ankylosing spondylitis (AS) Blood etanercept treatment upregulated 26273623 1098 Human hsa-miR-126-3p miRNA high-intensity interval training (HIIT) atherosclerosis (AS) individuals three exercise sessions/week of 4 ¡Á 30 s at maximum speed (all-out) with one extra session every week (up to 7 ¡Á 30 s) upregulated 28611681 1099 Human hsa-miR-126-3p miRNA low-intensity training atherosclerosis (AS) individuals three exercise sessions/week for 25 min <75% of maximum heart rate upregulated 28611681 1100 Human hsa-miR-126-3p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment downregulated 31722571 1101 Human hsa-miR-126-3p miRNA oxLDL and pitavastatin cholesterol homeostasis THP-1 cells oxLDL and pitavastatin treatment downregulated 27415822 1102 Human hsa-miR-126-3p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment downregulated 31722571 1103 Human hsa-miR-126-3p miRNA high-intensity interval training (HIIT) endothelial dysfunction blood high-intensity interval (HII) cycling exercise bouts treatment upregulated 31487226 1104 Human hsa-miR-126-3p miRNA hydroquinone (HQ) erythroid cell differentiation CD34 + hematopoietic progenitor cells hydroquinone (HQ) treatment downregulated 28733890 1105 Human hsa-miR-126-3p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 1106 Human hsa-miR-126-3p miRNA regorafenib frail metastatic colorectal cancer (mCRC) serum regorafenib treatment "Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia" 33916610 1107 Human hsa-miR-126-3p miRNA hydroquinone (HQ) hematotoxicity CD34 hematopoietic progenitor cells treat with HQ downregulated 28733890 1108 Human hsa-miR-126-3p miRNA Traumatic brain injury (TBI) hypopituitarism blood Traumatic brain injury (TBI) treatment downregulated 27027233 1109 Human hsa-miR-126-3p miRNA dabrafenib melanoma The BRAF-mutant human melanoma cell lines A375 and SK-Mel28 ?dabrafenib treatment downregulated 31227006 1110 Human hsa-miR-126-3p miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment upregulated 31452742 1111 Human hsa-miR-126-3p miRNA mono-(2-ethylhexyl) phthalate (MEHP) oxidative stress HTR-8/SVneo cell line mono-(2-ethylhexyl) phthalate (MEHP) treatment upregulation 26871967 1112 Human hsa-miR-126-3p miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" preeclampsia (PE) HUVECs "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 31323164 1113 Human hsa-miR-126-3p miRNA adalimumab(ADA) psoriasis circulating angiogenic cells (CACs) adalimumab treatment upregulated 26943583 1114 Human hsa-miR-126-3p miRNA infliximab rheumatoid arthritis (RA) serological infliximab treatment upregulated 25860297 1115 Human hsa-miR-126-3p miRNA high glucose (HG) wound healing defects and vascular dysfunction human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment "High glucose decreased the endogenous H2S and miR-126-3p levels and increased the DNMT1 expression, thus inducing the migration dysfunction of HUVECs." 32186933 1116 Human hsa-miR-126-3p miRNA hydrogen sulfide (H2S) wound healing defects and vascular dysfunction human umbilical vein endothelial cells (HUVECs) hydrogen sulfide (H2S) treatment upregulated 32186933 1117 Human hsa-miR-1264 miRNA paclitaxel (PTX) laryngeal cancer laryngeal cancer cell line hep2 Paclitaxel treatment the most markedly expression-changed 23826416 1118 Human hsa-miR-126-5p miRNA angiotensin II (Ang II) abdominal aortic aneurysm (AAA) human aortic smooth muscle cells (hAoSMCs) angiotensin II (Ang II) treatment miR-126-5p expression significantly decreased in primary hAoSMCs stimulated with Ang II. 32612287 1119 Human hsa-miR-126-5p miRNA bone morphogenetic protein 4 (BMP4) angiogenesis human umbilical vein endothelial cells (HUVECs) bone morphogenetic protein 4 (BMP4) treatment upregulated(miR-126-5p) ;downregulated (miR-494 ) 28124060 1120 Human hsa-miR-126-5p miRNA baicalin (BAI) atherosclerosis (AS) ox-LDL-treated HA-VSMCs baicalin (BAI) treatment upregulated 31204352 1121 Human hsa-miR-126-5p miRNA high-intensity interval training (HIIT) atherosclerosis (AS) individuals three exercise sessions/week of 4 ¡Á 30 s at maximum speed (all-out) with one extra session every week (up to 7 ¡Á 30 s) upregulated 28611681 1122 Human hsa-miR-126-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HA-VSMCs oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31204352 1123 Human hsa-miR-126-5p miRNA IL-1¦Â chondrocyte inflammation cartilage cells IL-1¦Â treatment upregulated 33098220 1124 Human hsa-miR-126-5p miRNA paclitaxel (PTX) colorectal cancer (CRC) SW480 cells; SW620 cells Paclitaxel (PTX) treatment ?CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis 32581554 1125 Human hsa-miR-126-5p miRNA high-intensity interval training (HIIT) endothelial dysfunction blood high-intensity interval (HII) cycling exercise bouts treatment upregulated 31487226 1126 Human hsa-miR-126-5p miRNA proresolution lipid mediator lipoxin (LX)A4 inflammation HUVECs and EMVs LXA4 treatment upregulated in HUVECs and in EMVs 28100645 1127 Human hsa-miR-126-5p miRNA lipopolysaccharide (LPS) liver damage L02 cells lipopolysaccharide (LPS) treatment LPS significantly elevated the expression of miR-126-5p in L02 cells. 32031750 1128 Human hsa-miR-126-5p miRNA Tubeimoside-1 (TBMS1) non-small cell lung cancer (NSCLC) NCI-H1299 cells Tubeimoside-1 (TBMS1) treatment upregulated 29363720 1129 Human hsa-miR-126-5p miRNA Tubeimoside-1 (TBMS1) non-small cell lung cancer (NSCLC) NCI-H1299 cells Tubeimoside-1 (TBMS1) treatment upregulated 30127904 1130 Human hsa-miR-1268a miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 1131 Human hsa-miR-1268a miRNA hypoxia cell proliferation human primary pulmonary artery smooth muscle cells hypoxia induce upregulated 31370272 1132 Human hsa-miR-1268a miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 1133 Human hsa-miR-1268b miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 1134 Human hsa-miR-1268b miRNA steviol gastrointestinal cancer MKN-45 cells steviol treatment upregulated 29899860 1135 Human hsa-miR-1269b miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment miR-1269b expression was upregulated in cisplatin-resistant NSCLC specimens and NSCLC cell lines. 32021259 1136 Human hsa-miR-1269b miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2.2.15 cells hepatitis B virus (HBV)? treatment upregulated 27349221 1137 Human hsa-miR-126a-5p miRNA H2O2 and hypoxia/reoxygenation (H/R) ischemia/reperfusion (I/R) injury H9C2 cells myocardial ischemia-reperfusion (M-I/R) upregulated 29212219 1138 Human hsa-miR-127 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)" bladder cancer "Human bladder carcinoma cell line,T24 cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment" upregulated 16766263 1139 Human hsa-miR-127 miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment downregulated 20346162 1140 Human hsa-miR-127 miRNA schizandrin A (SchA) inflammatory skin diseases HaCaT cells schizandrin A (SchA) treatment miR-127 expression was upregulated in LPS-treated HaCaT cells but downregulated after SchA treatment. 30257250 1141 Human hsa-miR-127 miRNA TGF-¦Â lung cancer HCC cell TGF-¦Â? treatment TGF¦Â decreases miR-127 expression by enhancing c-Jun-mediated inhibition of miR-127 promoter activity 23762330 1142 Human hsa-miR-127 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 1143 Human hsa-miR-127 miRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment "miR-127 was repressed by overexpressed TUG1, meanwhile the protective impacts of TUG1 against LPS-evoked inflammatory injury in MRC-5 cells were overturned by overexpressed miR-127." 31017717 1144 Human hsa-miR-127 miRNA cardio-pulmonary bypass (CPB) severe lung injury lung cardiopulmonary bypass (CPB) treatment upregulated 25347932 1145 Human hsa-miR-1270 miRNA cisplatin (DDP) ovarian cancer (OC) Human ovarian cancer cell lines (A2780 and SKOV-3) cisplatin treatment miR-1270 Plays an Oncogenic Role in Ovarian Cancer Cells and Reduces Their Cisplatin Chemosensitivity. 31479922 1146 Human hsa-miR-1271 miRNA huaier extract acute kidney injury (AKI) HK-2 cells Huaier extract (HE) treatment HE Downregulates CHOP and GRP78 and Upregulates miR-1271 in HK-2 Cells. 33457422 1147 Human hsa-miR-1271 miRNA hepatitis B virus (HBV) HBV-associated hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) tissues and cells hepatitis B virus (HBV) infection downregulated 30565670 1148 Human hsa-miR-1271 miRNA dietary saturated fatty acids (SFA) insulin resistance (IR) HepG2 cells Dietary saturated fatty acids (SFA) treatment upregulated 27613089 1149 Human hsa-miR-1271-5p miRNA respiratory syncytial virus (RSV) respiratory syncytial virus (RSV)-associated pneumonia whole blood respiratory syncytial virus (RSV) infection treatment upregulated 32410870 1150 Human hsa-miR-1273c miRNA XAV939 non-small cell lung cancer (NSCLC) "The NSCLC cell line, NCI-H1299" 10 ?M XAV939 for 12 h treatment The downregulated of lncRNA?MIR503HG?induced by XAV939 may serve an important role in NSCLC suppression via sponging?miR-1273c?and regulating?SOX4?expression 31186710 1151 Human hsa-miR-1273d miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 1152 Human hsa-miR-1273d miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 1153 Human hsa-miR-1273f miRNA hypoxia hepatocellular carcinoma (HCC) exosomes from Huh7 cells hypoxia induce upregulated 31562861 1154 Human hsa-miR-127-3p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 1155 Human hsa-miR-127-3p miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H1299 cells cisplatin treatment downregulated 32742197 1156 Human hsa-miR-1274a miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 1157 Human hsa-miR-1274a miRNA "myclobutanil, propiconazole, and triadimefon" hepatocellular carcinoma (HCC) HepG2 cells "myclobutanil, propiconazole, and triadimefon treatment" upregulated 23159985 1158 Human hsa-miR-1274b miRNA "myclobutanil, propiconazole, and triadimefon" hepatocellular carcinoma (HCC) HepG2 cells "myclobutanil, propiconazole, and triadimefon treatment" upregulated 23159985 1159 Human hsa-miR-1275 miRNA curcumin (Cur) corneal neovascularization (CNV) HUVECs curcumin treatment upregulated 27625050 1160 Human hsa-miR-1275 miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment upregulated 25129238 1161 Human hsa-miR-1275 miRNA "tamarix articulata, quercetin , epigallocatechin gallate (EGCG)" hepatocellular carcinoma (HCC) Huh-7 cells "T. articulata, quercetin and EGCG treatment" downregulated 28817968 1162 Human hsa-miR-1275 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 1163 Human hsa-miR-127-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epigenetic regulation HCT116 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30538122 1164 Human hsa-miR-127-5p miRNA glucocorticoid (GC) glucocorticoid-induced osteonecrosis of femoral head (GIONFH) human Bone mesenchymal stem cells (BMSCs) glucocorticoids (GCs) treatment upregulated 30579595 1165 Human hsa-miR-127-5p miRNA BAY11-7082 helicobacter pylori infection H. pylori infected gastric epithelial cells treated with 10 ¦ÌM Bay 11-7082 upregulated 28208005 1166 Human hsa-miR-1276 miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2R cells curcumin treatment upregulated 31793078 1167 Human hsa-miR-1276 miRNA macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL) osteoclast differentiation THP-1 cells macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL) treatment NF-¦ÊB promotes osteoclast differentiation by overexpressing MITF via down regulating microRNA-1276 expression 32673666 1168 Human hsa-miR-1277-5p miRNA IL-1¦Â osteoarthritis (OA) articular chondrocytes (ACs) IL-1¦Â treatment downregulated 31198977 1169 Human hsa-miR-1277-5p miRNA lipopolysaccharide (LPS) osteoarthritis (OA) CHON-001 chondrocytes lipopolysaccharide (LPS) treatment "HOTAIR and SGTB were upregulated, while miR-1277-5p was downregulated in OA cartilages and LPS-stimulated CHON-001 chondrocytes." 33721916 1170 Human hsa-miR-1277-5p miRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) brain tissues "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" downregulated 30671473 1171 Human hsa-miR-1277-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment downregulated 30671473 1172 Human hsa-miR-1277-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MMP+) treatment downregulated 33069733 1173 Human hsa-miR-128 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophages atherogenic Evs oxidized low-density lipoprotein (ox-LDL) treatment enrichment in atherogenic EVs 28882869 1174 Human hsa-miR-128 miRNA particulate matter (PM) cardiovascular disease (CVD) A549 pulmonary cell lines particulate matter (PM)treatment treatment upregulated 24515752 1175 Human hsa-miR-128 miRNA particulate matter (PM) cardiovascular disease (CVD) A549 pulmonary cell lines PM-ed A549 pulmonary cell lines in v treatment upregulated 24515752 1176 Human hsa-miR-128 miRNA IFN-¦Á chronic hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) interferon alpha treatment upregulated 21070682 1177 Human hsa-miR-128 miRNA TGF-¦Â1 cell differentiation human hair follicle mesenchymal stem cells (hHFMSCs) human hair follicle mesenchymal stem cells (hHFMSCs) treatment downregulated 27087048 1178 Human hsa-miR-128 miRNA H2O2 extracellular matrices (ECMs) homeostasis "human prostate cancer epithelial cell lines, LNCaP, C4-2, PC3, PC3M, and DU145" hydrogen peroxide upregulated 28831065 1179 Human hsa-miR-128 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) SGC-7901 cells Helicobacter pylori £¨H. pylori£©infection downregulated 29604247 1180 Human hsa-miR-128 miRNA radiation glioblastoma multiforme (GBM) U87 cells radiation treatment MicroRNA-128 increases glioma cell radio-sensitivity by suppressing senescent evasion through oncogene Bmi-1 31938239 1181 Human hsa-miR-128 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment upregulated 27893811 1182 Human hsa-miR-128 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) human glioma-derived cell lines U251 and U87 TMZ treatment downregulated 25017996 1183 Human hsa-miR-128 miRNA ginsenoside Rh2 glioblastoma multiforme (GBM) U251 cells ginsenoside Rh2 (Rh2) treatment The anti-proliferative effect of Rh2 in human glioma cells was mediated in part through upregulated of miRNA-128 expression 21372826 1184 Human hsa-miR-128 miRNA insulin glycolysis human HepG2 hepatocellular carcinoma cells insulin treatment dysregulated 24895527 1185 Human hsa-miR-128 miRNA NPV-LDE-225 (Erismodegib) human immunodeficiency virus (HIV)-1 infection Glioblastoma initiating cells (GICs) NPV-LDE-225 (Erismodegib) treatment downregulated 23482671 1186 Human hsa-miR-128 miRNA opiate neuroblastoma (NB) neuroblastoma SH-SY5Y cell line chronic opiate administration treatment "low doses of morphine (10nM) reduced the expression levels of miR133b, higher doses (1¦ÌM) downregulated levels of miR133b and miR128" 24440526 1187 Human hsa-miR-128 miRNA high glucose (HG) nonalcoholic fatty liver disease (NAFLD) HepG5 cells high glucose (HG) treatment downregulated 31889412 1188 Human hsa-miR-128 miRNA adipogenesis medium osteogenesis human mesenchymal stem cells adipogenic upregulated 27485180 1189 Human hsa-miR-128 miRNA P. gingivalis periodontitis THP-1 cells and CA9-22 cells P. gingivalis treatment upregulated 27240473 1190 Human hsa-miR-1281 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 1191 Human hsa-miR-1281 miRNA high glucose (HG) diabetes microvascular complications ARPE-19 cells high glucose (HG) treatment upregulated 32849308 1192 Human hsa-miR-1281 miRNA heat stress heat-induced pathophysiology human umbilical vein endothelial cells cultured in the incubator at 43¡ãC for 1 h "downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)" 29039486 1193 Human hsa-miR-1281 miRNA asbestos fibers malignant pleural mesothelioma (MPM) serum ex-exposed to asbestos fibers (WEA) upregulated 27716620 1194 Human hsa-miR-1281 miRNA radiation nasopharyngeal carcinoma (NPC) serum radiation treatment downregulated 32198434 1195 Human hsa-miR-1281 miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) primary human macrophages differentiated from PBMCs Mycobacterium tuberculosis (MTB) infection "microRNA-1281 inhibition in human macrophages, by the anti-sense sequence, increased CypD expression and potentiated MTB-induced cytotoxicity." 31884421 1196 Human hsa-miR-128-1-5P miRNA liraglutide atherosclerosis (AS) human vascular smooth muscle cells liraglutide treatment Liraglutide could curb the expression of inflammatory cytokines and apoptosis related protein in coronary atherosclerosis by regulating RMRP/miR-128-1-5P/Gadd45g signaling pathway 32196624 1197 Human hsa-miR-128-1-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 1198 Human hsa-miR-1282 miRNA lipopolysaccharide (LPS) acute inflammatory response HMEEC lipopolysaccharide (LPS) treatment upregulated 21377743 1199 Human hsa-miR-1282 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure downregulated 31359311 1200 Human hsa-miR-1283 miRNA hypoxia/reoxygenation (H/R) acute myocardial infarction (AMI) Human embryonic cardiomyocytes hypoxia/reoxygenation (H/R) treatment "GADD45A and miR-1283 were upregulated or downregulated in myocardial infarction, respectively" 33293495 1201 Human hsa-miR-1283 miRNA hypoxia/reoxygenation (H/R) acute myocardial infarction (AMI) human embryonic cardiomyocytes hypoxia /reoxygenation (H/R) treatment The miR-1283-GADD45A axis may protect against H/R -induced cardiomyocyte injury by suppressing the JNK and p38 MAPK pathways. 33293495 1202 Human hsa-miR-128-3p miRNA laminar shear stress atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) Laminar shear stress induce downregulated 30905197 1203 Human hsa-miR-128-3p miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 30905197 1204 Human hsa-miR-128-3p miRNA angiotensin II (Ang II) atrial fibrosis human atrial fibroblasts angiotensin II (Ang II) treatment LncRNA PVT1 promotes atrial fibrosis via miR-128-3p-SP1-TGF-¦Â1-Smad axis in atrial fibrillation. 30894138 1205 Human hsa-miR-128-3p miRNA kynurenine bone loss bone marrow stromal cells (BMSCs) kynurenine treatment upregulated 31790802 1206 Human hsa-miR-128-3p miRNA particulate matter (PM2.5) cardiotoxicity endothelial cells PM2.5 exposure treatment downregulated 30597786 1207 Human hsa-miR-128-3p miRNA particulate matter (PM2.5) cardiotoxicity of PM2.5 endothelial cells PM2.5 treatment downregulated 30597786 1208 Human hsa-miR-128-3p miRNA oxaliplatin colorectal cancer (CRC) SW480 cells; HCT116 cells; colorectal cancer (CRC) tissues oxaliplatin treatment miR-18b-5p was increased in oxaliplatin-resistant CRC cells and tissues 33147048 1209 Human hsa-miR-128-3p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) high glucose (HG) treatment High-level glucose (HG) treatment significantly upregulated miRNA-128- 3p expression in HRECs. 32572899 1210 Human hsa-miR-128-3p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) "Seven HCC cell lines PLC/PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC©\7721, and HCCLM3" sorafenib treatment downregulated 30132868 1211 Human hsa-miR-128-3p miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human bone marrow mesenchymal stem cells (BMSCs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31635801 1212 Human hsa-miR-128-3p miRNA gypenoside LI melanoma A375 cells; SK-MEL-28 cells gypenoside LI treatment Gypenoside LI can induce the upregulation of the tumor suppressor miR-128-3p during melanoma apoptosis. 32022984 1213 Human hsa-miR-128-3p miRNA all-trans retinoic acid (ATRA) neurogenesis amniotic epithelial cells (AECs) all-trans retinoic acid (ATRA) treatment "lncRNA MEG3 is upregulated by the ATRA/cAMP/CREB pathway, and it, in turn, is directly downregulated by miR-128-3p to increase the amount of neuron differentiation." 31921854 1214 Human hsa-miR-128-3p miRNA IL-1¦Â osteoarthritis (OA) C28/I2 cells IL-1¦Â treatment miR-128-3p was downregulated in chondrocytes stimulated with interleukin (IL)-1¦Â. 32830547 1215 Human hsa-miR-128-3p miRNA hydrochloric acid reflux esophagitis Het-1A cells hydrochloric acid (HCl) treatment miR-128-3p was upregulated in Het-1A cells after HCl treatment. 30223934 1216 Human hsa-miR-128-3p miRNA lipopolysaccharide (LPS) sepsis human dermal microvascular endothelial cells (HMEC-1) lipopolysaccharide (LPS) treatment HULC knockdown partially reversed LPS-induced sepsis via the regulation of miR-128-3p/RAC1 axis. 33174038 1217 Human hsa-miR-1284 miRNA propofol (PPF) lung cancer A549 cells propofol treatment upregulated 29402342 1218 Human hsa-miR-1284 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 29218085 1219 Human hsa-miR-1285 miRNA ionizing radiation (IR) anti-cancer therapy SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG ionizing radiation treatment upregulated 21453501 1220 Human hsa-miR-1285 miRNA methylmercury (MeHg) neurotoxicity human neural progenitor cells (ihNPCs) methylmercury (MeHg) treatment downregulated 27941687 1221 Human hsa-miR-1285-3p miRNA tumor necrosis factor alpha (TNF-¦Á) cervical cancer (CC) HeLa cells tumor necrosis factor alpha (TNF-¦Á) treatment "TNF-¦Á-induced lncRNA LOC105374902 may function as a ceRNA for miR-1285-3p to promote the expression of RPL14, promoting the migration, invasion and EMT of CC cells." 30935691 1222 Human hsa-miR-1285-3p miRNA herapy with transarterial chemoembolisation (TACE) hepatocellular carcinoma (HCC) HCC patients TACE treatment dysregulated 25230788 1223 Human hsa-miR-1285-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 1224 Human hsa-miR-1286 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" aortic stenosis cervical cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines" 23732000 1225 Human hsa-miR-1286 miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 1226 Human hsa-miR-1286 miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 1227 Human hsa-miR-1287 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" aortic stenosis cervical cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines" 23732000 1228 Human hsa-miR-1287-5p miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 1229 Human hsa-miR-1287-5p miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 1230 Human hsa-miR-1287-5p miRNA TGF-¦Â angiogenesis human umbilical vein endothelial cells (HUVECs) TGF-¦Â treatment downregulated 30414893 1231 Human hsa-miR-1287-5p miRNA vascular endothelial growth factor (VEGF) angiogenesis human umbilical vein endothelial cells (HUVECs) vascular endothelial cell growth factor (VEGF) treatment downregulated 30414893 1232 Human hsa-miR-1287-5p miRNA hepatitis B virus (HBV) chronic hepatitis B virus (HBV) infection Huh7 cells; HepG2 cells pHBV1.3 infection The expression of miR-1287-5p was significantly decreased in the circ_0004812 overexpressing cells. 32188476 1233 Human hsa-miR-1287-5p miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human bronchial epithelial (16HBE) cells infect with EV71 and CA16 dysregulated 27890633 1234 Human hsa-miR-1287-5p miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) Human bronchial epithelial (16HBE) cells Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment dysregulated 27890633 1235 Human hsa-miR-128a miRNA X-rays glioblastoma multiforme (GBM) U-87 MG glioblastoma cells X-ray radiation treatment "High doses of X-ray radiation increased the expression levels of Bmi-1, which may be associated with the evasion of cellular senescence miRNA-128a and its downstream target gene Bmi-1 may have an important role in the radioresistance of U-87 MG glioma cells" 26238021 1236 Human hsa-miR-128a miRNA "haloperidol, clozapine and olanzapine" schizophrenia (SZ) "HepG2 (ATCC,CRL-1573)" "haloperidol, clozapine , olanzapine treatment" downregulated 28429622 1237 Human hsa-miR-129 miRNA piceatannol (PIC) colorectal cancer (CRC) HCT116 and HT29 cells piceatannol treatment upregulated 25218158 1238 Human hsa-miR-129 miRNA gefitinib esophageal squamous cell carcinoma (ESCC) TE1 cells; KYSE-450 cells gefitinib treatment miR-129 is downregulated in both gefitinib-resistant cell lines in contrast with their respective parental cell lines. 30049286 1239 Human hsa-miR-129 miRNA cisplatin (DDP) gastric cancer (GC) MGC-803 cells cisplatin treatment downregulated 31378887 1240 Human hsa-miR-129 miRNA histone deacetylase (HDAC) histone deacetylase resistance in nasopharyngeal cancer (NPC) CNE1; CNE2; C666¨C1 Histone deacetylase treatment downregulated 32692721 1241 Human hsa-miR-129 miRNA magnolol multiple myeloma (MM) MM cells U266 and LP1 Magnolol treatment And magnolol increased the miR-129 expression in MM cells. 33440989 1242 Human hsa-miR-129 miRNA TGF-¦Â non-small cell lung cancer (NSCLC) A549 cells TGF-¦Â treatment TGF-¦Â induced EMT accompanied by the reduction of miR-129 and elevating of SOX4 30475081 1243 Human hsa-miR-129 miRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) Human neuroblastoma cell line SH©\SY5Y "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" downregulated 30260025 1244 Human hsa-miR-129 miRNA "pramipexole,piribedil, L-dopa, amantadine" parkinson's disease (PD) patients with Parkinson's disease "different medications (pramipexole,piribedil, L-dopa, amantadine) treatment" upregulated 25465742 1245 Human hsa-miR-129 miRNA resveratrol parkinson's disease (PD) MPTP-treated human neuroblastoma cell line SH©\SY5Y resveratrol (RS) treatment upregulated 30260025 1246 Human hsa-miR-129 miRNA resveratrol parkinson's disease (PD) SH©\SY5Y cells resveratrol (RS) treatment upregulated 30260025 1247 Human hsa-miR-129 miRNA perioglas (PG) and P-15 promote bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 1248 Human hsa-miR-129 miRNA TGF-¦Â1 renal fibrosis HK-3 cells TGF-¦Â1 treatment downregulated 32475133 1249 Human hsa-miR-1290 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" aortic stenosis cervical cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines" 23732000 1250 Human hsa-miR-1290 miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 9¡ã HDT bed rest experiment downregulated 28261104 1251 Human hsa-miR-1290 miRNA asiatic acid (AA) cardiomyocyte apoptosis human AC16 cardiomyocytes under hypoxia treat with various doses of AA for 24 h upregulated 28686797 1252 Human hsa-miR-1290 miRNA polygonatum odoratum lectin (POL) cell apoptosis and autophagy A549 cells Polygonatum odoratum lectin (POL) treatment downregulated 26562549 1253 Human hsa-miR-1290 miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 1254 Human hsa-miR-1290 miRNA polygonatum odoratum lectin (POL) lung adenocarcinoma (LUAD) A549 cells Polygonatum odoratum lectin (POL) treatment downregulated 26562549 1255 Human hsa-miR-1290 miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells influenza A virus (IAV) infection upregulated 31173947 1256 Human hsa-miR-1290 miRNA platinum lung adenocarcinoma (LUAD) LADC tissues platinum-based doublet chemotherapy treatment dysregulated 25142144 1257 Human hsa-miR-1290 miRNA asiatic acid (AA) non-small cell lung cancer (NSCLC) A549 NSCLC cells asiatic acid treatment upregulated 25016979 1258 Human hsa-miR-1290 miRNA TGF-¦Â1 lung fibrosis A549 cells TGF-¦Â1 treatment upregulated 32319530 1259 Human hsa-miR-1290 miRNA photodynamic therapy (PDT) skin cancer ATCC-No. CRL-1555 cells Photodynamic therapy (PDT) treatment upregulated 23466801 1260 Human hsa-miR-1290 miRNA toluene toluene-induced toxicity HL-60 human promyelocytic leukemia cells toluene treatment dysregulated 28245982 1261 Human hsa-miR-1291 miRNA ¦Á-melanocyte-stimulating hormone (¦Á-MSH) skin pigmentation disorders human skin primary melanocytes (MCs) ¦Á-MSH treatment downregulated 33318297 1262 Human hsa-miR-129-2 miRNA progesterone (P4) breast cancer "T47D, BT474, MDA-MB-231 and MCF7 breast cancer cell lines" 2.5 mg/ml Amphotericin-B (Abbott) and 1.25 ?l/ml Gentamycin (Abbott) treatment upregulated 28876975 1263 Human hsa-miR-129-2 miRNA neuron-glial antigen 2 (NG2) protein diffuse intrinsic pontine gliomas (DIPGs) Human DIPG cells neuron-glial antigen 2 (NG2) protein treatment downregulated 25987129 1264 Human hsa-miR-129-2 miRNA trichostatin A (TSA) glioblastoma multiforme (GBM) GBM patient specimens and cultured cell lines trichostatin A treatment miR-129-2 expression could be restored upon treatment with a histone deadetylase inhibitor (trichostatin A) but not a DNA methylation inhibitor (5-Aza-2'-deoxycytidine) 26320507 1265 Human hsa-miR-129-3p miRNA angiotensin II (Ang II) cardiovascular disease (CVD) HEK293N (AT1R-HEK) cells angiotensin II (Ang II) treatment upregulated 21449976 1266 Human hsa-miR-129-3p miRNA histone deacetylase inhibitor (HDACi) cell death "Huh7 cells, MGC-803 cells" Histone deacetylase inhibitors (HDACis) treatment upregulated 30852137 1267 Human hsa-miR-129-3p miRNA avenanthramide A (AVN A) colorectal cancer (CRC) "human colon carcinoma cell lines HCT-8, HCT-116" avenanthramide A (AVN A) treatment upregulated 30888162 1268 Human hsa-miR-129-3p miRNA "glucose deprived, galactose enriched (GAL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 1269 Human hsa-miR-129-3p miRNA "lipid reduced, cholesterol deficient (RL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 1270 Human hsa-miR-129-3p miRNA chidamide non-small cell lung cancer (NSCLC) H1355 and A549 cells chidamide treatment Chidamide repressed telomerase activity through ROS accumulation and cell cycle arrest by miR-129-3p upregulation in both H1355 and A549 cells. 30668358 1271 Human hsa-miR-129-3p miRNA chidamide non-small cell lung cancer (NSCLC) H1355 cells; A549 cells Chidamide treatment Chidamide upregulates miR-129-3p expression in lung cancer cells. 30668358 1272 Human hsa-miR-1294 miRNA arsenic trioxide (ATO) hepatocellular carcinoma (HCC) SMMC7721 cells; HepG2 cells arsenic trioxide (ATO) treatment miR-1294 was found to be significantly upregulated in ATO-treated HCC cells. 32280078 1273 Human hsa-miR-1294 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment downregulated 29860902 1274 Human hsa-miR-129-5p miRNA CoCl2 acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 CoCl2 treatment downregulated 33175458 1275 Human hsa-miR-129-5p miRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) HK-2 cells hypoxia/reoxygenation (H/R) treatment downregulated 33175458 1276 Human hsa-miR-129-5p miRNA alcohol alcoholic liver disease (ALD) differentiated Caco-2 cells alcohol treatment upregulated 31814565 1277 Human hsa-miR-129-5p miRNA physical exercise Alzheimer's disease (AD) serum physical exercise treatment miR-129-5p is significantly upregulated by physical exercise 32434194 1278 Human hsa-miR-129-5p miRNA suberoylanilide hydroxamic acid (SAHA) apoptosis "human lung adenocarcinoma (A549 and SL-LU-1), squamous cell carcinoma (HCC-95 and HCC-1588), large cell carcinoma (NCI-H460 and NCI-H1299), and small cell lung cancer (SCLC; HCC-33, NCI-H69, and Calu-6) cells ,human small airway epithelial cells (HSAEC), human bronchial epithelial cells (HBEC), human pulmonary artery endothelial cells (HPEC) and human pulmonary fibroblast (HPF) cells" SAHA treatment upregulated 28667779 1279 Human hsa-miR-129-5p miRNA CoCl2 apoptosis HK-2 cells CoCl2 treatment downregulated 33175458 1280 Human hsa-miR-129-5p miRNA angiotensin II (Ang II) cardiac hypertrophy Human cardiac myocytes (HCMs) angiotensin II (Ang II) treatment downregulated 33569456 1281 Human hsa-miR-129-5p miRNA IFN-¦Â cervical intraepithelial neoplasia (CIN) and cancer Hela cells;HPV 16-negative Siha cells;HPV-negative C33A cells; HCC94 cells Interferon-¦Â treatment Interferon-b Induced microRNA-129-5p Down-Regulates HPV-18 E6 and E7 Viral Gene Expression by Targeting SP1 in Cervical Cancer Cells 24358111 1282 Human hsa-miR-129-5p miRNA cisplatin (DDP) cisplatin (DDP) resistance MCF-7 and MDA-MB-231 cells cisplatin treatment lncRNA ZEB1-AS1 silencing protects against drug resistance in breast cancer by promoting miR-129-5p-dependent ZEB1 downregulated. 33430826 1283 Human hsa-miR-129-5p miRNA toxic acetaminophen (APAP) drug metabolizing enzymes (DMEs) expression HepaRG cells toxic acetaminophen (APAP) treatment APAP treatment increased the level of hsa-miR-129-5p 32273307 1284 Human hsa-miR-129-5p miRNA cisplatin (DDP) gastric adenocarcinoma (GAC) HGC27; AGS cisplatin treatment Circ_0000260 Regulates the Development and Deterioration of Gastric Adenocarcinoma with Cisplatin Resistance by Upregulating MMP11 via Targeting MiR-129-5p. 33122949 1285 Human hsa-miR-129-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) SGC7901/VCR gastric cancer multi-drug resistant cell line "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25344911 1286 Human hsa-miR-129-5p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) Pri GBM; Rec GBM; N3S; N3T3rd; U251; U251T3rd; glioblastoma (GBM) tissues temozolomide (TMZ) treatment downregulated 32039732 1287 Human hsa-miR-129-5p miRNA osteopontin (OPN) liver fibrosis human hepatic stellate cells (HSCs) LX-2 cells Osteopontin (OPN) treatment downregulated 29196165 1288 Human hsa-miR-129-5p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2R cells curcumin treatment upregulated 31793078 1289 Human hsa-miR-129-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" osteosarcoma (OS) OS tissues with pulmonary metastasis "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25566966 1290 Human hsa-miR-129-5p miRNA lipopolysaccharide (LPS) peritoneal fibrosis human peritoneal mesothelial cells (HPMCs) lipopolysaccharide (LPS) treatment downregulated 30855347 1291 Human hsa-miR-129-5p miRNA matrine peritoneal fibrosis LPS-treated human peritoneal mesothelial cells (HPMCs) matrine treatment upregulated 30855347 1292 Human hsa-miR-129-5p miRNA docetaxel (DTX) prostate cancer PC-3 cells docetaxel (DTX) treatment upregulated 31876385 1293 Human hsa-miR-129-5p miRNA royal jelly skin senescence human dermal microvascular endothelial cells (HDMEC) royal jelly treatment downregulated 31723098 1294 Human hsa-miR-129-5p miRNA ultraviolet (UV) irradiation skin senescence human dermal microvascular endothelial cells (HDMEC) UVB radiation treatment upregulated 31723098 1295 Human hsa-miR-129-5p miRNA histone deacetylase inhibitor (HDACi) thyroid cancer (TC) TPC-1 cells;BCPAP cells;8505C clls;CAL62 cells histone deacetylase inhibitors (HDACi) treatment miR-129-5p is involved in the antitumor activity of HDACi and highlight a miRNA-driven cell death mechanism. 21946411 1296 Human hsa-miR-1296 miRNA genistein renal fibrosis PC3 cells Genistein treatment downregulated 29967188 1297 Human hsa-miR-1296 miRNA trichostatin A (TSA) renal fibrosis PC3 cells TSA treatment downregulated 29967188 1298 Human hsa-miR-1297 miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment "We predicted and verified miR-1297 as the regulatory miRNA of COL1A2, and the expression of miR-1297 was decreased in DN tissues and HG-stimulated HK-2 cells." 33811432 1299 Human hsa-miR-1297 miRNA propofol (PPF) oral squamous cell carcinoma (OSCC) UM-SCC6 and SCC090 cells Propofol treatment downregulated 31583913 1300 Human hsa-miR-130 miRNA chemotherapy colorectal cancer (CRC) serum " modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2 , day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment" dysregulated 24304648 1301 Human hsa-miR-1301 miRNA cigarette smoke extract (CSE) head and neck squamous cell carcinoma (HNSCC) HaCaT cigarette smoke?extract?(CSE) treatment upregulated 28797462 1302 Human hsa-miR-1301-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated of NEAT1 repressed ¦Á-syn-induced activation of NLRP3 inflammasome via inhibiting the expression of GJB1 by targeting miR-1301-3p. 32712773 1303 Human hsa-miR-1301-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 32712773 1304 Human hsa-miR-1303 miRNA MLN4924/Pevonedistat breast cancer MCF-7 cells MLN4924/Pevonedistat treatment miR-1303 was significantly decreased after MLN4924 treatment in breast cancer cells. 32360865 1305 Human hsa-miR-1303 miRNA coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human umbilical vein endothelial cell (HUVECs) Coxsackievirus A16 (CA16) infection downregulated 30228270 1306 Human hsa-miR-1305 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HCC tissues hepatitis B virus (HBV) infection downregulated 33372396 1307 Human hsa-miR-1305 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 1308 Human hsa-miR-1305 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 1309 Human hsa-miR-1306 miRNA beryllium sulfate (BeSO4 ) beryllium toxicity 16HBE cells beryllium sulfate (BeSO4 ) treatment upregulated 33197057 1310 Human hsa-miR-1306-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment "SNHG7-003 may inhibit the proliferation, migration and invasion of VSMCs via the miR-1306-5p/SIRT7 signaling pathway." 33416100 1311 Human hsa-miR-1306-5p miRNA oxygen glucose deprivation (OGD) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation (OGD) treatment downregulated 31460837 1312 Human hsa-miR-1307 miRNA cisplatin (DDP) breast cancer MCF-7 cells; MDA-MB-468 cells cisplatin treatment MiR-1307 was downregulated while MDM4 was upregulated in MCF-7/cisplatin (CDDP) and MDA-MB-468/CDDP cells compared with parental MCF-7 and MDA-MB-468 cells. 29697201 1313 Human hsa-miR-1308 miRNA hypoxia gastroesophageal cancer (GEC) ESCC and AC cell lines Hypoxia treatment upregulated 26851030 1314 Human hsa-miR-130a miRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment downregulated 33716779 1315 Human hsa-miR-130a miRNA adriamycin (ADR) acute myeloid leukemia (AML) HL-60 cells adriamycin (ADR) treatment miR-130a expression was decreased in increasing Adr concentrations. 32945422 1316 Human hsa-miR-130a miRNA amyloid-¦Â (A¦Â) Alzheimer's disease (AD) U251 cells amyloid-¦Â (A¦Â) treatment upregulated 29238290 1317 Human hsa-miR-130a miRNA hypoxia angiogenesis human primary endothelial colony-forming cells (ECFCs) hypoxia induce "Here, we identify miR-130a as a mediator of the hypoxic response in human primary endothelial colony-forming cells (ECFCs)." 33614244 1318 Human hsa-miR-130a miRNA high glucose (HG) cell damage ARPE-19 cells high glucose (HG) treatment high-glucose (50 mM) significantly decreased the levels of miR-130a. 32018221 1319 Human hsa-miR-130a miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 7¡ã HDT bed rest experiment downregulated 28261104 1320 Human hsa-miR-130a miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 1321 Human hsa-miR-130a miRNA imatinib chronic myeloid leukemia (CML) CML patients imatinib (IM) treatment differently regulated 24629639 1322 Human hsa-miR-130a miRNA nilotinib chronic myeloid leukemia (CML) HL-60.BCR-ABL cells nilotinib (NIL) treatment differently regulated 24629639 1323 Human hsa-miR-130a miRNA curcumin (Cur) colorectal cancer (CRC) SW480 cells curcumin treatment downregulated 29225578 1324 Human hsa-miR-130a miRNA mesalazine (MSLZ) colorectal cancer (CRC) CaCo2 cell line Mesalazine (5-ASA) treatment downregulated 29794245 1325 Human hsa-miR-130a miRNA adherent-invasive escherichia coli (AIEC) crohn disease (CD) intestinal epithelial cells T84 cells adherent invasive escherichia coli (AIEC) treatment upregulated 24148619 1326 Human hsa-miR-130a miRNA adherent-invasive escherichia coli (AIEC) crohn disease (CD) T85 cells adherent invasive escherichia coli (AIEC) treatment upregulated 32583714 1327 Human hsa-miR-130a miRNA docetaxel (DTX) head and neck squamous cell carcinoma (HNSCC) UMSCC-1 cells;SQ20B cells docetaxel (DTX) treatment downregulated 21560177 1328 Human hsa-miR-130a miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cells cisplatin treatment upregulated 22846564 1329 Human hsa-miR-130a miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) Blood samples cisplatin treatment upregulated 22846564 1330 Human hsa-miR-130a miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 1331 Human hsa-miR-130a miRNA IL-2 immunotherapy NK-92 cells IL-2 treatment upregulated 31883616 1332 Human hsa-miR-130a miRNA Vitamin D and phorbol 12-myristate 13-acetate leukemia AML cell line (HL60 and NB4) Vitamin D and phorbol 12-myristate 13-acetate treatment downregulated 20981674 1333 Human hsa-miR-130a miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 parental hepatoma cells hepatitis C virus (HCV) infection downregulated 23418453 1334 Human hsa-miR-130a miRNA radiation lung cancer A549 cells radiation treatment upregulated 32968458 1335 Human hsa-miR-130a miRNA carbamate lung cancer Normal human bronchial epithelial (NHBE) cells carbamate treatment upregulated 19748927 1336 Human hsa-miR-130a miRNA apicidin myocardial infarction (MI) human bone marrow-derived MSC apicidin treatment downregulated 28498815 1337 Human hsa-miR-130a miRNA hypoxia myocardial infarction (MI) human cardiosphere-derived cells (CDCs) exosomes hypoxia induce upregulated 29243842 1338 Human hsa-miR-130a miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 1339 Human hsa-miR-130a miRNA hypoxia non-small cell lung cancer (NSCLC) A549 cells; H1299 cells hypoxia treatment downregulated 32450163 1340 Human hsa-miR-130a miRNA lipopolysaccharide (LPS) osteoarthritis (OA) C28/I2 cells lipopolysaccharide (LPS) treatment H19 negatively regulated the expression of miR-130a via acting as a molecular sponge for miR-130a. The stimulatory effects of H19 on cell damage were abolished following the restoration of miR-130a. 30900425 1341 Human hsa-miR-130a miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed downregulated 27915273 1342 Human hsa-miR-130a miRNA human immunodeficiency virus (HIV)-1 and cocaine pulmonary vascular remodeling human monocyte derived macrophages HIV-infected and cocaine treatment upregulated 29672222 1343 Human hsa-miR-130a miRNA lipopolysaccharide (LPS) systemic lupus erythematosus (SLE) HK-2 cells (human renal proximal tubule cells) lipopolysaccharide (LPS) treatment upregulated 29441906 1344 Human hsa-miR-130a miRNA liraglutide type 2 diabetes mellitus (T2DM) serum liraglutide treatment upregulated 33008044 1345 Human hsa-miR-130a* miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment downregulated 22647265 1346 Human hsa-miR-130a-3p miRNA indoxyl sulfate (IS) chronic kidney disease (CKD) human coronary artery endothelial cells (HCAECs) indoxyl sulfate (IS) treatment "Consistent with the clinical data, treatment with the uremia toxin indoxyl sulfate (IS) reduced miR-130a-3p levels in HCAEC-derived EVs." 33135066 1347 Human hsa-miR-130a-3p miRNA TGF-¦Â1 crohn disease (CD) human intestinal epithelial cells (HIECs); normal-derived colon mucosa cell line 460 (NCM460) cells TGF-¦Â1 treatment Hsa_circRNA_102610 upregulation in CD patients could promote the proliferation and EMT of intestinal epithelial cells via sponging of hsa-miR-130a-3p 32587447 1348 Human hsa-miR-130a-3p miRNA hypoxia hepatocellular carcinoma (HCC) HepG2; Huh7 hypoxia treatment knockdown of HOTAIR suppressed glycolysis by regulating miR-130a-3p and HIF1A in HCC cells treated by hypoxia 32062551 1349 Human hsa-miR-130a-3p miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 26669941 1350 Human hsa-miR-130a-3p miRNA tobacco smoke lung cancer "bronchial epithelial BEAS-2B cells that were malignantly transformed into S30 cells, human lung cancer cell lines A549 and H1299" tobacco smoke exposure downregulated 31526129 1351 Human hsa-miR-130a-3p miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 1352 Human hsa-miR-130a-3p miRNA lipopolysaccharide (LPS) osteoarthritis (OA) C28/I2 cells lipopolysaccharide (LPS) treatment downregulated 31678554 1353 Human hsa-miR-130a-3p miRNA activin A prostate cancer PC3 cells activin A treatment downregulated 27018851 1354 Human hsa-miR-130a-3p miRNA TGF-¦Â1 renal fibrosis "human renal proximal tubular epithelial cells (HRPTEpiCs, HK-2 and primary HRPTEpiCs)" TGF-¦Â1 treatment upregulated 31836508 1355 Human hsa-miR-130a-3p miRNA TGF-¦Â1 renal fibrosis HK-2 cells; HRPTEpiCs TGF-¦Â1 treatment "After TGF-¦Â1 treatment, miR-130a-3p was highly expressed in renal tubular epithelial cells" 31836508 1356 Human hsa-miR-130a-3p miRNA metformin (Met) cell senescence HK-2 cells Metformin treatment Metformin Increased the Stability of miR-130a-3p by Upregulating MBNL1 and Thus Reduced the High-Glucose- Induced Senescence of Renal Tubular Epithelial Cells. 32104542 1357 Human hsa-miR-130a-5p miRNA tamoxifen (TAM) breast cancer Human MCF-7 cells Tamoxifen (TAM) treatment Low expression of ADAMTS9-AS2 inhibits PTEN expression and enhances tamoxifen resistance through targeting microRNA-130a-5p 30840279 1358 Human hsa-miR-130a-5p miRNA angiotensin II (Ang II) membranous nephropathy (MN) podocyte cell line AB8/13 angiotensin II (Ang II) treatment downregulated 30394845 1359 Human hsa-miR-130a-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 1360 Human hsa-miR-130b miRNA tanshinone IIA (Tan IIA) atherosclerosis (AS) THP-1 cells Tanshinone IIA (Tan) treatment upregulated 31512787 1361 Human hsa-miR-130b miRNA 5-fluorouracil (5-Fu) diabetic nephropathy (DN) ?plasma 5-fluorouracil (5-FU) treatment upregulated 24119443 1362 Human hsa-miR-130b miRNA high glucose (HG) diabetic nephropathy (DN) human glomerular mesangial cells (HMCs) high glucose treatment upregulated 30260005 1363 Human hsa-miR-130b miRNA insulin-like growth factor 1 (IGF-1) glioblastoma multiforme (GBM) U87-MG cells IGF-1 treatment downregulated 28389653 1364 Human hsa-miR-130b miRNA lipopolysaccharide (LPS) hepatolithiasis Human intrahepatic biliary epithelial cells (HIBEpiCs) lipopolysaccharide (LPS) treatment Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium 33300069 1365 Human hsa-miR-130b miRNA 5-fluorouracil/mitomycin C (MMC-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) MMC-CRTX treatment downregulated 28347920 1366 Human hsa-miR-130b miRNA 5-fluorouracil (5-Fu) metastatic colorectal cancer (mCRC) ?plasma 5-fluorouracil (5-FU) treatment upregulated 24119443 1367 Human hsa-miR-130b miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx7 treatment" downregulated 21572246 1368 Human hsa-miR-130b miRNA lipopolysaccharide (LPS) vascular injury human umbilical vein endothelial cells (HUVECs) lipopolysaccharides (LPS) treatment downregulated 28759810 1369 Human hsa-miR-130b-3p miRNA high glucose (HG) diabetic pregnancy BeWo cells high glucose upregulated 28433632 1370 Human hsa-miR-130b-3p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 1371 Human hsa-miR-132 miRNA aspergillus fumigatus (A. fumigatus) Aspergillus fumigatus infection human monocytes and dendritic cells (DCs) infect with A. fumigatus upregulated 24841251 1372 Human hsa-miR-132 miRNA notoginsenoside R1 (NGR1) atherosclerosis (AS) Human umbilical vascular endothelial cells (HUVECs) Notoginsenoside R1 (NGR1) treatment downregulated 30504696 1373 Human hsa-miR-132 miRNA hypoxia blood-brain barrier (BBB) dysfunction human brain microvascular endothelial cells (BMEC) hypoxia induce upregulated 30617994 1374 Human hsa-miR-132 miRNA co-nanoencapsulated curcumin (Cur) and chrysin (Chr) breast cancer MDA-MB-231 breast cancer cells co-nanoencapsulated Curcumin (Cur) and Chrysin (Chr) treatment upregulated 30955355 1375 Human hsa-miR-132 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 1376 Human hsa-miR-132 miRNA luteolin bronchopneumonia BEAS-2B cells Luteolin treatment luteolin alleviated the LPS-induced miR-132 expression increase in BEAS-2B cells. 30119240 1377 Human hsa-miR-132 miRNA doxorubicin (DOX) cardiotoxicity human iPSC-derived cardiomyocytes doxorubicin treatment "In vitro, overexpression of the pro-hypertrophic miR-212/132 cluster in primary rodent and human iPSC-derived cardiomyocytes inhibited doxorubicin-induced toxicity." 30527757 1378 Human hsa-miR-132 miRNA angiotensin II (Ang II) cardiovascular disease (CVD) HEK293N (AT1R-HEK) cells angiotensin II (Ang II) treatment upregulated 21449976 1379 Human hsa-miR-132 miRNA recombinant human thymic stromal lymphopoietin (rhTSLP) cervical cancer (CC) HeLa and SiHa cells rhTSLP were significantly impaired inwith treatment upregulated 29250181 1380 Human hsa-miR-132 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) THP-1 cells cigarette smoke extract (CSE) treatment upregulated 30292646 1381 Human hsa-miR-132 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment LncRNA SNHG5 regulates cell apoptosis and inflammation by miR-132/PTEN axis in COPD 32145584 1382 Human hsa-miR-132 miRNA high glucose (HG) diabetic retinopathy (DR) retinal pigment epithelial cells (ARPE-19) high glucose (HG) treatment We revealed that HG-treated ARPE-19 cells exhibited significantly increased miR-132 expression 33563844 1383 Human hsa-miR-132 miRNA fluid shear stress (FSS) epairing the oral cavity human periodontal ligament (PDL) cells fluid shear stress? treatment dysregulated 24556727 1384 Human hsa-miR-132 miRNA high glucose (HG) gestational diabetes mellitus (GDM) HTR-8/SVneo cell high glucose (HG) treatment downregulated 31653266 1385 Human hsa-miR-132 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) LN229 cells; U251 cells temozolomide (TMZ) treatment exosome-mediated transfer of CircNFIX enhances TMZ resistance in glioma at least partially through sponging miR-132 32194140 1386 Human hsa-miR-132 miRNA TGF-¦Â glioblastoma multiforme (GBM) Human glioma cell lines U87MG TGF treatment upregulated 25983322 1387 Human hsa-miR-132 miRNA TGF-¦Â1 hard-to-heal skin wounds human dermal fibroblasts (HDFs) TGF-¦Â1 treatment upregulated 28798331 1388 Human hsa-miR-132 miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) HCC cells hepatitis C virus (HCV) infection downregulated 23376496 1389 Human hsa-miR-132 miRNA angiotensin II (Ang II) hypertension human breast artery tissues angiotensin II (Ang II) treatment upregulated 23712358 1390 Human hsa-miR-132 miRNA notoginsenoside R1 (NGR1) inflammation human lung fibroblast MRC-5 cell Notoginsenoside R1 (NGR1) treatment upregulated 30622031 1391 Human hsa-miR-132 miRNA palmitate inflammation THP-1 cells PA treatment upregulated 29258239 1392 Human hsa-miR-132 miRNA dextran sodium sulfate (DSS) inflammatory bowel disease (IBD) Colon mucosa dextran sulfate sodium treatment upregulated 26878986 1393 Human hsa-miR-132 miRNA oxygen glucose deprivation (OGD) hepatocellular carcinoma (HCC) HepG2 cells OGD treatment downregulated 24661879 1394 Human hsa-miR-132 miRNA citalopram major depressive disorder (MDD) plasma citalopram treatment Plasma miR-132 in the treatment-free MDD group was 2.4-fold that in the control group and significantly higher than that in the citalopram-treated MDD group. 29689690 1395 Human hsa-miR-132 miRNA nanocurcumin multiple sclerosis (MS) blood nanocurcumin treatment downregulated 30340096 1396 Human hsa-miR-132 miRNA basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) neurogenesis periodontal ligament-derived neural crest stem cells (NCSCs) basic fibroblast growth factor and epidermal growth factor treatment upregulated 30352481 1397 Human hsa-miR-132 miRNA Toll-like receptor (TLR) neurological diseases U251 human astrocytoma cell line Toll-like receptor (TLR) treatment upregulated 25957996 1398 Human hsa-miR-132 miRNA brain-derived neurotrophic factor (BDNF) neuronal development HeLa? cells brain-derived neurotrophic factor (BDNF) treatment upregulated 20307261 1399 Human hsa-miR-132 miRNA bupivacaine neurotoxicity SH-SY5Y cells bupivacaine treatment upregulated 30850243 1400 Human hsa-miR-132 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 1401 Human hsa-miR-132 miRNA ozone (O3) air pollution healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 1402 Human hsa-miR-132 miRNA cisplatin (DDP) oral squamous cell carcinoma (OSCC) CAL-27cells cisplatin treatment miR-132 expression was significantly decreased in the OSCC tissues and CDDP resistant OSCC cell line (CAL-27/CDDP). 31906769 1403 Human hsa-miR-132 miRNA dexamethasone (DEX) pancreatic cancer (PC) AsPC-1 CELLS; PANC-1 cells; ASAN-PaCa cells dexamethasone (Dex) treatment DEX inhibits miR-132 expression by promoter hypermethylation. 30387838 1404 Human hsa-miR-132 miRNA dexamethasone (DEX) pancreatic ductal adenocarcinoma (PDAC) "human primary pancreatic cancer cell line ASAN-PaCa, AsPC-1 and PANC-1 pancreatic cancer cell lines" dexamethasone (DEX) treatment downregulated 30387838 1405 Human hsa-miR-132 miRNA "pramipexole,piribedil, L-dopa, amantadine" parkinson's disease (PD) patients with Parkinson's disease "different medications (pramipexole,piribedil, L-dopa, amantadine) treatment" upregulated 25465742 1406 Human hsa-miR-132 miRNA lipopolysaccharide (LPS) periodontitis human periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment "TUG1 had a decreased expression in both periodontal ligament (PDL) tissues with periodontitis and PDLCs under a LPS-induced inflammatory condition, and TUG1 expression was negatively correlated with miR-132 expression in periodontitis-affected PDL tissues." 31735958 1407 Human hsa-miR-132 miRNA melatonin primary biliary cholangitis (PBC) H69 cells melatonin treatment downregulated 33352965 1408 Human hsa-miR-132 miRNA platelet-derived growth factor (PDGF) pulmonary arterial hypertension (PAH) pulmonary arterial smooth muscle cells (PASMCs) platelet-derived growth factor treatment upregulated 30896881 1409 Human hsa-miR-132 miRNA sevoflurane (SEV) sevoflurane-induced neuronal apoptosis human H4 neuroglioma cell line sevoflurane treatment downregulated 30272258 1410 Human hsa-miR-132* miRNA angiotensin II (Ang II) cardiovascular disease (CVD) HEK293N (AT1R-HEK) cells angiotensin II (Ang II) treatment upregulated 21449976 1411 Human hsa-miR-132* miRNA brain-derived neurotrophic factor (BDNF) neuronal development HeLa? cells brain-derived neurotrophic factor (BDNF) treatment upregulated 20307261 1412 Human hsa-miR-1323 miRNA ¦Â-elemene gastric cancer (GC) SGC7901 cells ¦Â-Elemene treatment downregulated 32199253 1413 Human hsa-miR-1323 miRNA high glucose (HG) gestational diabetes mellitus (GDM) HTR-8/SVneo cells; BeWo cells high-glucose (HG) treatment HG upregulated the miR-1323 expression and inhibited trophoblast cell viability. 33603839 1414 Human hsa-miR-132-3p miRNA 5-fluorouracil (5-Fu) advanced colorectal cancer (CRC) HCT-15 cells 5-fluorouracil (5-FU) treatment "HF inhibited the proliferation, invasion and migration of HCT-15/FU cells by upregulating the expression levels of miR-132-3p." 33154782 1415 Human hsa-miR-132-3p miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) HPN; SK-N-SH cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 31898085 1416 Human hsa-miR-132-3p miRNA berberine (BBR) Alzheimer's disease (AD) HPN; SK-N-SH cells berberine (BBR) treatment upregulated 31898085 1417 Human hsa-miR-132-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 1418 Human hsa-miR-132-3p miRNA oral zinc gluconate esophageal cancer (EC) barrett's esophagus (BE) oral zinc gluconate treatment upregulated 32415564 1419 Human hsa-miR-132-3p miRNA influenza A virus (IAV) innate immune response peripheral blood samples from IAV patients and A549 cells H1N1 influenza A virus (IAV) infection upregulated 31746331 1420 Human hsa-miR-132-3p miRNA Japanese encephalitis virus (JEV) Japanese Encephalitis virus (JEV) infection human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses Japanese encephalitis virus (JEV) infection downregulated 31578247 1421 Human hsa-miR-132-3p miRNA nephrotoxicants kidney injury and fibrosis Primary human proximal tubular epithelial cells (HPTECs) nephrotoxicants treatment upregulated 26707937 1422 Human hsa-miR-132-3p miRNA liposomal bupivacaine (BUP) neurotoxicity SH-SY5Y cells liposomal bupivacaine (BUP) treatment upregulated 32335807 1423 Human hsa-miR-132-3p miRNA methotrexate (MTX) rheumatoid arthritis (RA) whole-blood methotrexate (MTX) treatment downregulated 30511295 1424 Human hsa-miR-132-3p miRNA methotrexate (MTX) rheumatoid arthritis (RA) RA patients whole-blood methotrexate (MTX) treatment upregulated 30511295 1425 Human hsa-miR-132-5p miRNA candida albicans (C. albicans) and aspergillus fumigatus (A. fumigatus) fungal infection human monocyte-derived dendritic cells 6 and 12 h of infection with C. albicans and A. fumigatus as well as treatment with lipopolysaccharides (LPS) dysregulated 28280489 1426 Human hsa-miR-133 miRNA hypoxia cardiac fibrosis human endothelial progenitor cell (EPC) and EPCs-derived exosomes hypoxia induce upregulated 31443679 1427 Human hsa-miR-133 miRNA nicotine cardiomyocyte apoptosis Human embryonic kidney cell line (HEK293) nicotine treatment downregulated 24190542 1428 Human hsa-miR-133 miRNA nicotine cardiomyocyte apoptosis human embryonic kidney cell line nicotine treatment downregulated 24190542 1429 Human hsa-miR-133 miRNA angiotensin-converting enzyme 2 (ACE2) inhibitor cardiovascular disease (CVD) H9c2 cardiac myoblast cells ACE2 (angiotensin-converting enzyme 2) treatment upregulated 26400542 1430 Human hsa-miR-133 miRNA neurotensin (NT) colonic inflammation HCT-116 cells Neurotensin (NT) treatment upregulated 25112884 1431 Human hsa-miR-133 miRNA high glucose (HG) diabetic nephropathy (DN) Human renal proximal tubular epithelial cell line human kidney-2 (HK-2) high glucose (HG) treatment upregulated 31858564 1432 Human hsa-miR-133a miRNA brazilein acoustic neuroma The vestibular schwannoma (VS) cells brazilein treatment upregulated 30610843 1433 Human hsa-miR-133a miRNA coronary artery bypass graft (CABG) acute coronary syndrome (ACS) acute coronary syndrome patients heart CABG treatment upregulated 29506853 1434 Human hsa-miR-133a miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning upregulated 30602960 1435 Human hsa-miR-133a miRNA IL-13 asthma human BSM cells (hBSMCs) interleukin-13 (IL-13) treatment the level of miR-133a was significantly decreased in BSMs of the diseased animals. 33132251 1436 Human hsa-miR-133a miRNA high glucose (HG) hyperglycemia-induced beta-cell dysfunction human islet ?high glucose exposure Prolonged high-glucose exposure down-regulates PTB levels and insulin biosynthesis rates in human islets by increasing miR-133a levels 20520763 1437 Human hsa-miR-133a miRNA cigarette smoke (CS) chronic obstructive pulmonary disease (COPD) airway epithelial cells of smokers cigarette smoke (CS) exposure upregulated 30341388 1438 Human hsa-miR-133a miRNA bortezomib congenital muscular dystrophy congenital muscular dystrophy type 1A muscle cells bortezomib? treatment downregulated 24631023 1439 Human hsa-miR-133a miRNA aortic valve replacement (AVR) aortic stenosis plasma aortic valve replacement (AVR) treatmenr upregulated 23948643 1440 Human hsa-miR-133a miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 1441 Human hsa-miR-133a miRNA paclitaxel (PTX) esophageal squamous cell carcinoma (ESCC) esophageal squamous cell carcinoma (ESCC) tissues the patients received four cycles of paclitaxel-based chemotherapy treatment downregulated 25280517 1442 Human hsa-miR-133a miRNA ursolic acid (UA) gastric cancer (GC) BGC-823 cells UA treatment upregulated 26629938 1443 Human hsa-miR-133a miRNA benzene hematotoxicity workers benzene treatment downregulated 26435271 1444 Human hsa-miR-133a miRNA homocysteine (Hcy) hyperhomocysteinemia (HHcy) HL-1 cardiomyocytes 100 ¦ÌM homocysteine treatment downregulated 24495916 1445 Human hsa-miR-133a miRNA angiotensin II (Ang II) hypertension Human umbilical vein endothelial cells (HUVECs) angiotensin II (Ang II) treatment downregulated 31524252 1446 Human hsa-miR-133a miRNA hypoxia hypoxia-induced cardiac dysfunctions AC16 cells hypoxia treatment downregulated 31926162 1447 Human hsa-miR-133a miRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) human lung fibroblasts (HFL) transforming growth factor (TGF)-¦Â1 treatment upregulated 31511493 1448 Human hsa-miR-133a miRNA insect cell-derived anionic septapeptide innate immune response Primary human monocyte cultures insect cell-derived anionic septapeptide treatment upregulated 31075349 1449 Human hsa-miR-133a miRNA TGF-¦Â liver fibrosis hepatic stellate cells(HSC) TGF-¦Â treatment Treatment of primary murine and human HSC with transforming growth factor (TGF)-¦Â resulted in a significant downregulated of miR-133a in these cells 23183523 1450 Human hsa-miR-133a miRNA matrine lung cancer NCI-H1299 cells Matrine treatment upregulated 26379863 1451 Human hsa-miR-133a miRNA statins muscle injury plasma statins? treatment upregulated 26472872 1452 Human hsa-miR-133a miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment upregulated 31452742 1453 Human hsa-miR-133a miRNA Vitamin K2 osteogenesis human bone marrow stromal cells (hBMSCs) Vitamin K2 treatment downregulated 28447758 1454 Human hsa-miR-133a miRNA astragalus polysaccharide (APS) osteosarcoma (OS) MG63 cells astragalus polysaccharide (APS) treatment APS enhanced the expression of miR-133a in MG63 cells. 30462772 1455 Human hsa-miR-133a miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 1456 Human hsa-miR-133a miRNA normoxia pancreatic cancer (PC) "human PC cell lines PANC©\1, SW1990" normoxia condition induce downregulated 30693518 1457 Human hsa-miR-133a miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 1458 Human hsa-miR-133a miRNA propofol (PPF) pancreatic cancer (PC) peripheral blood Propofol treatment upregulated 26214431 1459 Human hsa-miR-133a miRNA lactoferrin (LF) prostate cancer DU-145 cells lactoferrin (LF) treatment upregulated 30285009 1460 Human hsa-miR-133a miRNA ¦Â-glycerophosphate (¦Â-GP) prostate cancer vascular smooth muscle cells (VSMCs) ?¦Â-glycerophosphate treatment downregulated 23798596 1461 Human hsa-miR-133a miRNA estrogen (ES) pulmonary arterial hypertension (PAH) human pulmonary smooth muscle cell (HPASMC) estrogen (ES) treatment upregulated 31562386 1462 Human hsa-miR-133a miRNA 20-hydroxyeicosatetraeonic acid (20-HETE) pulmonary hypertension (PH) vascular smooth muscle cell 20-Hydroxyeicosatetraeonic acid (20-HETE) treatment downregulated 26921441 1463 Human hsa-miR-133a miRNA endothelin-1 (ET-1) renal cytotoxicity human renal proximal tubule cells (RPTECs) endothelin-1 (ET-1) treatment upregulated 25871823 1464 Human hsa-miR-133a miRNA artesunate (ART) rhabdomyosarcoma (RMS) ERMS cell lines artesunate (ARS) treatment downregulated 26153023 1465 Human hsa-miR-133a miRNA high-intensity interval training (HIIT) skeletal muscle adaptation human human treatment downregulated 27101297 1466 Human hsa-miR-133a miRNA nuclear factor 90 (NF90)-NF45 complex skeletal muscle atrophy Mouse myoblast C2C12 cells nuclear factor 90 (NF90)-NF45 complex treatment downregulated 25918244 1467 Human hsa-miR-133a miRNA sprint interval training (SIT) training responses skeletal muscle and heart acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment downregulated 29126336 1468 Human hsa-miR-133a miRNA ultraviolet (UV) irradiation ultraviolet radiation (UV) effects human dermal fibroblasts (HDFs) ultraviolet radiation (UVA) treatment downregulated 30378537 1469 Human hsa-miR-133a miRNA inorganic phosphate (Pi) vascular calcification (VC) human aortic vascular smooth muscle cells (HAVSMC) inorganic phosphate (Pi) treatment downregulated 27419135 1470 Human hsa-miR-133a-3p miRNA puerarin breast cancer HCC38 cells Puerarin treatment upregulated 30483784 1471 Human hsa-miR-133a-3p miRNA IL-17A asthma human BSM cells (hBSMCs) IL-17A treatment upregulated 28267638 1472 Human hsa-miR-133a-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human VSMCs (HVSMCs) oxidized low-density lipoprotein (ox-LDL) treatment circ_0010283 participated in ox-LDL-induced dysfunctions of HVSMCs by modulating the miR-133a-3p/PAPPA pathway. 33162460 1473 Human hsa-miR-133a-3p miRNA puerarin breast cancer HCC38 cells Puerarin treatment upregulated 30483784 1474 Human hsa-miR-133a-3p miRNA bufothionine gastric cancer (GC) MGC-803 cells; BGC-823 cells bufothionine treatment miR-133a-3p was upregulated by Bufothionine. 32758622 1475 Human hsa-miR-133a-3p miRNA cigarette smoke extract (CSE) oropharyngeal squamous cell carcinoma (OPSCC) lymph node and serum cigarette smoke extract (CSE) treatment HPV(+) smokers exhibit lymph node metastasis and reduced miR-133a-3p in both lymph node and serum. 30289952 1476 Human hsa-miR-133a-3p miRNA warfarin anticoagulation Peripheral Blood Mononuclear Cells (PBMCs) warfarin treatment miR-133a-3p is involved in the coagulation pathway 29296264 1477 Human hsa-miR-133a-5p miRNA hypoxia/reoxygenation (H/R) hepatic ischemia/reperfusion injury (HIRI) QSG-7701 cells hypoxia condition for 15 h and then in reoxygenation condition for 6 h downregulated 28198596 1478 Human hsa-miR-133b miRNA thyroid hormone hepatocellular carcinoma (HCC) skeletal muscle thyroid hormone (TH) treatment downregulated 19567520 1479 Human hsa-miR-133b miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment downregulated 29393545 1480 Human hsa-miR-133b miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 31572518 1481 Human hsa-miR-133b miRNA dihydrotestosterone (DHT) androgenetic alopecia (AGA) human hair follicles (HFs) dihydrotestosterone (DHT) treatment upregulated 33290799 1482 Human hsa-miR-133b miRNA KHCO3 bone resorption of alkali human serum potassium bicarbonate [(KHCO3); 81 mmol/d; n = 12] vs placebo (n = 12) for 84 days upregulated in serum 29264553 1483 Human hsa-miR-133b miRNA doxorubicin (DOX) "cardiotoxicity,cardiomyopathy and heart failure" female patients from the placebo arm doxorubicin treatment upregulated 28052002 1484 Human hsa-miR-133b miRNA cisplatin (DDP) cisplatin (DDP) resistance SW 780 cells cisplatin treatment MST1P2 serves as a competing endogenous RNA for miR-133b to counteract miR-133b-induced suppression on Sirt1. 32052927 1485 Human hsa-miR-133b miRNA ¦Á-mangostin colorectal cancer (CRC) human colon cancer DLD-1 cell line ¦Á-mangostin treatment downregulated 26304927 1486 Human hsa-miR-133b miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment "CASC2 upregulation suppressed HG-induced proliferation, ECM accumulation and oxidative stress of HMCs through miR-133b /FOXP1 regulatory axis." 32016985 1487 Human hsa-miR-133b miRNA TGF-¦Â1 diabetic nephropathy (DN) HK-2 cells TGF-¦Â1 treatment miR-133b was highly expressed in TGF-¦Â1-treated HK-2 cells 30125566 1488 Human hsa-miR-133b miRNA paclitaxel (PTX) esophageal squamous cell carcinoma (ESCC) esophageal squamous cell carcinoma (ESCC) tissues the patients received four cycles of paclitaxel-based chemotherapy treatment downregulated 25280517 1489 Human hsa-miR-133b miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 1490 Human hsa-miR-133b miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) non-small cell lung cancer (NSCLC) tissues criplatin (DPP) treatment downregulated 29344640 1491 Human hsa-miR-133b miRNA insulin-like growth factor 1 (IGF-1) infertility oocytes at MI stage were obtained from patients who received intra-cytoplasmic sperm injection (ICSI) ments IGF-1 treatment upregulated 24959893 1492 Human hsa-miR-133b miRNA ionizing radiation (IR) low doses hyper-radiosensitivity (LDHRS) DLD-1 cells ionizing radiation (IR) treatment upregulated 29899866 1493 Human hsa-miR-133b miRNA opiate neuroblastoma (NB) neuroblastoma SH-SY5Y cell line chronic opiate administration treatment "low doses of morphine (10nM) reduced the expression levels of miR133b, higher doses (1¦ÌM) downregulated levels of miR133b and miR128" 24440526 1494 Human hsa-miR-133b miRNA methadone opioid use disorder (OUD) blood methadone treatment downregulated 31349687 1495 Human hsa-miR-133b miRNA hydrostatic pressure (HP) osteogenesis adipose-derived mesenchymal stem cells (AMSCs) hydrostatic pressure (HP) treatment miR-133b was downregulated during osteogenic differentiation of AMSCs. 32661199 1496 Human hsa-miR-133b miRNA cisplatin (DDP) osteosarcoma (OS) MG63 cell line cisplatin treatment upregulated 29399170 1497 Human hsa-miR-133b miRNA procaine (PCA) osteosarcoma (OS) osteosarcoma MG63 cells 2 ¦ÌM PCA treatment upregulated 28251881 1498 Human hsa-miR-133b miRNA NaHS and l-cysteine preeclampsia (PE) human placenta NaHS and l-cysteine treatment upregulated 28454695 1499 Human hsa-miR-133b miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 1500 Human hsa-miR-133b miRNA sprint interval training (SIT) training responses skeletal muscle and heart acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment downregulated 29126336 1501 Human hsa-miR-133¦Á miRNA neurotensin (NT) colonic inflammation NCM-460 neurotensin (NT) treatment upregulated 25112884 1502 Human hsa-miR-133¦Á miRNA neurotensin (NT) inflammatory bowel disease (IBD) human colonocytes NCM460 cells Neurotensin (NT) treatment upregulated 26005712 1503 Human hsa-miR-133¦Á miRNA neurotensin (NT) neurotensin receptor 1 recycling human NCM460 colonocytes neurotensin (NT) treatment upregulation 26902265 1504 Human hsa-miR-134 miRNA penicillin-binding protein?1A (PBP1A) mutation-positive H.?pylori (H.?pyloriCagA+/P+) gastric cancer (GC) SGC-7901 cells penicillin-binding protein?1A (PBP1A) mutation-positive H.?pylori (H.?pyloriCagA+/P+)?infection treatment downregulated 30569124 1505 Human hsa-miR-134 miRNA lambertianic acid (LA) apoptosis MCF-7 cells lambertianic acid (LA) treatment upregulated 31248140 1506 Human hsa-miR-134 miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 1507 Human hsa-miR-134 miRNA astragaloside IV (AS-IV) colorectal cancer (CRC) colorectal cancer cell line SW-480 astragaloside (AS-IV) treatment upregulated 29041002 1508 Human hsa-miR-134 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells TGF-¦Â1 treatment "the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2," 24258346 1509 Human hsa-miR-134 miRNA propofol (PPF) glioblastoma multiforme (GBM) glioma U87 cells ?propofol treatment "Compared with the blank group, the proliferation, invasion and migration capacity of U87 cells were reduced in the positive control group and the propofol groups after 48 hours (all?P<005), along with the decreased expression of Ki-67, MMP-2 and MMP-9 and the ratio of p-PI3K/PI3K and p-Akt/Akt (all?P<005), while the level of miR-134 was increased significantly" 33678632 1510 Human hsa-miR-134 miRNA pyrogallol hepatocellular carcinoma (HCC) Hep3B and Huh7 hepatocellular carcinoma cells pyrogallol treatment upregulated 31426282 1511 Human hsa-miR-134 miRNA TGF-¦Â1 liver fibrosis immortalized human hepatic stellate cell line LX-2 TGF-¦Â1 treatment downregulated 30645141 1512 Human hsa-miR-134 miRNA TGF-¦Â1 lung adenocarcinoma (LUAD) human adenocarcinoma cell lines transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment upregulated 24258346 1513 Human hsa-miR-134 miRNA ursolic acid (UA) malignant pleural mesothelioma (MPM) H2452 cells ursolic acid treatment upregulated 28090191 1514 Human hsa-miR-134 miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 1515 Human hsa-miR-134 miRNA glargine pancreatic cancer (PC) pancreatic cancer cells glargine treatment upregulated 22690071 1516 Human hsa-miR-134 miRNA valproic acid (VPA) temporal lobe epilepsy (TLE) epilepsy patients VPA treatment downregulated 29069823 1517 Human hsa-miR-134 miRNA titanium surface implant-host tissue interactions osteoblastic cells from human alveolar bone osteoblastic cells from human alveolar bone treatment dysregulated 27200092 1518 Human hsa-miR-134-5p miRNA hypoxia/reoxygenation (H/R) acute myocardial infarction (AMI) AC16 cells; human cardiomyocytes (HCM) hypoxia/reoxygenation (H/R) treatment Expression of miR-134-5p was upregulated in serum of AMI patients and hypoxia/reoxygenation (H/R)-induced cardiomyocytes (AC16 and HCM). 32797709 1519 Human hsa-miR-134-5p miRNA resveratrol autism spectrum disorder (ASD) peripheral blood resveratrol (Res) treatment downregulated 29510222 1520 Human hsa-miR-134-5p miRNA cisplatin (DDP) cervical cancer (CC) Cervical cancer HeLa cells cisplatin treatment si-NCK1-AS1 and miR-134-5p mimic both reduced MSH2 activity and increased cisplatin-induced apoptosis in cervical cancer cells. 30221354 1521 Human hsa-miR-134-5p miRNA high glucose (HG) diabetes mellitus (DM) Endothelial colony forming cells (ECFCs) high glucose treatment upregulated 26799933 1522 Human hsa-miR-134-5p miRNA high glucose (HG) diabetic nephropathy (DN) human podocytes high glucose (HG) treatment miR-134-5p was upregulated in high-glucose (HG)-treated podocytes. 29636888 1523 Human hsa-miR-134-5p miRNA ionizing radiation (IR) low doses hyper-radiosensitivity (LDHRS) DLD-1 cells ionizing radiation (IR) treatment downregulated 29899866 1524 Human hsa-miR-134-5p miRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) Human neuroblastoma cell line SH-SY5Y "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" "circDLGAP4 exerted its functions via regulating miR-134-5p, circDLGAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway both in human and mouse." 31761328 1525 Human hsa-miR-134-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y Cells 1-methyl-4-phenylpyridinium (MPP+) treatment miR-134-5p was verified to be increased in PD cell models. 31761328 1526 Human hsa-miR-135 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment downregulated 28484287 1527 Human hsa-miR-135 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" tissue regeneration Human adult DPSCs "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 26351742 1528 Human hsa-miR-135a miRNA L©\arginine acute edematous pancreatitis (AEP) pancreatic acinar cell line (AR43J) introperitoneal injection of L-arginine (150 mg/kg) treatment upregulated 24710937 1529 Human hsa-miR-135a miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment upregulated 25230140 1530 Human hsa-miR-135a miRNA visfatin acute myeloid leukemia (AML) HL60 cells visfatin treatment downregulated 30876976 1531 Human hsa-miR-135a miRNA prostaglandin E2 (PGE2) Alzheimer's disease (AD) human umbilical vein endothelial cells (HUVECs) PGE2 treatment upregulated 25554493 1532 Human hsa-miR-135a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) atherosclerosis (AS) oxidized low-density lipoprotein (ox-LDL) treatment GAS5 knockdown suppresses inflammation and oxidative stress induced by oxidized low-density lipoprotein in macrophages by sponging miR-135a 33128668 1533 Human hsa-miR-135a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33128668 1534 Human hsa-miR-135a miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh7.5.1 cells; liver tissues hepatitis C virus (HCV) infection miR-135a hepatic abundance is upregulated by HCV infection in both cultured hepatocytes and human liver. 30456659 1535 Human hsa-miR-135a miRNA dextran sodium sulfate (DSS) inflammatory bowel disease (IBD) Caco-2 and HT-29 cells dextran sodium sulfate (DSS) treatment downregulated 30476915 1536 Human hsa-miR-135a miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 1537 Human hsa-miR-135a miRNA paclitaxel (PTX) prostate cancer "Human prostate cancer cells (PC3, C4-2 and DU145)" Paclitaxel treatment downregulated of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a 31486484 1538 Human hsa-miR-135a miRNA acute stress stress response mice amygdala acute Stress treatment downregulated 24023867 1539 Human hsa-miR-135a* miRNA platinum lung adenocarcinoma (LUAD) LADC tissues platinum-based doublet chemotherapy treatment dysregulated 25142144 1540 Human hsa-miR-135a* miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 1541 Human hsa-miR-135a-3p miRNA tanshinone I and TRAIL prostate cancer "PC-3, M2182 and DU145 cells" co- of Tanshinone I and TRAIL treatment upregulated 25015549 1542 Human hsa-miR-135a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment miR-135a-5p was decreased in oxidized low-density lipoprotein (ox-LDL)-treated HUVECs. 31921409 1543 Human hsa-miR-135a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aortic vascular smooth muscle cells (T/G HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment LINC00299 regulated ox-LDL-induced T/G HA-VSMCs injury through the miR-135a-5p/XBP1 axis. 32700888 1544 Human hsa-miR-135a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33778018 1545 Human hsa-miR-135a-5p miRNA TGF-¦Â1 diabetic nephropathy (DN) HK-2 cells TGF-¦Â1 treatment upregulated 32705273 1546 Human hsa-miR-135b miRNA hypoxia cell proliferation human umbilical vein endothelial cells (HUVECs) hypoxia induce downregulated 30576641 1547 Human hsa-miR-135b miRNA ligustrazine (Lig) cell proliferation hypoxia-induced human umbilical vein endothelial cells (HUVECs) Ligustrazine (Lig) treatment upregulated 30576641 1548 Human hsa-miR-135b miRNA mesalazine (MSLZ) colorectal cancer (CRC) CaCo2 cell line Mesalazine (5-ASA) treatment downregulated 29794245 1549 Human hsa-miR-135b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) "high glucose (25 mmol/L, 1-7 days)" "downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)" 28706953 1550 Human hsa-miR-135b miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human retinal pigment epithelial cells TGF-¦Â1 treatment downregulated 25263462 1551 Human hsa-miR-135b miRNA hypoxia hypoxia-induced cardiac dysfunctions human umbilical vein endothelial cells (HUVECs) hypoxia treatment downregulated 29883713 1552 Human hsa-miR-135b miRNA X-rays improved radiosensitivity NSCLC cell lines (A549 and H1975) X-ray irradiation treatment downregulated 28117028 1553 Human hsa-miR-135b miRNA 5-aza-2'-deoxycytidine and trichostatin A leukemia human leukemia cell lines 5-aza-deoxycytidine and trichostatin A treatment upregulated 27570640 1554 Human hsa-miR-135b miRNA Vitamin D and phorbol 12-myristate 13-acetate leukemia AML cell line (HL60 and NB4) Vitamin D and phorbol 12-myristate 13-acetate treatment downregulated 20981674 1555 Human hsa-miR-135b miRNA morin lung cancer A549 cells Morin treatment downregulated 28975847 1556 Human hsa-miR-135b miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 1557 Human hsa-miR-135b miRNA transcriptional co-activator with PDZ-binding motif (TAZ) osteosarcoma (OS) U2OS and HOS cell lines TAZ treatment upregulated 28823959 1558 Human hsa-miR-135b miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) Human neuroblastoma cell line SH-SY5Y 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 31036506 1559 Human hsa-miR-135b miRNA ligustrazine (Lig) pressure ulcer (PU) human umbilical vein endothelial cells (HUVECs) ligustrazine (Lig) treatment miR-135b was upregulated by the treatment of Lig. 30576641 1560 Human hsa-miR-135b miRNA E. senticosus extract (ESE) cell proliferation normal human keratinocytes normal human keratinocytes treatment downregulated 27042261 1561 Human hsa-miR-135b-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "In this study, ox-LDL inhibited circRSF1 and HDAC1 expression while upregulated miR-135b-5p expression in Human umbilical vein endothelial cells (HUVECs)." 33757583 1562 Human hsa-miR-135b-5p miRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin treatment downregulated 30665445 1563 Human hsa-miR-135b-5p miRNA radiation chondrosarcoma SW1353 cells radiation treatment downregulated 32362797 1564 Human hsa-miR-135b-5p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) "Human gastric cancer cell lines (MKN45, SNU601 and SNU1)" Helicobacter pylori (H. pylori) infection upregulated 29985646 1565 Human hsa-miR-135b-5p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) "Human gastric cancer cell lines (MKN45, SNU601 and SNU1)" Helicobacter pylori infection upregulated 29985646 1566 Human hsa-miR-135b-5p miRNA sulforaphane (SFN) pancreatic ductal adenocarcinoma (PDAC) "The established human PDA cell lines AsPC-1, BxPC-3, PANC-1" sulforaphane treatment upregulated 31044154 1567 Human hsa-miR-136 miRNA platelet-derived growth factor (PDGF) atherosclerosis (AS) vascular smooth muscle cells platelet-derived growth factor (PDGF) treatment upregulated 25409743 1568 Human hsa-miR-136 miRNA TGF-¦Â1 skin wound healing HaCaT cells TGF-¦Â1 treatment downregulated 25654102 1569 Human hsa-miR-136 miRNA hypoxia spinal cord ischemia injury (SCII) human neuronal cell line AGE1.NH hypoxia for 3 day supplemented with 1% O2 upregulated 28753453 1570 Human hsa-miR-136 miRNA rapamycin complex (mTOR) tuberous sclerosis complex (TSC) serum rapamycin complex (mTOR) treatment upregulated 27680012 1571 Human hsa-miR-136* miRNA leuprolide endometriosis endometriotic tissues Leuprolide treatment upregulated 27709720 1572 Human hsa-miR-136-3p miRNA titanium surface implant-host tissue interactions osteoblastic cells from human alveolar bone osteoblastic cells from human alveolar bone treatment dysregulated 27200092 1573 Human hsa-miR-136-5p miRNA lipopolysaccharide (LPS) LPS-induced inflammation and damage ARPE-19 cells lipopolysaccharide (LPS) treatment "After the treatment of ripasudil, the expression levels of miR-136-5p was suppressed." 32252692 1574 Human hsa-miR-136-5p miRNA ripasudil LPS-induced inflammation and damage ARPE-19 cells ripasudil treatment "After the treatment of ripasudil, the expression levels of ROCK1, ROCK2 and miR-136-5p were suppressed" 32252692 1575 Human hsa-miR-136-5p miRNA gemcitabine (GEM) pancreatic cancer (PC) PANC-1 cells; CFPAC-1 cells gemcitabine treatment "MicroRNA-136-5p can reduce the proliferation rate and metastasis ability of PCa cells via regulating ZNF32, and thus alleviates gemcitabine resistance in PCa cells." 33155203 1576 Human hsa-miR-136-5p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 1577 Human hsa-miR-137 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y and human primary neuron (HPN) cells amyloid-¦Â (A¦Â) 25-35 treatment "A¦Â25-35 inhibited cell viability, induced cell apoptosis and increased the expression of SNHG1 in SH-SY5Y and human primary neuron (HPN) cells." 31447119 1578 Human hsa-miR-137 miRNA hypoxia apoptosis human embryonic kidney 293 (HEK-293) cells "5% O2, 90% N2 and 5% CO2," downregulated 29286063 1579 Human hsa-miR-137 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)" bladder cancer BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment" upregulated 23200812 1580 Human hsa-miR-137 miRNA osteogenic differentiation medium calcific aortic valve disease (CAVD) valve interstitial cells (VICs) isolated from human calcific aortic valves "a-minimal essential medium (Gibco, Carlsbad, CA, USA) containing 0.1% FBS, bioactive recombinant human bone morphogenetic protein-2 (BMP-2; 50 ng/mL), dexamethasone (100 nmol/L), ascorbic acid (50 mg/mL), and b-glycerophosphate (5 mmol/L) treatment" upregulated 30846207 1581 Human hsa-miR-137 miRNA high glucose (HG) diabetic nephropathy (DN) Human renal mesangial cells (HRMCs) high glucose treatment downregulated 28695984 1582 Human hsa-miR-137 miRNA triptolide (TPL) diabetic nephropathy (DN) high glucose-treated human renal mesangial cells (HRMCs) triptolide (TPL) treatment upregulated 28695984 1583 Human hsa-miR-137 miRNA high glucose (HG) diabetic nephropathy (DN) HRMCs high glucose treatment downregulated 28695984 1584 Human hsa-miR-137 miRNA triptolide (TPL) diabetic nephropathy (DN) HG-treat HRMCs high glucose treatment upregulated 28695984 1585 Human hsa-miR-137 miRNA cocaine drug addiction differentiated SH-SY5Y neuroblastoma cells cocaine treatment downregulated 30166527 1586 Human hsa-miR-137 miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 1587 Human hsa-miR-137 miRNA high glucose (HG) gestational diabetes mellitus (GDM) human umbilical vein endothelial cells (HUVECs) high-glucose (HG) treatment upregulated 29505767 1588 Human hsa-miR-137 miRNA high glucose (HG) gestational diabetes mellitus (GDM) HTR-8/SVneo cells high glucose (HG) treatment upregulated 29786111 1589 Human hsa-miR-137 miRNA high glucose (HG) gestational diabetes mellitus (GDM) trophoblast cell line HTR-8/Svneo high glucose (HG) treatment upregulated 31109274 1590 Human hsa-miR-137 miRNA H2O2 glaucoma RGCs H2O2 treatment We show that miR-137 was downregulated in H2O2-induced human trabecular meshwork cells (HTMCs) 33865939 1591 Human hsa-miR-137 miRNA phenformin glioblastoma multiforme (GBM) glioma stem cells (GSCs) Phenformin treatment upregulated 27486821 1592 Human hsa-miR-137 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 and A172 cells temozolomide (TMZ) treatment downregulated 31750728 1593 Human hsa-miR-137 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) T98G cells temozolomide (TMZ) treatment upregulated 22722712 1594 Human hsa-miR-137 miRNA olea europaea leaf extract (OLE) glioblastoma multiforme (GBM) GBM cell lines olea europaea leaf extract (OLE) treatment upregulation 25232498 1595 Human hsa-miR-137 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251; A172 cells temozolomide (TMZ) treatment NCK1-AS1 could increase drug resistance of glioma cells to TMZ by modulating miR-137/TRIM24 pathway 31750728 1596 Human hsa-miR-137 miRNA hepatitis B virus (HBV) hepatitis B virus (HBV) infection HEK293 cells transfection with pHBV1.3 upregulated 29441983 1597 Human hsa-miR-137 miRNA aspirin hepatocellular carcinoma (HCC) Huh-7 cells Aspirin treatment upregulated 32627038 1598 Human hsa-miR-137 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 1599 Human hsa-miR-137 miRNA propofol (PPF) melanoma Melanoma cells A2058 and WM793B Propofol treatment upregulated 31134615 1600 Human hsa-miR-137 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NSCLC patient tissue samples criplatin treatment microRNA-137 in cisplatin-treated NSCLC patient tissue samples was markedly lower than that in healthy tissue samples. 30008879 1601 Human hsa-miR-137 miRNA oxaliplatin oxaliplatin (L-OHP) resistance HCT116; W480 cells oxaliplatin (L-OHP) treatment Silencing OIP5-AS1 reversed the resistance of CC cells to L-OHP by promoting the expression of miR-137 32308348 1602 Human hsa-miR-137 miRNA cisplatin (DDP) pancreatic cancer (PC) PANC-1 cells; HS766T cells; AsPC-1 cells cisplatin treatment downregulated 32280243 1603 Human hsa-miR-137 miRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation and migration VSMCs cell lines (human aortic smooth muscle cells) platelet-derived growth factor-BB (PDGF-BB) treatment upregulated 29016699 1604 Human hsa-miR-137 miRNA bicalutamide prostate cancer human prostate cancer LNCaP cells bicalutamide treatment miR-137 modulate the response of human prostate cancer LNCaP cells to the antiandrogen bicalutamide. 31217891 1605 Human hsa-miR-137 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 1606 Human hsa-miR-138 miRNA adipogenesis medium adipogenesis adipose tissue-derived mesenchymal stem cells (AMSCs) adipogenic differentiation medium culture downregulated 31769250 1607 Human hsa-miR-138 miRNA platelet-derived growth factor (PDGF) bone homeostasis disorders Multipotent mesenchymal stromal cells PDGF treatment upregulated 24792185 1608 Human hsa-miR-138 miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 1609 Human hsa-miR-138 miRNA hypoxia tumorigenesis EA.hy926 endothelial cells ATCC (CRL-2922) ?hypoxia treatment upregulated 24244340 1610 Human hsa-miR-138 miRNA hypoxia cardiac dysfunction human cardiac cells hypoxia treatment downregulated 28899927 1611 Human hsa-miR-138 miRNA hypoxia cardiomyocyte apoptosis Myocardial samples of patients with congenital heart disease (CHD) hypoxia treatment upregulated 24211202 1612 Human hsa-miR-138 miRNA imatinib chronic myeloid leukemia (CML) K562 cells and primary CML samples 1 mmol/l imatinib for 24 or 48 h treatment downregulated 23208504 1613 Human hsa-miR-138 miRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cardiomyocytes high glucose (HG) treatment GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model 33682891 1614 Human hsa-miR-138 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high-glucose (HG) treatment upregulated 31251107 1615 Human hsa-miR-138 miRNA salidroside (SAL) diabetic retinopathy (DR) high-glucose (HG)-treated ARPE-19 cells salidroside (SAL) treatment downregulated 31251107 1616 Human hsa-miR-138 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) LC006 cells; LC021 cells TGF-¦Â1 treatment "Among those dysregulated miRNAs, the expression of microRNA-138 was time-dependently downregulated by TGF¦Â1 treatment" 29407170 1617 Human hsa-miR-138 miRNA ¦Á-solanine esophageal cancer (EC) human EC cells lines EC9706 and KYSE30 human EC cells lines EC9706 and KYSE30 treatment upregulation 27536892 1618 Human hsa-miR-138 miRNA ¦Á-solanine esophageal squamous cell carcinoma (ESCC) EC9706 and KYSE30 cells ¦Á-solanine treatment upregulated 29328459 1619 Human hsa-miR-138 miRNA hepatitis B virus (HBV) hepatitis B virus (HBV) infection T-cell hepatitis B virus (HBV)?treatment "We found that PD-1 was upregulated and miR-138 was downregulated in patients with CHB, LC, and HCC." 33410459 1620 Human hsa-miR-138 miRNA hepatitis B virus (HBV) hepatoblastoma HepG2 cells hepatitis B virus (HBV) infection downregulated 30367502 1621 Human hsa-miR-138 miRNA resveratrol low extremity deep vein thrombosis Endothelial progenitor cells (EPCs) resveratrol (Res) treatment downregulated 29447140 1622 Human hsa-miR-138 miRNA "MS-275, a histone deacetylase inhibitor" lung adenocarcinoma (LUAD) A549 and HCC827 cell lines MS-275 treatment upregulated 31090206 1623 Human hsa-miR-138 miRNA ¦Á-solanine lung cancer human lung adenocarcinoma cell lines (A549 and H1299) human lung adenocarcinoma cell lines (A549 and H1299) treatment upregulation 26631041 1624 Human hsa-miR-138 miRNA triptolide (TPL) medulloblastoma Daoy cells triptolide (TPL) treatment upregulated 30156009 1625 Human hsa-miR-138 miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 1626 Human hsa-miR-138 miRNA lentivirus non-small cell lung cancer (NSCLC) NSCLC cell lines H460 and SPC-A1 cells Lentivirus treatment upregulated 26201895 1627 Human hsa-miR-138 miRNA tumor necrosis factor alpha (TNF-¦Á) osteoarthritis (OA) human OA chondrocytes "TNF¦Á for 3, 6, and 12 h treatment" downregulated 28537665 1628 Human hsa-miR-138 miRNA "mechanical tension (10%, 0.5Hz)" osteogenesis human BMMSCs (hBMMSCs) "mechanical tension (10%, 0.5Hz)" downregulated 29253550 1629 Human hsa-miR-138 miRNA tension osteogenic capability Bone marrow mesenchymal stem cells (BMMSCs) tension treatment mechanical tension could suppress miR-138 expression 29253550 1630 Human hsa-miR-138 miRNA oestrogen (E2) osteoporosis HFOB and MG63 cells oestrogen (E2) treatment a dose-dependent upregulated of HOTAIR was observed in cells treated with oestrogen 33733597 1631 Human hsa-miR-138 miRNA curcumin (Cur) osteosarcoma (OS) human osteosarcoma cell line MG-63 curcumin treatment upregulated 26823826 1632 Human hsa-miR-138 miRNA desflurane ovarian cancer (OC) SKOV3 cells desflurane treatment "miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane." 33673181 1633 Human hsa-miR-138 miRNA sevoflurane (SEV) ovarian cancer (OC) SKOV3 cells sevoflurane treatment "miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane" 33673181 1634 Human hsa-miR-138 miRNA lipopolysaccharide (LPS) periodontal disease periodontal progenitors lipopolysaccharide (LPS) treatment upregulated 26518300 1635 Human hsa-miR-138 miRNA ¦Á-solanine prostate cancer human prostate cancer cell PC-3 ¦Á-solanine treatment upregulated 25116803 1636 Human hsa-miR-138 miRNA lipopolysaccharide (LPS) rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) lipopolysaccharides (LPS) treatment upregulated 31492495 1637 Human hsa-miR-138 miRNA cyanidin-3-glucoside (C3G) triple negative breast cancer (TNBC) TNBC lines MDA-MB-231 and BT-549 Cyanidin-3-glucoside (C3G) treatment downregulated 30876970 1638 Human hsa-miR-138-5p miRNA phenytoin antiepileptic drug (AED) resistance human brain microvascular endothelial cells (HBMECs) phenytoin treatment downregulated 31920517 1639 Human hsa-miR-138-5p miRNA manganese chloride (MnCl2 ) autophagy SH-SY5Y cells manganese chloride (MnCl2 ) treatment MnCl2 could induce autophagic dysregulation and inhibit expression of miR-138-5p. 30672645 1640 Human hsa-miR-138-5p miRNA bruceine D (BD) gastric cancer (GC) HGC27 cells; MKN45 cells bruceine D (BD) treatment upregulated 33390953 1641 Human hsa-miR-138-5p miRNA hypoxia gastric cancer (GC) SGC-7901; BGC-823 hypoxia treatment downregulated 32425596 1642 Human hsa-miR-138-5p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells; U87 cells temozolomide (TMZ) treatment LINC00174 downregulated decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis 31713817 1643 Human hsa-miR-138-5p miRNA tumor necrosis factor alpha (TNF-¦Á) insulin resistance (IR) HepG2 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30442237 1644 Human hsa-miR-138-5p miRNA resolvin D1 (RvD1) non small cell lung cancer (NSCLC) "A549 cells, H1299 and LLC cells" resolvin D1 (RvD1) treatment upregulated 31783879 1645 Human hsa-miR-138-5p miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment MiR-138-5p was downregulated in CHON-001 cells. 31486753 1646 Human hsa-miR-138-5p miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells; A2780 cells cisplatin treatment miR-138-5p was downregulated in DDP-resistant cells. 32349783 1647 Human hsa-miR-138-5p miRNA hypoxia pancreatic cancer (PC) "AsPC-1, BxPC-3, and PANC-1 cell lines" hypoxia treatment downregulated 28052003 1648 Human hsa-miR-138-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 31737212 1649 Human hsa-miR-138-5p miRNA lipopolysaccharide (LPS) preeclampsia (PE) HTR-8/SVneo cells; JEG-3 cells lipopolysaccharide (LPS) treatment downregulated 33550900 1650 Human hsa-miR-138-5p miRNA docetaxel (DTX) prostate cancer LNCaP and CWR22Rv1 cells docetaxel (DTX) treatment downregulated 30621625 1651 Human hsa-miR-139 miRNA hyperthermia breast cancer BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231 Hyperthermia treatment downregulated 27380148 1652 Human hsa-miR-139 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y Cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment MiR-139 was significantly downregulated whereas c-Jun was obviously upregulated after OGD/R treatment. 32807449 1653 Human hsa-miR-139 miRNA resveratrol osteosarcoma (OS) U20S and MG63 cells resveratrol (RS) treatment upregulated 31881225 1654 Human hsa-miR-139 miRNA a moderate-carbohydrate and high glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and high glycemic index diet downregulated 29233589 1655 Human hsa-miR-139 miRNA low fat diet (LFD) overweight and obese plasma low fat diet (LFD) treatment downregulated in plasma 29233590 1656 Human hsa-miR-139 miRNA TGF-¦Â scar formation after the glaucoma filtration surgery human Tenon's fibroblasts (HTFs) TGF-¦Â treatment downregulated 30648255 1657 Human hsa-miR-139-3p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 1658 Human hsa-miR-139-3p miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment downregulated 24589211 1659 Human hsa-miR-139-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid" renal cell carcinoma (RCC) renal cell; carcinoma cell lines (5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment upregulated 23707942 1660 Human hsa-miR-139-5p miRNA sevoflurane (SEV) breast cancer MDA-MB-231 and MCF-7 cells sevoflurane (SEV) treatment MiR-139-5p was upregulated in BC cells treated with SEV 33317757 1661 Human hsa-miR-139-5p miRNA T-helper type 2 (Th2)-biased cytokine environment allergic asthma (AA) Bronchial epithelial cells T-helper type 2 (Th2)-biased cytokine environment treatment downregulated 26289417 1662 Human hsa-miR-139-5p miRNA "IL-1¦Â, IFN-¦Ã and TNF-¦Á" asthma human airway smooth muscle cells "a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h" downregulated 28711603 1663 Human hsa-miR-139-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human arterial smooth muscle cells (HASMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33331071 1664 Human hsa-miR-139-5p miRNA sevoflurane (SEV) breast cancer MCF-10A cells Sevoflurane (SEV) treatment MiR-139-5p was upregulated in BC cells treated with SEV 33317757 1665 Human hsa-miR-139-5p miRNA high glucose (HG) diabetic vasculopathy human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment miR-139-5p expression was elevated in human umbilical vein endothelial cells (HUVECs) cultured in high glucose media. 33293476 1666 Human hsa-miR-139-5p miRNA ginsenoside Rg3 epithelial-mesenchymal transition (EMT) iE-DAP-treated human umbilical vein endothelial cells (HUVEC) Ginsenoside Rg3 (Rg3) treatment upregulated 32148412 1667 Human hsa-miR-139-5p miRNA ¦Ã-d-glutamyl-meso-diaminopimelic acid (iE-DAP) epithelial-mesenchymal transition (EMT) human umbilical vein endothelial cells (HUVEC) ¦Ã-d-glutamyl-meso-diaminopimelic acid (iE-DAP) treatment downregulated 32148412 1668 Human hsa-miR-139-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) tissues sorafenib treatment dysregulated 28049231 1669 Human hsa-miR-139-5p miRNA hypoxia kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection human KS-derived SLK and SLKK cells hypoxia treatment upregulated 28046107 1670 Human hsa-miR-139-5p miRNA particulate matter (PM2.5) lung cancer 16HBE cells PM2.5 stimulation treatment downregulated 32913469 1671 Human hsa-miR-139-5p miRNA ultraviolet (UV) irradiation lupus erythematosus (LE) HaCaT cells 30 mJ/cm2 UVB irradiation treatment upregulated 31966801 1672 Human hsa-miR-139-5p miRNA morphine morphine addiction HEK 293 cells morphine treatment Chronic morphine pretreatment alone elevated both c-Jun protein and miR-139-5p expression levels. 29916183 1673 Human hsa-miR-139-5p miRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) HNE1 cells cisplatin (DPP) treatment downregulated 29337244 1674 Human hsa-miR-139-5p miRNA compound C nonalcoholic fatty liver disease (NAFLD) HepG2 cells; primary human hepatocytes (HH) compound C treatment downregulated 32143184 1675 Human hsa-miR-139-5p miRNA cisplatin (DDP) ovarian cancer (OC) human ovarian cancer cells OVCAR-8R cisplatin treatment dysregulated 28861582 1676 Human hsa-miR-139-5p miRNA hyaluronic acid (HA) primary ovarian insufficiency (POI) ovarian granulosa cells (GCs) HA treatment downregulated 25232020 1677 Human hsa-miR-139-5p miRNA X-rays prostate cancer PC-3 cells; DU145 cells X-ray radiation treatment Knockdown of lncRNA TUG1 enhanced radiosensitivity in PCa via the TUG1/miR-139-5p/SMC1A axis 32256083 1678 Human hsa-miR-1-3p miRNA PI3K/mTOR dual inhibitor BEZ235 acute myeloid leukemia (AML) HL-60/VCR cells BEZ235 treatment upregulated 28042875 1679 Human hsa-miR-1-3p miRNA hepatocyte growth factor (HGF) lung cancer lung cancer cells PC-9 and HCC-827 Hepatocyte growth factor (HGF) treatment downregulated 29664235 1680 Human hsa-miR-1-3p miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 29218085 1681 Human hsa-miR-1-3p miRNA protein kinase C inhibitor GF109203X wound healing and regeneration of skin tissues. human keratinocytes GF109203X treatment "upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )" 28901412 1682 Human hsa-miR-140 miRNA lipopolysaccharide (LPS) colorectal cancer (CRC) SW480 cells; HCT116 cells lipopolysaccharide (LPS) treatment LPS could increase miR-140 expression in a time- and concentration-dependent manner. 31882548 1683 Human hsa-miR-140 miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose treatment upregulated 31362245 1684 Human hsa-miR-140 miRNA ¦Á-Mangostin diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) ¦Á-Mangostin treatment H19 exerted its function via the modulation of H19/miR-140/HE4 in hyperglycemia with ¦Á-Mangostin 31362245 1685 Human hsa-miR-140 miRNA Bie Jia Jian Pill (BJJP) hepatocellular carcinoma (HCC) cancer stem cells (CSCs) Bie Jia Jian Pill (BJJP) treatment ?BJJP or BMSCs treatment alone on CSCs lead to increased miR-140 expression and cell apoptosis 33632990 1686 Human hsa-miR-140 miRNA hypoxia hepatocellular carcinoma (HCC) HCC cells hypoxia treatment ?NR2F1-AS1 level was enhanced in HCC tissues and cells. 33488124 1687 Human hsa-miR-140 miRNA lipopolysaccharide (LPS) inflammation CD14©\positive cells lipopolysaccharides (LPS) treatment downregulated 30321456 1688 Human hsa-miR-140 miRNA aucubin intervertebral disc degeneration (IDD) IL©\1¦Â or TNF©\¦Á-induced human nucleus pulposus cells (HNPCs) aucubin treatment upregulated 30637726 1689 Human hsa-miR-140 miRNA IL-1¦Â intervertebral disc degeneration (IDD) human nucleus pulposus cells (HNPCs) IL-1¦Â treatment downregulated 30637726 1690 Human hsa-miR-140 miRNA tumor necrosis factor alpha (TNF-¦Á) intervertebral disc degeneration (IDD) human nucleus pulposus cells (HNPCs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 30637726 1691 Human hsa-miR-140 miRNA estradiol-17¦Â (E2) menopausal arthritis chondrocytes estradiol-17¦Â (E2) treatment upregulated 27165343 1692 Human hsa-miR-140 miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells free fatty acids (FFA) treatment NEAT1 and miR-140 are upregulated in hepacytes under the NAFLD conditions. The NEAT1-miR-140 axis play a crucial role in modulation of NAFLD via inactivation of AMPK/SREBP1 signaling. 31239155 1693 Human hsa-miR-140 miRNA TGF-¦Â non-small cell lung cancer (NSCLC) erlotinib-sensitive PC9 cells TGF¦Â treatment dysregulated 28646226 1694 Human hsa-miR-140 miRNA carnosic acid (CA) osteoarthritis (OA) human articular chondrocytes Carnosic acid (CA) treatment upregulated 29678719 1695 Human hsa-miR-140 miRNA IL-1¦Â osteoarthritis (OA) Human Chondrocytes IL-1¦Â treatment downregulated 31915516 1696 Human hsa-miR-140 miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-1¦Â treatment downregulated 32520081 1697 Human hsa-miR-140 miRNA IL-1¦Â osteoarthritis (OA) human cartilage cells line C28/I2 IL-1¦Â treatment Expression of miRNA-140 and MMP-13 was elevated in IL-1b-stimulated C28/I2 cells 22273691 1698 Human hsa-miR-140 miRNA mechanical loading and hydrostatic pressure (HP) osteoarthritis (OA) OA human chondrocytes mechanical loading and hydrostatic pressure (HP) treatment upregulated 28085114 1699 Human hsa-miR-140 miRNA melatonin osteoarthritis (OA) Human Chondrocytes melatonin treatment upregulated 31915516 1700 Human hsa-miR-140 miRNA melatonin osteosarcoma (OS) SaOS2 cells; MG63 cells Melatonin treatment upregulated 32592723 1701 Human hsa-miR-140 miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment downregulated 32901049 1702 Human hsa-miR-140 miRNA insulin polycystic ovarian syndrome (PCOS) human granulosa cells (GCs) insulin treatment High miR-140 expression was observed in insulin-treated granulosa cells compared to that in unstimulated cells. 32024547 1703 Human hsa-miR-140 miRNA TGF-¦Â1 lung fibrosis HBE and A549 cells TGF-¦Â1 treatment H19 knockdown attenuated pulmonary fibrosis via the regulatory network of lncRNA H19-miR-140-TGF-¦Â/Smad3 signaling 30988156 1704 Human hsa-miR-140-3p miRNA high glucose (HG) diabetes mellitus (DM) "Human retinal vascular endothelial cells (HRVECs), human umbilical vein endothelial cells (HUVECs), human coronary artery endothelial cells (HCAECs) and human coronary artery endothelial cells (EA.hy.926)" high glucose treatment downregulated 30862410 1705 Human hsa-miR-140-3p miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment Loss of circRNA_0084043 depressed HG-induced damage via sponging miR-140-3p and regulating TGFA. 32259630 1706 Human hsa-miR-140-3p miRNA astragaloside IV (AS-IV) endothelial dysfunction Oxidized low-density lipoprotein (ox-LDL)-treated human umbilical vein endothelial cells (HUVECs) astragaloside IV (AS-IV) treatment upregulated 31257467 1707 Human hsa-miR-140-3p miRNA oxidized low density lipoprotein (ox-LDL) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31257467 1708 Human hsa-miR-140-3p miRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) human umbilical vein endothelial cells (HUVECs) hypoxia/reoxygenation (H/R) induce downregulated 31792649 1709 Human hsa-miR-140-3p miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 1710 Human hsa-miR-140-3p miRNA epigallocatechin-3-gallate (EGCG) osteoarthritis (OA) interleukin-1¦Â-stimulated human osteoarthritis chondrocytes EGCG downregulated 28110479 1711 Human hsa-miR-140-3p miRNA epigallocatechin-3-gallate (EGCG) osteoarthritis (OA) human chondrocytes Epigallocatechin-3-O-gallate (EGCG) treatment EGCG inhibited IL-1¦Â-induced ADAMTS5 expression and upregulated the expression of hsa-miR-140-3p. 28110479 1712 Human hsa-miR-140-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 1713 Human hsa-miR-140-3p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-8¦Â treatment dysregulated 29123165 1714 Human hsa-miR-140-3p miRNA IL-1¦Â osteoarthritis (OA) CHON-001 chondrocyte cells IL-1¦Â treatment MiR-140-3p Ameliorates the Progression of Osteoarthritis via Targeting CXCR4. 32101839 1715 Human hsa-miR-140-3p miRNA activin A prostate cancer PC3 cells activin A treatment downregulated 27018851 1716 Human hsa-miR-140-3p miRNA tumor necrosis factor alpha (TNF-¦Á) asthma human airway smooth muscle cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 22773691 1717 Human hsa-miR-140-5p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment downregulated 30344669 1718 Human hsa-miR-140-5p miRNA particulate matter (PM2.5) airway inflammation 16HBE cells fine particulate matter (PM2.5) exposure treatment MiR-140-5p/TLR4 /NF-¦ÊB signaling pathway: Crucial role in inflammatory response in 16HBE cells induced by dust fall PM 25 33080424 1719 Human hsa-miR-140-5p miRNA particulate matter (PM2.5) airway inflammation human bronchial epithelial cells (16HBE) fine particulate matter (PM2.5) exposure treatment "In conclusion, this study revealed a new mechanism by which the miR-140-5p/TLR4 signaling pathway mediated the inflammatory response of 16HBE cells induced by PM25" 33080424 1720 Human hsa-miR-140-5p miRNA simvastatin breast cancer MDA-MB-231 cells Simvastatin treatment upregulated 31138773 1721 Human hsa-miR-140-5p miRNA hypoxia cerebral ischemia injury (CII) HUVECs hypoxia treatment downregulated 27035554 1722 Human hsa-miR-140-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment downregulated 32073611 1723 Human hsa-miR-140-5p miRNA high glucose (HG) diabetic-associated vascular injury Human umbilical vein endothelial cells (HUVECs) high-glucose (HG) treatment High glucose (HG) exposure downregulated the expression of circ_CLASP2 in HUVECs 33776760 1724 Human hsa-miR-140-5p miRNA propofol (PPF) gastric cancer (GC) SGC-7901 and MKN45 cells propofol?treatment treatment upregulated 31819507 1725 Human hsa-miR-140-5p miRNA heat stress heat-induced pathophysiology human umbilical vein endothelial cells cultured in the incubator at 43¡ãC for 1 h "downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)" 29039486 1726 Human hsa-miR-140-5p miRNA catalpol hepatocellular carcinoma (HCC) HCCLM3 cells; Huh7 cells catalpol treatment Catalpol increased the expression levels of E-cadherin and miR-140-5p. 33179108 1727 Human hsa-miR-140-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2/SOR cell line sorafenib treatment "miR-140-5p overexpression also increases the sensitivity of HepG2/SOR cells to sorafenib, and the effects of SNHG16 knockdown on sorafenib resistance could be blocked by miR-140-5p inhibitor" 30655679 1728 Human hsa-miR-140-5p miRNA TGF-¦Â1 hepatocellular carcinoma (HCC) MHCC-97H and SMMC-7721 cells TGF¦Â1 treatment downregulated 31402791 1729 Human hsa-miR-140-5p miRNA simvastatin hypercholesterolemia HepG2 cells; LO2 cells simvastatin treatment "Palmitic acid and simvastatin suppressed, whereas LDL-C upregulated the expression of miR-140-5p in HepG2 cells" 32109664 1730 Human hsa-miR-140-5p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 1731 Human hsa-miR-140-5p miRNA hypoxia hypoxic brain injury SH-SY5Y cells hypoxia treatment "LncRNA SNHG1-modulated miR-140-5p inhibition regulates Bcl-XL expression, thereby reducing cell apoptosis and recovering cell viability of SH-SY5Y cells." 32186226 1732 Human hsa-miR-140-5p miRNA oxygen glucose deprivation (OGD) hypoxic brain injury SH-SY5Y cells Oxygen glucose deprivation (OGD) treatment Oxygen glucose deprivation (OGD) treatment inhibited SNHG1 and Bcl-XL expression and enhanced miR-140-5p expression 32186226 1733 Human hsa-miR-140-5p miRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) nucleus pulposus (NP) cells lipopolysaccharides (LPS) treatment downregulated 29901170 1734 Human hsa-miR-140-5p miRNA pioglitazone metabolic syndrome endothelial progenitor cells (EPCs) Pioglitazone treatment downregulated 26898430 1735 Human hsa-miR-140-5p miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NSCLC cell lines (A549 and H1299) cisplatin treatment downregulated 31288529 1736 Human hsa-miR-140-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" osteoarthritis (OA) OA chondrocytes and synoviocytes "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31077718 1737 Human hsa-miR-140-5p miRNA IL-1¦Â osteoarthritis (OA) The normal human chondrocytes C28/I2 IL-1¦Â treatment downregulated 31712854 1738 Human hsa-miR-140-5p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes C28/I2 IL-1¦Â treatment upregulated 31712854 1739 Human hsa-miR-140-5p miRNA metformin (Met) pancreatic cancer (PC) human pancreatic cancer cell lines PANC-1 and BxPC-3 Metformin treatment dysregulated 28875433 1740 Human hsa-miR-140-5p miRNA metformin (Met) type 2 diabetes mellitus (T2DM) The human renal epithelial cells (294T cells) metformin treatment differently regulated in circulating 24478399 1741 Human hsa-miR-141 miRNA ultraviolet (UV) irradiation DNA damage U2OS;EH1; EH2 cell lines ultraviolet light treatment upregulated 24163379 1742 Human hsa-miR-141 miRNA esomeprazole adeno and squamous-cell-carcinoma human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines esomeprazole treatment upregulated 25175076 1743 Human hsa-miR-141 miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 1744 Human hsa-miR-141 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 26823756 1745 Human hsa-miR-141 miRNA influenza A virus (IAV) avian influenza virus (AIV) infection NCI-H292 cells avian influenza viruses treatment the modulation of TGF-¦Â2 expression by different influenza subtypes via miR-141 might be a critical step for determining the outcome of either normal or excessive inflammation progression 23663545 1746 Human hsa-miR-141 miRNA arsenic trioxide (ATO) breast cancer MDA-MB-231 cells arsenic trioxide (As2O3) treatment upregulated 24729530 1747 Human hsa-miR-141 miRNA glabridin (GLA) breast cancer MDA-MB-231 breast cancer cells Glabridin treatment upregulated 24754877 1748 Human hsa-miR-141 miRNA silibinin (SB) breast cancer T47D breast cancer cell line silibinin treatment "upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)" 28509572 1749 Human hsa-miR-141 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cancer-associated fibroblasts (CAFs) activation cultured cancer-associated fibroblasts (CAFs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30851420 1750 Human hsa-miR-141 miRNA TGF-¦Â1 cancer-associated fibroblasts (CAFs) activation cultured normal fibroblasts (NFs) TGF¦Â1 treatment downregulated 30851420 1751 Human hsa-miR-141 miRNA decabromodiphenyl ether (BDE-209) cardiovascular disease (CVD) THP-1 monocytes to human aortic endothelial cells (HAECs) decabromodiphenyl ether (BDE-209) treatment downregulated 30419430 1752 Human hsa-miR-141 miRNA decabromodiphenyl ether (BDE-209) cardiovascular disease (CVD) human aortic endothelial cells (HAECs) decabromodiphenyl ether (BDE-209) treatment downregulated 30419430 1753 Human hsa-miR-141 miRNA paeonol (PAE) chondrosarcoma human chondrosarcoma cell line JJ012 paeonol treatment upregulated 24992595 1754 Human hsa-miR-141 miRNA leukemia inhibitory factor(LIF) choriocarcinoma JEG-3 cells leukemia inhibitory factor(LIF) treatment downregulated 21726338 1755 Human hsa-miR-141 miRNA RM (Root methanol) colorectal cancer (CRC) HT-29 cells; HCT 119 cells RM (Root methanol) treatment upregulated 32691634 1756 Human hsa-miR-141 miRNA high glucose (HG) diabetic nephropathy (DN) human glomerular mesangial cells (HGMCs) high glucose (HG) treatment The results showed that SNHG15 was remarkably upregulated in pediatric DN tissues and HG-induced HGMCs. 33506255 1757 Human hsa-miR-141 miRNA high glucose (HG) endothelial inflammation human aortic endothelial cells (HAECs) high glucose (HG) treatment downregulated 29720943 1758 Human hsa-miR-141 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epithelial-mesenchymal transition (EMT) human conjunctival epithelial (HCjE) cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" 5-AzaC treatment induced increased expression of miR-141 towards the control level. 32387379 1759 Human hsa-miR-141 miRNA decitabine gastric cancer (GC) SGC-7902 cells decitabine treatment upregulated 25502084 1760 Human hsa-miR-141 miRNA decitabine gastric cancer (GC) SGC-7901 cells the chemotherapeutic agent decitabine treatment upregulated 25502084 1761 Human hsa-miR-141 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) people Helicobacter pylori infected treatment downregulated 24732377 1762 Human hsa-miR-141 miRNA TGF-¦Â gastric cancer (GC) SGC-7902 cells TGF-¦Â treatment downregulated 25502084 1763 Human hsa-miR-141 miRNA high glucose (HG) hepatic steatosis HepG2 cells high glucose (HG) treatment upregulated 31256424 1764 Human hsa-miR-141 miRNA 5-fluorouracil (5-Fu) hepatocellular carcinoma (HCC) HepG2 cells; SMMC-7721 cells 5-fluorouracil (5-FU) treatment miR-141 was sig- nificantly increased in 5-FU-resistant HCC cells. 30119680 1765 Human hsa-miR-141 miRNA lipopolysaccharide (LPS) infantile pneumonia (IP) WI-38 cells lipopolysaccharide (LPS) treatment downregulated 30500550 1766 Human hsa-miR-141 miRNA lipopolysaccharide (LPS) inflammation WI-38 fibroblasts lipopolysaccharides (LPS) treatment downregulated 30500550 1767 Human hsa-miR-141 miRNA TGF-¦Â1 liver fibrosis LX2 cells TGF-¦Â1 treatment downregulated of miR-141 deactivates hepatic stellate cells by targeting the PTEN/AKT/mTOR pathway 32319536 1768 Human hsa-miR-141 miRNA arsenite melanoma human keratinocyte HaCaT cell line arsenic (As) exposure upregulated 27054085 1769 Human hsa-miR-141 miRNA dacarbazine (DTIC) melanoma FEMX-1 melanoma cell line dacarbazine (DTIC) treatment upregulated 28387914 1770 Human hsa-miR-141 miRNA high glucose (HG) nonalcoholic fatty liver disease (NAFLD) HepG2 cells high glucose treatment upregulated 31256424 1771 Human hsa-miR-141 miRNA TGF-¦Â non-small cell lung cancer (NSCLC) erlotinib-sensitive PC9 cells TGF¦Â treatment dysregulated 28646226 1772 Human hsa-miR-141 miRNA human papilloma viruses (HPVs) 16 oropharyngeal squamous cell carcinoma (OPSCC) HOK-19B cells human papillomaviruses (HPVs) 19 treatment downregulated 31911577 1773 Human hsa-miR-141 miRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment miR-141 expression was low in LPS-induced MRC-5 cells. 32317619 1774 Human hsa-miR-141 miRNA hypoxia preeclampsia (PE) HTR-8/SVneo cells hypoxia induce upregulated 31004838 1775 Human hsa-miR-141 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary arterial smooth muscle cells (hPASMCs) hypoxia treatment The miR-141 expression was decreased under hypoxia culture. 32559140 1776 Human hsa-miR-141 miRNA honokiol renal cell carcinoma (RCC) A-498 cell line honokiol treatment upregulated 24810210 1777 Human hsa-miR-141 miRNA ginsenoside Rh3 retinal injury ARPE-19 cells; retinal ganglion cells (RGCs) ginsenoside Rh3 treatment Rh3 dose-dependently increased expression of miR-141. 29427790 1778 Human hsa-miR-141 miRNA metformin (Met) cell senescence BJ-1 human diploid fibroblasts (HDFs) metformin treatment upregulated 22356767 1779 Human hsa-miR-141 miRNA p16 INK4A cell senescence human fibroblast and epithelial cells p16 INK4A treatment upregulated 27596953 1780 Human hsa-miR-141-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment TUG1 enhanced the progression of AS in vitro by regulating the miR-141-3p/ROR2 axis. 32565910 1781 Human hsa-miR-141-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cells (HVSMCs) oxidized low-density lipoprotein (ox-LDL) treatment miR-141-3p was decreased in oxidized low-density lipoprotein (ox-LDL)-treated human vascular smooth muscle cells (VSMCs) 33818249 1782 Human hsa-miR-141-3p miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells high glucose upregulated 29246323 1783 Human hsa-miR-141-3p miRNA triptolide (TPL) diabetic nephropathy (DN) human mesangial cells triptolide (TPL) treatment downregulated 29246323 1784 Human hsa-miR-141-3p miRNA trans-nonachlor (TNC) melanoma melanoma cell lines trans-nonachlor (TNC) treatment downregulated 27616325 1785 Human hsa-miR-141-3p miRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment Long non-coding RNA SNHG15 is a competing endogenous RNA of miR-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression 32247266 1786 Human hsa-miR-141-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 1787 Human hsa-miR-141-3p miRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment "SNHG16 and sushi domain containing 2 (SUSD2) were upregulated, and miRNA (miR)-141-3p was downregulated in the serum of acute pneumonia patients and lipopolysaccharide (LPS)-challenged human lung fibroblasts WI-38." 33836533 1788 Human hsa-miR-141-3p miRNA hypoxia preeclampsia (PE) human umbilical vein endothelial cells (HUVECs) hypoxia treatment MiR-141-3p expression was upregulated in the HUVECs isolated from PE tissues and hypoxia-induced HUVECs. 33631423 1789 Human hsa-miR-141-3p miRNA TGF-¦Â1 renal interstitial fibrosis (RIF) HK-2 cells transforming growth factor (TGF)-¦Â1 treatment downregulated 33135476 1790 Human hsa-miR-141-3p miRNA lipopolysaccharide (LPS) rheumatoid arthritis (RA) synovial fibroblasts (SFs) lipopolysaccharide (LPS) treatment miR-141-3p was significantly decreased at the gene level ln LPS induced SFs. 32373221 1791 Human hsa-miR-141-3p miRNA arsenite tumorigenesis human bronchial epithelial (HBE) cells arsenic exposure "upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)" 28972549 1792 Human hsa-miR-141-5p miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning downregulated 30602960 1793 Human hsa-miR-141-5p miRNA imatinib chronic myeloid leukemia (CML) peripheral blood cells imatinib treatment miR-141-5p was remarkably elevated in patients after treatment with imatinib. 32038235 1794 Human hsa-miR-141-5p miRNA nilotinib chronic myeloid leukemia (CML) peripheral blood cells nilotinib treatment miR-141-5p was remarkably elevated in patients after treatment with nilotinib. 32038235 1795 Human hsa-miR-141-5p miRNA lectin prostate cancer Prostate cancer (PC) cell lines lectin treatment upregulated 26417675 1796 Human hsa-miR-142 miRNA tumor necrosis factor alpha (TNF-¦Á) chronic periodontitis human gingival epithelial cells (hGECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 28123644 1797 Human hsa-miR-142 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hepatocellular carcinoma (HCC) HCC cell lines HepG2 and SMMC7721 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28963738 1798 Human hsa-miR-142 miRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells; Hcc827 cells; lung adenocarcinoma (LAD) tissues cisplatin treatment downregulated 33416094 1799 Human hsa-miR-142 miRNA hypoxia pancreatic cancer (PC) human PC cell lines PANC©\1;SW1990 hypoxic condition induce "In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1¦Á axis under hypoxic condition." 30693518 1800 Human hsa-miR-142 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" lung fibrosis "The OHS cell line (IOR/OS14, IOR/OS10, IOR/SARG and IOR/MOS) and cell lines HOS, U-2 OS, MG-63 ;K562 leukemia cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" mir-142 is epigenetically repressed by DNA methylation 24236112 1801 Human hsa-miR-142-3p miRNA respected serum exosomes acute cellular rejection human Umbilical Vein Endothelial Cells (HUVECs) respected serum exosomes treatment upregulated 28073833 1802 Human hsa-miR-142-3p miRNA bone morphogenetic protein 7 (BMP7) apoptosis HA-VSMCs bone morphogenetic protein 7 (BMP7) treatment upregulated 29435112 1803 Human hsa-miR-142-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment MiR-142-3p expression was substantially upregulated during the ox-LDL-elicited apoptosis in HAECs. 29949787 1804 Human hsa-miR-142-3p miRNA macrophage migration inhibitory factor (MIF) cardioprotective therapy human adipose-derived MSCs (ADMSCs); Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes macrophage migration inhibitory factor (MIF) treatment LncRNA-NEAT1/miR-142-3p/FOXO1 at least partially mediates the cardioprotective roles of exosomeMIF in protecting cardiomyocytes from apoptosis. 31964409 1805 Human hsa-miR-142-3p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment downregulated 31722571 1806 Human hsa-miR-142-3p miRNA aspergillus fumigatus (A. fumigatus) cell activation CD4+?T cells "CD4+ T cells were activated by co-culturing with dendritic cells (DCs), which were pre-treated with AFE" "Forced expression of miRNA-142-3P dramatically suppressed RICTOR levels, phosphorylated AKT and IFN-¦Ã in AFE activated T cells." 31930050 1807 Human hsa-miR-142-3p miRNA lipopolysaccharide (LPS) cell death The dermal microvascular endothelial cells (HMVEC-D)£» the human skin fibroblasts (ATCC)£»breast cancer cell line MCF7£» prostate cancer cell line PC-3 lipopolysaccharide (LPS) treatment miR-142-3p in regulating DC responses to LPS 21474672 1808 Human hsa-miR-142-3p miRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation HA-VSMCs platelet-derived growth factor-BB (PDGF-BB) treatment downregulated 29435112 1809 Human hsa-miR-142-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury neuronal cell line SH-SY5Y oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 31863884 1810 Human hsa-miR-142-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y Cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment miR-142-3p expression was decreased after OGD/R induction. 31863884 1811 Human hsa-miR-142-3p miRNA imatinib mesylate chronic myeloid leukemia (CML) Peripheral blood cells imatinib mesylate treatment downregulated 20460641 1812 Human hsa-miR-142-3p miRNA lipopolysaccharide (LPS) cirrhosis liver sinusoidal endothelial cells (LSECs) lipopolysaccharide (LPS) treatment downregulated 32269710 1813 Human hsa-miR-142-3p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment downregulated 31722571 1814 Human hsa-miR-142-3p miRNA antrodia cinnamomea colorectal cancer (CRC) "The human colon cancer cell lines (SW480, SW620 and HCT116)" antrodia cinnamomea treatment upregulated 31349708 1815 Human hsa-miR-142-3p miRNA trichosanthes kirilowii extract (TKE) DNA damage HaCaT cells Trichosanthes kirilowii extract (TKE) treatment "TKE significantly upregulated the expression of the core clock protein, brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein-1 (BMAL1), and downregulated the expression of miRNA (miR)-142-3p" 29115465 1816 Human hsa-miR-142-3p miRNA leuprolide endometriosis endometriotic tissues Leuprolide treatment upregulated 27709720 1817 Human hsa-miR-142-3p miRNA etanercept gastric cancer (GC) ?serum Etanercept treatment downregulated 23600954 1818 Human hsa-miR-142-3p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 cells; SMMC-7721 cells Sorafenib treatment downregulated 29472524 1819 Human hsa-miR-142-3p miRNA lipopolysaccharide (LPS) hirschsprung's disease (HSCR) human 293T cells lipopolysaccharides (LPS) treatment downregulated 29956457 1820 Human hsa-miR-142-3p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 1821 Human hsa-miR-142-3p miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) downregulated 18648749 1822 Human hsa-miR-142-3p miRNA FTY-720 leukemia OCI-AML3 cells FTY-720 treatment downregulated 24858343 1823 Human hsa-miR-142-3p miRNA licochalcone A (LA) melanoma A375 cells licochalcone A (LCA) treatment MiR- 142-3p level was significantly upregulated in LCA-treated A375 cells in a time- and dose-dependent manner. 31793097 1824 Human hsa-miR-142-3p miRNA licochalcone A (LA) melanoma A375 and B16 melanoma cells Licochalcone A (LCA) treatment upregulated 31793097 1825 Human hsa-miR-142-3p miRNA autologous hematopoietic SCT(AHSCT) multiple sclerosis (MS) MS patients AHSCT treatment upregulated in T- and B-cell 25486582 1826 Human hsa-miR-142-3p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 1827 Human hsa-miR-142-3p miRNA high glucose (HG) cardiac fibrosis primary human aortic endothelial cells (HAECs) high glucose (HG) treatment MiR-142-3p screened by miRNA microarray was significantly downregulated in HAECs under HG stimulation in a dose and time dependent manner. 31938215 1828 Human hsa-miR-142-3p miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 1829 Human hsa-miR-142-3p miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human chondrocytes lipopolysaccharide (LPS) treatment downregulated 31836002 1830 Human hsa-miR-142-3p miRNA gemcitabine (GEM) pancreatic cancer (PC) "Pancreatic cancer cell lines including AsPC-1, HPAC, BxPC-3, and PANC-1" gemcitabine treatment knock-down of SBF2-AS1 inhibits the expression of TWF1 by competitively binding with miR-142-3p to induce gemcitabine resistance in pancreatic cancer. 31619579 1831 Human hsa-miR-142-3p miRNA triptolide and quercetin pancreatic ductal adenocarcinoma (PDAC) MIA PaCa-2; Capan-1; HEK-293 lines ;S2-013 cells triptolide and quercetin treatment upregulated 23635652 1832 Human hsa-miR-142-3p miRNA lipopolysaccharide (LPS) periodontitis primary human periodontal ligament cells (PDLC lipopolysaccharide (LPS) treatment upregulated of lncRNA FGD5-AS1 could protect against periodontitis via regulating the miR-142-3p/SOCS6/NF-¦ÊB signals. 31144533 1833 Human hsa-miR-142-3p miRNA lipopolysaccharide (LPS) rheumatoid arthritis (RA) Human rheumatoid fibroblast-like synoviocytes (MH7?A) lipopolysaccharide (LPS) treatment downregulated 31022596 1834 Human hsa-miR-142-3p miRNA salvianolic acid B (Sal B) rheumatoid arthritis (RA) LPS-treated Human rheumatoid fibroblast-like synoviocytes (MH7?A) salvianolic acid B (Sal B) treatment upregulated 31022596 1835 Human hsa-miR-142-3p miRNA lipopolysaccharide (LPS) sepsis Neonatal Polymorphonuclear Leukocytes lipopolysaccharide (LPS) treatment dysregulated 28655995 1836 Human hsa-miR-142-3p miRNA Trichosanthes kirilowii extract (TKE) skin diseases human keratinocytes TKE treatment downregulated 29115465 1837 Human hsa-miR-142-3p miRNA mycophenolic acid (MPA) systemic lupus erythematosus (SLE) lupus CD4(+)T cells Mycophenolic acid (MPA) treatment upregulated 25661834 1838 Human hsa-miR-142-3p miRNA curcumin (Cur) triple negative breast cancer (TNBC) MDA-MB-231 cells curcumin treatment curcumin suppressed p300/miR-142-3p/PSMB5 axis leading to the inhibition of the CT-l activity of 20S proteasome. 32866906 1839 Human hsa-miR-142-3p miRNA rapamycin complex (mTOR) tuberous sclerosis complex (TSC) serum rapamycin complex (mTOR) treatment upregulated 27680012 1840 Human hsa-miR-142-5p miRNA CoCl2 acute kidney injury (AKI) HK-2 cells CoCl2 treatment downregulated of XIST ameliorates acute kidney injury by sponging miR-142-5p and targeting PDCD4. 32347551 1841 Human hsa-miR-142-5p miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y Cells amyloid ¦Â1-42?(A¦Â) treatment upregulated 28769761 1842 Human hsa-miR-142-5p miRNA amyloid-¦Â (A¦Â) 42 Alzheimer's disease (AD) HN cells amyloid-¦Â (A¦Â) 42 treatment Berberine attenuates A¦Â42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells 32251633 1843 Human hsa-miR-142-5p miRNA imatinib chronic myeloid leukemia (CML) peripheral blood; bone marrow imatinib treatment miR-365a-3p showing the most significant downregulated in non-responders treatment by imatinib. 32999756 1844 Human hsa-miR-142-5p miRNA galacto-oligosaccharides (GOS) colitis normal and LPS-stimulated human colon epithelial FHC cells galacto-oligosaccharides (GOS) treatment downregulated 31226416 1845 Human hsa-miR-142-5p miRNA lipopolysaccharide (LPS) colitis human colon epithelial FHC cells lipopolysaccharide (LPS) treatment upregulated 31226416 1846 Human hsa-miR-142-5p miRNA rotavirus (RV) colorectal cancer (CRC) colon cancer cells rotavirus (SA11 or KU)treatment treatment upregulated 26572508 1847 Human hsa-miR-142-5p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cell (HREC) high glucose (HG) treatment miR-142-5p level was downregulated in high glucose (HG)-treated HRECs. 32116075 1848 Human hsa-miR-142-5p miRNA progesterone (P4) endometrial cancer (EC) Hec3A cells Progesterone treatment upregulated 22543862 1849 Human hsa-miR-142-5p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 1850 Human hsa-miR-142-5p miRNA triptolide (TPL) multiple myeloma (MM) the dexamethasone-sensitive MM.1S human MM cell line triptolide (TPL)? treatment downregulated 22260163 1851 Human hsa-miR-142-5p miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 1852 Human hsa-miR-142-5p miRNA high glucose (HG) nonalcoholic fatty liver disease (NAFLD) HepG2 cells high glucose (HG) treatment upregulated 31889412 1853 Human hsa-miR-142-5p miRNA high glucose (HG) nonalcoholic fatty liver disease (NAFLD) HepG3 cells high glucose (HG) treatment upregulated 31889412 1854 Human hsa-miR-142-5p miRNA IL-1¦Â osteoarthritis (OA) SW1353 cells IL-1¦Â treatment miR-142-5p was downregulated in IL-1¦Â-treated chondrocytes. 31903636 1855 Human hsa-miR-142-5p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment "CircSEC24A and SOX5 expression were enhanced, while miR-142-5p level was reduced in OA cartilage tissues and chondrocytes." 33751650 1856 Human hsa-miR-142-5p miRNA SDF-1 osteoarthritis (OA) primary human OA chondrocytes SDF-1 treatment miR-142-5p as a CXCR4-Targeted MicroRNA Attenuates SDF-1-Induced Chondrocyte Apoptosis and Cartilage Degradation via Inactivating MAPK Signaling Pathway 32047668 1857 Human hsa-miR-142-5p miRNA cisplatin (DDP) ovarian cancer (OC) "OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells" cisplatin treatment "in OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells, overexpression or inhibition of miR-142-5p increased or suppressed their sensitivities to cisplatin respectively." 30639456 1858 Human hsa-miR-142-5p miRNA neurofibromatosis type 1 (NF1) ovarian cancer (OC) OVCAR3 and SKOV3 cells Neurofibromatosis type 1 (NF1) deficiency downregulated 30543142 1859 Human hsa-miR-142-5p miRNA hydrocarbons (PAHs) hydrocarbons (PAHs) toxic action 20 exposed workers pooled plasma samples exposed to PAHs treatment dysregulated 24633190 1860 Human hsa-miR-142-5p miRNA rotavirus (RV) rotavirus (RV) infection blood rotavirus (SA11 or KU) infection treatment upregulated 26572508 1861 Human hsa-miR-142-5p miRNA sulforaphane (SFN) staphylococcus aureus infection THP-1 cells sulforaphane (SFN) treatment SFN pretreatment of the THP-1-derived macrophages significantly attenuated the S aureus-mediated increased expression levels of miR-142-5p 32323751 1862 Human hsa-miR-142-5p miRNA mycophenolic acid (MPA) systemic lupus erythematosus (SLE) lupus CD4(+)T cells Mycophenolic acid (MPA) treatment upregulated 25661834 1863 Human hsa-miR-142-5p miRNA benzo(a)pyrene (BaP) toxicity of Benzo[a]pyrene (BaP) THBEc1 cells benzo(a)pyrene (BaP) exposure downregulated 32681969 1864 Human hsa-miR-142-5p miRNA tumor necrosis factor alpha (TNF-¦Á) ulcerative colitis (UC) HT-29 cells tumor necrosis factor alpha (TNF-¦Á) treatment TUG1 negatively regulated inflammation in ulcerative colitis through miR-142-5p/SOCS1 axis 32173492 1865 Human hsa-miR-142-5p miRNA zika virus (ZIKV) Zika virus (ZIKV) infection Human umbilical cord mesenchymal stem cells (hUCMSCs) Zika virus (ZIKV) infection treatment miR-142-5p was significantly downregulated upon ZIKV infection 32902370 1866 Human hsa-miR-143 miRNA IFN-¦Â asthma airway smooth muscle (ASM) IFN-beta? treatment upregulated 20382746 1867 Human hsa-miR-143 miRNA hypoxia ischemia/reperfusion (I/R) injury Human umbilical vein endothelial cells (HUVECs) hypoxia induce upregulated 31607223 1868 Human hsa-miR-143 miRNA cytarabine (Ara-C) acute myeloid leukemia (AML) U937 cells; HL60 cells cytarabine treatment MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy. 33077697 1869 Human hsa-miR-143 miRNA IL-13 allergic rhinitis (AR) nasal epithelial cells (NECs) IL-13 treatment "miR-143 regulation of IL-13-induced inflammatory cytokine and mucus production in NECs from AR patients probably partly depends on inhibition of IL13R¦Á1. Therefore, the IL13R¦Á1 signaling pathway may be a potential target for the prevention and treatment of AR by miR-143." 25529447 1870 Human hsa-miR-143 miRNA IL-13 allergic rhinitis (AR) nasal epithelial cells (NECs) from AR patients IL-13 treatment upregulated 25529447 1871 Human hsa-miR-143 miRNA homocysteine (Hcy) atherosclerosis (AS) vascular smooth muscle cell (VSMC) homocysteine (Hcy) treatment downregulated 26573388 1872 Human hsa-miR-143 miRNA homocysteine (Hcy) atherosclerosis (AS) vascular smooth muscle cell (VSMC) homocysteine (Hcy) treatment downregulated 26573388 1873 Human hsa-miR-143 miRNA neutral bile mixture barrett's esophagus Het-1A cells neutral bile mixture treatment upregulated 24006894 1874 Human hsa-miR-143 miRNA estradiol breast cancer MCF-7 cells estradiol (E?) treatment "E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells" 22260523 1875 Human hsa-miR-143 miRNA estradiol breast cancer MCF-7 breast cancer cells Estradiol treatment downregulated 19528081 1876 Human hsa-miR-143 miRNA TGF-¦Â1 breast cancer human coronary artery smooth muscle cells TGF-¦Â1 treatment downregulated 21712382 1877 Human hsa-miR-143 miRNA histone deacetylase inhibitor (HDACi) burkitt lymphoma (BL) Raji B-cell lymphoma HDACi treatment upregulated 24577510 1878 Human hsa-miR-143 miRNA arsenite tumorigenesis derivative normal stem cell (SC) line arsenite exposure downregulated 24431212 1879 Human hsa-miR-143 miRNA conditioned media (CM) cardiovascular disease (CVD) human vascular smooth muscle cells (hVSMC) exposure to CM from primary human subcutaneous adipocytes treatment upregulated 24333576 1880 Human hsa-miR-143 miRNA taxol cervical squamous cell carcinoma (SCC) patients of cervical SCC taxol treatment upregulated 24774218 1881 Human hsa-miR-143 miRNA epidermal growth factor receptor (EGFR) colorectal cancer (CRC) colorectal cancer cells epidermal growth factor receptor (EGFR) treatment miRNA-143 expression levels serve as an independent prognostic biomarker for CRC in KRAS wild-type patients. No role for miRNA-143 expression as a predictive biomarker for EGFR-targeted agents could be identified 22549179 1882 Human hsa-miR-143 miRNA fluoropyrimidine colorectal cancer (CRC) colorectal cancer (CRC) cells Fluoropyrimidine treatment upregulated 26392389 1883 Human hsa-miR-143 miRNA ¦Á-Mangostin colorectal cancer (CRC) human colorectal cancer DLD-1 cells ¦Á-Mangostin treatment ?increased miR-143 expression in human colorectal cancer DLD-1 cells 17553685 1884 Human hsa-miR-143 miRNA baccharin and drupanin colorectal cancer (CRC) human colon cancer DLD-1 cells baccharin and drupanin treatment upregulated 24854570 1885 Human hsa-miR-143 miRNA hexavalent chromium [Cr(VI)] Cr(VI)-induced carcinogenesis blood samples of Cr(VI)-exposing workers and human bronchial epithelial cells (BEAS-2B cells) Hexavalent chromium [Cr(VI)] exposure downregulated 31152816 1886 Human hsa-miR-143 miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 1887 Human hsa-miR-143 miRNA IL-1¦Â endothelial activation human umbilical endothelial cells (HUVECs) IL-1¦Â treatment upregulated 28527816 1888 Human hsa-miR-143 miRNA endothelial growth medium©\2 (EGM©\2) plus VEGF endothelial dysfunction Adipose-derived stem cells (ADSCs) endothelial growth medium©\2 (EGM©\2) supplemented with 15 ng/mL VEGF innduce downregulated 31264280 1889 Human hsa-miR-143 miRNA shikonin glioblastoma multiforme (GBM) glioblastoma stem cells (GSCs) Shikonin treatment downregulated 26541455 1890 Human hsa-miR-143 miRNA TGF-¦Â glomerular diseases human podocytes TGF-¦Â treatment "a time dependent, TGF-¦Â inducible expression of miR-143 in human podocytes" 27941332 1891 Human hsa-miR-143 miRNA hepatitis B virus (HBV) hepatitis B virus (HBV) infection primary liver cells hepatitis B virus (HBV) infection upregulated 29236306 1892 Human hsa-miR-143 miRNA hexavalent chromium [Cr(VI)] lung cancer BEAS-2B cells Hexavalent chromium [Cr (VI)]?treatment downregulated 23748240 1893 Human hsa-miR-143 miRNA carbamate lung cancer Normal human bronchial epithelial (NHBE) cells carbamate treatment downregulated 19748927 1894 Human hsa-miR-143 miRNA cisplatin and paclitaxel metastatic bladder cancer T24 bladder cancer cells cisplatin and paclitaxel treatment downregulated 26356996 1895 Human hsa-miR-143 miRNA inorganic phosphate (Pi) migration of vascular smooth muscle cells human aortic vascular smooth muscle cells (VSMCs) inorganic phosphate (Pi) treatment downregulated 23094093 1896 Human hsa-miR-143 miRNA lenalidomide myelodysplastic syndrome (MDS) CD34(+) marrow cells lenalidomide? treatment upregulated 22929976 1897 Human hsa-miR-143 miRNA hypoxia myocardial infarction (MI) human cardiac cells hypoxia induce upregulated 29728596 1898 Human hsa-miR-143 miRNA retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) neuronal development SH-SY5Y cells retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment downregulated 29619741 1899 Human hsa-miR-143 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 1900 Human hsa-miR-143 miRNA gefitinib non-small cell lung cancer (NSCLC) The NSCLC cell lines (HCC827 and PC9) gefitinib treatment "repressed UCA1 promoted the miR-143 expression, and miR-143 could bind to the predicted binding site of UCA1." 31951852 1901 Human hsa-miR-143 miRNA gefitinib non-small cell lung cancer (NSCLC) HCC827 cells; PC9 cells gefitinib treatment lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer. 31951852 1902 Human hsa-miR-143 miRNA TGF-¦Â non-small cell lung cancer (NSCLC) NSCLC A549 cells TGF-¦Â treatment upregulated 25175415 1903 Human hsa-miR-143 miRNA ozone (O3) air pollution healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 1904 Human hsa-miR-143 miRNA cisplatin (DDP) osteosarcoma (OS) Sarcoma Osteogenic-2 (Saos-2) cells cisplatin treatment upregulated 32508321 1905 Human hsa-miR-143 miRNA TGF-¦Â1 osteosarcoma (OS) osteosarcoma cell TGF-¦Â1 treatment downregulated 25562163 1906 Human hsa-miR-143 miRNA cisplatin (DDP) ovarian cancer (OC) Human ovarian cancer cell lines (A2780 and SKOV-3) and normal ovarian epithelial cell line (IOSE-80) cisplatin treatment downregulated 31234009 1907 Human hsa-miR-143 miRNA H2O2 oxidative stress human normal liver cell line L02 H2O2 treatment upregulated 29258429 1908 Human hsa-miR-143 miRNA human mesenchymal stem cell conditioned medium (MSC-CM) oxidative stress human normal liver cell line L02 MSC-CM downregulated 29258429 1909 Human hsa-miR-143 miRNA everolimus pancreatic cancer (PC) Panc-1 human pancreatic cancer cells everolimus treatment upregulated 23251295 1910 Human hsa-miR-143 miRNA XMD8-92 pancreatic ductal adenocarcinoma (PDAC) human pancreatic cancer AsPC-1 cells XMD8-92 treatment upregulated 24880079 1911 Human hsa-miR-143 miRNA zirconia and titanium preosteoblast differentiation Osteoblast-like cells (MG63) zirconia and titanium? treatment downregulated 18241218 1912 Human hsa-miR-143 miRNA curcumin (Cur) prostate cancer "DU145, PC3, and RPWE-1 cells" curcumin treatment upregulated 28391351 1913 Human hsa-miR-143 miRNA curcumin (Cur) prostate cancer "PC3, DU145 and LNCaP cells" curcumin treatment upregulated 28391715 1914 Human hsa-miR-143 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment upregulated 30195228 1915 Human hsa-miR-143 miRNA 20-hydroxyeicosatetraeonic acid (20-HETE) pulmonary hypertension (PH) vascular smooth muscle cell 20-Hydroxyeicosatetraeonic acid (20-HETE) treatment downregulated 26921441 1916 Human hsa-miR-143 miRNA acidic bile salt reflux esophagitis Het-1A cells acidic bile salt treatment upregulated 24006894 1917 Human hsa-miR-143 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) sepsis mesenchymal stem cells (MSCs) poly(I:C) treatment downregulated 24105952 1918 Human hsa-miR-143 miRNA TGF-¦Â1 subconjunctival fibrosis Human tenon's capsule fibroblasts (HTFs) TGF-¦Â1 treatment upregulated 31081880 1919 Human hsa-miR-143 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" tissue regeneration Human adult DPSCs "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 26351742 1920 Human hsa-miR-143 miRNA TGF-¦Â type 2 diabetes mellitus (T2DM) Vascular smooth muscle cells (SMC) from T2DM exposure of ND-SMC to transforming growth factor beta (TGF¦Â) treatment upregulated 24927876 1921 Human hsa-miR-143 miRNA inorganic phosphate (Pi) vascular calcification (VC) human aortic vascular smooth muscle cells (HAVSMC) inorganic phosphate (Pi) treatment downregulated 27419135 1922 Human hsa-miR-143-1 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 1923 Human hsa-miR-143-3p miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y Cells amyloid ¦Â1-42?(A¦Â) treatment upregulated 32337953 1924 Human hsa-miR-143-3p miRNA angiotensin II (Ang II) aortic dissection (AD) human aortic endothelial cells (HAECs); human aortic smooth muscle cells (HASMCs) angiotensin II (Ang II) treatment "We found that lnc-OIP5-AS1 was upregulated, whereas miR-143-3p was downregulated in cells treated with angiotensin II (AngII) and AD tissues." 33577845 1925 Human hsa-miR-143-3p miRNA Resibufogenin (RES) breast cancer MDA-MB-453 cells; MCF-7 cells Resibufogenin (RES) treatment RES notably enhanced the expression of miR- 143-3p in both MDA-MB-453 and MCF-7 cells compared with the control group 32006291 1926 Human hsa-miR-143-3p miRNA dermatophagoides pteronyssinus peptidase 1 (Der p1) bronchial asthma BEAS-2B cells Dermatophagoides pteronyssinus peptidase 1 (Der p1) treatment OIP5-AS1 exacerbated Der p1-induced inflammation and apoptosis in BEAS-2B cells by targeting miR-143-3p via HMGB1. 33174035 1927 Human hsa-miR-143-3p miRNA cadmium (Cd) cadmium-induced toxicity human bone marrow mesenchymal stem cells (hBMSCs) cadmium (Cd) treatment Concentrations of CdCl 2 (2.5 and 5.0 ¦ÌM) increased miR-143-3p levels. 32522577 1928 Human hsa-miR-143-3p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 1929 Human hsa-miR-143-3p miRNA "hyperglycemia, insulin and lipopolysaccharide (LPS)" dyslipidemia HepG2 cells "hyperglycemia, insulin, and LPS treatment" "Levels of miR-143-3p increase in response to hyperglycemia, insulin, and LPS treatment." 30261196 1930 Human hsa-miR-143-3p miRNA progesterone (P4) endometrial cancer (EC) Ishikawa cells ?progesterone (P4) treatment upregulated 29661100 1931 Human hsa-miR-143-3p miRNA TGF-¦Â1 epithelial ovarian cancer (EOC) human ovarian tumour cells TGF-¦Â1 treatment upregulated 29238081 1932 Human hsa-miR-143-3p miRNA dexamethasone (DEX) esophageal cancer (EC) KYSE150 cells dexamethasone (DEX) treatment MiR-143-3p could be induced by DEX treatment in esophageal cancer cells. 32701250 1933 Human hsa-miR-143-3p miRNA high glucose (HG) hyperglycemia HepG2 cells high glucose induce upregulated 30261196 1934 Human hsa-miR-143-3p miRNA insulin hyperinsulinemic HepG2 cells insulin treatment upregulated 30261196 1935 Human hsa-miR-143-3p miRNA lipopolysaccharide (LPS) inflammatory response HepG2 cells lipopolysaccharide (LPS) treatment upregulated 30261196 1936 Human hsa-miR-143-3p miRNA TGF-¦Â1 myocardial infarction (MI) human cardiac fibroblasts (HCFs) transforming growth ¦Â1 (TGF¦Â1) treatment upregulated 30878395 1937 Human hsa-miR-143-3p miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment miR-143-3p level was upregulated in LPS-treated PDLCs. 32520926 1938 Human hsa-miR-143-3p miRNA sulfur mustard (SM) sulfur mustard induced lung disease serum sulfur mustard exposure treatment upregulated 29566027 1939 Human hsa-miR-143-3p miRNA TGF-¦Â1 asthma airway smooth muscle cells (ASMCs) TGF-¦Â1 treatment over expression 27639060 1940 Human hsa-miR-143-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1-treatment treatment upregulated 29557526 1941 Human hsa-miR-144 miRNA actinomycin X2 (AX2) apoptosis human prostate cancer cells (PC-3) actinomycin X2 (AX2) treatment miR-144 was decreased ; smiR-126 was increased 26645890 1942 Human hsa-miR-144 miRNA 7-chlorokynurenic acid (7-CTKA) cardiovascular disease (CVD) human aortic endothelial cells (HAECs) 7-CTKA intraperitoneal injection upregulated 24642088 1943 Human hsa-miR-144 miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 1944 Human hsa-miR-144 miRNA nanoparticle (NP) colorectal cancer (CRC) Human colon cancer HCT-116 cells Nanoparticle (NP) technology "Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulated of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms," 21929751 1945 Human hsa-miR-144 miRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment "MiR-144 expression level was enhanced, while CTRP3 expression was reduced in HG-induced AC16 cardiomyocytes." 32211094 1946 Human hsa-miR-144 miRNA high glucose (HG) diabetic nephropathy (DN) human renal mesangial cells (HRMCs) high glucose (HG) treatment "CASC2 could alleviate the degree and process of apoptosis, inflammation, and fibrosis in diabetic nephropathic models by regulating the miR-144/SOCS2 axis." 33227790 1947 Human hsa-miR-144 miRNA alcohol gastric cancer (GC) HEK293T cells;SH SY5Y cells;1321 N1 cells ?alcohol? treatment upregulated 24961422 1948 Human hsa-miR-144 miRNA valproic acid (VPA) hematopoietic differentiation hematopoietic stem cells (HSCs) VPA treatment different regulation 25241289 1949 Human hsa-miR-144 miRNA rapamycin hepatitis HT29 cells rapamycin treatment downregulated 22983984 1950 Human hsa-miR-144 miRNA human immunodeficiency virus (HIV)-1 HIV-1 infection-induced pneumonia human monocyte-derived macrophages (MDMs) HIV-1 infection MiR-144 expression was increased in AMs from HIV-1 Tg rats and in HIV-1-infected human MDMs compared to cells from WT rats and non-infected human MDMs. 32773107 1951 Human hsa-miR-144 miRNA lactobacillus casei (L. casei LC01) irritable bowel syndrome with diarrhea (IBS-D) intestinal epithelial cells (IECs) L. casei LC01 treatment L. casei LC01 decreased the expression of miR-144 in IECs. 32807750 1952 Human hsa-miR-144 miRNA baohuoside-I melanoma Human melanoma cell lines M14 and MV3 baohuoside-I treatment upregulated 29260980 1953 Human hsa-miR-144 miRNA triptolide (TPL) nasopharyngeal carcinoma (NPC) Epstein-Barr virus-negative human NPC cell lines (NPC-TW 039 and NPC-TW 076) triptolide (TPL) treatment downregulated 31059711 1954 Human hsa-miR-144 miRNA smoky coal non-small cell lung cancer (NSCLC) non-small cell lung cancers (NSCLCs) cells smoky coal treatment downregulated 26395400 1955 Human hsa-miR-144 miRNA patulin (PAT) oxidative stress HEK293 cells Patulin (PAT)? treatment PAT significantly decreased miR-144 33403569 1956 Human hsa-miR-144 miRNA XMD8-92 pancreatic ductal adenocarcinoma (PDAC) human pancreatic cancer AsPC-1 cells XMD8-92 treatment upregulated 24880079 1957 Human hsa-miR-144 miRNA cyclosporine A (CsA) cell proliferation and invasion human trophoblast (HT) cells CsA treatment downregulated 24453045 1958 Human hsa-miR-144 miRNA cisplatin (DDP) prostate cancer prostate cancer (PC) cells cisplatin treatment downregulated 26566625 1959 Human hsa-miR-144 miRNA hypoxia prostate cancer prostate cancer cell lines (DU145 and PC3) hypoxia treatment downregulated 26990493 1960 Human hsa-miR-144-3p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment upregulated 29492259 1961 Human hsa-miR-144-3p miRNA cisplatin (DDP) anaplastic thyroid carcinoma (ATC) TPC1 cells; BHT101 cells cisplatin (DPP) treatment downregulated 30540564 1962 Human hsa-miR-144-3p miRNA licochalcone A (LA) apoptosis H292 cells Natural compound licochalcone A (lico A) treatment lico A significantly promoted the tumor-suppressor miR-144-3p expression. 30709582 1963 Human hsa-miR-144-3p miRNA "oxidized low-density lipoprotein (ox-LDL), IL-6 and TNF-¦Á)" atherosclerosis (AS) human vascular smooth muscle cells (VSMCs) "oxidation Low Lipoprotein (Ox-LDL), interleukin-6 (IL-6) and tumor necrosis factor ¦Á (TNF ¦Á) radiation" LncRNA HCG11 regulates proliferation and apoptosis of vascular smooth muscle cell through targeting miR-144-3p/FOXF1 axis. 33008472 1964 Human hsa-miR-144-3p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment Our data indicated that LOC729178 was underexpressed in COPD tissues and CSE-treated 16HBE cells. 33847879 1965 Human hsa-miR-144-3p miRNA high glucose (HG) diabetic retinopathy (DR) Human umbilical vein endothelial cells (HUVEC) and Human Retinal Endothelial Cells (HREC) high glucose treatment downregulated 31292167 1966 Human hsa-miR-144-3p miRNA hemin inflammation "Neutrophils isolated from human peripheral blood, dHL-60 cells" hemin treatment upregulated 30499593 1967 Human hsa-miR-144-3p miRNA licochalcone A (LA) lung cancer Human Lung Cancer Cell Line H292 licochalcone A (lico A) treatment upregulated 30108506 1968 Human hsa-miR-144-3p miRNA TGF-¦Â1 lung cancer A549 cells transforming growth factor-¦Â1 (TGF-¦Â1) treatment downregulated 31038242 1969 Human hsa-miR-144-3p miRNA hypoxia oxidative stress Human retinal pigment epithelial (ARPE-19) cells hypoxia induce upregulated 31590045 1970 Human hsa-miR-144-3p miRNA tert-butyl hydroperoxide (TBHP) oxidative stress Human retinal pigment epithelial (ARPE-19) cells tert-butyl hydroperoxide (t-BHP) treatment upregulated 31590045 1971 Human hsa-miR-144-3p miRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) SH-SY5Y cells "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" downregulated 27329039 1972 Human hsa-miR-144-3p miRNA hemin inflammation Neutrophils isolated from human peripheral blood hemin treatment upregulated 30499593 1973 Human hsa-miR-144-3p miRNA tert-butyl hydroperoxide (TBHP) retinal dysfunction retinal pigment epithelium (RPE) cells tert-butyl hydroperoxide (t-BHP) treatment upregulated 31590045 1974 Human hsa-miR-144-5p miRNA oxidized low density lipoprotein (ox-LDL) abdominal aortic aneurysm (AAA) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32278833 1975 Human hsa-miR-144-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment miR-144-5p overexpression could inhibit proliferation and induce apoptosis in HUVECs. 31853287 1976 Human hsa-miR-144-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment miR-144-5p serves an important role in the development of atherosclerosis through regulating the function of HUVECs by targeting SMAD1. 31853287 1977 Human hsa-miR-144-5p miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-144-5p was downregulated in resistant patients when compared with sensitive patients 33072545 1978 Human hsa-miR-144-5p miRNA hypoxia oxidative stress Human retinal pigment epithelial (ARPE-19) cells hypoxia induce upregulated 31590045 1979 Human hsa-miR-144-5p miRNA tert-butyl hydroperoxide (TBHP) oxidative stress Human retinal pigment epithelial (ARPE-19) cells tert-butyl hydroperoxide (t-BHP) treatment upregulated 31590045 1980 Human hsa-miR-144-5p miRNA tert-butyl hydroperoxide (TBHP) retinal dysfunction retinal pigment epithelium (RPE) cells tert-butyl hydroperoxide (t-BHP) treatment upregulated 31590045 1981 Human hsa-miR-144-5p miRNA lipopolysaccharide (LPS) rheumatoid arthritis (RA) THP-1 macrophages lipopolysaccharide (LPS) treatment downregulated 31853295 1982 Human hsa-miR-144-5p miRNA lipopolysaccharide (LPS) rheumatoid arthritis (RA) THP-1 cell differentiated macrophages lipopolysaccharide (LPS) treatment downregulated 31853295 1983 Human hsa-miR-145 miRNA IFN-¦Â asthma airway smooth muscle (ASM) IFN-beta? treatment upregulated 20382746 1984 Human hsa-miR-145 miRNA basic fibroblast growth factor (bFGF) adipose-derived stem cells (ASCs) differentiation Adipose-derived stem cells (ASCs) ASCs were isolated from clinical lipoaspirates and cultured with DMEM or endothelial cell-conditioned medium. bFGF (basic fibroblast growth factor) released by ECs as inducer of ASCs differentiation. downregulated 31219744 1985 Human hsa-miR-145 miRNA tumor necrosis factor alpha (TNF-¦Á) anti-proliferative action human aortic vascular smooth muscle cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 27412561 1986 Human hsa-miR-145 miRNA genistein apoptosis human retinoblastoma cell line Y79 genistein treatment upregulated 28706438 1987 Human hsa-miR-145 miRNA lipopolysaccharide (LPS) apoptosis GES-1cells lipopolysaccharides (LPS) treatment MiR-145 inhibited lipopolysaccharide-induced apoptosis of gastric mucosal via up-regulating JNK-mediated cytoprotective autophagy. 30829205 1988 Human hsa-miR-145 miRNA arsenite arsenic-induced liver injury L-02 cells arsenic exposure upregulated 29705342 1989 Human hsa-miR-145 miRNA arsenite arsenic-induced multiorgan damage plasma arsenic exposure upregulated 31085440 1990 Human hsa-miR-145 miRNA neutral bile mixture barrett's esophagus Het-1A cells neutral bile mixture treatment upregulated 24006894 1991 Human hsa-miR-145 miRNA 5-fluorouracil and ixabepilone breast cancer MDA-MB-453?cells;MDA-kb2 cells 5-FU and ixabepilone treatment upregulated 24396484 1992 Human hsa-miR-145 miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment downregulated 25120778 1993 Human hsa-miR-145 miRNA TGF-¦Â1 breast cancer human coronary artery smooth muscle cells TGF-¦Â1 treatment downregulated 21712382 1994 Human hsa-miR-145 miRNA histone deacetylase inhibitor (HDACi) burkitt lymphoma (BL) Raji B-cell lymphoma HDACi treatment upregulated 24577510 1995 Human hsa-miR-145 miRNA cortisol tumorigenesis cervical cancer cells Cortisol?treatment downregulated 22287315 1996 Human hsa-miR-145 miRNA TGF-¦Â cancer-associated fibroblasts (CAFs) activation primary normal human fibroblasts TGF-¦Â treatment upregulated 29506142 1997 Human hsa-miR-145 miRNA conditioned media (CM) cardiovascular disease (CVD) human vascular smooth muscle cells (hVSMC) exposure to CM from primary human subcutaneous adipocytes treatment upregulated 24333576 1998 Human hsa-miR-145 miRNA (-)-epigallocatechin gallate (EGCG) cell proliferation Ang II-treated human coronary artery smooth muscle cells (HCASMCs) (-)-epigallocatechin gallate (EGCG) treatment upregulated 29127880 1999 Human hsa-miR-145 miRNA angiotensin II (Ang II) cell proliferation Human coronary artery smooth muscle cells (HCASMCs) angiotensin II (Ang II) treatment downregulated 29127880 2000 Human hsa-miR-145 miRNA homocysteine (Hcy) cell proliferation Human aortic vascular smooth muscle cells (HAVSMCs) homocysteine (HCY) treatment downregulated 31757424 2001 Human hsa-miR-145 miRNA tanshinone IIA (Tan IIA) cell proliferation Homocysteine (Hcy)-treated Human aortic vascular smooth muscle cells (HAVSMCs) Tanshinone IIA (Tan IIA) treatment upregulated 31757424 2002 Human hsa-miR-145 miRNA tanshinone IIA (Tan IIA) cervical cancer (CC) HeLa cells tanshinone II A treatment Treatment of tanshinone II A significantly upregulated the expression of GSDMD and miR-145 32232409 2003 Human hsa-miR-145 miRNA nilotinib chronic myeloid leukemia (CML) HL-60.BCR-ABL cells nilotinib (NIL) treatment differently regulated 24629639 2004 Human hsa-miR-145 miRNA pomegranate beverage (PG) colitis CCD-18Co colon-myofibroblastic cells treated with lipopolysaccharide (LPS) PG treatment upregulated 28282584 2005 Human hsa-miR-145 miRNA troglitazone collagen synthesis human dermal fibroblasts troglitazone treatment upregulated 25704091 2006 Human hsa-miR-145 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) parental 5-FU- sensitive DLD-1 cells 5-fluorouracil (5-FU) treatment upregulated 24447928 2007 Human hsa-miR-145 miRNA chemotherapy colorectal cancer (CRC) serum " modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2 , day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment" dysregulated 24304648 2008 Human hsa-miR-145 miRNA rosiglitazone colorectal cancer (CRC) "CaCo2, SW480, HCT116, and HT-29 cell lines" azone-mediated activation of PPAR¦Ã treatment upregulated 24631504 2009 Human hsa-miR-145 miRNA atorvastatin cytotoxicity HepG2 cells atorvastatin (Ato) treatment upregulated 29630879 2010 Human hsa-miR-145 miRNA high glucose (HG) diabetic atherosclerosis vascular smooth muscle cells (VSMCs) high glucose (HG) treatment miR-145 was downregulated in cultured human VSMCs exposed to high glucose. 29324316 2011 Human hsa-miR-145 miRNA high glucose (HG) diabetic cardiomyopathy (DCM) human AC16 cardiomyocytes high glucose (HG) treatment "the role of MEG3 in HG-treated human cardiomyocytes is to serve as a competing endogenous RNA (ceRNA), which negatively regulates miR-145" 31085717 2012 Human hsa-miR-145 miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment hyperglycemia significantly increased the level of MALAT1 but decreased miR-145 expression in a time-dependent manner in HK-2 cells. 31081103 2013 Human hsa-miR-145 miRNA high glucose (HG) diabetic nephropathy (DN) Human mesangial cells (HMCs) high glucose treatment downregulated 31737219 2014 Human hsa-miR-145 miRNA baicalin (BAI) diabetic retinopathy (DR) ARPE-19 cells and HRMECs high glucose (HG) and Baicalin (BAI) co-treatment the expression level of miR-145 was upregulated in HG-and BAI-co-treated cells. 30625293 2015 Human hsa-miR-145 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) "high glucose (25 mmol/L, 1-7 days)" "downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)" 28706953 2016 Human hsa-miR-145 miRNA high glucose (HG) diabetic retinopathy (DR) retinal endothelial cells (RECs) high glucose (HG) treatment miR-145 was significantly downregulated in high glucose (HG)-treated RECs. 29883722 2017 Human hsa-miR-145 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells and HRMECs high glucose (HG) and Baicalin (BAI) co-treatment the expression level of miR-145 was upregulated in HG-and BAI-co-treated cells. 30625293 2018 Human hsa-miR-145 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high-glucose (HG) treatment downregulated 31794890 2019 Human hsa-miR-145 miRNA schizandrin A (SchA) diabetic retinopathy (DR) ARPE-19 cells schizandrin A (SchA) treatment upregulated 31794890 2020 Human hsa-miR-145 miRNA schizandrin A (SchA) diabetic retinopathy (DR) high-glucose (HG)-induced ARPE-19 cells Schizandrin A (SchA) treatment upregulated 31794890 2021 Human hsa-miR-145 miRNA hypoxia cell differentiation umbilical cord mesenchymal stem cells (UCMSCs) hypoxia treatment upregulated 28789953 2022 Human hsa-miR-145 miRNA TGF-¦Â1 or bone morphogenetic protein-4 (BMP4) cell differentiation hASCs to smooth muscle cells (SMCs) "TGF-¦Â1,BMP4 treatment" upregulated 28440409 2023 Human hsa-miR-145 miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 2024 Human hsa-miR-145 miRNA quercetin endometrial fibrosis human endometrial stromal cells (hESCs) quercetin treatment The decreased expression of miR-145 induced by TGF-¦Â1 was upregulated with the increase of the concentration of quercetin 33066828 2025 Human hsa-miR-145 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human renal proximal tubular epithelial (HK-2) cells TGF-¦Â1 treatment MIAT served as an endogenous sponge for miR-145 in the TGF-¦Â1-induced-EMT in HK-2 cells 31863776 2026 Human hsa-miR-145 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) endothelial progenitor cells (EPCs) treat with TGF-¦Â1 treatment downregulated 28535533 2027 Human hsa-miR-145 miRNA X-rays esophageal cancer (EC) TE-3 cells; ECA109 cells X-ray radiation treatment lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR-145/p70S6K1 and p53 pathway 31789385 2028 Human hsa-miR-145 miRNA tumor necrosis factor alpha (TNF-¦Á) facial nerve damage SH-SY5Y cells tumor necrosis factor alpha (TNF-¦Á) treatment miR-145 was revealed to be significantly increased in response to TNF¦Á treatment 30551550 2029 Human hsa-miR-145 miRNA tumor necrosis factor alpha (TNF-¦Á) facial neuritis SH-SY5Y cell tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30551550 2030 Human hsa-miR-145 miRNA isorhapontigenin (ISO) glioblastoma multiforme (GBM) ?glioma stem cells (GSCs) Isorhapontigenin treatment downregulated 26681767 2031 Human hsa-miR-145 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) T98G cells temozolomide (TMZ) treatment upregulated 22722712 2032 Human hsa-miR-145 miRNA dendrosomal curcumin (DNC) glioblastoma multiforme (GBM) U87MG cells dendrosomal curcumin r treatment downregulated 24531649 2033 Human hsa-miR-145 miRNA olea europaea leaf extract (OLE) glioblastoma multiforme (GBM) GBM cell lines olea europaea leaf extract (OLE) treatment upregulation 25232498 2034 Human hsa-miR-145 miRNA insulin glycolysis human HepG2 hepatocellular carcinoma cells insulin treatment dysregulated 24895527 2035 Human hsa-miR-145 miRNA H2O2 granulosa cell (GC) apoptosis KGN cells H2O2 treatment downregulated 28564582 2036 Human hsa-miR-145 miRNA carboplatin (CBP) head and neck squamous cell carcinoma (HNSCC) Hep-2 cells; FaDu cells carboplatin treatment carboplatin induced the expression of miR-145 in a dose-dependent manner. 31886905 2037 Human hsa-miR-145 miRNA 5-aminolevulinic acid photodynamic therapy(ALA-PDT) head and neck squamous cell carcinoma (HNSCC) Two oral cancer cell lines SAS (tongue squamous cell carcinoma) and GNM (neck metastasis of gingival carcinoma) 5-Aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) treatment upregulated 29936107 2038 Human hsa-miR-145 miRNA carboplatin (CBP) head and neck squamous cell carcinoma (HNSCC) The human LSCC Hep-2 cell line and the human HSCC FaDu cell line carboplatin (CBP) treatment upregulated 31886905 2039 Human hsa-miR-145 miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HepG2 cells £¬ HepG2.2.15 cells. plasmid transfected treatment downregulated 25260533 2040 Human hsa-miR-145 miRNA emodin hepatitis LPS-treated L-02 cell Emodin treatment upregulated 31079494 2041 Human hsa-miR-145 miRNA lipopolysaccharide (LPS) hepatitis L-02 cell lipopolysaccharide (LPS) treatment downregulated 31079494 2042 Human hsa-miR-145 miRNA compound astragalus and salvia miltiorrhiza extract (CASE) hepatocellular carcinoma (HCC) DEN-induced HCC in rats Compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment upregulated 30412748 2043 Human hsa-miR-145 miRNA compound Astragalus and Salvia miltiorrhiza extract (CASE) hepatocellular carcinoma (HCC) HepG2 cells compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment CASE upregulated miR-145 expression in TGF-¦Â 1-stimulated HepG2 cells. 30412748 2044 Human hsa-miR-145 miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HepG2 cells Hepatitis B virus X protein (HBX)treatment downregulated 26512974 2045 Human hsa-miR-145 miRNA tanshinone IIA (Tan IIA) human aortic vascular smooth muscle cells (HA-VSMCs) injury vascular smooth muscle cells (VSMCs) Tanshinone IIA (Tan IIA) treatment "The miR-145 expression was downregulated and its targeted gene CD40 was upregulated in Hcy-treating VSMCs, while the Tan IIA reversed the effect of Hcy" 31757424 2046 Human hsa-miR-145 miRNA decabromodiphenyl ether (BDE-209) human embryonic development human embryonic stem cell lines FY-hES-10 and FY-hES-26 Decabromodiphenyl ether (BDE-209) treatment upregulated 26206603 2047 Human hsa-miR-145 miRNA high glucose (HG) hyperglycemia Human coronary artery smooth muscle cells (HCASMCs) high glucose treatment downregulated 26181633 2048 Human hsa-miR-145 miRNA baicalin (BAI) hypertension TNF-¦Á-treated human aortic endothelial cells (HAECs) baicalin (BAI) treatment upregulated 31793706 2049 Human hsa-miR-145 miRNA tumor necrosis factor alpha (TNF-¦Á) hypertension human aortic endothelial cells (HAECs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 31793706 2050 Human hsa-miR-145 miRNA TGF-¦Â1 hypertrophic scars (HS) skin myofibroblasts TGF-¦Â1 treatment upregulated 25876136 2051 Human hsa-miR-145 miRNA IL-1¦Â osteoarthritis (OA) OA chondrocytes IL-1¦Â treatment upregulated 24873879 2052 Human hsa-miR-145 miRNA platelet derived growth factor-BB (PDGF-BB) juvenile lupus nephritis (JLN) human vascular smooth muscle cells (HVSMCs) platelet-derived growth factor (PDGF)-BB treatment downregulated 31430759 2053 Human hsa-miR-145 miRNA TGF-¦Â1 cornea scarring light-scattering myofibroblasts TGF-¦Â1 treatment upregulated 26165705 2054 Human hsa-miR-145 miRNA listeria monocytogenes (L. monocytogenes) Listeria infection Human epithelial cells (Caco-2) Listeria infection downregulated 22312311 2055 Human hsa-miR-145 miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment miR-145 was downregulated in transforming growth factor-¦Â1 induced HSCs 29375381 2056 Human hsa-miR-145 miRNA pemetrexed lung adenocarcinoma (LUAD) serum pemetrexed treatment "Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations" 26687391 2057 Human hsa-miR-145 miRNA aspirin lung cancer A549 and H1299 cell lines aspirin treatment upregulated 30756509 2058 Human hsa-miR-145 miRNA cisplatin and paclitaxel metastatic bladder cancer T24 bladder cancer cells cisplatin and paclitaxel treatment upregulated 26356996 2059 Human hsa-miR-145 miRNA inorganic phosphate (Pi) migration of vascular smooth muscle cells human aortic vascular smooth muscle cells (VSMCs) inorganic phosphate (Pi) treatment downregulated 23094093 2060 Human hsa-miR-145 miRNA cerivastatin mitochondrial dysfunction RD cells cerivastatin (1 ¦ÌM for 48 h) treatment downregulated 28438533 2061 Human hsa-miR-145 miRNA TGF-¦Â1 multidrug resistance (MDR) The HepG2 cells transforming growth factor-¦Â1 (TGF-¦Â1) treatment downregulated 30698830 2062 Human hsa-miR-145 miRNA IFN-¦Â multiple sclerosis (MS) blood IFN-¦Â treatment downregulated 27752929 2063 Human hsa-miR-145 miRNA nanocurcumin multiple sclerosis (MS) blood nanocurcumin treatment downregulated 30340096 2064 Human hsa-miR-145 miRNA lenalidomide myelodysplastic syndrome (MDS) CD34(+) marrow cells lenalidomide? treatment upregulated 22929976 2065 Human hsa-miR-145 miRNA angiotensin II (Ang II) neointimal formation human coronary artery smooth muscle cells (HCASMCs) angiotensin II (Ang II) treatment downregulated 29127880 2066 Human hsa-miR-145 miRNA epigallocatechin-3-gallate (EGCG) neointimal formation human coronary artery smooth muscle cells (HCASMCs) EGCG upregulated 29127880 2067 Human hsa-miR-145 miRNA flavonoids (TFs) neointimal formation human coronary artery smooth muscle cells (HCASMCs) 100 nM flavonoids treatment upregulated 29127880 2068 Human hsa-miR-145 miRNA retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) neuronal development SH-SY5Y cells retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment downregulated 29619741 2069 Human hsa-miR-145 miRNA ethanol (EtOH) neuropsychological disorders human embryonic stem cells ethanol treatment upregulated 28833141 2070 Human hsa-miR-145 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 2071 Human hsa-miR-145 miRNA tacrolimus or high glucose new-onset diabetes after liver transplantation (NODALT) human hepatocytes tacrolimus or high glucose treatment dysregulated 27458792 2072 Human hsa-miR-145 miRNA erlotinib non-small cell lung cancer (NSCLC) The human NSCLC cell line A549 erlotinib treatment Pretreatment with miRNA-145 synergistically enhanced the sensitivity of the lung cancer cells to erlotinib. Results of apoptosis assay revealed that miRNA-145 can induce apoptosis and increase the erlotinib-mediated apoptosis. 31554377 2073 Human hsa-miR-145 miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 2074 Human hsa-miR-145 miRNA ozone (O3) air pollution healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 2075 Human hsa-miR-145 miRNA CoCl2 obstructive sleep apnoea-hypopnoea syndrome (OSAHS) HK-2 cells CoCl2 treatment CoCl2 induced expression of miR-145 while ROR overexpression downregulated expression of miR-145. 31164009 2076 Human hsa-miR-145 miRNA cigarette smoke condensate (CSC) oral cancer SCC4 cells; H357 cells; primary normal oral fibroblasts (NOF) Cigarette smoke condensate(CSC) treatment downregulated 23173553 2077 Human hsa-miR-145 miRNA prednisolone oral submucous fibrosis (OSF) OSF-fibroblast cells were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment upregulated 24921400 2078 Human hsa-miR-145 miRNA IL-1¦Â osteoarthritis (OA) primary cultured chondrocytes IL-1¦Â treatment downregulated 31637891 2079 Human hsa-miR-145 miRNA oleanolic acid (OLA) osteoarthritis (OA) chondrocytes oleanolic acid (OLA) treatment upregulated 32028542 2080 Human hsa-miR-145 miRNA tumor necrosis factor alpha (TNF-¦Á) osteoarthritis (OA) human OA cartilage tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29072705 2081 Human hsa-miR-145 miRNA osteogenic differentiation medium osteogenesis Human jaw bone marrow mesenchymal stem cells (h-JBMMSCs) osteogenic medium culture downregulated 31305177 2082 Human hsa-miR-145 miRNA ossotide osteogenesis imperfecta (OI) osteoblasts Ossotide treatment upregulated 27551756 2083 Human hsa-miR-145 miRNA zoledronic acid (ZA) osteoporosis serum ZOL treatment "?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment" 33637048 2084 Human hsa-miR-145 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" ovarian cancer (OC) "paclitaxel-resistant cell lines (A2780/PTX, SKOV3/PTX)" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 24510775 2085 Human hsa-miR-145 miRNA propofol (PPF) ovarian cancer (OC) ovarian cancer cell lines (A2780 and SKOV3) Propofol treatment Propofol suppressed the progression of ovarian cancer through up-regulating miR-145 via suppressing circVPS13C 33563314 2086 Human hsa-miR-145 miRNA quercetin ovarian cancer (OC) SKOV-3 and A2780 cells quercetin treatment upregulated 25937243 2087 Human hsa-miR-145 miRNA XMD8-92 pancreatic ductal adenocarcinoma (PDAC) human pancreatic cancer AsPC-1 cells XMD8-92 treatment upregulated 24880079 2088 Human hsa-miR-145 miRNA TGF-¦Â1 peritoneal fibrosis human peritoneal mesothelial cells (i.e. HMrSV5 cells) transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 31431501 2089 Human hsa-miR-145 miRNA curcumin (Cur) prostate cancer "PC3, DU145 and LNCaP cells" curcumin treatment upregulated 28391715 2090 Human hsa-miR-145 miRNA curcumin (Cur) prostate cancer HuPCaSCs curcumin treatment upregulated 28843521 2091 Human hsa-miR-145 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment upregulated 30195228 2092 Human hsa-miR-145 miRNA TGF-¦Â1 renal fibrosis human renal proximal tubular epithelial (HK2) cells TGF-¦Â1 treatment MALAT1 functions by acting as a miR-145 sponge in HK2 cells treated with TGF-¦Â1 32203053 2093 Human hsa-miR-145 miRNA hypoxia renal injury human renal inner medullary CD133+ progenitors hypoxia treatment downregulated 21900452 2094 Human hsa-miR-145 miRNA TGF-¦Â1 renal interstitial fibrosis (RIF) HK-2 cells TGF-¦Â1 treatment downregulated 31863776 2095 Human hsa-miR-145 miRNA lipopolysaccharide (LPS) rheumatoid arthritis (RA) human fibroblast-like synoviocyte line MH7A lipopolysaccharides (LPS) treatment downregulated 30191608 2096 Human hsa-miR-145 miRNA retinoic acid (RA) cell senescence SH-SY5Y cells retinoic acid (RA) treatment upregulated 27525675 2097 Human hsa-miR-145 miRNA retinoic acid (RA) cell senescence SH-SY5Y cells SH-SY5Y cells treatment upregulation 27525675 2098 Human hsa-miR-145 miRNA lipopolysaccharide (LPS) sepsis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment downregulated 30784922 2099 Human hsa-miR-145 miRNA lipopolysaccharide (LPS) sepsis-induced acute lung injury BEAS-2B cells lipopolysaccharide (LPS) treatment downregulated 30841464 2100 Human hsa-miR-145 miRNA cardio-pulmonary bypass (CPB) severe lung injury lung cardiopulmonary bypass (CPB) treatment upregulated 25347932 2101 Human hsa-miR-145 miRNA TGF-¦Â1 subconjunctival fibrosis Human tenon's capsule fibroblasts (HTFs) TGF-¦Â1 treatment upregulated 31081880 2102 Human hsa-miR-145 miRNA ultraviolet (UV) irradiation systemic lupus erythematosus (SLE) HaCaT cells UVB treatment miR-145 was upregulated by UVB irradiation 30198366 2103 Human hsa-miR-145 miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment upregulated 24396484 2104 Human hsa-miR-145 miRNA acetylated Low density lipoprotein (Ac-LDL) type 2 diabetes mellitus (T2DM) THP-1 cells; peripheral blood mononuclear cells (PBMCs) acetylated Low density lipoprotein (Ac-LDL) treatment upregulated 30941422 2105 Human hsa-miR-145 miRNA acetylated Low density lipoprotein (Ac-LDL) and high glucose (HG) type 2 diabetes mellitus (T2DM) THP-1 cells; peripheral blood mononuclear cells (PBMCs) acetylated Low density lipoprotein (Ac-LDL) treatment upregulated 30941422 2106 Human hsa-miR-145 miRNA free fatty acids (FFA) type 2 diabetes mellitus (T2DM) THP-1 cells;peripheral blood mononuclear cells free fatty acid (FFA) treatment upregulated 30941422 2107 Human hsa-miR-145 miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) THP-1 cells;peripheral blood mononuclear cells high glucose (HG) treatment upregulated 30941422 2108 Human hsa-miR-145 miRNA TGF-¦Â type 2 diabetes mellitus (T2DM) Vascular smooth muscle cells (SMC) from T2DM exposure of ND-SMC to transforming growth factor beta (TGF¦Â) treatment upregulated 24927876 2109 Human hsa-miR-145 miRNA mechanical stretch vascular disease HASMCs mechanical stretch treatment downregulated 24848371 2110 Human hsa-miR-145 miRNA high glucose (HG) vascular injury smooth muscle cells (VSMCs) high glucose treatment downregulated 26181633 2111 Human hsa-miR-145 miRNA homocysteine (Hcy) vascular smooth muscle cell proliferation Human vascular smooth muscle cell line (VSMCs) Homocysteine (Hcy) treatment Hcy decreased the expression of miR-145 in VSMCs. 32124010 2112 Human hsa-miR-145 miRNA TGF-¦Â and bleomycin A5 venous malformations (VMs) human umbilical vein endothelial cells (HUVECs) recombinant human TGF-¦Â and bleomycin A5 treatment upregulated 28104472 2113 Human hsa-miR-145-3p miRNA IFN-¦Ã and lipopolysaccharide (LPS) macrophage polarization THP1-derived macrophages IFN-gamma and LPS treatment downregulated 30634164 2114 Human hsa-miR-145-3p miRNA IL-4 and IL-13 macrophage polarization THP1-derived macrophages IL-4 and IL-13 treatment upregulated 30634164 2115 Human hsa-miR-145-5p miRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment downregulated 33602903 2116 Human hsa-miR-145-5p miRNA cigarette smoke (CS) airway diseases Normal human bronchial epithelial (NHBE) air-liquid interface (ALI) cultures cigarette smoke (CS) exposure upregulated 30595527 2117 Human hsa-miR-145-5p miRNA TGF-¦Â airway diseases Normal human bronchial epithelial (NHBE) air-liquid interface (ALI) cultures TGF-¦Â treatment upregulated 30595527 2118 Human hsa-miR-145-5p miRNA cigarette smoke (CS) chronic obstructive pulmonary disease (COPD) human lung tissues samples cigarette smoke (CS) exposure downregulated 30639269 2119 Human hsa-miR-145-5p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) Human pulmonary microvascular endothelial cells HPMECs and bronchial epithelial cells BEAS-2B cigarette smoke extract (CSE) treatment downregulated 33248690 2120 Human hsa-miR-145-5p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) HPMECs and BEAS-2B cells cigarette smoke extract (CSE) exposure "Hsa_circ_0006872 facilitated CSE-triggered apoptosis, inflammation and oxidative stress in HPMECs and BEAS-2B cells by regulating miR-145-5p/NF-¦ÊB pathway." 33248690 2121 Human hsa-miR-145-5p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) Human pulmonary microvascular endothelial cells HPMECs cigarette smoke extract (CSE) treatment "CircANKRD11 and BRD4 expression were increased, whereas miR-145-5p expression was decreased in the lung tissues of smokers with or without COPD and CSE-induced HPMECs" 33833509 2122 Human hsa-miR-145-5p miRNA TGF-¦Â chronic obstructive pulmonary disease (COPD) Primary human bronchial epithelial cells Transforming growth factor ¦Â (TGF-¦Â) treatment upregulated 30595527 2123 Human hsa-miR-145-5p miRNA puerarin diabetic nephropathy (DN) HK2 cells puerarin treatment upregulated 33122931 2124 Human hsa-miR-145-5p miRNA progesterone (P4) endometrial cancer (EC) Ishikawa cells ?progesterone (P4) treatment upregulated 29661100 2125 Human hsa-miR-145-5p miRNA "2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)" endothelial cell injury human umbilical vein endothelial cells (HUVECs) "2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment" downregulated 33093269 2126 Human hsa-miR-145-5p miRNA rapamycin endothelial dysfunction human umbilical vein endothelial cells (HUVECs) rapamycin treatment upregulated 29579170 2127 Human hsa-miR-145-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) freshly-frozen specimens in the ESCC tumors "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26254350 2128 Human hsa-miR-145-5p miRNA TGF-¦Â1 gastric cancer (GC) AGS and MKN45 cancer cells transforming growth factor ¦Â1 (TGF-¦Â1) secretion by MSCs treatment downregulated 30742067 2129 Human hsa-miR-145-5p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment upregulated 25129238 2130 Human hsa-miR-145-5p miRNA dexamethasone (DEX) glucocorticoid-induced osteoporosis (GIOP) Bone tissue dexamethasone (DEX) treatment hsa_circ_0006393 increases the expression levels of osteogenic genes during bone remodeling by sponging miR-145-5p and upregulating FOXO1. 31322188 2131 Human hsa-miR-145-5p miRNA cardiac resynchronization therapy heart failure (HF) plasma cardiac resynchronization therapy treatment upregulated 23736534 2132 Human hsa-miR-145-5p miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection human peripheral blood mononuclear cells (PBMC) HIV-1 infection treatment downregulated 25295610 2133 Human hsa-miR-145-5p miRNA dihydroartemisinin (DHA) hypertrophic scars (HS) human Tenon's capsule fibroblasts (HTFs) dihydroartemisinin (DHA) treatment DHA notably increased the expression of microRNA (miR)-145-5p in HTFs in a dose-dependent manner. 33688170 2134 Human hsa-miR-145-5p miRNA high fat diet (HFD) inflammation plasma high fat diet (HFD) feed upregulated 30885503 2135 Human hsa-miR-145-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic heart disease (IHD) human cardiomyocytes (HCM) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment MiR-145-5p inhibition reversed the effects of silencing circ_0010729 on OGD-induced injury and mTOR and MEK/ERK pathways 31482388 2136 Human hsa-miR-145-5p miRNA cisplatin and pemetrexed lung adenocarcinoma (LUAD) A549/DR cells cisplatin and pemetrexed treatment circPVT1 contributes to cisplatin and pemetrexed chemotherapy resistance through miR-145-5p/ABCC1 axis. 31986409 2137 Human hsa-miR-145-5p miRNA particulate matter (PM2.5) PM2.5-induced carcinogenesis human bronchial epithelial (HBE) cells fine particulate matter (PM2.2) treatment downregulated 33545377 2138 Human hsa-miR-145-5p miRNA tumor necrosis factor alpha (TNF-¦Á) preeclampsia (PE) HTR-8/SVneo cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30081007 2139 Human hsa-miR-145-5p miRNA bromocriptine prolactinoma prolactinoma clinical samples and prolactinoma cell line MMQ/BRC bromocriptine treatment downregulated 30370446 2140 Human hsa-miR-145-5p miRNA docetaxel (DTX) prostate cancer PC-3 cells docetaxel (DTX) treatment miR-145-5p in PC3-DTX cell was markedly lower than that of PC3 cells. 29633510 2141 Human hsa-miR-145-5p miRNA hantaan virus (HTNV) hemorrhagic fever with renal syndrome (HFRS) exosomes derived from HTNV-infected human vascular endothelial cells (HUVECs) (Exo-HV) Hantaan virus (HTNV) infection upregulated 32808389 2142 Human hsa-miR-145-5p miRNA valproic acid (VPA) thyroid cancer (TC) TC1889 cells VPA treatment upregulated 28486946 2143 Human hsa-miR-145-5p miRNA platelet derived growth factor-BB (PDGF-BB) VSMCs proliferation and migration vascular smooth muscle cells (VSMCs) PDGF-bb treatment miR-145-5p is downregulated in PDGF-mediated VSMCs in both time- and dose-dependent manners 30007992 2144 Human hsa-miR-146 miRNA docosahexaenoic acid (DHA) glioblastoma multiforme (GBM) human U87 MG glioma cell line docosahexaenoic acid (DHA) treatment upregulated 25182732 2145 Human hsa-miR-146 miRNA gamma-linolenic acid (GLA) glioblastoma multiforme (GBM) human U87 MG glioma cell line GLA treatment upregulated 25182732 2146 Human hsa-miR-146 miRNA ionizing radiation (IR) glioblastoma multiforme (GBM) human U87 MG glioma cell line irradiation treatment upregulated 25182732 2147 Human hsa-miR-146 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6A dysregulated 29163428 2148 Human hsa-miR-146 miRNA human herpesvirus 6B (HHV-6B) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6B dysregulated 29163428 2149 Human hsa-miR-146 miRNA carbamylated albumin renal cell carcinoma (RCC) human renal cell carcinoma cells Carbamylated albumin treatment upregulated 21472233 2150 Human hsa-miR-146 miRNA lipopolysaccharide (LPS) inflammation human vascular endothelial cell line EA. hy926 cells lipopolysaccharide (LPS) treatment downregulated 29442046 2151 Human hsa-miR-146 miRNA thrombin diabetic retinopathy (DR) human retinal endothelial cells (HRECs) were transfect miRNA mimics or antimiRs and thrombin treatment upregulated 24985472 2152 Human hsa-miR-146 miRNA TNF-a and MMP13 osteoarthritis (OA) human OA cartilage and bone TNF-a and MMP13 treatment downregulated 19008124 2153 Human hsa-miR-146 miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 2154 Human hsa-miR-1468-5p miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 2155 Human hsa-miR-1468-5p miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 2156 Human hsa-miR-1468-5p miRNA vascular endothelial growth factor (VEGF) angiogenesis human umbilical vein endothelial cells (HUVECs) vascular endothelial cell growth factor (VEGF) treatment downregulated 30414893 2157 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) falls and fractures among the elderly THP-1 cells lipopolysaccharide (LPS) lipopolysaccharide (LPS) induces a reactive oxygen species-/NF-kappaB-dependent pathway which increases the expression of the anti-inflammatory miR-146a 19390647 2158 Human hsa-miR-146a miRNA 6-mer HA oligosaccharides as sodium salt 6-mer HA-induced inflammation chondrocytes 6-mer HA oligosaccharides as sodium salt treatment upregulated 31583475 2159 Human hsa-miR-146a miRNA cutibacterium acnes (C. acnes) acne acne lesions or human keratinocytes cutibacterium acnes (C. acnes) infection upregulated 31194941 2160 Human hsa-miR-146a miRNA statins active hepatitis or cirrhosis HepG2 cells statins? treatment upregulated 26429200 2161 Human hsa-miR-146a miRNA high glucose (HG) acute coronary syndrome (ACS) Human Macrophages high glucose treatment upregulated 27519051 2162 Human hsa-miR-146a miRNA IL-1¦Â acute inflammatory response Human Lung Alveolar Epithelial Cells IL-1¦Â treatment upregulated 18390754 2163 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment downregulated 32399391 2164 Human hsa-miR-146a miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) The human promyelocytic cell line NB4£» humanembryonic kidney cell line 293T retinoid acid? treatment downregulated 20577838 2165 Human hsa-miR-146a miRNA human T-cell leukemia virus type 1 (HTLV-1) adult T-cell leukemia (ATL) CD4£«T cell human T-cell leukemia virus type 1 (HTLV-1) infection upregulated 20017139 2166 Human hsa-miR-146a miRNA particulate matter (PM2.5) air pollution-induced placental epigenetic alterations placental tissue Particulate matter (PM2.5) exposure treatment miR-146a was inversely associated with PM25 exposure during the 2nd trimester of pregnancy 27104955 2167 Human hsa-miR-146a miRNA chitin allergic airway diseases (AAD) bronchial epithelial cells and in A549 and H292 lung carcinoma cells chitin treatment upregulated 27463381 2168 Human hsa-miR-146a miRNA amyloid-¦Â (A¦Â) Alzheimer's disease (AD) N9 microglial cell line amyloid-¦Â (A¦Â) treatment upregulated 27797173 2169 Human hsa-miR-146a miRNA amyloid-¦Â (A¦Â) 42 Alzheimer's disease (AD) human neuronal-glial primary cell amyloid-¦Â (A¦Â) 42 peptide metal treatment upregulated 22043907 2170 Human hsa-miR-146a miRNA dipeptidyl vinyl sulfone (VS) Alzheimer's disease (AD) N9 microglial cell line treated with A¦Â VS treatment downregulated 27797173 2171 Human hsa-miR-146a miRNA neurotoxic metal Alzheimer's disease (AD) human neuronal-glial primary cell neurotoxic metal treatment upregulated 22043907 2172 Human hsa-miR-146a miRNA proinflammatory cytokines Alzheimer's disease (AD) human neuronal-glial primary cell pro-inflammatory cytokine treatment upregulated 22043907 2173 Human hsa-miR-146a miRNA herpes simplex virus 1 (HSV-1) alzheimer-type inflammatory HN cells Herpes simplex virus type-1 (HSV-1) infection upregulated 19801956 2174 Human hsa-miR-146a miRNA nanocurcumin ankylosing spondylitis (AS) peripheral blood mononuclear cells (PBMCs) nanocurcumin treatment upregulated 31074089 2175 Human hsa-miR-146a miRNA "dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)" anti-inflammatory responses primary astrocyte cultures derived from human brains stimulated with IL-1¦Â "pretreat with DMF, MMF" downregulated 28589165 2176 Human hsa-miR-146a miRNA immunoglobulin anti-inflammatory responses LPS-activated human monocytes intravenous immunoglobulin (IVIG) downregulated 28288804 2177 Human hsa-miR-146a miRNA mechanical pressure of 10 MPa apoptosis human chondrocytes mechanical pressure of 10 Mpa for 60 min treatment upregulated 24939082 2178 Human hsa-miR-146a miRNA epstein-barr virus (EBV) asthma "U2932,BL28 and BL41, BL28 E95A and BL41 E95C,BL28 EHRA and BL41 EHRA,Oma 4 ,Bjab and the B95-8" Epstein-Barr virus (EBV) downregulated 22614176 2179 Human hsa-miR-146a miRNA "IFN-¦Ã, IL-1¦Â and TNF-¦Á" asthma human airway smooth muscle cells (hASMCs) "cytomix (IL-1¦Â, TNF-¦Á, and IFN¦Ã) treatment" upregulated 25217662 2180 Human hsa-miR-146a miRNA IL-17A asthma primary conventional human bronchial epithelial cells (HBECs) culture IL-17A treatment upregulated 31798831 2181 Human hsa-miR-146a miRNA IL-1¦Â asthma airway smooth muscle cells (ASMCs) from asthmatic patients IL-1¦Â treatment downregulated 29946002 2182 Human hsa-miR-146a miRNA IL-4 asthma primary conventional human bronchial epithelial cells (HBECs) culture IL-4 treatment upregulated 31798831 2183 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) asthma primary conventional human bronchial epithelial cells (HBECs) culture tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31798831 2184 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) lipopolysaccharides (LPS) treatment upregulated 30710793 2185 Human hsa-miR-146a miRNA olive leaf extract (OLE) atherosclerosis (AS) Serum amyloid A (SAA)-induced human coronary artery endothelial cells (HCAEC) Olive leaf extract (OLE) treatment downregulated 31157238 2186 Human hsa-miR-146a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophages atherogenic Evs oxidized low-density lipoprotein (ox-LDL) treatment enrichment in atherogenic EVs 28882869 2187 Human hsa-miR-146a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human macrophage THP-1 cells exosomes oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31416388 2188 Human hsa-miR-146a miRNA serum amyloid A (SAA) atherosclerosis (AS) human coronary artery endothelial cells (HCAEC) Serum amyloid A (SAA) treatment upregulated 31157238 2189 Human hsa-miR-146a miRNA TNF-¦Á£¬IGF-1 atherosclerosis (AS) smooth muscle cell TNF-¦Á£¬IGF-1 treatment upregulated 26047583 2190 Human hsa-miR-146a miRNA ortho-silicic acid bone defects human mesenchymal stem cells (hMSCs) orthosilicic acid (Si(OH)4) treatment upregulated 27163405 2191 Human hsa-miR-146a miRNA coenzyme Q10 (CoQ10) breast cancer primary human umbilical vein endothelial cells (HUVECs) coenzyme Q10 (CoQ10H?) treatment downregulated 23727324 2192 Human hsa-miR-146a miRNA ionizing radiation (IR) breast cancer Blood The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min) upregulated 31150454 2193 Human hsa-miR-146a miRNA quercetin breast cancer human breast cancer cell lines MCF-7 and MDA-MB-231 quercetin treatment upregulated 25596948 2194 Human hsa-miR-146a miRNA triptolide (TPL) breast cancer MDA-MB-231 breast cancer cells triptolide (TPL) treatment upregulated 31072418 2195 Human hsa-miR-146a miRNA atorvastatin coronary artery disease (CAD) PBMCs (peripheral blood mononuclear cells) atorvastatin and telmisartan or atorvastatin treatment downregulated 20524934 2196 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) cardiac dysfunction cardiomyocyte cell line of human origin (AC16) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 26112171 2197 Human hsa-miR-146a miRNA Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cardiac hypertrophy human breast cancer? cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 23647548 2198 Human hsa-miR-146a miRNA doxorubicin (DOX) cardiotoxicity AC16 cardiomyocytes Doxorubicin (DOX) treatment upregulated 31511497 2199 Human hsa-miR-146a miRNA doxorubicin (DOX) "cardiotoxicity,cardiomyopathy and heart failure" female patients from the placebo arm doxorubicin treatment upregulated 28052002 2200 Human hsa-miR-146a miRNA gliadinN celiac disease (CD) PBMCs; monocytes gliadinN treatment upregulated 31781909 2201 Human hsa-miR-146a miRNA CoCl2 cell-based therapies human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) CoCl2 treatment CoCl2 leads to increased expression of microRNA- (miR-) 146a. 30254683 2202 Human hsa-miR-146a miRNA chikungunya virus chronic infection human synovial fibroblasts infect with chikungunya virus treatment upregulated 25083878 2203 Human hsa-miR-146a miRNA imatinib mesylate chronic myeloid leukemia (CML) Peripheral blood cells imatinib mesylate treatment upregulated 20460641 2204 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) corticosteroid-dependent dermatitis (CDD) HaCaT cells lipopolysaccharide (LPS) treatment downregulated 29913408 2205 Human hsa-miR-146a miRNA tripterine corticosteroid-dependent dermatitis (CDD) LPS-treated HaCaT cells Tripterine treatment upregulated 29913408 2206 Human hsa-miR-146a miRNA Kaposi¡¯s sarcoma-associated herpesvirus (KSHV) cryptosporidium parvum infection Human Umbilical Vein Endothelial Cells (HUVEC) Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) treatment upregulated 20023696 2207 Human hsa-miR-146a miRNA bisphenol A (BPA) cytotoxicity human placental cells bisphenol A (BPA) treatment upregulated 20417706 2208 Human hsa-miR-146a miRNA helicobacter pylori (H. pylori) dementia human gastric epithelial cells Helicobacter pylori (H. pylori) infection ?H. pylori infection upregulated the expression of miR-146a in gastric epithelial cells 20542134 2209 Human hsa-miR-146a miRNA high glucose (HG) diabetic retinopathy (DR) human REC high glucose (HG) treatment downregulated 26997759 2210 Human hsa-miR-146a miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) "high glucose (25 mmol/L, 1-7 days)" "downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)" 28706953 2211 Human hsa-miR-146a miRNA portland cement (PC) cell differentiation human periodontal ligament cells PC treatment upregulated 28528141 2212 Human hsa-miR-146a miRNA portland cement (PC) cell differentiation PDL cells Portland cement (PC) treatment "PC enhances the differentiation of PDL cells, especially osteogenic through miR-146a upregulation" 28528141 2213 Human hsa-miR-146a miRNA doxorubicin (DOX) doxorubicin (DOX)-induced cardiotoxicity plasma extracellular vesicle (EV) doxorubicin (Dox) treatment downregulated 32255536 2214 Human hsa-miR-146a miRNA leuprolide endometriosis endometriotic tissues Leuprolide treatment upregulated 27709720 2215 Human hsa-miR-146a miRNA oxidized low density lipoprotein (ox-LDL) endothelial cell migration THP-1 cell oxidized low-density lipoprotein (ox-LDL) treatment downregulated 21329689 2216 Human hsa-miR-146a miRNA phorbol-12-myristate-13-acetate(PMA) angiogenesis HMVECs PMA treatment PMA induced miR-146a expression in human microvascular endothelial cells 19944095 2217 Human hsa-miR-146a miRNA ionizing radiation (IR) endothelial dysfunction Human umbilical vein endothelial cells (HUVECs) Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT "2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h." 30711956 2218 Human hsa-miR-146a miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) L02 hepatocytes TGF-¦Â1 treatment downregulated 30711634 2219 Human hsa-miR-146a miRNA cyanobacterial lipopolysaccharide antagonist (CyP) endotoxin cross-tolerance THP-1 cells and human monocytes cyanobacterial lipopolysaccharide antagonist (CyP) treatment upregulated 30054544 2220 Human hsa-miR-146a miRNA enterovirus 71 (EV71) enterovirus infection human rhabdomyosarcoma cells line (RD) EV71 infection treatment upregulated 24561744 2221 Human hsa-miR-146a miRNA IFN-¦Ã epithelial-mesenchymal transition (EMT) human RPE cells interferon-¦Ã treatment upregulated 23592910 2222 Human hsa-miR-146a miRNA IL-1¦Â epithelial-mesenchymal transition (EMT) human RPE cells IL-1¦Â treatment upregulated 23592910 2223 Human hsa-miR-146a miRNA Kr¨¹ppel-like factor 8 (KLF8) epithelial-mesenchymal transition (EMT) "MCF-10A, MCF-7 , T47D, MDA-MB-231, Hs578T and BT-549 cell lines and the MCF-10A line" Kr¨¹ppel-like factor 8 treatment upregulated 23977446 2224 Human hsa-miR-146a miRNA "TGF-¦Â1 plus cytomix (a mixture of IL-1beta, IFN-gamma and TNF-alpha)" epithelial-mesenchymal transition (EMT) HBECs cytokine treatment "miRNA-146a was upregulated in human bronchial epithelial cells (HBECs) in response to stimulation by TGF-?1 plus cytomix (a mixture of IL-1?, IFN-c and TNF-a)" 19167348 2225 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) epithelial-mesenchymal transition (EMT) human RPE cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 23592910 2226 Human hsa-miR-146a miRNA epstein-barr virus (EBV) Epstein-Barr virus (EBV) infection B-cells Epstein-Barr virus (EBV) infection downregulated 19001862 2227 Human hsa-miR-146a miRNA porphyromonas gingivalis experimental periodontal disease human THP-1 monocytes Porphyromonas gingivalis treatment downregulated 21263019 2228 Human hsa-miR-146a miRNA purified lipooligosaccharides (LOS) facilitate bacterial survival and dissemination human monocytic THP-1 cells and primary monocytes LOS re of cells treatment upregulated 24442429 2229 Human hsa-miR-146a miRNA neutrophil elastase (NE) fat 16HBE cells neutrophil elastase (NE) treatment NE exerts a dose- and time-dependent induction of both MUC5AC and miR-146a in human bronchial epithelial cells (16HBE) 21773870 2230 Human hsa-miR-146a miRNA helicobacter pylori (H. pylori) gastritis gastric lesions Helicobacter pylori treatment upregulated 30219037 2231 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) gingival inflammation Human gingival fibroblasts (HGFs) lipopolysaccharide (LPS) treatment upregulated 29407755 2232 Human hsa-miR-146a miRNA monosodium urate (MSU) gouty tophus human monocytic THP-1 cells monosodium urate (MSU) treatment downregulated 25646371 2233 Human hsa-miR-146a miRNA IL-1¦Â graves' orbitopathy (GO) GO orbital adipose IL-1¦Âtreatment upregulated 27494344 2234 Human hsa-miR-146a miRNA TGF-¦Â graves' orbitopathy (GO) orbital fibroblasts from patients with Graves' orbitopathy (GO) TGF-¦Â treatment upregulated 29101123 2235 Human hsa-miR-146a miRNA TGF-¦Â graves' orbitopathy (GO) orbital fibroblasts from patients with GO TGF-¦Â treatment upregulated 29101123 2236 Human hsa-miR-146a miRNA IL-10 hepatocellular carcinoma (HCC) NK cells from CHB and HCC patients "IL-10 ,transforming growth factor-¦Â treatment" upregulated 26996068 2237 Human hsa-miR-146a miRNA "IL-12, IFN-¦Á and IFN-¦Â" hepatocellular carcinoma (HCC) NK cells from CHB and HCC patients "IL-12,IFN-¦Á , IFN-¦Â treatment" downregulated 26996068 2238 Human hsa-miR-146a miRNA TGF-¦Â hepatocellular carcinoma (HCC) NK cells from CHB and HCC patients "IL-10 ,transforming growth factor-¦Â treatment" upregulated 26996068 2239 Human hsa-miR-146a miRNA recombinant Schistosoma japonicum protein P40 (rSjP40) liver fibrosis LX-2 cells recombinant Schistosoma japonicum protein P40 (rSjP40) treatment rSjP40 could induce miR-146a expression in LX-2 cells 29953648 2240 Human hsa-miR-146a miRNA angiotensin-(1-7) hepatocellular carcinoma (HCC) human aortic endothelial cells (HAECs) angiotensin-(1-7) treatment downregulated 23246834 2241 Human hsa-miR-146a miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) HCC cell Paclitaxe treatment upregulated 25973036 2242 Human hsa-miR-146a miRNA hantaan virus (HTNV) hantaan virus (HTNV) infection human umbilical vein endothelial cells (HUVECs) infect with HTNV upregulated 28843856 2243 Human hsa-miR-146a miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection peripheral blood mononuclear cells (PBMCs) human immunodeficiency virus (HIV)-1 infection upregulated 31827152 2244 Human hsa-miR-146a miRNA heat shock factor 1 (HSF1) huntington's disease (HD) Blood Heat shock factor 1 (HSF1) treatment downregulated 26634350 2245 Human hsa-miR-146a miRNA simvastatin hyperlipidemia blood Simvastatin treatment downregulated 25727911 2246 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) angiogenesis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment upregulated 24863965 2247 Human hsa-miR-146a miRNA type I interferon (IFN) hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) type I interferon (IFN) treatment upregulated 23650597 2248 Human hsa-miR-146a miRNA vibrio cholerae O1 infection of Vibrio cholerae O1 colon carcinoma cell line T84 infect with Vibrio cholerae O1 treatment upregulated at acute stage of V cholerae infection and declined to normal at convalescent stage 28319200 2249 Human hsa-miR-146a miRNA alternariol (AOH) inflammation THP-1 cells alternariol (AOH) treatment downregulated 30175388 2250 Human hsa-miR-146a miRNA helicobacter pylori (H. pylori) inflammation human gastric epithelial cells Helicobacter pylori (H. pylori) infection upregulated 21947847 2251 Human hsa-miR-146a miRNA helicobacter pylori (H. pylori) inflammation human gastric mucosa Helicobacter pylori (H. pylori) infection upregulated 30535468 2252 Human hsa-miR-146a miRNA helicobacter pylori (H. pylori) inflammation human gastric mucosa Helicobacter pylori (H. pylori) infection upregulated 30535468 2253 Human hsa-miR-146a miRNA IL-17A inflammation SGC-7901 cells IL-17A treatment upregulated 30535468 2254 Human hsa-miR-146a miRNA IL-17A inflammation SGC-7901 cells interleukin (IL)-17A treatment upregulated 30535468 2255 Human hsa-miR-146a miRNA IL-1¦Â inflammation human lung fibroblasts IL-1¦Â treatment downregulated 30619270 2256 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) inflammation human microvascular endothelial cells (HMECs) lipopolysaccharides (LPS) treatment upregulated 31291804 2257 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) inflammation THP-1 monocytes lipopolysaccharide (LPS) treatment upregulated 21178010 2258 Human hsa-miR-146a miRNA outer membrane vesicles (OMVs) inflammation human intestinal epithelial cells T84 Vibrio cholerae outer membrane vesicles (OMVs) treatment upregulated 31076615 2259 Human hsa-miR-146a miRNA particulate matter (PM1) inflammation human lung bronchial epithelial BEAS-2B cells particulate matter (PM1) treatment upregulated 29667303 2260 Human hsa-miR-146a miRNA "PD98059, TPCA-1 and LY294002" inflammation A549 cells "exposure to PD98059, TPCA-1 and LY294002 treatment" downregulated 25183503 2261 Human hsa-miR-146a miRNA "1,25-dihydroxyvitamin D (1,25(OH)2D)" inflammation human adipocytes "1,25-dihydroxyvitamin D (1,25(OH)2D) treatment" downregulated 28055298 2262 Human hsa-miR-146a miRNA Tnf¦Á and Gm-csf heart failure (HF) cardiomyocyte cell line H9C2 Tnf¦Á and Gm-csf treatment upregulated 29258606 2263 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) inflammatory bowel disease (IBD) colonic epithelial cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 26752469 2264 Human hsa-miR-146a miRNA IL-1¦Â inflammatory diseases THP-1 cells IL-1¦Â treatment upregulated 25896300 2265 Human hsa-miR-146a miRNA IL-1¦Â inflammatory injury human umbilical cord-derived mesenchymal stem cells (MSCs) IL-1¦Â treatment upregulated 28090688 2266 Human hsa-miR-146a miRNA candida albicans (C. albicans) inflammatory response THP-1 cells candida albicans infection upregulated 28454101 2267 Human hsa-miR-146a miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells Influenza A virus (IAV) infection upregulated 30611999 2268 Human hsa-miR-146a miRNA "TLR2 ligand zymosan, the TLR3 ligand poly(I:C) or the TLR5 ligand flagellin" innate immune response keratinocytes "TLR2 ligand zymosan, the TLR3 ligand poly(I:C) or the TLR5 ligand flagellin treatment" upregulated 24588688 2269 Human hsa-miR-146a miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment upregulated 25959385 2270 Human hsa-miR-146a miRNA insect cell-derived anionic septapeptide innate immune response Primary human monocyte cultures insect cell-derived anionic septapeptide treatment upregulated 31075349 2271 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells lipopolysaccharide (LPS) treatment downregulated 28161709 2272 Human hsa-miR-146a miRNA IL-1¦Â intestinal inflammation Caco-2 cells IL-1¦Â treatment upregulated 30478292 2273 Human hsa-miR-146a miRNA Japanese encephalitis virus (JEV) Japanese encephalitis virus (JEV) infection serum Japanese encephalitis virus (JEV) infection miR-146a was found significantly decreased (p?=?0.0008) in JEV infected patients as compared to healthy controls. 30196835 2274 Human hsa-miR-146a miRNA Japanese encephalitis virus (JEV) Japanese encephalitis virus (JEV) infection human microglial CHME3 cells JEV-infected treatment upregulated 24885259 2275 Human hsa-miR-146a miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 18648749 2276 Human hsa-miR-146a miRNA Vitamin D and phorbol 12-myristate 13-acetate leukemia AML cell line (HL60 and NB4) Vitamin D and phorbol 12-myristate 13-acetate treatment downregulated 20981674 2277 Human hsa-miR-146a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" linesprostate cancer LNCaP£¬PC3 cell "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 24885368 2278 Human hsa-miR-146a miRNA ultraviolet (UV) irradiation hepatocellular carcinoma (HCC) HepG2 cells UV irradiation treatment upregulated 24431000 2279 Human hsa-miR-146a miRNA TGF-¦Â1 liver fibrosis L02 hepatocytes TGF-¦Â1 treatment downregulated 30711634 2280 Human hsa-miR-146a miRNA 5-fluorouracil/cisplatin (CDDP-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) CDDP-CRTX treatment dysregulated 28347920 2281 Human hsa-miR-146a miRNA IL-1¦Â lung cancer human airway smooth muscle (HASM) cells IL-1¦Â treatment upregulated 20525168 2282 Human hsa-miR-146a miRNA M2000 (¦Â-d-mannuronic acid) inflammatory response HEK-Blue hTLR2 cells M2000 at low and high doses (5 and 25¦Ìg/well) downregulated 28324845 2283 Human hsa-miR-146a miRNA oxidized low density lipoprotein (ox-LDL) macrophage maturation Human THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment "oxLDL positively regulates miR-146a via the JNK and NF-¦ÊB pathways in macrophages, and that miR-146a inhibits inflammatory activation." 26718614 2284 Human hsa-miR-146a miRNA mechanotransduction and pressure mechanically induced inflammation Primary human small airway epithelial cells (HSAEpCs) mechanotransduction and pressure treatment MiR-146a is a mechanosensitive miRNA that is rapidly upregulated by oscillatory pressure and plays an important role in regulating mechanically induced inflammation in lung epithelia. 22593544 2285 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) migration of human dental pulp cells human dental pulp cells lipopolysaccharide (LPS) treatment upregulated 23146644 2286 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) monocytic differentiation monocyte lipopolysaccharide (LPS) treatment dysregulated 25148686 2287 Human hsa-miR-146a miRNA "TNF¦Á , IFN¦Ã" multiple sclerosis (MS) human cerebral microvascular endothelial cells (hCMEC/D3) TNF¦Á and IFN¦Ã treatment upregulated 25515214 2288 Human hsa-miR-146a miRNA Toll-like receptor (TLR) neurological diseases U251 human astrocytoma cell line Toll-like receptor (TLR) treatment upregulated 25957996 2289 Human hsa-miR-146a miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 2290 Human hsa-miR-146a miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 2291 Human hsa-miR-146a miRNA free fatty acids (FFAs) and TNF-¦Á and IL-6 nonalcoholic fatty liver disease (NAFLD) HepG2 cells and human hepatocytes free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment upregulated 25562147 2292 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) oral lichen planus (OLP) HaCaT cells lipopolysaccharide (LPS) treatment The expression of miR-146a was upregulated in OLP tissues and in lipopolysaccharide (LPS)-incubated HaCaT cells. 30125971 2293 Human hsa-miR-146a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" osteoarthritis (OA) OA chondrocytes and synoviocytes "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31077718 2294 Human hsa-miR-146a miRNA dendrobine osteoarthritis (OA) synovial cells (OA-FLS) isolated from stage-IV-OA patients dendrobine treatment upregulated 25052989 2295 Human hsa-miR-146a miRNA H2O2 osteoarthritis (OA) human OA chondrocytes H2O2 treatment downregulated (miR-146a) ; upregulated(miR-34a) 29292727 2296 Human hsa-miR-146a miRNA hydrostatic pressure (HP) osteoarthritis (OA) human osteoarthritis (OA) chondrocytes hydrostatic pressure (HP) treatment upregulated 32455798 2297 Human hsa-miR-146a miRNA mechanical loading and hydrostatic pressure (HP) osteoarthritis (OA) OA human chondrocytes mechanical loading and hydrostatic pressure (HP) treatment upregulated 28085114 2298 Human hsa-miR-146a miRNA mud-bath therapy (MBT) osteoarthritis (OA) patients with bilateral knee osteoarthritis (OA) "daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks" downregulated 28785809 2299 Human hsa-miR-146a miRNA resistin osteoarthritis (OA) human OA synovial fibroblasts resistin treatment upregulated 31635187 2300 Human hsa-miR-146a miRNA visfatin osteoarthritis (OA) human OA synovial fibroblasts visfatin treatment upregulated 31635187 2301 Human hsa-miR-146a miRNA IL-1¦Â osteoporosis A549 cells IL-1¦Â treatment downregulated 19786024 2302 Human hsa-miR-146a miRNA proinflammatory cytokines otitis media (OM) Human middle ear epithelial cells proinflammatory cytokines treatment upregulated 27497395 2303 Human hsa-miR-146a miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) oxygen-glucose deprivation/reoxygenation (OGD/R) injury SK-N-SH cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 27449900 2304 Human hsa-miR-146a miRNA "3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) Colo357; Panc-1 cells "3,3'-diindolylmethane (DIM) treatment" upregulated 20124483 2305 Human hsa-miR-146a miRNA BxPC-3-conditioned medium (BxCM) pancreatic cancer (PC) human CD14£«monocyte-derived DCs BxPC-3-conditioned medium (BxCM) treatment "aberrant miRNA-146a expression is one of main factors responsible for inhibition of DC maturation and antigen presentation function, and this inhibitory effect on DCs may be due to the repression of Smad4 mediated signal pathway by BxCM" 22311263 2306 Human hsa-miR-146a miRNA curcumin-derived analogue CDF pancreatic cancer (PC) "human PC cell lines AsPC-1, BxPC-3, COLO-357, L3.6pl, PANC-1, PANC-28, MIAPaCa-2, MIAPaCa-2-GR" curcumin-derived analogue CDF treatment upregulated 24839931 2307 Human hsa-miR-146a miRNA isoflavone pancreatic cancer (PC) Colo357; Panc-1 cells isoflavone treatment upregulated 20124483 2308 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) pancreatic ductal adenocarcinoma (PDAC) THP-1 cells lipopolysaccharide (LPS) treatment upregulated 19840932 2309 Human hsa-miR-146a miRNA paraquat poisoning paraquat poisoning-induced lung injury "pulmonary macrophages, PBMCs and serum" paraquat poisoning treatment downregulated 29896267 2310 Human hsa-miR-146a miRNA intercept (amotosalen+ ultraviolet-A [UVA] light) pathogen reduction platelet gamma irradiation treatment downregulated 24749844 2311 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) periodontitis human periodontal ligament cells (hPDLCs) lipopolysaccharide (LPS) treatment upregulated 25948157 2312 Human hsa-miR-146a miRNA porphyromonas gingivalis periodontitis Human periodontal ligament fibroblasts (HPDLFs) Porphyromonas gingivialis (P. gingivalis) infection treatment upregulated 30378773 2313 Human hsa-miR-146a miRNA porphyromonas gingivalis periodontitis Human periodontal ligament fibroblasts (HPDLFs) Porphyromonas gingivialis (P. gingivalis) infection treatment upregulated 30378773 2314 Human hsa-miR-146a miRNA Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS) periodontitis Human periodontal ligament fibroblasts (HPDLFs) Porphyromonas gingivialis (P. gingivalis) LPS treatment upregulated 30378773 2315 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) peripheral inflammation mesenchymal stem cells (MSC) tumor necrosis factor alpha (TNF-¦Á) treatment over expression 20049872 2316 Human hsa-miR-146a miRNA TGF-¦Â1 cell differentiation human dermal fibroblasts TGF-¦Â1 treatment upregulated 21968601 2317 Human hsa-miR-146a miRNA TGF-¦Â1 podocyte injury Alexa Fluor 568-labeled phalloidin and HCS CellMask blue TGF-¦Â1 treatment downregulated 27913625 2318 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) preeclampsia (PE) HTR8 cells; SVneo cells tumor necrosis factor alpha (TNF-¦Á) treatment TRAIL downregulated the expressions of miR-146a 32090966 2319 Human hsa-miR-146a miRNA TPCA-1 pro-inflammatory activity human gingival fibroblasts (HGFs) high concentration (10 ¦ÌM) of IRAK1/4 inhibitor or the NF-¦ÊB inhibitor treatment downregulated 25598707 2320 Human hsa-miR-146a miRNA hepatitis C virus (HCV) promote regulatory T-cell development Human peripheral blood mononuclear cells (PBMCs) hepatitis C virus (HCV) infection upregulated 27004559 2321 Human hsa-miR-146a miRNA ascorbic acid angiogenesis ?I-PDL cells and primary PDL cells ascorbic acid?treatment upregulated 20110513 2322 Human hsa-miR-146a miRNA epstein-barr virus (EBV) prostate cancer Burkitt's lymphoma cells Epstein-Barr Virus (EBV)?infection upregulated 18347435 2323 Human hsa-miR-146a miRNA IL-17A psoriasis human primary keratinocytes IL-17A treatment upregulated 31630447 2324 Human hsa-miR-146a miRNA methotrexate (MTX) psoriasis Blood methotrexate treatment downregulated 26604920 2325 Human hsa-miR-146a miRNA methotrexate (MTX) psoriasis chronic plaque-type psoriasis patients PBMCs methotrexate (MTX) treatment downregulated in plasma 27535005 2326 Human hsa-miR-146a miRNA NB-UVB psoriasis Blood NB-UVB treatment downregulated 26604920 2327 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) psoriasis human primary keratinocytes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31630447 2328 Human hsa-miR-146a miRNA ionizing radiation (IR) radiation-induced acute and chronic complications EA.hy926 cells ionizing radiation (IR) treatment downregulated 32532422 2329 Human hsa-miR-146a miRNA iguratimod rheumatoid arthritis (RA) rheumatoid arthritis-fibroblast-like synoviocytes (RA-FLS) iguratimod treatment upregulated 32662411 2330 Human hsa-miR-146a miRNA quercetin rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) quercetin treatment Quercetin treatment elevated the RNA level of miR-146a. 32216502 2331 Human hsa-miR-146a miRNA tripterygium wilfordii Hook F (TwHF) rheumatoid arthritis (RA) RA patients peripheral blood mononuclear cells (PBMCs) TwHF treatment downregulated in peripheral blood mononuclear cells (PBMCs) 28514293 2332 Human hsa-miR-146a miRNA brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) cell senescence SH-SY5Y cells brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment upregulated 27525675 2333 Human hsa-miR-146a miRNA severe fever with thrombocytopenia syndrome virus (SFTSV) severe fever with thrombocytopenia syndrome (SFTS) Human monocyte cell line (THP-1)-derived macrophages Severe fever with thrombocytopenia syndrome virus (SFTSV) infection treatment upregulated 31156641 2334 Human hsa-miR-146a miRNA hydroxychloroquine systemic lupus erythematosus (SLE) "mesangial cells, T cells, pDCs, PBMCs, and the urine" hydroxychloroquine treatment "lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs." 24121037 2335 Human hsa-miR-146a miRNA prednisone systemic lupus erythematosus (SLE) "mesangial cells, T cells, pDCs, PBMCs, and the urine" prednisone treatment "lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs" 24121037 2336 Human hsa-miR-146a miRNA IFN systemic lupus erythematosus (SLE) THP-1 cells interferon (IFN) treatment downregulated 26315540 2337 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) systemic lupus erythematosus (SLE) THP-1 cells lipopolysaccharide (LPS) treatment downregulated 31572547 2338 Human hsa-miR-146a miRNA mycophenolic acid (MPA) systemic lupus erythematosus (SLE) lupus CD4(+)T cells Mycophenolic acid (MPA) treatment upregulated 25661834 2339 Human hsa-miR-146a miRNA IL-15 T cell immunotherapy na?ve CD8+ T cells IL-15 treatment upregulated 25331734 2340 Human hsa-miR-146a miRNA IL-2 T cell immunotherapy na?ve CD8+ T cells IL-2 treatment upregulated 25331734 2341 Human hsa-miR-146a miRNA human immunodeficiency virus (HIV)-1 thyroid cancer (TC) primary human fetal microglial cells HIV-1 infection upregulated 20181935 2342 Human hsa-miR-146a miRNA thyroid stimulating hormone thyroid eye disease (TED) orbital fibroblasts (OFs) thyroid stimulating hormone treatment upregulated 31622470 2343 Human hsa-miR-146a miRNA IL-1¦Â tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC) interleukin (IL)-1¦Â treatment downregulated 29467762 2344 Human hsa-miR-146a miRNA inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) LPS-treated primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC) inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) treatment downregulated 29467762 2345 Human hsa-miR-146a miRNA lipopolysaccharide (LPS) tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC) lipopolysaccharide (LPS) treatment upregulated 29467762 2346 Human hsa-miR-146a miRNA acyclovir type 2 diabetes mellitus (T2DM) human primary brain cells acyclovir treatment downregulated 20683212 2347 Human hsa-miR-146a miRNA amyloid-¦Â (A¦Â) 42 type 2 diabetes mellitus (T2DM) human primary brain cells amyloid-¦Â (A¦Â) 44 peptide metal treatment downregulated 20683212 2348 Human hsa-miR-146a miRNA butyrate and inulin type 2 diabetes mellitus (T2DM) peripheral blood mononuclear cells (PBMCs) butyrate and inulin treatment butyrate and concomitant use of butyrate and inulin caused a significant increase in the fold change of miR-146a and miR-9 compared with the placebo group. 32315958 2349 Human hsa-miR-146a miRNA IL-1¦Â and TNF-¦Á type 2 diabetes mellitus (T2DM) human pancreatic islets IL-1¦Â and TNF-¦Á treatment upregulated 20086228 2350 Human hsa-miR-146a miRNA chuyou yuyang granule (CYYY) ulcer relapse Helicobacter pylori (HP) infected Peptic ulcert patients blood Chuyou Yuyang granule (CYYY) four weeks or six weeks treatment downregulated 31034651 2351 Human hsa-miR-146a miRNA tumor necrosis factor alpha (TNF-¦Á) urethral stricture human umbilical cord-derived mesenchymal stem cells (MSCs) tumor necrosis factor alpha (TNF-¦Á) treatment "Exosomes derived from MSCs pretreated with TNF-¦Á were more effective in suppressing urethral fibrosis and stricture than exosomes from untreated MSCs We found that miR-146a, an anti-inflammatory miRNA, was strongly upregulated in TNF-¦Á-stimulated MSCs and was selectively packaged into exosomes" 31144307 2352 Human hsa-miR-146a miRNA baicalin (BAI) influenza A virus (IAV) infection IVA-infected A549 cells baicalin (BAI) treatment downregulated 31638222 2353 Human hsa-miR-146a miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells H1N1 and H3N2 viruses infection upregulated 31638222 2354 Human hsa-miR-146a miRNA zinc zinc deficiency illnesses Jurkat T cells zinc deficiency treatment downregulated 30316032 2355 Human hsa-miR-146a miRNA dengue virus (DENV) dengue virus (DENV) infection primary human monocytes; THP-1 cells dengue virus (DENV)infection upregulated 23685241 2356 Human hsa-miR-146a miRNA histone deacetylase inhibitor (HDACi) osteoarthritis (OA) fibroblast-like synoviocytes (OA-FLS) Histone deacetylase inhibitors?treatment upregulated 24107356 2357 Human hsa-miR-146a miRNA hepatitis B virus (HBV) vascular smooth muscle cell calcification HepG2.2.15 cells hepatitis B virus (HBV) infection MiR146a was upregulated in HBV+ HepG2.2.15 cells 23890093 2358 Human hsa-miR-146a-3p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) Human normal lung epithelial cell line BEAS-2B lipopolysaccharide (LPS) treatment Reduced SIRT1 and raised miR-146a-3p were found in LPS-induced BEAS-2B cells and ALI rats. 33185125 2359 Human hsa-miR-146a-3p miRNA lipoteichoic acid (LTA) lower respiratory tract infections BEAS-2B cells lipoteichoic acid (LTA) treatment upregulated 31837465 2360 Human hsa-miR-146a-3p miRNA polyinosinic-polycytidilic acid (Poly(I:C)) lower respiratory tract infections BEAS-2B cells poly(I:C) treatment upregulated 31837465 2361 Human hsa-miR-146a-3p miRNA tumor necrosis factor alpha (TNF-¦Á) lower respiratory tract infections BEAS-2B cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31837465 2362 Human hsa-miR-146a-5p miRNA zhenbao pill acute spinal cord injury (ASCI) hypoxia-induced SH-SY5Y cells zhenbao pill treatment upregulated 29187582 2363 Human hsa-miR-146a-5p miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment LINC01311 was downregulated whereas hsa-miR-146a-5p upregulated in AB1-42 treated SH-SY5Y cells. 33830627 2364 Human hsa-miR-146a-5p miRNA "IFN-¦Ã, IL-1¦Â and TNF-¦Á" asthma A549 cells "cytokine mixture containing IFN-¦Ã, IL-1¦Â and TNF-¦Á treatment" upregulated 31698144 2365 Human hsa-miR-146a-5p miRNA long-chain polyunsaturated fatty acids (LCPUFAs) asthma "cytokine mixture containing IFN-¦Ã, IL-1¦Â and TNF-¦Á-treated A549 cells" long-chain polyunsaturated fatty acids (LCPUFAs) treatment upregulated 31698144 2366 Human hsa-miR-146a-5p miRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin treatment downregulated 30245930 2367 Human hsa-miR-146a-5p miRNA doxorubicin (DOX) breast cancer MDA-MB-231 cells doxorubicin treatment downregulated 30245930 2368 Human hsa-miR-146a-5p miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) breast cancer MCF-7 cells methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment downregulated 30245930 2369 Human hsa-miR-146a-5p miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) breast cancer MDA-MB-231 cells methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment downregulated 30245930 2370 Human hsa-miR-146a-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 2371 Human hsa-miR-146a-5p miRNA tamoxifen and metformin breast cancer MCF-7 and MDA-MB-231 cell lines MCF-7 and MDA-MB-231 cell lines treatment dysregulated 27329603 2372 Human hsa-miR-146a-5p miRNA vinyl chloride monomer (VCM) chromosomal damage workers peripheral blood lymphocytes high VCM-expose treatment downregulated 28749179 2373 Human hsa-miR-146a-5p miRNA hepatitis B virus (HBV) chronic hepatitis B virus (HBV) infection "Human hepatic cell line, THLE-2" hepatitis B virus (HBV) infection upregulated 31018043 2374 Human hsa-miR-146a-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" dental pulp in?ammation human dental pulp cells (hDPCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30952010 2375 Human hsa-miR-146a-5p miRNA lipopolysaccharide (LPS) dental pulp in?ammation human dental pulp cells (hDPCs) lipopolysaccharide (LPS) treatment upregulated 30952010 2376 Human hsa-miR-146a-5p miRNA hypoxia diabetic retinopathy (DR) ARPE©\19 cells hypoxia treatment downregulated 31094072 2377 Human hsa-miR-146a-5p miRNA ethanol (EtOH) ethanol-induced neuroinflammation and brain damage plasma exosomes ethanol treatment downregulated 32937997 2378 Human hsa-miR-146a-5p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 2379 Human hsa-miR-146a-5p miRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells Ginsenoside Rh2 (Rh2) treatment upregulated 30197683 2380 Human hsa-miR-146a-5p miRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) A549 cells TGF-¦Â1 treatment CHRF and L1CAM expression were significantly upregulated and promoted the EMT process in A549 after treatment of TGF-¦Â1 33754922 2381 Human hsa-miR-146a-5p miRNA dexamethasone (DEX) inflammation "TNF-¦Á-treated A549 human lung carcinoma cell, NuLi-1 immortalized, normal human bronchial epithelial cells" dexamethasone (DEX) treatment downregulated 30300399 2382 Human hsa-miR-146a-5p miRNA particulate matter (PM2.5) inflammation THP-1 cells particulate matter (PM2.5) treatment upregulated 33160737 2383 Human hsa-miR-146a-5p miRNA particulate matter (PM2.5) inflammation human monocytic leukemia cell line (THP-1) PM2.5?extracts?treatment treatment "?we observed expression of miR-146a-5p was significantly increased, with the maximal response of six folds in WN group" 33160737 2384 Human hsa-miR-146a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation "A549 human lung carcinoma cell, NuLi-1 immortalized, normal human bronchial epithelial cells" tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30300399 2385 Human hsa-miR-146a-5p miRNA high glucose (HG) diabetic vasculopathy human aortic endothelial cells (HAECs) high glucose (HG) downregulated 28824448 2386 Human hsa-miR-146a-5p miRNA lipopolysaccharide (LPS) inflammatory response macrophages lipolysaccharide (LPS) treatment upregulated 25805648 2387 Human hsa-miR-146a-5p miRNA hepatitis A virus (HAV) innate immune response The human embryonic lung fbroblast cell line KMB17 hepatitis A virus (HAV) infection HAV infection upregulates the expression of hsa-miR-146a-5p 33459883 2388 Human hsa-miR-146a-5p miRNA lipopolysaccharide (LPS) liver fibrosis human HSC line LX-2 LPS treatment downregulated 28739486 2389 Human hsa-miR-146a-5p miRNA TGF-¦Â1 liver fibrosis human HSC line LX-2 TGF¦Â1 treatment downregulated 28739486 2390 Human hsa-miR-146a-5p miRNA TGF-¦Â1 liver fibrosis human hepatic stellate cell line LX2 TGF-¦Â1 treatment downregulated 31560641 2391 Human hsa-miR-146a-5p miRNA X rays liver fibrosis human hepatic stellate cell line LX2 LX2 cells were stimulated with 8 Gy of X rays treatment downregulated 31560641 2392 Human hsa-miR-146a-5p miRNA BRAF and MEK inhibitor melanoma LM16R cells; LM69 cells; LM70 cells BRAF and MEK inhibitor treatment miR-146a-5p expression was reduced in BRAF and MEK inhibitor-resistant melanoma cells and tissues. 31915008 2393 Human hsa-miR-146a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 2394 Human hsa-miR-146a-5p miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells free fatty acids (FFA) treatment downregulated 31484042 2395 Human hsa-miR-146a-5p miRNA CXCR4 antagonist TN14003 osteoarthritis (OA) SDF-1-treated OA chondrocytes CXCR4 antagonist TN14003 treatment upregulated 30942441 2396 Human hsa-miR-146a-5p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-9¦Â treatment dysregulated 29123165 2397 Human hsa-miR-146a-5p miRNA lipopolysaccharide (LPS) pneumonia human lung fibroblasts cell WI-38 lipopolysaccharide (LPS) treatment SNHG16 regulated LPS-induced inflammation injury in WI-38 cells through competitively binding miR-146a-5p with CCL5 further mediating JNK and NF-¦ÊB pathways 31071307 2398 Human hsa-miR-146a-5p miRNA ethanol (EtOH) prostate cancer cancer-associated fibroblasts (CAFs) ethanol (ETOH) treatment MiR-146a-5p level in exosomes from ETOH-treated CAFs was significantly reduced. 33317606 2399 Human hsa-miR-146a-5p miRNA selenium nanoparticles (SeNPs) prostate cancer LNCaP cells; LNCaP-A cells Selenium nanoparticles (SeNPs) treatment upregulated 33604641 2400 Human hsa-miR-146a-5p miRNA adalimumab(ADA) psoriasis circulating angiogenic cells (CACs) adalimumab treatment downregulated 26943583 2401 Human hsa-miR-146a-5p miRNA ionizing radiation (IR) radiation-induced liver disease (RILD) LX-2 cells ionizing radiation (IR) treatment upregulated 29348414 2402 Human hsa-miR-146a-5p miRNA irradiation and lipopolysaccharide (LPS) radiation-induced liver disease (RILD) LX-2 cells irradiation and lipopolysaccharide (LPS) treatment Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway. 32097101 2403 Human hsa-miR-146a-5p miRNA lipopolysaccharide (LPS) radiation-induced liver disease (RILD) LX-2 cells lipopolysaccharide (LPS) treatment upregulated 29348414 2404 Human hsa-miR-146a-5p miRNA radiation radiation-induced liver disease (RILD) LX2 cells radiation treatment downregulated 31960423 2405 Human hsa-miR-146a-5p miRNA infliximab rheumatoid arthritis (RA) serological infliximab treatment upregulated 25860297 2406 Human hsa-miR-146a-5p miRNA methotrexate (MTX) rheumatoid arthritis (RA) whole-blood methotrexate (MTX) treatment downregulated 30511295 2407 Human hsa-miR-146a-5p miRNA methotrexate (MTX) rheumatoid arthritis (RA) RA patients whole-blood methotrexate (MTX) treatment upregulated 30511295 2408 Human hsa-miR-146a-5p miRNA resolvin D1 (RvD1) rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS) resolvin D1 (RvD1) treatment RvD1 upregulated miRNA-146a-5p 32216830 2409 Human hsa-miR-146a-5p miRNA sulforaphane (SFN) staphylococcus aureus infection THP-1 cells sulforaphane (SFN) treatment SFN pretreatment of the THP-1-derived macrophages significantly attenuated the S aureus-mediated increased expression levels of miR-146a-5p 32323751 2410 Human hsa-miR-146a-5p miRNA ultraviolet (UV) irradiation skin photoaging human dermal fibroblasts (HDFs) UVA irradiation treatment downregulated 33025709 2411 Human hsa-miR-146b miRNA curcumin (Cur) anaplastic thyroid carcinoma (ATC) SW1736 and 8505C curcumin treatment downregulated 29197967 2412 Human hsa-miR-146b miRNA "IFN-¦Ã, IL-1¦Â and TNF-¦Á" asthma human airway smooth muscle cells (hASMCs) "cytomix (IL-1¦Â, TNF-¦Á, and IFN¦Ã) treatment" upregulated 25217662 2413 Human hsa-miR-146b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31479774 2414 Human hsa-miR-146b miRNA atorvastatin coronary artery disease (CAD) PBMCs (peripheral blood mononuclear cells) atorvastatin and telmisartan or atorvastatin treatment downregulated 20524934 2415 Human hsa-miR-146b miRNA suberoylanilide hydroxamic acid (SAHA) tumorigenesis MEG-01 cells; HEK-293 cells suberoylanilide hydroxamic acid (SAHA) treatment upregulated 23543665 2416 Human hsa-miR-146b miRNA ibrutinib chronic lymphocytic leukemia (CLL) CLL patients paired LN and PB samples ibrutinib treatment downregulated in paired LN and PB samples 27431016 2417 Human hsa-miR-146b miRNA lipopolysaccharide (LPS) gingival inflammation Human gingival fibroblasts (HGFs) lipopolysaccharide (LPS) treatment upregulated 29407755 2418 Human hsa-miR-146b miRNA TGF-¦Â intestinal cell differentiation intestinal epithelial cell (IEC-6) Growth factor TGF-¦Â?treatment treatment miR-146b expression increased rapidly 22570175 2419 Human hsa-miR-146b miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 18648749 2420 Human hsa-miR-146b miRNA carbamate lung cancer Normal human bronchial epithelial (NHBE) cells carbamate treatment upregulated 19748927 2421 Human hsa-miR-146b miRNA lipopolysaccharide (LPS) lupus nephritis (LN) Human renal mesangial cells (HRMCs) lipopolysaccharide (LPS) treatment "NEAT1 accelerated renal mesangial cell injury via directly targeting miR-146b, promoting the expression of TRAF6, and activating the NF-¦ÊB signaling in lupus nephritis." 32710276 2422 Human hsa-miR-146b miRNA free fatty acids (FFAs) and TNF-¦Á and IL-6 nonalcoholic fatty liver disease (NAFLD) HepG2 cells and human hepatocytes free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment upregulated 25562147 2423 Human hsa-miR-146b miRNA metformin (Met) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) metformin treatment upregulated 32143184 2424 Human hsa-miR-146b miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) palmitic acid (PA) treatment downregulated 32143184 2425 Human hsa-miR-146b miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmitic acid (PA) treatment downregulated 32143184 2426 Human hsa-miR-146b miRNA TNF-¦Á and IL-6 obesity mature human adipocytes TNF-¦Á and IL-6 treatment upregulated 24428800 2427 Human hsa-miR-146b miRNA platelet-derived growth factor (PDGF) oral cavity cancer U118-MG cells£»U87-MG glioblastoma cells£» human WI-38 fibroblasts?£» ovarian cells C272/hTert/E7 Platelet derived growth factor (PDGF)? treatment upregulated 21266476 2428 Human hsa-miR-146b miRNA IL-1¦Â osteoporosis A549 cells IL-1¦Â treatment downregulated 19786024 2429 Human hsa-miR-146b miRNA proinflammatory cytokines otitis media (OM) Human middle ear epithelial cells proinflammatory cytokines treatment upregulated 27497395 2430 Human hsa-miR-146b miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment downregulated 32901049 2431 Human hsa-miR-146b miRNA lipopolysaccharide (LPS) pneumonia WI-38 human lung fibroblasts cells lipopolysaccharide (LPS) treatment downregulated 31583932 2432 Human hsa-miR-146b miRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment miR-146b was downregulated in WI-38 cells treated with LPS. 31583932 2433 Human hsa-miR-146b miRNA TPCA-1 pro-inflammatory activity human gingival fibroblasts (HGFs) high concentration (10 ¦ÌM) of IRAK1/4 inhibitor or the NF-¦ÊB inhibitor treatment downregulated 25598707 2434 Human hsa-miR-146b miRNA Salmonella Typhimurium salmonella typhimurium infection human HeLa cells Salmonella Typhimurium infection treatment upregulated 21468030 2435 Human hsa-miR-146b miRNA severe fever with thrombocytopenia syndrome virus (SFTSV) severe fever with thrombocytopenia syndrome (SFTS) Human monocyte cell line (THP-1)-derived macrophages Severe fever with thrombocytopenia syndrome virus (SFTSV) infection treatment upregulated 31156641 2436 Human hsa-miR-146b miRNA coxsackievirus B3 (CVB3) viral myocarditis (VM) plasma and myocardial cells coxsackievirus B3 (CVB3) treatment upregulated 25815880 2437 Human hsa-miR-146b-3p miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment upregulated 29393545 2438 Human hsa-miR-146b-3p miRNA tumor necrosis factor alpha (TNF-¦Á) thrombosis THP-1 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 32337281 2439 Human hsa-miR-146b-5p miRNA ultraviolet (UV) irradiation DNA damage U2OS;EH1; EH2 cell lines ultraviolet light treatment upregulated 24163379 2440 Human hsa-miR-146b-5p miRNA TNF-¦Á£¬IGF-1 atherosclerosis (AS) smooth muscle cell TNF-¦Á£¬IGF-1 treatment upregulated 26047583 2441 Human hsa-miR-146b-5p miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment upregulated 29189128 2442 Human hsa-miR-146b-5p miRNA oxidized low density lipoprotein (ox-LDL) cell differentiation THP-1 cells stimulated with phorbol 12-myristate 13-acetate (100 nM) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29201219 2443 Human hsa-miR-146b-5p miRNA "cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)" diffuse large B-cell lymphoma (DLBCL) patients with DLBCL CHOP treatment downregulated 24931464 2444 Human hsa-miR-146b-5p miRNA "glucose deprived, galactose enriched (GAL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 2445 Human hsa-miR-146b-5p miRNA "lipid reduced, cholesterol deficient (RL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 2446 Human hsa-miR-146b-5p miRNA progesterone (P4) endometrial cancer (EC) human Ishikawa cells Progesterone treatment miR-146b-5p was notably decreased in Ishikawa cells while upregulated after treatment with progesterone 30452118 2447 Human hsa-miR-146b-5p miRNA progesterone (P4) endometrial cancer (EC) Ishikawa cells progesterone treatment miR-146b-5p was notably decreased in Ishikawa cells 30452118 2448 Human hsa-miR-146b-5p miRNA progesterone (P4) endometrial cancer (EC) Hec4A cells Progesterone treatment upregulated 22543862 2449 Human hsa-miR-146b-5p miRNA p-cresol (PcEMV) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) p-cresol (PcEMV) treatment upregulated 32606426 2450 Human hsa-miR-146b-5p miRNA IFN-¦Ã epithelial-mesenchymal transition (EMT) human RPE cells interferon-¦Ã treatment upregulated 23592910 2451 Human hsa-miR-146b-5p miRNA IL-1¦Â epithelial-mesenchymal transition (EMT) human RPE cells IL-1¦Â treatment upregulated 23592910 2452 Human hsa-miR-146b-5p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) papillary thyroid carcinoma cell line BCPAP TGF-¦Â1 treatment upregulated 24946010 2453 Human hsa-miR-146b-5p miRNA tumor necrosis factor alpha (TNF-¦Á) epithelial-mesenchymal transition (EMT) human RPE cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 23592910 2454 Human hsa-miR-146b-5p miRNA sevoflurane (SEV) glioblastoma multiforme (GBM) U87-MG and U251 cells Sevoflurane (Sev) treatment upregulated 31385537 2455 Human hsa-miR-146b-5p miRNA sevoflurane (SEV) glioblastoma multiforme (GBM) A172 cells; U251 cells sevoflurane (Sev) treatment "KCNQ1OT1 knockdown mediated the role of Sev in glioma cell proliferation, apoptosis, migration, and invasion both in vitro and in vivo through miR-146b-5p/STC1 pathway" 32996777 2456 Human hsa-miR-146b-5p miRNA IL-6 hepatocarcinogenesis non-transformed liver-derived PH5CH8 and THLE2 cells and in Huh-7 hepatoma cells Interleukin-6 (IL-6) treatment upregulated 30145833 2457 Human hsa-miR-146b-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1-treatment treatment upregulated 29557526 2458 Human hsa-miR-146b-5p miRNA EGFR tyrosine kinase inhibitors (TKIs) lung cancer lung cancer cells EGFR tyrosine kinase inhibitors (TKIs) treatment miR-146b-5p expression in lung cancer cells isolated from pleural effusions of treatment-naive patients was significantly higher than that after acquiring resistance to EGFR TKI treatment. 33230450 2459 Human hsa-miR-146b-5p miRNA hypoxia myocardial infarction (MI) serum hypoxia treatment "Herein, miR-146b-5p was found to be upregulated in the infarcted myocardium of mice and the serum of myocardial ischemia patients." 32845445 2460 Human hsa-miR-146b-5p miRNA dioxin neuroblastoma (NB) SK-N-SH cells dioxin treatment upregulated 29406108 2461 Human hsa-miR-146b-5p miRNA dioxin neuroblastoma (NB) SK-N-SH cells dioxin treatment upregulated 29406108 2462 Human hsa-miR-146b-5p miRNA cucurbitacin B (CuB) pancreatic cancer (PC) BxPC-3 cells; HPAC cells cucurbitacin B (CuB) treatment MiR-146b-5p is expressed differentially after CuB treatment and is associated with the EGFR. 30206930 2463 Human hsa-miR-146b-5p miRNA cucurbitacin B (CuB) pancreatic cancer (PC) "Human PC cell lines, ASPC©\1, BxPC©\3, HPAC, MiaPaCa©\2" cucurbitacin B (CuB) treatment CuB-induced high miR-146b-5p expression and inhibited the expression of AFAP1-AS1. 30206930 2464 Human hsa-miR-146b-5p miRNA p16 INK4A cell senescence human fibroblast and epithelial cells p16 INK4A treatment upregulated 27596953 2465 Human hsa-miR-147 miRNA hypoxia breakdown of blood-brain barrier (BBB) PC12 cells hypoxia treatment downregulated 29130945 2466 Human hsa-miR-147 miRNA insect cell-derived anionic septapeptide innate immune response Primary human monocyte cultures insect cell-derived anionic septapeptide treatment upregulated 31075349 2467 Human hsa-miR-147 miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 2468 Human hsa-miR-147 miRNA metformin (Met) type 2 diabetes mellitus (T2DM) blood Metformin treatment upregulated 30297296 2469 Human hsa-miR-1470 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells high glucose treatment downregulated 30784065 2470 Human hsa-miR-1471 miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 2471 Human hsa-miR-147a miRNA hypoxia-inducible factor 1¦Á (HIF-1¦Á) cervical cancer (CC) HeLa cells; ATCC cells; CCL-2 cells HIF1¦Á treatment upregulated 27260617 2472 Human hsa-miR-147a miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment downregulated 33009725 2473 Human hsa-miR-147a miRNA sodium new houttuyfonate (SNH) non-small cell lung cancer (NSCLC) A549 and NCI-H1299 cells sodium new houttuyfonate (SNH) treatment upregulated 30971296 2474 Human hsa-miR-147b miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment MiR-147b was downregulated in lipopolysaccharide (LPS)-induced ALI rats and LPS-treated A549 cells 33660808 2475 Human hsa-miR-147b miRNA platelet derived growth factor-BB (PDGF-BB) atherosclerosis (AS) Human aortic vascular smooth muscle cells (VSMCs) platelet-derived growth factor-BB (PDGF-BB) treatment upregulated 30060075 2476 Human hsa-miR-148-3p miRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) NB4 cells all-trans retinoic acid (ATRA) treatment downregulated 29901102 2477 Human hsa-miR-148-3p miRNA oleanolic acid (OLA) osteoarthritis (OA) chondrocytes oleanolic acid (OLA) treatment upregulated 32028542 2478 Human hsa-miR-148-3p miRNA polystyrene (PSNPs) toxicity of nanoparticles THP-1 cells polystyrene (PSNPs) treatment downregulated 32284792 2479 Human hsa-miR-148a miRNA statins active hepatitis or cirrhosis HepG2 cells statins? treatment upregulated 26429200 2480 Human hsa-miR-148a miRNA homocysteine (Hcy) atherosclerosis (AS) human monocyte leukemia cell line THP-1 homocysteine upregulated 28472596 2481 Human hsa-miR-148a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" breast cancer tamoxifen sensitive (TamS) MCF-7 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28063929 2482 Human hsa-miR-148a miRNA ailanthone (AIL) breast cancer DA-MB-231 cells ailanthone (AIL) treatment upregulated 30551356 2483 Human hsa-miR-148a miRNA ailanthone (AIL) breast cancer MDA-MB-231 cells ailanthone (AIL) treatment upregulated 30551356 2484 Human hsa-miR-148a miRNA estradiol breast cancer breast cancer cells Estradiol treatment downregulated 25928008 2485 Human hsa-miR-148a miRNA estradiol-17¦Â (E2) breast cancer MCF-7 and MDA-MB-231 cells estradiol-17¦Â (E2) treatment upregulated 25063027 2486 Human hsa-miR-148a miRNA gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor breast cancer BRCA1 wild-type cells (MDA-MB-231) gemcitabine-alone and in combination with PARP1 inhibitor treatment upregulated 25202071 2487 Human hsa-miR-148a miRNA glabridin (GLA) breast cancer MDA-MB-231 and Hs-578T breast cancer cell lines Glabridin (GLA) treatment upregulated 25980823 2488 Human hsa-miR-148a miRNA glabridin (GLA) breast cancer human breast cancer (MDA-MB-231 and Hs-578T) cells glabridin (GLA) downregulated 28464803 2489 Human hsa-miR-148a miRNA caffeic acid tumorigenesis Human TNBC cell line caffeic acid (CA) treatment upregulated 26106521 2490 Human hsa-miR-148a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human bone mesenchymal stromal cells (hBMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28656724 2491 Human hsa-miR-148a miRNA photodynamic therapy (PDT) cervical cancer (CC) HeLa cells photody-namic therapy (PDT) treatment upregulated 19953537 2492 Human hsa-miR-148a miRNA radiation cervical cancer (CC) SiHa cells; Hela cells radiation treatment LncRNA SNHG12 promoted CDK1 expression to regulate the sensitivity of CC cells to radiation through sponging miR-148a 33292254 2493 Human hsa-miR-148a miRNA fludarabine chronic lymphocytic leukemia (CLL) p53-mutant MEG-01 cells fludarabine treatment specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets 20504344 2494 Human hsa-miR-148a miRNA cisplatin (DDP) colorectal cancer (CRC) SW480 cell line cisplatin treatment MicroRNA (miRNA) array and qRT-PCR assay identified the downregulated of miR-148a in cisplatin-resistant SW480 cells. 30551544 2495 Human hsa-miR-148a miRNA cisplatin (DDP) colorectal cancer (CRC) SW480 cells criplatin (DPP) treatment downregulated 30551544 2496 Human hsa-miR-148a miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) nasopharyngeal carcinoma cell HK-1 TGF-¦Âtreatment upregulated 26032086 2497 Human hsa-miR-148a miRNA helicobacter pylori (H. pylori) gastric cancer (GC) SGC-7901 cells Helicobacter pylori £¨H. pylori£©infection downregulated 29604247 2498 Human hsa-miR-148a miRNA soft-shelled turtle peptide gastric cancer (GC) human GC AGS cells soft-shelled turtle peptide treatment differentlly regulated 29435044 2499 Human hsa-miR-148a miRNA nuclear factor kappa-B (NF-¦ÊB) glioblastoma multiforme (GBM) glioblastoma cells NF-¦ÊB treatment upregulated 25971746 2500 Human hsa-miR-148a miRNA arsenic trioxide (ATO) hepatocellular carcinoma (HCC) drug resistant (MDR) Bel-7402 cells (BelMDR) cells arsenic trioxide (ATO) treatment upregulated 31759055 2501 Human hsa-miR-148a miRNA rhamnetin hepatocellular carcinoma (HCC) HCC cells rhamnetin treatment rhamnetin increased expression of miR-148a (which is tumor-suppressive) in a P53-dependent manner 33570057 2502 Human hsa-miR-148a miRNA serum-free MSCM inflammation human adipose tissue-derived mesenchymal stem cells (hMSCs-Ad) human adipose tissue-derived mesenchymal stem cells (hMSCs-Ad) treatment upregulation 27878286 2503 Human hsa-miR-148a miRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells lipopolysaccharide (LPS) treatment downregulated 30186499 2504 Human hsa-miR-148a miRNA estradiol intrahepatic cholestasis of pregnancy (ICP) LO2 cells estradiol treatment upregulated 28575098 2505 Human hsa-miR-148a miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HepG2 cells hepatitis B virus (HBV) X protein (HBx) treatment downregulated 23321675 2506 Human hsa-miR-148a miRNA lipopolysaccharide (LPS) Dendritic cell (DC) maturation Dendritic cells (DCs) lipopolysaccharide (LPS) treatment downregulated 27714813 2507 Human hsa-miR-148a miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 2508 Human hsa-miR-148a miRNA Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS) periodontitis periodontal ligament stem cells (PDLSCs) Porphyromonas gingivalis lipopolysaccharide (LPS) treatment upregulated 31809209 2509 Human hsa-miR-148a miRNA receptor activator of nuclear factor-¦ÊB ligand (RANKL) hepatocellular carcinoma (HCC) CD14+ peripheral blood mononuclear cells (PBMCs) receptor activator of nuclear factor-¦ÊB ligand (RANKL) treatment upregulated 23225151 2510 Human hsa-miR-148a miRNA macrophage colony stimulating factor (M-CSF) osteoporosis CD14+ PBMCs macrophage colony stimulating factor (M-CSF) treatment upregulated 23225151 2511 Human hsa-miR-148a-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 2512 Human hsa-miR-148a-3p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRECs) high glucose (HG) treatment HG treatment reduced miR-148a-3p level in HRECs. 32661705 2513 Human hsa-miR-148a-3p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 2514 Human hsa-miR-148a-3p miRNA honokiol non-small cell lung cancer (NSCLC) NSCLC A549 cells honokiol treatment upregulated 31176168 2515 Human hsa-miR-148a-5p miRNA toosendanin (TSN) gastric cancer (GC) MKN-45 cells toosendanin (TSN) treatment upregulated 32582989 2516 Human hsa-miR-148a-5p miRNA honokiol non-small cell lung cancer (NSCLC) NSCLC A549 cells honokiol treatment upregulated 31176168 2517 Human hsa-miR-148a-5p miRNA metformin (Met) preeclampsia (PE) Trophoblast and HUVEC cells Metformin (Met) treatment upregulated 31203154 2518 Human hsa-miR-148b miRNA statins asthma Immortalized lymphoblastoid cell lines (LCLs) statins? treatment upregulated 25266681 2519 Human hsa-miR-148b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs). oxidized low-density lipoprotein (ox-LDL) treatment The level of H19 was increased and miR-148b expression was decreased in human AS patient serums and oxidized low-density lipoprotein (ox-LDL)-stimulated human aorta vascular smooth muscle cells (HA-VSMCs). 29415742 2520 Human hsa-miR-148b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human VSMC; human umbilical vein endothelial cells (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment TUG1 knockdown attenuated ox-LDL-induced injury through regulating proliferation and apoptosis of VSMC and HUVEC by miR-148b/IGF2 axis 31926240 2521 Human hsa-miR-148b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment Proliferation and migration were modified by MIAT/miR-148b/PAPPA axis in ox-LDL induced AS cell model. 32470448 2522 Human hsa-miR-148b miRNA radiation breast cancer MCF-7 cells; MDA-MB-231 cells radiation treatment Radiation treatment triggered a significant increase in CCAT1 and an obvious decrease in miR-148b 29024383 2523 Human hsa-miR-148b miRNA X-rays breast cancer human breast cancer cell lines MCF-7 and MDA-MB-231 radiation treatment downregulated 29024383 2524 Human hsa-miR-148b miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment downregulated 20346162 2525 Human hsa-miR-148b miRNA imatinib mesylate chronic myeloid leukemia (CML) patients with chronic myeloid leukemia (CML) discontinuing imatinib mesylate (IM) treatment downregulated 25187697 2526 Human hsa-miR-148b miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 2527 Human hsa-miR-148b miRNA remnant-like lipoproteins (RLPs) ePCs senescence Total peripheral mononuclear cells (PB-MNCs) Remnant-like lipoproteins (RLPs) treatment miR-148b and miR-155 were upregulated while miR-574-3p was downregulated 23044309 2528 Human hsa-miR-148b miRNA soft-shelled turtle peptide gastric cancer (GC) human GC AGS cells soft-shelled turtle peptide treatment differentlly regulated 29435044 2529 Human hsa-miR-148b miRNA lipopolysaccharide (LPS) Dendritic cell (DC) maturation Dendritic cells (DCs) lipopolysaccharide (LPS) treatment downregulated 27714813 2530 Human hsa-miR-148b-3p miRNA hypoxia hypoxia-induced injury human hepatic sinusoidal endothelial cells (HHSEC) hypoxia induce downregulated 31082428 2531 Human hsa-miR-148b-3p miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 2532 Human hsa-miR-148b-3p miRNA azacitidine (AZA) myelodysplastic syndrome (MDS) bone marrow CD34+ cells azacitidine (AZA) treatment downregulated 29630523 2533 Human hsa-miR-148b-3p miRNA "isoniazid, pyrazinamide and ethambutol" pulmonary tuberculosis (PTB) serum "isoniazid, pyrazinamide and ethambutol treatment" miR-148b-3p was downregulated in treated patients when compared with untreated patients. 29523324 2534 Human hsa-miR-149 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 33428703 2535 Human hsa-miR-149 miRNA platelet activating factor (PAF) asthma Human small airway epithelial cells (HSAECs) platelet activating factor (PAF) treatment LncRNA PVT1 exacerbates the inflammation and cell-barrier injury during asthma by regulating miR-149 32830409 2536 Human hsa-miR-149 miRNA TmPyP4 (Porphyrin) breast cancer MCF-7 breast cancer cells TmPyP4 (Porphyrin) treatment upregulated 30585723 2537 Human hsa-miR-149 miRNA formononetin colorectal cancer (CRC) colon carcinoma cell lines SW1116 and HCT116 Formononetin (Form) treatment upregulated 29620230 2538 Human hsa-miR-149 miRNA bisphenol A (BPA) endometrial cancer (EC) human endometrial cancer RL95-2 cells bisphenol A (BPA) treatment downregulated 28238728 2539 Human hsa-miR-149 miRNA tumor necrosis factor alpha (TNF-¦Á) endothelial dysfunction Eahy926 and HUVEC tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 24299952 2540 Human hsa-miR-149 miRNA tumor necrosis factor alpha (TNF-¦Á) endothelial dysfunction Eahy926 endothelial cells and HUVEC TNF¦Á treatment downregulated 24299952 2541 Human hsa-mir-149 miRNA fibroblast growth factor 2 (FGF2) fine tunes the angiogenic endothelial cells (ECs) FGF2 treatment upregulated 24463821 2542 Human hsa-miR-149 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) gastric cancer (GC) tissues; AGS cells 5-fluorouracil (5-FU) treatment miR-149 was significantly increased in 5-FU resistant tumor tissues and cells. 32977944 2543 Human hsa-miR-149 miRNA paeoniflorin gastric cancer (GC) Paired gastric normal fifbroblast (GNF) and gastric cancer associated fibroblasts (GCAFs) cultures Paeoniflorin (PF) treatment upregulated 30361813 2544 Human hsa-miR-149 miRNA paeoniflorin gastric cancer (GC) gastric cancer associated fibroblasts (GCAFs) Paeoniflorin (PF) treatment Paeoniflorin suppressed IL-6 production and secretion by up-regulating microRNA149 expression in GCAFs 30361813 2545 Human hsa-miR-149 miRNA triptolide (TPL) gastric cancer (GC) gastric cancer-associated fibroblasts (GCAFs) triptolide (TPL) treatment downregulated miR-301a expression and upregulated miR-149 29049979 2546 Human hsa-miR-149 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) human glioma-derived cell lines U251 and U87 TMZ treatment downregulated 25017996 2547 Human hsa-miR-149 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hypermethylation U87MG cell line "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "Treatment of U87MG cells with 5-aza-dC reversed the hypermethylation status of miR-149," 27783537 2548 Human hsa-miR-149 miRNA glucocorticoid (GC) myeloma sensitive RPMI-8226 cell line chronic glucocorticoid exposure downregulated 28035377 2549 Human hsa-miR-149 miRNA "N,N'-dinitrosopiperazine (DNP)" nasopharyngeal carcinoma (NPC) 6-10B cells "N,N'-dinitrosopiperazine (DNP) treatment" upregulated 30144176 2550 Human hsa-miR-149 miRNA long-chain fatty acid nonalcoholic fatty liver disease (NAFLD) liver cells genotyped as TT long-chain fatty acid treatment upregulated 28507283 2551 Human hsa-miR-149 miRNA IL-1¦Â osteoarthritis (OA) Human normal chondrocytes IL-1¦Â treatment downregulated 29524885 2552 Human hsa-miR-149 miRNA Silica lung fibrosis "A549 , HBE cell" silica treatment downregulated 24641842 2553 Human hsa-miR-149* miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment upregulated 26640557 2554 Human hsa-miR-149-3p miRNA quinidine cell proliferation and apoptosis human glioma U87-MG cells quinidine treatment the upregulation of miR-149-3p and downregulated of miR-424-5p 25420507 2555 Human hsa-miR-149-3p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) HBE135-E6E7 cells cigarette smoke extract (CSE) treatment MEG3 promoted proliferation and inhibited apoptosis by regulating the NF-¦ÊB signal pathway via miR-149-3p in CSE-treated HBE cells. 33365060 2556 Human hsa-miR-149-3p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) THP-1 cells cigarette smoke?extract?(CSE) treatment downregulated 28260877 2557 Human hsa-miR-149-3p miRNA cisplatin (DDP) colorectal cancer (CRC) "HCT116, SW480 and SW620 cells" ?cisplatin treatment downregulated 31866582 2558 Human hsa-miR-149-3p miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment upregulated 31597953 2559 Human hsa-miR-149-3p miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment upregulated 31597953 2560 Human hsa-miR-149-3p miRNA maimendong and qianjinweijing tang (Jin formula) lung cancer A549 cells; H1299 cells Maimendong and Qianjinweijing Tang (Jin formula) treatment Maimendong and Qianjinweijing Tang (Jin formula) suppresses lung cancer by regulation of miR-149-3p. 32344160 2561 Human hsa-miR-149-3P miRNA dioscin pancreatic cancer (PC) ASPC-1 and PANC-1 cell dioscin treatment upregulated 28095588 2562 Human hsa-miR-149-5p miRNA oxaliplatin advanced colorectal cancer (CRC) SW480 cells oxaliplatin (OXA) treatment LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer 33251049 2563 Human hsa-miR-149-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment Circular RNA circ_0124644 exacerbates the ox-LDL-induced endothelial injury in human vascular endothelial cells through regulating PAPP-A by acting as a sponge of miR-149-5p. 32500475 2564 Human hsa-miR-149-5p miRNA ursolic acid (UA) breast cancer MDA-MB-231 (231) and MDA-MB-231/PTX-resistance (231/PTX) cells ursolic acid (UA) treatment upregulated 31259152 2565 Human hsa-miR-149-5p miRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation vascular smooth muscle cells (VSMCs) PDGF-bb treatment downregulated 31595884 2566 Human hsa-miR-149-5p miRNA serum samples from patients with T2DM endoplasmic reticulum stress (ERS) human umbilical vein endothelial cells (HUVECs) incubated with serum samples from patients with T2DM treatment downregulated 28848152 2567 Human hsa-miR-149-5p miRNA lipoteichoic acid (LTA) inflammation BEAS-2B cells ?lipoteichoic acid treatment downregulated 31837465 2568 Human hsa-miR-149-5p miRNA polyinosinic-polycytidilic acid (Poly(I:C)) inflammation BEAS-2B cells viral dsRNA analogue poly(I:C) treatment downregulated 31837465 2569 Human hsa-miR-149-5p miRNA lipoteichoic acid (LTA) lower respiratory tract infections BEAS-2B cells lipoteichoic acid (LTA) treatment downregulated 31837465 2570 Human hsa-miR-149-5p miRNA polyinosinic-polycytidilic acid (Poly(I:C)) lower respiratory tract infections BEAS-2B cells poly(I:C) treatment downregulated 31837465 2571 Human hsa-miR-149-5p miRNA tumor necrosis factor alpha (TNF-¦Á) lower respiratory tract infections BEAS-2B cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 31837465 2572 Human hsa-miR-149-5p miRNA IL-6 osteoarthritis (OA) human chondrocyte-articular (HC-a) cells IL-6?treatment downregulated 32141427 2573 Human hsa-miR-149-5p miRNA IL-1¦Â and IFN-¦Ã type 1 diabetes mellitus (T1DM) human ¦Â-cells cytokines IL-1¦Â plus IFN-¦Ã treatment dysregulated 27737950 2574 Human hsa-miR-149-5p miRNA platelet derived growth factor-BB (PDGF-BB) vascular restenosis human aortic vascular smooth muscle cell (HA-VSMC) platelet derived growth factor-BB (PDGF-BB) treatment downregulated 32736703 2575 Human hsa-miR-15 miRNA ginsenoside Rg1 angiogenesis human umbilical vein endothelial cells (HUVECs) ginsenoside-Rg1 treatment downregulated 23688497 2576 Human hsa-miR-15 miRNA lipopolysaccharide (LPS) bedsore HaCaT cells lipopolysaccharide (LPS) treatment downregulated 31692058 2577 Human hsa-miR-15 miRNA microsciadia breast cancer MDA-MB-231 cells microsciadia treatment upregulated 32603285 2578 Human hsa-miR-15 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT116 cells 5-fluorouracil (5-FU) treatment miR-15 expression was significantly upregulated in HCT116 cells treated with 5-Fu. 29467857 2579 Human hsa-miR-15 miRNA oxaliplatin colorectal cancer (CRC) HCT116 cells oxaliplatin (OXA) treatment miR-15 expression was significantly upregulated in HCT116 cells treated with OX. 29467857 2580 Human hsa-miR-15 miRNA fibroblast growth factor 4 (FGF4) hepatocyte differentiation primary ccultured human amniotic epithelial cells (AECs) FGF4 treatment upregulated 30753902 2581 Human hsa-miR-15 miRNA hepatocyte growth factor (HGF) hepatocyte differentiation primary ccultured human amniotic epithelial cells (AECs) HGF treatment upregulated 30753902 2582 Human hsa-miR-15 miRNA lipopolysaccharide (LPS) inflammation Human WI©\38 cells lipopolysaccharide (LPS) treatment "MIAT2 reversely regulated miR-15 and miR-15 mimic could reverse the effects of MIAT2. Finally, MIAT2 restrained the p38MAPK and NF-¦ÊB pathways by downregulating miR-15." 31566734 2583 Human hsa-miR-15 miRNA lipopolysaccharide (LPS) inflammatory injury HaCaT cells lipopolysaccharide (LPS) treatment circANKRD36 remitted cell inflammatory damage upregulating miR-15/MyD88 via the NF-¦ÊB pathway in HaCaT cells. 31692058 2584 Human hsa-miR-15 miRNA lipopolysaccharide (LPS) neonatal pneumonia WI-38 cells lipopolysaccharide (LPS) treatment MIAT2 restrained the p38MAPK and NF-¦ÊB pathways by downregulating miR-15. 31566734 2585 Human hsa-miR-15 miRNA IL-1¦Â rheumatoid arthritis (RA) human RA fibroblast-like synoviocyte (FLS) cell line MH7A cells IL-1¦Â treatment downregulated 31611200 2586 Human hsa-miR-150 miRNA IL-1¦Â intervertebral disc degeneration (IDD) nucleus pulposus cells IL-1¦Â treatment downregulated 31726456 2587 Human hsa-miR-150 miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cell lipopolysaccharide (LPS) treatment downregulated 31398659 2588 Human hsa-miR-150 miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning downregulated 30602960 2589 Human hsa-miR-150 miRNA oxidized low density lipoprotein (ox-LDL) angiogenesis human umbilical vein endothelial cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 28254813 2590 Human hsa-miR-150 miRNA platelet derived growth factor-BB (PDGF-BB) asthma airway smooth muscle cells (ASMCs) platelet-derived growth factor BB (PDGF-BB) treatment downregulated 31695627 2591 Human hsa-miR-150 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment upregulated 27216461 2592 Human hsa-miR-150 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical cord vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28110404 2593 Human hsa-miR-150 miRNA ozone (O3) cardiovascular disease (CVD) plasma samples ozone (O3) exopusure upregulated 32414303 2594 Human hsa-miR-150 miRNA dextran sodium sulfate (DSS) chronic inflammatory bowel diseases (IBDs) colonic epithelial HT29 cells dextran sulphate sodium (DSS)? treatment upregulated 21590770 2595 Human hsa-miR-150 miRNA imatinib mesylate chronic myeloid leukemia (CML) Peripheral blood cells imatinib mesylate treatment upregulated 20460641 2596 Human hsa-miR-150 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) BEAS-2B airway epithelial cells cigarette smoke extract (CSE) treatment downregulated 29205062 2597 Human hsa-miR-150 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human airway epithelial cells BEAS-2B cells cigarette smoke extract (CSE) treatment downregulated 29205062 2598 Human hsa-miR-150 miRNA lipopolysaccharide (LPS) sepsis HUVECs lipopolysaccharide (LPS) treatment miR-150 affects sepsis-induced endothelial injury by regulating ER stress and inflammation via MALAT1-mediated NF-¦ÊB pathway. 33181172 2599 Human hsa-miR-150 miRNA Marek's disease virus (MDV) diabetes mellitus (DM) seven independentCD4+T-lymphoma cell line Marek's disease virus (MDV) treatment downregulated 19297609 2600 Human hsa-miR-150 miRNA TGF-¦Â "fibrotic diseases, myofibroblast activation" "human fetal lung fibroblast (HFL1, ECACC)" "human fetal lung fibroblast (HFL1, ECACC) treatment" upregulation 27226027 2601 Human hsa-miR-150 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) gastric cancer tissues 5-fluorouracil (5-FU) treatment upregulated 27081844 2602 Human hsa-miR-150 miRNA heroin human immunodeficiency virus (HIV)-1 infection Peripheral blood Heroin treatment downregulated 26583016 2603 Human hsa-miR-150 miRNA morphine human immunodeficiency virus (HIV)-1 infection peripheral blood mononuclear cells(PBMCs) morphine treatment downregulated 21224041 2604 Human hsa-miR-150 miRNA heat shock factor 1 (HSF1) huntington's disease (HD) Blood Heat shock factor 1 (HSF1) treatment downregulated 26634350 2605 Human hsa-miR-150 miRNA hypoxia hypoxia-induced cardiac dysfunctions human cardiomyocytes (HCMs) hypoxia treatment downregulated 29328381 2606 Human hsa-miR-150 miRNA "1,25-dihydroxyvitamin D (1,25(OH)2D)" inflammation human adipocytes "1,25-dihydroxyvitamin D (1,25(OH)2D) treatment" downregulated 28055298 2607 Human hsa-miR-150 miRNA celastrol insulin resistance (IR) palmitic acid (PA) treated HepG2 cells celastrol treatment upregulated 30287053 2608 Human hsa-miR-150 miRNA palmitic acid (PA) insulin resistance (IR) HepG2 cells palmitic acid (PA) treatment downregulated 30287053 2609 Human hsa-miR-150 miRNA palmitic acid (PA) insulin resistance (IR) HepG2 cells palmitic acid (PA) treatment downregulated 30287053 2610 Human hsa-miR-150 miRNA 5-fluorouracil/cisplatin (CDDP-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) CDDP-CRTX treatment dysregulated 28347920 2611 Human hsa-miR-150 miRNA rapamycin malignancies of the lymphocyte lineage human Jurkat T-cell acute lymphoblastic leukemia (T-ALL) cells rapamycin treatment upregulated 30269036 2612 Human hsa-miR-150 miRNA natalizumab multiple sclerosis (MS) MS patients natalizumab treatment downregulated in cell-free CSF 27144214 2613 Human hsa-miR-150 miRNA ionizing radiation (IR) nasopharyngeal carcinoma (NPC) CNE-2 cells Ionizing irradiation treatment upregulated 29516971 2614 Human hsa-miR-150 miRNA carbon disulfide (CS2) nerve system injury workers experienced injury to nerve system from carbon disulfide (CS2) treatment upregulated 25224332 2615 Human hsa-miR-150 miRNA oleic acid (OA) nonalcoholic fatty liver disease (NAFLD) human hepatocarcinoma cell line (HepG2) oleic acid (OA) treatment upregulated 31966555 2616 Human hsa-miR-150 miRNA cisplatin (DDP) pancreatic cancer (PC) K562 cells cisplatin (DPP) treatment miR-106 and miR-150 were downregulated 20428827 2617 Human hsa-miR-150 miRNA hpoxia pancreatic cancer (PC) pancreatic Hypoxia treatment downregulated 26622579 2618 Human hsa-miR-150 miRNA hypoxia pancreatic cancer (PC) CaPan2 human pancreatic cancer cell line hypoxia treatment downregulated 26622579 2619 Human hsa-miR-150 miRNA clopidogrel platelet inhibition serum clopidogrel treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 2620 Human hsa-miR-150 miRNA ticagrelor platelet inhibition serum ticagrelor treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 2621 Human hsa-miR-150 miRNA hypoxia pulmonary arterial hypertension (PAH) pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment downregulated 28715868 2622 Human hsa-miR-150 miRNA lipopolysaccharide (LPS) sepsis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment downregulated 29689269 2623 Human hsa-miR-150 miRNA lipopolysaccharide (LPS) sepsis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment MiR-150 was downregulated in LPS-induced HUVECs. 33181172 2624 Human hsa-miR-150-3p miRNA tumor necrosis factor alpha (TNF-¦Á) bone loss human bone marrow cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 26935950 2625 Human hsa-miR-150-5p miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment MALAT1 silencing can potentially suppress HPMEC apoptosis and alleviate lung injury in ARDS via miR-150-5p-targeted ICAM-1. 32315984 2626 Human hsa-miR-150-5p miRNA oxaliplatin advanced colorectal cancer (CRC) SW480 cells oxaliplatin (OXA) treatment LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer 33251049 2627 Human hsa-miR-150-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33278458 2628 Human hsa-miR-150-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment lncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis 33278458 2629 Human hsa-miR-150-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs. 33278458 2630 Human hsa-miR-150-5p miRNA Trypanosoma cruzi (T. cruzi) cardiac fibrosis human AC16 cardiomyocytes Trypanosoma cruzi (T. cruzi) infection treatment downregulated 31122130 2631 Human hsa-miR-150-5p miRNA oxidized low density lipoprotein (ox-LDL) cell proliferation and migration human aortic smooth muscle cells (HASMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31468685 2632 Human hsa-miR-150-5p miRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 high glucose (HG) treatment Overexpression of NORAD protects DCM development via miRNA-150-5p/ZEB1 axis. 33215445 2633 Human hsa-miR-150-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment "Our results showed that NEAT1 and Drp1 levels were upregulated, while miR-150-5p level was downregulated in HK-2 cells in response to HG." 33914383 2634 Human hsa-miR-150-5p miRNA simvastatin endometriosis Serum simvastatin treatment downregulated 29587611 2635 Human hsa-miR-150-5p miRNA free fatty acids (FFA) hepatic steatosis LO2 cells free fatty acid (FFA) treatment upregulated 31191607 2636 Human hsa-miR-150-5p miRNA astragaloside IV (AS-IV) hepatocellular carcinoma (HCC) SMMC-7721 cells; Huh7 cells astragaloside IV (AS-IV) treatment AS-IV treatment was supposed to significantly increase miR-150-5p level. 32417721 2637 Human hsa-miR-150-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 and HUH7 cells sorafenib treatment upregulated 31210410 2638 Human hsa-miR-150-5p miRNA hypoxia hypoxia-induced cardiac dysfunctions AC16 cells hypoxia treatment Hypoxia exposure caused a downregulated of miR-150-5p in AC16 cells. 32973515 2639 Human hsa-miR-150-5P miRNA marathon inflammation blood marathon treatment upregulated 25997943 2640 Human hsa-miR-150-5p miRNA glucocorticoid (GC) inflammatory bowel disease (IBD) serum Glucocorticoids (GCs) treatment downregulated 31938187 2641 Human hsa-miR-150-5p miRNA platelet derived growth factor-BB (PDGF-BB) liver fibrosis LX-2 cells platelet derived growth factor-BB (PDGF-BB) treatment downregulated 31833387 2642 Human hsa-miR-150-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment downregulated 31833387 2643 Human hsa-miR-150-5p miRNA physical exercise myasthenia gravis (MG) MG patients serum performed supervised aerobic and resistance training twice weekly for 12 weeks treatment downregulated 27935072 2644 Human hsa-miR-150-5p miRNA rituximab (RTX) myasthenia gravis (MG) serum exosome rituximab (RTX) treatment RTX decreased the serum exosomal miR-150-5p 32961347 2645 Human hsa-miR-150-5p miRNA trichloroethylene (TCE) non-Hodgkin lymphoma (NHL) serum trichloroethylene (TCE) exposure treatment downregulated 31161417 2646 Human hsa-miR-150-5p miRNA adipokine apelin (APLN) osteoarthritis (OA) human OA synovial fibroblasts (OASFs) adipokine apelin (APLN) treatment APLN inhibited levels of microRNA-150-5p (miR-150-5p). 32131466 2647 Human hsa-miR-150-5p miRNA paclitaxel (PTX) ovarian cancer (OC) CAOV3 cells; SKOV3 cells paclitaxel (Tax) treatment downregulated 33156701 2648 Human hsa-miR-150-5p miRNA TGF-¦Â1 lung fibrosis HFL1 cells TGF-¦Â1 treatment upregulated 32453709 2649 Human hsa-miR-151 miRNA genistein head and neck squamous cell carcinoma (HNSCC) LNCaP cells;PC-3 cells; DU145 cells; RWPE-1 cells Genistein? treatment downregulated 22928040 2650 Human hsa-miR-151-3p miRNA dexamethasone (DEX) Alzheimer's disease (AD) SH-SY5Ycells dexamethasone (DEX) treatment upregulated of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against ¦Â-amyloid by targeting DAPK-1 and TP53. 33275947 2651 Human hsa-miR-151-3p miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 11¡ã HDT bed rest experiment downregulated 28261104 2652 Human hsa-miR-151-3p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment miR-151-3p was decreased in HG-induced HK-2 cells. 32982348 2653 Human hsa-miR-151-3p miRNA hydroxyurea sickle cell anemia (SCA) Circulating erythroid cells Hydroxyurea treatment upregulated 21921042 2654 Human hsa-miR-151-5p miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 10¡ã HDT bed rest experiment downregulated 28261104 2655 Human hsa-miR-151-5p miRNA hantaan virus (HTNV) hantaan virus (HTNV) infection A549 cells hantavirus(HTNV)treatment upregulated 24074584 2656 Human hsa-miR-151-5p miRNA ionizing radiation (IR) anti-cancer therapy SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG ionizing radiation treatment upregulated 21453501 2657 Human hsa-miR-15-16 miRNA hypoxia colorectal cancer (CRC) colorectal carcinoma cell lines hypoxia treatment upregulated 24704828 2658 Human hsa-miR-151a miRNA baicalin (BAI) colorectal cancer (CRC) HT29 cells baicalin (BAI) treatment downregulated 30262902 2659 Human hsa-miR-151a-3p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) "Five human GBM cell lines (U87, LN229, A172, T98, U251)" temozolomide (TMZ) treatment downregulated 30992025 2660 Human hsa-miR-151a-3p miRNA BIX01294 lung cancer human NSCLC cells BIX01294 treatment downregulated 24932239 2661 Human hsa-miR-151a-5p miRNA vinyl chloride monomer (VCM) chromosomal damage workers peripheral blood lymphocytes high VCM-expose treatment downregulated 28749179 2662 Human hsa-miR-151a-5p miRNA l-carnitine male infertility sperm l-carnitine treatment upregulated 31749176 2663 Human hsa-miR-151b miRNA exercise (Ex) physiological impairments associated with aging circulating exosomes exercise treatment downregulated 32587527 2664 Human hsa-miR-152 miRNA statins asthma Immortalized lymphoblastoid cell lines (LCLs) statins? treatment upregulated 25266681 2665 Human hsa-miR-152 miRNA homocysteine (Hcy) atherosclerosis (AS) human monocyte leukemia cell line THP-1 homocysteine upregulated 28472596 2666 Human hsa-miR-152 miRNA lipopolysaccharide (LPS) atherosclerosis (AS) human aortic smooth muscle cells (HASMCs) lipopolysaccharide (LPS) treatment downregulated 22295098 2667 Human hsa-miR-152 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" breast cancer tamoxifen sensitive (TamS) MCF-7 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28063929 2668 Human hsa-miR-152 miRNA insulin-like growth factor 1 (IGF-1) breast cancer "human breast cancer cells MCF7, MDA-MB-231, T47D, MDA-MB-453" IGF-1 treatment upregulated 29162853 2669 Human hsa-miR-152 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (hRECs) high glucose treatment miR-152/LIN28B axis modulates high-glucose-induced angiogenesis in human retinal endothelial cells via VEGF signaling 31609010 2670 Human hsa-miR-152 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (hRECs) and retinal microvascular endothelial cell line (hRMECs) high-glucose (HG) treatment downregulated 31609010 2671 Human hsa-miR-152 miRNA progesterone (P4) endometrial cancer (EC) "human endometrial cancer cell lines (Ishikawa, HEC-1-b, and KLE)" P4 treatment upregulated 28122483 2672 Human hsa-miR-152 miRNA alcohol gastric cancer (GC) HEK293T cells;SH SY5Y cells;1321 N1 cells ?alcohol? treatment upregulated 24961422 2673 Human hsa-miR-152 miRNA TGF-¦Â gastric cancer (GC) BGC823 and SGC7901 TGF-¦Âtreatment treatment downregulated 26627200 2674 Human hsa-miR-152 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) human gastric carcinoma (AGS) cells infect with HP downregulated 28056089 2675 Human hsa-miR-152 miRNA lithium (Li) hyperglycemia lymphoblastoid cell lines (LCLs) Lithium (Li) treatment significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221 19254429 2676 Human hsa-miR-152 miRNA nickel sulfide (NiS) inflammation human bronchial epithelial (16HBE) cells nickel sulfide (NiS) treatment downregulated 23125218 2677 Human hsa-miR-152 miRNA TGF-¦Â liver fibrosis LX2 cells TGF-¦Â treatment downregulated 31258681 2678 Human hsa-miR-152 miRNA free fatty acids (FFAs) and TNF-¦Á and IL-6 nonalcoholic fatty liver disease (NAFLD) HepG2 cells and human hepatocytes free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment upregulated 25562147 2679 Human hsa-miR-152 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment downregulated 31611969 2680 Human hsa-miR-152 miRNA gemcitabine (GEM) osteosarcoma (OS) LncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. gemcitabine treatment "lncRNA PVT1 played a contributory role in chemoresistance of osteosarcoma cells through c-MET/PI3K/AKT pathway activation, which was largely dependent on miR-152." 30661902 2681 Human hsa-miR-152 miRNA "dietary 3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) "human pancreatic adenocarcinoma cell lines CaPan-1, CaPan-2, AsPC-1, BxPC-3, Hs766T, MiaPaCa-2, PANC-1, PANC-28, PANC-48, PaTu8902, FG, Colo357, L3.7" diet containing 2000 ppm of Bio-DIM for 6w upregulated 28659310 2682 Human hsa-miR-152 miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment upregulated 21093163 2683 Human hsa-miR-152 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" prostate cancer AA and CA derived prostate cancer cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25004396 2684 Human hsa-miR-152 miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed downregulated 27915273 2685 Human hsa-miR-152 miRNA TGF-¦Â renal fibrosis "human HK2, HEK293 cells" TGF¦Â treatment downregulated 28285987 2686 Human hsa-miR-152 miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment miR-152 expression was significantly reduced in TGF-¦Â1-treated HK-2 cells 29620271 2687 Human hsa-miR-152 miRNA vitamin D type 2 diabetes mellitus (T2DM) type 2 diabetes patients vitamin D treatment dysregulated 28945992 2688 Human hsa-miR-152-3p miRNA melatonin breast cancer MDA-MB-231 cells melatonin treatment melatonin treatment increases the gene expression of miR-152-3p. 29990486 2689 Human hsa-miR-152-3p miRNA paclitaxel (PTX) breast cancer MCF-7 cells Paclitaxel treatment downregulated 32913475 2690 Human hsa-miR-152-3p miRNA high glucose (HG) diabetic foot ulcer (DFU) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment Inhibition of miRNA-152-3p enhances diabetic wound repair via upregulation of PTEN 32620711 2691 Human hsa-miR-152-3p miRNA regorafenib frail metastatic colorectal cancer (mCRC) serum regorafenib treatment "Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia" 33916610 2692 Human hsa-miR-152-3p miRNA glial cell-derived neurotrophic factor (GDNF) glioblastoma multiforme (GBM) human U251 glioma cells 50 ng/mL GDNF for 24 h upregulated 29224008 2693 Human hsa-miR-152-3p miRNA metformin (Met) pancreatic cancer (PC) human pancreatic cancer cell lines PANC-1 and BxPC-3 Metformin treatment dysregulated 28875433 2694 Human hsa-miR-152-3p miRNA benzo(a)pyrene (BaP) toxicity of Benzo[a]pyrene (BaP) THBEc1 cells benzo(a)pyrene (BaP) exposure downregulated 32681969 2695 Human hsa-miR-153 miRNA estradiol breast cancer human breast cell lines estradiol treatment upregulated 27012032 2696 Human hsa-miR-153 miRNA alcohol gastric cancer (GC) HEK293T cells;SH SY5Y cells;1321 N1 cells ?alcohol? treatment upregulated 24961422 2697 Human hsa-miR-153 miRNA 4-phenylbutyric acid and 5-aza-2-deoxycytidine glioblastoma multiforme (GBM) DBTRG-05MG cells; T98G cells 4-phenylbutyric acid and 5-aza-20-deoxycytidine treatment upregulated 21213215 2698 Human hsa-miR-153 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) T98G cells temozolomide (TMZ) treatment upregulated 22722712 2699 Human hsa-miR-153 miRNA olea europaea leaf extract (OLE) glioblastoma multiforme (GBM) GBM cell lines olea europaea leaf extract (OLE) treatment upregulation 25232498 2700 Human hsa-miR-153 miRNA paraquat (PQ) neurotoxicity SH-SY5Y neuroblastoma cells paraquat (PQ) treatment upregulated 24866057 2701 Human hsa-miR-153 miRNA high glucose (HG) nonalcoholic fatty liver disease (NAFLD) HepG4 cells high glucose (HG) treatment downregulated 31889412 2702 Human hsa-miR-153 miRNA hypoxia pancreatic cancer (PC) NK cells hypoxia induce downregulated 31402756 2703 Human hsa-miR-153 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells SH-SY5Y cells treatment miR-153 was significantly increased in MPP+-induced SH-SY5Y cells. 31949812 2704 Human hsa-miR-153 miRNA mechanical stretch cell proliferation vascular smooth muscle cells (VSMCs) mechanical stretch-stimulated treatment downregulated 23046980 2705 Human hsa-miR-153 miRNA brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) cell senescence SH-SY5Y cells brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment upregulated 27525675 2706 Human hsa-miR-153 miRNA mifepristone (MIF) triple negative breast cancer (TNBC) MCF10A cells mifepristone (MIF) treatment upregulation 26941846 2707 Human hsa-miR-153 miRNA arsenic trioxide (ATO) glioblastoma and ovarian cancer K562 cells arsenic trioxide (As2O3) treatment downregulated 21267675 2708 Human hsa-miR-153-3p miRNA nutritional stress intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells low nutritional (LN) condition induce Upregulation of LINC00641 and downregulated of miR-153-3p are detected in NP cells under nutritional stress. 30378116 2709 Human hsa-miR-153-3p miRNA imatinib chronic myeloid leukemia (CML) KBM5 cells; K562 cells imatinib (IM) treatment miR-153-3p was identified to be downregulated in IM-resistant CML cells. 32342278 2710 Human hsa-miR-153-3p miRNA cocaine drug addiction differentiated SH-SY5Y neuroblastoma cells cocaine treatment downregulated 30166527 2711 Human hsa-miR-153-3p miRNA hypoxia ischemic stroke (IS) HUVECs hypoxia treatment downregulated 28985553 2712 Human hsa-miR-153-3p miRNA cisplatin (DDP) osteosarcoma (OS) "OS tissues, MG63/DDP, and U2OS/DDP cells." cisplatin treatment downregulated 31539112 2713 Human hsa-miR-153-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment SNHG1 aggravates MPP+-induced cellular toxicity in SH-SY5Y cells by regulating PTEN/AKT/mTOR signaling via sponging miR-153-3p. 31907031 2714 Human hsa-miR-1539 miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 2715 Human hsa-miR-1539 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment downregulated 29860902 2716 Human hsa-miR-1539 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 2717 Human hsa-miR-154 miRNA leuprolide endometriosis endometriotic tissues Leuprolide treatment downregulated 27709720 2718 Human hsa-miR-154 miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment downregulated 31359876 2719 Human hsa-miR-155 miRNA francisella tularensis microbial infection PBMCs (peripheral blood mononuclear cells) Francisella tularensis infection induction of miR-155 22919664 2720 Human hsa-miR-155 miRNA aspergillus fumigatus (A. fumigatus) Aspergillus fumigatus infection human monocytes and dendritic cells (DCs) infect with A. fumigatus upregulated 24841251 2721 Human hsa-miR-155 miRNA mycobacterium tuberculosis (Mtb) active tuberculosis (ATB) PBMCs (peripheral blood mononuclear cells) Mycobacterium tuberculosis (MTB) infection upregulated 22037148 2722 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) acute coronary syndrome (ACS) peripheral blood mononuclear cell (PBMC) of ACS patients lipopolysaccharide (LPS) treatment upregulated 28407320 2723 Human hsa-miR-155 miRNA rosuvastatin acute coronary syndrome (ACS) patients with ACS rosuvastatin treatment downregulated in serum 25319951 2724 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) acute graft-versus-host disease (aGVHD) human umbilical vein endothelial cells (EA.hy926) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 28423578 2725 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) acute inflammatory response human monocytic cells lipopolysaccharide (LPS) treatment upregulated 19596814 2726 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment LPS administration increased miR-155 levels in tubular epithelial cells in vitro. 32243922 2727 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment upregulated 32323747 2728 Human hsa-miR-155 miRNA adriamycin (ADR) acute myeloid leukemia (AML) U937 cells; THP-1 cells adriamycin (ADR) treatment upregulated 32359033 2729 Human hsa-miR-155 miRNA sulforaphane (SFN) acute myeloid leukemia (AML) "acute myelogenous leukemia cells U937, KG-1, HL-60, and NB-4" sulforaphane treatment downregulated 30350234 2730 Human hsa-miR-155 miRNA "IFN-¦Ã, IL-1¦Â and TNF-¦Á" age-related macular degeneration (AMD) human retinal pigment epithelial (HRPE) cell "IFN-¦Ã, TNF-¦Á and IL-1¦Â treatment" upregulated 20950585 2731 Human hsa-miR-155 miRNA chitin allergic airway diseases (AAD) bronchial epithelial cells and in A549 and H292 lung carcinoma cells chitin treatment upregulated 27463381 2732 Human hsa-miR-155 miRNA amyloid-¦Â (A¦Â) Alzheimer's disease (AD) N9 microglial cell line amyloid-¦Â (A¦Â) treatment upregulated 27797173 2733 Human hsa-miR-155 miRNA dipeptidyl vinyl sulfone (VS) Alzheimer's disease (AD) N9 microglial cell line treated with A¦Â VS treatment downregulated 27797173 2734 Human hsa-miR-155 miRNA arsenic trioxide (ATO) anti-cancer therapy human prostate cancer PC-3 and LNCaP cells arsenic trioxide (As2O3) treatment upregulated 25283513 2735 Human hsa-miR-155 miRNA oxysophocarpine (OSC) anti-inflammatory responses NCI-H292 and human primary airway epithelial cells Oxysophocarpine (OSC) treatment "The expression of miR-155 could be dramatically induced by LPS treatment in NCI-H292 cells, which could be attenuated by OSC treatment" 32603606 2736 Human hsa-miR-155 miRNA "dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)" anti-inflammatory responses primary astrocyte cultures derived from human brains stimulated with IL-1¦Â "pretreat with DMF, MMF" downregulated 28589165 2737 Human hsa-miR-155 miRNA M2000 (¦Â-d-mannuronic acid) anti-inflammatory responses LPS treated PBMCs 5 and 25 ¦Ìg/ml of M2000 in duplicates downregulated 28090274 2738 Human hsa-miR-155 miRNA pitavastatin (Pit) anti-inflammatory responses LPS pretreated HUVECs "Pit (0.01, 0.1, 1 ¦Ìmol/L) treatment" downregulated 28664667 2739 Human hsa-miR-155 miRNA H2O2 apoptosis Human umbilical vein endothelial cells (HUVEC) H2O2 treatment "endothelial cell proliferation was promoted, and oxidant-induced injury was decreased when the expression of miR-155 was inhibited." 30675289 2740 Human hsa-miR-155 miRNA arsenite arsenic-induced multiorgan damage plasma arsenic exposure upregulated 31085440 2741 Human hsa-miR-155 miRNA cockroach extract (CRE) asthma human bronchial epithelial cells cockroach extract (CRE) treatment upregulated 29967100 2742 Human hsa-miR-155 miRNA glucocorticoid (GC) asthma CD4+ T-cells glucocorticoids treatment Mir-155 is dysregulated in allergic T-cells exposed to DM extract compared to in non-allergic cells and it is inhibited by glucocorticoids. 30245919 2743 Human hsa-miR-155 miRNA "toluene 2,4-diisocyanate (TDI)" asthma human bronchial epithelial cells (HBEC) "toluene 2,4-diisocyanate (TDI) treatment" upregulated 32499335 2744 Human hsa-miR-155 miRNA imatinib atheroprotective Macrophages imatinib treatment upregulated 26721343 2745 Human hsa-miR-155 miRNA conjugated linoleic acid (CLA) atherosclerosis (AS) THP-1 cells conjugated linoleic acid (CLA) treatment CLA blend also decreased miR-155 expression in vitro in human THP-1 polarized macrophages. 33391256 2746 Human hsa-miR-155 miRNA genistein atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) "genistein (10, 100, and 1000 nM) for 6 h" downregulated 28550396 2747 Human hsa-miR-155 miRNA imatinib atherosclerosis (AS) human macrophages imatinib treatment upregulated 26721343 2748 Human hsa-miR-155 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human endothelial cells surrogate EA.hy926 lines (EA.hy926 cells) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29017169 2749 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) HUVECs TNF¦Á ed HUVECs treatment upregulated 24905663 2750 Human hsa-miR-155 miRNA TNF-¦Á£¬IGF-1 atherosclerosis (AS) smooth muscle cell TNF-¦Á£¬IGF-1 treatment upregulated 26047583 2751 Human hsa-miR-155 miRNA H2O2 autophagy Human umbilical vein endothelial cells (HUVEC) H2O2 treatment "endothelial cell proliferation was promoted, and oxidant-induced injury was decreased when the expression of miR-155 was inhibited." 30675289 2752 Human hsa-miR-155 miRNA hypoxia autophagy CNE (human nasopharyngeal cancer) or HeLa (human cervical cancer) cells 1% O2 treatment upregulated 24262949 2753 Human hsa-miR-155 miRNA oxidized low density lipoprotein (ox-LDL) autophagy human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28659666 2754 Human hsa-miR-155 miRNA oxidized low density lipoprotein (ox-LDL) autophagy human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 30015881 2755 Human hsa-miR-155 miRNA wogonin B lymphoma human cell line Raji wogonin treatment downregulated 28222771 2756 Human hsa-miR-155 miRNA camptothecin biologic and molecular activity of camptothecin hypoxic-human cancer cells camptothecin treatment upregulated 24252850 2757 Human hsa-miR-155 miRNA hedyotis diffusa plus scutellaria barbata bladder cancer human bladder cancer cell lines 5637 and T24 Hedyotis diffusa plus Scutellaria barbata treatment Further experiments showed that miR-155 was reduced by the herb-pair and miRNA-155 inhibitor induced cell apoptosis and suppressed Akt activation. 26989427 2758 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) blood-brain barrier (BBB) dysfunction human brain endothelium lipopolysaccharide (LPS) treatment upregulated 24604078 2759 Human hsa-miR-155 miRNA estradiol-17¦Â (E2) breast cancer MCF-7 cells estradiol-17¦Â (E2) treatment upregulated 23568502 2760 Human hsa-miR-155 miRNA genistein breast cancer MDA-MB-435 and Hs578t breast cancer cells genistein treatment downregulated 26771440 2761 Human hsa-miR-155 miRNA ionizing radiation (IR) breast cancer Blood The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min) upregulated 31150454 2762 Human hsa-miR-155 miRNA mastectomy breast cancer breast cancer tissues mastectomy treatment upregulated 25503185 2763 Human hsa-miR-155 miRNA oleuropein (OL) breast cancer MCF-7 cells oleuropein treatment Oleuropein significantly decreased expression of both miR-21 and miR-155 over time in a dose-dependent manner. 29905007 2764 Human hsa-miR-155 miRNA pomegranate polyphenolics breast cancer Human mammary carcinoma cell lines BT474 and MDA-MB-231 pomegranate polyphenolics treatment downregulated 22941571 2765 Human hsa-miR-155 miRNA schizandrin A (SchA) breast cancer MDA-MB-231 cells schizandrin A (SchA) treatment SchA strikingly decreases miR-155. 32623835 2766 Human hsa-miR-155 miRNA silibinin (SB) breast cancer MCF-7 breast cancer cells Silibinin treatment downregulated 27066095 2767 Human hsa-miR-155 miRNA tamoxifen (TAM) breast cancer Human breast cancer tissues Tamoxifen treatment upregulated 26692956 2768 Human hsa-miR-155 miRNA wound fluids (WFs) from breast cancer patients breast cancer human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line WFs treatment upregulated 28943910 2769 Human hsa-miR-155 miRNA brucella Omp25 brucellosis human Monocyte/Macrophages brucella Omp25 treatment upregulated 28694807 2770 Human hsa-miR-155 miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 2771 Human hsa-miR-155 miRNA polycyclic aromatic hydrocarbons (PAHs) cardiovascular disease (CVD) human umbilical cord vein cells (HUVECs) polycyclic aromatic hydrocarbons (PAHs) treatment upregulated 30144390 2772 Human hsa-miR-155 miRNA gliadinN celiac disease (CD) PBMCs; monocytes gliadinN treatment upregulated 31781909 2773 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) cell-to-cell communication human aortic endothelial cells (ECs) and their transfer to recipient cells tumor necrosis factor alpha (TNF-¦Á) treatment differently regulation 25315114 2774 Human hsa-miR-155 miRNA diesel exhaust particle (DEP) cellular protection and tumorigenesis "A549, H358 and 293 T cell lines" diesel exhaust particle (DEP) exposure downregulated 28315615 2775 Human hsa-miR-155 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y Cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 32090104 2776 Human hsa-miR-155 miRNA telbivudine chronic hepatitis B virus (HBV) infection CHB patients peripheral blood mononuclear cells (PBMCs) telbivudine treatment upregulated in peripheral blood mononuclear cells (PBMCs) 29018442 2777 Human hsa-miR-155 miRNA telbivudine or peg-IFN-¦Á-2a chronic hepatitis B virus (HBV) infection CHB patients peripheral blood mononuclear cells (PBMCs) telbivudine or peg-IFN-¦Á-2a treatment downregulated in peripheral blood mononuclear cells (PBMCs) 29018442 2778 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) chronic inflammatory diseases human bronchial epithelial cells 16HBE lipopolysaccharide (LPS) treatment upregulated 30905633 2779 Human hsa-miR-155 miRNA hypoxia chronic kidney disease (CKD) HK-2 cells chronic intermittent hypoxia (CIH) treatment upregulated 29953588 2780 Human hsa-miR-155 miRNA IL-4 chronic lymphocytic leukemia (CLL) MEC-1 cells interleukin (IL)-4 treatment upregulated 31289477 2781 Human hsa-miR-155 miRNA smoking chronic obstructive pulmonary disease (COPD) lung tissues smoking treatment MiR-155 expression was significantly increased in lung tissue of smokers and patients with COPD compared to never smokers 31819170 2782 Human hsa-miR-155 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) human colorectal cancer HCT-116 and HT-29 cells 5-fluorouracil (5-FU) treatment downregulated 28515355 2783 Human hsa-miR-155 miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 2784 Human hsa-miR-155 miRNA TGF-¦Â1 colorectal cancer (CRC) colorectal cancer cells TGF-¦Â1 treatment upregulated 27626488 2785 Human hsa-miR-155 miRNA surgery and chemotherapy colorectal cancer (CRC) patients blood surgery and chemotherapy for 3years treatment upregulated 24310813 2786 Human hsa-miR-155 miRNA NOD2-agonist muramyl dipeptide crohn disease (CD) Crohn's disease patients without NOD2 mutations monocytes NOD2-agonist muramyl dipeptide treatment downregulated in monocytes 29263823 2787 Human hsa-miR-155 miRNA Staphylococcus aureus enterotoxins (SE) cutaneous T-cell lymphoma (CTCL) primary malignant T cells Staphylococcus aureus enterotoxins (SE) treatment "Here, we show that SE induce expression of the oncogenic microRNA mir-155 in primary malignant T cells" 33862068 2788 Human hsa-miR-155 miRNA oligosaccharide nanomedicine of alginate sodium (ONAS) degenerative lumbar disease (DLD) serum oral administration of 100 mg ONAS daily) downregulated 29200854 2789 Human hsa-miR-155 miRNA dengue virus (DENV) dengue virus (DENV) infection Huh-7 cells dengue virus (DENV) infection downregulated 32277848 2790 Human hsa-miR-155 miRNA high glucose (HG) diabetic foot ulcer (DFU) primary endothelial progenitor cells (EPCs) high glucose treatment upregulated 29545091 2791 Human hsa-miR-155 miRNA angiotensin II (Ang II) diabetic nephropathy (DN) human vascular endothelial cells angiotensin II (Ang II) treatment downregulated 23174997 2792 Human hsa-miR-155 miRNA high glucose and free fatty acids (HG-FFA) diabetic osteoporosis human bone marrow-derived mesenchymal stem cells (hBMSCs) high glucose and free fatty acids (HG-FFA) treatment miR-155 levels in hBMSCs increased corresponding to the time of exposure to HG-FFA treatment. 32248286 2793 Human hsa-miR-155 miRNA vincristine (VCR) diffuse large B-cell lymphoma (DLBCL) DLBCL cell lines vincristine treatment miR-155 as highly expressed in vincristine-sensitive DLBCL cell lines compared with resistant ones 30967394 2794 Human hsa-miR-155 miRNA hydroquinone (HQ) DNA damage TK6 lymphoblastoid cells Hydroquinone (HQ) treatment upregulated 30448557 2795 Human hsa-miR-155 miRNA hydroquinone (HQ) DNA damage TK6 lymphoblastoid cells Hydroquinone (HQ) treatment miR-155 was significantly increased. 30448557 2796 Human hsa-miR-155 miRNA ionizing radiation (IR) endothelial dysfunction Human umbilical vein endothelial cells (HUVECs) Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT "2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h." 30711956 2797 Human hsa-miR-155 miRNA angiotensin II (Ang II) endothelial inflammation and migration human umbilical vein endothelial cells (HUVECs) ;vascular smooth muscle cells (VSMCs) angiotensin II (Ang II) treatment upregulated 21310411 2798 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) endothelial senescence human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31752013 2799 Human hsa-miR-155 miRNA TGF-¦Â cardiac fibrosis human coronary artery endothelial cells (HCAECs) TGF-¦Â treatment upregulated 28607031 2800 Human hsa-miR-155 miRNA dexamethasone (DEX) eosinophilic chronic rhinosinusitis with nasal polyps rhinal tissues dexamethasone (DEX) treatment DEX treatment inhibited the expression of cytokines and decreased the relapse rate of Eos CRSwNP via inhibiting NF-kappaB/miR-155. 32614806 2801 Human hsa-miR-155 miRNA remnant-like lipoproteins (RLPs) ePCs senescence Total peripheral mononuclear cells (PB-MNCs) Remnant-like lipoproteins (RLPs) treatment miR-148b and miR-155 were upregulated while miR-574-3p was downregulated 23044309 2802 Human hsa-miR-155 miRNA F. novicida F. novicida?infection Human peripheral blood monocytes (PBM) F. novicida?infection downregulated 20041145 2803 Human hsa-miR-155 miRNA bisphenol A (BPA) female fertility cumulus oocyte complex (COC) bisphenol A (BPA) treatment upregulated 33285269 2804 Human hsa-miR-155 miRNA fluoride fluorosis sodium fluoride (NaF) treated human osteosarcoma (HOS) cells fluoride treatment miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor ¦Ê-B ligand (RANKL) genes 26339601 2805 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) follicle development and oocyte maturation human endothelial cells TNF¦Á treatment upregulated 21982894 2806 Human hsa-miR-155 miRNA phorbol-12-myristate-13-acetate(PMA) functions of human macrophages U937 cells phorbol 12-myristate 13-acetate (PMA) treatment upregulated 33268675 2807 Human hsa-miR-155 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) GES-1 cells Helicobacter pylori (H. pylori) infection upregulated 31162747 2808 Human hsa-miR-155 miRNA helicobacter pylori (H. pylori) gastritis Blood H. pylori treatment upregulated 26191144 2809 Human hsa-miR-155 miRNA helicobacter pylori (H. pylori) gastritis gastric lesions Helicobacter pylori treatment upregulated 30219037 2810 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) gingival inflammation Human gingival fibroblasts (HGFs) lipopolysaccharide (LPS) treatment upregulated 29407755 2811 Human hsa-miR-155 miRNA metformin (Met) glioblastoma multiforme (GBM) U87 cells metformin(Met) treatment downregulated 33059952 2812 Human hsa-miR-155 miRNA melatonin glioblastoma multiforme (GBM) "human glioma cell lines U87, U373 and U251" "melatonin (100¦ÌM, 1¦ÌM and 1nM)" downregulated 28724215 2813 Human hsa-miR-155 miRNA monosodium urate (MSU) gout Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) from acute gouty arthritis patients monosodium urate (MSU) treatment upregulated 24708712 2814 Human hsa-miR-155 miRNA hepatitis B virus (HBV) hepatitis B virus (HBV) infection human hepatitis B virus (HBV)infection downregulated 27110261 2815 Human hsa-miR-155 miRNA borna disease virus (BDV) borna disease virus (BDV) infection human oligodendroglial borna disease virus (BDV)?infection downregulated 23428672 2816 Human hsa-miR-155 miRNA recombinant Schistosoma japonicum egg antigen P40 (rSjP40) liver fibrosis LX-2 cells recombinant Schistosoma japonicum egg antigen P40 (rSjP40) treatment microRNA-155 was raised in rSjP40-treated HSCs 30091834 2817 Human hsa-miR-155 miRNA hepatitis B virus (HBV) hepatitis B virus (HBV) infection HepG2 cells hepatitis B virus (HBV) infection miR-155 was inhibited on HBV infection. 31930529 2818 Human hsa-miR-155 miRNA arsenite hepatocellular carcinoma (HCC) L-02 cells arsenite exposure upregulated 29240254 2819 Human hsa-miR-155 miRNA pegylated interferon-¦Á (PEG-IFN) hepatocellular carcinoma (HCC) HepG2 cells pegylated interferon-¦Á (PEG-IFN) treatment downregulated 31036495 2820 Human hsa-miR-155 miRNA hepatitis C virus (HCV) liver damage monocytes hepatitis C virus (HCV) infection Serum levels of miR-122 were elevated in cHCV patients and correlated with increased ALT and AST levels and serum miR-155 levels 22846613 2821 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) herpes simplex virus 1 (HSV-1) infection human umbilical vein endothelial cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 23108656 2822 Human hsa-miR-155 miRNA Shenqi pollen capsules (SPCs) high-altitude deacclimatization syndrome (HADAS) serum Shenqi pollen capsules (SPCs) treatment downregulated 31828172 2823 Human hsa-miR-155 miRNA follicle stimulating hormone (FSH) high-grade serous ovarian carcinomas (HGSOC) fallopian tube secretory epithelial cells (FTSECs) follicular fluid (FF) treatment upregulated 32614381 2824 Human hsa-miR-155 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6A dysregulated 29163428 2825 Human hsa-miR-155 miRNA human herpesvirus 6B (HHV-6B) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6B dysregulated 29163428 2826 Human hsa-miR-155 miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection upregulated 31371699 2827 Human hsa-miR-155 miRNA recombinant Human immunodeficiency virus (HIV) viral protein gp120 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment upregulated 31371699 2828 Human hsa-miR-155 miRNA recombinant Human immunodeficiency virus (HIV) viral protein Tat HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment upregulated 31371699 2829 Human hsa-miR-155 miRNA lithium (Li) hyperglycemia lymphoblastoid cell lines (LCLs) Lithium (Li) treatment significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221 19254429 2830 Human hsa-miR-155 miRNA S-amlodipine hypertension human umbilical vein endothelial cells (HUVECs) S-amlodipine treatment downregulated 30951948 2831 Human hsa-miR-155 miRNA acidic bile hypopharyngeal cancer human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) acidic bile exposure upregulated 29516639 2832 Human hsa-miR-155 miRNA BAY11-7082 hypopharyngeal cancer Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) BAY 11-7082 treatment downregulated 29516639 2833 Human hsa-miR-155 miRNA Ig-like transcript 3 (ILT3) immune inflammatory human CD8(+) T suppressor cells Ig-like transcript 3 (ILT3) treatment upregulated 22387553 2834 Human hsa-miR-155 miRNA IFN-¦Ã immunoregulatory function MSCs IFN¦Ã treatment upregulated 23449975 2835 Human hsa-miR-155 miRNA IL-1¦Â immunoregulatory function MSCs IL-1¦Â treatment upregulated 23449975 2836 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) immunoregulatory function MSCs TNF¦Á treatment upregulated 23449975 2837 Human hsa-miR-155 miRNA steroids immune thrombocytopenic purpura (ITP) peripheral blood mononuclear cells of ITP patients steroid therapy treatment downregulated 25413124 2838 Human hsa-miR-155 miRNA corticosterone immunosuppression Su-DHL4 cells corticosterone (CORT) treatment downregulated 30414952 2839 Human hsa-miR-155 miRNA cocaine HIV-induced immunopathogenesis peripheral blood mononuclear cells (PBMC) Cocaine treatment downregulated 24391808 2840 Human hsa-miR-155 miRNA vibrio cholerae O1 infection of Vibrio cholerae O1 colon carcinoma cell line T84 infect with Vibrio cholerae O1 treatment upregulated at acute stage of V cholerae infection and declined to normal at convalescent stage 28319200 2841 Human hsa-miR-155 miRNA alternariol (AOH) inflammation THP-1 cells alternariol (AOH) treatment upregulated 30175388 2842 Human hsa-miR-155 miRNA cold inflammation LPS-induced human monocytes exposure to cold (32¡ãC) treatment upregulated 25231976 2843 Human hsa-miR-155 miRNA crataegus special extract WS 1442 inflammation Human umbilical vein endothelial cells (HUVECs) Crataegus Special Extract WS 1442 treatment upregulated 29660753 2844 Human hsa-miR-155 miRNA curcumin (Cur) inflammation LPS-induced THP-1 cells curcumin treatment downregulated 28264607 2845 Human hsa-miR-155 miRNA glucocorticoid (GC) inflammation RAW264.7 cells Glucocorticoids (GCs) treatment downregulated 22326887 2846 Human hsa-miR-155 miRNA helicobacter pylori (H. pylori) inflammation Human gastric cancer cell line AGS and human embryonickidney HEK-293 cell Helicobacter pylori infection upregulated 20219467 2847 Human hsa-miR-155 miRNA interferon regulatory factor 3 (IRF3) inflammation primary human astrocytes Interferon regulatory factor 3 (IRF3) treatment downregulated 22170100 2848 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) inflammation HUVECs lipopolysaccharide (LPS) treatment upregulated 28664667 2849 Human hsa-miR-155 miRNA nitric oxide (NO) inflammation human liver epithelial (HepG2) cells the NO-releasing S-nitroso-N-acetylpenicillamine (SNAP) 100 ¦ÌM for 4 h treatment MiR-155 was the only miRNA of the 887 arrayed that showed a change in expression after SNAP ment. 24687397 2850 Human hsa-miR-155 miRNA oxidized low density lipoprotein (ox-LDL) inflammation PMA-preprocessed THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment "overexpression of miR-155 promoted the activation of the ox-LDL-induced NLRP3 inflammasome, which could also be blocked by the ERK inhibitor U0126." 31865729 2851 Human hsa-miR-155 miRNA IFN-¦Ã and TNF-¦Á inflammation human dermal lymphatic endothelial cells (HDLECs) HDLECs with the treatment upregulated 29066622 2852 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation Human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29660753 2853 Human hsa-miR-155 miRNA "1,25-dihydroxyvitamin D (1,25(OH)2D)" inflammation human adipocytes "1,25-dihydroxyvitamin D (1,25(OH)2D) treatment" downregulated 28055298 2854 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammatory bowel disease (IBD) colonic epithelial cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 26752469 2855 Human hsa-miR-155 miRNA IFN-¦Ã and TNF-¦Á inflammatory response Normal human mesangial cells IFN-¦Ã and TNF-¦Á treatment upregulated 20948191 2856 Human hsa-miR-155 miRNA influenza A virus (IAV) influenza A virus (IAV) infection human pulmonary microvascular endothelial cells (HPMECs) influenza A virus strain H1N1 infection MiR-155 was elevated in response to the H1N1 infection in HPMECs (24 h post-infection. 32889908 2857 Human hsa-miR-155 miRNA candida albicans (C. albicans) innate immune response monocytes derived dendritic cells (DCs) candida albicans infection upregulated 32042774 2858 Human hsa-miR-155 miRNA "ferrylhemoglobin (ferrylHb, Fe4+)" intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) "ferrylhemoglobin (ferrylHb, Fe4+) treatment" upregulated 32961661 2859 Human hsa-miR-155 miRNA heme intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) heme treatment upregulated 32961661 2860 Human hsa-miR-155 miRNA "methemoglobin (metHb, Fe3+)" intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) "methemoglobin (metHb, Fe3+) treatment" upregulated 32961661 2861 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 32961661 2862 Human hsa-miR-155 miRNA panax notoginseng saponins (PNS) ischemic stroke (IS) SH-SY5Y cells panax notoginseng saponins (PNS) treatment "In OGD/R-induced SH-SY5Y cells, 160??g/mL PNS treatment promoted cell proliferation and cell cycle progression, as well as decreased inhibited apoptosis and miR-155 expression" 30587668 2863 Human hsa-miR-155 miRNA Japanese encephalitis virus (JEV) Japanese encephalitis virus (JEV) infection BV-2 cells JEV infection treatment upregulated 24522920 2864 Human hsa-miR-155 miRNA Japanese encephalitis virus (JEV) Japanese encephalitis virus (JEV) infection human microglial CHME3 cells JEV-infected treatment upregulated 24885259 2865 Human hsa-miR-155 miRNA epstein-barr virus (EBV) large B-cell lymphomas (DLBCLs) "EBV-positive BL cell lines Mutu I; Mutu III; Namalwa; Raji,;the EBV-positive DLBCL cell line IBL-1; EBV-negative BJAB cell line;EBV-infected human peripheral blood mononuclear cells (PBMCs) and 293T cells" Epstein-Barr virus (EBV) treatment upregulated 20844043 2866 Human hsa-miR-155 miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 18648749 2867 Human hsa-miR-155 miRNA anthraquinone-chalcone hybrids containing amide function compounds 6e leukemia K562 cells anthraquinone-chalcone hybrids containing amide function compounds 6e treatment upregulated 29970309 2868 Human hsa-miR-155 miRNA anthraquinone-chalcone hybrids containing amide function compounds 6g leukemia K562 cells anthraquinone-chalcone hybrids containing amide function compounds 6g treatment downregulated 29970309 2869 Human hsa-miR-155 miRNA anthraquinone-chalcone hybrids containing amide function compounds 6u leukemia K562 cells anthraquinone-chalcone hybrids containing amide function compounds 6u treatment upregulated 29970309 2870 Human hsa-miR-155 miRNA anthraquinone-chalcone hybrids containing amide function compounds 6v leukemia K562 cells anthraquinone-chalcone hybrids containing amide function compounds 6v treatment downregulated 29970309 2871 Human hsa-miR-155 miRNA listeria monocytogenes (L. monocytogenes) Listeria infection Human epithelial cells (Caco-2) Listeria infection downregulated 22312311 2872 Human hsa-miR-155 miRNA arsenite hepatocellular carcinoma (HCC) L-02 and THLE-3 cells arsenite exposure upregulated 27913196 2873 Human hsa-miR-155 miRNA arsenite hepatocellular carcinoma (HCC) L-02 cells arsenite exposure upregulated 29240254 2874 Human hsa-miR-155 miRNA hypoxia hepatocellular carcinoma (HCC) A549 cells hypoxia trreatment upregulated 22027557 2875 Human hsa-miR-155 miRNA NO-releasing S-nitroso-N-acetylpenicillamine liver inflammation and cancer human liver epithelial (HepG2) cells NO-releasing S-nitroso-N-acetylpenicillamine (SNAP) 100 ¦ÌM for 4 h a treatment differerntlly expressed 24687397 2876 Human hsa-miR-155 miRNA 5-fluorouracil/cisplatin (CDDP-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) CDDP-CRTX treatment dysregulated 28347920 2877 Human hsa-miR-155 miRNA arsenic trioxide (ATO) lung cancer human lung adenocarcinoma cell line A549 cells arsenic trioxide (ATO) treatment downregulated 29260515 2878 Human hsa-miR-155 miRNA poly-lactic acid nanoparticles (PLA-NP) lung cancer human lung epithelial A549 cells "PLA-NP for 24, 48 and 72 h treatment" downregulated 28143572 2879 Human hsa-miR-155 miRNA tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) lung cancer NCI cells; FaDu cells tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment upregulated 32326378 2880 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) Dendritic cell (DC) maturation Dendritic cells (DCs) lipopolysaccharide (LPS) treatment upregulated 27714813 2881 Human hsa-miR-155 miRNA ezetimibe monocytic differentiation Human monocytic cell lineTHP-1 Ezetimibe trratment downregulated 22989505 2882 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) monocytic differentiation monocyte lipopolysaccharide (LPS) treatment dysregulated 25148686 2883 Human hsa-miR-155 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) myeloma cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" in vitro methylation of part of the promoter and first exon abrogated the miR-155 expression 25497370 2884 Human hsa-miR-155 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 2885 Human hsa-miR-155 miRNA autologous hematopoietic SCT(AHSCT) multiple sclerosis (MS) MS patients AHSCT treatment upregulated in T- and B-cell 25486582 2886 Human hsa-miR-155 miRNA torpedo acetylcholine receptor (T-AChR) myasthenia gravis (MG) B cells of MG patients T-AChR treatment upregulated 24387321 2887 Human hsa-miR-155 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" myeloma MM cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25497370 2888 Human hsa-miR-155 miRNA RNA-directed DNA methylation myeloma MM cell lines Nucleofection with 141 siRNAs at a 20 nM concentration treatment downregulated 25497370 2889 Human hsa-miR-155 miRNA epstein-barr virus (EBV) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma cell EBV?infection upregulated 24241359 2890 Human hsa-miR-155 miRNA latent membrane protein 1 (LMP1) nasopharyngeal carcinoma (NPC) CNE-2 cells latent membrane protein 1 (LMP1) treatment upregulated 27123134 2891 Human hsa-miR-155 miRNA calcium oxalate (CaOx) nephrolithiasis HK-2 cells calcium oxalate (CaOx) treatment CaOx treatment caused upregulated of miR-155 and induced autophagy in renal tubular epithelial cells. 32417393 2892 Human hsa-miR-155 miRNA Toll-like receptor (TLR) neurological diseases U251 human astrocytoma cell line Toll-like receptor (TLR) treatment upregulated 25957996 2893 Human hsa-miR-155 miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 2894 Human hsa-miR-155 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 2895 Human hsa-miR-155 miRNA chemoradiation therapy (CRT) non-small cell lung cancer (NSCLC) patients with stage IIIB-IV NSCLC CRT treatment upregulated 25466375 2896 Human hsa-miR-155 miRNA IFN-¦Ã oral lichen planus (OLP) EOLP CD4(+) T cells IFN-¦Ã treatment upregulated 26594049 2897 Human hsa-miR-155 miRNA hydrostatic pressure (HP) osteoarthritis (OA) human OA chondrocyte "exposure to three hours of a cyclic HP (1-5 MPa, frequency 0.25 Hz)" downregulated 29150345 2898 Human hsa-miR-155 miRNA hydrostatic pressure (HP) osteoarthritis (OA) chondrocytes hydrostatic pressure (HP) treatment miR-155 and miR-181a resulted significantly downregulated immediately after pressurization (T0) in OA cells. 29150345 2899 Human hsa-miR-155 miRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment The expression level of miR-155 in primary chondrocytes was drastically induced upon IL-1¦Â treatment. 32562373 2900 Human hsa-miR-155 miRNA mud-bath therapy (MBT) osteoarthritis (OA) patients with bilateral knee osteoarthritis (OA) "daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks" downregulated 28785809 2901 Human hsa-miR-155 miRNA "rapamycin,2-deoxyglucose (2-DG)" osteoarthritis (OA) primary human articular chondrocytes and the T/C28a2 human chondrocyte cell line primary human articular chondrocytes and the T/C28a2 human chondrocyte cell line treatment upregulation 26805019 2902 Human hsa-miR-155 miRNA tanshinone IIA (Tan IIA) osteoarthritis (OA) human articular chondrocytes ?tanshinone IIA treatment tanshinone IIA ameliorates inflammation response in OA via inhibition of the miR-155/FOXO3 axis 33395681 2903 Human hsa-miR-155 miRNA hepatitis C virus (HCV) osteoblastic differentiation Human hepatic tis-sues hepatitis C virus (HCV) infection upregulated 22610915 2904 Human hsa-miR-155 miRNA IFN-¦Â osteoclast-mediated diseases HEK293T cells Interferon-¦Â treatment upregulated 22771905 2905 Human hsa-miR-155 miRNA bone morphogenetic protein 2 (BMP2) osteogenesis from preosteoblasts preosteoblast cell line MC3T3-E1 bone morphogenetic protein 2 (BMP2) treatment downregulated 28473977 2906 Human hsa-miR-155 miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx9 treatment" downregulated 21572246 2907 Human hsa-miR-155 miRNA adriamycin (ADR) osteosarcoma (OS) MG-63 cells adriamycin (ADR) treatment upregulated 29412697 2908 Human hsa-miR-155 miRNA cisplatin (DDP) osteosarcoma (OS) Human osteosarcoma cell lines (Saos-2 and MG-63) cisplatin (DDP) treatment upregulated 25009614 2909 Human hsa-miR-155 miRNA doxorubicin (DOX) osteosarcoma (OS) Human osteosarcoma cell lines (Saos-2 and MG-63) ?doxorubicin (DOX) treatment upregulated 25009614 2910 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) osteosarcoma (OS) U2OS cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31669646 2911 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) osteosarcoma (OS) U2OS cells tumor necrosis factor alpha (TNF-¦Á) treatment TNF-¦Á upregulated the miR-155 expression in U2OS cells 31669646 2912 Human hsa-miR-155 miRNA gemcitabine (GEM) pancreatic cancer (PC) human pancreatic cancer PANC-1 cells gemcitabine (GEM) treatment upregulated 20871480 2913 Human hsa-miR-155 miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 2914 Human hsa-miR-155 miRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) "PDAC cell lines (Panc1, MiaPaCa2, and PSN1 cell lines)" long-term exposure of GEM upregulated 28198398 2915 Human hsa-miR-155 miRNA iodine-131 (131I) papillary thyroid cancer (PTC) TPC-1 cells; IHH-4 cells Radioiodine (131I) treatment CASC2 increases 131I sensitivity in PTC by sponging miR-155 33134385 2916 Human hsa-miR-155 miRNA sevoflurane (SEV) papillary thyroid cancer (PTC) Human PTC cell lines (TPC-1 and IHH-4) ?Sevoflurane treatment downregulated 31378899 2917 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) periodontitis THP-1 cells lipopolysaccharide (LPS) from porphyromonas gingivalis (Pg-LPS) treatment downregulated 30012943 2918 Human hsa-miR-155 miRNA Staphylococcus aureus post-viral bacterial pneumonia lung macrophages staphylococcus aureus (CA-MRSA) infection treatment upregulated 26589478 2919 Human hsa-miR-155 miRNA aspirin preeclampsia (PE) TNF-¦Á-mediated human umbilical vein endothelial cells (HUVECs) aspirin treatment downregulated 28087411 2920 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) preeclampsia (PE) HTR-8 cells;SVneo cells ?injection of lipopolysaccharides (LPS) upregulated 21515911 2921 Human hsa-miR-155 miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment downregulated 21093163 2922 Human hsa-miR-155 miRNA arsenite pro-inflammatory activity human hepatic epithelial (L-02) cells arsenic exposure upregulated 27913196 2923 Human hsa-miR-155 miRNA paclitaxel (PTX) prostate cancer DU145 and PC-3 cells paclitaxel treatment downregulated 28599307 2924 Human hsa-miR-155 miRNA methotrexate (MTX) psoriasis chronic plaque-type psoriasis patients PBMCs methotrexate (MTX) treatment downregulated in PBMCs 27535005 2925 Human hsa-miR-155 miRNA TGF-¦Â lung fibrosis human pulmonary fibroblasts TGF-¦Â treatment miR-155 expression was decreased in human pulmonary fibroblasts by TGF-¦Â treatment 31556264 2926 Human hsa-miR-155 miRNA porphyromonas gingivalis pyroptosis The immortalized human monocyte cell line U937 Porphyromonas gingivalis infection treatment upregulated 31529565 2927 Human hsa-miR-155 miRNA hypoxia renal fibrosis HK-2 cells Hypoxia treatment upregulated 25672593 2928 Human hsa-miR-155 miRNA tanshinone IIA (Tan IIA) renal fibrosis HCT116 cells; HT-29 cells TanshinoneIIA treatment upregulated 22982040 2929 Human hsa-miR-155 miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment upregulated 30080287 2930 Human hsa-miR-155 miRNA hypoxia/reoxygenation (H/R) renal ischemia/reperfusion (I/R) injury HK2 cells hypoxia/reoxygenation (H/R) treatment upregulated 28006785 2931 Human hsa-miR-155 miRNA particulate matter (PM2.5) respiratory injury human bronchial epithelial (HBE) cells "fine particulate matter (PM2.5, particles <2.5?¦Ìm in size) exposure treatment" upregulated 31185220 2932 Human hsa-miR-155 miRNA hepatitis C virus (HCV) rheumatoid arthritis (RA) serum hepatitis C virus (HCV) infection The exo-miR-155 levels were significantly increased in RA patients with HCV infection compared with those without infection 29575671 2933 Human hsa-miR-155 miRNA silibinin (SB) rheumatoid arthritis (RA) peripheral blood T lymphocytes silibinin treatment downregulated 30174672 2934 Human hsa-miR-155 miRNA TGF-¦Â rheumatoid arthritis (RA) RA fibroblast-like synoviocytes (FLS) 50 ng/mL of tumor necrosis factor alpha (TNF-¦Á) for 1 h treatment downregulated 28401267 2935 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) MH7A cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29693176 2936 Human hsa-miR-155 miRNA triptolide (TPL) rheumatoid arthritis (RA) monocytes pre-stimulated by lipopolysaccharide (LPS) from rheumatoid arthritis (RA) patients triptolide (TPL) treatment downregulated 24909288 2937 Human hsa-miR-155 miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 2938 Human hsa-miR-155 miRNA Salmonella Typhimurium salmonella typhimurium infection human HeLa cells Salmonella Typhimurium infection treatment upregulated 21468030 2939 Human hsa-miR-155 miRNA valproic acid (VPA) seizure cerebrospinal fluid (CSF) valproic acid (VPA) treatment downregulated 29115566 2940 Human hsa-miR-155 miRNA dexamethasone (DEX) septic shock T lymphocytes dexamethasone (DEX) treatment downregulated 28105104 2941 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) septic shock human internal mammary artery (hIMA) rings lipopolysaccharide (LPS) treatment upregulated 29979224 2942 Human hsa-miR-155 miRNA hydroxychloroquine systemic lupus erythematosus (SLE) "mesangial cells, T cells, pDCs, PBMCs, and the urine" hydroxychloroquine treatment "lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs." 24121037 2943 Human hsa-miR-155 miRNA prednisone systemic lupus erythematosus (SLE) "mesangial cells, T cells, pDCs, PBMCs, and the urine" prednisone treatment "lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs" 24121037 2944 Human hsa-miR-155 miRNA IFN-¦Á systemic lupus erythematosus (SLE) HUVECs IFN-¦Á treatment upregulated 28779021 2945 Human hsa-miR-155 miRNA thyroid stimulating hormone thyroid eye disease (TED) orbital fibroblasts (OFs) thyroid stimulating hormone treatment upregulated 31622470 2946 Human hsa-miR-155 miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) serum Mycobacterium tuberculosis (M.TB) treatment downregulated 28061948 2947 Human hsa-miR-155 miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) human primary dendritic cells (DC) ?Mycobacterium tuberculosis (Mtb) infection upregulated 29300789 2948 Human hsa-miR-155 miRNA IL-1¦Â tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC) interleukin (IL)-1¦Â treatment downregulated 29467762 2949 Human hsa-miR-155 miRNA inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) LPS-treated primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC) inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) treatment downregulated 29467762 2950 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC) lipopolysaccharide (LPS) treatment upregulated 29467762 2951 Human hsa-miR-155 miRNA lipopolysaccharide (LPS) type 2 diabetes mellitus (T2DM) peripheral blood mononuclear cells (PBMC) lipopolysaccharide (LPS) treatment downregulated 23616185 2952 Human hsa-miR-155 miRNA propofol (PPF) unilateral ureteral obstruction (UUO) HK-2 cells HK-2 cells treatment downregulated 27158339 2953 Human hsa-miR-155 miRNA alprostadil uremia peripheral blood alprostadil treatment downregulated 26267685 2954 Human hsa-miR-155 miRNA palmitate vascular endothelial cell injury human umbilical vein endothelial cells (HUVECs) palmitate treatment downregulated 31485611 2955 Human hsa-miR-155 miRNA adrenaline vascular injury HT29 cells adrenaline treatment upregulated 23036199 2956 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) vascular injury human endothelial tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 24769202 2957 Human hsa-miR-155 miRNA everolimus waldenstrom macroglobulinemia Primary Waldenstrom macroglobulinemia cells Everolimus treatment downregulated 23048077 2958 Human hsa-miR-155 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment upregulated 21030878 2959 Human hsa-miR-155 miRNA hypoxia autophagy CNE cells ;HeLa cells hypoxia treatment upregulated 24262949 2960 Human hsa-miR-155 miRNA IL-10 breast cancer human bronchial epithelial cells (hBECs) IL-10 treatment downregulated 23967196 2961 Human hsa-miR-155 miRNA IL-4 cell differentiation human embryonic stem cells IL-4 ? treatment downregulated 21388667 2962 Human hsa-miR-155 miRNA IL-1¦Â epithelial-mesenchymal transition (EMT) lung fibroblasts IL-1¦Â treatment upregulated 19701459 2963 Human hsa-miR-155 miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) lung fibroblasts ?TGF-¦Â? treatment downregulated 19701459 2964 Human hsa-miR-155 miRNA tumor necrosis factor alpha (TNF-¦Á) epithelial-mesenchymal transition (EMT) lung fibroblasts tumor necrosis factor alpha (TNF-¦Á) treatment up regulation 19701459 2965 Human hsa-miR-155 miRNA type I interferon (IFN) hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) type I interferon (IFN) treatment upregulated 23650597 2966 Human hsa-miR-155* miRNA mycobacterium tuberculosis (Mtb) active tuberculosis (ATB) PBMCs (peripheral blood mononuclear cells) Mycobacterium tuberculosis (MTB) infection upregulated 22037148 2967 Human hsa-miR-155* miRNA lipopolysaccharide (LPS) B-cell lymphomas HTR-8/SVneo cells lipopolysaccharide (LPS)? treatment upregulated 23684381 2968 Human hsa-miR-155* miRNA interferon regulatory factor 3 (IRF3) inflammation primary human astrocytes Interferon regulatory factor 3 (IRF3) treatment downregulated 22170100 2969 Human hsa-miR-155-2 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human thyroid infect with HHV-6A downregulated 28081700 2970 Human hsa-miR-155-3p miRNA lithium (Li) bipolar disorder (BD) lymphoblastoid cell lines Lithium treatment dysregulated 31801218 2971 Human hsa-miR-155-3p miRNA lipopolysaccharide (LPS) innate immune response primary human monocyte-derived macrophages (1¡ãMDMs) lipopolysaccharide (LPS) treatment upregulated 31641696 2972 Human hsa-miR-155-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" mantle cell lymphoma (MCL) MCL cell line (REC-1) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25211095 2973 Human hsa-miR-155-3p miRNA "RESMENA (reduction of metabolic syndrome in Navarra, Spain)" metabolic syndrome MetS patients white blood cells (WBC) RESMENA treatment "miR-155-3p was decreased ,miR-Let-7b was strongly upregulated in white blood cells (WBC)" 26421388 2974 Human hsa-miR-155-3p miRNA polystyrene (PSNPs) toxicity of nanoparticles THP-1 cells polystyrene (PSNPs) treatment downregulated 32284792 2975 Human hsa-miR-155-5p miRNA H2O2 abdominal aortic aneurysm (AAA) vascular smooth muscle cells (VSMCs) H2O2 treatment upregulated 30898623 2976 Human hsa-miR-155-5p miRNA NaAsO2 abdominal aortic aneurysm (AAA) vascular smooth muscle cells (VSMCs) NaAsO2 treatment upregulated 30898623 2977 Human hsa-miR-155-5p miRNA prednisolone active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) prednisolone treatment downregulated 24215168 2978 Human hsa-miR-155-5p miRNA tumor necrosis factor alpha (TNF-¦Á) atopic dermatitis (AD) HaCaT cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31767859 2979 Human hsa-miR-155-5p miRNA lipopolysaccharide (LPS) bronchopneumonia BEAS-2B cells lipopolysaccharide (LPS) treatment "NEAT1 and MyD88 were upregulated in BEAS-2B cells by LPS, while miR-155-5p was downregulated." 33719773 2980 Human hsa-miR-155-5p miRNA oxalate and calcium calcium oxalate (CaOx) stone HK-2 cells Oxalate and calcium treatment miR-155-5p was significantly upregulated after oxalate and COM treated in HK-2 cells. 32215174 2981 Human hsa-miR-155-5p miRNA (-)-epigallocatechin gallate (EGCG) colorectal cancer (CRC) "human colon carcinoma cell line-HCT-116, DLD1" (-)-Epigallocatechin gallate (EGCG) treatment upregulated 30741544 2982 Human hsa-miR-155-5p miRNA enterotoxigenic bacteroides fragilis (ETBF) colorectal cancer (CRC) HCT-116 and DLD-1 cells Enterotoxigenic Bacteroides fragilis (ETBF) infection downregulated 31515468 2983 Human hsa-miR-155-5p miRNA dengue virus (DENV) dengue virus (DENV) infection human monocyte-derived macrophages (MDM) differentiated in absence or presence of vitamin D (D3-MDM) dengue virus (DENV) infection vitamin D in the control of inflammatory cytokine responses during DENV infection of human macrophages via the TLR4/NF-¦ÊB/miR-155-5p/SOCS-1 axis 30639520 2984 Human hsa-miR-155-5p miRNA high glucose (HG) diabetic nephropathy (DN) human glomerular mesangial cells (HGMCs) high glucose (HG) treatment "CTBP1-AS2 attenuated HG-induced HGMC proliferation, oxidative stress, ECM accumulation, and inflammation through miR-155-5p/FOXO1 signaling." 32868076 2985 Human hsa-miR-155-5p miRNA BAY11-7082 EBV-associated gastric cancer (EBVaGC) GT39 cells NF-¦ÊB inhibitor (BAY 11-7082) treatment downregulated 31469179 2986 Human hsa-miR-155-5p miRNA epstein-barr virus (EBV) EBV-associated gastric cancer (EBVaGC) SGC7901 cells EBV-encoded latent membrane protein 2A (LMP2A) treatment upregulated 31469179 2987 Human hsa-miR-155-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal cancer (EC) KYSE-30 cells; KYSE-140 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" miR-155-5p was upregulated in the indicated ESCC cell lines following treatment with 5-aza-dC for 72 h. 32323857 2988 Human hsa-miR-155-5p miRNA epstein-barr virus (EBV) gastric cancer (GC) GT38 cells; GT39 cells; SNU719 cells Epstein-Barr virus (EBV) infection The expression level of miR-155-5p in the EBV-positive cell lines was significantly higher than that in the EBV-negative cell lines 31469179 2989 Human hsa-miR-155-5p miRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) serum Enterovirus 71 (EV71) infection microRNA-155-5p (miR-155-5p) was found to be significantly upregulated in serum from patients with EV71 infection. 31856677 2990 Human hsa-miR-155-5p miRNA R-pulegone (PUL) hepatotoxicity liver tissues R-pulegone (PUL) treatment downregulated 29921785 2991 Human hsa-miR-155-5p miRNA olive oil polyphenol hydroxytyrosol (HT) inflammation TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes olive oil polyphenol hydroxytyrosol (HT) treatment downregulated 31627295 2992 Human hsa-miR-155-5p miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31627295 2993 Human hsa-miR-155-5p miRNA carbon monoxide-releasing compound CORM-2 inflammatory vascular disorders TNF-¦Á-stimulated HUVECs 200?¦Ìm CORM-2 treatment downregulated 29170479 2994 Human hsa-miR-155-5p miRNA enterovirus 71 (EV71) innate immune response "serum from patients with EV71 infection, Vero, RD, HT-29, HeLa, and THP-1 cells" Enterovirus 71 (EV71) infection upregulated 31856677 2995 Human hsa-miR-155-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) SH-SY5Y Cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment MiR-155-5p was upregulated in OGD/R-induced SH-SY5Y cells. 32096190 2996 Human hsa-miR-155-5p miRNA cigarette smoke (CS) lung cancer NCI-H292 cells cigarette smoke (CS) treatment "upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)" 28692419 2997 Human hsa-miR-155-5p miRNA "OTX015 (MK-8628, birabresib)" lymphomagenesis DOHH-2 cells; OCI-LY-1 cells OTX015 treatment OTX015 upregulates miR-96-5p in a time-dependent manner. 30076183 2998 Human hsa-miR-155-5p miRNA X-rays non-small cell lung cancer (NSCLC) Human NSCLC A549 and H460 cells "cells were irradiated using experimental X-ray irradiator (Gulmay Medical Inc., Atlanta, GA, xstrahl.com) at a rate of 2.4 Gy/min for the time required treatment" upregulated 30901121 2999 Human hsa-miR-155-5p miRNA oleacein (OA) obesity TNF-¦Á-treated Simpson-Golabi-Behmel syndrome (SGBS) adipocytes oleacein (OA) treatment downregulated 31766503 3000 Human hsa-miR-155-5p miRNA oleocanthal (OC) obesity TNF-¦Á-treated Simpson-Golabi-Behmel syndrome (SGBS) adipocytes oleocanthal (OC) treatment downregulated 31766503 3001 Human hsa-miR-155-5p miRNA tumor necrosis factor alpha (TNF-¦Á) obesity Simpson-Golabi-Behmel syndrome (SGBS) adipocytes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31766503 3002 Human hsa-miR-155-5p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-10¦Â treatment dysregulated 29123165 3003 Human hsa-miR-155-5p miRNA cisplatin (DDP) ovarian cancer (OC) human ovarian cancer cells OVCAR-8R cisplatin treatment dysregulated 28861582 3004 Human hsa-miR-155-5p miRNA mono-(2-ethylhexyl) phthalate (MEHP) oxidative stress HTR-8/SVneo cell line mono-(2-ethylhexyl) phthalate (MEHP) treatment upregulation 26871967 3005 Human hsa-miR-155-5p miRNA sulforaphane (SFN) pancreatic cancer (PC) Monocyte-Derived Dendritic Cells sulforaphane (SFN) treatment upregulated 33193420 3006 Human hsa-miR-155-5p miRNA porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS) periodontitis The exosomes were extracted from periodontal ligament stem cells (PDLSCs) Porphyromonas gingivalis lipopolysaccharide (LPS) treatment downregulated 31016751 3007 Human hsa-miR-155-5p miRNA selenium nanoparticles (SeNPs) prostate cancer LNCaP cells; LNCaP-A cells Selenium nanoparticles (SeNPs) treatment upregulated 33604641 3008 Human hsa-miR-155-5p miRNA radiation radiation-induced pulmonary fibrosis (RIPF) BEAS-2B cells radiation treatment adiation downregulates miR-155-5p in alveolar epithelial cells that induces EMT 33259794 3009 Human hsa-miR-155-5p miRNA radiation radiation-induced pulmonary fibrosis (RIPF) A549 cells; BEAS-2B cells radiation treatment we found that miR-155-5p was significantly downregulated through high-throughput sequencing 33259794 3010 Human hsa-miR-155-5p miRNA methotrexate (MTX) rheumatoid arthritis (RA) whole-blood methotrexate (MTX) treatment downregulated 30511295 3011 Human hsa-miR-155-5p miRNA methotrexate (MTX) rheumatoid arthritis (RA) RA patients whole-blood methotrexate (MTX) treatment upregulated 30511295 3012 Human hsa-miR-155-5p miRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) Fibroblast-like synoviocytes (FLSs) tumor necrosis factor alpha (TNF-¦Á) treatment LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-¦Á 32289665 3013 Human hsa-miR-155-5p miRNA Korean Red ginseng extract (KRGE) cell senescence human umbilical vein endothelial cells (HUVECs) Korean Red ginseng extract (KRGE) treatment "miR-155-5p levels were increased in senescent HUVECs compared to young cells, and this increase was blocked by KRGE." 33841015 3014 Human hsa-miR-155-5p miRNA nuclear factor kappa-B (NF-¦ÊB) inhibitor Bay11-708211 cell senescence human umbilical vein endothelial cells (HUVECs) NF-kB inhibitor Bay11-708211 treatment "miR-155-5p levels were increased in senescent HUVECs compared to young cells, and this increase was blocked by the NF-kB inhibitor Bay11-708211." 33841015 3015 Human hsa-miR-155-5p miRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) rheumatoid synovial fibroblasts (RASFs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 28807007 3016 Human hsa-miR-155-5p miRNA ARS labeled titanium dioxide nanoparticles (nano-TiO 2-ARS) toxicity of nanoparticles THP-1 cells ARS labeled Titanium dioxide nanoparticles (nano-TiO 2-ARS) treatment downregulated 32284792 3017 Human hsa-miR-155-5p miRNA polystyrene (PSNPs) toxicity of nanoparticles THP-1 cells polystyrene (PSNPs) treatment downregulated 32284792 3018 Human hsa-miR-155-5p miRNA bufalin triple negative breast cancer (TNBC) MDA-MB-231 and MCF-7/ADR TNBC cell lines bufalin treatment upregulated 26398931 3019 Human hsa-miR-155-5p miRNA Indoxyl sulfate (IS) vascular calcification (VC) human aortic smooth muscle cells (HASMCs) Indoxyl sulfate (IS) treatment upregulated 32979364 3020 Human hsa-miR-155-5p miRNA Korean Red ginseng extract (KRGE) vascular disease human umbilical vein endothelial cells (HUVECs) korean red ginseng extract (KRGE)? treatment The beneficial effects of KRGE were due to the induction of HO-1 and the inhibition of NF-¦ÊB-dependent biogenesis of miR-155-5p that led to the downregulated of eNOS. 33841015 3021 Human hsa-miR-155a miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) hepatitis C virus (HCV) infection miR-155a expression was upregulated in HCV-infected PBMC. 31696995 3022 Human hsa-miR-155a miRNA chuyou yuyang granule (CYYY) ulcer relapse Helicobacter pylori (HP) infected Peptic ulcert patients blood Chuyou Yuyang granule (CYYY) four weeks or six weeks treatment downregulated 31034651 3023 Human hsa-miR-1587 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 3024 Human hsa-miR-1587 miRNA botulinum toxin A (BTXA) keloids human skin keloid fibroblasts (HSFBs) botulinum toxin A (BTXA) treatment upregulated 31652445 3025 Human hsa-miR-15a miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 3026 Human hsa-miR-15a miRNA statins active hepatitis or cirrhosis HepG2 cells statins? treatment upregulated 26429200 3027 Human hsa-miR-15a miRNA recombinant tissue plasminogen activator (rt-PA) acute ischemic stroke (AIS) AIS patients blood samples rt-PA treatment upregulation of let-7i and downregulated of miR-15a 28892656 3028 Human hsa-miR-15a miRNA prednisolone acute lymphoblastic leukemia (ALL) CCRF-CEM cell line Prednisolone treatment upregulated 27281445 3029 Human hsa-miR-15a miRNA resveratrol acute lymphoblastic leukemia (ALL) CCRF-CEM cells resveratrol (RS) treatment upregulated 26434860 3030 Human hsa-miR-15a miRNA H2O2 age-related cataract (ARC) "human lens epithelial B3 cells, HLE-B3 cells" H2O2 treatment upregulated 31737898 3031 Human hsa-miR-15a miRNA BL-8040 apoptosis human acute myeloid leukemia (AML) blasts BL-8040 treatment upregulated 28280274 3032 Human hsa-miR-15a miRNA aloe-emodin (AE) breast cancer MCF-10AT cells; MCF-7 cells aloe-emodin (AE) treatment upregulated 32190086 3033 Human hsa-miR-15a miRNA bleomycin (BLM) breast cancer human breast cancer cell lines MCF-7 cells and/or MDA-MB-231 cells bleomycin (BLM) treatment upregulated 28337296 3034 Human hsa-miR-15a miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin (diferuloylmethane)? treatment upregulated 19908170 3035 Human hsa-miR-15a miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment upregulated 29189128 3036 Human hsa-miR-15a miRNA silibinin (SB) breast cancer T47D breast cancer cell line silibinin treatment "upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)" 28509572 3037 Human hsa-miR-15a miRNA tripterine breast cancer MDA-MB-231 cells Tripterine treatment upregulated 30913029 3038 Human hsa-miR-15a miRNA IL-23 cardiomyocyte apoptosis B-acute lymphoblastic leukemia cells IL-23 treatment upregulated 20671120 3039 Human hsa-miR-15a miRNA doxorubicin (DOX) chemoresistance of lymphoma Daudi and Namalwa cells doxorubicin treatment MCM3AP-AS1/miR-15a/EIF4E axis plays a role in the chemoresistance of Burkitt lymphoma 32765087 3040 Human hsa-miR-15a miRNA imatinib chronic myeloid leukemia (CML) CML patients imatinib (IM) treatment differently regulated 24629639 3041 Human hsa-miR-15a miRNA taxol colorectal cancer (CRC) HCT116 cells taxol treatment downregulated 30126852 3042 Human hsa-miR-15a miRNA high glucose (HG) diabetic retinopathy (DR) Primary human retinal endothelial cells (REC) high glucose (HG) treatment downregulated 29339083 3043 Human hsa-miR-15a miRNA resveratrol diabetic retinopathy (DR) high glucose-treated primary human retinal endothelial cells (REC) resveratrol (RSV) treatment upregulated 29339083 3044 Human hsa-miR-15a miRNA D-glucose epithelial-mesenchymal transition (EMT) peritoneal mesothelial cells (PMCs) D-glucose treatment downregulated 25683944 3045 Human hsa-miR-15a miRNA H2O2 gastric cancer (GC) HGC-27 cells H2O2 treatment upregulated 33329376 3046 Human hsa-miR-15a miRNA Helicobacter pylori (H. pylori) extract (HPE) gastric cancer (GC) HGC-27 cells Helicobacter pylori (H. pylori) infection upregulated 33065487 3047 Human hsa-miR-15a miRNA valproic acid (VPA) hematopoietic differentiation hematopoietic stem cells (HSCs) VPA treatment different regulation 25241289 3048 Human hsa-miR-15a miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells hepatitis B virus (HBV) infection downregulated 30103211 3049 Human hsa-miR-15a miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells; HepG2.2.15 cells; human normal liver cell line L-02 hepatitis B virus (HBV) infection upregulated 24089558 3050 Human hsa-miR-15a miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 3051 Human hsa-miR-15a miRNA curcumin (Cur) laryngeal cancer human laryngeal cancer cells curcumin treatment upregulated 29085504 3052 Human hsa-miR-15a miRNA curcumin (Cur) leukemia primary acute myeloid leukemia (AML) cells Pure curcumin treatment downregulated 22449094 3053 Human hsa-miR-15a miRNA bortezomib multiple myeloma (MM) The human multiple myeloma cell lines U266 and NCI-H929 bortezomib? treatment "via suppressing miRNA-15a expression, BMSCs provide survival support and protect myeloma cells from bortezomib induced apoptosis" 21534877 3054 Human hsa-miR-15a miRNA IL-6 multiple myeloma (MM) bone marrow mesenchymal stem cells(BMSCs) interleukin-6 (IL-6) treatment "via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells" 21936961 3055 Human hsa-miR-15a miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 3056 Human hsa-miR-15a miRNA hypoxia osteosarcoma (OS) MG63 human osteosarcoma cell line hypoxia induce downregulated 29484432 3057 Human hsa-miR-15a miRNA lipopolysaccharide (LPS) pneumonia Human lung bronchial epithelial cell line BEAS-2B lipopolysaccharide (LPS) treatment upregulated 29710526 3058 Human hsa-miR-15a miRNA xianyu decoction (XD) pneumonia LPS-treated human lung bronchial epithelial cell line BEAS-2B Xianyu decoction (XD) treatment downregulated 29710526 3059 Human hsa-miR-15a miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment downregulated 21093163 3060 Human hsa-miR-15a miRNA protein kinase C (PKC) ¦Á renal cell carcinoma (RCC) "renal clear-cell carcinoma cells,CP renal carcinoma cells, renal papillary cell carcinoma cells, renal oncocytoma cells and Normal renal tissue cells" protein kinase C (PKC) ¦Á treatment upregulated 22429968 3061 Human hsa-miR-15a miRNA running telomere homeostasis twenty-two healthy males white blood cells undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment upregulated 24752326 3062 Human hsa-miR-15a miRNA Roux-en-Y gastric bypass (RYGB) weight loss obese subjects without exercise program plasma RYGB treatment dysregulatedin plasma 28344345 3063 Human hsa-miR-15a miRNA retinoic acid (RA) epithelial-mesenchymal transition (EMT) NB4 cells£» HL-60U937 cells£»primary leukemic cells retinoic acid treatment upregulated 21838537 3064 Human hsa-miR-15a-5p miRNA IL-13 allergic rhinitis (AR) Human primary nasal epithelial cells (NECs) IL-13 treatment downregulated 31104300 3065 Human hsa-miR-15a-5p miRNA IL-13 allergic rhinitis (AR) Human nasal epithelial cells (HNECs) IL-13 treatment knockdown of ANRIL may suppress the production of inflammatory cytokines and mucin in IL-13-treated HNECs via regulation of the miR-15a-5p/JAK2 axis. 33325534 3066 Human hsa-miR-15a-5p miRNA IL-13 allergic rhinitis (AR) Human nasal epithelial cells (HNECs) IL-13 treatment "The expression levels of ANRIL and JAK2 were also upregulated in IL-13-induced HNECs, while the expression levels of miR-15a-5p were downregulated." 33325534 3067 Human hsa-miR-15a-5p miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment downregulated 26397152 3068 Human hsa-miR-15a-5p miRNA advanced glycation end product (AGE) long-term peritoneal dialysis (PD) ultrafiltration failure human peritoneal mesothelial cells (HPMCs) advanced glycation end (AGE) product treatment downregulated 30362573 3069 Human hsa-miR-15a-5p miRNA high glucose (HG) long-term peritoneal dialysis (PD) ultrafiltration failure human peritoneal mesothelial cells (HPMCs) high glucose (HG) treatment downregulated 30362573 3070 Human hsa-miR-15a-5p miRNA advanced glycation end product (AGE) long-term peritoneal dialysis (PD) ultrafiltration failure human peritoneal mesothelial cells (HPMCs) advanced glycation end (AGE) product treatment downregulated 30362573 3071 Human hsa-miR-15a-5p miRNA high glucose (HG) long-term peritoneal dialysis (PD) ultrafiltration failure human peritoneal mesothelial cells (HPMCs) high glucose treatment downregulated 30362573 3072 Human hsa-miR-15a-5p miRNA azacitidine (AZA) myelodysplastic syndrome (MDS) bone marrow CD34+ cells azacitidine (AZA) treatment downregulated 29630523 3073 Human hsa-miR-15a-5p miRNA simvastatin apoptosis Myocardial tissue biopsies Simvastatin treatment downregulated 29985281 3074 Human hsa-miR-15b miRNA paeoniflorin breast cancer MCF-7/4-hydroxytamoxifen (4-OHT) paeoniflorin (Pae) treatment downregulated 33519190 3075 Human hsa-miR-15b miRNA lipopolysaccharide (LPS) graft-versus-host disease (GVHD) Cord blood (CB) lipopolysaccharide (LPS) treatment upregulated 21913990 3076 Human hsa-miR-15b miRNA glucocorticoid (GC) acute lymphoblastic leukemia (ALL) human T-ALL cell Glucocorticoids (GCs) treatment downregulated 19148136 3077 Human hsa-miR-15b miRNA Korean Red ginseng extract (KRGE) angiogenesis HUVECs korean red ginseng extract (KRGE)? treatment downregulated 29021694 3078 Human hsa-miR-15b miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 3079 Human hsa-miR-15b miRNA hyperthermia breast cancer BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231 Hyperthermia treatment downregulated 27380148 3080 Human hsa-miR-15b miRNA ketogenic cell differentiation adipogenic induced stem cells Ketorolac treatment upregulated 29101812 3081 Human hsa-miR-15b miRNA triamcinolone cell differentiation hepatic induced stem cells triamcinolone treatment upregulated 29101812 3082 Human hsa-miR-15b miRNA high glucose (HG) diabetic retinopathy (DR) retinal endothelial cells (REC) high-glucose treatment downregulated 25888955 3083 Human hsa-miR-15B miRNA alcohol gastric cancer (GC) HEK293T cells;SH SY5Y cells;1321 N1 cells ?alcohol? treatment upregulated 24961422 3084 Human hsa-miR-15b miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 3085 Human hsa-miR-15b miRNA propofol (PPF) hypoxia/reoxygenation (H/R) injury human umbilical vein endothelial cells(HUVECs) propofol treatment miR-15b was downregulated in propofol-treated group 24454982 3086 Human hsa-miR-15b miRNA geniposide (GEN) inflammation and apoptosis Human umbilical vein endothelial cells (HUVECs) ginsenosides treatment upregulated 21872652 3087 Human hsa-miR-15b miRNA morphine inflammation and oxidative stress peripheral blood mononuclear cells (PBMCs) Morphine treatment upregulated 20564181 3088 Human hsa-miR-15b miRNA epigallocatechin-3-gallate (EGCG) inflammation human Jurkat E6.1 Cell Line 10 ¦ÌM EGCG upregulated 27851983 3089 Human hsa-miR-15b miRNA IL-1¦Â intervertebral disc degeneration (IDD) human nucleus pulposus cells IL-1¦Â treatment upregulated 28039556 3090 Human hsa-miR-15b miRNA IL-1¦Â intervertebral disc degeneration (IDD) NP cells IL-1¦Â treatment upregulated 28039556 3091 Human hsa-miR-15b miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment ?The expression of miR-15bwas decreased in TGF-¦Â1-stimulated LX-2 cells 33545201 3092 Human hsa-miR-15b miRNA dexamethasone (DEX) miRNA biogenesis human endothelial cells dexamethasone (Dex) treatment downregulated 28523344 3093 Human hsa-miR-15b miRNA ginsenoside Rg1 miRNA biogenesis human endothelial cells ginsenoside-Rg1 treatment downregulated 28523344 3094 Human hsa-mir-15b miRNA Copper(II) complex of quercetin Cu+Q osteogenesis and angiogenesis human osteoblast-like cells (MG-63) Cu+Q(Neo) upregulated 29208278 3095 Human hsa-miR-15b miRNA lipopolysaccharide (LPS) placentation HTR-8/SVneo cell lipopolysaccharides (LPS) treatment upregulated 27208409 3096 Human hsa-miR-15b miRNA ionizing radiation (IR) radiation-induced lung disease human bronchial epithelial cells IR treatment expression was highest after 2 h of IR and downregulated gradually 25092292 3097 Human hsa-miR-15b miRNA ketogenic cell differentiation adipogenic induced stem cells Ketorolac treatment upregulated 29101812 3098 Human hsa-miR-15b miRNA low-dose ionizing radiation (LDIR) stress response human Epstein-Barr virus-infected B-cells (EBV-B) low-dose ionizing radiation (LDIR) treatment upregulated 26809544 3099 Human hsa-miR-15b* miRNA leuprolide endometriosis endometriotic tissues Leuprolide treatment upregulated 27709720 3100 Human hsa-miR-15b-3p miRNA microcystin-leucine arginine (MC-LR) hepatotoxicity human normal liver cell line HL7702 "treatment with MC-LR at concentrations of 1, 2.5, 5 or 10 ¦ÌM" upregulated 29265921 3101 Human hsa-miR-15b-3p miRNA microcystin-leucine arginine (MC-LR) MC-LR-induced hepatotoxicity human normal liver cell line HL7702 icrocystin-LR (MC-LR) treatment upregulated 29265921 3102 Human hsa-miR-15b-3p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 3103 Human hsa-miR-15b-5p miRNA benzyl butyl phthalate (BBP) acute myeloid leukemia (AML) "The human acute monocytic leukemia AML U937 (isolated from the histiocytic lymph), Raji (lymphoblast Burkitt's lymph), and HL-60 (a promyelocytic cell line) cell lines" benzyl butyl phthalate (BBP) treatment downregulated 31629899 3104 Human hsa-miR-15b-5p miRNA benzyl butyl phthalate (BBP) acute Myeloid Leukemia (AML) U937 cells benzyl butyl phthalate (BBP) treatment BBP can decrease the expression of miR-15b-5p in AML cells. 31629899 3105 Human hsa-miR-15b-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 3106 Human hsa-miR-15b-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment downregulated 30842352 3107 Human hsa-miR-15b-5p miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis 33298110 3108 Human hsa-miR-15b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) human SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated lncRNA SNHG1 promotes MPP+ -induced cytotoxicity and ROS production through the miR-15b-5p/GSK3¦Â axis in human dopaminergic SH-SY5Y cells 30302821 3109 Human hsa-miR-15b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment downregulated 29217406 3110 Human hsa-miR-15b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment downregulated 29217406 3111 Human hsa-miR-15b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment downregulated 30302821 3112 Human hsa-miR-15b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment miR-15b-5p level was nota- bly reduced in MPP+-challenged SK-N-SH cells in dose- and time-dependent patterns 33208053 3113 Human hsa-miR-15b-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells. 33208053 3114 Human hsa-miR-15b-5p miRNA activin A prostate cancer LNCaP cells activin A treatment downregulated 27018851 3115 Human hsa-miR-15b-5p miRNA dexamethasone (DEX) steatosis HepG5 cells dexamethasone (Dex) treatment downregulated 29409992 3116 Human hsa-miR-15b-5p miRNA dexamethasone (DEX) steatosis ?HepG2 cell lines dexamethasone (DEX) treatment "ENST00000608794 plays an important role in dexamethasone induced steatosis, which was partly mediated by derepressing of PDK4 through competitively binding to miR-15b-5p." 31330194 3117 Human hsa-miR-15b-5p miRNA arsenite tumorigenesis human bronchial epithelial (HBE) cells arsenic exposure "upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)" 28972549 3118 Human hsa-miR-16 miRNA hyperoxia acute lung injury (ALI) primary human alveolar type II epithelial cells (AECII) hyperoxia induce downregulated 29484411 3119 Human hsa-miR-16 miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment downregulated 30784935 3120 Human hsa-miR-16 miRNA glucocorticoid (GC) acute lymphoblastic leukemia (ALL) human T-ALL cell Glucocorticoids (GCs) treatment downregulated 19148136 3121 Human hsa-miR-16 miRNA granulocyte-macrophage colony stimulating factor (GM-CSF) acute myeloid leukemia (AML) "human myeloid leukemic cell line, AML-193" GM-CSF treatment downregulated 22015065 3122 Human hsa-miR-16 miRNA IL-13 allergic rhinitis (AR) human nasal epithelial cells (JME/CF15) IL-13 treatment Interleukin (IL)-13 stimulation gradually decreased the levels of miR-16 in JME/CF15 cells. 30132525 3123 Human hsa-miR-16 miRNA cisplatin (DDP) apoptosis K562 cells cisplatin treatment upregulated 20428827 3124 Human hsa-miR-16 miRNA epigallocatechin-3-gallate (EGCG) apoptosis human hepatocellular carcinoma HepG2 cells Epigallocatechin gallate (EGCG)?treatment upregulated 19269153 3125 Human hsa-miR-16 miRNA puerarin bladder cancer T24 cells Puerarin treatment upregulated 29422113 3126 Human hsa-miR-16 miRNA estradiol breast cancer MCF-7 cells estradiol (E?) treatment "E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells" 22260523 3127 Human hsa-miR-16 miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment upregulated 29189128 3128 Human hsa-miR-16 miRNA dacarbazine and interferon-alfa-2b breast cancer circulating endothelial cells dacarbazine and interferon-alfa-2b treatment Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a 23217102 3129 Human hsa-miR-16 miRNA hesperidin breast cancer MCF-7 cells hesperidin treatment upregulated 33050842 3130 Human hsa-miR-16 miRNA lipopolysaccharide (LPS) breast cancer human neonatal cardiomyocytes lipopolysaccharide (LPS) treatment downregulated 32369253 3131 Human hsa-miR-16 miRNA luteolin breast cancer MCF-7 cells luteolin treatment upregulated 33050842 3132 Human hsa-miR-16 miRNA microsciadia breast cancer MDA-MB-231 cells microsciadia treatment upregulated 32603285 3133 Human hsa-miR-16 miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment upregulated 20346162 3134 Human hsa-miR-16 miRNA VEGF or basic fibroblast growth factor (bFGF) tumorigenesis endothelial vascellum VEGF or basic fibroblast growth factor (bFGF) treatment upregulated 21885851 3135 Human hsa-miR-16 miRNA bothrops moojeni snake venom (BmooLAAO-I) chronic myeloid leukemia (CML) "Bcr-Abl+ cell lines (HL-60.Bcr-Abl, K562-S, and K562-R)" bothrops moojeni snake venom (BmooLAAO-I) treatment upregulated 33354202 3136 Human hsa-miR-16 miRNA nilotinib chronic myeloid leukemia (CML) HL-60.BCR-ABL cells nilotinib (NIL) treatment differently regulated 24629639 3137 Human hsa-miR-16 miRNA Protein Arginine Deiminases (PADs) colorectal cancer (CRC) HCT 116 wild-type (WT) colon cancer cells Protein Arginine Deiminases (PADs)treatment treatment "p53-dependent G1 arrest associated with PAD inhibition was, in turn, dependent on miRNA-16 expression" 23308284 3138 Human hsa-miR-16 miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-16 was downregulated in resistant patients when compared with sensitive patients 33072545 3139 Human hsa-miR-16 miRNA high glucose (HG) diabetic retinopathy (DR) retinal endothelial cells (REC) high-glucose treatment downregulated 25888955 3140 Human hsa-miR-16 miRNA "2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)" endothelial cell injury human umbilical vein endothelial cells (HUVECs) "2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment" downregulated 33093269 3141 Human hsa-miR-16 miRNA nicotine gastric cancer (GC) Human gastric adenocarcinoma cells (AGS) Nicotine treatment "EP2 or EP4 siRNA or antagonists impaired the nicotine-mediated NF-kB activity, upregulation of miR-16 and miR-21 and cell proliferation." 21081469 3142 Human hsa-miR-16 miRNA osthole glioblastoma multiforme (GBM) "common glioma cell line, U87" osthole treatment upregulated 26082082 3143 Human hsa-miR-16 miRNA paeoniflorin glioblastoma multiforme (GBM) human glial cells Paeoniflorin (PF) treatment upregulated 25954855 3144 Human hsa-miR-16 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) Human glioblastoma cell lines (U-138MG and A172) Temozolomide (TMZ) treatment downregulated 26722459 3145 Human hsa-miR-16 miRNA valproic acid (VPA) hematopoietic differentiation hematopoietic stem cells (HSCs) VPA treatment different regulation 25241289 3146 Human hsa-miR-16 miRNA microcystin-leucine arginine (MC-LR) hepatitis HepG2 cells Microcystin-LR (MC-LR) treatment miR-16 may play a vital role in the cell cycle alteration of HepG2 cells after MC-LR exposure. 32066005 3147 Human hsa-miR-16 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells; HepG2.2.15 cells; human normal liver cell line L-02 hepatitis B virus (HBV) infection upregulated 24089558 3148 Human hsa-miR-16 miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) The human HepG2;SK-HEP-1; Huh7 HCC cell lines Hepatitis B virus X protein (HBx)?treatment downregulated 21629246 3149 Human hsa-miR-16 miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) serum hepatitis C virus (HCV) infection upregulated 29333940 3150 Human hsa-miR-16 miRNA lauric acid hepatocellular carcinoma (HCC) HepG2 cells lauric acid treatment upregulated 32156243 3151 Human hsa-miR-16 miRNA Pien Tze Huang (PZH) hepatocellular carcinoma (HCC) BEL-7402 HCC PZH treatment upregulated 29344256 3152 Human hsa-miR-16 miRNA sanguinarine hepatocellular carcinoma (HCC) "HepG2, Huh7, Hep3B cells" sanguinarine treatment "sanguinarine (SG), was capable of activating miR-16 in HCC cells with wildtype or mutated p53 expression but not in p53-deleted HCC cells" 31163195 3153 Human hsa-miR-16 miRNA fibroblast growth factor 4 (FGF4) hepatocyte differentiation primary ccultured human amniotic epithelial cells (AECs) FGF4 treatment upregulated 30753902 3154 Human hsa-miR-16 miRNA hepatocyte growth factor (HGF) hepatocyte differentiation primary ccultured human amniotic epithelial cells (AECs) HGF treatment upregulated 30753902 3155 Human hsa-miR-16 miRNA hepatitis C virus (HCV) liver cirrhosis liver hepatitis C virus (HCV) infection Serum miR-16 was significantly lower in HCC than in HCV patients (P = 0.033). 26133725 3156 Human hsa-miR-16 miRNA hepatitis C virus (HCV) liver fibrosis "liver cell line, QSG-7701" hepatitis C virus (HCV) infection upregulated 26071245 3157 Human hsa-miR-16 miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment ?The expression of miR-16 was decreased in TGF-¦Â1-stimulated LX-2 cells 33545201 3158 Human hsa-miR-16 miRNA quercetin lung adenocarcinoma (LUAD) lung adenocarcinoma A549 cells Quercetin treatment upregulated 26061016 3159 Human hsa-miR-16 miRNA particulate matter (PM2.5) lung cancer human non-small cell lung cancer cell line A549 chronic (five passages) PM2.5 exposure treatment downregulated 28846189 3160 Human hsa-miR-16 miRNA arctigenin mechanical trauma injury scratch-induced injury of human SH-SY5Y cells arctigenin (ARC) treatment upregulated 27389368 3161 Human hsa-miR-16 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" monocytic differentiation "HL60 cells," "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 31232026 3162 Human hsa-miR-16 miRNA IL-6 multiple myeloma (MM) bone marrow mesenchymal stem cells(BMSCs) interleukin-6 (IL-6) treatment "via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells" 21936961 3163 Human hsa-miR-16 miRNA autologous hematopoietic SCT(AHSCT) multiple sclerosis (MS) MS patients AHSCT treatment upregulated in T- and B-cell 25486582 3164 Human hsa-miR-16 miRNA nanocurcumin multiple sclerosis (MS) blood nanocurcumin treatment downregulated 30340096 3165 Human hsa-miR-16 miRNA hypoxia expression regulation ARPE-19 cells hypoxia downregulated 29237295 3166 Human hsa-miR-16 miRNA perfluorooctane sulfonic acid (PFOS) neurotoxicity SH-SY5Y human neuroblastoma cells Perfluorooctane sulfonate (PFOS) treatment downregulated 26649298 3167 Human hsa-miR-16 miRNA perfluorooctane sulfonic acid (PFOS) neurotoxicity SK-N-SH cells PFOS treatment upregulated 28441774 3168 Human hsa-miR-16 miRNA compound C nonalcoholic fatty liver disease (NAFLD) HepG2 cells compound C treatment downregulated 32143184 3169 Human hsa-miR-16 miRNA metformin (Met) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) metformin treatment downregulated 32143184 3170 Human hsa-miR-16 miRNA metformin (Met) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) metformin treatment upregulated 32143184 3171 Human hsa-miR-16 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) palmitic acid treatment downregulated 32143184 3172 Human hsa-miR-16 miRNA paclitaxel (PTX) non-small cell lung cancer (NSCLC) lung cancer cells Paclitaxel treatment downregulated 25435430 3173 Human hsa-miR-16 miRNA PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) non-small cell lung cancer (NSCLC) A549 cells PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) treatment upregulated 31411213 3174 Human hsa-miR-16 miRNA TGF-¦Â non-small cell lung cancer (NSCLC) "human NSCLC cell lines A549, NCI-H1299 and HCC827" TGF-¦Â treatment downregulated 29138833 3175 Human hsa-miR-16 miRNA quercetin oral cancer "Oral cancer cell line HSC-6, SCC-9" quercetin treatment upregulated 30639311 3176 Human hsa-miR-16 miRNA cisplatin (DDP) osteosarcoma (OS) "osteosarcoma cell lines (SAOS2, U2OS)" cisplatin (DPP) treatment "SNHG16 enhanced the cisplatin resistance in osteosarcoma cell lines, while miR-16 reversed this impact." 31427084 3177 Human hsa-miR-16 miRNA p-glycoprotein osteosarcoma (OS) HepG2 cells; SK-HEP-1 cells ;MiHa cells P-glycoprotein treatment upregulated 21336967 3178 Human hsa-miR-16 miRNA mono-(2-ethylhexyl) phthalate (MEHP) placental apoptosis HTR-8/SVneo cell line Mono-(2-ethylhexyl) phthalate treatment upregulated 26597031 3179 Human hsa-miR-16 miRNA mono-(2-ethylhexyl) phthalate (MEHP) placental apoptosis HTR-8/SVneo cell line Mono-(2-ethylhexyl) phthalate£¨MEHP£© treatment "our study demonstrates for the first time that MEHP induces miR-16, which in turn, alters BCL-2/BAX ratio leading to increased apoptosis." 26597031 3180 Human hsa-miR-16 miRNA selenium nanoparticles (SeNPs) prostate cancer LNCaP cells; LNCaP-A cells selenium nanoparticles (SeNPs) treatment upregulated 32357938 3181 Human hsa-miR-16 miRNA ionizing radiation (IR) radiation-induced intestinal fibrosis (RIF) human intestinal CCD-18Co fibroblasts cell lines;subepithelial SEMFs "Ionizing radiation (IR) was done with 6 MV photons, 8 Gy/min by a linear accelerator (Varian, America) at room temperature." downregulated 31262262 3182 Human hsa-miR-16 miRNA ketogenic cell differentiation adipogenic induced stem cells Ketorolac treatment upregulated 29101812 3183 Human hsa-miR-16 miRNA low-dose ionizing radiation (LDIR) stress response human Epstein-Barr virus-infected B-cells (EBV-B) low-dose ionizing radiation (LDIR) treatment upregulated 26809544 3184 Human hsa-miR-16 miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) serum Mycobacterium tuberculosis (M.TB) treatment upregulated 28061948 3185 Human hsa-miR-16 miRNA hypoxia expression regulation RPE-19 cells hypoxia treatment "After cultivating under hypoxia, the expression of microRNA-16 in ARPE-19 cells decreased." 29237295 3186 Human hsa-miR-16 miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin (diferuloylmethane)? treatment upregulated 19908170 3187 Human hsa-miR-16-1 miRNA prednisolone acute lymphoblastic leukemia (ALL) CCRF-CEM cell line Prednisolone treatment upregulated 27281445 3188 Human hsa-miR-16-1 miRNA resveratrol acute lymphoblastic leukemia (ALL) CCRF-CEM cells resveratrol (RS) treatment upregulated 26434860 3189 Human hsa-miR-16-1 miRNA triptolide (TPL) anastomotic fibrosis primary fibroblasts were obtained from strictured anastomosis tissue (SAT) samples triptolide (TPL) treatment downregulated 30942423 3190 Human hsa-miR-16-1 miRNA BL-8040 apoptosis human acute myeloid leukemia (AML) blasts BL-8040 treatment upregulated 28280274 3191 Human hsa-miR-16-1 miRNA aloe-emodin (AE) breast cancer MCF-10AT cells; MCF-7 cells aloe-emodin (AE) treatment upregulated 32190086 3192 Human hsa-miR-16-1 miRNA omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) colorectal cancer (CRC) HCT-116 cells Omega-3 fatty acid DHA treatment upregulated 29619114 3193 Human hsa-miR-16-1 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells hepatitis B virus (HBV) infection downregulated 30103211 3194 Human hsa-miR-16-1 miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 3195 Human hsa-miR-16-1 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 3196 Human hsa-miR-16-1 miRNA candida albicans (C. albicans) invasive candidiasis respiratory epithelial cells candida albicans infection upregulated 26313489 3197 Human hsa-miR-16-1 miRNA curcumin (Cur) leukemia primary acute myeloid leukemia (AML) cells Pure curcumin treatment downregulated 22449094 3198 Human hsa-miR-16-1 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 3199 Human hsa-miR-16-1 miRNA retinoic acid (RA) epithelial-mesenchymal transition (EMT) NB4 cells£» HL-60U937 cells£»primary leukemic cells retinoic acid treatment upregulated 21838537 3200 Human hsa-miR-16-1* miRNA triptolide (TPL) lymphocytic leukemia Molt-4 cells triptolide (TPL) treatment downregulated 21441948 3201 Human hsa-miR-16-1-3p miRNA particulate matter (PM2.5) hepatocellular carcinoma (HCC) human HCC cell line SMMC-7721 PM2.5 (particulate matter with an aerodynamic diameter less than 2.5 ¦Ìm) exposure treatment downregulated 31572802 3202 Human hsa-miR-16-2 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 3203 Human hsa-miR-16-2-3p miRNA glucocorticoid (GC) inflammatory bowel disease (IBD) serum Glucocorticoids (GCs) treatment downregulated 31938187 3204 Human hsa-miR-16-5p miRNA hypoxia/reoxygenation (H/R) acute myocardial infarction (AMI) AC16 cells hypoxia/re-oxygenation (H/R) treatment miR-16-5p was elevated in H/R-treated AC16 cells. 31870262 3205 Human hsa-miR-16-5p miRNA amyloid-¦Â (A¦Â) Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) treatment The expression levels of miR-16-5p and miR-19b-3p were reduced but BACE1 protein expression was enhanced in SH-SY5Y cells after treatment of amyloid ¦Â. 31876684 3206 Human hsa-miR-16-5p miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 3207 Human hsa-miR-16-5p miRNA bone morphogenetic protein 4 (BMP4) breast cancer breast epithelial cell line bone morphogenetic protein 4 (BMP4) treatment upregulated 26684238 3208 Human hsa-miR-16-5p miRNA bone morphogenetic protein 4 (BMP4) breast cancer BT-474 cell bone morphogenetic protein 4 (BMP4) treatment "four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment." 26684238 3209 Human hsa-miR-16-5p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment upregulated 31722571 3210 Human hsa-miR-16-5p miRNA ketogenic cell differentiation adipogenic induced stem cells Ketorolac treatment upregulated 29101812 3211 Human hsa-miR-16-5p miRNA etoposide (VP-16) cell senescence A549 and MCF-7 cells etoposide treatment downregulated 33141998 3212 Human hsa-miR-16-5p miRNA radiation cervical cancer (CC) SiHa cells; Hela cells radiation treatment miR-16-5p expression was low in radio-resistant CC cells 31872565 3213 Human hsa-miR-16-5p miRNA X-rays cervical cancer (CC) "Human cervical cancer cell lines (HeLa, C©\33A, CaSki, HeLa229, SiHa)" X-ray exposure treatment downregulated 31872565 3214 Human hsa-miR-16-5p miRNA resistin chondrosarcoma The human chondrosarcoma cell line JJ012 and SW1353 resistin treatment downregulated 30631040 3215 Human hsa-miR-16-5p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment downregulated 31722571 3216 Human hsa-miR-16-5p miRNA high glucose (HG) diabetic nephropathy (DN) human podocytes (HPDCs) high glucose (HG) treatment downregulated 31568645 3217 Human hsa-miR-16-5p miRNA melatonin gastric cancer (GC) BSG823 cells; SGC-7901 Melatonin treatment melatonin administration enhanced the expression of miR-16-5p. 29359963 3218 Human hsa-miR-16-5p miRNA tanshinone IIA (Tan IIA) glioblastoma multiforme (GBM) T98G cells; A172 cells Tanshinone IIA (TIIA) treatment "TIIA induced anti-glioma role, wherein miR-16-5p was upregulated" 33192091 3219 Human hsa-miR-16-5p miRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells and human astrocytoma (CCF-STTG1) cells infect with EV71 upregulated 29180670 3220 Human hsa-miR-16-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Bel7404; HepG2 cells sorafenib treatment LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1 33378944 3221 Human hsa-miR-16-5p miRNA silybin hepatoprotective HepG2 cells Silybin treatment upregulated 31058823 3222 Human hsa-miR-16-5p miRNA etoposide (VP-16) lung adenocarcinoma (LUAD) human senescent cells etoposide treatment ?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells. 33141998 3223 Human hsa-miR-16-5p miRNA lipopolysaccharide (LPS) lung cancer A549 cells lipopolysaccharides (LPS) treatment downregulated 30957556 3224 Human hsa-miR-16-5p miRNA anti-programmed cell death protein 1 (anti-PD-1) antibody malignant melanoma (MM) serum anti-programmed cell death protein 1 (anti-PD-1) antibody treatment Serum expression levels of miR-16-5p was significantly higher in responders than in non-responders. 31843231 3225 Human hsa-miR-16-5p miRNA oleacein (OA) melanoma 501Mel melanoma cells oleacein (OA) treatment upregulated 33071785 3226 Human hsa-miR-16-5p miRNA IL-1¦Â osteoarthritis (OA) human articular chondrocytes-knee cells IL-1¦Â treatment SNHG1 alleviates the inflammation of IL-1¦Â-induced OA through the activation of miR-16-5p-mediated p38MAPK and NF-¦ÊB signaling pathway. 31383786 3227 Human hsa-miR-16-5p miRNA ionizing radiation (IR) prostate cancer CaP LNCaP cells ionizing radiation (IR) treatment upregulated 30536619 3228 Human hsa-miR-16-5p miRNA X-rays and heavy ions prostate cancer LNCaP cells X-rays and heavy ions treatment upregulated 30536619 3229 Human hsa-miR-16-5p miRNA infliximab rheumatoid arthritis (RA) serological infliximab treatment upregulated 25860297 3230 Human hsa-miR-16-5p miRNA etoposide (VP-16) cell senescence A549; MCF-7 cells etoposide treatment downregulated 33141998 3231 Human hsa-miR-16-5p miRNA high glucose (HG) type 1 diabetes mellitus (T1DM) ¦Â-TC-tet cells high glucose treatment downregulated 32797474 3232 Human hsa-miR-16a-5p miRNA IL-6 intervertebral disc degeneration (IDD) Primary human chondrocytes IL-6 treatment downregulated 32746985 3233 Human hsa-miR-17 miRNA levonorgestrel (LNG) adenomyosis endometrial stromal cells (ESCs) levonorgestrel (LNG) treatment LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway. 32921982 3234 Human hsa-miR-17 miRNA phosphatase of regenerating liver-3 (PRL-3) angiogenesis colon cancer cells Phosphatase of regenerating liver-3 (PRL-3) treatment "overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3" 22677902 3235 Human hsa-miR-17 miRNA nanocurcumin ankylosing spondylitis (AS) peripheral blood mononuclear cells (PBMCs) nanocurcumin treatment downregulated 31074089 3236 Human hsa-miR-17 miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 3237 Human hsa-mir-17 miRNA estrogen receptor-¦Á breast cancer breast cancer cells The estrogen receptor-¦Á treatment upregulated 19706389 3238 Human hsa-miR-17 miRNA phenethyl isothiocyanate breast cancer PCa cells Phenethyl isothiocyanate treatment downregulated 23661605 3239 Human hsa-miR-17 miRNA oridonin and the antileukemia drugs Ara-C and VP-16 chemoresistant leukemia human leukemia cells oridonin and the antileukemia drugs Ara-C and VP-16 treatment downregulated 24872388 3240 Human hsa-miR-17 miRNA IL-6 chronic lymphocytic leukemia (CLL) chronic lymphocytic leukemia (CLL) cells IL-6 treatment upregulated 26041742 3241 Human hsa-miR-17 miRNA calycosin colorectal cancer (CRC) HCT-116 cells Calycosin treatment downregulated 26215320 3242 Human hsa-miR-17 miRNA oxidized low density lipoprotein (ox-LDL) coronary heart disease (CHD) Human umbilical vascular endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31296440 3243 Human hsa-miR-17 miRNA "IRE1¦Á, an ER bifunctional kinase/endoribonuclease (RNase)" diabetes mellitus (DM) Human THP-1 cells IRE1¦Á treatment downregulated 22883233 3244 Human hsa-miR-17 miRNA ruxolitinib glioblastoma multiforme (GBM) U87-MG cells ruxolitinib treatment Uxolitinib (195 nM) significantly increased miR-17 and miR-20a expression 31452174 3245 Human hsa-miR-17 miRNA hepatitis B virus (HBV) hepatitis B virus (HBV) induced liver fibrosis serum hepatitis B virus (HBV) infection Serum miR-17 level is highly expressed in HBV patients. 32572891 3246 Human hsa-mir-17 miRNA triptolide (TPL) hepatocellular carcinoma (HCC) HepG2 cells triptolide (TPL) treatment downregulated 29523159 3247 Human hsa-miR-17 miRNA lipopolysaccharide (LPS) inflammation HaCaT cells lipopolysaccharide (LPS) treatment downregulated 29704506 3248 Human hsa-miR-17 miRNA resveratrol inflammation LPS-treated HaCaT cells resveratrol (Res) treatment upregulated 29704506 3249 Human hsa-miR-17 miRNA VEGF-immobilized microparticles (VEGF-MPs) ischemic injury outgrowth endothelial progenitor cells (OEPCs) outgrowth endothelial progenitor cells (OEPCs) from human UCB sample treatment downregulated 28963481 3250 Human hsa-miR-17 miRNA resveratrol lymph node cancer of prostate Lymph node cancer of prostate (LNCaP)£»Du145 cells resveratrol (Res) treatment upregulated 21714127 3251 Human hsa-miR-17 miRNA lipopolysaccharide (LPS) macrophage inflammatory response HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells lipopolysaccharide (LPS) treatment upregulated 23562609 3252 Human hsa-miR-17 miRNA high glucose (HG) myocardial infarction (MI) myocardial infarction (MI) high-glucose (HG) treatment upregulated 31075259 3253 Human hsa-miR-17 miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells; L02 cells free fatty acids (FFA) treatment downregulated 30338914 3254 Human hsa-miR-17 miRNA keratinocyte-derived exosomes (Ker-Exo) osteoclast differentiation osteoclast precursor cells keratinocyte-derived exosomes (Ker-Exo) treatment exosomes miRNA-17 secreted by keratinocytes in patients with middle ear cholesteatoma can up-regulate the expression of RANKL in fibroblasts and induce osteoclast differentiation. 32093888 3255 Human hsa-miR-17 miRNA andrographolide oxidative stress HepG2 cells andrographolide treatment downregulated 30414976 3256 Human hsa-miR-17 miRNA Sphingosine-1-phosphate (S1P) papillary thyroid cancer (PTC) thyroid follicular cancer cell lines (ML-1 and FTC-133) Sphingosine-1-phosphate (S1P) treatment downregulated 25748447 3257 Human hsa-miR-17 miRNA intercept (amotosalen+ ultraviolet-A [UVA] light) pathogen reduction platelet gamma irradiation treatment downregulated 24749844 3258 Human hsa-miR-17 miRNA natalizumab multiple sclerosis (MS) CD4+ T cells natalizumab treatment downregulated 24901013 3259 Human hsa-miR-17 miRNA decitabine precursor B-cell acute lymphoblastic leukemia (B-ALL) Nalm6 cell line decitabine treatment downregulated 30912184 3260 Human hsa-miR-17 miRNA hypoxia pulmonary hypertension (PH) human plasma hypoxia treatment upregulated 28971974 3261 Human hsa-miR-17 miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin rhabdomyosarcoma (RMS) RD and Rh30 rhabdomyosarcoma (RMS) cells "Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment" downregulated 30610105 3262 Human hsa-miR-17 miRNA toxoplasma gondii (T. gondii) toxoplasma gondii infection primary human foreskin fibroblasts (HFFs) toxoplasma gondii (T. gondii) infection treatment upregulated 20090903 3263 Human hsa-miR-17 miRNA imatinib chronic myeloid leukemia (CML) chronic myeloid leukemia cells imatinib? treatment upregulated 23818358 3264 Human hsa-miR-17? miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 3265 Human hsa-miR-17-3p miRNA methyl-3-O-methyl gallate (M3OMG) antioxidant enzymes peripheral blood mononuclear cells and EVC-304 cells M3OMG treatment downregulated 24975036 3266 Human hsa-miR-17-3p miRNA lipopolysaccharide (LPS) breast cancer HeLa cells lipopolysaccharide (LPS) treatment the expression of miR-17-3p and miR-106a is regulated by LPS in HeLa cells 21370248 3267 Human hsa-miR-17-3p miRNA racemate endogenous antioxidant defenses Caco-2 cells subtoxic concentrations of racemate treatment upregulated 28264488 3268 Human hsa-miR-17-3p miRNA lipopolysaccharide (LPS) inflammation human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment "In HUVECs, LPS caused upregulation of miR-17-3p." 33623121 3269 Human hsa-miR-17-3p miRNA candida albicans (C. albicans) invasive candidiasis respiratory epithelial cells infected by invasive Candida species candida albicans infection downregulated 26313489 3270 Human hsa-miR-17-3p miRNA polyphenols "iron bioavailability,iron absorption" Caco-2 cells polyphenols treatment upregulated 25058155 3271 Human hsa-miR-17-3p miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human articular chondrocyte C28/I2 cells lipopolysaccharide (LPS) treatment downregulated 31966787 3272 Human hsa-miR-17-5p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment miR-17-5p expression was downregulated and FOXA1 expression was upregulated in LPS-treated A549 cells 31257497 3273 Human hsa-miR-17-5p miRNA influenza A virus (IAV) acute respiratory distress syndrome (ARDS) acute respiratory distress syndrome (ARDS) patients' BALF and in EVs of IAV-infected lung epithelial cells (A549) Influenza A virus (IAV) infection upregulated 30239899 3274 Human hsa-miR-17-5p miRNA cisplatin (DDP) apoptosis K562 cells cisplatin treatment upregulated 20428827 3275 Human hsa-miR-17-5p miRNA bortezomib apoptosis human endometrial cancer cells HTB-111£» Ishikawa cells bortezomib? treatment downregulated 23716467 3276 Human hsa-miR-17-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophage-derived foam cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31646601 3277 Human hsa-miR-17-5p miRNA hypoxia autophagy VSMCs hypoxia treatment upregulated 28450922 3278 Human hsa-miR-17-5p miRNA sunitinib (SU) autophagy 786-O-R cells; ACHN-R cells sunitinib treatment downregulated 32760216 3279 Human hsa-miR-17-5p miRNA camptothecin biologic and molecular activity of camptothecin hypoxic-human cancer cells camptothecin treatment upregulated 24252850 3280 Human hsa-miR-17-5p miRNA brown seaweed fucoidan breast cancer Human Breast Cancer Cells brown seaweed fucoidan treatment downregulated 27994679 3281 Human hsa-miR-17-5p miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 3282 Human hsa-miR-17-5p miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 3283 Human hsa-miR-17-5p miRNA casiopeina II-gly (Cas-II-gly) cervical cancer (CC) HeLa and CaSki cells Casiopeina II-gly (Cas-II-gly) treatment upregulated 31524268 3284 Human hsa-miR-17-5p miRNA IL-1¦Â chondrosarcoma SW1353 human chondrosarcoma cells IL-1¦Â treatment downregulated 29434766 3285 Human hsa-miR-17-5p miRNA curcumin (Cur) colorectal cancer (CRC) RKO; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts curcumin treatment downregulated 23194063 3286 Human hsa-miR-17-5p miRNA diabetes mellitus macrophage-conditioned media (DM-MCM) diabetes mellitus (DM) HASMC DM-MCM treatment upregulated 25409512 3287 Human hsa-miR-17-5p miRNA high glucose (HG) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 29786752 3288 Human hsa-miR-17-5p miRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells cisplatin treatment miR-17-5p expression is upregulated in SGC7901/DDP cells compared with SGC7901 cells. 29541229 3289 Human hsa-miR-17-5p miRNA H2O2 glaucoma Human trabecular meshwork cells (HTMCs) H2O2 treatment downregulated 30816540 3290 Human hsa-miR-17-5p miRNA X-rays glioblastoma multiforme (GBM) glioma patients serum samples irradiation at a dose of 6.4 Gy with a high-energy X-ray accelerator (2 Gy/min) treatment downregulated 28081732 3291 Human hsa-miR-17-5p miRNA angiotensin II (Ang II) glomerulonephritis podocytes angiotensin II (Ang II) treatment RT-qPCR analysis showed that miR-17-5p was downregulated in Ang II-induced podocytes. 33835671 3292 Human hsa-miR-17-5p miRNA pegylated interferon-¦Á and ribavirin (IFN/RBV) hepatitis C virus (HCV) infection patients who were infected with hepatitis C virus genotype 1b pegylated interferon-alpha and ribavirin combination therapy treatment downregulated 24819603 3293 Human hsa-miR-17-5p miRNA hypoglycemic hepatocellular carcinoma (HCC) HepG2 cells hypoglycemic treatment downregulated 27629773 3294 Human hsa-miR-17-5p miRNA hypoxia hypoxic pulmonary hypertension (HPH) human pulmonary arterial smooth muscle cell (PASMC) hypoxia induce upregulated 30305109 3295 Human hsa-miR-17-5p miRNA anti-programmed cell death protein 1 (anti-PD-1) antibody malignant melanoma (MM) serum anti-programmed cell death protein 1 (anti-PD-1) antibody treatment Serum expression levels of miR-17-5p was significantly higher in responders than in non-responders. 31843231 3296 Human hsa-miR-17-5p miRNA erlotinib non-small cell lung cancer (NSCLC) A549 cells erlotinib downregulated 27633093 3297 Human hsa-miR-17-5p miRNA erlotinib non-small cell lung cancer (NSCLC) A549 cells erlotinib treatment downregulated 27633093 3298 Human hsa-miR-17-5p miRNA IL-1¦Â osteoarthritis (OA) chondrocyte IL-1¦Â treatment downregulated 32765678 3299 Human hsa-miR-17-5p miRNA IL-1¦Â osteoarthritis (OA) Human chondrocytes IL-1¦Â treatment miR-17-5p was downregulated and FUT1 upregulated in OA cartilage tissues and IL-1¦Â-induced chondrocytes. 33093892 3300 Human hsa-miR-17-5p miRNA IL-1¦Â osteoarthritis (OA) SW1353 human chondrosarcoma cells interleukin-1¦Â treatment downregulated 29434766 3301 Human hsa-miR-17-5p miRNA mono-(2-ethylhexyl) phthalate (MEHP) oxidative stress HTR-8/SVneo cell line mono-(2-ethylhexyl) phthalate (MEHP) treatment upregulation 26871967 3302 Human hsa-miR-17-5p miRNA ionizing radiation (IR) pancreatic cancer (PC) oral carcinoma cell line OC3 ionizing radiation treatment upregulated 23780339 3303 Human hsa-miR-17-5p miRNA zirconia and titanium preosteoblast differentiation Osteoblast-like cells (MG63) zirconia and titanium? treatment downregulated 18241218 3304 Human hsa-miR-17-5p miRNA hypoxia pulmonary hypertension (PH) hPASMCs 1% O2 for 48 h treatment upregulated 24879052 3305 Human hsa-miR-17-5p miRNA fractionated radiation radiation-induced injury human peripheral blood mononuclear cells fractionated radiation treatment upregulated 25313363 3306 Human hsa-miR-17-5p miRNA lipopolysaccharide (LPS) rhinitis nasal epithelial RPMI2650 cells lipopolysaccharide (LPS) treatment upregulated 29433423 3307 Human hsa-miR-17-5p miRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment downregulated 32099901 3308 Human hsa-miR-17-5p miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 3309 Human hsa-miR-17-92 miRNA high iodine blocked BRAF(V600E) iodine intake on BRAF-mediated oncogenesis PCCl3 line V600E treatment upregulated 23998804 3310 Human hsa-miR-17-92 miRNA dexamethasone (DEX) acute lymphoblastic leukemia (ALL) "Pre-B ALL cell lines RS4;11, REH ;SUP-B15" dexamethasone (DEX) treatment downregulated 22475310 3311 Human hsa-miR-17-92 miRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) NB4 cells all-trans retinoic acid (ATRA) treatment downregulated 31264378 3312 Human hsa-miR-17-92 miRNA prostaglandin E2 (PGE2) apoptosis "human squamous cell carcinoma NSCLC cell line H157, H460 and RH2" PGE2 treatment upregulated 24469837 3313 Human hsa-miR-17-92 miRNA natalizumab B lymphocytic leukemia whole blood lymphocytes natalizumab treatment downregulated 22659298 3314 Human hsa-miR-17-92 miRNA E. faecalis bacterial infection human gastric adenocarcinoma cell line MKN74 E. faecalis infection treatment downregulated 25170597 3315 Human hsa-miR-17-92 miRNA SD or MF radiation breast cancer MDA-MB-361 cells SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment "upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)" 24626680 3316 Human hsa-miR-17-92 miRNA estrogen receptor ¦Â colorectal cancer (CRC) Cell lines (SW480;HT29 ;SW620) Estrogen receptor ¦Â treatment the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated 23436804 3317 Human hsa-miR-17-92 miRNA hypoxia colorectal cancer (CRC) Caco-2 ; HCT116 p53+/+?cells Hypoxia treatment downregulated 19696742 3318 Human hsa-miR-17-92 miRNA cycle-dependent kinase (CDK) inhibitor SNS-032 acute myeloid leukemia (AML) AML HL-60 cells cycle-dependent kinase (CDK) inhibitor SNS-032 treatment downregulated 26038136 3319 Human hsa-miR-17-92 miRNA glucocorticoid (GC) impair skeletal development HCS-2/8 cells GCs treatment downregulated 24859019 3320 Human hsa-miR-17-92 miRNA Kaposi¡¯s sarcoma-associated herpesvirus (KSHV) kaposi's sarcoma (KS) endothelial cells KSHV treatment upregulated 26545119 3321 Human hsa-miR-17-92 miRNA antrodia cinnamomea hepatocellular carcinoma (HCC) SK-Hep-1 liver cancer cell antrodia cinnamomea treatment "oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated" 24358224 3322 Human hsa-miR-17-92 miRNA dexamethasone (DEX) lymphocyte apoptosis The Jurkat GR¦Á cell line dexamethasone (DEX) treatment upregulated 20847043 3323 Human hsa-miR-17-92a miRNA estrogen (ES) estrogen protection of osteoblasts against apoptosis osteoblasts Estrogen treatment upregulated 23264746 3324 Human hsa-miR-18 miRNA adherent-invasive escherichia coli (AIEC) autophagy human intestinal epithelial T84 cells AIEC LF82 reference strain infection upregulated 30634511 3325 Human hsa-miR-18 miRNA glucocorticoid (GC) neuronal development NS1 cells;A549 cells; COS-1cells Glucocorticoids (GCs) treatment upregulated 19131573 3326 Human hsa-miR-181 miRNA TGF-¦Â breast cancer breast cancer cells Transforming growth factor (TGF)-¦Â treatment upregulated 21102523 3327 Human hsa-miR-181 miRNA imatinib chronic myeloid leukemia (CML) MYL; MYL-R human CML cells;K562-R cells;HL-60 cells; HEK293T cells ?imatinib treatment upregulated 20693279 3328 Human hsa-miR-181 miRNA tetra-arsenic tetra-sulfide (As4S4) chronic myeloid leukemia (CML) K562 cells As4S4 treatment downregulated 28072759 3329 Human hsa-miR-181 miRNA TGF-¦Â endothelium-dependent vasorelaxation HT-29 cells TGF-¦Â treatment downregulated 23483606 3330 Human hsa-miR-181 miRNA aplysin glioblastoma multiforme (GBM) "human glioma cell lines U87 MG, U251 MG, U373 MG and M059J" aplysin treatment upregulated 33104845 3331 Human hsa-miR-181 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6A dysregulated 29163428 3332 Human hsa-miR-181 miRNA human herpesvirus 6B (HHV-6B) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6B dysregulated 29163428 3333 Human hsa-miR-181 miRNA high fat diet (HFD) inflammation human CD14? monocytes high fat diet (HFD) feed downregulated 24870697 3334 Human hsa-miR-181 miRNA lipopolysaccharide (LPS) inflammation TLR4/2+ primary human dental pulp fibroblasts were stimulat Pg LPS treatment downregulated 24848932 3335 Human hsa-miR-181 miRNA lipopolysaccharide (LPS) inflammation astrocytes lipopolysaccharide (LPS) treatment over expression 23650073 3336 Human hsa-miR-181 miRNA "anti-CD3, anti-CD28, IL-12, , IL-18" innate and adaptive immune responses PB CD4+ T cells "co-stimulating with anti-CD3, anti-CD28, IL-12, and IL-18 treatment" downregulated 24704866 3337 Human hsa-miR-181 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 3338 Human hsa-miR-181 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 3339 Human hsa-miR-181 miRNA oxidized low density lipoprotein (ox-LDL) oxidative stress human endometrial cell-lines oxidized low-density lipoprotein (ox-LDL) treatment dysregulated 28499250 3340 Human hsa-miR-181 miRNA running telomere homeostasis twenty-two healthy males white blood cells undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment upregulated 24752326 3341 Human hsa-miR-181-5p miRNA chlorpyrifos (CPF) parkinson's disease (PD) SH-SY5Y cells chlorpyrifos (CPF) treatment upregulated 30835941 3342 Human hsa-miR-181a miRNA lipopolysaccharide (LPS) graft-versus-host disease (GVHD) Cord blood (CB) lipopolysaccharide (LPS) treatment upregulated 21913990 3343 Human hsa-miR-181a miRNA 5-fluorouracil (5-Fu) 5-fluorouracil (5-FU) induced nephrotoxicity The immortalized human mesangial cell (HMC) line 5-fluorouracil (5-FU) treatment upregulated 29795190 3344 Human hsa-miR-181a miRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) APL blasts and NB4 leukemia cells all-trans retinoic acid (ATRA) treatment downregulated 26041820 3345 Human hsa-miR-181a miRNA cisplatin (DDP) apoptosis HK-2 cells cisplatin treatment One pathway of DDP induces apoptosis of tubular epithelial cell by suppressing Bcl-2 expression is achieved by regulating the target gene of MicroRNA-181a. 22490414 3346 Human hsa-miR-181a miRNA H2O2 atherosclerosis (AS) HUVECs H2O2 treatment upregulated 27460740 3347 Human hsa-miR-181a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29737518 3348 Human hsa-miR-181a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30938884 3349 Human hsa-miR-181a miRNA IFN-¦Ã autophagy human hepatoma Huh7 cells IFN-¦Ë treatment upregulated 28131804 3350 Human hsa-miR-181a miRNA metformin (Met) breast cancer MCF-7 cells metformin?treatment downregulated 21368581 3351 Human hsa-miR-181a miRNA IL-1¦Â colorectal cancer (CRC) colon cancer cell IL-1¦Â treatment upregulated 27264420 3352 Human hsa-miR-181a miRNA high glucose (HG) diabetic wound healing Human lymphatic endothelial cells (LECs) high glucose (HG) treatment upregulated 30565672 3353 Human hsa-miR-181a miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) human hepatocyte cell line PH5CH8 TGF-¦Âtreatment treatment upregulated 24576072 3354 Human hsa-miR-181a miRNA kaempferol gastric cancer (GC) SNU-216 cells kaempferol treatment upregulated 30785478 3355 Human hsa-miR-181a miRNA H2O2 glaucoma trabecular meshwork (TM) cells H2O2 treatment "After the TM cells were treated with H2O2, miR-181a expression was significantly lower." 29616751 3356 Human hsa-miR-181a miRNA docosahexaenoic acid (DHA) glioblastoma multiforme (GBM) human U87 MG glioma cell line docosahexaenoic acid (DHA) treatment upregulated 25182732 3357 Human hsa-miR-181a miRNA TGF-¦Â granular corneal dystrophy type 2 (GCD2) Primary corneal fibroblasts TGF-¦Âtreatment treatment upregulated 26915797 3358 Human hsa-miR-181a miRNA cisplatin (DDP) head and neck squamous cell carcinoma (HNSCC) Head and neck squamous cell carcinoma (HNSCC) cells cisplatin treatment downregulated 21274007 3359 Human hsa-miR-181a miRNA dichlorvos (DDVP) hepatic cell toxicity HepaRG cells DDVP treatment upregulated 31966431 3360 Human hsa-miR-181a miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 cells HepG2 cells treatment downregulated 273849772 3361 Human hsa-miR-181a miRNA TGF-¦Â hepatocellular carcinoma (HCC) human hepatocyte cell line PH5CH8 TGF-¦Â treatment upregulated 24576072 3362 Human hsa-miR-181a miRNA "IFN-¦Á, IFN-¦Ã" human immunodeficiency virus (HIV)-1 infection astrocytes;microglia IFN-¦Á and IFN-¦Ã treatment downregulated 27219130 3363 Human hsa-miR-181a miRNA 8-bromo-cyclic adenosine monophosphate (8-bromo-cAMP) and medroxyprogesterone acetate (MPA) human endometrial stromal cell decidualization human endometrial stromal cell (hESC) 8-Br-cAMP and MPA treatment upregulated 25889210 3364 Human hsa-miR-181a miRNA lipopolysaccharide (LPS) infantile pneumonia (IP) WI-38 cells lipopolysaccharide (LPS) treatment downregulated 31889339 3365 Human hsa-miR-181a miRNA type III interferon (IFN¦Ë) inflammation human epithelial cells type III interferon (IFN¦Ë) treatment upregulated 24098127 3366 Human hsa-miR-181a miRNA adriamycin (ADR) leukemia HL-60 cells adriamycin (ADR) treatment downregulated 30964176 3367 Human hsa-miR-181a miRNA Vitamin D and phorbol 12-myristate 13-acetate leukemia AML cell line (HL60 and NB4) Vitamin D and phorbol 12-myristate 13-acetate treatment downregulated 20981674 3368 Human hsa-miR-181a miRNA TGF-¦Â liver fibrosis LX2 cells TGF-¦Â treatment upregulated 31166951 3369 Human hsa-miR-181a miRNA piceatannol (PIC) melanoma "WM266-4 , A2058 cells" treat with piceatannol treatment upregulated 29187907 3370 Human hsa-miR-181a miRNA bortezomib multiple myeloma (MM) Human MM cell line RPMI8226 bortezomib? treatment downregulated 26032093 3371 Human hsa-miR-181a miRNA triptolide (TPL) multiple myeloma (MM) the dexamethasone-sensitive MM.1S human MM cell line triptolide (TPL)? treatment downregulated 22260163 3372 Human hsa-miR-181a miRNA triptolide (TPL) neuroblastoma (NB) SH-SY5Y cells triptolide (TPL) treatment microRNA-181a (miR-181a) was upregulated after TPL treatment 29426375 3373 Human hsa-miR-181a miRNA cisplatin (DDP) neuroinflammation tongue squamous cell cisplatin (DPP) treatment downregulated 24148247 3374 Human hsa-miR-181a miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) LO-2 cells palmitic acid (PA) treatment upregulated 30558790 3375 Human hsa-miR-181a miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) The human normal liver cell line L02 cells palmitic acid (PA) treatment upregulated 30558790 3376 Human hsa-miR-181a miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment upregulated 20145152 3377 Human hsa-miR-181a miRNA hydrostatic pressure (HP) osteoarthritis (OA) human OA chondrocyte "exposure to three hours of a cyclic HP (1-5 MPa, frequency 0.25 Hz)" downregulated 29150345 3378 Human hsa-miR-181a miRNA hydrostatic pressure (HP) osteoarthritis (OA) chondrocytes hydrostatic pressure (HP) treatment miR-155 and miR-181a resulted significantly downregulated immediately after pressurization (T0) in OA cells. 29150345 3379 Human hsa-miR-181a miRNA hydrostatic pressure (HP) osteoarthritis (OA) human osteoarthritis (OA) chondrocytes hydrostatic pressure (HP) treatment upregulated 32455798 3380 Human hsa-miR-181a miRNA mud-bath therapy (MBT) osteoarthritis (OA) patients with bilateral knee osteoarthritis (OA) "daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks" downregulated 28785809 3381 Human hsa-miR-181a miRNA resistin osteoarthritis (OA) human OA synovial fibroblasts resistin treatment upregulated 31635187 3382 Human hsa-miR-181a miRNA visfatin osteoarthritis (OA) human OA chondrocytes visfatin treatment "upregulated, all the visfatin-caused effects were suppressed by using miR-34a and miR-181a inhibitors." 31405216 3383 Human hsa-miR-181a miRNA triptolide (TPL) osteosarcoma (OS) SAOS2 and U2OS cells "150?mol/L triptolide for 24, 48, and 72 h treatment" upregulated 28381158 3384 Human hsa-miR-181a miRNA follicle stimulating hormone (FSH) ovarian steroidogenesis human granulosa cell line KGN follicle-stimulating hormone (FSH) treatment dysregulated 26773729 3385 Human hsa-miR-181a miRNA andrographolide oxidative stress HepG2 cells andrographolide treatment downregulated 30414976 3386 Human hsa-miR-181a miRNA H2O2 oxidative stress KGN cells H2O2 treatment upregulated 31359035 3387 Human hsa-miR-181a miRNA sphingosine-1-phosphate (S1P) oxidative stress H2O2 treated KGN cells sphingosine-1-phosphate (S1P) treatment downregulated 31359035 3388 Human hsa-miR-181a miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) human SK-N-SH neuroblastoma cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 28365714 3389 Human hsa-miR-181a miRNA bufalin prostate cancer Human prostate carcinoma PC-3 cells ?bufalin treatment Bufalin was found to induce the expression of miR-181a 24267199 3390 Human hsa-miR-181a miRNA lipopolysaccharide (LPS) sepsis Monocytes lipopolysaccharide (LPS) treatment LPS stimulation in monocytes also led to a decrease in the expression of miR-181a. 32104257 3391 Human hsa-miR-181a miRNA high glucose (HG) wound healing human dermal lymphatic endothelial cells (LECs) high glucose (HG) treatment "ANRIL was downregulated, whereas miR-181a was upregulated in high glucose (HG)-induced LECs." 30565672 3392 Human hsa-miR-181a miRNA lipopolysaccharide (LPS) pancreatic cancer (PC) Pancreatic cancer cells lipopolysaccharide (LPS) treatment downregulated 24532253 3393 Human hsa-miR-181a* miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment downregulated 19022373 3394 Human hsa-miR-181a-1?3p miRNA benzo(a)pyrene (BaP) hepatocellular carcinoma (HCC) HepG2 benzo(a)pyrene (BaP) exposure upregulated 25690898 3395 Human hsa-miR-181a-2* miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment downregulated 26640557 3396 Human hsa-miR-181a-2-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 3397 Human hsa-miR-181a-2-3p miRNA cadmium (Cd) cadmium (Cd)-induced inflammatory responses human bronchial epithelial cell line (BEAS-2B) and normal human bronchial epithelial (NHBE) cells cadmium (Cd) treatment downregulated 31463135 3398 Human hsa-miR-181a-2-3p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment MEG3 expression was enhanced while miR-181a-2-3p abundance was reduced in the serum of patients with COPD and CSE-treated 16HBE cells. 33262837 3399 Human hsa-miR-181a-2-3p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment downregulated 25129238 3400 Human hsa-miR-181a-3p miRNA hypoxia lung cancer A549 cells hypoxia treatment downregulated 27524914 3401 Human hsa-miR-181a-5p miRNA lipopolysaccharide (LPS) sepsis THP-1 cell line lipopolysaccharide (LPS) treatment "si-CRNDE-1 and miR-181a-5p mimic were able to reverse the promoting effects of LPS on production of NF-kB, TNF-a, IL-1b and IL-6 by THP-1 cells." 31604377 3402 Human hsa-miR-181a-5p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment downregulated 33197806 3403 Human hsa-miR-181a-5p miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment downregulated 33197806 3404 Human hsa-miR-181a-5p miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) Human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment downregulated 33407436 3405 Human hsa-miR-181a-5p miRNA ionizing radiation (IR) colorectal cancer (CRC) SW480 cells irradiation treatment upregulated 33529508 3406 Human hsa-miR-181a-5p miRNA cisplatin (DDP) esophageal adenocarcinoma (EAC) OE19 cells cisplatin treatment miR-181a-5p was highly expressed while CBLB was lowly expressed in OE19 cell lines compared with OE19/CDDP cells. 32612385 3407 Human hsa-miR-181a-5p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells temozolomide (TMZ) treatment downregulated 32968457 3408 Human hsa-miR-181a-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HCC patients serum 3 months after the initiation of sorafenib treatment upregulated in serum 28275578 3409 Human hsa-miR-181a-5p miRNA IL-17 non-small cell lung cancer (NSCLC) H226 and H460 cells interleukin-17 (IL-17) treatment downregulated 28535543 3410 Human hsa-miR-181a-5p miRNA xiaoji decoction (XJD) non-small cell lung cancer (NSCLC) A549 and H1975 cells Xiaoji decoction (XJD) treatment upregulated 31707347 3411 Human hsa-miR-181a-5p miRNA xiaoji decoction (XJD) non-small cell lung cancer (NSCLC) A549 cells; H1975 cells xiaoji decoction (XJD) treatment XJD increased miR-181a-5p expressions. 31707347 3412 Human hsa-miR-181a-5p miRNA IL-1¦Â osteoarthritis (OA) SW1353 cells IL-1¦Â treatment IL-1¦Â increased hsa-miR-181a-5p and decreased SBP2 in a time- and dose-dependent manner. 30286747 3413 Human hsa-miR-181a-5p miRNA IL-1¦Â osteoarthritis (OA) Hyperplastic synovial fibroblasts (SFs) interleukin-1¦Â treatment upregulated 31777535 3414 Human hsa-miR-181a-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells; SK-N- AS cessl 1-methyl-4-phenylpyridinium (MPP+) treatment "We discovered that SNHG1 was significantly elevated, while miR-181a-5p was decreased in N-methyl-4-phenylpyridinium (MPP+)-treated neuroblastoma cells in dose-dependent manners." 33389428 3415 Human hsa-miR-181a-5p miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment downregulated 32921988 3416 Human hsa-miR-181a-5p miRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis. 31604377 3417 Human hsa-miR-181a-5p miRNA lipopolysaccharide (LPS) sepsis-induced renal injury HK-2 and HEK293 cells lipopolysaccharide (LPS) treatment miR-181a-5p was significantly upregulated in sepsis models. 31877497 3418 Human hsa-miR-181a-5p miRNA cisplatin (DDP) and?thiosemicarbazone compound 5 triple negative breast cancer (TNBC) MDA-MB 231 breast cancer cell line Cisplatin?+?thiosemicarbazone compound 4 treatment upregulated 31541355 3419 Human hsa-miR-181a-5p miRNA high glucose (HG) tubulointerstitial fibrosis (TIF) HK-2 cells high glucose downregulated 28077323 3420 Human hsa-miR-181b miRNA lipopolysaccharide (LPS) acute lung injury (ALI) BEAS-2B cells lipopolysaccharide (LPS) treatment upregulated 26622531 3421 Human hsa-miR-181b miRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) APL blasts and NB4 leukemia cells all-trans retinoic acid (ATRA) treatment downregulated 26041820 3422 Human hsa-miR-181b miRNA arsenite angiogenesis EA.hy926 cells arsenic (As) exposure downregulated 21503876 3423 Human hsa-miR-181b miRNA celastrol apoptosis A549 cells celastrol treatment upregulated 29434967 3424 Human hsa-miR-181b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29136944 3425 Human hsa-miR-181b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment MALAT1 suppression protects the endothelium from oxLDL-induced inflammation and oxidative stress in endothelial cells by upregulation of miR-181b and downregulated of TOX. 31949884 3426 Human hsa-miR-181b miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment upregulated 29189128 3427 Human hsa-miR-181b miRNA curcumin (Cur) breast cancer human metastatic breast cancer cells MDA©\MB©\231 curcumin treatment upregulated 24484937 3428 Human hsa-miR-181b miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 3429 Human hsa-miR-181b miRNA ibrutinib chronic lymphocytic leukemia (CLL) CLL patients paired LN and PB samples ibrutinib treatment downregulated in paired LN and PB samples 27431016 3430 Human hsa-miR-181b miRNA everolimus endothelial dysfunction TNF-¦Á treated human umbilical vein endothelial cell (HUVECs) everolimus treatment upregulated 29889836 3431 Human hsa-miR-181b miRNA TGF-¦Â endothelial dysfunction HCC cell lines TGFbeta treatment upregulated 20023698 3432 Human hsa-miR-181b miRNA tumor necrosis factor alpha (TNF-¦Á) endothelial dysfunction human umbilical vein endothelial cell (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29889836 3433 Human hsa-miR-181b miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) gastric cancer tissues 5-fluorouracil (5-FU) treatment upregulated 27081844 3434 Human hsa-miR-181b miRNA S-1/oxaliplatin gastric cancer (GC) gastric tumor specimens ?S-1/Oxaliplatin?(intravenous injection) treatment miR-181b and miR-21 was significantly overexpressed in gastric tumors 21876743 3435 Human hsa-miR-181b miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) T98G cells temozolomide (TMZ) treatment upregulated 22722712 3436 Human hsa-miR-181b miRNA oleuropein (OL) glioblastoma multiforme (GBM) GBM cell line T98G oleuropein (OL) treatment or OL+temozolomide (TMZ) combined treatment upregulated 31169033 3437 Human hsa-miR-181b miRNA cigarette smoke extract (CSE) head and neck squamous cell carcinoma (HNSCC) HaCaT cigarette smoke?extract?(CSE) treatment upregulated 28797462 3438 Human hsa-miR-181b miRNA TGF-¦Â1 hypertrophic scars (HS) fibroblasts TGF-¦Â1 treatment upregulated 25837671 3439 Human hsa-miR-181b miRNA hypoxia hypoxia-induced injury HK-2 cells hypoxia induce downregulated 30860638 3440 Human hsa-miR-181b miRNA morphine inflammation and oxidative stress peripheral blood mononuclear cells (PBMCs) Morphine treatment downregulated 20564181 3441 Human hsa-miR-181b miRNA "ferrylhemoglobin (ferrylHb, Fe4+)" intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) "ferrylhemoglobin (ferrylHb, Fe4+) treatment" upregulated 32961661 3442 Human hsa-miR-181b miRNA heme intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) heme treatment upregulated 32961661 3443 Human hsa-miR-181b miRNA "methemoglobin (metHb, Fe3+)" intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) "methemoglobin (metHb, Fe3+) treatment" upregulated 32961661 3444 Human hsa-miR-181b miRNA tumor necrosis factor alpha (TNF-¦Á) intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 32961661 3445 Human hsa-miR-181b miRNA Vitamin D and phorbol 12-myristate 13-acetate leukemia AML cell line (HL60 and NB4) Vitamin D and phorbol 12-myristate 13-acetate treatment downregulated 20981674 3446 Human hsa-miR-181b miRNA TGF-¦Â1 liver fibrosis human LX-2 cell transforming growth factor-¦Â1 treatment upregulated 25148875 3447 Human hsa-miR-181b miRNA celastrol lung cancer A549 cells; LTEP-a-2 cells celastrol treatment miR-181b was upregulated in celastrol-treated LTEP-a-2 cells. 29434967 3448 Human hsa-miR-181b miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmitic acid (PA) treatment upregulated 28899784 3449 Human hsa-miR-181b miRNA epidermal growth factor (EGF) oral carcinogenesis "HSC-3£¬OECM-1,SAS£¬NOK" EGF treatment upregulated 25229239 3450 Human hsa-miR-181b miRNA decitabine precursor B-cell acute lymphoblastic leukemia (B-ALL) Nalm6 cell line decitabine treatment downregulated 30912184 3451 Human hsa-miR-181b miRNA "antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)" schizophrenia (SZ) schizophrenia patients six-week antipsychotic treatment upregulated 24694668 3452 Human hsa-miR-181b miRNA methotrexate (MTX) vascular disease human umbilical vein endothelial cells (HUVECs) methotrexate (MTX) treatment upregulated 33416495 3453 Human hsa-miR-181b miRNA TGF-¦Â1 apoptosis serum of cirrhosis patients TGF-¦Â1 treatment ?miR-181b could be induced by TGF-¦Â1 and promote the growth of HSCs by directly targeting p27 22446332 3454 Human hsa-miR-181b miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 retinoic acid treatment downregulated 17260024 3455 Human hsa-miR-181b1 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human umbilical vein endothelial cells (HUVEC) TNF¦Á treatment upregulated 29666964 3456 Human hsa-miR-181b-5p miRNA TGF-¦Â1 non-small cell lung cancer (NSCLC) A549 cells TGF-¦Â1 treatment upregulated 28534939 3457 Human hsa-miR-181b-5p miRNA "1,25-dihydroxyvitamin D (1,25(OH)2D)" spontaneous preterm birth (SPB) human syncytiotrophoblast "1,25-dihydroxyvitamin D (1,25(OH)2D) treatment" "miR-181b-5p and miR-26b-5p in term human syncytiotrophoblast were increased in response to treatment with 1,25(OH)2D." 30395535 3458 Human hsa-miR-181c miRNA lipopolysaccharide (LPS) graft-versus-host disease (GVHD) Cord blood (CB) lipopolysaccharide (LPS) treatment upregulated 21913990 3459 Human hsa-miR-181c miRNA hypoxia acute ischemic stroke (AIS) Plasma hypoxia treatment downregulated 28053821 3460 Human hsa-miR-181c miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 3461 Human hsa-miR-181c miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 3462 Human hsa-miR-181c miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment downregulated 26397152 3463 Human hsa-miR-181c miRNA cigarette smoke (CS) chronic obstructive pulmonary disease (COPD) human bronchial epithelial cells (HBECs) cigarette smoke (CS) exposure downregulated 28806967 3464 Human hsa-miR-181c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric and colorectal cancer KATO-III cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 20080834 3465 Human hsa-miR-181c miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection liver biopsy specimens and Huh7.5 cells hepatitis C virus (HCV) infection downregulated 31400158 3466 Human hsa-miR-181c miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) downregulated 18648749 3467 Human hsa-miR-181c miRNA heme hepatocellular carcinoma (HCC) Huh?12 cells heme treatment upregulated 23538684 3468 Human hsa-miR-181c miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 3469 Human hsa-miR-181c* miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 3470 Human hsa-miR-181c-3p miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 29605252 3471 Human hsa-miR-181c-5p miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 29605252 3472 Human hsa-miR-181c-5p miRNA melatonin osteogenic differentiation and calcification Human jawbone-derived osteoblastic (hOB) cells melatonin (MEL) treatment upregulated 32945514 3473 Human hsa-miR-181c-5p miRNA protein kinase C inhibitor GF109203X wound healing and regeneration of skin tissues. human keratinocytes GF109203X treatment "upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )" 28901412 3474 Human hsa-miR-181d miRNA aidi injection (ADI) breast cancer MCF-7 cells aidi Injection (ADI) upregulated 21563499 3475 Human hsa-miR-181d miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 3476 Human hsa-miR-181d miRNA garcinol glioblastoma multiforme (GBM) U87MG or GBM8401 cells garcinol treatment upregulated 31783691 3477 Human hsa-miR-181d miRNA ionizing radiation (IR) glioblastoma multiforme (GBM) glioblastoma CD133+ cancer stem cell ionizing radiation (IR) treatment downregulated 31226325 3478 Human hsa-miR-181d miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) glioblastoma CD133+ cancer stem cell temozolomide (TMZ) treatment downregulated 31226325 3479 Human hsa-miR-181d miRNA insulin-like growth factor 1 (IGF-1) glioblastoma multiforme (GBM) U87-MG cells IGF-1 treatment downregulated 28389653 3480 Human hsa-miR-181d miRNA Vitamin D and phorbol 12-myristate 13-acetate leukemia AML cell line (HL60 and NB4) Vitamin D and phorbol 12-myristate 13-acetate treatment downregulated 20981674 3481 Human hsa-miR-181d-5p miRNA hypoxia/reoxygenation (H/R) acute kidney ischemia/reperfusion injury (IRI) HK-2 cells hypoxia/reoxygenation (H/R) treatment "miR-181d-5p in the H/R group increased at 6¨C12 h, but started to decrease at 24 h." 32581828 3482 Human hsa-miR-181d-5p miRNA t-butylhydroperoxide (t-BHP) atherosclerotic coronary heart disease (CHD) Primary HUVECs t-butylhydroperoxide (t-BHP) treatment downregulated 31352814 3483 Human hsa-miR-181d-5p miRNA 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS) inflammation BEAS-2B cells 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS) treatment "We identified a novel circRNA, circ_0035266, which was strongly upregulated in NNK+LPS-induced BEAS-2B cells and enhanced the inflammatory responses to NNK+LPS by regulating the secretion of pro-inflammatory cytokines interleukin (IL)-6 and IL-8." 33107911 3484 Human hsa-miR-182 miRNA isorhapontigenin (ISO) bladder cancer T24 cells isorhapontigenin (ISO) treatment downregulated 29409027 3485 Human hsa-miR-182 miRNA curcumin (Cur) breast cancer T47D breast cancer cells curcumin treatment 48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells. 30467667 3486 Human hsa-miR-182 miRNA TGF-¦Â cancer cell epithelial-mesenchymal transition (EMT) breast tumour TGF-¦Âtreatment treatment "TGF¦Â activates the expression of microRNA-182 (miR-182), which suppresses SMAD7 protein" 27996004 3487 Human hsa-miR-182 miRNA fentanyl colorectal cancer (CRC) human colorectal carcinoma (HCT116) cells Fentanyl treatment downregulated 25755709 3488 Human hsa-miR-182 miRNA TGF-¦Â gallbladder cancer (GBC) GBC cells TGF-¦Â induces expression in treatment upregulated 24445397 3489 Human hsa-miR-182 miRNA metformin (Met) glioblastoma multiforme (GBM) U87 cells metformin(Met) treatment downregulated 33059952 3490 Human hsa-miR-182 miRNA TGF-¦Â1 liver fibrosis human hepatocellular cell line LX-2 TGF-¦Â1 treatment upregulated 29323718 3491 Human hsa-miR-182 miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) patients with advanced hepatocellular carcinoma (HCC) cisplatin treatment upregulated 24447717 3492 Human hsa-miR-182 miRNA hypoxia hepatocellular carcinoma (HCC) HCC cells hypoxia treatment upregulated 26126858 3493 Human hsa-miR-182 miRNA herpes simplex virus 1 (HSV-1) herpes simplex virus 1 (HSV-1) infection 293A and 293T cells infect with HSV-1 upregulated 28783105 3494 Human hsa-miR-182 miRNA mangiferin prostate cancer PC3 human prostate cancer cells Mangiferin treatment upregulated 26870290 3495 Human hsa-miR-182 miRNA granulocyte-colony stimulating factor (G-CSF) leukemia CD34+ cells Granulocyte colony-stimulating factor?treatment upregulated 24056818 3496 Human hsa-miR-182 miRNA glucocorticoid (GC) lymphoblastic malignancies Th e mouse myeloma cell line SP2/0; lymphocytic leu-kemia line L1210;T-lymphoma line EL-4 ;acute pre-B lym-phoblastic leukemia line SUP-B15; acute T-lymphoblastic leukemia line CCRF-CEM; cutaneous T-lymphocyte line HUT-78; Burkitt lymphoma line Daudi; acute T-cell leukemia line Molt-4 ; acute T-cell leukemia line J Glucocorticoid (GC)treatment upregulated 22582938 3497 Human hsa-miR-182 miRNA cisplatin and paclitaxel metastatic bladder cancer T24 bladder cancer cells cisplatin and paclitaxel treatment upregulated 26356996 3498 Human hsa-miR-182 miRNA low intensity pulsed ultrasound (LIPUS) periodontal bone defect human primary periodontal ligament cells (hPDLCs) Low intensity pulsed ultrasound (LIPUS) treatment downregulated 31401188 3499 Human hsa-miR-182 miRNA atorvastatin prostate cancer PC3 prostate cancer cells atorvastatin? treatment upregulated 23936432 3500 Human hsa-miR-182 miRNA mangiferin prostate cancer PC3 human prostate cancer cells Mangiferin treatment upregulated 26870290 3501 Human hsa-miR-182 miRNA light retinal injury retinal pigment epithelial (RPE) cells light treatment upregulated 25955435 3502 Human hsa-miR-182 miRNA curcumin (Cur) schwannoma RT4 schwannoma cells curcumin treatment upregulated 30534000 3503 Human hsa-miR-182 miRNA iodine-131 (131I) thyroid cancer (TC) FTC-133 cells; TPC-1 cells iodine-131 (131I) treatment MEG3 expression appeared a decline and miR-182 expression displayed an increase in 131I-resistant FTC-133 (res-FTC-133) and TPC-1 (res-TPC-1) cells. 30021359 3504 Human hsa-miR-182-3p miRNA asymmetrical dimethylarginine atherosclerosis (AS) human aortic artery smooth muscle cell (SMC) asymmetrical dimethylarginine treatment downregulated 27199451 3505 Human hsa-miR-182-3p miRNA vibrio parahaemolyticus flagellin innate immune response grouper spleen (GS) cells Vibrio parahaemolyticus flagellin treatment "miR-182-3p expression significantly downregulated at 3h and 6h, compared with control group After stimulation for 12h and 24h, the expression of miR-182-3p was significantly upregulated" 31351112 3506 Human hsa-miR-1825 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 3507 Human hsa-miR-182-5p miRNA tert-butyl hydroperoxide (TBHP) intervertebral disc degeneration (IDD) nucleus pulposus cells (NPCs) tert-butyl hydroperoxide (TBHP) treatment upregulated 31582722 3508 Human hsa-miR-182-5p miRNA cisplatin (DDP) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 cisplatin treatment upregulated 33647908 3509 Human hsa-miR-182-5p miRNA H2O2 age-related cataract (ARC) HLE-B3 cells H2O2 treatment miR-182-5p expression was significantly decreased by the H2O2 exposure. 32552665 3510 Human hsa-miR-182-5p miRNA ropivacaine apoptosis umbilical cord mesenchymal stem cells (UCMSCs) ropivacaine treatment downregulated 30773504 3511 Human hsa-miR-182-5p miRNA Sufentanil apoptosis umbilical cord mesenchymal stem cells (UCMSCs) Sufentanil treatment upregulated 30773504 3512 Human hsa-miR-182-5p miRNA arsenite arsenic carcinogenesis HK-2 human renal epithelial cells arsenic exposure downregulated 30334557 3513 Human hsa-miR-182-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein smooth muscle cells (HUVSMCs) oxidized low-density lipoprotein (ox-LDL) treatment Knockdown of circ_USP36 alleviated ox-LDL-mediated injury of HUVSMCs by modulating miR-182-5p/KLF5 axis 33437365 3514 Human hsa-miR-182-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells oxidized low-density lipoprotein (ox-LDL) treatment "The expression level of miR-182-5p decreased, while the expression level of PAPPA increased significantly in the ox-LDL treated HA-VSMC cells." 32684596 3515 Human hsa-miR-182-5p miRNA doxorubicin (DOX) cardiotoxicity human-induced pluripotent stem cell (hiPSC) doxorubicin treatment upregulated 26842497 3516 Human hsa-miR-182-5p miRNA ethanol (EtOH) ethanol-induced neuroinflammation and brain damage plasma exosomes ethanol treatment downregulated 32937997 3517 Human hsa-miR-182-5p miRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells; BGC823C cells cisplatin treatment circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5p. 31898357 3518 Human hsa-miR-182-5p miRNA trichloroethylene (TCE) hepatocarcinogenesis human hepatoma cell line HepG2 Trichloroethylene (TCE) treatment upregulated 31524101 3519 Human hsa-miR-182-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7 cells; Hep3B; SNU©\387; SNU©\449 cells Sorafenib (SOR) treatment lncRNA-POIR promotes EMT progression and suppresses SOR sensitivity simultaneously by sponging miR-182-5p 32951268 3520 Human hsa-miR-182-5p miRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) human embryonic lung fibroblasts transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 31884830 3521 Human hsa-miR-182-5p miRNA human metapneumovirus (HMPV) innate immune response human dendritic cells Human metapneumovirus (HMPV) infection upregulated 29970194 3522 Human hsa-miR-182-5p miRNA mechanical stress intervertebral disc degeneration (IDD) NP cells mechanical stress treatment upregulated 33195225 3523 Human hsa-miR-182-5p miRNA TGF-¦Â1 lung fibrosis human embryonic lung fibroblasts TGF-¦Â1 treatment miR-182-5p was upregulated in pulmonary fibrosis 31884830 3524 Human hsa-miR-182-5p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2R cells curcumin treatment upregulated 31793078 3525 Human hsa-miR-182-5p miRNA lipopolysaccharide (LPS) neuropathic pain (NP) SH-SY5Y cells lipopolysaccharide (LPS) treatment HAGLR displayed high levels in spinal cords of CCI rats and in LPS treated SH-SY5Y cells. 33626373 3526 Human hsa-miR-182-5p miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment downregulated 31452742 3527 Human hsa-miR-182-5p miRNA matrine papillary thyroid cancer (PTC) TPC-1 cells; BCPAP cells Matrine treatment Matrine inhibited the expression of miR-182-5p. 32505823 3528 Human hsa-miR-1826 miRNA 5-fluorouracil (5-Fu) and oxaliplatin colorectal cancer (CRC) human colon cancer cells 5-Fluorouracil and oxaliplatin treatment downregulated 19956872 3529 Human hsa-miR-1827 miRNA lipopolysaccharide (LPS) acute inflammatory response HMEEC lipopolysaccharide (LPS) treatment upregulated 21377743 3530 Human hsa-miR-182a miRNA morphine neurogenesis hippocampal neural progenitor cell (hNPC) lineages morphine treatment upregulated 24964979 3531 Human hsa-miR-183 miRNA quinacrine apoptosis U937 cells quinacrine treatment upregulated 28867437 3532 Human hsa-miR-183 miRNA curcumin (Cur) breast cancer T47D breast cancer cells curcumin treatment 48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells. 30467667 3533 Human hsa-miR-183 miRNA oxidized low density lipoprotein (ox-LDL) cell damage human umbilical vascular endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31210063 3534 Human hsa-miR-183 miRNA IL-8 cholesterol efflux THP-1 macrophage-derived foam cells IL-8 treatment upregulated 29703573 3535 Human hsa-miR-183 miRNA CCL20 and CXCL8 colorectal cancer (CRC) human CRC cell lines SW480 and Caco-2 ?CCL20 and CXCL8 co-stimulation "miR-183 was negatively regulated by circ_0026344, and the inhibitory effects of circ_0026344 overexpression on Wnt/¦Â-catenin pathway were reversed when miR-183 was overexpressed." 31608699 3536 Human hsa-miR-183 miRNA elevated CO(2) concentrations (hypercapnia) helicobacter pylori infection fibroblasts (N12); A549 cells CO(2) treatment upregulated 21903582 3537 Human hsa-miR-183 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hepatocellular carcinoma (HCC) HCC cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28321157 3538 Human hsa-miR-183 miRNA herpes simplex virus 1 (HSV-1) herpes simplex virus 1 (HSV-1) infection 293A and 293T cells infect with HSV-1 upregulated 28783105 3539 Human hsa-miR-183 miRNA TGF-¦Â immunosuppression human NK cells TGF-¦Â treatment upregulated 24586048 3540 Human hsa-miR-183 miRNA cisplatin and paclitaxel metastatic bladder cancer T24 bladder cancer cells cisplatin and paclitaxel treatment upregulated 26356996 3541 Human hsa-miR-183 miRNA tacrolimus or high glucose new-onset diabetes after liver transplantation (NODALT) human hepatocytes tacrolimus or high glucose treatment dysregulated 27458792 3542 Human hsa-miR-183 miRNA baicalin (BAI) osteosarcoma (OS) MG-63 and Saos-2 cells baicalin (BAI) treatment upregulated 29845278 3543 Human hsa-miR-183 miRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) PDAC cells gemcitabine treatment downregulated 28849150 3544 Human hsa-miR-183 miRNA light retinal injury retinal pigment epithelial (RPE) cells light treatment upregulated 25955435 3545 Human hsa-miR-183* miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 3546 Human hsa-miR-183-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment SNHG15 knockdown protected against cerebral I/R injury via targeting miR-183-5p/FOXO1 axis 33194027 3547 Human hsa-miR-183-5p miRNA cytomegalovirus (CMV) cytomegalovirus infection plasma Cytomegalovirus (CMV) treatment upregulated 27684416 3548 Human hsa-miR-183-5p miRNA glial cell-derived neurotrophic factor (GDNF) glioblastoma multiforme (GBM) human U251 glioma cells 50 ng/mL GDNF for 24 h upregulated 29224008 3549 Human hsa-miR-183-5p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment Circ_DHRS3 expression was elevated in OA cartilage tissues and IL-1¦Â-treated chondrocytes. 33360372 3550 Human hsa-miR-184 miRNA adriamycin (ADR) chronic lymphocytic leukemia (CLL) human chronic myeloid leukemia cell line K562 and KCL22 adriamycin (ADR) treatment upregulated 31180580 3551 Human hsa-miR-184 miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-184 was upregulated in resistant patients when compared with sensitive patients 33072545 3552 Human hsa-miR-184 miRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) HLE-B3 cells TGF-¦Â2 treatment upregulated 32356563 3553 Human hsa-miR-184 miRNA cadmium (Cd) keratinocytes (KCs) diferentiation human primary epidermal keratinocytes (HPEK) exogenous Ca2+ treatment upregulated 31985037 3554 Human hsa-miR-184 miRNA TGF-¦Â idiopathic pulmonary fibrosis (IPF) A549 cells TGF-¦Â treatment TGF-¦Â could induce miR-31 and suppress miR-184 levels in A549 cells 31874165 3555 Human hsa-miR-184 miRNA TGF-¦Â idiopathic pulmonary fibrosis (IPF) A549 cells TGF-¦Â treatment downregulated 31874165 3556 Human hsa-miR-184 miRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) BEAS-2B cells; A549 cells TGF-¦Â1 treatment downregulated 32989231 3557 Human hsa-miR-184 miRNA IL-22 inflammatory skin diseases RHE cells; HaCaT cells IL-22 treatment cytokine-induced miR-184 attenuates AGO2 expression in keratinocytes 23696368 3558 Human hsa-miR-184 miRNA retinoic acid (RA) neuroblastoma (NB) Neuroblastoma tissue and cell lines retinoic acid treatment downregulated 17283129 3559 Human hsa-miR-184 miRNA doxorubicin (DOX) osteosarcoma (OS) OS cell line U-2 OS and MG-63 Doxorubicin treatment Doxorubicin induced time-dependent expression of miR-184 in OS cell line U-2 OS and MG-63. 27222034 3560 Human hsa-miR-184 miRNA "Trans10,cis12 conjugated linoleic acid (t10,c12 CLA)" ovarian cancer (OC) ovarian cancer cell lines SKOV-3 and A2780 "Trans10,cis12 conjugated linoleic acid (t10,c12 CLA) treatment" upregulated 29324748 3561 Human hsa-miR-184 miRNA artesunate (ART) prostate cancer "DU145,LNCaP cells" artesunate (ART) treatment downregulated 28209917 3562 Human hsa-miR-184 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid" renal cell carcinoma (RCC) renal cell; carcinoma cell lines (5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment upregulated 23707942 3563 Human hsa-miR-185 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophages atherogenic Evs oxidized low-density lipoprotein (ox-LDL) treatment enrichment in atherogenic EVs 28882869 3564 Human hsa-miR-185 miRNA oxidized low density lipoprotein (ox-LDL) Dendritic cell (DC) maturation Human peripheral blood monocytes differentiated DCs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29617044 3565 Human hsa-miR-185 miRNA angiotensin II (Ang II) HAVSMC dysfunction and hypertension human aortic vascular smooth muscle cells (HAVSMCs) angiotensin II (Ang II) treatment downregulated 28277742 3566 Human hsa-miR-185 miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment downregulated 29499960 3567 Human hsa-miR-185 miRNA TGF-¦Â1 liver fibrosis LX-2 Cells TGF-¦Â1 treatment downregulated 29499960 3568 Human hsa-miR-185 miRNA CdSe/ZnS-GSH lung cancer A549 cells CdSe/ZnS-GSH treatment upregulated 31883144 3569 Human hsa-miR-185 miRNA CdSe/ZnS-MPA lung cancer A549 cells CdSe/ZnS-MPA treatment upregulated 31883144 3570 Human hsa-miR-185 miRNA hypoxia myocardial infarction (MI) human umbilical vein endothelial cells (HUVECs) hypoxia induce downregulated 30450725 3571 Human hsa-miR-185 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) human HepG2 hepatocytes palmitic acid treatment downregulated 25548489 3572 Human hsa-miR-185 miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx4 treatment" downregulated 21572246 3573 Human hsa-miR-185 miRNA dexmedetomidine (DEX) ovarian cancer (OC) "SKOV3 , HO-8910 cells" dexamethasone (DEX) treatment DEX promoted miR-185 but suppressed SOX9 expression in OC cells. 33818283 3574 Human hsa-miR-185 miRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) SH5Y-SY cells "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" miR-185 was significantly downregulated in SH-SY5Y cells treated with MPTP. 29115479 3575 Human hsa-miR-185 miRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) SH5Y-SY cells "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" downregulated 31814881 3576 Human hsa-miR-185 miRNA radiation renal cell carcinoma (RCC) renal cell carcinoma cells radiation treatment downregulated 23807228 3577 Human hsa-miR-185 miRNA TGF-¦Â1 renal fibrosis HK2 cells TGF-¦Â1 treatment downregulated 30095214 3578 Human hsa-miR-185-3p miRNA ursolic acid (UA) breast cancer MCF-7 cells usnic acid treatment downregulated 31549595 3579 Human hsa-miR-185-3p miRNA hypoxia hypoxia-induced injury ?12 soft tissue sarcoma cell lines was exposed to 1% oxygen (hypoxia) for up to 48 h treatment upregulated 24927770 3580 Human hsa-miR-185-3p miRNA tumor necrosis factor alpha (TNF-¦Á) inflammatory bowel disease (IBD) Human colorectal cancer cell line Caco-2 tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 30615124 3581 Human hsa-miR-185-5p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 3582 Human hsa-miR-185-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment Circ_WBSCR17 aggravates inflammatory responses and fibrosis by targeting miR-185-5p/SOX6 regulatory axis in high glucose-induced human kidney tubular cells 32798559 3583 Human hsa-miR-185-5p miRNA regorafenib frail metastatic colorectal cancer (mCRC) serum regorafenib treatment "Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia" 33916610 3584 Human hsa-miR-185-5p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment downregulated 25129238 3585 Human hsa-miR-185-5p miRNA palmitate insulin resistance (IR) Human HepG2 cells and primary hepatocytes "To establish an insulin-resistant hepatocyte cell model, hepatocytes were stimulated by palmitate (0.25 mM, Sigma-Aldrich, St. Louis, MO, USA) for 24 h, and treated with insulin (100 nM) for 20 min before harvest. treatment" but miR-185-5p was downregulated in palmitate-treated insulin resistance hepatocytes and HFD mice 31298399 3586 Human hsa-miR-185-5p miRNA TNF-¦Á and IL-1¦Â intervertebral disc degeneration (IDD) NP cells TNF-¦Á and IL-1¦Â treatment circ-TIMP2 promoted TNF-¦Á- and IL-1¦Â-induced NP cell imbalance between ECM anabolism and catabolism via miR-185-5p-MMP2 signaling 32626912 3587 Human hsa-miR-185-5p miRNA hypoxia myocardial infarction (MI) human umbilical vein endothelial cells (HUVECs) hypoxia induce downregulated 30450725 3588 Human hsa-miR-185-5p miRNA noise noise-induced hearing loss (NIHL) plasma noise treatment downregulated 26278637 3589 Human hsa-miR-185-5p miRNA fractionated radiation radiation-induced injury human peripheral blood mononuclear cells fractionated radiation treatment upregulated 25313363 3590 Human hsa-miR-185-5p miRNA IFN-¦Â relapsing-remitting multiple sclerosis (RRMS) whole blood IFN-¦Â treatment miR-185¨C5p was downregulated in responders to IFN-¦Â therapy in RRMS patients. 32554287 3591 Human hsa-miR-185-5p miRNA escitalopram side effects of antidepressant drugs peripheral escitalopram treatment upregulated 31819986 3592 Human hsa-miR-186 miRNA resistin chondrosarcoma lymphatic endothelial cells (LECs) resistin treatment downregulated 29730230 3593 Human hsa-miR-186 miRNA methotrexate (MTX) colorectal cancer (CRC) human colorectal cancer cell lines HT-29-P/HT-29-R cell and HCT-8 cells methotrexate treatment downregulated 28805722 3594 Human hsa-miR-186 miRNA hypoxia hypoxia-induced injury Human umbilical vein endothelial cells (HUVECs) hypoxia induce upregulated 31511208 3595 Human hsa-miR-186 miRNA curcumin (Cur) lung cancer The A549 human lung adenocarcinoma cell line curcumin treatment Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186*signaling pathway 20878113 3596 Human hsa-miR-186 miRNA angiotensin II (Ang II) membranous nephropathy (MN) renal tissue and podocyte cells angiotensin II (Ang II) treatment downregulated 26382839 3597 Human hsa-miR-186 miRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) AC16 cells hypoxia/reoxygenation (H/R) treatment Knockdown of long non-coding RNA PVT1 protects human AC16 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis and autophagy by regulating miR-186/Beclin-1 axis. 32428696 3598 Human hsa-miR-186 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 3599 Human hsa-miR-186 miRNA cyclosporine A (CsA) nephrotoxicity HEK293 cyclosporine A treatment upregulated 28414804 3600 Human hsa-miR-186 miRNA lycorine non-small cell lung cancer (NSCLC) "NSCLC cell lines including A549, H1299 and H460, normal cell BEAS-2B" Lycorine treatment upregulated 31176784 3601 Human hsa-miR-186 miRNA repeatedly passed premature senescence lung fibroblast IMR-90 cells repeatedly passed until a senescence-like state was observed treatment upregulated 25139266 3602 Human hsa-miR-186 miRNA running telomere homeostasis twenty-two healthy males white blood cells undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment upregulated 24752326 3603 Human hsa-miR-186 miRNA aerobic exercise vascular cognitive impairment (VCI) serum aerobic exercise training (AET) treatment "Aerobic exercise could shorten the average time that mice reached the platform in the Morris water maze, increase the expression level of circRIMS2 and BDNF, reduce miR-186 expression, and inhibit neuronal apoptosis." 33413076 3604 Human hsa-miR-186 miRNA hypoxia "vascular endothelial cell proliferation , apoptosis" human umbilical vein endothelial cells (HUVECs) hypoxia treatment downregulated 28571741 3605 Human hsa-miR-186-5p miRNA ethanol (EtOH) alcoholic cardiomyopathy (ACM) AC16 cardiomyocytes ethanol treatment upregulated 30816481 3606 Human hsa-miR-186-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment E2F1/SNHG7/miR-186-5p/MMP2 axis modulates the proliferation and migration of vascular endothelial cell in atherosclerosis 32603818 3607 Human hsa-miR-186-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32735135 3608 Human hsa-miR-186-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Vascular smooth muscle cells (VSMCs); human mononuclear cells (U938) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32876518 3609 Human hsa-miR-186-5p miRNA propofol (PPF) heart failure (HF) Human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs) Propofol (PPF) treatment miR-186-5p was downregulated in HiPSC-CMs treated by propofol (PPF) 32968636 3610 Human hsa-miR-186-5p miRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment downregulated 29399065 3611 Human hsa-miR-186-5p miRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment miR-186-5p expression was downregulated in HG-treated cardiomyocytes. 30506923 3612 Human hsa-miR-186-5p miRNA high glucose (HG) diabetic cardiomyopathy (DCM) Human cardiomyocyte AC16 cells high glucose (HG) treatment downregulated 30506923 3613 Human hsa-miR-186-5p miRNA hypoxia dysfunction of vascular endothelial cells human umbilical vein endothelial cells (HUVECs) hypoxia treatment downregulated of TTTY15 ameliorated hypoxia-induced cell injury by targeting miR-186-5p in HUVECs. 32271447 3614 Human hsa-miR-186-5p miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment upregulated 30503955 3615 Human hsa-miR-186-5p miRNA high glucose (HG) high glucose (HG)-induced cytotoxicity and apoptosis AC16 cells HG downregulated 29399065 3616 Human hsa-miR-186-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 30443183 3617 Human hsa-miR-186-5p miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H1299 cells cisplatin treatment Expression of miR-186-5p was downregulated in DDP resistant NSCLC tissues and cells (A549/DDP and H1299/DDP). 31686523 3618 Human hsa-miR-186-5p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment upregulated 27143365 3619 Human hsa-miR-186-5p miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment IL-1¦Â treatment significantly upregulated miR-186-5p expression in CHON-001 cells. 33537828 3620 Human hsa-miR-187 miRNA IL-10 anti-inflammatory responses primary human monocytes IL-10 treatment downregulated 23071313 3621 Human hsa-miR-187 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment upregulated 25959385 3622 Human hsa-miR-187 miRNA 5-fluorouracil/cisplatin (CDDP-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) CDDP-CRTX treatment dysregulated 28347920 3623 Human hsa-miR-187 miRNA IL-17A psoriasis HaCaT cells and primary cultured normal human keratinocytes IL-6 treatment downregulated 30607907 3624 Human hsa-miR-187 miRNA IL-1¦Â psoriasis HaCaT cells and primary cultured normal human keratinocytes IL-6 treatment downregulated 30607907 3625 Human hsa-miR-187 miRNA IL-22 psoriasis HaCaT cells and primary cultured normal human keratinocytes IL-6 treatment downregulated 30607907 3626 Human hsa-miR-187 miRNA IL-6 psoriasis HaCaT cells and primary cultured normal human keratinocytes IL-6 treatment downregulated 30607907 3627 Human hsa-miR-187 miRNA tumor necrosis factor alpha (TNF-¦Á) psoriasis HaCaT cells and primary cultured normal human keratinocytes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 30607907 3628 Human hsa-miR-187-3p miRNA IFN-¦Ã epithelial-mesenchymal transition (EMT) PC-3M IE8 cells interferon-¦Ã (IFN-¦Ã) treatment downregulated in PC-3M IE8 cells in the EMT induction model 31882179 3629 Human hsa-miR-187-3p miRNA IFN-¦Ã epithelial-mesenchymal transition (EMT) PC-3M IE8 cells IFN-¦Ã treatment Hsa-miR-187-3p was downregulated in PC-3M IE8 cells treatment with IFN-¦Ã. 31882179 3630 Human hsa-miR-187-3p miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 29218085 3631 Human hsa-miR-187a miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 3632 Human hsa-miR-188 miRNA iodixanol contrast-induced acute kidney injury (CIAKI) HK-2 cells iodixanol treatment upregulated 31555692 3633 Human hsa-miR-188 miRNA erythropoietin (EPO) erythroid cell differentiation The original UT-7 cell line erythropoietin treatment upregulated 18492109 3634 Human hsa-miR-188-5p miRNA hypoxia cardiomyocyte apoptosis AC16 cells hypoxia treatment downregulated 32970504 3635 Human hsa-miR-188-5p miRNA morin chronic myeloid leukemia (CML) CML cell lines K562 and KCL22 Morin treatment downregulated 31515296 3636 Human hsa-miR-188-5p miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 3637 Human hsa-miR-188-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose treatment upregulated 30263007 3638 Human hsa-miR-188-5p miRNA triptolide (TPL) diabetic nephropathy (DN) high glucose-treated HK-2 cells triptolide (TPL) treatment downregulated 30263007 3639 Human hsa-miR-188-5p miRNA berberine (BBR) melanoma A375 cells berberine (BBR) treatment The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression. 32915362 3640 Human hsa-miR-188-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 3641 Human hsa-miR-188-5p miRNA oxygen glucose deprivation (OGD) stroke human neural cell line HNC oxygen glucose deprivation (OGD) treatment The expressions of miR-188-5p and PTEN got increased with increasing OGD treatment time. 32745469 3642 Human hsa-miR-189 miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment downregulated 20346162 3643 Human hsa-miR-18a miRNA camptothecin biologic and molecular activity of camptothecin hypoxic-human cancer cells camptothecin treatment upregulated 24252850 3644 Human hsa-miR-18a miRNA polyphyllin VI (PP-VI) breast cancer MDA-MB-231 cells Polyphyllin VI (PP-VI) treatment downregulated 30817902 3645 Human hsa-miR-18a miRNA trastuzumab breast cancer SKBR-3 cells trastuzumab treatment downregulated 29408336 3646 Human hsa-miR-18a miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment downregulated 20346162 3647 Human hsa-miR-18a miRNA AVM-derived brain endothelial cells Conditioned media (AVM-BEC-CM) cerebral arteriovenous malformation (AVM) brain-derived endothelial cells AVM-BEC-CM treatment upregulated 24837588 3648 Human hsa-miR-18a miRNA radiation cervical cancer (CC) cervical cancer cells radiation treatment Higher expression of miR-18a in cervical cancer cells leads to more radiosensitivity 30308669 3649 Human hsa-miR-18a miRNA hypoxia gastric cancer (GC) "Human gastric carcinoma cell lines, MGC-803 and HGC-27," Hypoxia treatment downregulated 26622381 3650 Human hsa-miR-18a miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) tissues sorafenib treatment dysregulated 28049231 3651 Human hsa-miR-18a miRNA human papillomavirus E6 and E7 human papillomaviruses (HPV) infection K16 and K38 supernatants Human papillomavirus E6 and E7 treatment "HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p." 27300513 3652 Human hsa-miR-18a miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 3653 Human hsa-miR-18a miRNA hypoxia lymphoma Human Burkitt lymphomas cell lines P3HR-1; Raji(EBV positive) hypoixa induce upregulated 30594162 3654 Human hsa-miR-18a miRNA ultraviolet (UV) irradiation lymphoma "Human Burkitt lymphomas cell lines P3HR-1, Raji(EBV positive)" UV irradiation treatment upregulated 30594162 3655 Human hsa-miR-18a miRNA ¦Á-mangostin (¦ÁM) and ¦Ã-mangostin (¦ÃM) pancreatic cancer (PC) human pancreatic cancer cell lines MIA PaCa-2 and PANC-1 ¦ÁM or ¦ÃM treatment downregulated 28822990 3656 Human hsa-miR-18a miRNA fractional CO(2) laser prostate cancer types I and III procollagen treatment with a fractional CO(2) laser miR-18a and miR-19a were dramatically upregulated 22907286 3657 Human hsa-miR-18a miRNA ¦Á-solanine prostate cancer Human normal prostate epithelial cell line RWPE-1 and PCa cell lines DU145 and PC-3 ¦Á-Solanine treatment downregulated 30970507 3658 Human hsa-miR-18a-5p miRNA paclitaxel (PTX) breast cancer MCF-7 cells and MDA-MB-231 cells paclitaxel (PTX) treatment downregulated 31352515 3659 Human hsa-miR-18a-5p miRNA PXR ligand rifampicin expression regulation HepG2 cells PXR ligand rifampicin treatment upregulated 31998607 3660 Human hsa-miR-18a-5p miRNA activin A prostate cancer LNCaP cells activin A treatment downregulated 27018851 3661 Human hsa-miR-18a-5p miRNA hypoxia pulmonary arterial hypertension (PAH) pulmonary arterial smooth muscle cells (PASMCs) hypoxia treatment upregulated 32585247 3662 Human hsa-miR-18a-5p miRNA bleomycin (BLM) lung fibrosis human PMC line MeT-5A bleomycin (BLM) treatment downregulated 28131417 3663 Human hsa-miR-18b miRNA bone morphogenetic protein 2 (BMP2) tumorigenesis NT2/D1 cells "BMP-2 at 6, 12, and 24 h, and on days 6 and 10 treatment" upregulated 24383669 3664 Human hsa-miR-18b miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment KCNQ1OT1 expression was increased and miR-18b expression was decreased in DN patients and HG-challenged HMCs. 32989627 3665 Human hsa-miR-18b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) high glucose treatment downregulated 26851511 3666 Human hsa-miR-18b miRNA TGF-¦Â cell differentiation Human hair follicle mesenchymal stem cells (hHF-MSCs) transforming growth factor-¦Â (TGF-¦Â) treatment upregulated 23916701 3667 Human hsa-miR-18b miRNA cisplatin (DDP) melanoma A375/DDP; M8/DDP cells cisplatin treatment lncRNA H19 could influence DDP-resistance by modulating the miR-18b/IGF axis in melanoma cells. 32265386 3668 Human hsa-miR-18b miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 3669 Human hsa-miR-18b-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 3670 Human hsa-miR-19 miRNA triptolide (TPL) hepatocellular carcinoma (HCC) HepG2 cells triptolide (TPL) treatment downregulated 29523159 3671 Human hsa-miR-19 miRNA estradiol-17¦Â (E2) innate immune response "THP-1 (human acute monocytic leukaemia cell line), U937 (Human monocytic [histiocytic lymphoma] cell line)" estradiol-17¦Â (E2) treatment upregulated 31266011 3672 Human hsa-miR-19 miRNA hydatid cyst fluid (HCF) liver fibrosis LX-2 cells LX-2 cells treatment downregulated 27177776 3673 Human hsa-miR-19 miRNA estradiol-17¦Â (E2) lung diseases human monocytic cells estradiol-17¦Â (E2) treatment E2 downregulated SLPI and upregulated miR-19 expression in monocytes. 31266011 3674 Human hsa-miR-19 miRNA aluminum maltolate (Al-malt) neurodegenerative pathogenesis neuroblastoma SH-SY5Y cells aluminum maltolate (Al-malt) treatment upregulated 26836165 3675 Human hsa-miR-190 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 3676 Human hsa-miR-190 miRNA hypoxia pulmonary hypertension (PH) human plasma hypoxia treatment upregulated 28971974 3677 Human hsa-miR-1907 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28804559 3678 Human hsa-miR-1908 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 3679 Human hsa-miR-1908 miRNA adipokines obesity-related complications mature human adipocytes resistin and leptin treatment downregulated 24898511 3680 Human hsa-miR-1908 miRNA TNF-¦Á and IL-6 obesity-related complications mature human adipocytes TNF-¦Á and IL-6 treatment upregulated 24898511 3681 Human hsa-miR-1909* miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 3682 Human hsa-miR-190a miRNA benzo(a)pyrene (BaP) cell proliferation primary cell cultures from normal endometrial tissue benzo(a)pyrene (BaP) exposure upregulated 30811740 3683 Human hsa-miR-190a miRNA dichlorodiphenyltrichloroethane (DDT) dichlorodiphenyltrichloroethane (DDT) exposure normal endometrial cells dichlorodiphenyltrichloroethane (DDT) exposure upregulated 30421125 3684 Human hsa-miR-190a miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 3685 Human hsa-miR-190a-5p miRNA hypoxia chronic obstructive pulmonary disease (COPD) human pulmonary endothelial cells (HPECs) hypoxia induce upregulated 30538440 3686 Human hsa-miR-190b miRNA tocotrienols (¦Ã and ¦ÄT3) apoptosis HeLa cells tocotrienols (¦Ã and ¦ÄT3) treatment Involvement of miR-190b in Xbp1 mRNA Splicing upon Tocotrienol Treatment 33396504 3687 Human hsa-miR-190b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 33378035 3688 Human hsa-miR-190b miRNA single-walled carbon nanotubes (SWCNTs) immune response normal human astrocytes (line NHA/TS) single-walled carbon nanotubes (SWCNTs) treatment upregulated 29906516 3689 Human hsa-miR-190b miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) LO-2 cells free fatty acid treatment upregulated 29575055 3690 Human hsa-miR-191 miRNA oxalic acid poisoning acute kidney injury (AKI) urinary oxalic acid poisoning upregulated 32910981 3691 Human hsa-miR-191 miRNA inorganic arsenic (iAs) arsenic poisoning human liver epithelial L-02 cells acute or chronic exposure to arsenite upregulated 29277653 3692 Human hsa-miR-191 miRNA arsenite arsenic-induced multiorgan damage plasma arsenic exposure upregulated 31085440 3693 Human hsa-miR-191 miRNA arsenite arsenic-induced multiorgan damage plasma arsenite exposure upregulated 31775542 3694 Human hsa-miR-191 miRNA arsenite arsenic-induced renal dysfunction Plasma arsenic (As) exposure upregulated 31775542 3695 Human hsa-miR-191 miRNA arsenite arsenicism L-02 cells arsenite exposure upregulated 33743404 3696 Human hsa-miR-191 miRNA estradiol breast cancer MCF7 and T-47D cells estradiol treatment upregulated 29247596 3697 Human hsa-miR-191 miRNA 5-fluorouracil (5-Fu) and oxaliplatin colorectal cancer (CRC) human colon cancer cells 5-Fluorouracil and oxaliplatin treatment downregulated 19956872 3698 Human hsa-miR-191 miRNA triptolide (TPL) colorectal cancer (CRC) Human CRC cell lines HT-29 and SW480 Triptolide (TPL) treatment downregulated 30684462 3699 Human hsa-miR-191 miRNA ¦Â-elemene colorectal cancer (CRC) colorectal carcinoma cells (HCT116 and HT29) beta-elemene treatment downregulated 29737579 3700 Human hsa-miR-191 miRNA cisplatin (DDP) DNA damage HeLa cells cisplatin treatment MicroRNA-191 modulates cisplatin-induced DNA damage response by targeting RCC2. 32803782 3701 Human hsa-miR-191 miRNA cigarette smoke extract (CSE) hepatic insulin resistance L-02 cells cigarette smoke extract (CSE) exposure CSE also increased miR-191 levels in L-02 cells. 28963693 3702 Human hsa-miR-191 miRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) LO-2 cells hypoxia induce upregulated 29769640 3703 Human hsa-miR-191 miRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) LO-2 cells hypoxia/reperfusion (H/R)?induce upregulated 29769640 3704 Human hsa-miR-191 miRNA arsenite hepatocellular carcinoma (HCC) human liver epithelial L-02 cells arsenite exposure upregulated 29277653 3705 Human hsa-miR-191 miRNA hypoxia inducible factor (HIF)-1 hypoxic breast tumors MCF7 cells;MM231 cells; breast adenocarcinoma cells hypoxia-inducible factor (HIF) treatment upregulated 25867965 3706 Human hsa-miR-191 miRNA dioxin kidney fibrosis "Hep3B, SNU423, andHepG2 cell lines" dioxin treatment upregulated 20924108 3707 Human hsa-miR-191 miRNA antrodia cinnamomea hepatocellular carcinoma (HCC) SK-Hep-1 liver cancer cell antrodia cinnamomea treatment "oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated" 24358224 3708 Human hsa-miR-191 miRNA arsenite lung cancer human bronchial epithelial (HBE) cells arsenite exposure upregulated 25252218 3709 Human hsa-miR-191 miRNA arsenite lung cancer HBE cells arsenite exposure upregulated 25252218 3710 Human hsa-miR-191 miRNA radiation lung cancer A549 cells radiation treatment upregulated 32968458 3711 Human hsa-miR-191 miRNA hypoxia non-small cell lung cancer (NSCLC) SK-MES-1cells; A549 cells; NCI-H460 cells;NSCLC cells chronic hypoxia upregulated 28075452 3712 Human hsa-miR-191 miRNA hypoxia rheumatoid arthritis (RA) rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) hypoxia induce upregulated 30894209 3713 Human hsa-miR-191 miRNA cigarette smoke (CS) type 2 diabetes mellitus (T2DM) L-02 cells cigarette smoke (CS)?exposure upregulated 28963693 3714 Human hsa-miR-1910-3p miRNA metformin (Met) polycystic ovarian syndrome (PCOS) human Ishikawa cells metformin treatment downregulated 30599813 3715 Human hsa-miR-1910-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 3716 Human hsa-miR-191-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 3717 Human hsa-miR-1914* miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 3718 Human hsa-miR-1914-5p miRNA heptapeptide angiotensin-(1-7) [ang-(1-7)] liver fibrosis LX-2 cells heptapeptide angiotensin-(1-7) [ang-(1-7)] treatment upregulated 29524604 3719 Human hsa-miR-1915 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) GC tissues and GC cells SGC-7901 and MKN45 Helicobacter pylori (HP) infection downregulated 30554489 3720 Human hsa-miR-1915-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 3721 Human hsa-miR-191-5p miRNA FTY-720 leukemia OCI-AML3 cells FTY-720 treatment upregulated 24858343 3722 Human hsa-miR-191-5p miRNA activin A prostate cancer PC3 cells activin A treatment upregulated 27018851 3723 Human hsa-miR-191-5p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) neutrophil M.tb infection downregulated 29477867 3724 Human hsa-miR-192 miRNA statins active hepatitis or cirrhosis HepG2 cells statins? treatment upregulated 26429200 3725 Human hsa-miR-192 miRNA silver nanoparticles (AgNPs) apoptosis lung cancer cell line (A549) Silver nanoparticles (AgNPs) treatment upregulated 30479160 3726 Human hsa-miR-192 miRNA aristolochic acid aristolochic acid nephropathy Primary human renal PTCs aristolochic acid (AA) treatment upregulated 24508230 3727 Human hsa-miR-192 miRNA neutral bile mixture barrett's esophagus Het-1A cells neutral bile mixture treatment upregulated 24006894 3728 Human hsa-miR-192 miRNA TGF-¦Â1 breast cancer Primary human renal epithelial PTCs ( Transforming growth factor ¦Â1 treatment downregulated 22264233 3729 Human hsa-miR-192 miRNA lipopolysaccharide (LPS) cervical cancer (CC) HeLa cells lipopolysaccharide (LPS) treatment upregulated 31450920 3730 Human hsa-miR-192 miRNA proline-rich polypeptide 1 (PRP-1) chondrosarcoma human JJ012 chondrosarcoma cell line PRP-1 treatment upregulated 24178909 3731 Human hsa-miR-192 miRNA suberoylanilide hydroxamic acid (SAHA) chronic myeloid leukemia (CML) K562 cells suberoylanilide hydroxamic acid (SAHA) treatment upregulated 29343029 3732 Human hsa-miR-192 miRNA simvastatin colorectal cancer (CRC) colon cancer HCT-116 cells Simvastatin treatment upregulated 30628692 3733 Human hsa-miR-192 miRNA muramyl dipeptide crohn disease (CD) ?HCT116 cells Muramyl dipeptide treatment downregulated 24297055 3734 Human hsa-miR-192 miRNA exendin-4 and high glucose (Ex-HG) diabetic nephropathy (DN) HK-2 cells exendin-4 and high glucose (Ex-HG) treatment HG and exendin-4 may have contributed to a decrease in miR-192 in both HK-2 cells and EVs in a p53-dependent manner. 29717107 3735 Human hsa-miR-192 miRNA bisphenol A (BPA) hepatic steatosis and lipid accumulation human HepG2 cells bisphenol A (BPA) treatment downregulated 28483554 3736 Human hsa-miR-192 miRNA hepatitis C virus (HCV) hepatitis C virus (HCV)-mediated hepatic fibrosis human hepatic stellate cells (HSCs) line LX-2 hepatitis C virus (HCV) infection upregulated 30753992 3737 Human hsa-miR-192 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Plasma hepatitis B virus (HBV) infection ?upregulated 22105822 3738 Human hsa-miR-192 miRNA acidic bile hypopharyngeal cancer human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) acidic bile exposure upregulated 29516639 3739 Human hsa-miR-192 miRNA BAY11-7082 hypopharyngeal cancer Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) BAY 11-7082 treatment downregulated 29516639 3740 Human hsa-miR-192 miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 parental hepatoma cells hepatitis C virus (HCV) infection downregulated 23418453 3741 Human hsa-miR-192 miRNA IL-17 multiple myeloma (MM) MM cells IL-17 treatment downregulated 25489847 3742 Human hsa-miR-192 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) Huh7 cells exosomes palmitic acid (PA) treatment upregulated in exosomes 28623272 3743 Human hsa-miR-192 miRNA nicotine non-small cell lung cancer (NSCLC) A549 and NCI-H460 cells nicotine treatment downregulated 29518612 3744 Human hsa-miR-192 miRNA opisthorchis viverrini opisthorchis viverrini infection human urine infect with Opisthorchis viverrini upregulated in the urine 26456596 3745 Human hsa-miR-192 miRNA acetaminophen (APAP) prostate cancer serum acetaminophen (APAP) treatment ?Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients 22045675 3746 Human hsa-miR-192 miRNA acidic bile salt reflux esophagitis Het-1A cells acidic bile salt treatment upregulated 24006894 3747 Human hsa-miR-192 miRNA astragaloside IV (AS-IV) renal fibrosis TGF-¦Â1-treated HK-2 cells astragaloside (AS-IV) treatment downregulated 31497219 3748 Human hsa-miR-192 miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment upregulated 31497219 3749 Human hsa-miR-192 miRNA retinoic acid (RA) cell senescence SH-SY5Y cells retinoic acid (RA) treatment upregulated 27525675 3750 Human hsa-miR-192 miRNA retinoic acid (RA) cell senescence SH-SY5Y cells SH-SY5Y cells treatment upregulation 27525675 3751 Human hsa-miR-192 miRNA metformin (Met) type 2 diabetes mellitus (T2DM) The human renal epithelial cells (293T cells) metformin treatment differently regulated in circulating 24478399 3752 Human hsa-miR-192-5p miRNA vancomycin (VAN) acute kidney injury (AKI) human renal tubular +H57epithelial cell line (HK-2) human renal tubular +H57epithelial cell line (HK-2) treatment upregulation 27941921 3753 Human hsa-miR-192-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 3754 Human hsa-miR-192-5p miRNA oleic acid (OA) diabetes-associated metabolic disorders HepG2 cells oleate treatment circHIPK3 contributes to hyperglycemia and insulin resistance by sponging miR-192-5p and up-regulating FOXO1. 31875589 3755 Human hsa-miR-192-5p miRNA chlorpromazine (CHLO) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) treatment upregulated 31198949 3756 Human hsa-miR-192-5p miRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells cisplatin treatment downregulated 30854110 3757 Human hsa-miR-192-5p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 3758 Human hsa-miR-192-5p miRNA "N,N-dimethylformamide (DMF)" hepatotoxicity HL-7702 liver cells "N,N-dimethylformamide (DMF) treatment" "Aberrant expression of miRNA-192-5p contributes to N,N-dimethylformamide-induced hepatic apoptosis." 32648274 3759 Human hsa-miR-192-5p miRNA perfluorooctanoic acid hepatotoxicity occupational workers serum Perfluorooctanoic acid (PFOA) exposure treatment upregulated 24459700 3760 Human hsa-miR-192-5p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 3761 Human hsa-miR-192-5p miRNA oleic acid (OA) hyperglycemia and insulin resistance HepG2 cells oleate treatment downregulated 31875589 3762 Human hsa-miR-192-5p miRNA metformin (Met) melanoma "The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951" Metformin treatment upregulated 30754729 3763 Human hsa-miR-192-5p miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) Huh7 cells palmitic acid (PA) treatment upregulated 29290651 3764 Human hsa-miR-192-5p miRNA curcumin (Cur) non-small cell lung cancer (NSCLC) non-small cell lung cancer cells curcumin treatment upregulated 26351877 3765 Human hsa-miR-192-5p miRNA curcumin (Cur) non-small cell lung cancer (NSCLC) A427 cells; A549 cells curcumin treatment Curcumin treatment promoting the expression levels of miR-192-5p. 32626956 3766 Human hsa-miR-192-5p miRNA curcumin (Cur) non-small cell lung cancer (NSCLC) H460 and A427 cells curcumin treatment upregulated 25444916 3767 Human hsa-miR-192-5p miRNA cisplatin (DDP) ovarian cancer (OC) human ovarian cancer cells OVCAR-8R cisplatin treatment dysregulated 28861582 3768 Human hsa-miR-192-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 3769 Human hsa-miR-192b-5p miRNA arsenite tumorigenesis human bronchial epithelial (HBE) cells arsenic exposure "upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)" 28972549 3770 Human hsa-miR-193 miRNA cisplatin (DDP) esophageal cancer (EC) TE-1 cells cisplatin treatment upregulated 32369495 3771 Human hsa-miR-193 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87 and T98G cells temozolomide (TMZ) treatment miR-93 and -193 decreased cell cycling quiescence and induced resistance to TMZ. 30853911 3772 Human hsa-miR-193-5p miRNA brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) cell senescence SH-SY5Y cells brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment upregulated 27525675 3773 Human hsa-miR-193-5p miRNA retinoic acid (RA) cell senescence SH-SY5Y cells retinoic acid (RA) treatment upregulated 27525675 3774 Human hsa-miR-193-5p miRNA retinoic acid (RA) cell senescence SH-SY5Y cells SH-SY5Y cells treatment upregulation 27525675 3775 Human hsa-miR-193a miRNA high glucose (HG) diabetic podocytopathy Human podocytes (PDs) high glucose (HG) treatment upregulated 29357419 3776 Human hsa-miR-193a miRNA D-glucose epithelial-mesenchymal transition (EMT) peritoneal mesothelial cells (PMCs) D-glucose treatment upregulated 25683944 3777 Human hsa-miR-193a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" lung cancer NSCLC A549 cells 5-aza-20-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A treatment upregulated 22282464 3778 Human hsa-miR-193a-3p miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 31857133 3779 Human hsa-miR-193a-3p miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment miR-193a-3p was significantly downregulated in SH-SY5Y cells. 31857133 3780 Human hsa-miR-193a-3p miRNA dextran sodium sulfate (DSS) colitis Human intestinal epithelial Caco2 dextran sodium sulfate (DSS) treatment "Intracolonic delivery of miR-193a-3p significantly ameliorated dextran sodium sulfate-induced colitis, whereas the overexpression of colonic PepT1 via PepT1 3'-untranslated region mutant lentivirus vector abolished the anti-inflammatory effect of miR-193a-3p" 25931122 3781 Human hsa-miR-193a-3p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment upregulated 25129238 3782 Human hsa-miR-193a-3p miRNA activin A liver fibrosis LX-2 cells activin A treatment downregulated 30945448 3783 Human hsa-miR-193a-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment downregulated 30945448 3784 Human hsa-miR-193a-3p miRNA oleacein (OA) melanoma 501Mel melanoma cells oleacein (OA) treatment upregulated 33071785 3785 Human hsa-miR-193a-3p miRNA intermittent hypoxia (IH) obstructive sleep apnea (OSA) human umbilical vein endothelial cells (HUVECs) intermittent hypoxia(IH) treatment miR-193a-3p was upregulated in HUVECs exposed to IH. 32003752 3786 Human hsa-miR-193a-3p miRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment downregulated 31632562 3787 Human hsa-miR-193a-3p miRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) MH7A cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31210318 3788 Human hsa-miR-193a-5p miRNA lipopolysaccharide (LPS) acute inflammatory response HMEEC lipopolysaccharide (LPS) treatment upregulated 21377743 3789 Human hsa-miR-193a-5p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human bronchial epithelial cells (HBECs) cigarette smoke extract (CSE) treatment "Circ-OSBPL2 was highly expressed in lung tissues of smokers without or with COPD, particularly in smokers with COPD." 33854310 3790 Human hsa-miR-193a-5p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U257 cells; U87 cells temozolomide (TMZ) treatment upregulated 29136760 3791 Human hsa-miR-193a-5p miRNA hypoxia kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection human KS-derived SLK and SLKK cells hypoxia treatment upregulated 28046107 3792 Human hsa-miR-193a-5p miRNA docetaxel (DTX) prostate cancer PC3 cells docetaxel (DTX) treatment upregulated 29216925 3793 Human hsa-miR-193b miRNA beryllium sulfate (BeSO4 ) beryllium toxicity 16HBE cells beryllium sulfate (BeSO4 ) treatment upregulated 33197057 3794 Human hsa-miR-193b miRNA zirconia and titanium bone formation Osteoblast-like cells (MG63) zirconia and titanium? treatment upregulated 18241218 3795 Human hsa-miR-193b miRNA TGF-¦Â1 gastric cancer (GC) BGC-823 cells; SGC7901 cells; MKN28 cell TGF-¦Â1 treatment downregulated 23372348 3796 Human hsa-miR-193b miRNA metformin (Met) triple negative breast cancer (TNBC) triple-negative breast cancer (TNBC) cell lines metformin treatment upregulated 25213330 3797 Human hsa-miR-193b miRNA IL-4 monocytic differentiation monocyte IL-4 treatment dysregulated 25148686 3798 Human hsa-miR-193b miRNA progesterone (P4) endometrial cancer (EC) Hec8A cells Progesterone treatment downregulated 22543862 3799 Human hsa-miR-193b* miRNA hypoxia gastroesophageal cancer (GEC) ESCC and AC cell lines Hypoxia treatment upregulated 26851030 3800 Human hsa-miR-193b-3p miRNA IL-1¦Â chondrogenesis and metabolism primary human chondrocytes (PHCs) IL-1¦Â treatment IL-1¦Â stimulation resulted in decreased miR-193b-3p expression. 29344280 3801 Human hsa-miR-193b-3p miRNA activin A liver fibrosis LX-2 cells activin A treatment downregulated 30945448 3802 Human hsa-miR-193b-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment downregulated 30945448 3803 Human hsa-miR-193b-3p miRNA triptolide (TPL) nephroblastoma human nephroblastoma cells (G-401 and WiT49) triptolide (TPL) treatment upregulated 30978333 3804 Human hsa-miR-193b-3p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment downregulated 29323744 3805 Human hsa-miR-193b-5p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes (PHCs) IL-1¦Â treatment downregulated 30854734 3806 Human hsa-miR-19-3p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 3807 Human hsa-miR-194 miRNA ethanol (EtOH) alcoholic liver disease (ALD) LO2 cells ethanol treatment "MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)." 33068587 3808 Human hsa-miR-194 miRNA yangonin (Yan) alcoholic liver disease (ALD) LO2 cells Yangonin (Yan) treatment "MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yan" 33068587 3809 Human hsa-miR-194 miRNA yangonin (Yan) alcoholic liver disease (ALD) ethanol-induced LO2 cells Yangonin (Yan) treatment "MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)" 33068587 3810 Human hsa-miR-194 miRNA aristolochic acid aristolochic acid nephropathy Primary human renal PTCs aristolochic acid (AA) treatment upregulated 24508230 3811 Human hsa-miR-194 miRNA neutral bile mixture barrett's esophagus Het-1A cells neutral bile mixture treatment upregulated 24006894 3812 Human hsa-miR-194 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells docosahexaenoic acid (DHA) fatty acids treatment MDA-MB-231 cells with DHA caused an increase in the miR-194 expression. 31713924 3813 Human hsa-miR-194 miRNA trastuzumab breast cancer BT474 cells;SKBr3 cells; MDA-MB-361 cells;MDA-MB-231 cells Trastuzumab treatment trastuzumab treatment upregulates miR-194 expression and may exert its cell migration-inhibitory effect through miR-194-mediated downregulated of cytoskeleton protein talin2 in HER2-overexpressing human breast cancer cells 22829924 3814 Human hsa-miR-194 miRNA hepatitis B virus (HBV) chronic hepatitis B virus (HBV) infection plasma or liver tissues of CHB patients hepatitis B virus (HBV)infection upregulated 30044042 3815 Human hsa-miR-194 miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 3816 Human hsa-miR-194 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Plasma hepatitis B virus (HBV) infection ?upregulated 22105822 3817 Human hsa-miR-194 miRNA palmitic acid (PA) inflammatory response Human THP-1 cells palmitic acid (PA) treatment downregulated 25984739 3818 Human hsa-miR-194 miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 alveolar epithelial cells (AECs) infec with IAV/Beijing/501/2009 (BJ501) downregulated 29163456 3819 Human hsa-miR-194 miRNA high glucose (HG) lung cancer Human lung cancer cell lines A549 and H1299 high glucose (HG) treatment downregulated 30900402 3820 Human hsa-miR-194 miRNA green tea (GT) nonalcoholic fatty liver disease (NAFLD) TNF-¦Á-treated HepG2 cells green tea (GT) treatment upregulated 31885789 3821 Human hsa-miR-194 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) human derived HepG2 cell palmitic acid treatment upregulated 28951211 3822 Human hsa-miR-194 miRNA tumor necrosis factor alpha (TNF-¦Á) nonalcoholic fatty liver disease (NAFLD) HepG2 cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 31885789 3823 Human hsa-miR-194 miRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3ip1 cells; HeyA8 cells paclitaxel (PTX) treatment downregulated 33028939 3824 Human hsa-miR-194 miRNA acidic bile salt reflux esophagitis Het-1A cells acidic bile salt treatment upregulated 24006894 3825 Human hsa-miR-194 miRNA hypoxia/reoxygenation (H/R) renal ischemia/reperfusion (I/R) injury HK-2 cells hypoxia/reperfusion (H/R) treatment miR-194 was decreased in H/R-induced HK-2 cells. 30485514 3826 Human hsa-miR-194 miRNA lycium barbarum polysaccharide (LBP) spinal cord injury (SCI) SH-SY5Y cells Lycium barbarum polysaccharides (LBPs) treatment downregulated 30308510 3827 Human hsa-miR-194 miRNA docosahexaenoic acid (DHA) triple negative breast cancer (TNBC) MDA-MB-231 cells Docosahexaenoic acid (DHA) treatment upregulated 31713924 3828 Human hsa-miR-194 miRNA hepatocyte nuclear factor-1 ¦Á intestinal cell differentiation Caco-2 cells hepatocyte nuclear factor-1 ¦Á upregulated 18492795 3829 Human hsa-miR-194-3p miRNA particulate matter (PM2.5) chronic obstructive pulmonary disease (COPD) Human bronchial epithelial cells (HBEpiCs) Fine particulate matter (PM2.5) exposure treatment downregulated 30122914 3830 Human hsa-miR-194-3p miRNA particulate matter (PM2.5) chronic obstructive pulmonary disease (COPD) blood Fine particulate exposure (PM2.5) treatment miR-194-3p was decreased significantly after fine particulate exposure (PM25) exposure 30746254 3831 Human hsa-miR-194-3p miRNA "benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)" embryo implantation human trophoblast Swan 71 cells "benzo[a]pyrene-7, 8-diol-9, 10-epoxide (BPDE) treatment" upregulated 30011042 3832 Human hsa-miR-194-5p miRNA IL-6 and TNF-¦Á intervertebral disc degeneration (IDD) "human osteoblast cells (hFOB1.19), nucleus pulposus cells (hNPCs), and annulus fibrosus cells (hAFCs)" IL-6 and TNF-¦Á treatment downregulated 30945295 3833 Human hsa-miR-194-5p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) human pulmonary alveolar epithelial cells (HPAEpiC) lipopolysaccharide (LPS) treatment MALAT1 knockdown alleviated HPAEpiC apoptosis by competitively binding to miR-194-5p and then elevating the inhibitory effect on its target FOXP2. 33117815 3834 Human hsa-miR-194-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" bladder cancer bladder cancer cell lines T24 and 5637 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30925453 3835 Human hsa-miR-194-5p miRNA cisplatin (DDP) bladder cancer bladder cancer cell lines T24 and 5637 ?cisplatin treatment upregulated 30925453 3836 Human hsa-miR-194-5p miRNA glial cell-derived neurotrophic factor (GDNF) glioblastoma multiforme (GBM) human U251 glioma cells 50 ng/mL GDNF for 24 h upregulated 29224008 3837 Human hsa-miR-194-5p miRNA histone deacetylase inhibitor SAHA leukemogenesis and drug resistance "U937, NB4, K562 and Molm-14 cells" SAHA upregulated 28216661 3838 Human hsa-miR-194-5p miRNA lipopolysaccharide (LPS) neurodegenerative diseases human astrocytes lipopolysaccharide (LPS) treatment miR-194-5p was downregulated in LPS-induced astrocytes. 32533463 3839 Human hsa-miR-194-5p miRNA cisplatin (DDP) ovarian cancer (OC) A2780 cells cisplatin treatment "Compared to cisplatin-sensitive ovarian cancer cells, higher miR-194-5p expression and lower SLC40A1 expression were found in cisplatin-resistant ovarian cancer cells." 32534701 3840 Human hsa-miR-194-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 3841 Human hsa-miR-194-5p miRNA IL-22 psoriasis HaCaT cells IL-22 treatment downregulated 33393621 3842 Human hsa-miR-195 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) acute stroke SH-SY5Y neural cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 30775405 3843 Human hsa-miR-195 miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 3844 Human hsa-miR-195 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aorta smooth muscle cells (HASMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 22802111 3845 Human hsa-miR-195 miRNA aidi injection (ADI) breast cancer MCF-7 cells aidi Injection (ADI) upregulated 21563499 3846 Human hsa-miR-195 miRNA mastectomy breast cancer breast cancer tissues mastectomy treatment upregulated 25503185 3847 Human hsa-miR-195 miRNA H2O2 cardiomyocyte apoptosis human cardiomyocytes (HCMs) Hydrogen peroxide (H2O2) treatment upregulated 30355909 3848 Human hsa-miR-195 miRNA doxorubicin (DOX) cardiotoxicity human AC16 cardiomyocytes Doxorubicin (DOX)? treatment "SNHG1 could counteract the inhibitory effect of miR-195 on Bcl-2, and miR-195 restoration blocked the beneficial effect of SNHG1 against DOX toxicity in AC16 cells" 31300525 3849 Human hsa-miR-195 miRNA triamcinolone cell differentiation hepatic induced stem cells triamcinolone treatment upregulated 29101812 3850 Human hsa-miR-195 miRNA hypoxia cerebral ischemia injury (CII) HUVECs hypoxia treatment downregulated 28849133 3851 Human hsa-miR-195 miRNA cigarette smoke (CS) chronic obstructive pulmonary disease (COPD) lung tissues cigarette smoke (CS) exposure upregulated 29223853 3852 Human hsa-miR-195 miRNA cisplatin (DDP) cisplatin (DDP) resistance TE-1/DDP cisplatin treatment Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis 31558183 3853 Human hsa-miR-195 miRNA Schizandrin A (SchA) colorectal cancer (CRC) HCT116 and SW480 cells Schizandrin A (SchA) treatment upregulated 29331856 3854 Human hsa-miR-195 miRNA hypoxia deep vein thrombosis (DVT) human EPCs (hEPCs) hypoxia treatment upregulated 27623937 3855 Human hsa-miR-195 miRNA astragalus polysaccharide (APS) diabetic retinopathy (DR) high glucose (HG)-treated ARPE-19 cells astragalus polysaccharide (APS) treatment downregulated 31117931 3856 Human hsa-miR-195 miRNA H2O2 diabetic retinopathy (DR) human umbilical vein endothelial cells (HUVECs); human retinal endothelial cells (HMRECs) H2O2 treatment upregulated 28487236 3857 Human hsa-miR-195 miRNA high glucose (HG) diabetic retinopathy (DR) human umbilical vein endothelial cells (HUVECs); human retinal endothelial cells (HMRECs) high glucose (HG) treatment upregulated 28487236 3858 Human hsa-miR-195 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment upregulated 31117931 3859 Human hsa-miR-195 miRNA high glucose (HG) diabetic retinopathy (DR) "human retinal and dermal microvascular ECs (HRECs, HMECs)" "exposure to 25 mmol/l glucose (high glucose, HG) treatment" upregulation 24570140 3860 Human hsa-miR-195 miRNA H2O2 diabetic retinopathy (DR) human retinal microvascular endothelial cells (HMRECs) H2O2 treatment We confirmed that over-expression of SNGH16 attenuated H2O2-induced angiogenesis by HMRECs. 33530902 3861 Human hsa-miR-195 miRNA high glucose (HG) diabetic vasculopathy human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 31115479 3862 Human hsa-miR-195 miRNA cisplatin (DDP) esophageal squamous cell carcinoma (ESCC) The human ESCC cell line TE-1 cisplatin treatment downregulated 31558183 3863 Human hsa-miR-195 miRNA propofol (PPF) gastric cancer (GC) MKN45 cells propofol treatment The expression of miR-195 was increased after propofol treatment 30171944 3864 Human hsa-miR-195 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87 cells; U251 cells temozolomide (TMZ) treatment The expression levels of miR-195 were drastically higher in both U87TR and U251TR cell lines 30442884 3865 Human hsa-miR-195 miRNA cyclosporine A (CsA) glioblastoma multiforme (GBM) human glioblastoma cells cyclosporine A treatment downregulated 26537083 3866 Human hsa-miR-195 miRNA TGF-¦Â glioblastoma multiforme (GBM) glioma cell line U87 glioma cell line U87 treatment "downregulated(miR-205), upregulation(miR-195)" 27574009 3867 Human hsa-miR-195 miRNA BAY11-7082 helicobacter pylori infection H. pylori infected gastric epithelial cells treated with 10 ¦ÌM Bay 11-7082 upregulated 28208005 3868 Human hsa-miR-195 miRNA 5-fluorouracil (5-Fu) hepatocellular carcinoma (HCC) "human hepatocellular carcinoma cell line, BEL-7402" 5-fluorouracil (5-FU) treatment upregulated 21947305 3869 Human hsa-miR-195 miRNA enterovirus 71 (EV71) infant encephalitis SH-SY5Y cells Enterovirus 71 (EV71) infection MicroRNA-195 suppresses enterovirus A71-induced pyroptosis in human neuroblastoma cells through targeting NLRX1 33253716 3870 Human hsa-miR-195 miRNA "MS-275, a histone deacetylase inhibitor" lung adenocarcinoma (LUAD) A549 and HCC827 cell lines MS-275 treatment upregulated 31090206 3871 Human hsa-miR-195 miRNA ailanthone (AIL) lung cancer A549 cells ailanthone (AIL) treatment upregulated 30565729 3872 Human hsa-miR-195 miRNA chronic brain hypoperfusion (CBH) murine atherosclerosis and vascular smooth muscle cell proliferation plasma chronic brain hypoperfusion (CBH) treatment downregulated 23447608 3873 Human hsa-miR-195 miRNA paraquat (PQ) neural degenerative diseases "human embryonic stem cell-derived neural progenitor cells, hESC-NPCs" paraquat (PQ) treatment upregulated 23807224 3874 Human hsa-miR-195 miRNA salidroside (SAL) non-small cell lung cancer (NSCLC) A549 cells Salidroside treatment upregulated 30880481 3875 Human hsa-miR-195 miRNA IL-1¦Â and TNF-¦Á osteoarthritis (OA) primary chondrocytes interleukin-1 beta (IL-1¦Â) and tumor necrosis factor-alpha (TNF-¦Á) treatment downregulated 30575896 3876 Human hsa-miR-195 miRNA enterovirus 71 (EV71) pyroptosis SH-SY5Y cells Enterovirus 71 (EV71) infection miR-195 was significantly down-regulate in EV-A71-infected SH-SY5Y human neuroblastoma cells. 33253716 3877 Human hsa-miR-195 miRNA lipopolysaccharide (LPS) sepsis NCM460 cells lipopolysaccharide (LPS) treatment upregulated 31894250 3878 Human hsa-miR-195 miRNA lipopolysaccharide (LPS) sepsis human intestinal epithelial cells lipopolysaccharide (LPS) treatment miR-195 was significantly upregulated following LPS treatment. 31894250 3879 Human hsa-miR-195 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" spinal ossification of the posterior longitudinal ligament (OPLL) posterior longitudinal ligament (PLL) cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated of miR-195 expression in CMS-treated PLL cells was restored by a demethylation reagent 5-aza-2'-deoxycytidine (AZA). 32432317 3880 Human hsa-miR-195 miRNA cyclic mechanical stretch (CMS) spinal ossification of the posterior longitudinal ligament (OPLL) posterior longitudinal ligament (PLL) cells cyclic mechanical stress (CMS) treatment miR-195 was downregulated in treated PLL cells. 32432317 3881 Human hsa-miR-195 miRNA transretinoic acid/hydrocortisone (tRA/H) thyroid cancer (TC) MCF-7 human breast cancer cells tRA/H treatment downregulated 25404690 3882 Human hsa-miR-195 miRNA resistanceor endurance training type 2 diabetes mellitus (T2DM) middle-aged Polynesian men and women with morbid obesity (44 kg/m(2) ¡À 10) and Type 2 diabetes 16 wk of resistanceor endurance training treatment dysregulated 25138607 3883 Human hsa-miR-195-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 3884 Human hsa-miR-195-5p miRNA caerulein (Cae) acute pancreatitis (AP) Human pancreatic duct epithelial cells (HPDE) caerulein (Cae) treatment "As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased." 32856219 3885 Human hsa-miR-195-5p miRNA homocysteine (Hcy) atherosclerosis (AS) human aortic smooth muscle cells (HASMCs) homocysteine (HCY) treatment downregulated 31629816 3886 Human hsa-miR-195-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells oxidized low-density lipoprotein (ox-LDL) treatment lncRNA CTBP1-AS2 may serve a role in AS by inhibiting the proliferation and promoting the autophagy of VSMCs through ATG14 modulation via miR-195-5p. 32626936 3887 Human hsa-miR-195-5p miRNA low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) cervical cancer (CC) serum low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) treatment upregulated 32851067 3888 Human hsa-miR-195-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HT29 cells 5-fluorouracil (5-FU) treatment upregulated 25526515 3889 Human hsa-miR-195-5p miRNA propofol (PPF) gastric cancer (GC) HGC-27 cells; AGS cells Propofol treatment "Propofol inhibited the proliferation and invasion, but enhanced the apoptosis of GC cells by regulating the circ-PVT1/miR-195-5p/ETS1 axis" 32945521 3890 Human hsa-miR-195-5p miRNA microwave ablation (MWA) hepatocellular carcinoma (HCC) HCC cell lines microwave ablation (MWA) treatment SP1-induced upregulation of lncRNA CTBP1-AS2 accelerates the hepatocellular carcinoma tumorigenesis through targeting CEP55 via sponging miR-195-5p. 32988587 3891 Human hsa-miR-195-5p miRNA lipopolysaccharide (LPS) lung injury human small airway epithelial cells (HSAECs) Lipopolysaccharide (LPS) treatment CASC9 protects lung epithelial cells from sepsis-induced injury via regulating miR-195-5p/PDK4 axis. 32221619 3892 Human hsa-miR-195-5p miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 3893 Human hsa-miR-195-5p miRNA simulated tension strain osteogenic differentiation and bone formation human periodontal ligament cells (PDLCs) simulated tension strain treatment downregulated 28181691 3894 Human hsa-miR-195-5p miRNA treponema pallidum (T. pallidum) infection treponema pallidum (Tp) infection peripheral blood mononuclear cells (PBMCs) treponema pallidum (T. pallidum) infection treatment upregulated 32087699 3895 Human hsa-miR-195a miRNA endothelin-1 (ET-1) sickle cell disease (SCD) THP-1 cells and human peripheral blood monocytes Endothelin-1 treatment downregulated 20952681 3896 Human hsa-miR-195a miRNA advanced glycation end product (AGE) intervertebral disc degeneration (IDD) human nucleus pulposus cells (HNPC) advanced glycation end product (AGE) treatment downregulated 32850952 3897 Human hsa-miR-196 miRNA "IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1" chronic hepatitis C virus (HCV) infection Huh7 cells "types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment" dysregulated 24844965 3898 Human hsa-miR-196 miRNA IFN-¦Á chronic hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) interferon alpha treatment upregulated 21070682 3899 Human hsa-miR-196 miRNA heme hepatocellular carcinoma (HCC) Huh?8 cells heme treatment upregulated 23538684 3900 Human hsa-miR-196-5p miRNA hypoxia hepatocellular carcinoma (HCC) "HCC (HCCLM3, SMMC7721, HepG2, Huh7, and Hep3B) cell lines" hypoxia induce downregulated 31713780 3901 Human hsa-miR-196a miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment LncRNA SNHG1 regulates vascular endothelial cell proliferation and angiogenesis via miR-196a 32297149 3902 Human hsa-miR-196a miRNA hemin erythropoiesis K562 cells hemin treatment miR-196a overexpression inhibits apoptosis in hemin-induced K562 cells through downregulating p27kip1. 31913716 3903 Human hsa-miR-196a miRNA hypoxia glioblastoma multiforme (GBM) Glioblastoma (GBM) hypoxia treatment We identified miR-196a as a hypoxia-inducible and hypoxia-inducible factor (HIF)-regulated miRNA that plays an oncogenic role in GBM. 33469841 3904 Human hsa-miR-196a miRNA BAY11-7082 helicobacter pylori infection H. pylori infected gastric epithelial cells treated with 10 ¦ÌM Bay 11-7082 upregulated 28208005 3905 Human hsa-miR-196a miRNA hepatitis C virus (HCV) core protein hepatocellular carcinoma (HCC) HepG2 and Huh-7 HCC cell lines hepatitis C virus (HCV) core protein treatment upregulated 27108614 3906 Human hsa-miR-196a miRNA vascular endothelial growth factor (VEGF) hepatocellular carcinoma (HCC) Human umbilical vein endothelial cells (HUVECs) treatment treatment downregulated 22773844 3907 Human hsa-miR-196a miRNA propofol (PPF) hypoxia/reoxygenation (H/R) injury human umbilical vein endothelial cells(HUVECs) propofol treatment miR-196a was upregulated in propofol-treated group 24454982 3908 Human hsa-miR-196a miRNA progesterone (P4) infertility "human endometrial carcinoma cell line, SNU-1077" progesterone treatment dysregulated 30603515 3909 Human hsa-miR-196a miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 3910 Human hsa-miR-196a miRNA "high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)" skin fibrosis human skin fibroblast HF-LED-RL at 320 and 640?J/cm2 radiation upregulated 30182520 3911 Human hsa-miR-196a-1 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cervical cancer (CC) "cervical cell lines SiHa, CaSki and HeLa" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31326568 3912 Human hsa-miR-196a2 miRNA cisplatin (DDP) myeloproliferative disorder Blood samples gemcitabine or cisplatin treatment the SNP might affect mature?miR©\196a?expression and binding of mature?hsa©\miR©\196a2¨C3p 23143626 3913 Human hsa-miR-196a2 miRNA gemcitabine (GEM) myeloproliferative disorder Blood samples gemcitabine or cisplatin treatment the SNP might affect mature?miR©\196a?expression and binding of mature?hsa©\miR©\196a2¨C3p 23143626 3914 Human hsa-miR-196a-5p miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 3915 Human hsa-miR-196a-5p miRNA cigarette smoke (CS) lung cancer NCI-H292 cells cigarette smoke (CS) treatment "upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)" 28692419 3916 Human hsa-miR-196a-5p miRNA anti-microbial peptide LL-37 rosacea skin tissues LL37 treatment downregulated 33678493 3917 Human hsa-miR-196b miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) cancer cell 5-fluorouracil treatment upregulated 23167930 3918 Human hsa-miR-196b miRNA capecitabine colorectal cancer (CRC) cancer cell capecitabine treatment upregulated 23167930 3919 Human hsa-miR-196b miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 3920 Human hsa-miR-196b miRNA curcumin (Cur) chronic myeloid leukemia (CML) Chronic Myelogenous Leukemia (CML) cells curcumin treatment upregulated 26116834 3921 Human hsa-miR-196b miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment downregulated 31744065 3922 Human hsa-miR-196b miRNA 5-aza-2'-deoxycytidine and trichostatin A leukemia human leukemia cell lines 5-aza-deoxycytidine and trichostatin A treatment upregulated 27570640 3923 Human hsa-miR-196b miRNA platinum lung adenocarcinoma (LUAD) LADC tissues platinum-based doublet chemotherapy treatment dysregulated 25142144 3924 Human hsa-miR-196b miRNA ursolic acid (UA) malignant pleural mesothelioma (MPM) H2452 cells ursolic acid treatment upregulated 28090191 3925 Human hsa-miR-196b miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 3926 Human hsa-miR-196b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" primary gastric tumors U937;K562; HL60; Hep3B; HepG2;Huh-7; HT29; MDA-MB231; MCF-7; HeLa;LNCap; MRC5; H1299; GBM-8901; GBM-8401;U87; SHY5Y; HCS3; Cal27; MIA paca2; NCCIT;293T; GM05387; AGS; AZ-521; HR; TSGH;NUGC "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 20662076 3927 Human hsa-miR-196b miRNA bacillus calmette-guerin (BCG) tuberculosis (TB) TB patients bacillus calmette-guerin (BCG) treatment downregulated 24586438 3928 Human hsa-miR-196-b miRNA suberoylanilide hydroxamic acid (SAHA) neuroblastoma (NB) SH-SY5Y cells suberoylanilide hydroxamic acid (SAHA) treatment downregulated 30091530 3929 Human hsa-miR-196b-3p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) gastric cancer (GC) tissues Helicobacter pylori (H. pylori) infection Patients with H. pylori infection had a higher expression of hsa-miR-196b-3p and CALML4 than those without H. pylori infection. 32802507 3930 Human hsa-miR-196b-5p miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 3931 Human hsa-miR-196b-5p miRNA IFN-¦Ã epithelial-mesenchymal transition (EMT) PC-3M IE8 cells interferon-¦Ã (IFN-¦Ã) treatment upregulated in PC-3M IE8 cells in the EMT induction model 31882179 3932 Human hsa-miR-196b-5p miRNA IFN-¦Ã epithelial-mesenchymal transition (EMT) PC-3M IE8 cells IFN-¦Ã treatment Hsa-miR-196b-5p was upregulated in PC-3M IE8 cells treatment with IFN-¦Ã. 31882179 3933 Human hsa-miR-196b-5p miRNA activin A prostate cancer LNCaP cells activin A treatment upregulated 27018851 3934 Human hsa-miR-196b-5p miRNA aldosterone renal injury HK-2 cells aldosterone treatment upregulated 32727744 3935 Human hsa-miR-197 miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment upregulated 27158236 3936 Human hsa-miR-197 miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment upregulated 27158236 3937 Human hsa-miR-197 miRNA aspirin atherothrombotic risk in type 2 diabetes mellitus blood aspirin treatment Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p?=?0.039) or prasugrel. 31910903 3938 Human hsa-miR-197 miRNA prasugrel atherothrombotic risk in type 2 diabetes mellitus blood prasugrel treatmrnt treatment Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p?=?0039) or prasugrel 31910903 3939 Human hsa-miR-197 miRNA hepatitis B virus (HBV) chronic hepatitis B virus (HBV) infection Peripheral Blood Mononuclear Cells(PBMC) hepatitis B virus (HBV) infection downregulated 23710316 3940 Human hsa-miR-197 miRNA 5-fluorouracil (5-Fu) and oxaliplatin colorectal cancer (CRC) human colon cancer cells 5-Fluorouracil and oxaliplatin treatment downregulated 19956872 3941 Human hsa-miR-197 miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 31108165 3942 Human hsa-miR-197 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 3943 Human hsa-miR-197 miRNA docetaxel (DTX) head and neck squamous cell carcinoma (HNSCC) UMSCC-1 cells;SQ20B cells docetaxel (DTX) treatment downregulated 21560177 3944 Human hsa-miR-197 miRNA IL-6 and signal transducers and activators of transcription 3 (STAT3) hepatocellular carcinoma (HCC) human HCC cell lines HepG2 IL-6/STAT3 treatment downregulated 26451302 3945 Human hsa-miR-197 miRNA proanthocyanidin extract (GSPE) hepatocellular carcinoma (HCC) HepG2 cells proanthocyanidin extract (GSPE) treatment upregulated 21998738 3946 Human hsa-miR-197 miRNA quercetin meningioma HBL-52 meningioma cells quercetin treatment Quercetin treatment increases miR-197 mRNA 32585423 3947 Human hsa-miR-197 miRNA taxol ovarian cancer (OC) ovarian cancer cells Taxol resistance treatment upregulated 25833695 3948 Human hsa-miR-197 miRNA clopidogrel platelet inhibition serum clopidogrel treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 3949 Human hsa-miR-197 miRNA ticagrelor platelet inhibition serum ticagrelor treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 3950 Human hsa-miR-197 miRNA enterovirus 71 (EV71) severe central nervous system complications "Human rhabdomyosarcoma (RD) cells,human embryonic kidney (HEK293T) cells" Enterovirus 71 (EV71) treatment downregulated 26581983 3951 Human hsa-miR-1972 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 3952 Human hsa-miR-1972 miRNA cisplatin (DDP) ovarian cancer (OC) OC lines (SKOV-3 and A2780) cisplatin treatment upregulated 31865363 3953 Human hsa-miR-1973 miRNA hantaan virus (HTNV) hantaan virus (HTNV) infection A549 cells hantavirus(HTNV)treatment upregulated 24074584 3954 Human hsa-miR-1973 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 3955 Human hsa-miR-1973 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 3956 Human hsa-miR-197-3p miRNA asbestos fibers malignant pleural mesothelioma (MPM) serum ex-exposed to asbestos fibers (WEA) downegulated 27716620 3957 Human hsa-miR-197-3p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) neutrophil M.tb infection downregulated 29477867 3958 Human hsa-miR-1975 miRNA influenza A virus (IAV) innate immune response A549 cells Influenza virus A (IVA) infection upregulated 31416454 3959 Human hsa-miR-198 miRNA bortezomib diffuse large B-cell lymphoma (DLBCL) DLBCL CRL-2630 cells bortezomib? treatment upregulated 30216798 3960 Human hsa-miR-198 miRNA cisplatin (DDP) gastric cancer (GC) "GC tissues and cells SGC7901, BGC823" cisplatin treatment downregulated 30927924 3961 Human hsa-miR-198 miRNA TGF-¦Â1 glioblastoma multiforme (GBM) glioblastoma cells TGF-¦Â1 treatment ?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling 32813021 3962 Human hsa-miR-198 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 3963 Human hsa-miR-199 miRNA tumor necrosis factor alpha (TNF-¦Á) human nucleus pulposus cells injury Human nucleus pulposus cells tumor necrosis factor alpha (TNF-¦Á) treatment miR-199 was extremely decreased in Human nucleus pulposus cells after TNF-¦Á treatment 30309653 3964 Human hsa-miR-199 miRNA molecular hydrogen inflammatory injury Retinal Microglia cells Molecular hydrogen?treatment upregulated 23826519 3965 Human hsa-miR-199 miRNA TGF-¦Â1 myofibroblast proliferation foreskins of unidentified normal neonates tissue Transforming growth factor-¦Â1 treatment "TGF-¦Â1 downregulated HGF in primary human adult pulmonary fibroblasts (HLFb) and increased the expression of miR-199a-3p, a microRNA (miRNA) associated with fibrotic remodeling" 23657814 3966 Human hsa-miR-199a miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK2 cells lipopolysaccharide (LPS) treatment The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells 32069473 3967 Human hsa-miR-199a miRNA propofol (PPF) apoptosis HepG2 cells Propofol?treatment treatment Propofol significantly elevated the expression of miR-199a and inhibited the invasiveness of HepG2 cells 23742776 3968 Human hsa-miR-199a miRNA dacarbazine and interferon-alfa-2b breast cancer circulating endothelial cells dacarbazine and interferon-alfa-2b treatment Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a 23217102 3969 Human hsa-miR-199a miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) "high glucose (25 mmol/L, 1-7 days)" "downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)" 28706953 3970 Human hsa-miR-199a miRNA hypoxia epithelial ovarian cancer (EOC) EOCC 1-3% O2 treatment upregulated 24706848 3971 Human hsa-miR-199a miRNA reactive oxygen species (ROS) Epstein-Barr virus (EBV) infection ovarian cancer cells reactive oxygen species (ROS) treatment downregulated 23146892 3972 Human hsa-miR-199a miRNA hypoxia fat non-small cell lung cancer cells hypoxia treatment downregulated 22119803 3973 Human hsa-miR-199a miRNA dauricine (Dau) hepatocellular carcinoma (HCC) HepG2 and Huh-7 HCC cells Dauricine (Dau) treatment upregulated 30171973 3974 Human hsa-miR-199a miRNA propofol (PPF) hepatocellular carcinoma (HCC) hepatocellular carcinoma cells Propofol treatment upregulated 23319430 3975 Human hsa-miR-199a miRNA hypoxia hypoxia-induced injury human dermal microvascular endothelial cells (hDMECs) hypoxia induce downregulated 31537150 3976 Human hsa-miR-199a miRNA progesterone (P4) infertility "human endometrial carcinoma cell line, SNU-1077" progesterone treatment dysregulated 30603515 3977 Human hsa-miR-199a miRNA sodium selenite and Se-methylselenocysteine (MSC) hepatocellular carcinoma (HCC) HLF cells sodium selenite and Se-methylselenocysteine (MSC) treatment downregulated 32656599 3978 Human hsa-miR-199a miRNA hepatitis C virus (HCV) liver cirrhosis liver hepatitis C virus (HCV) infection The serum level of miR-199a in chronic HCV patients was significantly lower than in healthy controls (P = 0.001). 26133725 3979 Human hsa-miR-199a miRNA chemokine CCL5 malignant bone cancer JJ012/CCL5 cells CCL5 treatment downregulated 25444917 3980 Human hsa-miR-199a miRNA arctigenin mechanical trauma injury scratch-induced injury of human SH-SY5Y cells arctigenin (ARC) treatment upregulated 27389368 3981 Human hsa-miR-199a miRNA nitric oxide donors nitrate tolerance human umbilical vein endothelial cells nitric oxide donors treatment upregulated 29431644 3982 Human hsa-miR-199a miRNA emodin ovarian cancer (OC) A2780 cells emodin treatment upregulated 29512773 3983 Human hsa-miR-199a miRNA curcumin (Cur) pancreatic cancer (PC) The BxPC-3 human pancreatic carcinoma cell line curcumin (diferuloylmethane)? treatment downregulated 18347134 3984 Human hsa-miR-199a miRNA dexamethasone (DEX) steatosis HepG3 cells dexamethasone (Dex) treatment downregulated 29409992 3985 Human hsa-miR-199a miRNA physcion 8-O-¦Â-glucopyranoside (PG) testicular germ cell tumors (TGCTs) NTERA2 and NCCIT cells Physcion 8-O-¦Â-Glucopyranoside (PG) treatment upregulated 31802647 3986 Human hsa-miR-199a miRNA physcion 8-O-¦Â-glucopyranoside (PG) testicular germ cell tumors (TGCTs) NTERA2 cells; NCCIT cells Physcion 8-O-¦Â-Glucopyranoside (PG) treatment miR-199a was decreased in TGCTs but was increased by PG in a dose-dependent manner. 31802647 3987 Human hsa-miR-199a* miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) downregulated 18648749 3988 Human hsa-miR-199a* miRNA ozone (O3) air pollution healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 3989 Human hsa-miR-199a2 miRNA placenta growth factor (PlGF) hypertension endothelial cells PlGF treatment downregulated 25389292 3990 Human hsa-miR-199a-3p miRNA p53 acute kidney injury (AKI) HK-2 human renal tubular epithelial cells p53 deficiency treatment downregulated 31148231 3991 Human hsa-miR-199a-3p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) human epithelial cell line A549 and the human macrophage cell line U937 ?lipopolysaccharide (LPS) treatment downregulated 31754335 3992 Human hsa-miR-199a-3p miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 12¡ã HDT bed rest experiment downregulated 28261104 3993 Human hsa-miR-199a-3p miRNA CL 316243 disodium salt brown adipocyte differentiation human brown adipocyte CL 316243 disodium salt treatment downregulated 29753771 3994 Human hsa-miR-199a-3p miRNA forskolin (FSK) brown adipocyte differentiation human brown adipocyte forskolin (FSK) treatment downregulated 29753771 3995 Human hsa-miR-199a-3p miRNA H2O2 brown adipocyte differentiation human brown adipocyte H2O2 treatment upregulated 29753771 3996 Human hsa-miR-199a-3p miRNA norepinephrine (NE) brown adipocyte differentiation human brown adipocyte norepinephrine treatment downregulated 29753771 3997 Human hsa-miR-199a-3p miRNA lipopolysaccharide (LPS) cervical remodeling ect1/e6e7 cells; end1/e6e7 cells lipopolysaccharide (LPS) treatment downregulated 32468045 3998 Human hsa-miR-199a-3p miRNA palmitate diabetes mellitus (DM) Human islets palmitate (Pal) treatment upregulated 30131392 3999 Human hsa-miR-199a-3p miRNA bone morphogenetic protein 2 (BMP2) glioblastoma multiforme (GBM) Glioblastoma stem-like cells (GSCs) cell U87S bone morphogenetic protein 2 (BMP2) treatment upregulated 32884997 4000 Human hsa-miR-199a-3p miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) Hepatic stem-like epithelial cells (LE/6) hepatitis B virus X protein (HBx) treatment upregulated 31740785 4001 Human hsa-miR-199a-3p miRNA hypoxia hepatocellular carcinoma (HCC) SNU-182 cells; HUH7 cells hypoxia treatment downregulated 32670881 4002 Human hsa-miR-199a-3p miRNA TGF-¦Â1 hepatocellular carcinoma (HCC) Hepatic stem-like epithelial cells (LE/6) TGF-¦Â1 treatment upregulated 31740785 4003 Human hsa-miR-199a-3p miRNA dapagliflozin hypertensive patients with type 2 diabetes plasma dapagliflozin treatment downregulated 31162549 4004 Human hsa-miR-199a-3p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 4005 Human hsa-miR-199a-3p miRNA dextran-capped nanosized europium(III) hydroxides [Eu(OH)3] nanoclusters (NCs) ischemic heart/limb diseases and tissue regeneration human umbilical vein endothelial cells (HUVECs) dextran-capped nanosized europium(III) hydroxides [Eu(OH)3] nanoclusters (NCs) treatment upregulated 30148600 4006 Human hsa-miR-199a-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1-treatment treatment upregulated 29557526 4007 Human hsa-miR-199a-3p miRNA gambogic acid (GA) melanoma A375 cells gambogic acid (GA) treatment upregulated 29959879 4008 Human hsa-miR-199a-3p miRNA oleic acid (OA) nonalcoholic fatty liver disease (NAFLD) Hepa1-6 cells oleic acid treatment downregulated 28469795 4009 Human hsa-miR-199a-3p miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) Hepa1-6 cells palmitic acid (PA) treatment downregulated 28469795 4010 Human hsa-miR-199a-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 33494069 4011 Human hsa-miR-199a-3p miRNA TGF-¦Â and EGF pterygium human conjunctival epithelial cells (HCEs) TGF-¦Â and EGF treatment TGF-¦Â and EGF induce EMT of HCEs through miR-199a-3p/5p-DUSP5/MAP3K11 axes 32867783 4012 Human hsa-miR-199a-3p miRNA high glucose (HG) renal tubular epithelial cells (RTEC) injury HK-2 cells high glucose (HG) treatment miR-199a-3p expression was time-dependently decreased in the HG-induced cell damage model. 33125105 4013 Human hsa-miR-199a-3p miRNA Bt2cAMP type II pneumocyte differentiation cultured human fetal lung (HFL) epithelial cells Bt2cAMP treatment downregulated 29507184 4014 Human hsa-miR-199a-3p miRNA TGF-¦Â1 unilateral ureteral obstruction (UUO) human kidney tubular epithelial cells (HK-2) TGF-¦Â1 treatment upregulated 28240316 4015 Human hsa-miR-199a-5p miRNA human serum albumin (HSA) diabetic nephropathy (DN) extracellular vesicles from HSA-induced HK-2 cells human serum albumin (HSA) treatment upregulated 31208912 4016 Human hsa-miR-199a-5p miRNA alpha-1 antitrypsin (AAT) anti-inflammatory responses monocytes of AAT deficient (ZZ) individuals alpha-1 antitrypsin (AAT) treatment downregulated 29062067 4017 Human hsa-miR-199a-5p miRNA peroxisome proliferator activated receptor gamma (PPAR¦Ã) aplastic anemia (AA) bone marrow-derived mesenchymal stem cells (BM-MSCs) PPAR gamma (PPAR¦Ã) treatment upregulated 31400610 4018 Human hsa-miR-199a-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" arsenite-induced carcinogenesis arsenic-exposured lung epithelial cells (BEAS-2B and HLF1) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31170415 4019 Human hsa-miR-199a-5p miRNA arsenite arsenite-induced carcinogenesis lung epithelial cells (BEAS-2B and HLF1) arsenic exposure downregulated 31170415 4020 Human hsa-miR-199a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32339345 4021 Human hsa-miR-199a-5p miRNA hypoxia cardiac dysfunction serum chronic hypoxia at high altitudes "The level of miR-199a-5p was significantly higher in individuals with poor exercise capacity at 3,800 m, compared with those with good exercise capacity" 33633582 4022 Human hsa-miR-199a-5p miRNA human cytomegalovirus (HCMV) cell migration and tube formation Human umbilical vein endothelial cells (HUVECs) human cytomegalovirus infection upregulated 23760629 4023 Human hsa-miR-199a-5p miRNA imatinib chronic lymphocytic leukemia (CLL) K562 cells Imatinib (IM) treatment downregulated 29890129 4024 Human hsa-miR-199a-5p miRNA steroids endometriosis ovarian endometrial steroid hormones treatment upregulated 26819477 4025 Human hsa-miR-199a-5p miRNA hypoxia endoplasmic reticulum stress (ERS) Human umbilical vein endothelial cells (HUVECs) and derived exosomes hypoxia induce upregulated 31634452 4026 Human hsa-miR-199a-5p miRNA hypoxia/reoxygenation (H/R) endoplasmic reticulum stress (ERS) human umbilical vein endothelial cells (HUVEC) hypoxia/re-oxygenation (H/R) treatment H/R administration increased miR-199a-5p levels both in HUVECs and exosomes. 31634452 4027 Human hsa-miR-199a-5p miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells; SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 4028 Human hsa-miR-199a-5p miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 4029 Human hsa-miR-199a-5p miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) ?human HCC cell lines cisplatin (DPP) treatment downregulated 22713463 4030 Human hsa-miR-199a-5p miRNA hypoxia multiple myeloma (MM) multiple myeloma (MM) cells hypoxia treatment downregulated 24839982 4031 Human hsa-miR-199a-5p miRNA deoxycholic acid (DCA) non-small cell lung cancer (NSCLC) human primary colonic epithelial cells The deoxycholic acid? treatment downregulated 22903020 4032 Human hsa-miR-199a-5p miRNA visfatin osteoarthritis (OA) human OA synovial fibroblasts (OASFs) visfatin treatment downregulated 29316707 4033 Human hsa-miR-199a-5p miRNA metformin (Met) pancreatic cancer (PC) human pancreatic cancer cell lines PANC-1 and BxPC-3 Metformin treatment dysregulated 28875433 4034 Human hsa-miR-199a-5p miRNA high glucose (HG) peritoneal dialysis (PD) human peritoneal mesothelial cells (HPMCs) high-glucose (HG) upregulated 28428333 4035 Human hsa-miR-199a-5p miRNA high glucose (HG) renal fibrosis HK-2 cells high glucose (HG) treatment LUCAT1 likely promotes HG-induced EMT through ZEB1 by sponging miR-199a-5p. 33426083 4036 Human hsa-miR-199a-5p miRNA hypoxia seizure epileptic brain hypoxia treatment downregulated 25539181 4037 Human hsa-miR-199a-5p miRNA brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) cell senescence SH-SY5Y cells brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment upregulated 27525675 4038 Human hsa-miR-199a-5p miRNA retinoic acid (RA) cell senescence SH-SY5Y cells retinoic acid (RA) treatment upregulated 27525675 4039 Human hsa-miR-199a-5p miRNA retinoic acid (RA) cell senescence SH-SY5Y cells SH-SY5Y cells treatment upregulation 27525675 4040 Human hsa-miR-199a-5p miRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment "CircVMA21 and NRP1 were decreased, and miR-199a-5p was increased in LPS-induced THP-1 cells." 33647793 4041 Human hsa-miR-199a-5p miRNA arsenite arsenite-induced carcinogenesis human lung epithelial BEAS-2B cells arsenic exposure upregulated 24413338 4042 Human hsa-miR-199a-5p miRNA Bt2cAMP type II pneumocyte differentiation cultured human fetal lung (HFL) epithelial cells Bt2cAMP treatment downregulated 29507184 4043 Human hsa-miR-199b miRNA lipopolysaccharide (LPS) acute spinal cord injury (ASCI) primary microglia lipopolysaccharide (LPS) treatment miR-199b was significantly decreased in microglia stimulated by LPS. 29631367 4044 Human hsa-miR-199b miRNA TGF-¦Â1 diabetic nephropathy (DN) HK-2 cells TGF-¦Â1 treatment miR-199b was highly expressed in TGF-¦Â1-treated HK-2 cells 30125566 4045 Human hsa-miR-199b miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment downregulated 19022373 4046 Human hsa-miR-199b miRNA trichloroethylene (TCE) liver damage human HL-7702 cells Trichloroethylene (TCE) treatment downregulated 31140026 4047 Human hsa-miR-199b miRNA 5-fluorouracil (5-Fu) locally advanced rectal cancer (LARC) SW480 cells 5-fluorouracil (5-FU) treatment downregulated 32580513 4048 Human hsa-miR-199b miRNA nitric oxide donors nitrate tolerance human umbilical vein endothelial cells nitric oxide donors treatment upregulated 29431644 4049 Human hsa-miR-199b-5p miRNA imatinib chronic lymphocytic leukemia (CLL) K562 cells Imatinib (IM) treatment downregulated 29890129 4050 Human hsa-miR-199b-5p miRNA atrasentan diabetic nephropathy (DN) Human renal proximal tubular epithelial HK-2 cells atractylon (Atr)?treatment downregulated 29623952 4051 Human hsa-miR-199b-5p miRNA tigecycline (TGC) malignant glioma U87 glioma cells tigecycline treatment upregulated 26823491 4052 Human hsa-miR-199b-5p miRNA ozone (O3) air pollution healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 4053 Human hsa-miR-199b-5p miRNA lipopolysaccharide (LPS) rejection after lung transplantation THP-1 monocytes lipopolysaccharide (LPS) treatment downregulated 29779167 4054 Human hsa-miR-199b-5p miRNA imatinib mesylate chronic myeloid leukemia (CML) Peripheral blood cells imatinib mesylate treatment downregulated 20460641 4055 Human hsa-miR-19a miRNA D-galactosamine/lipopolysaccharide (D-GalN/LPS) acute liver failure (ALF) primary hepatocyte and hepatocytes line HL-7702 D-GalN and LPS treatment upregulated 28586153 4056 Human hsa-miR-19a miRNA phosphatase of regenerating liver-3 (PRL-3) angiogenesis colon cancer cells Phosphatase of regenerating liver-3 (PRL-3) treatment "overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3" 22677902 4057 Human hsa-miR-19a miRNA D-galactosamine/lipopolysaccharide (D-GalN/LPS) autophagy primary human hepatocytes; HL-7702 cells D-galactosamine (D-GalN) and lipopolysaccharide (LPS) treatment upregulated 28586153 4058 Human hsa-miR-19a miRNA arsenic trioxide (ATO) bladder cancer T24 human bladder carcinoma cells arsenic trioxide?treatment downregulated 20857258 4059 Human hsa-miR-19a miRNA bisphenol A (BPA) breast cancer MCF-7 human breast cancer cells bisphenol A (BPA) treatment upregulated 24831732 4060 Human hsa-miR-19a miRNA butyl benzyl phthalate (BBP) breast cancer MCF-7 cells; MDA-MB-231 cells Butyl benzyl phthalate (BBP) treatment BBP significantly induced the expression of miR-19a. 29864457 4061 Human hsa-miR-19a miRNA cold atmospheric plasma (CAP) breast cancer MCF-7 breast cancer cell Cold atmospheric plasma (CAP) treatment downregulated 27445062 4062 Human hsa-miR-19a miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment downregulated 29189128 4063 Human hsa-miR-19a miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 4064 Human hsa-miR-19a miRNA hypoxia cell proliferation and migration human pulmonary arterial smooth muscle cells (HPASMCs) hypoxia induce upregulated 31682848 4065 Human hsa-miR-19a miRNA IL-6 chronic lymphocytic leukemia (CLL) chronic lymphocytic leukemia (CLL) cells IL-6 treatment upregulated 26041742 4066 Human hsa-miR-19a miRNA hepatitis C virus (HCV) cognitive impairment monocyte-derived exosome hepatitis C virus (HCV) infection upregulated 32157304 4067 Human hsa-miR-19a miRNA human immunodeficiency virus (HIV)-1 cognitive impairment monocyte-derived exosome human immunodeficiency virus (HIV)-1 infectiom upregulated 32157304 4068 Human hsa-miR-19a miRNA oxaliplatin colorectal cancer (CRC) SW480 cells; HT29 cells Oxaliplatin treatment miR-19a was significantly increased in SW480/R and HT29/R compared to their parental SW480 and HT29 32209726 4069 Human hsa-miR-19a miRNA tumor necrosis factor alpha (TNF-¦Á) colorectal cancer (CRC) colorectal cancer (CRC) cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 26302825 4070 Human hsa-miR-19a miRNA lipopolysaccharide (LPS) apoptosis HUVECs and EAhy926 cells lipopolysaccharide (LPS) treatment downregulated 25982447 4071 Human hsa-miR-19a miRNA deacetylase inhibitors (DACi) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cell Deacetylase inhibitors (DACi)treatment downregulated 24375802 4072 Human hsa-miR-19a miRNA deacetylase inhibitors (DACi) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cell lines Deacetylase inhibitors (DACi) treatment downregulated 24375802 4073 Human hsa-miR-19a miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) plasma hepatitis B virus (HBV) infection downregulated 22105822 4074 Human hsa-miR-19a miRNA pterostilbene hepatocellular carcinoma (HCC) SMMC-7721 HCC cells Pterostilbene (Pter) treatment miR-19a expression was decreased by Pter treatment in a dose-depen-dent manner in SMMC-7721 cells 29393488 4075 Human hsa-miR-19a miRNA human papillomavirus E6 and E7 human papillomaviruses (HPV) infection K16 and K38 supernatants Human papillomavirus E6 and E7 treatment "HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p." 27300513 4076 Human hsa-miR-19a miRNA berberine (BBR) multiple myeloma (MM) RPMI-8266 cells; U266 cells berberine (BBR) treatment Berberine downregulated miR-19a expression in multiple myeloma (MM) cells. 29687521 4077 Human hsa-miR-19a miRNA aluminum maltolate (Al-malt) neurodegenerative pathogenesis neuroblastoma SH-SY5Y cells aluminum maltolate (Al-malt) treatment downregulated 26836165 4078 Human hsa-miR-19a miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) "lung tissues, A549 and H460 cells" ?cisplatin treatment lncRNA-AC0788833/miR-19a/PTEN/AKT pathway contributed to the development of chemoresistance against cisplatin 31111480 4079 Human hsa-miR-19a miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human primary chondrocytes lipopolysaccharide (LPS) treatment "Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro." 33283483 4080 Human hsa-miR-19a miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human primary chondrocytes lipopolysaccharide (LPS)? treatment "Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro." 33283483 4081 Human hsa-miR-19a miRNA Rh-endostatin pancreatic cancer (PC) ASPC-1 cells Rh-endostatin treatment downregulated 26041879 4082 Human hsa-miR-19a miRNA perfluorooctane sulfonic acid (PFOS) perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity HTR-8/SVneo cells Perfluorooctane sulfonic acid (PFOS) treatment downregulated 32738709 4083 Human hsa-miR-19a miRNA fractional CO(2) laser prostate cancer types I and III procollagen treatment with a fractional CO(2) laser miR-18a and miR-19a were dramatically upregulated 22907286 4084 Human hsa-miR-19a miRNA radon radiation ionizing radiation (IR) injury Blood samples radon radiation treatment downregulated 32165872 4085 Human hsa-miR-19a miRNA lipopolysaccharide (LPS) sepsis human bronchial epithelial cells (HBEpCs) lipopolysaccharide (LPS) treatment "THRIL is upregulated in sepsis and may sponge miR-19a to upregulate TNF-¦Á, thereby promoting lung cell apoptosis." 32944003 4086 Human hsa-miR-19a miRNA dextran sodium sulfate (DSS) ulcerative colitis (UC) human colon tissue with UC and DSS-treated mice colitis tissues dextran sodium sulfate (DSS) treatment downregulated 23795660 4087 Human hsa-miR-19a-3p miRNA SD or MF radiation breast cancer MDA-MB-361 cells SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment "upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)" 24626680 4088 Human hsa-miR-19a-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia injury (CII) SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment H19 was upregulated whereas miR-19a-3p was downregulated in I/R tissues and OGD/R induced cells 32335212 4089 Human hsa-miR-19a-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y Cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment miR-19a-3p was significantly upregulated in rat I/R brain tissues and OGD/R induced SH-SY5Y cells. 32312329 4090 Human hsa-miR-19a-3p miRNA baicalin (BAI) cervical cancer (CC) Human CC cell lines (HeLa and SiHa) baicalin (BAI) treatment downregulated 33603395 4091 Human hsa-miR-19a-3p miRNA TGF-¦Â1 fibrogenesis human cardiac fibroblasts TGF-¦Â1? treatment downregulated 27098600 4092 Human hsa-miR-19a-3p miRNA shock wave therapy (SWT) ischemic heart disease (IHD) human umbilical vein endothelial cells (HUVECs) shock wave therapy (SWT) treatment miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy 31410448 4093 Human hsa-miR-19b miRNA oxalic acid poisoning acute kidney injury (AKI) urinary oxalic acid poisoning upregulated 32910981 4094 Human hsa-miR-19b miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) Endothelial cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 26459935 4095 Human hsa-miR-19b miRNA bisphenol A (BPA) breast cancer MCF-7 human breast cancer cells bisphenol A (BPA) treatment upregulated 24831732 4096 Human hsa-miR-19b miRNA butyl benzyl phthalate (BBP) breast cancer MCF-7 cells; MDA-MB-231 cells Butyl benzyl phthalate (BBP) treatment BBP significantly induced the expression of miR-19b. 29864457 4097 Human hsa-miR-19b miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment downregulated 29189128 4098 Human hsa-miR-19b miRNA glucagon-like peptide-1 (GLP-1) cholesterol-induced lipotoxicity HepG2 cells Glucagon-like peptide-1 (GLP-1) treatment downregulated 30308521 4099 Human hsa-miR-19b miRNA galacto-oligosaccharides (GOS) colitis normal and LPS-stimulated human colon epithelial FHC cells galacto-oligosaccharides (GOS) treatment upregulated 31226416 4100 Human hsa-miR-19b miRNA lipopolysaccharide (LPS) colitis human colon epithelial FHC cells lipopolysaccharide (LPS) treatment downregulated 31226416 4101 Human hsa-miR-19b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (hRMECs) high glucose (HG) treatment upregulated 32519748 4102 Human hsa-miR-19b miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression. 33022863 4103 Human hsa-miR-19b miRNA acetaminophen (APAP) drug-induced liver injury (DILI) human LO2 cells ?acetaminophen (APAP) treatment downregulated 31077331 4104 Human hsa-miR-19b miRNA mechanical stretch epithelial-mesenchymal transition (EMT) primary human alveolar epithelial type II (AEII) cells mechanical stretch upregulated 27508324 4105 Human hsa-miR-19b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) human GC cell lines SGC-7901 and BGC-823 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25270964 4106 Human hsa-miR-19b miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) plasma hepatitis B virus (HBV) infection downregulated 22105822 4107 Human hsa-miR-19b miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection peripheral blood mononuclear cells of LTNPs Human immunodeficiency virus (HIV) infection The levels of microRNA-19b (miR-19b) were found to be significantly increased in peripheral blood mononuclear cells of LTNPs with lower rather than higher viral load. 30687333 4108 Human hsa-miR-19b miRNA lipopolysaccharide (LPS) inflammation human aortic endothelial cells lipopolysaccharide (LPS) treatment upregulated 28213977 4109 Human hsa-miR-19b miRNA lipopolysaccharide (LPS) inflammation human aortic endothelial cells lipopolysaccharide (LPS) treatment upregulated 28213977 4110 Human hsa-miR-19b miRNA alcohol liver damage LX2 cells alcohol exposure downregulated 27291156 4111 Human hsa-miR-19b miRNA paclitaxel (PTX) breast cancer MCF-7 cells low-dose metronomic (LDM) paclitaxel treatment downregulated 25552929 4112 Human hsa-miR-19b miRNA AZD8055 neuroblastoma (NB) neuroblastoma cells AZD8055 treatment downregulated 27492819 4113 Human hsa-miR-19b miRNA rapamycin neuroblastoma (NB) neuroblastoma cells rapamycin treatment upregulated 27492819 4114 Human hsa-miR-19b miRNA aluminum maltolate (Al-malt) neurodegenerative pathogenesis neuroblastoma SH-SY5Y cells aluminum maltolate (Al-malt) treatment downregulated 26836165 4115 Human hsa-miR-19b miRNA perfluorooctane sulfonic acid (PFOS) perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity HTR-8/SVneo cells Perfluorooctane sulfonic acid (PFOS) treatment downregulated 32738709 4116 Human hsa-miR-19b miRNA herbal formula HQT rheumatoid arthritis (RA) fibroblast-like synoviocytes herbal formula HQT treatment downregulated 32696503 4117 Human hsa-mir-19b miRNA Tongbi formula (HQT) rheumatoid arthritis (RA) RA-derived human fibroblast-like synoviocytes (HFLS-RA) Tongbi formula (HQT) treatment downregulated 32696503 4118 Human hsa-miR-19b miRNA H2O2 skin wound healing Human adipose-derived mesenchymal stem cells (ADMSCs) H2O2 treatment "Exosomal miR-19b derived from ADMSCs regulates the TGF-¦Â pathway by targeting CCL1, thereby promoting the healing of skin wounds." 33364805 4119 Human hsa-miR-19b miRNA lipopolysaccharide (LPS) ulcerative colitis (UC) Caco2 cells lipopolysaccharide (LPS) treatment "LPS significantly induced Caco2 cell inflammatory injury, downregulated miR-19b expression." 30178853 4120 Human hsa-miR-19b miRNA high glucose (HG) diabetic retinopathy (DR) retinal pigment epithelial cells (ARPE-19) high glucose (HG) treatment "Our results showed that lncRNA H19 and SIRT1 were reduced, while miR-19b was increased in ARPE-19 cells with HG condition." 33022863 4121 Human hsa-miR-19b1 miRNA deacetylase inhibitors (DACi) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cell Deacetylase inhibitors (DACi)treatment downregulated 24375802 4122 Human hsa-miR-19b-1 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment downregulated 29860902 4123 Human hsa-miR-19b1 miRNA deacetylase inhibitors (DACi) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cell lines Deacetylase inhibitors (DACi) treatment downregulated 24375802 4124 Human hsa-miR-19b-1-5p miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 4125 Human hsa-miR-19b-3p miRNA amyloid-¦Â (A¦Â) Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) treatment The expression levels of miR-16-5p and miR-19b-3p were reduced but BACE1 protein expression was enhanced in SH-SY5Y cells after treatment of amyloid ¦Â. 31876684 4126 Human hsa-miR-19b-3p miRNA SD or MF radiation breast cancer MDA-MB-361 cells SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment "upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)" 24626680 4127 Human hsa-miR-19b-3p miRNA hypoxia endothelial cell injury human umbilical vein endothelial cells (HUVECs) hypoxia treatment downregulated 31933110 4128 Human hsa-miR-19b-3p miRNA TGF-¦Â1 fibrogenesis human cardiac fibroblasts TGF-¦Â1? treatment downregulated 27098600 4129 Human hsa-miR-19b-3p miRNA matrine melanoma A375 cells; SK-MEL-2 melanoma cells Matrine treatment downregulated 29845233 4130 Human hsa-miR-19b-3p miRNA IL-1¦Â osteoarthritis (OA) chondrocyte IL-1¦Â treatment miR-19b-3p prevent osteoarthritis progression by targeting EZH2. 32765678 4131 Human hsa-miR-2 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" colorectal cancer (CRC) HCT116 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28100780 4132 Human hsa-miR-20 miRNA triptolide (TPL) hepatocellular carcinoma (HCC) HepG2 cells triptolide (TPL) treatment downregulated 29523159 4133 Human hsa-miR-200 miRNA busulfan anti-osteosarcoma effect human osteosarcoma U2OS and MG63 cells lines busulfan treatment upregulated 24815002 4134 Human hsa-miR-200 miRNA retinoic acid (RA) breast cancer MDA-MB-231 breast cancer cells retinoic acid treatment upregulated 23904188 4135 Human hsa-miR-200 miRNA tamoxifen (TAM) breast cancer MCF-7 cells Tamoxifen treatment upregulated 29738694 4136 Human hsa-miR-200 miRNA 3-acetyl-11-keto-¦Â-boswellic acid (AKBA) colorectal cancer (CRC) HCT116 cells£»HT29 cells£»SW480 cells£» SW620 cells 3-acetyl-11-keto-¦Â-boswellic acid (AKBA) upregulated 22983985 4137 Human hsa-miR-200 miRNA catalpol colorectal cancer (CRC) human HCT116 colorectal cancer cells catalpol treatment upregulated 28927141 4138 Human hsa-miR-200 miRNA NPV-LDE-225 (Erismodegib) human immunodeficiency virus (HIV)-1 infection Glioblastoma initiating cells (GICs) NPV-LDE-225 (Erismodegib) treatment downregulated 23482671 4139 Human hsa-miR-200 miRNA "3,3'-diindolylmethane (DIM)" human cytomegalovirus (HCMV) infection Breast cancer cell lines SKBR3£» MDA-MB-468 cells "?3, 3'-diindolylmethane (DIM) treatment" upregulated 23372748 4140 Human hsa-miR-200 miRNA high fat diet (HFD) inflammation plasma high fat diet (HFD) feed upregulated 30885503 4141 Human hsa-miR-200 miRNA triacetyl resveratrol (TCRV) pancreatic cancer (PC) human pancreatic cancer AsPC-1 and PANC-1 cells triacetyl resveratrol (TCRV) treatment upregulated 30720134 4142 Human hsa-miR-200 miRNA Pomegranate juice (PJ) prostate cancer ?prostate cancer cells Pomegranate juice (PJ) treatment upregulated 21594291 4143 Human hsa-miR-200 miRNA tamoxifen (TAM) epithelial-mesenchymal transition (EMT) Endometrial epithelial cancer ECC-1 cells Although tamoxifen treatment TAM can repress the miR-200 family and induce EMT via the upregulated of c-Myc in endometrial cancer cells 23295740 4144 Human hsa-miR-200-3p miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment miR-200-3p suppresses cell proliferation and reduces apoptosis in diabetic retinopathy via blocking the TGF-¦Â2/Smad pathway 33150936 4145 Human hsa-miR-200a miRNA Pien Tze Huang (PZH) anti-cancer therapy human colorectal carcinoma HCT-8 cells PZH treatment upregulated 25422078 4146 Human hsa-miR-200a miRNA curcumin (Cur) breast cancer MCF-10F cells curcumin (Cur) treatment upregulated 31894298 4147 Human hsa-miR-200a miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 4148 Human hsa-miR-200a miRNA glabridin (GLA) breast cancer MDA-MB-231 breast cancer cells Glabridin treatment upregulated 24754877 4149 Human hsa-miR-200a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cancer-associated fibroblasts (CAFs) activation cultured cancer-associated fibroblasts (CAFs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30851420 4150 Human hsa-miR-200a miRNA TGF-¦Â1 cancer-associated fibroblasts (CAFs) activation cultured normal fibroblasts (NFs) TGF¦Â1 treatment downregulated 30851420 4151 Human hsa-miR-200a miRNA estrogen receptor ¦Â colorectal cancer (CRC) Cell lines (SW480;HT29 ;SW620) Estrogen receptor ¦Â treatment the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated 23436804 4152 Human hsa-miR-200a miRNA astaxanthin colorectal cancer (CRC) The human colon cancer cell HCT116 astaxanthin (ATX) treatment upregulated 31263239 4153 Human hsa-miR-200a miRNA Pien Tze Huang (PZH) colorectal cancer (CRC) human colorectal carcinoma HCT-8 cells Pien Tze Huang (PZH) treatment upregulated 25422078 4154 Human hsa-miR-200a miRNA RM (Root methanol) colorectal cancer (CRC) HT-29 cells; HCT 116 cells RM (Root methanol) treatment upregulated 32691634 4155 Human hsa-miR-200a miRNA ursolic acid (UA) colorectal cancer (CRC) HCT116 and HCT-8 cells Ursolic acid (UA) treatment upregulated 31452805 4156 Human hsa-miR-200a miRNA LEFTY2 endometrial cancer (EC) Ishikawa cells LEFTY2 treatment upregulated 27497669 4157 Human hsa-miR-200a miRNA high glucose (HG) endothelial inflammation human aortic endothelial cells (HAECs) high glucose (HG) treatment downregulated 29720943 4158 Human hsa-miR-200a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epithelial-mesenchymal transition (EMT) human conjunctival epithelial (HCjE) cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" 5-AzaC treatment induced increased expression of miR-200a towards the control level. 32387379 4159 Human hsa-miR-200a miRNA metformin (Met) epithelial-mesenchymal transition (EMT) SW480 cells; HCT116 cells metformin treatment upregulated 30017802 4160 Human hsa-miR-200a miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) HK-2 cells treat with TGF ¦Â1 treatment downregulated 28817830 4161 Human hsa-miR-200a miRNA dexamethasone (DEX) femoral head necrosis (FHN) human osteoblasts dexamethasone (DEX) treatment downregulated 29285219 4162 Human hsa-miR-200a miRNA allopurinol fructose-induced hepatic inflammation fructose-induced rats HepG2 cells allopurinol treatemnt upregulated 30248460 4163 Human hsa-miR-200a miRNA curcumin (Cur) fructose-induced hepatic inflammation fructose-induced rats HepG2 cells curcumin treatment upregulated 30248460 4164 Human hsa-miR-200a miRNA fructose fructose-induced hepatic inflammation HepG2 cells fructose treatment downregulated 30248460 4165 Human hsa-miR-200a miRNA toosendanin (TSN) gastric cancer (GC) SGC-7901 cells TSN treatment upregulated 29048657 4166 Human hsa-miR-200a miRNA TGF-¦Â glaucoma filtration surgery (GFS) primary human Tenon's capsule fibroblasts (HTFs) TGF-¦Â treatment H19 exerted its effects by interacting with miR-200a in TGF-¦Â-treated HTFs 31877306 4167 Human hsa-miR-200a miRNA radiotherapy head and neck squamous cell carcinoma (HNSCC) neck squamous cell carcinoma patients saliva samples radiotherapy treatment upregulated in saliva samples 28677748 4168 Human hsa-miR-200a miRNA TGF-¦Â1 liver fibrosis Hepatic stellate cell (HSC) TGF-¦Â1 treatment downregulated 24242045 4169 Human hsa-miR-200a miRNA HepG2-CORE cells conditioned media (CM) hepatitis C virus (HCV)-related liver fibrosis LX-2 cells treated with HepG2-CORE CM downregulated 28302418 4170 Human hsa-miR-200a miRNA histone deacetylase 4 (HDAC4) hepatocellular carcinoma (HCC) Human HCC Tissues histone deacetylase 4 (HDAC4)? treatment downregulated 21837748 4171 Human hsa-miR-200a miRNA hypoxia hepatocellular carcinoma (HCC) Hep3B cells hypoxia induce "LncRNA MALAT1 was involved in proliferation, migration, invasion, and apoptosis by interacting with miR-200a in hypoxic Hep3B cells, revealing a new mechanism of MALAT1 involved in hypoxic HCC progression." 31347327 4172 Human hsa-miR-200a miRNA transarterial chemoembolization (TACE) hepatocellular carcinoma (HCC) HCC patients plasma TACE treatment differently regulated 25275448 4173 Human hsa-miR-200a miRNA angiotensin II (Ang II) hypertension and diabetes AB8/13 cells angiotensin II (Ang II) treatment upregulated 32887498 4174 Human hsa-miR-200a miRNA high glucose (HG) hypertension and diabetes AB8/13 cells high glucose (HG) treatment upregulated 32887498 4175 Human hsa-miR-200a miRNA progesterone (P4) infertility "human endometrial carcinoma cell line, SNU-1077" progesterone treatment dysregulated 30603515 4176 Human hsa-miR-200a miRNA carbon tetrachloride (CCl4) liver fibrosis LX-2 cells carbon tetrachloride (CCl4) treatment miR-200a was significantly reduced in liver tissues of a carbon tetrachloride (CCl4)- activated LX2 cells. 32319630 4177 Human hsa-miR-200a miRNA gefitinib lung cancer A549 cells gefitinib treatment "MALAT1 promoted the proliferation and gefitinib resistance of lung cancer cells by sponging miR-200a, which regulates expression of ZEB1 in the A549 cells." 31133357 4178 Human hsa-miR-200a miRNA arsenite melanoma human keratinocyte HaCaT cell line arsenic (As) exposure upregulated 27054085 4179 Human hsa-miR-200a miRNA dacarbazine (DTIC) melanoma FEMX-1 melanoma cell line dacarbazine (DTIC) treatment upregulated 28387914 4180 Human hsa-miR-200a miRNA beraprost sodium metabolic disorders C57BL/7JNju mice beraprost sodium downregulated 28732575 4181 Human hsa-miR-200a miRNA beraprost sodium metabolic disorders human-derived HepG3 cells beraprost sodium downregulated 28732575 4182 Human hsa-miR-200a miRNA thymosin ¦Â4 (T¦Â4) myocardial ischemia/reperfusion (I/R) injury (MIRI) hypoxia-induced cardiac microvascular endothelial cells (CMECs) Thymosin ¦Â-4 (T¦Â4) treatment upregulated 31265170 4183 Human hsa-miR-200a miRNA 1-methyl-4-phenylpyridinium (MPP+) neurodegenerative diseases SH5Y-SY cells 1-methyl-4- phenylpyridinium iodide(MPP +) treatment upregulated 29936262 4184 Human hsa-miR-200a miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 4185 Human hsa-miR-200a miRNA free fatty acids (FFAs) and TNF-¦Á and IL-6 nonalcoholic fatty liver disease (NAFLD) HepG2 cells and human hepatocytes free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment upregulated 25562147 4186 Human hsa-miR-200a miRNA high fructose nonalcoholic fatty liver disease (NAFLD) HepG2 cells high fructose treatment downregulated 30014902 4187 Human hsa-miR-200a miRNA polydatin (PD) nonalcoholic fatty liver disease (NAFLD) high fructose-induced HepG2 cells "Polydatin (3,4',5-trihydroxy-stilbene-3-¦Â-D-glucoside) treatment" upregulated 30014902 4188 Human hsa-miR-200a miRNA human papilloma viruses (HPVs) 16 oropharyngeal squamous cell carcinoma (OPSCC) HOK-16B cells human papillomaviruses (HPVs) 16 treatment downregulated 31911577 4189 Human hsa-miR-200a miRNA emodin ovarian cancer (OC) A2780 cells emodin treatment upregulated 29512773 4190 Human hsa-miR-200a miRNA morin oxidative stress A549 cells upon traffic PM2.5 exposure Morin treatment downregulated 31284452 4191 Human hsa-miR-200a miRNA particulate matter (PM2.5) oxidative stress A549 cells traffic PM2.5 treatment upregulated 31284452 4192 Human hsa-miR-200a miRNA IL-9 pancreatic cancer (PC) PANC-1;AsPC-1 cells line IL-9 treatment downregulated 28349057 4193 Human hsa-miR-200a miRNA TGF-¦Â1 peritoneal fibrosis human peritoneal mesothelial cells (HPMCs) transforming growth factor (TGF)-¦Â1 treatment downregulated 29357421 4194 Human hsa-miR-200a miRNA docetaxel (DTX) prostate cancer CRP patients docetaxel (DTX) treatment "miR-200b levels, miR-20a levels, were independent predictors of overall survival" 24714754 4195 Human hsa-miR-200a miRNA metformin (Met) cell senescence BJ-1 human diploid fibroblasts (HDFs) metformin treatment upregulated 22356767 4196 Human hsa-miR-200a miRNA arsenite urothelial carcinoma HUC1 cells arsenic (As) exposure downregulated 25586904 4197 Human hsa-miR-200a-3p miRNA hypoxia/reoxygenation (H/R) angiogenesis human umbilical vein endothelial cells (HUVECs) hypoxia/reoxygenation (H/R) treatment upregulated 32572929 4198 Human hsa-miR-200a-3p miRNA enterotoxigenic bacteroides fragilis (ETBF) colorectal cancer (CRC) HCT-116 and DLD-1 cells Enterotoxigenic Bacteroides fragilis (ETBF) infection downregulated 31515468 4199 Human hsa-miR-200a-3p miRNA hepatitis B virus X protein (HBx) HBV-associated tumorigenesis LO2 cells hepatitis B virus X protein (HBx) treatment HBX downregulated miR-200a-3p mRNA expression 29231260 4200 Human hsa-miR-200a-3p miRNA metformin (Met) HBV-associated tumorigenesis LO2 cells metformin treatment Metformin enhanced miR-200a-3p mRNA expression 29231260 4201 Human hsa-miR-200a-3p miRNA free fatty acids (FFA) hepatic steatosis LO2 cells free fatty acid (FFA) treatment upregulated 31191607 4202 Human hsa-miR-200a-3p miRNA radix tetrastigma hemsleyani (RTH) lung cancer A549 cells radix tetrastigma hemsleyani (RTH) treatment upregulated 30100735 4203 Human hsa-miR-200a-3p miRNA TGF-¦Â lung cancer A549 Transforming growth factor ¦Â (TGF¦Â) treatment LINC00273 promoted TGF¦Â-induced lung cancer EMT through miR-200a-3p/ZEB1 feedback loop 32017082 4204 Human hsa-miR-200a-3p miRNA lipopolysaccharide (LPS) sepsis-induced brain injury (SIBI) human brain microvascular endothelial cells lipopolysaccharide (LPS) treatment overexpression of miRNA-200a-3p promoted inflammation in sepsis-induced brain injury through reactive oxygen species-induced NLRP3. 31485604 4205 Human hsa-miR-200a-c miRNA XMD8-92 pancreatic ductal adenocarcinoma (PDAC) human pancreatic cancer AsPC-1 cells XMD8-92 treatment upregulated 24880079 4206 Human hsa-miR-200b miRNA esomeprazole adeno and squamous-cell-carcinoma human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines esomeprazole treatment upregulated 25175076 4207 Human hsa-miR-200b miRNA Pien Tze Huang (PZH) anti-cancer therapy human colorectal carcinoma HCT-8 cells PZH treatment upregulated 25422078 4208 Human hsa-miR-200b miRNA TGF-¦Â1 bladder cancer HTB9 and T24 bladder cancer cells TGF-¦Â1 treatment downregulated 25017509 4209 Human hsa-miR-200b miRNA artemisinin (ART) breast cancer MCF-7/DDP cells artemisinin treatment upregulated 28361857 4210 Human hsa-miR-200b miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 4211 Human hsa-miR-200b miRNA epstein-barr virus (EBV) tumorigenesis EBV-positive B-lymphocytic cell lines;Epithelial gastric carcinoma AGSB95.8 cells;MCF-7 cells (ATCC) Epstein-Barr Virus (EBV) infection downregulated 20668090 4212 Human hsa-miR-200b miRNA suberoylanilide hydroxamic acid (SAHA) tumorigenesis MEG-01 cells; HEK-293 cells suberoylanilide hydroxamic acid (SAHA) treatment downregulated 23543665 4213 Human hsa-miR-200b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cancer-associated fibroblasts (CAFs) activation cultured cancer-associated fibroblasts (CAFs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30851420 4214 Human hsa-miR-200b miRNA TGF-¦Â1 cancer-associated fibroblasts (CAFs) activation cultured normal fibroblasts (NFs) TGF¦Â1 treatment downregulated 30851420 4215 Human hsa-miR-200b miRNA 5-fluorouracil (5-Fu) tumorigenesis human colon cancer cells 5-fluorouracil (5-FU) treatment downregulated 17702597 4216 Human hsa-miR-200b miRNA carbon tetrachloride (CCl4) chondrosarcoma human chondrosarcoma cell line (JJ012) CCl4 treatment downregulated 25301739 4217 Human hsa-miR-200b miRNA hypoxia chronic hypoxia human endothelial cells binder CO2/O2 incubator treatment upregulated 25550463 4218 Human hsa-miR-200b miRNA bone morphogenetic protein 2 (BMP2) chronic pancreatitis (CP) human primary pancreatic stellate cells; human primary pancreatic fibroblast (hPFBs) bone morphogenetic protein 2 (BMP2) treatment upregulated 29303912 4219 Human hsa-miR-200b miRNA TGF-¦Â chronic pancreatitis (CP) human primary pancreatic fibroblast (hPFBs) TGF-¦Â treatment downregulated 29303912 4220 Human hsa-miR-200b miRNA estrogen receptor ¦Â colorectal cancer (CRC) Cell lines (SW480;HT29 ;SW620) Estrogen receptor ¦Â treatment the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated 23436804 4221 Human hsa-miR-200b miRNA Pien Tze Huang (PZH) colorectal cancer (CRC) human colorectal carcinoma HCT-8 cells Pien Tze Huang (PZH) treatment upregulated 25422078 4222 Human hsa-miR-200b miRNA RM (Root methanol) colorectal cancer (CRC) HT-29 cells; HCT 117 cells RM (Root methanol) treatment upregulated 32691634 4223 Human hsa-miR-200b miRNA ursolic acid (UA) colorectal cancer (CRC) HCT116 and HCT-8 cells Ursolic acid (UA) treatment upregulated 31452805 4224 Human hsa-miR-200b miRNA cyclosporine A (CsA) cyclosporine A (CsA)-induced gingival overgrowth normal human gingival fibroblasts (HGFs) cyclosporine A (CsA) treatment downregulated 30449457 4225 Human hsa-miR-200b miRNA high glucose (HG) diabetic retinopathy (DR) retinal pigment epithelial cells (ARPE-19) high glucose (HG) treatment We found that SNHG4 was downregulated in DR. 33822671 4226 Human hsa-miR-200b miRNA hyperglycemia diabetic wound angiogenesis human microvascular endothelial cells (HMECs) HG downregulated 29037594 4227 Human hsa-miR-200b miRNA high glucose (HG) endothelial inflammation human aortic endothelial cells (HAECs) high glucose (HG) treatment downregulated 29720943 4228 Human hsa-miR-200b miRNA glucose and TGF¦Â1 epithelial-mesenchymal transition (EMT) human retinal microvascular endothelial cells 25 mM glucose with TGF¦Â1 treatment upregulated 25335984 4229 Human hsa-miR-200b miRNA TGF-¦Â endothelium-dependent vasorelaxation HT-29 cells TGF-¦Â treatment downregulated 23483606 4230 Human hsa-miR-200b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epithelial-mesenchymal transition (EMT) human conjunctival epithelial (HCjE) cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" 5-AzaC treatment induced increased expression of miR-200b towards the control level. 32387379 4231 Human hsa-miR-200b miRNA erythropoietin (EPO) epithelial-mesenchymal transition (EMT) HK-2 cells EPO treatment upregulated 28535509 4232 Human hsa-miR-200b miRNA TGF-¦Â1 fibrosis human Tenon's fibroblasts (HTFs) TGF-¦Â1 treatment upregulated 30512998 4233 Human hsa-miR-200b miRNA TGF-¦Â1 fibrosis human Tenon's fibroblasts (HTFs) TGF-¦Â1 treatment upregulated 30512998 4234 Human hsa-miR-200b miRNA diallyl disulfide (DADS) gastric cancer (GC) Five gastric cancer cell lines (MGC-803; BGC-823; MKN-28; SGC-7901; HGC-27; AGS) diallyl disulfide treatment upregulated 23851184 4235 Human hsa-miR-200b miRNA helicobacter pylori (H. pylori) gastric cancer (GC) human gastric carcinoma (AGS) cells infect with HP downregulated 28056089 4236 Human hsa-miR-200b miRNA TGF-¦Â1 glaucoma human Tenon's capsule fibroblasts were various doses of TGF-¦Â1 for 24 hours treatment upregulated 24667864 4237 Human hsa-miR-200b miRNA TGF-¦Â1 hepatic steatosis intestinal epithelial cells (IECs) TGF-¦Â1 treatment downregulated 23492772 4238 Human hsa-miR-200b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hepatocellular carcinoma (HCC) HCC cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26919246 4239 Human hsa-miR-200b miRNA TGF-¦Â1 hypertrophic scars (HS) fibroblasts TGF-¦Â1 treatment downregulated 26500110 4240 Human hsa-miR-200b miRNA hypoxia hypoxic-related diseases primary human umbilical vein endothelial cells (HUVECs) hypoxia treatment miR-200b and miR-429 are upregulated in response to hypoxia. 29737439 4241 Human hsa-miR-200b miRNA tumor necrosis factor alpha (TNF-¦Á) inflammatory bowel disease (IBD) Caco-2 cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 27979826 4242 Human hsa-miR-200b miRNA 5-fluorouracil/mitomycin C (MMC-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) MMC-CRTX treatment upregulated 28347920 4243 Human hsa-miR-200b miRNA tobacco carcinogens lung cancer HBECs tobacco carcinogens treatment "EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205" 21363915 4244 Human hsa-miR-200b miRNA dacarbazine (DTIC) melanoma FEMX-1 melanoma cell line dacarbazine (DTIC) treatment upregulated 28387914 4245 Human hsa-miR-200b miRNA "anthranilamide-pyrazolo[1,5-a]pyrimidine" neuroblastoma (NB) neuronalcancer cells lines MR-32; SK-N-SH "anthranilamide-pyrazolo[1,5-a]pyrimidine treatment" upregulated 23992861 4246 Human hsa-miR-200b miRNA free fatty acids (FFAs) and TNF-¦Á and IL-6 nonalcoholic fatty liver disease (NAFLD) HepG2 cells and human hepatocytes free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment upregulated 25562147 4247 Human hsa-miR-200b miRNA arecoline oral submucous fibrosis (OSF) human buccal mucosal fibroblasts (BMFs) arecoline treatment downregulated 29893466 4248 Human hsa-miR-200b miRNA human papilloma viruses (HPVs) 16 oropharyngeal squamous cell carcinoma (OPSCC) HOK-17B cells human papillomaviruses (HPVs) 17 treatment downregulated 31911577 4249 Human hsa-miR-200b miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human chondrocytes lipopolysaccharide (LPS) treatment "The expression level of miR-200b was downregulated, and that of FUT4 was upregulated in OA cartilage tissues and LPS-treated normal chondrocytes compared with normal cartilage tissues and chondrocytes." 33692838 4250 Human hsa-miR-200b miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment downregulated 32901049 4251 Human hsa-miR-200b miRNA "3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells "3,3'-diindolylmethane (DIM) treatment" upregulated 19654291 4252 Human hsa-miR-200b miRNA gemcitabine (GEM) pancreatic cancer (PC) "Capan-1, Capan-2, Panc-1, MIAPaCa-2, BxPC-3 and PL45 cells" Gemcitabine (GEM) treatment the expression of miR-200b correlated positively with chemosensitivity. 30628651 4253 Human hsa-miR-200b miRNA isoflavone pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells isoflavone treatment upregulated 19654291 4254 Human hsa-miR-200b miRNA metformin (Met) pancreatic cancer (PC) Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR Metformin? treatment downregulated 22086681 4255 Human hsa-miR-200b miRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) PDAC cells gemcitabine treatment downregulated 28849150 4256 Human hsa-miR-200b miRNA hypoxia proangiogenic function human endothelial cells a CO2/O2 incubator for hypoxia research (Tri-gas Binder CB150) upregulated 29042072 4257 Human hsa-miR-200b miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 4258 Human hsa-miR-200b miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 4259 Human hsa-miR-200b miRNA docetaxel (DTX) prostate cancer CRP patients docetaxel (DTX) treatment "miR-200b levels, miR-20a levels, were independent predictors of overall survival" 24714754 4260 Human hsa-miR-200b miRNA lactoferrin (LF) prostate cancer DU-145 cells lactoferrin (LF) treatment upregulated 30285009 4261 Human hsa-miR-200b miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) human retinal endothelial cells (HRECs) high glucose downregulated 28122089 4262 Human hsa-miR-200b miRNA arsenite urothelial carcinoma HUC1 cells arsenic (As) exposure downregulated 25586904 4263 Human hsa-miR-200b miRNA hypoxia inflammatory bowel disease (IBD) human microvascular endothelial cells (HMECs) hypoxia? treatment downregulated 21081489 4264 Human hsa-miR-200b-3p miRNA copper (Cu) Alzheimer's disease (AD) human primary microvascular endothelial cells (MVECs) chronic exposure to copper "In human primary microvascular endothelial cells (MVECs), microRNA-200b-3p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure." 30923833 4265 Human hsa-miR-200b-3p miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) Immortalized primary bronchial epithelial cell line (BEAS-2B cells) transforming growth factor-¦Â (TGF-¦Â) treatment downregulated 31283671 4266 Human hsa-miR-200b-3p miRNA TGF-¦Â1 hepatocarcinogenesis Hep3B cells TGF-¦Â1 treatment upregulated 32269736 4267 Human hsa-miR-200b-3p miRNA xiaoai Jiedu recipe (XJR) hepatocellular carcinoma (HCC) HepG2 cells Xiaoai Jiedu recipe (XJR) treatment XJR could effectively inhibit HCC and might exert its antitumor effect through the miR-200b-3p/Notch1 axis 33173345 4268 Human hsa-miR-200b-3p miRNA oridonin pancreatic cancer (PC) The BxPC-3 and PANC-1 human pancreatic cancer cell lines Oridonin treatment downregulated 27878247 4269 Human hsa-miR-200b-3p miRNA doxorubicin (DOX) osteosarcoma (OS) MG63 cells; KHOS cells; U2OS cells doxorubicin treatment miR-200b-3p expression was greatly downregulated in the chemo-resistant OS tissues. 30204936 4270 Human hsa-miR-200b-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 4271 Human hsa-miR-200b-3p miRNA arsenite tumorigenesis human bronchial epithelial (HBE) cells arsenic exposure "upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)" 28972549 4272 Human hsa-miR-200b-3p miRNA ¦Â-glycerophosphate (¦Â-GP) vascular calcification (VC) human aortic smooth muscle cells (HASMCs) ¦Â-glycerophosphate (¦Â-GP) treatment upregulated 32818704 4273 Human hsa-miR-200b-5p miRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells Ginsenoside Rh2 (Rh2) treatment upregulated 30197683 4274 Human hsa-miR-200c miRNA H2O2 endothelial cell apoptosis and senescence Human umbilical vein endothelial cells (HUVEC) H2O2 treatment upregulated 21527937 4275 Human hsa-miR-200c miRNA Pien Tze Huang (PZH) anti-cancer therapy human colorectal carcinoma HCT-8 cells PZH treatment upregulated 25422078 4276 Human hsa-miR-200c miRNA arsenic trioxide (ATO) breast cancer breast cancer cells arsenic trioxide (As(2)O(3)) treatment upregulated 24729530 4277 Human hsa-miR-200c miRNA arsenic trioxide (ATO) breast cancer MDA-MB-231 cells arsenic trioxide (As2O3) treatment upregulated 24729530 4278 Human hsa-miR-200c miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 4279 Human hsa-miR-200c miRNA glabridin (GLA) breast cancer MDA-MB-231 breast cancer cells Glabridin treatment upregulated 24754877 4280 Human hsa-miR-200c miRNA silibinin (SB) breast cancer T47D breast cancer cell line silibinin treatment "upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)" 28509572 4281 Human hsa-miR-200c miRNA SK228 breast cancer MDA-MB-231 human breast cancer cell lines SK228 treatment upregulated 24967704 4282 Human hsa-miR-200c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cancer-associated fibroblasts (CAFs) activation cultured cancer-associated fibroblasts (CAFs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30851420 4283 Human hsa-miR-200c miRNA TGF-¦Â1 cancer-associated fibroblasts (CAFs) activation cultured normal fibroblasts (NFs) TGF¦Â1 treatment downregulated 30851420 4284 Human hsa-miR-200c miRNA doxorubicin (DOX) cardiotoxicity human cardiac mesenchymal progenitor cells DOXO upregulated 28837147 4285 Human hsa-miR-200c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" clear cell renal cell carcinoma (ccRCC) ccRCC cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27123083 4286 Human hsa-miR-200c miRNA Clostridium butyricum (C. butyricum) colitis-associated colon cancer (CAC) human intestinal cell line Vaco2-BBE infect with C. butyricum upregulated 28478805 4287 Human hsa-miR-200c miRNA bicotine colorectal cancer (CRC) SW620 and HT-29 cells nicotine treatment downregulated 30076725 4288 Human hsa-miR-200c miRNA nicotine colorectal cancer (CRC) CRC tissues and cell lines SW620 and HT-29 cigarette smoking exposure downregulated 30076725 4289 Human hsa-miR-200c miRNA Pien Tze Huang (PZH) colorectal cancer (CRC) human colorectal carcinoma HCT-8 cells Pien Tze Huang (PZH) treatment upregulated 25422078 4290 Human hsa-miR-200c miRNA resveratrol colorectal cancer (CRC) NA-anti-miR-200c transfected HCT-116 cells resveratrol (RS) treatment upregulated 27918105 4291 Human hsa-miR-200c miRNA RM (Root methanol) colorectal cancer (CRC) HT-29 cells; HCT 118 cells RM (Root methanol) treatment upregulated 32691634 4292 Human hsa-miR-200c miRNA Short-chain fatty acid sodium butyrate (NaB) colorectal cancer (CRC) HCT116 and LOVO CRC cells Short-chain fatty acid sodium butyrate (NaB) treatment upregulated 29418071 4293 Human hsa-miR-200c miRNA ursolic acid (UA) colorectal cancer (CRC) HCT116 and HCT-8 cells Ursolic acid (UA) treatment upregulated 31452805 4294 Human hsa-miR-200c miRNA surgery and chemotherapy colorectal cancer (CRC) patients blood surgery and chemotherapy for 3years treatment upregulated 24310813 4295 Human hsa-miR-200c miRNA mammosphere culture epithelial-mesenchymal transition (EMT) MCF-7 cells mammosphere culture treatment "suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221" 21553120 4296 Human hsa-miR-200c miRNA high glucose (HG) endothelial inflammation human aortic endothelial cells (HAECs) high glucose (HG) treatment downregulated 29720943 4297 Human hsa-miR-200c miRNA antcin A (ATA) epithelial-mesenchymal transition (EMT) "Human breast cancer cell lines, MCF-7 and MDA-MB-231" Antcin-A (ATA) treatment upregulated 31185503 4298 Human hsa-miR-200c miRNA TGF-¦Â endothelium-dependent vasorelaxation HT-29 cells TGF-¦Â treatment downregulated 23483606 4299 Human hsa-miR-200c miRNA insulin-like growth factor 1 (IGF-1) epithelial-mesenchymal transition (EMT) human gastric cell lines MGC803;SGC-7901 IGF-I treatment downregulated 24885194 4300 Human hsa-miR-200c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epithelial-mesenchymal transition (EMT) human conjunctival epithelial (HCjE) cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" 5-AzaC treatment induced increased expression of miR-200c towards the control level. 32387379 4301 Human hsa-miR-200c miRNA metformin (Met) epithelial-mesenchymal transition (EMT) SW480 cells; HCT116 cells metformin treatment upregulated 30017802 4302 Human hsa-miR-200c miRNA platinum-based chemotherapy esophageal squamous cell carcinoma (ESCC) Venous blood samples platinum-based chemotherapy treatment upregulated 24349623 4303 Human hsa-miR-200c miRNA curcumin (Cur) thyroid cancer (TC) "human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101" curcumin treatment downregulated 28265769 4304 Human hsa-miR-200c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "human GC cell lines NCI-N87, SGC7901 ,AGS ,HGC27 and MGC803" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27498672 4305 Human hsa-miR-200c miRNA decitabine gastric cancer (GC) SGC-7902 cells decitabine treatment upregulated 25502084 4306 Human hsa-miR-200c miRNA decitabine gastric cancer (GC) SGC-7901 cells the chemotherapeutic agent decitabine treatment upregulated 25502084 4307 Human hsa-miR-200c miRNA TGF-¦Â gastric cancer (GC) SGC-7902 cells TGF-¦Â treatment downregulated 25502084 4308 Human hsa-miR-200c miRNA hepatocyte growth factor (HGF) head and neck squamous cell carcinoma (HNSCC) HNSCC; adjacent normal squamous epithelial tissues Hepatocyte growth factor (HGF) treatment downregulated 21899661 4309 Human hsa-miR-200c miRNA lanthionine lanthionine toxicity EA.hy926 cell cultures lanthionine treatment upregulated 31071929 4310 Human hsa-miR-200c miRNA hypoxia lung cancer "The human cell lines A549 (lung carcinoma), NCI-H460 (lung carcinoma)" hypoxia induce downregulated 31061665 4311 Human hsa-miR-200c miRNA paclitaxel (PTX) lung cancer A549 cells paclitaxel treatment "miRNA-200c was significantly lower in A549/TAX cells, which are paclitaxel-resistant A549 cells" 29219949 4312 Human hsa-miR-200c miRNA tobacco carcinogens lung cancer HBECs tobacco carcinogens treatment "EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205" 21363915 4313 Human hsa-miR-200c miRNA silica lung function decline blood silica treatment downregulated 29280772 4314 Human hsa-miR-200c miRNA dacarbazine (DTIC) melanoma FEMX-1 melanoma cell line dacarbazine (DTIC) treatment upregulated 28387914 4315 Human hsa-miR-200c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 4316 Human hsa-miR-200c miRNA free fatty acids (FFAs) and TNF-¦Á and IL-6 nonalcoholic fatty liver disease (NAFLD) HepG2 cells and human hepatocytes free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment upregulated 25562147 4317 Human hsa-miR-200c miRNA TGF-¦Â non-small cell lung cancer (NSCLC) erlotinib-sensitive PC9 cells TGF¦Â treatment dysregulated 28646226 4318 Human hsa-miR-200c miRNA sulforaphane (SFN) oral squamous cell carcinoma (OSCC) OSCC cancer stem cells (CSCs)isolated from SAS and GNM cells sulforaphane treatment upregulated 26879838 4319 Human hsa-miR-200c miRNA arecoline oral submucous fibrosis (OSF) fibrotic buccal mucosal fibroblasts (fBMFs arecoline treatment downregulated 29958727 4320 Human hsa-miR-200c miRNA human papilloma viruses (HPVs) 16 oropharyngeal squamous cell carcinoma (OPSCC) HOK-18B cells human papillomaviruses (HPVs) 18 treatment downregulated 31911577 4321 Human hsa-miR-200c miRNA methotrexate (MTX) osteosarcoma (OS) MG63 cells; HOS cells methotrexate (MTX) treatment miR-200c was downregulated in methotrexate resistance osteosarcoma cells 29170124 4322 Human hsa-miR-200c miRNA methotrexate (MTX) osteosarcoma (OS) "osteosarcoma cell lines (MG-63, U2OS, HOS and SAOS-2)" methotrexate treatment downregulated 29170124 4323 Human hsa-miR-200c miRNA olaparib ovarian cancer (OC) UWB cells; UWB-BRCA cells olaparib treatment downregulated 31898520 4324 Human hsa-miR-200c miRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3ip1 cells paclitaxel (PTX) treatment downregulated 33028939 4325 Human hsa-miR-200c miRNA H2O2 oxidative stress human renal tubular epithelium (HK-2) cells hydrogen peroxide (H2O2) treatment upregulated 31199854 4326 Human hsa-miR-200c miRNA "3,3'-diindolylmethane (DIM)" pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells "3,3'-diindolylmethane (DIM) treatment" upregulated 19654291 4327 Human hsa-miR-200c miRNA garcinol pancreatic cancer (PC) PANC-1 SP cells Garcinol treatment upregulated 26400206 4328 Human hsa-miR-200c miRNA isoflavone pancreatic cancer (PC) MiaPaCa-2; Panc-1; Aspc-1 cells isoflavone treatment upregulated 19654291 4329 Human hsa-miR-200c miRNA metformin (Met) pancreatic cancer (PC) Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR Metformin? treatment downregulated 22086681 4330 Human hsa-miR-200c miRNA TGF-¦Â1 peritoneal fibrosis Immortalized human mesothelial cells (Met-5A cells) TGF-¦Â1 treatment downregulated 31226520 4331 Human hsa-miR-200c miRNA hydrogen sulfide (H2S) preeclampsia (PE) placental cells obtained from pregnant women with preeclampsia placental cells obtained from pregnant women with preeclampsia treatment downregulated 26992682 4332 Human hsa-miR-200c miRNA endothelin-1 (ET-1) pulmonary arterial hypertension (PAH) pulmonary arterial smooth muscle cells (PASMCs) endothelin-1 (ET-1) treatment upregulated 29044995 4333 Human hsa-miR-200c miRNA neoadjuvant chemoradiotherapy (CRT) rectal cancer patients with rectal cancer received neoadjuvant chemoradiotherapy treatment downregulated 24617665 4334 Human hsa-miR-200c miRNA docetaxel (DTX) tongue squamous cell carcinoma (TSCC) HSC-3 cells docetaxel (DTX) treatment downregulated 32310826 4335 Human hsa-miR-200c miRNA isoliquiritigenin triple negative breast cancer (TNBC) BT-549 cells; MDA-MB-231 cells isoliquiritigenin (ISL)?treatment "In this study, PCR array screened a significant increase of miR-200c in BT-549 and MDA-MB-231 cells after ISL treatment, and ISH exerted that miR-200c was expressed at a low level in breast cancer tissue of patients." 33641651 4336 Human hsa-miR-200c miRNA tamoxifen (TAM) triple negative breast cancer (TNBC) TNBC cells (MCF-7/ADR and MDA-MB-231) TAM treatment downregulated 28724364 4337 Human hsa-miR-200c miRNA arsenite urothelial carcinoma HUC1 cells arsenic (As) exposure downregulated 25586904 4338 Human hsa-miR-200c miRNA sulforaphane (SFN) oral squamous cell carcinoma (OSCC) "normal oral epithelial cells (SG) and SAS or GNM cells,OSCC-CSCs" sulforaphane treatment upregulated 26879838 4339 Human hsa-miR-200c* miRNA hypoxia gastroesophageal cancer (GEC) ESCC and AC cell lines Hypoxia treatment upregulated 26851030 4340 Human hsa-miR-200c-3p miRNA influenza virus acute respiratory distress syndrome (ARDS) A549 cells infect with H5N1 upregulated 28690868 4341 Human hsa-miR-200c-3p miRNA copper (Cu) Alzheimer's disease (AD) human primary microvascular endothelial cells (MVECs) chronic exposure to copper "In human primary microvascular endothelial cells (MVECs), microRNA-200c-3p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure." 30923833 4342 Human hsa-miR-200c-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 4343 Human hsa-miR-200c-3p miRNA resveratrol breast cancer breast cancer cell resveratrol (RS) treatment downregulated 26890143 4344 Human hsa-miR-200c-3p miRNA yin yang 1 (YY1) cholangiocarcinoma (CCA) CCLP-1 and QBC939 cells yin yang 1 (YY1) treatment downregulated 33040228 4345 Human hsa-miR-200c-3p miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment downregulated 26397152 4346 Human hsa-miR-200c-3p miRNA H2O2 glaucoma human trabecular meshwork (HTM) cells H2O2 treatment downregulated 32626945 4347 Human hsa-miR-200c-3p miRNA ferulic acid (FA) intestinal barrier dysfunction Caco-2 cells Ferulic acid (FA) treatment "LPS stimulation decreased miR-200c-3p expression, whereas this decrease was inhibited by FA pretreatment." 32308620 4348 Human hsa-miR-200c-3p miRNA IL-1B intestinal inflammation Caco-2 cells IL-1B treatment MIR200C-3p was rapidly increased in Caco-2 cells incubated with IL-1B. 32569770 4349 Human hsa-miR-200c-3p miRNA ultrasound (US) multidrug resistance (MDR) MCF-7/ADR and HEPG2/ADM cells ultrasound (US) irradiation treatment upregulated 30231924 4350 Human hsa-miR-200c-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 4351 Human hsa-miR-200c-3p miRNA NaF skeletal fluorosis SaoS2 cells NaF treatment upregulated 29471239 4352 Human hsa-miR-200s miRNA estradiol-17¦Â (E2) endometriosis Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells estradiol-17¦Â (E2) treatment downregulated 30500775 4353 Human hsa-miR-200s miRNA estradiol-17¦Â (E2) epithelial-mesenchymal transition (EMT) Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells estradiol-17¦Â (E2) treatment downregulated 30500775 4354 Human hsa-miR-200s miRNA TGF-¦Â tumorigenicity glioma stem-like cell (GSC) TGF-¦Â treatment downregulated 31599491 4355 Human hsa-miR-201 miRNA catalpol proliferation and apoptosis OVCAR-3 cells catalpol treatment upregulated 25347277 4356 Human hsa-miR-202 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 4357 Human hsa-miR-202 miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment downregulated 19022373 4358 Human hsa-miR-202 miRNA angiotensin II (Ang II) liver fibrosis hepatic stellate cells (HSC) angiotensin II (Ang II) treatment The expression level of miR-202 significantly increased after hepatic stellate cells (HSC) were stimulated by AngII. 32270431 4359 Human hsa-miR-202 miRNA TGF-¦Â1 osteosarcoma (OS) high grade osteosarcom TGF-¦Â1 treatment upregulated 26276504 4360 Human hsa-miR-202 miRNA bone morphogenetic protein 4 (BMP4) varicose vein human venous smooth muscle cells (HUVSMCs) bone morphogenetic protein 4 (BMP4) treatment downregulated 30556158 4361 Human hsa-miR-202 miRNA platelet-derived growth factor (PDGF) varicose vein human venous smooth muscle cells (HUVSMCs) platelet-derived growth factor (PDGF) treatment upregulated 30556158 4362 Human hsa-miR-202 miRNA TGF-¦Â varicose vein human venous smooth muscle cells (HUVSMCs) TGF©\¦Â treatment upregulated 30556158 4363 Human hsa-miR-202-3p miRNA IL-1¦Â intervertebral disc degeneration (IDD) human nucleus pulposus (NP) interleukin-1¦Â (IL-1¦Â) treatment downregulated 30458287 4364 Human hsa-miR-202-3p miRNA oxidized low density lipoprotein (ox-LDL) coronary heart disease (CHD) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment Oxidized low-density lipoprotein (ox-LDL) induced miR-202-3p expression. 31956131 4365 Human hsa-miR-202-3p miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 4366 Human hsa-miR-202-3p miRNA angiotensin II (Ang II) essential hypertension (EH) THP-1 cells angiotensin II (Ang II) treatment upregulated 32338289 4367 Human hsa-miR-202-3p miRNA IL-1¦Â intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells IL-1¦Â treatment downregulated 30458287 4368 Human hsa-miR-202-3p miRNA hypoxia lung cancer A549 cells hypoxia treatment downregulated 27524914 4369 Human hsa-miR-203 miRNA nickel esophageal cancer (EC) NSTCs nickel treatment downregulated 23968727 4370 Human hsa-miR-203 miRNA curcumin (Cur) bladder cancer "Non-malignant human uroepithelial cell line (SV-HUC-1)£» bladder cancer cell lines (T24, J82£»TCCSUP)" curcumin (CUR) treatment downregulated 21836020 4371 Human hsa-miR-203 miRNA lead (Pb) blood-cerebrospinal fluid barrier (BCB) choroidal epithelial cells (Pb) exposure upregulated 25975750 4372 Human hsa-miR-203 miRNA estradiol breast cancer MCF-7 cells estradiol (E?) treatment "E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells" 22260523 4373 Human hsa-miR-203 miRNA estradiol breast cancer ER¦Á-positive breast cancer MCF-7 cells estradiol treatment downregulated 28962215 4374 Human hsa-miR-203 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 4375 Human hsa-miR-203 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 4376 Human hsa-miR-203 miRNA huaier extract breast cancer tamoxifen-resistant cells (M7-TR) and fulvestrant-resistant cells (M7-FR) Huaier extract downregulated 28779143 4377 Human hsa-miR-203 miRNA luteolin breast cancer MDA-MB-453 and MCF-7 cells luteolin treatment upregulated 31368817 4378 Human hsa-miR-203 miRNA paclitaxel (PTX) breast cancer "HER2-positive cell lines, BT-474 and SKBR3" paclitaxel treatment upregulated 28509576 4379 Human hsa-miR-203 miRNA sevoflurane (SEV) breast cancer MDA-MB-231 cells sevoflurane treatment upregulated 29750301 4380 Human hsa-miR-203 miRNA folic acid cervical cancer (CC) CaSki cells folic acid treatment upregulated 27313708 4381 Human hsa-miR-203 miRNA adriamycin (ADR) colorectal cancer (CRC) HCT116 adriamycin (ADR) treatment upregulated 26397233 4382 Human hsa-miR-203 miRNA sevoflurane (SEV) colorectal cancer (CRC) SW620 and HCT116 cells sevoflurane treatment upregulated 30685432 4383 Human hsa-miR-203 miRNA sodium butyrate (NaB) colorectal cancer (CRC) HT-29 and Caco-2 cell lines sodium butyrate (NaBt) treatment upregulated 27771718 4384 Human hsa-miR-203 miRNA AZD6244 cytotoxicity breast cancer cell lines MDA-MB-231 and HCC1937 10¦ÌM AZD6244 for 24 h treatment upregulated 24938872 4385 Human hsa-miR-203 miRNA mammosphere culture epithelial-mesenchymal transition (EMT) MCF-7 cells mammosphere culture treatment "suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221" 21553120 4386 Human hsa-miR-203 miRNA glycolaldehyde-modified advanced glycation end product (AGE) diabetic foot ulcer (DFU) The immortalized human keratinocyte lines HaCaT and HFF1 glycolaldehyde-modified advanced glycation end product (AGE) treatment upregulated 31707396 4387 Human hsa-miR-203 miRNA human papilloma virus (HPV) cell differentiation Normal human foreskin keratinocytes (NHKs) Human papillomaviruses (HPV)?infection downregulated 20219920 4388 Human hsa-miR-203 miRNA alcohol gastric cancer (GC) HEK293T cells;SH SY5Y cells;1321 N1 cells ?alcohol? treatment upregulated 24961422 4389 Human hsa-miR-203 miRNA berberine (BBR) gastric cancer (GC) Gastric cancer cell lines SGC-7901 and BGC-823 berberine (BBR) treatment upregulated 27142767 4390 Human hsa-miR-203 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) GBM patients tissues and serum TMZ treatment upregulated 28187000 4391 Human hsa-miR-203 miRNA bufalin glioblastoma multiforme (GBM) U251 and U87 cells bufalin treatment upregulated 29169175 4392 Human hsa-miR-203 miRNA TGF-¦Â head and neck squamous cell carcinoma (HNSCC) MSCC-1 and MSCC-inv1 cells TGF-¦Â treatment downregulated 26882562 4393 Human hsa-miR-203 miRNA hyperthermia heat shock human OSCC cell lines HSC-2;HSC-3;HSC-4 HT at 44?C for 60 min treatment dysregulated 24789751 4394 Human hsa-miR-203 miRNA lipopolysaccharide (LPS) liver fibrosis Human HSC line LX2 cells lipopolysaccharide (LPS) treatment downregulated 31719209 4395 Human hsa-miR-203 miRNA TGF-¦Â liver fibrosis Human HSC line LX2 cells TGF-¦Â treatment downregulated 31719209 4396 Human hsa-miR-203 miRNA human papilloma viruses (HPVs) 16 human papillomaviruses (HPV) infection human foreskin keratinocytes(HFKs) human papillomavirus type 16 (HPV16) infection downregulated 20702634 4397 Human hsa-miR-203 miRNA platelet derived growth factor-BB (PDGF-BB) and insulin-like growth factor (IGF)-1 idiopathic pulmonary fibrosis (IPF) human fibroblastic cell line (LL-24) PDGF-BB and IGF-1 treatment circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2 32694556 4398 Human hsa-miR-203 miRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) Primary human lung fibroblasts TGF¦Â1 treatment upregulated 31488543 4399 Human hsa-miR-203 miRNA sulfur mustard (SM) impaired tissue regeneration normal human epidermal keratinocytes (NHEK) sulfur mustard (SM) treatment upregulated 26383628 4400 Human hsa-miR-203 miRNA kaempferol inflammation LPS or AngII-disposed human aortic endothelial cells (HAECs) Kaempferol (KAE)?treatment upregulated 31022599 4401 Human hsa-miR-203 miRNA TGF-¦Â inflammation breast cancer cells transforming growth factor ¦Â (TGF-¦Â)? treatment downregulated 23447531 4402 Human hsa-miR-203 miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells influenza A virus (IAV) infection upregulated 29717211 4403 Human hsa-miR-203 miRNA oleic acid (OA) keratinocytes (KCs) diferentiation neonatal human epidermal keratinocytes (HEKn) oleic acid (OA) treatment OA increased the expression of miR-203. 29638027 4404 Human hsa-miR-203 miRNA imatinib leukemia The K562 cells; HL-60 cells; the KU812 cells imatinib treatment demethylation of miR-203 is one of the molecular mechanisms of imatinib-induced inhibition of BCR-ABL1-positive leukemic cells 23953880 4405 Human hsa-miR-203 miRNA TGF-¦Â lung adenocarcinoma (LUAD) A549 cell TGF¦Â treatment upregulated 31131047 4406 Human hsa-miR-203 miRNA Sendai virus (SeV) lung cancer A549 cells Sendai Virus treatment "miR-203isanIFN-inducible miRNA that can negatively regulate a number of cellular mRNAs,including an IFN-stimulated gene target,IFIT1/ISG56,by destabilizing its mRNA transcript" 23785202 4407 Human hsa-miR-203 miRNA temozolomide (TMZ) malignant melanoma (MM) human MM cells TMZ treatment downregulated 28597996 4408 Human hsa-miR-203 miRNA aspirin nasopharyngeal carcinoma (NPC) "Human NPC cell line C666-1, C2089" aspirin treatment upregulated 31265948 4409 Human hsa-miR-203 miRNA X-rays nasopharyngeal carcinoma (NPC) 5-8F; SUNE-1 cells 4 Gy radiation treatment LINC00114 contributed to NPC development and radioresistance through the regulation of ERK/JNK signaling pathway and the mediation of miR-203 32196600 4410 Human hsa-miR-203 miRNA riboflavin (RF) neuroprotective effects SH-SY5Y neuroblostoma cell line RF treatment upregulated 24884571 4411 Human hsa-miR-203 miRNA cisplatin (DDP) oral squamous cell carcinoma (OSCC) Tca8113 cells cisplatin treatment downregulated 26946357 4412 Human hsa-miR-203 miRNA arecoline oral submucous fibrosis (OSF) human buccal mucosal fibroblasts arecoline treatment downregulated 25872484 4413 Human hsa-miR-203 miRNA prednisolone oral submucous fibrosis (OSF) OSF-fibroblast cells were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment upregulated 24921400 4414 Human hsa-miR-203 miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment IL-1¦Â stimulation induced the expression of miR-203. 31894489 4415 Human hsa-miR-203 miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human cartilage C28/I2 cells lipopolysaccharide (LPS) treatment upregulated 28764893 4416 Human hsa-miR-203 miRNA cisplatin (DDP) pancreatic cancer (PC) SW1990 cells cisplatin treatment downregulated 31696470 4417 Human hsa-miR-203 miRNA hypoxia pathological retinal neovascularization disease human retinal microvascular endothelial cells (HRMECs) hypoxia treatment downregulated 32084532 4418 Human hsa-miR-203 miRNA IL-17 psoriasis HaCaT cells IL-17 treatment upregulated 29039484 4419 Human hsa-miR-203 miRNA Kr¨¹ppel-like factor 4 (KLF4) cell senescence pluripotent stem (iPS) cells Kr¨¹ppel-like factor 4 (KLF4) treatment upregulated 27531889 4420 Human hsa-miR-203 miRNA COTI-2 T-cell acute lymphoblastic leukemia (T-ALL) Jurkat cells COTI-2 treatment upregulated 32063077 4421 Human hsa-miR-203 miRNA sulfur mustard (SM) tissue injury human epidermal keratinocytes (NHEK) sulfur mustard (SM) treatment upregulated 26383628 4422 Human hsa-miR-203 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) type 2 diabetes mellitus (T2DM) "human hepatocytes (JHH5, JHH7, and HepG2)" oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 28955777 4423 Human hsa-miR-203a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) esophageal cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26577858 4424 Human hsa-miR-203a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) "human esophageal cancer cell lines TE1, TE13, Eca109, Yes-2, and T.Tn" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26577858 4425 Human hsa-miR-203a miRNA hepatitis C virus (HCV) core protein hepatocellular carcinoma (HCC) "human hepatoblastoma cell line, HepG2" Hepatitis C virus (HCV) Core protein treatment downregulated 26210453 4426 Human hsa-miR-203a miRNA hypoxia hepatocellular carcinoma (HCC) HepG2 cells hypoxia treatment downregulated 32468055 4427 Human hsa-miR-203a miRNA cadmium (Cd) epidermal development HaCaT Cells cadmium (Cd) treatment upregulated 28754589 4428 Human hsa-miR-203a miRNA lipopolysaccharide (LPS) osteoarthritis (OA) murine chondrogenic ATDC5 cells lipopolysaccharide (LPS) treatment upregulated 29679904 4429 Human hsa-miR-203a miRNA tanshinone IIA (Tan IIA) osteoarthritis (OA) LPS-treated murine chondrogenic ATDC5 cells Tanshinone IIA (Tan IIA) treatment downregulated 29679904 4430 Human hsa-miR-203a-3p miRNA acidosis acidosis R3327-AT-1 prostate incubated at pH 6.6 downregulated 28685435 4431 Human hsa-miR-203a-3p miRNA TGF-¦Â1 asthma BEAS-2B cells; 16HBE cells TGF-¦Â1 treatment Transforming growth factor-¦Â1 (TGF-¦Â1) treatment induced the reduction of miR-203a-3p in BEAS-2B and 16HBE cells in a time-dependent manner 32065213 4432 Human hsa-miR-203a-3p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment MALAT1 affect angiogenesis by sponging miR-203a-3p in DR. 31689123 4433 Human hsa-miR-203a-3p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 31689123 4434 Human hsa-miR-203a-3p miRNA atorvastatin endothelial senescence ox-LDL treated HUVECs atorvastatin treatment downregulated 29248491 4435 Human hsa-miR-203a-3p miRNA oxidized low density lipoprotein (ox-LDL) endothelial senescence HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29248491 4436 Human hsa-miR-203a-3p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 4437 Human hsa-miR-203a-3p miRNA steviol gastrointestinal cancer HCT-116 cells steviol treatment upregulated 29899860 4438 Human hsa-miR-203a-3p miRNA atorvastatin hyperlipidemia HUVECs atorvastatin treatment downregulated 29248491 4439 Human hsa-miR-203a-3p miRNA oxidized low density lipoprotein (ox-LDL) hyperlipidemia HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29248491 4440 Human hsa-miR-203a-3p miRNA carnosic acid (CA) liver fibrosis LX-2 cells carnosic acid (CA) treatment Inhibition of p66Shc Oxidative Signaling via CA-Induced Upregulation of miR-203a-3p Alleviates Liver Fibrosis Progression. 32781430 4441 Human hsa-miR-203a-3p miRNA high glucose (HG) proliferative diabetic retinopathy (PDR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 31408201 4442 Human hsa-miR-203a-3p miRNA high glucose (HG) proliferative diabetic retinopathy (PDR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 31408201 4443 Human hsa-miR-203a-3p miRNA oxidized low density lipoprotein (ox-LDL) cell senescence human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28347692 4444 Human hsa-miR-203b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) esophageal cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26577858 4445 Human hsa-miR-203b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) "human esophageal cancer cell lines TE1, TE13, Eca109, Yes-2, and T.Tn" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26577858 4446 Human hsa-miR-204 miRNA arsenic trioxide (ATO) acute myeloid leukemia (AML) "Human AML cell lines, AML-5 and HL-60" arsenic trioxide (ATO) treatment upregulated 30982490 4447 Human hsa-miR-204 miRNA high inorganic phosphate (Pi) arterial calcification Human aorta vascular smooth muscle cells (HA-VSMCs) high phosphate treatment downregulated 29850805 4448 Human hsa-miR-204 miRNA trichostatin A (TSA) breast cancer MCF-7 and ;MDA-MB-231 cells Trichostatin A (TSA) treatment downregulated 26436206 4449 Human hsa-miR-204 miRNA triiodo-l-thyronine (T3) breast cancer BC cell lines MCF-7 and T47-D Triiodothyronine (T3) treatment downregulated 30406874 4450 Human hsa-miR-204 miRNA TGF-¦Â1 or bone morphogenetic protein 2 (BMP-2) calcific aortic valve disease (CAVD) human aortic valve interstitial cells (AVICs) "TGF-¦Â1,BMP-2 treatment" dysregulated 28377507 4451 Human hsa-miR-204 miRNA photodynamic therapy (PDT) cervical cancer (CC) HeLa cells photody-namic therapy (PDT) treatment upregulated 19953537 4452 Human hsa-miR-204 miRNA hypoxia cervical spondylotic Human neuronal cell lines hypoxia treatment upregulated 26350953 4453 Human hsa-miR-204 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT116; HT-29; SW620; SW480; DLD-1; RKO; LoVo cells 5-fluorouracil (5-FU) treatment PCAT6 knockdown attenuated CRC chemoresistance to 5-FU through miR-204/HMGA2/PI3K; miR-204 inhibition could partially reverse the effect of PCAT6 knockdown. 30938104 4454 Human hsa-miR-204 miRNA palmitate diabetes mellitus (DM) Human islets palmitate (Pal) treatment downregulated 30131392 4455 Human hsa-miR-204 miRNA melatonin diabetic retinopathy (DR) MIO-M1 cells melatonin (MEL) treatment miR-204 increased in HG-treated MIO-M1 cells and that melatonin (MEL) inhibited miR-204 expression 32324260 4456 Human hsa-miR-204 miRNA particulate matter (PM2.5) epithelial-mesenchymal transition (EMT) human bronchial epithelial cell lines (HBE and BEAS-2B) Organic extracts of PM2.5 treatment "NF-¦ÊB transcriptionally regulates MALAT1, which, by binding with miR-204 and releasing ZEB1, promotes the EMT" 31042084 4457 Human hsa-miR-204 miRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) Primary human LECs (HLECs) TGF-¦Â2 treatment "TGF-¦Â2 induces NEAT1 overexpression, which in turn suggests that NEAT1 acts as a ceRNA targeting Snail1 or Zeb1 by binding miR-34a or miR-204" 32596382 4458 Human hsa-miR-204 miRNA Sinomenine (SIN) gastric cancer (GC) MKN45 and SGC-7901 cells Sinomenine (SIN) treatment upregulated 31243880 4459 Human hsa-miR-204 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells temozolomide (TMZ) treatment miR-204 was downregulated in U251MG-resistant (-R) cells 29725461 4460 Human hsa-miR-204 miRNA hypoxia hepatocellular carcinoma (HCC) LO2 cells;Hep3B cells;Huh7 cells hypoxia induce downregulated 30279729 4461 Human hsa-miR-204 miRNA vemurafenib melanoma A375 melanoma cells vemurafenib treatment upregulated 28445987 4462 Human hsa-miR-204 miRNA IL-1¦Â osteoarthritis (OA) human OA chondrocytes;chondrogenic SW1353 cells IL-12¦Â treatment downregulated 29441883 4463 Human hsa-miR-204 miRNA metformin (Met) preeclampsia (PE) HUVEC and HPASMC cells Metformin treatment upregulated 31582211 4464 Human hsa-miR-204 miRNA propofol (PPF) expression regulation human adipocyte stem cells "50 ?M propofol, or 100 ?M propofol in culture media for 3 hours treatment" "The lowest expression was seen for miR-204, The highest expression was seen for miR-208b" 25568843 4465 Human hsa-miR-204 miRNA oxibendazole (OBZ) prostate cancer 22Rv1 cells; PC-3 cells oxibendazole (OBZ) treatment OBZ increased the expression of microRNA-204 (miR-204) 29434928 4466 Human hsa-miR-204 miRNA dehydroepiandrosterone (DHEA) pulmonary arterial hypertension (PAH) pulmonary artery smooth muscle cell (PASMC) Dehydroepiandrosterone (DHEA) treatment upregulated 21890685 4467 Human hsa-miR-204 miRNA hypoxia pulmonary hypertension (PH) human pulmonary artery endothelial cells (HPAECs) hypoxia induce downregulated 31542480 4468 Human hsa-miR-204 miRNA lipopolysaccharide (LPS) sepsis rats lung tissues lipopolysaccharide (LPS) treatment downregulated 28901393 4469 Human hsa-miR-204 miRNA cardio-pulmonary bypass (CPB) severe lung injury lung cardiopulmonary bypass (CPB) treatment upregulated 25347932 4470 Human hsa-miR-204 miRNA hypoxia spinal cord ischemia/reperfusion injury (SCII) AGE1.HN cells; P12 cells hypoxia treatment "The expression of MALAT1 and Bcl-2 was decreased, while miRNA-204 (miR-204) was upregulated in rats SCIRI model and neurocyte lines under hypoxic conditions." 29998804 4471 Human hsa-miR-2042 miRNA IL-6 epithelial ovarian cancer (EOC) human ovarian cancer cell line A2780;its related cDDP-resistant cell lines (ACRP) interleukin-6 (IL-6) treatment downregulated 28388577 4472 Human hsa-miR-204-3p miRNA lipopolysaccharide (LPS) familial Mediterranean fever THP-1 cells lipopolysaccharide (LPS) treatment The expression of miR-204-3p was suppressed by LPS stimulation in the macrophages derived from THP-1 cells 29294109 4473 Human hsa-miR-204-5p miRNA TGF-¦Â1 asthma human airway smooth muscle cells TGF-¦Â1 treatment MiR-204-5p was downregulated notably in asthmatic airway smooth muscle cells as well as cells stimulated with TGF-¦Â1 31955160 4474 Human hsa-miR-204-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "silence of XIST displayed a protective role in ox-LDL-induced injury in HUVECs by regulating miR-204-5p/TLR4 axis, providing a novel mechanism for understanding the pathogenesis of atherosclerosis." 32345778 4475 Human hsa-miR-204-5p miRNA ¦Ã-rays ionizing radiation (IR) injury whole blood samples from healthy donors extracellular vesicles (ELVs) irradiate with 2 Gy gamma rays treatment upregulated 28264626 4476 Human hsa-miR-204-5p miRNA "2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)" endothelial cell injury human umbilical vein endothelial cells (HUVECs) "2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment" downregulated 33093269 4477 Human hsa-miR-204-5p miRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) human lens epithelial cells (LECs) TGF-¦Â2 treatment downregulated 33327804 4478 Human hsa-miR-204-5p miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) HBMEC;bEnd.3 cells oxygen-glucose deprivation (OGD) treatment downregulated 33607153 4479 Human hsa-miR-204-5p miRNA vemurafenib melanoma A375 cells vemurafenib treatment upregulated 29229605 4480 Human hsa-miR-204-5p miRNA triptolide (TPL) non-small cell lung cancer (NSCLC) A549 cells triptolide (TPL) treatment TL upregulated miR204-5p mRNA expression in NSCLC 32733649 4481 Human hsa-miR-204-5p miRNA docetaxel (DTX) prostate cancer PCa samples; PC3 cells; DU145 cells docetaxel (DTX) treatment downregulated 31672604 4482 Human hsa-miR-204-5p miRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) RA-FLS cells tumor necrosis factor alpha (TNF-¦Á) treatment "We found that NEAT1 was upregulated, and miR-204-5p was downregulated in the RA patients' synovial tissue and TNF-¦Á treated RA-FLSs" 33394349 4483 Human hsa-miR-204-5p miRNA lipopolysaccharide (LPS) sepsis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment "LPS impaired cell viability, and promoted cell apoptosis, inflammatory response and oxidative stress in HUVECs by regulating HULC/miR-204-5p/TRPM7 axis." 32484206 4484 Human hsa-miR-204-5p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) B cells M.tb infection upregulated 29477867 4485 Human hsa-miR-205 miRNA garcinol acute myocardial infarction (AMI) Human myocardial cell line (AC16) Garcinol treatment garcinol enhanced the expression of microRNA-205 33809417 4486 Human hsa-miR-205 miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) A549 cells lipopolysaccharide (LPS) treatment "SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice." 33170429 4487 Human hsa-miR-205 miRNA transglutaminase 2 (TG2) breast cancer "MCF-7, MDA-MB-231 breast cancer cells" transglutaminase 2 (TG2) overexpression downregulated 30949413 4488 Human hsa-miR-205 miRNA 5-fluorouracil and ixabepilone breast cancer MDA-MB-453?cells;MDA-kb2 cells 5-FU and ixabepilone treatment upregulated 24396484 4489 Human hsa-miR-205 miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment downregulated 25120778 4490 Human hsa-miR-205 miRNA entinostat breast cancer MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells entinostat treatment downregulated 23519125 4491 Human hsa-miR-205 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 4492 Human hsa-miR-205 miRNA MEK inhibitor U0126 or PD98059 breast cancer ErbB2-overexpressing nontumorigenic human breast epithelial cell line MCF10A U0126 or PD98059 upregulated 28781955 4493 Human hsa-miR-205 miRNA paclitaxel (PTX) breast cancer MCF-7 cells; MDA-MB-231 cells paclitaxel treatment downregulated 30019863 4494 Human hsa-miR-205 miRNA paclitaxel (PTX) breast cancer BT-474 cells paclitaxel treatment upregulated 30019863 4495 Human hsa-miR-205 miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 4496 Human hsa-miR-205 miRNA arsenite tumorigenesis derivative normal stem cell (SC) line arsenite exposure downregulated 24431212 4497 Human hsa-miR-205 miRNA particulate matter (PM2.5) cardiovascular disease (CVD) AC16 cells fine particulate matter (PM 2.5) treatment miR-205 was decreased in the PM25 group 32880505 4498 Human hsa-miR-205 miRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation human aortic smooth muscle cell (HASMC) platelet-derived growth factor (PDGF)-BB treatment downregulated 31441592 4499 Human hsa-miR-205 miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 4500 Human hsa-miR-205 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cellular stress response prostate cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated of miR-205 and miR-31 21368878 4501 Human hsa-miR-205 miRNA baicalin (BAI) colorectal cancer (CRC) HT29 cells baicalin (BAI) treatment downregulated 30262902 4502 Human hsa-miR-205 miRNA mammosphere culture epithelial-mesenchymal transition (EMT) MCF-7 cells mammosphere culture treatment "suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221" 21553120 4503 Human hsa-miR-205 miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment downregulated 29435044 4504 Human hsa-miR-205 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" glioblastoma multiforme (GBM) glioblastoma U87MG cell line "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28792704 4505 Human hsa-miR-205 miRNA TGF-¦Â glioblastoma multiforme (GBM) glioma cell line U87 glioma cell line U87 treatment "downregulated(miR-205), upregulation(miR-195)" 27574009 4506 Human hsa-miR-205 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Hepatoma cell lines HepG2 hepatitis B virus (HBV) infection downregulated 24339740 4507 Human hsa-miR-205 miRNA gemcitabine (GEM) hepatocellular carcinoma (HCC) HuCCT1 cells; HuH28 cells Gemcitabine treatment upregulated 24147037 4508 Human hsa-miR-205 miRNA carboplatin (CBP) lung cancer A549 and H1975 lung cancer cells carboplatin (CBP) treatment upregulated 25917317 4509 Human hsa-miR-205 miRNA tobacco carcinogens lung cancer HBECs tobacco carcinogens treatment "EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205" 21363915 4510 Human hsa-miR-205 miRNA oleacein (OA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells oleic acid (OA) treatment upregulated 31799678 4511 Human hsa-miR-205 miRNA asbestos non-small cell lung cancer (NSCLC) serum asbestos exposure upregulated 30257964 4512 Human hsa-miR-205 miRNA ¦Â-glycerophosphate (¦Â-GP) osteogenesis human aortic smooth muscle cells (HASMCs) ¦Â-glycerophosphate treatment downregulated 25012146 4513 Human hsa-miR-205 miRNA melatonin osteosarcoma (OS) SaOS2 cells; MG63 cells Melatonin treatment upregulated 32592723 4514 Human hsa-miR-205 miRNA cancer-associated fibroblasts (CAFs) prostate cancer prostate cancer (PCa) cells PCa cells upon CAF stimulation treatment downregulated 23924028 4515 Human hsa-miR-205 miRNA hypoxia prostate cancer DU145 and LNCaP cells hypoxia treatment downregulated 27160121 4516 Human hsa-miR-205 miRNA Pomegranate juice (PJ) prostate cancer ?prostate cancer cells Pomegranate juice (PJ) treatment upregulated 21594291 4517 Human hsa-miR-205 miRNA hypoxia renal ischemia/reperfusion (I/R) injury HK-2 cells hypoxia induce downregulated 31934284 4518 Human hsa-miR-205 miRNA metformin (Met) cell senescence BJ-1 human diploid fibroblasts (HDFs) metformin treatment upregulated 22356767 4519 Human hsa-miR-205 miRNA lipopolysaccharide (LPS) sepsis HK-2 cells lipopolysaccharide (LPS) treatment TapSAKI was upregulated and miR-205 was downregulated in LPS-induced HK-2 cells. 33869780 4520 Human hsa-miR-205 miRNA tumor resection squamous cell carcinoma (SQCC) and adenocarcinoma (ADC£© SQCC and ADC patients tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28634901 4521 Human hsa-miR-205 miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment upregulated 24396484 4522 Human hsa-miR-205-3p miRNA ultraviolet (UV) irradiation corneal damage human corneal epithelial cells ultraviolet (UV) radiation treatment upregulated 32633336 4523 Human hsa-miR-205-3p miRNA TGF-¦Â glioblastoma multiforme (GBM) glioma cell lines TGF-¦Â treatment downregulated 31558707 4524 Human hsa-miR-205-3p miRNA ionizing radiation (IR) low doses hyper-radiosensitivity (LDHRS) DLD-1 cells ionizing radiation (IR) treatment upregulated 29899866 4525 Human hsa-miR-205-5p miRNA copper (Cu) Alzheimer's disease (AD) human primary microvascular endothelial cells (MVECs) chronic exposure to copper "In human primary microvascular endothelial cells (MVECs), microRNA-205-5p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure." 30923833 4526 Human hsa-miR-205-5p miRNA anabolic-androgenic ateroids (AASs) anabolic-Androgenic Steroids (AASs)-induced renal damage kidney tissues anabolic-androgenic ateroids (AASs) treatment upregulated 33041804 4527 Human hsa-miR-205-5p miRNA H2O2 angiogenesis The ARPE-19 human cell line H2O2 treatment upregulated 31863632 4528 Human hsa-miR-205-5p miRNA N-acetyl-L-cysteine (NAC) angiogenesis H2O2-treated the ARPE-19 human cell line N-acetylcysteine (NAC) treatment downregulated 31863632 4529 Human hsa-miR-205-5p miRNA gemcitabine (GEM) breast cancer MDA-MB-231 and BT549 cells Gemcitabine (GEM) treatment Overexpression of miR-205-5p significantly augmented cytotoxicity effects of gemcitabine treatment in MDA-MB-231 and BT549 cells. 31602229 4530 Human hsa-miR-205-5p miRNA low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) cervical cancer (CC) serum low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) treatment upregulated 32851067 4531 Human hsa-miR-205-5p miRNA hematoporphyrin glioblastoma multiforme (GBM) U87 glioma cells hematoporphyrin treatment upregulated 29344634 4532 Human hsa-miR-205-5p miRNA glial cell-derived neurotrophic factor (GDNF) glioblastoma multiforme (GBM) human U251 glioma cells 50 ng/mL GDNF for 24 h upregulated 29224008 4533 Human hsa-miR-205-5p miRNA 5-fluorouracil (5-Fu) hepatocellular carcinoma (HCC) Bel-7402 (Bel) cells 5-fluorouracil (5-FU) treatment upregulated 28979703 4534 Human hsa-miR-205-5p miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment downregulated 31452742 4535 Human hsa-miR-205-5p miRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) SH-SY5Y cells "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" downregulated 32057949 4536 Human hsa-miR-205-5p miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary arterial smooth muscle cells (PASMCs) hypoxia induce downregulated 30853343 4537 Human hsa-miR-205-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) stroke human brain microvascular endothelial cells (HBMECs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 32217110 4538 Human hsa-miR-20-5p miRNA H2O2 cell senescence multipotent stromal cells H2O2 treatment downregulated 32174776 4539 Human hsa-miR-206 miRNA thyroid hormone hepatocellular carcinoma (HCC) skeletal muscle thyroid hormone (TH) treatment downregulated 19567520 4540 Human hsa-miR-206 miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment downregulated 33635017 4541 Human hsa-miR-206 miRNA IL-1¦Â and forskolin (Fsk) adrenal steroid production NCI-H295R cells IL-1¦Â and forskolin (Fsk) treatment downregulated 33508847 4542 Human hsa-miR-206 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cell line oxidized low-density lipoprotein (ox-LDL) treatment "miR-206 was predicted as a target of UCA1 and knockdown of UCA1 was able to repress miR-206 expression. Furthermore, overexpression of miR-206 inhibited oxidative stress process and it was reversed by UCA1 upregulation in vitro." 30633352 4543 Human hsa-miR-206 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1-derived macrophages and differentiated human monocyte-derived macrophages (hMDMs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33526034 4544 Human hsa-miR-206 miRNA IL-1¦Â autoimmune thyroiditis (AIT) Nthy-ori 3-1 cells IL-1¦Â treatment downregulated 33452572 4545 Human hsa-miR-206 miRNA ursolic acid (UA) autoimmune thyroiditis (AIT) IL-1¦Â-treated Nthy-ori 3-1 cells ursolic acid (UA) treatment upregulated 33452572 4546 Human hsa-miR-206 miRNA acetyl-11-keto-¦Â-boswellic acid (AKBA) breast cancer MCF-10AT cells Acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment AKBA could induce cell apoptosis and G1-phase arrest and inhibit ER-¦Á expression via LINC00707/miR-206 in MCF-10AT cells. 32013235 4547 Human hsa-miR-206 miRNA physical activity breast cancer MCF-7 cells physical activity treatment upregulated 32547708 4548 Human hsa-miR-206 miRNA antrodia cinnamomea cancer treatment "THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68" antrodia cinnamomea treatment downregulated 28602756 4549 Human hsa-miR-206 miRNA tocotrienol-rich fraction (TRF) cell differentiation senescent human skeletal muscle myoblasts (HSMM) senescent human skeletal muscle myoblasts (HSMM) were treated with 50 ¦Ìg/mL TRF for 24 h treatment upregulated 30519366 4550 Human hsa-miR-206 miRNA high glucose (HG) cell proliferation and extracellular matrix (ECM) deposition ?human glomerular mesangial cells (hMCs) high glucose (HG) treatment downregulated 31880296 4551 Human hsa-miR-206 miRNA amphiregulin chondrosarcoma human chondrosarcoma cells amphiregulin treatment downregulated 27826039 4552 Human hsa-miR-206 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human pulmonary microvascular endothelial cells (HPMECs) cigarette smoke extract (CSE) treatment upregulated 30335896 4553 Human hsa-miR-206 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human pulmonary microvascular endothelial cells (HPMECs) cigarette smoke extract (CSE) exposure upregulated 30335896 4554 Human hsa-miR-206 miRNA lipopolysaccharide (LPS) chronic obstructive pulmonary disease (COPD) MRC-5 cells lipopolysaccharide (LPS) treatment upregulated 31279225 4555 Human hsa-miR-206 miRNA prostaglandin E2 (PGE2) colorectal cancer (CRC) HCT-116 and Caco-2 cells prostaglandin E2 (PGE2) treatment downregulated 30135139 4556 Human hsa-miR-206 miRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose (HG) treatment upregulated 31608712 4557 Human hsa-miR-206 miRNA cisplatin (DDP) epithelial ovarian cancer (EOC) OV2008 cells cisplatin treatment miR-206 expression was increased in primary platinum-resistant EOC. 33292230 4558 Human hsa-miR-206 miRNA propofol (PPF) glioblastoma multiforme (GBM) U251 cells; LN229 cells propofol treatment "MiR-206 was decreased in glioma tissues and cells, while propofol exposure induced the upregulation of miR-206 in glioma cells." 32021281 4559 Human hsa-miR-206 miRNA BAY11-7082 helicobacter pylori infection H. pylori infected gastric epithelial cells treated with 10 ¦ÌM Bay 11-7082 upregulated 28208005 4560 Human hsa-miR-206 miRNA high fat diet (HFD) hepatosteatosis and hyperglycemia human hepatocytes high fat diet (HFD) feed downregulated 28025059 4561 Human hsa-miR-206 miRNA lipopolysaccharide (LPS) inflammation human astrocytes lipopolysaccharide (LPS) treatment upregulated 25452104 4562 Human hsa-miR-206 miRNA dexamethasone (DEX) legg Calve Perthes disease (LCPD) chondrocytes obtained from patients with LCPD dexamethasone (DEX) treatment upregulated 29387248 4563 Human hsa-miR-206 miRNA dexamethasone (DEX) left ventricular hypertrophy (LVH) primary chondrocytes of the LCPD and normal control group dexamethasone (DEX) treatment upregulated 29387248 4564 Human hsa-miR-206 miRNA active pterocarpanquinone LQB-118 active pterocarpanquinone LQB-118 cytotoxicity "PC3, LNCaP, and LAPC4 PCa cells" LQB-118 downregulated 29105806 4565 Human hsa-miR-206 miRNA hepatocyte growth factor (HGF) lung cancer lung cancer cells PC-9 and HCC-827 Hepatocyte growth factor (HGF) treatment downregulated 29664235 4566 Human hsa-miR-206 miRNA l-carnitine male infertility sperm l-carnitine treatment upregulated 31749176 4567 Human hsa-miR-206 miRNA statins muscle injury plasma statins? treatment upregulated 26472872 4568 Human hsa-miR-206 miRNA GW501516 nasopharyngeal carcinoma (NPC) C666-1 cells GW501516 treatment upregulated 30982495 4569 Human hsa-miR-206 miRNA propofol (PPF) neurotoxicity human embryonic stem cells (hESCs) expose to propofol (50 ¦ÌM) for 6 hr treatment upregulated 28869449 4570 Human hsa-miR-206 miRNA curcumin (Cur) non-small cell lung cancer (NSCLC) A549 cells curcumin treatment "Curcumin significantly inhibited migration and invasion in A549 cells, accompanied by significantly elevated miR-206 expression." 32074070 4571 Human hsa-miR-206 miRNA prednisolone oral submucous fibrosis (OSF) OSF-fibroblast cells were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment upregulated 24921400 4572 Human hsa-miR-206 miRNA bromocriptine pituitary adenoma pituitary adenoma tissue bromocriptine treatment upregulated 22366961 4573 Human hsa-miR-206 miRNA particulate matter (PM2.5) pulmonary arterial hypertension (PAH) plasma particulate matter (PM2.5) treatment "Based on microarray analyses, we found that microRNA-206 may be involved in asthma induced PAH stimulated by PM25" 33086901 4574 Human hsa-miR-206 miRNA hypoxia pulmonary hypertension (PH) pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment downregulated 23628900 4575 Human hsa-miR-206 miRNA artesunate (ART) rhabdomyosarcoma (RMS) ERMS cell lines artesunate (ARS) treatment downregulated 26153023 4576 Human hsa-miR-206 miRNA tin protoporphyrin rhabdomyosarcoma (RMS) RD and SMS-CTR cells RD and SMS-CTR cells treatment downregulated 27488535 4577 Human hsa-miR-206 miRNA "vincristine, dactinomycin, cyclophosphamide (VAC)" rhabdomyosarcoma (RMS) rhabdomyosarcoma patients VAC treatment upregulated 28834127 4578 Human hsa-miR-206 miRNA triiodo-l-thyronine (T3) thyroid hormone-induced disorders of lipid metabolism HepG2 cells triiodothyronine (T3) treatment downregulated 29484422 4579 Human hsa-miR-206 miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) THP-1 cells Mycobacterium tuberculosis (M.tb) treatment upregulated 27291149 4580 Human hsa-miR-206 miRNA mesalamine ulcerative colitis (UC) HT29 colon cells mesalamine treatment downregulated 30204869 4581 Human hsa-miR-206 miRNA mood stabilizers bipolar disorder type I (BD-I) blood mood stabilizers treatment downregulated 24767015 4582 Human hsa-miR-206-3p miRNA "4,4'-methylene diphenyl diisocyanate (MDI)" occupational asthma (OA) THP-1 cells "4,4'-methylene diphenyl diisocyanate (MDI) treatment" Both in vivo murine MDI aerosol exposure and in vitro MDI-GSH exposures in THP-1 macrophages result in downregulated of endogenous miR-206-3p and miR-381-3p and upregulation of PPP3CA and iNOS expression. 31609387 4583 Human hsa-miR-208 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 4584 Human hsa-miR-208a miRNA coronary artery bypass graft (CABG) acute coronary syndrome (ACS) acute coronary syndrome patients heart CABG treatment upregulated 29506853 4585 Human hsa-miR-208a miRNA caffeine cardiovascular disease (CVD) HL-1 and primary embryonic cardiomyocytes exposure to physiologically relevant doses of caffeine treatment downregulated 25354728 4586 Human hsa-miR-208a miRNA cyclic mechanical stretch (CMS) cardiovascular disease (CVD) human cardiac fibroblasts-adult atrial (HCF-aa) cyclic stretching treatment "MiR208a was upregulated early by stretching and returned to normal levels with longer stretching cycles, whereas the expression of miR499 and Bcl-2 was upregulated by longer stretching times." 33605072 4587 Human hsa-miR-208a miRNA H2O2 myocardial injury AC16 cardiomyocytes H2O2 treatment "miR-208a mimic aggravated H2O2-induced apoptosis and oxidative injury in cardiomyocytes, while miR-208a inhibitor hadan inverse effect." 31545986 4588 Human hsa-miR-208b miRNA caffeine cardiovascular disease (CVD) HL-1 and primary embryonic cardiomyocytes exposure to physiologically relevant doses of caffeine treatment upregulated 25354728 4589 Human hsa-miR-208b miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh7 cells hepatitis C virus (HCV) infection upregulated 24241692 4590 Human hsa-miR-208b miRNA propofol (PPF) expression regulation human adipocyte stem cells "50 ?M propofol, or 100 ?M propofol in culture media for 3 hours treatment" "The lowest expression was seen for miR-204, The highest expression was seen for miR-208b" 25568843 4591 Human hsa-miR-20a miRNA hypoxia paracrine function Primary human adipose-derived stem cells (ADSCs) hypoxia induce downregulated 31368162 4592 Human hsa-miR-20a miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment downregulated 31874343 4593 Human hsa-miR-20a miRNA oxalic acid poisoning acute kidney injury (AKI) urinary oxalic acid poisoning upregulated 32910981 4594 Human hsa-miR-20a miRNA hypoxia acute tubular injury HK-2 cells-derived exosomes hypoxia treatment upregulated 32808649 4595 Human hsa-miR-20a miRNA particulate matter (PM2.5) air pollution-induced placental epigenetic alterations placental tissue Particulate matter (PM2.5) exposure treatment miR-20a was positively associated with 1st trimester exposure 27104955 4596 Human hsa-miR-20a miRNA hypoxia angiogenesis adipose-derived stem cells (ADSCs) hypoxia treatment miR-20a expression was significantly downregulated compared to that under normoxia. 31368162 4597 Human hsa-miR-20a miRNA vascular endothelial growth factor (VEGF) angiogenesis HUVECs vascular endothelial growth factor (VEGF) treatment upregulated 28097093 4598 Human hsa-miR-20a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29653364 4599 Human hsa-miR-20a miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 13¡ã HDT bed rest experiment downregulated 28261104 4600 Human hsa-miR-20a miRNA rapamycin breast cancer breast cancer cells rapamycin treatment over expression 26829385 4601 Human hsa-miR-20a miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment upregulated 20346162 4602 Human hsa-miR-20a miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 4603 Human hsa-miR-20a miRNA oridonin and the antileukemia drugs Ara-C and VP-16 chemoresistant leukemia human leukemia cells oridonin and the antileukemia drugs Ara-C and VP-16 treatment downregulated 24872388 4604 Human hsa-miR-20a miRNA proline-rich polypeptide 1 (PRP-1) chondrosarcoma human JJ012 chondrosarcoma cell line PRP-1 treatment upregulated 24178909 4605 Human hsa-miR-20a miRNA curcumin (Cur) colorectal cancer (CRC) RKO ; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts curcumin treatment downregulated 23194063 4606 Human hsa-miR-20a miRNA hypoxia colorectal cancer (CRC) The human colon cancer cell lines LoVo and SW48 hypoxia induce downregulated 30883936 4607 Human hsa-miR-20a miRNA chemotherapy colorectal cancer (CRC) serum " modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2 , day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment" dysregulated 24304648 4608 Human hsa-miR-20a miRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose treatment downregulated 32868134 4609 Human hsa-miR-20a miRNA docetaxel (DTX) gastric cancer (GC) MKN45 cells docetaxel (DTX) treatment downregulated 31368060 4610 Human hsa-miR-20a miRNA ruxolitinib glioblastoma multiforme (GBM) U87-MG cells ruxolitinib treatment upregulated 31452174 4611 Human hsa-miR-20a miRNA endothelial-monocyte-activating polypeptide-II (EMAP-II) glioblastoma multiforme (GBM) U-87 and U-251 cells endothelial-monocyte-activating polypeptide-II (EMAP-II) treatment downregulated 27242439 4612 Human hsa-miR-20a miRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) LO2 cells hypoxia induce downregulated 31566731 4613 Human hsa-miR-20a miRNA progesterone (P4) infertility "human endometrial carcinoma cell line, SNU-1077" progesterone treatment dysregulated 30603515 4614 Human hsa-miR-20a miRNA vascular endothelial growth factor (VEGF) inflammation endothelial cell vascular endothelial growth factor (VEGF)treatment treatment ?miR-20a expression is increased by VEGF 22696064 4615 Human hsa-miR-20a miRNA sulfur mustard (SM) lung diseases plasma and serum Sulfur mustard (SM) treatment downregulated 26525353 4616 Human hsa-miR-20a miRNA resveratrol lymph node cancer of prostate Lymph node cancer of prostate (LNCaP)£»Du145 cells resveratrol (Res) treatment upregulated 21714127 4617 Human hsa-miR-20a miRNA lipopolysaccharide (LPS) macrophage inflammatory response HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells lipopolysaccharide (LPS) treatment upregulated 23562609 4618 Human hsa-miR-20a miRNA bortezomib multiple myeloma (MM) Human MM cell line RPMI8226 bortezomib? treatment downregulated 26032093 4619 Human hsa-miR-20a miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells; L02 cells free fatty acids (FFA) treatment downregulated 30338914 4620 Human hsa-miR-20a miRNA lipopolysaccharide (LPS) osteoarthritis (OA) cultured chondrocytes lipopolysaccharides (LPS) treatment upregulated 31451219 4621 Human hsa-miR-20a miRNA "phorbol-12-myristate-13-acetate (PMA), macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-¦ÊB ligand RANKL" osteoclastogenesis THP-1 human acute monocytic leukemia cells "phorbol-12-myristate-13-acetate (PMA), macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-¦ÊB ligand RANKL treatment" downregulated 31545439 4622 Human hsa-miR-20a miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx2 treatment" downregulated 21572246 4623 Human hsa-miR-20a miRNA lipopolysaccharide (LPS) pediatric pneumonia A549 cells lipopolysaccharide (LPS) treatment upregulated 29115456 4624 Human hsa-miR-20a miRNA hypoxia pelvic endometriosis stromal cells Hypoxia treatment Levels of miR20a were upregulated in endometriotic stromal cells. Elevation of miR20a was upregulated by hypoxia inducible factor-1¦Á 22648654 4625 Human hsa-miR-20a miRNA lipopolysaccharide (LPS) periodontal inflammation Primary human gingival fibroblasts (HGFs) lipopolysaccharide (LPS) treatment downregulated 31552681 4626 Human hsa-miR-20a miRNA lipopolysaccharide (LPS) pneumonia A549 cells lipopolysaccharide (LPS) treatment upregulated 29115456 4627 Human hsa-miR-20a miRNA hydrogen sulfide (H2S) preeclampsia (PE) placental cells obtained from pregnant women with preeclampsia placental cells obtained from pregnant women with preeclampsia treatment downregulated 26992682 4628 Human hsa-miR-20a miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment downregulated 21093163 4629 Human hsa-miR-20a miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin rhabdomyosarcoma (RMS) RD and Rh30 rhabdomyosarcoma (RMS) cells "Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment" downregulated 30610105 4630 Human hsa-miR-20a-3p miRNA IL-22 psoriasis HaCaT cells (human keratinocyte cell line) Interleukin-22 (IL-22) treatment downregulated 29886071 4631 Human hsa-miR-20a-5p miRNA phorbol-12-myristate-13-acetate(PMA) allergic inflammation HMC-1 mast cells PMA/A23187 treatment downregulated 30684894 4632 Human hsa-miR-20a-5p miRNA mycobacterium tuberculosis (Mtb) active tuberculosis (ATB) human macrophages Mycobacterium tuberculosis (Mtb) infection downregulated 27494776 4633 Human hsa-miR-20a-5p miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment "PVT1 expression was significantly increased, whereas miR-20a-5p expression was significantly decreased in sepsis model mice and LPS-induced HK-2 cells compared with sham mice and control HK-2 cells" 33576456 4634 Human hsa-miR-20a-5p miRNA TGF-¦Â1 asthma BEAS-2B cells TGF-¦Â1 treatment MiR-20a-5p was downregulated in TGF-¦Â1-treated human bronchial epithelial cells 31883454 4635 Human hsa-miR-20a-5p miRNA TGF-¦Â1 asthma human bronchial epithelial BEAS-2B cells transforming growth factor (TGF)-¦Â1 treatment downregulated 31883454 4636 Human hsa-miR-20a-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 4637 Human hsa-miR-20a-5p miRNA SD or MF radiation breast cancer MDA-MB-361 cells SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment "upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)" 24626680 4638 Human hsa-miR-20a-5p miRNA tamoxifen and metformin breast cancer MCF-7 and MDA-MB-231 cell lines MCF-7 and MDA-MB-231 cell lines treatment dysregulated 27329603 4639 Human hsa-miR-20a-5p miRNA pks+ E. coli colorectal cancer (CRC) HCT116 cells colonised by pks+ E. coli treatment upregulated 24658599 4640 Human hsa-miR-20a-5p miRNA high glucose (HG) dysfunction of endothelial progenitor cells (EPCs) human endothelial progenitor cells (EPCs) high glucose (HG) treatment Circ-ADAM9 targeting PTEN and ATG7 promotes autophagy and apoptosis of diabetic endothelial progenitor cells by sponging mir-20a-5p. 32661238 4641 Human hsa-miR-20a-5p miRNA IFN-¦Ã epithelial-mesenchymal transition (EMT) PC-3M IE8 cells IFN-¦Ã treatment Hsa-miR-196b-5p was downregulated in PC-3M IE8 cells treatment with IFN-¦Ã. 31882179 4642 Human hsa-miR-20a-5p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment downregulated 25129238 4643 Human hsa-miR-20a-5p miRNA hypoglycemic hepatocellular carcinoma (HCC) HepG2 cells hypoglycemic treatment downregulated 27629773 4644 Human hsa-miR-20a-5p miRNA anti-programmed cell death protein 1 (anti-PD-1) antibody malignant melanoma (MM) serum anti-programmed cell death protein 1 (anti-PD-1) antibody treatment Serum expression levels of miR-20a-5p was significantly higher in responders than in non-responders. 31843231 4645 Human hsa-miR-20a-5p miRNA IFN-¦Â multiple sclerosis (MS) RRMS patients blood sample IFN-¦Â treatment downregulated 27752929 4646 Human hsa-miR-20a-5p miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells free fatty acid (FFA) treatment downregulated 33344451 4647 Human hsa-miR-20b miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MCF-7 cells anacardic acid (AnAc) treatment upregulated 28886127 4648 Human hsa-miR-20b miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MDA-MB-231 cells anacardic acid (AnAc) treatment upregulated 28886127 4649 Human hsa-miR-20b miRNA propofol (PPF) autophagic cell death Human umbilical vein endothelial cells (HUVECs) propofol treatment Propofol promoted the expression of miR-20b 32826852 4650 Human hsa-miR-20b miRNA BAY11-7082 autophagy Mycobacterium tuberculosis (Mtb)-infected THP-1 cells BAY 11-7082 treatment upregulated 30011088 4651 Human hsa-miR-20b miRNA rapamycin breast cancer breast cancer cells rapamycin treatment over expression 26829385 4652 Human hsa-miR-20b miRNA hypoxia cerebral ischemia injury (CII) Human umbilical vein endothelial cells (HUVECs) hypoxia induce upregulated 30628668 4653 Human hsa-miR-20b miRNA tumor necrosis factor alpha (TNF-¦Á) endothelial senescence human pulmonary microvascular endothelial cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28595801 4654 Human hsa-miR-20b miRNA propofol (PPF) hypoxia/reoxygenation (H/R) injury human umbilical vein endothelial cells(HUVECs) propofol treatment miR-20b was upregulated in propofol-treated group 24454982 4655 Human hsa-miR-20b miRNA "myclobutanil, propiconazole, and triadimefon" hepatocellular carcinoma (HCC) HepG2 cells "myclobutanil, propiconazole, and triadimefon treatment" downregulated 23159985 4656 Human hsa-miR-20b miRNA resveratrol lymph node cancer of prostate Lymph node cancer of prostate (LNCaP)£»Du145 cells resveratrol (Res) treatment upregulated 21714127 4657 Human hsa-miR-20b miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 4658 Human hsa-miR-20b miRNA triptolide (TPL) osteoarthritis (OA) LPS-induced human monocytic cell line THP-1 triptolide (TPL) treatment downregulated 29974310 4659 Human hsa-miR-20b miRNA triptolide (TPL) osteoarthritis (OA) LPS-treated human monocytic cell line THP-1 triptolide (TPL) treatment downregulated 29974310 4660 Human hsa-miR-20b miRNA hydrogen sulfide (H2S) preeclampsia (PE) placental cells obtained from pregnant women with preeclampsia placental cells obtained from pregnant women with preeclampsia treatment downregulated 26992682 4661 Human hsa-miR-20b miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) THP-1 cells Mycobacterium tuberculosis (Mtb) infection downregulated 30011088 4662 Human hsa-miR-20b-3p miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MCF-7 cells anacardic acid (AnAc) treatment upregulated 28886127 4663 Human hsa-miR-20b-3p miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MDA-MB-231 cells anacardic acid (AnAc) treatment upregulated 28886127 4664 Human hsa-miR-20b-3p miRNA temozolomide (TMZ) temozolomide (TMZ) resistance in glioblastoma (GBM) "LN229, U251, 551 W, and HG7 cells" temozolomide (TMZ) treatment lnc-TALC correlated with TMZ resistance via competitively binding miR-20b-3p to facilitate c-Met expression 31053733 4665 Human hsa-miR-20b-5p miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MCF-7 cells anacardic acid (AnAc) treatment upregulated 28886127 4666 Human hsa-miR-20b-5p miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MDA-MB-231 cells anacardic acid (AnAc) treatment upregulated 28886127 4667 Human hsa-miR-20b-5p miRNA platelet-derived growth factor (PDGF) asthma fetal airway smooth muscle (ASM) cells platelet-derived growth factor (PDGF) treatment downregulated 29549727 4668 Human hsa-miR-20b-5p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) High Glucose (HG) treatment upregulated 31636010 4669 Human hsa-miR-20b-5p miRNA propofol (PPF) ischemia/reperfusion (I/R) injury human umbilical vein endothelial cells (HUVECs) propofol treatment miR-20b-5p was significantly higher and ULK1 was lower in propofol-preconditioned HUVECs with HR injury than in HUVECs with HR injury only 32098914 4670 Human hsa-miR-20b-5p miRNA fractionated radiation radiation-induced injury human peripheral blood mononuclear cells fractionated radiation treatment upregulated 25313363 4671 Human hsa-miR-21 miRNA "3,3'-diindolylmethane (DIM)" adipogenesis MCF-7 cells "3,3'-Diindolylmethane (DIM) treatment" treatment of MCF-7 cells with DIM increased miR-21 expression and downregulated Cdc25A 21761201 4672 Human hsa-miR-21 miRNA taxol breast cancer The human breast adenocarcinoma MCF-7 cells taxol treatment downregulated 20082533 4673 Human hsa-miR-21 miRNA thymic stromal lymphopoietin (TSLP) fungal keratitis dendritic cells (DCs) from peripheral blood of healthy volunteers thymic stromal lymphopoietin (TSLP)?treatment treatment miR-21 was highly expressed in exosomes from TSLP-treated DCs 33253708 4674 Human hsa-miR-21 miRNA IFN-¦Ã graft-versus-host disease (GVHD) Cord blood (CB) interferon-¦Ã treatment downregulated 21913990 4675 Human hsa-miR-21 miRNA resveratrol inflammation glioma cells resveratrol (Res) treatment downregulated 23793554 4676 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) cell division human peripheral blood mononuclear cells LPS treatment upregulated 17700064 4677 Human hsa-miR-21 miRNA TGF-¦Â non-small cell lung cancer (NSCLC) ?SSc fibroblasts TGF-¦Â treatment upregulated 23657402 4678 Human hsa-miR-21 miRNA docosahexaenoic acid (DHA) osteogenesis human breast cancer cell lines MDA-MB-231 ;MCF-7 docosahexaenoic acid (DHA) treatment downregulated 22678116 4679 Human hsa-miR-21 miRNA 5-fluorouracil (5-Fu) pancreatic cancer (PC) HT-29 cells 5-fluorouracil (5-FU) treatment downregulated 24275137 4680 Human hsa-miR-21 miRNA statins active hepatitis or cirrhosis HepG2 cells statins? treatment upregulated 26429200 4681 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) acute coronary syndrome (ACS) human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 30233677 4682 Human hsa-miR-21 miRNA CoCl2 acute kidney injury (AKI) Human proximal tubular cell lines (HK-2 cells) CoCl2 treatment upregulated 30013485 4683 Human hsa-miR-21 miRNA CoCl2 acute kidney injury (AKI) human umbilical vein endothelial cells (HUVECs) treated with CoCl2 upregulated 28677811 4684 Human hsa-miR-21 miRNA hypoxia acute kidney injury (AKI) Human proximal tubular cell lines (HK-2 cells) hypoxia induce upregulated 30013485 4685 Human hsa-miR-21 miRNA L-mimosine acute kidney injury (AKI) Human proximal tubular cell lines (HK-2 cells) L-Mimosine treatment upregulated 30013485 4686 Human hsa-miR-21 miRNA kanglaite advanced lung cancer serum Kanglaite treatment Kanglaite injection on serum miRNA-21 in patients with advanced lung cancer was shown to significantly reduce the expression of miRNA-21. 29735968 4687 Human hsa-miR-21 miRNA particulate matter (PM2.5) air pollution-induced placental epigenetic alterations placental tissue Particulate matter (PM2.5) exposure treatment miR-21 was inversely associated with PM25 exposure during the 2nd trimester of pregnancy 27104955 4688 Human hsa-miR-21 miRNA particulate matter (PM2.5) air pollution-induced placental epigenetic alterations placental tissue Particulate matter (PM2.5) exposure treatment miR-21 was positively associated with 1st trimester exposure 27104955 4689 Human hsa-miR-21 miRNA budesonide airway remodeling Human bronchial fibroblasts ?budesonide treatment downregulated 31204163 4690 Human hsa-miR-21 miRNA calcitriol airway remodeling Human bronchial fibroblasts calcitriol treatment downregulated 31204163 4691 Human hsa-miR-21 miRNA receptor inhibitor (SB431542) airway remodeling human bronchial fibroblasts (HBFs) receptor inhibitor (SB431542) treatment The high expression of miR-21 induced by TGF¦Â1 was reduced following the treatment with the SB431542 in HBFs. 29621415 4692 Human hsa-miR-21 miRNA SB431542 airway remodeling TGF¦Â1-treated human bronchial fibroblasts (HBFs) SB431542 treatment downregulated 29621415 4693 Human hsa-miR-21 miRNA TGF-¦Â1 airway remodeling human bronchial fibroblasts (HBFs) TGF-¦Â3 treatment upregulated 29621415 4694 Human hsa-miR-21 miRNA alcohol alcohol stress alcohol consumption in heavy drinkers were allowed to drink up to 750 cc of beer? treatment upregulated 25421511 4695 Human hsa-miR-21 miRNA chitin allergic airway diseases (AAD) bronchial epithelial cells and in A549 and H292 lung carcinoma cells chitin treatment upregulated 27463381 4696 Human hsa-miR-21 miRNA hepatitis C virus (HCV) allergies and bronchial asthma Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 23633945 4697 Human hsa-miR-21 miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment upregulated 29635890 4698 Human hsa-miR-21 miRNA curcumin (Cur) anaplastic thyroid carcinoma (ATC) SW1736 and 8505C curcumin treatment downregulated 29197967 4699 Human hsa-miR-21 miRNA propofol (PPF) anesthesia-induced neural cytotoxicity human embryonic stem cell propofol treatment downregulated 24950164 4700 Human hsa-miR-21 miRNA ionizing radiation (IR) angiogenesis HUVEC cells ionizing radiation (IR) treatment upregulated 31128066 4701 Human hsa-miR-21 miRNA phosphatase of regenerating liver-3 (PRL-3) angiogenesis colon cancer cells Phosphatase of regenerating liver-3 (PRL-3) treatment "overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3" 22677902 4702 Human hsa-miR-21 miRNA sulfasalazine ankylosing spondylitis (AS) patients blood sulfasalazine treatment upregulated 24786924 4703 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) ankylosing spondylitis (AS) fibroblasts tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 32009856 4704 Human hsa-miR-21 miRNA metformin (Met) anti-cancer therapy "human skin keratinocyte cell line, HaCaT" metformin treatment downregulated 29286158 4705 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) anti-inflammatory responses myocardial cell line H9c2(2-1) exposed to LPS treatment upregulated 25131238 4706 Human hsa-miR-21 miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 4707 Human hsa-miR-21 miRNA CC2238/¦ÁANP apoptosis CASMCs CC2238/¦ÁANP treatment downregulated 25401746 4708 Human hsa-miR-21 miRNA contrast medium (CM) apoptosis human renal proximal tubular epithelial (HK-2) cells contrast medium (CM) treatment downregulated 28901491 4709 Human hsa-miR-21 miRNA oxidized low density lipoprotein (ox-LDL) apoptosis HUVECs oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31966898 4710 Human hsa-miR-21 miRNA temozolomide (TMZ) apoptosis human glioblastoma U87MG cells temozolomide treatment over-express miR-21 in U87MG cells could significantly reduce TMZ-induced apoptosis 20633539 4711 Human hsa-miR-21 miRNA resveratrol apoptosis pancreatic cancers cells resveratrol (RS) treatment downregulated 23359184 4712 Human hsa-miR-21 miRNA arsenite arsenic-induced multiorgan damage plasma arsenic exposure upregulated 31085440 4713 Human hsa-miR-21 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 4714 Human hsa-miR-21 miRNA arsenic trioxide (ATO) As2O3 cardiotoxicity hERG-HEK293 cells and neonatal cardiomyocytes arsenic trioxide (As2O3) treatment upregulated 25395240 4715 Human hsa-miR-21 miRNA inhaled corticosteroids asthma bronchial epidermal cells from asthma patients inhaled corticosteroids treatment downregulated 24995087 4716 Human hsa-miR-21 miRNA angiotensin II (Ang II) atherosclerosis (AS) human microvascular endothelial cells (HMECs) angiotensin II (Ang II) treatment upregulated 30950039 4717 Human hsa-miR-21 miRNA dihydromyricetin (DHM) atherosclerosis (AS) human umbilical vein endothelial cells (HUVEC) dihydromyricetin (DMY) treatment DMY decreases microRNA-21 (miR-21). 32301289 4718 Human hsa-miR-21 miRNA geniposide (GEN) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) geniposide treatment geniposide pretreatment significantly increased miR-21 level in human umbilical vein endothelial cells (HUVECs) under ox-LDL condition. 32323738 4719 Human hsa-miR-21 miRNA teniposide atherosclerosis (AS) human aortic vascular smooth muscle cells (HASMCs) teniposide treatment upregulated 30409428 4720 Human hsa-miR-21 miRNA tongxinluo (TXL) atherosclerosis (AS) normal human proximal tubular epithelial cells (HKCs) £» serum Tongxinluo? treatment downregulated 24370587 4721 Human hsa-miR-21 miRNA angiotensin II (Ang II) atrial fibrosis Neonatal cardiac fibroblasts angiotensin II (Ang II) treatment upregulated 22760500 4722 Human hsa-miR-21 miRNA connective tissue growth factor (CTGF) atrial fibrosis Neonatal cardiac fibroblasts CTGF treatment upregulated 22760500 4723 Human hsa-miR-21 miRNA arsenite autophagy L-02 cells arsenite exposure upregulated 27107786 4724 Human hsa-miR-21 miRNA isoflavone formononetin bladder cancer T24 cells formononetin downregulated 28139790 4725 Human hsa-miR-21 miRNA resveratrol bladder cancer T24 and 5637 cells resveratrol (RS) treatment downregulated 24535223 4726 Human hsa-miR-21 miRNA benzo(a)pyrene (BaP) breast cancer MDA-MB-231 cells benzo(a)pyrene (BaP) exposure downregulated 30155724 4727 Human hsa-miR-21 miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment upregulated 25120778 4728 Human hsa-miR-21 miRNA collagenase-2 breast cancer breast cancer cells collagenase-2?treatment downregulated 23851508 4729 Human hsa-miR-21 miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment downregulated 28599484 4730 Human hsa-miR-21 miRNA DDT and BPA breast cancer MCF-7 breast cancer cells DDT and BPA treatment upregulated 22403704 4731 Human hsa-miR-21 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 4732 Human hsa-miR-21 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 4733 Human hsa-miR-21 miRNA hesperidin breast cancer MCF-7 cells hesperidin treatment downregulated 33050842 4734 Human hsa-miR-21 miRNA luteolin breast cancer MCF-7 cells luteolin treatment downregulated 33050842 4735 Human hsa-miR-21 miRNA oleuropein (OL) breast cancer MCF-7 cells oleuropein treatment Oleuropein significantly decreased expression of both miR-21 and miR-155 over time in a dose-dependent manner. 29905007 4736 Human hsa-miR-21 miRNA paclitaxel (PTX) breast cancer "HER2-positive cell lines, BT-474 and SKBR3" paclitaxel treatment upregulated 28509576 4737 Human hsa-miR-21 miRNA propofol (PPF) breast cancer MCF-7 cells Propofol treatment downregulated 30942630 4738 Human hsa-miR-21 miRNA silibinin (SB) breast cancer MCF-7 breast cancer cells Silibinin treatment downregulated 27066095 4739 Human hsa-miR-21 miRNA silibinin (SB) breast cancer T47D breast cancer cell line silibinin treatment "upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)" 28509572 4740 Human hsa-miR-21 miRNA TGF-¦Â breast cancer tumor samples of breast cancer transforming growth factor-beta (TGF-beta) treatment upregulated 18932017 4741 Human hsa-miR-21 miRNA TGF-¦Â1 breast cancer MCF-7 cell line TGF-¦Â1 treatment upregulated 29151919 4742 Human hsa-miR-21 miRNA trastuzumab breast cancer BT474 cells trastuzumab treatment upregulated 29981261 4743 Human hsa-miR-21 miRNA trastuzumab breast cancer serum Trastuzumab treatment downregulated 30246355 4744 Human hsa-miR-21 miRNA trastuzumab or lapatinib breast cancer patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer chemotherapy combin either trastuzumab or lapatinib treatment upregulated 25086636 4745 Human hsa-miR-21 miRNA wound fluids (WFs) from breast cancer patients breast cancer human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line WFs treatment upregulated 28943910 4746 Human hsa-miR-21 miRNA zoledronic acid (ZA) breast cancer human breast cancer cell lines zoledronic acid (ZA) treatment downregulated 26905520 4747 Human hsa-miR-21 miRNA ¦Á-linolenic acid (ALA) breast cancer MCF-7 cells ¦Á-linolenic acid (ALA) treatment ALA reduced miR-21 expression 29342901 4748 Human hsa-miR-21 miRNA X-irradiated bystander effect HaCaT cells X-irradiated treatment downregulated 26080011 4749 Human hsa-miR-21 miRNA radiation bystander effect human fetal lung MRC-5 fibroblasts different types of radiation treatment upregulation 25483031 4750 Human hsa-miR-21 miRNA arsenite tumorigenesis HBE cells; A549 cells;HUVEC cells arsenite exposure upregulated 24012885 4751 Human hsa-miR-21 miRNA arsenite tumorigenesis human bronchial epithelial (HBE) cells by a low concentration (1.0¦ÌM) of arsenite arsenic exposure upregulated 25445583 4752 Human hsa-miR-21 miRNA high glucose (HG) cardiac fibrosis Human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 31680453 4753 Human hsa-miR-21 miRNA polychlorinated biphenyls (PCBs) cardiac injury HUVECs polychlorinated biphenyls (PCBs) treatment upregulated 27288564 4754 Human hsa-miR-21 miRNA IFN cardiomyocyte apoptosis prostate cancer cells IFN? treatment cytokine IFN rapidly induces miR-21 expression in cells 20813833 4755 Human hsa-miR-21 miRNA kaempferol cardioprotective therapy vascular smooth muscle cell (VSMC) Bioflavonoids treatment "Kaempferol activates the BMP signaling pathway, induces miR-21 expression and downregulates DOCK4, 5, and 7, leading to inhibition of cell migration." 26048714 4756 Human hsa-miR-21 miRNA arsenic trioxide (ATO) cardiotoxicity hERG-HEK293 cells and neonatal cardiomyocytes arsenic trioxide (As2O3) treatment upregulated 25395240 4757 Human hsa-miR-21 miRNA hypoxia cardiovascular disease (CVD) human umbilical vein endothelial cells (HUVECs) hypoxia treatment downregulated 22282338 4758 Human hsa-miR-21 miRNA H2O2 cataract HLECs H2O2 treatment lncRNA ANRIL attenuated H2O2-induced cell injury in HELCs via up-regulating miR-21 via the activation of AMPK and ¦Â-catenin. 32310822 4759 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) cell differentiation human dental pulp stem cells (DPSCs) tumor necrosis factor alpha (TNF-¦Á) treatment "the expression of miR-21 and STAT3 increased gradually in low concentration (1-10?ng/mL) of TNF-¦Á, while they were suppressed in high concentration (50-100?ng/mL)" 29620442 4760 Human hsa-miR-21 miRNA high glucose (HG) cell proliferation human aortic vascular smooth muscle cells (HASMCs) high glucose treatment upregulated 31672498 4761 Human hsa-miR-21 miRNA metformin (Met) cell proliferation "human skin keratinocyte cell line, HaCaT" Metformin treatment downregulated 29286158 4762 Human hsa-miR-21 miRNA substance P (SP) cell proliferation exosomes from human colonic epithelial cells (NCM460 and NCM460-NK1R) substance P (SP) treatment upregulated 31545921 4763 Human hsa-miR-21 miRNA tanshinone IIA (Tan IIA) cell proliferation high glucose-treated human aortic vascular smooth muscle cells (HASMCs) Tanshinone IIA treatment downregulated 31672498 4764 Human hsa-miR-21 miRNA arsenite cell transformation Immortalized HELF cells arsenic exposure upregulated 22387281 4765 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) cell-to-cell communication human aortic endothelial cells (ECs) and their transfer to recipient cells tumor necrosis factor alpha (TNF-¦Á) treatment differently regulation 25315114 4766 Human hsa-miR-21 miRNA H2O2 cellular oxidative injury human umbilical vein endothelial cells (HUVECs) hydrogen peroxide (H2O2) treatment upregulated 30037352 4767 Human hsa-miR-21 miRNA high glucose (HG) cellular oxidative injury human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 30037352 4768 Human hsa-miR-21 miRNA oscillating glucose cellular oxidative injury human umbilical vein endothelial cells (HUVECs) oscillating glucose treatment upregulated 30037352 4769 Human hsa-miR-21 miRNA cisplatin (DDP) cervical cancer (CC) Human cervical adenocarcinoma cell Hela;human cervical squamous cancer cell line Siha cisplatin treatment downregulated 30352127 4770 Human hsa-miR-21 miRNA human papilloma viruses 16 (HPV16) E6 cervical cancer (CC) SiHa cells human papillomavirus E6 oncoprotein treatment dysregulated 25539644 4771 Human hsa-miR-21 miRNA N-nitroso carcinogen N-methyl-N-nitro-N'-nitrosoguanidine (MNNG) chemical carcinogenesis GES-1 cells MNNG treatment upregulated 24821435 4772 Human hsa-miR-21 miRNA prostaglandin E2 (PGE2) cholangiocarcinoma (CCA) human cholangiocarcinoma cells PGE2 treatment upregulated 24699315 4773 Human hsa-miR-21 miRNA galangin cholangiocarcinoma (CCA) HCCC9810 cells Galangin treatment downregulated 32626749 4774 Human hsa-miR-21 miRNA HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA) chronic heart failure (CHF) human aortic endothelial cells HDLNYHA treatment downregulated 24958738 4775 Human hsa-miR-21 miRNA quercetin chronic kidney disease (CKD) HK-2 cells quercetin treatment Quercetin treatment significantly inhibited TGF-¦Â-induced miR-21 upregulation 30210596 4776 Human hsa-miR-21 miRNA berberine (BBR) chronic lymphocytic leukemia (CLL) peripheral blood mononuclear cells (PBMCs) berberine (BBR) treatment berberine could reduce the expression of miR-21 in comparison to the untreated group. 33174291 4777 Human hsa-miR-21 miRNA fludarabine chronic lymphocytic leukemia (CLL) p53-mutant MEG-01 cells fludarabine treatment specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets 20504344 4778 Human hsa-miR-21 miRNA berberine (BBR) chronic lymphocytic leukemia (CLL) peripheral blood mononuclear cells (PBMCs) of CLL patients berberine (BBR) treatment "Interestingly, berberine could reduce the expression of miR-21 in comparison to the untreated group." 33174291 4779 Human hsa-miR-21 miRNA curcumin (Cur) chronic myeloid leukemia (CML) K562 and LAMA84 cells curcumin treatment upregulated 27050372 4780 Human hsa-miR-21 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human bronchial epithelial (16HBE) cells cigarette smoke extract (CSE) exposure upregulated 29543496 4781 Human hsa-miR-21 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human bronchial epithelial (HBE) cells; bronchial fibroblasts (MRC-5 cells) cigarette smoke extract (CSE) exposure miR-21 levels were increased in CSE-treated HBE cells and in MRC-5 cells 30555555 4782 Human hsa-miR-21 miRNA bone morphogenetic protein 2 (BMP2) chronic pancreatitis (CP) human primary pancreatic stellate cells; human primary pancreatic fibroblast (hPFBs) bone morphogenetic protein 2 (BMP2) treatment downregulated 29303912 4783 Human hsa-miR-21 miRNA TGF-¦Â1 chronic rhinosinusitis with nasal polyps (CRSwNP) Primary human nasal epithelial cells (PHNECs) TGF-¦Â1 treatment upregulated 30982052 4784 Human hsa-miR-21 miRNA TGF-¦Â1 chronic rhinosinusitis with nasal polyps (CRSwNP) epithelial-mesenchymal transition (EMT) TGF-¦Â1 treatment upregulated 30982052 4785 Human hsa-miR-21 miRNA doxorubicin (DOX) classical hodgkin lymphoma L428 cells doxorubicin (DOX) treatment "in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL" 23725219 4786 Human hsa-miR-21 miRNA doxorubicin (DOX) classical hodgkin lymphoma L428 cells doxorubicin (DOX) treatment "in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL." 23725219 4787 Human hsa-miR-21 miRNA p-Cresyl sulfate (pCS) clear cell renal cell carcinoma (ccRCC) A498 and 786-O cells of ccRCC p-Cresyl sulfate (pCS) treatment upregulated 30824757 4788 Human hsa-miR-21 miRNA berberine (BBR) colorectal cancer (CRC) HCT116 cells berberine (BBR) treatment Berberine inhibited miR-21 expression. 29564000 4789 Human hsa-miR-21 miRNA epidermal growth factor (EGF) colorectal cancer (CRC) colon cancer cells (HT29; SW480; Caco-2) epidermal growth factor (EGF) treatment downregulated 23827854 4790 Human hsa-miR-21 miRNA TGF-¦Â colorectal cancer (CRC) OVCAR3 cells; Hela cells; HCT116 cells; MRC-5 cells; OSE cells; Human ovarian cancer tissue specimens and Primary fibroblast TGF-¦Â treatment upregulated 20533548 4791 Human hsa-miR-21 miRNA ursolic acid (UA) colorectal cancer (CRC) U251 cells Ursolic acid treatment downregulated 22028478 4792 Human hsa-miR-21 miRNA butylcycloheptyl prodiginine (bPGN) colorectal cancer (CRC) HCT-116 colorectal cancer cells butylcycloheptyl prodiginine (bPGN) treatment downregulated 31155509 4793 Human hsa-miR-21 miRNA cigarette smoke extract (CSE) colorectal cancer (CRC) human colorectal adenocarcinoma cell line (Caco-2) cigarette smoke extract (CSE) exposure upregulated 31574306 4794 Human hsa-miR-21 miRNA curcumol colorectal cancer (CRC) "Human colorectal cancer cells lines LoVo, HCT-116, SW480" curcumol treatment downregulated 30811964 4795 Human hsa-miR-21 miRNA docosahexaenoic acid (DHA) colorectal cancer (CRC) HCT-116 and HCT-8 cells docosahexaenoic acid (DHA) treatment downregulated 26853468 4796 Human hsa-miR-21 miRNA fusobacterium nucleatum (F. nucleatum) colorectal cancer (CRC) "HCT116, HT29, LoVo, and SW480 CRC cell lines" Fusobacterium nucleatum upregulated 27876571 4797 Human hsa-miR-21 miRNA gambogic acid (GA) colorectal cancer (CRC) HT-29 cells gambogic acid (GA) treatment treatment with GA significantly decreased miR-21 expression in these cells. 30186399 4798 Human hsa-miR-21 miRNA hypoxia colorectal cancer (CRC) "CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)" 1 and 0.2% oxygen upregulated 28207045 4799 Human hsa-miR-21 miRNA "JQ-1, Bromodoamin and extraterminal (BET) protein inhibitor" colorectal cancer (CRC) SW480 colon cancer cells "JQ-1, Bromodoamin and extraterminal (BET) protein inhibitor treatment" downregulated 29600711 4800 Human hsa-miR-21 miRNA pomegranate juice (PJ) colorectal cancer (CRC) ?prostate cancer cells Pomegranate juice (PJ) treatment downregulated 21594291 4801 Human hsa-miR-21 miRNA sulforaphane (SFN) colorectal cancer (CRC) Human RKO colon cancer cells Sulforaphane (SFN) treatment downregulated 28176652 4802 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) colorectal cancer (CRC) HT29 cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28192117 4803 Human hsa-miR-21 miRNA COX-2 inhibitor NS398 colorectal cancer (CRC) HCA-7 cell COX-2 inhibitor NS398 significantly decreased treatment downregulated 25310697 4804 Human hsa-miR-21 miRNA metformin and 5-fluorouracil and oxaliplatin (FuOx) colorectal cancer (CRC) human colon cancer cells HT-29 and HCT-116 combinatorial treatment upregulated 24465408 4805 Human hsa-miR-21 miRNA acute exercise congestive heart failure (CHF) CHF patients acute exercise treatment upregulated 26799589 4806 Human hsa-miR-21 miRNA AS1411 corneal neovascularization (CNV) human limbus stroma (HLSC) AS1411 treatment AS1411 treatment also significantly reduced VEGF-stimulated induction of miR-21 and miR-221 in HLSC. 32081668 4807 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) coronary artery disease (CAD) human endothelial cell from umbilical vein (HU-VECs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28804550 4808 Human hsa-miR-21 miRNA thrombospondin-1 (TSP-1) coronary heart disease (CHD) Human aortic VSMCs Thrombospondin-1 (TSP-1)?treatment treatment ?Acute inhibition of miR-21 led to a decrease in VSMC migration and proliferation caused by TSP-1 24314882 4809 Human hsa-miR-21 miRNA corticosteroid corticosteroid resistance Airway smooth muscle cells (ASMCs) corticosteroid treatment CASC7 increased corticosteroid sensitivity by inhibiting the PI3K/AKT signaling pathway via targeting miR-21. 31412983 4810 Human hsa-miR-21 miRNA dexamethasone (DEX) corticosteroid resistance Airway smooth muscle cells (ASMCs) dexamethasone (DEX) treatment Overexpression of CASC7 suppressed the PI3K/AKT signaling pathway and promoted the inhibition effects of dexamethasone on cell proliferation and cytokines secretion via targeting miR-21. 31412983 4811 Human hsa-miR-21 miRNA coxsackievirus B3 (CVB3) coxsackievirus B3 (CVB3) infection disease Hela cells CVB3 infection upregulated 31585536 4812 Human hsa-miR-21 miRNA matrine sorafenib-induced cytotoxicity HepG2 cells;Hep3B cells exposure to matrine treatment downregulated 25721136 4813 Human hsa-miR-21 miRNA dengue virus (DENV) dengue virus (DENV) infection HepG2 (liver) cells DENV infection dysregulated 28365456 4814 Human hsa-miR-21 miRNA hyperglycemia diabetes-induced retinal pathology ARPE-19 cells "hyperglycemic condition (high glucose, 33mM)" upregulated 28465657 4815 Human hsa-miR-21 miRNA atrasentan diabetic nephropathy (DN) high glucose (HG)-induced podocytes atractylon (Atr)?treatment downregulated 30876973 4816 Human hsa-miR-21 miRNA high glucose (HG) diabetic nephropathy (DN) podocytes high glucose (HG) treatment upregulated 30876973 4817 Human hsa-miR-21 miRNA tongxinluo (TXL) diabetic nephropathy (DN) human proximal tubular epithelial cell (HKCs) line TXL treatment downregulated 24370587 4818 Human hsa-miR-21 miRNA paclitaxel (PTX) drug resistance Human Gastric Adenocarcinoma Cell Line paclitaxel treatment expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901 27040946 4819 Human hsa-miR-21 miRNA synthetic preimplantation factor (sPIF) duchenne muscular dystrophy (DMD) myoblast Synthetic preimplantation factor (sPIF) treatment downregulated 30692507 4820 Human hsa-miR-21 miRNA acidic microenvironment early-stage hepatocellular carcinoma (E-HCC) The human HCC cell lines SMMC-7721 and Hep3B acidic microenvironment treatment upregulated 31037150 4821 Human hsa-miR-21 miRNA progesterone (P4) endometrial cancer (EC) Hec2A cells Progesterone treatment upregulated 22543862 4822 Human hsa-miR-21 miRNA "2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)" endothelial cell injury human umbilical vein endothelial cells (HUVECs) "2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment" downregulated 33093269 4823 Human hsa-miR-21 miRNA high glucose (HG) endothelial cytotoxicity The blood samples from diabetes patients high glucose treatment upregulated 23771797 4824 Human hsa-miR-21 miRNA dihydromyricetin (DHM) endothelial dysfunction TNF-¦Á treated human umbilical vein endothelial cells (HUVECs) dihydromyricetin (DMY) treatment downregulated 29682517 4825 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29682517 4826 Human hsa-miR-21 miRNA propofol (PPF) epithelial-mesenchymal transition (EMT) MCF-7 cells Propofol treatment downregulated 30942630 4827 Human hsa-miR-21 miRNA Smilax glabra Roxb (PTFS) epithelial-mesenchymal transition (EMT) TGF-¦Â1-treated HK-2 cells Smilax glabra Roxb (PTFS) treatment downregulated 30304552 4828 Human hsa-miR-21 miRNA high glucose (HG) epithelial-mesenchymal transition (EMT) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment High glucose (HG) upregulated miR-21 and induced EndMT in ECs 31680453 4829 Human hsa-miR-21 miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) Human umbilical vein endothelial cells (HUVECs) TGF-¦Â treatment upregulated 22095988 4830 Human hsa-miR-21 miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) HT-29 cells TGF-¦Â treatment upregulated 23483606 4831 Human hsa-miR-21 miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) nasopharyngeal carcinoma cell HK-1 TGF-¦Âtreatment upregulated 26032086 4832 Human hsa-miR-21 miRNA high glucose (HG) epithelial-mesenchymal transition (EMT) human peritoneal mesothelial cells (HPMCs) high glucose (HG) treatment HG upregulated miRNA-21 expression and downregulated PTEN expression. 30210695 4833 Human hsa-miR-21 miRNA nicotine esophageal cancer (EC) human esophageal cells nicotine treatment upregulated 24756761 4834 Human hsa-miR-21 miRNA zinc deficiency esophageal cancer (EC) human ESCC and OSCC zinc deficiency? treatment upregulated 22689922 4835 Human hsa-miR-21 miRNA isoalantolactone esophageal squamous cell carcinoma (ESCC) ECA-109 cells; KYSE30 cells Isoalantolactone treatment downregulated 29781054 4836 Human hsa-miR-21 miRNA radiation esophageal squamous cell carcinoma (ESCC) TE-1 cells; esophageal squamous cell carcinoma (ESCC) tissues radiation treatment miR-21 expression is much lower in radiation sensitive ESCC tissues than radiation resistant tissues 31866421 4837 Human hsa-miR-21 miRNA radiation esophageal squamous cell carcinoma (ESCC) esophageal squamous cell carcinoma (ESCC) tumor tissues; ESCC TE-1 cells radiation treatment MiR-21 levels were increased in radiation-resistant compared with radiation-sensitive patients 32268810 4838 Human hsa-miR-21 miRNA X-rays esophageal squamous cell carcinoma (ESCC) ESCC tissues and TE-1 celss 2 Gy X-ray treatment downregulated 31866421 4839 Human hsa-miR-21 miRNA curcumin (Cur) fat esophageal cancer cell lines curcumin treatment downregulated 22363450 4840 Human hsa-miR-21 miRNA bisphenol A (BPA) female fertility cumulus oocyte complex (COC) bisphenol A (BPA) treatment upregulated 33285269 4841 Human hsa-miR-21 miRNA TGF-¦Â fibrosis Dermal fibroblasts TGF-¦Â treatment upregulated 31155965 4842 Human hsa-miR-21 miRNA matrine follicular thyroid cancer FTC-133 follicular thyroid cancer cells Matrine treatment downregulated 31579406 4843 Human hsa-miR-21 miRNA thrombospondin-1 (TSP-1) fungal keratitis exosomes of dendritic cells (DCs) Thymic stromal lymphopoietin (TSLP) treatment miR-21 was highly expressed in exosomes from TSLP-treated DCs 33253708 4844 Human hsa-miR-21 miRNA curcumin (Cur) thyroid cancer (TC) "human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101" curcumin treatment downregulated 28265769 4845 Human hsa-miR-21 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "BGC-823 cells, SCG7901 cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 31572012 4846 Human hsa-miR-21 miRNA celastrol gastric cancer (GC) human gastric cancer cell line MKN45 celastrol treatment downregulated 30989726 4847 Human hsa-miR-21 miRNA celastrol gastric cancer (GC) "human gastric adenocarcinoma cell line BGC-823, gastric mucinous adenocarcinoma cell line MGC-803" celastrol treatment upregulated 24434352 4848 Human hsa-miR-21 miRNA chidamide gastric cancer (GC) "BGC-823 cells, SCG7901 cells" chidamide treatment downregulated 31572012 4849 Human hsa-miR-21 miRNA cisplatin (DDP) gastric cancer (GC) AGS cells cisplatin treatment DDP-resistant GC cells expressed higher levels of miR-21 compared with the parent cells. 31913198 4850 Human hsa-miR-21 miRNA curcumin (Cur) gastric cancer (GC) MGC-803 cell line curcumin treatment downregulated 30727807 4851 Human hsa-miR-21 miRNA docetaxel (DTX) gastric cancer (GC) MKN-45 cells docetaxel (DTX) treatment upregulated 33416185 4852 Human hsa-miR-21 miRNA H2O2 gastric cancer (GC) HGC-27 cells H2O2 treatment upregulated 33329376 4853 Human hsa-miR-21 miRNA nicotine gastric cancer (GC) Human gastric adenocarcinoma cells (AGS) Nicotine treatment "EP2 or EP4 siRNA or antagonists impaired the nicotine-mediated NF-kB activity, upregulation of miR-16 and miR-21 and cell proliferation." 21081469 4854 Human hsa-miR-21 miRNA S-1/oxaliplatin gastric cancer (GC) gastric tumor specimens ?S-1/Oxaliplatin?(intravenous injection) treatment miR-181b and miR-21 was significantly overexpressed in gastric tumors 21876743 4855 Human hsa-miR-21 miRNA myricetin-loaded mixed micelles (MYR-MCs) glioblastoma multiforme (GBM) human glioblastoma cells myricetin-loaded mixed micelles (MYR-MCs) treatment downregulated 27757032 4856 Human hsa-miR-21 miRNA temozolomide and irradiation glioblastoma multiforme (GBM) primary glioblastoma cells; U87MG cells; U251MG cells; U118MG cells temozolomide and irradiation treatment upregulated 33082482 4857 Human hsa-miR-21 miRNA type I interferon (IFN) glioblastoma multiforme (GBM) T98 cells; SKMG1 cells; U251MG cells; U87MG cells Type I IFNs treatment The Modulation of MicroRNAs by Type I IFN through the Activation of Signal Transducers and Activators of Transcription 3 in Human Glioma 19934272 4858 Human hsa-miR-21 miRNA Cl-amidine glioblastoma multiforme (GBM) LN18 and LN229 cells Cl-amidine treatment downregulated 30597867 4859 Human hsa-miR-21 miRNA metformin (Met) glioblastoma multiforme (GBM) U87 cells metformin(Met) treatment downregulated 33059952 4860 Human hsa-miR-21 miRNA hypoxia glioblastoma multiforme (GBM) glioma-derived exosomes (GDEs) hypoxia treatment The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN). 29713056 4861 Human hsa-miR-21 miRNA si wei xiao xiu yin glioblastoma multiforme (GBM) U87 cells Si wei xiao xiu yin treatment downregulated 32448616 4862 Human hsa-miR-21 miRNA TGF-¦Â granular corneal dystrophy type 2 (GCD2) Primary corneal fibroblasts TGF-¦Âtreatment treatment upregulated 26915797 4863 Human hsa-miR-21 miRNA sophocarpine (SC) head and neck squamous cell carcinoma (HNSCC) UM-SCC-22B and UM-SCC-47 cells SC treatment downregulated 28571917 4864 Human hsa-miR-21 miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 cells cisplatin treatment downregulated 27874954 4865 Human hsa-miR-21 miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HepG2 cells £¬ HepG2.2.15 cells. hepatitis B virus X protein (HBx) treatment downregulated 25260533 4866 Human hsa-miR-21 miRNA mineral pitch (MP) hepatocellular carcinoma (HCC) Huh-7 cells Mineral Pitch (MP) treatment downregulated 27233240 4867 Human hsa-miR-21 miRNA TGF-¦Â1 liver fibrosis QSG-7701 cells TGF-¦Â1 treatment upregulated 25661333 4868 Human hsa-miR-21 miRNA "3,3'-diindolylmethane (DIM)" liver fibrosis HSC-T6 cell line and primary hepatic stellate cells (HSCs) "3,3'-Diindolylmethane (DIM) treatment" downregulated 23902531 4869 Human hsa-miR-21 miRNA compound astragalus and salvia miltiorrhiza extract (CASE) hepatocellular carcinoma (HCC) TGF-¦Â1-stimulated HepG2 cells Compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment downregulated 30412748 4870 Human hsa-miR-21 miRNA compound Astragalus and Salvia miltiorrhiza extract (CASE) hepatocellular carcinoma (HCC) HepG2 cells compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment CASE downregulated miR-21 expression in TGF-¦Â 1-stimulated HepG2 cells. 30412748 4871 Human hsa-mir-21 miRNA dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S) hepatocellular carcinoma (HCC) HepG2 human hepatoma cells 10nM DHEA and DHEA-S treatment upregulated 24845419 4872 Human hsa-miR-21 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Plasma hepatitis B virus (HBV) infection ?upregulated 22105822 4873 Human hsa-miR-21 miRNA indole-3-carbinol (I3C) hepatocellular carcinoma (HCC) "human HCC cell lines, SK-Hep-1 and SNU-449" I3C treatment downregulated 25447674 4874 Human hsa-miR-21 miRNA kaempferol hepatocellular carcinoma (HCC) HepG2 cells kaempferol treatment downregulated 30477356 4875 Human hsa-miR-21 miRNA mycobacterium leprae hepatocellular carcinoma (HCC) monocytes Mycobacterium leprae treatment "The most dysregulated miRNA in L-lep lesions, hsa-mir-21, was upregulated in Mycobacterium leprae-infected monocytes" 22286305 4876 Human hsa-miR-21 miRNA notoginsenoside R1 (NGR1) hepatocellular carcinoma (HCC) "human HCC cell lines MHCC97H, BEL7402, Huh7, HepG2, PLC/PRF/5 (PLC), and SMMC7721" Notoginsenoside R1 (NG-R1) treatment downregulated 31559550 4877 Human hsa-miR-21 miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 4878 Human hsa-miR-21 miRNA polysaccharides (PRP1£© hepatocellular carcinoma (HCC) HepG2 cells polysaccharides (PRP1£©treatment downregulated 32380108 4879 Human hsa-miR-21 miRNA pSG5-HBx plasmid hepatocellular carcinoma (HCC) Huh 7 and Hep G2 cells transfect treatment upregulated 24633222 4880 Human hsa-miR-21 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) "Human HCC HepG2 and Huh7 cells, and SR-HCC cells" sorafenib treatment "Sorafenib induced translocation of miR-21 to the nucleus, where it promoted the expression of SNHG1" 31053148 4881 Human hsa-miR-21 miRNA transarterial chemoembolization (TACE) hepatocellular carcinoma (HCC) HCC patients plasma TACE treatment differently regulated 25275448 4882 Human hsa-miR-21 miRNA visfatin hepatocellular carcinoma (HCC) HepG2 cells visfatin treatment upregulated 29808800 4883 Human hsa-miR-21 miRNA Shenqi pollen capsules (SPCs) high-altitude deacclimatization syndrome (HADAS) serum Shenqi pollen capsules (SPCs) treatment upregulated 31828172 4884 Human hsa-miR-21 miRNA NPV-LDE-225 (Erismodegib) human immunodeficiency virus (HIV)-1 infection Glioblastoma initiating cells (GICs) NPV-LDE-225 (Erismodegib) treatment downregulated 23482671 4885 Human hsa-miR-21 miRNA epigallocatechin-3-gallate (EGCG) hormone refractory prostate cancer (HRPC) LNCaP and 22R¦Í cells Green tea polyphenol EGCG treatment downregulated 21177307 4886 Human hsa-miR-21 miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection upregulated 31371699 4887 Human hsa-miR-21 miRNA recombinant Human immunodeficiency virus (HIV) viral protein gp120 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment upregulated 31371699 4888 Human hsa-miR-21 miRNA recombinant Human immunodeficiency virus (HIV) viral protein Tat HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment upregulated 31371699 4889 Human hsa-miR-21 miRNA platelet derived growth factor-BB (PDGF-BB) hypertension vascular smooth muscle cells (VSMCs) PDGF©\bb treatment "?GAS5 inhibits PDGF-bb-induced VSMC proliferation and migration, partly through acting as a competing endogenous RNA of miR-21" 31069831 4890 Human hsa-miR-21 miRNA TGF-¦Â1 hypertrophic scars (HS) fibroblasts TGF-¦Â1 treatment upregulated 26500110 4891 Human hsa-miR-21 miRNA acidic bile hypopharyngeal cancer human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) acidic bile exposure upregulated 29516639 4892 Human hsa-miR-21 miRNA BAY11-7082 hypopharyngeal cancer Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) BAY 11-7082 treatment downregulated 29516639 4893 Human hsa-miR-21 miRNA intermittent hypoxia (IH) hypoxemia blood intermittent (HI) hypoxia treatment miR-21 was upregulated in intermittent (HI) hypoxia treatment group. 30416683 4894 Human hsa-miR-21 miRNA hypoxia hypoxic pulmonary hypertension (HPH) human pulmonary artery smooth muscle cells hypoxia treatment miR-21 expression was upregulated in hypoxia cell models. 29198701 4895 Human hsa-miR-21 miRNA hypoxia hypoxic brain injury human neural stem cells (hNSCs) oxygen and glucose deprivation (OGD) treatment upregulated 30291880 4896 Human hsa-miR-21 miRNA imatinib imatinib resistance human acute lymphoblastic leukemia cell line Sup-b15 imatinib treatment upregulated 25451263 4897 Human hsa-miR-21 miRNA Ig-like transcript 3 (ILT3) immune inflammatory human CD8(+) T suppressor cells Ig-like transcript 3 (ILT3) treatment upregulated 22387553 4898 Human hsa-miR-21 miRNA medroxyprogesterone acetate (MPA) impaired decidualization human endometrial stromal cell (hESC) medroxyprogesterone acetate (MPA) treatment downregulated 30772912 4899 Human hsa-miR-21 miRNA collagen IV and vascular endothelial growth factor (VEGF) cell differentiation pluripotent stem cells (iPSC) collagen IV and VEGF treatment upregulated 24356956 4900 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) infantile pneumonia (IP) MRC5 cells tumor necrosis factor alpha (TNF-¦Á) treatment NKILA weakens TNF-¦Á-induced inflammation of MRC-5 cells by miR-21 upregulated 32013579 4901 Human hsa-miR-21 miRNA progesterone (P4) infertility "human endometrial carcinoma cell line, SNU-1077" progesterone treatment dysregulated 30603515 4902 Human hsa-miR-21 miRNA cigarette smoke extract (CSE) inflammation Airway normal and cancer epithelial cells (16HBE and A549) cigarette smoke extracts (CSE) exposure upregulated 31054160 4903 Human hsa-miR-21 miRNA H2O2 oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 4904 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 4905 Human hsa-miR-21 miRNA molecular hydrogen inflammatory injury Retinal Microglia cells Molecular hydrogen?treatment downregulated 23826519 4906 Human hsa-miR-21 miRNA propofol (PPF) inflammatory response human umbilical vein endothelial cells (HUVECs) propofol treatment upregulated 29039542 4907 Human hsa-miR-21 miRNA retinoic acid (RA) inflammatory response "breast carcinoma cells,MCF-7 Cells" retinoic acid? treatment upregulated 21131358 4908 Human hsa-miR-21 miRNA extract of Celastrus orbiculatus (COE) inflammatory response H. pylori-infected GES-1 cells The extract of Celastrus orbiculatus (COE) treatment downregulated 31035975 4909 Human hsa-miR-21 miRNA helicobacter pylori (H. pylori) inflammatory response GES-1 cells Helicobacter pylori (H. pylori) infection upregulated 31035975 4910 Human hsa-miR-21 miRNA gemcitabine (GEM) insulin resistance accompanies obesity ?serum gemcitabine treatment downregulated 23177026 4911 Human hsa-miR-21 miRNA galla chinensis ointment keloids human keloid-derived fibroblasts Galla chinensis ointment treatment Galla chinensis inhibited the expression of miR-21. 32216491 4912 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) kidney damage HK-2 cell lipopolysaccharide (LPS) treatment upregulated 28821165 4913 Human hsa-miR-21 miRNA calcium oxalate monohydrate (COM) kidney stone disease HK-2 cells calcium oxalate monohydrate (COM) treatment MiR-21 promotes calcium oxalate-induced renal tubular cell injury by targeting PPARA. 32628541 4914 Human hsa-miR-21 miRNA K. pneumoniae reference strains (K. pneumoniae ATCC 10031) klebsiella pneumoniae infection BEAS 2B cells K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection upregulated 33322147 4915 Human hsa-miR-21 miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells KPC-producing K. pneumoniae infection upregulated 33322147 4916 Human hsa-miR-21 miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells MS K. pneumoniae infection upregulated 33322147 4917 Human hsa-miR-21 miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 18648749 4918 Human hsa-miR-21 miRNA granulocyte-colony stimulating factor (G-CSF) leukemia CD34+ cells Granulocyte colony-stimulating factor?treatment upregulated 24056818 4919 Human hsa-miR-21 miRNA leukemia microvesicles leukemia healthy hematopoietic stem cells leukemia microvesicles transformation upregulated 28218044 4920 Human hsa-miR-21 miRNA leukemia microvesicles leukemia hematopoietic stem progenitor cells (HSPCs) leukemia microvesicles treatment upregulated 31429853 4921 Human hsa-miR-21 miRNA decabromodiphenyl ether (BDE-209) lipid accumulation THP-1 macrophages decabromodiphenyl ether (BDE-209) treatment downregulated 30597220 4922 Human hsa-miR-21 miRNA decabromodiphenyl ether (BDE-209) lipid uptake THP-1 cells decabromodiphenyl ether (BDE-209) treatment "miR-21 were significantly suppressed by BDE-209?at concentrations of 6.25, 12.5 and 25?¦ÌM." 30597220 4923 Human hsa-miR-21 miRNA berberine (BBR) inflammation human dental pulp fibroblast berberine (BBR) treatment downregulated 31837588 4924 Human hsa-miR-21 miRNA antrodia cinnamomea hepatocellular carcinoma (HCC) SK-Hep-1 liver cancer cell antrodia cinnamomea treatment "oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated" 24358224 4925 Human hsa-miR-21 miRNA coptidis rhizoma aqueous extract hepatocellular carcinoma (HCC) human hcc mhcc97-l cells Coptidis rhizoma aqueous extract treatment upregulated 22977465 4926 Human hsa-miR-21 miRNA microcystin-leucine arginine (MC-LR) hepatocellular carcinoma (HCC) WRL-68 cells microcystin-LR treatment upregulated 22265967 4927 Human hsa-miR-21 miRNA ultraviolet (UV) irradiation hepatocellular carcinoma (HCC) HepG2 cells UV irradiation treatment downregulated 24431000 4928 Human hsa-miR-21 miRNA trichloroethylene (TCE) liver damage human HL-7702 cells Trichloroethylene (TCE) treatment downregulated 31140026 4929 Human hsa-miR-21 miRNA angiotensin-(1-7) liver fibrosis HEK-293 cells angiotensin-(1-7) treatment downregulated 27502441 4930 Human hsa-miR-21 miRNA corilagin liver fibrosis hepatic stellate LX2 cell line Corilagin treatment downregulated 31752524 4931 Human hsa-miR-21 miRNA 5-fluorouracil (5-Fu) lung cancer A549 cells 5-fluorouracil (5-FU) treatment "Our findings demonstrated that the overexpression of miR-21 decreased 5-fluorouracil-induced apoptosis and necrosis, and the opposite effects were obtained by the suppression of miR-21." 31934061 4932 Human hsa-miR-21 miRNA cigarette smoke extract (CSE) lung cancer human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) treatment upregulated 29501572 4933 Human hsa-miR-21 miRNA cisplatin (DDP) lung cancer A549 cells cisplatin treatment upregulated 30644017 4934 Human hsa-miR-21 miRNA clopidogrel lung cancer NCI cells; FaDu cells clopidogrel treatment upregulated 32326378 4935 Human hsa-miR-21 miRNA curcumin (Cur) lung cancer Human lung adenocarcinoma A549 cells curcumin treatment downregulated 24293118 4936 Human hsa-miR-21 miRNA curcumin (Cur) lung cancer A549 cells curcumin treatment upregulated 24293118 4937 Human hsa-miR-21 miRNA lidocaine lung cancer A549/DDP cells Lidocaine (Lido) treatment downregulated 30644017 4938 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) lung cancer primary human lung cancer cells lipopolysaccharide (LPS) treatment upregulated 27286259 4939 Human hsa-miR-21 miRNA Sinomenine (SIN) lung cancer A549 cells; H1299 cells Sinomenine treatment Sinomenine downregulates oncogenic microRNA-21 (miR-21) 32349289 4940 Human hsa-miR-21 miRNA Skullcapflavone I (SF I) lung cancer A549 and H1975 cells Skullcapflavone I treatment downregulated 31301304 4941 Human hsa-miR-21 miRNA solasonine (SS) lung cancer human lung cancer cell A5492 solasodine treatment downregulated 28283413 4942 Human hsa-miR-21 miRNA carbamate lung cancer Normal human bronchial epithelial (NHBE) cells carbamate treatment upregulated 19748927 4943 Human hsa-miR-21 miRNA ¦Â-adrenergic agonist and Epac activator malignant astrocytic gliomas human glioblasoma cell line U87MG and human astrocytoma cell line 1321N1 ¦Â-adrenergic agonist and Epac activator treatment downregulated 27504157 4944 Human hsa-miR-21 miRNA prolactin (PRL) mammary development HC11 mammary cells levels increased in upon prolactin treatment upregulated 24497923 4945 Human hsa-miR-21 miRNA Penetratin-tagged STAT3-NTD inhibitor (S3-NTDi) medulloblastoma "MB cell lines DAOY (SHH-TP53-mutated) and D341 (Group 3, Non-WNT/SHH), HD-MB03 cells (Group 3, Non-WNT/SHH, MYC amplified)" Penetratin-tagged STAT3-NTD inhibitor (S3-NTDi) treatment downregulated 29280516 4946 Human hsa-miR-21 miRNA Akt inhibitor and the EGFR inhibitor (Gefitinib) melanogenesis A375.S2 cells gefitinib downregulated 28398611 4947 Human hsa-miR-21 miRNA ultraviolet (UV) irradiation melanogenesis A375.S2 cells UV treatment upregulated 28398611 4948 Human hsa-miR-21 miRNA arsenite melanoma human keratinocyte HaCaT cell line arsenic (As) exposure upregulated 27054085 4949 Human hsa-miR-21 miRNA cantharidin (CTD) melanoma A375 cells cantharidin (CTD) treatment CTD treatment reduced microRNA (miR)-21 expression. 30221692 4950 Human hsa-miR-21 miRNA cordycepin migration of renal cell carcinoma Caki-1 cells cordycepin downregulated 29070781 4951 Human hsa-miR-21 miRNA ibrutinib multiple myeloma (MM) "Human MM cell lines, LP-1, U266, MM.1S, and MM.1R, Primary patient MM (ppMM) cells" ibrutinib treatment downregulated 29320977 4952 Human hsa-miR-21 miRNA berberine (BBR) multiple myeloma (MM) human multiple myeloma cells berberine (BBR) treatment downregulated 23247593 4953 Human hsa-miR-21 miRNA berberine (BBR) multiple myeloma (MM) multiple myeloma cells berberine (BBR) treatment upregulated 25000828 4954 Human hsa-miR-21 miRNA hypoxia multiple myeloma (MM) U266 cells hypoxia treatment upregulated 29158801 4955 Human hsa-miR-21 miRNA fumaric acid esters multiple sclerosis (MS) T helper-17 cells fumaric acid esters treatment downregulated 30698680 4956 Human hsa-miR-21 miRNA TGF-¦Â myelodysplastic syndrome (MDS) MDS marrow samples ?TGF-¦Â treatment upregulated 23390194 4957 Human hsa-miR-21 miRNA arsenic trioxide (ATO) myeloid leukemia HL60 cells;K562 cells arsenic trioxide (ATO) treatment "pre-miR-21 expression increased resistance to ATO, nevertheless not affecting cell growth alone. miRNA-21 by targeting PDCD4 may play a functional role in modulating ATO-induced cell death." 20143188 4958 Human hsa-miR-21 miRNA hypoxia myocardial ischaemic injury H9c2 cells;HL-1 cells;HCM cells cells under hypoxic conditions (2% O2 or CoCl2) treatment upregulated 24983504 4959 Human hsa-miR-21 miRNA graphene oxide (GO) nanoparticles toxicity MCF-7 cells graphene oxide (GO) treatment upregulated 32070776 4960 Human hsa-miR-21 miRNA graphene oxide (GO) nanoparticles toxicity KMBC/71 cells graphene oxide (GO) treatment downregulated 32070776 4961 Human hsa-miR-21 miRNA graphene oxide (GO) nanoparticles toxicity human umbilical vein endothelial cells (HUVECs) graphene oxide (GO) treatment upregulated 32070776 4962 Human hsa-miR-21 miRNA graphene quantum dots (GQDs) nanoparticles toxicity MCF-7 cells graphene quantum dots (GQDs) treatment downregulated 32070776 4963 Human hsa-miR-21 miRNA graphene quantum dots (GQDs) nanoparticles toxicity KMBC/71 cells graphene quantum dots (GQDs) treatment downregulated 32070776 4964 Human hsa-miR-21 miRNA latent membrane protein 1 (LMP1) nasopharyngeal carcinoma (NPC) cancer stem cells (CSCs) in NPC latent membrane protein 1 (LMP1) treatment upregulated 26568302 4965 Human hsa-miR-21 miRNA cyclosporine A (CsA) nephrotoxicity HEK293 cyclosporine A treatment upregulated 28414804 4966 Human hsa-miR-21 miRNA cyclosporine A (CsA) nephrotoxicity human proximal tubular epithelial cells (HPTECs) exposure to cyclosporine A (CsA) treatment upregulated 25266172 4967 Human hsa-miR-21 miRNA doxorubicin (DOX) bladder cancer "bladder cancer cells,T24 cells" doxorubicin treatment upregulated 21468550 4968 Human hsa-miR-21 miRNA lycopene nonalcoholic fatty liver disease (NAFLD) Hepa 1¨C6 cells Lycopene treatment downregulated 22968990 4969 Human hsa-miR-21 miRNA epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) non-small cell lung cancer (NSCLC) NSCLC patients EGFR-TKI treatment upregulated 24331411 4970 Human hsa-miR-21 miRNA ionizing radiation (IR) non-small cell lung cancer (NSCLC) NCI-H460 cells; A549 cells ionizing radiation (IR) treatment IR enhanced the interaction between lncRNA GAS5 and the miR-21/PTEN/Akt axis. 32020207 4971 Human hsa-miR-21 miRNA osimertinib non-small cell lung cancer (NSCLC) H1975 cells osimertinib treatment The relative expression levels of miR-21 was significantly upregulated after treated with 100 nM osimertinib for 24 h. 32375124 4972 Human hsa-miR-21 miRNA propofol (PPF) non-small cell lung cancer (NSCLC) A549 cells Propofol treatment Propofol inhibited miR-21 expression 32925348 4973 Human hsa-miR-21 miRNA triptolide (TPL) non-small cell lung cancer (NSCLC) The human lung cancer cell line PC-9 triptolide (TPL) treatment upregulated 26847601 4974 Human hsa-miR-21 miRNA oxidized low density lipoprotein (ox-LDL) breast cancer human mammary epithelial cells (MCF10A) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 23091604 4975 Human hsa-miR-21 miRNA "TNF-¦Á, IL-6, leptin, resistin , free fatty acids (FFAs)" obesity and obesity-associated insulin resistance human mature adipocytes "TNF-¦Á, IL-6, leptin, resistin , FFAs treatment" upregulated 28627656 4976 Human hsa-miR-21 miRNA thyroid hormone opioid tolerance hepatoma cells Thyroid hormone (T(3))? treatment over expression 23442323 4977 Human hsa-miR-21 miRNA opisthorchis viverrini opisthorchis viverrini infection human urine infect with Opisthorchis viverrini upregulated in the urine 26456596 4978 Human hsa-miR-21 miRNA curcumin (Cur) oral cancer oral cancer stem cells of UD-SCC2 (HPV+ve) and UPCI:SCC131 and UPCI: SCC 84(HPV¨Cve) cell lines curcumin treatment downregulated 30319975 4979 Human hsa-miR-21 miRNA hypoxia oral squamous cell carcinoma (OSCC) oral squamous cell carcinoma (OSCC) cells hypoxia treatment upregulated 26992424 4980 Human hsa-miR-21 miRNA porphyromonas gingivalis oral squamous cell carcinoma (OSCC) OSCC Tca8113 cells Porphyromonas gingivalis infection treatment upregulated 31243990 4981 Human hsa-miR-21 miRNA arecoline oral submucous fibrosis (OSF) buccal mucosal fibroblasts (BMFs) arecoline treatment MiR-21 expression was induced in BMFs by arecoline treatment in a dose-dependent manner. 33191095 4982 Human hsa-miR-21 miRNA hypoxia orthodontic tooth movement Periodontal ligament cells (PDLCs) hypoxia induce upregulated 30930976 4983 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) orthopedic diseases osteoblastic hFOB1.19 cells lipopolysaccharide (LPS) treatment downregulated 26516113 4984 Human hsa-miR-21 miRNA mechanical stretch osteogenesis human periodontal ligament stem cells (PDLSCs) exposed to mechanical stretch treatment upregulated 25203845 4985 Human hsa-miR-21 miRNA honokiol osteosarcoma (OS) Saos-2 cells; Mg-63 cells honokiol (HNK) treatment "HNK was able to induce aberrant expression of miRNAs in human OS cells, and miR-21 was one of the miRNAs that was most significantly downregulated." 29393336 4986 Human hsa-miR-21 miRNA Piceatannol (Pice) osteosarcoma (OS) MG-63; Saos-2 cells Piceatannol (Pice) treatment downregulated 32901863 4987 Human hsa-miR-21 miRNA celastrol ovarian cancer (OC) human ovarian carcinoma cells celastrol treatment downregulated 27840916 4988 Human hsa-miR-21 miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 4989 Human hsa-miR-21 miRNA TGF-¦Â1 ovarian cancer (OC) human fibroblasts TGF-¦Â1 treatment "In primary cultured fibroblasts, mature miR-21 increases after TGF-¦Â1 treatment" 23784029 4990 Human hsa-miR-21 miRNA caudatin oxidative stress human gastric carcinoma cell lines caudatin? treatment downregulated 23708208 4991 Human hsa-miR-21 miRNA titanium dioxide nanoparticles (TiO2 NPs) oxidative stress human lung carcinoma cell line (A549) NPs treatment downregulated 28400205 4992 Human hsa-miR-21 miRNA hypoxia pancreatic cancer (PC) human pancreatic cancer (PC) cells Hypoxia treatment upregulated 23272057 4993 Human hsa-miR-21 miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 4994 Human hsa-miR-21 miRNA propofol (PPF) pancreatic cancer (PC) PANC-1 pancreatic cancer cells Propofol treatment downregulated 27829997 4995 Human hsa-miR-21 miRNA epidermal growth factor (EGF) pancreatic ductal adenocarcinoma (PDAC) PANC-1 cells epidermal growth factor (EGF) treatment upregulated 30464258 4996 Human hsa-miR-21 miRNA H2O2 pancreatic ductal adenocarcinoma (PDAC) primary human pancreatic stellate cells (PSCs) ?H2O2 treatment upregulated 29854071 4997 Human hsa-miR-21 miRNA N-acetyl-L-cysteine (NAC) pancreatic ductal adenocarcinoma (PDAC) ?H2O2-treated primary human pancreatic stellate cells (PSCs) N-acetyl-L-cysteine (NAC) treatment downregulated 29854071 4998 Human hsa-miR-21 miRNA resveratrol pancreatic ductal adenocarcinoma (PDAC) ?H2O2-treated primary human pancreatic stellate cells (PSCs) resveratrol (Res) treatment downregulated 29854071 4999 Human hsa-miR-21 miRNA matrine papillary thyroid cancer (PTC) TPC-1 cells matrine treatment downregulated 30127885 5000 Human hsa-miR-21 miRNA docosahexaenoic acid (DHA) parkinson's disease (PD) SH-Y5Y cells docosahexaenoic acid (DHA) treatment downregulated 28346830 5001 Human hsa-miR-21 miRNA high glucose (HG) peritoneal fibrosis human peritoneal mesothelial cell lines HMrSV5 cells high glucose (HG) treatment upregulated 29207016 5002 Human hsa-miR-21 miRNA glucocorticoid (GC) polymyositis (PM) PM patients glucocorticoids upregulated 26873848 5003 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) postoperative peritoneal adhesion (PPA) The human peritoneal mesothelium cells (HPMCs) lipopolysaccharide (LPS) treatment the effect of Cox-2 on LPS induced HPMCs injury was achieved by negatively regulation of miR-21 and targeted TLR4 through NF-¦ÊB pathway axis. 31885500 5004 Human hsa-miR-21 miRNA vitamin D preeclampsia (PE) HTR-8/SVneo cells Vitamin D treatment downregulated 31068287 5005 Human hsa-miR-21 miRNA emodin pressure ulcer (PU) HaCaT cells Emodin treatment upregulated 31250665 5006 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) pressure ulcer (PU) HaCaT cells lipopolysaccharide (LPS) treatment downregulated 31250665 5007 Human hsa-miR-21 miRNA "4', 5, 7-trihydroxy-3', 5'-dimethoxyflavone (Tricin)" prostate cancer PC3 cell line "4', 5, 7-Trihydroxy-3', 5'-dimethoxyflavone (Tricin) treatment" downregulated 29447469 5008 Human hsa-miR-21 miRNA docetaxel (DTX) prostate cancer "The human androgen-insensitive prostate carcinoma cell line, PC3" docetaxel (DTX) treatment upregulated 20581857 5009 Human hsa-miR-21 miRNA hyperoside and quercetin in combination (QH; 1:1) prostate cancer human prostate cancer cells QH treatment downregulated 25354548 5010 Human hsa-miR-21 miRNA methylated urolithin A prostate cancer human prostate cancer cells Methylated urolithin A treatment downregulated 27725205 5011 Human hsa-miR-21 miRNA TGF-¦Â prostate cancer HASCs TGF-¦Â treatment upregulated 19816956 5012 Human hsa-miR-21 miRNA ¦Á-solanine prostate cancer human prostate cancer cell PC-3 ¦Á-solanine treatment downregulated 25116803 5013 Human hsa-miR-21 miRNA methotrexate (MTX) psoriasis chronic plaque-type psoriasis patients PBMCs methotrexate (MTX) treatment downregulated in plasma 27535005 5014 Human hsa-miR-21 miRNA tumor necrosis factor alpha (TNF-¦Á) psoriasis HaCaT and NHEKs cell lines tumor necrosis factor alpha (TNF-¦Á) treatment "MEG3/miR-21 axis may regulate the expression of caspase-8, and further influence the proliferation and apoptosis of psoriasis keratinocyte, Act-HaCaT and Act- HHEK" 31660855 5015 Human hsa-miR-21 miRNA SB431542 lung fibrosis IMR-90 cells SB431542 treatment "miR-21 expression was promoted by single TGF¦Â1 treatment, whereas reduced by SB431542" 30213983 5016 Human hsa-miR-21 miRNA hypoxia pulmonary hypertension (PH) human pulmonary artery smooth muscle cell hypoxia treatment upregulated 29198701 5017 Human hsa-miR-21 miRNA hypoxia pulmonary hypertension (PH) human pulmonary microvascular endothelial cells (HPECs) hypoxia treatment miR-21 was upregulated in the hypoxia-treated HPECs and its conditioned media in a time-dependent manner. 30449992 5018 Human hsa-miR-21 miRNA berberine (BBR) pulpitis LPS treated human dental pulp fibroblast (HDPF) berberine (BBR) treatment upregulated 31837588 5019 Human hsa-miR-21 miRNA lipopolysaccharide (LPS) pulpitis human dental pulp fibroblast (HDPF) lipopolysaccharide (LPS) treatment downregulated 31837588 5020 Human hsa-miR-21 miRNA gemcitabine (GEM) renal cell carcinoma (RCC) Panc-1 cells gemcitabine treatment downregulated 23564788 5021 Human hsa-miR-21 miRNA eupatilin renal cell carcinoma (RCC) 786-O cells Eupatilin treatment downregulated 31179326 5022 Human hsa-miR-21 miRNA insulin-like growth factor 1 (IGF-1) renal cell carcinoma (RCC) human renal cell carcinoma cell IGF-I treatment upregulated 28453463 5023 Human hsa-miR-21 miRNA metformin (Met) renal cell carcinoma (RCC) CAKI-1 and CAKI-2 cells Metformin (MET) treatment downregulated 26496641 5024 Human hsa-miR-21 miRNA sorafenib (SOR) renal cell carcinoma (RCC) "Human RCC cell lines, OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P" sorafenib treatment GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis 29895198 5025 Human hsa-miR-21 miRNA angiotensin II (Ang II) renal fibrosis HK-2 cells angiotensin II (Ang II) treatment upregulated 31611175 5026 Human hsa-miR-21 miRNA bone morphogenetic protein 4 (BMP4) renal fibrosis vascular smooth muscle cell (vSMC) ?bone morphogenetic protein 4 (BMP4)? treatment upregulated 22158624 5027 Human hsa-miR-21 miRNA high glucose (HG) renal interstitial fibrosis (RIF) human kidney-2 (HK-2) cells high glucose (HG) treatment upregulated 31389582 5028 Human hsa-miR-21 miRNA pure total flavonoids from Smilax glabra Roxb (PTFS) renal interstitial fibrosis (RIF) HK-2 cells pure total flavonoids from Smilax glabra Roxb (PTFS) treatment PTFS treatment inhibited TGF-¦Â1-induced EMT progress by blocking miR-21/PTEN/PI3K/Akt signaling 30304552 5029 Human hsa-miR-21 miRNA Smilax glabra Roxb (PTFS) renal interstitial fibrosis (RIF) TGF-¦Â1-treated HK-2 cells Smilax glabra Roxb (PTFS) treatment downregulated 30304552 5030 Human hsa-miR-21 miRNA hypoxia/reoxygenation (H/R) renal ischemia/reperfusion (I/R) injury HK-2 cell hypoxia/reoxygenation upregulated 27030384 5031 Human hsa-miR-21 miRNA hypoxia renal ischemia/reperfusion (I/R) injury human umbilical vein endothelial cells hypoxia (1% O2 for 24 hours) upregulated 28737660 5032 Human hsa-miR-21 miRNA aspirin residual platelet reactivity DAMI cell aspirin treatment Aspirin induces the modulation of platelet miR-21 expression levels. 30046765 5033 Human hsa-miR-21 miRNA doxorubicin (DOX) glioblastomas (GBMs) "GBM cell lines A172, U87MG" DOX treatment downregulated 25628933 5034 Human hsa-miR-21 miRNA IL-34 rheumatoid arthritis (RA) fibroblast-like synovial cells (FLS) of RA and OA patients IL-34 treatment upregulated 27084907 5035 Human hsa-miR-21 miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 5036 Human hsa-miR-21 miRNA mitomycin C (MMC) scar adhesion after joint surgery primary fibroblasts mitomycin C (MMC) treatment MMC induced apoptosis of fibroblasts and decreased the expression of miR-21. 31669961 5037 Human hsa-miR-21 miRNA brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) cell senescence SH-SY5Y cells brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment upregulated 27525675 5038 Human hsa-miR-21 miRNA cardio-pulmonary bypass (CPB) severe lung injury lung cardiopulmonary bypass (CPB) treatment upregulated 25347932 5039 Human hsa-miR-21 miRNA hepatitis C virus (HCV) short bowel syndrome (SBS) human liver hepatitis C virus (HCV) infection downregulated 20625373 5040 Human hsa-miR-21 miRNA arsenite skin cancer HaCaT arsenic (As) exposure upregulated 28069514 5041 Human hsa-miR-21 miRNA "high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)" skin fibrosis human skin fibroblast HF-LED-RL at 320 and 640?J/cm2 radiation downregulated 30182520 5042 Human hsa-miR-21 miRNA ultraviolet (UV) irradiation skin pigmentation disorders melanocytes exosome ultraviolet (UV) irradiation treatment upregulated 31909885 5043 Human hsa-miR-21 miRNA TGF-¦Â1 skin wound healing HaCaT cells TGF-¦Â1 treatment upregulated 27735045 5044 Human hsa-miR-21 miRNA rapamycin squamous cell carcinoma (SCC) HUVECs Rapamycin treatment Rapamycin treatment increased the expression of miR-21 in HUVECs 23313253 5045 Human hsa-miR-21 miRNA low-dose ionizing radiation (LDIR) stress response human Epstein-Barr virus-infected B-cells (EBV-B) low-dose ionizing radiation (LDIR) treatment upregulated 26809544 5046 Human hsa-miR-21 miRNA rapamycin subependymal giant cell astrocytoma (SEGA) primary cultures of SEGA-derived cells rapamycin (mTOR) treatment upregulated 30509037 5047 Human hsa-miR-21 miRNA hydroxychloroquine systemic lupus erythematosus (SLE) "mesangial cells, T cells, pDCs, PBMCs, and the urine" hydroxychloroquine treatment "lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs." 24121037 5048 Human hsa-miR-21 miRNA prednisone systemic lupus erythematosus (SLE) "mesangial cells, T cells, pDCs, PBMCs, and the urine" prednisone treatment "lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs" 24121037 5049 Human hsa-miR-21 miRNA IL-1¦Â systemic sclerosis (SSc) fibroblasts IL-1¦Â treatment "Performing microRNA (miRNA) inhibition experiments in the presence of TGF-¦Â1, we showed that the pro-fibrotic effect of IL-1¦Â may be mediated by a miRNA-21/TGF-¦Â receptor II axis" 33662666 5050 Human hsa-miR-21 miRNA TGF-¦Â testicular lesion human renal glomerular mesangial cells TGF¦Â treatment upregulated 22879939 5051 Human hsa-miR-21 miRNA baicalin (BAI) cell differentiation human lung fibroblasts baicalin (BAI) treatment "Baicalein diminished the expression of miR-21, and miR-21 mimics partially antagonized the effects of baicalein." 30201452 5052 Human hsa-miR-21 miRNA hypoxia transplacental clastogenic and epigenetic effects pancreatic cancer cells hypoxia treatment Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells 23726431 5053 Human hsa-miR-21 miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment upregulated 24396484 5054 Human hsa-miR-21 miRNA carboplatin (CBP) triple negative breast cancer (TNBC) human TNBC cell lines MDA©\MB©\231 and BT©\ 20 carboplatin (CBP) treatment miR-21 overexpression led to promoted cancer cells proliferation and improved cancer cell viability under carboplatin treatment. 31033015 5055 Human hsa-miR-21 miRNA folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) triple negative breast cancer (TNBC) TNBC cell line MDA-MB-231 folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) treatment downregulated 33405856 5056 Human hsa-miR-21 miRNA folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) triple negative breast cancer (TNBC) "TNBC cell line ,MDAMB-231" folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) treatment downregulated 33405856 5057 Human hsa-miR-21 miRNA rapamycin tuberous sclerosis complex (TSC) serum rapamycin (mTOR) treatment upregulated 30509037 5058 Human hsa-miR-21 miRNA TGF-¦Â renal fibrosis tubular epithelial cells (TECs) TGF-¦Â treatment upregulated 21852586 5059 Human hsa-miR-21 miRNA "IL-1¦Â, IFN-¦Ã and TNF-¦Á" type 1 diabetes mellitus (T1DM) INS-1 832/13 beta cells "a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h" upregulated 28280903 5060 Human hsa-miR-21 miRNA IL-1¦Â and TNF-¦Á type 2 diabetes mellitus (T2DM) human pancreatic islets IL-1¦Â and TNF-¦Á treatment upregulated 20086228 5061 Human hsa-miR-21 miRNA metformin (Met) type 2 diabetes mellitus (T2DM) human umbilical vein endothelial cells (HUVECs) metformin treatment downregulated 28230206 5062 Human hsa-miR-21 miRNA statins unstable angina (UA) plasma statins? treatment downregulated 26474612 5063 Human hsa-miR-21 miRNA ailanthone (AIL) vestibular schwannomas (VSs) human primary vestibular schwannomas (VSs) cells ailanthone (AIL) treatment miR-21 was lowly expressed in AIL-treated cells. 29298734 5064 Human hsa-miR-21 miRNA centrin gene deleted Leishmania donovani parasites (LdCen?/?) visceral leishmaniasis human macrophages LdCen-/- parasites infection LdCen-/- infection suppresses the expression of microRNA-21 (miR-21) in human macrophages compared to LdWT infection. 31608064 5065 Human hsa-miR-21 miRNA TGF-¦Â1 wound healing mesenchymal stem cells (MSCs) TGF-¦Â1 treatment Higher TGF-¦Â1concentrations (1¨C10 ng/ml) in the culture medium led to reduced miR-21 expression 32080965 5066 Human hsa-miR-21 miRNA estradiol breast cancer MCF-7 breast cancer cells Estradiol treatment downregulated 19264808 5067 Human hsa-miR-21 miRNA TGF-¦Â1 cardiac hypertrophy HaCaT cell TGF-¦Â1 treatment upregulated 21647251 5068 Human hsa-miR-21 miRNA arsenite epithelial-mesenchymal transition (EMT) human bronchial epithelial cells ?Arsenite treatment upregulated 24004609 5069 Human hsa-miR-21 miRNA curcumin (Cur) hepatocellular carcinoma (HCC) Rko cells; HCT116 cells curcumin (diferuloylmethane)? treatment downregulated 20815812 5070 Human hsa-miR-21 miRNA cisplatin (DDP) liver fibrosis A549 cell cisplatin (DPP) treatment downregulated 23485110 5071 Human hsa-miR-21 miRNA hypoxia pulmonary artery smooth muscle cell proliferation and migration pulmonary artery smooth muscle cell (PASMC) hypoxia treatment upregulated 20693317 5072 Human hsa-miR-21* miRNA granulocyte-macrophage colony stimulating factor (GM-CSF) allergic inflammation Peripheral blood eosinophils GM-CSF treatment "the increased in vitro viability of GM-CSF-treated eosinophils and upregulated expression of miRNA-21* (miR-21*), a complementary miRNA of miR-21, in GM-CSF-treated eosinophils." 22698984 5073 Human hsa-miR-210 miRNA hypoxia hepatocellular carcinoma (HCC) HEK (humanembryonic kidney) 293T;SMMC-7721; Huh-7 cells Hypoxia treatment upregulated 22144109 5074 Human hsa-miR-210 miRNA radiation radiation enteropathy intestinal samples;fibrotic cultured cells radiation treatment miR-210 overexpression 24290534 5075 Human hsa-miR-210 miRNA sulfated polysaccharide that inhibits angiogenesis(WSS25) adipogenesis HMEC-1 cells WSS25 treatment down-regulating microRNA-210 23322395 5076 Human hsa-miR-210 miRNA gemcitabine (GEM) advanced pancreatic cancer (PC) BxPC-3 cells gemcitabine (GEM) treatment Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. 31713003 5077 Human hsa-miR-210 miRNA connective tissue growth factor (CTGF) angiogenesis human synovial fibroblasts CTGF treatment upregulated 25341039 5078 Human hsa-miR-210 miRNA hypoxia angiogenesis K562 cells£» ¦Â-thalassemia/HbE progenitor cells ?hypoxia treatment upregulated 23623309 5079 Human hsa-miR-210 miRNA rosuvastatin apoptosis factor-¦Á induced human mesenchymal stem cells (MSCs) rosuvastatin treatment upregulated 25620256 5080 Human hsa-miR-210 miRNA IL-13 asthma human bronchial epithelial cells (NHBE) IL-13 treatment upregulated 31386204 5081 Human hsa-miR-210 miRNA hypoxia autophagy human colon cancer cell lines SW480;SW620 cells hypoxia treatment upregulated 25385144 5082 Human hsa-miR-210 miRNA hypoxia breast cancer SKBR-3 cells; MCF-7 cells; MDA-MB-231 cells hypoxia treatment upregulated 32945512 5083 Human hsa-miR-210 miRNA hypoxia breast cancer breast adenocarcinoma cell line MCF7£» hepatoblastoma cell line Hep3B; uterine cervix adenocarcinoma cell line HeLa£» renal cancer cell line RCC4 Hypoxia treatment upregulated 18316553 5084 Human hsa-miR-210 miRNA trastuzumab or lapatinib breast cancer patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer chemotherapy combin either trastuzumab or lapatinib treatment upregulated 25086636 5085 Human hsa-miR-210 miRNA hypoxia tumorigenesis neural progenitor cells (NPCs) ?hypoxia treatment upregulated 23039253 5086 Human hsa-miR-210 miRNA natural compound 1'S-1'-acetoxychavicol acetate (ACA) cervical cancer (CC) human cervical cancer cells Ca Ski and SiHa ACA downregulated 28401751 5087 Human hsa-miR-210 miRNA hepatitis B virus (HBV) chronic hepatitis B virus (HBV) infection peripheral blood monocytes (PBMs) and serum of patients with CHB hepatitis B virus (HBV) infection downregulated 30592291 5088 Human hsa-miR-210 miRNA acute exercise chronic kidney disease (CKD) blood acute exercise treatment downregulated 26475583 5089 Human hsa-miR-210 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human bronchial epithelial cells (HBECs) cigarette smoke extract (CSE) treatment upregulated 26563733 5090 Human hsa-miR-210 miRNA hypoxia colorectal cancer (CRC) "CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)" 1 and 0.2% oxygen upregulated 28207045 5091 Human hsa-miR-210 miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 5092 Human hsa-miR-210 miRNA surgery and chemotherapy colorectal cancer (CRC) patients blood surgery and chemotherapy for 3years treatment upregulated 24310813 5093 Human hsa-miR-210 miRNA high glucose (HG) diabetic retinopathy (DR) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 32498701 5094 Human hsa-miR-210 miRNA hypoxia endometriosis CRL-7566 cells hypoxia treatment upregulated 26914112 5095 Human hsa-miR-210 miRNA paraquat (PQ) epithelial-mesenchymal transition (EMT) human lung adenocarcinoma epithelial cells (A549) paraquat (PQ) treatment upregulated 28699703 5096 Human hsa-miR-210 miRNA erythropoietin (EPO) erythroid cell differentiation The original UT-7 cell line erythropoietin treatment upregulated 18492109 5097 Human hsa-miR-210 miRNA hypoxia esophageal cancer (EC) Eca-109 and HEK 293t/17 cells under hypoxic conditions in ESCC treatment upregulated 25069478 5098 Human hsa-miR-210 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 5099 Human hsa-miR-210 miRNA hypoxia gastric cancer (GC) gastric cancer cell line AGS cells hypoxia treatment upregulated 26548949 5100 Human hsa-miR-210 miRNA phosphatase of regenerating liver-3 (PRL-3) gastric cancer (GC) Gastric cancer cell line AGS Phosphatase of regenerating liver-3 (PRL-3) treatment upregulated 26548949 5101 Human hsa-miR-210 miRNA hypoxia gastroesophageal cancer (GEC) ESCC and AC cell lines Hypoxia treatment upregulated 26851030 5102 Human hsa-miR-210 miRNA hypoxia glioblastoma multiforme (GBM) human glioma cell lines U87;SHG44 hypoxia treatment upregulated 24930954 5103 Human hsa-miR-210 miRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) L02 cells hypoxia treatment downregulated 32155285 5104 Human hsa-miR-210 miRNA zeaxanthin dipalmitate (ZD) hepatic tissue-repairing human adipose-derived mesenchymal stem cells (hADMSCs) ZD treatment upregulated 27983913 5105 Human hsa-miR-210 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hepatocellular carcinoma (HCC) neural progenitor cells (NPCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 23039253 5106 Human hsa-miR-210 miRNA nickel oxide nanoparticles (NiO NPs) hepatocellular carcinoma (HCC) HepG2 cells Nickel oxide nanoparticles (NiO-NPs) treatment upregulated 31812053 5107 Human hsa-miR-210 miRNA transarterial chemoembolization (TACE) hepatocellular carcinoma (HCC) HCC patients plasma transarterial chemoembolization treatment upregulated in serum 24935355 5108 Human hsa-miR-101 miRNA influenza A virus (IAV) host-Influenza A virus (IAV) infection A549 cells "The X-31 virus, a reassortant between PR8 and A/Aichi/68(H3N2) IAV strain ifection" downregulated 32326380 5109 Human hsa-miR-210 miRNA hypoxia cell proliferation Primary human pulmonary arterial smooth muscle cells (HPASMC) hypoxia treatment "miR-210 as a hypoxia-inducible miRNA both in vitro and in vivo, which inhibits pulmonary vascular smooth muscle cell apoptosis in hypoxia by specifically repressing E2F3 expression." 22886504 5110 Human hsa-miR-210 miRNA hypoxia hypoxia-induced injury C28/I2 human chondrocytes hypoxia treatment upregulated 24790587 5111 Human hsa-miR-210 miRNA hypoxia hypoxia-induced cell death human umbilical vein endothelial cells (HUVEC) hypoxia treatment both ROD1 mRNA and protein were down-modulated upon hypoxia in a miR-210 dependent manner. ROD1 targeting by miR-210 was biologically significant: the rescue of ROD1 inhibition significantly increased hypoxia-induced cell death 23024754 5112 Human hsa-miR-210 miRNA hypoxia hypoxia-induced renal tubular cell apoptosis human renal tubular HK-2 cells hypoxia treatment upregulated 29387863 5113 Human hsa-miR-210 miRNA hypoxia idiopathic pulmonary fibrosis (IPF) IPF fibroblasts hypoxia treatment upregulated 24951777 5114 Human hsa-miR-210 miRNA hypoxia non-small cell lung cancer (NSCLC) HNSCC hypoxia?treatment the level of hsa-miR-210 was significantly correlated with other markers of hypoxia 20187102 5115 Human hsa-miR-210 miRNA hypoxia kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection human KS-derived SLK and SLKK cells hypoxia treatment upregulated 28046107 5116 Human hsa-miR-210 miRNA paclitaxel (PTX) laryngeal cancer laryngeal cancer cell line hep2 Paclitaxel treatment the most markedly expression-changed 23826416 5117 Human hsa-miR-210 miRNA leishmania leishmaniasis ?human primary macrophages Leishmania (L.) infection upregulated 24098824 5118 Human hsa-miR-210 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 5119 Human hsa-miR-210 miRNA sodium selenite hepatocellular carcinoma (HCC) HLF cells sodium selenite treatment "miR-210 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM" 32656599 5120 Human hsa-miR-210 miRNA pemetrexed lung adenocarcinoma (LUAD) serum pemetrexed treatment "Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations" 26687391 5121 Human hsa-miR-210 miRNA epigallocatechin-3-gallate (EGCG) lung cancer lung cancer cells Green tea polyphenol EGCG treatment upregulated 21965273 5122 Human hsa-miR-210 miRNA lipopolysaccharide (LPS) lupus nephritis (LN) HK-2 cells lipopolysaccharide (LPS) treatment miR-210 level in LPS-treated cells was elevated by ALK. 30372870 5123 Human hsa-miR-210 miRNA hypoxia myocardial infarction (MI) human mesenchymal stem cells (hMSCs) hypoxia treatment upregulated 23388440 5124 Human hsa-miR-210 miRNA hypoxia myocardial infarction (MI) human cardiosphere-derived cells (CDCs) exosomes hypoxia induce upregulated 29243842 5125 Human hsa-miR-210 miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) HK1 cell line concentration treatment dysregulated 24896104 5126 Human hsa-miR-210 miRNA melatonin nickel toxicity BEAS-2B cells melatonin treatment "NiCl2 induced a sharp increase in miR210 expression, while melatonin treatment signifi- cantly repressed miR210 overexpression." 32566089 5127 Human hsa-miR-210 miRNA vascular endothelial growth factor (VEGF) obesity haematopoietic stem cells (HSCs) vascular endothelial growth factor? treatment upregulated 22360314 5128 Human hsa-miR-210 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) apoptosis primary cardiomyocytes oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 29461605 5129 Human hsa-miR-210 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" osteonecrosis of femoral head (ONFH) SONFH tissues (ONs) and the adjacent normal tissues (NLs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26805628 5130 Human hsa-miR-210 miRNA lipopolysaccharide (LPS) otitis media with effusion (OME) human middle ear epithelial cells (HMEECs) lipopolysaccharide (LPS) treatment the miR-210 level is significantly reduced in culture supernatant of lipopolysaccharide (LPS) treated human middle ear epithelial cells (HMEECs). 33248692 5131 Human hsa-miR-210 miRNA lipopolysaccharide (LPS) otitis media with effusion (OME) human middle ear epithelial cells (HMEECs) lipopolysaccharides (LPS) treatment downregulated 33248692 5132 Human hsa-miR-210 miRNA hypoxia ovarian cancer (OC) "OVCAR-3 , SK-OV-3 EOC cell lines" hypoxia treatment upregulated 24715221 5133 Human hsa-miR-210 miRNA sevoflurane (SEV) ovarian cancer (OC) SKOV3 cells sevoflurane treatment "miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane" 33673181 5134 Human hsa-miR-210 miRNA CoCl2 ovulation and corpus luteum (CL) formation human primary (hGLCs) and immortalized (SVOG) granulosa-lutein cells CoCl2 treatment upregulated 29301980 5135 Human hsa-miR-210 miRNA hypoxia ovulation and corpus luteum (CL) formation human primary (hGLCs) and immortalized (SVOG) granulosa-lutein cells hypoxia induce upregulated 29301980 5136 Human hsa-miR-210 miRNA ginsenoside Rb1 oxidative stress H2O2-treated human endothelial EA.hy926 cells Ginsenoside Rb1 (Rb1) treatment upregulated 31359794 5137 Human hsa-miR-210 miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 upregulated 28367268 5138 Human hsa-miR-210 miRNA H2O2 oxidative stress Human endothelial EA.hy926 cells H2O2 treatment downregulated 31359794 5139 Human hsa-miR-210 miRNA morin oxidative stress A549 cells upon traffic PM2.5 exposure Morin treatment downregulated 31284452 5140 Human hsa-miR-210 miRNA particulate matter (PM2.5) oxidative stress A549 cells traffic PM2.5 treatment upregulated 31284452 5141 Human hsa-miR-210 miRNA curcumin-derived analogue CDF pancreatic cancer (PC) human pancreatic cancer (PC) cells curcumin-derived analogue CDF treatment downregulated 23272057 5142 Human hsa-miR-210 miRNA gemcitabine (GEM) pancreatic cancer (PC) BxS and PANC-1 cells Gemcitabine (GEM) treatment upregulated 31713003 5143 Human hsa-miR-210 miRNA hypoxia pancreatic cancer (PC) "PC cell lines (AsPC-1, BxPC-3, MIAPaCa-2, PANC-1, Su86.86 and SW1990)" hypoxia treatment upregulated 22672828 5144 Human hsa-miR-210 miRNA hypoxia pancreatic cancer (PC) PANC-1 cells hypoxia induce upregulated 31875764 5145 Human hsa-miR-210 miRNA lapatinib and 5-fluorouracil (5-Fu) pancreatic cancer (PC) PANC-1 and MIA PaCa-2 cells lapatinib and 5-FU treatment upregulated 26998056 5146 Human hsa-miR-210 miRNA hypoxia preeclampsia (PE) placental hypoxia treatment upregulated 27746364 5147 Human hsa-miR-210 miRNA hypoxia pregnancy complication preeclampsia trophoblasts hypoxia treatment upregulated 31616934 5148 Human hsa-miR-210 miRNA hypoxia prostate cancer "NCaP, 22RV1, and PC3" hypoxia treatment Hypoxia-induced miR-210 expression can contribute to prostate cancer. 31975433 5149 Human hsa-miR-210 miRNA hypoxia prostate cancer human prostate fibroblasts (HPFs) hypoxia treatment upregulated 25091736 5150 Human hsa-miR-210 miRNA radiation radiation enteropathy enteropathy and fibrotic cultured cells radiation treatment upregulated 24290534 5151 Human hsa-miR-210 miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment upregulated 26640557 5152 Human hsa-miR-210 miRNA hypoxia squamous cell carcinoma (SCC) SCC2 and SCC38 cell lines hypoxia treatment upregulated 28099149 5153 Human hsa-miR-210 miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment upregulated 24396484 5154 Human hsa-miR-210 miRNA hypoxia tumor-initiating cells (TICs) activation HCT116 cells;HT29 cells;LS174t cells hypoxia treatment upregulated 27589845 5155 Human hsa-miR-210 miRNA propranolol (PRO) Von Hippel-Lindau (VHL) disease VHL patients plasma administered 120 mg propranolol daily treatment downregulated 28662711 5156 Human hsa-miR-210 miRNA trastuzumab H1N1 influenza virus infection Plasma trastuzumab treatment upregulated 22370716 5157 Human hsa-miR-210 miRNA hypoxia cardiac hypertrophy SMMC-7721 cells; HepG2 cells; HuH7 cells hypoxia?treatment downregulated 22387901 5158 Human hsa-miR-210-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) angiogenesis Endothelial progenitor cells (EPCs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31164807 5159 Human hsa-miR-210-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31680642 5160 Human hsa-miR-210-3p miRNA cytomegalovirus (CMV) cytomegalovirus infection plasma Cytomegalovirus (CMV) treatment upregulated 27684416 5161 Human hsa-miR-210-3p miRNA hypoxia elective intrauterine growth restriction (sIUGR) The human extravillous trophoblast cell line HTR©\8/SVneo hypoxia induce upregulated 30993882 5162 Human hsa-miR-210-3p miRNA hypoxia endometriosis primary endometrial stromal cells (ESCs) and Ishikawa cells hypoxia induce upregulated 30760709 5163 Human hsa-miR-210-3p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment upregulated 25129238 5164 Human hsa-miR-210-3p miRNA candida albicans (C. albicans) inflammatory response THP-1 cells candida albicans infection upregulated 28454101 5165 Human hsa-miR-210-3p miRNA cisplatin (DDP) ovarian cancer (OC) SKOV-3 cells cisplatin treatment downregulated 30957179 5166 Human hsa-miR-210-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 5167 Human hsa-miR-210a miRNA liraglutide type 2 diabetes mellitus (T2DM) serum liraglutide treatment upregulated 33008044 5168 Human hsa-miR-211 miRNA hypoxia angiogenesis human umbilical vein endothelial cells (HUVEC) hypoxia induce downregulated 31589383 5169 Human hsa-miR-211 miRNA hypoxia-inducible factor 1¦Á (HIF-1¦Á) angiogenesis human umbilical vein endothelial cells (HUVEC) hypoxia-inducible factor 1¦Á (HIF-1¦Á) treatment downregulated 31589383 5170 Human hsa-miR-211 miRNA vemurafenib melanoma A375 melanoma cells vemurafenib treatment upregulated 28445987 5171 Human hsa-miR-211 miRNA 4-nitroquinoline 1-oxide (4NQO) oral squamous cell carcinoma (OSCC) human oral squamous cell carcinoma (OSCC) cells 4-nitroquinoline 1-oxide (4NQO) treatment upregulated 27221705 5172 Human hsa-miR-211 miRNA IL-1¦Â osteoarthritis (OA) chondrocyte IL-1¦Â treatment miR-211 expression could be significantly inhibited by IL-1¦Â stimulation. 30005876 5173 Human hsa-miR-211 miRNA ligustrazine (Lig) ovarian cancer (OC) "SK-OV-3 , OVCAR-3 cells" Ligustrazine (Lig) treatment LSZ could significantly increase the expression of miR-211 in both SK-OV-3 and OVCAR-3 33245099 5174 Human hsa-miR-211 miRNA gemcitabine (GEM) pancreatic cancer (PC) human Pancreatic Cancer tissue gemcitabine treatment upregulated 23155457 5175 Human hsa-miR-211 miRNA ultraviolet (UV) irradiation repigmentation outcomes human melanocytes UVB treatment downegulated 31985026 5176 Human hsa-miR-211 miRNA lipopolysaccharide (LPS) sepsis rats lung tissues lipopolysaccharide (LPS) treatment downregulated 28901393 5177 Human hsa-miR-211 miRNA lipopolysaccharide (LPS) spinal cord injury (SCI) normal human astrocytes (NHAs) lipopolysaccharide (LPS) treatment downregulated 28790168 5178 Human hsa-miR-2113 miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment downregulated 29393545 5179 Human hsa-miR-2113 miRNA high glucose (HG) diabetic retinopathy (DR) MIO-M1 cells high glucose (HG) treatment downregulated 29654764 5180 Human hsa-miR-211-3p miRNA lipopolysaccharide (LPS) endoplasmic reticulum stress (ERS) ccultured human skin fibroblasts lipopolysaccharide (LPS) treatment downregulated 31221950 5181 Human hsa-miR-2115? miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 5182 Human hsa-miR-211-5p miRNA hepatitis B virus X protein (HBx) HBV-associated hepatocellular carcinoma (HCC) HepG2.2.15 cells HBx-induce upregulated 31880390 5183 Human hsa-miR-211-5p miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2.2.15 cells hepatitis B virus (HBV) infection upregulated 31880390 5184 Human hsa-miR-211-5p miRNA BRAF melanoma melanoma cell lines MML-1 and A375 BRAF treatment upregulated 28684402 5185 Human hsa-miR-211-5p miRNA vemurafenib melanoma A375 cells vemurafenib treatment upregulated 29229605 5186 Human hsa-miR-211-5p miRNA alpinetin (ALP) oral squamous cell carcinoma (OSCC) Human OSCC cell lines (CAL-27 and TCA-8113) alpinetin (ALP) treatment upregulated 31403340 5187 Human hsa-miR-211-5p miRNA lipopolysaccharide (LPS) osteoarthritis (OA) C28/I2 cells lipopolysaccharide (LPS) treatment "KCNQ1OT1 and TCF4 were highly expressed in the cartilage tissues of patients with OA and C28/I2 cells treated with LPS (OA cells), whereas miR-211-5p was downregulated concomitantly in OA tissues and cells." 33747189 5188 Human hsa-miR-211-5p miRNA benzo(a)pyrene (BaP) toxicity of Benzo[a]pyrene (BaP) THBEc1 cells benzo(a)pyrene (BaP) exposure downregulated 32681969 5189 Human hsa-miR-211-5p miRNA IL-1¦Â and IFN-¦Ã type 1 diabetes mellitus (T1DM) human islets (IL-1¦Â+IFN-¦Ã) treatment downregulated 31277072 5190 Human hsa-miR-2116-3p miRNA omeprazole barrett's esophagus Barrett's esophagus (BE) organoids omeprazole treatment upregulated 30705106 5191 Human hsa-miR-2116-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 5192 Human hsa-miR-212 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y; IMR-32 cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 32474742 5193 Human hsa-miR-212 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29174964 5194 Human hsa-miR-212 miRNA hypoxia blood-brain barrier (BBB) dysfunction human brain microvascular endothelial cells (BMEC) hypoxia induce upregulated 30617994 5195 Human hsa-miR-212 miRNA 4?-12-O-tetradecanoylphorbol-13-acetate (TPA) carcinoma of nasopharyngeal epithelial (CNE) NSCLC cell lines 4?-12-O-tetradecanoylphorbol-13-acetate (TPA) treatment upregulated 22357618 5196 Human hsa-miR-212 miRNA doxorubicin (DOX) cardiotoxicity human iPSC-derived cardiomyocytes doxorubicin treatment "In vitro, overexpression of the pro-hypertrophic miR-212/132 cluster in primary rodent and human iPSC-derived cardiomyocytes inhibited doxorubicin-induced toxicity." 30527757 5197 Human hsa-miR-212 miRNA angiotensin II (Ang II) cardiovascular disease (CVD) HEK293N (AT1R-HEK) cells angiotensin II (Ang II) treatment upregulated 21449976 5198 Human hsa-miR-212 miRNA imatinib chronic myeloid leukemia (CML) human immortalized myelogenous leukemia line K-562 cells imatinib treatment downregulated 22241070 5199 Human hsa-miR-212 miRNA lipopolysaccharide (LPS) delayed union of femoral neck fracture MG-63 cells lipopolysaccharide (LPS) treatment downregulated 33725277 5200 Human hsa-miR-212 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) human gastric cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 21053104 5201 Human hsa-miR-212 miRNA ionizing radiation (IR) glioblastoma multiforme (GBM) U251 cells irradiation treatment miR-212 is downregulated in human glioma U251 cells following irradiation. 29286157 5202 Human hsa-miR-212 miRNA hepatitis B virus (HBV) HBV-infection-related liver diseases serum hepatitis B virus (HBV) infection upregulated 31608838 5203 Human hsa-miR-212 miRNA lactobacillus plantarum dy-1 (LFBE) hepatocellular carcinoma (HCC) HepG2 cells Lactobacillus plantarum dy-1 (LFBE) treatment LFBE and VA normalized the upregulaton of miR-212. 30369345 5204 Human hsa-miR-212 miRNA angiotensin II (Ang II) hypertension human breast artery tissues angiotensin II (Ang II) treatment upregulated 23712358 5205 Human hsa-miR-212 miRNA brain-derived neurotrophic factor (BDNF) neuronal development HeLa? cells brain-derived neurotrophic factor (BDNF) treatment upregulated 20307261 5206 Human hsa-miR-212 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 29611404 5207 Human hsa-miR-212 miRNA alcohol gut leakiness Caco-2 cells; colon biopsy tissue alcohol exposure upregulated 18162065 5208 Human hsa-miR-212* miRNA brain-derived neurotrophic factor (BDNF) neuronal development HeLa? cells brain-derived neurotrophic factor (BDNF) treatment upregulated 20307261 5209 Human hsa-miR-212-3p miRNA macrocalyxin C gastric cancer (GC) "AGS, MKN45, SGC7901 cells" macrocalyxin C treatment upregulated 31726103 5210 Human hsa-miR-212-3p miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) Huh7 cells paclitaxel (PTX) treatment downregulated 32774496 5211 Human hsa-miR-212-3p miRNA mycobacterium tuberculosis (Mtb) latent tuberculosis infection (LTBI) peripheral blood mononuclear cells (PBMCs) of TB patients and individuals with LTBI Mycobacterium tuberculosis (M.tb) infection upregulated 31082644 5212 Human hsa-miR-212-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1-treatment treatment upregulated 29557526 5213 Human hsa-miR-212-3p miRNA zoledronic acid (ZA) osteosarcoma (OS) The KHOS/NP and U2OS OS cell lines Zoledronic acid (ZOL) treatment upregulated 31752184 5214 Human hsa-miR-212-3p miRNA IL-1¦Â preterm labour human myometrial smooth muscle cells interleukin (IL)1B treatment upregulated 30892651 5215 Human hsa-miR-212-3p miRNA IL-6 preterm labour human myometrial smooth muscle cells IL-6 treatment upregulated 30892651 5216 Human hsa-miR-212-3p miRNA helicobacter pylori (H. pylori) sophageal carcinogenesis human esophageal cell line HET-1A Helicobacter pylori infection miR-212-3p was significantly decreased in HET-1A cells exposure to H. pylor. 30783439 5217 Human hsa-miR-212-5p miRNA H2O2 abdominal aortic aneurysm (AAA) human vascular smooth muscle cells (VSMCs) H2O2 treatment LINC00473 inhibits vascular smooth muscle cell viability to promote aneurysm formation via miR-212-5p/BASP1 axis. 31954705 5218 Human hsa-miR-212-5p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) NCI-H292 cells cigarette smoke extract (CSE) treatment downregulated 30695677 5219 Human hsa-miR-212-5p miRNA candida albicans (C. albicans) and aspergillus fumigatus (A. fumigatus) fungal infection human monocyte-derived dendritic cells 6 and 12 h of infection with C. albicans and A. fumigatus as well as treatment with lipopolysaccharides (LPS) dysregulated 28280489 5220 Human hsa-miR-21-3p miRNA lipopolysaccharide (LPS) age-related macular degeneration (AMD) human retinal pigment epithelial (ARPE-19) cells lipopolysaccharide (LPS) treatment upregulated 31330059 5221 Human hsa-miR-21-3p miRNA berberine (BBR) breast cancer estrogen receptor (ER)¦Á(+) MCF-7 breast cancer cells berberine (BBR) treatment upregulated 29143794 5222 Human hsa-miR-21-3p miRNA IL-4 chronic lymphocytic leukemia (CLL) Peripheral blood Interleukin 4 (IL-4) treatment upregulated 25909590 5223 Human hsa-miR-21-3p miRNA TGF-¦Â chronic obstructive pulmonary disease (COPD) primary parenchymal lung fibroblasts TGF-¦Â treatment upregulated 28910321 5224 Human hsa-miR-21-3p miRNA high glucose (HG) diabetic atherosclerosis Human aortic VSMCs; vascular endothelial cells (VECs) high glucose (HG) treatment The high-glucose medium induced the downregulated of ADAM10 via excessive production of miR-21-3p in the vascular endothelial cells (VECs). 32196704 5225 Human hsa-miR-21-3p miRNA D-glucose diabetic foot ulcer (DFU) Human skin fibroblasts D-glucose treatment miR-21-3p may treat DFU by reducing SPRY1. 32634115 5226 Human hsa-miR-21-3p miRNA chlorpromazine (CHLO) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) treatment upregulated 31198949 5227 Human hsa-miR-21-3p miRNA cyclosporine A (CsA) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) cyclosporine A (CYCA) treatment upregulated 31198949 5228 Human hsa-miR-21-3p miRNA ¦Á-naphthylisothiocyanate (ANIT) drug-induced liver injury (DILI) upcyte hepatocytes ¦Á-naphthyl isothiocyanate (ANIT) treatment upregulated 31198949 5229 Human hsa-miR-21-3p miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 5230 Human hsa-miR-21-3p miRNA oxidized glycerophospholipids (oxGPs) and IL-1¦Â inflammation human aortic endothelial cells (HAECs) oxGPs and interleukin 1¦Â (IL-1¦Â) treatment upregulated 25327529 5231 Human hsa-miR-21-3p miRNA "OTX015 (MK-8628, birabresib)" lymphomagenesis DOHH-2 cells; OCI-LY-1 cells OTX015 treatment OTX015 upregulates miR-96-5p in a time-dependent manner. 30076183 5232 Human hsa-miR-21-3p miRNA platinum-based chemotherapy ovarian tumours ovarian cancer cell line A2780 cisplatin and carboplatin treatment upregulated 25579119 5233 Human hsa-miR-21-3p miRNA ultraviolet (UV) irradiation skin inflammation epidermis UV exposure treatment upregulated 27250636 5234 Human hsa-miR-214 miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK2 cells Lipopolysaccharide (LPS) treatment DANCR Suppressed Lipopolysaccharide-Induced Septic Acute Kidney Injury by Regulating miR-214 in HK-2 Cells 32222722 5235 Human hsa-miR-214 miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning upregulated 30602960 5236 Human hsa-miR-214 miRNA berberine (BBR) alveolar bone regeneration human alveolar osteoblasts (HAOBs) berberine (BBR) treatment miR-214 was reduced as BBR concentrations increased. 32688361 5237 Human hsa-miR-214 miRNA berberine (BBR) alveolar bone regeneration primary human alveolar osteoblasts (HAOBs) berberine (BBR) treatment downregulated 32688361 5238 Human hsa-miR-214 miRNA isoflurane anesthesia-induced neural cytotoxicity human neuroblastoma cell line SH-SY5Y Isoflurane treatment downregulated 31704096 5239 Human hsa-miR-214 miRNA ginsenoside Rg1 angiogenesis human umbilical vein endothelial cells (HUVECs) ginsenoside-Rg1 treatment downregulated 19733659 5240 Human hsa-miR-214 miRNA Korean Red ginseng extract (KRGE) angiogenesis HUVECs korean red ginseng extract (KRGE)? treatment downregulated 29021694 5241 Human hsa-miR-214 miRNA IFN-¦Ã autophagy human hepatoma Huh7 cells IFN-¦Ë treatment upregulated 28131804 5242 Human hsa-miR-214 miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) human bone marrow stromal cells (BMSC) dexamethasone (DEX) treatment upregulated 31678133 5243 Human hsa-miR-214 miRNA zirconia and titanium bone formation Osteoblast-like cells (MG63) zirconia and titanium? treatment upregulated 18241218 5244 Human hsa-miR-214 miRNA tamoxifen (TAM) breast cancer MCF-7 breast cancer cells tamoxifen treatment upregulated 30072833 5245 Human hsa-miR-214 miRNA tamoxifen (TAM) breast cancer MCF-7 breast cancer cells tamoxifen treatment upregulated 30072833 5246 Human hsa-miR-214 miRNA lipopolysaccharide (LPS) calcific aortic valve disease (CAVD) aortic valve interstitial cells (AVICs) lipopolysaccharide (LPS) treatment upregulated 30519780 5247 Human hsa-miR-214 miRNA H2O2 cataract SRA01/04 cell lines H2O2 treatment downregulated 28535504 5248 Human hsa-miR-214 miRNA hypoxia chronic obstructive pulmonary disease (COPD) pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment upregulated 27381447 5249 Human hsa-miR-214 miRNA hypoxia chronic obstructive pulmonary disease (COPD) pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment upregulated 28684904 5250 Human hsa-miR-214 miRNA 5-aza-2'-deoxycytidine and trichostatin A colonic inflammation Squamous cell carcinoma (SCC) cell line 5-aza-deoxycytidine and trichostatin A treatment downregulated 22828925 5251 Human hsa-miR-214 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) Two colon cancer cell lines were used: HT-29 and LoVo 5-fluorouracil (5-FU) treatment "miR-214 is downregulated in 5-FU-resistant colon cancer cells compared to normal cells. In vitro, miR-214 could sensitize non-resistant colon cancer cells and 5-FU-resistant colon cancer cellsto 5-FU." 30915129 5252 Human hsa-miR-214 miRNA high glucose (HG) diabetic corneal endothelial keratopathy HCEC-B4G12 cells treatment downregulated 31693400 5253 Human hsa-miR-214 miRNA high glucose (HG) diabetic nephropathy (DN) Human proximal tubular epithelial cells HK2 high glucose (HG) treatment upregulated 31240704 5254 Human hsa-miR-214 miRNA TGF-¦Â endothelium-dependent vasorelaxation HT-29 cells TGF-¦Â treatment downregulated 23483606 5255 Human hsa-miR-214 miRNA steroids eosinophilic esophagitis (EoE) esophageal mucosal tissue Steroids treatment upregulated 22815788 5256 Human hsa-miR-214 miRNA astragaloside IV (AS-IV) gastric cancer (GC) gastric cancer-associated fibroblast (GCAF) astragaloside (AS-IV) treatment upregulated 29358859 5257 Human hsa-miR-214 miRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells cisplatin treatment upregulated 29456019 5258 Human hsa-miR-214 miRNA hypoxia gastric cancer (GC) human gastric cancer cells hypoxia treatment upregulated 29129783 5259 Human hsa-miR-214 miRNA hypoxia gastric cancer (GC) MKN-45 cells hypoxia induce upregulated 29129783 5260 Human hsa-miR-214 miRNA carvedilol heart failure (HF) serum carvedilol treatment upregulated 32943906 5261 Human hsa-miR-214 miRNA H2O2 cardiac dysfunction human cardiomyocyte (HCM) H2O2 treatment downregulated 28849090 5262 Human hsa-miR-214 miRNA heat shock factor 1 (HSF1) huntington's disease (HD) Blood Heat shock factor 1 (HSF1) treatment downregulated 26634350 5263 Human hsa-miR-214 miRNA dexamethasone (DEX) left ventricular hypertrophy (LVH) human articular chondrocytes and immortalized costal chondrocytes (TC28 cells) dexamethasone (DEX) treatment downregulated 31180556 5264 Human hsa-miR-214 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 5265 Human hsa-miR-214 miRNA dexamethasone (DEX) miRNA biogenesis human endothelial cells dexamethasone (Dex) treatment downregulated 28523344 5266 Human hsa-miR-214 miRNA ginsenoside Rg1 miRNA biogenesis human endothelial cells ginsenoside-Rg1 treatment downregulated 28523344 5267 Human hsa-miR-214 miRNA ¦Â-glycerophosphate + ascorbic acid + dexamethasone osteogenesis human Bone marrow mesenchymal stem cells (BMSCs) "10 mM ¦Â-glycerophosphate (Sigma-Aldrich, USA), 200 ¦ÌM ascorbic acid (Sigma-Aldrich, USA) and 100 nM dexamethasone (Sigma-Aldrich, USA) treatment" KCNQ1OT1 was significantly upregulated during the process of osteogenic induction while miR-214 was contrarily downregulated 30703347 5268 Human hsa-miR-214 miRNA curcumin (Cur) ovarian cancer (OC) cisplatin-resistant A2780cp cells curcumin treatment downregulated 28175963 5269 Human hsa-miR-214 miRNA TGF-¦Â ovarian cancer (OC) A2780 cells; SKOV3 cells TGF-¦Â treatment Knockdown of DANCR Suppressed the Biological Behaviors of Ovarian Cancer Cells Treated with Transforming Growth Factor-¦Â (TGF-¦Â) by Sponging MiR-214 32417846 5270 Human hsa-miR-214 miRNA ethanol (EtOH) oxidative stress "human hepatoma cell (Bel7402), human embryonic kidney 293 cell (HEK293)," ethanol (EtOH) treatment upregulated 23905773 5271 Human hsa-miR-214 miRNA lipopolysaccharide (LPS) sepsis THP-1 cell line lipopolysaccharide (LPS) treatment downregulated 30896848 5272 Human hsa-miR-214 miRNA advanced glycation end product (AGE) apoptosis THP-1 cells advanced glycation end products (AGEs) treatment "Overexpression of pre¨CmiR-214 led to impaired PTEN expression and delayed apoptosis of THP-1 cells, whereas knockdown of miR-214 level largely abolished AGE-induced cell survival." 21228352 5273 Human hsa-miR-214 miRNA dexamethasone (DEX) steroid-induced avascular necrosis of femoral head (SANFH) human bone marrow stromal cells (BMSC) dexamethasone (DEX) treatment upregulated 31678133 5274 Human hsa-miR-214 miRNA Bt2cAMP type II pneumocyte differentiation cultured human fetal lung (HFL) epithelial cells Bt2cAMP treatment downregulated 29507184 5275 Human hsa-miR-214 miRNA IL-6 ulcerative colitis (UC) NCM460 cells IL-6 treatment upregulated 31382166 5276 Human hsa-miR-214 miRNA limonin ulcerative colitis (UC) IL-6-treated NCM460 cells limonin treatment downregulated 31382166 5277 Human hsa-miR-214 miRNA coxsackievirus B3 (CVB3) viral myocarditis (VM) plasma and myocardial cells coxsackievirus B3 (CVB3) treatment upregulated 25815880 5278 Human hsa-miR-214 miRNA hypoxia pulmonary arterial hypertension (PAH) Pulmonary artery smooth muscle cells (hPASMCs) hypoxia treatment upregulated 27144530 5279 Human hsa-miR-214-3p miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment downregulated 33197504 5280 Human hsa-miR-214-3p miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease. 33197504 5281 Human hsa-miR-214-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment Circ_CHFR contributed to the progression of AS through the miR-214-3p/Wnt3/¦Â-catenin signals. 32271446 5282 Human hsa-miR-214-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cells (HVSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33818550 5283 Human hsa-miR-214-3p miRNA high glucose (HG) brain injury in diabetes mellitus (DM) SH-SY5Y cells high glucose (HG) treatment MicroRNA-214-3p (miR-214-3p) was decreased in HG-treated cells. 32910484 5284 Human hsa-miR-214-3p miRNA melatonin brain injury in diabetes mellitus (DM) SH-SY5Y cells melatonin (MEL) treatment "MicroRNA-214-3p (miR-214-3p) was decreased in DM mice and HG-treated cells, and such a downregulated was corrected by melatonin" 32910484 5285 Human hsa-miR-214-3p miRNA bone morphogenetic protein 2 (BMP2) cell differentiation maxillary sinus membrane stem cells (MSMSCs) bone morphogenetic protein 2 (BMP2) treatment Hsa_circRNA_33287 promotes the osteogenic differentiation of maxillary sinus membrane stem cells via miR-214-3p/Runx3. 30551425 5286 Human hsa-miR-214-3p miRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment downregulated 30355944 5287 Human hsa-miR-214-3p miRNA high glucose (HG) diabetic cataract (DC) Human lens epithelial (HLE) B-3 cells ?high glucose (HG) induce treatment lncRNA?PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via miR-214-3p/MMP2 axis 31755246 5288 Human hsa-miR-214-3p miRNA high glucose (HG) diabetic cataract (DC) Human lens epithelial (HLE) B-3 cells high glucose (HG) treatment downregulated 31755246 5289 Human hsa-miR-214-3p miRNA "3,3'5-tri-iodo-L-thyronine (T3)" hepatocellular carcinoma (HCC) HepG2 cells "3,3'5-tri-iodo-L-thyronine (T3) treatment" upregulated 29093516 5290 Human hsa-miR-214-3p miRNA oleacein (OA) melanoma 501Mel melanoma cells oleacein (OA) treatment downregulated 33071785 5291 Human hsa-miR-214-3p miRNA bisphenol A (BPA) nasopharyngeal carcinoma (NPC) CNE1 cell; 5-8F cells bisphenol A (BPA) treatment BPA treatment also decreased the expression of miR-214-3p in both CNE1 and 5-8F cells. 32360864 5292 Human hsa-miR-214-3p miRNA bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) neuroblastoma (NB) neuroblastoma cells bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment downregulated 25498991 5293 Human hsa-miR-214-3p miRNA bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) neurological disorders SK-N-SH cells bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment downregulated 25498991 5294 Human hsa-miR-214-3p miRNA cisplatin (DDP) oral squamous cell carcinoma (OSCC) "The normal human oral keratinocyte (NHOK) and OSCC cell lines, including TSCCA, CAL-27, SCC-9, and Tca8113" cisplatin treatment downregulated 31275988 5295 Human hsa-miR-214-3p miRNA gemcitabine (GEM) pancreatic cancer (PC) PANC-1 and SW 1990 cells gemcitabine (GEM) treatment downregulated 31632071 5296 Human hsa-miR-214-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 33071725 5297 Human hsa-miR-214-3p miRNA high glucose (HG) peritoneal dialysis (PD) human peritoneal mesothelial cells (HPMCs) high-glucose (HG) upregulated 28428333 5298 Human hsa-miR-214-3p miRNA hypoxia renal fibrosis HK-2 cells hypoxia treatment upregulated 29277613 5299 Human hsa-miR-214-3p miRNA hypoxia renal fibrosis ?HK-2?cells hypoxia induce upregulated 29277613 5300 Human hsa-miR-214-5p miRNA hypoxia cervical cancer (CC) HeLa and C-33A cells hypoxia induce downregulated 33394293 5301 Human hsa-miR-214-5p miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment upregulated 30503955 5302 Human hsa-miR-214-5p miRNA IL-1¦Â osteoarthritis (OA) human primary chondrocytes IL-1¦Â treatment "The results showed that SNHG7 was distinctly downregulated, while miR-214-5p was significantly upregulated in OA patients and primary chondrocytes treated with IL-1¦Â." 33296783 5303 Human hsa-miR-214-5p miRNA IL-1¦Â osteoarthritis (OA) primary chondrocytes IL-1¦Â treatment SNHG7 prevents IL-1¦Â induced OA by inhibiting NLRP3 inflammasome and apoptosis through miR-214-5p/PPARGC1B axis. 33296783 5304 Human hsa-miR-214-5p miRNA dexamethasone (DEX) postmenopausal osteoporosis (PMOP) human bone marrow stem cells (BMSCs) dexamethasone (DEX) treatment upregulated 29532880 5305 Human hsa-miR-215 miRNA hypoxia colorectal cancer (CRC) "Cancer stem cells, also known as tumor-initiating cells (TICs)" hypoxia induce upregulated 30790680 5306 Human hsa-miR-215 miRNA adriamycin (ADR) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) subcel adriamycin (ADR) treatment upregulated 26135967 5307 Human hsa-miR-215 miRNA curcumin (Cur) non-small cell lung cancer (NSCLC) H460 and A427 cells curcumin treatment upregulated 25444916 5308 Human hsa-miR-215 miRNA "Trans10,cis12 conjugated linoleic acid (t10,c12 CLA)" ovarian cancer (OC) ovarian cancer cell lines SKOV-3 and A2780 "Trans10,cis12 conjugated linoleic acid (t10,c12 CLA) treatment" upregulated 29324748 5309 Human hsa-miR-215 miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed upregulated 27915273 5310 Human hsa-miR-215 miRNA lipopolysaccharide (LPS) ulcerative colitis (UC) CCD-18Co cells lipopolysaccharide (LPS) treatment knockdown of miR-215 alleviated oxidative stress and inflammatory response in LPS-treated CCD-18Co cells by upregulating GDF11 expression and inactivating the TLR4/NF-¦ÊB and JNK/p38 signaling pathways. 33146403 5311 Human hsa-miR-215-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 5312 Human hsa-miR-215-5p miRNA melatonin colorectal cancer (CRC) "Human colon cancer cell lines HCT116, SW480, COLO320, DLD-1, HT29, RKO, CaCO2, and SW620" melatonin treatment upregulated 30590435 5313 Human hsa-miR-215-5p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 5314 Human hsa-miR-215-5p miRNA exercise (Ex) physiological impairments associated with aging circulating exosomes exercise treatment upregulated 32587527 5315 Human hsa-miR-215-5p miRNA particulate matter (PM2.5) PM2.5-induced carcinogenesis human bronchial epithelial (HBE) cells fine particulate matter (PM2.4) treatment upregulated 33545377 5316 Human hsa-miR-215-5p miRNA IL-17A psoriasis HaCaT cells IL-17A treatment downregulated 32881074 5317 Human hsa-miR-215-5p miRNA IL-22 psoriasis HaCaT cells IL-22 treatment downregulated 32881074 5318 Human hsa-miR-215-5p miRNA IL-6 psoriasis HaCaT cells IL-6?treatment downregulated 32881074 5319 Human hsa-miR-215-5p miRNA imiquimod (IMQ) psoriasis skin tissues imiquimod (IMQ) treatment The expression of miR-215-5p was downregulated in imiquimod (IMQ)-treated skin tissues. 32881074 5320 Human hsa-miR-21-5p miRNA immunoglobulin E (IgE) airway remodeling human primary airway smooth muscle cell (ASMC) immunoglobulin E (IgE) treatment upregulated 30781615 5321 Human hsa-miR-21-5p miRNA anabolic-androgenic ateroids (AASs) anabolic-Androgenic Steroids (AASs)-induced renal damage kidney tissues anabolic-androgenic ateroids (AASs) treatment upregulated 33041804 5322 Human hsa-miR-21-5p miRNA high glucose (HG) angiogenesis human retinal microvascular endothelial cells (HRMECs) high glucose treatment upregulated 29658404 5323 Human hsa-miR-21-5p miRNA KHCO3 bone resorption of alkali human serum potassium bicarbonate [(KHCO3); 81 mmol/d; n = 12] vs placebo (n = 12) for 84 days upregulated in serum 29264553 5324 Human hsa-miR-21-5p miRNA ethanol extract of antrodia cinnamomea (AC) breast cancer MCF-7 and tamoxifen-resistant MCF-7 cells ethanol extract of antrodia cinnamomea (AC) treatment upregulated 29743060 5325 Human hsa-miR-21-5p miRNA brucella Omp25 brucellosis human Monocyte/Macrophages brucella Omp25 treatment upregulated 28694807 5326 Human hsa-miR-21-5p miRNA hepatitis C virus (HCV) chronic hepatitis C virus (HCV) infection "hepatic tissues from HCV-infected patients, Huh-7 cells" hepatitis C virus (HCV) infection upregulated 30938910 5327 Human hsa-miR-21-5p miRNA IL-4 chronic lymphocytic leukemia (CLL) Peripheral blood Interleukin 4 (IL-4) treatment upregulated 25909590 5328 Human hsa-miR-21-5p miRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment GAS5 could competitively bind with miR-21-5p and miR-21-5p inhibition alleviated the beneficial effects of GAS5 knockdown against HG stimulation. 31865425 5329 Human hsa-miR-21-5p miRNA high glucose (HG) diabetic cardiomyopathy (DCM) human cardiomyocyte-like AC16 cells high glucose (HG) treatment downregulated 31865425 5330 Human hsa-miR-21-5p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial ARPE-19 cells high-glucose (HG) treatment "XIST, likely through competitive binding of hsa-miR-21-5p, provides protection against hyperglycemia-associated injury in human retinal pigment epithelial cells." 32106367 5331 Human hsa-miR-21-5p miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 5332 Human hsa-miR-21-5p miRNA saponin extract endometriosis human endometrial stromal cells (HESCs) obtained from patients with endometriosis saponin extract treatment downregulated 28558522 5333 Human hsa-miR-21-5p miRNA atorvastatin endothelial senescence ox-LDL treated HUVECs atorvastatin treatment downregulated 29248491 5334 Human hsa-miR-21-5p miRNA oxidized low density lipoprotein (ox-LDL) endothelial senescence HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29248491 5335 Human hsa-miR-21-5p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) SMMC-7721 cells-derived exosomes TGF-¦Â1 treatment upregulated 33194074 5336 Human hsa-miR-21-5p miRNA ethanol (EtOH) ethanol-induced neuroinflammation and brain damage plasma exosomes ethanol treatment downregulated 32937997 5337 Human hsa-miR-21-5p miRNA hypoxia flap surgeries human umbilical vein endothelial cells (HUVEC) hypoxia treatment upregulated 28880208 5338 Human hsa-miR-21-5p miRNA hematoporphyrin glioblastoma multiforme (GBM) U87 glioma cells hematoporphyrin treatment upregulated 29344634 5339 Human hsa-miR-21-5p miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment upregulated 30503955 5340 Human hsa-miR-21-5p miRNA radiochemotherapy head and neck squamous cell carcinoma (HNSCC) ?blood plasma radiochemotherapy?treatment treatment "six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)" 24373621 5341 Human hsa-miR-21-5p miRNA TGF-¦Â1 hepatocarcinogenesis Hep3B cells TGF-¦Â1 treatment upregulated 32269736 5342 Human hsa-miR-21-5p miRNA curcumin (Cur) hepatocellular carcinoma (HCC) Hep3B cells; Huh-7 cells curcumin treatment miR-21-5p level was decreased in curcumin-treated cells. 32757994 5343 Human hsa-miR-21-5p miRNA atorvastatin hyperlipidemia HUVECs atorvastatin treatment downregulated 29248491 5344 Human hsa-miR-21-5p miRNA oxidized low density lipoprotein (ox-LDL) hyperlipidemia HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29248491 5345 Human hsa-miR-21-5p miRNA metformin (Met) hypopharyngeal cancer human hypopharyngeal carcinoma cell line (FaDu) metformin treatment downregulated 27688683 5346 Human hsa-miR-21-5p miRNA electron beam (EB) irradiation keloids keloid fibroblast Electron beam (EB) irradiation downregulated 31558773 5347 Human hsa-miR-21-5p miRNA electron beam (EB) irradiation keloids keloid fibroblasts Electron beam (EB) irradiation treatment MiR-21-5p expression was found to be significantly downregulated after keloid fibroblasts were exposed to 20 Gy of EB irradiation. 31558773 5348 Human hsa-miR-21-5p miRNA TGF-¦Â1 liver fibrosis NTCP-Huh7.5.1 cells TGF-¦Â1 treatment TGF-¦Â1 incubation significantly increased miR-21-5p levels 33456536 5349 Human hsa-miR-21-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment TGF-¦Â1 incubation significantly increased miR-21-5p levels 33456536 5350 Human hsa-miR-21-5p miRNA cigarette smoke (CS) lung cancer NCI-H292 cells cigarette smoke (CS) treatment "upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)" 28692419 5351 Human hsa-miR-21-5p miRNA physical exercise myasthenia gravis (MG) MG patients serum performed supervised aerobic and resistance training twice weekly for 12 weeks treatment downregulated 27935072 5352 Human hsa-miR-21-5p miRNA prednisone myasthenia gravis (MG) serum prednisone treatment Levels of miR-21-5p displayed a negative correlation with the prednisone dose within the prednisone-only group 29511707 5353 Human hsa-miR-21-5p miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment downregulated 31452742 5354 Human hsa-miR-21-5p miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 5355 Human hsa-miR-21-5p miRNA ovatodiolide (OV) oral squamous cell carcinoma (OSCC) cancer stem cell-derived extracellular vesicles (CSC_EVs) generated from CAL27 and SCC-15 OSCC cells ovatodiolide (OV) treatment downregulated 31878245 5356 Human hsa-miR-21-5p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment downregulated 31053150 5357 Human hsa-miR-21-5p miRNA pulsed electromagnetic field (PEMF) osteoblastic differentiation human bone marrow stromal cells (hBMSCs) PEMFs treatment upregulated 28512472 5358 Human hsa-miR-21-5p miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment upregulated 26987780 5359 Human hsa-miR-21-5p miRNA lectin prostate cancer Prostate cancer (PC) cell lines lectin treatment upregulated 26417675 5360 Human hsa-miR-21-5p miRNA radiation prostate cancer serum curative radiotherapy (RT) treatment upregulated 30103771 5361 Human hsa-miR-21-5p miRNA "isoniazid, pyrazinamide and ethambutol" pulmonary tuberculosis (PTB) serum "isoniazid, pyrazinamide and ethambutol treatment" miR-21-5p was downregulated in treated patients when compared with untreated patients. 29523324 5362 Human hsa-miR-21-5p miRNA lipopolysaccharide (LPS) pulpal inflammation human dental pulp cells (hDPCs) lipopolysaccharide (LPS) treatment upregulated 31042008 5363 Human hsa-miR-21-5p miRNA pioglitazone renal fibrosis TGF-¦Â1-treated HK-2 cells Pioglitazone treatment downregulated 31254585 5364 Human hsa-miR-21-5p miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment upregulated 31254585 5365 Human hsa-miR-21-5p miRNA oxidized low density lipoprotein (ox-LDL) cell senescence human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28347692 5366 Human hsa-miR-21-5p miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 5367 Human hsa-miR-21-5p miRNA "IL-1¦Â, IFN-¦Ã and TNF-¦Á" type 1 diabetes mellitus (T1DM) EndoC-¦ÂH1 beta cell lines and human islets "a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h" upregulated 29445851 5368 Human hsa-miR-21-5p miRNA metformin (Met) type 2 diabetes mellitus (T2DM) "SUM159PT, MCF-7, BT-474 and BT-549" metformin treatment downregulated 28698800 5369 Human hsa-miR-216 miRNA photodynamic therapy (PDT) cervical cancer (CC) HeLa cells photody-namic therapy (PDT) treatment upregulated 19953537 5370 Human hsa-miR-216 miRNA chemotherapy colorectal cancer (CRC) serum " modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2 , day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment" dysregulated 24304648 5371 Human hsa-miR-216 miRNA BAY11-7082 helicobacter pylori infection H. pylori infected gastric epithelial cells treated with 10 ¦ÌM Bay 11-7082 upregulated 28208005 5372 Human hsa-miR-216 miRNA emodin ovarian cancer (OC) A2780 cells emodin treatment upregulated 29512773 5373 Human hsa-miR-216 miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 5374 Human hsa-miR-216-3p miRNA metformin (Met) preeclampsia (PE) Trophoblast and HUVEC cells Metformin (Met) treatment upregulated 31203154 5375 Human hsa-miR-216a miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) downregulated 31784954 5376 Human hsa-miR-216a miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment downregulated 31784954 5377 Human hsa-miR-216a miRNA ginsenoside Rb2 inflammation human umbilical vein endothelial cells (HUVECs); human aortic endothelial cells Ginsenoside Rb2 (Rb2) treatment Rb2 decreased the expression of endogenous miR-216a. 33786633 5378 Human hsa-miR-216a miRNA lipopolysaccharide (LPS) macrophage polarization THP-1 derived macrophage 1 ng/ml lipopolysaccharide (LPS) and 20 ng/ml interferon (IFN)-¦Ã treatment upregulated 29940270 5379 Human hsa-miR-216a miRNA dihydrotestosterone (DHT) prostate cancer LNCaP cells dihydrotestosterone treatment upregulated 26506397 5380 Human hsa-miR-216a-3p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2R cells curcumin treatment upregulated 31793078 5381 Human hsa-miR-216a-5p miRNA H2O2 asthma human bronchial epithelial cell (16HBE) H2O2 treatment downregulated 30502088 5382 Human hsa-miR-216a-5p miRNA H2O2 asthma 16HBE cells H2O2 treatment downregulated 30502088 5383 Human hsa-miR-216a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31029709 5384 Human hsa-miR-216a-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose treatment ZEB1-AS1 suppressed HG-induced EMT and fibrogenesis by regulating miR-216a-5p and BMP-7. 32294702 5385 Human hsa-miR-216a-5p miRNA hypoxia hypoxia-induced injury ?12 soft tissue sarcoma cell lines was exposed to 1% oxygen (hypoxia) for up to 48 h treatment upregulated 24927770 5386 Human hsa-miR-216a-5p miRNA treponema pallidum (T. pallidum) infection syphilis plasma Treponema pallidum (T. pallidum) infectionn treatment downregulated 31358689 5387 Human hsa-miR-216b miRNA Cetuximab colorectal cancer (CRC) CRC cells cetuximab treatment downregulated 27158405 5388 Human hsa-miR-216b miRNA ethanol extract of Salviamiltiorrhiza (SM) endoplasmic reticulum stress (ERS) U266 and U937 cells ethanol extract of Salviamiltiorrhiza (SM) treatment upregulated 29671785 5389 Human hsa-miR-216b miRNA cigarette smoke condensate (CSC) non-small cell lung cancer (NSCLC) HPL1A cells cigarette smoke condensate (CSC) treatment upregulated 32668597 5390 Human hsa-miR-216b miRNA paclitaxel (PTX) non-small cell lung cancer (NSCLC) NSCLC cells paclitaxel treatment downregulated 26852748 5391 Human hsa-miR-216b miRNA IL-1¦Â osteoarthritis (OA) human chondrosarcoma cells (SW1353) IL-1¦Â treatment upregulated 28356485 5392 Human hsa-miR-216b miRNA oxygen glucose deprivation (OGD) spinal cord injury (SCI) human SY-SH-5Y cells oxygen-glucose deprivation treatment "TCTN2 was downregulated in the spinal cord tissues of a rat model of SCI and in oxygen-glucose deprivation-induced hypoxic SY-SH-5Y cells, while microRNA-216b (miR-216b) was upregulated" 31050183 5393 Human hsa-miR-217 miRNA arsenite acceleration of the cell cycle and carcinogenesis HaCaT cells arsenic exposure upregulated 28062277 5394 Human hsa-miR-217 miRNA human cytomegalovirus (HCMV) acute myeloid leukemia (AML) endothelial cells(ECs) Human cytomegalovirus(HCMV)? infection upregulated 24376725 5395 Human hsa-miR-217 miRNA TGF-¦Â1 asthma Human airway smooth muscle cells (ASMCs) transforming growth factor-¦Â (TGF-¦Â1) treatment downregulated 30212709 5396 Human hsa-miR-217 miRNA TGF-¦Â1 asthma human bronchial epithelial cells BEAS-2B TGF-¦Â1 treatment "TGF-¦Â1, GAS5, HDAC4 were upregulated, while miR-217 was downregulated in bronchial mucosal tissues of asthmatic children and TGF-¦Â1-treated BEAS-2B cells" 33864612 5397 Human hsa-miR-217 miRNA high glucose (HG) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) high glucose (HG) treatment miR-217 was found to be upregulated in VSMCs treated by high glucose and aorta VSMCs of diabetic rats. 33283391 5398 Human hsa-miR-217 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 acute monocytic leukemia cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31432137 5399 Human hsa-miR-217 miRNA arsenite bladder cancer Normal bladder SV-HUC-1 cells ?arsenite treatment downregulated 33386469 5400 Human hsa-miR-217 miRNA dasatinib chronic myeloid leukemia (CML) K562 cells dasatinib treatment miR-217 was significantly downregulated in K562 cells. 30195077 5401 Human hsa-miR-217 miRNA baicalin (BAI) colorectal cancer (CRC) DLD1 and HCT-116 cells baicalin (BAI) treatment downregulated 30737617 5402 Human hsa-miR-217 miRNA high glucose (HG) diabetes mellitus (DM) human lymphatic endothelial cells (LECs) high glucose (HG) treatment "GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model." 33865922 5403 Human hsa-miR-217 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment upregulated 31702814 5404 Human hsa-miR-217 miRNA rapamycin endothelial dysfunction human umbilical vein endothelial cells (HUVECs) rapamycin treatment upregulated 29579170 5405 Human hsa-miR-217 miRNA cigarette smoke condensate (CSC) esophageal adenocarcinoma (EAC) esophageal adenocarcinoma (EAC) cells cigarette smoke condensate (CSC) treatment downregulated 25703328 5406 Human hsa-miR-217 miRNA pegylated interferon-¦Á and ribavirin (IFN/RBV) hepatitis C virus (HCV) infection HCV patients IFN/RBV for 12 months treatment upregulated 24033414 5407 Human hsa-miR-217 miRNA orafenib hepatocellular carcinoma (HCC) Huh7; Hep3B; SNU-387; SNU-449 orafenib treatment Lnc HOTAIR could increase sorafenib resistance in HCC by inhibiting miR-217. 32462038 5408 Human hsa-miR-217 miRNA oxidized low density lipoprotein (ox-LDL) inflammatory injury human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment miR-217 ameliorates inflammatory damage of endothelial cells induced by oxidized LDL by targeting EGR1. 32737769 5409 Human hsa-miR-217 miRNA cigarette smoke extract (CSE) lung cancer human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) treatment downregulated 26415832 5410 Human hsa-miR-217 miRNA angiotensin II (Ang II) membranous nephropathy (MN) Conditionally immortalized human podocyte cell line AB8/13 angiotensin II (Ang II) treatment downregulated 30414341 5411 Human hsa-miR-217 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 29218085 5412 Human hsa-miR-217 miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 5413 Human hsa-miR-217 miRNA TGF-¦Â1 pancreatic cancer (PC) "The human pancreatic cancer cell lines BxPC-3, PANC-1" TGF-¦Â1 treatment downregulated 25172416 5414 Human hsa-miR-217 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 31737212 5415 Human hsa-miR-217 miRNA dasatinib and 5-Aza-2'-deoxycytidine chronic myeloid leukemia (CML) K562 cells exposure to dasatinib (10 nM) together with 5-AzadC(0.1 ¦ÌM) treatment upregulated 24350829 5416 Human hsa-miR-217-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells oxidized low-density lipoprotein (OX-LDL) treatment downregulated 31744714 5417 Human hsa-miR-217-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) SH-SY5Y Cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment The level of miR-217-5p was significantly decreased in SH-SY5Y cells following OGD/R treatment 32683553 5418 Human hsa-miR-218 miRNA cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) advanced gastric cancers (AGCs) advanced gastric cancers patients CRS and HIPEC treatment upregulated 25170221 5419 Human hsa-miR-218 miRNA triptolide (TPL) benign prostatic hypertrophy (BPH) BPH-1 cells triptolide (TPL) treatment upregulated 30453799 5420 Human hsa-miR-218 miRNA ionizing radiation (IR) breast cancer breast cancer cells and tissues ionizing radiation treatment upregulated 30429228 5421 Human hsa-miR-218 miRNA cigarette smoke extract (CSE) carcinogenesis of cigarette smoke human bronchial epithelial (HBE) cells cigarette smoke?extract?(CSE) treatment upregulated 25526925 5422 Human hsa-miR-218 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human bronchial epithelial (HBE) cells cigarette smoke?extract?(CSE) treatment downregulated 28864214 5423 Human hsa-miR-218 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment downregulated 31668807 5424 Human hsa-miR-218 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) CSE-treated 16HBE cells cigarette smoke extract (CSE) treatment MiR-218 was downregulated in COPD tissues and CSE-treated or MEG3 overexpressed 16HBE cells. MiR-218 overexpression attenuated CSE-blocked proliferation and CSE-induced apoptosis or inflammation. 31668807 5425 Human hsa-miR-218 miRNA smoking chronic obstructive pulmonary disease (COPD) lung tissues smoking treatment MiR-218 was downregulated in COPD tissues 31668807 5426 Human hsa-miR-218 miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment miR-218 was highly expressed in renal proximal tubule under high-glucose conditions. 32028854 5427 Human hsa-miR-218 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelium (RPE) cells (ARPE-19) high glucose (HG) treatment upregulated 31830266 5428 Human hsa-miR-218 miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 5429 Human hsa-miR-218 miRNA high glucose (HG) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 29693114 5430 Human hsa-miR-218 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26610476 5431 Human hsa-miR-218 miRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells criplatin treatment miR-218 was decreased in cisplatin resistant SGC7901/DDP cells. 30542435 5432 Human hsa-miR-218 miRNA thermo-chemotherapy gastric cancer (GC) SGC7901 cells thermo-chemotherapy treatment upregulated 25694126 5433 Human hsa-miR-218 miRNA propofol (PPF) glioblastoma multiforme (GBM) U373 glioblastoma cell Propofol treatment upregulated 26133092 5434 Human hsa-miR-218 miRNA genistein gliosarcoma human gliosarcoma cells (U251) exposed to genistein (12.5-200 ¦Ìg) for 24 h upregulated 28776680 5435 Human hsa-miR-218 miRNA cigarette smoke condensate (CSC) glomerulosclerosis primary bronchial epithelial cells and H1299 cells cigarette smoke condensate (CSC) treatment mir-218 expression is reduced in primary bronchial epithelium exposed to cigarette smoke condensate (CSC) 19168627 5436 Human hsa-miR-218 miRNA benzophenone-3 (BP-3) hirschsprung's disease (HSCR) maternal urine benzophenone-3 (BP-3) treatment BP-3 influenced cell migration via SLIT2/ROBO1-miR-218-RET/PLAG1 pathway 26454118 5437 Human hsa-miR-218 miRNA cigarette smoke extract (CSE) human bronchial epithelial (HBE) cells injury human bronchial epithelial (HBE) cells cigarette smoke?extract?(CSE) treatment downregulated 25526925 5438 Human hsa-miR-218 miRNA Legionella pneumophila (L. pneumophila) Legionella pneumophila (L. pneumophila) infection u937 cells L. pneumophila infection L. pneumophila infection upregulated the expression of miR-218. 30509489 5439 Human hsa-miR-218 miRNA "1,6,7-trihydroxyxanthone (THA)" hepatocellular carcinoma (HCC) liver cancer cell lines HepG2 "1,6,7-trihydroxyxanthone (THA) treatment" upregulated 25416134 5440 Human hsa-miR-218 miRNA andes hantavirus (ANDV) liver damage human endothelial cells (ECs) andes hantavirus (ANDV) infection downregulated 20844033 5441 Human hsa-miR-218 miRNA andrographolide lung cancer human alveolar epithelial A549 cells andrographolide treatment upregulated 24298938 5442 Human hsa-miR-218 miRNA carboplatin (CBP) lung cancer A549 and H1975 lung cancer cells carboplatin (CBP) treatment downregulated 25917317 5443 Human hsa-miR-218 miRNA cigarette smoke extract (CSE) lung cancer human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) treatment downregulated 27212446 5444 Human hsa-miR-218 miRNA human papilloma virus (HPV) malignant transformation of esophageal epithelial cells Het-1A cells HPV and MNNG treatment downregulated 33189795 5445 Human hsa-miR-218 miRNA andrographolide oral cancer human oral cancer stem cells (OCSCs) andrographolide treatment upregulated 27926533 5446 Human hsa-miR-218 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 29218085 5447 Human hsa-miR-218 miRNA gemcitabine (GEM) pancreatic cancer (PC) PANC-1 cells gemcitabine (GEM) treatment downregulated 26157323 5448 Human hsa-miR-218 miRNA lipopolysaccharide (LPS) periodontitis human periodontal ligament progenitor cells lipopolysaccharide (LPS) treatment downregulated 30444938 5449 Human hsa-miR-218 miRNA Legionella pneumophila (L. pneumophila) pneumonia The human macrophage-like cell line U937 Legionella pneumophila infection upregulated 30509489 5450 Human hsa-miR-218 miRNA hypoxia preeclampsia (PE) cell line HTR-8/Svneo;the trophoblast-derived choriocarcinoma cell line JEG-3 exposed to 0.5% O2 upregulated 28412444 5451 Human hsa-miR-218 miRNA hypoxia renal cell carcinoma (RCC) renal cell carcinoma cell lines hypoxia treatment downregulated 27133059 5452 Human hsa-miR-218 miRNA cisplatin (DDP) small-cell lung cancer (SCLC) NCI-H69 cells cisplatin treatment Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression 31477834 5453 Human hsa-miR-218-2* miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 5454 Human hsa-miR-218-5p miRNA IL-13 asthma human bronchial epithelial (HBE) cells; BEAS-2B cells IL-13 treatment downregulated 31520422 5455 Human hsa-miR-218-5p miRNA IL-13 asthma HBE and BEAS-2B cells interleukin 13 (IL-13) treatment downregulated 31520422 5456 Human hsa-miR-218-5p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 5457 Human hsa-miR-218-5p miRNA cigarette smoke (CS) chronic obstructive pulmonary disease (COPD) plasma cigarette smoke (CS) treatment downregulated 30024625 5458 Human hsa-miR-218-5p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human pulmonary microvascular endothelial cell (HPMECs) cigarette smoke extract (CSE) treatment downregulated 32129458 5459 Human hsa-miR-218-5p miRNA KSHV-encoded viral interferon regulatory factor 1 (vIRF1) kaposi's sarcoma (KS) endothelial cell KSHV-encoded viral interferon regulatory factor 1 (vIRF1) treatment downregulated 30699189 5460 Human hsa-miR-219 miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment upregulated 27158236 5461 Human hsa-miR-219 miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment upregulated 27158236 5462 Human hsa-miR-219 miRNA lactobacillus casei (L. casei LC01) irritable bowel syndrome with diarrhea (IBS-D) intestinal epithelial cells (IECs) L. casei LC01 treatment upregulated 32807750 5463 Human hsa-miR-219-2-3p miRNA 5-aza-2'-deoxycytidine and trichostatin A gastric cancer (GC) human GC cell lines MGC-803; HGC-27; MKN-45; SGC-7901 5-aza-2'-deoxycytidine and trichostatin A treatment downregulated 23637748 5464 Human hsa-miR-219-5p miRNA paraquat (PQ) acute paraquat (PQ) poisoning serum paraquat (PQ) treatment Serum miR-219-5p level was decreased and negatively correlated with TLR4 level in MODS patients. 33233960 5465 Human hsa-miR-219-5p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial (RPE) cells high glucose (HG) treatment miR-219-5p was significantly upregulated by high glucose (HG) treatment. 29749515 5466 Human hsa-miR-219-5p miRNA propofol (PPF) hepatocellular carcinoma (HCC) Huh7 and SMMC7721 cells Propofol treatment upregulated 31104336 5467 Human hsa-miR-219-5p miRNA AgNPs toxicity of silver (Ag) Jurkat T cells AgNPs treatment downregulated 24974767 5468 Human hsa-miR-219-5p miRNA hypoxia wound healing HaCaTs hypoxia treatment MiR-219-5p was markedly increased in hypoxia group. 30338788 5469 Human hsa-miR-21a-5p miRNA chlorpromazine (CHLO) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) treatment upregulated 31198949 5470 Human hsa-miR-22 miRNA paclitaxel (PTX) colorectal cancer (CRC) HT-29 cells; HCT-15 cells Paclitaxel treatment over expression 21594648 5471 Human hsa-miR-22 miRNA IFN-¦Ã graft-versus-host disease (GVHD) Cord blood (CB) interferon-¦Ã treatment downregulated 21913990 5472 Human hsa-miR-22 miRNA L©\arginine acute edematous pancreatitis (AEP) pancreatic acinar cell line (AR42J) introperitoneal injection of L-arginine (150 mg/kg) treatment upregulated 24710937 5473 Human hsa-miR-22 miRNA hypoxia acute kidney injury (AKI) Distal convoluted tubule cells (DCT) hypoxia induce upregulated 29791781 5474 Human hsa-miR-22 miRNA sodium butyrate (NaB) apoptosis Huh 7 cells sodium butyrate treatment upregulated 28288414 5475 Human hsa-miR-22 miRNA high glucose (HG) atherosclerosis (AS) EA.hy926 human endothelial cells (EA.hy926?cells) high glucose treatment Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22. 30591217 5476 Human hsa-miR-22 miRNA myeloperoxidase oxidized LDL (Mox-LDL) atherosclerosis (AS) HUVEC Cells Mox-LDL treatment upregulated 25530680 5477 Human hsa-miR-22 miRNA lipopolysaccharide (LPS) breast cancer 182R-6 fulvestrant-resistant breast cancer line LPS treatment downregulated 30057418 5478 Human hsa-miR-22 miRNA sc-514 (a selective IKK¦Â inhibitor) breast cancer LPS-treated 182R-6 fulvestrant-resistant breast cancer line "sc-514, a selective IKK¦Â inhibitor treatment" upregulated 30057418 5479 Human hsa-miR-22 miRNA "anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)" bronchial epithelial cell cancer human bronchial epithelial cells 16HBE "anti-benzo[a]pyrene-7,8-diol-9,10-epoxide treatment" upregulated 20170724 5480 Human hsa-miR-22 miRNA high glucose (HG) cell pyroptosis EA.hy926 human endothelial cells (EA.hy926?cells) high glucose treatment Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22. 30591217 5481 Human hsa-miR-22 miRNA salidroside (SAL) cell senescence 50 population doubling (PD) of the 2BS cell line isolated from human fetal lung fibroblasts salidroside (SAL) treatment downregulated 31612074 5482 Human hsa-miR-22 miRNA ultraviolet (UV) irradiation cellular stress response Human embryonic kidney cell line HEK293T UV radiation treatment ?UV radiation induces a significant increase of miR-22 expression 22166214 5483 Human hsa-miR-22 miRNA ibrutinib chronic lymphocytic leukemia (CLL) CLL patients paired LN and PB samples ibrutinib treatment downregulated in paired LN and PB samples 27431016 5484 Human hsa-miR-22 miRNA phorbol-12-myristate-13-acetate(PMA) chronic myeloid leukemia (CML) CML cell line K562 20 nM PMA for 48 h in a 25 mm petri dish treatment downregulated 27889568 5485 Human hsa-miR-22 miRNA phorbol-12-myristate-13-acetate(PMA) chronic myeloid leukemia (CML) CML cell line K562 CML cell line K562 treatment upregulation 27889568 5486 Human hsa-miR-22 miRNA butyrate colorectal cancer (CRC) HCT116 and DLD-1 cells butyrate treatment upregulated 30252536 5487 Human hsa-miR-22 miRNA butyrate colorectal cancer (CRC) human colon cancer HCT116 and DLD-1 cells butyrate treatment upregulated 30252536 5488 Human hsa-miR-22 miRNA Pien Tze Huang (PZH) colorectal cancer (CRC) human CRC cell line (HCT-8/5-FU) PZH treatment upregulated 29042944 5489 Human hsa-miR-22 miRNA propionate colorectal cancer (CRC) HCT116 and DLD-1 cells propionate treatment upregulated 30252536 5490 Human hsa-miR-22 miRNA propionate colorectal cancer (CRC) human colon cancer HCT116 and DLD-1 cells propionate treatment upregulated 30252536 5491 Human hsa-miR-22 miRNA retinoic acid (RA) colorectal cancer (CRC) HCT116 and DLD-1 cells retinoic acid (RA) treatment upregulated 30252536 5492 Human hsa-miR-22 miRNA retinoic acid (RA) colorectal cancer (CRC) human colon cancer HCT116 and DLD-1 cells retinoic acid (RA) treatment upregulated 30252536 5493 Human hsa-miR-22 miRNA SAHA colorectal cancer (CRC) human colon cancer HCT116 and DLD-1 cells SAHA treatment upregulated 30252536 5494 Human hsa-miR-22 miRNA suberoylanilide hydroxamic acid (SAHA) colorectal cancer (CRC) HCT116 and DLD-1 cells suberanilohydroxamic acid (SAHA) treatment upregulated 30252536 5495 Human hsa-miR-22 miRNA valerate colorectal cancer (CRC) HCT116 and DLD-1 cells valerate treatment upregulated 30252536 5496 Human hsa-miR-22 miRNA valerate colorectal cancer (CRC) human colon cancer HCT116 and DLD-1 cells valerate treatment upregulated 30252536 5497 Human hsa-miR-22 miRNA "rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" diffuse large B-cell lymphoma (DLBCL) serum "rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) treatment" We showed a significant modulation of serum miR-22 after R-CHOP treatment. 29716630 5498 Human hsa-miR-22 miRNA endosulfan endothelial dysfunction human umbilical vein endothelial cells (HUVECs) endosulfan upregulated 28161397 5499 Human hsa-miR-22 miRNA TGF-¦Â endothelium-dependent vasorelaxation HT-29 cells TGF-¦Â treatment downregulated 23483606 5500 Human hsa-miR-22 miRNA simulated microgravity (SMG) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) simulated microgravity (SMG) treatment upregulated 30017544 5501 Human hsa-miR-22 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 5502 Human hsa-miR-22 miRNA diallyl disulfide (DADS) gastric cancer (GC) Five gastric cancer cell lines (MGC-803; BGC-823; MKN-28; SGC-7901; HGC-27; AGS) diallyl disulfide treatment upregulated 23851184 5503 Human hsa-miR-22 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) "BGC-823, AGS and THP-1 cells" Helicobacter pylori (H. pylori) infection downregulated 29059152 5504 Human hsa-miR-22 miRNA IL-1¦Â gastric cancer (GC) "BGC-823, AGS and THP-1 cells" IL-1¦Â treatment downregulated 29059152 5505 Human hsa-miR-22 miRNA mineral pitch (MP) hepatocellular carcinoma (HCC) Huh-7 cells Mineral Pitch (MP) treatment upregulated 27233240 5506 Human hsa-miR-22 miRNA lipopolysaccharide (LPS) kidney damage HK-2 cells lipopolysaccharide (LPS) treatment downregulated 30130540 5507 Human hsa-miR-22 miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 leukemia cell line 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 20214878 5508 Human hsa-miR-22 miRNA sodium selenite hepatocellular carcinoma (HCC) HLF cells sodium selenite treatment "miR-22 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM" 32656599 5509 Human hsa-miR-22 miRNA haloperidol neuroblastoma (NB) SK-N-SH cell lines haloperidol at 10¦Ìm concentration for 24 hours downregulated 28886082 5510 Human hsa-miR-22 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 5511 Human hsa-miR-22 miRNA perfluorooctane sulfonic acid (PFOS) neurotoxicity SK-N-SH cells PFOS treatment upregulated 28441774 5512 Human hsa-miR-22 miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) L02 cells free fatty acids (FFAs) treatment Free fatty acids induced miR-22 upregulation and lipogenesis in human hepatocytes. 33159388 5513 Human hsa-miR-22 miRNA pemetrexed non-small cell lung cancer (NSCLC) NSCLC tissue pemetrexed treatment upregulated 23794259 5514 Human hsa-miR-22 miRNA quercetin oral lichen planus (OLP) human oral keratinocytes (HOKs) quercetin treatment "Quercetin can mitigate LPS-induced injury in HOKs by downregulating miR-22, thereby activating PI3K/AKT and JAK1/STAT3 cascades" 32329368 5515 Human hsa-miR-22 miRNA arecoline oral squamous cell carcinoma (OSCC) ORL-48(T) and ORL-136(T) cell lines arecoline treatment downregulated 29385191 5516 Human hsa-miR-22 miRNA quercetin oral squamous cell carcinoma (OSCC) Human normal oral keratinocytes (hNOK) and OSCC cell line Tca8113 and SAS cells Quercetin (Que) treatment upregulated 31257059 5517 Human hsa-miR-22 miRNA IL-1 osteoarthritis (OA) primary cultured chondrocytes ?IL-1 treatment miR-22 downregulated in patients with OA 30887601 5518 Human hsa-miR-22 miRNA osteogenic inductive cocktail osteogenesis human periodontal ligament stem cells (PDLSCs) osteogenic inductive cocktail upregulated 28195408 5519 Human hsa-miR-22 miRNA cisplatin (DDP) osteosarcoma (OS) human osteosarcoma cell lines (U-2 OS and MG-63) cisplatin (DDP) treatment upregulated 24609901 5520 Human hsa-miR-22 miRNA doxorubicin (DOX) osteosarcoma (OS) human osteosarcoma cell lines (U-2 OS and MG-63) doxorubicin (DOX) treatment upregulated 24609901 5521 Human hsa-miR-22 miRNA isoflurane ovarian cancer (OC) SKOV3 cells;TOV21G cells isoflurane treatments at 1 and 2 h upregulated 28951521 5522 Human hsa-miR-22 miRNA curcumin (Cur) pancreatic cancer (PC) The BxPC-3 human pancreatic carcinoma cell line curcumin (diferuloylmethane)? treatment upregulated 18347134 5523 Human hsa-miR-22 miRNA zirconia and titanium preosteoblast differentiation Osteoblast-like cells (MG63) zirconia and titanium? treatment downregulated 18241218 5524 Human hsa-miR-22 miRNA Hypoxia pulmonary arterial hypertension (PAH) HepG2 cells Hypoxia treatment downregulated 20110569 5525 Human hsa-mir-22 miRNA hypoxia/reoxygenation (H/R) reperfusion injury Human iPS-derived cardiomyocytes (iPS-CM) hypoxia and hypoxia-reoxygenation treatment upregulated 32826883 5526 Human hsa-miR-22 miRNA curcumin (Cur) retinoblastoma (RB) human Y79 retinoblastoma cells curcumin (CUR) treatment upregulated 22510010 5527 Human hsa-miR-22 miRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury HK-2 cells lipopolysaccharide (LPS) treatment "TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway." 30666657 5528 Human hsa-miR-22 miRNA IL-21 systemic lupus erythematosus (SLE) normal and SLE B cells IL-21 treatment upregulated 25101889 5529 Human hsa-miR-22 miRNA perfluorooctane sulfonic acid (PFOS) toxicity of perfluorooctane sulfonate (PFOS) SH-SY5Y human neuroblastoma cells Perfluorooctane sulfonate (PFOS) treatment upregulated 26649298 5530 Human hsa-miR-22 miRNA vitamin D colorectal cancer (CRC) Human colon cancer SW480-ADH£»HCT116£»HT29£» LS174T£»DLD-1£»SW620£» SW1417£» SW480-R cell lines ?vitamin D? treatment upregulated 22328083 5531 Human hsa-miR-22* miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human retinal pigment epithelial cells TGF-¦Â1 treatment downregulated 25263462 5532 Human hsa-miR-221 miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection HUVECs human immunodeficiency virus-1 (HIV-1) infection downregulated 23555914 5533 Human hsa-miR-221 miRNA prednisolone active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) prednisolone treatment downregulated 24215168 5534 Human hsa-miR-221 miRNA curcumin (Cur) anaplastic thyroid carcinoma (ATC) SW1736 and 8505C curcumin treatment downregulated 29197967 5535 Human hsa-miR-221 miRNA metformin (Met) angiogenesis human endothelial progenitor cells (EPCs) metformin treatment downregulated 31581911 5536 Human hsa-miR-221 miRNA resveratrol anti-inflammatory responses HUVECs treated with TNF-¦Á resveratrol (RS) treatment upregulated 28338009 5537 Human hsa-miR-221 miRNA tumor necrosis factor alpha (TNF-¦Á) anti-inflammatory responses HUVECs tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28338009 5538 Human hsa-miR-221 miRNA TGF-¦Â asthma ASM cells (ASMCs) from patients with severe asthma TGF-¦Â treatment upregulated 23944957 5539 Human hsa-miR-221 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29859752 5540 Human hsa-miR-221 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31565033 5541 Human hsa-miR-221 miRNA hydroquinone (HQ) benzene-induced carcinogenesis hydroquinone (HQ)-transformed 16HBE cells secreted exosomes Hydroquinone (HQ) treatment upregulated 31468561 5542 Human hsa-miR-221 miRNA IFN-¦Ã biliary inflammation H69 cells interferon-gamma treatment downregulated 20110463 5543 Human hsa-miR-221 miRNA necrosis factor related apoptosis-inducing ligand (TRAIL) bladder cancer T24 cells; RT4 cells;SV-HUC-1 cells necrosis factor related apoptosis-inducing ligand (TRAIL) treatment upregulated 19767219 5544 Human hsa-miR-221 miRNA leptin borna disease virus (BDV)?infection human pre-adipocytes leptin treatment downregulated 23756832 5545 Human hsa-miR-221 miRNA tumor necrosis factor alpha (TNF-¦Á) borna disease virus (BDV)?infection human pre-adipocytes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 23756832 5546 Human hsa-miR-221 miRNA adriamycin (ADR) breast cancer MCF-7 cells adriamycin (ADR) treatment upregulated 31899608 5547 Human hsa-miR-221 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment upregulated 33159957 5548 Human hsa-miR-221 miRNA ionizing radiation (IR) breast cancer Blood The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min) upregulated 31150454 5549 Human hsa-miR-221 miRNA TGF-¦Â breast cancer MCF-7 cells MCF-7 cells treatment upregulation 27174021 5550 Human hsa-miR-221 miRNA wound fluids (WFs) from breast cancer patients breast cancer human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line WFs treatment upregulated 28943910 5551 Human hsa-miR-221 miRNA TGF-¦Â1 cancer-associated fibroblasts (CAFs) activation cultured normal fibroblasts (NFs) TGF¦Â1 treatment upregulated 30851420 5552 Human hsa-miR-221 miRNA minocycline (MNC) cell proliferation PDGF-BB-treated human aortic smooth muscle cell (SMC) Minocycline treatment downregulated 30716386 5553 Human hsa-miR-221 miRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation human aortic smooth muscle cell (SMC) platelet-derived growth factor BB homodimer (PDGF-BB) treatment upregulated 30716386 5554 Human hsa-miR-221 miRNA hepatitis C virus (HCV) chronic hepatitis C virus (HCV) infection Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 25019494 5555 Human hsa-miR-221 miRNA TGF-¦Â1 chronic kidney disease (CKD) ?renal tubule epithelial cells TGF-¦Â1 treatment downregulated 26806834 5556 Human hsa-miR-221 miRNA imatinib chronic lymphocytic leukemia (CLL) CML cell lines (K562 and imatinib-resistant K562/G) imatinib treatment "MiR-221 expression was markedly decreased in K562/G cells and peripheral blood mononuclear cells from patients with treatment failure, when compared to imatinib-sensitive CML cells and patients with optimal responses respectively." 30516071 5557 Human hsa-miR-221 miRNA hepatitis C virus (HCV) cognitive impairment monocyte-derived exosome hepatitis C virus (HCV) infection upregulated 32157304 5558 Human hsa-miR-221 miRNA human immunodeficiency virus (HIV)-1 cognitive impairment monocyte-derived exosome human immunodeficiency virus (HIV)-1 infectiom upregulated 32157304 5559 Human hsa-miR-221 miRNA temozolomide (TMZ) colorectal cancer (CRC) "U87MG cells;T98G cells; LN428 cells; LN308 cells; A172 cells; HEK-293 cells cells;LN229 cells;T98G, U87MG, and LN229 ,LN428 cells; LN308 cells; A172 cells" temozolomide (TMZ) treatment upregulated 24147153 5560 Human hsa-miR-221 miRNA microcystin-leucine arginine (MC-LR) colorectal cancer (CRC) colon cell line DLD-1 microcystin-LR (MC-LR) treatment upregulated 30312888 5561 Human hsa-miR-221 miRNA microcystin-leucine arginine (MC-LR) colorectal cancer (CRC) colon cell line DLD-1 microcystin-LR (MC-LR) treatment upregulated 30312888 5562 Human hsa-miR-221 miRNA AS1411 corneal neovascularization (CNV) human limbus stroma (HLSC) AS1411 treatment AS1411 treatment also significantly reduced VEGF-stimulated induction of miR-21 and miR-221 in HLSC. 32081668 5563 Human hsa-miR-221 miRNA estradiol depression MCF7 cells estradiol (E2) treatment miR-221/222 expression is increased in antiestrogen-resistant breast cancer cell lines and is upregulated by fulvestrant in antiestrogen-sensitive MCF7 cells 21057537 5564 Human hsa-miR-221 miRNA diabetes mellitus macrophage-conditioned media (DM-MCM) diabetes mellitus (DM) HASMC DM-MCM treatment upregulated 25409512 5565 Human hsa-miR-221 miRNA mammosphere culture epithelial-mesenchymal transition (EMT) MCF-7 cells mammosphere culture treatment "suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221" 21553120 5566 Human hsa-miR-221 miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment miR-221 in EVs mediated proximal tubule cells injury through Wnt/¦Â-catenin signaling. 32926967 5567 Human hsa-miR-221 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (hRMEC) high glucose (HG) treatment High glucose (HG) treatment enhanced expression of miR-221. 32698791 5568 Human hsa-miR-221 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment "ox-LDL-induced apoptotic human umbilical cord vein endothelial cells. MiR-221/222 inhibition enhanced apoptosis in ECs, whereas over-expression of miR-221/222 could partly alleviate apoptotic cell death mediated by ox-LDL through suppression of Ets-1 and its downstream target p21." 25893733 5569 Human hsa-miR-221 miRNA high glucose (HG) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) high glucose treatment upregulated 19351599 5570 Human hsa-miR-221 miRNA ionizing radiation (IR) endothelial dysfunction Human umbilical vein endothelial cells (HUVECs) Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT "2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h." 30711956 5571 Human hsa-miR-221 miRNA atorvastatin endothelial dysfunction Human umbilical vein endothelial cells (HUVEC) atorvastatin treatment downregulated 25517390 5572 Human hsa-miR-221 miRNA ezetimibe endothelial dysfunction human umbilical vein endothelial cells (HUVEC) exposed to ezetimibe (0 to 5.0 ¦ÌM) treatment downregulated 25517390 5573 Human hsa-miR-221 miRNA simvastatin endothelial dysfunction human umbilical vein endothelial cells (HUVEC) exposed to simvastatin (0 to 5.0 ¦ÌM) treatment downregulated 25517390 5574 Human hsa-miR-221 miRNA angiotensin II (Ang II) endothelial inflammation and migration human umbilical vein endothelial cells (HUVECs) ;vascular smooth muscle cells (VSMCs) angiotensin II (Ang II) treatment upregulated 21310411 5575 Human hsa-miR-221 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) gastric cancer tissue 5-fluorouracil (5-FU) treatment upregulated 27081844 5576 Human hsa-miR-221 miRNA propofol (PPF) gastric cancer (GC) gastric cancer cells Propofol treatment downregulated 26214494 5577 Human hsa-miR-221 miRNA radiation glioblastoma multiforme (GBM) glioablastoma cells radiation treatment upregulated 24295494 5578 Human hsa-miR-221 miRNA platelet-derived growth factor (PDGF) glioblastoma multiforme (GBM) pancreatic cancer cells platelet-derived growth factor (PDGF)?treatment treatment downregulated 23967190 5579 Human hsa-miR-221 miRNA si wei xiao xiu yin glioblastoma multiforme (GBM) U87 cells Si wei xiao xiu yin treatment downregulated 32448616 5580 Human hsa-miR-221 miRNA valproic acid (VPA) hematopoietic differentiation hematopoietic stem cells (HSCs) VPA treatment different regulation 25241289 5581 Human hsa-miR-221 miRNA pegylated interferon-¦Á and ribavirin (IFN/RBV) hepatitis C virus (HCV) infection HCV patients IFN/RBV for 12 months treatment upregulated 24033414 5582 Human hsa-miR-221 miRNA astragaloside IV (AS-IV) hepatocellular carcinoma (HCC) HepG2 cells astragaloside IV (AS-IV) treatment downregulated 28179291 5583 Human hsa-miR-221 miRNA curcumin (Cur) hepatocellular carcinoma (HCC) HepG2 cells curcumin treatment downregulated 28179291 5584 Human hsa-miR-221 miRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) HepG2 and Hep3B cell lines doxorubicin treatment upregulated 24324033 5585 Human hsa-miR-221 miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) serum hepatitis C virus (HCV) infection upregulated 29333940 5586 Human hsa-miR-221 miRNA indole-3-carbinol (I3C) hepatocellular carcinoma (HCC) "human HCC cell lines, SK-Hep-1 and SNU-449" I3C treatment downregulated 25447674 5587 Human hsa-miR-221 miRNA myrothecine A hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cell line SMMC-7721 Myrothecine A treatment downregulated 31376622 5588 Human hsa-miR-221 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) tissues sorafenib treatment dysregulated 28049231 5589 Human hsa-miR-221 miRNA ¦Á-pinene hepatocellular carcinoma (HCC) HepG2 cells ¦Á-pinene treatment ¦Á-pinene treatment led to miR-221 and CDK1 downregulated. 30473536 5590 Human hsa-miR-221 miRNA hepatitis E virus (HEV) hepatitis HEK 293 cells(human embryonic kidney 293 cell line) Hepatitis E virus (HEV)? infection downregulated 23579640 5591 Human hsa-miR-221 miRNA human cytomegalovirus (HCMV) human cytomegalovirus (HCMV) infection Neural Precursor Cells (NPCs) Human cytomegalovirus (HCMV) infection upregulated 31550968 5592 Human hsa-miR-221 miRNA "13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3)" pancreatic ductal adenocarcinoma (PDAC) pancreatic ductal adenocarcinoma (PDAC) cells "13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3) treatment" "Moreover, treatment of SP600125 (a specific inhibitor of JNK pathway) or cotreatment of 13-cis RA and 1,25-VD3 significantly induced a decreased expression of miR-221 and an increased expression of TIMP-3 protein." 33730072 5593 Human hsa-miR-221 miRNA lithium (Li) hyperglycemia lymphoblastoid cell lines (LCLs) Lithium (Li) treatment significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221 19254429 5594 Human hsa-miR-221 miRNA cryptosporidium parvum IgA nephropathy (IgAN) biliary epithelial cells cryptosporidium parvum? infection downregulated 21236259 5595 Human hsa-miR-221 miRNA extracts from wild bitter gourd fruit (WBGE) inflammation TNF-¦Á-treated alveolar epithelial (A549) cells extracts from wild bitter gourd fruit (WBGE) treatment upregulated 29655703 5596 Human hsa-miR-221 miRNA lipopolysaccharide (LPS) inflammation WI-38 lung fibroblasts lipopolysaccharide (LPS) treatment upregulated 30849307 5597 Human hsa-miR-221 miRNA quercetin inflammation LPS-induced WI-38 lung fibroblasts quercetin treatment downregulated 30849307 5598 Human hsa-miR-221 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human umbilical vein endothelial cells (HUVEC) TNF¦Á treatment upregulated 29666964 5599 Human hsa-miR-221 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation alveolar epithelial (A549) cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29655703 5600 Human hsa-miR-221 miRNA H2O2 oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 5601 Human hsa-miR-221 miRNA lipopolysaccharide (LPS) oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 5602 Human hsa-miR-221 miRNA eicosapentaenoic acid (EPA) ischemic injury human endothelial progenitor cells EPA treatment downregulated 24927915 5603 Human hsa-miR-221 miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 18648749 5604 Human hsa-miR-221 miRNA emodin leukemia K562 cells Emodin treatment downregulated 23744534 5605 Human hsa-miR-221 miRNA xenotropic murine leukemia virus-related retrovirus (XMRV) leukemia LNCaPcells; DU145 cells Xenotropic murine leukemia virus-related retrovirus (XMRV) infection treatment upregulated of miR-221 and miR-222 expression 21932423 5606 Human hsa-miR-221 miRNA gemcitabine (GEM) hepatocellular carcinoma (HCC) HuCCT1 cells; HuH28 cells Gemcitabine treatment upregulated 24147037 5607 Human hsa-miR-221 miRNA microcystin-leucine arginine (MC-LR) hepatocellular carcinoma (HCC) WRL-69 cells microcystin-LR treatment upregulated 22265967 5608 Human hsa-miR-221 miRNA hyperoxia lung injury human epithelial cells human epithelial cells treatment upregulation in derived microvesicles (MVs) 27731391 5609 Human hsa-miR-221 miRNA resveratrol melanoma melanoma cell lines (A375 and MV3) resveratrol (Res) treatment downregulated 28936555 5610 Human hsa-miR-221 miRNA dexamethasone (DEX) multiple myeloma (MM) "Human MM cell lines MM.1S, MM.1R, RPMI-8226, U266, NCIH929, and ARH-77" dexamethasone (DEX) treatment downregulated 30765325 5611 Human hsa-miR-221 miRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) human cardiomyocytes (HCM) cells hypoxia/reoxygenation (H/R) induce upregulated 31115025 5612 Human hsa-miR-221 miRNA organosulfur garlic compounds neovasculogenesis Human endothelial progenitor cells (EPCs) Organosulfur garlic compounds treatment downregulated 23663050 5613 Human hsa-miR-221 miRNA chemoradiation therapy (CRT) non-small cell lung cancer (NSCLC) patients with stage IIIB-IV NSCLC CRT treatment upregulated 25466375 5614 Human hsa-miR-221 miRNA palmitic acid (PA) obesity HepG2 cells palmitic acid (PA) treatment upregulated 31828133 5615 Human hsa-miR-221 miRNA adriamycin (ADR) oral squamous cell carcinoma (OSCC) Tca8113 and UM2 cells adriamycin (ADR) treatment upregulated 26796268 5616 Human hsa-miR-221 miRNA doxorubicin (DOX) oral squamous cell carcinoma (OSCC) SCC4 and SCC9 cells doxorubicin treatment upregulated 28677788 5617 Human hsa-miR-221 miRNA ginsenoside Rg3 oral squamous cell carcinoma (OSCC) human OSCC SCC-9 and HSC-5?cells Ginsenoside Rg3 treatment downregulated 30928631 5618 Human hsa-miR-221 miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 5619 Human hsa-miR-221 miRNA lapatinib and 5-fluorouracil (5-Fu) pancreatic cancer (PC) PANC-1 and MIA PaCa-2 cells lapatinib and 5-FU treatment upregulated 26998056 5620 Human hsa-miR-221 miRNA metformin (Met) pancreatic cancer (PC) human pancreatic cancer PANC-1 cells metformin treatment downregulated 25955843 5621 Human hsa-miR-221 miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 5622 Human hsa-miR-221 miRNA ovalbumin (OVA) pediatric asthma Lymphocytes ovalbumin (OVA) treatment Upregulated 22895815 5623 Human hsa-miR-221 miRNA "androgen receptor (AR) agonist, CI-4AS-1" prostate cancer prostate cancer cell line AR agonists treatment downregulated 25846647 5624 Human hsa-miR-221 miRNA IFN-¦Á renal fibrosis glioblastoma U251 cells IFN-¦Á downregulated 20428775 5625 Human hsa-miR-221 miRNA hydroxyurea sickle cell disease (SCD) human umbilical vein endothelial cell (HUVEC) hydroxyurea treatment dysregulated 24925859 5626 Human hsa-miR-221 miRNA hypoxia spinal cord ischemia/reperfusion injury (SCII) AGE1.HN and SY-SH-5Y neuronal cell lines oxygen-glucose deprivation (OGD) treatment downregulated 29596155 5627 Human hsa-miR-221 miRNA Buyang Huanwu decoction (BYHWD) stroke mesenchymal stem cell (MSC) Buyang Huanwu decoction (BYHWD) treatment downregulated 25796380 5628 Human hsa-miR-221 miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment upregulated 24396484 5629 Human hsa-miR-221 miRNA Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) triple negative breast cancer (TNBC) MDA-MB-157 and HCC1806 cells Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) dual treatment downregulated 30591655 5630 Human hsa-miR-221 miRNA Roux-en-Y gastric bypass (RYGB) weight loss obese subjects without exercise program plasma RYGB treatment dysregulatedin plasma 28344345 5631 Human hsa-miR-221-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment ox-LDL significantly inhibited the expression of miR-221-3p. 32401923 5632 Human hsa-miR-221-3p miRNA adriamycin (ADR) breast cancer MCF-7 cells adriamycin (ADR) treatment upregulated 32160712 5633 Human hsa-miR-221-3p miRNA paroxetine depression serum paroxetine treatment downregulated 29791588 5634 Human hsa-miR-221-3p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 5635 Human hsa-miR-221-3p miRNA conditioned media (CM) metabolic disease human adipocytes conditioned medium of lipopolysaccharide-stimulated macrophages upregulated 28938482 5636 Human hsa-miR-221-3p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-2¦Â treatment downregulated 28236026 5637 Human hsa-miR-221-5p miRNA P. longifolia leaf extract apoptosis HeLa cells P. longifolia leaf extract treatment downregulated 32850286 5638 Human hsa-miR-221-5p miRNA polyalthia longifolia apoptosis HeLa cells Polyalthia longifolia treatment downregulated miR-221-5p was involved in regulating apoptosis in HeLa cancer cells 32110879 5639 Human hsa-miR-221-5p miRNA polyalthia longifolia leaf extract cell death HeLa cells Polyalthia longifolia leaf extract treatment downregulated 31383043 5640 Human hsa-miR-221-5p miRNA oxLDL and pitavastatin cholesterol homeostasis THP-1 cells oxLDL and pitavastatin treatment downregulated 27415822 5641 Human hsa-miR-222 miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection HUVECs human immunodeficiency virus-1 (HIV-1) infection downregulated 23555914 5642 Human hsa-miR-222 miRNA neoadjuvant multimodality ment adenocarcinomas serum received neoadjuvant therapy and subsequently underwent surgical resection treatment upregulation 25429911 5643 Human hsa-miR-222 miRNA particulate matter (PM2.5) air pollution-induced placental epigenetic alterations placental tissue Particulate matter (PM2.5) exposure treatment miR-222 was inversely associated with PM25 exposure during the 2nd trimester of pregnancy 27104955 5644 Human hsa-miR-222 miRNA curcumin (Cur) anaplastic thyroid carcinoma (ATC) SW1736 and 8505C curcumin treatment downregulated 29197967 5645 Human hsa-miR-222 miRNA resveratrol anti-inflammatory responses HUVECs treated with TNF-¦Á resveratrol (RS) treatment upregulated 28338009 5646 Human hsa-miR-222 miRNA tumor necrosis factor alpha (TNF-¦Á) anti-inflammatory responses HUVECs tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28338009 5647 Human hsa-miR-222 miRNA asbestos asbestos toxicity BEAS-2B cells asbestos exposure upregulated 32006662 5648 Human hsa-miR-222 miRNA asbestos asbestos-related malignancies serum asbestos treatment upregulated 30257964 5649 Human hsa-miR-222 miRNA TGF-¦Â asthma ASM cells (ASMCs) from patients with severe asthma TGF-¦Â treatment upregulated 23944957 5650 Human hsa-miR-222 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment upregulated 33159957 5651 Human hsa-miR-222 miRNA doxorubicin (DOX) breast cancer MCF-7 cancer cells doxorubicin (DOX) treatment upregulated 31273056 5652 Human hsa-miR-222 miRNA ionizing radiation (IR) breast cancer Blood The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min) upregulated 31150454 5653 Human hsa-miR-222 miRNA helicobacter pylori (H. pylori) tumorigenesis Human gastric cancer cell line A Helicobacter pylori (H. pylori) infection upregulated 22321642 5654 Human hsa-miR-222 miRNA inorganic arsenic (iAs) tumorigenesis human Jurkat leukemic T cell "Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment" upregulated 24317173 5655 Human hsa-miR-222 miRNA minocycline (MNC) cell proliferation PDGF-BB-treated human aortic smooth muscle cell (SMC) Minocycline treatment downregulated 30716386 5656 Human hsa-miR-222 miRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation human aortic smooth muscle cell (SMC) platelet-derived growth factor BB homodimer (PDGF-BB) treatment upregulated 30716386 5657 Human hsa-miR-222 miRNA HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA) chronic heart failure (CHF) human aortic endothelial cells HDLNYHA treatment downregulated 24958738 5658 Human hsa-miR-222 miRNA fludarabine chronic lymphocytic leukemia (CLL) p53-mutant MEG-01 cells fludarabine treatment specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets 20504344 5659 Human hsa-miR-222 miRNA 5-fluorouracil (5-Fu) and oxaliplatin colorectal cancer (CRC) human colon cancer cells 5-Fluorouracil and oxaliplatin treatment downregulated 19956872 5660 Human hsa-miR-222 miRNA temozolomide (TMZ) colorectal cancer (CRC) "U87MG cells;T98G cells; LN428 cells; LN308 cells; A172 cells; HEK-293 cells cells;LN229 cells;T98G, U87MG, and LN229 ,LN428 cells; LN308 cells; A172 cells" temozolomide (TMZ) treatment upregulated 24147153 5661 Human hsa-miR-222 miRNA estradiol depression MCF7 cells estradiol (E2) treatment miR-221/222 expression is increased in antiestrogen-resistant breast cancer cell lines and is upregulated by fulvestrant in antiestrogen-sensitive MCF7 cells 21057537 5662 Human hsa-miR-222 miRNA mammosphere culture epithelial-mesenchymal transition (EMT) MCF-7 cells mammosphere culture treatment "suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221" 21553120 5663 Human hsa-miR-222 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment "ox-LDL-induced apoptotic human umbilical cord vein endothelial cells. MiR-221/222 inhibition enhanced apoptosis in ECs, whereas over-expression of miR-221/222 could partly alleviate apoptotic cell death mediated by ox-LDL through suppression of Ets-1 and its downstream target p21." 25893733 5664 Human hsa-miR-222 miRNA ionizing radiation (IR) endothelial dysfunction Human umbilical vein endothelial cells (HUVECs) Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT "2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h." 30711956 5665 Human hsa-miR-222 miRNA atorvastatin endothelial dysfunction human umbilical vein endothelial cells (HUVEC) exposed to atorvastatin (0 to 5.0 ¦ÌM) treatment downregulated 25517390 5666 Human hsa-miR-222 miRNA streptozocin (STZ) gestational diabetes mellitus (GDM) placenta tissues streptozocin treatment MiR-222 was increased while CXCR4 was decreased in GDM patients and mice 33278386 5667 Human hsa-miR-222 miRNA radiation glioblastoma multiforme (GBM) glioablastoma cells radiation treatment upregulated 24295494 5668 Human hsa-miR-222 miRNA valproic acid (VPA) hematopoietic differentiation hematopoietic stem cells (HSCs) VPA treatment different regulation 25241289 5669 Human hsa-miR-222 miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HepG2 cells £¬ HepG2.2.15 cells. hepatitis B virus X protein (HBx) treatment downregulated 25260533 5670 Human hsa-miR-222 miRNA indole-3-carbinol (I3C) hepatocellular carcinoma (HCC) "human HCC cell lines, SK-Hep-1 and SNU-449" I3C treatment downregulated 25447674 5671 Human hsa-miR-222 miRNA hepatitis E virus (HEV) hepatitis HEK 293 cells(human embryonic kidney 293 cell line) Hepatitis E virus (HEV)? infection downregulated 23579640 5672 Human hsa-miR-222 miRNA extracts from wild bitter gourd fruit (WBGE) inflammation TNF-¦Á-treated alveolar epithelial (A549) cells extracts from wild bitter gourd fruit (WBGE) treatment upregulated 29655703 5673 Human hsa-miR-222 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human umbilical vein endothelial cells (HUVEC) TNF¦Á treatment upregulated 29666964 5674 Human hsa-miR-222 miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation alveolar epithelial (A549) cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29655703 5675 Human hsa-miR-222 miRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) human intervertebral disc nucleus pulposus (NP) cells lipopolysaccharide (LPS) treatment upregulated 31432092 5676 Human hsa-miR-222 miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 18648749 5677 Human hsa-miR-222 miRNA emodin leukemia K562 cells Emodin treatment downregulated 23744534 5678 Human hsa-miR-222 miRNA xenotropic murine leukemia virus-related retrovirus (XMRV) leukemia LNCaP cells; DU145 cells Xenotropic murine leukemia virus-related retrovirus (XMRV) infection treatment upregulated of miR-221 and miR-222 expression 21932423 5679 Human hsa-miR-222 miRNA metformin (Met) medulloblastoma lung cancer cells Metformin? treatment downregulated 23974492 5680 Human hsa-miR-222 miRNA ezetimibe monocytic differentiation Human monocytic cell lineTHP-1 Ezetimibe trratment downregulated 22989505 5681 Human hsa-miR-222 miRNA IL-4 monocytic differentiation monocyte IL-4 treatment dysregulated 25148686 5682 Human hsa-miR-222 miRNA dexamethasone (DEX) multiple myeloma (MM) "Human MM cell lines MM.1S, MM.1R, RPMI-8226, U266, NCIH929, and ARH-77" dexamethasone (DEX) treatment downregulated 30765325 5683 Human hsa-miR-222 miRNA compound C nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) compound C treatment downregulated 32143184 5684 Human hsa-miR-222 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) palmitic acid (PA) treatment downregulated 32143184 5685 Human hsa-miR-222 miRNA asbestos non-small cell lung cancer (NSCLC) serum asbestos exposure upregulated 30257964 5686 Human hsa-miR-222 miRNA ozone (O3) air pollution healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 5687 Human hsa-miR-222 miRNA epidermal growth factor (EGF) oral carcinogenesis "HSC-3£¬OECM-1,SAS£¬NOK" EGF treatment upregulated 25229239 5688 Human hsa-miR-222 miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx10 treatment" downregulated 21572246 5689 Human hsa-miR-222 miRNA morin oxidative stress A549 cells upon traffic PM2.5 exposure Morin treatment downregulated 31284452 5690 Human hsa-miR-222 miRNA particulate matter (PM2.5) oxidative stress A549 cells traffic PM2.5 treatment upregulated 31284452 5691 Human hsa-miR-222 miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 5692 Human hsa-miR-222 miRNA adenovirus (ADV) prostate cancer human prostate Cancer Cells adenovirus treatment downregulated 28114818 5693 Human hsa-miR-222 miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed downregulated 27915273 5694 Human hsa-miR-222 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia treatment CASC2 attenuated hypoxia-induced PASMC proliferation and migration by regulating the miR-222/ING5 axis to prevent vascular remodeling and the development of PAH. 32206065 5695 Human hsa-miR-222 miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 5696 Human hsa-miR-222 miRNA brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) cell senescence SH-SY5Y cells brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment upregulated 27525675 5697 Human hsa-miR-222 miRNA retinoic acid (RA) cell senescence SH-SY5Y cells retinoic acid (RA) treatment upregulated 27525675 5698 Human hsa-miR-222 miRNA retinoic acid (RA) cell senescence SH-SY5Y cells SH-SY5Y cells treatment upregulation 27525675 5699 Human hsa-miR-222 miRNA hydroxyurea sickle cell disease (SCD) human umbilical vein endothelial cell (HUVEC) hydroxyurea treatment dysregulated 24925859 5700 Human hsa-miR-222 miRNA Buyang Huanwu decoction (BYHWD) stroke mesenchymal stem cell (MSC) Buyang Huanwu decoction (BYHWD) treatment downregulated 25796380 5701 Human hsa-miR-222 miRNA Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) triple negative breast cancer (TNBC) MDA-MB-157 and HCC1806 cells Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) dual treatment downregulated 30591655 5702 Human hsa-miR-222 miRNA arsenite arsenite-induced carcinogenesis human lung epithelial BEAS-2B cells arsenic (As) exposure upregulated 26909602 5703 Human hsa-miR-222 miRNA metformin (Met) type 2 diabetes mellitus (T2DM) The human renal epithelial cells (295T cells) metformin treatment differently regulated in circulating 24478399 5704 Human hsa-miR-222* miRNA arsenic trioxide (ATO) bladder cancer T24 human bladder carcinoma cells arsenic trioxide?treatment upregulated 20857258 5705 Human hsa-miR-222-3p miRNA H2O2 age-related cataract (ARC) human lens epithelial B3 (HLE-B3) cells H2O2 treatment upregulated 33851769 5706 Human hsa-miR-222-3p miRNA dexamethasone (DEX) airway epithelial injury 9HTE cells dexamethasone (Dex) treatment downregulated 32202184 5707 Human hsa-miR-222-3p miRNA vinyl chloride monomer (VCM) chromosomal damage workers peripheral blood lymphocytes high VCM-expose treatment upregulated 28749179 5708 Human hsa-miR-222-3p miRNA doxorubicin (DOX) colorectal cancer (CRC) LoVo cells Doxorubicin (DOX) treatment miR-222-3p was upregulated in LoVo/ADR compared with the expression in LoVo/S cells. 30904920 5709 Human hsa-miR-222-3p miRNA high glucose (HG) diabetic nephropathy (DN) Human mesangial cells high glucose (HG) treatment Real-time PCR was performed to detect the relative NEAT1 and miR-222-3p expressions and further confirmed the relationship between NEAT1 and miR-222-3p. 33585566 5710 Human hsa-miR-222-3p miRNA high glucose (HG) endometrial cancer (EC) "Human endometrial carcinoma cell lines (HEC1-B, HEC1-A and Ishikawa)" high glucose (HG) treatment upregulated 31105847 5711 Human hsa-miR-222-3p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) Gastric cancer tissues and cells Helicobacter pylori (H. pylori)?infection upregulated 29227536 5712 Human hsa-miR-222-3p miRNA cigarette smoke (CS) lung cancer NCI-H292 cells cigarette smoke (CS) treatment "upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)" 28692419 5713 Human hsa-miR-222-3p miRNA osteogenic differentiation medium osteogenesis Adipose-derived mesenchymal stem cells (ADSCs) osteogenic differentiation media induce downregulated 30511267 5714 Human hsa-miR-222-3p miRNA activin A prostate cancer LNCaP cells activin A treatment downregulated 27018851 5715 Human hsa-miR-222-3p miRNA CoCl2 spinal cord injury (SCI) AGE1.HN cells ?CoCl2 treatment upregulated 33770577 5716 Human hsa-miR-222-5p miRNA hypoxia kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection human KS-derived SLK and SLKK cells hypoxia treatment downregulated 28046107 5717 Human hsa-miR-223 miRNA high glucose (HG) acute coronary syndrome (ACS) Human Macrophages high glucose treatment upregulated 27519051 5718 Human hsa-miR-223 miRNA glucocorticoid (GC) acute lymphoblastic leukemia (ALL) human T-ALL cell Glucocorticoids (GCs) treatment downregulated 19148136 5719 Human hsa-miR-223 miRNA H2O2 age-related cataract (ARC) SRA01/04 cells H2O2 treatment MEG3 promoted ARC progression by up-regulating TP53INP1 expression through suppressing miR-223 and promoting P53 expression. 32841649 5720 Human hsa-miR-223 miRNA baicalin (BAI) age-related macular degeneration (AMD) ARPE-19 cells baicalin (BAI) treatment Baicalin significantly induced upregulation of miR-223. 31578016 5721 Human hsa-miR-223 miRNA baicalin (BAI) age-related macular degeneration (AMD) A¦Â-envoked ARPE-19 cells baicalin (BAI) treatment upregulated 31578016 5722 Human hsa-miR-223 miRNA melatonin atherosclerosis (AS) human aortic endothelial cells (HAECs) melatonin treatment upregulated 29024030 5723 Human hsa-miR-223 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29024030 5724 Human hsa-miR-223 miRNA platelet derived growth factor-BB (PDGF-BB) atherosclerosis (AS) human aortic smooth muscle cells (HASMCs) platelet-derived growth factor-BB (PDGF-BB) treatment downregulated 33373321 5725 Human hsa-miR-223 miRNA arachidonic acid (AA) breast cancer platelet microvesicle (MV) arachidonic acid (AA) treatment upregulated 31665654 5726 Human hsa-miR-223 miRNA IL-4 breast cancer CD4+ T cells;breast cancer cells interleukin-4 (IL-4) treatment upregulated 21939504 5727 Human hsa-miR-223 miRNA celastrol breast cancer human breast cancer cell line MCF-7 and prostate cancer PC3 celastrol treatment upregulated 26552919 5728 Human hsa-miR-223 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) NCI-H292 cells cigarette smoke extract (CSE) treatment downregulated 30695677 5729 Human hsa-miR-223 miRNA hepatitis C virus (HCV) cognitive impairment monocyte-derived exosome hepatitis C virus (HCV) infection upregulated 32157304 5730 Human hsa-miR-223 miRNA human immunodeficiency virus (HIV)-1 cognitive impairment monocyte-derived exosome human immunodeficiency virus (HIV)-1 infectiom upregulated 32157304 5731 Human hsa-miR-223 miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment downregulated 31744065 5732 Human hsa-miR-223 miRNA clopidogrel coronary artery disease (CAD) patients with coronary artery disease (CAD) clopidogrel treatment upregulated 25350775 5733 Human hsa-miR-223 miRNA prasugrel/ticagrelor coronary artery disease (CAD) patients with coronary artery disease (CAD) prasugrel/ticagrelor treatment upregulated 25350775 5734 Human hsa-miR-223 miRNA lipopolysaccharide (LPS) crohn disease (CD) HT-29 colonic epithelial cell line lipopolysaccharide (LPS) treatment downregulated 30299179 5735 Human hsa-miR-223 miRNA high protein diet diet-induced weight loss human HDL constituents high protein diet treatment downregulated 26962854 5736 Human hsa-miR-223 miRNA acrolein environmental pollutants human umbilical vein endothelial cells acrolein treatment upregulated 24812010 5737 Human hsa-miR-223 miRNA ozone (O3) epigenetic regulation of responses to O3 exposure healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 5738 Human hsa-miR-223 miRNA etanercept gastric cancer (GC) ?serum Etanercept treatment downregulated 23600954 5739 Human hsa-miR-223 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 and U118 cells TMZ treatment upregulated 28035389 5740 Human hsa-miR-223 miRNA lipopolysaccharide (LPS) liver fibrosis Human HSC line LX2 cells lipopolysaccharide (LPS) treatment downregulated 31719209 5741 Human hsa-miR-223 miRNA TGF-¦Â liver fibrosis Human HSC line LX2 cells TGF-¦Â treatment downregulated 31719209 5742 Human hsa-miR-223 miRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) "Human HCC cell lines (HepG2, Huh7, SNU387, and SNU449)" doxorubicin treatment downregulated 31695022 5743 Human hsa-miR-223 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) plasma hepatitis B virus (HBV) infection downregulated 22105822 5744 Human hsa-miR-223 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) "Huh7, SNU387 and SNU449 cells" sorafenib treatment upregulated 30535501 5745 Human hsa-miR-223 miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 5746 Human hsa-miR-223 miRNA fibroblast growth factor (FGF) and the insulin-like growth factor receptor (IGF-1R) human embryonic stem cell differentiation human embryonic stem cells (hESCs) fibroblast growth factor (FGF) and the insulin-like growth factor receptor (IGF-1R)? treatment upregulated 24250812 5747 Human hsa-miR-223 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6A dysregulated 29163428 5748 Human hsa-miR-223 miRNA human herpesvirus 6B (HHV-6B) human herpesvirus 6A (HHV-6A) infection human NK cell line (NK-92) infected with HHV-6B dysregulated 29163428 5749 Human hsa-miR-223 miRNA medium prepared with pIgA from patients with glomerular endothelial proliferation IgA nephropathy (IgAN) glomerular endothelial cells (GEnCs) incubate with the medium prepar pIgA from patients with glomerular endothelial proliferation treatment downregulated 24284509 5750 Human hsa-miR-223 miRNA dextran sodium sulfate (DSS) inflammatory bowel disease (IBD) Colon mucosa dextran sulfate sodium treatment upregulated 26878986 5751 Human hsa-miR-223 miRNA influenza A virus (IAV) influenza A virus (IAV) infection BEAS-2B cells; serum Influenza A virus (IAV) infection downregulated 33278394 5752 Human hsa-miR-223 miRNA insect cell-derived anionic septapeptide innate immune response Primary human monocyte cultures insect cell-derived anionic septapeptide treatment upregulated 31075349 5753 Human hsa-miR-223 miRNA celastrol insulin resistance (IR) palmitic acid (PA) treated HepG2 cells celastrol treatment upregulated 30287053 5754 Human hsa-miR-223 miRNA palmitic acid (PA) insulin resistance (IR) HepG2 cells palmitic acid (PA) treatment downregulated 30287053 5755 Human hsa-miR-223 miRNA palmitic acid (PA) insulin resistance (IR) HepG2 cells palmitic acid (PA) treatment downregulated 30287053 5756 Human hsa-miR-223 miRNA "ferrylhemoglobin (ferrylHb, Fe4+)" intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) "ferrylhemoglobin (ferrylHb, Fe4+) treatment" upregulated 32961661 5757 Human hsa-miR-223 miRNA heme intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) heme treatment upregulated 32961661 5758 Human hsa-miR-223 miRNA "methemoglobin (metHb, Fe3+)" intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) "methemoglobin (metHb, Fe3+) treatment" upregulated 32961661 5759 Human hsa-miR-223 miRNA tumor necrosis factor alpha (TNF-¦Á) intraventricular hemorrhage (IVH) human choroid plexus epithelial cell (HCPEpiC) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 32961661 5760 Human hsa-miR-223 miRNA K. pneumoniae reference strains (K. pneumoniae ATCC 10031) klebsiella pneumoniae infection BEAS 2B cells K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection upregulated 33322147 5761 Human hsa-miR-223 miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells KPC-producing K. pneumoniae infection upregulated 33322147 5762 Human hsa-miR-223 miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells MS K. pneumoniae infection upregulated 33322147 5763 Human hsa-miR-223 miRNA lipopolysaccharide (LPS) lupus nephritis (LN) HK2 cells lipopolysaccharide (LPS) treatment LPS treatment significantly enhanced the ex- pression of miR-223 in HK-2 cells. 29800915 5764 Human hsa-miR-223 miRNA mycobacterium tuberculosis (Mtb) macrophage apoptosis Human macrophages Mycobacterium tuberculosis (Mtb) treatment upregulated 26505221 5765 Human hsa-miR-223 miRNA estrogen (ES) estrogen-mediated immune regulation Splenic lymphocytes Estrogen treatment upregulated 18791161 5766 Human hsa-miR-223 miRNA inorganic phosphate (Pi) migration of vascular smooth muscle cells human aortic vascular smooth muscle cells (VSMCs) inorganic phosphate (Pi) treatment upregulated 23094093 5767 Human hsa-miR-223 miRNA radiation nasopharyngeal carcinoma (NPC) NP460; CNE2; CNE2R cells radiation treatment "MINCR diminished NPC cell radiosensitivity by sponging miR-223, increasing ZEB1 and activating the AKT/PI3K axis" 33290841 5768 Human hsa-miR-223 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) "The human NLCLC cell lines, A549, NCI-H460, NCI-H1299 and NCI-H358" cisplatin (DPP) treatment downregulated 30431074 5769 Human hsa-miR-223 miRNA clopidogrel non-ST elevation acute coronary syndrome (NSTE-ACS) patients with coronary heart disease 300 mg (for at least 24 h) or 75 mg clopidogel (for at least 5 days) plus aspirin treatment downregulated 24202700 5770 Human hsa-miR-223 miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human ATDC5 cells lipopolysaccharide (LPS) treatment miR-223 expression was downregulated by lncRNA-ATB and miR-223 overexpression declined the protective effect of lncRNA-ATB on LPS-injured ATDC5 cells. 30771739 5771 Human hsa-miR-223 miRNA mud-bath therapy (MBT) osteoarthritis (OA) patients with bilateral knee osteoarthritis (OA) "daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks" downregulated 28785809 5772 Human hsa-miR-223 miRNA cisplatin (DDP) pancreatic cancer (PC) BXPC3 cells cisplatin treatment upregulated 31599414 5773 Human hsa-miR-223 miRNA genistein pancreatic cancer (PC) pancreatic cancer cells Genistein? treatment downregulated 23834147 5774 Human hsa-miR-223 miRNA intercept (amotosalen+ ultraviolet-A [UVA] light) pathogen reduction platelet gamma irradiation treatment downregulated 24749844 5775 Human hsa-miR-223 miRNA clopidogrel platelet inhibition serum clopidogrel treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 5776 Human hsa-miR-223 miRNA ticagrelor platelet inhibition serum ticagrelor treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 5777 Human hsa-miR-223 miRNA mechanical stretch cell proliferation vascular smooth muscle cells (VSMCs) mechanical stretch-stimulated treatment downregulated 23046980 5778 Human hsa-miR-223 miRNA methotrexate (MTX) psoriasis chronic plaque-type psoriasis patients PBMCs methotrexate (MTX) treatment downregulated in plasma 27535005 5779 Human hsa-miR-223 miRNA hypoxia pulmonary arterial hypertension (PAH) pulmonary arterial smooth muscle cells (PASMCs) hypoxia treatment CircATP2B4 potentiated hypoxia-induced proliferation and migration of PASMCs through the miR-223/ATR axis. 32926932 5780 Human hsa-miR-223 miRNA lipopolysaccharide (LPS) pulpitis human dental pulp fibroblasts (HDPFs) lipopolysaccharide (LPS) treatment downregulated 32966618 5781 Human hsa-miR-223 miRNA IL-6 traumatic brain injury (TBI) Glomerular endothelial cells (GEnCs) IL-6 treatment downregulated 24284509 5782 Human hsa-miR-223 miRNA ellagic acid (EA) type 2 diabetes mellitus (T2DM) high glucose-exposed HepG2 cells ellagic acid (EA) treatment upregulated 30466006 5783 Human hsa-miR-223 miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) HepG2 cells high glucose (HG) treatment downregulated 30466006 5784 Human hsa-miR-223 miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) HepG2 cells high glucose treatment downregulated 30466006 5785 Human hsa-miR-223 miRNA ellagic acid (EA) type 2 diabetes mellitus (T2DM) HepG2 cells Ellagic acid (EA) treatment upregulated 30466006 5786 Human hsa-miR-223 miRNA clopidogrel colorectal cancer (CRC) purified platelets clopidogrel treatment downregulated 23498169 5787 Human hsa-miR-223 miRNA Marek's disease virus (MDV) diabetes mellitus (DM) seven independentCD4+T-lymphoma cell line Marek's disease virus (MDV) treatment downregulated 19297609 5788 Human hsa-miR-223* miRNA clopidogrel platelet inhibition serum clopidogrel treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 5789 Human hsa-miR-223* miRNA ticagrelor platelet inhibition serum ticagrelor treatment "Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase." 32326325 5790 Human hsa-miR-223-3p miRNA colchicine acute gouty arthritis (AGA) plasma colchicine treatment Comparison of differences between pre- and 5-day post-treatment values confirmed that the upregulation of miR-223-3p and downregulated of IL-1¦Â induced by colchicine were more significant than etoricoxib. 31360199 5791 Human hsa-miR-223-3p miRNA colchicine acute gouty arthritis (AGA) plasma Colchicine treatment "Colchicine could upregulate miR-223-3p and downregulate IL-1¦Â in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2." 31360199 5792 Human hsa-miR-223-3p miRNA etoricoxib acute gouty arthritis (AGA) plasma etoricoxib treatment "Colchicine could upregulate miR-223-3p and downregulate IL-1¦Â in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2." 31360199 5793 Human hsa-miR-223-3p miRNA baicalin (BAI) acute kidney injury (AKI) HK-2 cells baicalin (BAI) treatment Baicalin attenuates lipopolysaccharide-induced renal tubular epithelial cell injury by inhibiting the TXNIP/NLRP3 signalling pathway via increasing miR-223-3p expression 32392921 5794 Human hsa-mir-223-3p miRNA high-density lipoproteins (HDL) atherosclerosis (AS) Polymorphonuclear neutrophils (PMNs) and human monocyte derived macrophages (HMDMs) high-density lipoproteins (HDL) treatment upregulated 31096070 5795 Human hsa-miR-223-3p miRNA ginkgolide B (GB) bladder cancer bladder cancer cells Ginkgolide B (GB) treatment downregulated 27744452 5796 Human hsa-miR-223-3p miRNA H2O2 cataract human lens epithelial cells (SRA01/04) H2O2 treatment downregulated 33744257 5797 Human hsa-miR-223-3p miRNA p-cresol (PcEMV) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) p-cresol (PcEMV) treatment upregulated 32606426 5798 Human hsa-miR-223-3p miRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells; BGC823C cells cisplatin treatment miR-223-3p was higher in cisplatin-resistant GC (CR-GC) cells than their parental cisplatin-sensitive GC (CS-GC) cells. 32516127 5799 Human hsa-miR-223-3p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) "AGS, BGC-823 and SGC-7901 cells" Helicobacter pylori (H. pylori) infection upregulated 29317648 5800 Human hsa-miR-223-3p miRNA monosodium urate (MSU) gouty inflammation THP-1 cells monosodium urate treatment downregulated 33650318 5801 Human hsa-miR-223-3p miRNA helicobacter pylori (H. pylori) H. pylori infection human immune cells Helicobacter pylori infection upregulated 29145789 5802 Human hsa-miR-223-3p miRNA silybin hepatoprotective HepG2 cells Silybin treatment upregulated 31058823 5803 Human hsa-miR-223-3p miRNA lipopolysaccharide (LPS) inflammation human adipose stem cells lipopolysaccharide (LPS) treatment downregulated 30807577 5804 Human hsa-miR-223-3p miRNA tumor necrosis factor alpha (TNF-¦Á) kaposi's sarcoma (KS) human coronary artery endothelial cells (HCAECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31396494 5805 Human hsa-miR-223-3p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 5806 Human hsa-miR-223-3p miRNA dexamethasone (DEX) neuroprotective effects human hippocampal neuronal cells dexamethasone (DEX) treatment upregulated 30569136 5807 Human hsa-miR-223-3p miRNA dexamethasone (DEX) neuroprotective effects human hippocampal neuronal cells dexamethasone (DEX) treatment DEX enhanced the expression of miR-223-3p. 30569136 5808 Human hsa-miR-223-3p miRNA dexmedetomidine (DEX) oxidative stress H2O2 treated human hippocampal neuronal cells dexamethasone (DEX) treatment upregulated 30569136 5809 Human hsa-miR-223-3p miRNA H2O2 oxidative stress human hippocampal neuronal cells H2O2 treatment downregulated 30569136 5810 Human hsa-miR-223-3p miRNA infliximab rheumatoid arthritis (RA) serological infliximab treatment upregulated 25860297 5811 Human hsa-miR-223-3p miRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury HK-2 cells lipopolysaccharide (LPS) treatment downregulated 32666494 5812 Human hsa-miR-223-3p miRNA Treponema pallidum subsp pallidum (T pallidum) syphilis human umbilical vein endothelial cells (HUVECs) Treponema pallidum subsp pallidum (T pallidum) infection treatment MiR-223-3p inhibits rTp17-induced inflammasome activation and pyroptosis by targeting NLRP3 33145937 5813 Human hsa-miR-223-3p miRNA polystyrene (PSNPs) toxicity of nanoparticles THP-1 cells polystyrene (PSNPs) treatment downregulated 32284792 5814 Human hsa-miR-223-3p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) plasma Mycobacterium tuberculosis (MTB) treatment downregulated 32048448 5815 Human hsa-miR-223-5p miRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment "?LINC00707 was increased, and miR-223-5p was decreased in LPS-treated MRC-5 cells." 33604647 5816 Human hsa-miR-22-3p miRNA calcium oxalate monohydrate (COM) kidney stone disease human renal proximal tubular epithelial (HK-2) cells ?calcium oxalate monohydrate (COM)?treatment treatment lncRNA LINC00339 promotes cell pyroptosis by sponging miR-22-3p to regulate NLRP3 expression in COM-treated HK-2 cells 30614043 5817 Human hsa-miR-22-3p miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment miR-22-3p was downregulated in LPS-stimulated HK-2 cells. 33335994 5818 Human hsa-miR-22-3p miRNA lipopolysaccharide (LPS) age-related macular degeneration (AMD) "Human retinal pigment epithelial cell line, ARPE©\19 cells" LPS combined with rotenone treatment downregulated 30927257 5819 Human hsa-miR-22-3p miRNA rotenone (ROT) age-related macular degeneration (AMD) "Human retinal pigment epithelial cell line, ARPE©\19 cells" LPS combined with rotenone treatment downregulated 30927257 5820 Human hsa-miR-22-3p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment downregulated 31722571 5821 Human hsa-miR-22-3p miRNA vinyl chloride monomer (VCM) chromosomal damage workers peripheral blood lymphocytes high VCM-expose treatment downregulated 28749179 5822 Human hsa-miR-22-3p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment downregulated 31722571 5823 Human hsa-miR-22-3p miRNA cyclosporine A (CsA) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) cyclosporine A (CYCA) treatment upregulated 31198949 5824 Human hsa-miR-22-3p miRNA TGF-¦Â2 fibrotic cataract human lens epithelial explants TGF-¦Â2 treatment miR-22-3p prevents lens fibrotic progression by targeting HDAC6 thereby promoting ¦Á-tubulin acetylation. 32985730 5825 Human hsa-miR-22-3p miRNA oxaliplatin gastric cancer (GC) "GC tissues;Normal cells (GES-1); GC cells (SGC-7901, BGC-823); GC/OXA cells (SGC-7901/OXA; BCG-823/OXA" oxaliplatin (OXA) treatment MALAT1 modulates ZFP91 to promote GC cells OXA resistance via sponging miR-22-3p 32104001 5826 Human hsa-miR-22-3p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment upregulated 27893811 5827 Human hsa-miR-22-3p miRNA monosodium urate (MSU) gouty inflammation THP-1 cells monosodium urate treatment downregulated 33650318 5828 Human hsa-miR-22-3p miRNA betulinic acid (BA) hepatocellular carcinoma (HCC) PLC/PRF/5; MHCC97L betulinic acid (BA) treatment lncRNA MALAT1 functioned as a ceRNA (competing endogenous RNA) to contribute to BA-mediated degradation of IAPs by sponging miR-22-3p. 33135336 5829 Human hsa-miR-22-3p miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HCC cells ?hepatitis B virus-encoded X (HBx) protein treatment we found that translation regulatory lncRNA 1 (TRERNA1) upregulation by HBx not only promoted HCC cell proliferation by regulating the cell cycle in vitro and in vivo but also correlated positively with poor prognosis in HCC 33839325 5830 Human hsa-miR-22-3p miRNA Japanese encephalitis virus (JEV) Japanese Encephalitis virus (JEV) infection human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses Japanese encephalitis virus (JEV) infection downregulated 31578247 5831 Human hsa-miR-22-3p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29505299 5832 Human hsa-miR-22-3p miRNA nicotinamide periodontitis periodontal ligament stem cell (PDLSC) nicotinamide treatment upregulated 31769563 5833 Human hsa-miR-22-3p miRNA lipopolysaccharide (LPS) sepsis HK-2 cells lipopolysaccharide (LPS) treatment miR-22-3p was significantly downregulated LPS-induced sepsis model in HK-2 cells. 32412059 5834 Human hsa-miR-224 miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) human umbilical vein endothelial cells (HUVEC) and EA.hy926 cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 25463084 5835 Human hsa-miR-224 miRNA paclitaxel (PTX) cervical cancer (CC) SiHa cells paclitaxel treatment downregulated 26390698 5836 Human hsa-miR-224 miRNA "rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" diffuse large B-cell lymphoma (DLBCL) diffuse large B cell lymphoma (DLBCL) patients serum 6 cycles of R-CHOP treatment dysregulated 24858372 5837 Human hsa-miR-224 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) gastric cancer tissue 5-fluorouracil (5-FU) treatment upregulated 27081844 5838 Human hsa-miR-224 miRNA hypoxia gastric cancer (GC) human gastric cancer cell lines SGC-7901; MGC-803 "maintained with 5% CO2, 1% O2" upregulated 28173803 5839 Human hsa-miR-224 miRNA ionizing radiation (IR) glioblastoma multiforme (GBM) U87 MG cells irradiation at a dose of 6Gy treatment downregulated 24785373 5840 Human hsa-miR-224 miRNA pegylated interferon-¦Á and ribavirin (IFN/RBV) hepatitis C virus (HCV) infection HCV patients IFN/RBV for 12 months treatment upregulated 24033414 5841 Human hsa-miR-224 miRNA geniposide (GEN) hepatocellular carcinoma (HCC) HepG2 and Huh7 cells geniposide (GEN) treatment downregulated 31778668 5842 Human hsa-miR-224 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) tissues sorafenib treatment dysregulated 28049231 5843 Human hsa-miR-224 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HCC patients Sorafenib treatment upregulated 24804874 5844 Human hsa-miR-224 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 5845 Human hsa-miR-224 miRNA oxygen glucose deprivation (OGD) neuronal cell injury HCN-2 cells oxygen/glucose deprivation (OGD) treatment upregulated 27165196 5846 Human hsa-miR-224 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 5847 Human hsa-miR-224 miRNA palliative chemotherapy non-small cell lung cancer (NSCLC) NSCLC tissues platinum derivatives in combination with paclitaxel or gemcitabine treatment upregulated 29387235 5848 Human hsa-miR-224 miRNA andrographolide oxidative stress HepG2 cells andrographolide treatment downregulated 30414976 5849 Human hsa-miR-224 miRNA hypoxia prostate cancer NK cells oxygen-glucose deprivation (OGD) treatment upregulated 29885835 5850 Human hsa-miR-224 miRNA zinc(II) ions prostate cancer 22Rv1 cell line zinc(II) ions treatment upregulated 23064315 5851 Human hsa-miR-224-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic ECs (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33510945 5852 Human hsa-miR-224-3p miRNA hypoxia autophagy Human glioblastoma multiforme hypoxia treatment downregulated 26536662 5853 Human hsa-miR-224-3p miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment upregulated 26397152 5854 Human hsa-miR-224-3p miRNA hypoxia glioblastoma multiforme (GBM) glioma LN229 and astrocytoma U-251MG cell lines hypoxia induce downregulated 30569180 5855 Human hsa-miR-224-3p miRNA hypoxia glioblastoma multiforme (GBM) glioma LN229 and astrocytoma U-251MG cell lines hypoxia induce downregulated 30569180 5856 Human hsa-miR-224-3p miRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells Ginsenoside Rh2 (Rh2) treatment upregulated 30197683 5857 Human hsa-miR-224-3p miRNA thymosin ¦Á1 (T¦Á1) non-segmental vitiligo (NSV) peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV) thymosin ¦Á1 (T¦Á1) treatment upregulated 25495156 5858 Human hsa-miR-224-5p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment dysregulated 29067470 5859 Human hsa-miR-224-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) Human colorectal carcinoma HCT116 and human colorectal adenocarcinoma DLD-1 cells 5-fluorouracil (5-FU) treatment he decrease in miR-224-5p expression in the 5-fluorouracil-resistant cells correlated with drug insensitivity due to its overexpression-induced drug-dependent apoptosis. 31810268 5860 Human hsa-miR-224-5p miRNA transarterial chemoembolization (TACE) hepatocellular carcinoma (HCC) HCC patients plasma TACE treatment differently regulated 25275448 5861 Human hsa-miR-224-5p miRNA glucocorticoid (GC) inflammatory bowel disease (IBD) serum Glucocorticoids (GCs) treatment downregulated 31938187 5862 Human hsa-miR-22-5p miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 5863 Human hsa-miR-2278 miRNA cardenolide analog 3¦Â-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) renal cell carcinoma (RCC) "renal cell carcinoma cell lines (786-O, Caki-2)" AMANTADIG treatment downregulated 28099931 5864 Human hsa-miR-23 miRNA high glucose (HG) epithelial-mesenchymal transition (EMT) human mesotheial peritoneal cells(HPMCs) high glucose treatment upregulated 28942023 5865 Human hsa-miR-23 miRNA intermittent hypoxia (IH) hypoxemia blood intermittent (HI) hypoxia treatment miR-23 was upregulated in intermittent (HI) hypoxia treatment group. 30416683 5866 Human hsa-miR-23-3p miRNA infliximab rheumatoid arthritis (RA) serological infliximab treatment upregulated 25860297 5867 Human hsa-miR-2355-5p miRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) nucleus pulposus (NP) cells lipopolysaccharide (LPS) treatment upregulated 30817728 5868 Human hsa-miR-2392 miRNA botulinum toxin A (BTXA) keloids human skin keloid fibroblasts (HSFBs) botulinum toxin A (BTXA) treatment upregulated 31652445 5869 Human hsa-miR-2392 miRNA glial cell-derived neurotrophic factor (GDNF) parkinson's disease (PD) SH-SY5Y human neuroblastoma cells GDNF downregulated 28829278 5870 Human hsa-miR-23a miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment downregulated 27158236 5871 Human hsa-miR-23a miRNA Korean Red ginseng extract (KRGE) angiogenesis HUVECs korean red ginseng extract (KRGE)? treatment downregulated 29021694 5872 Human hsa-miR-23a miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment downregulated 27158236 5873 Human hsa-miR-23a miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 5874 Human hsa-miR-23a miRNA arsenic trioxide (ATO) As2O3 cardiotoxicity hERG-HEK293 cells and neonatal cardiomyocytes arsenic trioxide (As2O3) treatment upregulated 25395240 5875 Human hsa-miR-23a miRNA IL-4 asthma BEAS©\2B cells IL©\4 treatment upregulated 31020662 5876 Human hsa-miR-23a miRNA thymic stromal lymphopoietin (TSLP) asthma "Human lung fibroblasts, HFL©\1" TSLP treatment upregulated 31020662 5877 Human hsa-miR-23a miRNA lipopolysaccharide (LPS) autophagy RAW 264.7 cells lipopolysaccharide (LPS) treatment downregulated 29845275 5878 Human hsa-miR-23a miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 5879 Human hsa-miR-23a miRNA arsenic trioxide (ATO) cardiotoxicity hERG-HEK293 cells and neonatal cardiomyocytes arsenic trioxide (As2O3) treatment upregulated 25395240 5880 Human hsa-miR-23a miRNA heat stress cellular stress response PErTA70 cells circulating water bath at 43?¡ãC for 1?h treatment upregulated 25429623 5881 Human hsa-miR-23a miRNA baicalin (BAI) colorectal cancer (CRC) HT29 cells baicalin (BAI) treatment downregulated 30262902 5882 Human hsa-miR-23a miRNA hypoxia colorectal cancer (CRC) HT29 cells; SW480 cells; Caco2 cells hypoxia treatment upregulated 30393198 5883 Human hsa-miR-23a miRNA hypoxia colorectal cancer (CRC) "HT-29, Caco2 and SW480 cells" hypoxia induce upregulated 30393198 5884 Human hsa-miR-23a miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) human HCT116 and HT29 colon carcinoma cell lines 5-fluorouracil (5-FU) treatment upregulated 24249161 5885 Human hsa-miR-23a miRNA IL-2 cytotoxicity PBMCs or tumor cell line K562; lymphoblastoid cell line R69 IL-2 treatment downregulated 24440757 5886 Human hsa-miR-23a miRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose (HG) treatment upregulated 28707079 5887 Human hsa-miR-23a miRNA tumor necrosis factor alpha (TNF-¦Á) apoptosis human primary endothelial cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 22038739 5888 Human hsa-miR-23a miRNA high glucose (HG) epithelial-mesenchymal transition (EMT) HK2 cells high glucose treatment upregulated 28707079 5889 Human hsa-miR-23a miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) A549 cells;PC9 cells; PC14 cells; LC2/ad; RERF-LC-KJ; RERF-LC-OK adenocarcinoma (AC) cell lines; PC1; PC10; LK2; SQ5 squamous cell carcinoma cell lines (SCC) TGF-¦Â treatment upregulated 22752005 5890 Human hsa-miR-23a miRNA fas ligand (FasL) gastric cancer (GC) human GI cancer cell lines Fas ligand (FasL) treatment upregulated 23929433 5891 Human hsa-miR-23a miRNA hyperthermia heat shock human OSCC cell lines HSC-2;HSC-3;HSC-4 HT at 44?C for 60 min treatment dysregulated 24789751 5892 Human hsa-miR-23a miRNA berberine (BBR) hepatocellular carcinoma (HCC) human HCC cells berberine (BBR) treatment upregulated 24942805 5893 Human hsa-miR-23a miRNA estrogen (ES) hepatocellular carcinoma (HCC) human liver cancer cell lines Estrogen (E2)treatment upregulated 26439986 5894 Human hsa-miR-23a miRNA etoposide (VP-16) hepatocellular carcinoma (HCC) HCC cells etoposide treatment upregulated 24103454 5895 Human hsa-miR-23a miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells hepatitis B virus (HBV) infection downregulated 31769216 5896 Human hsa-miR-23a miRNA TGF-¦Â endometrial endometrioid adenocarcinoma (EEC) HEC-1-A cells TGF-¦Â treatment downregulated 27601936 5897 Human hsa-miR-23a miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection upregulated 31371699 5898 Human hsa-miR-23a miRNA recombinant Human immunodeficiency virus (HIV) viral protein gp120 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment upregulated 31371699 5899 Human hsa-miR-23a miRNA recombinant Human immunodeficiency virus (HIV) viral protein Tat HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment upregulated 31371699 5900 Human hsa-miR-23a miRNA TGF-¦Â immunoregulatory function human CD8(+) T cells TGF-¦Â treatment upregulation 25030422 5901 Human hsa-miR-23a miRNA coptidis rhizoma aqueous extract hepatocellular carcinoma (HCC) human hcc mhcc97-l cells Coptidis rhizoma aqueous extract treatment upregulated 22977465 5902 Human hsa-miR-23a miRNA pristimerin lung cancer A549 and NCI-H446 cells Pristimerin treatment downregulated 30664149 5903 Human hsa-miR-23a miRNA dexamethasone (DEX) miRNA biogenesis human endothelial cells dexamethasone (Dex) treatment downregulated 28523344 5904 Human hsa-miR-23a miRNA ginsenoside Rg1 miRNA biogenesis human endothelial cells ginsenoside-Rg1 treatment downregulated 28523344 5905 Human hsa-miR-23a miRNA tumor necrosis factor alpha (TNF-¦Á) osteoblasts apoptosis "The clonal murine osteoblastic cell line, MC3T3-E1 £»Human embryonic kidney cell line (HEK-293)" tumor necrosis factor alpha (TNF-¦Á) treatment microRNA-23a depletion significantly enhances TNF-alpha-induced MC3T3-E1 cell apoptosis and over-expressing microRNA-23a remarkably attenuates this phenomenon 23804233 5906 Human hsa-miR-23a miRNA dexamethasone (DEX) osteogenesis human bone marrow-derived mesenchymal stem cells (hBMSCs) dexamethasone (DEX) treatment upregulated 24802236 5907 Human hsa-miR-23a miRNA follicle stimulating hormone (FSH) ovarian steroidogenesis human granulosa cell line KGN follicle-stimulating hormone (FSH) treatment dysregulated 26773729 5908 Human hsa-miR-23a miRNA H2O2 oxidative stress ARPE-19 cells ARPE-19 cells treatment upregulated 27411920 5909 Human hsa-miR-23a miRNA Sinomenine (SIN) prostate cancer PC3 and LNCaP cells Sinomenine (SIN) treatment downregulated 30784907 5910 Human hsa-miR-23a miRNA zinc(II) ions prostate cancer NCaP cells£» PC-3 human cell line£» 22Rv1 cell line zinc(II) ions treatment upregulated 23064315 5911 Human hsa-miR-23a miRNA lipopolysaccharide (LPS) psoriatic arthritis (PsA) primary synovial fibroblasts (SFC) lipopolysaccharide (LPS) treatment downregulated 30181004 5912 Human hsa-miR-23a miRNA lipopolysaccharide (LPS) psoriatic arthritis (PsA) PsA synovial fibroblasts (SFC) lipopolysaccharide (LPS) treatment downregulated 30181004 5913 Human hsa-miR-23a miRNA polyinosinic-polycytidilic acid (Poly(I:C)) psoriatic arthritis (PsA) PsA synovial fibroblasts (SFC) poly I:C treatment downregulated 30181004 5914 Human hsa-miR-23a miRNA polyinosinic-polycytidilic acid (Poly(I:C)) psoriatic arthritis (PsA) primary synovial fibroblasts (SFC) poly(I:C) treatment downregulated 30181004 5915 Human hsa-miR-23a miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia induce upregulated 29864909 5916 Human hsa-miR-23a miRNA X-rays stress response human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A a single dose of 5Gy ?-radiation downregulated 28851536 5917 Human hsa-miR-23a miRNA ultraviolet (UV) irradiation UVB-induced injury human keratinocyte cell line (HaCaT) cells UVB-irradiated? treatment upregulated 23158364 5918 Human hsa-miR-23a miRNA 2-deoxy glucose (2-DG) and thapsigargin (TG) warburg effect HeLa cells 2-Deoxy glucose (2-DG); Thapsigargin (TG) treatment downregulated 29377281 5919 Human hsa-miR-23a miRNA 1'-acetoxychavicol acetate extracellular signal-regulated kinase (ERK) phosphorylation HN4 cells 1'-acetoxychavicol acetate treatment downregulated 24317043 5920 Human hsa-miR-23a miRNA TGF-¦Â hepatocellular carcinoma (HCC) Huh-7 cells Transforming growth factor-beta (TGF-beta) treatment upregulated 18508316 5921 Human hsa-miR-23a-3p miRNA bone morphogenetic protein 4 (BMP4) breast cancer breast epithelial cell line bone morphogenetic protein 4 (BMP4) treatment upregulated 26684238 5922 Human hsa-miR-23a-3p miRNA bone morphogenetic protein 4 (BMP4) breast cancer BT-474 cell bone morphogenetic protein 4 (BMP4) treatment "four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment." 26684238 5923 Human hsa-miR-23a-3p miRNA H2O2 cataract human lens epithelial cells HLE-B3 H2O2 treatment "The results of the present study revealed that the expression levels of miR-23a-3p were significantly upregulated, while the expression levels of BCL2 were significantly downregulated in H2O2-induced HLE-B3 cells compared to untreated control cells." 33777189 5924 Human hsa-miR-23a-3p miRNA oxLDL and pitavastatin cholesterol homeostasis THP-1 cells oxLDL and pitavastatin treatment downregulated 27415822 5925 Human hsa-miR-23a-3p miRNA IL-17C colorectal cancer (CRC) DLD-1 cells IL-17C treatment "The expression of miR-23a-3p is higher in IL-17C (100 ng/mL, 3 h)-treated DLD-1 cells." 32492770 5926 Human hsa-miR-23a-3p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HT29 cells 5-fluorouracil (5-FU) treatment upregulated 25526515 5927 Human hsa-miR-23a-3p miRNA high glucose (HG) dilated cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment downregulated 33049089 5928 Human hsa-miR-23a-3p miRNA high glucose (HG) dilated cardiomyopathy (DCM) cardiomyocytes high-glucose (HG) treatment We observed that PVT1 and CASP10 were upregulated while miR-23a-3p was downregulated in high glucose-induced cardiomyocytes. 33049089 5929 Human hsa-miR-23a-3p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) SMMC-7721 cells-derived exosomes TGF-¦Â1 treatment upregulated 33194074 5930 Human hsa-miR-23a-3p miRNA toosendanin (TSN) gastric cancer (GC) MKN-45 cells toosendanin (TSN) treatment TSN upregulated the expression of miR-23a-3p 32582989 5931 Human hsa-miR-23a-3p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 5932 Human hsa-miR-23a-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment downregulated 27143365 5933 Human hsa-miR-23a-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment upregulated 27143365 5934 Human hsa-miR-23a-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 5935 Human hsa-miR-23a-3p miRNA osthole prostate cancer The PC3 and DU145 human AIPC cell lines Osthole treatment downregulated 26110567 5936 Human hsa-miR-23a-3p miRNA dexamethasone (DEX) steatosis HepG4 cells dexamethasone (Dex) treatment downregulated 29409992 5937 Human hsa-miR-23a-3p miRNA IL-1¦Â and IFN-¦Ã type 1 diabetes mellitus (T1DM) human ¦Â-cells cytokines IL-1¦Â plus IFN-¦Ã treatment dysregulated 27737950 5938 Human hsa-miR-23a-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 5939 Human hsa-miR-23a-5p miRNA ultraviolet (UV) irradiation cell senescence human fibroblast "the UVB irradiation output was monitored using a Waldmann UV meter (Waldmann, Villigen©\Schwenningen, Germany). UVB dose = UVB irradiance ¡Á time in second (s), with a distance of 15 cm between the lamp and cell culture dish. The UVB with 10 mJ/cm2 was delivered to cells daily for 5 days and at 48 hr after the last irradiation treatment" "circRNA_100797 could target miR-23a-5p, their expression levels were inversely associated in fibroblasts, and the miR-23a-5p overexpression blocked the effect of the overexpression of circRNA_100797 in UVB-SIPS" 30908647 5940 Human hsa-miR-23a-5p miRNA high glucose (HG) diabetic nephropathy (DN) GEnCs high glucose (HG) treatment LncOR13C9 could regulate ABCA1 by inhibiting the action of miR-23a-5p in the LXR pathway. 33192550 5941 Human hsa-miR-23a-5p miRNA prostaglandin E2 (PGE2) liver fibrosis TGF-¦Â1-treated LX-2 cells PGE2 treatment downregulated 29109031 5942 Human hsa-miR-23a-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment upregulated 29109031 5943 Human hsa-miR-23a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) MH7A cells tumor necrosis factor alpha (TNF-¦Á) treatment The results of the present study revealed that the expression levels of miR-23a-5p were significantly downregulated in the plasma of patients with RA and in MH7A cells 33767774 5944 Human hsa-miR-23b miRNA pulsatile shear (PS) flow retinoblastoma (RB) vascular endothelial cells (ECs) pulsatile shear (PS) flow treatment downregulated 20133741 5945 Human hsa-miR-23b miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MDA-MB-231 cells anacardic acid (AnAc) treatment downregulated 28886127 5946 Human hsa-miR-23b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP1 cells oxidized low-density lipoprotein (ox-LDL) treatment "LINC01140 was downregulated, while p53 and miR-23b were upregulated in oxLDL-induced inflammatory response of macrophages." 31748847 5947 Human hsa-miR-23b miRNA IL-17 autoimmune inflammation human fibroblast-like synoviocytes£»astrocytes IL-17 treatment downregulated 22660635 5948 Human hsa-miR-23b miRNA beryllium sulfate (BeSO4 ) beryllium toxicity 16HBE cells beryllium sulfate (BeSO4 ) treatment downregulated 33197057 5949 Human hsa-miR-23b miRNA genistein breast cancer MCF-7 cell Genistein treatment upregulated 26199568 5950 Human hsa-miR-23b miRNA genistein breast cancer "MCF-7 cell, line" genistein treatment miR-23b was found to be upregulated 56.69 fold 26199568 5951 Human hsa-miR-23b miRNA sulforaphane (SFN) breast cancer "breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)" SFN (5-10 ?M) treatment downregulated 28912888 5952 Human hsa-miR-23b miRNA brucella Omp25 brucellosis human Monocyte/Macrophages brucella Omp25 treatment upregulated 28694807 5953 Human hsa-miR-23b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cervical cancer (CC) "HeLa, SiHa, CaSki and C33A cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26622315 5954 Human hsa-miR-23b miRNA oxaliplatin colorectal cancer (CRC) Human colorectal carcinoma HCT116 and human colorectal adenocarcinoma DLD-1 cells oxaliplatin treatment "miR-23b/27b/24-1 cluster was overexpressed in oxaliplatin-resistant cells The knockout of miR-23b led to the partial restoration of oxaliplatin susceptibility, showing the essential role of miR-23b in the development of drug resistance by this cluster" 31810268 5955 Human hsa-miR-23b miRNA high glucose (HG) diabetic nephropathy (DN) "human kidney proximal tubular epithelial cells ,HK2" "human kidney proximal tubular epithelial cells ,HK2 treatment" downregulated 26646104 5956 Human hsa-miR-23b miRNA high glucose (HG) diabetic nephropathy (DN) human kidney proximal tubular epithelial cells (HK2) high glucose (HG) treatment downregulated 26646104 5957 Human hsa-miR-23b miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells HK-2 cells treatment downregulated 26839366 5958 Human hsa-miR-23b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" glioblastoma multiforme (GBM) "glioma stem cells (GSCs) ,U87 cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 22982144 5959 Human hsa-miR-23b miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Plasma hepatitis B virus (HBV) infection ?upregulated 22105822 5960 Human hsa-miR-23b miRNA BAY11-7082 osteogenesis TNF-¦Á-treated bone marrow mesenchymal stem cell (BMSC) BAY 11-7082 treatment downregulated 29234953 5961 Human hsa-miR-23b miRNA tumor necrosis factor alpha (TNF-¦Á) osteogenesis bone marrow mesenchymal stem cell (BMSC) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29234953 5962 Human hsa-miR-23b miRNA tumor necrosis factor alpha (TNF-¦Á) osteogenesis human bone marrow mesenchymal stem cell (BMSC) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29234953 5963 Human hsa-miR-23b miRNA r-rays pancreatic cancer (PC) pancreatic cancer cell lines radiation treatment "In pancreatic cancer cells, reduced levels of the miRNA MIR23B increase levels of ATG12 and autophagy to promote radioresistance MIR23B might be used to increase the sensitivity of pancreatic cancer cells to radiation therapy" 23916944 5964 Human hsa-miR-23b miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 5965 Human hsa-miR-23b miRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment downregulated 31780861 5966 Human hsa-miR-23b miRNA "high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)" skin fibrosis human skin fibroblast HF-LED-RL at 320 and 640?J/cm2 radiation downregulated 30182520 5967 Human hsa-miR-23b miRNA low-dose ionizing radiation (LDIR) stress response human Epstein-Barr virus-infected B-cells (EBV-B) low-dose ionizing radiation (LDIR) treatment upregulated 26809544 5968 Human hsa-miR-23b miRNA retinoic acid (RA) rhinovirus 1B (RV1B) infection hela cells Retinoic acid treatment downregulated 21642441 5969 Human hsa-miR-23b-3p miRNA angiotensin II (Ang II) atrial fibrillation (AF) Human atrial fibroblasts (HAFs) angiotensin II (Ang II) treatment upregulated 30729664 5970 Human hsa-miR-23b-3p miRNA bone morphogenetic protein 4 (BMP4) breast cancer breast epithelial cell line bone morphogenetic protein 4 (BMP4) treatment upregulated 26684238 5971 Human hsa-miR-23b-3p miRNA bone morphogenetic protein 4 (BMP4) breast cancer BT-474 cell bone morphogenetic protein 4 (BMP4) treatment "four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment." 26684238 5972 Human hsa-miR-23b-3p miRNA TGF-¦Â cataract lens epithelial cells (LECs) TGF-¦Â treatment upregulated 31235073 5973 Human hsa-miR-23b-3p miRNA 5-fluorouracil (5-Fu) chemoresistance of 5-fluorouracil (5-FU) SW480 and SW620 5-fluorouracil (5-FU) treatment UCA1 mediated 5-FU resistance of CRC cells through facilitating autophagy and inhibiting apoptosis via miR-23b-3p/ZNF281 axis in vivo and in vitro. 32801774 5974 Human hsa-miR-23b-3p miRNA oxLDL and pitavastatin cholesterol homeostasis THP-1 cells oxLDL and pitavastatin treatment downregulated 27415822 5975 Human hsa-miR-23b-3p miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (MCs) high glucose (HG) treatment downregulated 32322310 5976 Human hsa-miR-23b-3p miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) high glucose treatment upregulated 26687158 5977 Human hsa-miR-23b-3p miRNA 10-hydroxycamptothecin (HCPT) epidural fibrosis human fibroblasts 10-Hydroxycamptothecin (HCPT) treatment upregulated 30720099 5978 Human hsa-miR-23b-3p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment upregulated 25129238 5979 Human hsa-miR-23b-3p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 5980 Human hsa-miR-23b-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 5981 Human hsa-miR-23b-3p miRNA IL-1¦Â osteoarthritis (OA) Human chondrocyte cell line CHON-001 IL-1¦Â treatment upregulated 31440033 5982 Human hsa-miR-23b-3p miRNA IL-1¦Â and IFN-¦Ã type 1 diabetes mellitus (T1DM) human ¦Â-cells cytokines IL-1¦Â plus IFN-¦Ã treatment dysregulated 27737950 5983 Human hsa-miR-23b-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 5984 Human hsa-miR-23c miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment downregulated 29393545 5985 Human hsa-miR-23c miRNA oxLDL and pitavastatin cholesterol homeostasis THP-1 cells oxLDL and pitavastatin treatment downregulated 27415822 5986 Human hsa-miR-23c miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells downregulated 27964927 5987 Human hsa-miR-23c miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells streptozotocin treatment downregulated 27964927 5988 Human hsa-miR-23c miRNA high glucose (HG) diabetic nephropathy (DN) mouse mesangial cells (MMCs) high glucose (HG) treatment downregulated 32096162 5989 Human hsa-miR-23c miRNA steviol gastrointestinal cancer MKN-45 cells steviol treatment downregulated 29899860 5990 Human hsa-miR-24 miRNA H2O2 age-related cataract (ARC) human lens epithelial cells (LECs) H2O2 treatment upregulated 29393409 5991 Human hsa-miR-24 miRNA celastrol apoptosis A549 cells celastrol treatment upregulated 29434967 5992 Human hsa-miR-24 miRNA etoposide (VP-16) apoptosis highly differentiated CD8(+) T cells etoposide treatment upregulated 22435726 5993 Human hsa-miR-24 miRNA cholesterol atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) cholesterol treatment downregulated 33755271 5994 Human hsa-miR-24 miRNA theaflavin (TF) atherosclerosis (AS) cholesterol-treated human umbilical vein endothelial cells (HUVECs) theaflavin (TF)?treatment treatment upregulated 33755271 5995 Human hsa-miR-24 miRNA hypoxia brain injury SH-SY5Y cells hypoxia treatment downregulated 27349868 5996 Human hsa-miR-24 miRNA propofol (PPF) breast cancer MDA-MB-435 cells propofol treatment downregulated 29103019 5997 Human hsa-miR-24 miRNA TGF-¦Â breast cancer "Human HaCaT keratinocytes, human embryonic kidney cells(HEK293) and thehuman cancer cell lines (MDAMB231, T47D, DU145, BT474,SKBR3 and MCF7)" TGF-¦Â treatment over expression 21986943 5998 Human hsa-miR-24 miRNA phenylephrine (PE) cardiac hypertrophy cardiomyocytes Phenylephrine (PE) treatment upregulated 32898528 5999 Human hsa-miR-24 miRNA hypoxia/reoxygenation (H/R) cerebral ischemia/reperfusion (I/R) injury human umbilical cord MSCs (HMCs)-derived exosome hypoxia/reoxygenation (H/R) treatment upregulated 33258087 6000 Human hsa-miR-24 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) The bronchial epithelial cells (BEAS-2B and 16HBE) cigarette smoke extract (CSE) treatment Circ_0006892 expression was reduced in lung tissues of smokers with COPD and CSE-stimulated bronchial epithelial cells. 33734482 6001 Human hsa-miR-24 miRNA melatonin colorectal cancer (CRC) HCT 116 and MCF-7 cells melatonin treatment downregulated 26967561 6002 Human hsa-miR-24 miRNA hypoxia colorectal cancer (CRC) "HT-29, Caco2 and SW480 cells" hypoxia induce upregulated 30393198 6003 Human hsa-miR-24 miRNA hypoxia colorectal cancer (CRC) HT29 cells; SW480 cells; Caco2 cells hypoxia treatment upregulated 30393198 6004 Human hsa-miR-24 miRNA Helicobacter pylori (H. pylori) extract (HPE) gastric cancer (GC) HGC-27 cells Helicobacter pylori (H. pylori) infection upregulated 33065487 6005 Human hsa-miR-24 miRNA cyclic mechanical stretch (CMS) glaucoma human trabecular meshwork cells cyclic mechanical stress (CMS) treatment downregulated 20945401 6006 Human hsa-miR-24 miRNA TGF-¦Â1 hypertrophic scars (HS) fibroblasts TGF-¦Â1 treatment downregulated 25837671 6007 Human hsa-miR-24 miRNA nicotine idiopathic pulmonary fibrosis (IPF) Normal human lung epithelial cells nicotine treatment downregulated 30446578 6008 Human hsa-miR-24 miRNA nicotine idiopathic pulmonary fibrosis (IPF) Primary human lung epithelial cells nicotine treatment downregulated 30446578 6009 Human hsa-miR-24 miRNA "anti-CD3, anti-CD28, IL-12, , IL-18" innate and adaptive immune responses PB CD4+ T cells "co-stimulating with anti-CD3, anti-CD28, IL-12, and IL-18 treatment" downregulated 24704866 6010 Human hsa-miR-24 miRNA trinitrobenzene sulfonic acid (TNBS) irritable bowel syndrome (IBS) trinitro-benzene-sulfonic acid (TNBS) treatment upregulated 26631964 6011 Human hsa-miR-24 miRNA kidney transplantation kidney transplantation patients kidney kidney transplantation treatment upregulated 24854275 6012 Human hsa-miR-24 miRNA sodium selenite hepatocellular carcinoma (HCC) HLF cells sodium selenite treatment "miR-24 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM" 32656599 6013 Human hsa-miR-24 miRNA celastrol lung cancer A549 cells; LTEP-a-2 cells celastrol treatment miR-24 was upregulated in celastrol-treated LTEP-a-2 cells. 29434967 6014 Human hsa-miR-24 miRNA noise noise-induced hearing loss (NIHL) plasma noise treatment downregulated 26278637 6015 Human hsa-miR-24 miRNA fatty acid nonalcoholic fatty liver disease (NAFLD) human hepatocytes incubat fatty acid treatment upregulated 24677249 6016 Human hsa-miR-24 miRNA pemetrexed non-small cell lung cancer (NSCLC) NSCLC tissue pemetrexed treatment upregulated 23794259 6017 Human hsa-miR-24 miRNA oleic acid (OA) obesity HepG2 cells oleic acid (OA) treatment downregulated 29787826 6018 Human hsa-miR-24 miRNA palmitic acid (PA) obesity HepG2 cells palmitic acid (PA) treatment upregulated 29787826 6019 Human hsa-miR-24 miRNA ¦Ã- Mangostin (¦Ã-MS) osteoarthritis (OA) SW982 cells ¦Ã- Mangostin (¦Ã-MS) treatment upregulated 32302289 6020 Human hsa-miR-24 miRNA follicle stimulating hormone (FSH) ovarian steroidogenesis human granulosa cell line KGN follicle-stimulating hormone (FSH) treatment dysregulated 26773729 6021 Human hsa-miR-24 miRNA H2O2 periodontal tissue damage and repair periodontal ligament cells (PDLCs) H2O2 treatment upregulated 27188727 6022 Human hsa-miR-24 miRNA zirconia and titanium preosteoblast differentiation Osteoblast-like cells (MG63) zirconia and titanium? treatment downregulated 18241218 6023 Human hsa-miR-24 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" prostate cancer AfA cell line (MDA-PCa-2b) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28157714 6024 Human hsa-miR-24 miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed downregulated 27915273 6025 Human hsa-miR-24 miRNA Staphylococcus aureus staphylococcus aureus infection human macrophage cell lines infect with S. aureus treatment downregulated 28303416 6026 Human hsa-miR-24 miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 6027 Human hsa-mir-24 miRNA stress cell senescence CD138+ plasma cells stress treatment mir-24 activity propagates stress-induced senescence by down regulating TOP1 26748253 6028 Human hsa-miR-24 miRNA IL-1¦Â terminal chondrogenesis primary OA chondrocytes;mesenchymal stem cells IL-1-¦Â treatment downregulated 24572376 6029 Human hsa-miR-24-1 miRNA ionizing radiation (IR) anti-cancer therapy SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG ionizing radiation treatment upregulated 21453501 6030 Human hsa-miR-24-1 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 6031 Human hsa-miR-24-1-5p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 6032 Human hsa-miR-24-2 miRNA X-rays stress response human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A a single dose of 5Gy ?-radiation downregulated 28851536 6033 Human hsa-miR-24-2-5p miRNA kynurenine bone loss bone marrow stromal cells (BMSCs) kynurenine treatment upregulated 31790802 6034 Human hsa-miR-24-2-5p miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 6035 Human hsa-miR-24-3p miRNA IL-6 spermatogonial differentiation "primary B cells, plasma blasts, plasma cells, and in plasmacytoma cells" interleukin-6 treatment upregulated 23934711 6036 Human hsa-miR-24-3p miRNA platelet derived growth factor-BB (PDGF-BB) arteriosclerosis obliterans (ASO) HASMCs Platelet-derived growth factor BB (PDGF-BB) treatment downregulated 26159387 6037 Human hsa-miR-24-3p miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment downregulated 26151338 6038 Human hsa-miR-24-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 33675584 6039 Human hsa-miR-24-3p miRNA etoposide (VP16) and cisplatin (DDP) advanced-stage small-cell lung cancer (SCLC) VP16-DDP-resistant SCLC cells (H446/EP) etoposide (VP16) and cisplatin (DDP) treatment dysregulated 25426560 6040 Human hsa-miR-24-3p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) SMMC-7721 cells-derived exosomes TGF-¦Â1 treatment upregulated 33194074 6041 Human hsa-miR-24-3p miRNA TGF-¦Â1 hepatocarcinogenesis Hep3B cells TGF-¦Â1 treatment upregulated 32269736 6042 Human hsa-miR-24-3p miRNA azacitidine (AZA) myelodysplastic syndrome (MDS) bone marrow CD34+ cells azacitidine (AZA) treatment downregulated 29630523 6043 Human hsa-miR-24-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment upregulated 27143365 6044 Human hsa-miR-24-3p miRNA cisplatin (DDP) ovarian cancer (OC) human ovarian cancer cells OVCAR-8R cisplatin treatment dysregulated 28861582 6045 Human hsa-miR-24-3p miRNA paclitaxel (PTX) paclitaxel (PTX) resistance PC3-TXR cells; DU145-TXR cells Paclitaxel (PTX) treatment Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1 32089062 6046 Human hsa-miR-24-3p miRNA hydrocarbons (PAHs) hydrocarbons (PAHs) toxic action 20 exposed workers pooled plasma samples exposed to PAHs treatment dysregulated 24633190 6047 Human hsa-miR-2467 miRNA cisplatin (DDP) epithelial ovarian cancer (EOC) "Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)" cisplatin treatment Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel. 31581131 6048 Human hsa-miR-2467 miRNA paclitaxel (PTX) epithelial ovarian cancer (EOC) "Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)" paclitaxel treatment Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel 31581131 6049 Human hsa-miR-24a-3p miRNA polyinosinic-polycytidilic acid (Poly(I:C)) lower respiratory tract infections BEAS-2B cells poly(I:C) treatment downregulated 31837465 6050 Human hsa-miR-25 miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis and coronary heart disease vascular smooth muscle cell tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 25672882 6051 Human hsa-miR-25 miRNA epigallocatechin-3-gallate (EGCG) breast cancer MCF-7 cells epigallocatechin-3-gallate (EGCG) treatment downregulated 31431131 6052 Human hsa-miR-25 miRNA oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) chronic inflammatory diseases human umbilical vein endothelial cells (HUVECs) exosomes oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment upregulated 29161413 6053 Human hsa-miR-25 miRNA helicobacter pylori (H. pylori) coronary heart disease (CHD) gastric epithelial cells Helicobacter pylori infection upregulated 31750260 6054 Human hsa-miR-25 miRNA cyclopamine cholangiocarcinoma (CCA) human cholangiocyte cell line H69£»KMCH cells £»Mz-ChA-1 cells cyclopamine treatment downregulated 21953056 6055 Human hsa-miR-25 miRNA high glucose (HG) diabetic nephropathy (DN) human kidney (HK-2) cells high glucose treatment downregulated 29031207 6056 Human hsa-miR-25 miRNA ozone (O3) epigenetic regulation of responses to O3 exposure healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 6057 Human hsa-miR-25 miRNA suberoylanilide hydroxamic acid (SAHA) hepatocellular carcinoma (HCC) Hep3B and Huh7 HCC cell lines suberanilohydroxamic acid (SAHA) treatment upregulated 31092334 6058 Human hsa-mir-25 miRNA triptolide (TPL) hepatocellular carcinoma (HCC) HepG2 cells triptolide (TPL) treatment downregulated 29523159 6059 Human hsa-miR-25 miRNA oxygen glucose deprivation (OGD) ischemia/reperfusion (I/R) injury Human SH-SY5Y and IMR-32 cells oxygen-glucose deprivation (OGD) treatment downregulated 26768135 6060 Human hsa-miR-25 miRNA K. pneumoniae reference strains (K. pneumoniae ATCC 10031) klebsiella pneumoniae infection BEAS 2B cells K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection upregulated 33322147 6061 Human hsa-miR-25 miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells KPC-producing K. pneumoniae infection upregulated 33322147 6062 Human hsa-miR-25 miRNA klebsiella pneumoniae klebsiella pneumoniae infection BEAS 2B cells MS K. pneumoniae infection upregulated 33322147 6063 Human hsa-miR-25 miRNA pemetrexed lung adenocarcinoma (LUAD) serum pemetrexed treatment "Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations" 26687391 6064 Human hsa-miR-25 miRNA radiation lung cancer A549 cells radiation treatment upregulated 32968458 6065 Human hsa-miR-25 miRNA berberine (BBR) multiple myeloma (MM) "human multiple myeloma cell, RPMI-8266 and U266" berberine (BBR) treatment downregulated 27647143 6066 Human hsa-miR-25 miRNA methylmercury (MeHg) neurotoxicity human neural progenitor cells (ihNPCs) methylmercury (MeHg) treatment downregulated 27941687 6067 Human hsa-miR-25 miRNA diet obesity Plasma diet treatment "Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss." 32439373 6068 Human hsa-miR-25 miRNA ginsenoside Rb1 ovarian cancer (OC) "human ovarian cancer cell lines, SKOV3 and 3AO" Ginsenoside Rb1 downregulated 28928801 6069 Human hsa-miR-25 miRNA hypoxia ovarian cancer (OC) "human ovarian cancer cell lines, SKOV3 ;3AO" hypoxia treatment upregulated 28928801 6070 Human hsa-miR-25 miRNA physcion 8-O-¦Â-glucopyranoside (PG) ovarian cancer (OC) SKOV3 and OVCAR-3 cells Physcion 8-O-¦Â-Glucopyranoside (PG) treatment downregulated 31298363 6071 Human hsa-miR-25 miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment downregulated 21093163 6072 Human hsa-miR-25 miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 6073 Human hsa-miR-25 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 6074 Human hsa-miR-25 miRNA hypoxia prostate cancer PCa cell lines (LNCaP£» PC3)£»neural crest (NC) cells hypoxia treatment downregulated 24135225 6075 Human hsa-miR-25 miRNA hypoxia prostate cancer LNCaP cells 5% O2 treatment upregulated 24135225 6076 Human hsa-miR-25 miRNA salvianolic acid B (Sal B) renal fibrosis human kidney proximal tubular epithelial cells (HK-2 cells) Sal B treatment upregulated 25094038 6077 Human hsa-miR-25 miRNA TGF-¦Â1 renal fibrosis human kidney proximal tubular epithelial cells (HK-2 cells) TGF-¦Â1 treatment downregulated 25094038 6078 Human hsa-miR-25 miRNA lipopolysaccharide (LPS) sepsis peripheral blood mononuclear cells (PBMCs) derived macrophages lipopolysaccharide (LPS) treatment downregulated 30250569 6079 Human hsa-miR-25 miRNA ginkgolide A (GA) sepsis-induced renal injury NRK-52E cells Ginkgolide A (GA) treatment The sepsis-induced decrease of miR-25 was enhanced by GA treatment. 33677255 6080 Human hsa-miR-25 miRNA lipopolysaccharide (LPS) sepsis-induced renal injury NRK-52E cells lipopolysaccharide (LPS) treatment The sepsis-induced decrease of miR-25 was enhanced by GA treatment. 33677255 6081 Human hsa-miR-25 miRNA ginsenoside Rb1 skin wrinkle formation human dermal fibroblasts Ginsenoside Rb1 treatemnt downregulated 22692056 6082 Human hsa-miR-25 miRNA IL-23 thyroid cancer (TC) thyroid cancer cells IL-23 treatment upregulated 26437444 6083 Human hsa-miR-25 miRNA statins unstable angina (UA) plasma statins? treatment downregulated 26474612 6084 Human hsa-miR-25-3p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment upregulated 31722571 6085 Human hsa-miR-25-3p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment upregulated 31722571 6086 Human hsa-miR-25-3p miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment High-glucose inhibited METTL3 and miR-25-3p expressions in RPE cells. 32365051 6087 Human hsa-miR-25-3p miRNA IL-1¦Â intervertebral disc degeneration (IDD) NP cells IL-1¦Â treatment MicroRNA-25-3p therapy for intervertebral disc degeneration by targeting the IL-1¦Â/ZIP8/MTF1 signaling pathway with a novel thermo-responsive vector 33313245 6088 Human hsa-miR-25-3p miRNA H2O2 mitophagy HeLa and HEK 293T cells H2O2 treatment "We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions." 33627622 6089 Human hsa-miR-25-3p miRNA cigarette smoke condensate (CSC) pancreatic cancer (PC) HPDE6-C7 cells cigarette smoke condensate (CSC) treatment upregulated 31015415 6090 Human hsa-miR-25-3p miRNA particulate matter (PM2.5) PM2.5-induced carcinogenesis human bronchial epithelial (HBE) cells fine particulate matter (PM2.3) treatment upregulated 33545377 6091 Human hsa-miR-25-5p miRNA thrombospondin-1 (TSP-1) angiogenesis vascular smooth muscle cell (VSMC) Thrombospondin-1 (TSP-1) treatment downregulated 26728995 6092 Human hsa-miR-25-5p miRNA racemate endogenous antioxidant defenses Caco-2 cells subtoxic concentrations of racemate treatment upregulated 28264488 6093 Human hsa-miR-25-5p miRNA curcumin (Cur) lung cancer human non-small cell lung cancer A549 cell line curcumin treatment dysregulated 28660665 6094 Human hsa-miR-25-5p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) HK1 cell line concentration treatment dysregulated 24896104 6095 Human hsa-miR-25-5p miRNA oxidized low density lipoprotein (ox-LDL) vascular disease human brain microvessel endothelial cells (HBMECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31365884 6096 Human hsa-miR-26 miRNA TGF-¦Â endothelium-dependent vasorelaxation HT-29 cells TGF-¦Â treatment downregulated 23483606 6097 Human hsa-miR-26 miRNA oxaliplatin gastric cancer (GC) HGC-27 cells; BGC-823 cells oxaliplatin (OXA) treatment downregulated 31617275 6098 Human hsa-miR-26 miRNA hypoxia hypoxemia blood chronic hypoxia (CH) miR-26 was upregulated in chronic hypoxia (CH) treatment group. 30416683 6099 Human hsa-miR-26 miRNA bushen yijing decoction (BSYJ) systemic sclerosis (SSc) primary skin fibroblasts Bushen Yijing decoction (BSYJ)? treatment BSYJ-containing rat serum suppressed miR-26a expression 33843426 6100 Human hsa-miR-26-5p miRNA ethanol extract of antrodia cinnamomea (AC) breast cancer MCF-7 and tamoxifen-resistant MCF-7 cells ethanol extract of antrodia cinnamomea (AC) treatment upregulated 29743060 6101 Human hsa-miR-26a miRNA cisplatin (DDP) acute kidney injury (AKI) HK-2 cells cisplatin treatment downregulated 31887787 6102 Human hsa-miR-26a miRNA cisplatin (DDP) acute kidney injury (AKI) HK2 cells cisplatin treatment miR-26a was significantly downregulated during cisplatin-induced AKI and during cisplatin co-cultured HK2 cells. 31887787 6103 Human hsa-miR-26a miRNA H2O2 acute respiratory distress syndrome (ARDS) Type II alveolar epithelial cells (AEC-II) H2O2 treatment downregulated 29424907 6104 Human hsa-miR-26a miRNA vascular endothelial growth factor (VEGF) angiogenesis HUVECs VEGF treatment downregulated 28602162 6105 Human hsa-miR-26a miRNA mechanical stretch asthma human airway smooth muscle cells (HASMCs) Mechanical stretch up treatment upregulated 20525681 6106 Human hsa-miR-26a miRNA tanshinol (TAN) atherosclerosis (AS) endothelial cells tanshinol treatment upregulated 27508018 6107 Human hsa-miR-26a miRNA gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor breast cancer BRCA1 wild-type cells (MDA-MB-231) gemcitabine-alone and in combination with PARP1 inhibitor treatment upregulated 25202071 6108 Human hsa-miR-26a miRNA metformin (Met) breast cancer MCF-7 breast cancer cell lines metformin treatment upregulated 27517917 6109 Human hsa-miR-26a miRNA trastuzumab breast cancer HER2-positive (SKBR3£» BT474) £» HER2-negetive (MCF7 £» MDA-MB-231) cells Trastuzumab treatment upregulated 22384020 6110 Human hsa-miR-26a miRNA trastuzumab breast cancer BT474 wt cells trastuzumab treatment upregulated 28120942 6111 Human hsa-miR-26a miRNA "dexamethasone (DEX), ascorbic acid, and ¦Â-glycerol phosphate" cell differentiation human adipose tissue¨Cderived stem cells(hADSCs) "dexametha-sone, ascorbic acid, and ¦Â-glycerol phosphate treatment" upregulated 18197755 6112 Human hsa-miR-26a miRNA estrogen (ES) cell proliferation "MCF-7¡¢T47D¡¢MDA-MB-231 , BT549 cell" estrogen treatment downregulated 24735615 6113 Human hsa-miR-26a miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia injury (CII) SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31486504 6114 Human hsa-miR-26a miRNA omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) cholangiocarcinoma (CCA) human cholangiocarcinoma cell omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) treatment downregulated 25691459 6115 Human hsa-miR-26a miRNA ginsenoside Rg1 diabetic retinopathy (DR) high glucose (HG)-treated human retinal pigment epithelium cells (ARPE-19) Ginsenoside Rg1 (Rg1) treatment upregulated 30763577 6116 Human hsa-miR-26a miRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelium cells (ARPE-19) high glucose (HG) treatment downregulated 30763577 6117 Human hsa-miR-26a miRNA thapsigargin (Tg) endoplasmic reticulum stress (ERS) HepG2 cells thapsigargin (Tg) treatment upregulated 32567701 6118 Human hsa-miR-26a miRNA tunicamycin (TM) endoplasmic reticulum stress (ERS) HepG2 cells tunicamycin (Tu) treatment upregulated 32567701 6119 Human hsa-miR-26a miRNA oxidized low density lipoprotein (ox-LDL) endothelial cells injury and autophagy dysfunction human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment GAS5 expression was upregulated and miR-26a was downregulated in the plasma samples of patients with atherosclerosis and ox-LDL-treated HAECs. 30468731 6120 Human hsa-miR-26a miRNA oxidized low density lipoprotein (ox-LDL) endothelial dysfunction human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment "GAS5 knockdown inhibited cell apoptosis and activated autophagy flux, whereas inhibition of miR-26a reversed the effect of GAS5 in HAECs." 30468731 6121 Human hsa-miR-26a miRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) Primary human lens epithelial cells (LECs) TGF-¦Â2 treatment downregulated 31143769 6122 Human hsa-miR-26a miRNA curcumin (Cur) thyroid cancer (TC) "human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101" curcumin treatment downregulated 28265769 6123 Human hsa-miR-26a miRNA cisplatin (DDP) gastric cancer (GC) SGC-7901 / DDP cisplatin-resistant treatment downregulated 26458859 6124 Human hsa-miR-26a miRNA cisplatin (DDP) glioblastoma multiforme (GBM) human glioblastoma cells cisplatin treatment downregulated 28499919 6125 Human hsa-miR-26a miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia induce upregulated 30425242 6126 Human hsa-miR-26a miRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) "HepG2,Huh-7, 293T" DOX at a range of 0.5¨C25?¦ÌM over a period of 10 months downregulated 28079894 6127 Human hsa-miR-26a miRNA lipopolysaccharide (LPS) inflammation "Human renal proximal tubular epithelial cell lines, HK-2 and RPTECs" lipopolysaccharide (LPS) treatment downregulated 31158334 6128 Human hsa-miR-26a miRNA notoginsenoside R1 (NGR1) inflammation "LPS-treated Human renal proximal tubular epithelial cell lines, HK-2 and RPTECs" Notoginsenoside R1 (NGR1) treatment upregulated 31158334 6129 Human hsa-miR-26a miRNA hypoxia ischemia/reperfusion (I/R) injury human mesenchymal stem cells (MSCs) hypoxia treatment "miRNA-26a was significantly increased in EV(HM), compared with EV(NM)." 29978610 6130 Human hsa-miR-26a miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated 18648749 6131 Human hsa-miR-26a miRNA ultraviolet (UV) irradiation hepatocellular carcinoma (HCC) HepG2 cells UV irradiation treatment upregulated 24431000 6132 Human hsa-miR-26a miRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells cisplatin treatment upregulated 31432162 6133 Human hsa-miR-26a miRNA TLR9 ligand CpG-oligodeoxynucleotides (CpG-ODN) lung cancer H460 human lung cancer cells CpG-ODN treatment upregulated 24788552 6134 Human hsa-miR-26a miRNA water-extracted PM10 (WE-PM10) lung cancer human lung adenocarcinoma A549 cells exposure to 25 and 50 ¦Ìg/ml of WE-PM10 for 48 h treatment downregulated 29222745 6135 Human hsa-miR-26a miRNA IFN-¦Â multiple sclerosis (MS) MS patients interferon-¦Â treatment downregulated 28962897 6136 Human hsa-miR-26a miRNA palmitic acid (PA) myocardial lipotoxic injury human cardiomyocytes (AC16 cells) palmitic acid (PA) treatment downregulated 31123414 6137 Human hsa-miR-26a miRNA A23187 nonalcoholic fatty liver disease (NAFLD) "HepG2, Huh7, 786-O cells" A23187 treatment upregulated 32567701 6138 Human hsa-miR-26a miRNA compound C nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) compound C treatment downregulated 32143184 6139 Human hsa-miR-26a miRNA compound C nonalcoholic fatty liver disease (NAFLD) HepG2 cells compound C treatment downregulated 32143184 6140 Human hsa-miR-26a miRNA oleic acid (OA) nonalcoholic fatty liver disease (NAFLD) "HepG2, Huh7, 786-O cells" oleate acid (OA) treatment upregulated 32567701 6141 Human hsa-miR-26a miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) "HepG2, Huh7, 786-O cells" palmitate acid (PA) treatment upregulated 32567701 6142 Human hsa-miR-26a miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmitic acid treatment downregulated 32143184 6143 Human hsa-miR-26a miRNA particulate matter (PM2.5) nonalcoholic fatty liver disease (NAFLD) HepG2 cells particular matters (PM) PM2.5 treatment downregulated 30798028 6144 Human hsa-miR-26a miRNA thapsigargin (Tg) nonalcoholic fatty liver disease (NAFLD) "HepG2, Huh7, 786-O cells" thapsigargin (Tg) treatment upregulated 32567701 6145 Human hsa-miR-26a miRNA tunicamycin (TM) nonalcoholic fatty liver disease (NAFLD) "HepG2, Huh7, 786-O cells" tunicamycin (Tu) treatment upregulated 32567701 6146 Human hsa-miR-26a miRNA pan-HDAC inhibitor ITF2357 non-Hodgkin lymphoma (NHL) human B-cell non-Hodgkin lymphomas (B-NHLs) pan-HDAC inhibitor ITF2357 treatment upregulated 24648290 6147 Human hsa-miR-26a miRNA metformin (Met) oral cancer KB human oral cancer cells metformin treatment upregulated 27082123 6148 Human hsa-miR-26a miRNA IL-1¦Â osteoarthritis (OA) human Chondrocytes-articular IL-1¦Â treatment downregulated 28276108 6149 Human hsa-miR-26a miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-1¦Â treatment downregulated 29208566 6150 Human hsa-miR-26a miRNA IL-1¦Â osteoarthritis (OA) SW1353 cells IL-1¦Â treatment upregulated 32522568 6151 Human hsa-miR-26a miRNA metformin (Met) pancreatic cancer (PC) Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR Metformin? treatment downregulated 22086681 6152 Human hsa-miR-26a miRNA cadmium (Cd) preeclampsia (PE) JEG-3 cells cadmium (Cd) treatment upregulated 28774740 6153 Human hsa-miR-26a miRNA metformin (Met) renal cancer 786-O cells metformin treatment upregulated 25419360 6154 Human hsa-miR-26a miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment upregulated 17653614 6155 Human hsa-miR-26a miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment downregulated 18573151 6156 Human hsa-miR-26a miRNA S-adenosylhomocysteine hydrolase (AHCY) prostate cancer LNCaP-hr cells AHCY treatment upregulated 28705714 6157 Human hsa-miR-26a miRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment downregulated 30542439 6158 Human hsa-miR-26a miRNA resistance exercise training skeletal muscle hypertrophy Vastus lateralis biopsies resistance exercise training treatment upregulated 21030674 6159 Human hsa-miR-26a miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) caco-2?cell line high glucose treatment upregulated 31493868 6160 Human hsa-miR-26a miRNA ¦Â-glycerophosphate (¦Â-GP) vascular calcification (VC) vascular smooth muscle cells (VSMCs) incubated with 10 mmol/L ¦Â-glycerol phos_x0002_phate (¦Â-GP) for 7 and 14 days treatment downregulated 29050490 6161 Human hsa-miR-26a miRNA TGF-¦Â1 wound healing HaCaT cells; NHEK cells TGF-¦Â1 treatment The RNA expression of miR-26a was downregulated and ITGA5 protein expression was upregulated by TGF-¦Â1 treatment in HaCaT and NHEK cells in a time-dependent manner 32955094 6162 Human hsa-miR-26a-5p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment downregulated 32102754 6163 Human hsa-miR-26a-5p miRNA IL-1¦Â adrenal steroid production NCI-H295R cells IL-1¦Â treatment downregulated 33508847 6164 Human hsa-miR-26a-5p miRNA kaempferol atherosclerosis (AS) human aortic endothelial cells (HAECs) kaempferol treatment Kaempferol upregulated miR-26a-5p expression in ox-LDL-stimulated HAECs. 30372882 6165 Human hsa-miR-26a-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vascular endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31865360 6166 Human hsa-miR-26a-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) RKO cells 5-fluorouracil (5-FU) treatment SNHG6 may promote chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in CRC cells. 31516391 6167 Human hsa-miR-26a-5p miRNA di(2-ethylhexyl) phthalate (DEHP) Di (2-ethylhexyl) phthalate (DEHP)-induced lung toxicity A549 cells di(2-ethylhexyl) phthalate (DEHP) treatment MiR-26a-5p was significantly enriched in DEHP-elicited sEV. 33229049 6168 Human hsa-miR-26a-5p miRNA high glucose (HG) diabetic cataract (DC) SRA01/04 cells high glucose treatment downregulated 32950535 6169 Human hsa-miR-26a-5p miRNA bovine serum albumin (BSA) diabetic nephropathy (DN) HK-2 cells bovine serum albumin (BSA) treatment miR-26a-5p expression in exosomes secreted by BSA-treated HK-2 cells was significantly increased. 32853650 6170 Human hsa-miR-26a-5p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 6171 Human hsa-miR-26a-5p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 6172 Human hsa-miR-26a-5p miRNA IFN-¦Â multiple sclerosis (MS) RRMS patients IFN-¦Â treatment upregulated 24885345 6173 Human hsa-miR-26a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 6174 Human hsa-miR-26a-5p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 6175 Human hsa-miR-26a-5p miRNA IL-1¦Â osteoarthritis (OA) synovial fibroblast IL-1¦Â treatment downregulated 31784400 6176 Human hsa-miR-26a-5p miRNA activin A prostate cancer PC3 cells activin A treatment upregulated 27018851 6177 Human hsa-miR-26a-5p miRNA dexamethasone (DEX) steroid-induced osteonecrosis of femoral head (ONFH) human bone marrow-derived mesenchymal stem cells (hBMSCs) dexamethasone (DEX) treatment "NORAD expression was downregulated in SONFH tissues, while miR-26a-5p expression was upregulated." 33413642 6178 Human hsa-miR-26b miRNA yin yang 1 (YY1) acute myeloid leukemia (AML) "Human AML cells U937, KG-1, THP-1, and HL-60" yin yang 1 (YY1) treatment downregulated 33318617 6179 Human hsa-miR-26b miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 6180 Human hsa-miR-26b miRNA ionizing radiation (IR) breast cancer MCF7 breast cancer cells "Cells were given for IR 24 h after transfection and harvested by centrifugation at 13,201 x g for 3 min at room temperature for analysis. IR was delivered at a rate of 0.38 Gy/min (180 kV; 18 mA) using an XSZ-Z20/20 X-ray generator (Kang Jia Instrument Equipment Co., Ltd., Dandong, China)." downregulated 29399189 6181 Human hsa-miR-26b miRNA radiation breast cancer MCF7 breast cancer cells radiation treatment downregulated 29399189 6182 Human hsa-miR-26b miRNA estrogen (ES) cell proliferation "MCF-7¡¢T47D¡¢MDA-MB-231 , BT549 cell" estrogen treatment downregulated 24735615 6183 Human hsa-miR-26b miRNA chloroquine chloroquine in inducing apoptosis of human hepatocellular carcinoma cells HepG2 cells chloroquine treatment chloroquine significantly increased the expression of miR-26b and downregulated the expression of Mcl-1 in HepG2 cells. 29735440 6184 Human hsa-miR-26b miRNA omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) cholangiocarcinoma (CCA) human cholangiocarcinoma cell omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) treatment downregulated 25691459 6185 Human hsa-miR-26b miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 6186 Human hsa-miR-26b miRNA etanercept gastric cancer (GC) ?serum Etanercept treatment downregulated 23600954 6187 Human hsa-miR-26b miRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) "HepG2,Huh-7, 293T" DOX at a range of 0.5¨C25?¦ÌM over a period of 10 months downregulated 28079894 6188 Human hsa-miR-26b miRNA tumor necrosis factor alpha (TNF-¦Á) cell differentiation Human preadipocytes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 23275201 6189 Human hsa-miR-26b miRNA arsenite liver fibrosis human hepatic (L-02) cells arsenite exposure exosomal MALAT1 derived from arsenite-treated L-02 cells promoted the activation of LX-2 cells via microRNA-26b regulation of COL1A2. 31513886 6190 Human hsa-miR-26b miRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells cisplatin treatment upregulated 31432162 6191 Human hsa-miR-26b miRNA ¦Ã-rays lung cancer H1299 lung cancer cells ¦Ã-rays treatment downregulated 21901137 6192 Human hsa-miR-26b miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 6193 Human hsa-miR-26b miRNA tacrolimus or high glucose new-onset diabetes after liver transplantation (NODALT) human hepatocytes tacrolimus or high glucose treatment dysregulated 27458792 6194 Human hsa-miR-26b miRNA high glucose (HG) osteoarthritis (OA) human osteoarthritis (OA) chondrocytes high-glucose (HG) treatment downregulated 31625803 6195 Human hsa-miR-26b miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-1¦Â treatment downregulated 29208566 6196 Human hsa-miR-26b miRNA pioglitazone osteoarthritis (OA) high-glucose (HG) treated human osteoarthritis (OA) chondrocytes pioglitazone (PGZ) treatment upregulated 31625803 6197 Human hsa-miR-26b miRNA TGF-¦Â2 posterior capsular opacification (PCO) human PCO-attached lens epithelial cells (LECs) and SRA01/04 cells TGF-¦Â2 treatment downregulated 25063219 6198 Human hsa-miR-26b miRNA epidermal growth factor (EGF) posterior capsular opacification (PCO) primary human lens epithelial cells (HLECs) epidermal growth factor (EGF) treatment downregulated 29977916 6199 Human hsa-miR-26b miRNA lipopolysaccharide (LPS) sepsis Neonatal Polymorphonuclear Leukocytes lipopolysaccharide (LPS) treatment dysregulated 28655995 6200 Human hsa-miR-26b miRNA hydroxyurea sickle cell anemia (SCA) Circulating erythroid cells Hydroxyurea treatment upregulated 21921042 6201 Human hsa-miR-26b miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) caco-2?cell line high glucose treatment upregulated 31493868 6202 Human hsa-miR-26b miRNA desferrioxamine (DFOM) immune response carcinoma of nasopharyngeal epithelial (CNE) cells desferrioxamine (DFOM) upregulated 20100477 6203 Human hsa-miR-26b-3p miRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells Ginsenoside Rh2 (Rh2) treatment downregulated 30197683 6204 Human hsa-miR-26b-5p miRNA huaier anti-cancer therapy pulmonary adenocarcinoma A549 cells huaier treatment upregulated 24815696 6205 Human hsa-miR-26b-5p miRNA high glucose (HG) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment LncRNA HCG11/miR-26b-5p/QKI5 feedback loop reversed high glucose-induced proliferation and angiogenesis inhibition of HUVECs. 33128346 6206 Human hsa-miR-26b-5p miRNA cardiac resynchronization therapy heart failure (HF) plasma cardiac resynchronization therapy treatment upregulated 23736534 6207 Human hsa-miR-26b-5p miRNA perfluorooctanoic acid hepatotoxicity occupational workers serum Perfluorooctanoic acid (PFOA) exposure treatment upregulated 24459700 6208 Human hsa-miR-26b-5p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 6209 Human hsa-miR-26b-5p miRNA "1,25-dihydroxyvitamin D (1,25(OH)2D)" spontaneous preterm birth (SPB) human syncytiotrophoblast "1,25-dihydroxyvitamin D (1,25(OH)2D) treatment" "miR-181b-5p and miR-26b-5p in term human syncytiotrophoblast were increased in response to treatment with 1,25(OH)2D." 30395535 6210 Human hsa-miR-26b-5p miRNA phosphorus (Pi) vascular calcification (VC) human aortic vascular smooth muscle cells (HASMCs) phosphorus treatment upregulated 32347320 6211 Human hsa-miR-27 miRNA nanocurcumin ankylosing spondylitis (AS) peripheral blood mononuclear cells (PBMCs) nanocurcumin treatment downregulated 31074089 6212 Human hsa-miR-27 miRNA hepatitis C virus (HCV) chronic hepatitis C virus (HCV) infection Huh7.5 cells hepatitis C virus (HCV) infection upregulated 23897856 6213 Human hsa-miR-27 miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) HT-29 cells TGF-¦Â treatment upregulated 23483606 6214 Human hsa-miR-27 miRNA hepatitis C virus (HCV) hepatic steatosis Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 23897856 6215 Human hsa-miR-27a miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 6216 Human hsa-miR-27a miRNA alcohol alcoholic liver disease (ALD) monocyte alcohol exposure upregulated 25716995 6217 Human hsa-miR-27a miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 6218 Human hsa-miR-27a miRNA betulinic acid (BA) atherosclerosis (AS) The RKO and SW480 colon cancer cell lines betulinic acid (BA) treatment downregulated 21864401 6219 Human hsa-miR-27a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP1-derived macrophages oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31518965 6220 Human hsa-miR-27a miRNA C8 fluoride derivative of cheliensisin A (ChlA-F) bladder cancer T24 cells ChlA-F treatment downregulated 30118841 6221 Human hsa-miR-27a miRNA arsenic trioxide (ATO) breast cancer breast cancer cells arsenic trioxide (ATO) treatment downregulated 26592661 6222 Human hsa-miR-27a miRNA arsenic trioxide (ATO) breast cancer MDA-MB-231 and SK-BR-3 arsenic trioxide (ATO) treatment downregulated 26592661 6223 Human hsa-miR-27a miRNA betulinic acid (BA) breast cancer Human mammary carcinoma cell lines MDA-MB-231£»MDA-MB-435£» BT474£»MDA-MB-468£»MDA-MB-453£»HS-578T betulinic acid (BA) treatment downregulated 22407812 6224 Human hsa-miR-27a miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment upregulated 25120778 6225 Human hsa-miR-27a miRNA estradiol breast cancer MCF-7 breast cancer cells Estradiol treatment downregulated 19528081 6226 Human hsa-miR-27a miRNA liraglutide breast cancer MCF-7 cells liraglutide treatment liraglutide treatment downregulated miR-27a expression in MCF-7 cells. 29393459 6227 Human hsa-miR-27a miRNA metformin (Met) breast cancer breast cancer MCF-7 cells metformin treatment downregulated 27779715 6228 Human hsa-miR-27a miRNA pomegranate polyphenolics breast cancer Human mammary carcinoma cell lines BT474 and MDA-MB-231 pomegranate polyphenolics treatment downregulated 22941571 6229 Human hsa-miR-27a miRNA tamoxifen (TAM) breast cancer MCF7 cells; T47D luminal A breast cancer cells tamoxifen treatment Tamoxifen-resistant cells showed decreased expression of ER¦Á and miR-27a. 30415143 6230 Human hsa-miR-27a miRNA tamoxifen (TAM) breast cancer MCF7 and T47D luminal A breast cancer cell lines tamoxifen treatment downregulated 30415143 6231 Human hsa-miR-27a miRNA vascular endothelial growth factor (VEGF) breast cancer breast cancer stem like cells (BCSLCs) vascular endothelial growth factor (VEGF) treatment upregulated 23752185 6232 Human hsa-miR-27a miRNA vascular endothelial growth factor (VEGF) breast cancer MDA-MB-231 breast cancer cell line VEGF treatment upregulated 23752185 6233 Human hsa-miR-27a miRNA lipopolysaccharide (LPS) bronchopneumonia BEAS-2B cells lipopolysaccharide (LPS) treatment upregulated 29772436 6234 Human hsa-miR-27a miRNA tanshinone IIA (Tan IIA) bronchopneumonia LPS-treated BEAS-2B cells Tanshinone IIA (Tan) treatment downregulated 29772436 6235 Human hsa-miR-27a miRNA SV40 small T antigen tumorigenesis human bronchial epithelial cells(HBERST) SV40 small T antigen treatment upregulated 21460851 6236 Human hsa-miR-27a miRNA "ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094)" candida albicans infection RKO and SW480 colon cancer cells "Ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094) treatment" downregulated 21156786 6237 Human hsa-miR-27a miRNA high glucose (HG) cell damage human renal tubular epithelial HK-2 high glucose (HG) treatment miR-27a participates in the effects of GAS5 silencing on HG-stimulated HK-2 cells; BNIP3 is regulated by miR-27a and related to the HG toxicity to HK-2 cells. 31159592 6238 Human hsa-miR-27a miRNA cholesterol clear cell renal cell carcinoma (ccRCC) The human ccRCC cell line 786-O cholesterol treatment upregulated 29782853 6239 Human hsa-miR-27a miRNA "2,3-dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)]" colorectal cancer (CRC) colon cancer cells "2,3-Dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)] treatment" downregulated 24030632 6240 Human hsa-miR-27a miRNA curcumin (Cur) colorectal cancer (CRC) RKO ; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts curcumin treatment downregulated 23194063 6241 Human hsa-miR-27a miRNA curcuminoids colorectal cancer (CRC) colon cancer SW-480 cells curcuminoids treatment downregulated 23471840 6242 Human hsa-miR-27a miRNA resveratrol and quercetin colorectal cancer (CRC) HT-29 cells Resveratrol and quercetin treatment downregulated 23530649 6243 Human hsa-miR-27a miRNA hypoxia colorectal cancer (CRC) "HT-29, Caco2 and SW480 cells" hypoxia induce upregulated 30393198 6244 Human hsa-miR-27a miRNA hypoxia colorectal cancer (CRC) HT29 cells; SW480 cells; Caco2 cells hypoxia treatment upregulated 30393198 6245 Human hsa-miR-27a miRNA oxidized low density lipoprotein (ox-LDL) Dendritic cell (DC) maturation Human peripheral blood monocytes differentiated DCs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29617044 6246 Human hsa-miR-27a miRNA arbutin (ARB) diabetic nephropathy (DN) HK-2 cells high glucose (HG) and Arbutin (ARB) co-treatment "MiR-27a expression was reduced in HG-treated cells, but was accelerated in HG and ARB co-treated HK-2 cells with the increased concentration." 31319730 6247 Human hsa-miR-27a miRNA high glucose (HG) diabetic nephropathy (DN) human renal tubular epithelial HK-2 high glucose (HG) treatment miR-27a participates in the effects of GAS5 silencing on HG-stimulated HK-2 cells; BNIP3 is regulated by miR-27a and related to the HG toxicity to HK-2 cells. 31159592 6248 Human hsa-miR-27a miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment "MiR-27a expression was reduced in HG-treated cells, but was accelerated in HG and ARB co-treated HK-2 cells with the increased concentration." 31319730 6249 Human hsa-miR-27a miRNA high glucose (HG) diabetic retinopathy (DR) RPE-1 cells high glucose (HG) treatment downregulated 29896271 6250 Human hsa-miR-27a miRNA hemin erythroid cell differentiation K562 cells hemin treatment miR-27a levels gradually increased after 0 hours and decreased after the 24- hour time point during hemin-induced erythroid differentiation. 29590650 6251 Human hsa-miR-27a miRNA hyperthermia heat shock human OSCC cell lines HSC-2;HSC-3;HSC-4 HT at 44?C for 60 min treatment dysregulated 24789751 6252 Human hsa-miR-27a miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin hepatic stellate cells (HSC) transdifferentiate into myofibroblasts colon cancer cells "Methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate (CDODA-Me) treatment" downregulated 19582879 6253 Human hsa-miR-27a miRNA genistein hepatocellular carcinoma (HCC) human uveal melanoma cells Genistein?treatment downregulated 19639204 6254 Human hsa-miR-27a miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) plasma hepatitis B virus (HBV) infection downregulated 22105822 6255 Human hsa-miR-27a miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection upregulated 31371699 6256 Human hsa-miR-27a miRNA recombinant Human immunodeficiency virus (HIV) viral protein gp120 HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment upregulated 31371699 6257 Human hsa-miR-27a miRNA recombinant Human immunodeficiency virus (HIV) viral protein Tat HIV-associated neurocognitive disorders (HAND) human monocyte-derived macrophages (MDMs) and THP-1 cells recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment upregulated 31371699 6258 Human hsa-miR-27a miRNA lipopolysaccharide (LPS) hypothyroidism The human thyroid follicular epithelial cells (Nthy-ori 3-1) lipopolysaccharide (LPS) treatment downregulated 30300656 6259 Human hsa-miR-27a miRNA salidroside (SAL) hypothyroidism LPS-treated the human thyroid follicular epithelial cells (Nthy-ori 3-1) salidroside (SAL) treatment upregulated 30300656 6260 Human hsa-miR-27a miRNA mycobacterium tuberculosis (Mtb) immune response THP-1 cells infect with Mtb downregulated 31966878 6261 Human hsa-miR-27a miRNA lipopolysaccharide (LPS) inflammation MRC-5 cells lipopolysaccharide (LPS) treatment LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression. 31735661 6262 Human hsa-miR-27a miRNA lipopolysaccharide (LPS) inflammation BMDMs lipopolysaccharide (LPS) treatment downregulated 24835395 6263 Human hsa-miR-27a miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human mitral valve interstitial cells (hMVICs) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29694513 6264 Human hsa-miR-27a miRNA quercetin and hyperoside (QH) injury in vascular smooth muscle cells renal cancer cells quercetin and hyperoside treatment downregulated 24173369 6265 Human hsa-miR-27a miRNA doxorubicin (DOX) leukemia myeloid leukemic cell lines NB4; human promyelocytic leukaemia cell line;HL60 doxorubicin (DOX)? treatment downregulated 21070600 6266 Human hsa-miR-27a miRNA genistein lung cancer A549 cells Genistein treatment upregulated 27602162 6267 Human hsa-miR-27a miRNA glucagon-like peptide-1 (GLP-1) lung fibrosis human embryonic lung fibroblast (MRC-5) cells Glucagon-like peptide-1 (GLP-1) treatment "After pretreating MRC-5 cells via GLP-1, with or without compound C (AMPK inhibitor), the expression of miR-27a in the GLP-1 treated group was significantly lower than that in Vehicle group." 33850889 6268 Human hsa-miR-27a miRNA alcohol macrophage activation plasma alcohol exposure upregulated 26527689 6269 Human hsa-miR-27a miRNA alcohol macrophage activation THP-1 alcohol exposure upregulated 26527689 6270 Human hsa-miR-27a miRNA metformin (Met) pancreatic cancer (PC) Panc1 cells;L3.6pL cells;Panc28 cells Metformin? treatment downregulated 23803693 6271 Human hsa-miR-27a miRNA lipopolysaccharide (LPS) monocytic differentiation monocyte lipopolysaccharide (LPS) treatment dysregulated 25148686 6272 Human hsa-miR-27a miRNA high glucose (HG) nonalcoholic fatty liver disease (NAFLD) HepG2 cells high glucose (HG) treatment upregulated 31889412 6273 Human hsa-miR-27a miRNA high glucose (HG) nonalcoholic fatty liver disease (NAFLD) HepG2 cells high glucose (HG) treatment upregulated 31889412 6274 Human hsa-miR-27a miRNA lipopolysaccharide (LPS) oral lichen planus (OLP) human oral keratinocytes (HOKs) lipopolysaccharide (LPS) treatment downregulated 31942011 6275 Human hsa-miR-27a miRNA IL-1¦Â osteoarthritis (OA) Human chondrosarcoma (SW1353) cells and primary cultured articular chondrocytes IL-1¦Â treatment upregulated 31460867 6276 Human hsa-miR-27a miRNA IL-1¦Â osteoarthritis (OA) OA cartilage tissues and primary human articular chondrocyte IL-1¦Â treatment upregulated 31520995 6277 Human hsa-miR-27a miRNA IL-1¦Â and TNF-¦Á osteoarthritis (OA) Chondrocytes IL-1¦Â and TNF-¦Á treatment CircTMBIM6 promotes osteoarthritis-induced chondrocyte extracellular matrix degradation via miR-27a/MMP13 axis. 32767318 6278 Human hsa-miR-27a miRNA mechanical loading and hydrostatic pressure (HP) osteoarthritis (OA) OA human chondrocytes mechanical loading and hydrostatic pressure (HP) treatment upregulated 28085114 6279 Human hsa-miR-27a miRNA glucocorticoid (GC) osteogenesis human bone marrow stromal cells ( hBMSCs) glucocorticoid (GC) treatment miR-27a expression profiles were found to be downregulated in ONFH samples and GC-induced hBMSCs using microarray analysis and real-time quantitative polymerase chain reaction 33532936 6280 Human hsa-miR-27a miRNA astragalus polysaccharide (APS) ovarian cancer (OC) OV-90 cells astragalus polysaccharide (APS) treatment APS dose-dependently decreased the levels of miR-27a in OV-90 cells. 32159214 6281 Human hsa-miR-27a miRNA hypoxia ovarian cancer (OC) Skov3 cells hypoxia treatment The expression of the miR-27a was obviously upregulated under hypoxia and involved in hypoxia-induced paclitaxel resistance. 32190895 6282 Human hsa-miR-27a miRNA H2O2 oxidative stress human trabecular meshwork (HTM) cells H2O2 treatment downregulated 31062616 6283 Human hsa-miR-27a miRNA salidroside (SAL) oxidative stress H2O2-treated human trabecular meshwork (HTM) cells salidroside (SAL) treatment upregulated 31062616 6284 Human hsa-miR-27a miRNA genistein pancreatic cancer (PC) BxPC-3 and PANC-1 cell genistein treatment downregulated 24479798 6285 Human hsa-miR-27a miRNA paraquat (PQ) paraquat poisoning serum paraquat treatment Decreased serum miR-27a level and increased IL-10 expression levels were detected in patients with paraquat poisoning compared with healthy controls 32104255 6286 Human hsa-miR-27a miRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression. 31735661 6287 Human hsa-miR-27a miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed downregulated 27915273 6288 Human hsa-miR-27a miRNA hemin pulmonary hypertension (PH) human pulmonary artery endothelial cells (HPAECs) hemin for 72 hours upregulated 27612006 6289 Human hsa-miR-27a miRNA hypoxia pulmonary hypertension (PH) Human pulmonary artery endothelial cells (HPAECs) hypoxia treatment downregulated 24244514 6290 Human hsa-miR-27a miRNA rosiglitazone pulmonary hypertension (PH) mouse "rosiglitazone (RSG), 10 mg/kg/day treatment" upregulated 27612006 6291 Human hsa-miR-27a miRNA quercetin and hyperoside (QH) renal cell carcinoma (RCC) 786-O renal cancer cells quercetin and hyperoside (QH) in combination (1:1 ratio) treatment downregulated 24173369 6292 Human hsa-miR-27a miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin rhabdomyosarcoma (RMS) RD and Rh30 rhabdomyosarcoma (RMS) cells "Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment" downregulated 30610105 6293 Human hsa-miR-27a miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 6294 Human hsa-miR-27a miRNA "haloperidol, clozapine and olanzapine" schizophrenia (SZ) "HepG2 (ATCC,CRL-1573)" "haloperidol, clozapine , olanzapine treatment" downregulated 28429622 6295 Human hsa-miR-27a miRNA folate squamous cell carcinoma (SCC) HeLa cells; SiHa cells Folate treatment "There was a highly significant difference between the 200 and 500 nM folate groups, in which miR-27a expression levels were significantly downregulated between the 200 and 500 nM concentration groups." 31918266 6296 Human hsa-miR-27a miRNA X-rays stress response human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A a single dose of 5Gy ?-radiation downregulated 28851536 6297 Human hsa-miR-27a miRNA hypoxia urothelial bladder carcinoma human bladder cancer cell line (J82) hypoxia treatment upregulated 24462738 6298 Human hsa-miR-27a-3p miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) A549 cells; BEAS-2B cells lipopolysaccharide (LPS) treatment MiR-27a-3p was downregulated in LPS-induced alveolar epithelial cells. 32993961 6299 Human hsa-miR-27a-3p miRNA adriamycin (ADR) breast cancer MCF-7 cells adriamycin (ADR) treatment Significantly higher miR-27a-3p expression was confirmed in MCF-7/ADR as compared with sensitive cell line MCF-7. 32764979 6300 Human hsa-miR-27a-3p miRNA tamoxifen and metformin breast cancer MCF-7 and MDA-MB-231 cell lines MCF-7 and MDA-MB-231 cell lines treatment dysregulated 27329603 6301 Human hsa-miR-27a-3p miRNA folate cervical cancer (CC) HeLa-GFP and SiHa cells 500nM Folate treatment downregulated 31918266 6302 Human hsa-miR-27a-3p miRNA lipopolysaccharide (LPS) dysfunction of vascular endothelial cells human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment "TUG1 could repress cell apoptosis, autophagy, and inflammatory response in LPS-treated HUVECs by sponging miR-27a-3p to target SLIT2." 32738556 6303 Human hsa-miR-27a-3p miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment downregulated 30503955 6304 Human hsa-miR-27a-3p miRNA dihydrotestosterone (DHT) cardiovascular disease (CVD) EA.hy926 dihydrotestosterone treatment downregulated 28240250 6305 Human hsa-miR-27a-3p miRNA hypoxia ischemic heart disease (IHD) AC16 cell hypoxia exposure circ_0010729 knockdown alleviated hypoxia-induced AC16 cell injuries by mediating the miR-27a-3p/TRAF5 axis. 33010282 6306 Human hsa-miR-27a-3p miRNA TGF-¦Â1 lung fibrosis human lung fibroblasts transforming growth factor-¦Â1 treatment upregulated 26600197 6307 Human hsa-miR-27a-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment downregulated 27143365 6308 Human hsa-miR-27a-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment upregulated 27143365 6309 Human hsa-miR-27a-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 6310 Human hsa-miR-27a-3p miRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment downregulated 29749508 6311 Human hsa-miR-27a-3p miRNA IL-1¦Â and/or TNF-¦Á osteoarthritis (OA) Human cartilage C28/I2 cells IL-1¦Â and/or TNF-¦Á treatment FOXD2-AS1 upregulated the expression level of TLR4 by sponging miR-27a-3p. 30945573 6312 Human hsa-miR-27a-3p miRNA hydrocarbons (PAHs) hydrocarbons (PAHs) toxic action 20 exposed workers pooled plasma samples exposed to PAHs treatment dysregulated 24633190 6313 Human hsa-miR-27a-3p miRNA insulin polycystic ovarian syndrome (PCOS) human granulosa-like tumor cell line (KGN) insulin treatment downregulated 29029022 6314 Human hsa-miR-27a-3p miRNA hypoxia/reoxygenation (H/R) renal ischemia/reperfusion (I/R) injury HK-2 cells hypoxia/reoxygenation (H/R) treatment upregulated 32084559 6315 Human hsa-miR-27a-3p miRNA adalimumab(ADA) rheumatoid arthritis (RA) plasma adalimumab(ADA) treatment "In the ADA group, a higher pretreatment level of miR-27a-3p was significantly associated with remission at 12 months. The level decreased in remitting patients between pretreatment and 3 months, and increased in nonremitting patients." 29142030 6316 Human hsa-miR-27a-3p miRNA CoCl2 acute kidney injury (AKI) human kidney tubular cells (HK-2) CoCl2?-stimulated HK-2 cells miR-27a-3p was downregulated in AKI patients compared with healthy control. 31090110 6317 Human hsa-miR-27a-3p miRNA ischemia acute kidney injury (AKI) serum from AKI patients ischemia©\induced AKI The level of miR©\27a©\3p in HK©\2 cells treated with CoCl2 was decreased in a dose©\dependent manner. 31090110 6318 Human hsa-miR-27a-5p miRNA TGF-¦Â1 against cancer human natural killer (NK) cells TGF-¦Â1 treatment upregulated 28791023 6319 Human hsa-miR-27a-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 6320 Human hsa-miR-27a-5p miRNA chlorpromazine (CHLO) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) treatment upregulated 31198949 6321 Human hsa-miR-27a-5p miRNA cyclosporine A (CsA) drug-induced liver injury (DILI) upcyte hepatocytes cyclosporine A (CYCA) treatment upregulated 31198949 6322 Human hsa-miR-27a-5p miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 6323 Human hsa-miR-27a-5p miRNA oxidized glycerophospholipids (oxGPs) and IL-1¦Â inflammation human aortic endothelial cells (HAECs) oxGPs and interleukin 1¦Â (IL-1¦Â) treatment upregulated 25327529 6324 Human hsa-miR-27a-5p miRNA hypoxia myocardial infarction (MI) human cardiomyocyte primary cells (HCM) hypoxia treatment downregulated 32528555 6325 Human hsa-miR-27a-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 6326 Human hsa-miR-27a-5p miRNA lipopolysaccharide (LPS) sepsis human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment upregulated 32546573 6327 Human hsa-miR-27a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) sepsis human pulmonary microvascular endothelial cells (HPMECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 32546573 6328 Human hsa-miR-27a-5p miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 6329 Human hsa-miR-27-a-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine protects SH-SY5Y cells against oxygen-glucose deprivation and reoxygenation-induced injury partly through the inhibition of microRNA-27-a-5p and promotion of the Bach1/HO-1 signaling pathway. 32706194 6330 Human hsa-miR-27b miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 6331 Human hsa-miR-27b miRNA tumor necrosis factor alpha (TNF-¦Á) apoptosis fibroblast-like synoviocytes (FLSs) cells (MH7A) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 31124343 6332 Human hsa-miR-27b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP1-derived macrophages oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31518965 6333 Human hsa-miR-27b miRNA leptin bone malignancy chondrosarcoma cells Leptin treatment "the expression of microRNA-27b was negatively regulated by leptin via the FAK, PI3K and Akt cascade." 27345723 6334 Human hsa-miR-27b miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment downregulated 25120778 6335 Human hsa-miR-27b miRNA estradiol breast cancer MCF-7 breast cancer cells Estradiol treatment downregulated 19528081 6336 Human hsa-miR-27b miRNA IL-6 breast cancer MCF-7 and MDA-MB-231 cells interleukin-6 (IL-6) treatment downregulated 31515600 6337 Human hsa-miR-27b miRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation ARPE-19 cells platelet-derived growth factor (PDGF)-BB treatment downregulated 29858119 6338 Human hsa-miR-27b miRNA adiponectin chondrosarcoma human lymphatic endothelial cells adiponectin (ApN) treatment downregulated 27252405 6339 Human hsa-miR-27b miRNA IL-6 colorectal cancer (CRC) HCT116 and SW480 cells IL-6 treatment downregulated 25333344 6340 Human hsa-miR-27b miRNA oxidized low density lipoprotein (ox-LDL) Dendritic cell (DC) maturation Human peripheral blood monocytes differentiated DCs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29617044 6341 Human hsa-miR-27b miRNA alagebrium chloride (ALT711) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) alagebrium chloride (ALT711) treatment upregulated 30972183 6342 Human hsa-miR-27b miRNA N¦Å-carboxymethyl-lysine (CML)-BSA diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) N¦Å-carboxymethyl-lysine (CML)-BSA treatment downregulated 30972183 6343 Human hsa-miR-27b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (hRECs) high-glucose treatment downregulated 29786744 6344 Human hsa-miR-27b miRNA TGF-¦Â fibrosis A549 human alveolar epithelial cells TGF-¦Â treatment downregulated 24633904 6345 Human hsa-miR-27b miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 31046802 6346 Human hsa-miR-27b miRNA human cytomegalovirus (HCMV) human cytomegalovirus (HCMV) infection human glioma U251 cells infect with HCMV upregulated 28343438 6347 Human hsa-miR-27b miRNA hepatocyte growth factor (HGF) head and neck squamous cell carcinoma (HNSCC) HNSCC; adjacent normal squamous epithelial tissues Hepatocyte growth factor (HGF) treatment downregulated 21899661 6348 Human hsa-miR-27b miRNA tetrandrine hypertrophic scars (HS) human hypertrophic scar fibroblasts (HSFs) tetrandrine treatment upregulated 26909951 6349 Human hsa-miR-27b miRNA insulin insulin resistance (IR) human mesenchymal stem cell (hMSC)-derived adipocytes insulin treatment upregulated 29455245 6350 Human hsa-miR-27b miRNA fumonisin B? hepatocellular carcinoma (HCC) human hepatoma cell line (HepG2) Fumonisin B? treatment downregulated 24614526 6351 Human hsa-miR-27b miRNA 5-fluorouracil/mitomycin C (MMC-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) MMC-CRTX treatment upregulated 28347920 6352 Human hsa-miR-27b miRNA (6)-gingerol (6G) myeloid leukemia U937 cells; K562 cells (6)-gingerol (6G) treatment upregulated 24378438 6353 Human hsa-miR-27b miRNA lipopolysaccharide (LPS) oral lichen planus (OLP) human oral keratinocytes (HOKs) lipopolysaccharide (LPS) treatment downregulated 31942011 6354 Human hsa-miR-27b miRNA mechanical loading and hydrostatic pressure (HP) osteoarthritis (OA) OA human chondrocytes mechanical loading and hydrostatic pressure (HP) treatment upregulated 28085114 6355 Human hsa-miR-27b miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 6356 Human hsa-miR-27b miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary arterial endothelial cells (HPAECs) hypoxia treatment The results revealed that PPAR¦Ã expression was downregulated and miR-27b expression was upregulated in the HPAECs exposed to hypoxia. 33907846 6357 Human hsa-miR-27b miRNA lipopolysaccharide (LPS) transitional cell carcinomas (TCCs) primary human macrophages lipopolysaccharide (LPS) treatment upregulated 20164187 6358 Human hsa-miR-27b miRNA liraglutide type 2 diabetes mellitus (T2DM) serum liraglutide treatment upregulated 33008044 6359 Human hsa-miR-27b miRNA bisphenol A (BPA) vascular endothelial dysfunction primary cultured human endometrial stromal cells (HESCs) bisphenol A (BPA) treatment downregulated 30328349 6360 Human hsa-miR-27b miRNA estradiol-17¦Â (E2) vascular endothelial dysfunction primary cultured human endometrial stromal cells (HESCs) estradiol-17¦Â (E2) treatment downregulated 30328349 6361 Human hsa-miR-27b-3p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment upregulated 28951593 6362 Human hsa-miR-27b-3p miRNA platelet derived growth factor-BB (PDGF-BB) aortic dissection (AD) Human aortic smooth muscle cells (HASMCs) platelet derived growth factor-BB (PDGF-BB) treatment "In AD, PVT1 expression was upregulated, yet that of miR-27b-3p was downregulated" 33106979 6363 Human hsa-miR-27b-3p miRNA house dust mite (HDM) asthma human dust mite treatment downregulated 30406061 6364 Human hsa-miR-27b-3p miRNA angiotensin II (Ang II) atrial fibrillation (AF) Human atrial fibroblasts (HAFs) angiotensin II (Ang II) treatment upregulated 30729664 6365 Human hsa-miR-27b-3p miRNA tamoxifen (TAM) breast cancer MCF-7/TAM-1 and T47D/TAM-1 cells tamoxifen treatment downregulated 27809310 6366 Human hsa-miR-27b-3p miRNA oxaliplatin colorectal cancer (CRC) SW480 cells; HCT116 cells Oxaliplatin (OXA) treatment miR-27b-3p expression was significantly downregulated in oxaliplatin-resistant cell lines (SW480-OxR and HCT116-OxR) 32104496 6367 Human hsa-miR-27b-3p miRNA geniposide (GEN) diffuse large B-cell lymphoma (DLBCL) OCI-LY7; OCI-LY3 cells geniposide treatment Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis 33162801 6368 Human hsa-miR-27b-3p miRNA Rg3-enhanced red ginseng extract (Rg3E) endometriosis human endometrial stromal cells (HESCs) 400??L/mL Rg3E and cultured for 48?h treatment downregulated 29247225 6369 Human hsa-miR-27b-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) MKN-45 and SGC-7901 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31539861 6370 Human hsa-miR-27b-3p miRNA radiation gastric cancer (GC) MKN-45 and AGS cells radiation treatment NEAT1 depletion enhanced radio-sensitivity of GC by negatively regulating miR-27b-3p in vitro and in vivo 33292252 6371 Human hsa-miR-27b-3p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 6372 Human hsa-miR-27b-3p miRNA dihydrotestosterone (DHT) cardiovascular disease (CVD) EA.hy926 dihydrotestosterone treatment downregulated 28240250 6373 Human hsa-miR-27b-3p miRNA l-carnitine male infertility sperm l-carnitine treatment upregulated 31749176 6374 Human hsa-miR-27b-3p miRNA cisplatin (DDP) oral squamous cell carcinoma (OSCC) oral squamous cell carcinoma (OSCC) cells cisplatin treatment downregulated 33191714 6375 Human hsa-miR-27b-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment downregulated 27143365 6376 Human hsa-miR-27b-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment upregulated 27143365 6377 Human hsa-miR-27b-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 6378 Human hsa-miR-27b-3p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-7¦Â treatment dysregulated 29123165 6379 Human hsa-miR-27b-3p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-11¦Â treatment dysregulated 29123165 6380 Human hsa-miR-27b-3p miRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment downregulated 31863917 6381 Human hsa-miR-27b-3p miRNA IL-1¦Â osteoarthritis (OA) Human transformed chondrocytes C28/I2 IL-1¦Â treatment downregulated 31863917 6382 Human hsa-miR-27b-5p miRNA sulforaphane (SFN) cancer treatment NCI-60 cells sulforaphane treatment downregulated 32429039 6383 Human hsa-miR-27b-5p miRNA IL-10 hemangioma (HA) human primary HDEC recombinant IL-10 (rIL-10) treatment rIL-10 can increase expression of miR-27b-5p 32416101 6384 Human hsa-miR-27b-5p miRNA mono-(2-ethylhexyl) phthalate (MEHP) oral squamous cell carcinoma (OSCC) SCC-4 cells Mono-2-ethyhexyl phthalate (MEHP) treatment downregulated 30858031 6385 Human hsa-miR-27b-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 6386 Human hsa-miR-28 miRNA heroin human immunodeficiency virus (HIV)-1 infection Peripheral blood Heroin treatment downregulated 26583016 6387 Human hsa-miR-28 miRNA morphine human immunodeficiency virus (HIV)-1 infection peripheral blood mononuclear cells(PBMCs) morphine treatment downregulated 21224041 6388 Human hsa-miR-281 miRNA platelet derived growth factor-BB (PDGF-BB) pulmonary arterial hypertension (PAH) pulmonary artery smooth muscle cells (PASMCs) platelet-derived growth factor (PDGF)-BB treatment downregulated 29514810 6389 Human hsa-miR-28-3p miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 6390 Human hsa-miR-28-5p miRNA particulate matter (PM2.5) cardiotoxicity endothelial cells PM2.5 exposure treatment downregulated 30597786 6391 Human hsa-miR-28-5p miRNA particulate matter (PM2.5) cardiotoxicity of PM2.5 endothelial cells PM2.5 treatment downregulated 30597786 6392 Human hsa-miR-28-5p miRNA perfluorooctanoic acid hepatotoxicity occupational workers serum Perfluorooctanoic acid (PFOA) exposure treatment upregulated 24459700 6393 Human hsa-miR-28-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" myeloma human myeloma cell lines (HMCLs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28775176 6394 Human hsa-miR-28-5p miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 6395 Human hsa-miR-28-5p miRNA "glucose,hydrogen peroxide" oxidative stress primary human tenocytes high (17.5 mM) and 100 ¦ÌM hydrogen peroxide treatment upregulated 24556689c 6396 Human hsa-miR-28-5p miRNA hydrocarbons (PAHs) hydrocarbons (PAHs) toxic action 20 exposed workers pooled plasma samples exposed to PAHs treatment dysregulated 24633190 6397 Human hsa-miR-28-5p miRNA retinoic acid (RA) cell senescence SH-SY5Y cells retinoic acid (RA) treatment upregulated 27525675 6398 Human hsa-miR-28-5p miRNA retinoic acid (RA) cell senescence SH-SY5Y cells SH-SY5Y cells treatment upregulation 27525675 6399 Human hsa-miR-2861 miRNA ultraviolet (UV) irradiation UVB-induced cellular response normal human dermal papilla cells UVB radiation of ¡Ý50 mJ/cm2 treatment upregulated 25069581 6400 Human hsa-miR-28a miRNA lithocholic acid (LCA) glutathione synthesis and antioxidant capacity Huh-7 cells lithocholic acid (LCA) treatment upregulated 25226452 6401 Human hsa-miR-28a-5p miRNA prostaglandin E2 (PGE2) liver fibrosis TGF-¦Â1-treated LX-2 cells PGE2 treatment downregulated 29109031 6402 Human hsa-miR-28a-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment upregulated 29109031 6403 Human hsa-miR-28b miRNA dexamethasone (DEX) central fat accumulation primary SVF cells derived from human SAT and VAT dexamethasone (DEX) treatment upregulated 25187367 6404 Human hsa-miR-28b miRNA lithocholic acid (LCA) glutathione synthesis and antioxidant capacity Huh-7 cells lithocholic acid (LCA) treatment upregulated 25226452 6405 Human hsa-miR-28b miRNA ERK1/2 inhibitor leukemia TIB152 human leukemia cell line ER¦Á-neutralizing antibody or ERK1/2 inhibitor treatment downregulated 24974218 6406 Human hsa-miR-28b miRNA ER¦Á-neutralizing antibody leukemia TIB152 human leukemia cell line ER¦Á-neutralizing antibody or ERK1/2 inhibitor treatment downregulated 24974218 6407 Human hsa-miR-29 miRNA microsciadia breast cancer MDA-MB-231 cells microsciadia treatment upregulated 32603285 6408 Human hsa-miR-29 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" burkitt lymphoma (BL) The BL cell lines: Raji (EBV+) and BL41 (EBV-) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31173259 6409 Human hsa-miR-29 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial cells (RPEs) high glucose treatment upregulated 32447557 6410 Human hsa-miR-29 miRNA progesterone (P4) esophageal cancer (EC) T47D cells; MCF7 cells Progesterone treatment progestin treatment decreases miR-29 22330642 6411 Human hsa-miR-29 miRNA TGF-¦Â fibrosis Dermal fibroblasts TGF-¦Â treatment downregulated 31155965 6412 Human hsa-miR-29 miRNA cisplatin and docetaxel gastric cancer (GC) gastric cancer cell cisplatin and docetaxel treatment upregulated 25634213 6413 Human hsa-miR-29 miRNA TGF-¦Â glioblastoma multiforme (GBM) human trabecular meshwork (HTM) cells transforming growth factor-betas treatment downregulated 21273536 6414 Human hsa-miR-29 miRNA lauric acid hepatocellular carcinoma (HCC) HepG2 cells lauric acid treatment upregulated 32156243 6415 Human hsa-miR-29 miRNA high glucose (HG) hyperglycemia human retinal pigment epithelial (RPE) high glucose treatment upregulated 26822433 6416 Human hsa-miR-29 miRNA TGF-¦Â2 innate immunity trabecular meshwork (TM) TGF-¦Â2 treatment the incubation of TM cells with TGF-¦Â2 induced miR-29a and suppressed miR-29b levels 21330653 6417 Human hsa-miR-29 miRNA TGF-¦Â1 leprosy human lung fibroblasts TGF-¦Â1 treatment Treatment of the human embryonic lung fibroblast cell line IMR90 with TGF¦Â1 caused a decrease in expression of miR-29a/b/c 23238947 6418 Human hsa-miR-29 miRNA TGF-¦Â1 lung cancer proximal tubular cells; primary mesangial cells; podocytes TGF-¦Â1 treatment downregulated 22095944 6419 Human hsa-miR-29 miRNA IFN-¦Ã melanoma melanoma cell lines ?IFN-¦Ã?treatment treatment downregulated 23245396 6420 Human hsa-miR-29 miRNA IFN-¦Â multiple sclerosis (MS) Peripheral blood mononuclear cells (PBMC) Interferon-¦Â treatment downregulated 23921681 6421 Human hsa-miR-29 miRNA TGF-¦Â1 orbital fibrosis human orbital fibroblasts (OFs) TGF-¦Â1 treatment downregulated 25550793 6422 Human hsa-miR-29 miRNA oxidized low density lipoprotein (ox-LDL) oxidative stress human endometrial cell-lines oxidized low-density lipoprotein (ox-LDL) treatment dysregulated 28499250 6423 Human hsa-miR-29 miRNA Salmonella salmonella typhimurium infection human monocytes Salmonella Typhimurium infection treatment upregulated 22248082 6424 Human hsa-miR-29 miRNA "high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)" skin fibrosis human skin fibroblast HF-LED-RL at 320 and 640?J/cm2 radiation upregulated 30182520 6425 Human hsa-miR-29 miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection hepatic stellate cell (HSC) hepatitis C virus (HCV) infection downregulated 21606534 6426 Human hsa-miR-29?b-1-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 6427 Human hsa-miR-29* miRNA progesterone (P4) endometrial cancer (EC) Hec7A cells Progesterone treatment upregulated 22543862 6428 Human hsa-miR-2909 miRNA lipopolysaccharide (LPS) inflammation human adipose stem cells lipopolysaccharide (LPS) treatment downregulated 30807577 6429 Human hsa-miR-291 miRNA "WIN55,212-2 (WIN)" osteosarcoma (OS) Human osteosarcoma MG63 cells "WIN55,212-2 (WIN) treatment" upregulated 31652569 6430 Human hsa-miR-296 miRNA 5-fluorouracil and ixabepilone breast cancer MDA-MB-453?cells;MDA-kb2 cells 5-FU and ixabepilone treatment downregulated 24396484 6431 Human hsa-miR-296 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 6432 Human hsa-miR-296 miRNA "IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1" chronic hepatitis C virus (HCV) infection Huh7 cells "types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment" dysregulated 24844965 6433 Human hsa-miR-296 miRNA IFN-¦Á chronic hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) interferon alpha treatment upregulated 21070682 6434 Human hsa-miR-296 miRNA epigallocatechin-3-gallate (EGCG) nasopharyngeal carcinoma (NPC) TW01 cells; TW06 cells Epigallocatechin gallate (EGCG) treatment Involvement of MicroRNA-296 in the Inhibitory Effect of Epigallocatechin Gallate against the Migratory Properties of Anoikis-Resistant Nasopharyngeal Carcinoma Cells 32326395 6435 Human hsa-miR-296 miRNA 5-fluorouracil and ixabepilone triple negative breast cancer (TNBC) MDA-MB-453 LAR-type TNBC tumor cells 5-fluorouracil together with ixabepilone treatment downregulated 24396484 6436 Human hsa-miR-296-3p miRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) HONE1 and SUNE1 cells cisplatin treatment downregulated 29525743 6437 Human hsa-miR-296-3p miRNA nicotine nasopharyngeal carcinoma (NPC) HONE1 and SUNE1 cells nicotine treatment downregulated 29525743 6438 Human hsa-miR-2965p miRNA tensile hepatocellular carcinoma (HCC) HepG2 cells tensile treatment upregulated 32323778 6439 Human hsa-miR-296-5p miRNA aloperine colorectal cancer (CRC) SW480 and HT29 cells aloperine treatment upregulated 33664565 6440 Human hsa-miR-296-5p miRNA heme hepatocellular carcinoma (HCC) Huh?11 cells heme treatment upregulated 23538684 6441 Human hsa-miR-296-5p miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) "NSCLC tissues and cells (A549, H1650, A549/DDP, H1650/DDP)" cisplatin treatment downregulated 31647948 6442 Human hsa-miR-296-5p miRNA Fusobacterium nucleatum (F. nucleatum) oral squamous cell carcinoma (OSCC) human immortalized oral epithelial cells (HIOECs); SCC-9 cells; HSC-4 cells F. nucleatum infection downregulated 31997506 6443 Human hsa-miR-296-5p miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) vascular smooth muscle cell (VSMC) high glucose (HG) treatment upregulated 29386225 6444 Human hsa-miR-296-5p miRNA platelet derived growth factor-BB (PDGF-BB) type 2 diabetes mellitus (T2DM) vascular smooth muscle cell (VSMC) platelet-derived growth factor-BB (PDGF-BB) treatment upregulated 29386225 6445 Human hsa-miR-297 miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment miR-297 was decreased in LPS-induced A549 cells. 31945608 6446 Human hsa-miR-297 miRNA hypoxia myocardial ischaemic injury human umbilical vein endothelial cells (HUVECs) hypoxia treatment "hsa_circ_0007623 can bind to miR-297, promote cardiac repair after acute myocardial ischemia, and protect cardiac function." 31973814 6447 Human hsa-miR-297 miRNA aluminum oxide nanoparticles (Al2O3 NPs) pulmonary inflammation human bronchial epithelial (HBE) cells aluminum oxide nanoparticles (Al2O3 NPs) treatment upregulated 31918133 6448 Human hsa-miR-297 miRNA lipopolysaccharide (LPS) sepsis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment downregulated 30921508 6449 Human hsa-miR-298 miRNA bufalin gastric cancer (GC) gastric cancer cells bufalin treatment downregulated 26064232 6450 Human hsa-miR-299 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 6451 Human hsa-miR-299 miRNA hypoxia ovarian cancer (OC) human ovarian cancer cell lines Caov3;Skov3 hypoxia treatment upregulated 28726915 6452 Human hsa-miR-299 miRNA oleuropein (OL) ovarian cancer (OC) Caov3 cells oleuropein upregulated 28726915 6453 Human hsa-miR-299-3p miRNA cisplatin (DDP) gastric cancer (GC) AGS cells; HGC-27 cells cisplatin (DPP) treatment "circ_0110805 knockdown increased the sensitivity of gastric cancer to cisplatin, which also repressed gastric cancer progression by sponging miR-299-3p to downregulate ENDOPDI expression." 33192077 6454 Human hsa-miR-299-3p miRNA graphene oxide (GO) graphene oxide (GO) toxicity GLC-82 cells GO treatment dysregulated 24512264 6455 Human hsa-miR-299-5p miRNA palmitate diabetes mellitus (DM) Human islets palmitate (Pal) treatment downregulated 30131392 6456 Human hsa-miR-299-5p miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 6457 Human hsa-miR-299-5p miRNA 6'-O-galloylpaeoniflorin (GPF) non-small cell lung cancer (NSCLC) A549 cells 6'-O-galloylpaeoniflorin (GPF) treatment GPF up-regulates miR-299-5p expression via the AMPK pathway. 32014006 6458 Human hsa-miR-29a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cholangiocarcinoma (CCA) Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 19407485 6459 Human hsa-miR-29a miRNA IFN-¦Ã graft-versus-host disease (GVHD) Cord blood (CB) interferon-¦Ã treatment downregulated 21913990 6460 Human hsa-miR-29a miRNA ultraviolet (UV) irradiation age-related cataract (ARC) Human lens epithelial cells (HLECs) ultraviolet irradiation treatment "the interaction among lncRNA H19, miR-29a and TDG is involved in early ARC lncRNA H19 could be a useful marker of early ARC and oxidative damage repair pathway of lncRNA H19/miR-29a/TDG may be a promising target for the treatment of ARC" 31282110 6461 Human hsa-miR-29a miRNA klotho Alzheimer's disease (AD) human peripheral blood mononuclear cells (PBMCs) of AD patients klotho treatment upregulated 31197641 6462 Human hsa-miR-29a miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29386999 6463 Human hsa-miR-29a miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 29386999 6464 Human hsa-miR-29a miRNA ¦Â-hydroxybutyrate Alzheimer's disease (AD) SH-SY5Y cells ¦Â-hydroxybutyrate treatment "microRNA-29a expression was downregulated in 2 ¦ÌM A¦Â25-35-exposed SH-SY5Y cells, but respectively decreased and upregulated in 10 ¦ÌM A¦Â25-35-exposed cells, which were all reversed by ¦Â-hydroxybutyrate" 29386999 6465 Human hsa-miR-29a miRNA etanercept ankylosing spondylitis (AS) Blood etanercept treatment upregulated 26273623 6466 Human hsa-miR-29a miRNA arsenite arsenic induced senescence (AIS) HEK 293 cells arsenic (As) exposure upregulated 29107899 6467 Human hsa-miR-29a miRNA platelet derived growth factor-BB (PDGF-BB) arteriosclerosis obliterans (ASO) human arterial smooth muscle cells (HASMCs) platelet-derived growth factor-BB (PDGF-BB) treatment downregulated 31614351 6468 Human hsa-miR-29a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic smooth muscle cells (HASMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29074464 6469 Human hsa-miR-29a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HASMCs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29074464 6470 Human hsa-miR-29a miRNA insulin breast cancer "human breast cancer cells, namely, MCF-7 and T47D cells" human insulin treatment upregulated 28427228 6471 Human hsa-miR-29a miRNA isoflavone apoptosis PCa cells isoflavone? treatment downregulated 22805767 6472 Human hsa-miR-29a miRNA dexamethasone (DEX) cell differentiation human multipotent adipose stem (hMADS) cells dexamethasone (DEX) treatment upregulated 30742779 6473 Human hsa-miR-29a miRNA human papilloma virus (HPV) cervical cancer (CC) human foreskin keratinocytes (HFK)K-derived organotypic raft cultures HPV infectionn downregulated 33436409 6474 Human hsa-miR-29a miRNA galacto-oligosaccharides (GOS) colitis normal and LPS-stimulated human colon epithelial FHC cells galacto-oligosaccharides (GOS) treatment downregulated 31226416 6475 Human hsa-miR-29a miRNA lipopolysaccharide (LPS) colitis human colon epithelial FHC cells lipopolysaccharide (LPS) treatment upregulated 31226416 6476 Human hsa-miR-29a miRNA doxorubicin (DOX) colorectal cancer (CRC) HT29 cells doxorubicin (DOX) treatment miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via upregulated of PTEN in colon cancer cells 32416187 6477 Human hsa-miR-29a miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 6478 Human hsa-miR-29a miRNA photodynamic therapy (PDT) colorectal cancer (CRC) HCT116 cells PDT treatment downregulated 29807108 6479 Human hsa-miR-29a miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) High Glucose (HG) treatment downregulated 30520097 6480 Human hsa-miR-29a miRNA high glucose (HG) diabetes mellitus (DM) HepG2 cells high glucose (HG) treatment upregulated 30296791 6481 Human hsa-miR-29a miRNA morin diabetes mellitus (DM) high glucose (HG)-induced HepG2 cells Morin treatment downregulated 30296791 6482 Human hsa-miR-29a miRNA TGF-¦Â2 diabetic nephropathy (DN) human dermal microvascular endothelial cells (HMVECs) TGF-¦Â2 treatment Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT 33324218 6483 Human hsa-miR-29a miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 30936982 6484 Human hsa-miR-29a miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 6485 Human hsa-miR-29a miRNA high glucose (HG) epithelial-mesenchymal transition (EMT) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 30936982 6486 Human hsa-miR-29a miRNA high glucose (HG) and TGF-¦Â1 excess collagen deposition in PTCs ?HK-2 cells high glucose /TGF-¦Â1 treatment downregulated 20067797 6487 Human hsa-miR-29a miRNA bisphenol A (BPA) female fertility cumulus oocyte complex (COC) bisphenol A (BPA) treatment upregulated 33285269 6488 Human hsa-miR-29a miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment upregulated 29435044 6489 Human hsa-miR-29a miRNA cisplatin (DDP) glioblastoma multiforme (GBM) T98G cells; U87MG cells cisplatin (DPP) treatment Cisplatin increased CD133 expression by suppressing miR-29a levels. 30267383 6490 Human hsa-miR-29a miRNA sevoflurane (SEV) hepatocellular carcinoma (HCC) Huh7 and HepG2 cells sevoflurane (SEVO) treatment upregulated 31190353 6491 Human hsa-miR-29a miRNA TGF-¦Â hepatocellular carcinoma (HCC) human HCC cell lines human HCC cell lines with TGF-¦Â treatment downregulated 23789939 6492 Human hsa-miR-29a miRNA xiaoai jiedu recipe (XJR) hepatocellular carcinoma (HCC) SK-Hep-1 cells; Hep3B cells Xiaoai Jiedu Recipe (XJR) treatment XJR treatment significantly increased the expression of miR-29a 32848411 6493 Human hsa-miR-29a miRNA Intestinal Salmonella typhimurium intestinal Salmonella typhimurium infection human intestinal cells Intestinal Salmonella typhimurium infection upregulated 23826261 6494 Human hsa-miR-29a miRNA leukemia microvesicles leukemia healthy hematopoietic stem cells leukemia microvesicles transformation upregulated 28218044 6495 Human hsa-miR-29a miRNA arsenic trioxide (ATO) hepatocellular carcinoma (HCC) HepG-2 cells arsenic trioxide?treatment upregulated 21175813 6496 Human hsa-miR-29a miRNA rosiglitazone liver fibrosis human hepatic stellate cell line LX-2 rosiglitazone (RSG) treatment upregulated 30781750 6497 Human hsa-miR-29a miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment upregulated 32933544 6498 Human hsa-miR-29a miRNA graphene oxide (GO) nanoparticles toxicity MCF-7 cells graphene oxide (GO) treatment upregulated 32070776 6499 Human hsa-miR-29a miRNA graphene oxide (GO) nanoparticles toxicity KMBC/71 cells graphene oxide (GO) treatment downregulated 32070776 6500 Human hsa-miR-29a miRNA graphene quantum dots (GQDs) nanoparticles toxicity KMBC/71 cells graphene quantum dots (GQDs) treatment downregulated 32070776 6501 Human hsa-miR-29a miRNA ionizing radiation (IR) nasopharyngeal carcinoma (NPC) "A radio-resistant sub-cell line, CNE-2R" irradiation (IR) exposure downregulated 31034464 6502 Human hsa-miR-29a miRNA retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) neuronal development SH-SY5Y cells retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment upregulated 29619741 6503 Human hsa-miR-29a miRNA oleic acid (OA) nonalcoholic fatty liver disease (NAFLD) JFH-I-infected Huh-7 cells oleic acid (OA) treatment upregulated 28097097 6504 Human hsa-miR-29a miRNA methotrexate (MTX) osteosarcoma (OS) "osteosarcoma cell lines, MG-63 and U2OS" methotrexate (MTX) treatment downregulated 30518744 6505 Human hsa-miR-29a miRNA ischemia peripheral arterial disease (PAD) human umbilical vein endothelial cells (HUVEC) "exposed to simulated ischemia (2% oxygen, BioSpherix, Lacona, NY and starvation medium)" downregulated 28637396 6506 Human hsa-miR-29a miRNA TGF-¦Â1 prostatic hyperplasia (BPH) prostate stromal cells (PrSCs) were primary cultured from BPH tissue TGF¦Â1 treatment "miR-29a expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR-29a" 31694982 6507 Human hsa-miR-29a miRNA TGF-¦Â1 pulmonary fibroblasts proliferation IMR-90 TGF-¦Â1 treatment downregulated 26410313 6508 Human hsa-miR-29a miRNA radiation radiation-induced lung injury (RILI) HFL-1; WI-38 TGF-¦Â1 and radiation treatment downregulated 33117089 6509 Human hsa-miR-29a miRNA fibroblast growth factor 2 (FGF2) regeneration of skeletal muscle human myoblasts fibroblast growth factor-2 (FGF2) treatment we demonstrate using microRNA (miRNA) profiling in mouse and human myoblasts that the capacity of FGF2 to stimulate myoblast proliferation is mediated by miR-29a. FGF2 induces miR-29a expression and inhibition of miR-29a using pharmacological or genetic deletion decreases myoblast proliferation. 26731484 6510 Human hsa-miR-29a miRNA arsenite cell senescence HEK 293 cells arsenite exposure upregulated 29107899 6511 Human hsa-miR-29a miRNA resistance exercise training skeletal muscle hypertrophy Vastus lateralis biopsies resistance exercise training treatment upregulated 21030674 6512 Human hsa-miR-29a miRNA glucose type 2 diabetes mellitus (T2DM) INS-1E beta-cells; human islets of Langerhans glucose treatment upregulated 22940552 6513 Human hsa-miR-29a miRNA resistanceor endurance training type 2 diabetes mellitus (T2DM) middle-aged Polynesian men and women with morbid obesity (44 kg/m(2) ¡À 10) and Type 2 diabetes 16 wk of resistanceor endurance training treatment dysregulated 25138607 6514 Human hsa-miR-29a miRNA phosphorus (Pi) vascular calcification (VC) vascular smooth muscle cell (VSMC) phosphorus (Pi) treatment upregulated 26610870 6515 Human hsa-miR-29a miRNA high glucose (HG) vascular injury human umbilical vein endothelial cells (HUVEC) high glucose (HG) treatment 72-hour exposure to HG-decreased hsa-miRNA-29a. 30520097 6516 Human hsa-miR-29a miRNA "3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064)" liver fibrosis hepatic stellate cells (HSCs) "3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064) treatment" upregulated 21511916 6517 Human hsa-miR-29a-3p miRNA tamoxifen and metformin breast cancer MCF-7 and MDA-MB-231 cell lines MCF-7 and MDA-MB-231 cell lines treatment dysregulated 27329603 6518 Human hsa-miR-29a-3p miRNA hypoxia cell differentiation human (P3 and U87) glioma cell lines hypoxia induce upregulated 30536597 6519 Human hsa-miR-29a-3p miRNA astaxanthin colorectal cancer (CRC) The human colon cancer cell HCT116 astaxanthin (ATX) treatment upregulated 31263239 6520 Human hsa-miR-29a-3p miRNA high glucose (HG) diabetic retinopathy (DR) ACBRI-183 cells high glucose (HG) treatment upregulated 32343678 6521 Human hsa-miR-29a-3p miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 6522 Human hsa-miR-29a-3p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) gastric mucosa tissues and gastric cells BGC-823 and GES-1 Helicobacter pylori (H. pylori)?infection upregulated 30485838 6523 Human hsa-miR-29a-3p miRNA cardiac resynchronization therapy heart failure (HF) plasma cardiac resynchronization therapy treatment upregulated 23736534 6524 Human hsa-miR-29a-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment miR-29a-3p expression in LX-2 cells showed the greatest decrease among four candidate microRNAs in response to TGF-¦Â1 treatment 32819600 6525 Human hsa-miR-29a-3p miRNA hypoxia myocardial ischaemic injury AC16 cells hypoxia treatment downregulated 33165134 6526 Human hsa-miR-29a-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 6527 Human hsa-miR-29a-3p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) plasma Mycobacterium tuberculosis (Mtb) infection upregulated 30711160 6528 Human hsa-miR-29a-3p miRNA Roux-en-Y gastric bypass (RYGB) type 2 diabetes mellitus (T2DM) patients with T2DM peripheral blood on the peripheral blood microRNAs (miRNAs) of treatment downregulated in the peripheral blood 28273212 6529 Human hsa-miR-29a-5p miRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells Ginsenoside Rh2 (Rh2) treatment downregulated 30197683 6530 Human hsa-miR-29a-5p miRNA hypoxia hypoxic pulmonary hypertension (HPH) human pulmonary alveolar epithelial cells (HPAECS) hypoxia treatment "MIAT was upregulated in both in vivo and in vitro HPH models, while miR-29a-5p was downregulated." 32964992 6531 Human hsa-miR-29b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cholangiocarcinoma (CCA) Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 19407485 6532 Human hsa-miR-29b miRNA IFN-¦Ã graft-versus-host disease (GVHD) Cord blood (CB) interferon-¦Ã treatment downregulated 21913990 6533 Human hsa-miR-29b miRNA high glucose (HG) inflammation HUVECs high glucose (HG) treatment positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress. 31737629 6534 Human hsa-miR-29b miRNA AR-42 osteoblastic differentiation Increased anti-leukemic activity of decitabine AR-42 treatment upregulated 23178755 6535 Human hsa-miR-29b miRNA prostaglandin E2 (PGE2) abdominal aortic aneurysm (AAA) human aortic smooth muscle cells (HASMCs) prostaglandin E2 (PGE2) treatment upregulated 29896234 6536 Human hsa-miR-29B miRNA transcription factor NRF2 acute myeloid leukemia (AML) peripheral blood Transcription factor NRF2 treatment downregulated 25323587 6537 Human hsa-miR-29b miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning upregulated 30602960 6538 Human hsa-miR-29b miRNA wear particles adverse biological responses to prostheses wear particles THP-1 cells wear particles treatment upregulated 27812842 6539 Human hsa-miR-29b miRNA ethanol (EtOH) alcoholic liver fibrosis (ALF) Human HSC cells (LX-2) ethanol treatment downregulated 31418997 6540 Human hsa-miR-29b miRNA angiotensin II (Ang II) angiotensin II (Ang II)-induced human glomerular mesangial cell (HGMC) activation Human glomerular mesangial cells (HGMCs) angiotensin II (Ang II) treatment Treatment with Ang II led to upregulated of miR-29b in a time-dependent manner. 31630337 6541 Human hsa-miR-29b miRNA epigallocatechin-3-gallate (EGCG) anti-cancer therapy AGS and SGC7901 GC cells Epigallocatechin gallate (EGCG) treatment Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis 32512188 6542 Human hsa-miR-29b miRNA alginate oligosaccharide (AOS) aortic aneurysmal disease aortic aneurysm patients oral administration 10-mg AOS daily downregulated 28919708 6543 Human hsa-miR-29b miRNA glucocorticoid (GC) apoptosis human plasmacytoid dendritic cells(pDCs) Glucocorticoids (GCs) treatment both of these miRNAs promoted pDC apoptosis by directly targeting Mcl-1 and Bcl-2 in human primary pDCs 23894561 6544 Human hsa-miR-29b miRNA lipopolysaccharide (LPS) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment upregulated 29398368 6545 Human hsa-miR-29b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) primary human aortic smooth muscle cell (HASMC) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 21266537 6546 Human hsa-miR-29b miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29398368 6547 Human hsa-miR-29b miRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29398368 6548 Human hsa-miR-29b miRNA IFN-¦Ã atopic dermatitis (AD) human keratinocytes "treat with IFN-¦Ã (10 ng/ml for 12 h, 24 h and 48 h)" upregulated 31966903 6549 Human hsa-miR-29b miRNA benzo(a)pyrene (BaP) breast cancer MDA-MB-231 cells benzo(a)pyrene (BaP) exposure downregulated 30155724 6550 Human hsa-miR-29b miRNA gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor breast cancer BRCA1 wild-type cells (MDA-MB-231) gemcitabine-alone and in combination with PARP1 inhibitor treatment upregulated 25202071 6551 Human hsa-miR-29b miRNA anthracycline (AC) cardiotoxicity children plasma anthracycline (AC) treatment upregulated 28377429 6552 Human hsa-miR-29b miRNA angiotensin II (Ang II) cardiovascular disease (CVD) HEK293N (AT1R-HEK) cells angiotensin II (Ang II) treatment upregulated 21449976 6553 Human hsa-miR-29b miRNA lovastatin cardiovascular disease (CVD) human umbilical vein endothelial cells (HUVECs) lovastatin upregulated in time/dose-dependently 28061433 6554 Human hsa-miR-29b miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 6555 Human hsa-miR-29b miRNA cisplatin (DDP) cervical cancer (CC) human cervical caner cell lines (HeLa and Caski cells) cisplatin treatment upregulated 28122338 6556 Human hsa-miR-29b miRNA indoxyl sulfate (IS) chronic kidney disease (CKD) human aortic smooth muscle cells (HASMCs) indoxyl sulfate (IS) treatment upregulated 29195902 6557 Human hsa-miR-29b miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) HBE cells cigarette smoke extract (CSE) treatment downregulated 30652495 6558 Human hsa-miR-29b miRNA N-acetyl-L-cysteine (NAC) chronic obstructive pulmonary disease (COPD) cigarette smoke extract (CSE)-treated HBE cells N-acetylcysteine treatment upregulated 30652495 6559 Human hsa-miR-29b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 30936982 6560 Human hsa-miR-29b miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (hRMECs) high glucose (HG) treatment Circular RNA COL1A2 promotes angiogenesis via regulating miR-29b/VEGF axis in diabetic retinopathy. 32497630 6561 Human hsa-miR-29b miRNA quercetin diabetic retinopathy (DR) ARPE-19 cells quercetin treatment "miR-29b was low expressed in high glucose-treated cell, but quercetin elevated its expression" 31960917 6562 Human hsa-miR-29b miRNA "2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)" endothelial cell injury human umbilical vein endothelial cells (HUVECs) "2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment" downregulated 33093269 6563 Human hsa-miR-29b miRNA lipopolysaccharide (LPS) endothelial cell injury human umbilical vein endothelial cells (HUVEC) lipopolysaccharide (LPS) treatment MiR-29b was upregulated in LPS-treated HUVEC and Eahy926 cells. 29665646 6564 Human hsa-miR-29b miRNA high glucose (HG) epithelial-mesenchymal transition (EMT) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 30936982 6565 Human hsa-miR-29b miRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) human retinal pigment epithelial (RPE) cells TGF-¦Â2 treatment downregulated 31850164 6566 Human hsa-miR-29b miRNA H2O2 epithelial ovarian cancer (EOC) human ovarian cancer cell lines SKOV3 and A2780 H2O2 downregulated 29050034 6567 Human hsa-miR-29b miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human retinal pigment epithelial cells TGF-¦Â1 treatment downregulated 25263462 6568 Human hsa-miR-29b miRNA TGF-¦Â extracellular-matrix (ECM) and fibril formation LX-2 cells TGF-¦Â treatment downregulated 24650661 6569 Human hsa-miR-29b miRNA TGF-¦Â fibrosis human Tenon's fibroblasts (HTFs) TGF-¦Â treatment miR-29b in TGF-b treatment group was significantly decreased compared to that in blank group 32124130 6570 Human hsa-miR-29b miRNA ochratoxin A (OTA) fibrosis human embryonic kidney cells (HEK293) cells OTA treatment downregulated 25091173 6571 Human hsa-miR-29b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "human gastric cancer cell lines including AGS, BGC-823, SGC-7901, and MGC-803" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29221174 6572 Human hsa-miR-29b miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment upregulated 29435044 6573 Human hsa-miR-29b miRNA lithium chloride (LiCl) glaucoma human TM cells incubat lithium chloride (LiCl) treatment upregulated 25352117 6574 Human hsa-miR-29b miRNA TGF-¦Â1 glaucoma human subconjunctival fibroblasts TGF-¦Â1 treatment miR-29b acted as a suppressor of type I collagen gene by repressing the PI3K/Akt/Sp1 pathway in HTFs 22297492 6575 Human hsa-miR-29b miRNA TGF-¦Â2 glaucoma Tenon's capsule fibroblasts TGF-¦Â2 treatment downregulated 26191170 6576 Human hsa-miR-29b miRNA angiotensin II (Ang II) henoch Sch?nlein purpura nephritis (HSPN) human glomerular mesangial cell (HGMC) angiotensin II (Ang II) treatment upregulated 31630337 6577 Human hsa-miR-29b miRNA fusaric acid (FA) hepatocellular carcinoma (HCC) HepG2 cells Fusaric acid (FA) treatment upregulated 31060424 6578 Human hsa-miR-29b miRNA brucea javanica oil (BJO) hepatocellular carcinoma (HCC) HCC cells brucea javanica oil (BJO) treatment BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level and p53 expression. 33341052 6579 Human hsa-miR-29b miRNA brusatol hepatocellular carcinoma (HCC) HCC cells brusatol treatment BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level and p53 expression. 33341052 6580 Human hsa-miR-29b miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection plasma HIV-1 infection upregulated 25808800 6581 Human hsa-miR-29b miRNA lipopolysaccharide (LPS) inflammation THP1-differentiated macrophages lipopolysaccharide (LPS) treatment downregulated 24062196 6582 Human hsa-miR-29b miRNA dexamethasone (DEX) ischemic brain injury SK-N-SH cells dexamethasone (DEX) treatment Dex treatment could reduce miR-29b expression. 29087603 6583 Human hsa-miR-29b miRNA dexmedetomidine (DEX) ischemic brain injury human neuroblastoma SK-N-SH cells subjected to oxygen-glucose deprivation (OGD) dexamethasone (DEX) treatment downregulated 29087603 6584 Human hsa-miR-29b miRNA angiotensin II (Ang II) kidney damage human podocytes angiotensin II (Ang II) treatment upregulated 26867059 6585 Human hsa-miR-29b miRNA gemcitabine (GEM) hepatocellular carcinoma (HCC) HuCCT1 cells; HuH28 cells Gemcitabine treatment upregulated 24147037 6586 Human hsa-miR-29b miRNA astaxanthin liver fibrosis human hepatic stellate cell (HSC) line LX-2 astaxanthin (AST) treatment upregulated 30896849 6587 Human hsa-miR-29b miRNA curcumin (Cur) liver fibrosis activated HSCs curcumin? treatment upregulated 24138392 6588 Human hsa-miR-29b miRNA high glucose (HG) memory impairment in diabetes SH-SY5Y cells high glucose (HG) treatment downregulated 32198621 6589 Human hsa-miR-29b miRNA bortezomib multiple myeloma (MM) Bone marrow bortezomib? treatment upregulated 30967527 6590 Human hsa-miR-29b miRNA genistein multiple myeloma (MM) human MM cell line U266 Genistein treatment upregulated 26718793 6591 Human hsa-miR-29b miRNA genistein multiple myeloma (MM) U266 cells genistein treatment upregulated 26718793 6592 Human hsa-miR-29b miRNA paeoniflorin multiple myeloma (MM) SKO-007 cells Paeoniflorin (PF) treatment upregulated 27430753 6593 Human hsa-miR-29b miRNA berberine (BBR) myocardial infarction (MI) human umbilical vein endothelial cells (HUVECs) berberine (BBR) treatment upregulated 28722488 6594 Human hsa-miR-29b miRNA haloperidol neuroblastoma (NB) SK-N-SH cell lines haloperidol at 10¦Ìm concentration for 24 hours downregulated 28886082 6595 Human hsa-miR-29b miRNA retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) neuronal development SH-SY5Y cells retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment upregulated 29619741 6596 Human hsa-miR-29b miRNA methotrexate (MTX) osteosarcoma (OS) "osteosarcoma cell lines, MG-63 and U2OS" methotrexate (MTX) treatment downregulated 30518744 6597 Human hsa-miR-29b miRNA oxymatrine ovarian cancer (OC) OVCAR-3 ovary cancer cell line Oxymatrine treatment upregulated 26099492 6598 Human hsa-miR-29b miRNA high glucose (HG) oxidative stress HUVECs high glucose (HG) treatment positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress. 31737629 6599 Human hsa-miR-29b miRNA corticosteroid pancreatic cancer (PC) PC12 cells corticosterone (CORT) treatment downregulated 27501468 6600 Human hsa-miR-29b miRNA lipopolysaccharide (LPS) peritoneal fibrosis human peritoneal mesothelial cells (HPMCs) lipopolysaccharide (LPS) treatment downregulated 30855347 6601 Human hsa-miR-29b miRNA matrine peritoneal fibrosis LPS-treated human peritoneal mesothelial cells (HPMCs) matrine treatment upregulated 30855347 6602 Human hsa-miR-29b miRNA TGF-¦Â1 cell proliferation ARPE-19 cells TGF-¦Â1 treatment downregulated 25263462 6603 Human hsa-miR-29b miRNA TGF-¦Â1 prostatic hyperplasia (BPH) prostate stromal cells (PrSCs) were primary cultured from BPH tissue TGF¦Â1 treatment "miR-29b expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR29b" 31694982 6604 Human hsa-miR-29b miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (PASMCs) hypoxia induce downregulated 29662889 6605 Human hsa-miR-29b miRNA TGF-¦Â1 pulmonary fibroblasts proliferation IMR-90 TGF-¦Â1 treatment downregulated 26410313 6606 Human hsa-miR-29b miRNA infliximab rheumatoid arthritis (RA) peripheral blood monocytes (PBMs) from RA patients infliximab treatment downregulated 31473844 6607 Human hsa-miR-29b miRNA brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) cell senescence SH-SY5Y cells brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment upregulated 27525675 6608 Human hsa-miR-29b miRNA retinoic acid (RA) cell senescence SH-SY5Y cells retinoic acid (RA) treatment upregulated 27525675 6609 Human hsa-miR-29b miRNA retinoic acid (RA) cell senescence SH-SY5Y cells SH-SY5Y cells treatment upregulation 27525675 6610 Human hsa-miR-29b miRNA silica silicosis A549 cells silica treatment miRNA-29b (miR-29b) was dynamically downregulated by silica 30529807 6611 Human hsa-miR-29b miRNA indoxyl sulfate (IS) vascular calcification (VC) human aortic smooth muscle cells (HASMCs) Indoxyl sulfate (IS) treatment downregulated 29195902 6612 Human hsa-miR-29b miRNA phosphorus (Pi) vascular calcification (VC) vascular smooth muscle cell (VSMC) phosphorus (Pi) treatment upregulated 26610870 6613 Human hsa-miR-29b-1-5p miRNA sulforaphane (SFN) cancer treatment NCI-60 cells sulforaphane treatment downregulated 32429039 6614 Human hsa-miR-29b-2 miRNA "CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)" breast cancer MCF-7 cells TBB treatment upregulated 25120778 6615 Human hsa-miR-29b-2-5p miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary arterial smooth muscle cells (hPASMCs) hypoxia treatment hsa_circNFXL1_009 directly sponged hsa-miR-29b-2-5p (miR-29b) and positively regulated the expression of voltage-gated potassium (K+) channel subfamily B member 1 (KCNB1) at the mRNA level. 33614247 6616 Human hsa-miR-29b-3p miRNA walnut benefits of walnuts Plasma exosomes walnuts treatment upregulated 32979076 6617 Human hsa-miR-29b-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment upregulated 29154802 6618 Human hsa-miR-29b-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 6619 Human hsa-miR-29b-3p miRNA platelet lysate (PL) chondrogenesis human umbilical cord-derived mesenchymal stem cells (hUCMSCs) platelet lysate (PL) treatment PL induced chondrogenic differentiation of hUCMSCs by regulating the H19/miR-29b-3p/SOX9 axis 33058414 6620 Human hsa-miR-29b-3p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 6621 Human hsa-miR-29b-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells; HL-7702 cells TGF-¦Â1 treatment Transforming growth factor beta 1 (TGF-¦Â1)-induced hepatic stellate cell (HSC) activation significantly decreased miR-29b-3p expression 32653922 6622 Human hsa-miR-29b-3p miRNA bortezomib multiple myeloma (MM) "Human MM cell lines H929, U266" bortezomib? treatment "H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis." 30728351 6623 Human hsa-miR-29b-3p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 6624 Human hsa-miR-29b-3p miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models. 32037864 6625 Human hsa-miR-29b-3p miRNA Bone morphogenetic protein 1 (BMP1) osteogenesis human bone marrow-derived mesenchymal stem cells (hBMSCs) BMP1 treatment NEAT1 promotes osteogenic differentiation in hBMSCs by regulating miR-29b-3p/BMP1 axis. 30638953 6626 Human hsa-miR-29b-3p miRNA paclitaxel (PTX) ovarian cancer (OC) A2780 cells; SK-OV-3 cells Paclitaxel (PTX) treatment TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells 32189969 6627 Human hsa-miR-29b-3p miRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) Human pancreatic cancer cell lines PANC-1 and BxPC-3 gemcitabine treatment MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14. 30915884 6628 Human hsa-miR-29b-3p miRNA radiation prostate cancer LNCaP cells radiation treatment miR-29b-3p expression is increased in response to IR in LNCaP cells 33033519 6629 Human hsa-miR-29b-3p miRNA cigarette smoke extract (CSE) smoke-induced lung injury (SILI) A549 cells; H460 cells cigarette smoke extract (CSE) treatment upregulated 33523607 6630 Human hsa-miR-29b-3p miRNA Rb3 smoke-induced lung injury (SILI) A549 cells; H460 cells Rb3 treatment downregulated 33523607 6631 Human hsa-miR-29c miRNA IFN-¦Ã graft-versus-host disease (GVHD) Cord blood (CB) interferon-¦Ã treatment downregulated 21913990 6632 Human hsa-miR-29c miRNA glucocorticoid (GC) apoptosis human plasmacytoid dendritic cells(pDCs) Glucocorticoids (GCs) treatment both of these miRNAs promoted pDC apoptosis by directly targeting Mcl-1 and Bcl-2 in human primary pDCs 23894561 6633 Human hsa-miR-29c miRNA SGI-1027 biliary atresia-related fibrosis HIBEpiC cells SGI-1027 treatment upregulated 30906331 6634 Human hsa-miR-29c miRNA TGF-¦Â1 biliary atresia-related fibrosis HIBEpiC cells TGF-¦Â1 treatment downregulated 30906331 6635 Human hsa-miR-29c miRNA brown seaweed fucoidan breast cancer Human Breast Cancer Cells brown seaweed fucoidan treatment upregulated 27994679 6636 Human hsa-miR-29c miRNA paclitaxel (PTX) breast cancer "The breast cancer cell lines (MDA-MB-231, MCF-7, Hs-578T, and T47D) and the immortalized breast epithelial cell line MCF-10A" paclitaxel treatment LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells by upregulating miR-29c 31047896 6637 Human hsa-miR-29c miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment upregulated 20346162 6638 Human hsa-miR-29c miRNA ibrutinib chronic lymphocytic leukemia (CLL) CLL patient cells ibrutinib treatment upregulated 28299881 6639 Human hsa-miR-29c miRNA astragaloside IV (AS-IV) colorectal cancer (CRC) CRC cell lines (SW620 and HCT116) astragaloside (AS-IV) treatment upregulated 29710520 6640 Human hsa-miR-29c miRNA progesterone (P4) endometrial cancer (EC) Hec6A cells Progesterone treatment upregulated 22543862 6641 Human hsa-miR-29c miRNA celecoxib gastric cancer (GC) AGS cells; MKN45 cells celecoxib treatment downregulated 23001726 6642 Human hsa-miR-29c miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) plasma hepatitis B virus (HBV) infection downregulated 22105822 6643 Human hsa-miR-29c miRNA tumor necrosis factor alpha-induced protein 3 (TNFAIP3) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cell line (HepG2) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 21763284 6644 Human hsa-miR-29c miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells Influenza A virus treatment upregulated 22850539 6645 Human hsa-miR-29c miRNA influenza A virus (IAV) innate immune response human CRC cell lines SW620 and RKO infect with IAVs treatment upregulated 24953694 6646 Human hsa-miR-29c miRNA "tranilast (N-3,4-dimethoxycinnamoyl anthranilic acid)" leiomyoma leiomyoma smooth muscle cells (LSMC) of leiomyoma patients tranilast treatment upregulated 28114878 6647 Human hsa-miR-29c miRNA methamphetamine (METH) locomotor sensitization mouse nucleus accumbens (NAc) tissues methamphetamine (METH) treatment downregulated 30639389 6648 Human hsa-miR-29c miRNA silica lung function decline blood silica treatment downregulated 29280772 6649 Human hsa-miR-29c miRNA mycoplasma pneumoniae (M. pneumoniae) mycoplasma pneumoniae pneumonia(MPP) peripheral blood monouclear cells Mycoplasma pneumoniae (M. pneumoniae) infection downregulated 31088519 6650 Human hsa-miR-29c miRNA paclitaxel (PTX) nasopharyngeal carcinoma (NPC) "human NPC cell lines, SUNE-1 and C666-1" Paclitaxel (Taxol) treatment downregulated 30779921 6651 Human hsa-miR-29c miRNA retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) neuronal development SH-SY5Y cells retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment upregulated 29619741 6652 Human hsa-miR-29c miRNA compound C nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) compound C treatment downregulated 32143184 6653 Human hsa-miR-29c miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmitic acid treatment downregulated 32143184 6654 Human hsa-miR-29c miRNA methotrexate (MTX) osteosarcoma (OS) "osteosarcoma cell lines, MG-63 and U2OS" methotrexate (MTX) treatment downregulated 30518744 6655 Human hsa-miR-29c miRNA palmitic acid (PA) pancreatic cancer (PC) human PC cells palmitic acid (PA) treatment downregulated 28088520 6656 Human hsa-miR-29c miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment downregulated 31732967 6657 Human hsa-miR-29c miRNA TGF-¦Â1 pulmonary fibroblasts proliferation IMR-90 TGF-¦Â1 treatment downregulated 26410313 6658 Human hsa-miR-29c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" triple negative breast cancer (TNBC) MCF10A cell line "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28160548 6659 Human hsa-miR-29c miRNA ultraviolet (UV) irradiation ultraviolet radiation (UV) effects human dermal fibroblasts (HDFs) ultraviolet radiation (UVA) treatment upregulated 30378537 6660 Human hsa-miR-29c miRNA tranilast leiomyoma leiomyoma smooth muscle cells (LSMC) tranilast treatment downregulated 28114878 6661 Human hsa-miR-29c-3p miRNA TGF-¦Â2 age-related cataract (ARC) SRA01/04 cells TGF-¦Â2 traetment treatment "miR-29c-3p regulated FOS to repress EMT, cell proliferation and facilitate apoptosis in TGF-¦Â2-treated SRA01/04 cells mediated by KCNQ1OT1" 32534225 6662 Human hsa-miR-29c-3p miRNA sanguinarine gastric cancer (GC) BGC-823 cells sanguinarine treatment downregulated 31243669 6663 Human hsa-miR-29c-3p miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 6664 Human hsa-miR-29c-3p miRNA cisplatin (DDP) medulloblastoma "Medulloblastoma cell lines D283, Daoy, D425, and D341" cisplatin treatment downregulated 31753063 6665 Human hsa-miR-29c-3p miRNA cisplatin (DDP) medulloblastoma Daoy; D341 cisplatin (DDP) treatment downregulated 31753063 6666 Human hsa-miR-29c-3p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment upregulated 27143365 6667 Human hsa-miR-30 miRNA IFN-¦Á chronic hepatitis C virus (HCV) infection peripheral blood mononuclear cells (PBMCs) interferon alpha treatment upregulated 21070682 6668 Human hsa-miR-30 miRNA cadmium (Cd) chronic obstructive pulmonary disease (COPD) BEAS-2B cells cadmium (Cd) treatment Cd exposure repressed miR-30 levels 33756289 6669 Human hsa-miR-30 miRNA tumor necrosis factor alpha (TNF-¦Á) crohn disease (CD) Caco2 and HIEC cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 33436852 6670 Human hsa-miR-30 miRNA TGF-¦Â endothelium-dependent vasorelaxation HT-29 cells TGF-¦Â treatment downregulated 23483606 6671 Human hsa-miR-30 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) human gastric cell line SNU-5 5-fluorouracil (5-FU) treatment downregulated 26209295 6672 Human hsa-miR-30 miRNA cadmium (Cd) lung diseases BEAS-2B cells cadmium (Cd) treatment downregulated 30998937 6673 Human hsa-miR-30 miRNA high glucose (HG) podocyte injury ?human podocyte cell high glucose (HG) treatment downregulated 33490186 6674 Human hsa-miR-30 miRNA lipopolysaccharide (LPS) podocytopathy human podocytes lipopolysaccharide (LPS) treatment downregulated 24029422 6675 Human hsa-miR-30 miRNA puromycin aminonucleoside (PAN) podocytopathy human podocytes PAN treatment downregulated 24029422 6676 Human hsa-miR-30 miRNA TGF-¦Â podocytopathy human podocytes TGF-¦Â treatment downregulated 24029422 6677 Human hsa-miR-30 miRNA hypoxia pulmonary arterial hypertension (PAH) HepG2 cells Hypoxia treatment downregulated 20110569 6678 Human hsa-miR-300 miRNA Shikimic acid (SA) breast cancer MCF-7 and T47D cells Shikimic acid (SA) treatment upregulated 31048002 6679 Human hsa-miR-300 miRNA X-rays gastric cancer (GC) human gastric cancer tissue samples "4 Gy of X-rays (6 MV, 0.8 Gy/min) treatment" downregulated 24919435 6680 Human hsa-miR-300 miRNA ionizing radiation (IR) lung cancer human lung cancer cells ionizing radiation (IR) treatment upregulated 28895780 6681 Human hsa-miR-300 miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx3 treatment" downregulated 21572246 6682 Human hsa-miR-301 miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 parental hepatoma cells hepatitis C virus (HCV) infection downregulated 23418453 6683 Human hsa-miR-301 miRNA lipopolysaccharide (LPS) osteoarthritis (OA) human cartilage ATDC5 cells lipopolysaccharide (LPS) treatment downregulated 29414810 6684 Human hsa-miR-301 miRNA emodin ovarian cancer (OC) A2780 cells emodin treatment upregulated 29512773 6685 Human hsa-miR-301 miRNA gemcitabine (GEM) pancreatic cancer (PC) Capan-2 and Panc-1 Gemcitabine (GEM) treatment gemcitabine-resistant cells (Capan-2 and Panc-1) exhibited upregulated miR-301 expression and downregulated gemcitabine-induced apoptosis. 30628651 6686 Human hsa-miR-301 miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 6687 Human hsa-miR-301 miRNA luteolin prostate cancer PC3 and LNCaP cells luteolin treatment downregulated 27307749 6688 Human hsa-miR-301a miRNA plasminogen activator inhibitor-1 (PAI-1) apoptosis human pulmonary endothelial cells PAI-1 (plasminogen activator inhibitor-1) ? treatment downregulated 21175428 6689 Human hsa-miR-301a miRNA arsenite arsenite-induced carcinogenesis BEAS-2B cells arsenic (As) exposure upregulated 30185897 6690 Human hsa-miR-301a miRNA astragaloside IV (AS-IV) gastric cancer (GC) gastric cancer-associated fibroblast (GCAF) astragaloside (AS-IV) treatment downregulated 29358859 6691 Human hsa-miR-301a miRNA triptolide (TPL) gastric cancer (GC) gastric cancer-associated fibroblasts (GCAFs) triptolide (TPL) treatment downregulated miR-301a expression and upregulated miR-149 29049979 6692 Human hsa-miR-301a miRNA placenta growth factor (PlGF) lung fibrosis endothelial cells placenta growth factor (PlGF) treatment downregulated 26460070 6693 Human hsa-miR-301a miRNA hypoxia pancreatic cancer (PC) PaCa-2 and BxPC-3 cells hypoxia induce upregulated 29772221 6694 Human hsa-miR-301a miRNA hypoxia prostate cancer Caco2-BBE cells hypoxia treatment upregulated 26813459 6695 Human hsa-miR-301a miRNA TGF-¦Â lung fibrosis HFL1 cells TGF-¦Â treatment upregulated 32788629 6696 Human hsa-miR-301a miRNA Japanese encephalitis virus (JEV) viral-induced neuroinflammation The human cell line of fetal microglial origin CHME3 and human brains Japanese encephalitis virus (JEV) infection upregulated 31527198 6697 Human hsa-miR-301a-3p miRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) NB4 cells all-trans retinoic acid (ATRA) treatment upregulated 29901102 6698 Human hsa-miR-301a-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment miR-301a-3p expression is highly expressed in ox-LDL-induced HUVECs. 33850541 6699 Human hsa-miR-301a-3p miRNA ¦Â-elemene non-small cell lung cancer (NSCLC) A549 cells ¦Â-elemene treatment ¦Â-elemene suppressed the expression of miR-301a-3p 32463461 6700 Human hsa-miR-301a-3p miRNA hypoxia pancreatic cancer (PC) PANC-1 cells and cell-derived exosomes hypoxia induce upregulated 29880482 6701 Human hsa-miR-301b miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 6702 Human hsa-miR-301b miRNA caffeine inflammatory response MLE-12 and MH-S cells caffeine treatment downregulated 27670114 6703 Human hsa-miR-301b miRNA pseudomonas aeruginosa (PA) inflammatory response MLE-12 and MH-S cells Pseudomonas aeruginosa treatment upregulated 27670114 6704 Human hsa-miR-301b miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 6705 Human hsa-miR-301b miRNA isoliquiritigenin melanoma "Human melanoma cell line(A375, A2058)" Isoliquiritigenin (ISL) treatment downregulated 30081934 6706 Human hsa-miR-301b miRNA hypoxia prostate cancer Caco2-BBE cells hypoxia treatment upregulated 26813459 6707 Human hsa-miR-301b-3p miRNA hypoxia prostate cancer "Human prostate cancer cell lines (DU145, PC-3, LNCaP and IA8)" hypoxia induce upregulated 31442444 6708 Human hsa-miR-302 miRNA pulsatile shear stress cerebral ischemia injury (CII) SH-SY5Y cells pulsatile shear stress?treatment treatment downregulated 31096001 6709 Human hsa-miR-302 miRNA enterovirus 71 (EV71) innate immune response THP-1¨Cderived macrophages Enterovirus 71 (EV71) infection downregulated 29777028 6710 Human hsa-miR-302 miRNA zoledronic acid (ZA) osteoporosis serum ZOL treatment "?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment" 33637048 6711 Human hsa-miR-302 miRNA cisplatin (DDP) ovarian cancer (OC) A2780 cells cisplatin treatment miR-302 is downregulated in cisplatin-resistant ovarian cancer cells and involved in chemosensitivity. 32835657 6712 Human hsa-miR-302 miRNA sodium butyrate (NaB) somatic cell reprogramming human foreskin fibroblasts (HFFs) NaB treatment upregulated 24568633 6713 Human hsa-miR-302a miRNA H2O2 age-related macular degeneration (AMD) ARPE-19 cells H2O2 treatment downregulated 31784665 6714 Human hsa-miR-302a miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 6715 Human hsa-miR-302a miRNA suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) gastric cancer (GC) gastric and liver cancer cells suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) treatment upregulated 24861464 6716 Human hsa-miR-302a miRNA radiation non-small cell lung cancer (NSCLC) NCI-H1299 ; NCI-H1299R cells radiation treatment downregulated 31928130 6717 Human hsa-miR-302a miRNA rapamycin reperfusion injury in diabetic heart human-pluripotent-stem-cells-derived cardiomyocytes (HG-hiPSC-CMs) rapamycin (RAPA) treatment Rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling 33319180 6718 Human hsa-miR-302a-3p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HT29 cells 5-fluorouracil (5-FU) treatment downregulated 25526515 6719 Human hsa-miR-302a-3p miRNA brahma (BRM) pancreatic cancer (PC) BxPC-3 and T3M4 cells brahma (BRM) dificiency "silencing BRM reduced PC cell migration and invasion both in vivo and in vitro, accompanied by reduced level of miR-302a-3p." 30790683 6720 Human hsa-miR-302a-3p miRNA cisplatin (DDP) testicular germ cell tumors (TGCTs) TGCT cell lines NT2-D1 and 833?K cisplatin treatment downregulated 31235829 6721 Human hsa-miR-302b miRNA fentanyl esophageal squamous cell carcinoma (ESCC) ESCC Eca109 and TE1 cell lines Fentanyl treatment upregulated 29928433 6722 Human hsa-miR-302b miRNA all-trans retinoic acid (ATRA) glioblastoma multiforme (GBM) U87 MG cells all-trans retinoic acid (ATRA) treatment upregulated 25040912 6723 Human hsa-miR-302b miRNA monosodium urate (MSU) gouty arthritis THP-1 cells monosodium urate (MSU) crystal treatment upregulated 29482609 6724 Human hsa-miR-302b miRNA lipopolysaccharide (LPS) osteoarthritis (OA) Human OA chondrocytes (C28/12 cell line) lipopolysaccharide (LPS) treatment upregulated 29414803 6725 Human hsa-miR-302b miRNA epirubicin osteosarcoma (OS) osteosarcoma MG-63cells; SAOS-2 cells; hFOB119 cells Epirubicin treatment "miR-302b, which is stably low-expressed in osteosarcoma, could be induced by the epirubicin" 23845851 6726 Human hsa-miR-302b miRNA tetramethylpyrazine (TMP) Periodontitis human periodontal ligament stem cells (hPDLSCs) tetramethylpyrazine (TMP) treatment TMP downregulated microRNA (miR)-302b levels in LPS-stimulated cells. 32236610 6727 Human hsa-miR-302b miRNA TGF-¦Â1 renal fibrosis HK-2 cells cisplatin (DDP) treatment miR-302b was significantly downregulated in UUO mouse kidney tissue and TGF-¦Â1-treated HK-2 cells 33503202 6728 Human hsa-miR-302b miRNA ethanol (EtOH) neuronal cell death SH-SY5Y cells ethanol treatment upregulated 21878650 6729 Human hsa-miR-302b* miRNA estradiol breast cancer MCF-7 breast cancer cells Estradiol treatment downregulated 19528081 6730 Human hsa-miR-302b-3p miRNA cisplatin (DDP) testicular germ cell tumors (TGCTs) TGCT cell lines NT2-D1 and 833?K cisplatin treatment downregulated 31235829 6731 Human hsa-miR-302c miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 6732 Human hsa-miR-302c miRNA particulate matter (PM) cardiovascular disease (CVD) A549 pulmonary cell lines particulate matter (PM)treatment treatment upregulated 24515752 6733 Human hsa-miR-302c miRNA particulate matter (PM) cardiovascular disease (CVD) A549 pulmonary cell lines PM-ed A549 pulmonary cell lines in v treatment upregulated 24515752 6734 Human hsa-miR-302c miRNA inositol hexaphosphate (IP6) colorectal cancer (CRC) Caco-2 colon cancer cells 5 mM IP6 treatment upregulated 31744065 6735 Human hsa-miR-302c miRNA IL-8 gastric cancer (GC) "Human gastric cancer cell lines, HGC-27, MGC80-3, AGS, NCI-N87, SGC-7901, and BGC-823" IL8 expression downregulated 26199092 6736 Human hsa-miR-302c miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251MG-TMZ cells and LN229-TMZ cells temozolomide (TMZ) treatment downregulated 31409725 6737 Human hsa-miR-302c miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 6738 Human hsa-miR-302c miRNA influenza A virus (IAV) influenza A virus (IAV) infection Human lung epithelial cells A549 influenza A virus (IAV) treatment downregulated 26602079 6739 Human hsa-miR-302c miRNA TGF-¦Â liver fibrosis LX-2 cells; primary hepatic stellate cells (HSCs) TGF-¦Â treatment Induction of E6AP by microRNA-302c dysregulation inhibits TGF-¦Â-dependent fibrogenesis in hepatic stellate cells 33037648 6740 Human hsa-miR-302c miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" lung fibrosis Kasumi-1 cells; K562 cells;MCF7 cells; MDA-MB-231 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 23820258 6741 Human hsa-miR-302c miRNA TGF-¦Â1 mesothelial/epithelial-mesenchymal transition (MMT/EMT) human peritoneal mesothelial cell line (HMrSV5) TGF-¦Â1 treatment downregulated 30693641 6742 Human hsa-miR-302c miRNA proline-rich polypeptide 1 (PRP-1) metastatic chondrosarcoma human chondrosarcoma JJ012 cell line "proline-rich polypeptide 1, (PRP-1) treatment" downregulated 26094604 6743 Human hsa-miR-302c-3p miRNA hepatitis B virus (HBV) chronic hepatitis B virus (HBV) infection HepG2©\hNTCP©\C4 cells hepatitis B virus (HBV) infection miR-302c-3p suppresses HBV replication and HBsAg production 30828831 6744 Human hsa-miR-302c-3p miRNA cisplatin (DDP) testicular germ cell tumors (TGCTs) TGCT cell lines NT2-D1 and 833?K cisplatin treatment downregulated 31235829 6745 Human hsa-miR-302e miRNA phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA) allergic inflammation HMC-1 cells phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA) treatment miR-302e was significantly decreased in response to phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA) stimulation 29748238 6746 Human hsa-miR-302e miRNA sevoflurane (SEV) neurotoxicity human hippocampal cells (HN-h) sevoflurane treatment upregulated 30221705 6747 Human hsa-miR-302f miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 6748 Human hsa-miR-302f miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 6749 Human hsa-miR-30-5p miRNA ethanol extract of antrodia cinnamomea (AC) breast cancer MCF-7 and tamoxifen-resistant MCF-7 cells ethanol extract of antrodia cinnamomea (AC) treatment upregulated 29743060 6750 Human hsa-miR-30-5p miRNA candida albicans (C. albicans) inflammatory response THP-1 cells candida albicans infection upregulated 28454101 6751 Human hsa-miR-3065-5p miRNA antrodia cinnamomea cancer treatment "THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68" antrodia cinnamomea treatment downregulated 28602756 6752 Human hsa-miR-30a miRNA hypoxia acute myocardial infarction (AMI) Blood samples hypoxia treatment upregulated 26857375 6753 Human hsa-miR-30a miRNA low-frequency electromagnetic fields (LF-EMF) Alzheimer's disease (AD) human neuroblastoma SH-SY5Y cells low-frequency electromagnetic fields (LF-EMF) treatment downregulated 24676932 6754 Human hsa-miR-30a miRNA hepatitis B virus X protein (HBx) autophagosome formation liver hepatitis B virus X protein treatment "HBx induces autophagosome formation via beclin-1 expression, whereas miRNA-30a overexpression could successfully inhibit the beclin-1 expression induced by HBx, thereby modulating autophagosome formation in hepatic cells." 25620738 6755 Human hsa-miR-30a miRNA cisplatin (DDP) autophagy HeLa cells£» MCF-7 cells£» HepG2 cells cis-dichloro-diamine platinum (cis-DDP) treatment upregulated 22157765 6756 Human hsa-miR-30a miRNA taxol autophagy HeLa cells£» MCF-7 cells£» HepG2 cells taxol treatment upregulated 22157765 6757 Human hsa-miR-30a miRNA BAY11-7082 bladder cancer HTB-1 and T24 cells The addition of BAY11-7082 into the tumor-associated macrophages (TAMs)/HTB-1 or T24 co-culture system downregulated 31002892 6758 Human hsa-miR-30a miRNA androgen breast cancer MDA-MB-453 breast cancer cells androgen treatment downregulated 29085503 6759 Human hsa-miR-30a miRNA imatinib mesylate chronic myeloid leukemia (CML) peripheral blood mononuclear cells Imatinib Mesylate treatment miR-30a was over expressed and Beclin 1 was under expressed in imatinib responders compared to resistant cases. 31945609 6760 Human hsa-miR-30a miRNA imatinib chronic myeloid leukemia (CML) ?human chronic myeloid leukemia cells ?imatinib? treatment upregulated 22395361 6761 Human hsa-miR-30a miRNA cisplatin (DDP) gastric cancer (GC) SGC-7901 cells cisplatin (DPP) treatment 29375703 6762 Human hsa-miR-30a miRNA norcantharidin (NCTD) giant cell tumor of bone (GCTB) GCTB stromal tumor cells norcantharidin (NCTD) treatment Expression of miR-30a was significantly upregulated by NCTD treatment. 29710674 6763 Human hsa-miR-30a miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells temozolomide (TMZ) treatment TMZ led to a significant reduction in miR-30a levels in a dose-dependent manner in U251 cells 29805498 6764 Human hsa-miR-30a miRNA alcohol head and neck squamous cell carcinoma (HNSCC) normal oral keratinocytes alcohol exposure upregulated 26472042 6765 Human hsa-miR-30a miRNA hyperthermia heat shock human OSCC cell lines HSC-2;HSC-3;HSC-4 HT at 44?C for 60 min treatment dysregulated 24789751 6766 Human hsa-miR-30a miRNA TGF-¦Â1 liver fibrosis HSCs and LX-2 exosomes TGF-¦Â1 treatment downregulated in exosomes 28766848 6767 Human hsa-miR-30a miRNA mycobacterium tuberculosis (Mtb) mycobacterium tuberculosis (Mtb) infection THP-1 human monocytes cells during infection infect with MTB H37Rv upregulated 28912881 6768 Human hsa-miR-30a miRNA carbon disulfide (CS2) nerve system injury workers experienced injury to nerve system from carbon disulfide (CS2) treatment upregulated 25224332 6769 Human hsa-miR-30a miRNA low-dose ionizing radiation (LDIR) non-small cell lung cancer (NSCLC) A549 and NCI-H292 cells low-dose radiation (50 mGy) exposure upregulated 30424954 6770 Human hsa-miR-30a miRNA low-dose ionizing radiation (LDIR) non-small cell lung cancer (NSCLC) A549 cells low-dose radiation (LDR) radiation upregulated 30424954 6771 Human hsa-miR-30a miRNA IL-1¦Â osteoarthritis (OA) human osteoarthritis human osteoarthritis treatment downregulated 27067395 6772 Human hsa-miR-30a miRNA beclin-1 osteosarcoma (OS) human osteosarcoma MG-63 cell Beclin-1 treatment downregulated 26708607 6773 Human hsa-miR-30a miRNA titanium dioxide nanoparticles (TiO2 NPs) oxidative stress human lung carcinoma cell line (A549) NPs treatment downregulated 28400205 6774 Human hsa-miR-30a miRNA TGF-¦Â2 posterior capsular opacification (PCO) The human lens epithelial cell line SRA01/04 and HLE B-3 cells TGF-¦Â2 treatment downregulated 31049834 6775 Human hsa-miR-30a miRNA activin A prostate cancer LNCaP cells activin A treatment upregulated 27018851 6776 Human hsa-miR-30a miRNA hypoxia prostate cancer DU145 and LNCaP cells hypoxia treatment downregulated 27160121 6777 Human hsa-miR-30a miRNA metformin (Met) prostate cancer Vcap and PC-3 cells metformin treatment downregulated 25201727 6778 Human hsa-miR-30a miRNA TGF-¦Â renal fibrosis "human HK2, HEK293 cells" TGF¦Â treatment downregulated 28285987 6779 Human hsa-miR-30a miRNA dexamethasone (DEX) steatosis HepG2 cells dexamethasone (Dex) treatment downregulated 29409992 6780 Human hsa-miR-30a-3p miRNA "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)" breast cancer MCF-7 cells "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment" Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells. 33652854 6781 Human hsa-miR-30a-3p miRNA metformin (Met) anti-cancer therapy CD8 + T cells Metformin treatment downregulated 32221038 6782 Human hsa-miR-30a-3p miRNA recombinant early secreted antigenic target 6 (rESAT-6) autophagy Calcimycin-treated dTHP-1 cells recombinant early secreted antigenic target 6 (rESAT-6) treatment upregulated 31181223 6783 Human hsa-miR-30a-3p miRNA TGF-¦Â angiogenesis Human umbilical vein endothelial cells TGF-¦Â treatment downregulated 23960241 6784 Human hsa-miR-30a-3p miRNA IFN-¦Ã systemic sclerosis (SSc) arthritis fibroblasts;SSc HDF IFN-¦Ã treatment downregulated 25360821 6785 Human hsa-miR-30a-5p miRNA bisphenol A (BPA) arterial hypertension urine; whole blood bisphenol A (BPA) treatment downregulated 32438192 6786 Human hsa-miR-30a-5p miRNA recombinant early secreted antigenic target 6 (rESAT-6) autophagy Calcimycin-treated dTHP-1 cells recombinant early secreted antigenic target 6 (rESAT-6) treatment downregulated 31181223 6787 Human hsa-miR-30a-5p miRNA paclitaxel (PTX) tumorigenesis NCI60 cancer cell line£¬Ovarian cancer (OVCA) cell lines and Human stem cell lines (H9) paclitaxel treatment miR-367 upregulated and miR-30a-5p downregulated 24220856 6788 Human hsa-miR-30a-5p miRNA curcumol colorectal cancer (CRC) HCT116 cells curcumol treatment Curcumol treatment was identified to increase miR-30a-5p expression 33732375 6789 Human hsa-miR-30a-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HT29 cells 5-fluorouracil (5-FU) treatment upregulated 25526515 6790 Human hsa-miR-30a-5p miRNA steroids focal segmental glomerulosclerosis (FSGS) urine steroid treatment downregulated 25107948 6791 Human hsa-miR-30a-5p miRNA valproic acid (VPA) hepatic differentiation human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs) valproic acid (VPA) treatment upregulated 27001466 6792 Human hsa-miR-30a-5p miRNA respiratory syncytial virus (RSV) innate immune response human dendritic cells respiratory syncytial virus (RSV) infection treatment upregulated 29970194 6793 Human hsa-miR-30a-5p miRNA deoxycholic acid (DCA) intestinal metaplasia GES-1 cells deoxycholic acid treatment deoxycholic acid-induced macrophage-derived exosomes (D-Exos) may promote intestinal metaplasia and suppress proliferation of GES-1 cells via hsa-miR-30a-5p targeting FOXD1. 32950501 6794 Human hsa-miR-30a-5p miRNA trichostatin A (TSA) keloids cultured keloid fibroblasts Trichostatin A (TSA) treatment downregulated 31059100 6795 Human hsa-miR-30a-5p miRNA lithium (Li) and valproic acid (VPA) neurodegeneration (ND) human neuroblastoma cell line (SH-SY5Y) L-glutamate and Li-VPA treatment both L-glutamate and Li-VPA caused an increase in miR-30a-5p expression at 24 h of incubation and a downregulated at 48 h 25149854 6796 Human hsa-miR-30a-5p miRNA perfluorooctane sulfonic acid (PFOS) neurotoxicity SK-N-SH cells PFOS treatment upregulated 28441774 6797 Human hsa-miR-30a-5p miRNA IL-6 and TNF-¦Á osteoarthritis (OA) chondrocytes IL-6 and TNF-¦Á treatment LINC00461 may modulate the development of OA by suppressing miR-30a-5p expression in chondrocytes. 32155130 6798 Human hsa-miR-30a-5p miRNA L-dopa parkinson's disease (PD) Plasma and White Blood Cells L-dopa-treated treatment upregulated 28540642 6799 Human hsa-miR-30a-5p miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery endothelial cells (HPAECs) hypoxia induce downregulated 31115541 6800 Human hsa-miR-30a-5p miRNA ultraviolet (UV) irradiation UVB-induced cellular response normal human dermal papilla cells UVB radiation of ¡Ý50 mJ/cm2 treatment upregulated 25069581 6801 Human hsa-miR-30b miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment upregulated 29635893 6802 Human hsa-miR-30b miRNA oxalic acid poisoning acute kidney injury (AKI) urinary oxalic acid poisoning upregulated 32910981 6803 Human hsa-miR-30b miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 6804 Human hsa-miR-30b miRNA androgen breast cancer MDA-MB-453 breast cancer cells androgen treatment downregulated 29085503 6805 Human hsa-miR-30b miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 6806 Human hsa-miR-30b miRNA kynurenine breast cancer 95D cells Kynurenine (Kyn) treatment downregulated 31093946 6807 Human hsa-miR-30b miRNA trastuzumab breast cancer HER2-positive (SKBR3£» BT474)£» HER2-negetive (MCF7£» MDA-MB-231) cells Trastuzumab treatment upregulated 22384020 6808 Human hsa-miR-30b miRNA trastuzumab breast cancer BT474 wt cells trastuzumab treatment upregulated 28120942 6809 Human hsa-miR-30b miRNA vascular endothelial growth factor (VEGF) capillary morphogenesis human umbilical vein endothelial cells (HUVECs) VEGF treatment downregulated 28977001 6810 Human hsa-miR-30b miRNA homocysteine (Hcy) cardiovascular disease (CVD) HCAECs Homocysteine (Hcy) treatment downregulated 26263983 6811 Human hsa-miR-30b miRNA ¦Ã-rays cell senescence CD34+ cells ¦Ã-radiation treatment upregulated 23144934 6812 Human hsa-miR-30b miRNA cisplatin (DDP) gastric cancer (GC) "The human GC cell line AGS,;HGC-27 cells" cisplatin treatment downregulated 30365113 6813 Human hsa-miR-30b miRNA bone morphogenetic protein 2 (BMP2) hepatocellular carcinoma (HCC) vascular smooth muscle cell (VSMC) bone morphogenetic protein 2 (BMP2) treatment BMP-2 downregulates miR-30b and miR-30c to increase Runx2 expression in CASMCs and promote mineralization 23316327 6814 Human hsa-miR-30b miRNA tanshinone IIA (Tan IIA) hepatocellular carcinoma (HCC) HepG2 cell Tanshinone IIA treatment downregulated 27894814 6815 Human hsa-miR-30b miRNA tanshinone IIA (Tan IIA) hepatocellular carcinoma (HCC) HepG2 cells Tanshinone IIA treatment downregulated 27894814 6816 Human hsa-miR-30b miRNA propofol (PPF) hypoxia/reoxygenation (H/R) injury human umbilical vein endothelial cells(HUVECs) propofol treatment miR-30b was upregulated in propofol-treated group 24454982 6817 Human hsa-miR-30b miRNA hypoxia hypoxic-ischemic encephalopathy (HIE) Human brain microvascular endothelial cells (HBMECs) hypoxia treatment "In hypoxia-induced HBMECs, the mRNA and protein expression levels of PAI-1 were significantly upregulated, while the miR-30b expression level was significantly downregulated." 33360521 6818 Human hsa-miR-30b miRNA Ig-like transcript 3 (ILT3) immune inflammatory human CD8(+) T suppressor cells Ig-like transcript 3 (ILT3) treatment upregulated 22387553 6819 Human hsa-miR-30b miRNA L-kynurenine (L-Kyn) immune response BCL-1 cells L-kynurenine (L-Kyn) treatment downregulated 26590946 6820 Human hsa-miR-30b miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 parental hepatoma cells hepatitis C virus (HCV) infection downregulated 23418453 6821 Human hsa-miR-30b miRNA kynurenine lung cancer 95D cells 50 ¦ÌM Kyn downregulated 28905195 6822 Human hsa-miR-30b miRNA compound C nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) compound C treatment downregulated 32143184 6823 Human hsa-miR-30b miRNA compound C nonalcoholic fatty liver disease (NAFLD) HepG2 cells compound C treatment downregulated 32143184 6824 Human hsa-miR-30b miRNA metformin (Met) nonalcoholic fatty liver disease (NAFLD) primary human hepatocytes (HH) metformin treatment upregulated 32143184 6825 Human hsa-miR-30b miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmitic acid treatment downregulated 32143184 6826 Human hsa-miR-30b miRNA low-dose ionizing radiation (LDIR) non-small cell lung cancer (NSCLC) A549 and NCI-H292 cells low-dose radiation (50 mGy) exposure upregulated 30424954 6827 Human hsa-miR-30b miRNA low-dose ionizing radiation (LDIR) non-small cell lung cancer (NSCLC) A549 cells low-dose radiation (LDR) radiation upregulated 30424954 6828 Human hsa-miR-30b miRNA TGF-¦Â1 ovarian cancer (OC) SKOV3 and 3AO cells TGF-¦Â1 treatment downregulated 26501435 6829 Human hsa-miR-30b miRNA perioglas (PG) and P-15 bone formation osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment upregulated 17653614 6830 Human hsa-miR-30b miRNA inorganic phosphate (Pi) vascular calcification (VC) human aortic vascular smooth muscle cells (HAVSMC) inorganic phosphate (Pi) treatment downregulated 27419135 6831 Human hsa-miR-30b* miRNA hypoxia gastroesophageal cancer (GEC) ESCC and AC cell lines Hypoxia treatment upregulated 26851030 6832 Human hsa-miR-30b-3p miRNA angiotensin II (Ang II) cardiac hypertrophy AC16 cells angiotensin II (Ang II) treatment upregulated 33130312 6833 Human hsa-miR-30b-3p miRNA angiotensin II (Ang II) cardiac hypertrophy human AC-16 cell lines angiotensin II (Ang II) treatment downregulated 33130312 6834 Human hsa-miR-30b-3p miRNA ebola virus (EBOV) Ebola virus (EBOV) therapy 293T cells EBOV treatment downregulated 29209594 6835 Human hsa-miR-30b-3p miRNA hypoxia glioblastoma multiforme (GBM) Glioma stem-like cells (GSCs) hypoxia treatment The miRNA profiling revealed that miR-30b-3p was significantly upregulated in the EVs from hypoxic GSCs. 33408780 6836 Human hsa-miR-30b-3p miRNA respiratory syncytial virus (RSV) respiratory syncytial virus (RSV)-associated pneumonia whole blood respiratory syncytial virus (RSV) infection treatment upregulated 32410870 6837 Human hsa-miR-30b-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cell line HAEC cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 33812169 6838 Human hsa-miR-30b-5p miRNA high glucose (HG) diabetic nephropathy (DN) renal tissues high glucose (HG) treatment "In high glucose induced HK-2 cells, expression levels of miR-30b-5p and E-cadherin were decreased, while SNAI1, a-SMA and Vimentin were increased." 33383483 6839 Human hsa-miR-30b-5p miRNA estradiol endothelial dysfunction human umbilical vein endothelial cells (HUVEC) estradiol treatment upregulated 29510375 6840 Human hsa-miR-30b-5p miRNA hypoxia hypoxia-induced injury AC16 human cardiomyocytes hypoxia induce upregulated 31768184 6841 Human hsa-miR-30b-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 6842 Human hsa-miR-30b-5p miRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment downregulated 33817304 6843 Human hsa-miR-30b-5p miRNA selenium nanoparticles (SeNPs) prostate cancer LNCaP cells; LNCaP-A cells Selenium nanoparticles (SeNPs) treatment upregulated 33604641 6844 Human hsa-miR-30c miRNA hypoxia acute myeloid leukemia (AML) human renal cell carcinoma Hypoxia treatment downregulated 24112779 6845 Human hsa-miR-30c miRNA plasminogen activator inhibitor-1 (PAI-1) apoptosis human pulmonary endothelial cells PAI-1 (plasminogen activator inhibitor-1) ? treatment downregulated 21175428 6846 Human hsa-miR-30c miRNA adriamycin (ADR) breast cancer "MCF-10A, MCF-7, and ZR-75-1 cells" adriamycin (ADR) treatment upregulated 31511498 6847 Human hsa-miR-30c miRNA androgen breast cancer MDA-MB-453 breast cancer cells androgen treatment downregulated 29085503 6848 Human hsa-miR-30c miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 6849 Human hsa-miR-30c miRNA ¦Ã-rays cell senescence CD34+ cells ¦Ã-radiation treatment upregulated 23144934 6850 Human hsa-miR-30c miRNA ¦Ã-rays cell senescence human fetal osteoblast cell line (hFOB) ¦Ã-radiation treatment downregulated 23144934 6851 Human hsa-miR-30c miRNA baicalin (BAI) colorectal cancer (CRC) HT29 cells baicalin (BAI) treatment downregulated 30262902 6852 Human hsa-miR-30c miRNA coffee colorectal cancer (CRC) Caco-2 human colon carcinoma cells coffee treatment upregulated 28693281 6853 Human hsa-miR-30c miRNA adherent-invasive escherichia coli (AIEC) crohn disease (CD) intestinal epithelial cells T84 cells adherent invasive escherichia coli (AIEC) treatment upregulated 24148619 6854 Human hsa-miR-30c miRNA adherent-invasive escherichia coli (AIEC) crohn disease (CD) T84 cells adherent invasive escherichia coli (AIEC) treatment upregulated 32583714 6855 Human hsa-miR-30c miRNA estradiol-17¦Â (E2) endometrial cancer (EC) ER-positive Ishikawa and ER-negative HEC-1-B cells estradiol-17¦Â (E2) treatment downregulated 24595016 6856 Human hsa-miR-30c miRNA hyperthermia heat shock human OSCC cell lines HSC-2;HSC-3;HSC-4 HT at 44?C for 60 min treatment dysregulated 24789751 6857 Human hsa-miR-30c miRNA bone morphogenetic protein 2 (BMP2) hepatocellular carcinoma (HCC) vascular smooth muscle cell (VSMC) bone morphogenetic protein 2 (BMP2) treatment BMP-2 downregulates miR-30b and miR-30c to increase Runx2 expression in CASMCs and promote mineralization 23316327 6858 Human hsa-miR-30c miRNA hepatitis C virus (HCV) core protein hepatocellular carcinoma (HCC) "human hepatoblastoma cell line, HepG2" Hepatitis C virus (HCV) Core protein treatment downregulated 26210453 6859 Human hsa-miR-30c miRNA lipopolysaccharide (LPS) inflammation human aortic endothelial cells lipopolysaccharide (LPS) treatment downregulated 28213977 6860 Human hsa-miR-30c miRNA lipopolysaccharide (LPS) inflammation human aortic endothelial cells lipopolysaccharide (LPS) treatment downregulated 28213977 6861 Human hsa-miR-30c miRNA pravastatin lipid homeostasis subjects recruited from a lipid clinic pravastatin for 1year treatment upregulated 28062296 6862 Human hsa-miR-30c miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 parental hepatoma cells hepatitis C virus (HCV) infection downregulated 23418453 6863 Human hsa-miR-30c miRNA cisplatin (DDP) nephrotoxicity HK-2 and NRK-52E cells cisplatin treatment downregulated 28796263 6864 Human hsa-miR-30c miRNA compound C nonalcoholic fatty liver disease (NAFLD) HepG2 cells; primary human hepatocytes (HH) compound C treatment downregulated 32143184 6865 Human hsa-miR-30c miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells; primary human hepatocytes (HH) palmitic acid treatment downregulated 32143184 6866 Human hsa-miR-30c miRNA bevacizumab non-small cell lung cancer (NSCLC) Serum bevacizumab treatment Serum miR-30c level is elevated during bevacizumab chemotherapy. 29737469 6867 Human hsa-miR-30c miRNA curcumin (Cur) non-small cell lung cancer (NSCLC) Paclitaxel-resistant NSCLC cell lines of A549 and H460 curcumin treatment upregulated 28443468 6868 Human hsa-miR-30c miRNA TGF-¦Â1 ovarian cancer (OC) SKOV3 and 3AO cells TGF-¦Â1 treatment downregulated 26501435 6869 Human hsa-miR-30c miRNA NaSH spinal cord ischemia/reperfusion injury (SCII) SH5Y-SY cells NaSH treatment NaSH preprocessing upregulated CasC7 and downregulated miR-30c in OGD/R-induced SH5Y-SY cells. 29571256 6870 Human hsa-miR-30c-1-3p miRNA benzo(a)pyrene (BaP) lung fibrosis BEAS-2B cells benzo(a)pyrene (BaP) exposure downregulated 30543962 6871 Human hsa-miR-30c-1-3p miRNA benzo(a)pyrene (BaP) lung fibrosis BEAS-2B cells benzo(a)pyrene (BaP) exposure downregulated 30543962 6872 Human hsa-miR-30c-1-3p miRNA sulfur dioxide (SO2) lung fibrosis BEAS-2B cells SO2 treatment downregulated 30543962 6873 Human hsa-miR-30c-1-3p miRNA sulfur dioxide (SO2) lung fibrosis BEAS-2B cells sulfur dioxide (SO2)?exposure treatment downregulated 30543962 6874 Human hsa-miR-30c-2* miRNA epidermal growth factor (EGF) tumorigenesis OVCAR-3;SKOV-3;A549 cells The epidermal growth factor treatment upregulated 22024689 6875 Human hsa-miR-30c-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophage line oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29016810 6876 Human hsa-miR-30c-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30119891 6877 Human hsa-miR-30c-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment MiR-30c-5p was downregulated and JAK1 was upregulated in renal fibrosis tissue and HG stimulated HK2 cells. 32096183 6878 Human hsa-miR-30c-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment "Compared with the controls, DN tissues and high glucose-induced HK-2 cells had significantly reduced miR-30c-5p levels." 33817282 6879 Human hsa-miR-30c-5p miRNA chlorpromazine (CHLO) drug-induced liver injury (DILI) upcyte hepatocytes chlorpromazine (CHLO) treatment downregulated 31198949 6880 Human hsa-miR-30c-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment "Silence of LINC00657 repressed ox-LDL-induced injury via inhibiting EndMT, inflammatory response, and apoptosis in HUVEC cells by regulating miR-30c-5p/Wnt7b/¦Â-catenin." 32577947 6881 Human hsa-miR-30c-5p miRNA oxidized low density lipoprotein (ox-LDL) inflammation HUVEC oxidized low-density lipoprotein (ox-LDL) treatment "PTEN was a target of miR-30c-5p, and its interference led to great inhibition of cell apoptosis and inflammatory response induced by ox-LDL in HUVEC, while this effect was attenuated by miR-30c-5p deficiency or XIST overexpression." 31539155 6882 Human hsa-miR-30c-5p miRNA sodium oxalate kidney stone disease HK-2 cells sodium oxalate treatment downregulated 31894301 6883 Human hsa-miR-30c-5p miRNA sodium oxalate sodium oxalate-induced kidney stones HK-2 cells sodium oxalate treatment miR-30c-5p expression was significantly downregulated by exposure to 750 ?M sodium oxalate. 31894301 6884 Human hsa-miR-30d miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 6885 Human hsa-miR-30d miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 6886 Human hsa-miR-30d miRNA ¦Ã-rays cell senescence CD34+ cells ¦Ã-radiation treatment upregulated 23144934 6887 Human hsa-miR-30d miRNA doxorubicin (DOX) classical hodgkin lymphoma L428 cells doxorubicin (DOX) treatment "in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL" 23725219 6888 Human hsa-miR-30d miRNA doxorubicin (DOX) classical hodgkin lymphoma L428 cells doxorubicin (DOX) treatment "in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL" 23725219 6889 Human hsa-miR-30d miRNA hypoxia colorectal cancer (CRC) "CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)" 1 and 0.2% oxygen upregulated 28207045 6890 Human hsa-miR-30d miRNA lipopolysaccharide (LPS) epithelial-mesenchymal transition (EMT) hippocampus lipopolysaccharide (LPS) treatment The treatment of HBMECs with Meth or LPS significantly increased the circHECW2 expression in HBMECs. 29260931 6891 Human hsa-miR-30d miRNA methamphetamine (METH) epithelial-mesenchymal transition (EMT) primary human brain microvascular endothelial cells (HBMECs) methamphetamine (Meth) treatment miR-30d was significantly downregulated 29260931 6892 Human hsa-miR-30d miRNA methamphetamine (METH) epithelial-mesenchymal transition (EMT) primary human brain microvascular endothelial cells (HBMECs) methamphetamine (Meth) treatment The treatment of HBMECs with Meth or LPS significantly increased the circHECW2 expression in HBMECs. 29260931 6893 Human hsa-miR-30d miRNA ricolinostat (ACY-1215) esophageal squamous cell carcinoma (ESCC) "The human cell lines EC109, KYSE150, TE-1, TE-13" Ricolinostat (ACY-1215) treatment upregulated 30050135 6894 Human hsa-miR-30d miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Li-7 cells; Hep3B cells; HepG2 cells; Huh7 cells sorafenib (SOR) treatment upregulated 32724415 6895 Human hsa-miR-30d miRNA methylmercury (MeHg) neurotoxicity human neural progenitor cells (ihNPCs) methylmercury (MeHg) treatment downregulated 27941687 6896 Human hsa-miR-30d miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx5 treatment" downregulated 21572246 6897 Human hsa-miR-30d miRNA TGF-¦Â1 ovarian cancer (OC) SKOV3 and 3AO cells TGF-¦Â1 treatment downregulated 26501435 6898 Human hsa-miR-30d miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment downregulated 18573151 6899 Human hsa-miR-30d miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 6900 Human hsa-miR-30d miRNA helicobacter pylori (H. pylori) gastric cancer (GC) human AGS cells and GES-1 cells Helicobacter pylori (H. pylori) infection upregulated 27099441 6901 Human hsa-miR-30d-3p miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 6902 Human hsa-miR-30d-5p miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment upregulated 31452742 6903 Human hsa-miR-30d-5p miRNA activin A prostate cancer LNCaP cells activin A treatment upregulated 27018851 6904 Human hsa-miR-30e miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-30e was downregulated in resistant patients when compared with sensitive patients 33072545 6905 Human hsa-miR-30e miRNA propofol (PPF) gastric cancer (GC) SGC7901/CDDP propofol treatment lncRNA MALAT1/miR-30e/ATG5 mediated autophagy-related chemoresistance in GC 32302291 6906 Human hsa-miR-30e miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 cells hepatitis C virus (HCV) infection downregulated 31334444 6907 Human hsa-miR-30e miRNA IFN-¦Á immune tolerance of maternal-fetal interface peripheral blood NK cells (PB-NK cells) and decidua NK cells (D-NK cells) IFN-¦Á treatment downregulated 30551399 6908 Human hsa-miR-30e miRNA mycobacterium tuberculosis (Mtb) mycobacterium tuberculosis (Mtb) infection THP-1 human monocytes cells during infection infect with MTB H37Rv upregulated 28912881 6909 Human hsa-miR-30e miRNA radon radiation ionizing radiation (IR) injury Blood samples radon radiation treatment downregulated 32165872 6910 Human hsa-miR-30e miRNA "antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)" schizophrenia (SZ) schizophrenia patients six-week antipsychotic treatment upregulated 24694668 6911 Human hsa-miR-30e miRNA schisandrin B (Sch B) tubulointerstitial fibrosis (TIF) TGF-¦Â1-treated HK-2 cells Schisandrin B (Sch B) treatment upregulated 31697999 6912 Human hsa-miR-30e miRNA TGF-¦Â1 tubulointerstitial fibrosis (TIF) HK-2 cells TGF-¦Â1 treatment downregulated 31697999 6913 Human hsa-miR-30e miRNA dexamethasone (DEX) intestinal cell differentiation ?IEC-6 cells dexamethasone (DEX) treatment upregulated 20372961 6914 Human hsa-miR-30e* miRNA dengue virus (DENV) dengue virus (DENV) infection human monocyte cell line U937 DENV infection upregulated 25122182 6915 Human hsa-miR-30e* miRNA insect cell-derived anionic septapeptide innate immune response Primary human monocyte cultures insect cell-derived anionic septapeptide treatment upregulated 31075349 6916 Human hsa-miR-30e-3p miRNA glucocorticoid (GC) inflammatory bowel disease (IBD) serum Glucocorticoids (GCs) treatment downregulated 31938187 6917 Human hsa-miR-30e-5p miRNA hypoxia coronary microembolization human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hypoxia induce downregulated 31182924 6918 Human hsa-miR-30e-5p miRNA demethoxycurcumin glioblastoma multiforme (GBM) LN-229 and A172 cells demethoxycurcumin treatment upregulated 30305611 6919 Human hsa-miR-30e-5p miRNA cardiac resynchronization therapy heart failure (HF) plasma cardiac resynchronization therapy treatment upregulated 23736534 6920 Human hsa-miR-30e-5p miRNA dapagliflozin hypertensive patients with type 2 diabetes plasma dapagliflozin treatment upregulated 31162549 6921 Human hsa-miR-31 miRNA puerarin acute kidney injury (AKI) HK-2 cells puerarin treatment Puerarin alleviates cisplatin-induced acute renal damage and upregulates microRNA-31-related signaling 32855680 6922 Human hsa-miR-31 miRNA vascular endothelial growth factor (VEGF) angiogenesis HUVECs vascular endothelial growth factor (VEGF) treatment upregulated 28097093 6923 Human hsa-miR-31 miRNA arsenite arsenite-induced carcinogenesis Beas-2B cells arsenic (As) exposure Arsenic downregulated miRNA-31. 29603397 6924 Human hsa-miR-31 miRNA promoted in platelet-derived growth factor (PDGF)-BB arteriosclerosis obliterans (ASO) human ASMCs (HASMCs) (PDGF)-BB treatment upregulated 29403548 6925 Human hsa-miR-31 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" breast cancer MDA-MB-231 cell "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27593563 6926 Human hsa-miR-31 miRNA halofuginone (HF) breast cancer MCF-7 cell Halofuginone (HF) treatment "miRNAs knockdown experiment in exosomes and the MCF-7 growth inhibition assay showed that exosomal microRNA-31 (miR-31) modulates MCF-7 cells growth by specially targeting the histone deacetylase 2 (HDAC2), which increases the levels of cyclin-dependent kinases 2 (CDK2) and cyclin D1 and suppresses the expression of p21." 30916359 6927 Human hsa-miR-31 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cellular stress response prostate cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated of miR-205 and miR-31 21368878 6928 Human hsa-miR-31 miRNA galacto-oligosaccharides (GOS) colitis normal and LPS-stimulated human colon epithelial FHC cells galacto-oligosaccharides (GOS) treatment downregulated 31226416 6929 Human hsa-miR-31 miRNA lipopolysaccharide (LPS) colitis human colon epithelial FHC cells lipopolysaccharide (LPS) treatment upregulated 31226416 6930 Human hsa-miR-31 miRNA kaempferol-3-O-glycoside colorectal cancer (CRC) RKO cells kaempferol-3- O-glycoside treatment downregulated 31441682 6931 Human hsa-miR-31 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) Human colorectal malignant cell lines DLD©\1 and SW480 5-fluorouracil (5-FU) treatment upregulated 31162779 6932 Human hsa-miR-31 miRNA baicalin (BAI) colorectal cancer (CRC) HT29 cells baicalin (BAI) treatment downregulated 30262902 6933 Human hsa-miR-31 miRNA kaempferol-3-O-glycoside colorectal cancer (CRC) colon cancer cell line (RKO) kaempferol-3-O-glycoside treatment downregulated 31441682 6934 Human hsa-miR-31 miRNA TGF-¦Â1 cutaneous lupus erythematosus primary adult keratinocytes and PBMCs isolated from discoid lupus erythematosus (DLE) patients TGF-¦Â1 treatment upregulated 30130620 6935 Human hsa-miR-31 miRNA ultraviolet (UV) irradiation cutaneous lupus erythematosus primary adult keratinocytes and PBMCs isolated from discoid lupus erythematosus (DLE) patients UV irradiation treatment upregulated 30130620 6936 Human hsa-miR-31 miRNA TGF-¦Â1 discoid lupus erythematosus (DLE) keratinocyte transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 30130620 6937 Human hsa-miR-31 miRNA ultraviolet (UV) irradiation discoid lupus erythematosus (DLE) keratinocyte UV radiation treatment upregulated 30130620 6938 Human hsa-miR-31 miRNA high glucose (HG) endothelial dysfunction primary endothelial progenitor cells (EPCs) high glucose treatment upregulated 29566115 6939 Human hsa-miR-31 miRNA cigarette smoke condensate (CSC) cell differentiation normal human respiratory epithelia and lung cancer cells cigarette smoke condensate (CSC) treatment Cigarette smoke induces expression of miR-31 targeting several antagonists of cancer stem cell signaling in normal respiratory epithelia and lung cancer cells 21048943 6940 Human hsa-miR-31 miRNA zinc deficiency esophageal cancer (EC) human ESCC and OSCC zinc deficiency? treatment upregulated 22689922 6941 Human hsa-miR-31 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 6942 Human hsa-miR-31 miRNA TGF-¦Â idiopathic pulmonary fibrosis (IPF) A549 cells TGF-¦Â treatment TGF-¦Â could induce miR-31 and suppress miR-184 levels in A549 cells 31874165 6943 Human hsa-miR-31 miRNA TGF-¦Â idiopathic pulmonary fibrosis (IPF) A549 cells TGF-¦Â treatment upregulated 31874165 6944 Human hsa-miR-31 miRNA polychlorinated biphenyls (PCBs) inflammation HUVECs polychlorinated biphenyls (PCBs) treatment upregulated 27288564 6945 Human hsa-miR-31 miRNA neoadjuvant chemoradiotherapy (CRT) locally advanced rectal cancer (LARC) Rectal Cancer tissues neoadjuvant chemoradiotherapy (CRT) treatment upregulation 27271609 6946 Human hsa-miR-31 miRNA carbamate lung cancer Normal human bronchial epithelial (NHBE) cells carbamate treatment upregulated 19748927 6947 Human hsa-miR-31 miRNA ginsenoside Rh2 medulloblastoma human medulloblastoma cell line Daoy ginsenoside Rh2 treatment downregulated 29377269 6948 Human hsa-miR-31 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 6949 Human hsa-miR-31 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 6950 Human hsa-miR-31 miRNA epidermal growth factor (EGF) oral carcinogenesis "HSC-3£¬OECM-1,SAS£¬NOK" EGF treatment upregulated 25229239 6951 Human hsa-miR-31 miRNA tumor necrosis factor alpha (TNF-¦Á) osteogenesis bone marrow stromal stem cells (BMSCs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30132874 6952 Human hsa-miR-31 miRNA tumor necrosis factor alpha (TNF-¦Á) osteogenesis ethanol-induced osteonecrosis bone marrow stromal stem cells (BMSCs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30132874 6953 Human hsa-miR-31 miRNA estramustine phosphate prostate cancer PC3 cells Estramustine phosphate treatment MiR-31 level decreased after estramustine phosphate treatment. 29364469 6954 Human hsa-miR-31 miRNA mocetinostat prostate cancer primary prostate cancer stem cells mocetinostat treatment activation of miR-31 and downregulated of E2F6 constitute an important mechanism in mocetinostat-induced apoptosis in prostate cancer. 27551526 6955 Human hsa-miR-31 miRNA "high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)" skin fibrosis human skin fibroblast HF-LED-RL at 320 and 640?J/cm2 radiation downregulated 30182520 6956 Human hsa-mir-31 miRNA aminosulfonylarylisoxazole transgenerational pancreatic impairment human embryonic kidney cells (HEK-293T) aminosulfonylarylisoxazole upregulated 28867213 6957 Human hsa-miR-31 miRNA aminosulfonylarylisoxazole transgenerational pancreatic impairment human embryonic kidney cells (HEK-293T) aminosulfonylarylisoxazole downregulated 28867213 6958 Human hsa-miR-31* miRNA paclitaxel (PTX) laryngeal cancer laryngeal cancer cell line hep2 Paclitaxel treatment the most markedly expression-changed 23826416 6959 Human hsa-miR-3121-3p miRNA nilotinib chronic myeloid leukemia (CML) human umbilical vein derived EA.hy926 cells and human umbilical vein endothelial cells (HUVECs) nilotinib treatment downregulated 28501737 6960 Human hsa-miR-3126-5p miRNA hypoxia kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection human KS-derived SLK and SLKK cells hypoxia treatment upregulated 28046107 6961 Human hsa-miR-3126-5p miRNA gefitinib lung cancer PC-9 cells gefitinib treatment upregulated 32052182 6962 Human hsa-miR-3129-5p miRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) Human HCC cell line HepG2 and Huh7 Doxorubicin (DOX) treatment downregulated 30615851 6963 Human hsa-miR-3129-5p miRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) Huh-7 cell; Hep3B cells doxorubicin treatment downregulated 32965597 6964 Human hsa-miR-3131 miRNA ganoderma lucidum polysaccharides (GLPs) anti-cancer therapy human hepatocarcinoma cells (HepG2) GLPs treatment upregulated 24528735 6965 Human hsa-miR-3131 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 6966 Human hsa-miR-3131 miRNA ganoderma lucidum polysaccharides (GLPs) hepatocellular carcinoma (HCC) human hepatocarcinoma cells (HepG2) Ganoderma lucidum polysaccharides (GLPs) treatment upregulated 24528735 6967 Human hsa-miR-3131 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 6968 Human hsa-miR-3135b miRNA acupuncture in vitro fertilization and embryo transplantation endometrial tissues acupuncture treatment upregulated 31824817 6969 Human hsa-miR-3138 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human retinal pigment epithelial cells TGF-¦Â1 treatment downregulated 25263462 6970 Human hsa-miR-31-3p miRNA ultraviolet (UV) irradiation chronic actinic dermatitis (CAD) HaCaT cells ultraviolet (UV) irradiation treatment The expression of hsa-miR-31-3p was increased after treated with UV irradiation for 48 h 32907715 6971 Human hsa-miR-31-3p miRNA IFN-¦Ã colitis human colonic epithelial cells NCM460 cells interferon-¦Ã(IFN-¦Ã) treatment upregulated 29253460 6972 Human hsa-miR-31-3p miRNA IL-6 colitis human colonic epithelial cells NCM460 cells IL-6 treatment upregulated 29253460 6973 Human hsa-miR-31-3p miRNA IL-8 colitis human colonic epithelial cells NCM460 cells IL8 treatment upregulated 29253460 6974 Human hsa-miR-31-3p miRNA jun N-terminal kinase inhibitor colitis Substance P (SP)-treated human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R) Jun N-terminal kinase inhibitor treatment downregulated 29253460 6975 Human hsa-miR-31-3p miRNA substance P (SP) colitis human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R) substance P (SP) treatment upregulated 29253460 6976 Human hsa-miR-31-3p miRNA tumor necrosis factor alpha (TNF-¦Á) colitis human colonic epithelial cells NCM460 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29253460 6977 Human hsa-miR-31-3p miRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment downregulated 31793082 6978 Human hsa-miR-31-3p miRNA sepsis pneumonia human embryonic lung fibroblast MRC-5 cell human embryonic lung fibroblast MRC-5 cell injury irritated by lipopolysaccharide (LPS) treatment "Silencing miR-31-3p mitigated the impacts of circANKRD36 silence on LPS-irritated MRC-5 cells Besides, MyD88 was a downstream target of miR-31-3p, and 3'UTR of IL-34 mRNA was targeted by miR-31-5p" 31793082 6979 Human hsa-miR-31-3p miRNA titanium surface implant-host tissue interactions osteoblastic cells from human alveolar bone osteoblastic cells from human alveolar bone treatment dysregulated 27200092 6980 Human hsa-miR-3148 miRNA atropine myopia Human corneal epithelial cells 0.003% atropine treatment dysregulated 31540331 6981 Human hsa-miR-3148 miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment downregulated 29409992 6982 Human hsa-miR-3149 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 6983 Human hsa-miR-3150a-3p miRNA melatonin rheumatoid arthritis (RA) human rheumatoid fibroblast-like synoviocytes melatonin treatment upregulated 30648758 6984 Human hsa-miR-3150b-5p miRNA paclitaxel (PTX) laryngeal cancer laryngeal cancer cell line hep2 Paclitaxel treatment the most markedly expression-changed 23826416 6985 Human hsa-miR-3154 miRNA CCAAT/enhancer binding protein delta (CEBPD) leukemia human monocytic leukemic cell line THP-1 and the human myeloid cell line U937 CEBPD treatment upregulated 29120412 6986 Human hsa-miR-3156-5p miRNA bevacizumab and FOLFOX metastatic colorectal cancer (mCRC) mCRC patients tumor tissue bevacizumab/FOLFOX upregulated 28693229 6987 Human hsa-miR-31-5p miRNA low-intensity pulsed ultrasound (LIPUS) bone regeneration hMSCs low-intensity pulsed ultrasound (LIPUS) induce upregulated 30925808 6988 Human hsa-miR-31-5p miRNA ¦Ã-rays ionizing radiation (IR) injury whole blood samples from healthy donors extracellular vesicles (ELVs) irradiate with 2 Gy gamma rays treatment upregulated 28264626 6989 Human hsa-miR-31-5p miRNA IL-6 colitis-associated colon cancer (CAC) THP-1 and Caco2 cells IL-6 treatment upregulated 31100679 6990 Human hsa-miR-31-5p miRNA tumor necrosis factor alpha (TNF-¦Á) colitis-associated colon cancer (CAC) THP-1 and Caco2 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31100679 6991 Human hsa-miR-31-5p miRNA water extract of I. rotunda (WIR) colitis-associated colon cancer (CAC) IL-6/TNF-¦Á-treated THP-1 and Caco2 cells water extract of I. rotunda (WIR) treatment downregulated 31100679 6992 Human hsa-miR-31-5p miRNA epidermal growth factor receptor (EGFR) colorectal cancer (CRC) FFPE tissues or colon cancer cell lines epidermal growth factor receptor (EGFR) treatment upregulated 25472647 6993 Human hsa-miR-31-5p miRNA anti-EGFR therapy colorectal cancer (CRC) patients with CRC anti-EGFR therapeutics treatment upregulated 25472647 6994 Human hsa-miR-31-5p miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 cells and Huh7 cells cisplatin treatment "When miR-31-5p was downregulated, the proliferation and invasion of HepG2 cells and Huh7 cells were enhanced and the cisplatin-induced apoptosis was inhibited, while LINC01234 knockdown could diminish the effects caused by miR-31-5p depletion." 31838274 6995 Human hsa-miR-31-5p miRNA tumor necrosis factor alpha (TNF-¦Á) preeclampsia (PE) human placental arterial vessels tumor necrosis factor alpha (TNF-¦Á) treatment miR-31-5p was upregulated in human endothelial cells treated with TNF¦Á 30279269 6996 Human hsa-miR-31-5p miRNA protein kinase C inhibitor GF109203X wound healing and regeneration of skin tissues. human keratinocytes GF109203X treatment "upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )" 28901412 6997 Human hsa-miR-3162 miRNA CCAAT/enhancer binding protein delta (CEBPD) leukemia human monocytic leukemic cell line THP-1 and the human myeloid cell line U937 CEBPD treatment upregulated 29120412 6998 Human hsa-miR-3162-3p miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection IIIB-MT2 cells human immunodeficiency virus (HIV)-1 infection downregulated 29627523 6999 Human hsa-miR-3170 miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed upregulated 27915273 7000 Human hsa-miR-3171 miRNA ursolic acid (UA) breast cancer BT474 cells usnic acid treatment downregulated 31549595 7001 Human hsa-miR-3178 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment upregulated 27893811 7002 Human hsa-miR-3178 miRNA H2O2 primary open angle glaucoma (POAG) Human trabecular meshwork cells (HTMCs) H2O2 induced oxidative stress "lncRNA-RP11-820 directly binds miR-3178, through which the expression of MYOD1 is regulated." 31495061 7003 Human hsa-miR-318 miRNA propofol (PPF) pancreatic cancer (PC) pancreatic cell lines Panc1 and Bxpc3 Propofol treatment upregulated 30861616 7004 Human hsa-miR-3180-5p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 7005 Human hsa-miR-3182 miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human bronchial epithelial (16HBE) cells infect with EV71 and CA16 dysregulated 27890633 7006 Human hsa-miR-3182 miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) Human bronchial epithelial (16HBE) cells Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment dysregulated 27890633 7007 Human hsa-miR-3182 miRNA aspirin heart repair mesenchymal stem cells (MSCs) aspirin treatment upregulated 32044414 7008 Human hsa-miR-3184-5p miRNA p53 activator mithramycin A cervical cancer (CC) HeLa cells; SiHa cells p53 activator Mithramycin A treatment p53 activator Mithramycin A stimulated p53 and miR-3184-5p expression 33416166 7009 Human hsa-miR-3188 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 derived macrophages oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29442044 7010 Human hsa-miR-3189-3p miRNA fenofibrate glioblastoma multiforme (GBM) LN-229 and U87MG cells fenofibrate treatment upregulated 25645911 7011 Human hsa-miR-3195 miRNA "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)" breast cancer MCF-7 cells "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment" Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells. 33652854 7012 Human hsa-miR-3195 miRNA melatonin prostate cancer hypoxic PC-3 cells melatonin treatment upregulated 25553085 7013 Human hsa-miR-3197 miRNA aspirin heart repair mesenchymal stem cells (MSCs) aspirin treatment upregulated 32044414 7014 Human hsa-miR-3197 miRNA amB with copper (II) ions (AmB-Cu2+) renal fibrosis normal human renal proximal tubule epithelial cells (RPTEC) complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower downregulated 28534445 7015 Human hsa-miR-3198 miRNA ursolic acid (UA) breast cancer BT474 cells usnic acid treatment downregulated 31549595 7016 Human hsa-miR-3198 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 7017 Human hsa-miR-31a-5p miRNA high temperature hypertrophic scars (HS) human dermal fibroblast cells (CC-2511 cells) CC-2511 cells were incubated at high temperature conditions (41?¡ãC-43?¡ãC for 1-3?h). upregulated 30075370 7018 Human hsa-miR-32 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" acute myeloid leukemia (AML) HL60-G cells and U937 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 21816906 7019 Human hsa-miR-32 miRNA adriamycin (ADR) acute myeloid leukemia (AML) AML cell lines adriamycin (ADR) treatment miR-32 was identified as the downstream target of SNHG5 and miR-32 inhibitor abrogated the inhibiting effects of downregulated SNHG5 on AML cell viability. 31884339 7020 Human hsa-miR-32 miRNA oridonin colorectal cancer (CRC) "Human colorectal carcinoma cell lines HCT-116, SW620 and HT-29" Oridonin treatment downregulated 26054686 7021 Human hsa-miR-32 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 7022 Human hsa-miR-32 miRNA lipopolysaccharide (LPS) inflammation THP1-differentiated macrophages lipopolysaccharide (LPS) treatment downregulated 24062196 7023 Human hsa-miR-32 miRNA particulate matter (PM2.5) lung cancer human lung cancer cells PM2.5 treatment upregulated 28601662 7024 Human hsa-miR-32 miRNA isoliquiritigenin nasopharyngeal carcinoma (NPC) "nasopharyngeal carcinoma cell lines, including C666-1 and CNE2" isoliquiritigenin treatment downregulated 31004603 7025 Human hsa-miR-320 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cholangiocarcinoma (CCA) Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 19407485 7026 Human hsa-miR-320 miRNA cardio-pulmonary bypass (CPB) acute lung injury (ALI) blood cardio-pulmonary bypass (CPB) treatment upregulated 25972997 7027 Human hsa-miR-320 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29902461 7028 Human hsa-miR-320 miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment miR-320 expression was significantly downregulated. 31449822 7029 Human hsa-miR-320 miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 31449822 7030 Human hsa-miR-320 miRNA streptozocin (STZ) diabetic retinopathy (DR) M¨¹ller cells streptozotocin (STZ) treatment DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas 33762162 7031 Human hsa-miR-320 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) MKN28 (human gastric epithelial cells)£»AGS (human gastric epithelial cells) Helicobacter pylori infection downregulated 24136787 7032 Human hsa-miR-320 miRNA ionizing radiation (IR) glioblastoma multiforme (GBM) glioma tissues; U251 cells; U87 cells ionizing radiation (IR) treatment downregulated 29331678 7033 Human hsa-miR-320 miRNA IL-1¦Â osteoarthritis (OA) primary chondrocytes IL-1¦Â treatment downregulated 30280762 7034 Human hsa-miR-320 miRNA high-dose steroid steroid-induced avascular necrosis of femoral head (SANFH) bone tissues high-dose steroid treatment downregulated 29551500 7035 Human hsa-miR-3200-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 7036 Human hsa-miR-3202 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human T lymphocyte cigarette smoke?extract?(CSE) treatment downregulated 29208459 7037 Human hsa-miR-3202 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) T lymphocytes cigarette smoke extract (CSE) exposure downregulated 29208459 7038 Human hsa-miR-3202 miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 7039 Human hsa-miR-320a miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) children serum samples acetaminophen(APAP) treatment upregulated in serum samples 29067470 7040 Human hsa-miR-320a miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment dysregulated 29067470 7041 Human hsa-miR-320a miRNA acetaminophen (APAP) acute liver failure (ALF) serum acetaminophen (APAP) treatment hsa-miR-320a and hsa-miR-877-5p levels were significantly elevated in serum samples obtained from children with APAP overdose compared to health controls. 29067470 7042 Human hsa-miR-320a miRNA alpha-1 antitrypsin (AAT) anti-inflammatory responses monocytes of AAT deficient (ZZ) individuals alpha-1 antitrypsin (AAT) treatment downregulated 29062067 7043 Human hsa-miR-320a miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 7044 Human hsa-miR-320a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment OIP5-AS1 knockdown modulated cell progression via regulating miR-320a/LOX1 axis in ox-LDL-treated HUVECs. 32072428 7045 Human hsa-miR-320a miRNA lithium (Li) bipolar disorder (BD) lymphoblastoid cell lines Lithium treatment dysregulated 31801218 7046 Human hsa-miR-320a miRNA artemisinin (ART) breast cancer MCF-7/Dox cells artemisinin treatment upregulated 28361857 7047 Human hsa-miR-320a miRNA tamoxifen (TAM) breast cancer breast cancer cells Tamoxifen treatment downregulated 25736597 7048 Human hsa-miR-320a miRNA ¦¤Np63¦Á cancer invasion HaCaT and A431 cells ¦¤Np63¦Á deficiency treatment downregulated 31515469 7049 Human hsa-miR-320a miRNA oxidized low density lipoprotein (ox-LDL) electrophilic stress response human umbilical vein endothelial cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 24786516 7050 Human hsa-miR-320a miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 7051 Human hsa-miR-320a miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 7052 Human hsa-miR-320a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) GC cell lines and tissues "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31662823 7053 Human hsa-miR-320a miRNA rebamipide gastric cancer (GC) cancer-initiating cells (C-IC) Rebamipide treatment upregulated 27265143 7054 Human hsa-miR-320a miRNA hydroxygenkwanin (HGK) hepatocellular carcinoma (HCC) The hepatocellular carcinoma cell lines HepG2 and Huh7 hydroxygenkwanin (HGK) treatment upregulated 31877715 7055 Human hsa-miR-320a miRNA high glucose (HG) hyperglycemia human umbilical vein endothelial cells high glucose treatment upregulated 27070575 7056 Human hsa-miR-320a miRNA hypoxia/reoxygenation (H/R) hypoxia/reoxygenation (H/R) injury human umbilical vein endothelial cell (HUVEC) hypoxia/reoxygenation (H/R) treatment MALAT1 represses H/R-stimulated HUVEC injury by targeting the miR-320a/RAC1 axis. 31408432 7057 Human hsa-miR-320a miRNA IL-33 inflammatory bowel disease (IBD) Caco2 colonic intestinal epithelial cell (IEC) line IL-33 treatment upregulated 30224451 7058 Human hsa-miR-320a miRNA hyperoxia lung injury human epithelial cells human epithelial cells treatment upregulation in derived microvesicles (MVs) 27731391 7059 Human hsa-miR-320a miRNA fluoxetine (Prozac) neurodevelopmental processes SH-SY5Y cell lines fluoxetine treatment upregulated 27716787 7060 Human hsa-miR-320a miRNA IL-1¦Â osteoarthritis (OA) human cartilage cells (C28/I2) IL-4¦Â treatment upregulated 28404547 7061 Human hsa-miR-320a miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx6 treatment" downregulated 21572246 7062 Human hsa-miR-320a miRNA follicle stimulating hormone (FSH) ovarian steroidogenesis human granulosa cell line KGN follicle-stimulating hormone (FSH) treatment dysregulated 26773729 7063 Human hsa-miR-320a miRNA insulin-like growth factor 1 (IGF-1) polycystic ovarian syndrome (PCOS) cumulus cells (CCs) of PCOS patients IGF1 (10-8 M) treatment upregulated 27965096 7064 Human hsa-mir-320a miRNA ionizing radiation (IR) radiosensitivity of cancer cells HeLa cells ionizing radiation (IR) treatment Pri-miR-320a expression increased linearly with the IR dose and treatment duration. 30066913 7065 Human hsa-miR-320a miRNA ionizing radiation (IR) radiosensitivity of cancer cells HeLa cells; HCT116 cells ionizing radiation (IR) treatment miR-320a expression increased linearly with the IR dose and treatment duration. 30066913 7066 Human hsa-miR-320a miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) B cells M.tb infection upregulated 29477867 7067 Human hsa-miR-320a miRNA Roux-en-Y gastric bypass (RYGB) type 2 diabetes mellitus (T2DM) patients with T2DM peripheral blood on the peripheral blood microRNAs (miRNAs) of treatment downregulated in the peripheral blood 28273212 7068 Human hsa-miR-320a-3p miRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin treatment upregulated 30245930 7069 Human hsa-miR-320a-3p miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) breast cancer MCF-7 cells methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment upregulated 30245930 7070 Human hsa-miR-320a-3p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment upregulated 31722571 7071 Human hsa-miR-320a-3p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment upregulated 31722571 7072 Human hsa-miR-320b miRNA intermittent hypoxia (IH) lung cancer A549 cells; H1650 cells intermittent hypoxia (IH) treatment downregulated 33898105 7073 Human hsa-miR-320b miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment upregulated 27893811 7074 Human hsa-miR-320b miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 7075 Human hsa-miR-320b miRNA androgen prostate cancer Human prostate cancer cell lines DU145 androgen stimulation "the silencing of MALAT1 inactivated AR signaling by sponging miR-320b, and inhibited proliferation and cell cycle progression in prostate cancer cells" 30642743 7076 Human hsa-miR-320c miRNA gemcitabine (GEM) pancreatic cancer (PC) The human pancreatic cell lines MiaPaCa2;PSN1 gemcitabine treatment upregulated 23799850 7077 Human hsa-miR-320c miRNA lipopolysaccharide (LPS) pulmonary diseases HL60 cells lipopolysaccharide (LPS) treatment lipopolysaccharide (LPS) showed increase in miR-320c expression in HL60 cells. 32439252 7078 Human hsa-miR-320c miRNA toluene toluene-induced toxicity HL-60 human promyelocytic leukemia cells toluene treatment dysregulated 28245982 7079 Human hsa-miR-320d miRNA "cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)" diffuse large B-cell lymphoma (DLBCL) patients with DLBCL CHOP treatment downregulated 24931464 7080 Human hsa-miR-320d miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 7081 Human hsa-miR-320d miRNA norcantharidin (NCTD) prostate cancer human prostate cancer cells intraperitoneal injection of different concentration of NCTD treatment upregulated 28760656 7082 Human hsa-miR-320d miRNA ultraviolet (UV) irradiation ultraviolet radiation (UV) effects Exosomes derived from human primary melanocytes ultraviolet B (UVB) irradiation treatment upregulated 32785244 7083 Human hsa-miR-322 miRNA aluminum maltolate (Al-malt) Alzheimer's disease (AD) "human neuroblastoma cell line, SH-SY5Y" treat with Al-Malt for 3 day downregulated 28656195 7084 Human hsa-miR-322 miRNA hypoxia pulmonary arterial hypertension (PAH) HepG2 cells Hypoxia treatment upregulated 20110569 7085 Human hsa-miR-322/424 miRNA carbon tetrachloride (CCl4) liver fibrosis human liver tissue CCl4 treatment "miR-322/424 level in liver cirrhosis patients, mouse liver fibrosis induced by CCl4?and BDL, and rat liver fibrosis induced by CCl4?and dimethylnitrosamine was increased." 33333053 7086 Human hsa-miR-323a-5p miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment miR-323a-5p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs. 33125125 7087 Human hsa-miR-323a-5p miRNA vitamin C oxidative stress human umbilical vein endothelial cells (HUVECs) vitamin C treatment miR-323a-5p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2. 33125125 7088 Human hsa-miR-323b-5p miRNA lipopolysaccharide (LPS) ulcerative colitis (UC) fetal human cells (FHCs) lipopolysaccharide (LPS) treatment downregulated 30477744 7089 Human hsa-miR-32-3p miRNA asbestos fibers malignant pleural mesothelioma (MPM) serum ex-exposed to asbestos fibers (WEA) downregulated 27716620 7090 Human hsa-miR-324 miRNA hypoxia prostate cancer LNCaP cells; LNCaP cells exosomes hypoxia treatment upregulated 29568403 7091 Human hsa-miR-324-3p miRNA dexamethasone (DEX) pulmonary inflammatory response IL-1¦Â-treated A549 cells dexamethasone (Dex) treatment downregulated 33413425 7092 Human hsa-miR-324-3p miRNA IL-1¦Â pulmonary inflammatory response A549 cells IL-1¦Â treatment upregulated 33413425 7093 Human hsa-miR-324-3p miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 29956723 7094 Human hsa-miR-324-3p miRNA oxaliplatin colorectal cancer (CRC) CRC tissues; HCT116 cells; HCT8 cells oxaliplatin (OXA) treatment miR-324-3p was downregulated in Ox-resistant CRC tissues and cells 33005106 7095 Human hsa-miR-324-3p miRNA high glucose (HG) diabetic retinopathy (DR) HK-2 cells High Glucose (HG) treatment downregulated 31430717 7096 Human hsa-miR-324-3p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 7097 Human hsa-miR-324-5p miRNA oxaliplatin colorectal cancer (CRC) HT29 cells; HCT116 cells; HCT8 cells oxaliplatin treatment "hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-¦Á pathway in human colon cancer" 32243061 7098 Human hsa-miR-324-5p miRNA high glucose (HG) inflammatory response VSMCs high glucose (HG) treatment MiRNA-324-5p exerts an inhibitory effect on T2DM-induced inflammation in blood vessels by negatively regulating CPT1A level and reducing the release of inflammatory factors. 33378033 7099 Human hsa-miR-324-5p miRNA high glucose (HG) inflammatory response vascular smooth muscle cells (VSMCs) high glucose (HG) treatment miRNA-324-5p was dose-dependently downregulated. 33378033 7100 Human hsa-miR-324-5p miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 parental hepatoma cells hepatitis C virus (HCV) infection downregulated 23418453 7101 Human hsa-miR-324-5p miRNA H2O2 myocardial infarction (MI) Endothelial progenitor cells (EPCs) derived from peripheral blood H2O2 treatment downregulated 31066044 7102 Human hsa-miR-325 miRNA cisplatin (DDP) bladder cancer 5637 cells; T24 cells cisplatin treatment miR-325 was downregulated in 5637/R and T24/R cells compared to their parental 5637 and T24 cells. 33015771 7103 Human hsa-miR-325-3p miRNA sevoflurane (SEV) sevoflurane-induced neurotoxicity HCN-2 cells sevoflurane treatment miR-325-3p is downregulated in HCN-2 cells exposed to sevoflurane 32191629 7104 Human hsa-miR-32-5p miRNA walnut benefits of walnuts Plasma exosomes walnuts treatment upregulated 32979076 7105 Human hsa-miR-32-5p miRNA MLN4924/Pevonedistat breast cancer MCF-7 cells MLN4924/Pevonedistat treatment miR-32-5p was significantly decreased after MLN4924 treatment in breast cancer cells. 32360865 7106 Human hsa-miR-32-5p miRNA high glucose (HG) cardiac fibrosis human cardiac fibroblasts (CFs) high glucose (HG) treatment upregulated 31438862 7107 Human hsa-miR-32-5p miRNA perfluorooctanoic acid hepatotoxicity occupational workers serum Perfluorooctanoic acid (PFOA) exposure treatment upregulated 24459700 7108 Human hsa-miR-32-5p miRNA glucocorticoid (GC) inflammatory bowel disease (IBD) serum Glucocorticoids (GCs) treatment downregulated 31938187 7109 Human hsa-miR-32-5p miRNA vmycobacterium tuberculosis (M.tb) mycobacterium tuberculosis (Mtb) infection THP-1 and U937 cells infect with M.tb treatment upregulated 28215633 7110 Human hsa-miR-32-5p miRNA helicobacter pylori (H. pylori) pediatric enteritis "serum, human intestinal epithelial cell line HIEC-6" Helicobacter pylori (H. pylori) infection upregulated 31749593 7111 Human hsa-miR-326 miRNA H2O2 age-related cataract (ARC) HLEC-B3 human lens epithelial cells H2O2 treatment upregulated 30268497 7112 Human hsa-miR-326 miRNA platelet-derived growth factor (PDGF) airway remodeling airway smooth muscle cells (ASMCs) platelet-derived growth factor (PDGF) treatment downregulated 32450169 7113 Human hsa-miR-326 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment downregulated 32336203 7114 Human hsa-miR-326 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment A¦Â25-35-induced ERS and apoptosis in SH-SY5Y cells can be attenuated by lncRNA RPPH1 through regulating miR-326/PKM2 axis. 32336203 7115 Human hsa-miR-326 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment dysregulated 31804889 7116 Human hsa-miR-326 miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment upregulated 31597953 7117 Human hsa-miR-326 miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment upregulated 31597953 7118 Human hsa-miR-326 miRNA sulforaphane (SFN) gastric cancer (GC) MKN45 cells sulforaphane treatment upregulated 30096452 7119 Human hsa-miR-326 miRNA curcumin (Cur) glioblastoma multiforme (GBM) U87 cells; U251 cells curcumin (Cur) treatment Curcumin promoted the expression of miR-326. 27819521 7120 Human hsa-miR-326 miRNA pyruvate kinase M2(PKM2) glioblastoma multiforme (GBM) "U87MG, U251MG, T98G, U373MG, and A172" Pyruvate kinase M2(PKM2) treatment "cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326" 20667897 7121 Human hsa-miR-326 miRNA sevoflurane (SEV) lung cancer H446 cells; H1975 cells sevoflurane (Sev) treatment upregulated 33987473 7122 Human hsa-miR-326 miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 7123 Human hsa-miR-326 miRNA propofol (PPF) non-small cell lung cancer (NSCLC) human bronchial epithelioid(16HBE) Propofol treatment "?Importantly, treatment with Propofol inhibited circ-RHOT1 expression in NSCLC cells" 33515563 7124 Human hsa-miR-326 miRNA resveratrol cell proliferation and apoptosis various tumor cells resveratrol (Res) treatment upregulated 27960279 7125 Human hsa-miR-326-3p miRNA cadmium (Cd) renal toxic HK-2 cells cadmium (Cd) treatment upregulated 31626960 7126 Human hsa-miR-326-3p miRNA cadmium (Cd) toxic effects of cadmium HK-2 cells cadmium (Cd) treatment upregulated 31626960 7127 Human hsa-miR-328 miRNA H2O2 apoptosis H9c2 cells H2O2 treatment downregulated 28544404 7128 Human hsa-miR-328 miRNA sodium selenite apoptosis H9c2 cells sodium selenite treatment downregulated 28544404 7129 Human hsa-miR-328 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30324654 7130 Human hsa-miR-328 miRNA arsenic trioxide (ATO) breast cancer MCF-7 cells arsenic trioxide (As2O3) treatment upregulated 25824027 7131 Human hsa-miR-328 miRNA imatinib chronic lymphocytic leukemia (CLL) K562 cells Imatinib treatment downregulated 31701195 7132 Human hsa-miR-328 miRNA imatinib chronic myeloid leukemia (CML) human immortalized myelogenous leukemia line K-562 cells imatinib treatment downregulated 22241070 7133 Human hsa-miR-328 miRNA high glucose (HG) epithelial-mesenchymal transition (EMT) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 29859985 7134 Human hsa-miR-328 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) gastric mucosa H. pylori treatment downregulated 25479940 7135 Human hsa-miR-328 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin (DPP) treatment upregulated 30221716 7136 Human hsa-miR-328 miRNA resveratrol osteosarcoma (OS) osteosarcoma cells resveratrol (Res) treatment upregulated 25605016 7137 Human hsa-miR-328 miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment TGF-¦Â1 could induce EMT expression and fibrogenesis and significantly downregulated the expression of miR-328 30160133 7138 Human hsa-miR-328-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment MiR-328-3p expression was downregulated in oxidized low-density lipoprotein (ox-LDL) induced human umbilical vein endothelial cells (HUVECs). 32329448 7139 Human hsa-miR-328-3p miRNA puerarin bladder cancer T24 cells; UM-UC-3 cells puerarin treatment upregulated 33016781 7140 Human hsa-miR-328-3p miRNA palmitate nonalcoholic fatty liver disease (NAFLD) hepatocyte cell lines palmitate treatment downregulated 25314137 7141 Human hsa-miR-328-3p miRNA 5¦Á©\dihydrotestosterone (DHT) triple negative breast cancer (TNBC) MDA-MB-231 cells 5¦Á-dihydrotestosterone (DHT) treatment upregulated 29964098 7142 Human hsa-miR-328-5p miRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) APL cell line NB4 all-trans retinoic acid (ATRA) treatment downregulated 30453015 7143 Human hsa-miR-328-5p miRNA p-Coumaric acid (p-CA) autoimmune hepatitis (AIH) SNU-16 cells p-Coumaric acid (p-CA) treatment downregulated 32462517 7144 Human hsa-miR-328-5p miRNA oxidized low density lipoprotein (ox-LDL) lipid accumulation human acute monocytic leukemia cel (THP-1) oxidized low-density lipoprotein (ox-LDL) treatment The results showed that miR-328-5p expression was robustly decreased in oxidized low-density lipoprotein (ox-LDL)-treated macrophages. 33663010 7145 Human hsa-miR-329-3p miRNA high glucose (HG) endothelial cell injury Human umbilical vein endothelial cells (HUVECs) high glucose treatment downregulated 33262815 7146 Human hsa-miR-329-3p miRNA X-rays glioblastoma multiforme (GBM) U251 cells X-ray radiation treatment "XIST accelerates cell proliferation, invasion and inhibits cell apoptosis by repressing radio-sensitivity of glioma via enhancing CREB1 expression through sponging miR-329-3p" 32271437 7147 Human hsa-miR-329-3p miRNA cisplatin (DDP) neuroblastoma (NB) SK-N-AS; LAN-6 cells cisplatin (DPP) treatment LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis. 32329857 7148 Human hsa-miR-329-3p miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment "The results revealed that plasma miR-329-3p expression was decreased patients with T2DM compared with healthy controls, and in HUVECs treated with high glucose concentrations." 33262815 7149 Human hsa-miR-33 miRNA betulinic acid (BA) alcoholic fatty liver disease Human THP-1 macrophages betulinic acid (BA) treatment BA promoted ABCA1 expression via downregulated of miR-33s 24086374 7150 Human hsa-miR-33 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y Cells amyloid-¦Â (A¦Â) 25-35 treatment miR-33 expression level was markedly upregulated in SH-SY5Y cells treated with A?25-35. 32119650 7151 Human hsa-miR-33 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31933767 7152 Human hsa-miR-33 miRNA tanshinone IIA (Tan IIA) atherosclerosis (AS) ox-LDL-induced THP-1 macrophages Tanshinone IIA (Tan) treatment downregulated 31933767 7153 Human hsa-miR-33 miRNA citrus peel flavonoid extracts (CPFE) lipid metabolism HepG2 cells citrus peel flavonoid extracts (CPFE) treatment downregulated 31017523 7154 Human hsa-miR-33 miRNA resveratrol and epigallocatechin hepatocellular carcinoma (HCC) hepatic cell lines resveratrol and epigallocatechin treatment 24165878 7155 Human hsa-miR-330 miRNA epigallocatechin-3-gallate (EGCG) hormone refractory prostate cancer (HRPC) LNCaP and 22R¦Í cells Green tea polyphenol EGCG treatment upregulated 21177307 7156 Human hsa-miR-330 miRNA fructose kidney damage HK-2 cells fructose treatment downregulated 28205387 7157 Human hsa-miR-330-3p miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment downregulated 26397152 7158 Human hsa-miR-330-3p miRNA tumor necrosis factor alpha (TNF-¦Á) temporomandibular joint osteoarthritis synoviocyte tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 32332704 7159 Human hsa-miR-330-5p miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 7160 Human hsa-miR-330-5p miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 7161 Human hsa-miR-330-5p miRNA angiopoietin-2 (Ang-2) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-2 (Ang-2) treatment downregulated 30414893 7162 Human hsa-miR-330-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment MiR-330-5p was greatly decreased in THP-1 cells incubated with ox-LDL. 29698635 7163 Human hsa-miR-330-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophages THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment MiR-330-5p was greatly decreased in THP-1 cells incubated with ox-LDL and overexpression of miR-330-5p was able to inhibit oxidative stress and inflammation process. 30187491 7164 Human hsa-miR-330-5p miRNA doxorubicin (DOX) doxorubicin (DOX)-induced cardiotoxicity human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) doxorubicin treatment "The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a" 32392088 7165 Human hsa-miR-330-5p miRNA curcumin (Cur) lung cancer human non-small cell lung cancer A549 cell line curcumin treatment dysregulated 28660665 7166 Human hsa-miR-330-5p miRNA arsenic trioxide (ATO) pancreatic cancer (PC) Human PC cell lines Patu8988 and Panc-1 arsenic trioxide (ATO) treatment upregulated 30847385 7167 Human hsa-miR-330-5p miRNA gemcitabine (GEM) pancreatic cancer (PC) Pancreatic cancer tissues Gemcitabine (GEM) treatment downregulated 32104074 7168 Human hsa-miR-330-5p miRNA lipopolysaccharide (LPS) pulmonary vascular endothelial cell (PVEC) injury Human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment PRNCR1 was upregulated in LPS-induced PVEC and aggravated its injury via modulating the miR-330-5p/TLR4 axis. 33049095 7169 Human hsa-miR-330-5p miRNA H2O2 thoracic aortic aneurysm (TAA) mouse aortic smooth muscle cells (SMCs) H2O2 treatment long noncoding RNA (lncRNA) Sox2ot modulates the progression of TAA by regulating miR-330-5p/Myh11 axis. 32578852 7170 Human hsa-miR-331 miRNA particulate matter (PM2.5) airway epithelial injury human airway epithelial Beas-2B (B2B) cells PM2.5 treatment downregulated 28192748 7171 Human hsa-miR-331 miRNA platelet derived growth factor-BB (PDGF-BB) proliferative vascular diseases Human VSMCs platelet derived growth factor-BB (PDGF-BB) treatment circSFMBT2 plays a vital role in VSMC proliferation and migration through the miR-331/HDAC5/Aggf1 axis 33166591 7172 Human hsa-miR-331-3p miRNA amyloid-¦Â (A¦Â) 1-40 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 1-40 treatment "In AD patients and A¦Â1-40?treated SH-SY5Y cells, the expression of miR-331-3p was significantly downregulated." 33279668 7173 Human hsa-miR-331-3p miRNA amyloid-¦Â (A¦Â) 1-40 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 1-40 treatment "In A¦Â1-40 treated SH-SY5Y cells, the expression of miR-331-3p was significantly downregulated." 33279668 7174 Human hsa-miR-331-3p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 7175 Human hsa-miR-331-3p miRNA rapamycin and methylprednisolone (MP) glucocorticoids (GCs) resistance CCL-119 cells rapamycin and methylprednisolone (MP) treatment upregulated 32776229 7176 Human hsa-miR-331-3p miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HCC cell lines hepatitis B virus (HBV) infection upregulated 25750939 7177 Human hsa-miR-331-3p miRNA gemcitabine (GEM) pancreatic cancer (PC) PANC1 cells; MIAPaCa2 cells; plasma gemcitabine treatment miR-331-3p is upregulated in gemcitabine-treated pancreatic cancer cells and plasma from chemotherapy patients. 32924881 7178 Human hsa-miR-331-3p miRNA ¦Ã-rays prostate cancer 22RV1; DU145 cells Gy radiation treatement LncRNA UCA1 deletion suppressed the radioresistance to PCa by suppressing EIF4G1 expression via miR-331-3p. 32943997 7179 Human hsa-miR-331-3p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) B cells M.tb infection upregulated 29477867 7180 Human hsa-miR-331-5p miRNA doxorubicin (DOX) leukemia myeloid leukemic cell lines NB4; human promyelocytic leukaemia cell line;HL60 doxorubicin (DOX)? treatment downregulated 21070600 7181 Human hsa-miR-335 miRNA glucocorticoid (GC) acute lymphoblastic leukemia (ALL) Mononuclear cells glucocorticoid (GC) treatment downregulated 23888996 7182 Human hsa-miR-335 miRNA cytarabine (Ara-C) acute myeloid leukemia (AML) bone marrow aspirates cytarabine (Ara-C) treatment upregulated 26287405 7183 Human hsa-miR-335 miRNA hypoxia aging hMSCs "hypoxia (3% O2, for 7 days) treatment" downregulated 24648336 7184 Human hsa-miR-335 miRNA pro-inflammatory growth factors aging hMSCs pro-inflammatory growth factors treatment downregulated 24648336 7185 Human hsa-miR-335 miRNA ¦Ã-rays aging hMSCs ¦Ã-irradiation (0.5¨C10 Gy) treatment upregulated 24648336 7186 Human hsa-miR-335 miRNA platycodin D (PD) bladder cancer T24; RT4 Platycodin D (PD) treatment "PD inhibited LncRNA-XIST expressions, while increased miR-335 expression levels in bladder cancer cells" 32919956 7187 Human hsa-miR-335 miRNA NT21MP2 breast cancer MCF-7 and SKBR-3 cells NT21MP2 treatment downregulated 28731125 7188 Human hsa-miR-335 miRNA "TCDD and 6-methyl-1,3,-trichlorodibenzofuran (MCDF)" breast cancer MDA-MB-231 ;BT474 cells "TCDD and 6-methyl-1,3,-trichlorodibenzofuran (MCDF)?treatment treatment" Both TCDD and MCDF induced miR-335 in MDA-MB-231 and BT474 cells 22034498 7189 Human hsa-miR-335 miRNA "leptin, resistin, TNF-¦Á, and IL-6" fat human mature adipocytes "leptin, resistin, TNF-¦Á, and IL-6 treatment" upregulated 23801157 7190 Human hsa-miR-335 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) gastric cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25520857 7191 Human hsa-miR-335 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 or Bel7404 sorafenib (Sora) treatment "lncRNA NEAT1 mediates Sora resistance of HCC cells by suppressing miR-335 expression, and disinhibition on c-Met-Akt signaling pathway" 30937906 7192 Human hsa-miR-335 miRNA decabromodiphenyl ether (BDE-209) human embryonic development human embryonic stem cell lines FY-hES-10 and FY-hES-26 Decabromodiphenyl ether (BDE-209) treatment upregulated 26206603 7193 Human hsa-miR-335 miRNA Pomegranate juice (PJ) prostate cancer ?prostate cancer cells Pomegranate juice (PJ) treatment upregulated 21594291 7194 Human hsa-miR-335 miRNA radon radiation ionizing radiation (IR) injury Blood samples radon radiation treatment downregulated 32165872 7195 Human hsa-miR-335 miRNA gemcitabine (GEM) renal cell carcinoma (RCC) renal tissues or TK10 and UO31 cells gemcitabine treatment "Hsa-miR-335 is the target regulatory point of hsa_circ_0035483. In addition, hsa_circ_0035483 promotes autophagy and tumor growth and enhances gemcitabine resistance in RCC by regulating hsa-miR-335/CCNB1." 31492499 7196 Human hsa-miR-335-3p miRNA H2O2 age-related nuclear cataract human lens epithelial B3 (HLE-B3) cell H2O2 treatment downregulated 29653565 7197 Human hsa-miR-335-3p miRNA TGF-¦Â hereditary gingival fibromatosis (HGF) human gingival fibroblasts (NHGFs) transforming growth factor ¦Â (TGF-¦Â) treatment downregulated 31323181 7198 Human hsa-miR-335-3p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2 cells curcumin treatment "miR-335-3p was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression." 32127962 7199 Human hsa-miR-335-5p miRNA H2O2 atherosclerosis (AS) human umbilical vein endothelial cells H2O2 treatment upregulated 30785341 7200 Human hsa-miR-335-5p miRNA H2O2 preeclampsia (PE) JEG-3 cells H2O2 treatment H2O2 significantly increased the intracellular ROS levels and miR-335-5p expression. 31894323 7201 Human hsa-miR-335-5p miRNA H2O2 preeclampsia (PE) JEG-3 cells H2O2 treatment upregulated 31894323 7202 Human hsa-miR-337 miRNA zirconia and titanium bone formation Osteoblast-like cells (MG63) zirconia and titanium? treatment upregulated 18241218 7203 Human hsa-miR-337 miRNA high glucose (HG) osteogenesis ?high-glucose (HG) treatment High glucose inhibited osteogenic differentiation but increased the level of miR-337 33748908 7204 Human hsa-miR-337 miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 7205 Human hsa-miR-337 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 7206 Human hsa-miR-337-3p miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment upregulated 29393545 7207 Human hsa-miR-337-3p miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H1299 cells cisplatin treatment upregulated 33276753 7208 Human hsa-miR-337-5p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 7209 Human hsa-miR-338 miRNA Iodine-125 (125I) hepatocellular carcinoma (HCC) HCCLM3 and SMMC-7721 cells 125I irradiation treatment upregulated 31514072 7210 Human hsa-miR-338-3p miRNA silver nanoparticles (AgNPs) breast cancer "MCF7, T47D and MDA-MB-231 cells" silver nanoparticles (AgNPs)?treatment treatment upregulated 33613979 7211 Human hsa-miR-338-3p miRNA particulate matter (PM2.5) allergic rhinitis (AR) "RPMI-2650 cells, a human nasal epithelial cell line" fine particulate matter (PM2.5) exposure treatment The results showed that miR-338-3p was downregulated in both nasal mucosa of PM25-exacerbated AR rat models and PM25-treated RPMI-2650 cells 33770685 7212 Human hsa-miR-338-3p miRNA mepolizumab asthma serum 6 patients with mepolizumab after 8 weeks of treatment upregulated 33808110 7213 Human hsa-miR-338-3p miRNA reslizumab asthma serum 10 patients treated with reslizumab for 8 weeks treatment upregulated 33808110 7214 Human hsa-miR-338-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVEC cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 30556591 7215 Human hsa-miR-338-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment miR-338-3p was increased in patients with AS and oxidized low-density lipoprotein (ox-LDL)-induced HUVEC cells. 30556591 7216 Human hsa-miR-338-3p miRNA baicalin (BAI) breast cancer "MCF-10A, MCF-7 and MDA-MB-231 cells" baicalin (BAI) treatment upregulated 31908485 7217 Human hsa-miR-338-3p miRNA hypoxia breast cancer MCF7 cells; HCC1937 cells hypoxia treatment miR-338-3p level was decreased in a dose- and time-dependent manner after hypoxia treatment. 32726486 7218 Human hsa-miR-338-3p miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment downregulated 22647265 7219 Human hsa-miR-338-3p miRNA radiation colorectal cancer (CRC) colon cancer tissues radiation treatment circ_0001313 was significantly upregulated and miR-338-3p was downregulated in radio-resistant colon cancer tissues compared to radio-sensitive tissues 30630646 7220 Human hsa-miR-338-3p miRNA X-rays colorectal cancer (CRC) SW480 and SW620 cells 6-MV X-ray exposure Radiation treatment in colon cells triggered a remarkable upregulation of circ_0001313 and a downregulated of miR-338-3p. 30630646 7221 Human hsa-miR-338-3p miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 32680978 7222 Human hsa-miR-338-3p miRNA cisplatin (DDP) neuroblastoma (NB) SK-N-AS cells; SK-N-SH cells cisplatin treatment downregulated 32164348 7223 Human hsa-miR-338-3p miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment upregulated 31452742 7224 Human hsa-miR-338-3p miRNA resveratrol osteoporosis human osteoblast (HOB) cells "Resveratrol (3,5,4-tri-hydroxystilbene; RESV) treatment" downregulated 25845653 7225 Human hsa-miR-338-3p miRNA lipopolysaccharide (LPS) pneumonia 16HBE cells lipopolysaccharide (LPS) treatment Circ_0038467 was upregulated and miR-338-3p was downregulated in LPS-treated 16HBE cells. 32181994 7226 Human hsa-miR-338-5p miRNA hypoxia colorectal cancer (CRC) The human colon cancer cell lines HCT116 and HCT8 hypoxia induce downregulated 31208913 7227 Human hsa-miR-338-5p miRNA anticancer bioactive peptide-3 (ACBP-3) gastric cancer (GC) GC MKN45 cells anticancer bioactive peptide-3 (ACBP-3) treatment ACBP-3 induced the expression of miR-338-5p and the BAK and BIM proteins and promoted GCSC apoptosis. 27688872 7228 Human hsa-miR-339 miRNA zirconia and titanium bone formation Osteoblast-like cells (MG63) zirconia and titanium? treatment upregulated 18241218 7229 Human hsa-miR-339 miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment upregulated 19022373 7230 Human hsa-miR-339-3p miRNA granulocyte-colony stimulating factor (G-CSF) leukemia CD34+ cells Granulocyte colony-stimulating factor?treatment upregulated 24056818 7231 Human hsa-miR-339-5p miRNA prednisolone active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) prednisolone treatment downregulated 24215168 7232 Human hsa-miR-339-5p miRNA prolactin (PRL) breast cancer MCF-7 and T47D breast cancer cells Prolactin (PRL) treatment upregulated 27066093 7233 Human hsa-miR-339-5p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 7234 Human hsa-miR-339-5p miRNA high glucose (HG) diabetic vasculopathy human aortic endothelial cells (HAECs) high glucose (HG) downregulated 28824448 7235 Human hsa-miR-339-5p miRNA hypoxia/reoxygenation (H/R) intestinal ischemia/reperfusion (I/R) injury Caco-2 cells hypoxia/reoxygenation (H/R) treatment circ-PRKCB/miR-339-5p/p66Shc signaling pathway in regulating oxidative stress in the I/R intestine. 32929374 7236 Human hsa-miR-339-5p miRNA ionizing radiation (IR) lung cancer A549 cells; H460 cells ionizing radiation (IR) treatment upregulated 30462625 7237 Human hsa-miR-339-5p miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment downregulated 26640557 7238 Human hsa-miR-33a miRNA metformin (Met) breast cancer ALDHbright cells metformin treatment upregulated 24980829 7239 Human hsa-miR-33a miRNA xuezhikang (XZK) cellular cholesterol export participating patients with low baseline levels of HDL cholesterol "XZK capsule, 600 mg twice daily for 6 months treatment" upregulated 24591767 7240 Human hsa-miR-33a miRNA cholesterol colorectal cancer (CRC) HT-29 and SW480 cells cholesterol treatment downregulated 30827510 7241 Human hsa-miR-33a miRNA "rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" diffuse large B-cell lymphoma (DLBCL) diffuse large B cell lymphoma (DLBCL) patients serum 6 cycles of R-CHOP treatment dysregulated 24858372 7242 Human hsa-miR-33a miRNA grape pomace extract (GPE) dyslipidemia and insulin resistance rat hepatoma cell line (ECACC); FAO cells grape pomace extract (GPE) treatment GPE reduced miR-122 but increased miR-33a expression. 24165878 7243 Human hsa-miR-33a miRNA grape seed proanthocyandin extract (GSPE) dyslipidemia and insulin resistance rat hepatoma cell line (ECACC); FAO cells grape seed proanthocyandin extract (GSPE) treatment GSPE reduced both miR-122 and miR-33a levels. 24165878 7244 Human hsa-miR-33a miRNA curcumin (Cur) formation of foam cells THP-1 cells curcumin treatment "ox-LDL significantly promoted the expression of miR33a, while the expression of miR33a mRNA was significantly decreased in curcumin pre-treated cells." 32782494 7245 Human hsa-miR-33a miRNA TGF-¦Â2 liver fibrosis Lx-2 cells TGF-¦Â2 treatment upregulated 24100264 7246 Human hsa-miR-33a miRNA hypoxia hepatocellular carcinoma (HCC) HepG2 cells;BEL-7402 cells hypoxia treatment downregulated 27460728 7247 Human hsa-miR-33a miRNA H2O2 oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 7248 Human hsa-miR-33a miRNA lipopolysaccharide (LPS) oxidative stress human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC dysregulated 28403739 7249 Human hsa-miR-33a miRNA aflatoxin B1 (AFB1) ischemic injury hepatocellular carcinoma (HCC) cells aflatoxin B1 (AFB1) treatment upregulated 24015284 7250 Human hsa-miR-33a miRNA resistin osteoarthritis (OA) THP-1 cells resistin treatment downregulated 30845380 7251 Human hsa-miR-33a miRNA "bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2" osteogenesis osteoclast-like cells (OLCs) "BMP2, Osteocalcin, and Runx8 treatment" downregulated 21572246 7252 Human hsa-miR-33a miRNA lovastatin osteosarcoma (OS) MG63 cells; SaOS2 cells lovastatin treatment lovastatin increased the expression of SREBP-2 and miR-33a. 30466075 7253 Human hsa-miR-33a miRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) "Human pancreatic carcinoma cells, SW1990 and MiaPaCa-2, and human embryonic kidney (HEK) 293 T cells" gemcitabine (GEM) treatment downregulated 26113407 7254 Human hsa-miR-33a miRNA TGF-¦Â1 liver fibrosis hepatic stellate cells (HSCs) TGF-¦Â1? treatment upregulated 24100264 7255 Human hsa-miR-33a* miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 7256 Human hsa-miR-33a-5p miRNA celastrol lung adenocarcinoma (LUAD) A549 and LTEP-a-2 cells celastrol treatment upregulated 29484434 7257 Human hsa-miR-33a-5p miRNA PD-L1 inhibitor glioblastoma multiforme (GBM) U87 MG cells; U251 cells PD-L1 inhibitor treatment "PD-L1 inhibitor significantly decreased the expression of the target gene, miR-33a-5p" 32537433 7258 Human hsa-miR-33a-5p miRNA high glucose (HG) hyperglycemic ST-segment elevation myocardial infarction (STEMI) Human aortic endothelial cells (HAECs; PCS©\100©\011?) and pulmonary artery endothelial cells (CPAEs; CCL©\209) high glucose treatment upregulated 31294459 7259 Human hsa-miR-33a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) osteogenesis Human bonemarrow stromal cells (hBMSCs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 26785690 7260 Human hsa-miR-33a-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 7261 Human hsa-miR-33a-5p miRNA chidamide triple negative breast cancer (TNBC) The MDA-MB-231 and BT-20 TNBC cell lines chidamide treatment upregulated 31257519 7262 Human hsa-miR-33b miRNA xuezhikang (XZK) cellular cholesterol export participating patients with low baseline levels of HDL cholesterol "XZK capsule, 600 mg twice daily for 6 months treatment" upregulated 24591767 7263 Human hsa-miR-33b miRNA high glucose (HG) hyperglycemic ST-segment elevation myocardial infarction (STEMI) Human aortic endothelial cells (HAECs; PCS©\100©\011?) and pulmonary artery endothelial cells (CPAEs; CCL©\209) high glucose treatment upregulated 31294459 7264 Human hsa-miR-33b miRNA MLN9708/2238 ischemia/reperfusion (I/R) injury multiple myeloma (MM) cellls proteasome inhibitor? treatment upregulated 22983447 7265 Human hsa-miR-33b miRNA high glucose (HG) lipid accumulation HepG2 cells high glucose treatment upregulated 31686542 7266 Human hsa-miR-33b miRNA metformin (Met) lipid accumulation high glucose-induced HepG2 cells Metformin treatment downregulated 31686542 7267 Human hsa-miR-33b miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 7268 Human hsa-miR-33b miRNA cordycepin malignant melanoma (MM) highly-metastatic melanoma cell lines cordycepin treatment upregulated 25868853 7269 Human hsa-miR-33b miRNA lovastatin medulloblastoma "HEK293T, D283;Daoy cells" lovastatin? treatment upregulated 22887866 7270 Human hsa-miR-33b miRNA resistin osteoarthritis (OA) THP-1 cells resistin treatment downregulated 30845380 7271 Human hsa-miR-33b-3p miRNA cisplatin (DDP) lung cancer A549 cells cisplatin treatment downregulated 27559850 7272 Human hsa-miR-33b-3p miRNA IL-1¦Â osteoarthritis (OA) primary cultured chondrocytes IL-1¦Â treatment downregulated 31522815 7273 Human hsa-miR-33b-3p miRNA yhexamethylene guanidine phosphate (PHMG-phosphate) lung fibrosis A549 cells yhexamethylene guanidine phosphate (PHMG-phosphate) treatment downregulated 29337256 7274 Human hsa-miR-33b-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 7275 Human hsa-miR-33b-5p miRNA rosuvastatin atherosclerosis (AS) atherosclerotic plaques rosuvastatin treatment downregulated 31409515 7276 Human hsa-miR-33b-5p miRNA rosuvastatin atherosclerosis (AS) atherosclerotic plaques rosuvastatin treatment downregulated 31409515 7277 Human hsa-miR-33b-5p miRNA arsenite tumorigenesis human bronchial epithelial (HBE) cells arsenic exposure "upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)" 28972549 7278 Human hsa-miR-34 miRNA IL-13 autophagy BEAS-2B cells IL-13 treatment upregulated 28796252 7279 Human hsa-miR-34 miRNA resveratrol chronic obstructive pulmonary disease (COPD) Peripheral blood resveratrol (RS) treatment upregulated 26191210 7280 Human hsa-miR-34 miRNA corticosteroid erythroid cell differentiation bronchial epithelial? cells corticosteroids treatment downregulated 22955319 7281 Human hsa-miR-34 miRNA curcumin (Cur) ischemia/reperfusion (I/R) injury colon cancer cell lines curcumin (CUR) treatment CDF was very effective in the re-expression of miR-34a and miR-34c 22992310 7282 Human hsa-miR-34 miRNA melatonin primary biliary cholangitis (PBC) H69 cells melatonin treatment downregulated 33352965 7283 Human hsa-miR-34 miRNA ¦Ã-rays renal disease HeLa? cells gamma radiation treatment miR-34 is significantly induced by ¦Ã-radiation in HeLa cells 23091481 7284 Human hsa-miR-340 miRNA lipopolysaccharide (LPS) acute liver injury (ALI) Kupffer cells (KCs) lipopolysaccharides (LPS) treatment downregulated 33155227 7285 Human hsa-miR-340 miRNA tetrachloromethane (CCl4) acute liver injury (ALI) Kupffer cells (KCs) tetrachloromethane (CCl4) treatment downregulated 33155227 7286 Human hsa-miR-340 miRNA kaempferol lung cancer A549 cells kaempferol treatment miR-340 was upregulated by kaempferol treatment. 30253373 7287 Human hsa-miR-340 miRNA lentinan (LNT) osteosarcoma (OS) human OS MG63 cells lentinan (LNT) treatment upregulated 31949775 7288 Human hsa-miR-340 miRNA cisplatin (DDP) osteosarcoma (OS) MG63 cells criplatin (DPP) treatment downregulated 29494357 7289 Human hsa-miR-340 miRNA a moderate-carbohydrate and high glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and high glycemic index diet downregulated 29233589 7290 Human hsa-miR-340 miRNA a moderate-carbohydrate and low glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and low glycemic index diet downregulated 29233588 7291 Human hsa-miR-340 miRNA curcumin (Cur) pancreatic cancer (PC) human pancreatic cancer cells curcumin treatment upregulated 28789415 7292 Human hsa-miR-340 miRNA ultraviolet (UV) irradiation pigmentation Pig-1 cells ultraviolet B (UVB) irradiation treatment Expression of miR-340 was reduced in human Pig-1 cells after UVB irradiation 33179560 7293 Human hsa-miR-340 miRNA ultraviolet (UV) irradiation UVB-mediated retinal damage retinal pigment epithelium (RPE) cells ultraviolet B (UVB) treatment UVB significantly increased miR-340 levels 29982095 7294 Human hsa-miR-340-5p miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 and HepG2/CDDP cisplatin treatment downregulated 30030687 7295 Human hsa-miR-340-5p miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells influenza A virus infection downregulated 30753994 7296 Human hsa-miR-340-5p miRNA paclitaxel (PTX) breast cancer MCF-7 cells low-dose metronomic (LDM) paclitaxel treatment downregulated 25552929 7297 Human hsa-miR-340-5p miRNA hypoxia melanoma melanoma stem-like cells hypoxia treatment downregulated 26554847 7298 Human hsa-miR-340-5p miRNA Hypoxia oesophageal squamous cell carcinoma (ESCC) "human OSCC cell lines (Te13, Te1 , Eca109)" Hypoxia treatment miR-340-5p was highly expressed in hypoxic exosomes 33485367 7299 Human hsa-miR-340-5p miRNA ferulic acid (FA) osteogenesis human bone marrow-derived mesenchymal stem cell (MSC) FA downregulated 28764862 7300 Human hsa-miR-340-5p miRNA silver nanoparticles (AgNPs) silver nanoparticles (SNPs) induced cytotoxicity human dermal fibroblasts (HDFs) silver nanoparticles (SNPs) treatment upregulated 30305212 7301 Human hsa-miR-342 miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment MiR-342 attenuates lipopolysaccharide-induced acute lung injury via inhibiting MAPK1 expression. 32248545 7302 Human hsa-miR-342 miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment upregulated 27158236 7303 Human hsa-miR-342 miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment upregulated 27158236 7304 Human hsa-miR-342 miRNA all-trans retinoic acid (ATRA) crohn disease (CD) acute promyelocytic leukemia cells ?all-trans-retinoic acid (ATRA) treatment upregulated 19151778 7305 Human hsa-miR-342 miRNA retinoic acid (RA) acute promyelocytic leukemia (APL) human promyelocytic cell line NB4 Retinoic acid treatment upregulated 17260024 7306 Human hsa-miR-342 miRNA paraquat (PQ) lung injury Beas-2B cells paraquat (PQ) treatment downregulated 32758486 7307 Human hsa-miR-342 miRNA palliative chemotherapy non-small cell lung cancer (NSCLC) NSCLC tissues platinum derivatives in combination with paclitaxel or gemcitabine treatment downregulated 29387235 7308 Human hsa-miR-342-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment NEAT1 was significantly increased in THP-1 cells incubated with ox-LDL and meanwhile miR-342-3p was greatly decreased. 30259979 7309 Human hsa-miR-342-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30259979 7310 Human hsa-miR-342-3p miRNA high glucose (HG) diabetic nephropathy (DN) mouse renal mesangial cells (MCs) high glucose (HG) treatment miR-342-3p suppresses the progression of DKD by inducing the degradation of SOX6. 31746345 7311 Human hsa-miR-342-3p miRNA advanced glycation end product modified bovine serum albumin (AGE-BSA) diabetic retinopathy (DR) human retinal pericytes (HRPCs) advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment "MIAT and CASP1 expression were substantially increased, while that of miR-342-3p was decreased in AGE-BSA-treated HRPCs." 33065089 7312 Human hsa-miR-342-3p miRNA advanced glycation end product modified bovine serum albumin (AGE-BSA) diabetic retinopathy (DR) primary human retinal pericytes (HRPCs) advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by mdulating miR-342-3p targeting of CASP1 in diabetic retinopathy. 33065089 7313 Human hsa-miR-342-3p miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 7314 Human hsa-miR-342-3p miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 7315 Human hsa-miR-342-3p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) gastric cancer tissue 5-fluorouracil (5-FU) treatment upregulated 27081844 7316 Human hsa-miR-342-3p miRNA sophorae Fructus hepatocellular carcinoma (HCC) Huh7 cells sophorae Fructus treatment "Flavonoids of Sophorae Fructus could inhibite the proliferation, migration and invasion of hepatoma cells by regulating LncRNA FBXL19-AS1/miR-342-3p pathway" 33164374 7317 Human hsa-miR-342-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) "KMS-12-PE , RPMI-8226R cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29242101 7318 Human hsa-miR-342-3p miRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) "The human PDAC cell lines PANC-1, MiaPaCa-2 and the normal pancreatic ductal epithelial cell line HPDE6c7" gemcitabine (GEM) treatment "expression levels of obesity-associated miR-342-3p were significantly upregulated in gemcitabine (GEM)-resistant PDAC tissues and cells, and this upregulation was associated with poor postchemotherapy prognosis." 30638935 7319 Human hsa-miR-342-5p miRNA 5-fluorouracil/cisplatin (CDDP-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) CDDP-CRTX treatment dysregulated 28347920 7320 Human hsa-miR-344a-3p miRNA curcumin (Cur) schwannoma RT4 schwannoma cells curcumin treatment upregulated 30534000 7321 Human hsa-miR-345 miRNA "trans-3,5,4-trimethoxystilbene (TMS)" non-small cell lung cancer (NSCLC) H1299 and PC©\9/GR cells "trans-3,5,4-trimethoxystilbene (TMS) treatment" upregulated 30701693 7322 Human hsa-miR-345-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (oxLDL) treatment downregulated 31825793 7323 Human hsa-miR-345-3p miRNA acupuncture in vitro fertilization and embryo transplantation endometrial tissues acupuncture treatment upregulated 31824817 7324 Human hsa-miR-345-5p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 7325 Human hsa-miR-345-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 7326 Human hsa-miR-346 miRNA tumor necrosis factor alpha (TNF-¦Á) colorectal cancer (CRC) human colon cancer cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 25192497 7327 Human hsa-miR-346 miRNA thapsigargin (Tg) endoplasmic reticulum stress (ERS) HeLa cells thapsigargin (Tg) treatment upregulated 29107113 7328 Human hsa-miR-346 miRNA leishmania leishmaniasis U937 and/or THP-1 human monocytic cells leishmania infection upregulated 29867904 7329 Human hsa-miR-346 miRNA tumor necrosis factor alpha (TNF-¦Á) oral lichen planus (OLP) HaCat cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29335479 7330 Human hsa-miR-34a miRNA TGF-¦Â colitis HepG2 cells; Hepa1-6 cells; WRL68 cells; CD4+CD25+ T cells;CD4+CD25- T cells TGF-¦Â treatment downregulated 22975373 7331 Human hsa-miR-34a miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT8; SW480 cells 5-fluorouracil (5-FU) treatment LncRNA NEAT1 could target miR-34a and promote autophagy to facilitate 5-FU chemoresistance in CRC. 31802650 7332 Human hsa-miR-34a miRNA adriamycin (ADR) acute myeloid leukemia (AML) Human bone marrow stromal cell line HS-5 and human AML cell line HL60 adriamycin (ADR) treatment downregulated 30551433 7333 Human hsa-miR-34a miRNA adriamycin (ADR) acute myeloid leukemia (AML) HL60 cells adriamycin (ADR) treatment downregulated 30551433 7334 Human hsa-miR-34a miRNA all-trans retinoic acid (ATRA) acute myeloid leukemia (AML) KG-1 cells all-trans retinoic acid (ATRA) treatment upregulated 32006898 7335 Human hsa-miR-34a miRNA decitabine acute myeloid leukemia (AML) KG-1 cells decitabine (DAC) treatment upregulated 32006898 7336 Human hsa-miR-34a miRNA H2O2 age-related macular degeneration (AMD) ARPE-19 cells H2O2 treatment upregulated 31249522 7337 Human hsa-miR-34a miRNA flavonoids (TFs) aging human umbilical vein endothelial cells (HUVEC) flavonoids (TFs) treatment downregulated 31106472 7338 Human hsa-miR-34a miRNA ethanol (EtOH) and lipopolysaccharide (LPS) alcoholic liver injury Normal human hepatocytes (N-Heps) £» human intrahepatic biliary epithelial cells (HiBECs) ethanol and lipopolysaccharide treatment upregulated 22841474 7339 Human hsa-miR-34a miRNA amyloid-¦Â (A¦Â) 1-40 Alzheimer's disease (AD) Human neuroblastoma SH-SY5Y cells amyloid-¦Â (A¦Â) 1-40 treatment downregulated 31281568 7340 Human hsa-miR-34a miRNA advanced glycation end product (AGE) apoptosis endothelial progenitor cells advanced glycation end products (AGEs) treatment upregulated 31397599 7341 Human hsa-miR-34a miRNA capsaicin apoptosis "human lung cancer cell lines, A549 and H1299" capsaicin treatment upregulated 24444609 7342 Human hsa-miR-34a miRNA hyperthermia apoptosis colorectal carcinoma (CRC) HCT116 cells exposure to hyperthermia (42¡ãC for 2-4 h) upregulated 29285066 7343 Human hsa-miR-34a miRNA hypofractionated radiotherapy apoptosis human NPC cells hypofractionated radiotherapy treatment upregulated 25231528 7344 Human hsa-miR-34a miRNA metformin (Met) apoptosis MCF-7 cells metformin treatment upregulated 24970682 7345 Human hsa-miR-34a miRNA temozolomide (TMZ) apoptosis peripheral blood lymphocytes (PBLs) obtained from oncology nurses handling antineoplastic drugs TMZ treatment upregulated 28944882 7346 Human hsa-miR-34a miRNA thymosin ¦Â4 (T¦Â4) apoptosis advanced glycation endproducts (AGEs)-treated endothelial progenitor cells thymosin beta 4 (T¦Â4) treatment downregulated 31397599 7347 Human hsa-miR-34a miRNA IL-13 asthma human bronchial epithelial cells (NHBE) IL-13 treatment upregulated 31386204 7348 Human hsa-miR-34a miRNA genistein atherosclerosis (AS) ox-LDL-treat human umbilical vein endothelial cells (HUVECs) "pretreated with genistein at different concentrations (10nM, 100nM and 1000nM) for 6h" downregulated 28688900 7349 Human hsa-miR-34a miRNA H2O2 atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) H2O2 treatment "miR-34a upregulation was accompanied with reduced SIRT1 expression in HUVECs, following H2O2?treatment." 33488795 7350 Human hsa-miR-34a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29328474 7351 Human hsa-miR-34a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29704100 7352 Human hsa-miR-34a miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment ox-LDL treatment significantly increased the levels of miR-34a in a dose-dependent manner in the HUVECs. 29750293 7353 Human hsa-miR-34a miRNA sulforaphane (SFN) atherosclerosis (AS) H2O2-treated human umbilical vein endothelial cells (HUVECs) sulforaphane (SFN) treatment downregulated 33488795 7354 Human hsa-miR-34a miRNA indoxyl sulfate (IS) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs); human aortic vascular smooth muscle cells (HA-VSMCs) indoxyl sulfate (IS) treatment IS up-regulates the expression of miR-34a in vitro. 32593718 7355 Human hsa-miR-34a miRNA dexamethasone (DEX) B-cell malignant multiple myeloma£¨MM£© MM cells dexamethasone (DEX) treatment downregulated 23759586 7356 Human hsa-miR-34a miRNA benzene benzene toxicity workers blood benzene treatment upregulated 27939626 7357 Human hsa-miR-34a miRNA etoposide (VP-16) brain tumour MHH-Med1 cells etoposide? treatment upregulated 25250818 7358 Human hsa-miR-34a miRNA "3,6-dihydroxyflavone (3,6-DHF)" breast cancer MDA-MB-231 cells "3,6-dihydroxyflavone (3,6-DHF) treatment" upregulated 28870206 7359 Human hsa-miR-34a miRNA adoMet breast cancer MCF-7 cells adoMet treatment upregulated 30533999 7360 Human hsa-miR-34a miRNA artemisinin (ART) breast cancer MCF-7/S cells artemisinin treatment upregulated 28361857 7361 Human hsa-miR-34a miRNA artemisinin and artesunate breast cancer Human breast cancer cells artemisinin and artesunate treatment upregulated 25789847 7362 Human hsa-miR-34a miRNA curcumin (Cur) breast cancer MCF-7 cells curcumin treatment upregulated 29189128 7363 Human hsa-miR-34a miRNA curcumin (Cur) breast cancer MCF-10F and MDA-MB-231 breast cell lines curcumin treatment upregulated 31894298 7364 Human hsa-miR-34a miRNA curcumin (Cur) breast cancer MCF-10F cells curcumin (Cur) treatment upregulated 31894298 7365 Human hsa-miR-34a miRNA delphinidin breast cancer "Breast cancer cells MDA©\MB©\231, MCF©\7, and MDA©\MB©\453 w" delphinidin treatment upregulated 31325197 7366 Human hsa-miR-34a miRNA diallyl disulfide (DADS) breast cancer MDA-MB-231 cells Diallyl disulfide (DADS) treatment upregulated 25396727 7367 Human hsa-miR-34a miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment upregulated 33159957 7368 Human hsa-miR-34a miRNA hesperidin breast cancer MCF-7 cells hesperidin treatment upregulated 33050842 7369 Human hsa-miR-34a miRNA IL-6 breast cancer DLD-1 cells;HT-29 CRC;MCF7 breast cancer cells exposure to IL-6 treatment downregulated 24642471 7370 Human hsa-miR-34a miRNA Indolo-pyrido-isoquinolin based?alkaloid breast cancer breast cancer cells Indolo-pyrido-isoquinolin based?alkaloid treatment upregulated 27259808 7371 Human hsa-miR-34a miRNA luteolin breast cancer MCF-7 cells luteolin treatment upregulated 33050842 7372 Human hsa-miR-34a miRNA microsciadia breast cancer MDA-MB-231 cells microsciadia treatment upregulated 32603285 7373 Human hsa-miR-34a miRNA rhamnetin breast cancer MCF-7 cell rhamnetin treatment upregulated 30655816 7374 Human hsa-miR-34a miRNA rhamnetin breast cancer MCF-7 cells rhamnetin treatment miR-34a expression in MCF-7 cells was significantly increased following treatment with 20 and 25 ¦ÌM rhamnetin for 48 h compared with the untreated cells 30655816 7375 Human hsa-miR-34a miRNA tamoxifen (TAM) breast cancer MCF-7 breast cancer cells tamoxifen treatment upregulated 30072833 7376 Human hsa-miR-34a miRNA tamoxifen (TAM) breast cancer MCF-7 breast cancer cells tamoxifen treatment upregulated 30072833 7377 Human hsa-miR-34a miRNA "3,6-dihydroxyflavone (3,6-DHF)" breast cancer human breast epithelial MCF10A cells "3,6-dihydroxyflavone (3,6-DHF) treatment" upregulated 25784176 7378 Human hsa-miR-34a miRNA radiation cardiac radiation-associated injury human cardiomyocytes radiation treatment miR-34a was significantly increased in HCMs exposed to radiation 30226567 7379 Human hsa-miR-34a miRNA H2O2 cataract HLE-B3 cells H2O2 treatment upregulated 27990356 7380 Human hsa-miR-34a miRNA silver nanoparticles (AgNPs) cell toxicity human dermal fibroblasts (HDFs) "200 nM SNPs on HDFs after1, 4 and 8h treatment" upregulated 26000389 7381 Human hsa-miR-34a miRNA 5-aminolevulinic acid photodynamic therapy(ALA-PDT) cervical cancer (CC) "HPV-positive Hela, SiHa, Caski and HPV-negative C33?A cervical cancer cell lines" 5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment downregulated 30118903 7382 Human hsa-miR-34a miRNA high-risk human papillomavirus (hrHPV) cervical cancer (CC) cervical epithelium high-risk human papillomavirus (HR-HPV) infection downregulated 20442590 7383 Human hsa-miR-34a miRNA "(1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI)" cervical cancer (CC) HeLa cells "(1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI) treatment" upregulated 30362332 7384 Human hsa-miR-34a miRNA cisplatin (DDP) cervical cancer (CC) HeLa cells cisplatin (DPP) treatment upregulated 30362332 7385 Human hsa-miR-34a miRNA doxorubicin (DOX) cervical cancer (CC) HeLa cells doxorubicin (DOX) treatment upregulated 30362332 7386 Human hsa-miR-34a miRNA selective S-adenosyl-methionine-competitive small-molecule (GSK126) or 5-Aza-2'-deoxycytidine cholangiocarcinoma (CCA) human cholangiocarcinoma (CCA) GSK126 or 5-Aza-2'-deoxycytidine treatment upregulated 28923203 7387 Human hsa-miR-34a miRNA cyclophosphamide (CP) chronic lymphocytic leukemia (CLL) "WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines" cyclophosphamide treatment upregulated 30111844 7388 Human hsa-miR-34a miRNA fludarabine chronic lymphocytic leukemia (CLL) "WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines" fludarabine treatment upregulated 30111844 7389 Human hsa-miR-34a miRNA rituximab (RTX) chronic lymphocytic leukemia (CLL) "WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines" rituximab treatment upregulated 30111844 7390 Human hsa-miR-34a miRNA ibrutinib chronic lymphocytic leukemia (CLL) CLL patients paired LN and PB samples ibrutinib treatment downregulated in paired LN and PB samples 27431016 7391 Human hsa-miR-34a miRNA H2O2 chronic obstructive pulmonary disease (COPD) BEAS2B cells (human airway epithelial) BEAS2B cells (human airway epithelial) treatment upregulated 27767101 7392 Human hsa-miR-34a miRNA trichostatin A (TSA) chronic obstructive pulmonary disease (COPD) human pulmonary microvascular endothelial cells (HPMVEC) trichostatin A (TSA) treatment upregulated 21224215 7393 Human hsa-miR-34a miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) colon cancer cells 5-fluorouracil (5-FU) treatment downregulated 25333573 7394 Human hsa-miR-34a miRNA "epigallocatechin-3-gallate (EGCG), resveratrol (RES) and ¦Á-mangostin (¦Á-M)" colorectal cancer (CRC) Human colon cancer cell lines DLD-1;SW480 ;COLO201 "epigallocatechin-3-gallate (EGCG), resveratrol (RES) and ¦Á-mangostin (¦Á-M) treatment" upregulated 23954321 7395 Human hsa-miR-34a miRNA proteinase activated receptor 2 (PAR2) colorectal cancer (CRC) The human colonic epithelial cell line HT-29; Caco-2; HCT-116;RKO ;human lung adenocarcinoma A549 cell line proteinase activated receptor 2 (PAR2) treatment downregulated 23991105 7396 Human hsa-miR-34a miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) "Human normal colonic epithelial cell line, FHC, and colorectal carcinoma cell lines, HT29, HCT8, HCT116, SW480, SW620" 5-fluorouracil (5-FU) treatment Inhibition of miR-34a or overexpression of HMGB1 could effectively reverse elevated 5-FU sensitivity upon NEAT1 knockdown. 31802650 7397 Human hsa-miR-34a miRNA desflurane colorectal cancer (CRC) DLD-1 cells desflurane treatment downregulated of miR-34a and upregulation of LOXL3 were required for desflurane-induced EMT in CRC cells. 32658033 7398 Human hsa-miR-34a miRNA ethanol extract of Spica Prunellae (EESP) colorectal cancer (CRC) human colon carcinoma HCT-8 cells EESP upregulated 28713966 7399 Human hsa-miR-34a miRNA melatonin colorectal cancer (CRC) HCT116 cells melatonin treatment "Compared with the control group, melatonin significantly enhanced the expression levels of the miR-34a/449a cluster" 33398374 7400 Human hsa-miR-34a miRNA oxaliplatin colorectal cancer (CRC) CRC patients colorectal cancer (CRC) tissues treated with OXA-based chemotherapy treatment downregulated in colorectal cancer (CRC) tissues 28348487 7401 Human hsa-miR-34a miRNA oxaliplatin colorectal cancer (CRC) Human colon cancer cell lines HCT116 and SW480 oxaliplatin (L-OHP) treatment downregulated 31040703 7402 Human hsa-miR-34a miRNA Scutellaria barbata D. Don (SB) colorectal cancer (CRC) human colon cancer HCT-8 cells ECSB treatment upregulated 28498458 7403 Human hsa-miR-34a miRNA sevoflurane (SEV) colorectal cancer (CRC) HCT116 and SW480 cells sevoflurane treatment upregulated 31305122 7404 Human hsa-miR-34a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" colorectal cancer (CRC) LOVO colorectal cancer cell line "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25422210 7405 Human hsa-miR-34a miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) parental 5-FU- sensitive DLD-1 cells 5-fluorouracil (5-FU) treatment upregulated 24447928 7406 Human hsa-miR-34a miRNA cyclin-dependent kinase 1 (CDK1) neuroblastoma (NB) Human SH-SY5Y£»BE(2)-M17neuroblastoma cells Cyclin-dependent kinase 1 (CDK1) treatment CDK1 inhibition caused elevation of microRNA-34a 22703967 7407 Human hsa-miR-34a miRNA X-rays dental pulp repair and regeneration MCF-10A cells; T-47D cells; MCF-7 cells "low dose, low energy X-ray? treatment" upregulated 24094113 7408 Human hsa-miR-34a miRNA palmitate diabetes mellitus (DM) Human islets palmitate (Pal) treatment upregulated 30131392 7409 Human hsa-miR-34a miRNA high glucose (HG) diabetic cardiomyopathy (DCM) cultured human adult cardiomyocytes high glucose (HG) treatment upregulated 29302057 7410 Human hsa-miR-34a miRNA advanced glycation end product (AGE) diabetic nephropathy (DN) serum advanced glycation end (AGE) treatment "The expression of acetylated p53 and miR-34a was upregulated, SIRT1was downregulated in glomeruli from patients with DN and STZ induced diabetic mice, as well as in human podocytes treated with advanced glycation end (AGE)." 33932899 7411 Human hsa-miR-34a miRNA high glucose (HG) diabetic retinopathy (DR) retinal pigment epithelial cells (ARPE-19) high glucose (HG) treatment HG stimulation notably upregulated miR-34a expression 33536772 7412 Human hsa-miR-34a miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression. 30529346 7413 Human hsa-miR-34a miRNA yiqichutan diffuse large B-cell lymphoma (DLBCL) SUDHL-6 cells Yiqichutan treatment "Yiqichutan treatment increased miR-34a expression levels and induced apoptosis, as well as reducing Foxp1 expression level in SUDHL-6 cells" 32765691 7414 Human hsa-miR-34a miRNA arsenite DNA methylation human keratinocytes arsenic exposure produces cumulative disruptions to epigenetic regulation of miR-34a expression 25281835 7415 Human hsa-miR-34a miRNA cigarette smoke extract (CSE) apoptosis human pulmonary microvascular endothelial cells (HPMECs) cigarette smoke extract (CSE) treatment miR-34a was significantly increased in CSE-treated HPMECs. 29373969 7416 Human hsa-miR-34a miRNA ionizing radiation (IR) endothelial dysfunction A172 glioblastoma cells irradiation treatment downregulated 23155233 7417 Human hsa-miR-34a miRNA laminar shear stress cell differentiation human umbilical cord blood-derived EPCs parallel plate flow chamber system treatment upregulated 24792364 7418 Human hsa-miR-34a miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) "Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)" transforming growth factor (TGF)-¦Â1 treatment XIST promotes TGF-¦Â1-induced EMT by regulating the miR-34a-YAP-EGFR axis in PC 31013436 7419 Human hsa-miR-34a miRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) Human lens epithelial cells (LECs) transforming growth factor (TGF)-¦Â2 treatment downregulated 31158382 7420 Human hsa-miR-34a miRNA bleomycin (BLM) epithelial-mesenchymal transition (EMT) A549/ABCA3 cells bleomycin (BLM) treatment upregulated 31603744 7421 Human hsa-miR-34a miRNA methotrexate (MTX) epithelial-mesenchymal transition (EMT) A549/ABCA3 cells methotrexate (MTX) treatment upregulated 31603744 7422 Human hsa-miR-34a miRNA curcumin (Cur) fat esophageal cancer cell lines curcumin treatment downregulated 22363450 7423 Human hsa-miR-34a miRNA pterostilbene fructose-induced hepatic lipid accumulation HepG2 cells Pterostilbene treatment Pterostilbene recovered the fructose-disturbed miR-34a expression 31927917 7424 Human hsa-miR-34a miRNA curcumin (Cur) gastric cancer (GC) Human gastric cancer cell line SGC-7901 curcumin treatment upregulated 31539270 7425 Human hsa-miR-34a miRNA diallyl disulfide (DADS) gastric cancer (GC) SGC-7901 cells Diallyl disulfide (DADS) treatment upregulated 27073535 7426 Human hsa-miR-34a miRNA docetaxel (DTX) gastric cancer (GC) MKN-45 cells docetaxel (DTX) treatment downregulated 33416185 7427 Human hsa-miR-34a miRNA luteolin gastric cancer (GC) gastric cancer cells Luteolin treatment upregulated 24988056 7428 Human hsa-miR-34a miRNA luteolin gastric cancer (GC) AGS cells; BGC823 cells; SGC7901 cells luteolin (LTL) treatment miR-34a was found to be markedly upregulated in GC cells induced by luteolin and decreased miR-34a level was found in the artificial luteolin-resistant GC cells. 29054762 7429 Human hsa-miR-34a miRNA luteolin gastric cancer (GC) "human gastric cancer cell lines AGS, BGC823 and SGC7901" luteolin treatment upregulated 29054762 7430 Human hsa-miR-34a miRNA luteolin gastric cancer (GC) BGC-823 and SGC-7901 human gastric carcinoma cell lines luteolin treatment upregulated 24988056 7431 Human hsa-miR-34a miRNA soft-shelled turtle peptide gastric cancer (GC) human GC AGS cells soft-shelled turtle peptide treatment differentlly regulated 29435044 7432 Human hsa-miR-34a miRNA dexamethasone (DEX) glucocorticoid-induced osteonecrosis of femoral head (GIONFH) human umbilical vein endothelial cells (HUVECs) dexamethasone (Dex) treatment Dex inhibited mMSC proliferation and mir-34a expression. 28543623 7433 Human hsa-miR-34a miRNA genistein head and neck squamous cell carcinoma (HNSCC) HNC-TICs -1; HNC-TICs-2 genistein treatment Genistein induced ROS production through upregulation of miR-34a. 32610494 7434 Human hsa-miR-34a miRNA benzene hematotoxicity workers benzene treatment upregulated 27939626 7435 Human hsa-miR-34a miRNA hypoxia/reoxygenation (H/R) hepatic ischemia/reperfusion injury (HIRI) HL7702 cells hypoxia re-oxygenation (H/R) treatment upregulated 28708282 7436 Human hsa-miR-34a miRNA hypoxia/reoxygenation (H/R) hepatic ischemia/reperfusion injury (HIRI) HL7702 cells hypoxia re-oxygenation (H/R) treatment downregulated 28708282 7437 Human hsa-miR-34a miRNA aflatoxin B1 (AFB1) hepatocellular carcinoma (HCC) human HCC cell lines HepG2 aflatoxin B1 (AFB1) treatment upregulated 26567713 7438 Human hsa-miR-34a miRNA "DNA-damaging compound, 0404" hepatocellular carcinoma (HCC) HepG2 cells 404 downregulated 28667294 7439 Human hsa-miR-34a miRNA emodin hepatocellular carcinoma (HCC) HepG2 cells Emodin?treatment upregulated 30976957 7440 Human hsa-miR-34a miRNA emodin hepatocellular carcinoma (HCC) HepG2 cells emodin treatment Emodin inhibited the expression of SMAD2/4 in HepG2 cells by inducing the miR-34a level. 30976957 7441 Human hsa-miR-34a miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) serum hepatitis C virus (HCV) infection upregulated 29333940 7442 Human hsa-miR-34a miRNA low-intensity ultrasound (LIUS) hepatocellular carcinoma (HCC) Huh7 and HCCLM3 cell low-intensity ultrasound (LIUS) treatment upregulated 31115495 7443 Human hsa-miR-34a miRNA nanocurcumin hepatocellular carcinoma (HCC) HepG2 and Huh7 cells nanocurcumin treatment upregulation 27165229 7444 Human hsa-miR-34a miRNA taxol hepatocellular carcinoma (HCC) HepG2/Taxol; SMMC7721/Taxol Taxol treatment LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a 32700738 7445 Human hsa-miR-34a miRNA human papillomavirus E6 and E7 human papillomaviruses (HPV) infection K16 and K38 supernatants Human papillomavirus E6 and E7 treatment "HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p." 27300513 7446 Human hsa-miR-34a miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 7447 Human hsa-miR-34a miRNA lithium (Li) hyperglycemia lymphoblastoid cell lines (LCLs) Lithium (Li) treatment significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221 19254429 7448 Human hsa-miR-34a miRNA angiotensin II (Ang II) hypertension and diabetes AB8/13 cells angiotensin II (Ang II) treatment upregulated 32887498 7449 Human hsa-miR-34a miRNA high glucose (HG) hypertension and diabetes AB8/13 cells high glucose (HG) treatment upregulated 32887498 7450 Human hsa-miR-34a miRNA curcumin with emodin hypertension breast cancer cells curcumin with emodin treatment upregulated 23771315 7451 Human hsa-miR-34a miRNA acidic bile hypopharyngeal cancer human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) acidic bile exposure downregulated 29516639 7452 Human hsa-miR-34a miRNA BAY11-7082 hypopharyngeal cancer Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) BAY 11-7082 treatment upregulated 29516639 7453 Human hsa-miR-34a miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells influenza A virus-infected downregulated 27610823 7454 Human hsa-miR-34a miRNA "2,4,5-trihydroxybenzaldehyde (TDB)" ischemic vascular injuries HUVEC cells following OGD/R "2,4,5-trihydroxybenzaldehyde (TDB) treatment" downregulated 27885275 7455 Human hsa-miR-34a miRNA ingenol-mebutate keloids keloid fibroblasts Ingenol-mebutate treatment "In particular, the upregulation of miR-34a was detected in keloid fibroblasts during and following Ingenol-mebutate exposure." 29568916 7456 Human hsa-miR-34a miRNA phorbol-12-myristate-13-acetate(PMA) leukemia human chronic myelocytic leukemia cell line K562 Phorbol 12-myristate 13-acetate (PMA) treatment upregulated 20299489 7457 Human hsa-miR-34a miRNA resistin lipid metabolism HepG2 resistin treatment upregulated 29197627 7458 Human hsa-miR-34a miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) human HCC and adjacent non-tumoral liver tissues sorafenib treatment downregulated 23862748 7459 Human hsa-miR-34a miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) expression and chemoresistance has not been explored in HCC sorafenib treatment downregulated 23862748 7460 Human hsa-miR-34a miRNA ultraviolet (UV) irradiation hepatocellular carcinoma (HCC) HepG2 cells UV irradiation treatment upregulated 24431000 7461 Human hsa-miR-34a miRNA cisplatin (DDP) lung cancer "NSCLC cancer cells, including H226, H1299, A549, H1975 and HCC827" cisplatin treatment upregulated 27836543 7462 Human hsa-miR-34a miRNA particulate matter (PM2.5) lung cancer human non-small cell lung cancer cell line A549 chronic (five passages) PM2.5 exposure treatment downregulated 28846189 7463 Human hsa-miR-34a miRNA PRIMA-1 lung cancer human lung cancer cells PRIMA-1 treatment upregulated 19921694 7464 Human hsa-miR-34a miRNA radiation malignant mesothelioma (MM) epithelial type M28K cells radiation treatment upregulated 22237142 7465 Human hsa-miR-34a miRNA lenalidomide myelodysplastic syndrome (MDS) peripheral blood CD14+ monocytes lenalidomide treatment upregulated 25287904 7466 Human hsa-miR-34a miRNA lenalidomide myelodysplastic syndrome (MDS) peripheral blood Lenalidomide treatment upregulated 25287904 7467 Human hsa-miR-34a miRNA estradiol-17¦Â (E2) myofibroblast differentiation MCF-7 cells estradiol-17¦Â (E2) treatment "in MCF-7, which is an ER¦Á-positive breast cancer cell line, miR-34a is remarkably downregulated after E2 treatment" 24050776 7468 Human hsa-miR-34a miRNA ethanol (EtOH) neural differentiation Neural crest cells (NCCs) ethanol exposure upregulated 31247197 7469 Human hsa-miR-34a miRNA "anthranilamide-pyrazolo[1,5-a]pyrimidine" neuroblastoma (NB) neuronalcancer cells lines MR-32; SK-N-SH "anthranilamide-pyrazolo[1,5-a]pyrimidine treatment" upregulated 23992861 7470 Human hsa-miR-34a miRNA retinoic acid (RA) neuroblastoma (NB) SK-N-BE cell line retinoic acid treatment "miR-34a expression increases during retinoic acid-induced differentiation of the SK-N-BE cell line, whereas E2F3 protein levels decrease" 17297439 7471 Human hsa-miR-34a miRNA compound C nonalcoholic fatty liver disease (NAFLD) HepG2 cells; primary human hepatocytes (HH) compound C treatment downregulated 32143184 7472 Human hsa-miR-34a miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmitic acid (PA) treatment downregulated 32143184 7473 Human hsa-miR-34a miRNA ursodeoxycholic acid (UDCA) nonalcoholic fatty liver disease (NAFLD) morbidly obese NAFLD-patients vesicle-free fraction in serum UDCA treatment downregulated in the vesicle-free fraction in serum 28853202 7474 Human hsa-miR-34a miRNA erlotinib non-small cell lung cancer (NSCLC) NSCLC cells erlotinib treatment upregulated 24551227 7475 Human hsa-miR-34a miRNA nutlin-3a non-small cell lung cancer (NSCLC) normal human fibroblasts Nutlin-3a treatment upregulated 18451145 7476 Human hsa-miR-34a miRNA palliative chemotherapy non-small cell lung cancer (NSCLC) NSCLC tissues platinum derivatives in combination with paclitaxel or gemcitabine treatment upregulated 29387235 7477 Human hsa-miR-34a miRNA PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) non-small cell lung cancer (NSCLC) A549 cells PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) treatment upregulated 31411213 7478 Human hsa-miR-34a miRNA pemetrexed non-small cell lung cancer (NSCLC) NSCLC tissue pemetrexed treatment upregulated 23794259 7479 Human hsa-miR-34a miRNA Rhamnetin and cirsiliol non-small cell lung cancer (NSCLC) "NSCLC cells, NCI-H1299 and NCI-H460" Rhamnetin and cirsiliol treatment upregulated 23902763 7480 Human hsa-miR-34a miRNA Delta-tocotrienol non-small cell lung cancer (NSCLC) Human NSCLC cell lines (A549 and H1650) Delta-tocotrienol treatment upregulated 22438124 7481 Human hsa-miR-34a miRNA tumor necrosis factor alpha (TNF-¦Á) apoptosis nucleus pulposus cell (NPC) tumor necrosis factor alpha (TNF-¦Á) treatment MiR-34a is upregulated in TNF-¦Á- induced NPCs 30138895 7482 Human hsa-miR-34a miRNA hypoxia oropharyngeal squamous cell carcinoma (OPSCC) SCC25 cells; SCC090 cells hypoxia treatment upregulated 32102296 7483 Human hsa-miR-34a miRNA H2O2 osteoarthritis (OA) human OA chondrocytes H2O2 treatment downregulated (miR-146a) ; upregulated(miR-34a) 29292727 7484 Human hsa-miR-34a miRNA hydrostatic pressure (HP) osteoarthritis (OA) human osteoarthritis (OA) chondrocytes hydrostatic pressure (HP) treatment upregulated 32455798 7485 Human hsa-miR-34a miRNA IL-1¦Â osteoarthritis (OA) primary cultured chondrocytes IL-1¦Â treatment upregulated 29236314 7486 Human hsa-miR-34a miRNA resistin osteoarthritis (OA) human OA synovial fibroblasts resistin treatment upregulated 31635187 7487 Human hsa-miR-34a miRNA visfatin osteoarthritis (OA) human OA chondrocytes visfatin treatment "upregulated, all the visfatin-caused effects were suppressed by using miR-34a and miR-181a inhibitors." 31405216 7488 Human hsa-miR-34a miRNA visfatin osteoarthritis (OA) human OA synovial fibroblasts visfatin treatment upregulated 31635187 7489 Human hsa-miR-34a miRNA etoposide (VP-16) osteosarcoma (OS) human osteosarcoma cell lines etoposide treatment upregulated 25490093 7490 Human hsa-miR-34a miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells cisplatin (DPP) treatment downregulated 29561664 7491 Human hsa-miR-34a miRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment downregulated 32901049 7492 Human hsa-miR-34a miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 7493 Human hsa-miR-34a miRNA H2O2 oxidative stress Human bone marrow mesenchymal stromal/stem cells (hMSCs) H2O2 treatment upregulated 29331104 7494 Human hsa-miR-34a miRNA H2O2 oxidative stress Human umbilical vein endothelial cells (HUVECs) H2O2 treatment upregulated 29992759 7495 Human hsa-miR-34a miRNA kallistatin oxidative stress HEK293T cells Kallistatin treatment downregulated 28544111 7496 Human hsa-miR-34a miRNA kallistatin oxidative stress H2O2-treated human umbilical vein endothelial cells (HUVECs) Kallistatin treatment downregulated 29992759 7497 Human hsa-miR-34a miRNA morin oxidative stress A549 cells upon traffic PM2.5 exposure Morin treatment downregulated 31284452 7498 Human hsa-miR-34a miRNA particulate matter (PM2.5) oxidative stress A549 cells traffic PM2.5 treatment upregulated 31284452 7499 Human hsa-miR-34a miRNA genistein pancreatic cancer (PC) "Human PC cell lines, including AsPC-1 and MiaPaCa-2" Genistein treatment upregulated 21301871 7500 Human hsa-miR-34a miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 7501 Human hsa-miR-34a miRNA propofol (PPF) pancreatic cancer (PC) PANC-1 cells propofol treatment "Propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression" 32303144 7502 Human hsa-miR-34a miRNA TGF-¦Â1 pancreatic cancer (PC) "Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)" transforming growth factor (TGF)-¦Â1 treatment XIST promotes TGF-¦Â1-induced EMT by regulating the miR-34a-YAP-EGFR axis in PC 31013436 7503 Human hsa-miR-34a miRNA rotenone (ROT) parkinson's disease (PD) SH-SY5Y cell rotenone treatment downregulated 28259991 7504 Human hsa-miR-34a miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH5Y-SY cells 1-methyl-4- phenylpyridinium iodide(MPP +) treatment upregulated 30221494 7505 Human hsa-miR-34a miRNA TGF-¦Â2 posterior capsular opacification (PCO) Human lens epithelial cells (LECs) transforming growth factor (TGF)-¦Â2 treatment downregulated 31158382 7506 Human hsa-miR-34a miRNA doxorubicin (DOX) posterior capsular opacification (PCO) human lens epithelial cell line HLE B3 doxorubicin treatment upregulated 30980790 7507 Human hsa-mir-34a miRNA hypoxia preeclampsia (PE) JEG-3 cells hypoxia treatment upregulated 24081307 7508 Human hsa-miR-34a miRNA propofol (PPF) propofol-induced neurotoxicity and cognitive dysfunction SH-SY5Y cells propofol treatment microRNA-34a was upregulated after propofol treatment 29578002 7509 Human hsa-miR-34a miRNA butyl benzyl phthalate (BBP) prostate cancer Human prostate cancer LNCaP and PC-3 cells butyl benzyl phthalate (BBP) treatment downregulated 30243731 7510 Human hsa-miR-34a miRNA butyl benzyl phthalate (BBP) prostate cancer LNCaP and PC-3 cells butyl benzyl phthalate (BBP) treatment downregulated 30243731 7511 Human hsa-miR-34a miRNA "codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone" prostate cancer "LNCaP, C4-2 , DU145 , and PC3 cells" "codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone treatment" upregulated 28428276 7512 Human hsa-miR-34a miRNA curcumin (Cur) prostate cancer "Human prostate cancer 22RV1, PC©\3, and DU145 cells" curcumin treatment upregulated 31042325 7513 Human hsa-miR-34a miRNA fractionated radiation prostate cancer Human Prostate Cancer Cells radiation treatment Tumor suppressor miR-34a and let-7 miRNAs were upregulated by fractionated radiation in radiosensitive LNCaP (p53 positive) and PC3 (p53-null) cells indicating 22827214 7514 Human hsa-miR-34a miRNA genistein prostate cancer LNCaP cells£» PC3 cells£» DU145 cells£» RWPE-1 cells genistein treatment genistein inhibited PCa cell growth through downregulated of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a 23936419 7515 Human hsa-miR-34a miRNA hypermethylation prostate cancer PCa tissues and cell lines hypermethylation treatment downregulated 26499184 7516 Human hsa-miR-34a miRNA hypoxia renal cell carcinoma (RCC) HK-2 cells hypoxia treatment downregulated 22363487 7517 Human hsa-miR-34a miRNA dihydromyricetin (DHM) renal fibrosis TGF-¦Â1-treated HK-2 cells Dihydromyricetin (DHM) treatment downregulated 30853453 7518 Human hsa-miR-34a miRNA TGF-¦Â1 renal fibrosis HK-2 cells transforming growth factor ¦Â1 (TGF-¦Â1) treatment upregulated 30853453 7519 Human hsa-miR-34a miRNA dioscin renal injury cisplatin (CDDP)-induced NRK-52E and HK-2 cells dioscin treatment upregulated 28514495 7520 Human hsa-miR-34a miRNA vascular endothelial growth factor (VEGF) retinal angiogenesis human retinal microvascular endothelial cells (HRMECs) vascular endothelial growth factor (VEGF) treatment downregulated 30571142 7521 Human hsa-miR-34a miRNA vascular endothelial growth factor (VEGF) retinal angiogenesis human retinal microvascular endothelial cells (HRMECs) vascular endothelial growth factor (VEGF) treatment downregulated 30571142 7522 Human hsa-miR-34a miRNA "antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)" schizophrenia (SZ) schizophrenia patients six-week antipsychotic treatment upregulated 24694668 7523 Human hsa-miR-34a miRNA lipopolysaccharide (LPS) sepsis U937 cells lipopolysaccharide (LPS) treatment miR-34a was upregulated in Lipopolysaccharide (LPS)-induced U937 cell lines. 30021364 7524 Human hsa-miR-34a miRNA cisplatin (DDP) sinonasal squamous cell carcinoma Tumor samples cis-diamminedichloroplatinum treatment downregulated 22624980 7525 Human hsa-miR-34a miRNA high glucose (HG) stress-associated premature senescence (SAPS) Human retinal microvascular endothelial cells (HuREC) high glucose (HG) treatment upregulated 31443378 7526 Human hsa-miR-34a miRNA lipopolysaccharide (LPS) systemic lupus erythematosus (SLE) HK2 cells lipopolysaccharide (LPS) treatment LPS reduced the expression of miR-34a. 30414207 7527 Human hsa-miR-34a miRNA IL-1¦Â and TNF-¦Á type 2 diabetes mellitus (T2DM) human pancreatic islets IL-1¦Â and TNF-¦Á treatment upregulated 20086228 7528 Human hsa-miR-34a miRNA metformin (Met) type 2 diabetes mellitus (T2DM) "ACHN, 769-P, and A498 cells" metformin treatment upregulated 28045889 7529 Human hsa-miR-34a miRNA lopinavir vascular aging vascular endothelial cells (ECs) lopinavir treatment upregulated 27889708 7530 Human hsa-miR-34a miRNA ritonavir vascular aging vascular endothelial cells (ECs) ritonavir treatment upregulated 27889708 7531 Human hsa-miR-34a miRNA high glucose (HG) vascular endothelial dysfunction human microvascular endothelial cell-1 (HMEC-1) cells high glucose (HG) treatment upregulated 31533227 7532 Human hsa-miR-34a miRNA vaccarin (VAC) vascular endothelial dysfunction high glucose (HG)-treated human microvascular endothelial cell-1 (HMEC-1) cells Vaccarin (VAC) treatment downregulated 31533227 7533 Human hsa-miR-34a miRNA Roux-en-Y gastric bypass (RYGB) weight loss obese subjects without exercise program plasma RYGB treatment dysregulatedin plasma 28344345 7534 Human hsa-miR-34a miRNA hypoxia wet age-related macular degeneration (wAMD) ARPE-19 cells hypoxia induce HIF-1¦Á-dependent p53 activation upregulated miRNA-34a expression in ARPE-19 cells following hypoxia. 33438362 7535 Human hsa-miR-34a miRNA adriamycin (ADR) colorectal cancer (CRC) human colon cancer cell line HCT 116 adriamycin (ADR) treatment upregulated 17875987 7536 Human hsa-miR-34a miRNA phorbol ester megakaryocytic differentiation K562 cells phorbol ester treatment upregulated 19584398 7537 Human hsa-miR-34a miRNA thyroid hormone renal tubular epithelial to mesenchymal transition human proximal tubular epithelial cell line HK-2 Thyroid hormone?treatment treatment downregulated 23770290 7538 Human hsa-miR-34a* miRNA lenalidomide myelodysplastic syndrome (MDS) peripheral blood CD14+ monocytes lenalidomide treatment upregulated 25287904 7539 Human hsa-miR-34a* miRNA lenalidomide myelodysplastic syndrome (MDS) peripheral blood Lenalidomide treatment upregulated 25287904 7540 Human hsa-miR-34a-3p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) gastric cancer (GC) tissues Helicobacter pylori (HP) treatment downregulated 30242897 7541 Human hsa-miR-34a-3p miRNA ultrasound (US) multidrug resistance (MDR) MCF-7/ADR and HEPG2/ADM cells ultrasound (US) irradiation treatment upregulated 30231924 7542 Human hsa-miR-34a-3p miRNA metformin (Met) cell senescence dental pulp stem cells (DPSCs) Metformin (Met) treatment metformin significantly suppressed microRNA-34a-3p (miR-34a-3p) expression 33505470 7543 Human hsa-miR-34a-5p miRNA H2O2 age-related nuclear cataract human lens epithelial B3 (HLE-B3) cell H2O2 treatment upregulated 29653565 7544 Human hsa-miR-34a-5p miRNA p-Coumaric acid (p-CA) autoimmune hepatitis (AIH) SNU-16 cells p-Coumaric acid (p-CA) treatment upregulated 32462517 7545 Human hsa-miR-34a-5p miRNA hypoxia autophagy "human coronary artery endothelial cells (HCAECs)," ?chronic intermittent hypoxia (CIH) induce upregulated 31218746 7546 Human hsa-miR-34a-5p miRNA doxorubicin (DOX) breast cancer MDA-MB-231 cells doxorubicin treatment downregulated 30245930 7547 Human hsa-miR-34a-5p miRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin (Dox) treatment upregulated 30245930 7548 Human hsa-miR-34a-5p miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) breast cancer MCF-7 cells methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment upregulated 30245930 7549 Human hsa-miR-34a-5p miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) breast cancer MDA-MB-231 cells methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment upregulated 30245930 7550 Human hsa-miR-34a-5p miRNA methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin breast cancer MDA-MB-231 cells methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin treatment upregulated 30245930 7551 Human hsa-miR-34a-5p miRNA imatinib chronic myeloid leukemia (CML) K562 cells imatinib treatment downregulated 31923418 7552 Human hsa-miR-34a-5p miRNA sevoflurane (SEV) colorectal cancer (CRC) SW480 cells; LOVO cells sevoflurane treatment sevoflurane inhibited colon cancer progression by modulating the exosome-transmitted circ-HMGCS1/miR-34a-5p/SGPP1 axis 33125091 7553 Human hsa-miR-34a-5p miRNA paroxetine depression serum paroxetine treatment downregulated 29791588 7554 Human hsa-miR-34a-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" diffuse large B-cell lymphoma (DLBCL) HT and U2932 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 24722400 7555 Human hsa-miR-34a-5p miRNA ¦Á-naphthylisothiocyanate (ANIT) drug-induced liver injury (DILI) upcyte hepatocytes ¦Á-naphthyl isothiocyanate (ANIT) treatment upregulated 31198949 7556 Human hsa-miR-34a-5p miRNA steroids endometriosis ovarian endometrial steroid hormones treatment upregulated 26819477 7557 Human hsa-miR-34a-5p miRNA toosendanin (TSN) gastric cancer (GC) MKN-45 cells toosendanin (TSN) treatment upregulated 32582989 7558 Human hsa-miR-34a-5p miRNA "cisplatin, N-ethyl-N-nitrosourea, etoposide, mitomycin C, methyl methanesulphonate, taxol, and X-ray radiation" genotoxicity TK6 cells "cisplatin, N-ethyl-N-nitrosourea, etoposide, mitomycin C, methyl methanesulphonate, taxol, and X-ray radiation" upregulated 32929177 7559 Human hsa-miR-34a-5p miRNA olive oil polyphenol hydroxytyrosol (HT) inflammation TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes olive oil polyphenol hydroxytyrosol (HT) treatment downregulated 31627295 7560 Human hsa-miR-34a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31627295 7561 Human hsa-miR-34a-5p miRNA compression force (CF) intervertebral disc degeneration (IDD) nucleus pulposus (NP) cells compression treatment upregulated 32114390 7562 Human hsa-miR-34a-5p miRNA hypoxia/reoxygenation (H/R) intestinal hypoxia/reoxygenation injury caco-2 cells hypoxia-reoxygeneration (H/R) treatment upregulated 26935288 7563 Human hsa-miR-34a-5p miRNA lipopolysaccharide (LPS) LPS-induced injury human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment MiR-34a-5p expression was significantly enhanced in HUVECs after 24 h of LPS treatment. 33155244 7564 Human hsa-miR-34a-5p miRNA oleacein (OA) melanoma 501Mel melanoma cells oleacein (OA) treatment upregulated 33071785 7565 Human hsa-miR-34a-5p miRNA hypoxia myocardial infarction (MI) human cardiac myocytes hypoxia induce upregulated 30312158 7566 Human hsa-miR-34a-5p miRNA ionizing radiation (IR) nasopharyngeal carcinoma (NPC) human NPC cell lines CNE-1 and CNE-2 ionizing radiation upregulated 28985197 7567 Human hsa-miR-34a-5p miRNA luteolin non-small cell lung cancer (NSCLC) A549 cells; H460 cells luteolin (LTL) treatment miR-34a-5p was dramatically upregulated upon LTL treatment in tumor tissues. 29393891 7568 Human hsa-miR-34a-5p miRNA oleacein (OA) obesity Simpson-Golabi-Behmel syndrome (SGBS) adipocytes oleacein (OA) treatment downregulated 31766503 7569 Human hsa-miR-34a-5p miRNA oleocanthal (OC) obesity Simpson-Golabi-Behmel syndrome (SGBS) adipocytes oleocanthal (OC) treatment downregulated 31766503 7570 Human hsa-miR-34a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) obesity Simpson-Golabi-Behmel syndrome (SGBS) adipocytes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31766503 7571 Human hsa-miR-34a-5p miRNA IL-1¦Â osteoarthritis (OA) Hyperplastic synovial fibroblasts (SFs) interleukin-1¦Â treatment upregulated 31777535 7572 Human hsa-miR-34a-5p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-1¦Â treatment "SNHG7 sponged miR-34a-5p to affect cell proliferation, apoptosis and autophagy through targeting SYVN1" 32066502 7573 Human hsa-miR-34a-5p miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells; A2780 cells cisplatin treatment miR-34a-5p was decreased in DDP-resistant cells. 31777260 7574 Human hsa-miR-34a-5p miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 and A2780 ovarian cancer cell lines cisplatin treatment downregulated 31777260 7575 Human hsa-miR-34a-5p miRNA docetaxel (DTX) prostate cancer PCa samples; PC3 cells; DU145 cells docetaxel (DTX) treatment downregulated 31672604 7576 Human hsa-miR-34a-5p miRNA high glucose (HG) tubulointerstitial fibrosis (TIF) human proximal tubule cell line(HK-2) cells high glucose treatment upregulated 29371016 7577 Human hsa-miR-34a-c miRNA cisplatin (DDP) apoptosis K562 cells cisplatin treatment upregulated 20428827 7578 Human hsa-miR-34b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" acute lymphoblastic leukemia (ALL) HL-60 and K562 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26861642 7579 Human hsa-miR-34b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" chronic lymphocytic leukemia (CLL) MEC1 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 24559316 7580 Human hsa-miR-34b miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment "miR-34b overexpression inhibited apoptosis and expression levels of TNF-alpha, IL-1?, IL-6, and caspase-3 in HG-treated HK-2 cells." 31665127 7581 Human hsa-miR-34b miRNA nanocurcumin hepatocellular carcinoma (HCC) HepG2 and Huh7 cells nanocurcumin treatment upregulation 27165229 7582 Human hsa-miR-34b miRNA CdSe/ZnS-GSH lung cancer A549 cells CdSe/ZnS-GSH treatment upregulated 31883144 7583 Human hsa-miR-34b miRNA CdSe/ZnS-MPA lung cancer A549 cells CdSe/ZnS-MPA treatment upregulated 31883144 7584 Human hsa-miR-34b miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" melanoma melanoma tissue "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 21949788 7585 Human hsa-miR-34b miRNA extremely low-frequency magnetic fields (ELF-MFs) neurodegeneration (ND) SH-SY5Y human neuroblastoma cells ELF-MFs downregulated 29039021 7586 Human hsa-miR-34b miRNA extremely low-frequency magnetic fields (ELF-MFs) neurodegenerative diseases SH-SY5Y human neuroblastoma cells extremely low-frequency magnetic fields (ELF-MFs) treatment downregulated 29039021 7587 Human hsa-miR-34b miRNA nutlin-3a non-small cell lung cancer (NSCLC) normal human fibroblasts Nutlin-3a treatment upregulated 18451145 7588 Human hsa-miR-34b miRNA sirolimus osteosarcoma (OS) Human OS cell line MG63/ADM sirolimus treatment upregulated 26924291 7589 Human hsa-miR-34b-5p miRNA melatonin oral cancer SAS cells; SCC9 cells Melatonin treatment Melatonin reduced the drug resistance and promoted the apoptosis of VCR-resistant oral cancer cells through the upregulation of microRNA-892a (miR-892a) and miR-34b-5p expressions. 31982774 7590 Human hsa-miR-34b-5p miRNA melatonin vincristine (VCR) resistance SAS cells; SCC9 cells Melatonin treatment upregulated 31982774 7591 Human hsa-miR-34c miRNA high glucose (HG) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) high glucose (HG) treatment MicroRNA-34c suppresses proliferation of vascular smooth muscle cell via modulating high mobility group box protein 1 32157741 7592 Human hsa-miR-34c miRNA adoMet breast cancer MCF-7 cells adoMet treatment upregulated 30533999 7593 Human hsa-miR-34c miRNA benzo(a)pyrene (BaP) cell transformation human bronchial epithelial (HBE) cells benzo(a)pyrene (BaP) exposure downregulated 24362009 7594 Human hsa-miR-34c miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) BEAS-2B cells cigarette smoke extract (CSE) treatment LncRNA TUG1 knockdown mitigates inflammatory injury induced by cigarette smoke extract in chronic obstructive pulmonary disease via miR-34c/BRD4 axis 32812639 7595 Human hsa-miR-34c miRNA high glucose (HG) diabetic nephropathy (DN) CIHP-1 cells high glucose (HG) treatment CASC15 is upregulated in DCRF patients and promotes the apoptosis of podocytes by sponging miR-34c. 32053576 7596 Human hsa-miR-34c miRNA bisphenol A (BPA) female fertility cumulus oocyte complex (COC) bisphenol A (BPA) treatment upregulated 33285269 7597 Human hsa-miR-34c miRNA zika virus (ZIKV) glioblastoma multiforme (GBM) glioblastoma stem cells (GSCs) Zika virus (ZIKV) infection treatment upregulated 30890698 7598 Human hsa-miR-34c miRNA nanocurcumin hepatocellular carcinoma (HCC) HepG2 and Huh7 cells nanocurcumin treatment upregulation 27165229 7599 Human hsa-miR-34c miRNA extremely low-frequency magnetic fields (ELF-MFs) neurodegeneration (ND) SH-SY5Y human neuroblastoma cells ELF-MFs downregulated 29039021 7600 Human hsa-miR-34c miRNA extremely low-frequency magnetic fields (ELF-MFs) neurodegenerative diseases SH-SY5Y human neuroblastoma cells extremely low-frequency magnetic fields (ELF-MFs) treatment downregulated 29039021 7601 Human hsa-miR-34c miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 7602 Human hsa-miR-34c miRNA nutlin-3a non-small cell lung cancer (NSCLC) normal human fibroblasts Nutlin-3a treatment upregulated 18451145 7603 Human hsa-miR-34c miRNA radiation prostate cancer LNCaP cells;C4-2 cells radiation treatment upregulated 18668526 7604 Human hsa-miR-34c miRNA doxycycline reprogramming activity of somatic cell nuclear transfer (SCNT) embryos Primary fibroblast cell cultures doxycycline (DXC) treatment upregulated 25437869 7605 Human hsa-miR-34c miRNA S-adenosyl-L-methionine (AdoMet) triple negative breast cancer (TNBC) MDA-MB-231; MDA-MB-468 cells S-adenosyl-L-methionine (AdoMet) treatment AdoMet exerts its antitumor effects in TNBC cells through upregulating the expression of miR-34c and miR-449a 33396625 7606 Human hsa-miR-34c-3p miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human primary monocyte-derived macrophages infect with HIV-1 upregulated 28594894 7607 Human hsa-miR-34c-3p miRNA glargine pancreatic cancer (PC) pancreatic cancer cells glargine treatment upregulated 22690071 7608 Human hsa-miR-34c-3p miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment downregulated 26987780 7609 Human hsa-miR-34c-5p miRNA sodium valproate (VPA) autophagy SH-SY5Y cells sodium valproate (VPA) treatment upregulated 30613007 7610 Human hsa-miR-34c-5p miRNA ultraviolet (UV) irradiation breast cancer normal human primary dermal fibroblasts ultraviolet irradiation treatment upregulated 23983607 7611 Human hsa-miR-34c-5p miRNA arsenite tumorigenesis derivative normal stem cell (SC) line arsenite exposure downregulated 24431212 7612 Human hsa-miR-34c-5p miRNA doxorubicin (DOX) cardiotoxicity human-induced pluripotent stem cell (hiPSC) doxorubicin treatment upregulated 26842497 7613 Human hsa-miR-34c-5p miRNA pirarubicin (THP) cervical cancer (CC) cervical cancer cells Pirarubicin (THP)treatment downregulated 27097054 7614 Human hsa-miR-34c-5p miRNA Pien Tze Huang (PZH) colorectal cancer (CRC) HCT-8 cells PZH treatment upregulated 29042999 7615 Human hsa-miR-34c-5p miRNA heat stress heat-induced pathophysiology human umbilical vein endothelial cells cultured in the incubator at 43¡ãC for 1 h "downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)" 29039486 7616 Human hsa-miR-34c-5p miRNA high glucose (HG) vascular calcification (VC) human aorta vascular smooth muscle cells (HA-VSMCs) high glucose treatment "Overexpression of miR-34c-5p alleviated calcification/senescence of HA-VSMCs, whereas inhibition of miR-34c-5p received the opposite results." 30654331 7617 Human hsa-miR-351 miRNA "IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1" chronic hepatitis C virus (HCV) infection Huh7 cells "types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment" dysregulated 24844965 7618 Human hsa-miR-3605-5p miRNA coxsackievirus A16 (CVA16) and enterovirus 71(EV71) hand-foot-mouth disease (HFMD) human embryonic kidney 293T cells infect with CVA16 and EV71 downregulated 28198671 7619 Human hsa-miR-3607-3p miRNA TGF-¦Â1 renal fibrosis human kidney proximal tubular cells (HK-2) TGF-¦Â1 treatment downregulated 31455266 7620 Human hsa-miR-3607-5p miRNA particulate matter (PM2.5) airway inflammation "human bronchial epithelial cell line, BEAS-4B" particulate matter 2.5 (PM2.5) exosure treatment "CircRNA104250 and lncRNAuc001dgp1 target miR-3607-5p and affect expression of interleukin 1 receptor 1 (IL1R1), which influences the nuclear factor ¦ÊB (NF-¦ÊB) signaling pathway" 31864925 7621 Human hsa-miR-3609 miRNA statins atherosclerosis (AS) peripheral blood mononuclear cells (PBMCs) statins? treatment upregulated 32885808 7622 Human hsa-miR-3609 miRNA glial cell-derived neurotrophic factor (GDNF) glioblastoma multiforme (GBM) human U251 glioma cells 50 ng/mL GDNF for 24 h upregulated 29224008 7623 Human hsa-miR-361 miRNA prednisolone active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) prednisolone treatment downregulated 24215168 7624 Human hsa-miR-361 miRNA Somatostatin (SRIF) antiangiogenic human umbilical vein endothelial cells Somatostatin (SRIF)? treatment downregulated 23128854 7625 Human hsa-miR-361 miRNA a moderate-carbohydrate and low glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and low glycemic index diet downregulated 29233588 7626 Human hsa-miR-361 miRNA TGF-¦Â1 prostatic hyperplasia (BPH) prostate stromal cells (PrSCs) were primary cultured from BPH tissue TGF¦Â1 treatment "miR-361 expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR-361" 31694982 7627 Human hsa-miR-3610 miRNA Traumatic brain injury (TBI) hypopituitarism blood Traumatic brain injury (TBI) treatment upregulated 27027233 7628 Human hsa-miR-3613 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 7629 Human hsa-miR-3613-3p miRNA palbociclib triple negative breast cancer (TNBC) MDA-MB-231 cells palbociclib treatment Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib 33330073 7630 Human hsa-miR-3613-5p miRNA simvastatin endometriosis Serum simvastatin treatment upregulated 29587611 7631 Human hsa-miR-3613-5p miRNA ursolic acid (UA) malignant pleural mesothelioma (MPM) H2452 cells ursolic acid treatment upregulated 28090191 7632 Human hsa-miR-361-3p miRNA resveratrol Alzheimer's disease (AD) SK-N-SH cells; CHP-212 cells resveratrol (Res) treatment upregulated 32741808 7633 Human hsa-miR-361-3p miRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cell (HUVEC) high glucose (HG) treatment Knockdown of MALAT1 inhibits HG-induced vascular endothelial injury through regulating miR-361-3p/SOCS3 axis. 32509100 7634 Human hsa-miR-361-3p miRNA enzalutamide (Enz) prostate cancer C4-2 cells enzalutamide (Enz) treatment downregulated 32978369 7635 Human hsa-miR-361-3p miRNA helicobacter pylori (H. pylori) sophageal carcinogenesis human esophageal cell line HET-1A Helicobacter pylori infection miR-361-3p was significantly decreased in HET-1A cells exposure to H. pylor. 30783439 7636 Human hsa-miR-361-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31312370 7637 Human hsa-miR-361-5p miRNA dexmedetomidine (DEX) osteoporosis human umbilical vein endothelial cells (HUVECs) dexamethasone (DEX) treatment "After Dex treatment, the expressions of miR-361-5p, VEGFA, BMD related indexes were increased in OP rats." 33631172 7638 Human hsa-miR-361-5p miRNA hypoxia pulmonary arterial hypertension (PAH) Human pulmonary artery smooth muscle cells (hPASMCs) hypoxia induce upregulated 29339076 7639 Human hsa-miR-3619-5p miRNA platelet-derived growth factor (PDGF) asthma Human fetal airway smooth muscle (ASM) cells platelet-derived growth factor (PDGF) treatment downregulated 31014672 7640 Human hsa-miR-3619-5p miRNA 5-fluorouracil (5-FU) gastric cancer (GC) AGS cell; MKN45 cells 5-fluorouracil (5-FU) treatment downregulated 32300102 7641 Human hsa-miR-3619-5p miRNA cisplatin (DDP) gastric cancer (GC) AGS/DPP; NUGC-3/DPP cells cisplatin treatment PVT1 silencing attenuated the DPP resistance in GC by downregulating TBL1XR1 via sponging miR-3619-5p. 32407172 7642 Human hsa-miR-3619-5p miRNA oxaliplatin gastric cancer (GC) AGS cell; MKN45 cells oxaliplatin (OXA) treatment downregulated 32300102 7643 Human hsa-miR-3619-5p miRNA heat stress hepatocellular carcinoma (HCC) Huh7 cells; MHCC97 cells heating treatment downregulated 32799553 7644 Human hsa-miR-3619-5p miRNA naringenin lung cancer A549 cells; PC9 cells naringenin treatment Naringenin hindered cell metastasis in vitro and tumor growth in vivo by reducing circFOXM1 and SPAG5 expression and inducing the expression of miR-3619-5p in lung cancer. 32598178 7645 Human hsa-miR-3619-5p miRNA isoimperatorin (ISO) melanin metabolism disorders HaCaT cells Isoimperatorin (ISO) treatment downregulated 32299303 7646 Human hsa-miR-362 miRNA erythropoietin (EPO) erythroid cell differentiation The original UT-7 cell line erythropoietin treatment upregulated 18492109 7647 Human hsa-miR-3620-5p miRNA high glucose (HG) calcification/senescence human aortic vascular smooth muscle cells (HA-VSMCs) high glucose (HG) treatment downregulated 32483833 7648 Human hsa-miR-362-3p miRNA palmitate diabetes mellitus (DM) Human islets palmitate (Pal) treatment downregulated 30131392 7649 Human hsa-miR-362-3p miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 7650 Human hsa-miR-362-3p miRNA regorafenib frail metastatic colorectal cancer (mCRC) serum regorafenib treatment "Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia" 33916610 7651 Human hsa-miR-362-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" miR-362-3p expression increased while methylation of its promoter significantly decreased in human HCC cells and tissues compared with normal cells and adjacent noncancerous tissues. 25649327 7652 Human hsa-miR-362-5p miRNA "chlorpromazine, haloperidol and clozapine" psychosis JM-Jurkat T-lymphocytes "chlorpromazine, haloperidol and clozapine treatment" dysregulated 24480591 7653 Human hsa-miR-362-5p miRNA kynurenine bone loss bone marrow stromal cells (BMSCs) kynurenine treatment downregulated 31790802 7654 Human hsa-miR-362-5p miRNA cisplatin (DDP) gastric cancer (GC) GC cell line SGC7901 cisplatin treatment downregulated 31423228 7655 Human hsa-miR-362-5p miRNA crizotinib non-small cell lung cancer (NSCLC) ALK-positive NSCLC patients plasma crizotinib treatment upregulated 28514730 7656 Human hsa-miR-363 miRNA lipopolysaccharide (LPS) graft-versus-host disease (GVHD) Cord blood (CB) lipopolysaccharide (LPS) treatment upregulated 21913990 7657 Human hsa-miR-363 miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 14¡ã HDT bed rest experiment downregulated 28261104 7658 Human hsa-miR-363 miRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 cells cisplatin treatment downregulated 26143754 7659 Human hsa-miR-363 miRNA oxaliplatin hepatocellular carcinoma (HCC) Huh7 cells; HepG2 cells oxaliplatin (OXA) treatment miR-363 expression levels were downregulated in oxaliplatin-resis- tant HCC cell lines compared with parental cell lines 29602203 7660 Human hsa-miR-363 miRNA "myclobutanil, propiconazole, and triadimefon" hepatocellular carcinoma (HCC) HepG2 cells "myclobutanil, propiconazole, and triadimefon treatment" downregulated 23159985 7661 Human hsa-miR-363-3p miRNA dual MEK/Aurora kinase inhibitor BI-847325 anaplastic thyroid carcinoma (ATC) ATC cell lines (C643 and SW1736) dual MEK/Aurora kinase inhibitor BI-847325 treatment upregulated 31077090 7662 Human hsa-miR-363-3p miRNA clopidogrel gastric mucosal injury GES-1 cells clopidogrel treatment The expression of miR-363-3p in gastric mucosal injury caused by clopidogrel was higher than that in normal samples. 33208005 7663 Human hsa-miR-363-3p miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment The level of miR-363-3p was significantly decreased in TGF-¦Â1-treated HK-2 cells 33630202 7664 Human hsa-miR-363-3p miRNA cadmium (Cd) renal injury serum cadmium (Cd) treatment We tested five dysregulated miRNAs and determined a significant increase of sera miR-363-3p. 33857584 7665 Human hsa-miR-3648 miRNA thapsigargin (TG) and tunicamycin (TM) cell proliferation HeLa and HEK293T cells Thapsigargin (TG) and Tunicamycin (TM)s treatment upregulated 28661420 7666 Human hsa-miR-365 miRNA intermittent cyclic mechanical tension (ICMT) intervertebral disc degeneration (IDD) primary human end plate chondrocytes intermittent cyclic mechanical tension (ICMT) treatment downregulated 31472300 7667 Human hsa-miR-365 miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 7668 Human hsa-miR-365 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophages atherogenic Evs oxidized low-density lipoprotein (ox-LDL) treatment enrichment in atherogenic EVs 28882869 7669 Human hsa-miR-365 miRNA crocin cervical cancer (CC) sensitive human cervical cancer cell line (OV2008) and resistant one (C13) crocin treatment downregulated 28763753 7670 Human hsa-miR-365 miRNA chondrogenic medium chondrogenesis "articular cartilage-derived mesenchymal stem cells from osteoarthritis patients (OA-MSC), bone marrow-derived mesenchymal stem cells (BMSC)" chondrogenic medium cultures upregulated 31287025 7671 Human hsa-miR-365 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose treatment "High glucose treatment led to downregulated RPSAP52 and Timp3, but upregulated miR-365 in RPE cells." 33178344 7672 Human hsa-miR-365 miRNA hydatid cyst fluid (HCF) melanoma human melanoma cell A375 Hydatid cyst fluid (HCF) treatment "The fold change of Bax/Bcl-2 ratio, Caspase-9, miR-365 and Caspase-3 activity was higher in the fertile HCF-treated melanoma cells compared to infertile fluid treated A375 cells and human normal epithelial cell (as control cell)." 33609644 7673 Human hsa-miR-365 miRNA mechanical loading and hydrostatic pressure (HP) osteoarthritis (OA) OA human chondrocytes mechanical loading and hydrostatic pressure (HP) treatment upregulated 28085114 7674 Human hsa-miR-365 miRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment downregulated 30233734 7675 Human hsa-miR-365 miRNA oxidized low density lipoprotein (ox-LDL) focal cerebral ischemia HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 21640710 7676 Human hsa-miR-3651 miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human bronchial epithelial (16HBE) cells infect with EV71 and CA16 dysregulated 27890633 7677 Human hsa-miR-3651 miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) Human bronchial epithelial (16HBE) cells Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment dysregulated 27890633 7678 Human hsa-miR-3652 miRNA gefitinib lung cancer PC-9 cells gefitinib treatment upregulated 32052182 7679 Human hsa-miR-3653-3p miRNA melatonin osteoporosis human bone marrow mesenchymal stem cell (hBMSC) melatonin (MEL) treatment Circ_0003865 expression in BMSCs was significantly decreased by MEL treatment. 33632317 7680 Human hsa-miR-3656 miRNA graphene oxide (GO) graphene oxide (GO) toxicity GLC-82 cells GO treatment dysregulated 24512264 7681 Human hsa-miR-3659 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 7682 Human hsa-miR-3659 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 7683 Human hsa-miR-365a-3p miRNA toosendanin (TSN) gastric cancer (GC) MKN-45 cells toosendanin (TSN) treatment upregulated 32582989 7684 Human hsa-miR-365a-3p miRNA sulforaphane (SFN) pancreatic ductal adenocarcinoma (PDAC) AsPC-1 cells sulforaphane treatment upregulated 30910589 7685 Human hsa-miR-365a-5p miRNA excessive mechanical tension intervertebral disc degeneration (IDD) primary human endplate chondrocytes culture Excessive mechanical tension induce "circRNA_0058097 can upregulate the expression of downstream target gene histone deacetylase 4 by sponge adsorption of miR-365a-5p, which promoted morphological changes of endplate chondrocytes, and increased extracellular matrix degradation and degeneration of endplate cartilage." 31222836 7686 Human hsa-miR-365b-3p miRNA platelet derived growth factor-BB (PDGF-BB) coronary atherosclerosis (CAS) human coronary artery smooth muscle cells (HCASMCs) platelet-derived growth factor-BB (PDGF-BB) treatment downregulated 30402161 7687 Human hsa-miR-3663 miRNA sodium butyrate (NaB) sickle cell anemia (SCA) CD133 hematopoietic stem cells sodium butyrate treatment dysregulated 26837891 7688 Human hsa-miR-3663-3p miRNA toluene toluene-induced toxicity HL-60 human promyelocytic leukemia cells toluene treatment dysregulated 28245982 7689 Human hsa-miR-3666 miRNA all-trans retinoic acid (ATRA) colorectal cancer (CRC) Human CRC HCT116 cells all-trans retinoic acid (ATRA) treatment upregulated 29772445 7690 Human hsa-miR-3666 miRNA palmitic acid (PA) hepatic steatosis HepG2 cells palmitic acid (PA) treatment In PA treated HepG2 cells during development of hepatic steatosis PPAR¦Ã was significantly upregulated concomitant with downregulated of miR-3666 32755726 7691 Human hsa-miR-367 miRNA c-reactive protein (CRP) atherosclerosis (AS) Human vascular smooth muscle cell line HA-VSMC CRP treatment upregulated 31646586 7692 Human hsa-miR-367 miRNA hypoxia atherosclerosis (AS) Human vascular smooth muscle cell line HA-VSMC hypoxia induce upregulated 31646586 7693 Human hsa-miR-367 miRNA paclitaxel (PTX) tumorigenesis NCI60 cancer cell line£¬Ovarian cancer (OVCA) cell lines and Human stem cell lines (H9) paclitaxel treatment miR-367 upregulated and miR-30a-5p downregulated 24220856 7694 Human hsa-miR-367 miRNA sodium butyrate (NaB) somatic cell reprogramming human foreskin fibroblasts (HFFs) NaB treatment upregulated 24568633 7695 Human hsa-miR-3675-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 7696 Human hsa-miR-3676 miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine (GEM) treatment downregulated 25722110 7697 Human hsa-miR-3676-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 7698 Human hsa-miR-3679-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 7699 Human hsa-miR-3682-3p miRNA gefitinib lung cancer PC-9 cells gefitinib treatment upregulated 32052182 7700 Human hsa-miR-3687 miRNA lucidum breast cancer MCF-7 breast cancer cells lucidum treatment upregulated 25954907 7701 Human hsa-miR-369 miRNA azacitidine (AZA) gastric cancer (GC) "HGC27, SGC7091, MGC803, and MKN45 cell lines" azacitidine (AZA) treatment upregulated 31162777 7702 Human hsa-miR-369-3p miRNA cocaine drug addiction differentiated SH-SY5Y neuroblastoma cells cocaine treatment downregulated 30166527 7703 Human hsa-miR-369-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epigenetic regulation HCT116 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30538122 7704 Human hsa-miR-369-3p miRNA bleomycin (BLM) idiopathic pulmonary fibrosis (IPF) A549 cells bleomycin (BLM) treatment TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells. DLEU2 directly targeted miR-369-3p. 33760118 7705 Human hsa-miR-369-3p miRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) A549 cells TGF-¦Â1 treatment TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells DLEU2 directly targeted miR-369-3p 33760118 7706 Human hsa-miR-37 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" acute myeloid leukemia (AML) THP-1 line "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26191124 7707 Human hsa-miR-370 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31900142 7708 Human hsa-miR-370 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33298736 7709 Human hsa-miR-370 miRNA oxygen glucose deprivation (OGD) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y Cells oxygen glucose deprivation (OGD) treatment miR-370 expression was significantly promoted in SH-SY5Y cells after OGD treated. 32311231 7710 Human hsa-miR-370 miRNA homoharringtonine (HHT) chronic myeloid leukemia (CML) chronic myeloid leukemia K562 cells Homoharringtonine (HHT) treatment upregulated 24148180 7711 Human hsa-miR-370 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) human GC cell lines SGC-7901 and BGC-823 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25270964 7712 Human hsa-miR-370 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells; LN229 cells;glioma tissues temozolomide (TMZ) treatment miR-370 expression was significantly downregulated in TMZ-resistant glioma tissues and glioma cells 33188501 7713 Human hsa-miR-370 miRNA Japanese encephalitis virus (JEV) Japanese encephalitis virus (JEV) infection Glioblastoma cells Japanese encephalitis virus (JEV) infection downregulated 27703358 7714 Human hsa-miR-370 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" osteosarcoma (OS) human osteosarcoma cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28539830 7715 Human hsa-miR-370-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment circ_0010283 mediated cell viability and migration via a miR-370-3p/HMGB1 axis in ox-LDL-induced VSMCs. 32945389 7716 Human hsa-miR-370-3p miRNA 6-thioguanine (6-TG) breast cancer MCF-7 cells 6-thioguanine (6-TG) treatment downregulated 33376537 7717 Human hsa-miR-370-3p miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) SKOV-3 cells; OVCAR3 cells TGF-¦Â treatment TGF-¦Â treatment upregulated H19 and downregulated miR-370-3p 29403287 7718 Human hsa-miR-370-3p miRNA baohuoside-I nasopharyngeal carcinoma (NPC) CNE1 cells; CNE2 cells baohuoside-I treatment upregulated 32945196 7719 Human hsa-miR-370-3p miRNA osteogenic differentiation medium osteogenesis human bone marrow-derived mesenchymal stem cells (HBMSCs) "osteogenic differentiation medium with 100 mmol/L dexamethasone, 0.05 mmol/L ascorbic acid, and 10 mmol/L ¦Â-glycerophosphate treatment" downregulated 30795799 7720 Human hsa-miR-370-3p miRNA lipopolysaccharide (LPS) pneumonia WI-38 human lung fibroblasts cells lipopolysaccharide (LPS) treatment downregulated 31066476 7721 Human hsa-miR-370-3p miRNA lipopolysaccharide (LPS) pneumonia A549 cells LPS treatment "SNHG16 impeded cell viability and promoted apoptosis, inflammatory injury by targeting IGF2 mediated by miR-370-3p in LPS-induced A549 cells." 31841752 7722 Human hsa-miR-370-3p miRNA lipopolysaccharide (LPS) pneumonia A549 cells lipopolysaccharides (LPS) treatment downregulated 31841752 7723 Human hsa-miR-370-3p miRNA cisplatin (DDP) triple negative breast cancer (TNBC) Exosomes were isolated from MDA-MB-231 cells cisplatin treatment upregulated 31424364 7724 Human hsa-miR-371a-3p miRNA orchiectomy germ cell tumour (GCT) serum orchiectomy treatment downregulated in serum 25187505 7725 Human hsa-miR-371a-5p miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) tumor tissue and serum from HCC patients hepatitis B virus (HBV) infection upregulated 29928866 7726 Human hsa-miR-371a-5p miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine (GEM) treatment upregulated 25722110 7727 Human hsa-miR-371b-5p miRNA glial cell-derived neurotrophic factor (GDNF) parkinson's disease (PD) SH-SY5Y human neuroblastoma cells GDNF downregulated 28829278 7728 Human hsa-miR-372 miRNA cadmium (Cd) cell cycle and proliferation hepatoma cell line (HepG2) cadmium (Cd) treatment upregulated 25101185 7729 Human hsa-miR-372 miRNA chemotherapy colorectal cancer (CRC) serum " modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2 , day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment" dysregulated 24304648 7730 Human hsa-miR-372 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" hepatocellular carcinoma (HCC) Huh7 or HCCLM3 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" miR-372 expression was restored upon 5-aza-dCyd treatment 25880458 7731 Human hsa-miR-372 miRNA propofol (PPF) lung cancer A549 cells propofol treatment downregulated 30547768 7732 Human hsa-miR-372 miRNA ionizing radiation (IR) nasopharyngeal carcinoma (NPC) "Two NPC cell lines, 5©\8F and C666©\1" ionization radiation treatment upregulated 30656832 7733 Human hsa-miR-372 miRNA caudatin oxidative stress human gastric carcinoma cell lines caudatin? treatment downregulated 23708208 7734 Human hsa-miR-372 miRNA IL-1¦Â spinal cord injury (SCI) human neural stem cells (hNSC) IL-3¦Â treatment upregulated 28298306 7735 Human hsa-miR-372-3p miRNA rapamycin dyslipidemia serum rapamycin treatment hsa-miR-372-3p was filtered using RNA sequencing and identified as a key regulator in rapamycin-induced TGs accumulation 33705959 7736 Human hsa-miR-372-3p miRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) serum Dox treatment We found a significantly higher level of miR-372-3p in the blood of the responder group of HCC patients who received TACE with Dox than of non-responders 32416702 7737 Human hsa-miR-372-3p miRNA fructose liver fibrosis primary human hepatocytes fructose treatment downregulated 31299062 7738 Human hsa-miR-372-3p miRNA high glucose (HG) liver fibrosis LX-2 and HepG2 cells high glucose treatment downregulated 31299062 7739 Human hsa-miR-372-3p miRNA palmitate liver fibrosis primary human hepatocytes palmitate treatment downregulated 31299062 7740 Human hsa-miR-372-3p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2R cells curcumin treatment upregulated 31793078 7741 Human hsa-miR-372-5p miRNA mono-(2-ethylhexyl) phthalate (MEHP) oral squamous cell carcinoma (OSCC) SCC-4 cells Mono-2-ethyhexyl phthalate (MEHP) treatment downregulated 30858031 7742 Human hsa-miR-373 miRNA berberine (BBR) abnormal lipid accumulation MIHA cells; HepG2 cells berberine (BBR) treatment MicroRNA-373 (MiR-373) was consistently upregulated in both cell lines upon berberine treatments. 29477657 7743 Human hsa-miR-373 miRNA trastuzumab or lapatinib breast cancer patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer chemotherapy combin either trastuzumab or lapatinib treatment upregulated 25086636 7744 Human hsa-miR-373 miRNA arsenite tumorigenesis RWPE-1 human prostate epithelial line arsenite exposure downregulated 24431212 7745 Human hsa-miR-373 miRNA pomegranate juice (PJ) colorectal cancer (CRC) ?prostate cancer cells Pomegranate juice (PJ) treatment downregulated 21594291 7746 Human hsa-miR-373 miRNA suberoylanilide hydroxamic acid (SAHA) non-small cell lung cancer (NSCLC) Calu-6 non-small cell lung cancer (NSCLC) cell line SAHA treatment upregulated 25063738 7747 Human hsa-miR-373 miRNA trichostatin A (TSA) non-small cell lung cancer (NSCLC) A549 and Calu-6 cells trichostatin A treatment downregulated 25063738 7748 Human hsa-miR-373 miRNA lipopolysaccharide (LPS) osteoarthritis (OA) C28/I2 cells lipopolysaccharide (LPS) treatment circRNA-UBE2G1 facilitates the progression in the LPS-induced OA cell model via regulating the miR-373/HIF-1a axis. 32476580 7749 Human hsa-miR-373 miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 7750 Human hsa-miR-373 miRNA TGF-¦Â1 renal fibrosis human kidney-2 cells TGF-¦Â1 treatment upregulated 29723660 7751 Human hsa-miR-373 miRNA TGF-¦Â1 renal fibrosis human kidney-2 cells TGF-¦Â1 treatment upregulated 29723660 7752 Human hsa-miR-373 miRNA cisplatin (DDP) triple negative breast cancer (TNBC) Exosomes were isolated from MDA-MB-231 cells cisplatin treatment upregulated 31424364 7753 Human hsa-miR-373-3p miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment lncRNA SNHG16 knockdown significantly limited the progression of OA by sponging miR-373-3p in vitro 33300061 7754 Human hsa-miR-373-3p miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine (GEM) treatment upregulated 25722110 7755 Human hsa-miR-373-3p miRNA lipopolysaccharide (LPS) sepsis-induced acute hepatic injury THLE-3 cells Lipopolysaccharide (LPS) treatment downregulated of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis. 33129786 7756 Human hsa-miR-374a miRNA isoliquiritigenin breast cancer "MDA-MB-231, MCF-7, BT474, 4T1, MCF-10A and 293 T" isoliquiritigenin treatment downregulated 28827662 7757 Human hsa-miR-374a miRNA high glucose (HG) diabetic nephropathy (DN) HK2 human renal tubular epithelial cells high glucose (HG) treatment downregulated 30147653 7758 Human hsa-miR-374a miRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment "Serum miR-374a was progressively accelerated in patients with NDR, NPDR and PDR than in healthy controls." 33941051 7759 Human hsa-miR-374a miRNA etoposide (VP-16) glioblastoma multiforme (GBM) "Human glioma cell lines A172, U118-MG and LN-18" Etoposide (VP-16) treatment knockdown of miR-374a was able to enhance the etoposide-induced cytotoxicity against glioma cells. 30841958 7760 Human hsa-miR-374a miRNA cisplatin (DDP) head and neck squamous cell carcinoma (HNSCC) Head and neck squamous cell carcinoma (HNSCC) cells cisplatin treatment downregulated 21274007 7761 Human hsa-miR-374a miRNA ferric ammonium citrate (FAC) liver fibrosis LO-2 cells ferric ammonium citrate (FAC) treatment downregulated 31171361 7762 Human hsa-miR-374a miRNA propofol (PPF) hepatocellular carcinoma (HCC) HepG2 and SMMC-7721 cells Propofol treatment downregulated 30257238 7763 Human hsa-miR-374a miRNA ¦Ã-rays irradiation-induced ischemic stroke HA-1800 cells ¦Ã-radiation treatment downregulated 29984671 7764 Human hsa-miR-374a miRNA propofol (PPF) ovarian cancer (OC) A2780 cells propofol treatment Propofol decreased miR-374a expression levels in A2780 cells 32016462 7765 Human hsa-miR-374a-5p miRNA TGF-¦Â1 hepatocarcinogenesis Hep3B cells TGF-¦Â1 treatment upregulated 32269736 7766 Human hsa-miR-374b miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 7767 Human hsa-miR-374b miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) "human HCC cell lines (Hep3B, HepG2, and HCCLM3)" sorafenib treatment The suppression of PKM2 by miR-374b re-sensitizes sorafenib-resistant HCC cells and mouse xenografts to sorafenib treatment by antagonizing glycolysis pathway. 31106002 7768 Human hsa-miR-374b miRNA melatonin prostate cancer hypoxic PC-3 cells melatonin treatment upregulated 25553085 7769 Human hsa-miR-374b miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 7770 Human hsa-miR-374b-5p miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment "The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35." 33279663 7771 Human hsa-miR-374b-5p miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y amyloid-¦Â (A¦Â) 25-35 treatment MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells. 33279663 7772 Human hsa-miR-374c-5p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) cervical squamous cell TGF¦Â1 treatment downregulated 28810526 7773 Human hsa-miR-375 miRNA tumor necrosis factor alpha (TNF-¦Á) allergic rhinitis (AR) Human nasal mucosa cells HNEpC tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29677549 7774 Human hsa-miR-375 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment "Overexpression of WT1-AS can inhibit the miR-375/SIX4 axis, OSI and neuronal apoptosis in AD by inhibiting WT1 expression." 33234729 7775 Human hsa-miR-375 miRNA PAX8/PPAR¦Ã fusion protein (PPFP) anaplastic thyroid carcinoma (ATC) "ATC cell lines: BHT-101; FRO, C-643; KTC-2;KTC-3" PAX8/PPAR¦Ã fusion protein (PPFP) treatment upregulated 23598436 7776 Human hsa-miR-375 miRNA ketamine anesthesia-induced neural cytotoxicity human embryonic stem cell (hESC)-derived neuron Ketamine treatment upregulated 30500346 7777 Human hsa-miR-375 miRNA phytoestrogens anti-cancer therapy "human osteosarcoma cell line, U2OS" Phytoestrogens treatment upregulated 26381132 7778 Human hsa-miR-375 miRNA platelet-derived growth factor (PDGF) asthma airway smooth muscle (ASM) cells platelet-derived growth factor (PDGF) treatment miR-375 expression was significantly decreased in fetal ASM cells that were treated with PDGF 29245068 7779 Human hsa-miR-375 miRNA biochanin A breast cancer breast cancer cells biochanin A treatment upregulated 25613180 7780 Human hsa-miR-375 miRNA biochanin A breast cancer "ER¦Á-positive breast cancer cells (T47D, MCF-7)" biochanin A treatment upregulated 25613180 7781 Human hsa-miR-375 miRNA formononetin breast cancer "HUVEC cells, MCF-7 cells" Formononetin treatment upregulated 25663261 7782 Human hsa-miR-375 miRNA tamoxifen (TAM) breast cancer "The human breast cancer cell lines, MCF-7 and MDA-MB-231, and lung cancer cell lines, H1703 and H1299 ;HEK-293FT cells and The human ovarian cancer cell line, Ovcar-5" tamoxifen treatment downregulated 22508479 7783 Human hsa-miR-375 miRNA formononetin cell proliferation "HUVEC, MCF-7" Formononetin treatment upregulated 25663261 7784 Human hsa-miR-375 miRNA doxorubicin (DOX) cell senescence K562 cells Doxorubicin (DOX) treatment upregulated 22606351 7785 Human hsa-miR-375 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cervical cancer (CC) "cervical cell lines SiHa, CaSki and HeLa" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31326568 7786 Human hsa-miR-375 miRNA folic acid cervical cancer (CC) CaSki cells folic acid treatment upregulated 27313708 7787 Human hsa-miR-375 miRNA paclitaxel (PTX) cervical cancer (CC) SiHa and Caski cells paclitaxel treatment upregulated 23778521 7788 Human hsa-miR-375 miRNA paclitaxel (PTX) cervical cancer (CC) "two human cervical cancer cell lines, SiHa and CaSki" paclitaxel treatment upregulated 25330011 7789 Human hsa-miR-375 miRNA high-risk human papillomavirus (hrHPV) cervical cancer (CC) The HPV16-immortalized keratinocyte cellline FK16A high-risk human papillomavirus (hrHPV)infection downregulated 22987659 7790 Human hsa-miR-375 miRNA formaldehyde chronic respiratory disease (CRD) human bronchial epithelial cells 16HBE formaldehyde treatment downregulated 31172816 7791 Human hsa-miR-375 miRNA high glucose (HG) diabetic nephropathy (DN) enteric glia cell (EGC) high glucose treatment upregulated 30140011 7792 Human hsa-miR-375 miRNA cyclic hydroxamic acid-containing peptide 31 (CHAP31) esophageal squamous cell carcinoma (ESCC) The human ESCC cell lines ( T.Tn cells; TE2 cells; CHAP31 ) cyclic hydroxamic acid-containing peptide 31 (CHAP31) treatment upregulated 22752059 7793 Human hsa-miR-375 miRNA imatinib and lapatinib fulvestrant-resistant breast cancer fulvestrant-resistant breast cancer (FRBC) MCF-7 cells imatinib+lapatinib dual treatment upregulated 29522716 7794 Human hsa-miR-375 miRNA cisplatin (DDP) gastric cancer (GC) human gastric cancer cells cisplatin treatment downregulated 26893657 7795 Human hsa-miR-375 miRNA lipopolysaccharide (LPS) gastric cancer (GC) gastric epithelial cells lipopolysaccharide (LPS) treatment downregulated 25307786 7796 Human hsa-miR-375 miRNA lipopolysaccharide (LPS) gastric cancer (GC) "human gastric epithelial cell lines, AGS and MKN45" LPS from H. pylori 26695 treatment downregulated 25307786 7797 Human hsa-miR-375 miRNA soft-shelled turtle peptide gastric cancer (GC) human GC AGS cells soft-shelled turtle peptide treatment differentlly regulated 29435044 7798 Human hsa-miR-375 miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment upregulated 29435044 7799 Human hsa-miR-375 miRNA everolimus hepatocellular carcinoma (HCC) "Human HCC cell lines PLC/PRF/5, and JHH-6" everolimus (EVE) treatment downregulated 31406139 7800 Human hsa-miR-375 miRNA hypoxia hepatocellular carcinoma (HCC) HCCs hypoxia treatment "MiR-375 presented an obviously differential expression in human HCCs versus background livers (BLs) and HCCs versus normal liver tissues (NLTs). In rat models, miR-375 was gradually declined during hepatocarcinogenesis." 32215815 7801 Human hsa-miR-375 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7 cells Sorafenib treatment downregulated 32431510 7802 Human hsa-miR-375 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Hep3B cells; HepG2 cells sorafenib treatment downregulated 32616906 7803 Human hsa-miR-375 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" human papillomaviruses (HPV) infection Ca Ski and SiHa cell "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28521287 7804 Human hsa-miR-375 miRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection human foreskin keratinocytes Using CD4+ T-cells expressing only Human immunodeficiency virus (HIV)-1 envelope inoculated on human adult foreskin tissues upregulated 28443609 7805 Human hsa-miR-375 miRNA acidic bile hypopharyngeal cancer human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) acidic bile exposure downregulated 29516639 7806 Human hsa-miR-375 miRNA BAY11-7082 hypopharyngeal cancer Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) BAY 11-7082 treatment upregulated 29516639 7807 Human hsa-miR-375 miRNA helicobacter pylori (H. pylori) helicobacter pylori (H. pylori) infection GES-1 and BGC-823 cells H. pylori infection treatment downregulated 24718681 7808 Human hsa-miR-375 miRNA ketamine ketamine-induced neurotoxicity human embryonic stem cell (hESC) ketamine treatment upregulated 30500346 7809 Human hsa-miR-375 miRNA ASH1 lung cancer CLC cell line; ACC-LC-172; A549 cells The transcription factor ASH1 treatment upregulated 21856745 7810 Human hsa-miR-375 miRNA SGI-110 and/or trichostatin A multiple myeloma (MM) human myeloma cell lines (HMCLs) SGI-110 and/or trichostatin A treatment upregulated 28439875 7811 Human hsa-miR-375 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 7812 Human hsa-miR-375 miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells palmiticacid (PA) treatment upregulated 29569260 7813 Human hsa-miR-375 miRNA radiation non-small cell lung cancer (NSCLC) non-small cell lung cancer (NSCLC) tissues radiation treatment downregulated 32940043 7814 Human hsa-miR-375 miRNA teriparatide (TP) osteoporosis human marrow mesenchymal cells (hMSCs) teriparatide (TP) treatment downregulated 31858576 7815 Human hsa-miR-375 miRNA platelet-derived growth factor (PDGF) pediatric asthma human fetal airway smooth muscle cells PDGF treatment downregulated 29245068 7816 Human hsa-miR-375 miRNA docetaxel (DTX) prostate cancer DU145 and PC-3 cells docetaxel (DTX) treatment upregulated 27832783 7817 Human hsa-miR-375 miRNA TGF-¦Â lung fibrosis human lung fibroblasts TGF-¦Â treatment miR-375 was markedly upregulated in human lung fibroblasts after TGF-¦Â stimulation 32582987 7818 Human hsa-miR-375 miRNA trichostatin A (TSA) tongue squamous cell carcinoma (TSCC) human tongue cancer cell lines SCC-15 and CAL27 human tongue cancer cell lines SCC-15 and CAL27 treatment upregulated 27878285 7819 Human hsa-miR-375 miRNA trichostatin A (TSA) tongue squamous cell carcinoma (TSCC) human tongue cancer cell lines SCC-15 and CAL27 TSA treatment upregulated 27878285 7820 Human hsa-miR-375 miRNA "polycistronic viral vector expressing Sox2, Klf4, c-Myc, and Oct4" type 1 diabetes mellitus (T1DM) hiPSCs from human foreskin fibroblasts polycistronic viral vector treatment upregulated 24469711 7821 Human hsa-miR-375 miRNA formononetin vascular endothelial cells (ECs) proliferation human umbilical vein endothelial cells (HUVECs) Formononetin (Form) treatment upregulated 29722068 7822 Human hsa-miR-375 miRNA androgen adipogenic differentiation mature adipocytes androgen treatment downregulated 26219823 7823 Human hsa-miR-375 miRNA particulate matter (PM) and diesel exhaust particles (DEP) asthma ?human bronchial epithelial cells particulate matter (PM) and diesel exhaust particles (DEP) treatment upregulated 23455502 7824 Human hsa-miR-375 miRNA radiation and etoposide gastric cancer (GC) gastric cancer cell lines(BGC823; MGC803; SGC7901;AGS; N87;MKN45) radiation and etoposide treatment upregulated 23835407 7825 Human hsa-miR-375-3p miRNA hypoxia congenital heart disease (CHD) serum hypoxia induce miR-375-3p was upregulated and FOXP1/Bcl2l2 was downregulated in maternal serum of women with fetal CHD and hypoxia-induced rat cardiomyocyte h9c2 cells. 33128129 7826 Human hsa-miR-375-3p miRNA solasonine (SS) hepatocellular carcinoma (HCC) "HepG2 cells, QGY-7703 cells" Solasonine (SS) treatment upregulated 31681610 7827 Human hsa-miR-376 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" hepatocellular carcinoma (HCC) "everolimus (EVE) resistant PLC/PRF/5, and JHH-6 cells" "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 31406139 7828 Human hsa-miR-376 miRNA human cytomegalovirus (HCMV) human cytomegalovirus (HCMV) infection HFF cells infect with HCMV upregulated 24586166 7829 Human hsa-miR-376a miRNA esomeprazole adeno and squamous-cell-carcinoma human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines esomeprazole treatment downregulated 25175076 7830 Human hsa-miR-376a miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) HCMEC/D3 cells Oxygen-glucose deprivation (OGD) treatment LncRNA SNHG1 depressed apoptosis and inflammation of IS cell model via inhibiting miR-376a and upregulating CBS/H2S signal 32532171 7831 Human hsa-miR-376a miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 7832 Human hsa-miR-376a miRNA N-succinimidyl N-methylcarbamate pancreatic cancer (PC) Normal human pancreatic ductal epithelial (HPDE-6) cells Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate upregulated 24563415 7833 Human hsa-miR-376a miRNA arsenic trioxide (ATO) retinoblastoma (RB) retinoblastoma cells arsenic trioxide?treatment downregulated 23373993 7834 Human hsa-miR-376b-3p miRNA matrine acute lymphoblastic leukemia (ALL) CCRF-CEM cells matrine treatment downregulated 29045804 7835 Human hsa-miR-376c miRNA IL-1¦Â osteosarcoma (OS) hFOB;Saos2;MG63;U2OS;SW1353 IL-1¦Â?treatmrnt upregulated 29441940 7836 Human hsa-miR-376c miRNA Thrombospondin-1 (TSP-1) prostate cancer human PCa cells TSP-1 treatment downregulated 28122633 7837 Human hsa-miR-376c miRNA bacillus calmette-guerin (BCG) tuberculosis (TB) TB patients bacillus calmette-guerin (BCG) treatment upregulated 24586438 7838 Human hsa-miR-376c-3p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 7839 Human hsa-miR-376c-3p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment upregulated 25129238 7840 Human hsa-miR-376c-3p miRNA oxygen glucose deprivation (OGD) neonatal hypoxic-ischemic encephalopathy SH-SY5Y cells oxygen-glucose deprivation (OGD) treatment downregulated 31844418 7841 Human hsa-miR-376C-3p miRNA titanium surface implant-host tissue interactions osteoblastic cells from human alveolar bone osteoblastic cells from human alveolar bone treatment dysregulated 27200092 7842 Human hsa-miR-377 miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment downregulated 27158236 7843 Human hsa-miR-377 miRNA Korean Red ginseng extract (KRGE) angiogenesis HUVECs korean red ginseng extract (KRGE)? treatment downregulated 29021694 7844 Human hsa-miR-377 miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment downregulated 27158236 7845 Human hsa-miR-377 miRNA zirconia and titanium bone formation Osteoblast-like cells (MG63) zirconia and titanium? treatment upregulated 18241218 7846 Human hsa-miR-377 miRNA high glucose (HG) diabetic nephropathy (DN) Primary cultures of normal human mesangial cells (NHMCs) high glucose treatment upregulated 18716028 7847 Human hsa-miR-377 miRNA TGF-¦Â diabetic nephropathy (DN) Primary cultures of normal human mesangial cells (NHMCs) transforming growth factor-¦Â treatment ?upregulated 18716028 7848 Human hsa-miR-377 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells high glucose treatment upregulated 30706373 7849 Human hsa-miR-377 miRNA hypoxia diabetic retinopathy (DR) human retinal endothelial cells hypoxia induce upregulated 30706373 7850 Human hsa-miR-377 miRNA hypoxia ischemic heart disease (IHD) Hypoxic MSCs "cultured in DMEM without glucose and with 1% FBS under hypoxic conditions of 1% O2, 5% CO2 treatment" downregulated 25251394 7851 Human hsa-miR-377 miRNA gefitinib lung adenocarcinoma (LUAD) PC9 cells; A549 cells gefitinib treatment upregulated 29592872 7852 Human hsa-miR-377 miRNA carbamate lung cancer Normal human bronchial epithelial (NHBE) cells carbamate treatment upregulated 19748927 7853 Human hsa-miR-377 miRNA hypoxia/reoxygenation (H/R) myocardial ischaemic injury human neonatal cardiomyocytes hypoxia/reoxygenation (H/R) treatment miR-377 expression was downregulated in cardiomyocyte exposed to H/R. 32647500 7854 Human hsa-miR-377 miRNA andrographolide oxidative stress HepG2 cells andrographolide treatment downregulated 30414976 7855 Human hsa-miR-377 miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 7856 Human hsa-miR-377 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 7857 Human hsa-miR-377 miRNA titanium (Ti) particle wear particle-induced osteolysis (PIO) Bone marrow macrophages (BMMs) titanium (Ti) particle treatment downregulated 30958621 7858 Human hsa-miR-377-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment MiR-377-3p inhibits atherosclerosis-associated vascular smooth muscle cell proliferation and migration via targeting neuropilin2. 32373927 7859 Human hsa-miR-377-3p miRNA IL-1¦Â osteoarthritis (OA) Normal human articular chondrocytes IL-1¦Â treatment downregulated 31831175 7860 Human hsa-miR-377-3p miRNA oleanolic acid (OLA) osteoarthritis (OA) chondrocytes oleanolic acid (OLA) treatment downregulated 32028542 7861 Human hsa-miR-377-3p miRNA cisplatin (DDP) osteosarcoma (OS) MG63 cells; Saos-2 cells cisplatin treatment OIP5-AS1 positively modulated FOSL2 expression to decrease CDDP sensitivity in OS by sponging miR-377-3p. 32440152 7862 Human hsa-miR-377-3p miRNA tuberculosis (MTB) tuberculosis (TB) THP-1 cells Mycobacterium tuberculosis (MTB) infection treatment downregulated 33271233 7863 Human hsa-miR-378 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 7864 Human hsa-miR-378 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) Human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) exposure downregulated 31696490 7865 Human hsa-miR-378 miRNA acute exercise congestive heart failure (CHF) CHF patients acute exercise treatment upregulated 26799589 7866 Human hsa-miR-378 miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment downregulated 19022373 7867 Human hsa-miR-378 miRNA Fatty acid nonalcoholic fatty liver disease (NAFLD) HepG2 cells Fatty acid treatment miR-378 was significantly increased in Fatty acid treated human hepatoma HepG2 cells. 29625129 7868 Human hsa-miR-378 miRNA oleacein (OA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells oleate treatment upregulated 30281809 7869 Human hsa-miR-378 miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 7870 Human hsa-miR-378 miRNA IL-6 obesity matured human adipocytes "TNF-¦Á, IL-6, leptin, or resistin treatment" upregulated 24771406 7871 Human hsa-miR-378 miRNA leptin obesity matured human adipocytes "TNF-¦Á, IL-6, leptin, or resistin treatment" upregulated 24771406 7872 Human hsa-miR-378 miRNA resistin obesity matured human adipocytes "TNF-¦Á, IL-6, leptin, or resistin treatment" upregulated 24771406 7873 Human hsa-miR-378 miRNA tumor necrosis factor alpha (TNF-¦Á) obesity matured human adipocytes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 24771406 7874 Human hsa-miR-378 miRNA high-intensity interval training (HIIT) skeletal muscle adaptation human human treatment downregulated 27101297 7875 Human hsa-miR-378 miRNA resistance exercise training skeletal muscle hypertrophy Vastus lateralis biopsies resistance exercise training treatment downregulated 21030674 7876 Human hsa-miR-378 miRNA adipokines systemic adipose tissue inflammation human visceral preadipocytes adipokines and inflammatory cytokines on treatment upregulated 24923530 7877 Human hsa-miR-378-3p miRNA morphine morphine tolerance Be(2)C cells morphine treatment Chronic morphine treatment significantly increased the miR-378-3p level in Be(2)C cells. 31999011 7878 Human hsa-miR-378a-3p miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment downregulated 26151338 7879 Human hsa-miR-378a-3p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7; HCCLM3; SK-HEP-1 sorafenib treatment downregulated 32754282 7880 Human hsa-miR-378a-3p miRNA radiation tumor radiotherapy U87 cells-derived exosome radiation treatment upregulated 32267172 7881 Human hsa-miR-378a-5p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment upregulated 28951593 7882 Human hsa-miR-378a-5p miRNA forskolin (FSK) choriocarcinoma human choriocarcinoma cell line BeWo forskolin treatment downregulated 25122062 7883 Human hsa-miR-378a-5p miRNA IL-1¦Â osteoarthritis (OA) OA synovial explants IL-1¦Âtreatment upregulated 27143365 7884 Human hsa-miR-378b miRNA arctiin antiviral immune response normal human dermal fibroblasts (nHDFs) arctiin treatment downregulated 28990056 7885 Human hsa-miR-378b miRNA ultraviolet (UV) irradiation dermal fibroblasts aging human dermal fibroblasts (HDFs) UVB-exposed treatment upregulated 28983623 7886 Human hsa-miR-378b miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment downregulated 29435044 7887 Human hsa-miR-378b miRNA titanium dioxide nanoparticles (TiO2 NPs) TiO2-NPs-mediated colonic cytotoxicity NCM460 cells; HCT116 cells Titanium dioxide nanoparticles (TiO2-NPs) treatment upregulated 32423014 7888 Human hsa-miR-378c miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human bronchial epithelial (16HBE) cells infect with EV71 and CA16 dysregulated 27890633 7889 Human hsa-miR-378c miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) Human bronchial epithelial (16HBE) cells Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment dysregulated 27890633 7890 Human hsa-miR-378d miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 7891 Human hsa-miR-378d miRNA sodium fluoride (NaF) female reproductive dysfunction KGN cells sodium fluoride (NaF) treatment The miR-378d was the most significantly upregulated one dose dependently by NaF 33405077 7892 Human hsa-miR-378f miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 7893 Human hsa-miR-378g miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 7894 Human hsa-miR-378g miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment miR-378g was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs. 33125125 7895 Human hsa-miR-378g miRNA vitamin C oxidative stress human umbilical vein endothelial cells (HUVECs) vitamin C treatment miR-miR-378g was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2. 33125125 7896 Human hsa-miR-378g miRNA titanium dioxide nanoparticles (TiO2 NPs) TiO2-NPs-mediated colonic cytotoxicity HCT116 cells Titanium dioxide nanoparticles (TiO2-NPs) treatment upregulated 32423014 7897 Human hsa-miR-378g miRNA titanium dioxide nanoparticles (TiO2 NPs) TiO2-NPs-mediated colonic cytotoxicity NCM460 cells Titanium dioxide nanoparticles (TiO2-NPs) treatment downregulated 32423014 7898 Human hsa-miR-378h miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment downregulated 26151338 7899 Human hsa-miR-378h miRNA estradiol endothelial dysfunction human umbilical vein endothelial cells (HUVEC) estradiol treatment downregulated 29510375 7900 Human hsa-miR-378h miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment downregulated 29435044 7901 Human hsa-miR-378i miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment downregulated 26151338 7902 Human hsa-miR-379 miRNA coenzyme Q10 (CoQ10) atherosclerosis (AS) human THP-1 macrophages CoQ10 treatment downregulated 24675663 7903 Human hsa-miR-379 miRNA genistein hepatocellular carcinoma (HCC) HepG2 cells Genistein (GNT) treatment downregulated 25781341 7904 Human hsa-miR-379 miRNA rifampicin hepatocellular carcinoma (HCC) HepG2 cells rifampicin treatment a miRNA negatively regulating ABCC2 on the post-transcriptional level and provide evidence that this miRNA impedes overexpression of ABCC2 protein after a PXR-mediated external transcriptional stimulus 21540293 7905 Human hsa-miR-379-5p miRNA arsenite arsenite-induced liver damage L-02 cells arsenite exposure downregulated 30643918 7906 Human hsa-miR-380 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) Human Bronchial Epithelial (HBE) cells cigarette smoke extract (CSE) treatment miR-380 showed a tendency of high expression in COPD patients and CSE models. 31821848 7907 Human hsa-miR-380 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) Human Bronchial Epithelial cells cigarette smoke extract (CSE) exposure upregulated 31821848 7908 Human hsa-miR-380-3p miRNA cigarette smoke (CS) chronic obstructive pulmonary disease (COPD) lung tissue cigarette smoke (CS) exposure upregulated 31819170 7909 Human hsa-miR-381 miRNA sulforaphane (SFN) breast cancer "breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)" SFN (5-10 ?M) treatment downregulated 28912888 7910 Human hsa-miR-381 miRNA oxidized low density lipoprotein (ox-LDL) coronary heart disease (CHD) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment Protective effect of microRNA-381 against inflammatory damage of endothelial cells during coronary heart disease by targeting CXCR4. 32016478 7911 Human hsa-miR-381 miRNA periostin epithelial-mesenchymal transition (EMT) human lung adenocarcinoma cell line A549 periostin treatment downregulated 28977942 7912 Human hsa-miR-381 miRNA radiotherapy esophageal cancer (EC) tissues from primary ESCC and recurrent ESCC in situ after radiotherapy radiotherapy treatment downregulated 25628936 7913 Human hsa-miR-381 miRNA metformin (Met) non-small cell lung cancer (NSCLC) A549 cells metformin treatment Metformin dose- and time- dependently increased the RNA level of miR-381. 31906986 7914 Human hsa-miR-381 miRNA lipopolysaccharide (LPS) respiratory infections A549 cells lipopolysaccharide (LPS) treatment upregulated 26688820 7915 Human hsa-miR-381 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 7916 Human hsa-miR-381-3p miRNA kartogenin chondrogenesis Small extracellular vesicles (sEVs) derived from human umbilical cord mesenchymal stem cells (hUCMSCs) kartogenin preconditioned upregulated 31864017 7917 Human hsa-miR-381-3p miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human primary monocyte-derived macrophages infect with HIV-1 upregulated 28594894 7918 Human hsa-miR-381-3p miRNA hypoxia intestinal ischemia/reperfusion (I/R) injury Caco-2 cells hypoxia induce upregulated 29706629 7919 Human hsa-miR-381-3p miRNA Hypoxia nasopharyngeal carcinoma (NPC) HK-1 and C666-1 hypoxia treatment "XIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis, providing new insights into the pathogenesis of NPC." 32196601 7920 Human hsa-miR-381-3p miRNA "4,4'-methylene diphenyl diisocyanate (MDI)" occupational asthma (OA) THP-1 cells "4,4'-methylene diphenyl diisocyanate (MDI) treatment" Both in vivo murine MDI aerosol exposure and in vitro MDI-GSH exposures in THP-1 macrophages result in downregulated of endogenous miR-206-3p and miR-381-3p and upregulation of PPP3CA and iNOS expression. 31609387 7921 Human hsa-miR-381-3p miRNA fingolimod relapsing-remitting multiple sclerosis (RRMS) peripheral blood Fingolimod treatment upregulated 32215780 7922 Human hsa-miR-382 miRNA hypoxia gastric cancer (GC) MKN1 human gastric cancer cells hypoxia treatment upregulated 24914051 7923 Human hsa-miR-382 miRNA sulforaphane (SFN) breast cancer "breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)" SFN (5-10 ?M) treatment downregulated 28912888 7924 Human hsa-miR-382 miRNA polydatin (PD) colorectal cancer (CRC) The CRC cell lines (Caco-2 and HCT 116) Polydatin treatment upregulated 31755739 7925 Human hsa-miR-382 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human kidney epithelial cell HK-2 transforming growth factor-¦Â1 (TGF-¦Â1) treatment "Knockdown of miR-382, which was upregulated by TGF-¦Â1,attenuated TGF-¦Â1-induced loss of the epithelial marker E-cadherin" 20716515 7926 Human hsa-miR-382 miRNA heroin human immunodeficiency virus (HIV)-1 infection Peripheral blood Heroin treatment downregulated 26583016 7927 Human hsa-miR-382 miRNA morphine human immunodeficiency virus (HIV)-1 infection peripheral blood mononuclear cells(PBMCs) morphine treatment downregulated 21224041 7928 Human hsa-miR-382 miRNA curcumin (Cur) prostate cancer DU145 cells; 22Rv1 cells curcumin treatment downregulated 29172709 7929 Human hsa-miR-382 miRNA propranolol (PRO) infantile hemangioma (IH) XPTS-1 cells propranolol treatment downregulated 28112362 7930 Human hsa-miR-382 miRNA phosphorus (Pi) vascular calcification (VC) human aortic vascular smooth muscle cells high levels of phosphate treatment downregulated 28522697 7931 Human hsa-miR-382-3p miRNA IL-1¦Â osteoarthritis (OA) human OA chondrocytes IL-1¦Â treatment downregulated 31144313 7932 Human hsa-miR-382-5p miRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) NB4 cells all-trans retinoic acid (ATRA) treatment upregulated 30453015 7933 Human hsa-miR-382-5p miRNA TGF-¦Â epidural fibrosis Primary human fibroblasts TGF-¦Â treatment upregulated 29949138 7934 Human hsa-miR-382-5p miRNA diesel exhaust particle (DEP) PM 2.5 or DEPs-induced inflammatory response HBE cells diesel exhaust particle (DEP) exposure The expression level of miR-382-5p was downregulated after exposure to DEPs. 32146367 7935 Human hsa-miR-382-5p miRNA particulate matter (PM2.5) PM 2.5 or DEPs-induced inflammatory response HBE cells fine particulate matter (PM 2.5) exposure treatment The expression level of miR-382-5p was downregulated in HBE cells after exposure to PM 25 32146367 7936 Human hsa-miR-382-5p miRNA TGF-¦Â1 primary myelofibrosis (PMF) PMF CD34+ cells transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 30259659 7937 Human hsa-miR-383 miRNA high glucose (HG) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 31994599 7938 Human hsa-miR-383 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 human RPE cell lines high glucose upregulated 28559987 7939 Human hsa-miR-383 miRNA high glucose (HG) diabetic retinopathy (DR) high glucose treatment AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of ARPE-19 cells by downregulating miR-383. 31391356 7940 Human hsa-miR-383 miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment downregulated 24589211 7941 Human hsa-miR-383-5p miRNA resveratrol diabetic nephropathy (DN) human podocytes resveratrol (RS) treatment downregulated 28374806 7942 Human hsa-miR-384 miRNA luteolin colorectal cancer (CRC) HT-29 cells "Luteolin (3,4,5,7-tetrahydroxyflavone) treatment" upregulated 31059061 7943 Human hsa-miR-384 miRNA high glucose (HG) endothelial dysfunction human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment CircBPTF knockdown protected against HG-induced inflammatory injuries and oxidative stress by mediating the miR-384/LIN28B axis in HUVECs. 32524321 7944 Human hsa-miR-384 miRNA curcumin (Cur) non-small cell lung cancer (NSCLC) "NSCLC cells (H1650, H1299, H460, A549)" curcumin treatment "After curcumin treatment, the expression tendency of circ-PRKCA, miR-384, and ITGB1 in NSCLC cells was overturned." 33684690 7945 Human hsa-miR-3907 miRNA radon lung cancer BEAS-2B cells radon treatment upregulated 33447367 7946 Human hsa-miR-3911 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 7947 Human hsa-miR-3923 miRNA radix tetrastigma hemsleyani (RTH) lung cancer A549 cells radix tetrastigma hemsleyani (RTH) treatment downregulated 30100735 7948 Human hsa-miR-3928 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment downregulated 29860902 7949 Human hsa-miR-3928-5p miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment miR-3928-5p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs. 33125125 7950 Human hsa-miR-3928-5p miRNA vitamin C oxidative stress human umbilical vein endothelial cells (HUVECs) vitamin C treatment miR-3928-5p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2. 33125125 7951 Human hsa-miR-3928v miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HBV (+) HCC tissues hepatitis B virus (HBV) infection upregulated 29378599 7952 Human hsa-miR-3929 miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 7953 Human hsa-miR-3935 miRNA sodium butyrate (NaB) lung cancer A549 cells sodium butyrate(NaB) treatment upregulated 29231270 7954 Human hsa-miR-3940-5p miRNA thymosin ¦Á1 (T¦Á1) non-segmental vitiligo (NSV) peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV) thymosin ¦Á1 (T¦Á1) treatment downregulated 25495156 7955 Human hsa-miR-3941 miRNA lipopolysaccharide (LPS) acute pancreatitis (AP) A549 cells lipopolysaccharides (LPS) treatment downregulated 29328418 7956 Human hsa-miR-3941 miRNA lipopolysaccharide (LPS) acute pneumonia A549 cells lipopolysaccharide (LPS) treatment LPS treatment also resulted in a significantly decreased expression of miR-3941 in A549 cells. 29328418 7957 Human hsa-miR-399-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aorta vascular smooth muscle cells (HA-VSMCs); human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment ANRIL promoted AS progression by sponging miR-399-5p and regulating RAS/RAF/ERK signal pathway. 32141564 7958 Human hsa-miR-409-3p miRNA resveratrol breast cancer breast cancer cell resveratrol (RS) treatment downregulated 26890143 7959 Human hsa-miR-409-3p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 7960 Human hsa-miR-410 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29518604 7961 Human hsa-miR-410 miRNA human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) early non-genotoxic events HepaRG cells human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) treatment upregulated 26609139 7962 Human hsa-miR-410 miRNA aflatoxin B1 (AFB1) genotoxicity HepaRG cells aflatoxin B1 (AFB1) treatment upregulated 26609139 7963 Human hsa-miR-410 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 7964 Human hsa-miR-410 miRNA andes hantavirus (ANDV) liver damage human endothelial cells (ECs) andes hantavirus (ANDV) infection downregulated 20844033 7965 Human hsa-miR-410 miRNA TGF-¦Â3 osteoarthritis (OA) human bone marrow mesenchymal stem cells TGF-¦Â3 treatment upregulated 28123640 7966 Human hsa-miR-410 miRNA "rapamycin, doxorubicin , cisplatin" osteosarcoma (OS) U2OS and MG-63 human osteosarcoma cell lines "rapamycin, doxorubicin , cisplatin treatment" upregulated 28138700 7967 Human hsa-miR-410 miRNA vascular endothelial growth factor (VEGF) osteosarcoma (OS) OS cell lines VEGF treatment "restoration of VEGF reversed the effect of miR-410 on OS cells, and upregulated the expression of phosphorylated AKT" 25385479 7968 Human hsa-miR-410 miRNA 6-hydroxydopamine (6-OHDA) parkinson's disease (PD) SH-SY5Y cells 6-hydroxydopamine (6-OHDA) treatment downregulated 31067440 7969 Human hsa-miR-410 miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment upregulated 21093163 7970 Human hsa-miR-410 miRNA vascular endothelial growth factor (VEGF) pulmonary arterial hypertension (PAH) human pulmonary artery endothelial cells (hPAECs) vascular endothelial growth factor (VEGF) treatment downregulated 31289307 7971 Human hsa-miR-410-3p miRNA vemurafenib melanoma A375 cells; G361 cells; SKMEL1 cells vemurafenib treatment miR-410-3p is induced by vemurafenib. 32555626 7972 Human hsa-miR-410-3p miRNA calcium chloride or osteogenic medium osteogenic-like differentiation human renal interstitial fibroblasts (hRIFs) calcium chloride or osteogenic medium treatment Suppression of osteogenic-like differentiation in human renal interstitial fibroblasts by miRNA-410-3p through MSX2 33209671 7973 Human hsa-miR-410-3p miRNA magnoflorine osteosarcoma (OS) MG-63 cells; U-2 OS cells Magnoflorine treatment "Magnoflorine significantly suppressed HMGB1 expression and NF-¦ÊB activation, but upregulated miR-410-3p level." 32553931 7974 Human hsa-miR-410-3p miRNA gemcitabine (GEM) pancreatic cancer (PC) human pancreatic cancer xenograft (HPCx) in mouse gemcitabine treatment downregulated 29296182 7975 Human hsa-miR-411 miRNA curcumin (Cur) prostate cancer 22Rv1 cells curcumin treatment upregulated 29172709 7976 Human hsa-miR-411 miRNA IL-1¦Â osteoarthritis (OA) C28/I2 cells IL-1¦Â treatment miRNA-411 Regulates Chondrocyte Autophagy in Osteoarthritis by Targeting Hypoxia-Inducible Factor 1 alpha (HIF-1¦Á) 32072994 7977 Human hsa-miR-411 miRNA a moderate-carbohydrate and low glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and low glycemic index diet downregulated 29233588 7978 Human hsa-miR-421 miRNA "chlorpromazine, haloperidol and clozapine" psychosis JM-Jurkat T-lymphocytes "chlorpromazine, haloperidol and clozapine treatment" dysregulated 24480591 7979 Human hsa-miR-421 miRNA lidocaine cervical cancer (CC) HeLa cells lidocaine treatment lidocaine inhibited the growth of cervical cancer cells by modulating the lncRNA-MEG3/miR-421/BTG1 signaling pathway 31632519 7980 Human hsa-miR-421 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) human GC MGC-803 cells 5-fluorouracil (5-FU) treatment upregulated 31115533 7981 Human hsa-miR-421 miRNA Helicobacter pylori (H. pylori) extract (HPE) gastric cancer (GC) HGC-27 cells Helicobacter pylori (H. pylori) infection upregulated 33065487 7982 Human hsa-miR-421 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) A172 cells; U251 cells temozolomide (TMZ) treatment "Circ-HIPK3 was obviously increased in TMZ-resistant glioma cells and their exosomes, miR-421, was downregulated in TMZ-resistant glioma" 32644821 7983 Human hsa-miR-421 miRNA lidocaine hepatocellular carcinoma (HCC) HCC cells ?lidocaine treatment "circ_ITCH and CPEB3 levels were decreased in hepatocellular carcinoma tissues and cells, and were restored in cells via lidocaine treatment" 33433806 7984 Human hsa-miR-421 miRNA bitter melon seed water extract (BMSW) hepatocellular carcinoma (HCC) HepG2 cells Bitter melon seed water extract (BMSW) treatment The expression level of miR-421 in HepG2 was distinctly downregulated by 13.74 fold with 600 ?g/ml of BMSW. 33844303 7985 Human hsa-miR-421 miRNA tunicamycin (TM) vitiligo human melanocytes tunicamycin (TM) treatment upregulated 31974624 7986 Human hsa-miR-422a miRNA "chenodeoxycholic acid, GW4064" bile acid synthesis human primary hepatocytes "chenodeoxycholic acid, GW4064 treatment" upregulated 20351063 7987 Human hsa-miR-422a miRNA fibroblast growth factor 19 ( FGF19) bile acid synthesis human primary hepatocytes fibroblast growth factor ( FGF)19 treatment upregulated 20351063 7988 Human hsa-miR-422a miRNA doxorubicin (DOX) gastric cancer (GC) BGC823 cells doxorubicin (DOX) treatment The results showed that the miR-422a level was markedly elevated 6 hr after DOX stimulation. 30195778 7989 Human hsa-miR-422a miRNA IFN-¦Á human immunodeficiency virus (HIV)-1 infection PBMC TNF-¦Á treatment downregulated 25275557 7990 Human hsa-miR-422a miRNA tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) lung cancer NCI cells; FaDu cells tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment downregulated 32326378 7991 Human hsa-miR-422a miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) neuron apoptosis SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 32999283 7992 Human hsa-miR-422a miRNA metformin (Met) nonalcoholic fatty liver disease (NAFLD) HepG2 cells; primary human hepatocytes (HH) metformin treatment upregulated 32143184 7993 Human hsa-miR-422a miRNA palmitic acid (PA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells; primary human hepatocytes (HH) palmitic acid (PA) treatment downregulated 32143184 7994 Human hsa-miR-422a miRNA TGF-¦Â1 oral squamous cell carcinoma (OSCC) "human OSCC cell lines (Te13, Te1 , Eca109)" TGF-¦Â1 treatment Microarray analysis revealed that miR-422a exhibited the greatest downregulated (fold change: 022) in the presence of TGF-¦Â1 33107637 7995 Human hsa-miR-422a miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment miR-422a was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs. 33125125 7996 Human hsa-miR-422a miRNA vitamin C oxidative stress human umbilical vein endothelial cells (HUVECs) vitamin C treatment miR-422a was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2. 33125125 7997 Human hsa-miR-422a miRNA high iodine thyroid cancer (TC) "TPC-1cells, K1 cells and Nthy-3 cells" high iodine downregulated 28992617 7998 Human hsa-miR-423 miRNA lipopolysaccharide (LPS) acute inflammatory response HMEEC lipopolysaccharide (LPS) treatment upregulated 21377743 7999 Human hsa-miR-423 miRNA zirconia and titanium bone formation Osteoblast-like cells (MG63) zirconia and titanium? treatment upregulated 18241218 8000 Human hsa-miR-423 miRNA lanthionine lanthionine toxicity EA.hy926 cell cultures lanthionine treatment downregulated 31071929 8001 Human hsa-miR-423 miRNA a moderate-carbohydrate and low glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and low glycemic index diet downregulated 29233588 8002 Human hsa-miR-423 miRNA low fat diet (LFD) overweight and obese plasma low fat diet (LFD) treatment downregulated in plasma 29233590 8003 Human hsa-miR-423 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 8004 Human hsa-miR-423 miRNA amB with copper (II) ions (AmB-Cu2+) renal fibrosis normal human renal proximal tubule epithelial cells (RPTEC) complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower upregulated 28534445 8005 Human hsa-miR-423-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 8006 Human hsa-miR-423-5 miRNA IL-1¦Â disc degeneration NP cells IL-1¦Â treatment upregulated 32467560 8007 Human hsa-miR-423-5p miRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) human kidney (HK-2) cells hypoxia/reoxygenation (H/R) treatment upregulated 29137244 8008 Human hsa-miR-423-5p miRNA T-helper type 2 (Th2)-biased cytokine environment allergic asthma (AA) Bronchial epithelial cells T-helper type 2 (Th2)-biased cytokine environment treatment downregulated 26289417 8009 Human hsa-miR-423-5p miRNA doxorubicin (DOX) "cardiotoxicity,cardiomyopathy and heart failure" female patients from the placebo arm doxorubicin treatment upregulated 28052002 8010 Human hsa-miR-423-5p miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment upregulated 31455213 8011 Human hsa-miR-423-5p miRNA chaenomeles speciosa (CSTT) gastric injury GES-1 cells Chaenomeles speciosa (CSTT) treatment CSTT obviously downregulated miR-423-5p mRNA. 31895380 8012 Human hsa-miR-423-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Hepatocellular carcinoma (HCC) cells sorafenib treatment upregulated 25782064 8013 Human hsa-miR-423-5p miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 8014 Human hsa-miR-423-5p miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 8015 Human hsa-miR-423-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment Our data showed that MPP+?induced UCA1 expression in SK-N-SH cells. 33464446 8016 Human hsa-miR-423-5p miRNA cisplatin (DDP) triple negative breast cancer (TNBC) Exosomes were isolated from MDA-MB-231 cells cisplatin treatment upregulated 31424364 8017 Human hsa-miR-424 miRNA lipopolysaccharide (LPS) graft-versus-host disease (GVHD) Cord blood (CB) lipopolysaccharide (LPS) treatment upregulated 21913990 8018 Human hsa-miR-424 miRNA CoCl2 acute mountain sickness (AMS) Human pulmonary microvascular ECs (HPMECs) and HUVECs CoCl2 treatment upregulated 31461385 8019 Human hsa-miR-424 miRNA hypoxia acute mountain sickness (AMS) Human pulmonary microvascular ECs (HPMECs) and HUVECs hypoxia induce upregulated 31461385 8020 Human hsa-miR-424 miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) Human alveolar epithelial cells A549 and BEAS-2B lipopolysaccharide (LPS) treatment downregulated 31881228 8021 Human hsa-miR-424 miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) A549 cells; BEAS-2B cells lipopolysaccharide (LPS) treatment downregulated 31881228 8022 Human hsa-miR-424 miRNA hypoxia apoptosis A375;U251;HCT116;HEK293T cells hypoxia treatment upregulated 24967963 8023 Human hsa-miR-424 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 8024 Human hsa-miR-424 miRNA VEGF or basic fibroblast growth factor (bFGF) tumorigenesis endothelial vascellum VEGF or basic fibroblast growth factor (bFGF) treatment upregulated 21885851 8025 Human hsa-miR-424 miRNA TGF-¦Â cell cycle arrest MCF-10A and MCF-12 cells TGF-¦Â treatment upregulated 25266660 8026 Human hsa-miR-424 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment lncRNA SNHG1 regulates OGD/R-induced cell death through serving as a ceRNA for miR-424 in SH-SY5Y cells 31900069 8027 Human hsa-miR-424 miRNA ozone (O3) epigenetic regulation of responses to O3 exposure healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 8028 Human hsa-miR-424 miRNA TGF-¦Â1 lung fibrosis human lung fibroblasts (HLFs) TGF-¦Â1 treatment miR-424 expression was increased by 26-fold in HLFs in response to TGF-¦Â1 32712053 8029 Human hsa-miR-424 miRNA ezetimibe monocytic differentiation Human monocytic cell lineTHP-1 Ezetimibe trratment downregulated 22989505 8030 Human hsa-miR-424 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 8031 Human hsa-miR-424 miRNA tumor necrosis factor alpha (TNF-¦Á) obesity human visceral preadipocytes (HPA©\V cells) tumor necrosis factor alpha (TNF-¦Á) treatment TNF-¦Á treatment significantly downregulated the expression levels of miR-424 via binding to its promoter region and reducing its transcriptional activity 33179089 8032 Human hsa-miR-424 miRNA recombinant lentivirus cell differentiation hDPCs recombinant lentivirus?infection treatment downregulated 24331995 8033 Human hsa-miR-424 miRNA cisplatin (DDP) osteosarcoma (OS) MG63 cells cisplatin treatment "Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma." 31642110 8034 Human hsa-miR-424 miRNA cisplatin and doxorubicin osteosarcoma (OS) MG63 cells cisplatin and doxorubicin treatment "Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma." 31642110 8035 Human hsa-miR-424 miRNA doxorubicin (DOX) osteosarcoma (OS) MG63 cells doxorubicin treatment "Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma." 31642110 8036 Human hsa-miR-424 miRNA melatonin osteosarcoma (OS) SaOS2 cells; MG63 cells Melatonin treatment upregulated 32592723 8037 Human hsa-miR-424 miRNA H2O2 oxidative stress hTERT-transduced human adipose derived mesenchymal stem cells (hASCs) H2O2 treatment downregulated 28186136 8038 Human hsa-miR-424 miRNA IL-13 pulmonary arterial hypertension (PAH) primary human pulmonary artery endothelial cells (HPAECs) Interleukin-13 (IL-13) treatment downregulated 29102771 8039 Human hsa-miR-424 miRNA IL-13 pulmonary arterial hypertension (PAH) human pulmonary artery endothelial cells (HPAECs) Interleukin-13 (IL-13) treatment downregulated 29102771 8040 Human hsa-miR-424 miRNA hypoxia wilson's disease human endothelial cells Hypoxia treatment downregulated 20972335 8041 Human hsa-miR-424-3p miRNA hypoxia lung cancer A549 cells hypoxia treatment downregulated 27524914 8042 Human hsa-miR-424-3p miRNA baicalin (BAI) non-small cell lung cancer (NSCLC) A549 and H460 cells baicalin (BAI) treatment downregulated 29392841 8043 Human hsa-miR-424-5p miRNA ginsenoside Rg3 breast cancer MCF-7 breast cancer cells ginsenoside Rg3 treatment upregulated 33477683 8044 Human hsa-miR-424-5p miRNA amyloid-¦Â (A¦Â) Alzheimer's disease (AD) Human cerebral microvascular endothelia cells (hCMEC/D3) amyloid-¦Â (A¦Â) treatment upregulated 31375213 8045 Human hsa-miR-424-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment Circ_0029589 silence might inhibit the progression of AS by regulating miR-424-5p/IGF2 axis 32860985 8046 Human hsa-miR-424-5p miRNA 6-thioguanine (6-TG) breast cancer MCF-7 cells 6-thioguanine (6-TG) treatment downregulated 33376537 8047 Human hsa-miR-424-5p miRNA quinidine cell proliferation and apoptosis human glioma U87-MG cells quinidine treatment the upregulation of miR-149-3p and downregulated of miR-424-5p 25420507 8048 Human hsa-miR-424-5p miRNA high glucose (HG) diabetic nephropathy (DN) Human glomerular mesangial cells (HGMC) high glucose (HG) treatment "Knockdown of CDKN2B-AS1 suppressed proliferation, ECM accumulation and PI3K/AKT signaling by increasing miR-424-5p and decreasing HMGA2 in high glucose-treated HMGC cells." 31707340 8049 Human hsa-miR-424-5p miRNA high glucose (HG) diabetic nephropathy (DN) Human glomerular mesangial cells (HGMC) high glucose (HG) treatment downregulated 31707340 8050 Human hsa-miR-424-5p miRNA ropivacaine glioblastoma multiforme (GBM) T98G cells; LN229 cells ropivacaine treatment upregulated 33817285 8051 Human hsa-miR-424-5p miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Huh7-HBV;Hep3B-HBV cells hepatitis B virus (HBV) infection "Circ-RNF13 was upregulated in HBV-infected human HCC tissues and HBV-expressing cells (Huh7-HBV and Hep3B-HBV), accompanied with TGIF2 upregulation and miR-424-5p downregulated." 33714261 8052 Human hsa-miR-424-5p miRNA saturated fatty acids (SFA) palmitate (PA) obesity-induced hepatic insulin resistance HepG2 cells saturated fatty acids (SFA) palmitate (PA) treatment miR-424-5p was upregulated in PA-treated HepG2 cells 30033101 8053 Human hsa-miR-424-5p miRNA silver nanoparticles (AgNPs) silver nanoparticles (SNPs) induced cytotoxicity human dermal fibroblasts (HDFs) silver nanoparticles (SNPs) treatment upregulated 30305212 8054 Human hsa-miR-424-5p miRNA titanium surface implant-host tissue interactions osteoblastic cells from human alveolar bone osteoblastic cells from human alveolar bone treatment dysregulated 27200092 8055 Human hsa-miR-425 miRNA "IL-1¦Â, IFN-¦Ã and TNF-¦Á" acute respiratory distress syndrome (ARDS) A549 and HFL-1 cells "a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h" downregulated 31934088 8056 Human hsa-miR-425 miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 8057 Human hsa-miR-425 miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 8058 Human hsa-miR-425 miRNA IL-1¦Â gastric cancer (GC) AGS cells IL-1¦Â treatment upregulated 24571667 8059 Human hsa-miR-425 miRNA angiotensin II (Ang II) heart failure (HF) Human adult atrial fibroblast primary cultures (NHCF-A) angiotensin II (Ang II) treatment downregulated 30392569 8060 Human hsa-miR-425 miRNA glucose obesity and diabetes Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and HepG2 cells glucose treatment upregulated 26892417 8061 Human hsa-miR-425 miRNA CuO nanowire fabricated with folic acid (CuO-Nw-FA) triple negative breast cancer (TNBC) MDAMB-231 cells MDAMB-231 cells treatment downregulated 26520043 8062 Human hsa-miR-425-3p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HCC cell lines sorafenib treatment upregulation 25040368 8063 Human hsa-miR-425-3p miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells secreted exosomes cisplatin (DPP) treatment upregulated 31632022 8064 Human hsa-miR-425-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 8065 Human hsa-miR-425-5p miRNA sodium arsenite (NaAsO2) cardiovascular disease (CVD) HUVECs sodium arsenite (NaAsO2) treatment downregulated 27132035 8066 Human hsa-miR-425-5p miRNA high glucose (HG) diabetes-associated endothelial dysfunction human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 31711985 8067 Human hsa-miR-425-5p miRNA high glucose (HG) and IL-1¦Â endothelial cell injury human umbilical vein endothelial cells (HUVECs) high glucose (HG) and interleukin-1¦Â (IL-1¦Â) treatment miR-425-5p was significantly upregulated in diabetic patients and human umbilical vein endothelial cells (HUVECs) treated with high glucose (HG) and interleukin-1¦Â (IL-1¦Â). 31711985 8068 Human hsa-miR-425-5p miRNA radiochemotherapy head and neck squamous cell carcinoma (HNSCC) ?blood plasma radiochemotherapy?treatment treatment "six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)" 24373621 8069 Human hsa-miR-425-5p miRNA TGF-¦Â1 liver fibrosis LX©\2 cells transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 31148365 8070 Human hsa-miR-4257 miRNA radon lung cancer BEAS-2B cells radon treatment upregulated 33447367 8071 Human hsa-miR-4262 miRNA lipopolysaccharide (LPS) acute lung injury (ALI) human lung fibroblast WI-38 cells and human PMVECs lipopolysaccharide (LPS) treatment MEG3 was downregulated by LPS and its knockdown aggravated LPS-induced injury of human lung cells through miR-4262-mediated downregulated of KLF4. 31184231 8072 Human hsa-miR-4262 miRNA dextran sodium sulfate (DSS) inflammatory bowel disease (IBD) Caco-2 cells dextran sulfate sodium (DSS) treatment miR-4262 is upregulated in 2% DSS©\stimulated Caco-2 cells. 32765699 8073 Human hsa-miR-4267 miRNA aspirin heart repair mesenchymal stem cells (MSCs) aspirin treatment upregulated 32044414 8074 Human hsa-miR-4269 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 8075 Human hsa-miR-4271 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8076 Human hsa-miR-4274 miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment upregulated 26397152 8077 Human hsa-miR-4274 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment upregulated 25959385 8078 Human hsa-miR-4275 miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment upregulated 29393545 8079 Human hsa-miR-4281 miRNA IL-2 immunological self-tolerance and suppress human PBMCs IL-2 treatment upregulated 29282311 8080 Human hsa-miR-4284 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 8081 Human hsa-miR-4286 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32141990 8082 Human hsa-miR-4287 miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment downregulated 29806389 8083 Human hsa-miR-4288 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment upregulated 28619522 8084 Human hsa-miR-4289 miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment upregulated 26151338 8085 Human hsa-miR-4289 miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 8086 Human hsa-miR-4289 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment upregulated 28619522 8087 Human hsa-miR-429 miRNA Vitamin E ¦Ä-tocotrienol breast cancer TNBC cell lines (MDA-MB-231 and MDA-MB-468) Vitamin E ¦Ä-tocotrienol treatment upregulated 26629059 8088 Human hsa-miR-429 miRNA epstein-barr virus (EBV) tumorigenesis EBV-positive B-lymphocytic cell lines;Epithelial gastric carcinoma AGSB95.8 cells;MCF-7 cells (ATCC) Epstein-Barr Virus (EBV) infection downregulated 20668090 8089 Human hsa-miR-429 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury HT22 cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment miR-429 expression levels were upregulated in cultured neurons with OGD/R treatment 29624520 8090 Human hsa-miR-429 miRNA hypoxia chronic hypoxia human endothelial cells binder CO2/O2 incubator treatment upregulated 25550463 8091 Human hsa-miR-429 miRNA hypoxia-inducible factor 1¦Á (HIF-1¦Á) chronic hypoxia endothelial cells HIF1A treatment "miR-429 attenuates HIF-1 activity by decreasing HIF1A message during the early stages of hypoxia before HIF-2 is activated, and this regulatory network helps explain the HIF-1 transition to HIF-2 during chronic hypoxia in endothelial cells." 25550463 8092 Human hsa-miR-429 miRNA high glucose (HG) endothelial inflammation human aortic endothelial cells (HAECs) high glucose (HG) treatment downregulated 29720943 8093 Human hsa-miR-429 miRNA tacrolimus (FK506) epidural fibrosis human fibroblasts FK506 treatment downregulated 28669722 8094 Human hsa-miR-429 miRNA metformin (Met) epithelial-mesenchymal transition (EMT) SW480 cells; HCT116 cells metformin treatment upregulated 30017802 8095 Human hsa-miR-429 miRNA soft-shelled turtle peptide gastric cancer (GC) human GC AGS cells soft-shelled turtle peptide treatment differentlly regulated 29435044 8096 Human hsa-miR-429 miRNA hypoxia hypoxic-related diseases primary human umbilical vein endothelial cells (HUVECs) hypoxia treatment miR-200b and miR-429 are upregulated in response to hypoxia. 29737439 8097 Human hsa-miR-429 miRNA hypoxia myocardial ischaemic injury human cardiomyocytes hypoxia treatment upregulated 27082497 8098 Human hsa-miR-429 miRNA lipopolysaccharide (LPS) neonatal pneumonia WI-38 cells lipopolysaccharide (LPS) treatment MiR-429 expression level was increased in LPS-stimulated WI-38 cells. 32003671 8099 Human hsa-miR-429 miRNA human papilloma viruses (HPVs) 16 oropharyngeal squamous cell carcinoma (OPSCC) HOK-20B cells human papillomaviruses (HPVs) 20 treatment downregulated 31911577 8100 Human hsa-miR-429 miRNA H2O2 osteogenesis human adipose-derived mesenchymal stem cells hydrogen peroxid (H2O2) treatment upregulated 31885708 8101 Human hsa-miR-429 miRNA H2O2 osteogenesis hADMSCs H2O2 treatment upregulated 31885708 8102 Human hsa-miR-429 miRNA H2O2 renal cell carcinoma (RCC) ACHN and Caki-1 cells H2O2 treatment downregulated 31550675 8103 Human hsa-miR-429 miRNA metformin (Met) cell senescence BJ-1 human diploid fibroblasts (HDFs) metformin treatment upregulated 22356767 8104 Human hsa-miR-429 miRNA Schizandrin A (SchA) thyroid cancer (TC) TC cell line TPC-1 Schizandrin A (SchA) treatment downregulated 30909188 8105 Human hsa-miR-429 miRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) hepatoma cells Hepatitis B virus X protein (HBx)? treatment downregulated 23471881 8106 Human hsa-miR-429 miRNA hypoxia hypoxia-induced injury primary human umbilical vein endothelial cells hypoxia treatment downregulated 26954587 8107 Human hsa-miR-4291 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 8108 Human hsa-miR-4295 miRNA H2O2 glaucoma human trabecular meshwork (HTM) cells H2O2 treatment downregulated 30594603 8109 Human hsa-miR-4295 miRNA H2O2 and Lycium barbarum polysaccharides (LBPs) glaucoma human trabecular meshwork (HTM) cells H2O2 and Lycium barbarum polysaccharides (LBPs) treatment MiR-4295 expression was upregulated in H 2O 2 and LBPs treated cells. 30594603 8110 Human hsa-miR-4295 miRNA lycium barbarum polysaccharide (LBP) glaucoma H2O2 treated human trabecular meshwork (HTM) cells Lycium barbarum polysaccharides (LBPs) treatment upregulated 30594603 8111 Human hsa-miR-4295 miRNA propranolol (PRO) infantile hemangioma (IH) Human umbilical vein endothelial cells (HUVECs) propranolol treatment downregulated 30368887 8112 Human hsa-miR-4295 miRNA propranolol (PRO) infantile hemangioma (IH) human umbilical vein endothelial cells (HUVECs) propranolol treatment Propranolol treatment downregulated miR-4295 expression in HUVECs. 30368887 8113 Human hsa-miR-4295 miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 8114 Human hsa-miR-4298 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 8115 Human hsa-miR-4298 miRNA amB with copper (II) ions (AmB-Cu2+) renal fibrosis normal human renal proximal tubule epithelial cells (RPTEC) complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower downregulated 28534445 8116 Human hsa-miR-4299 miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment downregulated 29435044 8117 Human hsa-miR-4306 miRNA MnCl2 neurodegeneration (ND) SH-SY5Y cells MnCl2 treatment upregulated 28302480 8118 Human hsa-miR-431 miRNA IFN-¦Â cell proliferation human embryo-derived fibroblasts IFN-¦Â? treatment downregulated 22293894 8119 Human hsa-miR-431 miRNA "IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1" chronic hepatitis C virus (HCV) infection Huh7 cells "types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment" dysregulated 24844965 8120 Human hsa-miR-431 miRNA hypoxia hepatocellular carcinoma (HCC) SNU-387 cells; Huh7 cells hypoxia treatment miR-431 expression was reduced in SNU-387 and Huh7 cells under hypoxia treatment. 33193848 8121 Human hsa-miR-431 miRNA lactobacillus casei (L. casei LC01) irritable bowel syndrome with diarrhea (IBS-D) intestinal epithelial cells (IECs) L. casei LC01 treatment downregulated 32807750 8122 Human hsa-miR-431 miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment upregulated 21093163 8123 Human hsa-miR-4310 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 8124 Human hsa-miR-4313 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 8125 Human hsa-miR-431-5p miRNA yhexamethylene guanidine phosphate (PHMG-phosphate) lung fibrosis A549 cells yhexamethylene guanidine phosphate (PHMG-phosphate) treatment downregulated 29337256 8126 Human hsa-miR-4317 miRNA aspirin lung cancer A549 and H1299 cell lines aspirin treatment upregulated 30756509 8127 Human hsa-miR-4319 miRNA IL-4 macrophage polarization peripheral blood mononuclear cells (PBMCs) IL-4 treatment downregulated 31267263 8128 Human hsa-miR-432 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" aortic stenosis cervical cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines" 23732000 8129 Human hsa-miR-432 miRNA thermal stress heat shock HeLa cells were subjected to heat shock at 42C for 60 min and kept at 37C for 4 h treatment upregulated 25280995 8130 Human hsa-miR-432 miRNA dopamine cocktail and retinoic acid neuronal differentiation SH-SY5Y and IMR-32 cells were dopamine cocktail and retinoic acid treatment dysregulated 24657437 8131 Human hsa-miR-432 miRNA a moderate-carbohydrate and low glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and low glycemic index diet downregulated 29233588 8132 Human hsa-miR-432 miRNA low fat diet (LFD) overweight and obese plasma low fat diet (LFD) treatment downregulated in plasma 29233590 8133 Human hsa-miR-432 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 8134 Human hsa-miR-4320 miRNA hypoxia kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection human KS-derived SLK and SLKK cells hypoxia treatment upregulated 28046107 8135 Human hsa-miR-4324 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 8136 Human hsa-miR-4327 miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" downregulated 28397044 8137 Human hsa-miR-4328 miRNA everolimus lung cancer A549 cells everolimus (EVE) treatment downregulated 31612036 8138 Human hsa-miR-433 miRNA hypoxia cerebral infarction (CI) HUVECs hypoxia treatment downregulated 27815672 8139 Human hsa-miR-433 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) human GC cell lines SGC-7901 and BGC-823 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25270964 8140 Human hsa-miR-433 miRNA manganese (Mn) idiopathic Parkinson's disease human neuroblastoma SH-SY5Y cells manganese (100¦ÌM) treatment downregulated 28986288 8141 Human hsa-miR-433 miRNA manganese (Mn) manganese induced neurotoxic SH-SY5Y cells manganese treatment The expressions of miR-7 and miR-433 significantly reduced upon manganese exposure. 28986288 8142 Human hsa-miR-433 miRNA hypoxia neuron proliferation and migration human umbilical vein vascular endothelial cells (HUVECs) hypoxia treatment downregulated 27815672 8143 Human hsa-miR-433 miRNA andrographolide oxidative stress HepG2 cells andrographolide treatment downregulated 30414976 8144 Human hsa-miR-433 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment downregulated 29860902 8145 Human hsa-miR-4417 miRNA nickel epithelial-mesenchymal transition (EMT) BEAS-2B and A549 nickel upregulated 29127306 8146 Human hsa-miR-4417 miRNA TGF-¦Â inhibitor SB525334 epithelial-mesenchymal transition (EMT) TGF-¦Â-treated BEAS-2B and A549 SB525334 treatment downregulated 29127306 8147 Human hsa-miR-4421 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment downregulated 28619522 8148 Human hsa-miR-4422 miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2 cells curcumin treatment "miR-4422 was downregulated in CNE-2 cells after treatment by radiation, while curcumin treatment upregulated the expression." 32127962 8149 Human hsa-miR-4423-3p miRNA doxorubicin (DOX) cardiotoxicity human-induced pluripotent stem cell (hiPSC) doxorubicin treatment upregulated 26842497 8150 Human hsa-miR-4425 miRNA ginsenoside 20(S)-Rg3 ovarian cancer (OC) SKOV3 cells; 3AO cells ginsenoside 20(S)-Rg3 treatment 20(S)-Rg3 reduced miR-4425 to alleviate the malignant phenotypes of ovarian cancer cells. 32877662 8151 Human hsa-miR-4428 miRNA tensile hepatocellular carcinoma (HCC) HepG2 cells tensile treatment downegulated 32323778 8152 Human hsa-miR-4428 miRNA hyperbaric oxygen (HBO) hepatocellular carcinoma (HCC) Hepatoma cell lines (BEL-7402 and SK-Hep1) HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment upregulated 24956259 8153 Human hsa-miR-4430 miRNA ursolic acid (UA) breast cancer BT474 cells usnic acid treatment upregulated 31549595 8154 Human hsa-miR-4433 miRNA suberoylanilide hydroxamic acid (SAHA) chronic lymphocytic leukemia (CLL) CML cells K562 suberoylanilide hydroxamic acid (SAHA) treatment upregulated 31737104 8155 Human hsa-miR-4433 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment upregulated 25959385 8156 Human hsa-miR-4433-3p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8157 Human hsa-miR-4434 miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment upregulated 26397152 8158 Human hsa-miR-4442 miRNA prednisolone polymyositis (PM) plasma prednisolone treatment downregulated 29321815 8159 Human hsa-miR-4446-3p miRNA mechanical compression breast cancer MDA-MB-231 cells and CAFs mechanical compression treatment upregulated 27027350 8160 Human hsa-miR-4448 miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment downregulated 26151338 8161 Human hsa-miR-4448 miRNA IFN-¦Ã corneal allograft rejection human corneal epithelial cells (HCECs) IFN-¦Ã treatment downregulated 30013574 8162 Human hsa-miR-4448 miRNA suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) gastric cancer (GC) gastric and liver cancer cells suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) treatment upregulated 24861464 8163 Human hsa-miR-4448 miRNA heat stress heat-induced pathophysiology human umbilical vein endothelial cells cultured in the incubator at 43¡ãC for 1 h "downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)" 29039486 8164 Human hsa-miR-4448 miRNA respiratory syncytial virus (RSV) innate immune response human dendritic cells respiratory syncytial virus (RSV) infection treatment upregulated 29970194 8165 Human hsa-miR-4448 miRNA titanium (Ti) osteoblastic differentiation human bone marrow mesenchymal stem cells (hMSCs) Ti treatment downregulated 24619927 8166 Human hsa-miR-4455 miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment downregulated 29435044 8167 Human hsa-miR-4455 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment upregulated 25959385 8168 Human hsa-miR-4455 miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine (GEM) treatment downregulated 25722110 8169 Human hsa-miR-4458 miRNA propofol (PPF) hepatocellular carcinoma (HCC) Huh7 cells; Hep3B cells propofol treatment miR-4458 was significantly increased by propofol 32705160 8170 Human hsa-miR-4458 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H460 cells cisplatin treatment Circ-PRMT5 promoted DDP resistance via REV3L by sponging miR-4458 in NSCLC 32808744 8171 Human hsa-miR-4459 miRNA hematoporphyrin glioblastoma multiforme (GBM) U87 glioma cells hematoporphyrin treatment upregulated 29344634 8172 Human hsa-miR-446 miRNA graphene oxide (GO) graphene oxide (GO) toxicity GLC-82 cells GO treatment dysregulated 24512264 8173 Human hsa-miR-4463 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33245416 8174 Human hsa-miR-4463 miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 upregulated 28713907 8175 Human hsa-miR-4463 miRNA high glucose (HG) type 2 diabetes mellitus (T2DM) human umbilical vein endothelial cells (HUVECs) high glucose treatment upregulated 30244253 8176 Human hsa-miR-4463 miRNA hypoxia type 2 diabetes mellitus (T2DM) human umbilical vein endothelial cells (HUVECs) hypoxia induce upregulated 30244253 8177 Human hsa-miR-4463 miRNA oxidized low density lipoprotein (ox-LDL) vascular smooth muscle cell (VSMC) phenotypic switching human aortic smooth muscle cells oxidized low-density lipoprotein (ox-LDL) treatment Ox-LDL decreased the level of miR-4463. 33245416 8178 Human hsa-miR-4465 miRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3 and Hey-8 Paclitaxel (PTX) treatment SDHAP1 was upregulated in PTX-resistant SKOV3 and Hey-8 ovarian cancer cell lines while the level of miR-4465 was downregulated 32211849 8179 Human hsa-miR-4468 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment downregulated 28619522 8180 Human hsa-miR-4474 miRNA fusobacterium nucleatum (F. nucleatum) colorectal cancer (CRC) The human epithelial colorectal cell line Caco-2 Fusobacterium nucleatum (F. nucleatum) infection upregulated 30951563 8181 Human hsa-miR-4478 miRNA particulate matter (PM2.5) cardiotoxicity endothelial cells PM2.5 exposure treatment downregulated 30597786 8182 Human hsa-miR-4478 miRNA particulate matter (PM2.5) cardiotoxicity of PM2.5 endothelial cells PM2.5 treatment downregulated 30597786 8183 Human hsa-miR-448 miRNA hypoxia antiarrhythmic RL14 cells hypoxia treatment upregulated 33108349 8184 Human hsa-miR-448 miRNA "IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1" chronic hepatitis C virus (HCV) infection Huh7 cells "types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment" dysregulated 24844965 8185 Human hsa-miR-448 miRNA platelet derived growth factor-BB (PDGF-BB) coronary artery disease (CAD) human VSMCs PDGF-bb (20 ng/ml) treatment upregulated 28799067 8186 Human hsa-miR-448 miRNA IL-1¦Â osteoarthritis (OA) Chondrocytes IL-1¦Â treatment The level of miR-448 was significantly higher in IL-1¦Â-induced chondrocytes. 29483929 8187 Human hsa-miR-448 miRNA hypoxia spinal cord ischemia/reperfusion injury (SCII) AGE1.HN cells hypoxia induce upregulated 29561961 8188 Human hsa-miR-448 miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) plasma Mycobacterium tuberculosis (MTB) treatment downregulated 32048448 8189 Human hsa-miR-4484 miRNA radix tetrastigma hemsleyani (RTH) lung cancer A549 cells radix tetrastigma hemsleyani (RTH) treatment downregulated 30100735 8190 Human hsa-miR-4485-3p miRNA beryllium sulfate (BeSO4 ) beryllium toxicity 16HBE cells beryllium sulfate (BeSO4 ) treatment upregulated 33197057 8191 Human hsa-miR-4485-5p miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human bronchial epithelial (16HBE) cells infect with EV71 and CA16 dysregulated 27890633 8192 Human hsa-miR-4485-5p miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) Human bronchial epithelial (16HBE) cells Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment dysregulated 27890633 8193 Human hsa-miR-448-5p miRNA TGF-¦Â1 allergic asthma (AA) 16HBE cells TGF-¦Â1 treatment miR-448-5p was dramatically decreased in TGF-¦Â1-stimulated bronchial epithelial cells 30362537 8194 Human hsa-miR-448-5p miRNA TGF-¦Â1 asthma "Human bronchial epithelial cells, 16HBE" transforming growth factor-¦Â1 (TGF-¦Â1) treatment downregulated 30362537 8195 Human hsa-miR-448-5p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) "Human bronchial epithelial cells, 16HBE" transforming growth factor-¦Â1 (TGF-¦Â1) treatment downregulated 30362537 8196 Human hsa-miR-448-5p miRNA TGF-¦Â1 lung fibrosis "Human bronchial epithelial cells, 16HBE" transforming growth factor-¦Â1 (TGF-¦Â1) treatment downregulated 30362537 8197 Human hsa-miR-4487 miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH5Y-SY cells amyloid-¦Â (A¦Â) 25-35 treatment A¦Â 25-35 downregulated hsa-miR-4487 in SH-SY5Y cell lines associated with A¦Â-mediated pathophysiology. 30547775 8198 Human hsa-miR-4488 miRNA adeno-associated virus (AAV) cellular physiology Huh-7 cells; ARPE-19 cells adeno-associated virus (AAV) serotypes 2 and 3 infection downregulated 31629820 8199 Human hsa-miR-4488 miRNA adeno-associated virus (AAV) adeno-associated virus (AAV) infection ARPE-19 cells adeno-associated virus (AAV) treatment downregulated 31629820 8200 Human hsa-miR-4488 miRNA ultraviolet (UV) irradiation ultraviolet radiation (UV) effects Exosomes derived from human primary melanocytes ultraviolet B (UVB) irradiation treatment upregulated 32785244 8201 Human hsa-miR-449 miRNA IL-13 autophagy BEAS-2B cells IL-13 treatment upregulated 28796252 8202 Human hsa-miR-449 miRNA corticosteroid erythroid cell differentiation bronchial epithelial? cells corticosteroids treatment downregulated 22955319 8203 Human hsa-miR-449 miRNA doxorubicin (DOX) triple negative breast cancer (TNBC) "The MDA-MB-231, MDA-MB-468, and MCF-7 breast cancer cell lines" doxorubicin treatment upregulated 30926829 8204 Human hsa-miR-4496 miRNA rebamipide gastric cancer (GC) cancer-initiating cells (C-IC) Rebamipide treatment upregulated 27265143 8205 Human hsa-miR-4499 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 8206 Human hsa-miR-449a miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment dysregulated 29067470 8207 Human hsa-miR-449a miRNA IL-1¦Â cartilage destruction chondrocytes IL-1¦Â treatment upregulated 27421775 8208 Human hsa-miR-449a miRNA E2F transcription factor 1 (E2F1) cell proliferation and apoptosis HCT116 cells;H1299;U2OS;GH;833KE ;Saos-2 cells E2F1 treatment upregulated 19960022 8209 Human hsa-miR-449a miRNA cigarette smoke (CS) chronic obstructive pulmonary disease (COPD) human air-liquid-interface (ALI) airway cultures cigarette smoke (CS)?exposure "In particular, a time-dependent decrease in the expression of miR-449a, a conserved miRNA highly enriched in ciliated airway epithelia and implicated in motile ciliogenesis, was observed in CS-exposed cultures. Similar alterations in miR-449a have been reported in smokers with COPD." 33704509 8210 Human hsa-miR-449a miRNA melatonin colorectal cancer (CRC) HCT116 cells melatonin treatment "Compared with the control group, melatonin significantly enhanced the expression levels of the miR-34a/449a cluster" 33398374 8211 Human hsa-miR-449a miRNA neferine (NEF) gastrointestinal stromal tumor (GIST) GIST cell line GIST-T1 Neferin (Nef) treatment upregulated 30551450 8212 Human hsa-miR-449a miRNA bromopyruvate (3-BrPA) glioblastoma multiforme (GBM) Malignantly transformed macrophages (tM?); dendritic cells (tDC) bromopyruvate (3-BrPA) treatment upregulated 31710894 8213 Human hsa-miR-449a miRNA bromopyruvate (3-BrPA) glioblastoma multiforme (GBM) Malignantly transformed macrophages (tM?) and dendritic cells (tDC) induced by glioma stem cells in the glioma microenvironment bromopyruvate (3-BrPA) treatment upregulated 31710894 8214 Human hsa-miR-449a miRNA hepatitis C virus (HCV) liver fibrosis human Primary Hepatocytes£» HEPG2 Cell Line hepatitis C virus (HCV) infection downregulated 23226395 8215 Human hsa-miR-449a miRNA acupuncture in vitro fertilization and embryo transplantation endometrial tissues acupuncture treatment downregulated 31824817 8216 Human hsa-miR-449a miRNA ionizing radiation (IR) non-small cell lung cancer (NSCLC) A549 cells at doses ranging from 4 to 8 Gy at 24 h upregulated 28800787 8217 Human hsa-miR-449a miRNA ionizing radiation (IR) non-small cell lung cancer (NSCLC) A549 cells ionizing radiation (IR) treatment upregulated 28800787 8218 Human hsa-miR-449a miRNA hypoxia organs hypoxia Primary human fibroblasts hypoxia treatment downregulated 20356416 8219 Human hsa-miR-449a miRNA hypoxia pressure ulcer (PU) HaCaT cells hypoxia treatment circ-Ttc3 alleviated hypoxic injury and activated NF-¦ÊB and PI3K/AKT pathways by downregulating miR-449a in HaCaT cells. 32043754 8220 Human hsa-miR-449a miRNA S-adenosyl-L-methionine (AdoMet) triple negative breast cancer (TNBC) MDA-MB-231; MDA-MB-468 cells S-adenosyl-L-methionine (AdoMet) treatment AdoMet exerts its antitumor effects in TNBC cells through upregulating the expression of miR-34c and miR-449a 33396625 8221 Human hsa-miR-449b miRNA E2F transcription factor 1 (E2F1) cell proliferation and apoptosis HCT116 cells;H1299;U2OS;GH;833KE ;Saos-2 cells E2F1 treatment upregulated 19960022 8222 Human hsa-miR-449b miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 8223 Human hsa-miR-449b miRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) NP69 cells cisplatin (DPP) treatment downregulated 29795279 8224 Human hsa-miR-449b miRNA hypoxia organs hypoxia Primary human fibroblasts hypoxia treatment downregulated 20356416 8225 Human hsa-miR-449b-3p miRNA acupuncture in vitro fertilization and embryo transplantation endometrial tissues acupuncture treatment downregulated 31824817 8226 Human hsa-miR-449b-5p miRNA hypoxia glioblastoma multiforme (GBM) LN229 cells hypoxia treatment downregulated 32849915 8227 Human hsa-miR-449b-5p miRNA radiation radiation resistance of breast cancer (BRCA) MCF©\7; T47D; LM©\MCF©\7; BT©\474;SKBR©\3; MDA©\MB©\231 radiation treatment LncRNA HOTAIR facilitates the expression of HSPA1A by sequestering miR-449b-5p post-transcriptionally and thereby endows BRCA with radiation resistance 32374522 8228 Human hsa-miR-449c miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" osteosarcoma tumorigenesis human osteosarcoma cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28924385 8229 Human hsa-miR-4500 miRNA ursolic acid (UA) colorectal cancer (CRC) HCT116 and HT29 colorectal cancer cells ursolic acid (UA) treatment upregulated 30597956 8230 Human hsa-miR-4505 miRNA lipopolysaccharide (LPS) endothelial cell injury human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment miR-4505 was highly expressed in HUVECs stimulated by LPS. 29115487 8231 Human hsa-miR-4505 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8232 Human hsa-miR-4505 miRNA lipopolysaccharide (LPS) vascular endothelial cell injury HUVECs lipopolysaccharide (LPS) treatment upregulated 29115487 8233 Human hsa-miR-4508 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8234 Human hsa-miR-4508 miRNA MnCl2 neurodegeneration (ND) SH-SY5Y cells MnCl2 treatment upregulated 28302480 8235 Human hsa-miR-450a miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) cancer cell 5-fluorouracil treatment upregulated 23167930 8236 Human hsa-miR-450a miRNA capecitabine colorectal cancer (CRC) cancer cell capecitabine treatment upregulated 23167930 8237 Human hsa-miR-450a miRNA aristolochic acid aristolochic acid nephropathy Primary human renal PTCs aristolochic acid (AA) treatment upregulated 24508230 8238 Human hsa-miR-450b-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) cancer cell 5-fluorouracil treatment upregulated 23167930 8239 Human hsa-miR-450b-5p miRNA capecitabine colorectal cancer (CRC) cancer cell capecitabine treatment upregulated 23167930 8240 Human hsa-miR-450b-5p miRNA p-Coumaric acid (p-CA) autoimmune hepatitis (AIH) SNU-16 cells p-Coumaric acid (p-CA) treatment upregulated 32462517 8241 Human hsa-miR-450b-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HT-29 cells and HCT-116 cells 5-fluorouracil (5-FU) treatment downregulated 26845645 8242 Human hsa-miR-450b-5p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2 cells curcumin treatment "miR-450b-5p was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression." 32127962 8243 Human hsa-miR-451 miRNA erythropoietin (EPO) apoptosis SH-SY5Y neuronal-like cells EPO treatment downregulated 25324845 8244 Human hsa-miR-451 miRNA tamoxifen (TAM) breast cancer breast cancer cell Tamoxifen treatment downregulated 21666713 8245 Human hsa-miR-451 miRNA hypoxia cerebral ischemia injury (CII) human umbilical vein endothelial cells (HUVECs) hypoxia induce downregulated 31173234 8246 Human hsa-miR-451 miRNA docetaxel (DTX) gastric cancer (GC) MKN-45 cells docetaxel (DTX) treatment downregulated 33416185 8247 Human hsa-miR-451 miRNA propofol (PPF) gastric cancer (GC) SGC-7901 cell Propofol treatment upregulated 27173190 8248 Human hsa-miR-451 miRNA erythropoietin (EPO) glioblastoma multiforme (GBM) U87 human glioblastoma cell line EPO treatment downregulated 28629521 8249 Human hsa-miR-451 miRNA ¦Â2 adrenergic agonist glioblastoma multiforme (GBM) 1321N1 astrocytoma cells a selective ¦Â2 adrenergic agonist treatment upregulated 24714982 8250 Human hsa-miR-451 miRNA valproic acid (VPA) hematopoietic differentiation hematopoietic stem cells (HSCs) VPA treatment different regulation 25241289 8251 Human hsa-miR-451 miRNA microcystin-leucine arginine (MC-LR) liver damage HL7702 cells Microcystin-LR treatment downregulated 30875960 8252 Human hsa-miR-451 miRNA 5-fluorouracil/mitomycin C (MMC-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) MMC-CRTX treatment upregulated 28347920 8253 Human hsa-miR-451 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NSCLC tissues and cell lines cisplatin treatment "?TATDN1 and TRIM66 was significantly upregulated while miR-451 was downregulated in NSCLC tissues and cell lines, especially in DDP-resistant tumor tissues and cells." 30481109 8254 Human hsa-miR-451 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H157 cells cisplatin treatment downregulated 30481109 8255 Human hsa-miR-451 miRNA hypoxia pulmonary arterial hypertension (PAH) HepG2 cells Hypoxia treatment upregulated 20110569 8256 Human hsa-miR-451 miRNA resistance exercise training skeletal muscle hypertrophy Vastus lateralis biopsies resistance exercise training treatment upregulated 21030674 8257 Human hsa-miR-451 miRNA statins unstable angina (UA) plasma statins? treatment downregulated 26474612 8258 Human hsa-miR-451-1 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection human T-cell lines infect with HHV-6A upregulated 28081700 8259 Human hsa-miR-4516 miRNA BET inhibitors (JQ1) anaplastic thyroid carcinoma (ATC) ATC-derived cell lines (SW1736 and 8505c) treat with either 5 ?M JQ1 downregulated 29251329 8260 Human hsa-miR-4516 miRNA BET inhibitors (JQ1) anaplastic thyroid carcinoma (ATC) SW1736 cells; 8505c cells BET inhibitors (JQ1) treatment upregulated 29251329 8261 Human hsa-miR-4516 miRNA melatonin chronic kidney disease (CKD) mesenchymal stem/stromal cell (MSC) melatonin treatment upregulated 31989677 8262 Human hsa-miR-4516 miRNA coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) 16HBE cells coxsackievirus A16 (CV-A16) treatment upregulated 29686973 8263 Human hsa-miR-4516 miRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) 16HBE cells Enterovirus 71 (EV71) infection downregulated 29686973 8264 Human hsa-miR-4516 miRNA cyclosporine A (CsA) nephrotoxicity human proximal tubule cells cyclosporine A treatment dysregulated 28925592 8265 Human hsa-miR-4516 miRNA particulate matter (PM2.5) non-small cell lung cancer (NSCLC) A549 cells particulate matter (PM2.5) treatment upregulated 27329587 8266 Human hsa-miR-4516 miRNA photochemotherapy with psoralens and ultraviolet A (PUVA) psoriasis human keratinocytes (HaCaT cells) PUVA treatment upregulated 24610393 8267 Human hsa-miR-4516 miRNA house dust mite (HDM) lung fibrosis serum dust exposure upregulated 30090591 8268 Human hsa-miR-451a miRNA common aeroallergens asthma peripheral blood lymphocytes common aeroallergens treatment downregulated of miRNA-451a Promotes the Differentiation of CD4+ T Cells towards Th2 Cells by Upregulating ETS1 in Childhood Asthma 33271553 8269 Human hsa-miR-451a miRNA head-down tilt (HDT) bed rest bone loss male volunteers invited to participate in the 45 days of 15¡ã HDT bed rest experiment downregulated 28261104 8270 Human hsa-miR-451a miRNA microcystin-leucine arginine (MC-LR) cytoskeletal reorganization HL7702 liver cells microcystin (MC)-LR treatment downregulated 30422063 8271 Human hsa-miR-451a miRNA paroxetine depression serum paroxetine treatment upregulated 29791588 8272 Human hsa-miR-451a miRNA 4-hydroxynonenal (4-HNE) diabetic retinopathy (DR) RPE cells 4-hydroxynonenal (4-HNE) treatment The expression of miR-451a was downregulated both in the retina of Akita mice and 4-hydroxynonenal (4-HNE)-treated RPE cells. 30576241 8273 Human hsa-miR-451a miRNA simvastatin endometriosis Serum simvastatin treatment downregulated 29587611 8274 Human hsa-miR-451a miRNA hydroquinone (HQ) erythroid cell differentiation CD34 + hematopoietic progenitor cells hydroquinone (HQ) treatment downregulated 28733890 8275 Human hsa-miR-451a miRNA glucocorticoid (GC) glucocorticoid-induced osteoporosis (GIOP) vertebral samples treatment upregulated 30503955 8276 Human hsa-miR-451a miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human bronchial epithelial (16HBE) cells infect with EV71 and CA16 dysregulated 27890633 8277 Human hsa-miR-451a miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) Human bronchial epithelial (16HBE) cells Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment dysregulated 27890633 8278 Human hsa-miR-451a miRNA hydroquinone (HQ) hematotoxicity CD34 hematopoietic progenitor cells treat with HQ downregulated 28733890 8279 Human hsa-miR-451a miRNA endothelin-1 (ET-1) cardiac dysfunction Cor.4U human inducible pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) endothelin-1 (ET-1) treatment downregulated 31618079 8280 Human hsa-miR-451a miRNA hypoxia cardiac dysfunction Cor.4U human inducible pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) hypoxia induce downregulated 31618079 8281 Human hsa-miR-451a miRNA acidic bile hypopharyngeal cancer human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) acidic bile exposure downregulated 29516639 8282 Human hsa-miR-451a miRNA BAY11-7082 hypopharyngeal cancer Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage) BAY 11-7082 treatment upregulated 29516639 8283 Human hsa-miR-451a miRNA doxorubicin (DOX) lung cancer A549 cells; PC9 cells doxorubicin (Dox) treatment upregulated 32106373 8284 Human hsa-miR-451a miRNA microcystin-leucine arginine (MC-LR) MC-LR-induced hepatotoxicity human normal liver cell line HL7702 icrocystin-LR (MC-LR) treatment downregulated 29265921 8285 Human hsa-miR-451a miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 8286 Human hsa-miR-451a miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 8287 Human hsa-miR-451a miRNA noise noise-induced hearing loss (NIHL) plasma noise treatment downregulated 26278637 8288 Human hsa-miR-451a miRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells "free fatty acids (FFAs; oleate/palmitate, 2:1 ratio) treatment" downregulated 29604329 8289 Human hsa-miR-451a miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment upregulated 31452742 8290 Human hsa-miR-451a miRNA radiation oesophageal adenocarcinoma (OAC) OE19 cells radiation treatment Inhibition of miR-451a in the radiation resistant OAC cell line OE19 increased radiosensitivity 33255413 8291 Human hsa-miR-451a miRNA 4-hydroxynonenal (4-HNE) proliferative diabetic retinopathy (PDR) ARPE-19 cells and primary human RPE cells 4-hydroxynonenal (4-HNE) treatment downregulated 30576241 8292 Human hsa-miR-451a miRNA radon radiation ionizing radiation (IR) injury Blood samples radon radiation treatment downregulated 32165872 8293 Human hsa-miR-452 miRNA adriamycin (ADR) breast cancer adriamycin-resistant MCF-7 cells (MCF-7/ADR) adriamycin (ADR) treatment downregulated 25040964 8294 Human hsa-miR-452 miRNA hypoxia sleep apnea syndrome (SAS) human SW872 adipocytes hypoxia treatment downregulated 31013606 8295 Human hsa-miR-4521 miRNA hypoxia gastric cancer (GC) GC cells hypoxia treatment Further studies showed that hypoxia repressed miR-4521 expression via inducing ETS1 and miR-4521 mitigated hypoxia-mediated metastasis 33407516 8296 Human hsa-miR-4521 miRNA microcystin-leucine arginine (MC-LR) hepatotoxicity human normal liver cell line HL7702 "treatment with MC-LR at concentrations of 1, 2.5, 5 or 10 ¦ÌM" downregulated 29265921 8297 Human hsa-miR-4521 miRNA microcystin-leucine arginine (MC-LR) MC-LR-induced hepatotoxicity human normal liver cell line HL7702 icrocystin-LR (MC-LR) treatment downregulated 29265921 8298 Human hsa-miR-452-3p miRNA glucocorticoid (GC) steroid-induced osteonecrosis of femoral head (ONFH) bone marrow mesenchymal stem cells (BMSCs) glucocorticoid (GC) treatment upregulated 29590087 8299 Human hsa-miR-4525 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8300 Human hsa-miR-452-5p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose treatment upregulated 31849505 8301 Human hsa-miR-452-5p miRNA sunitinib (SU) metastatic renal cell carcinoma (mRCC) OSRC-2 and SW839 cells sunitinib treatment downregulated 30419914 8302 Human hsa-miR-453 miRNA cisplatin (DDP) cell death A549 cell cisplatin (DPP) treatment downregulated 21880462 8303 Human hsa-miR-4530 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure downregulated 31359311 8304 Human hsa-miR-4532 miRNA ultraviolet (UV) irradiation cataract human lens epithelial cells (HLECs) Ultra-violet radiation (UVR) exposure treatment "Functional studies show that UVR-induced cytotoxicity and apoptosis in HLECs were potentiated by miR-4532 overexpression, Nrf2 depletion or SIRT6 shRNA" 31079921 8305 Human hsa-miR-454 miRNA cisplatin (DDP) cisplatin (DDP) resistance A2780; SKOV3 cisplatin treatment CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells. 32124583 8306 Human hsa-miR-454 miRNA advanced glycation end product (AGE) epithelial-mesenchymal transition (EMT) primary human peritoneal mesothelial cells (HPMCs) advanced glycation end products (AGEs) treatment "iRNA-454, potentially targeting STAT3, was downregulated in AGEs-treated HPMCs. Overexpression of miRNA-454 prevented AGEs- induced EMT in HPMCs." 30820783 8307 Human hsa-miR-454 miRNA placenta growth factor (PlGF) lung fibrosis endothelial cells placenta growth factor (PlGF) treatment downregulated 26460070 8308 Human hsa-miR-454 miRNA TGF-¦Â1 schistosomiasis LX-2 cells TGF-¦Â1 treatment downregulated 24685242 8309 Human hsa-miR-454-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) ?human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment "In the present study, the results revealed that miR-454-3p expression was substantially downregulated in human aortic endothelial cells (HAECs) following oxidized low-density lipoprotein (ox-LDL) treatment." 33732296 8310 Human hsa-miR-454-3p miRNA X-rays laryngeal cancer "Laryngeal cancer cell lines TU212, LLN and TU686" X-ray radiation treatment HOTAIR knockdown reduced laryngeal cancer cell radiosensitivity by sponging miR-454-3p to silence E2F2 31849488 8311 Human hsa-miR-454-3p miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment downregulated 19022373 8312 Human hsa-miR-454-3p miRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells; H157 cells cisplatin treatment miR-454-3p was expressed lower in cisplatin-resistant LUAD cells than that in the parental LUAD cells. 30099826 8313 Human hsa-miR-454-3p miRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) C666-1 cells; HNE1 cells cisplatin treatment elevated HOXA11-AS and reduced miR-454-3p were found in NPC tissue and cisplatin-resistant NPC cells. 33115978 8314 Human hsa-miR-455 miRNA arsenite arsenite-induced carcinogenesis human keratinocyte (HaCaT) cells arsenite exposure downregulated 29216394 8315 Human hsa-miR-455 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human umbilical vein endothelial cells (HUVECs) TGF-¦Â1 treatment UCA1 exerted its role via regulating the UCA1/miR-455/ZEB1 regulatory axis in HUVECs treated with TGF-¦Â1 32584608 8316 Human hsa-miR-455 miRNA CoCl2 hypoxia-induced injury Human lung epithelial cells BEAS-2B CoCl2 treatment downregulated 30193773 8317 Human hsa-miR-455 miRNA hydrogen sulfide (H2S) hypoxia-induced injury CoCl2-induced human lung epithelial cells BEAS-2B hydrogen sulfide (H2S) treatment upregulated 30193773 8318 Human hsa-miR-455 miRNA H2O2 oxidative stress human endometrial stromal cells (HESCs) hydrogen peroxide (H2O2) treatment downregulated 31638263 8319 Human hsa-miR-455-3p miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) human neuroblastoma cells amyloid ¦Â1-42?(A¦Â) treatment upregulated 28934394 8320 Human hsa-miR-455-3p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 8321 Human hsa-miR-455-3p miRNA TGF-¦Â chronic obstructive pulmonary disease (COPD) primary parenchymal lung fibroblasts TGF-¦Â treatment upregulated 28910321 8322 Human hsa-miR-455-3p miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMC) and human proximal tubule epithelial cells (HK-2) high glucose (HG) treatment downregulated 29932921 8323 Human hsa-miR-455-3p miRNA TGF-¦Â1 diabetic nephropathy (DN) human mesangial cells (HMC) and human proximal tubule epithelial cells (HK-2) transforming growth factor beta 1 (TGF-¦Â1) treatment downregulated 29932921 8324 Human hsa-miR-455-3p miRNA "rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" diffuse large B-cell lymphoma (DLBCL) diffuse large B cell lymphoma (DLBCL) patients serum 6 cycles of R-CHOP treatment dysregulated 24858372 8325 Human hsa-miR-455-3p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human retinal pigment epithelial cells TGF-¦Â1 treatment downregulated 25263462 8326 Human hsa-miR-455-3p miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 8327 Human hsa-miR-455-3p miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 8328 Human hsa-miR-455-3p miRNA bicyclol idiopathic pulmonary fibrosis (IPF) human lung epithelial cells HPAEpiC bicyclol treatment upregulated 31407409 8329 Human hsa-miR-455-3p miRNA vehicle and bicyclol idiopathic pulmonary fibrosis (IPF) human pulmonary alveolar epithelial cells (HPAEpiCs) vehicle and bicyclol treatment upregulated 31407409 8330 Human hsa-miR-455-3p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 8331 Human hsa-miR-455-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells transforming growth factor ¦Â1 (TGF-¦Â1) treatment downregulated 31150929 8332 Human hsa-miR-455-3p miRNA IL-1¦Â osteoarthritis (OA) cultured chondrocytes interleukin-1¦Â (IL-1¦Â) treatment downregulated 31508417 8333 Human hsa-miR-455-3p miRNA IL-1¦Â osteoarthritis (OA) human chondrocyte cell line CHON-001 IL-1¦Â treatment upregulated 31809639 8334 Human hsa-miR-455-3p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment "miR-455-3p continued to increase in the first 21 days during chondrogenesis, peaked at day 21, and then declined." 32343998 8335 Human hsa-miR-455-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32982172 8336 Human hsa-miR-455-5p miRNA MLN4924/Pevonedistat breast cancer MCF-7 cells MLN4924/Pevonedistat treatment miR-455-5p was significantly decreased after MLN4924 treatment in breast cancer cells. 32360865 8337 Human hsa-miR-455-5p miRNA intermittent cyclic mechanical tension (ICMT) degeneration of endplate chondrocytes human endplate cartilage tissues Intermittent cyclic mechanical tension (ICMT) downregulated 30132981 8338 Human hsa-miR-455-5p miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) human brain microvascular endothelial cells (BMECs) oxygen glucose deprivation (OGD) treatment CircPHC3 was highly expressed in human BMECs after OGD 33519202 8339 Human hsa-miR-455-5p miRNA hypoxia myocardial infarction (MI) human cardiomyocyte hypoxia induce Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p. 30898696 8340 Human hsa-miR-455-5p miRNA total flavonoids (TFs) oxLDL-induced vascular smooth muscle cell inflammation vascular smooth muscle cells total flavones of Clematis filamentosa Dunn treatment The total flavones of Clematis filamentosa Dunn promoted the expression of miR-455-5p. 33040830 8341 Human hsa-miR-4634 miRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) mesenchymal stem cells (MSCs) dexamethasone (DEX) treatment downregulated 26151338 8342 Human hsa-miR-4634 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment upregulated 27893811 8343 Human hsa-miR-4634 miRNA Human metapneumovirus (HMPV) innate immune response human dendritic cells Human metapneumovirus (HMPV) infection upregulated 29970194 8344 Human hsa-miR-4634 miRNA respiratory syncytial virus (RSV) innate immune response human dendritic cells respiratory syncytial virus (RSV) infection treatment upregulated 29970194 8345 Human hsa-miR-4650 miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine (GEM) treatment downregulated 25722110 8346 Human hsa-miR-4651 miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 8347 Human hsa-miR-4653-3p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8348 Human hsa-miR-4654 miRNA alternariol (AOH) antagonistic cytotoxic HepG2 cells alternariol (AOH) treatment upregulated 28007639 8349 Human hsa-miR-4654 miRNA alternariol (AOH) cytotoxicity HepG2 cells alternariol (AOH) treatment upregulated 28007639 8350 Human hsa-miR-4654 miRNA resveratrol hypertrophic scars (HS) HS-derived fibroblasts (HSFBs) resveratrol (RS) treatment microRNA-4654 (miR-4654) was significantly decreased in the HSFBs and re-upregulated by resveratrol treatment dose-dependently 32945452 8351 Human hsa-miR-4656 miRNA heat stress heat-induced pathophysiology human umbilical vein endothelial cells cultured in the incubator at 43¡ãC for 1 h "downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)" 29039486 8352 Human hsa-miR-466 miRNA p53 esophageal squamous cell carcinoma (ESCC) ESCC cell lines ?p53 overexpression treatment downregulated 31185143 8353 Human hsa-miR-4665-3p miRNA arsenic sulfide gastric cancer (GC) AGS cells arsenic sulfide treatment upregulated 31692505 8354 Human hsa-miR-4665-5p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8355 Human hsa-miR-4667-5p miRNA statins atherosclerosis (AS) peripheral blood mononuclear cells (PBMCs) statins? treatment upregulated 32885808 8356 Human hsa-miR-4668 miRNA fluticasone eosinophilic esophagitis (EoE) salivary fluticasone treatment downregulated 32923026 8357 Human hsa-miR-4669 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 8358 Human hsa-miR-467 miRNA high glucose (HG) angiogenesis HUVECs;HDMECs;HAECs ?high glucose treatment upregulated 23316333 8359 Human hsa-miR-4680-3p miRNA all-trans retinoic acid (ATRA) cleft palate (CP) human embryonic palatal mesenchymal (HEPM) cells all-trans retinoic acid (ATRA) treatment We found that?all-trans?retinoic acid (atRA) specifically induces?miR-4680-3p?in cultured human embryonic palatal mesenchymal (HEPM) cells. 33585479 8360 Human hsa-miR-4689 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 8361 Human hsa-miR-4701-5p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 8362 Human hsa-miR-4708 miRNA titanium (Ti) osteoblastic differentiation human bone marrow mesenchymal stem cells (hMSCs) Ti treatment downregulated 24619927 8363 Human hsa-miR-4709-3p miRNA TGF-¦Â1 renal fibrosis human kidney proximal tubular cells (HK-2) TGF-¦Â1 treatment upregulated 31455266 8364 Human hsa-miR-4710 miRNA estradiol endothelial dysfunction human umbilical vein endothelial cells (HUVEC) estradiol treatment upregulated 29510375 8365 Human hsa-miR-4712-3p miRNA thymosin ¦Á1 (T¦Á1) non-segmental vitiligo (NSV) peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV) thymosin ¦Á1 (T¦Á1) treatment upregulated 25495156 8366 Human hsa-miR-4715-3p miRNA alternariol (AOH) antagonistic cytotoxic HepG2 cells alternariol (AOH) treatment upregulated 28007639 8367 Human hsa-miR-4715-3p miRNA alternariol (AOH) cytotoxicity HepG2 cells alternariol (AOH) treatment upregulated 28007639 8368 Human hsa-miR-4716-5p miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment downregulated 29860902 8369 Human hsa-miR-4717 miRNA fusobacterium nucleatum (F. nucleatum) colorectal cancer (CRC) The human epithelial colorectal cell line Caco-2 Fusobacterium nucleatum (F. nucleatum) infection upregulated 30951563 8370 Human hsa-miR-4717-3p miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 8371 Human hsa-miR-4726-5p miRNA sodium butyrate (NaB) sickle cell anemia (SCA) CD133 hematopoietic stem cells sodium butyrate treatment dysregulated 26837891 8372 Human hsa-miR-4728-3p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 8373 Human hsa-miR-4734 miRNA aspirin heart repair mesenchymal stem cells (MSCs) aspirin treatment upregulated 32044414 8374 Human hsa-miR-4739 miRNA bleomycin (BLM) pleural fibrosis The human pleural mesothelial cells (PMCs) bleomycin (BLM) treatment upregulated 30850350 8375 Human hsa-miR-4739 miRNA TGF-¦Â1 pleural fibrosis The human pleural mesothelial cells (PMCs) TGF-¦Â1 treatment upregulated 30850350 8376 Human hsa-miR-4741 miRNA herapy with transarterial chemoembolisation (TACE) hepatocellular carcinoma (HCC) HCC patients TACE treatment dysregulated 25230788 8377 Human hsa-miR-4747-5p miRNA high glucose (HG) calcification/senescence human aortic vascular smooth muscle cells (HA-VSMCs) high glucose (HG) treatment downregulated 32483833 8378 Human hsa-miR-4749-5p miRNA xanthohumol (XN) glioblastoma multiforme (GBM) A172 cells; U87-MG cells xanthohumol (XN) treatment upregulated 32422304 8379 Human hsa-miR-4750 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment upregulated 25959385 8380 Human hsa-miR-4756 miRNA albumin diabetic nephropathy (DN) HK-2 cells albumin treatment upregulated 30145827 8381 Human hsa-miR-4756 miRNA albumin diabetic nephropathy (DN) HK-2 cells albumin treatment Albumin stimulation significantly increased miR-4756 levels in HK-2 cells. 30145827 8382 Human hsa-miR-4763-3p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 8383 Human hsa-miR-4769-5p miRNA mechanical compression breast cancer MDA-MB-231 cells and CAFs mechanical compression treatment upregulated 27027350 8384 Human hsa-miR-4773 miRNA titanium (Ti) osteoblastic differentiation human bone marrow mesenchymal stem cells (hMSCs) Ti treatment downregulated 24619927 8385 Human hsa-miR-4784 miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment downregulated 26397152 8386 Human hsa-miR-4785 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment downregulated 25959385 8387 Human hsa-miR-4788 miRNA radon lung cancer BEAS-2B cells radon treatment upregulated 33447367 8388 Human hsa-miR-4792 miRNA radix tetrastigma hemsleyani (RTH) lung cancer A549 cells radix tetrastigma hemsleyani (RTH) treatment upregulated 30100735 8389 Human hsa-miR-4795-5p miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment downregulated 26397152 8390 Human hsa-miR-483 miRNA sera from acute KD patients acute Kawasaki disease (KD) human umbilical vein endothelial cell sera from acute KD patients treatment downregulated 27923814 8391 Human hsa-miR-483 miRNA TGF-¦Â1 anaplastic thyroid carcinoma (ATC) 8505C cells; FRO cells TGF-¦Â1 treatment TGF-¦Â1 increases miR-483 expression and decreases Pard3 expression 30171257 8392 Human hsa-miR-483 miRNA tunicamycin (TM) apoptosis HEK293 cells tunicamycin treatment upregulated 31792031 8393 Human hsa-miR-483 miRNA "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)" hepatocellular carcinoma (HCC) Hep3B cells "3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment" upregulated 23588479 8394 Human hsa-miR-483 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 29218085 8395 Human hsa-miR-483-3p miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment upregulated 29393545 8396 Human hsa-miR-483-3p miRNA black raspberry (BRB) anthocyanins colorectal cancer (CRC) LoVo cells; SW480 cells; HCT116 cells black raspberry (BRB) anthocyanins treatment downregulated 31763724 8397 Human hsa-miR-483-3p miRNA black raspberry (BRB) anthocyanins colorectal cancer (CRC) "Human HCT116 and HT29 CRC cell lines, LoVo cells and SW480 cells" black raspberry (BRB) anthocyanins treatment downregulated 31763724 8398 Human hsa-miR-483-3p miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 8399 Human hsa-miR-483-3p miRNA heartmate II left ventricular assist device (LVAD) implantation heartmate II left ventricular assist device (LVAD) implantation therapy effect plasma and myocardial samples LVAD treatment upregulated 24961598 8400 Human hsa-miR-483-3p miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 8401 Human hsa-miR-483-5p miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 8402 Human hsa-miR-483-5p miRNA hypoxia acute myocardial infarction (AMI) AC16 cells hypoxia treatment miR-483-5p were also upregulated in hypoxia-induced AC16 cell injury. 32206064 8403 Human hsa-miR-483-5p miRNA statins atherosclerosis (AS) peripheral blood mononuclear cells (PBMCs) statins? treatment upregulated 32885808 8404 Human hsa-miR-483-5p miRNA retinoic acid (RA) breast cancer Human embryonic kidney cells (HEK293T) ;HepG2 cells; Huh7 cells; adjacent non-tumor tissues retinoic acid treatment downregulated 22971576 8405 Human hsa-miR-483-5p miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 8406 Human hsa-miR-483-5p miRNA palmitate diabetes mellitus (DM) Human islets palmitate (Pal) treatment upregulated 30131392 8407 Human hsa-miR-483-5p miRNA granulocyte-colony stimulating factor (G-CSF) leukemia CD34+ cells Granulocyte colony-stimulating factor?treatment upregulated 24056818 8408 Human hsa-miR-483-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 8409 Human hsa-miR-483-5p miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine (GEM) treatment upregulated 25722110 8410 Human hsa-miR-483-5p miRNA benzo(a)pyrene (BaP) toxicity of Benzo[a]pyrene (BaP) THBEc1 cells benzo(a)pyrene (BaP) exposure downregulated 32681969 8411 Human hsa-miR-484 miRNA forskolin (Fsk) adrenal steroid production NCI-H295R cells forskolin (Fsk) treatment upregulated 33508847 8412 Human hsa-miR-484 miRNA polyalthia longifolia leaf extract cell death HeLa cells Polyalthia longifolia leaf extract treatment downregulated 31383043 8413 Human hsa-miR-484 miRNA 5-fluorouracil (5-Fu) diabetic nephropathy (DN) ?plasma 5-fluorouracil (5-FU) treatment upregulated 24119443 8414 Human hsa-miR-484 miRNA 5-fluorouracil (5-Fu) metastatic colorectal cancer (mCRC) mCRC patients 5-fluorouracil (5-FU) treatment upregulated 24119443 8415 Human hsa-miR-484 miRNA palmitate nonalcoholic fatty liver disease (NAFLD) hepatocyte cell lines palmitate treatment downregulated 25314137 8416 Human hsa-miR-484 miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment downregulated 26298803 8417 Human hsa-miR-484 miRNA intercept (amotosalen+ ultraviolet-A [UVA] light) pathogen reduction platelet gamma irradiation treatment downregulated 24749844 8418 Human hsa-miR-485 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SK-N-SH; SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment Long Noncoding RNA MIR210HG Promotes the Warburg Effect and Tumor Growth by Enhancing HIF-1¦Á Translation in Triple-Negative Breast Cancer 31794744 8419 Human hsa-miR-485 miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment downregulated 31727371 8420 Human hsa-miR-485 miRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment miR-485 expression is significantly decreased in HG-stimulated HMCs. 31727371 8421 Human hsa-miR-485 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) human neuroblastoma cell lines SK-N-SH and SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 31794744 8422 Human hsa-miR-485 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment downregulated 30182373 8423 Human hsa-miR-485 miRNA epigallocatechin-3-gallate (EGCG) non-small cell lung cancer (NSCLC) A549/cisplatin (A549/CDDP) cells epigallocatechin-3-gallate (EGCG) treatment upregulated 30182373 8424 Human hsa-miR-485-3p miRNA amyloid-¦Â (A¦Â) Alzheimer's disease (AD) SH-SY5Y Cells amyloid-¦Â (A¦Â) treatment upregulated 33220166 8425 Human hsa-miR-485-3p miRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment upregulated 33220166 8426 Human hsa-miR-485-3p miRNA hypoxia angiogenesis Human Brain Microvascular Endothelial Cells (HBMEC) hypoxia induce downregulated 31737200 8427 Human hsa-miR-485-3p miRNA paclitaxel (PTX) breast cancer SK-BR-3 cells paclitaxel (PTX) treatment downregulated 32897218 8428 Human hsa-miR-485-3p miRNA IL-1¦Á cutaneous lupus erythematosus primary PBMCs isolated from discoid lupus erythematosus (DLE) patients IL-1¦Á treatment upregulated 30130620 8429 Human hsa-miR-485-3p miRNA TGF-¦Â1 cutaneous lupus erythematosus primary PBMCs isolated from discoid lupus erythematosus (DLE) patients TGF-¦Â1 treatment upregulated 30130620 8430 Human hsa-miR-485-3p miRNA IL-1¦Á discoid lupus erythematosus (DLE) peripheral mononuclear blood cells from DLE patients IL-1¦Á treatment upregulated 30130620 8431 Human hsa-miR-485-3p miRNA TGF-¦Â1 discoid lupus erythematosus (DLE) peripheral mononuclear blood cells from DLE patients transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 30130620 8432 Human hsa-miR-485-3p miRNA ovalbumin (OVA) pediatric asthma Lymphocytes ovalbumin (OVA) treatment Upregulated 22895815 8433 Human hsa-miR-485-3p miRNA fludarabine prostate cancer DU-145 cells Fludarabine treatment "?in fludarabine treated cells the release of miR-485-3p, as well as its association with exosomes, was reduced suggesting that miR-485-3p was retained by surviving cells" 23734815 8434 Human hsa-miR-485-5p miRNA resveratrol benign prostatic hyperplasia (BPH) Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1 resveratrol (RS) treatment upregulated 33718067 8435 Human hsa-miR-485-5p miRNA TGF-¦Â1 benign prostatic hyperplasia (BPH) Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1 TGF-¦Â1 treatment downregulated 33718067 8436 Human hsa-miR-485-5p miRNA hypoxia hypoxia-induced injury ?12 soft tissue sarcoma cell lines was exposed to 1% oxygen (hypoxia) for up to 48 h treatment upregulated 24927770 8437 Human hsa-miR-485-5p miRNA epigallocatechin-3-gallate (EGCG) non-small cell lung cancer (NSCLC) "A549, H1299, H460 cells" epigallocatechin-3-gallate (EGCG) treatment upregulated 30058740 8438 Human hsa-miR-485-5p miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 8439 Human hsa-miR-486 miRNA high glucose (HG) acute coronary syndrome (ACS) Human Macrophages high glucose treatment upregulated 27519051 8440 Human hsa-miR-486 miRNA TGF-¦Â1 or bone morphogenetic protein 2 (BMP-2) calcific aortic valve disease (CAVD) human aortic valve interstitial cells (AVICs) "TGF-¦Â1,BMP-2 treatment" dysregulated 28377507 8441 Human hsa-miR-486 miRNA tocotrienol-rich fraction (TRF) cell differentiation senescent human skeletal muscle myoblasts (HSMM) senescent human skeletal muscle myoblasts (HSMM) were treated with 50 ¦Ìg/mL TRF for 24 h treatment upregulated 30519366 8442 Human hsa-miR-486 miRNA hypoxia erythroid cell differentiation TF-1 cells hypoxia treatment upregulated 28043832 8443 Human hsa-miR-486 miRNA hypoxia erythroid cell differentiation erythroleukemia TF-1 cells hypoxia treatment upregulated 28043832 8444 Human hsa-miR-486 miRNA cigarette smoke extract (CSE) head and neck squamous cell carcinoma (HNSCC) HaCaT cigarette smoke?extract?(CSE) treatment upregulated 28797462 8445 Human hsa-miR-486 miRNA hypoxia hypoxic/ischemic injury bone marrow-derived mesnechymal stem cells (BM-MSCs) hypoxia treatment upregulated 26801559 8446 Human hsa-miR-486 miRNA propofol (PPF) lung cancer lung cancer cell lines H1299 and H1792 propofol treatment upregulated 28076456 8447 Human hsa-miR-486 miRNA high-intensity interval training (HIIT) skeletal muscle adaptation human human treatment downregulated 27101297 8448 Human hsa-miR-486 miRNA lidocaine skin healing process denatured skin tissues Lidocaine treatment "lidocaine treatment promoted the skin healing after thermal injury through up-regulating miR-486 and miR-663 expression, and partially explained how lidocaine modulates wound healing processes." 31815358 8449 Human hsa-miR-486 miRNA sprint interval training (SIT) training responses skeletal muscle and heart acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment downregulated 29126336 8450 Human hsa-miR-486-3p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment upregulated 31722571 8451 Human hsa-miR-486-3p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment upregulated 31722571 8452 Human hsa-miR-486-3p miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 8453 Human hsa-miR-486-3p miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 8454 Human hsa-miR-486-3p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 8455 Human hsa-miR-486-3p miRNA nintedanib idiopathic pulmonary fibrosis (IPF) Human IPF lung fibroblasts nintedanib treatment downregulated 30841487 8456 Human hsa-miR-486-3p miRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells;DDP cells cisplatin treatment upregulated 24589211 8457 Human hsa-miR-486-5p miRNA hesperetin breast cancer MDA-MB-231 and MCF-7 cells hesperetin treatment "?Hesperetin restored the expression of miR-486-5p, inhibited H19 lncRNA and ICAM-1 expression and selectively regressed mBC cell aggressiveness." 33882812 8458 Human hsa-miR-486-5p miRNA cisplatin (DDP) bladder cancer 5637 cells; EJ138 cancer cells cisplatin treatment MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and downregulated of metastatic genes. 32527702 8459 Human hsa-miR-486-5p miRNA adoMet breast cancer MCF-7 cells adoMet treatment downregulated 30533999 8460 Human hsa-miR-486-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment "XIST and GAB2 were significantly highly expressed, while miR-486-5p was low expressed in SH-SY5Y cells under I/R" 33660813 8461 Human hsa-miR-486-5p miRNA hydroquinone (HQ) erythroid cell differentiation CD34 + hematopoietic progenitor cells hydroquinone (HQ) treatment downregulated 28733890 8462 Human hsa-miR-486-5p miRNA solasonine (SS) gastric cancer (GC) SNU1 cells; SNU5 cells solasonine treatment Solasonine increased the expression of miR-486-5p significantly. 32774717 8463 Human hsa-miR-486-5p miRNA hydroquinone (HQ) hematotoxicity CD34 hematopoietic progenitor cells treat with HQ downregulated 28733890 8464 Human hsa-miR-486-5p miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh-7 cells hepatitis C virus (HCV) infection downregulated 27698829 8465 Human hsa-miR-486-5p miRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) nucleus pulposus (NP) cells lipopolysaccharides (LPS) treatment downregulated 30790508 8466 Human hsa-miR-486-5p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 29505299 8467 Human hsa-miR-486-5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" non-small cell lung cancer (NSCLC) human NSCLC cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28965852 8468 Human hsa-miR-486-5p miRNA estrogen (ES) ovarian cancer (OC) SKOV3 cells SKOV3 cells treatment downregulated 26871282 8469 Human hsa-miR-486-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 8470 Human hsa-miR-486-5p miRNA exercise (Ex) physiological impairments associated with aging circulating exosomes exercise treatment upregulated 32587527 8471 Human hsa-miR-486-5p miRNA TGF-¦Â2 posterior capsular opacification (PCO) SRA01/04 cells TGF-¦Â2 treatment downregulated 29229876 8472 Human hsa-miR-487a miRNA TGF-¦Â1 breast cancer MCF-7 and MDA-MB-231 MCF-7 and MDA-MB-231 treatment upregulation 27019625 8473 Human hsa-miR-487a-3p miRNA 5-fluorouracil (5-FU) locally advanced rectal cancer (LARC) tumor tissues 5-fluorouracil (5-FU) treatment upregulated 32345666 8474 Human hsa-miR-487a-3p miRNA capecitabine locally advanced rectal cancer (LARC) tumor tissues capecitabine treatment upregulated 32345666 8475 Human hsa-miR-487a-3p miRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment Expression level of circHIPK3 in HK-2 cells was remarkably decreased after the treatment of HG. 33628038 8476 Human hsa-miR-487a-5p miRNA estradiol endothelial dysfunction human umbilical vein endothelial cells (HUVEC) estradiol treatment upregulated 29510375 8477 Human hsa-miR-487b miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment upregulated 27158236 8478 Human hsa-miR-487b miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment upregulated 27158236 8479 Human hsa-miR-487b miRNA cigarette smoke condensate (CSC) breast cancer Primary lung cancer specimens and adjacent histologically normal lung parenchyma cigarette smoke condensate (CSC) treatment downregulated 23426183 8480 Human hsa-miR-487b miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells TGF-¦Â1 treatment "the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2," 24258346 8481 Human hsa-miR-487b miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 8482 Human hsa-miR-487b miRNA TGF-¦Â1 lung adenocarcinoma (LUAD) human adenocarcinoma cell lines transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment upregulated 24258346 8483 Human hsa-miR-487b miRNA photodynamic therapy (PDT) skin cancer ATCC-No. CRL-1555 cells Photodynamic therapy (PDT) treatment upregulated 23466801 8484 Human hsa-miR-487b-3p miRNA glial cell-derived neurotrophic factor (GDNF) glioblastoma multiforme (GBM) human U251 glioma cells 50 ng/mL GDNF for 24 h upregulated 29224008 8485 Human hsa-miR-487b-5p miRNA temozolomide (TMZ) lung cancer A549 and H1299 cells Temozolomide (TMZ) treatment downregulated 27097129 8486 Human hsa-miR-488 miRNA high glucose (HG) diabetic nephropathy (DN) Human mesangial cells (HMCs) high glucose (HG) treatment upregulated 31173306 8487 Human hsa-miR-488 miRNA BAY11-7082 helicobacter pylori infection H. pylori infected gastric epithelial cells treated with 10 ¦ÌM Bay 11-7082 upregulated 28208005 8488 Human hsa-miR-488 miRNA 18¦Â-glycyrrhetinic acid (GA) prostate cancer LNCaP cells 18¦Â-glycyrrhetinic acid (GA) treatment miR-488 was markedly induced by GA treatment. 32219716 8489 Human hsa-miR-488-3p miRNA aristolochic acid chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC) paraffin-embedded tissue aristolochic acid (AA) treatment upregulated 26397152 8490 Human hsa-miR-489 miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment downregulated 27158236 8491 Human hsa-miR-489 miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment downregulated 27158236 8492 Human hsa-miR-489 miRNA fluoxetine (Prozac) neurodevelopmental processes SK-N-SH cell lines fluoxetine treatment upregulated 27716787 8493 Human hsa-miR-489 miRNA fluoxetine (Prozac) neurodevelopmental processes SH-SY5Y cell lines fluoxetine treatment upregulated 27716787 8494 Human hsa-miR-489 miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment downregulated 17653614 8495 Human hsa-miR-489 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 8496 Human hsa-miR-489-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells; HSC-T6 cells TGF-¦Â1 treatment downregulated 32144602 8497 Human hsa-miR-489-3p miRNA bupivacaine spinal cord injury (SCI) "human neural cell lines, AGE1.HN and SY-SH-5Y" bupivacaine treatment upregulated 29441872 8498 Human hsa-miR-490 miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) human HCC cell lines HepG2 and Hep3B hepatitis C virus (HCV) infection upregulated 28781655 8499 Human hsa-miR-490 miRNA hepatitis C virus E2 envelope glycoprotein (HCV-E2) hepatocellular carcinoma (HCC) mast cells (MCs) line HMC-1 HCV-E2 upregulated 28781655 8500 Human hsa-miR-490 miRNA IL-1¦Â osteoarthritis (OA) primary cultured chondrocytes IL-1¦Â treatment downregulated 31435813 8501 Human hsa-miR-490-3p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) HPAEpiC (human type II alveolar epithelial cell) lipopolysaccharide (LPS) treatment downregulated 33456519 8502 Human hsa-miR-490-3p miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells; HPAEpiC (human type II alveolar epithelial cell) lipopolysaccharide (LPS) treatment downregulated 33456519 8503 Human hsa-miR-490-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) "The HepG2 cell, hCASMC, and human coronary artery endothelial cell (hCAEC)" oxidized low-density lipoprotein (ox-LDL) treatment upregulated 23821525 8504 Human hsa-miR-490-3p miRNA proline-rich polypeptide 1 (PRP-1) chondrosarcoma human JJ012 chondrosarcoma cell line PRP-1 treatment downregulated 24178909 8505 Human hsa-miR-490-3p miRNA helicobacter pylori (H. pylori) gastric cancer (GC) AGS cells Helicobacter pylori (H. pylori) infection downregulated 32735911 8506 Human hsa-miR-490-3p miRNA TGF-¦Â invasive ductal carcinoma (IDC) MCF10A cells TGF-¦Â treatment The expression of miR-490-3p was induced following transforming growth factor (TGF)-¦Â-induced epithelial-to-mesenchymal transition (EMT) in MCF10A cells 33416185 8507 Human hsa-miR-490-3p miRNA TGF-¦Â1 silicosis MRC-5 cells TGF-¦Â1treatment treatment MiR-490-3p was significantly downregulated in silica-induced fibrotic mouse lung tissues and TGF-¦Â1 treated fibroblasts 33482250 8508 Human hsa-miR-490-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 8509 Human hsa-miR-491 miRNA curcumin (Cur) colorectal cancer (CRC) human HCT-116 cells curcumin treatment upregulated 29058812 8510 Human hsa-miR-491 miRNA arsenic trioxide (ATO) hepatocellular carcinoma (HCC) human hepatocellular carcinoma (HCC) arsenic trioxide (As2O3) treatment upregulated 25304214 8511 Human hsa-miR-491 miRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) SMMC-7721 cells Ginsenoside Rh2 treatment upregulated 25561284 8512 Human hsa-miR-491 miRNA arsenic trioxide (ATO) hepatocellular carcinoma (HCC) human liver cancer cells arsenic trioxide (As2O3) treatment upregulated 24680928 8513 Human hsa-miR-491 miRNA ginsenoside Rh2 lung adenocarcinoma (LUAD) hypoxia-induced A549 and H1299 cells Ginsenoside Rh2 (Rh2) treatment upregulated 31272362 8514 Human hsa-miR-491 miRNA hypoxia lung adenocarcinoma (LUAD) A549 and H1299 cells hypoxia induce downregulated 31272362 8515 Human hsa-miR-491 miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection The hepatoma-derived cell line Huh7 hepatitis C virus (HCV) infection suppression of HCV replication by miR-491 was dependent on the PI3 kinase/Akt pathway. miRNAs altered by HCV infection would then affect HCV replication 21802413 8516 Human hsa-miR-491-3p miRNA atorvastatin hypercholesterolemia HepG2 cells atorvastatin treatment downregulated 27575876 8517 Human hsa-miR-491-3p miRNA metformin (Met) polycystic ovarian syndrome (PCOS) human Ishikawa cells metformin treatment downregulated 30599813 8518 Human hsa-miR-492 miRNA glucose atherosclerosis (AS) HUVEC CRL-1730 cells high glucose stress treatment downregulated 24526524 8519 Human hsa-miR-492 miRNA radiation chondrosarcoma SW1353 cells radiation treatment upregulated 32362797 8520 Human hsa-miR-492 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" clear cell renal cell carcinoma (ccRCC) ccRCC tissues and matched adjacent normal tissues "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25815441 8521 Human hsa-miR-492 miRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells cisplatin treatment miR-492 was upregulated in SGC7901-CDDP Cells. 32065219 8522 Human hsa-miR-493 miRNA lidocaine melanoma melanoma cell line SK-MEL-2 (0-100 uM) lidocaine upregulated 29442040 8523 Human hsa-miR-493 miRNA radiation premature senescence WI-38 cells (human embryonic lung diploid fibroblasts) radiation treatment upregulated 21093163 8524 Human hsa-miR-493 miRNA hypoxia renal fibrosis HK2 cells hypoxia induce upregulated 30183377 8525 Human hsa-miR-493 miRNA Shear stress ruptured intracranial aneurysm (IA) human umbilical vein endothelial cells (HUVECs) Shear stress treatment miR-493 was significantly downregulated in HUVECs exposed to shear stress 33332775 8526 Human hsa-miR-493 miRNA nicotine head and neck squamous cell carcinoma (HNSCC) head and neck cancer cell lines UPCI:SCC131 and SCC172 Nicotine treatment downregulated 27956702 8527 Human hsa-miR-493-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 8528 Human hsa-miR-493-5p miRNA kynurenine bone loss bone marrow stromal cells (BMSCs) kynurenine treatment upregulated 31790802 8529 Human hsa-miR-493-5p miRNA imatinib chronic myeloid leukemia (CML) CML cell line (K562) imatinib in a CML cell line (K562) treatment upregulated 25506832 8530 Human hsa-miR-493-5p miRNA acrolein environmental pollutants human umbilical vein endothelial cells acrolein treatment upregulated 24812010 8531 Human hsa-miR-494 miRNA cisplatin (DDP) acute kidney injury (AKI) HK-2 cells cisplatin treatment downregulated 31930399 8532 Human hsa-miR-494 miRNA bone morphogenetic protein 4 (BMP4) angiogenesis human umbilical vein endothelial cells (HUVECs) bone morphogenetic protein 4 (BMP4) treatment upregulated(miR-126-5p) ;downregulated (miR-494 ) 28124060 8533 Human hsa-miR-494 miRNA ionizing radiation (IR) apoptosis medulloblastoma (MB) cells ionizing radiation (IR) treatment upregulated 23728345 8534 Human hsa-miR-494 miRNA "N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99)" arthritis Human mononuclear suspension cells THP-1 "N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99) treatment" upregulated 31881378 8535 Human hsa-miR-494 miRNA C8 fluoride derivative of cheliensisin A (ChlA-F) bladder cancer "Human BC cell lines (UMUC3, T24T and HT1197)" ChlA-F treatment upregulated 31167152 8536 Human hsa-miR-494 miRNA diesel exhaust particle (DEP) bronchial epithelial cell cancer Primary human bronchial epithelial cells diesel exhaust particle (DEP) exposure upregulated 20049127 8537 Human hsa-miR-494 miRNA ethanol extract of spica prunellae (EESP) colorectal cancer (CRC) HCT-8/5-FU cells ethanol extract of Spica Prunellae (EESP) treatment with 48h upregulated 31662984 8538 Human hsa-miR-494 miRNA nerve growth factor (NGF) cornea epithelial diseases hCECs NGF downregulated 28765880 8539 Human hsa-miR-494 miRNA cinobufacini gastric cancer (GC) BGC-823 cells; SGC-7901 cinobufacini treatment "miR-494 and BAG-1 exhibited opposing trends of in cinobufacini-treated cells, with miR-494 was upregulated and BAG-1 downregu- lated by cinobufacini." 29568970 8540 Human hsa-miR-494 miRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) plasma enterovirus 71 treatment Circulating miR-494 was abnormally upregulated in plasma of the children with EV71-induced HFMD. 32985212 8541 Human hsa-miR-494 miRNA estrogen (ES) hepatocellular carcinoma (HCC) HuH-7 cells Estrogen treatment miR-494 levels are upregulated following estrogen treatment in HuH-7 liver cells in association with downregulated PROS1 mRNA and PS levels. 23789915 8542 Human hsa-miR-494 miRNA hepatitis C virus (HCV) liver fibrosis Huh 7.5.1 cells hepatitis C virus (HCV) infection downregulated 26157120 8543 Human hsa-miR-494 miRNA hexavalent chromium [Cr(VI)] lung cancer human bronchial epithelial cells BEAS-2B Hexavalent chromium [Cr(VI)] exposure downregulated 31504995 8544 Human hsa-miR-494 miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 8545 Human hsa-miR-494 miRNA compound 331 malignant glioma glioma cells compound 331 treatment upregulated 26153143 8546 Human hsa-miR-494 miRNA silibinin (SB) neck squamous cell carcinomas (HNC) neck squamous cell carcinomas (HNC) silibinin (SB) treatment upregulated 26090866 8547 Human hsa-miR-494 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 8548 Human hsa-miR-494 miRNA silybin osteosarcoma (OS) Saos-2 cells silybin treatment upregulated 29068478 8549 Human hsa-miR-494 miRNA TGF-¦Â3 preeclampsia (PE) Decidual mesenchymal stem cells (dMSCs) TGF-¦Â3 treatment upregulated 27149081 8550 Human hsa-miR-494 miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed upregulated 27915273 8551 Human hsa-miR-494 miRNA amB with copper (II) ions (AmB-Cu2+) renal fibrosis normal human renal proximal tubule epithelial cells (RPTEC) complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower downregulated 28534445 8552 Human hsa-miR-494 miRNA titanium surface implant-host tissue interactions osteoblastic cells from human alveolar bone osteoblastic cells from human alveolar bone treatment dysregulated 27200092 8553 Human hsa-miR-494 miRNA TGF-¦Â tumor immune evasion in gastric cancer (GC) T cells TGF-¦Â treatment upregulated 33247701 8554 Human hsa-miR-494-3p miRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment lncRNA TUG1 was decreased while miR-494-3p was elevated in vivo and in vitro. 33663500 8555 Human hsa-miR-494-3p miRNA hypoxia/reoxygenation (H/R) cardiac surgery-associated acute kidney injury (CSA-AKI) human kidney tubular epithelial (HK2) cells hypoxia/reoxygenation (H/R) treatment "Our result showed that Hsa-miR-494-3p was elevated in the serum of patients with CSA-AKI, and also induced in hypoxic reoxygenated HK2 cells." 33462352 8556 Human hsa-miR-494-3p miRNA enterovirus 71 (EV71) endometrial cancer (EC) Rhabdomyosarcoma (RD) and human embryonic kidney (HEK) 293 cells Enterovirus 71 (EV71) infection upregulated 30234021 8557 Human hsa-miR-494-3p miRNA sodium butyrate (NaB) lung cancer A549 cells sodium butyrate(NaB) treatment upregulated 29231270 8558 Human hsa-miR-494-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 29567426 8559 Human hsa-miR-494-3p miRNA pramipexole (PPX) parkinson's disease (PD) SK-N-SH cells; CHP 212 cells Pramipexole (PPX) treatment PPX inhibited MPP+-induced neurotoxicity in SK-N-SH and CHP 212 cells by decreasing miR-494-3p and increasing BDNF 31811458 8560 Human hsa-miR-494-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH and CHP 212 cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 31811458 8561 Human hsa-miR-494-3p miRNA pramipexole (PPX) parkinson's disease (PD) 1-Methyl-4-phenylpyridinium (MPP+) treated SK-N-SH and CHP 212 cells Pramipexole (PPX) treatment downregulated 31811458 8562 Human hsa-miR-494-3p miRNA rotenone (ROT) RPE mitochondrial dysfunction ARPE-19 cells rotenone treatment Elevated levels of miR-494-3p in EVs released by ARPE-19 cells indicate diminished capacity of the mitochondria within these cells 32240720 8563 Human hsa-miR-495 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" breast cancer "human BC cell lines MCF-7 , HCC1973, the immortalized breast epithelial MCF10A,human embryonic kidney 293T" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28498478 8564 Human hsa-miR-495 miRNA high glucose (HG) cardiac fibrosis human cardiac fibroblasts (CFs) high glucose treatment downregulated 29760746 8565 Human hsa-miR-495 miRNA propofol (PPF) chondrosarcoma JEG-3 cells propofol treatment upregulated 31046467 8566 Human hsa-miR-495 miRNA galacto-oligosaccharides (GOS) colitis normal and LPS-stimulated human colon epithelial FHC cells galacto-oligosaccharides (GOS) treatment upregulated 31226416 8567 Human hsa-miR-495 miRNA lipopolysaccharide (LPS) colitis human colon epithelial FHC cells lipopolysaccharide (LPS) treatment downregulated 31226416 8568 Human hsa-miR-495 miRNA muramyl dipeptide crohn disease (CD) ?HCT116 cells Muramyl dipeptide treatment downregulated 24297055 8569 Human hsa-miR-495 miRNA dextran sodium sulfate (DSS) inflammatory bowel disease (IBD) "human colonic epithelial cell lines (HT-29, LOVO, and Caco-2)" dextran sulfate sodium (DSS) treatment miR-495 was lowly expressed in the colonic epithelial cell lines. 31251902 8570 Human hsa-miR-495 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment The cisplatin-R group exhibited lower levels of UCA1 and NRF2 expression but a higher level of miR-495 expression than the cisplatin-S group 31583720 8571 Human hsa-miR-495 miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment CircSERPINE2 could mediate TGFBR2 expression by binding with miR-495. 33094798 8572 Human hsa-miR-495-3p miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment downregulated 33856026 8573 Human hsa-miR-495-3p miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment downregulated 33830389 8574 Human hsa-miR-495-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) AGS cells; SNU484 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28991363 8575 Human hsa-miR-495-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "AGS, MKN28, MKN45 , SNU216, SNU484 cancer cell lines" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" restore miR-495-3p expression 28991363 8576 Human hsa-miR-495-3p miRNA tumor necrosis factor alpha (TNF-¦Á) intervertebral disc degeneration (IDD) human Nucleus Pulposus Cells tumor necrosis factor alpha (TNF-¦Á) treatment MiRNA-495-3p Attenuates TNF-¦Á Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Targeting IL5RA 32445070 8577 Human hsa-miR-495-3p miRNA hypoxia/reoxygenation (H/R) intestinal hypoxia/reoxygenation injury caco-2 cells hypoxia-reoxygeneration (H/R) treatment upregulated 26935288 8578 Human hsa-miR-495-3p miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment downregulated 26987780 8579 Human hsa-miR-496 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 30597231 8580 Human hsa-miR-496 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 30597231 8581 Human hsa-miR-496 miRNA hypoxia/reoxygenation (H/R) myocardial infarction (MI) human cardiomyocyte (HCM) hypoxia/reoxygenation (H/R) treatment miR-496 was lowly expressed in H/R-treated human cardiomyocyte (HCM). 31436348 8582 Human hsa-miR-496 miRNA IL-1¦Â osteogenesis human bone marrow-derived mesenchymal stem cells (hBMMSC) IL-1¦Â treatment upregulated 28509407 8583 Human hsa-miR-496 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 8584 Human hsa-miR-496 miRNA oxidized low density lipoprotein (ox-LDL) vascular endothelial dysfunction human umbilical vascular endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 30811087 8585 Human hsa-miR-497 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 27918592 8586 Human hsa-miR-497 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28653788 8587 Human hsa-miR-497 miRNA cisplatin (DDP) tumorigenesis A549 cells cisplatin treatment downregulated 21258880 8588 Human hsa-miR-497 miRNA hypoxia cell proliferation human primary pulmonary artery smooth muscle cells hypoxia induce upregulated 31370272 8589 Human hsa-miR-497 miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) treatment downregulated 31696986 8590 Human hsa-miR-497 miRNA bufalin colorectal cancer (CRC) human colorectal cancer HCT116 cells bufalin treatment upregulated 24375248 8591 Human hsa-miR-497 miRNA probucol coronary artery disease (CAD) HUVECs probucol treatment upregulated 26897284 8592 Human hsa-miR-497 miRNA high glucose (HG) diabetic foot ulcer (DFU) human dermal fibroblasts cells high glucose treatment downregulated 31707336 8593 Human hsa-miR-497 miRNA lipopolysaccharide (LPS) diabetic foot ulcer (DFU) human dermal fibroblasts cells lipopolysaccharide (LPS) treatment downregulated 31707336 8594 Human hsa-miR-497 miRNA high glucose (HG) diabetic nephropathy (DN) kidney tissues high glucose (HG) treatment ANRIL and TXNIP were elevated in DN kidney tissues and HG-treated HK-2 cells while miR-497 was reduced.?miR-497 mimics inhibited caspase-1-dependent pyroptosis while co-overexpression of TXNIP blocked its effects in HG-treated HK-2 cells. 33160992 8595 Human hsa-miR-497 miRNA high glucose (HG) diabetic nephropathy (DN) human renal tubular epithelial cell cells (HK-2) high glucose (HG) treatment ANRIL promotes pyroptosis and kidney injury in DN via acting as miR-497 sponge to disinhibit TXNIP expression. 33160992 8596 Human hsa-miR-497 miRNA melatonin diabetic nephropathy (DN) glomerular endothelial cells (GEnCs) melatonin (MT) treatment MiR-497 expression was increased in melatonin-treated glomerular endothelial cells (GEnCs). 30212830 8597 Human hsa-miR-497 miRNA high glucose (HG) and lipopolysaccharide (LPS) diabetic retinopathy (DR) HDF; WI38 cells high glucose (HG) and LPS treatment downregulated 31707336 8598 Human hsa-miR-497 miRNA metformin (Met) esophageal squamous cell carcinoma (ESCC) KYSE510 cells metformin treatment upregulated 30771436 8599 Human hsa-miR-497 miRNA hypoxia glioblastoma multiforme (GBM) Glioma cells U87 and U251 and HEK293T cells 1% oxygen for 12 h treatment upregulated 25080009 8600 Human hsa-miR-497 miRNA cigarette smoke extract (CSE) human bronchial epithelial (HBE) cells injury HBE cells cigarette smoke extract (CSE) exposure CSE treatment decreased miR-497 level in HBE cells. 31696986 8601 Human hsa-miR-497 miRNA vincristine (VCR) lung cancer human gastric cancer cell line SGC7901 vincristine (VCR) treatment downregulated 21258880 8602 Human hsa-miR-497 miRNA ethanol (EtOH) neuronal cell death SH-SY5Y cells ethanol treatment upregulated 21878650 8603 Human hsa-miR-497 miRNA amikacin neuronal cell death SH-SY5Y cells treat with amikacin downregulated 27209189 8604 Human hsa-miR-497 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 8605 Human hsa-miR-497 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" spinal ossification of the posterior longitudinal ligament (OPLL) posterior longitudinal ligament (PLL) cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated of miR-497 in CMS-treated PLL cells was restored by a demethylation reagent 5-aza-2'-deoxycytidine (AZA). 32432317 8606 Human hsa-miR-497 miRNA cyclic mechanical stretch (CMS) spinal ossification of the posterior longitudinal ligament (OPLL) posterior longitudinal ligament (PLL) cells cyclic mechanical stress (CMS) treatment miR-497 was downregulated in treated PLL cells. 32432317 8607 Human hsa-miR-497-5p miRNA mitogen activated-protein kinase pathway inhibitors (MAPKis) cutaneous malignant melanoma (CMM) extracellular microvesicle in matched plasma Mitogen activated-protein kinase pathway inhibitors (MAPKis) treatment upregulated 30399176 8608 Human hsa-miR-497-5p miRNA cisplatin (DDP) gastric cancer (GC) BGC823 cells; SGC7901 cisplatin treatment downregulated 33149605 8609 Human hsa-miR-497-5p miRNA IL-1¦Â osteoarthritis (OA) human Osteoarthritis Chondrocytes IL-1¦Â treatment dysregulated 27152662 8610 Human hsa-miR-497-5p miRNA IL-1¦Â osteoarthritis (OA) Chondrocytes IL-1¦Â treatment downregulated 31934153 8611 Human hsa-miR-497-5p miRNA X-rays radiosensitivity "KYSE-30, KYSE-180, KYSE-150 and TE-5" X-ray radiation treatment LINC00473 reduces the radiosensitivity of ESCC cells by modulating the miR-497-5p/CDC25A axis 32468021 8612 Human hsa-miR-498 miRNA IL-13 allergic rhinitis (AR) nasal epithelial cells (NECs) IL-13 treatment upregulated 31315126 8613 Human hsa-miR-498 miRNA IL-13 allergic rhinitis (AR) nasal epithelial cells (NECs) IL-13 treatment "Linc00632 inhibited IL-13-induced GM-CSF, eotaxin, and MUAC5AC production in IL-13-treated NECs by targeting miR-498" 31315126 8614 Human hsa-miR-498 miRNA propofol (PPF) esophageal cancer (EC) EC109; KYSE70 cells Propofol treatment "Propofol suppresses hypoxia-induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO-AS1/miR-498 axis" 32643321 8615 Human hsa-miR-498 miRNA hypoxia myocardial infarction (MI) human induced pluripotent stem-derived cardiomyocytes (HCMs) hypoxia treatment Circ_0068655 Promotes Cardiomyocyte Apoptosis via miR-498/PAWR Axis 32767028 8616 Human hsa-miR-498 miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) CNE-2R cells curcumin treatment upregulated 31793078 8617 Human hsa-miR-498 miRNA "trans-3,5,4-trimethoxystilbene (TMS)" non-small cell lung cancer (NSCLC) H1299 and PC©\9/GR cells "trans-3,5,4-trimethoxystilbene (TMS) treatment" upregulated 30701693 8618 Human hsa-miR-498 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment downregulated 28619522 8619 Human hsa-miR-498 miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment upregulated 26987780 8620 Human hsa-miR-498 miRNA lipopolysaccharide (LPS) periodontitis human periodontal ligament cells (hPDLCs) lipopolysaccharide (LPS) treatment ?TUG1 was downregulated upon LPS stimulation in hPDLCs. 32762066 8621 Human hsa-miR-498 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" tissue injury OVCAR3 cells; A2780 cells;A2780-CP cells; C13 cells;OV2008 cells; CAOV3 cells; MCF-7 cells; Ishikawa cells;HeLa cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" "miR-498 induced by 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3)) decreases the mRNA expression of the human telomerase reverse transcriptase" 23055531 8622 Human hsa-miR-498-5p miRNA neodymium oxide (Nd2O3) inflammation human bronchial epithelial (16HBE) cells neodymium oxide treatment upregulated 32199215 8623 Human hsa-miR-499 miRNA hemodialysis cardiac hypertrophy cardiac patients on hemodialysis plasma treat with high-flux or low-flux dialysis downregulated 29064177 8624 Human hsa-miR-499 miRNA anthracycline (AC) cardiotoxicity children plasma anthracycline (AC) treatment upregulated 28377429 8625 Human hsa-miR-499 miRNA caffeine cardiovascular disease (CVD) HL-1 and primary embryonic cardiomyocytes exposure to physiologically relevant doses of caffeine treatment upregulated 25354728 8626 Human hsa-miR-499 miRNA cyclic mechanical stretch (CMS) cardiovascular disease (CVD) human cardiac fibroblasts-adult atrial (HCF-aa) cyclic stretching treatment "MiR208a was upregulated early by stretching and returned to normal levels with longer stretching cycles, whereas the expression of miR499 and Bcl-2 was upregulated by longer stretching times." 33605072 8627 Human hsa-miR-499 miRNA homocysteine (Hcy) hyperhomocysteinemia (HHcy) HL-1 cardiomyocytes 100 ¦ÌM homocysteine treatment downregulated 24495916 8628 Human hsa-miR-499-5p miRNA exercise (Ex) muscle injury muscle exercise treatment upregulated 26472872 8629 Human hsa-miR-499-5p miRNA statins muscle injury plasma statins? treatment upregulated 26472872 8630 Human hsa-miR-499a-5p miRNA ursolic acid (UA) breast cancer "breast CSCs enriched from breast cancer cell lines, MCF7, MDA-MB-231 and T47D" ursolic acid (UA) treatment "UA can target breast CSCs via Wnt by suppressing miR-499a-5p and upregulating the Wnt antagonist, sFRP4" 33278391 8631 Human hsa-miR-499a-5p miRNA tumor necrosis factor alpha (TNF-¦Á) intervertebral disc degeneration (IDD) human nucleus pulposus cells (NPC) tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 30856535 8632 Human hsa-miR-499a-5p miRNA forskolin (Fsk) adrenal steroid production NCI-H295R cells forskolin (Fsk) treatment upregulated 33508847 8633 Human hsa-miR-499a-5p miRNA IL-1¦Â and forskolin (Fsk) adrenal steroid production NCI-H295R cells IL-1¦Â and forskolin (Fsk) treatment downregulated 33508847 8634 Human hsa-miR-499a-5p miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh7 cells hepatitis C virus (HCV) infection upregulated 24241692 8635 Human hsa-miR-499b-5p miRNA lipopolysaccharide (LPS) neonatal pneumonia WI-38 cells lipopolysaccharide (LPS) treatment UCA1 inhibition protected WI-38 cells against LPS-managed inflammatory injury and apoptosis process via miR-499b-5p/TLR4 crosstalk. 33368965 8636 Human hsa-miR-499b-5p miRNA lipopolysaccharide (LPS) neonatal pneumonia WI-38 cells lipopolysaccharide (LPS) treatment ?We displayed that UCA1 was elevated in LPS-injured WI-38 cells. 33368965 8637 Human hsa-miR-4a-5p miRNA oral zinc gluconate esophageal cancer (EC) barrett's esophagus (BE) oral zinc gluconate treatment upregulated 32415564 8638 Human hsa-miR-500 miRNA granulocyte-colony stimulating factor (G-CSF) leukemia CD34+ cells Granulocyte colony-stimulating factor?treatment upregulated 24056818 8639 Human hsa-miR-5001-5p miRNA radon lung cancer BEAS-2B cells radon treatment upregulated 33447367 8640 Human hsa-miR-5006-5p miRNA kynurenine bone loss bone marrow stromal cells (BMSCs) kynurenine treatment upregulated 31790802 8641 Human hsa-miR-5006-5p miRNA ursolic acid (UA) breast cancer BT474 cells usnic acid treatment upregulated 31549595 8642 Human hsa-miR-500a-3p miRNA cisplatin (DDP) acute kidney injury (AKI) HK2 cell cisplatin treatment downregulated 30365367 8643 Human hsa-miR-500a-3P miRNA cisplatin (DDP) acute kidney injury (AKI) HK-2 cells cisplatin treatment hsa-miR-500a-3P was significantly suppressed in cisplatin-treated human tubular epithelial (HK2) cells. 30365367 8644 Human hsa-miR-500a-3p miRNA cisplatin (DDP) gastric cancer (GC) MGC803 cells; MKN45 cells cisplatin treatment Exosomal miR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer 32588541 8645 Human hsa-miR-500a-5p miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment downregulated 31597953 8646 Human hsa-miR-500a-5p miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment downregulated 31597953 8647 Human hsa-miR-500a-5p miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human primary monocyte-derived macrophages infect with HIV-1 upregulated 28594894 8648 Human hsa-miR-500a-5p miRNA angiotensin II (Ang II) membranous nephropathy (MN) AB8/13 podocytes angiotensin II (Ang II) treatment "AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p." 32974919 8649 Human hsa-miR-500a-5p miRNA angiotensin II (Ang II) membranous nephropathy (MN) human podocyte cell line AB8/13 podocytes angiotensin II (Ang II) treatment "AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p, and induced cell apoptosis in podocytes." 32974919 8650 Human hsa-miR-501 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 8651 Human hsa-miR-501 miRNA doxorubicin (DOX) gastric cancer (GC) SGC7901 cells doxorubicin treatment "Endogenous miR-501 was higher, whereas BLID was lower, in doxorubicin-resistant gastric cancer SGC7901/ADR cells compared with their parental SGC7901 cells." 30195794 8652 Human hsa-miR-501 miRNA doxorubicin (DOX) gastric cancer (GC) doxorubicin-resistant gastric cancer (GC) SGC7901/ADR cell-secreted exosomes (ADR Exo) doxorubicin treatment upregulated 31173853 8653 Human hsa-miR-501-3p miRNA estradiol endothelial dysfunction human umbilical vein endothelial cells (HUVEC) estradiol treatment upregulated 29510375 8654 Human hsa-miR-501-3p miRNA cisplatin (DDP) glioblastoma multiforme (GBM) U251 cells cisplatin treatment Cisplatin treatment inhibited the level of miR-501-3p in a time-dependent way. 30221699 8655 Human hsa-miR-501-3p miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 31076402 8656 Human hsa-miR-501-3p miRNA hepatitis C virus (HCV) hepatitis C virus (HCV)-induced liver disease and hepatocarcinogenesis Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 31076402 8657 Human hsa-miR-501-5p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 8658 Human hsa-miR-501-5p miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 8659 Human hsa-miR-502 miRNA doxorubicin (DOX) doxorubicin (DOX)-induced cardiotoxicity plasma extracellular vesicle (EV) doxorubicin (Dox) treatment upregulated 32255536 8660 Human hsa-miR-502 miRNA BAY11-7082 intervertebral disc degeneration (IDD) TNF-¦Á treated human nucleus pulposus (NP) cell BAY 11-7082 treatment "Moreover, both TNF-¦Á?and BAY 11-7082 treatments were associated with marked miRNA dysregulation, with miR-502 being upregulated by TNF-¦Á?treatment and downregulated by BAY 11-7082 treatment, respectively." 33869626 8661 Human hsa-miR-502 miRNA tumor necrosis factor alpha (TNF-¦Á) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cell tumor necrosis factor alpha (TNF-¦Á) treatment "Moreover, both TNF-¦Á?and BAY 11-7082 treatments were associated with marked miRNA dysregulation, with miR-502 being upregulated by TNF-¦Á?treatment and downregulated by BAY 11-7082 treatment, respectively" 33869626 8662 Human hsa-miR-502-3p miRNA niacin insulin resistance (IR) hMADS adipocytes niacin treatment upregulated 30482933 8663 Human hsa-miR-502-3p miRNA niacin insulin resistance (IR) human adipocytes niacin treatment upregulated 30482933 8664 Human hsa-miR-502-5p miRNA IL-1¦Â osteoarthritis (OA) human primary chondrocytes IL-1¦Â treatment downregulated 26861148 8665 Human hsa-miR-502c miRNA co-nanoencapsulated curcumin (Cur) and chrysin (Chr) breast cancer MDA-MB-231 breast cancer cells co-nanoencapsulated Curcumin (Cur) and Chrysin (Chr) treatment upregulated 30955355 8666 Human hsa-miR-503 miRNA hypoxia tumor angiogenesis and growth Cell lines HepG2 and LO2 ?hypoxia treatment downregulated 23352645 8667 Human hsa-miR-503 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophages atherogenic Evs oxidized low-density lipoprotein (ox-LDL) treatment enrichment in atherogenic EVs 28882869 8668 Human hsa-miR-503 miRNA ionizing radiation (IR) tumorigenesis Human dermal microvascular endothelial cells(HDMEC) ionizing radiation treatment downregulated 20346162 8669 Human hsa-miR-503 miRNA TGF-¦Â cell cycle arrest MCF-10A and MCF-12 cells TGF-¦Â treatment upregulated 25266660 8670 Human hsa-miR-503 miRNA TGF-¦Â liver fibrosis LX-2 cells TGF-¦Â treatment upregulated 32648079 8671 Human hsa-miR-503 miRNA tumor necrosis factor alpha (TNF-¦Á) hepatocellular apoptosis Hep-nonstructural protein 5A (Hep-NS5A) cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28343379 8672 Human hsa-miR-503 miRNA lactobacillus casei (L. casei LC01) irritable bowel syndrome with diarrhea (IBS-D) intestinal epithelial cells (IECs) L. casei LC01 treatment downregulated 32807750 8673 Human hsa-miR-503 miRNA ezetimibe monocytic differentiation Human monocytic cell lineTHP-1 Ezetimibe trratment downregulated 22989505 8674 Human hsa-miR-503 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" non-small cell lung cancer (NSCLC) NSCLC cell lines from patients with NSCLC "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 24486548 8675 Human hsa-miR-503 miRNA high glucose (HG) proximal tubular cell apoptosis Human proximal tubular (HK-2) cells high glucose (HG) treatment MIR503HG indirectly regulates Bcl-2 by promoting the co-transcription of miRNA-503 to participate high-glucose-induced proximal tubular cell apoptosis. 33262626 8676 Human hsa-miR-503 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (hPASMCs) hypoxia treatment lncRNA MALAT1 promotes the proliferation and migration of hPASMCs and inhibits their apoptosis by inhibiting the miR-503/TLR4 signal axis. 32712618 8677 Human hsa-miR-503 miRNA IL-13 pulmonary arterial hypertension (PAH) primary human pulmonary artery endothelial cells (HPAECs) Interleukin-13 (IL-13) treatment downregulated 29102771 8678 Human hsa-miR-503 miRNA IL-13 pulmonary arterial hypertension (PAH) human pulmonary artery endothelial cells (HPAECs) Interleukin-13 (IL-13) treatment downregulated 29102771 8679 Human hsa-miR-503-5p miRNA microgravity apoptosis human pulmonary microvascular endothelial cells (HPMECs) microgravity treatment upregulated 30216505 8680 Human hsa-miR-503-5p miRNA microgravity endothelial dysfunction human pulmonary microvascular endothelial cells (HPMECs) microgravity treatment miR-503-5p is dramatically upregulated in HPMECs in simulated microgravity. 30216505 8681 Human hsa-miR-503-5p miRNA tensile hepatocellular carcinoma (HCC) HepG2 cells tensile treatment downegulated 32323778 8682 Human hsa-miR-504 miRNA oral zinc gluconate esophageal cancer (EC) barrett's esophagus (BE) oral zinc gluconate treatment upregulated 32415564 8683 Human hsa-miR-504 miRNA IFN-¦Â multiple sclerosis (MS) whole blood IFN-¦Â treatment "The expression level of miR-504 was significantly higher in patients who respond to IFN-¦Â therapy, compared with non-responders." 32199199 8684 Human hsa-miR-505 miRNA prednisolone active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) prednisolone treatment downregulated 24215168 8685 Human hsa-miR-505 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) exosomes from human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31768526 8686 Human hsa-miR-505 miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) nasopharyngeal carcinoma cell HK-1 TGF-¦Âtreatment upregulated 26032086 8687 Human hsa-miR-505 miRNA cisplatin (DDP) gastric cancer (GC) BGC823 cells; SGC7901 cells cisplatin treatment upregulated 31885317 8688 Human hsa-miR-505 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 8689 Human hsa-miR-505 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH5Y-SY cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 30025813 8690 Human hsa-miR-505 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 8691 Human hsa-miR-506 miRNA TGF-¦Â1 lung fibrosis MRC-5 cells TGF-¦Â1 treatment downregulated 31214773 8692 Human hsa-miR-506 miRNA estradiol breast cancer MCF-7 breast cancer cells Estradiol treatment downregulated 19528081 8693 Human hsa-miR-506 miRNA "anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)" bronchial epithelial cell cancer 16HBE-T cells and the control untransformed cell line 16HBE-N cells "anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide (anti-BPDE) treatment" expression of miR-506 was reduced in 16HBE-T transformed malignant human bronchial epithelial cells compared with 16HBE normal human bronchial epithelial cells 21726609 8694 Human hsa-miR-506 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) SK-HEP-1 cells; Huh-7 cells; HCC tissues sorafenib treatment miR-506 was downregulated in sorafenib-resistant HCC tissues and cells 33000204 8695 Human hsa-miR-506 miRNA H2O2 cardiac dysfunction human cardiomyocyte (HCM) H2O2 treatment downregulated 28849090 8696 Human hsa-miR-506 miRNA ¦Ã-rays laryngeal cancer human larynx squamous carcinoma cell line Hep-2 637 cGy 60Co rays radiation downregulated 30980388 8697 Human hsa-miR-506 miRNA IL-1¦Â osteosarcoma (OS) "human OS cell line(Saos2, MG63, U2OS, and SW1353)" IL-6¦Â treatment downregulated 28926924 8698 Human hsa-miR-506 miRNA rosmarinic acid (RA) pancreatic cancer (PC) Pancreatic cancer cell lines (Panc-1 and SW1990) rosmarinic acid treatment upregulated 31060006 8699 Human hsa-miR-506-3p miRNA erlotinib non-small cell lung cancer (NSCLC) HCC4006 cells erlotinib treatment miR-506-3p expression was markedly reduced in erlotinib-resistant (ER) cells. 33291316 8700 Human hsa-miR-506-3p miRNA gefitinib non-small cell lung cancer (NSCLC) PC-9 cells gefitinib treatment downregulated 30535506 8701 Human hsa-miR-506-3p miRNA high glucose (HG) oxidative stress HK-2 cells high glucose (HG) treatment "downregulated of KCNQ1OT1 inhibited the inflammation, oxidative stress and pyroptosis of HG-induced HK-2 cells by up-regulating the expression of miR-506-3p." 32104033 8702 Human hsa-miR-506-5p miRNA estradiol-17¦Â (E2) endometriosis ectopic endometrial tissue estradiol-17¦Â (E2) treatment LINC01541 functions as a ceRNA that modulates the Wnt/¦Â-catenin pathway by decoying miR-506-5p. 32833189 8703 Human hsa-miR-508-3p miRNA graphene oxide (GO) graphene oxide (GO) toxicity GLC-82 cells GO treatment dysregulated 24512264 8704 Human hsa-miR-508-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment ZNF295-AS1 inhibits autophagy via the ZNF295-AS1/miR-508-5p/ATG7 axis in AS 32633396 8705 Human hsa-miR-508-5p miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 8706 Human hsa-miR-509-3p miRNA proline-rich polypeptide 1 (PRP-1) chondrosarcoma human JJ012 chondrosarcoma cell line PRP-1 treatment downregulated 24178909 8707 Human hsa-miR-509-3p miRNA respiratory syncytial virus (RSV) respiratory syndrome virus (PRRSV) infection sputum specimens; A549 cells; BEAS-2B cells respiratory syncytial virus (RSV) infection treatment upregulated 32102886 8708 Human hsa-miR-5094 miRNA X-rays cellular radiation response HeLa cells X-ray irradiation treatment "upregulated of miR-5094 downregulated the expression of STAT5b, thereby suppressing cell proliferation after X-ray irradiation" 32127949 8709 Human hsa-miR-5095 miRNA X-rays cervical cancer (CC) Hela cells irradiated with 6?Gy of X-ray treatment downregulated 31169309 8710 Human hsa-miR-5096 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 8711 Human hsa-miR-512 miRNA prostaglandin E1 (PGE1) contrast-induced nephropathy (CIN) THP-1 cells; peripheral blood samples PGE1 treatment MiR-512 could directly bind to and negatively regulate the expression of PTGS1 and HULC 32678165 8712 Human hsa-miR-512 miRNA muramyl dipeptide crohn disease (CD) ?HCT116 cells Muramyl dipeptide treatment downregulated 24297055 8713 Human hsa-miR-512-3p miRNA thrombospondin-1 (TSP-1) angiogenesis vascular smooth muscle cell (VSMC) Thrombospondin-1 (TSP-1) treatment upregulated 26728995 8714 Human hsa-miR-512-3p miRNA hypoxia hepatocellular carcinoma (HCC) Hep3B cells hypoxia treatment Hypoxia could elevate miR-512-3p levels in HCC cells. 32612368 8715 Human hsa-miR-512-5p miRNA radiation cervical cancer (CC) cervical cancer tissues radiation treatment miR-512-5p expression was dramatically downregulated in the radiotherapy resistant group 32126879 8716 Human hsa-miR-512-5p miRNA retinoic acid (RA) non-small cell lung cancer (NSCLC) NSCLC cell lines A549 and H1299 retinoic acid treatment downregulated 26648284 8717 Human hsa-miR-512-5p miRNA retinoic acid (RA) non-small cell lung cancer (NSCLC) A549 and H1299 cell lines retinoic acid treatment upregulated 26648284 8718 Human hsa-miR-513 miRNA cryptosporidium parvum human biliary cryptosporidiosis cholangiocytes H69 cells cryptosporidium parvum? infection downregulated 19916867 8719 Human hsa-miR-513 miRNA IFN-¦Ã immune response H69 cells IFN-¦Ã treatment downregulated 19155478 8720 Human hsa-miR-513a-5p miRNA 5-fluorouracil (5-Fu) retinoblastoma (RB) retinoblastoma cells 5-fluorouracil (5-Fu) treatment silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells. 31264280 8721 Human hsa-miR-513a-5p miRNA carboplatin (CBP) retinoblastoma (RB) retinoblastoma cells carboplatin (CBP) treatment silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells. 31264280 8722 Human hsa-miR-513a-5p miRNA cisplatin (DDP) retinoblastoma (RB) retinoblastoma cells cisplatin treatment silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells. 31264280 8723 Human hsa-miR-513a-5p miRNA vincristine (VCR) retinoblastoma (RB) retinoblastoma cells vincristine (VCR) treatment silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells. 31264280 8724 Human hsa-miR-513a-5p miRNA etoposide (VP-16) retinoblastoma (RB) retinoblastoma cells Etoposide (VP-16) treatment silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells 31264280 8725 Human hsa-miR-513a-5p miRNA dichlorvos (DDVP) apoptosis human kidney cell line HK-2 dichlorvos treatment upregulated 30372899 8726 Human hsa-miR-513a-5p miRNA TNF-¦Á and lipopolysaccharide (LPS) apoptosis human umbilical vein endothelial cells (HUVECs) ?tumour necrosis factor-¦Á (TNF-¦Á) and lipopolysaccharide (LPS) treatment upregulated 22504158 8727 Human hsa-miR-513a-5p miRNA platelet derived growth factor-BB (PDGF-BB) atherosclerosis (AS) human aortic vascular smooth muscle cells (HA-VSMCs) platelet derived growth factor-BB (PDGF-BB)?treatment treatment downregulated 33592319 8728 Human hsa-miR-513a-5p miRNA diesel exhaust particle (DEP) bronchial epithelial cell cancer Primary human bronchial epithelial cells diesel exhaust particle (DEP) exposure upregulated 20049127 8729 Human hsa-miR-513a-5p miRNA etoposide (VP-16) cardioprotective therapy retinoblastoma cells etoposide treatment downregulated 22886978 8730 Human hsa-miR-513a-5p miRNA 4-aminobiphenyl (4-ABP) DNA damage HepG2 cells 4-Aminobiphenyl (4-ABP) treatment upregulation 24857880 8731 Human hsa-miR-513a-5p miRNA insulin-like growth factor 1 (IGF-1) glioblastoma multiforme (GBM) U87 glioblastoma cells ?Insulin-like growth factor (IGF)-1 treatment upregulated 31805126 8732 Human hsa-miR-513a-5p miRNA heme hepatocellular carcinoma (HCC) Huh?7 cells heme treatment downregulated 23538684 8733 Human hsa-miR-513a-5p miRNA carboplatin (CBP) retinoblastoma (RB) SO-RB50 cells carboplatin (CBP) treatment downregulated 31702387 8734 Human hsa-miR-513a-5p miRNA vincristine (VCR) retinoblastoma (RB) SO-RB50 cells vincristine (VCR) treatment downregulated 31702387 8735 Human hsa-miR-513b miRNA lipopolysaccharide (LPS) procalcitonin (PCT) production HepG2 cells lipopolysaccharide (LPS) treatment downregulated 29891911 8736 Human hsa-miR-515-3p miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 8737 Human hsa-miR-515-5p miRNA estrogen receptor breast cancer Human breast cancer cell lines (MCF7; ZR-75-1; MDA-MB-231) estrogen receptor treatment downregulated 23928990 8738 Human hsa-miR-515-5p miRNA cigarette smoke (CS) epithelial-mesenchymal transition (EMT) human bronchial epithelial (HBE) cells Cigarette smoke (CS) exposure downregulated 32768781 8739 Human hsa-miR-515-5p miRNA oxaliplatin gastric cancer (GC) HGC-27 cells; AGS cells oxaliplatin (OXA) treatment "A marked upregulation of miR- 515-5p was viewed in HGC-27 and AGS cells compared with HGC-27/OXA, and AGS/OXA cells" 33123829 8740 Human hsa-miR-515-5p miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment Circ_0134111 was overexpressed in OA cartilage tissues and IL-1¦Â-induced chondrocytes. 33684877 8741 Human hsa-miR-515-5p miRNA radiation radioresistance C666-1; 5¨C8F cells radiation exposure treatment "PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis" 33116864 8742 Human hsa-miR-516 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 8743 Human hsa-miR-516b miRNA bromocriptine pituitary adenoma pituitary adenoma tissue bromocriptine treatment upregulated 22366961 8744 Human hsa-miR-516b-5p miRNA glucocorticoid (GC) steroid-induced osteonecrosis of femoral head (ONFH) bone marrow mesenchymal stem cells (BMSCs) glucocorticoid (GC) treatment upregulated 29590087 8745 Human hsa-miR-517c miRNA human immunodeficiency virus (HIV)-1 pregnancy peripheral plasmas human immunodeficiency virus (HIV)-1 infection upregulated 26757431 8746 Human hsa-miR-517c miRNA plasmodium falciparum pregnancy peripheral plasmas Plasmodium falciparum infection treatment upregulated 26757431 8747 Human hsa-miR-518a-5p miRNA dasatinib chronic myeloid leukemia (CML) CML cell line K562 dasatinib treatment upregulated 30814857 8748 Human hsa-miR-518a-5p miRNA hypoxia periodontitis human periodontal ligament cells (hPDLCs) hypoxia treatment "We selected LINC01126, which was the most highly expressed lncRNA, to further verify its functions in periodontitis-induced hypoxia." 33231338 8749 Human hsa-miR-518a-5p miRNA cysteine-rich 61 (CCN1) rheumatoid arthritis (RA) "human osteoblast-like cell line MG63, human fetal osteoblastic cell line hFOB" cysteine-rich 61 (CCN1) treatment downregulated 28341837 8750 Human hsa-miR-518b miRNA gambogic acid (GA) apoptosis SW1353 cells GA treatment upregulated 24173143 8751 Human hsa-miR-518b miRNA bone morphogenetic protein 2 (BMP2) tumorigenesis NT2/D1 cells "BMP-2 at 6, 12, and 24 h, and on days 6 and 10 treatment" upregulated 24383669 8752 Human hsa-miR-518b miRNA gambogic acid (GA) chondrosarcoma SW1353 human chondrosarcoma cells Gallic acid (GA) treatment upregulated 24173143 8753 Human hsa-miR-518b miRNA oral zinc gluconate esophageal cancer (EC) barrett's esophagus (BE) oral zinc gluconate treatment upregulated 32415564 8754 Human hsa-miR-518d-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 8755 Human hsa-miR-519 miRNA hypoxia pancreatic cancer (PC) PANC-1 and SW1990 cell hypoxia induce downregulated 31966071 8756 Human hsa-miR-519 miRNA hypoxia pancreatic cancer (PC) PANC-1 cells; SW1990 cells hypoxia treatment downregulated 31966071 8757 Human hsa-miR-5194 miRNA ursolic acid (UA) breast cancer BT474 cells usnic acid treatment downregulated 31549595 8758 Human hsa-miR-5194 miRNA melatonin osteosarcoma (OS) SaOS2 cells; MG63 cells Melatonin treatment upregulated 32592723 8759 Human hsa-miR-5195 miRNA aspirin lung cancer A549 and H1299 cell lines aspirin treatment upregulated 30756509 8760 Human hsa-miR-5195-3p miRNA paclitaxel (PTX) triple negative breast cancer (TNBC) BT549 and MDA-MB-231 cells paclitaxel (PTX) treatment downregulated 31308851 8761 Human hsa-miR-519a miRNA cisplatin (DDP) head and neck squamous cell carcinoma (HNSCC) Head and neck squamous cell carcinoma (HNSCC) cells cisplatin treatment downregulated 21274007 8762 Human hsa-miR-519a-3p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) A172 ; LN229 temozolomide (TMZ) treatment Exosomal lncRNA HOTAIR mediated TMZ resistance through miR-519a-3p/RRM1 axis in GB 32721218 8763 Human hsa-miR-519b miRNA TGF-¦Â1 osteoarthritis (OA) human osteoarthritic synovial fibroblasts (OASFs) TGF-¦Â1 treatment downregulated 28423042 8764 Human hsa-miR-519c-5p miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 8765 Human hsa-miR-519c-5p miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 8766 Human hsa-miR-519d miRNA resistin chondrosarcoma human chondrosarcoma cells resistin treatment downregulated 25404641 8767 Human hsa-miR-519d miRNA connective tissue growth factor (CTGF) osteosarcoma (OS) human osteosarcoma CTGF/CCN2 treatment downregulated 25003330 8768 Human hsa-miR-519d-3p miRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 8769 Human hsa-miR-519e-5p miRNA human papilloma viruses 16 (HPV16) E6 cervical cancer (CC) C33A cells; SiHa cells; CaSki cells human papillomaviruses 16 (HPV16) E6 infection downregulated 32844486 8770 Human hsa-miR-520 miRNA oxymatrine lung cancer A549 cells Oxymatrine (OMT) treatment upregulated 31091971 8771 Human hsa-miR-520-3p miRNA CH12 hepatocellular carcinoma (HCC) HCC cells CH12 treatment upregulated 24007863 8772 Human hsa-miR-520a-3p miRNA lidocaine colorectal cancer (CRC) SW480 cells; HCT116 cells Lidocaine treatment upregulated 30262429 8773 Human hsa-miR-520a-3p miRNA lidocaine retinoblastoma (RB) "The RB cell line, Y79" Lidocaine treatment upregulated 31173241 8774 Human hsa-miR-520b miRNA apigenin hepatocellular carcinoma (HCC) doxorubicin-resistant hepatocellular carcinoma cell line BEL-7402/ADM apigenin treatment upregulated 29191453 8775 Human hsa-miR-520b miRNA apigenin hepatocellular carcinoma (HCC) hepatocellular carcinoma cell line BEL-7402/ADM apicidin treatment upregulated 29191453 8776 Human hsa-miR-520b miRNA bufalin prostate cancer prostate cancer DU145 and PC3 cells bufalin treatment upregulated 31028291 8777 Human hsa-miR-520b-3p miRNA thapsigargin (Tg) cellular stress response HeLa cells thapsigargin (Tg) treatment Diverse stress conditions trigger a rapid and dramatic decrease in miR-520b-3p and a corresponding increase in ATF5 mRNA over time in HeLa cells. 32603335 8778 Human hsa-miR-520c miRNA glucocorticoid (GC) myeloma sensitive RPMI-8226 cell line chronic glucocorticoid exposure upregulated 28035377 8779 Human hsa-miR-520c miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" lung fibrosis Kasumi-1 cells; K562 cells;MCF7 cells; MDA-MB-231 cells? "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 23820258 8780 Human hsa-miR-520c-3p miRNA adriamycin (ADR) acute myeloid leukemia (AML) U937 cells; THP-1 cells adriamycin (ADR) treatment downregulated 30466095 8781 Human hsa-miR-520c-3p miRNA hypoxia preeclampsia (PE) HTR8/SVneo cells hypoxia induce downregulated 31143973 8782 Human hsa-miR-520d-3p miRNA monoclonal antibody CH12 inflammatory breast cancer (IBC) HCC cells The monoclonal antibody CH12 treatment CH12 treatment upregulated miR-520-3p and downregulated E2F-1 and TS at the mRNA and protein levels 24007863 8783 Human hsa-miR-520d-3p miRNA "rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" diffuse large B-cell lymphoma (DLBCL) diffuse large B cell lymphoma (DLBCL) patients serum 6 cycles of R-CHOP treatment dysregulated 24858372 8784 Human hsa-miR-520d-3p miRNA hypoxia/reoxygenation (H/R) myocardial hypoxia/reoxygenation (H/R) injury human myocardial cell (HCM) Hypoxia/reoxygenation (H/R)? treatment "Hypoxia/reoxygenation (H/R) injury could inhibit cell viability, apoptosis and inhibited microRNA-520d-3p expression in HCM." 33389611 8785 Human hsa-miR-520d-5p miRNA midazolam (MDZ) non-small cell lung cancer (NSCLC) A549 cells midazolam treatment upregulated 31938232 8786 Human hsa-miR-520e miRNA TGF-¦Â non-small cell lung cancer (NSCLC) A549 cells transforming growth factor-¦Â (TGF-¦Â) treatment upregulated 30475986 8787 Human hsa-miR-520g miRNA bortezomib multiple myeloma (MM) Human MM cell lines RPMI-8266 and H929 bortezomib? treatment miR-520g were significantly downregulated in bortezomib-resistant MM cell lines 31204563 8788 Human hsa-miR-520g miRNA asbestos non-small cell lung cancer (NSCLC) serum asbestos exposure upregulated 30257964 8789 Human hsa-miR-520h miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment upregulated 27158236 8790 Human hsa-miR-520h miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment upregulated 27158236 8791 Human hsa-miR-520h miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) gastric cancer tissue 5-fluorouracil (5-FU) treatment downregulated 27081844 8792 Human hsa-miR-520h miRNA bortezomib multiple myeloma (MM) Human MM cell lines RPMI-8266 and H929 bortezomib? treatment miR-520h were significantly downregulated in bortezomib-resistant MM cell lines 31204563 8793 Human hsa-miR-521 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 8794 Human hsa-miR-521 miRNA hypoxia prostate cancer LNCaP cells; LNCaP cells exosomes hypoxia treatment upregulated 29568403 8795 Human hsa-miR-521 miRNA radiation prostate cancer LNCaP cells;C4-2 cells radiation treatment upregulated 18668526 8796 Human hsa-miR-522 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells; SMMC-7721 cells hepatitis B virus (HBV) infection upregulated 32128112 8797 Human hsa-miR-522-3p miRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3ip1 cells; HeyA8 cells paclitaxel (PTX) treatment downregulated 33028939 8798 Human hsa-miR-523 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells; SMMC-7721 cells hepatitis B virus (HBV) infection upregulated 32128112 8799 Human hsa-miR-524* miRNA ginsenoside Rg3 angiogenesis HUVECs ginsenoside-Rg3 (Rg3) treatment upregulated 27158236 8800 Human hsa-miR-524* miRNA ginsenoside Rg3 angiomodulation HUVECs Ginsenoside-Rg3 treatment upregulated 27158236 8801 Human hsa-miR-524-5p miRNA nifedipine angina and hypertension MDA-MB-231 cells nifedipine treatment downregulated 25436889 8802 Human hsa-miR-524-5p miRNA PLX4032 (vemurafenib) melanoma SK-Mel-19 cells PLX4032 (vemurafenib) treatment downregulated 33142243 8803 Human hsa-miR-525-3p miRNA ionizing radiation (IR) tumorigenesis RPE£» HUVEC£»tumor-derived cell lines (HeLa;U2-Os;EA.hy926) cell lines Ionizing radiation (IR)?treatment upregulated 24147004 8804 Human hsa-miR-525-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 8805 Human hsa-miR-525-3p miRNA RV (human Wa RV or Rhesus RV) strains rotavirus (RV) infection "human colon cancer Caco-2, HT-29, and HEK293 cells" infect with RV treatment downregulated 28890396 8806 Human hsa-miR-525-5p miRNA lipopolysaccharide (LPS) inflammation monocytes£» U937 cells liposaccharide (LPS) treatment upregulated 20706588 8807 Human hsa-miR-526b miRNA CoCl2 breast cancer MCF-7 cells CoCl2 treatment upregulated 32707933 8808 Human hsa-miR-526b miRNA platelet derived growth factor-BB (PDGF-BB) and insulin-like growth factor (IGF)-1 idiopathic pulmonary fibrosis (IPF) human fibroblastic cell line (LL-24) PDGF-BB and IGF-1 treatment circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2 32694556 8809 Human hsa-miR-527 miRNA dasatinib chronic myeloid leukemia (CML) CML cell line K562 dasatinib treatment upregulated 30814857 8810 Human hsa-miR-532 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 8811 Human hsa-miR-532-3p miRNA rituximab (RTX) chronic lymphocytic leukemia (CLL) CD19 cells of CML patients rituximab treatment downregulated 28126961 8812 Human hsa-miR-532-3p miRNA proanthocyanidin extract (GSPE) hepatocellular carcinoma (HCC) HepG2 cells proanthocyanidin extract (GSPE) treatment upregulated 21998738 8813 Human hsa-miR-532-3p miRNA ginsenoside 20(S)-Rg3 ovarian cancer (OC) SKOV3 ovarian cancer cells Ginsenoside 20(S)-Rg3 treatment upregulated 29558748 8814 Human hsa-miR-532-3p miRNA estrogen (ES) postmenopausal osteoporosis (PMOP) human bone marrow mesenchymal stem cells (BMSCs) estrogen treatment downregulated 33577975 8815 Human hsa-miR-532-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 33867350 8816 Human hsa-miR-532-5p miRNA tripterine hepatocellular carcinoma (HCC) HCCLM3 celsl; MHCC97H cells tripterine treatment "Under tripterine treatment, the level of miR-532-5p was strikingly raised" 32308429 8817 Human hsa-miR-532-5p miRNA 5-fluorouracil/mitomycin C (MMC-CRTX) locally advanced head and neck squamous cell carcinoma (HNSCC) HNSCC patients head and neck squamous cell carcinoma (HNSCC) MMC-CRTX treatment downregulated 28347920 8818 Human hsa-miR-539 miRNA lidocaine lung cancer A549 and NCI-H1299 cells Lidocaine treatment upregulated 31299862 8819 Human hsa-miR-539-5p miRNA oxygen glucose deprivation (OGD) cerebral ischemia injury (CII) HCN-2 cells oxygen glucose deprivation (OGD) treatment downregulated 32491927 8820 Human hsa-miR-539-5p miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment downregulated 26987780 8821 Human hsa-miR-541-3p miRNA carfilzomib familial dysautonomia(FD) FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs) carfilzomib treatment dysregulated 28404519 8822 Human hsa-miR-541-3p miRNA staphylococcal protein A (SpA) osteomyelitis Human bone mesenchymal stem cells (hBMSCs) staphylococcal protein A (SpA) treatment FAM83H-AS1/miR-541-3p/WNT3A ameliorated SpA-mediated inhibition of the osteogenic differentiation of hBMSCs 31871129 8823 Human hsa-miR-541-6p miRNA TGF-¦Â idiopathic pulmonary fibrosis (IPF) Human normal pulmonary fibroblasts MRC-5 and hFL1 and HEK-293 cells treat with TGF-¦Â treatment downregulated 28816543 8824 Human hsa-miR-542-3p miRNA T-helper type 2 (Th2)-biased cytokine environment allergic asthma (AA) Bronchial epithelial cells T-helper type 2 (Th2)-biased cytokine environment treatment downregulated 26289417 8825 Human hsa-miR-542-3p miRNA aristolochic acid aristolochic acid nephropathy Primary human renal PTCs aristolochic acid (AA) treatment upregulated 24508230 8826 Human hsa-miR-542-3p miRNA p-Coumaric acid (p-CA) autoimmune hepatitis (AIH) SNU-16 cells p-Coumaric acid (p-CA) treatment upregulated 32462517 8827 Human hsa-miR-542-3p miRNA angiopoietin-1 (Ang-1) breast cancer HUVECs angiopoietin-1 (Ang-1) treatment downregulated 26272182 8828 Human hsa-miR-542-3p miRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin treatment upregulated 30245930 8829 Human hsa-miR-542-3p miRNA resveratrol breast cancer breast cancer cell resveratrol (RS) treatment downregulated 26890143 8830 Human hsa-miR-542-3p miRNA trastuzumab breast cancer SKBR3 and MCF7/Her2 breast cancer cell lines Trastuzumab treatment Trastuzumab induced miRNA-542-3p expression in SKBR3 and MCF7/Her2 cells 25586125 8831 Human hsa-miR-542-3p miRNA TGF-¦Â1 liver fibrosis LX©\2 cells transforming growth factor ¦Â1 (TGF¦Â1) treatment upregulated 30368874 8832 Human hsa-miR-542-3p miRNA 8-bromo-cyclic adenosine monophosphate (8-bromo-cAMP) and medroxyprogesterone acetate (MPA) migration and invasion of endometriotic cells human ectopic endometrial stromal cells (HEcESCs) 8-Br-cAMP and MPA treatment downregulated 29259466 8833 Human hsa-miR-542-3p miRNA resveratrol recanalization of thrombi Endothelial progenitor cells (EPCs) resveratrol (RSV) treatment downregulated 31606730 8834 Human hsa-miR-542-3p miRNA high glucose (HG) renal fibrosis HK-2 cells high glucose (HG) treatment upregulated 32470449 8835 Human hsa-miR-542-5p miRNA pristimerin breast cancer MCF-7 cells; MDA-MB-231 cells pristimerin treatment upregulated 32753899 8836 Human hsa-miR-542-5p miRNA pristimerin ectopic pregnancy (EP) HTR-8/SVneo cells pristimerin treatment downregulated 33173276 8837 Human hsa-miR-542-5p miRNA pristimerin glioblastoma multiforme (GBM) Human U373 glioma cells Pristimerin treatment downregulated 31015365 8838 Human hsa-miR-542-5p miRNA forskolin and dexamethasone (FSK/DEX) hyperglycemia and hyperlipoidemia HepG2 cells forskolin/dexamethasone (FSK/DEX) treatment downregulated 32882762 8839 Human hsa-miR-542-5p miRNA oleic acid (OA) hyperglycemia and hyperlipoidemia HepG2 cells oleate treatment downregulated 32882762 8840 Human hsa-miR-542-5p miRNA "anthranilamide-pyrazolo[1,5-a]pyrimidine" neuroblastoma (NB) neuronalcancer cells lines MR-32; SK-N-SH "anthranilamide-pyrazolo[1,5-a]pyrimidine treatment" upregulated 23992861 8841 Human hsa-miR-542¨C5p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid" renal cell carcinoma (RCC) renal cell; carcinoma cell lines (5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment upregulated 23707942 8842 Human hsa-miR-543 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment dysregulated 31804889 8843 Human hsa-miR-543 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT8 cells 5-fluorouracil (5-FU) treatment upregulated 30842340 8844 Human hsa-miR-543 miRNA dichloroacetate (DCA) colorectal cancer (CRC) The L-OHP-resistant cell line HCT-8/L and its parental cell line HCT-8 dichloroacetate (DCA) treatment downregulated 31762813 8845 Human hsa-miR-543 miRNA oxaliplatin colorectal cancer (CRC) The L-OHP-resistant cell line HCT-8/L and its parental cell line HCT-8 oxaliplatin (L-OHP) treatment upregulated 31762813 8846 Human hsa-miR-543 miRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (hRECs) high glucose (HG) treatment upregulated 31056258 8847 Human hsa-miR-543 miRNA "glucose deprived, galactose enriched (GAL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 8848 Human hsa-miR-543 miRNA "lipid reduced, cholesterol deficient (RL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 8849 Human hsa-miR-543 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) "human gastric cancer tissue, the human gastric cancer cell lines SNU1, AGS, MGC803, and MKN1" Helicobacter pylori (H. pylori) infection upregulated 31423013 8850 Human hsa-miR-543 miRNA tumor necrosis factor alpha (TNF-¦Á) hypertension insulin-resistant HepG2 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 26562529 8851 Human hsa-miR-543 miRNA suberoylanilide hydroxamic acid (SAHA) neuroblastoma (NB) SH-SY5Y cells suberoylanilide hydroxamic acid (SAHA) treatment downregulated 30091530 8852 Human hsa-miR-543 miRNA TGF-¦Â2 cell proliferation ARPE-19 cells TGF-¦Â2 treatment "miR-543 was found in exosomes from EMTed RPE cells, and miR-543-enriched exosomes significantly induced the EMT of recipient RPE cells" 33047885 8853 Human hsa-miR-543 miRNA H2O2 cell senescence hMSCs 400 ¦ÌM hydrogen peroxide solution treatment downregulated 25465621 8854 Human hsa-miR-543 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 8855 Human hsa-miR-543* miRNA paclitaxel (PTX) breast cancer MCF-7 cells low-dose metronomic (LDM) paclitaxel treatment upregulated 25552929 8856 Human hsa-miR-544 miRNA cisplatin (DDP) esophageal squamous cell carcinoma (ESCC) "The EC9706, KYSE450 and TE-1 human ESCC cell lines and the human immortalized normal esophageal epithelial cell line HET-1A" cisplatin treatment "overexpression of miR-544 led to increased sensitivity of ESCC cells to cisplatin, an anticancer drug." 31579422 8857 Human hsa-miR-544a-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epigenetic regulation HCT116 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30538122 8858 Human hsa-miR-545 miRNA lipopolysaccharide (LPS) HK-2 cells injury HK-2 cells Lipopolysaccharide (LPS) treatment highly expressed circPRKCI relieved inflammatory injury induced by LPS in HK2 cells by suppressing miR-545/ZEBs and depressing the briskness of NF-kB pathway. 32104945 8859 Human hsa-miR-545 miRNA H2O2 oxidative stress SH-SY5Y neuronal cells H2O2 treatment upregulated 31053300 8860 Human hsa-miR-545-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 8861 Human hsa-miR-548a-3p miRNA IL-22 psoriasis human keratinocytes (HaCaT) Interleukin-22 (IL-22) treatment upregulated 29181737 8862 Human hsa-miR-548a-5p miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment upregulated 26987780 8863 Human hsa-miR-548aa miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment upregulated 29393545 8864 Human hsa-miR-548ah-5p miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HT29 cells 5-fluorouracil (5-FU) treatment downregulated 25526515 8865 Human hsa-miR-548an miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment downregulated 28619522 8866 Human hsa-miR-548as-3p miRNA tumor necrosis factor alpha (TNF-¦Á) non-small cell lung cancer (NSCLC) H1299 NSCLC cell line tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30727918 8867 Human hsa-miR-548c-3p miRNA doxorubicin (DOX) breast cancer MDA-MB-231;MDA-MB-468;MCF-10A;MCF-7 cell lines doxorubicin treatment miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability 25802200 8868 Human hsa-miR-548d-3p miRNA BET inhibitors (JQ1) breast cancer MDA-MB-231 cells; BT549 cells BET bromodomain inhibitors (BETi)-JQ1 treatment "JQ1 treatment evicts BRD4 from the FOXD3-localized MIR548D1 gene promoter, leading to repression of miR-548d-3p." 31937753 8869 Human hsa-miR-548d-5p miRNA dexamethasone (DEX) corticosteroid-induced osteonecrosis hBMSCs dexamethasone (DEX) treatment downregulated 24929254 8870 Human hsa-miR-548d-5p miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 8871 Human hsa-miR-548d-5p miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 8872 Human hsa-miR-548j miRNA graphene oxide (GO) graphene oxide (GO) toxicity GLC-82 cells GO treatment dysregulated 24512264 8873 Human hsa-miR-548z miRNA oral zinc gluconate esophageal cancer (EC) barrett's esophagus (BE) oral zinc gluconate treatment upregulated 32415564 8874 Human hsa-miR-549 miRNA neoadjuvant multimodality ment adenocarcinomas serum received neoadjuvant therapy and subsequently underwent surgical resection treatment upregulation 25429911 8875 Human hsa-miR-550 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 8876 Human hsa-miR-550 miRNA proline-rich polypeptide 1 (PRP-1) chondrosarcoma human JJ012 chondrosarcoma cell line PRP-1 treatment downregulated 24178909 8877 Human hsa-miR-550 miRNA bromocriptine pituitary adenoma pituitary adenoma tissue bromocriptine treatment upregulated 22366961 8878 Human hsa-miR-550a miRNA tumor necrosis factor alpha (TNF-¦Á) diabetes mellitus (DM) B cells of diabetic patients tumor necrosis factor alpha (TNF-¦Á) treatment upregulation 27935135 8879 Human hsa-miR-550a miRNA "glucose deprived, galactose enriched (GAL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 8880 Human hsa-miR-550a miRNA "lipid reduced, cholesterol deficient (RL)" distinct metabolic stressors human dermal fibroblasts "glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment" dysregulated 24246224 8881 Human hsa-miR-550a miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human retinal pigment epithelial cells TGF-¦Â1 treatment downregulated 25263462 8882 Human hsa-miR-550a-5p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 8883 Human hsa-miR-551a miRNA 5-fluorouracil (5-Fu) drug resistance Hep3B cells 5-fluorouracil (5-FU) treatment "miR-551a-expressing cells (Hep3B-lenti-miR-551a) were resistant to 5-FU-induced cell death, and after 5-FU treatment, and showed significant increases in cell viability, cell survival, and sphere formation." 30703870 8884 Human hsa-miR-551a miRNA oral zinc gluconate esophageal cancer (EC) barrett's esophagus (BE) oral zinc gluconate treatment upregulated 32415564 8885 Human hsa-miR-551a miRNA demethoxycurcumin ovarian cancer (OC) human epithelia ovarian cancer cells demethoxycurcumin treatment upregulated 28345465 8886 Human hsa-miR-551b-5p miRNA mechanical stretch endothelial dysfunction human umbilical vein endothelial cells (HUVECs) "mechanical stretch for 3 h (60 cycles/min, 15% elongation)" upregulated 28639574 8887 Human hsa-miR-552-3p miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment downregulated 31597953 8888 Human hsa-miR-552-3p miRNA dichloroacetate (DCA) colorectal cancer (CRC) HCT116 cells dichloroacetate (DCA) treatment downregulated 31597953 8889 Human hsa-miR-556-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 32536864 8890 Human hsa-miR-557 miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 8891 Human hsa-miR-557 miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 8892 Human hsa-miR-557 miRNA angiopoietin-2 (Ang-2) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-2 (Ang-2) treatment downregulated 30414893 8893 Human hsa-miR-557 miRNA fibroblast growth factor 2 (FGF2) angiogenesis human umbilical vein endothelial cells (HUVECs) fibroblast growth factor 2 (FGF2) treatment downregulated 30414893 8894 Human hsa-miR-558 miRNA IL-1¦Â osteoarthritis (OA) human articular chondrocytes and OA chondrocytes IL-1¦Â treatment downregulated 23611898 8895 Human hsa-miR-558 miRNA CoCl2 spinal cord injury (SCI) AGE1.HN CoCl2 treatment circ-HIPK3 relieves the neuronal cell apoptosis through regulating miR-588/DPYSL5 axis in SCI. 32247616 8896 Human hsa-miR-5583-5p miRNA alternariol (AOH) antagonistic cytotoxic HepG2 cells alternariol (AOH) treatment downregulated 28007639 8897 Human hsa-miR-5583-5p miRNA altertoxin II (ATX II) cytotoxicity HepG2 altertoxin II (ATX II) treatment downregulated 28007639 8898 Human hsa-miR-561 miRNA acetaminophen (APAP) hepatotoxicity HepG2 cells acetaminophen (APAP) treatment upregulated 24104199 8899 Human hsa-miR-561 miRNA retinoic acid (RA) human neuronal differentiation SH-SY5Y cells retinoic acid (RA) treatment downregulated 30951518 8900 Human hsa-miR-561 miRNA acetaminophen (APAP) macular degeneration HepG2 cells and primary human hepatocytes acetaminophen (APAP) treatment upregulated 24104199 8901 Human hsa-miR-564 miRNA TGF-¦Â epithelial-mesenchymal transition (EMT) hPC and HEK 293 TGF-¦Â treatment TMEM63C Is Regulated by MicroRNA-564 and Transforming Growth Factor beta in Human Renal Cells 33080601 8902 Human hsa-miR-564 miRNA gefitinib lung cancer PC-9 cells gefitinib treatment upregulated 32052182 8903 Human hsa-miR-565 miRNA hepatitis C virus (HCV) hepatocellular carcinoma (HCC) Huh7.5 parental hepatoma cells hepatitis C virus (HCV) infection downregulated 23418453 8904 Human hsa-miR-5680 miRNA high glucose (HG) autophagy human umbilical vein endothelial cells (HUVECs) high glucose treatment LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680. 30957640 8905 Human hsa-miR-5680 miRNA 3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) vascular endothelial cells (VECs) autophagy and apoptosis human vascular endothelial cells (VECs) 3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment 3BDO promoted the expression of miR-5680 in VECs under high glucose conditions. 30957640 8906 Human hsa-miR-569 miRNA radix tetrastigma hemsleyani (RTH) lung cancer A549 cells radix tetrastigma hemsleyani (RTH) treatment upregulated 30100735 8907 Human hsa-miR-5701 miRNA 6-hydroxydopamine (6-OHDA) parkinson's disease (PD) SH-SY5Y cells 6-hydroxydopamine (6-OHDA) treatment The level of miR-5701 was significantly downregulated in the presence of 6-OHDA. 28710704 8908 Human hsa-miR-5701 miRNA 6-hydroxydopamine (6-OHDA) parkinson's disease (PD) SH-SY5Y Cells 6-hydroxydopamine (6-OHDA) treatment downregulated 28710704 8909 Human hsa-miR-5703 miRNA luteolin and gefitinib prostate cancer PC-3 cells luteolin and/or gefitinib treatment upregulated 24971999 8910 Human hsa-miR-570-3p miRNA metformin (Met) osteosarcoma (OS) 143B and U2OS cells Metformin treatment upregulated 29795113 8911 Human hsa-miR-571 miRNA alcohol liver cirrhosis blood alcohol exposure upregulated 22412969 8912 Human hsa-miR-572 miRNA fluoxetine (Prozac) neurodevelopmental processes SK-N-SH cell lines fluoxetine treatment upregulated 27716787 8913 Human hsa-miR-572 miRNA fluoxetine (Prozac) neurodevelopmental processes SH-SY5Y cell lines fluoxetine treatment upregulated 27716787 8914 Human hsa-miR-572 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 8915 Human hsa-miR-573 miRNA hyperbaric oxygen (HBO) intervertebral disc degeneration (IDD) human degenerative nucleus pulposus (NP) cells hyperbaric oxygen (HBO)?induce MiR-573 was induced by HBO and simultaneous suppression of Bax was observed in NP cells. 33413477 8916 Human hsa-miR-574 miRNA polyinosinic-polycytidilic acid (Poly(I:C)) innate immune defense Human nasal epithelial cells (HNECs) poly I:C treatment upregulated 25959385 8917 Human hsa-miR-574-3p miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 8918 Human hsa-miR-574-3p miRNA remnant-like lipoproteins (RLPs) ePCs senescence Total peripheral mononuclear cells (PB-MNCs) Remnant-like lipoproteins (RLPs) treatment miR-148b and miR-155 were upregulated while miR-574-3p was downregulated 23044309 8919 Human hsa-miR-574-3p miRNA cisplatin (DDP) epithelial ovarian cancer (EOC) SKOV3 and CAOV3 cells cisplatin treatment downregulated 31396325 8920 Human hsa-miR-574-3p miRNA paclitaxel (PTX) epithelial ovarian cancer (EOC) SKOV3 and CAOV3 cells paclitaxel treatment downregulated 31396325 8921 Human hsa-miR-574-3p miRNA TGF-¦Â1 gastric cancer (GC) AGS cells TGF-¦Â1 treatment upregulated 28042090 8922 Human hsa-miR-574-3p miRNA X-rays genotoxicity the lung cancer cell line A549 X-ray irradiation treatment upregulated 24566139 8923 Human hsa-miR-574-3p miRNA radiochemotherapy head and neck squamous cell carcinoma (HNSCC) ?blood plasma radiochemotherapy?treatment treatment "six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)" 24373621 8924 Human hsa-miR-574-3p miRNA "myclobutanil, propiconazole, and triadimefon" hepatocellular carcinoma (HCC) HepG2 cells "myclobutanil, propiconazole, and triadimefon treatment" downregulated 23159985 8925 Human hsa-miR-574-3p miRNA sodium butyrate (NaB) lung cancer A549 cells sodium butyrate(NaB) treatment upregulated 29231270 8926 Human hsa-miR-574-3p miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) HK1 cell line concentration treatment dysregulated 24896104 8927 Human hsa-miR-574-3p miRNA TGF-¦Â1 gastric cancer (GC) AGS cells induced upregulation in treatment upregulated 28042090 8928 Human hsa-miR-574-3p miRNA genistein prostate cancer "Human PCa cell lines, PC3£» DU145£»non-malignant epithelial prostate cell line, RWPE-1" Genistein? treatment upregulated 23554959 8929 Human hsa-miR-574-3p miRNA lectin prostate cancer Prostate cancer (PC) cell lines lectin treatment upregulated 26417675 8930 Human hsa-miR-574-5p miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 8931 Human hsa-miR-574-5p miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) Human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment "In ARDS models, microRNA-574-5p (miR-574-5p) expression could be induced by the TLR4/NF-¦ÊB pathway upon LPS stimulation." 33202146 8932 Human hsa-miR-574-5p miRNA TGF-¦Â cardiac fibrosis human cardiac fibroblasts (HCFs) TGF-¦Â treatment upregulated 31672272 8933 Human hsa-miR-574-5p miRNA palmitate nonalcoholic fatty liver disease (NAFLD) hepatocyte cell lines palmitate treatment downregulated 25314137 8934 Human hsa-miR-575 miRNA 5-fluorouracil (5-Fu) actinobacillus pleuropneumoniae infection MCF-7 cells 5-fluorouracil (5-FU) treatment upregulated 21506117 8935 Human hsa-miR-575 miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 8936 Human hsa-miR-575 miRNA angiopoietin-1 (Ang-1) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment downregulated 30414893 8937 Human hsa-miR-575 miRNA angiopoietin-2 (Ang-2) angiogenesis human umbilical vein endothelial cells (HUVECs) angiopoietin-2 (Ang-2) treatment downregulated 30414893 8938 Human hsa-miR-575 miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment downregulated 19022373 8939 Human hsa-miR-576-3p miRNA hypoxia glioblastoma multiforme (GBM) U87 and U251 cells hypoxia induce downregulated 31017266 8940 Human hsa-miR-576-3p miRNA granulocyte-colony stimulating factor (G-CSF) leukemia CD34+ cells Granulocyte colony-stimulating factor?treatment upregulated 24056818 8941 Human hsa-miR-577 miRNA TGF-¦Â gastric cancer (GC) human GC cell lines (MKN45 and MGC803) Transforming growth factor ¦Â (TGF-¦Â) treatment upregulated 30879950 8942 Human hsa-miR-579 miRNA mycobacterium tuberculosis (Mtb) apoptosis primary human monocyte-derived macrophages Mycobacterium tuberculosis (MTB) infection upregulated 31434611 8943 Human hsa-miR-579 miRNA dexamethasone (DEX) cytotoxicity DEX-treated human OB-6 osteoblastic cells dexamethasone (Dex) treatment miR-579 is upregulated in the necrotic femoral head tissues of DEX-taking human patients as well as in DEX-treated human osteoblasts. Forced miR-579 overexpression induced significant cytotoxicity in human osteoblasts. 31376935 8944 Human hsa-miR-580-3p miRNA bisphenol A (BPA) arterial hypertension urine; whole blood bisphenol A (BPA) treatment downregulated 32438192 8945 Human hsa-miR-582-3p miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" osteogenesis human adipose-derived Mesenchymal stem cells (hAMSCs) "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 29218085 8946 Human hsa-miR-582-5p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment NNT-AS1 played a promoting role in smoking-induced COPD via modulating miR-582-5p/FBXO11 signaling. 32768929 8947 Human hsa-miR-582-5p miRNA ozone (O3) epigenetic regulation of responses to O3 exposure healthy adult human sputum exposed to 0.4 ppm O3 for 2 h treatment upregulated 24771714 8948 Human hsa-miR-582-5p miRNA heroin immunosuppression monocytes heroin treatment downregulated 26978739 8949 Human hsa-miR-582-5p miRNA particulate matter (PM2.5) lung cancer BEAS-2B and HBE cells particulate matter (PM2.5) treatment Loss of NEAT1 represses the malignant transformation of BEAS-2B and HBE cells induced by PM25 33829382 8950 Human hsa-miR-582-5p miRNA berberine (BBR) melanoma A375 cells berberine (BBR) treatment The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression. 32915362 8951 Human hsa-miR-584 miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MCF-7 cells anacardic acid (AnAc) treatment downregulated 28886127 8952 Human hsa-miR-584 miRNA porphyromonas gingivalis anti-inflammatory responses OBA-9(immortalized HGECs) Pg treatment upregulated 24228808 8953 Human hsa-miR-584 miRNA TGF-¦Â breast cancer breast cancer cells ?TGF-¦Â treatment downegulated 23479725 8954 Human hsa-miR-584 miRNA porphyromonas gingivalis destructive periodontitis Human Gingival Epithelial Cells(HGECs) Porphyromonas gingivalis treatment upregulated 24228808 8955 Human hsa-miR-584 miRNA bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) neuroblastoma (NB) neuroblastoma cells bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment downregulated 25498991 8956 Human hsa-miR-584 miRNA bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) neurological disorders SK-N-SH cells bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment downregulated 25498991 8957 Human hsa-miR-584-3p miRNA metformin (Met) melanoma "The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951" Metformin treatment upregulated 30754729 8958 Human hsa-miR-584-5p miRNA radix tetrastigma hemsleyani (RTH) lung cancer A549 cells radix tetrastigma hemsleyani (RTH) treatment downregulated 30100735 8959 Human hsa-miR-585-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y Cells 1-methyl-4-phenylpyridinium (MPP+) treatment H19 knockdown markedly increased miR-585-3p expression. 32356199 8960 Human hsa-miR-589 miRNA antrodia cinnamomea cancer treatment "THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68" antrodia cinnamomea treatment downregulated 28602756 8961 Human hsa-miR-589 miRNA proline-rich polypeptide 1 (PRP-1) chondrosarcoma human JJ012 chondrosarcoma cell line PRP-1 treatment downregulated 24178909 8962 Human hsa-miR-589 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) HMrSV5 cells TGF-¦Â1 treatment The changes were accompanied with notably decreased level of miRNA589 in HMrSV5 cells treated with TGF¦Â1 23118514 8963 Human hsa-miR-589 miRNA H2O2 oxidative stress SH-SY5Y neuronal cells H2O2 treatment upregulated 31053300 8964 Human hsa-miR-589-3p miRNA lipopolysaccharide (LPS) lumbar disc degeneration (LDD) human NP cell line lipopolysaccharide (LPS) treatment upregulated 29434746 8965 Human hsa-miR-589-3p miRNA lipopolysaccharide (LPS) lumbar disc degeneration (LDD) Nucleus pulposus (NP) cells Lipopolysaccharide (LPS) treatment upregulated 29434746 8966 Human hsa-miR-590 miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning upregulated 30602960 8967 Human hsa-miR-590 miRNA oxidized low density lipoprotein (ox-LDL) apoptosis HUVEC oxidized low-density lipoprotein (ox-LDL) treatment downregulated 26648441 8968 Human hsa-miR-590 miRNA nobiletin atherosclerosis (AS) human THP-1 macrophages Nobiletin treatment upregulated 30471854 8969 Human hsa-miR-590 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) The human umbilical vascular endothelial cell (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 26648441 8970 Human hsa-miR-590 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30799593 8971 Human hsa-miR-590 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein ECs (HUVECs); human coronary artery ECs (HCAECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33022677 8972 Human hsa-miR-590 miRNA Ag¨CTiO2 photocatalyst particles nasopharyngeal carcinoma (NPC) 5-8F human NPC cell derived exosomes Ag¨CTiO2 treatment upregulated 27598726 8973 Human hsa-miR-590 miRNA hydroxychloroquine plus prednisone systemic lupus erythematosus (SLE) Th17 cells Hydroxychloroquine (HCQ) plus prednisone treatment upregulated 29545450 8974 Human hsa-miR-590-3p miRNA oxidized low density lipoprotein (ox-LDL) angiogenesis human umbilical vein endothelial cells (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29436491 8975 Human hsa-miR-590-3p miRNA melatonin apoptosis human fetal osteoblastic cell line hFOB 1.19 Melatonin treatment downregulated 29568931 8976 Human hsa-miR-590-3p miRNA radiation colorectal cancer (CRC) HCT116 cells radiation treatment upregulated 33738143 8977 Human hsa-miR-590-3p miRNA hypoxia coronary artery disease (CAD) human umbilical vein endothelial cells (HUVECs) hypoxia exposure Long non-coding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR-590-3p under hypoxic conditions. 32323787 8978 Human hsa-miR-590-3p miRNA high glucose (HG) diabetic retinopathy (DR) Human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment downregulated 31618425 8979 Human hsa-miR-590-3p miRNA hypoxia angiogenesis Primary human ADSCs (ADSCs) hypoxia treatment downregulated 32277427 8980 Human hsa-miR-590-3p miRNA IL-1¦Â osteoarthritis (OA) The immortalized human chondrocytes cell lines C20/A4 IL-1¦Â treatment upregulated 31571401 8981 Human hsa-miR-590-3p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) MES23.5 and SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 27064872 8982 Human hsa-miR-590-3p miRNA YKL-40 rheumatoid arthritis (RA) human osteoblast-like cell line MG-63 stimulated with YKL-40 for 24 h treatment downregulated 28448439 8983 Human hsa-miR-590-3p miRNA H2O2 cell senescence hMSCs 400 ¦ÌM hydrogen peroxide solution treatment downregulated 25465621 8984 Human hsa-miR-590-5p miRNA platelet derived growth factor-BB (PDGF-BB) asthma human airway smooth muscle cells (ASMCs) platelet derived growth factor-BB (PDGF-BB)?treatment treatment downregulated 33825599 8985 Human hsa-miR-590-5p miRNA platelet-derived growth factor (PDGF) asthma fetal airway smooth muscle (ASM) cells platelet-derived growth factor (PDGF) treatment downregulated 30154893 8986 Human hsa-miR-590-5p miRNA angiotensin II (Ang II) cardiovascular disease (CVD) HUVEC angiotensin II (Ang II) treatment downregulated 26906623 8987 Human hsa-miR-590-5p miRNA galacto-oligosaccharides (GOS) colitis normal and LPS-stimulated human colon epithelial FHC cells galacto-oligosaccharides (GOS) treatment upregulated 31226416 8988 Human hsa-miR-590-5p miRNA lipopolysaccharide (LPS) colitis human colon epithelial FHC cells lipopolysaccharide (LPS) treatment downregulated 31226416 8989 Human hsa-miR-590-5p miRNA hypoxia colorectal cancer (CRC) human colorectal cancer cell lines RKO and HCT116 hypoxia treatment upregulated 29247825 8990 Human hsa-miR-590-5p miRNA hypoxia colorectal cancer (CRC) "colorectal cancer (CRC) cell lines RKO, HCT116, SW480, HT29, SW620, LS174T, LoVo, SW403, Colo205, DLD-1, HCT15" hypoxia induce upregulated 29247825 8991 Human hsa-miR-590-5p miRNA radiochemotherapy head and neck squamous cell carcinoma (HNSCC) ?blood plasma radiochemotherapy?treatment treatment "six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)" 24373621 8992 Human hsa-miR-590-5p miRNA human papillomavirus E6 and E7 human papillomaviruses (HPV) infection K16 and K38 supernatants Human papillomavirus E6 and E7 treatment "HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p." 27300513 8993 Human hsa-miR-590-5p miRNA heroin immunosuppression monocytes heroin treatment downregulated 26978739 8994 Human hsa-miR-590-5p miRNA TGF-¦Â1 intrauterine adhesion (IUA) human embryonic stem cells (hESCs) TGF-¦Â1 treatment lncRNA TUG1 promotes endometrial fibrosis and inflammation by sponging miR-590-5p to regulate Fasl in intrauterine adhesions 32599321 8995 Human hsa-miR-590-5p miRNA influenza A virus (IAV) influenza A virus (IAV) infection MRC-5 cells IAV/Hong Kong/498/97 (H3N2) treatment Viral infection up-regulates miR-590-5p expression. 30291142 8996 Human hsa-miR-592 miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment upregulated 26298803 8997 Human hsa-miR-593 miRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) NPC cells curcumin treatment upregulated 27313684 8998 Human hsa-miR-593-3p miRNA insulin hepatocellular carcinoma (HCC) hepatocellular carcinoma HepG2 and Bel7402 cells Insulin treatment upregulated 27613819 8999 Human hsa-miR-593-5p miRNA cisplatin (DDP) rectal cancer SW837 cells; HR8348 cells cisplatin treatment "LINC00461 mediates cisplatin resistance of rectal cancer by targeting miR-593-5p/CCND1 axis, shedding new light on the treatment of rectal cancer." 31972361 9000 Human hsa-miR-593-5p miRNA cisplatin (DDP) tongue squamous cell carcinoma (TSCC) tongue squamous cell carcinoma (TSCC) cells cisplatin treatment downregulated 25912308 9001 Human hsa-miR-596 miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 9002 Human hsa-miR-596 miRNA steroids non-traumatic osteonecrosis of femoral head (ONFH) bone marrow steroid treatment upregulated 32410637 9003 Human hsa-miR-598 miRNA alpha-1 antitrypsin (AAT) anti-inflammatory responses monocytes of AAT deficient (ZZ) individuals alpha-1 antitrypsin (AAT) treatment downregulated 29062067 9004 Human hsa-miR-599 miRNA lipopolysaccharide (LPS) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment downregulated 32248560 9005 Human hsa-miR-599 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33235026 9006 Human hsa-miR-599 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33566259 9007 Human hsa-miR-599 miRNA IL-1¦Â osteoarthritis (OA) human chondrocytes IL-1¦Â treatment circANKRD36 sponge miR-599 to up-regulate the expression of Casz1 and thus prevent apoptosis and inflammation in OA. 33205602 9008 Human hsa-miR-599 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment downregulated 30720180 9009 Human hsa-miR-601 miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment upregulated 29393545 9010 Human hsa-miR-601 miRNA H2O2 oxidative stress ARPE-19?cells and primary human RPE cells H2O2 treatment upregulated 31178131 9011 Human hsa-miR-601 miRNA glucocorticoid (GC) steroid-induced osteonecrosis of femoral head (ONFH) bone marrow mesenchymal stem cells (BMSCs) glucocorticoid (GC) treatment upregulated 29590087 9012 Human hsa-miR-602 miRNA troxerutin alopecia HDP cells troxerutin treatment has-miR-602 was the most markedly upregulated by troxerutin in the H2O2-treated HDP cells 25955790 9013 Human hsa-miR-605 miRNA "anthranilamide-pyrazolo[1,5-a]pyrimidine" neuroblastoma (NB) neuronalcancer cells lines MR-32; SK-N-SH "anthranilamide-pyrazolo[1,5-a]pyrimidine treatment" upregulated 23992861 9014 Human hsa-miR-608 miRNA "2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)" neuroblastoma (NB) SK-N-SH neuroblastoma cells "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment" upregulated 28860601 9015 Human hsa-miR-608 miRNA doxorubicin (DOX) non-small cell lung cancer (NSCLC) NSCLC cell lines A549 and HCC4006 doxorubicin treatment "overexpression of miR-608 promoted doxorubicin-induced apoptosis in NSCLC cell lines A549 and HCC4006 by inhibiting the expression of transcription factor activating enhancer-binding protein 4 (TFAP4), and high expression levels of TFAP4 were observed in NSCLC tissues." 31552102 9016 Human hsa-miR-608 miRNA physcion 8-O-¦Â-glucopyranoside (PG) ovarian cancer (OC) SKOV3 cells physcion 8-O-¦Â-glucopyranoside (PG) treatment downregulated 31299866 9017 Human hsa-miR-6086 miRNA tumor necrosis factor alpha (TNF-¦Á) TNF¦Á-induced endothelial dysfunction human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29605606 9018 Human hsa-miR-6088 miRNA steviol gastrointestinal cancer HCT-116 cells steviol treatment downregulated 29899860 9019 Human hsa-miR-6088 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 9020 Human hsa-miR-612 miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MCF-7 cells anacardic acid (AnAc) treatment upregulated 28886127 9021 Human hsa-miR-612 miRNA anacardic acid (AnAc) anacardic acid (AnAc) activity MDA-MB-231 cells anacardic acid (AnAc) treatment upregulated 28886127 9022 Human hsa-miR-6126 miRNA yhexamethylene guanidine phosphate (PHMG-phosphate) lung fibrosis A549 cells yhexamethylene guanidine phosphate (PHMG-phosphate) treatment upregulated 29337256 9023 Human hsa-miR-6127 miRNA cyclosporine A (CsA) colorectal cancer (CRC) HCT116 and SW480 cell extracellular vesicle (EV) cyclosporine A (CsA) treatment downregulated 31371743 9024 Human hsa-miR-6127 miRNA rapamycin colorectal cancer (CRC) HCT116 and SW480 cell extracellular vesicle (EV) rapamycin (RAPA) treatment upregulated 31371743 9025 Human hsa-miR-613 miRNA paclitaxel (PTX) breast cancer MCF-7 cells paclitaxel (PTX) treatment Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis 32425595 9026 Human hsa-miR-613 miRNA oleic acid (OA) nonalcoholic fatty liver disease (NAFLD) L02 cells oleic acid (OA) treatment "CCAT1 increases LXR¦Á transcription by serving as a competing endogenous RNA for miR-613 in an LXRE-dependent manner, thereby promoting lipid droplet formation and NAFLD." 32413192 9027 Human hsa-miR-613 miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment MiRNA-613 alleviates IL-1¦Â-induced injury in chondrogenic CHON-001 cells by targeting fibronectin 1. 33042421 9028 Human hsa-miR-6132 miRNA "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)" breast cancer MCF-7 cells "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment" Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells. 33652854 9029 Human hsa-miR-615 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 9030 Human hsa-miR-615-3p miRNA oxidized low density lipoprotein (ox-LDL) myocardial infarction (MI) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31355606 9031 Human hsa-miR-615-3p miRNA palmitate nonalcoholic fatty liver disease (NAFLD) hepatocyte cell lines palmitate treatment downregulated 25314137 9032 Human hsa-miR-615-3p miRNA hypoxia non-small cell lung cancer (NSCLC) two NSCLC cell lines (A549 and H1299) hypoxia induce downregulated 31422060 9033 Human hsa-miR-615-5p miRNA bovine serum albumin (BSA) focal segmental glomerulosclerosis (FSGS) HK-2 cells bovine serum albumin (BSA) treatment downregulated 32800553 9034 Human hsa-miR-615-5p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment upregulated 23525256 9035 Human hsa-miR-616 miRNA tissue factor pathway inhibitor TFPI-2 metabolic syndrome prostate cancer cells tissue factor pathway inhibitor TFPI-2 treatment "reexpression of TFPI-2 in LNCaP cells with stable miR-616 overexpression rescued the AD phenotype, TFPI-2 expression to be inversely correlated to miR-616 in a series of prostate cell lines" 21224345 9036 Human hsa-miR-616-5p miRNA sulforaphane (SFN) lung cancer "human NSCLC cell lines H1299, 95C and 95D" sulforaphane treatment upregulated 27890917 9037 Human hsa-miR-616-5p miRNA sulforaphane (SFN) non-small cell lung cancer (NSCLC) "human H1299, 95C, and 95D NSCLC cell lines" 100 ¦Ìg/mL streptomycin treatment downregulated 27890917 9038 Human hsa-miR-616¨C5p miRNA glial cell-derived neurotrophic factor (GDNF) parkinson's disease (PD) SH-SY5Y human neuroblastoma cells GDNF downregulated 28829278 9039 Human hsa-miR-617 miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 9040 Human hsa-miR-617 miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 9041 Human hsa-miR-619 miRNA arsenite arsenic-induced skin lesions plasma arsenic exposure upregulated 31359311 9042 Human hsa-miR-619-3p miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 31076402 9043 Human hsa-miR-619-3p miRNA hepatitis C virus (HCV) hepatitis C virus (HCV)-induced liver disease and hepatocarcinogenesis Huh7.5.1 cells hepatitis C virus (HCV) infection upregulated 31076402 9044 Human hsa-miR-620 miRNA TGF-¦Â1 asthma human airway smooth muscle cells (ASMCs) TGF-¦Â1 treatment upregulated 32583575 9045 Human hsa-miR-622 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury human brain microvascular endothelial cells (HBMECs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment "The expression of circ_ANRIL in OGD/R-induced human brain microvascular endothelial cells (HBMECs) was significantly upregulated, while that of miR-622 was significantly downregulated" 32616043 9046 Human hsa-miR-622 miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 9047 Human hsa-miR-622 miRNA 5-fluorouracil (5-Fu) locally advanced rectal cancer (LARC) Tumor tissues 5-fluorouracil (5-FU) treatment upregulated 25961730 9048 Human hsa-miR-622 miRNA FOXO3a lung cancer U0126-treated A549 cells FOXO3a treatment upregulated 26528854 9049 Human hsa-miR-622 miRNA hypoxia lung cancer A549 cells hypoxia treatment downregulated 27524914 9050 Human hsa-miR-622 miRNA high glucose (HG) vascular smooth muscle aging human umbilical vein endothelial cell (HUVEC) high glucose (HG) treatment HG-HUVECs derived exosomes induced the VSMCs senescence by circRNA0077930-miR622-Kras CeRNA network. 32307741 9051 Human hsa-miR-623 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment downregulated 22647265 9052 Human hsa-miR-623 miRNA hypoxia myocardial infarction (MI) human cardiomyocytes (HMCs) hypoxia treatment downregulated 32222118 9053 Human hsa-miR-625 miRNA 1-methyl-4-phenylpyridinium (MPP+) neuronal cell injury human neuroblastoma SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment lnc-p21 regulated MPP + -induced neuronal injury by sponging miR-625 and upregulating TRPM2 in SH-SY5Y cells 31004593 9054 Human hsa-miR-625 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) human neuroblastoma SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment lnc-p21 regulated MPP + -induced neuronal injury by sponging miR-625 and upregulating TRPM2 in SH-SY5Y cells 31004593 9055 Human hsa-miR-625* miRNA progesterone (P4) endometrial cancer (EC) Hec1A cells Progesterone treatment upregulated 22543862 9056 Human hsa-miR-625-3p miRNA oxaliplatin metastatic colorectal cancer (mCRC) HCT116 cells; LoVo cells oxaliplatin? treatment High expression of microRNA-625-3p 23506979 9057 Human hsa-miR-625-3p miRNA gefitinib non-small cell lung cancer (NSCLC) HCC827 cells; PC-9 cells Gefitinib treatment miR-625-3p expression was downregulated in the HCC827GR cells. 32319651 9058 Human hsa-miR-625-3p miRNA icariin (ICA) thyroid cancer (TC) SW579 cells;TPC1 cells icariin (ICA) treatment downregulated 30551506 9059 Human hsa-miR-625-3p miRNA icariin (ICA) thyroid cancer (TC) SW579 and TPC1 cells icariin (ICA) treatment downregulated 30551506 9060 Human hsa-miR-625-5p miRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) human nucleus pulposus cells (hNPC) and annulus fibrosus cells (hAFC) lipopolysaccharide (LPS) treatment upregulated 30972168 9061 Human hsa-miR-625-5p miRNA lipopolysaccharide (LPS) asthma human bronchial epithelial cells (HBECs) 16HBEC lipopolysaccharide (LPS) treatment upregulated 30628701 9062 Human hsa-miR-625-5p miRNA hypoxia glioblastoma multiforme (GBM) "The normal human astrocyte line SVGp12 and two human glioma cell lines, U87MG and A172" hypoxia induce downregulated 30988674 9063 Human hsa-miR-625-5p miRNA hypoxia hypoxia-induced injury ?12 soft tissue sarcoma cell lines was exposed to 1% oxygen (hypoxia) for up to 48 h treatment downregulated 24927770 9064 Human hsa-miR-626 miRNA H2O2 age-related macular degeneration (AMD) ARPE-19?cells and primary human RPE cells H2O2 treatment downregulated 31446056 9065 Human hsa-miR-627 miRNA TGF-¦Â1 lung fibrosis normal human lung fibroblast TGF-¦Â1 treatment downregulated 30536600 9066 Human hsa-miR-627 miRNA TGF-¦Â1 lung fibrosis normal human lung fibroblast (NHLF) TGF-¦Â1 treatment downregulated 30536600 9067 Human hsa-miR-627 miRNA TGF-¦Â1 lung fibrosis normal human primary lung fibroblasts (NHLFs) TGF-¦Â1 treatment downregulated 33482190 9068 Human hsa-miR-627-5p miRNA bisphenol A (BPA) arterial hypertension urine; whole blood bisphenol A (BPA) treatment downregulated 32438192 9069 Human hsa-miR-627-5p miRNA palbociclib glioblastoma multiforme (GBM) "HMC3 cells, temozolomide-resistant (TMZ-R) cells" palbociclib treatment "SNHG15 to promote GBM tumorigenesis was by inhibiting tumor suppressor, miR-627-5p which leads to activation of CDK6" 31462285 9070 Human hsa-miR-628-5p miRNA acute bout of resistance exercise "ageing, activation of Rho signalling" older (60-75 years) people acute bout of resistance exercise upregulated 27739650 9071 Human hsa-miR-628-5p miRNA sevoflurane (SEV) glioblastoma multiforme (GBM) A-172; SHG-44 Sevoflurane (Sev) treatment Sev mediated glioma progression via circ_0002755/miR-628-5p/MAGT1 axis 32669871 9072 Human hsa-miR-629 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia induce upregulated 31240850 9073 Human hsa-miR-629-3p miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) human bronchial epithelial (16HBE) cells infect with EV71 and CA16 dysregulated 27890633 9074 Human hsa-miR-629-3p miRNA enterovirus 71 (EV71) and coxsackievirus A16 (CA16) hand-foot-mouth disease (HFMD) Human bronchial epithelial (16HBE) cells Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment dysregulated 27890633 9075 Human hsa-miR-629-5p miRNA glial cell-derived neurotrophic factor (GDNF) glioblastoma multiforme (GBM) human U251 glioma cells 50 ng/mL GDNF for 24 h upregulated 29224008 9076 Human hsa-miR-630 miRNA 4-aminobiphenyl (4-ABP) 4-Aminobiphenyl (4-ABP)-induced liver injury Hep3B cells; L-02 cells 4-Aminobiphenyl (4-ABP) treatment 4-ABP induced miR-630 expression in Hep3B and L-02 cells. 32433928 9077 Human hsa-miR-630 miRNA H2O2 age-related nuclear cataract human lens epithelial B3 (HLE-B3) cell H2O2 treatment upregulated 29653565 9078 Human hsa-miR-630 miRNA H2O2 cataract HLE-B3 cells H2O2 treatment miR-630 was significantly upregulated in HLE-B3 after H2O2 treatment. 31869263 9079 Human hsa-miR-630 miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 9080 Human hsa-miR-630 miRNA ionizing radiation (IR) colorectal cancer (CRC) "Human colorectal cancer cell lines Ls174T, SW480, HCT116, SW837, HR8348, and HT29" ionic radiation (IR) treatment "After IR treatment, miR-630 induced apoptosis in cells" 26263387 9081 Human hsa-miR-630 miRNA 4-aminobiphenyl (4-ABP) DNA damage HepG2 cells 4-Aminobiphenyl (4-ABP) treatment upregulation 24857880 9082 Human hsa-mir-630 miRNA cisplatin (DDP) DNA damage human lung cancer A549 cells cisplatin treatment upregulated 24909689 9083 Human hsa-miR-630 miRNA cisplatin (DDP) head and neck squamous cell carcinoma (HNSCC) Head and neck squamous cell carcinoma (HNSCC) cells cisplatin treatment upregulated 21274007 9084 Human hsa-miR-630 miRNA bone morphogenetic protein 4 (BMP4) and TGF-¦Â2 heterotopic ossification (HO) HD-MVECs bone morphogenetic protein 4 (BMP4) and TGF-¦Â2 treatment downregulated 26940839 9085 Human hsa-miR-630 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 9086 Human hsa-miR-630 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment upregulated 20145152 9087 Human hsa-miR-630 miRNA H2O2 oxidative stress human lens epithelium cell line HLE-B3 H2O2 treatment upregulated 31869263 9088 Human hsa-miR-630 miRNA luteolin and gefitinib prostate cancer PC-3 cells luteolin and/or gefitinib treatment upregulated 24971999 9089 Human hsa-miR-630 miRNA radiation radioresistance "human glioma cell lines BT325, U373, U87 and U251" radiation treatment downregulated 28386351 9090 Human hsa-miR-630 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9091 Human hsa-miR-630 miRNA ultraviolet (UV) irradiation UVB-induced cellular response normal human dermal papilla cells UVB radiation of ¡Ý50 mJ/cm2 treatment upregulated 25069581 9092 Human hsa-miR-633 miRNA progesterone (P4) endometrial cancer (EC) Hec5A cells Progesterone treatment upregulated 22543862 9093 Human hsa-miR-633 miRNA anacardic acid (AnAc) rheumatoid arthritis (RA) RA fibroblast-like synoviocytes (RA-FLSs) anacardic acid (AnAc) treatment upregulated 30273785 9094 Human hsa-miR-634 miRNA photodynamic therapy (PDT) skin cancer ATCC-No. CRL-1555 cells Photodynamic therapy (PDT) treatment upregulated 23466801 9095 Human hsa-miR-636 miRNA Bu-Shen-Huo-Xue-Fang (BSHXF) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells Bu-Shen-Huo-Xue-Fang (BSHXF) treatment upregulated 29393545 9096 Human hsa-miR-636 miRNA bisphenol A (BPA) arterial hypertension urine; whole blood bisphenol A (BPA) treatment upregulated 32438192 9097 Human hsa-miR-636 miRNA paclitaxel (PTX) ovarian cancer (OC) HeyA8 cells paclitaxel (PTX) treatment downregulated 33028939 9098 Human hsa-miR-636 miRNA brain-derived neurotrophic factor (BDNF) proangiogenic function CFU-Hill cells brain-derived neurotrophic factor (BDNF) treatment upregulated 29860902 9099 Human hsa-miR-637 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cell line (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment MiR-637 expression was decreased in a dose- and time-dependent manner in animal models with ox-LDL-induced atherosclerosis. 32399056 9100 Human hsa-miR-637 miRNA sevoflurane (SEV) glioblastoma multiforme (GBM) U251 cell Sevoflurane treatment upregulated 27840895 9101 Human hsa-miR-637 miRNA heme hepatocellular carcinoma (HCC) Huh?10 cells heme treatment upregulated 23538684 9102 Human hsa-miR-638 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment NEAT1 adjusted the AKT/mTOR signaling pathway via miR-638 in ox-LDL-induced HAECs to accelerate their proliferation and impede their apoptosis. 32377692 9103 Human hsa-miR-638 miRNA PhIP and 17-¦Â-estradiol breast cancer MCF-7 human breast adenocarcinoma cell line PhIP and 17-¦Â-estradiol (E2) treatment dysregulated 24877718 9104 Human hsa-miR-638 miRNA inorganic arsenic (iAs) tumorigenesis human Jurkat leukemic T cell "Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment" upregulated 24317173 9105 Human hsa-miR-638 miRNA platelet-derived growth factor (PDGF) cell proliferation and migration human vascular smooth muscle cells(SMCs) platelet-derived growth factor (PDGF) treatment downregulated 23554459 9106 Human hsa-miR-638 miRNA extract of Stellerachamaejasme L(ESC) hepatocellular carcinoma (HCC) HepG2 and MHCC97H cells extract of Stellerachamaejasme L(ESC) treatment upregulated 29554896 9107 Human hsa-miR-638 miRNA benzo(a)pyrene (BaP) leukemia peripheral lymphocytes benzo(a)pyrene (BaP) exposure miR-638 is involved in the BaP-induced carcinogenesis by targeting BRCA1 22048643 9108 Human hsa-miR-638 miRNA bostrycin lung cancer human lung carcinoma A549 cells bostrycin treatment upregulated 21303527 9109 Human hsa-miR-638 miRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) human cardiomyocytes (HCMs) hypoxia/reoxygenation (H/R) treatment "Hypoxia/reoxygenation (H/R) treatment suppressed cell viability, increased cell apoptotic rate and suppressed miR-638 expression in the HCMs." 30556888 9110 Human hsa-miR-638 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 9111 Human hsa-miR-638 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NSCLC cell line SPC-A1 cisplatin treatment upregulated 25952770 9112 Human hsa-miR-638 miRNA SMPD3 inhibitor GW4869 release of microRNAs into extracellular spaces SW480 and HuH-7 cells the SMPD3 inhibitor GW4869 treatment extracellular and intracellular miR-638 were dose-dependently downregulated and upregulated 25394686 9113 Human hsa-miR-638 miRNA ginsenoside Rh2 retinoblastoma (RB) Human RB Y79 and RBL-13 cells Ginsenoside Rh2 (GRh2) treatment downregulated 30853612 9114 Human hsa-miR-638 miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment upregulated 26640557 9115 Human hsa-miR-638 miRNA ultraviolet (UV) irradiation UVB-induced cellular response normal human dermal papilla cells UVB radiation of ¡Ý50 mJ/cm2 treatment upregulated 25069581 9116 Human hsa-miR-639 miRNA TGF-¦Â tongue cancer TSCC cell lines SCC9 and CAL27 human recombinant TGF¦Â1 for 48 h treatment ?downregulated 25130698 9117 Human hsa-miR-640 miRNA hydrogen sulfide (H2S) angiogenesis vascular endothelial cells (ECs) hydrogen sulfide (H2S) treatment downregulated 26879375 9118 Human hsa-miR-640 miRNA IL-1¦Â intervertebral disc degeneration (IDD) Nucleus pulposus (NP) cells IL©\1¦Â treatment upregulated 31343104 9119 Human hsa-miR-640 miRNA tumor necrosis factor alpha (TNF-¦Á) intervertebral disc degeneration (IDD) Nucleus pulposus (NP) cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31343104 9120 Human hsa-miR-640 miRNA angiopoietin-1 (Ang-1) Ang-1-induced endothelial cell migration and differentiation human umbilical vein endothelial cells (HUVECs) angiopoietin-1 (Ang-1) treatment Exposure to Ang-1 (300 ng/mL) from 6 to 72 h significantly decreased expression of mature miR-640. 32630670 9121 Human hsa-miR-640 miRNA oxidized low density lipoprotein (ox-LDL) inflammatory injury human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment miRNA-640 expression was gradually increased in HUVECs treatment with OX-LDL. 33300444 9122 Human hsa-miR-640 miRNA hydrogen sulfide (H2S) proangiogenic function vascular endothelial cells (ECs) hydrogen sulfide (H2S) treatment downregulated 26879375 9123 Human hsa-miR-641 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" aortic stenosis cervical cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines" 23732000 9124 Human hsa-miR-642 miRNA X-rays gastric cancer (GC) human gastric cancer tissue samples "4 Gy of X-rays (6 MV, 0.8 Gy/min) treatment" downregulated 24919435 9125 Human hsa-miR-642 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid" renal cell carcinoma (RCC) renal cell; carcinoma cell lines (5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment upregulated 23707942 9126 Human hsa-miR-642-5p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 9127 Human hsa-miR-642a miRNA organophosphorus(OP) acute organophosphorus(OP) pesticide poisoning serum organophosphorus(OP) pesticide poisoning downregulated 30602960 9128 Human hsa-miR-642a-3p miRNA vorinostat (SAHA) breast cancer BT474 cells vorinostat (SAHA) treatment upregulated 29620153 9129 Human hsa-miR-642a-3p miRNA rosmarinic acid (RA) gastric cancer (GC) SGC7901 cells rosmarinic acid (RA) treatment RA treated SGC7901/5-Fu cells showed reduced expression levels of miR-642a-3p and miR-6785-5p compared to untreated SGC7901/5-Fu cells 30551491 9130 Human hsa-miR-642a-5p miRNA lipopolysaccharide (LPS) acute Lung Injury (ALI)/acute respiratory distress syndrome (ARDS) pulmonary microvascular endothelial cells (PMVECs) lipopolysaccharide (LPS) treatment miR-642a-5p levels are significantly upregulated in LPS-stimulated PMVECs. 32881411 9131 Human hsa-miR-642a-5p miRNA glucocorticoid (GC) inflammatory bowel disease (IBD) serum Glucocorticoids (GCs) treatment downregulated 31938187 9132 Human hsa-miR-643 miRNA gemcitabine (GEM) pancreatic cancer (PC) SW1990 pancreatic cancer cells gemcitabine treatment upregulated 25722110 9133 Human hsa-miR-643 miRNA entamoeba histolytica parasites infection SW-480 colon cells Entamoeba histolytica infection upregulated 30671387 9134 Human hsa-miR-646 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment hsa_circ_0041795 contributes to human retinal pigment epithelial cells (ARPE 19) injury induced by high glucose via sponging miR-646 and activating VEGFC 32259632 9135 Human hsa-miR-646 miRNA TGF-¦Â1 gastric cancer (GC) human GC cell lines TGF-¦Â1 treatment upregulated 28632723 9136 Human hsa-miR-646 miRNA hypoxia pancreatic cancer (PC) PANC-1 cells hypoxia treatment MiR-646 is critical for downregulated of MIIP under hypoxia. 29343850 9137 Human hsa-miR-646 miRNA ischemia preeclampsia (PE) endothelial progenitor cells ischemia treatment microRNA-646 inhibits angiogenesis of endothelial progenitor cells in pre-eclamptic pregnancy by targeting the VEGF-A/HIF-1¦Á axis 32782496 9138 Human hsa-miR-646 miRNA R-2-hydroxyglutarate (R-2HG) prostate cancer "C4-2, PC3, DU145, LNCaP cells" R-2-hydroxyglutarate (R-2HG) treatment downregulated 31846689 9139 Human hsa-miR-647 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aorta vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31486513 9140 Human hsa-miR-647 miRNA argon-helium cryoablation treatment non-small cell lung cancer (NSCLC) A549 cells; H1299 cells argon-helium cryoablation treatment miR-647 was high expression in tumor that under argon-helium cryoablation treatment in contrast to the tumor under non argon-helium cryoablation treatment and inhibited cell proliferation of A549 and H1299 cells by inducing G1-S transition. 30349310 9141 Human hsa-miR-647 miRNA glucocorticoid (GC) steroid-induced osteonecrosis of femoral head (ONFH) bone marrow mesenchymal stem cells (BMSCs) glucocorticoid (GC) treatment upregulated 29590087 9142 Human hsa-miR-648 miRNA placenta growth factor (PlGF) sickle cell anemia (SCA) human umbilical vein endothelial cells (HUVEC) placenta growth factor (PlGF) treatment downregulated 25403488 9143 Human hsa-miR-649 miRNA herpes simplex virus 1 (HSV-1) herpes simplex virus 1 (HSV-1) infection HeLa cells infect with HSV-1 downregulated 27813118 9144 Human hsa-miR-649 miRNA herpes simplex virus 1 (HSV-1) herpes simplex virus 1 (HSV-1) infection HeLa cells infect wirh HSV-1 downregulated 27813118 9145 Human hsa-miR-650 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) gastric cancer (GC) tissues; HGC-27 cells; MKN-45 cells helicobacter pylori (HP) treatment upregulated 33147052 9146 Human hsa-miR-650 miRNA helicobacter pylori (H. pylori) gastric cancer (GC) GC cells Helicobacter pylori (HP) treatment miR-650 was upregulated in HP+ tissues and cells 33147052 9147 Human hsa-miR-651-3p miRNA atropine myopia Human corneal epithelial cells 0.003% atropine treatment dysregulated 31540331 9148 Human hsa-miR-652 miRNA acidity pancreatic cancer (PC) "human pancreatic cancer cell lines AsPC-1, BxPC-3, PANC-1, SW1990 and MIAPaCa-2" acidity treatment downregulated 26498682 9149 Human hsa-miR-652-3p miRNA simvastatin aberrant endothelial function human umbilical vein endothelial cells (HUVECs) Simvastatin treatment Simvastatin blocked oxidized LDL (ox-LDL)-induced increases in miR-652-3p and ox-LDL-induced decreases in ISL1 protein expression. 32277945 9150 Human hsa-miR-652-3p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 9151 Human hsa-miR-653-5p miRNA IL-1¦Â chondrocyte apoptosis CHON-001 cells IL-1¦Â treatment upregulated 32517436 9152 Human hsa-miR-654-3p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32349937 9153 Human hsa-miR-654-3p miRNA curcumin (Cur) prostate cancer DU145 cells; 22Rv1 cells curcumin treatment downregulated 29172709 9154 Human hsa-miR-654-3p miRNA IFN-¦Ã immunoregulatory function human mesenchymal stem cells (MSCs) "150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h" upregulated 28397044 9155 Human hsa-miR-654-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9156 Human hsa-miR-654-3p miRNA silver ions Ag+ toxicity of silver (Ag) Jurkat T cells Ag ions treatment downregulated 24974768 9157 Human hsa-miR-654-5p miRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3 cells; HeyA8 cells paclitaxel (PTX) treatment downregulated 32016960 9158 Human hsa-miR-655 miRNA CoCl2 breast cancer MCF-7 cells CoCl2 treatment upregulated 32707933 9159 Human hsa-miR-655 miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells TGF-¦Â1 treatment "the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2," 24258346 9160 Human hsa-miR-655 miRNA benzyl butyl phthalate (BBP) hemangioma (HA) The human HA HDEC and CRL-2586 EOMA cells benzyl butyl phthalate (BBP) treatment downregulated 31212022 9161 Human hsa-miR-655 miRNA TGF-¦Â1 lung adenocarcinoma (LUAD) human adenocarcinoma cell lines transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment upregulated 24258346 9162 Human hsa-miR-655-3p miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epigenetic regulation HCT116 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 30538122 9163 Human hsa-miR-655-3p miRNA echinacea purpurea (EP) hepatoblastoma human hepatoblastoma HepG2 cells 50 ?g/mL methanolic extract of commercial EP capsules downregulated 28990842 9164 Human hsa-miR-656-3p miRNA resveratrol benign prostatic hyperplasia (BPH) Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1 resveratrol (RS) treatment upregulated 33718067 9165 Human hsa-miR-656-3p miRNA TGF-¦Â1 benign prostatic hyperplasia (BPH) Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1 TGF-¦Â1 treatment downregulated 33718067 9166 Human hsa-miR-657 miRNA Spatholobus suberectus Dunn (SSD) apoptosis U266 and U937 cells Spatholobus suberectus Dunn (SSD) treatment downregulated 30696076 9167 Human hsa-miR-657 miRNA IFN-¦Ã and lipopolysaccharide (LPS) gestational diabetes mellitus (GDM) THP-1 cells LPS and IFN-¦Ã treatment upregulated 31915414 9168 Human hsa-miR-658 miRNA gefitinib lung cancer PC-9 cells gefitinib treatment upregulated 32052182 9169 Human hsa-miR-658 miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 9170 Human hsa-miR-660 miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment upregulated 19022373 9171 Human hsa-miR-660 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 9172 Human hsa-miR-660-3p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 cells; SKhep1 cells; Huh7 cells; LM3 cells sorafenib treatment downregulated 33222692 9173 Human hsa-miR-660-3p miRNA carbon tetrachloride (CCl4) liver fibrosis primary hepatic stellate cells (HSCs) carbon tetrachloride (CCl4) treatment upregulated 32584784 9174 Human hsa-miR-660-5p miRNA tumor necrosis factor alpha (TNF-¦Á) multiple sclerosis (MS) serum exosomes tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 29505299 9175 Human hsa-miR-663 miRNA waltonitone apoptosis H460 and H3255 lung cancer cells waltonitone treatment upregulated 25301444 9176 Human hsa-miR-663 miRNA oscillatory shear stress (OS) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oscillatory shear stress (OS) treatment miR-663 plays a key role in OS-induced inflammatory responses by mediating the expression of inflammatory gene network in HUVECs 21378144 9177 Human hsa-miR-663 miRNA vascular endothelial growth factor (VEGF) atherosclerosis (AS) Human umbilical vein ECs (HUVECs) and human coronary artery ECs (HCAECs) VEGF treatment "miR-663 is critically important for 2 key events induced in ECs by stress agents and oxidized lipids, namely induction of transcription factor ATF4 and its downstream gene VEGF" 22776647 9178 Human hsa-miR-663 miRNA PhIP and 17-¦Â-estradiol breast cancer MCF-7 human breast adenocarcinoma cell line PhIP and 17-¦Â-estradiol (E2) treatment dysregulated 24877718 9179 Human hsa-miR-663 miRNA inorganic arsenic (iAs) tumorigenesis human Jurkat leukemic T cell "Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment" upregulated 24317173 9180 Human hsa-miR-663 miRNA arsenite chronic arsenic toxicity skin cancer tissues arsenic (As) exposure miR-663 was significantly reduced in arsenic induced skin cancer tissues compared to control tissue. 32563914 9181 Human hsa-miR-663 miRNA 4-hydroxynonenal (4-HNE) leukemia HL-60 leukemic cells 4-Hydroxynonenal (HNE) treatment upregulated 19022373 9182 Human hsa-miR-663 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" multiple myeloma (MM) Human MM Cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 26164366 9183 Human hsa-miR-663 miRNA rotenone (ROT) oxidative stress human fibroblasts of different age 0.6 ¦ÌM rotenone in stressed conditions treatment upregulated 24664125 9184 Human hsa-miR-663 miRNA metformin (Met) pancreatic cancer (PC) BxPC-3 cells; MIAPaCa-2 cells metformin treatment miR-663 was upregulated after treatment of metformin. 33116621 9185 Human hsa-miR-663 miRNA lidocaine skin healing process denatured skin tissues Lidocaine treatment "lidocaine treatment promoted the skin healing after thermal injury through up-regulating miR-486 and miR-663 expression, and partially explained how lidocaine modulates wound healing processes." 31815358 9186 Human hsa-miR-663a miRNA ultraviolet (UV) irradiation cell senescence primary human dermal fibroblasts UVB-irradiated treatment "RP11-670E136/miR-663a/CDK4?and?RP11-670E136/miR-663a/CDK6?axis, which may function as competitive endogenous RNA networks, played important roles in UVB-induced cellular senescence" 31444317 9187 Human hsa-miR-663a miRNA antimicrobial peptides (AMPs) colorectal cancer (CRC) HCT116 cells administration of the human cathelicidin AMP upregulated 28061765 9188 Human hsa-miR-663a miRNA "irbesartan, fenofibrate, omeprazole" drug-induced liver injury (DILI) human HepG2 cells "irbesartan, fenofibrate, omeprazole" upregulated 28179883 9189 Human hsa-miR-663a miRNA thapsigargin (Tg) endoplasmic reticulum stress (ERS) "human osteosarcoma cells U2OS, 143B, MG63, Saos-2" thapsigargin (Tg) treatment upregulated 30753838 9190 Human hsa-miR-663a miRNA tunicamycin (TM) endoplasmic reticulum stress (ERS) "human osteosarcoma cells U2OS, 143B, MG63, Saos-2" tunicamycin (TM)? treatment upregulated 30753838 9191 Human hsa-miR-663a miRNA hematoporphyrin glioblastoma multiforme (GBM) U87 glioma cells hematoporphyrin treatment upregulated 29344634 9192 Human hsa-miR-663a miRNA graphene oxide (GO) graphene oxide (GO) toxicity GLC-82 cells GO treatment dysregulated 24512264 9193 Human hsa-miR-663a miRNA fluoxetine (Prozac) neurodevelopmental processes SK-N-SH cell lines fluoxetine treatment upregulated 27716787 9194 Human hsa-miR-663a miRNA fluoxetine (Prozac) neurodevelopmental processes SH-SY5Y cell lines fluoxetine treatment upregulated 27716787 9195 Human hsa-miR-663a miRNA IL-1¦Â osteoarthritis (OA) OA cartilage tissues IL-1¦Â treatment "The expression of HOTTIP and FRK were upregulated, while miR-663a was downregulated in OA cartilage tissues." 33435956 9196 Human hsa-miR-663a miRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) "Human PDAC cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2)" Gemcitabine (GEM) treatment upregulated 30788003 9197 Human hsa-miR-663a miRNA OSI-027 pancreatic ductal adenocarcinoma (PDAC) "Human PDAC cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2)" OSI-027 treatment downregulated 30788003 9198 Human hsa-miR-663b miRNA beryllium sulfate (BeSO4 ) beryllium toxicity 16HBE cells beryllium sulfate (BeSO4 ) treatment downregulated 33197057 9199 Human hsa-miR-663b miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment downregulated 22647265 9200 Human hsa-miR-663b miRNA tamoxifen (TAM) breast cancer MCF-7 cells tamoxifen (TAM) treatment miRNA-663b was upregulated in breast cancer with TAM resistance 29845295 9201 Human hsa-miR-663b miRNA pterostilbene endometrial cancer (EC) HTB-111 and Ishikawa cells PT (25-100 ¦Ìmol/L) treatment downregulated 28552912 9202 Human hsa-miR-664 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 9203 Human hsa-miR-664-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9204 Human hsa-miR-664a-3p miRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) Beas-2B cells cigarette smoke extract (CSE) exposure upregulated 31632001 9205 Human hsa-miR-664a-5p miRNA all-trans retinoic acid (ATRA) neuronal differentiation SH-SY5Y cells all-trans retinoic acid (ATRA) treatment upregulated 29341475 9206 Human hsa-miR-665 miRNA hypoxia cell proliferation human primary pulmonary artery smooth muscle cells hypoxia induce upregulated 31370272 9207 Human hsa-miR-665 miRNA propofol (PPF) neurotoxicity human stem cell-derived neurons Propofol treatment upregulated 31656124 9208 Human hsa-miR-665 miRNA high fat diet (HFD) prostate cancer PCa cells high fat diet (HFD) feed upregulated 27915273 9209 Human hsa-miR-665 miRNA olmesartan (OMST) vascular senescence vascular smooth muscle cells (VSMCs) Olmesartan (OMST) treatment downregulated 33042414 9210 Human hsa-miR-665-3p miRNA hypoxia intestinal ischemia/reperfusion (I/R) injury Caco-2 cells hypoxia induce upregulated 29706629 9211 Human hsa-miR-671 miRNA muramyl dipeptide crohn disease (CD) ?HCT116 cells Muramyl dipeptide treatment downregulated 24297055 9212 Human hsa-miR-671 miRNA IL-1¦Â osteoarthritis (OA) chondrocytes CHON-001 IL-1¦Â treatment downregulated 31085006 9213 Human hsa-miR-671 miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment The expression of circ_0114876 was increased in OA tissues and inhibition of circ_0114876 could induce cell viability and suppress inflammation as well as inhibit cell apoptosis in IL-1¦Â induced CHON-001 cells. 33404903 9214 Human hsa-miR-671-3p miRNA bisphenol A (BPA) arterial hypertension urine; whole blood bisphenol A (BPA) treatment downregulated 32438192 9215 Human hsa-miR-671-5p miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 9216 Human hsa-miR-671-5p miRNA hypoxia hepatocellular carcinoma (HCC) Hep3B cells hypoxia induce downregulated 30250300 9217 Human hsa-miR-671-5p miRNA lipopolysaccharide (LPS) inflammation OFSCs (OFSCs-CM) upon co-culture with activated macrophages treatment downregulated 25124290 9218 Human hsa-miR-671-5p miRNA 3-methyladenine (3-MA) oral squamous cell carcinoma (OSCC) Tca-8113 cells 3-Methyladenine (3-MA) treatment downregulated 31582727 9219 Human hsa-miR-671-5p miRNA hypoxia oral squamous cell carcinoma (OSCC) Tca-8113 cells hypoxia induce downregulated 31582727 9220 Human hsa-miR-671-5p miRNA rapamycin oral squamous cell carcinoma (OSCC) Tca-8113 cells rapamycin treatment downregulated 31582727 9221 Human hsa-miR-671-5p miRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment "Circ-IQGAP1 abundance was enhanced in the cartilage tissues from OA patients compared with normal subjects (n = 32), and its expression was increased in CHON-001 cells after treatment of IL-1¦Â in a dose-dependent pattern." 33675175 9222 Human hsa-miR-671-5p miRNA bromocriptine pituitary adenoma pituitary adenoma tissue bromocriptine treatment downregulated 22366961 9223 Human hsa-miR-6720-3p miRNA alternariol (AOH) antagonistic cytotoxic HepG2 cells alternariol (AOH) treatment upregulated 28007639 9224 Human hsa-miR-6720-3p miRNA alternariol (AOH) cytotoxicity HepG2 alternariol (AOH) treatment upregulated 28007639 9225 Human hsa-miR-6731-5p miRNA IL-22 psoriasis HaCaT cells IL-22 treatment downregulated 29339075 9226 Human hsa-miR-6732-3p miRNA radon lung cancer BEAS-2B cells radon treatment upregulated 33447367 9227 Human hsa-miR-6732-3p miRNA radiation nasopharyngeal carcinoma (NPC) serum radiation treatment downregulated 32198434 9228 Human hsa-miR-6734-3p miRNA arsenic resistance protein 2 (Ars2) acute myeloid leukemia (AML) U937 cells Ars2 deficiency downregulated 30518811 9229 Human hsa-miR-6734-5p miRNA arsenic trioxide (ATO) bladder cancer T24 cells arsenic trioxide (As2O3) treatment lncRNA OTUD6B-AS1 Exacerbates As 2 O 3-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2 32952848 9230 Human hsa-miR-6740 miRNA stiff (50 kPa) hydrogel substrates cardiovascular disease (CVD) human umbilical vein endothelial cells stiff (50 kPa) hydrogel substrates cultures treatment downregulated 31606530 9231 Human hsa-miR-6746-5p miRNA cyclosporine A (CsA) colorectal cancer (CRC) HCT116 and SW480 cell extracellular vesicle (EV) cyclosporine A (CsA) treatment downregulated 31371743 9232 Human hsa-miR-6746-5p miRNA rapamycin colorectal cancer (CRC) HCT116 and SW480 cell extracellular vesicle (EV) rapamycin (RAPA) treatment upregulated 31371743 9233 Human hsa-miR-675 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" diabetic nephropathy (DN) CIHP©\1 and HEK 293 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 30815865 9234 Human hsa-miR-675 miRNA early growth response protein 1 (EGR1) diabetic nephropathy (DN) CIHP©\1 and HEK 293 cells early growth response protein 1 (EGR1) treatment upregulated 30815865 9235 Human hsa-miR-675 miRNA synthetic preimplantation factor (sPIF) duchenne muscular dystrophy (DMD) myoblast Synthetic preimplantation factor (sPIF) treatment upregulated 30692507 9236 Human hsa-miR-675 miRNA lipopolysaccharide (LPS) gestational diabetes mellitus (GDM) Human leukemia cell line THP©\1 cells lipopolysaccharide (LPS) treatment upregulated 30362558 9237 Human hsa-miR-675 miRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" glioblastoma multiforme (GBM) SH©\SY5Y and SNB©\19 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 31468534 9238 Human hsa-miR-675 miRNA curcumin (Cur) glioblastoma multiforme (GBM) SH©\SY5Y and SNB©\19 cells curcumin (CUR) treatment downregulated 31468534 9239 Human hsa-miR-675 miRNA curcumin (Cur) glioblastoma multiforme (GBM) SH-SY5Y cells; SNB-19 cells curcumin (CUR) treatment CUR downregulated the expression of miR-675. 31468534 9240 Human hsa-miR-675 miRNA curcumin (Cur) glioblastoma multiforme (GBM) SH-SY5Y cells; SNB-19 cells curcumin (CUR) treatment "1,25(OH) 2 D3 downregulated the expression of H19 and miR-675." 31468534 9241 Human hsa-miR-675 miRNA hepatitis B virus (HBV) hepatoblastoma HepG2 cells hepatitis B virus (HBV) infection upregulated 30367502 9242 Human hsa-miR-675 miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7; Hep3B; SNU©\449; SNU©\387 sorafenib treatment Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675 32627034 9243 Human hsa-miR-675 miRNA TGF-¦Â hepatocellular carcinoma (HCC) Hep3B cells 2 ng/ml TGF-¦Â for 48 h treatment upregulation 24703882 9244 Human hsa-miR-675 miRNA hepatitis B virus X protein (HBx) liver damage L02 cells hepatitis B X protein (HBx) treatment "the expression of lncRNA H19 and miR-675 was upregulated in patients with chronic hepatitis B. Inhibition of lncRNA H19 or miR-675 in L02 cells increased cell viability, suppressed hepatitis B X protein (HBx)-induced cell apoptosis, inflammatory cytokine production, and oxidative stress, and remodelled energy metabolism." 31574452 9245 Human hsa-miR-675 miRNA angelica polysaccharide (AP) neuroblastoma (NB) SH-SY5Y cells angelica polysaccharide (AP) treatment downregulated 29465760 9246 Human hsa-miR-675 miRNA hypoxia osteoarthritis (OA) human cartilage cells Hypoxia treatment upregulated 22527881 9247 Human hsa-miR-675 miRNA IL-1¦Â and TNF-¦Á osteoarthritis (OA) human cartilage cells IL-1¦Â and TNF-¦Á?treatment downregulated 22527881 9248 Human hsa-miR-675 miRNA H2O2 premature senescence C-kit(+) cardiac progenitor cells (CPCs) H2 O2 treatment downregulated 27062045 9249 Human hsa-miR-675 miRNA melatonin subarachnoid hemorrhage (SAH) U87 cells; U251 cells melatonin (MT) treatment upregulated 29367587 9250 Human hsa-miR-6751 miRNA triptolide (TPL) ovarian cancer (OC) cisplatin-resistant ovarian cancer cell line A2780/CP70 triptolide (TPL) treatment upregulated 29966441 9251 Human hsa-miR-6752-5p miRNA tensile hepatocellular carcinoma (HCC) HepG2 cells tensile treatment upregulated 32323778 9252 Human hsa-miR-675-3p miRNA IL-1¦Â osteoarthritis (OA) Human chondrocytes IL-1¦Â treatment The overexpression of miR-675-3p inhibited apoptosis and cartilage matrix degradation and promoted cell proliferation in human chondrocytes. 32336544 9253 Human hsa-miR-675-3p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment upregulated 28707489 9254 Human hsa-miR-675-5p miRNA hypoxia bone ossification hMSCs hypoxia treatment upregulated 29111380 9255 Human hsa-miR-675-5p miRNA huaier extract breast cancer "breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF8" downregulated 29145193 9256 Human hsa-miR-675-5p miRNA hypoxia colorectal cancer (CRC) SW620 cells; HCT116 cells hypoxia treatment Hypoxia-Induced miR-675-5p Supports ¦Â-Catenin Nuclear Localization by Regulating GSK3-¦Â Activity in Colorectal Cancer Cell Lines 32481626 9257 Human hsa-miR-675-5p miRNA Prostaglandin E2 (PGE2) colorectal cancer (CRC) LS174T colorectal cancer cells Prostaglandin E2 (PGE2) treatment upregulated 31734182 9258 Human hsa-miR-675-5p miRNA prostaglandin E2 (PGE2) colorectal cancer (CRC) LS174T cells Prostaglandin E2 (PGE2) treatment Prostaglandin E 2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression 31734182 9259 Human hsa-miR-6776-5p miRNA high glucose (HG) calcification/senescence human aortic vascular smooth muscle cells (HA-VSMCs) high glucose (HG) treatment downregulated 32483833 9260 Human hsa-miR-6779-5p miRNA yhexamethylene guanidine phosphate (PHMG-phosphate) lung fibrosis A549 cells yhexamethylene guanidine phosphate (PHMG-phosphate) treatment downregulated 29337256 9261 Human hsa-miR-6785-5p miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC7901 cells 5-fluorouracil (5-FU) treatment upregulated 30551491 9262 Human hsa-miR-6785-5p miRNA rosmarinic acid (RA) gastric cancer (GC) SGC7901/5-Fu cells Rosmarinic acid (RA) treatment downregulated 30551491 9263 Human hsa-miR-6785-5p miRNA rosmarinic acid (RA) gastric cancer (GC) SGC7901 cells rosmarinic acid (RA) treatment RA treated SGC7901/5-Fu cells showed reduced expression levels of miR-642a-3p and miR-6785-5p compared to untreated SGC7901/5-Fu cells 30551491 9264 Human hsa-miR-6787-5p miRNA cyclosporine A (CsA) colorectal cancer (CRC) HCT116 and SW480 cell extracellular vesicle (EV) cyclosporine A (CsA) treatment downregulated 31371743 9265 Human hsa-miR-6787-5p miRNA rapamycin colorectal cancer (CRC) HCT116 and SW480 cell extracellular vesicle (EV) rapamycin (RAPA) treatment upregulated 31371743 9266 Human hsa-miR-6794-5p miRNA tensile hepatocellular carcinoma (HCC) HepG2 cells tensile treatment upregulated 32323778 9267 Human hsa-miR-6797-5p miRNA parathyroid hormone (PTH) cell differentiation human bone marrow stromal cells (hBMSCs) Parathyroid hormone (PTH) treatment upregulated 30562548 9268 Human hsa-miR-6797-5p miRNA parathyroid hormone (PTH) osteoblastic differentiation human bone marrow stromal cells (hBMSCs) parathyroid hormone (PTH) treatment PTH-treatment increased the expression of miR-6797-5p in hBMSCs 30562548 9269 Human hsa-miR-6808-5p miRNA particulate matter (PM2.5) cardiotoxicity endothelial cells PM2.5 exposure treatment downregulated 30597786 9270 Human hsa-miR-6808-5p miRNA particulate matter (PM2.5) cardiotoxicity of PM2.5 endothelial cells PM2.5 treatment downregulated 30597786 9271 Human hsa-miR-6809-5p miRNA luteolin hepatocellular carcinoma (HCC) "Huh7 cells, HepG2 cells" "Luteolin (3,4,5,7-tetrahydroxy flavone) treatment" upregulated 30668319 9272 Human hsa-miR-6809-5p miRNA luteolin hepatocellular carcinoma (HCC) "Huh7 cells, HepG2 cells" "Luteolin (3,4,5,7-tetrahydroxy flavone) treatment" upregulated 30668319 9273 Human hsa-miR-6810-5p miRNA gefitinib lung cancer PC-9 cells gefitinib treatment upregulated 32052182 9274 Human hsa-miR-6813-5p miRNA "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)" breast cancer MCF-7 cells "(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment" Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells. 33652854 9275 Human hsa-miR-6816 miRNA suberoylanilide hydroxamic acid (SAHA) chronic myeloid leukemia (CML) K562 cells suberoylanilide hydroxamic acid (SAHA) treatment upregulated 29343029 9276 Human hsa-miR-6817-5p miRNA Nel-like molecule type 1 (NELL-1) osteogenesis human adipose-derived stem cells (hASCs) "recombinant nel-like molecule, type 1 (NELL-1) treatment" downregulated 31633307 9277 Human hsa-miR-682 miRNA hypoxia intestinal ischemia/reperfusion (I/R) injury human colonic epithelial cells hypoxia treatment upregulated 27124584 9278 Human hsa-miR-6825-5p miRNA "oxaliplatin, 5-fluorouracil and pirarubicin (THP)" hepatocellular carcinoma (HCC) "human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w" THP treatment downregulated 28166203 9279 Human hsa-miR-6832-5p miRNA high glucose (HG) diabetic vasculopathy Human umbilical vein endothelial cells (HUVECs) high-glucose (HG) treatment "he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels." 33537821 9280 Human hsa-miR-6839-5p miRNA radiation chondrosarcoma SW1353 cells radiation treatment upregulated 32362797 9281 Human hsa-miR-684 miRNA paclitaxel (PTX) breast cancer MCF-7 cells low-dose metronomic (LDM) paclitaxel treatment upregulated 25552929 9282 Human hsa-miR-6842-5p miRNA high glucose (HG) diabetic vasculopathy Human umbilical vein endothelial cells (HUVECs) high-glucose (HG) treatment "he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels." 33537821 9283 Human hsa-miR-6845-3p miRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH5Y-SY cells amyloid-¦Â (A¦Â) 25-35 treatment A¦Â 25-35 upregulated hsa-miR-6845-3p in SH-SY5Y cell lines associated with A¦Â-mediated pathophysiology. 30547775 9284 Human hsa-miR-6845-5p miRNA "oxaliplatin, 5-fluorouracil and pirarubicin (THP)" hepatocellular carcinoma (HCC) "human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w" THP treatment downregulated 28166203 9285 Human hsa-miR-6873-3p miRNA oxidized low density lipoprotein (ox-LDL) endothelial inflammation human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment circ-RELL1 modulate inflammatory response by miR-6873-3p/MyD88/NF-¦ÊB axis in ox-LDL induced endothelial cells. 33008595 9286 Human hsa-miR-6886-3p miRNA "oxaliplatin, 5-fluorouracil and pirarubicin (THP)" hepatocellular carcinoma (HCC) "human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w" THP treatment downregulated 28166203 9287 Human hsa-miR-6889-5p miRNA tensile hepatocellular carcinoma (HCC) HepG2 cells tensile treatment upregulated 32323778 9288 Human hsa-miR-7 miRNA hepatocyte growth factor (HGF) breast cancer MCF-10A cells HGF upregulated 29133945 9289 Human hsa-miR-7 miRNA trichostatin A (TSA) breast cancer lapatinib-ed triple-negative breast cancer cells TSA treatment upregulated 24707474 9290 Human hsa-miR-7 miRNA estradiol-17¦Â (E2) breast cancer MCF-7 cells estradiol-17¦Â (E2) treatment upregulated 23227519 9291 Human hsa-miR-7 miRNA estrogen (ES) breast cancer MCF-7 cells; SK-BR-3 cells estrogen treatment miRNAs were significantly induced by E2 treatment in the MCF-7 cell line.miR-7 suppress epidermal growth factor receptor (EGFR) expression in several human malignancies. 23227519 9292 Human hsa-miR-7 miRNA photodynamic therapy (PDT) cervical cancer (CC) HeLa cells photody-namic therapy (PDT) treatment upregulated 19953537 9293 Human hsa-miR-7 miRNA oleic acid (OA) cervical cancer (CC) HeLa cells OA induces production in upregulated 28483648 9294 Human hsa-miR-7 miRNA gefitinib drug resistance A549 sub-clone gefitinib-resistant was established by exposure to escalating gefitinib concentrations over a period of 16-24 months treatment downregulated 25339453 9295 Human hsa-miR-7 miRNA alcohol gastric cancer (GC) HEK293T cells;SH SY5Y cells;1321 N1 cells ?alcohol? treatment upregulated 24961422 9296 Human hsa-miR-7 miRNA IL-1¦Â and TNF-¦Á gastric cancer (GC) gastric tumor cells IL-1¦Â and TNF-¦Á treatment downregulated 22139078 9297 Human hsa-miR-7 miRNA soft-shelled turtle peptide gastric cancer (GC) AGS cells soft-shelled turtle peptide treatment upregulated 29435044 9298 Human hsa-miR-7 miRNA yangzheng sanjie decoction (YZSJD) gastric cancer (GC) GC MKN-45 cell line yangzheng Sanjie Decoction (YZSJD) treatment upregulated 29467883 9299 Human hsa-miR-7 miRNA H2O2 glaucoma human trabecular meshwork (TM) cells "For the stimulation with H2 O2 , the cells were cultured in Trabecular Meshwork Cell Medium (TMCM) containing 50-400 ¦ÌM H2O2 (Sigma-Aldrich, St. Louis, MO, USA) for 24 h after they reached 80-85% confluence." miR-7 overexpression abrogated the effects of lncRNA ANRIL on H2O2-treated TM cells. Phosphorylation levels of the key kinases in the mTOR and MEK/ERK pathways were enhanced by lncRNA ANRIL via down-regulating miR-7 in H2O2-treated TM cells. 31081068 9300 Human hsa-miR-7 miRNA lapatinib HER2-positive breast cancer primary human breast cancer cells lapatinib treatment "microRNA-7 directly binds and inhibits Raf-1 3'UTR activity, and that downregulated of miR-7 by lapatinib contributes to the activation of Raf-1 signaling pathway and the induction of IL-6 expression" 26513016 9301 Human hsa-miR-7 miRNA manganese (Mn) idiopathic Parkinson's disease human neuroblastoma SH-SY5Y cells manganese (100¦ÌM) treatment downregulated 28986288 9302 Human hsa-miR-7 miRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) The human lung fibroblasts (WI-38 cells) TGF-¦Â1 treatment downregulated 31786325 9303 Human hsa-miR-7 miRNA single-walled carbon nanotubes (SWCNTs) immune response normal human astrocytes (line NHA/TS) single-walled carbon nanotubes (SWCNTs) treatment upregulated 29906516 9304 Human hsa-miR-7 miRNA docetaxel (DTX) lung cancer NSCLC cell lines A549 and H460 docetaxel (DTX) treatment upregulated 26464649 9305 Human hsa-miR-7 miRNA gefitinib lung cancer A549 human lung cancer cell gefitinib treatment downregulated 25339453 9306 Human hsa-miR-7 miRNA manganese (Mn) manganese induced neurotoxic SH-SY5Y cells manganese treatment The expressions of miR-7 and miR-433 significantly reduced upon manganese exposure. 28986288 9307 Human hsa-miR-7 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 9308 Human hsa-miR-7 miRNA metformin (Met) non-small cell lung cancer (NSCLC) A549 cells metformin (Met) treatment "Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells." 31789625 9309 Human hsa-miR-7 miRNA IL-1¦Â osteoarthritis (OA) Human OA chondrocytes (C28/12 cell line) IL-1¦Â treatment upregulated 30925324 9310 Human hsa-miR-7 miRNA curcumin (Cur) pancreatic cancer (PC) pancreatic carcinoma PANC-1 cells curcumin treatment upregulated 28259961 9311 Human hsa-miR-7 miRNA curcumin (Cur) pancreatic cancer (PC) human AsPC-1 and BxPC-3 PC cells curcumin treatment upregulated 25256401 9312 Human hsa-miR-7 miRNA gemcitabine (GEM) pancreatic cancer (PC) PANC-1 cells gemcitabine treatment miR-7 expression was decreased in gemcitabine-resistant pancreatic cancer cells. 33552258 9313 Human hsa-miR-7 miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated 29953413 9314 Human hsa-miR-7 miRNA pramipexole (PPX) parkinson's disease (PD) 1-methyl-4-phenylpyridinium (MMP+) treated SH-SY5Y cells pramipexole (PPX) treatment upregulated 29953413 9315 Human hsa-miR-7 miRNA "pramipexole,piribedil, L-dopa, amantadine" parkinson's disease (PD) patients with Parkinson's disease "different medications (pramipexole,piribedil, L-dopa, amantadine) treatment" upregulated 25465742 9316 Human hsa-miR-7 miRNA astaxanthin parkinson's disease (PD) SH-SY5Y Cells astaxanthin (AST) treatment AST reverses the dysregulation of miR-7 and SNCA in SH-SY5Y cells induced by MPP+. 32333925 9317 Human hsa-miR-7 miRNA lipopolysaccharide (LPS) periodontitis Human periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment "CDR1as was significantly downregulated in LPS-treated PDLSCs compared to untreated cells, as well as in normal periodontal ligament tissues compared to periodontitis tissues." 31582895 9318 Human hsa-miR-7 miRNA ultraviolet (UV) irradiation pigmented skin diseases HaCaT cells; FB cells Ultraviolet B (UVB)? treatment downregulated 33687273 9319 Human hsa-miR-7 miRNA docetaxel (DTX) prostate cancer PC-3 cells; DU145 cells docetaxel (DTX) treatment miR-7 was downregulated in DTX-resistant PCa tissues and cells. 32714093 9320 Human hsa-miR-7 miRNA lapatinib triple negative breast cancer (TNBC) triple-negative MDA-MB-231 breast cancer cells Lapatinib treatment downregulated 23355539 9321 Human hsa-miR-7 miRNA "antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)" schizophrenia (SZ) schizophrenia patients six-week antipsychotic treatment upregulated 24694668 9322 Human hsa-miR-7 miRNA silica silicosis HBE cells; A549 cells silica treatment miR-7 was downregulated in HBE and A549 cells treated with silica 30202956 9323 Human hsa-miR-7 miRNA IL-21 systemic lupus erythematosus (SLE) normal and SLE B cells IL-21 treatment upregulated 25101889 9324 Human hsa-miR-7 miRNA vitamin D type 2 diabetes mellitus (T2DM) type 2 diabetes patients vitamin D treatment dysregulated 28945992 9325 Human hsa-miR-7 miRNA Roux-en-Y gastric bypass (RYGB) weight loss obese subjects without exercise program plasma RYGB treatment dysregulatedin plasma 28344345 9326 Human hsa-miR-7 miRNA nicotine wound healing periodontal ligament-derived stem cells (PDLSC) nicotine treatment upregulated 23030247 9327 Human hsa-miR-7013-3p miRNA hydroxyurea melanoma B16 melanoma cells Hydroxyurea (HU) treatment We found that miR-7013-3p exhibited increased expression after HU treatment and could bind to MITF. 33746605 9328 Human hsa-miR-706 miRNA H2O2 hepatitis L02 cells H2O2 treatment miR-706 mimic partly abolished the influence of H2O2-resulted damage on L02 cells. 31479678 9329 Human hsa-miR-706 miRNA H2O2 hepatitis L02 cells H2O2 treatment downregulated 31479678 9330 Human hsa-miR-708 miRNA ethanol (EtOH) alcoholic liver disease (ALD) L0-2 cells ethanol treatment downregulated 32721464 9331 Human hsa-miR-708 miRNA maritoclax apoptosis "renal carcinoma (Caki, ACHN and A498), lung cancer (A549) and hepatocellular carcinoma (SK-Hep1) cells" Maritoclax treatment upregulated 30463333 9332 Human hsa-miR-708 miRNA antcin A (ATA) breast cancer human breast cancer cells MCF-7 and MDA-MB-231 antcin A (ATA) treatment upregulated 30726934 9333 Human hsa-miR-708 miRNA dexamethasone (DEX) breast cancer human breast cancer cells MCF-7 and MDA-MB-231 dexamethasone (DEX) treatment upregulated 30726934 9334 Human hsa-miR-708 miRNA dexamethasone (DEX) breast cancer MDA-MB-231 cells dexamethasone (DEX) treatment The dose dependent induction of miR-708 by DEX was observed in the MDA-MB-231 cells from 1 nM to 100 nM. 33065150 9335 Human hsa-miR-708 miRNA carnosic acid (CA) chronic lymphocytic leukemia (CLL) CML KBM-7 cell line Carnosic acid (CA) treatment downregulated 30003745 9336 Human hsa-miR-708 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) human neuroblastoma cells (SH-SY5Y) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 29128627 9337 Human hsa-miR-708 miRNA glucocorticoid (GC) osteonecrosis of femoral head (ONFH) mesenchymal stem cells (MSCs) glucocorticoid (GC) treatment upregulated 26932538 9338 Human hsa-miR-708 miRNA deubiquitinases inhibitor (WP1130) renal cell carcinoma (RCC) Caki cells WP1130 treatment upregulated 30862047 9339 Human hsa-miR-708-5p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) human macrophages (HTP-1 and U937 cells) Mycobacterium tuberculosis (M.tb) infection upregulated 31599428 9340 Human hsa-miR-709 miRNA cyclosporine A (CsA) nephrotoxicity HEK293 cyclosporine A treatment upregulated 28414804 9341 Human hsa-miR-710 miRNA carbon monoxide (CO) colonic inflammation The YAMC (Young Adult Mouse Colon) cell carbon monoxide (CO) treatment downregulated 20005208 9342 Human hsa-miR-7109-5p miRNA sodium butyrate (NaB) sickle cell anemia (SCA) CD133 hematopoietic stem cells sodium butyrate treatment dysregulated 26837891 9343 Human hsa-miR-711 miRNA dexamethasone (DEX) ischemic liver injury L-02 cells dexamethasone (DEX) treatment "Dexmedetomidine attenuated OGD-induced apoptosis and inflammation, and dexmedetomidine downregulated the expression of miR-711." 30338821 9344 Human hsa-miR-7-1-3p miRNA rapamycin glioblastoma multiforme (GBM) U87MG and T98G rapamycin (RAPA) treatment upregulated 26573275 9345 Human hsa-miR-718 miRNA toluene toluene-induced toxicity HL-60 human promyelocytic leukemia cells toluene treatment dysregulated 28245982 9346 Human hsa-miR-720 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 9347 Human hsa-miR-744 miRNA lactic acid (LA) cervical cancer (CC) HPV16 positive SiHa cells lactic acid treatment upregulated 30423314 9348 Human hsa-miR-744 miRNA oxaliplatin colorectal cancer (CRC) HCT116 cells oxaliplatin treatment upregulated 31884801 9349 Human hsa-miR-744 miRNA oxaliplatin colorectal cancer (CRC) colorectal cancer tissues; HCT116 cells oxaliplatin (OXA) treatment upregulated 31884801 9350 Human hsa-miR-744 miRNA angiotensin II (Ang II) heart failure (HF) Human adult atrial fibroblast primary cultures (NHCF-A) angiotensin II (Ang II) treatment downregulated 30392569 9351 Human hsa-miR-744 miRNA CCAAT/enhancer binding protein delta (CEBPD) leukemia human monocytic leukemic cell line THP-1 and the human myeloid cell line U937 CEBPD treatment upregulated 29120412 9352 Human hsa-miR-744 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 9353 Human hsa-miR-744-5p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9354 Human hsa-miR-758 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVECs or HAECs (human artery cells) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29660520 9355 Human hsa-miR-758 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment CircRSF1 could protect against ox-LDL-induced endothelial cell injury in vitro via miR-758/CCND2 axis 32791147 9356 Human hsa-miR-758 miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 9357 Human hsa-miR-758 miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 9358 Human hsa-miR-7-5p miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) human alveolar epithelial cell line A549 lipopolysaccharide (LPS) treatment upregulated 27331901 9359 Human hsa-miR-7-5p miRNA ccrriizottiiniib anaplastic lymphoma kinase positive anaplastic large cell lymphomas Karpas-299 cells; SU-DHL-1 cells ccrriizottiiniib treatment downregulated 31626878 9360 Human hsa-miR-7-5p miRNA hydroquinone (HQ) cell proliferation and apoptosis TK6 cells Hydroquinone (HQ) treatment downregulated 29421518 9361 Human hsa-miR-7-5p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment miR-7-5p expression was upregulated in OGD/R-treated SH-SY5Y cells. 32453073 9362 Human hsa-miR-7-5p miRNA hyperoxia experimental retinopathy human umbilical vein endothelial cells incubated at 2% oxygen upregulated 28353063 9363 Human hsa-miR-7-5p miRNA 2-deoxy-d-glucose (2-DG) glioblastoma multiforme (GBM) U87MG cells; LN229 cells; A172 cells; T98G cells 2-Deoxy-d-glucose (2-DG) treatment 2-DG treatment downregulates the tumor suppressive miR-7-5p in GBM cell lines in vitro. 29621542 9364 Human hsa-miR-7-5p miRNA verbascoside (VB) glioblastoma multiforme (GBM) U87 cells; U251 cells Verbascoside (VB) treatment VB promoted the expression of miR-7-5p in GBM 33768139 9365 Human hsa-miR-7-5p miRNA aspirin hepatocellular carcinoma (HCC) Huh-7 cells Aspirin treatment downregulated 32627038 9366 Human hsa-miR-7-5p miRNA honokiol non-small cell lung cancer (NSCLC) NSCLC A549 cells honokiol treatment downregulated 31176168 9367 Human hsa-miR-7-5p miRNA steroids osteonecrosis of femoral head (ONFH) bone marrow mesenchymal stem cells (BMSCs) steroid treatment downregulated 32018039 9368 Human hsa-miR-7-5p miRNA activin A prostate cancer PC3 cells activin A treatment downregulated 27018851 9369 Human hsa-miR-7-5p miRNA hypoxia pulmonary hypertension (PH) Human pulmonary artery smooth muscle cell (HPASMC) hypoxia treatment CDR1as/miR-7-5p/CNN3 and CAMK2D regulatory axis mediates HPASMC osteoblastic differentiation and calcification induced by hypoxia. 33230455 9370 Human hsa-miR-760 miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT116 cells; Caco2 cells 5-fluorouracil (5-FU) treatment miR-760 expression was markedly increased in CRC resistant cells. 32982440 9371 Human hsa-miR-760 miRNA methotrexate (MTX) colorectal cancer (CRC) The human CRC cell line HT29 and Caco2 cells methotrexate (MTX) treatment KCNQ1OT1 enhanced the MTX resistance of CRC cells by regulating miR-760-mediated PPP1R1B expression via the cAMP signalling pathway 30997746 9372 Human hsa-miR-760 miRNA peiminine colorectal cancer (CRC) SW620 and HT29 cells peiminine treatment "Peiminine notably downregulated the expression of LINC00659, while the expression of miR-760 was upregulated by peiminine treatment" 32740014 9373 Human hsa-miR-760 miRNA rituximab (RTX) neuromyelitis optica (NMO) NMO patients NMO patients treatment dysregulated in the blood 27393339 9374 Human hsa-miR-760 miRNA X-rays non-small cell lung cancer (NSCLC) Human NSCLC A549 and H460 cells "cells were irradiated using experimental X-ray irradiator (Gulmay Medical Inc., Atlanta, GA, xstrahl.com) at a rate of 2.4 Gy/min for the time required treatment" upregulated 30901121 9375 Human hsa-miR-760 miRNA insulin polycystic ovarian syndrome (PCOS) KGN cells; SVOG cells insulin treatment "miR-760 expression was decreased in PCOS tissues insulin treated GCs, KGN and SVOG cells." 32540374 9376 Human hsa-miR-760 miRNA repeatedly passed premature senescence lung fibroblast IMR-90 cells repeatedly passed until a senescence-like state was observed treatment upregulated 25139266 9377 Human hsa-miR-760 miRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cell (hPASMC) hypoxia induce downregulated 30226538 9378 Human hsa-miR-761 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 32772311 9379 Human hsa-miR-761 miRNA sevoflurane (SEV) glioblastoma multiforme (GBM) T98G cell; LN229 cells sevoflurane (Sev) treatment miR-761 was upregulated in sevoflurane-treated glioma cells 32495888 9380 Human hsa-miR-761 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment downregulated 28619522 9381 Human hsa-miR-762 miRNA vorinostat (SAHA) breast cancer BT474 cells vorinostat (SAHA) treatment upregulated 29620153 9382 Human hsa-miR-762 miRNA pseudomonas aeruginosa (PA) infection and excessive inflammation human corneal epithelial cells Pseudomonas aeruginosa treatment upregulated 23469087 9383 Human hsa-miR-762 miRNA tear fluid infection and excessive inflammation human corneal epithelial cells tear fluid treatment upregulated 23469087 9384 Human hsa-miR-762 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 9385 Human hsa-miR-762 miRNA gefitinib non-small cell lung cancer (NSCLC) "Human NSCLC cell lines, including A549, NCI-H820, NCI-H2170, NCI-H1650, NCI-H1993, NCI-H2126, NCI-H1975, NCIH1299, NCI-H1648, NCI-H1703, NCI-H2347, PC-9 and a normal human lung epithelial cell line NuLi-1 ATCC-CRL-4011)" gefitinib treatment upregulated 31823748 9386 Human hsa-miR-7641 miRNA hematoporphyrin glioblastoma multiforme (GBM) U87 glioma cells hematoporphyrin treatment upregulated 29344634 9387 Human hsa-miR-765 miRNA capecitabine-oxaliplatin and radiotherapy colorectal cancer (CRC) human fresh biopsies of rectal tumors capecitabine-oxaliplatin and radiotherapy upregulated 22172905 9388 Human hsa-miR-765 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87MG cells Temozolomide (TMZ) treatment downregulated 27893811 9389 Human hsa-miR-765 miRNA hyperbaric oxygen (HBO) hepatocellular carcinoma (HCC) Hepatoma cell lines (BEL-7402 and SK-Hep1) HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment upregulated 24956259 9390 Human hsa-miR-765 miRNA vincristine (VCR) multidrug resistance (MDR) SGC7901 cells vincristine (VCR) treatment upregulated 32166887 9391 Human hsa-miR-765 miRNA cisplatin (DDP) osteosarcoma (OS) 9901 cells cisplatin treatment upregulated 28775773 9392 Human hsa-miR-765 miRNA fulvestrant prostate cancer DU145 cells; PC-3 cells Fulvestrant treatment upregulated 24837491 9393 Human hsa-miR-765 miRNA fulvestrant prostate cancer prostate cancer patients a single dose (250 mg) of fulvestrant 28 days before prostatectomy treatment downregulated 24837491 9394 Human hsa-miR-766 miRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) EAC cells;SCC cells 5-fluorouracil (5-FU) treatment downregulated 21743970 9395 Human hsa-miR-766 miRNA cisplatin (DDP) esophageal cancer (EC) EAC cells;SCC cells cisplatin (DPP) treatment downregulated 21743970 9396 Human hsa-miR-766 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 9397 Human hsa-miR-766 miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 9398 Human hsa-miR-766-3p miRNA baicalin (BAI) osteoarthritis (OA) primary chondrocytes baicalin (BAI) treatment Baicalin protects human OA chondrocytes against IL-1¦Â-induced apoptosis and the degradation of ECM through activating autophagy via miR-766-3p/AIFM1 axis. 32753846 9399 Human hsa-miR-766-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9400 Human hsa-miR-766-3p miRNA abatacept rheumatoid arthritis (RA) plasma abatacept treatment downregulated 30769772 9401 Human hsa-miR-769-5p miRNA hypoxia lung cancer A549 cells hypoxia treatment upregulated 27524914 9402 Human hsa-miR-769-5p miRNA ultraviolet (UV) irradiation ultraviolet radiation-induced bystander effects (UV-RIBEs) Human skin fibroblasts ultraviolet radiation treatment Exosomal MiR-769-5p Exacerbates Ultraviolet-Induced Bystander Effect by Targeting TGFBR1 33329055 9403 Human hsa-miR-770 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "human gastric cancer cell lines MKN45, SGC7901, BGC823, and AGS" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28345805 9404 Human hsa-miR-7704 miRNA MnCl2 neurodegeneration (ND) SH-SY5Y cells MnCl2 treatment upregulated 28302480 9405 Human hsa-miR-7704 miRNA ultraviolet (UV) irradiation ultraviolet radiation (UV) effects Exosomes derived from human primary melanocytes ultraviolet B (UVB) irradiation treatment upregulated 32785244 9406 Human hsa-miR-770-5p miRNA X-rays breast cancer MCF7 cells "2, 8, and 24 h post irradiation" upregulated 28333152 9407 Human hsa-miR-770-5p miRNA methotrexate (MTX) colorectal cancer (CRC) HT-29 cells Methotrexate (MTX) treatment Upregulation of miR-770-5p significantly decreased the sensitivity of HT-29 cells to MTX. 31853309 9408 Human hsa-miR-770-5p miRNA dexamethasone (DEX) cytotoxicity primary human osteoblasts dexamethasone (DEX) treatment upregulated 31313024 9409 Human hsa-miR-770-5p miRNA high glucose (HG) diabetic nephropathy (DN) human podocytes high glucose (HG) treatment upregulated 32696822 9410 Human hsa-miR-770-5p miRNA curcumin (Cur) prostate cancer DU145 cells; 22Rv1 cells curcumin treatment upregulated 29172709 9411 Human hsa-miR-770-5p miRNA methotrexate (MTX) methotrexate (MTX) resistance HT-29 cells Methotrexate (MTX) treatment miR-770-5p modulates resistance to methotrexate in human colorectal adenocarcinoma cells by downregulating HIPK1. 31853309 9412 Human hsa-miR-770-5p miRNA curcumin (Cur) prostate cancer HuPCaSC lines DU145 and 22Rv1 curcumin treatment dysregulated 29172709 9413 Human hsa-miR-7845-5p miRNA tensile hepatocellular carcinoma (HCC) HepG2 cells tensile treatment upregulated 32323778 9414 Human hsa-miR-7a-2-3p miRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment downregulated 26987780 9415 Human hsa-miR-801 miRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Plasma hepatitis B virus (HBV) infection ?upregulated 22105822 9416 Human hsa-miR-802 miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) A547 cells lipopolysaccharide (LPS) treatment downregulated 31696241 9417 Human hsa-miR-802 miRNA arsenite arsenic carcinogenesis HK-2 human renal epithelial cells arsenic exposure downregulated 30334557 9418 Human hsa-miR-802 miRNA cisplatin (DDP) gastric cancer (GC) AGS cells; HGC cells cisplatin treatment circDONSON promoted cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis. 32581651 9419 Human hsa-miR-802 miRNA hepatitis B virus (HBV) HBV-associated hepatocellular carcinoma (HCC) HepG2.2.15 cells hepatitis B virus (HBV) infection upregulated 31611549 9420 Human hsa-miR-802 miRNA high fat diet (HFD) insulin resistance (IR) human liver tissues high fat diet (HFD) treatment upregulated 23389544 9421 Human hsa-miR-802 miRNA lipopolysaccharide (LPS) oral lichen planus (OLP) human oral keratinocytes lipopolysaccharide (LPS) treatment upregulated 30074824 9422 Human hsa-miR-802 miRNA vitamin D oral lichen planus (OLP) LPS-treated human oral keratinocytes Vitamin D treatment downregulated 30074824 9423 Human hsa-miR-8055 miRNA H2O2 oxidative stress human umbilical vein endothelial cells (HUVECs) H2O2 treatment miR-8055 was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs. 33125125 9424 Human hsa-miR-8055 miRNA vitamin C oxidative stress human umbilical vein endothelial cells (HUVECs) vitamin C treatment miR-8055 was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2. 33125125 9425 Human hsa-miR-8056 miRNA high glucose (HG) diabetic vasculopathy Human umbilical vein endothelial cells (HUVECs) high-glucose (HG) treatment "he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels." 33537821 9426 Human hsa-miR-8485 miRNA bone marrow mesenchymal stem cells (BMSCs) chondrogenesis chondrocytes bone marrow mesenchymal stem cells (BMSCs) treatment chondrocytes-derived exosomal miR-8485 regulated the Wnt/¦Â-catenin pathways to promote chondrogenic differentiation of BMSCs 31898972 9427 Human hsa-miR-873 miRNA norcantharidin (NCTD) breast cancer MCF-7 and ZR75-1 cells Norcantharidin (NCTD) treatment upregulated 31120927 9428 Human hsa-miR-873-5p miRNA genistein non-small cell lung cancer (NSCLC) human NSCLC cell lines (H292 and A549) genistein treatment "circ_0031250 abundance was elevated in NSCLC samples and cell lines, and it was reduced via genistein exposure." 33159503 9429 Human hsa-miR-874 miRNA tumor necrosis factor alpha (TNF-¦Á) asthma human fetal airway smooth muscle (fASM) cells tumor necrosis factor alpha (TNF-¦Á) treatment TNF-¦Á treatment significantly downregulated the expression of miR-874 in fASM cells 29448029 9430 Human hsa-miR-874 miRNA psoralen diabetic nephropathy (DN) HK-2 cells psoralen treatment Psoralen could significantly alleviate HG-induced HK-2 cell injury via upregulation of miR-874 32698907 9431 Human hsa-miR-874 miRNA rifampicin drug metabolism and pharmacokinetics human hepatocytes 10 ?M rifampicin treatment dysregulated 24552687 9432 Human hsa-miR-874 miRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) Jurkat cells Enterovirus 71 (EV71) infection EV71 infection significantly decreased the expression of miR-874 in Jurkat cells. 32851429 9433 Human hsa-miR-874 miRNA ¦Ä-opioid receptor (DOR) hepatocellular carcinoma (HCC) Bel-7402 cells; SK-hep-1 cells; HepG2 cells; Huh7 cells; Li-7 cells; LO2 cells ¦Ä-opioid receptor (DOR) treatment upregulated 29374140 9434 Human hsa-miR-874-3p miRNA doxorubicin (DOX) doxorubicin (DOX)-induced renal podocyte injury human podocytes doxorubicin (DOX) treatment upregulated 32908641 9435 Human hsa-miR-874-3p miRNA high glucose (HG) diabetic vasculopathy human aortic endothelial cells (HAECs) high glucose (HG) downregulated 28824448 9436 Human hsa-miR-874-3p miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 31200256 9437 Human hsa-miR-874-5p miRNA atropine myopia Human corneal epithelial cells 0.003% atropine treatment dysregulated 31540331 9438 Human hsa-miR-874-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment HOTAIR promoted MPP+-induced neuronal injury via modulating the miR-874-5p/ATG10 axis in SK-N-SH cells. 33013268 9439 Human hsa-miR-876 miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28723693 9440 Human hsa-miR-876-3p miRNA rosiglitazone insulin resistance (IR) adipocytes rosiglitazone treatment Rosiglitazone treatment in CI-induced IR adipocytes drastically reduced miR-876-3p expression 30307150 9441 Human hsa-miR-877 miRNA 5-fluorouracil (5-Fu) gastric cancer (GC) SGC-7901 cells 5-fluorouracil (5-FU) treatment downregulated 23525256 9442 Human hsa-miR-877 miRNA paclitaxel (PTX) hepatocellular carcinoma (HCC) The HepG2 human HCC cell line Paclitaxel treatment upregulated 24060847 9443 Human hsa-miR-877-3p miRNA high glucose (HG) autophagy human umbilical vein endothelial cells (HUVECs) high glucose treatment LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680. 30957640 9444 Human hsa-miR-877-3p miRNA oxidized low density lipoprotein (ox-LDL) human aortic vascular smooth muscle cells (HA-VSMCs) injury human aortic vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31957850 9445 Human hsa-miR-877-3p miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9446 Human hsa-miR-877-3P miRNA 3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) vascular endothelial cells (VECs) autophagy and apoptosis human vascular endothelial cells (VECs) 3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment 3BDO promoted the expression of miR-877-3P in VECs under high glucose conditions. 30957640 9447 Human hsa-miR-877-5p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) children serum samples acetaminophen(APAP) treatment upregulated in serum samples 29067470 9448 Human hsa-miR-877-5p miRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen(APAP) treatment dysregulated 29067470 9449 Human hsa-miR-877-5p miRNA acetaminophen (APAP) acute liver failure (ALF) serum acetaminophen (APAP) treatment hsa-miR-320a and hsa-miR-877-5p levels were significantly elevated in serum samples obtained from children with APAP overdose compared to health controls. 29067470 9450 Human hsa-miR-885 miRNA hypoxia/reoxygenation (H/R) ischemia/reperfusion (I/R) injury human cardiomyocytes (HCMs) hypoxia/reoxygenation (H/R) treatment miR-885 in HCMs was markedly repressed after H/R stimulation. 31960416 9451 Human hsa-miR-885 miRNA hypoxia prostate cancer LNCaP cells; LNCaP cells exosomes hypoxia treatment upregulated 29568403 9452 Human hsa-miR-885-3p miRNA radiochemotherapy head and neck squamous cell carcinoma (HNSCC) ?blood plasma radiochemotherapy?treatment treatment "six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)" 24373621 9453 Human hsa-miR-885-5p miRNA erythropoietin (EPO) apoptosis SH-SY5Y neuronal-like cells EPO treatment downregulated 25324845 9454 Human hsa-miR-885-5p miRNA hepatitis C virus (HCV) liver fibrosis hepatoma cells hepatitis C virus (HCV) infection upregulated 26157120 9455 Human hsa-miR-886 miRNA aspirin lung cancer A549 and H1299 cell lines aspirin treatment upregulated 30756509 9456 Human hsa-miR-886-3p miRNA radon lung cancer BEAS2B cells RADON treatment upregulated 23294299 9457 Human hsa-miR-886-5p miRNA paclitaxel (PTX) ovarian cancer (OC) HeyA8 cells paclitaxel (PTX) treatment downregulated 33028939 9458 Human hsa-miR-888-5p miRNA methyl donor S-Adenosylmethionine (AdoMet) laryngeal squamous cell carcinoma (LSCC) JHU-SCC-011 cells; HNO210 LSCC cells methyl donor S-Adenosylmethionine (AdoMet) treatment miR-888-5p Is Involved in S-Adenosylmethionine Antitumor Effects in Laryngeal Squamous Cancer Cells 33297397 9459 Human hsa-miR-889 miRNA arsenite arsenite-induced carcinogenesis HaCaT cells arsenite exposure upregulated 30167605 9460 Human hsa-miR-889 miRNA paraquat (PQ) parkinson's disease (PD) human neural progenitor cells (hNPCs) 10¦ÌM PQ treatment upregulated 28619522 9461 Human hsa-miR-891a miRNA lipopolysaccharide (LPS) inflammation THP1-differentiated macrophages lipopolysaccharide (LPS) treatment downregulated 24062196 9462 Human hsa-miR-891a miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid" renal cell carcinoma (RCC) renal cell; carcinoma cell lines (5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment upregulated 23707942 9463 Human hsa-miR-891b miRNA enterovirus 71 (EV71) apoptosis Human rhabdomyosarcoma cells (RD) EV71 infection "host cells suppress lnc-IRAK3-3 to relieve lnc-IRAK3-3-sequestered miR-891b, restrain GADD45¦Â, and attenuate apoptosis in EV71 infection that prevent host cells from severe damages." 31099182 9464 Human hsa-miR-892a miRNA melatonin oral cancer SAS cells; SCC9 cells Melatonin treatment Melatonin reduced the drug resistance and promoted the apoptosis of VCR-resistant oral cancer cells through the upregulation of microRNA-892a (miR-892a) and miR-34b-5p expressions. 31982774 9465 Human hsa-miR-892a miRNA melatonin vincristine (VCR) resistance SAS cells; SCC9 cells Melatonin treatment upregulated 31982774 9466 Human hsa-miR-892c-3p miRNA ursolic acid (UA) breast cancer BT474 cells usnic acid treatment upregulated 31549595 9467 Human hsa-miR-9 miRNA tetramethylpyrazine (TMP) activation of hepatic stellate cells (HSCs) hepatic stellate cells (HSCs) were transfect TMP treatment upregulated 25560232 9468 Human hsa-miR-9 miRNA daunorubicin acute myeloid leukemia (AML) "The AML cell lines HL-60, KG-1, THP-1 and Kasumi-1" Daunorubicin (Dnr) treatment downregulated 30745844 9469 Human hsa-miR-9 miRNA arsenite angiogenesis EA.hy926 cells arsenic (As) exposure downregulated 21503876 9470 Human hsa-miR-9 miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 9471 Human hsa-miR-9 miRNA N-(4-hydoxyphenyl)-retinamide (4HPR) apoptosis human retinal pigment epithelial (HRPE) cell N-(4-hydoxyphenyl)-retinamide (4HPR) treatment upregulated 20806079 9472 Human hsa-miR-9 miRNA proanthocyanidin atherosclerosis (AS) THP-1 cells proanthocyanidins treatment "proanthocyanidins suppressed the expression of ACAT1 via up-regulating the expression of miR-9, thus lessening the intracellular lipid accumulation and eventually inhibiting macrophage foam cell formation" 31967154 9473 Human hsa-miR-9 miRNA P. aeruginosa GroEL bacterial infection "A549 cells (human alveolar epithelial cells), THP-1 cells (human monocytes), and U937 cells (human monocytes)" infect with P. aeruginosa GroEL treatment downregulated 28031262 9474 Human hsa-miR-9 miRNA docosahexaenoic acid (DHA) breast cancer MDA-MB-231 cells-derived exosomes docosahexaenoic acid (DHA) treatment downregulated 33159957 9475 Human hsa-miR-9 miRNA estradiol breast cancer MCF-7 breast cancer cells Estradiol treatment downregulated 19528081 9476 Human hsa-miR-9 miRNA mechanical compression breast cancer MDA-MB-231 and BT-474 breast cancer cell lines mechanical compression downregulated 28252641 9477 Human hsa-miR-9 miRNA cigarette smoke (CS) cell proliferation na?ve and desialylated human alveolar epithelial cells (A549 cells) cigarette smoke (CS) treatment downregulated 29492899 9478 Human hsa-miR-9 miRNA dexamethasone (DEX) cell proliferation cigarette smoke-induced na?ve and desialylated human alveolar epithelial cells (A549 cells) dexamethasone (DEX) treatment upregulated 29492899 9479 Human hsa-miR-9 miRNA lipopolysaccharide (LPS) cell proliferation cigarette smoke-induced na?ve and desialylated human alveolar epithelial cells (A549 cells) lipopolysaccharide (LPS) treatment upregulated 29492899 9480 Human hsa-miR-9 miRNA staurosporine cervical cancer (CC) iPSCs staurosporine treatment downregulated 24143176 9481 Human hsa-miR-9 miRNA lipopolysaccharide (LPS) cervical cancer (CC) HeLa cells lipopolysaccharide (LPS) treatment upregulated 31450920 9482 Human hsa-miR-9 miRNA high glucose (HG) diabetic cardiomyopathy (DCM) hearts high glucose treatment downregulated 26898797 9483 Human hsa-miR-9 miRNA high glucose (HG) diabetic nephropathy (DN) human podocytes cells (HPCs) high glucose (HG) treatment SOX2OT overexpression alleviates the HG-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis. 31301307 9484 Human hsa-miR-9 miRNA high glucose (HG) diabetic vasculopathy Human umbilical vein endothelial cells (HUVECs) high-glucose (HG) treatment miR-9 expression remarkably decreased 33721156 9485 Human hsa-miR-9 miRNA dopaminergic (DA) neuron differentiation medium dopaminergic (DA) neuron differentiation human trabecular meshwork mesenchymal stem cells "the induction medium was prepared by adding 10 ¦ÌM retinoic acid (RA) (Sigma, USA), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma, USA) and 0.5 mM N6,2¡ä-O-Dibutyryladenosine 3¡ä,5¡ä-cyclic monophosphate (dbcAMP) (Sigma, USA) to 10% FBS supplemented DMEM." upregulated 31173848 9486 Human hsa-miR-9 miRNA enterovirus 71 (EV71) endometrial cancer (EC) "293T, Vero, RD, HT-29, HeLa, and THP-1 cells" Enterovirus 71 (EV71) infection downregulated 30186747 9487 Human hsa-miR-9 miRNA nicotine epithelial-mesenchymal transition (EMT) "head and neck squamous cell carcinoma cell lines, UMSCC-10B ;HN-1" nicotine treatment upregulated 23300583 9488 Human hsa-miR-9 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) "human esophageal cancer cell lines TE1, TE13, Eca109, YES2, and T.Tn" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 28539329 9489 Human hsa-miR-9 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) human GC cell lines SGC-7901 and BGC-823 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 25270964 9490 Human hsa-miR-9 miRNA GSK1059615 gastric cancer (GC) AGS cells and primary human GC cells GSK1059615 treatment downregulated 30765226 9491 Human hsa-miR-9 miRNA sulforaphane (SFN) gastric cancer (GC) MKN45 cells sulforaphane treatment upregulated 30096452 9492 Human hsa-miR-9 miRNA sulforaphane (SFN) gastric cancer (GC) HF2FF cells sulforaphane treatment upregulated 30096452 9493 Human hsa-miR-9 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 glioma cells temozolomide (TMZ) treatment upregulated 31186688 9494 Human hsa-miR-9 miRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) SCC90 cells; SCC47 cells; SCC104 cells human papillomavirus (HPV) treatment miR-9 was upregulated in HPV + HNSCC cells. 32120025 9495 Human hsa-miR-9 miRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) "exosome of SCC90 cells, SCC47 cells and SCC104 cells" human papillomavirus (HPV) treatment miR-9 was upregulated in HPV + HNSCC exosomes. 32120025 9496 Human hsa-miR-9 miRNA angiotensin II (Ang II) hypertension human umbilical vein endothelial cells angiotensin II (Ang II) treatment microRNA-9 (miR-9) suppressed angiotensin II-induced apoptosis and enhanced proliferation in human umbilical vein endothelial cells. 31345003 9497 Human hsa-miR-9 miRNA high glucose (HG) inflammation smooth muscle cell line C-12511 high glucose treatment downregulated 31122000 9498 Human hsa-miR-9 miRNA lipopolysaccharide (LPS) inflammation HK-2 cells lipopolysaccharides (LPS) treatment downregulated 31432701 9499 Human hsa-miR-9 miRNA molecular hydrogen inflammatory injury Retinal Microglia cells Molecular hydrogen?treatment downregulated 23826519 9500 Human hsa-miR-9 miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells infect with IAV upregulated 27322373 9501 Human hsa-miR-9 miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) SH-SY5Y cells oxygen-glucose deprivation (OGD) treatment The oxygen-glucose deprivation (OGD) in SH-SY5Y cells significantly reduced miR-9 expression 30539420 9502 Human hsa-miR-9 miRNA glucosamine ischemic stroke (IS) OGD-treated SH-SY5Y cells Glucosamine treatment upregulated 30539420 9503 Human hsa-miR-9 miRNA hypoxia ischemic stroke (IS) SH-SY5Y cells oxygen-glucose deprivation (OGD) treatment downregulated 30539420 9504 Human hsa-miR-9 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" leukemia UoCM1 and K562 cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31054042 9505 Human hsa-miR-9 miRNA VitB12 methylmalonic acidemia (MMA) MMA patient VitB12 treatment upregulated 24798023 9506 Human hsa-miR-9 miRNA ultraviolet (UV) irradiation nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells UV light treatment upregulated 25891118 9507 Human hsa-miR-9 miRNA retinoic acid (RA) nervous system cancers SK-N-BE(2)-C £»SH SY5Y??cells?;SH-EP cells£» HEK 293T cells retinoic acid treatment upregulated 22848373 9508 Human hsa-miR-9 miRNA ionizing radiation (IR) non-small cell lung cancer (NSCLC) A549 cells ionizing radiation (IR) treatment "microRNA-9 overexpression increased the radiosensitivity of A549 cells by inhibiting cell activity and migration, and by increasing apoptosis." 31158449 9509 Human hsa-miR-9 miRNA prophylactic cranial irradiation (PCI) non-small cell lung cancer (NSCLC) A549 cells prophylactic cranial irradiation (PCI)? treatment levels of miR-9 secreted by irradiated M1 microglia significantly increased 33758511 9510 Human hsa-miR-9 miRNA TGF-¦Â1 non-small cell lung cancer (NSCLC) A549 and HCC827 cells TGF-¦Â1 treatment upregulated 28266181 9511 Human hsa-miR-9 miRNA TGF-¦Â1 non-small cell lung cancer (NSCLC) "cell lines A549, NCI-H1299 and HCC827" 5 ng/ml TGF-¦Â1 for 24 h treatment upregulated 29118814 9512 Human hsa-miR-9 miRNA alkannin oral squamous cell carcinoma (OSCC) CAL-27 and SCC-9 cells alkannin (ALK) treatment downregulated 31349748 9513 Human hsa-miR-9 miRNA hydroxytyrosol (HT) osteoarthritis (OA) human primary and C-28/I2 chondrocytes were pre-treated with 100 ¦ÌM HT 30 min before 100 ¦ÌM H2O2 upregulated 27914878 9514 Human hsa-miR-9 miRNA IL-1¦Â osteoarthritis (OA) OA chondrocytes IL-1¦Â treatment upregulated 25917063 9515 Human hsa-miR-9 miRNA TNF-a and MMP13 osteoarthritis (OA) human OA cartilage and bone TNF-a and MMP13 treatment upregulated 19008124 9516 Human hsa-miR-9 miRNA vorinostat (SAHA) osteoarthritis (OA) human OA chondrocytes SAHA treatment downregulated 27404795 9517 Human hsa-miR-9 miRNA estradiol-17¦Â (E2) osteosarcoma (OS) Human OS cell line MG-63 estradiol-17¦Â (E2) treatment upregulated 25592968 9518 Human hsa-miR-9 miRNA curcumin (Cur) ovarian cancer (OC) SKOV3 cells curcumin treatment upregulated 24870723 9519 Human hsa-miR-9 miRNA propofol (PPF) ovarian cancer (OC) ES-2 cells propofol treatment upregulated 27982283 9520 Human hsa-miR-9 miRNA platelet derived growth factor-BB (PDGF-BB) prion infection U87 glioblastoma cells and neonatal cardiomyocytes PDGFR-beta treatment upregulated 21684288 9521 Human hsa-miR-9 miRNA perioglas(PG) bone formation Osteoblast-like cells (MG63) PerioGlas(PG) treatment upregulated 18573151 9522 Human hsa-miR-9 miRNA platelet derived growth factor-BB (PDGF-BB) prostate cancer neuronal progenitor cells platelet-derived growth factor-BB (PDGF-BB) treatment upregulated 24336080 9523 Human hsa-miR-9 miRNA tumor resection squamous cell carcinoma (SQCC) and adenocarcinoma (ADC£© SQCC and ADC patients tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 28634901 9524 Human hsa-miR-9 miRNA butyrate and inulin type 2 diabetes mellitus (T2DM) peripheral blood mononuclear cells (PBMCs) butyrate and inulin treatment butyrate and concomitant use of butyrate and inulin caused a significant increase in the fold change of miR-146a and miR-9 compared with the placebo group. 32315958 9525 Human hsa-miR-9 miRNA human immunodeficiency virus (HIV)-1 and methamphetamine uveal melanoma human frontal cortex human immunodeficiency virus (HIV) and methamphetamine treatment significantly increased expression of the neuron-specific miR-9 23508624 9526 Human hsa-miR-9 miRNA ultraviolet (UV) irradiation vitiligo repigmentation HaCaT keratinocytes UVB irradiation treatment downregulated 31499059 9527 Human hsa-miR-9* miRNA hydroxychloroquine apoptosis cervical cancer SiHa cells HCQ treatment downregulated 24944668 9528 Human hsa-miR-9* miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid" renal cell carcinoma (RCC) renal cell; carcinoma cell lines (5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment upregulated 23707942 9529 Human hsa-miR-9-1 miRNA decitabine acute myeloid leukemia (AML) RUNX1-RUNX1T1 (+) AML cell lines decitabine£¬trichostatin A upregulated 27770540 9530 Human hsa-mir-92 miRNA estrogen receptor-¦Á breast cancer breast cancer cells The estrogen receptor-¦Á treatment upregulated 19706389 9531 Human hsa-mir-92 miRNA triptolide (TPL) hepatocellular carcinoma (HCC) HepG2 cells triptolide (TPL) treatment downregulated 29523159 9532 Human hsa-miR-92 miRNA 12-O-tetradecanoylphorbol-13-acetate (TPA) leukemia HL-60 cells 12-O-tetradecanoylphorbol-13-acetate (TPA) downregulated 18648749 9533 Human hsa-miR-92 miRNA perioglas (PG) and P-15 bone formation Osteoblast-like cell (MG63) PerioGlas (PG) and P-15 treatment upregulated 17653614 9534 Human hsa-miR-92 miRNA platelet derived growth factor-BB (PDGF-BB) vascular restenosis human vascular smooth muscle cells (VSMCs) platelet-derived growth factor (PDGF)-BB treatment upregulated 31933825 9535 Human hsa-miR-923 miRNA diesel exhaust particle (DEP) bronchial epithelial cell cancer Primary human bronchial epithelial cells diesel exhaust particle (DEP) exposure upregulated 20049127 9536 Human hsa-miR-923 miRNA bostrycin lung cancer human lung carcinoma A549 cells bostrycin treatment upregulated 21303527 9537 Human hsa-miR-923 miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment upregulated 26640557 9538 Human hsa-miR-92-3p miRNA silybin hepatoprotective HepG2 cells Silybin treatment downregulated 31058823 9539 Human hsa-miR-92a miRNA high glucose (HG) acute coronary syndrome (ACS) Human Macrophages high glucose treatment upregulated 27519051 9540 Human hsa-miR-92a miRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment upregulated 33015189 9541 Human hsa-miR-92a miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment upregulated 31841757 9542 Human hsa-miR-92a miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) pulmonary microvascular endothelial cells (HPMEC); A549 cells lipopolysaccharide (LPS) treatment upregulated 32534035 9543 Human hsa-miR-92a miRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment Inhibition of microRNA-92a ameliorates lipopolysaccharide-induced endothelial barrier dysfunction by targeting ITGA5 through the PI3K/Akt signaling pathway in human pulmonary microvascular endothelial cells 31841757 9544 Human hsa-miR-92a miRNA hyperbaric oxygen (HBO) angiogenesis human coronary artery endothelial cells (HCAECs) Hyperbaric oxygen (HBO) treatment downregulated 30301563 9545 Human hsa-miR-92a miRNA triptolide (TPL) angiogenesis human dermal microvascular endothelial cells (HMEC-1) triptolide (TPL) treatment upregulated 31691162 9546 Human hsa-miR-92a miRNA curcumin (Cur) antioxidant defense human ARPE-19 cells curcumin (diferuloylmethane)? treatment downregulated 23559849 9547 Human hsa-miR-92a miRNA serum apoptosis vascular smooth muscle cell (VSMC) serum treatment upregulated 24705900 9548 Human hsa-miR-92a miRNA ML-7 (an inhibitor of myosin light chain kinase) atherosclerosis (AS) Human aortic smooth muscle cells (HASMCs) ML-7 (an inhibitor of myosin light chain kinase) treatment downregulated 30907506 9549 Human hsa-miR-92a miRNA 5-fluorouracil (5-Fu) and oxaliplatin colorectal cancer (CRC) human colon cancer cells 5-Fluorouracil and oxaliplatin treatment downregulated 19956872 9550 Human hsa-miR-92a miRNA butyrate colorectal cancer (CRC) human colon cancer cells butyrate treatment downregulated 26463716 9551 Human hsa-miR-92a miRNA kaempferol-3-O-glycoside colorectal cancer (CRC) RKO cells kaempferol-3- O-glycoside treatment downregulated 31441682 9552 Human hsa-miR-92a miRNA kaempferol-3-O-glycoside colorectal cancer (CRC) colon cancer cell line (RKO) kaempferol-3-O-glycoside treatment downregulated 31441682 9553 Human hsa-miR-92a miRNA oxaliplatin colorectal cancer (CRC) plasma oxaliplatin treatment miR-92a was downregulated in resistant patients when compared with sensitive patients 33072545 9554 Human hsa-miR-92a miRNA advanced glycation end products (AGEs) and oxidized low-density lipoprotein (ox-LDL) diabetes mellitus (DM) human umbilical vein endothelial Cells (HUVEC£© AGEs and oxidized low-density lipoprotein upregulated 28683566 9555 Human hsa-miR-92a miRNA "H2O2, angiotensin II (AngII) and oxidized low-density lipoprotein (ox-LDL)" endothelial dysfunction HUVECs "with H2O2, Ang II, and oxidized LDL (ox-LDL) treatment" upregulated 25550450 9556 Human hsa-miR-92a miRNA swainsonine (SW) glioblastoma multiforme (GBM) U251 and LN444 cells swainsonine (SW) treatment downregulated 30890138 9557 Human hsa-miR-92a miRNA alkannin hepatocellular carcinoma (HCC) Huh7 and Hep3B2.1-7 cells alkannin (ALK) treatment downregulated 30909147 9558 Human hsa-miR-92a miRNA human cytomegalovirus (HCMV; human herpesvirus 5) human cytomegalovirus (HCMV) infection HFFF cells human cytomegalovirus (HCMV; human herpesvirus 5) treatment hsa-miR-92a downregulated 21471310 9559 Human hsa-miR-92a miRNA sulfur mustard (SM) lung diseases plasma and serum Sulfur mustard (SM) treatment downregulated 26525353 9560 Human hsa-miR-92a miRNA AZD6244 lymphoma "Raji, MOLT4 and 293T cells w" AZD6244 treatment downregulated 24375836 9561 Human hsa-miR-92a miRNA berberine (BBR) multiple myeloma (MM) RPMI-8266 cells; U266 cells berberine (BBR) treatment Berberine downregulated miR-92a cluster expression in multiple myeloma (MM) cells. 29687521 9562 Human hsa-miR-92a miRNA TGF-¦Â1 neointimal hyperplasia human umbilical vein endothelial cells (HUVEC) TGF-¦Â1 treatment TGF-¦Â1 treatment of HUVECs significantly increased miR-92a expression and induced EndMT 33253710 9563 Human hsa-miR-92a miRNA hyperbaric oxygen (HBO) neovascularization human coronary artery endothelial cells (HCAECs) hyperbaric oxygen (HBO) treatment downregulated 30301563 9564 Human hsa-miR-92a miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment downregulated 26878281 9565 Human hsa-miR-92a miRNA TGF-¦Â1 osteoarthritis (OA) human osteoarthritis synovial fibroblasts (OASFs) TGF-¦Â1 treatment downregulated 31232696 9566 Human hsa-miR-92a miRNA integrin ¦Á5 ovarian cancer (OC) "The ovarian cancer cell lines, A2780£» CaOV3 cells£» RMUG-S£» OVISE£»and RMG-1 cell lines£»SKOV3ip1 cells £»HeyA-8 cell" integrin ¦Á5 treatment miR-92a overexpression 23499550 9567 Human hsa-miR-92a miRNA advanced glycation end product (AGE) oxidative stress human umbilical vein endothelial cells (HUVECs) advanced glycation end products (AGEs) treatment upregulated 28683566 9568 Human hsa-miR-92a miRNA oxidized low density lipoprotein (ox-LDL) oxidative stress human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28683566 9569 Human hsa-miR-92a miRNA statins unstable angina (UA) plasma statins? treatment downregulated 26474612 9570 Human hsa-miR-92a miRNA TGF-¦Â1 vein grafts human umbilical vein endothelial cells (HUVECs) TGF-¦Â1 treatment we show that TGF-¦Â1 treatment of HUVECs significantly increased miR-92a expression and induced EndMT 33253710 9571 Human hsa-miR-92a-1-5p miRNA regorafenib frail metastatic colorectal cancer (mCRC) serum regorafenib treatment "Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia" 33916610 9572 Human hsa-miR-92a-1-5p miRNA bile acids gastric intestinal metaplasia (IM) "BGC823, GES-1, SGC7901, MKN28, MKN45 and AGS cells" bile acids treatment upregulated 30635407 9573 Human hsa-miR-92a-1-5p miRNA "OTX015 (MK-8628, birabresib)" lymphomagenesis DOHH-2 cells; OCI-LY-1 cells OTX015 treatment OTX015 upregulates miR-96-5p in a time-dependent manner. 30076183 9574 Human hsa-miR-92a-3p miRNA H2O2 angiogenesis human umbilical vein endothelial cells (HUVECs) exosomes H2O2 treatment Primary miR-92a (pri-miR-92a-1) was decreased in Exo-H2O2-treated HUVECs. 32901851 9575 Human hsa-miR-92a-3p miRNA clozapine (CLZ) cardiotoxicity plasma clozapine (CLZ) treatment upregulated 31722571 9576 Human hsa-miR-92a-3p miRNA hypoxia cell differentiation human (P3 and U87) glioma cell lines hypoxia induce upregulated 30536597 9577 Human hsa-miR-92a-3p miRNA ¦Ã-rays ionizing radiation (IR) injury whole blood samples from healthy donors extracellular vesicles (ELVs) irradiate with 2 Gy gamma rays treatment upregulated 28264626 9578 Human hsa-miR-92a-3p miRNA clozapine (CLZ) clozapine (CLZ)-induced cardiotoxicities Plasma clozapine (CLZ) treatment upregulated 31722571 9579 Human hsa-miR-92a-3p miRNA doxorubicin (DOX) doxorubicin (DOX)-induced cardiotoxicity cardiomyocytes Doxorubicin (Dox) treatment Dox-treated cardiomyocytes expressed a higher level of miR-92a-3p. 32384281 9580 Human hsa-miR-92a-3p miRNA cardiac resynchronization therapy heart failure (HF) plasma cardiac resynchronization therapy treatment upregulated 23736534 9581 Human hsa-miR-92a-3p miRNA "MS-275, a histone deacetylase inhibitor" melanoma TRAIL-resistant or TRAIL-sensitive cutaneous and uveal melanoma cells MS-275 treatment downregulated 27620505 9582 Human hsa-miR-92a-3p miRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes (PHCs) IL-1¦Â downregulated 29241192 9583 Human hsa-miR-92a-3p miRNA "isoniazid, pyrazinamide and ethambutol" pulmonary tuberculosis (PTB) serum "isoniazid, pyrazinamide and ethambutol treatment" miR-92a-3p was downregulated in treated patients when compared with untreated patients. 29523324 9584 Human hsa-miR-92b miRNA IL-13 asthma human bronchial epithelial cells (NHBE) IL-13 treatment upregulated 31386204 9585 Human hsa-miR-92b miRNA sulforaphane (SFN) breast cancer "breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)" SFN (5-10 ?M) treatment downregulated 28912888 9586 Human hsa-miR-92b-3p miRNA hypoxia cell proliferation Human primary pulmonary artery smooth muscle cells (PASMCs) hypoxia induce upregulated 30518907 9587 Human hsa-miR-92b-3p miRNA deoxycholic acid (DCA) gallbladder cancer (GBC) NOZ cells; GBC-SD cells deoxycholic acid (DCA) treatment DCA treatment decreased miR-92b-3p expression. 32514152 9588 Human hsa-miR-92b-3p miRNA hypoxia glioblastoma multiforme (GBM) U87MG cells hypoxia treatment downregulated 25129238 9589 Human hsa-miR-92b-3p miRNA dipogenic differentiation mixture (MDI) liver fibrosis LX-2 cells dipogenic differentiation mixture (MDI) treatment "We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1. However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)." 33618248 9590 Human hsa-miR-92b-3p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment "We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1 However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)" 33618248 9591 Human hsa-miR-92b-3p miRNA bevacizumab and FOLFOX metastatic colorectal cancer (mCRC) mCRC patients tumor tissue bevacizumab/FOLFOX upregulated 28693229 9592 Human hsa-miR-92b-3p miRNA palmitate nonalcoholic fatty liver disease (NAFLD) hepatocyte cell lines palmitate treatment downregulated 25314137 9593 Human hsa-miR-93 miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment downregulated 33505213 9594 Human hsa-miR-93 miRNA estradiol-17¦Â (E2) breast cancer MCF-10A cells;T47D cells estradiol-17¦Â (E2) treatment upregulated 23492819 9595 Human hsa-miR-93 miRNA vitamin C breast cancer MCF-10A cells;T47D cells vitamin C treatment downregulated 23492819 9596 Human hsa-miR-93 miRNA oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) chronic inflammatory diseases human umbilical vein endothelial cells (HUVECs) exosomes oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment upregulated 29161413 9597 Human hsa-miR-93 miRNA 5-fluorouracil (5-Fu) and oxaliplatin colorectal cancer (CRC) human colon cancer cells 5-Fluorouracil and oxaliplatin treatment downregulated 19956872 9598 Human hsa-miR-93 miRNA ionizing radiation (IR) colorectal cancer (CRC) SW480 cells; HCT116 cells ionizing radiation (IR) treatment HOTAIR knockdown enhances radiosensitivity through regulating microRNA-93/ATG12 axis in colorectal cancer. 32144238 9599 Human hsa-miR-93 miRNA TGF-¦Â1 diabetic nephropathy (DN) HK-2 cells TGF-¦Â1 treatment miR-93 was dramatically decreased in TGF-¦Â1-stimulated HK2 cells 29551286 9600 Human hsa-miR-93 miRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment H19 played an important role in regulating inflammatory processes in retinal endothelial cells under high-glucose condition through modulating miR-93/XBP1s axis. 31953562 9601 Human hsa-miR-93 miRNA high glucose (HG) diabetic retinopathy (DR) Primary human retinal pigment epithelium (RPE) cells and ARPE-19 cells high glucose (HG) treatment "lncRNA MEG3 depresses HG-induced apoptosis and inflammation of RPE via miR-93/Nrf2 axis, providing a novel perspective on the genesis and development of DR." 32473920 9602 Human hsa-miR-93 miRNA advanced glycation end product modified bovine serum albumin (AGE-BSA) diabetic vasculopathy human umbilical vein endothelial cells (HUVECs) advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment downregulated 30544204 9603 Human hsa-miR-93 miRNA cigarette smoke (CS) emphysema HBE cells Cigarette smoke (CS) exposure upregulated 33660100 9604 Human hsa-miR-93 miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87 and T98G cells temozolomide (TMZ) treatment miR-93 and -193 decreased cell cycling quiescence and induced resistance to TMZ. 30853911 9605 Human hsa-miR-93 miRNA hepatitis B virus (HBV) hepatitis B virus (HBV) infection human primary hepatocytes isolated from humanized chimeric uPA/SCID mice as efficient sources hepatitis B virus (HBV) infection downregulated 25026299 9606 Human hsa-miR-93 miRNA radiotherapy head and neck squamous cell carcinoma (HNSCC) neck squamous cell carcinoma patients saliva samples radiotherapy treatment upregulated in saliva samples 28677748 9607 Human hsa-miR-93 miRNA triptolide (TPL) hepatocellular carcinoma (HCC) HepG2 cells triptolide (TPL) treatment downregulated 29523159 9608 Human hsa-miR-93 miRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells influenza A virus (IAV) infection influenza A virus (IAV) infection significantly inhibited miR-93 expression in alveolar epithelial type II cells through RIG-I/JNK pathway. 32652502 9609 Human hsa-miR-93 miRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells cisplatin treatment upregulated 31432162 9610 Human hsa-miR-93 miRNA H2O2 mitophagy HeLa and HEK 293T cells H2O2 treatment "We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions." 33627622 9611 Human hsa-miR-93 miRNA diet obesity Plasma diet treatment "Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss." 32439373 9612 Human hsa-miR-93 miRNA cisplatin (DDP) ovarian cancer (OC) A2780 cells cisplatin (DPP) treatment upregulated 31128026 9613 Human hsa-miR-93 miRNA berberine (BBR) ovarian cancer (OC) cisplatin resistant A2780 cell lines berberine (BBR) treatment upregulated 26087719 9614 Human hsa-miR-93 miRNA L-tetrahydropalmatine (L-THP) ovarian cancer (OC) A2780 cells L-Tetrahydropalmatine (L-THP) treatment downregulated 31128026 9615 Human hsa-miR-93 miRNA morin oxidative stress A549 cells upon traffic PM2.5 exposure Morin treatment downregulated 31284452 9616 Human hsa-miR-93 miRNA particulate matter (PM2.5) oxidative stress A549 cells traffic PM2.5 treatment upregulated 31284452 9617 Human hsa-miR-93 miRNA curcumin (Cur) peripheral arterial disease (PAD) Human umbilical vein endothelial cells (HUVECs) curcumin treatment upregulated 30651865 9618 Human hsa-miR-93 miRNA hypoxia peripheral arterial disease (PAD) EA.hy926 endothelial cells hypoxia induce upregulated 31059098 9619 Human hsa-miR-93 miRNA green tea polysaccharide (GTP) prostate cancer PC-3 cells green tea (Camellia sinensis) polysaccharide (GTP) treatment downregulated 30342140 9620 Human hsa-miR-93 miRNA green tea polysaccharide (GTP) prostate cancer PC-3 cells green tea polysaccharide (GTP) treatment downregulated 30342140 9621 Human hsa-miR-93 miRNA hypoxia prostate cancer LNCaP cells 5% O2 treatment upregulated 24135225 9622 Human hsa-miR-93 miRNA TGF-¦Â renal cell carcinoma (RCC) renal cancer cells TGF-¦Â treatment downregulated 25183046 9623 Human hsa-miR-93 miRNA salvianolic acid B (Sal B) renal fibrosis human kidney proximal tubular epithelial cells (HK-2 cells) Sal B treatment upregulated 25094038 9624 Human hsa-miR-93 miRNA TGF-¦Â1 renal fibrosis human kidney proximal tubular epithelial cells (HK-2 cells) TGF-¦Â1 treatment downregulated 25094038 9625 Human hsa-miR-93 miRNA leptin rheumatoid arthritis (RA) human osteoblasts leptin treatment downregulated 25198901 9626 Human hsa-miR-9-3 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)" bladder cancer BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment" upregulated 23200812 9627 Human hsa-miR-9-3 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" lung cancer NSCLC A549 cells 5-aza-20-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A treatment upregulated 22282464 9628 Human hsa-miR-9-3 miRNA sulforaphane (SFN) lung cancer lung cancer A549 cells Sulforaphane (SFN) treatment upregulated 29525530 9629 Human hsa-miR-933 miRNA 27-hydroxycholesterol (27-OHC) Alzheimer's disease (AD) microvascular endothelial cell (HMVEC) 27 hydroxycholesterol (27-OHC) treatment upregulated 29966198 9630 Human hsa-miR-933 miRNA ursolic acid (UA) breast cancer MCF-7 cells usnic acid treatment downregulated 31549595 9631 Human hsa-miR-933 miRNA palmitate diabetes mellitus (DM) Human islets palmitate (Pal) treatment upregulated 30131392 9632 Human hsa-miR-933 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9633 Human hsa-miR-93-3p miRNA human immunodeficiency virus (HIV)-1 HIV-associated neurocognitive disorders (HAND) human primary monocyte-derived macrophages infect with HIV-1 upregulated 28594894 9634 Human hsa-miR-934 miRNA alcohol head and neck squamous cell carcinoma (HNSCC) normal oral keratinocytes alcohol exposure upregulated 26472042 9635 Human hsa-miR-935 miRNA intermediate-sized hyaluronan (INT-HA) macrophage polarization Primary human macrophages derived from peripheral blood monocytes Intermediate-sized hyaluronan (INT-HA) treatment downregulated 30341559 9636 Human hsa-miR-935 miRNA intermediate-sized hyaluronan (INT-HA) macrophage polarization Primary human macrophages Intermediate-sized hyaluronan (INT-HA) treatment downregulated 30341559 9637 Human hsa-miR-93-5p miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment Endothelial progenitor cells-secreted extracellular vesicles containing microRNA-93-5p confer protection against sepsis-induced acute kidney injury via the KDM6B/H3K27me3/TNF-¦Á axis 32679234 9638 Human hsa-miR-93-5p miRNA high glucose (HG) diabetic nephropathy (DN) ?human renal tubular epithelial HK-2 cells ?high glucose (HG) induce silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN 31545928 9639 Human hsa-miR-93-5p miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection "serum of patients with HCV-1b infection, Huh7 cells" hepatitis C virus (HCV) infection upregulated 29375208 9640 Human hsa-miR-93-5p miRNA neodymium oxide (Nd2O3) inflammation human bronchial epithelial cells (16HBE) neodymium oxide (Nd2O3) treatment upregulation of circ_0039411 mediated Nd2O3-induced inflammation and dysfunction by sponging miR-93-5p. 30903189 9641 Human hsa-miR-93-5p miRNA IL-1¦Â osteoarthritis (OA) cultured primary chondrocyte IL-1¦Â treatment downregulated 30930294 9642 Human hsa-miR-93-5p miRNA activin A prostate cancer LNCaP cells activin A treatment downregulated 27018851 9643 Human hsa-miR-939 miRNA monocyte chemoattractant protein-1 (MCP-1) complex regional pain syndrome (CRPS) THP-1 monocytes secreted small extracellular vesicles (sEVs) monocyte chemoattractant protein-1 (MCP-1) treatment upregulated 31489147 9644 Human hsa-miR-939 miRNA leuprolide endometriosis endometriotic tissues Leuprolide treatment downregulated 27709720 9645 Human hsa-miR-939 miRNA water particulate matter 2.5 (PM2.5 ) respiratory toxicity human alveolar epithelial cell (A549) water particulate matter 2.5 (PM2.5 ) treatment upregulated 26791009 9646 Human hsa-miR-93a miRNA H2O2 apoptosis vascular smooth muscle cell (VSMC) H2O2 treatment downregulated 24705900 9647 Human hsa-miR-9-3p miRNA oxidized low density lipoprotein (ox-LDL) coronary artery disease (CAD) endothelial cells oxidized low-density lipoprotein (ox-LDL) treatment miR-9-3p was downregulated by oxLDL treatment in endothelial cell. 30485507 9648 Human hsa-miR-9-3p miRNA insulin-like growth factor 1 (IGF-1) glioblastoma multiforme (GBM) U87-MG cells IGF-1 treatment downregulated 28389653 9649 Human hsa-miR-9-3p miRNA "pramipexole,piribedil, L-dopa, amantadine" parkinson's disease (PD) patients with Parkinson's disease "different medications (pramipexole,piribedil, L-dopa, amantadine) treatment" upregulated 25465742 9650 Human hsa-miR-940 miRNA dasatinib chronic myeloid leukemia (CML) CML cell line K562 dasatinib treatment downregulated 30814857 9651 Human hsa-miR-940 miRNA acute exercise congestive heart failure (CHF) CHF patients acute exercise treatment upregulated 26799589 9652 Human hsa-miR-940 miRNA hypoxia epithelial ovarian cancer (EOC) macrophages of human epithelial ovarian cancer (EOC) exosomes hypoxia treatment upregulated 28586039 9653 Human hsa-miR-940 miRNA sodium butyrate (NaB) sickle cell anemia (SCA) CD133 hematopoietic stem cells sodium butyrate treatment dysregulated 26837891 9654 Human hsa-miR-941 miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemia/reperfusion (I/R) injury T-HESC; primary human endometrial cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment miR-941 activates Nrf2 cascade to protect human endometrial cells from OGDR-induced oxidative stress and programmed necrosis 32102665 9655 Human hsa-miR-941 miRNA exercise (Ex) physiological impairments associated with aging circulating exosomes exercise treatment upregulated 32587527 9656 Human hsa-miR-942 miRNA "chlorpromazine, haloperidol and clozapine" psychosis JM-Jurkat T-lymphocytes "chlorpromazine, haloperidol and clozapine treatment" dysregulated 24480591 9657 Human hsa-miR-942 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment upregulated 22647265 9658 Human hsa-miR-942 miRNA oxidized low density lipoprotein (ox-LDL) carotid artery atherosclerosis HCtAEC | Human Carotid Artery Endothelial Cells; THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment LncRNA ZEB1-AS1 contributed to ox-LDL-mediated injury and apoptosis of HCtAEC cells and the oxidative stress and inflammation of THP-1 cells through up-regulating HMGB1 via sponging miR-942. 31962131 9659 Human hsa-miR-942 miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection human hepatoma cell line HLCZ01 infectious HCV isolate JFH1 treatment downregulated 24727952 9660 Human hsa-miR-942 miRNA lipopolysaccharide (LPS) liver fibrosis human primary hepatic stellate cells; LX-2 cells lipopolysaccharide (LPS) treatment upregulated 30097701 9661 Human hsa-miR-942 miRNA TGF-¦Â1 liver fibrosis human primary hepatic stellate cells; LX-2 cells TGF-¦Â1 treatment upregulated 30097701 9662 Human hsa-miR-942-5p miRNA lipopolysaccharide (LPS) sepsis HK-2 cells lipopolysaccharide (LPS) treatment MiR-942-5p expression was reduced in lipopolysaccharide (LPS)-treated HK-2 cells. 32572890 9663 Human hsa-miR-944 miRNA low-glycaemic load dietary breast cancer serum (pre-menopausal women) low-glycaemic load dietary treatment downregulated 22647265 9664 Human hsa-miR-95 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" aortic stenosis cervical cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines" 23732000 9665 Human hsa-miR-95 miRNA glargine pancreatic cancer (PC) pancreatic cancer cells glargine treatment upregulated 22690071 9666 Human hsa-miR-95 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid" renal cell carcinoma (RCC) renal cell; carcinoma cell lines (5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment upregulated 23707942 9667 Human hsa-miR-9500 miRNA hematoporphyrin glioblastoma multiforme (GBM) U87 glioma cells hematoporphyrin treatment upregulated 29344634 9668 Human hsa-miR-95-5p miRNA high glucose (HG) calcification/senescence human aortic vascular smooth muscle cells (HA-VSMCs) high glucose (HG) treatment downregulated 32483833 9669 Human hsa-miR-9-5p miRNA traffic-originated PM2.5 organic component (tPo) chronic obstructive pulmonary disease (COPD) human bronchial epithelial cells (HBECs) Traffic-related air pollution particulate matter 2.5 (TRAPM2.5) treatment LncRNA RP11-86H71 promotes airway inflammation induced by TRAPM25 by acting as a ceRNA of miRNA-9-5p to regulate NFKB1 in HBECS 32665564 9670 Human hsa-miR-9-5p miRNA cocaine drug addiction differentiated SH-SY5Y neuroblastoma cells cocaine treatment downregulated 30166527 9671 Human hsa-miR-9-5p miRNA "2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)" endothelial cell injury human umbilical vein endothelial cells (HUVECs) "2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment" downregulated 33093269 9672 Human hsa-miR-9-5p miRNA insulin-like growth factor 1 (IGF-1) glioblastoma multiforme (GBM) U87-MG cells IGF-1 treatment downregulated 28389653 9673 Human hsa-miR-9-5p miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) SH-SY5Y cells oxygen-glucose deprivation (OGD) treatment downregulated 31500865 9674 Human hsa-miR-9-5p miRNA Japanese encephalitis virus (JEV) Japanese Encephalitis virus (JEV) infection human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses Japanese encephalitis virus (JEV) infection downregulated 31578247 9675 Human hsa-miR-9-5p miRNA TGF-¦Â1 liver fibrosis LX-2 cells TGF-¦Â1 treatment downregulated 29073595 9676 Human hsa-miR-9-5p miRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 30826419 9677 Human hsa-miR-9-5p miRNA "pramipexole,piribedil, L-dopa, amantadine" parkinson's disease (PD) patients with Parkinson's disease "different medications (pramipexole,piribedil, L-dopa, amantadine) treatment" upregulated 25465742 9678 Human hsa-miR-9-5p miRNA lithium (Li) spinal cord injury (SCI) SH-SY5Y cells lithium treatment Lithium treatment rescued the upregulation of BDNF-AS expression and downregulated of miR-9-5p expression induced by H2O2 in SH-SY5Y cells. 33464390 9679 Human hsa-miR-9-5p miRNA high glucose (HG) vascular endothelial cell injury human umbilical vascular endothelial cells (HUVECs) high glucose (HG) treatment downregulated 30716366 9680 Human hsa-miR-96 miRNA curcumin (Cur) breast cancer T47D breast cancer cells curcumin treatment 48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells. 30467667 9681 Human hsa-miR-96 miRNA coffee colorectal cancer (CRC) Caco-2 human colon carcinoma cells coffee treatment upregulated 28693281 9682 Human hsa-miR-96 miRNA oxaliplatin colorectal cancer (CRC) SW480 cells oxaliplatin (OXA) treatment Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1 32765688 9683 Human hsa-miR-96 miRNA cisplatin and doxorubicin gastric cancer (GC) SGC7901 cells cisplatin and doxorubicin treatment treatment with a low dose of either chemotherapeutic agent induced miR-96 expression. 30128023 9684 Human hsa-miR-96 miRNA herpes simplex virus 1 (HSV-1) herpes simplex virus 1 (HSV-1) infection 293A and 293T cells infect with HSV-1 upregulated 28783105 9685 Human hsa-miR-96 miRNA mitochondrial dysfunction insulin resistance (IR) SK-Hep1 cells (ATCC HTB-52) mitochondrial dysfunction treatment upregulated 23583389 9686 Human hsa-miR-96 miRNA cisplatin and paclitaxel metastatic bladder cancer T24 bladder cancer cells cisplatin and paclitaxel treatment upregulated 26356996 9687 Human hsa-miR-96 miRNA hyperoxia oxygen-induced retinopathy (OIR) human retinal microvascular endothelial cells (HRMEC) hyperoxia treatment MicroRNA-96 Promotes Vascular Repair in Oxygen-Induced Retinopathy-A Novel Uncovered Vasoprotective Function. 32116694 9688 Human hsa-miR-96 miRNA hypoxia prostate cancer prostate cancer cell lines LNCaP;22Rv1 cells hypoxia treatment upregulated 25333253 9689 Human hsa-miR-96 miRNA carbon black nanoparticle (CBNP) lung fibrosis human bronchial epithelial (16HBE) cells carbon black nanoparticle (CBNP) treatment downregulated 31683435 9690 Human hsa-miR-96 miRNA light retinal injury retinal pigment epithelial (RPE) cells light treatment upregulated 25955435 9691 Human hsa-miR-96 miRNA running telomere homeostasis twenty-two healthy males white blood cells undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment upregulated 24752326 9692 Human hsa-miR-96-3p miRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment downregulated 32342116 9693 Human hsa-miR-96-5p miRNA cytarabine (Ara-C) acute myeloid leukemia (AML) human AML cell lines HL60 and THP-1 cytarabine (Ara-C) treatment "miR-96 downregulated abolished the effects of MALAT1 knockdown on the proliferation, apoptosis, Ara-C sensitivity in AML cells." 30970520 9694 Human hsa-miR-96-5p miRNA titanium dioxide nanoparticles (TiO2 NPs) autophagy human HTR-8/SVneo (HTR) cells Titanium dioxide nanoparticles (TiO2 NPs) treatment upregulated 30345998 9695 Human hsa-miR-96-5p miRNA particulate matter (PM2.5) cardiotoxicity endothelial cells PM2.5 exposure treatment downregulated 30597786 9696 Human hsa-miR-96-5p miRNA particulate matter (PM2.5) cardiotoxicity of PM2.5 endothelial cells PM2.5 treatment downregulated 30597786 9697 Human hsa-miR-96-5p miRNA TGF-¦Â1 diabetic nephropathy (DN) HK-2 cells TGF-¦Â1 treatment The expression of miR-96-5p were significantly increased in the GAS5 knockdown group The level of miR-96-5p was downregulated in the renal tissues of DM mice miR-96- 5p mimic downregulated GAS5 expression 31810140 9698 Human hsa-miR-96-5p miRNA sanguinarine gastric cancer (GC) BGC-823 cells sanguinarine treatment downregulated 31243669 9699 Human hsa-miR-96-5p miRNA "OTX015 (MK-8628, birabresib)" lymphomagenesis DOHH-2 cells; OCI-LY-1 cells OTX015 treatment OTX015 upregulates miR-96-5p in a time-dependent manner. 30076183 9700 Human hsa-miR-96-5p miRNA cryptotanshinone non-small cell lung cancer (NSCLC) A549 cells cryptotanshinone treatment downregulated 31452742 9701 Human hsa-miR-96-5p miRNA malathion organophosphate-induced cytotoxicity HK-2 cells Malathion treatment Malathion decreased HK-2 cell viability and the expression of miR-96-5p in a dose- and time-dependent manner. 32897819 9702 Human hsa-miR-96-5p miRNA H2O2 oxidative stress ARPE-19 cells H2O2 treatment downregulated 28707489 9703 Human hsa-miR-96-5p miRNA hypoxia pancreatic cancer (PC) human umbilical vein endothelial cells (HUVECs) hypoxia exposure hypoxic exosomal UCA1 could promote angiogenesis and tumor growth through the miR-96-5p/AMOTL2/ERK1/2 axis 32942233 9704 Human hsa-miR-96-5p miRNA titanium dioxide nanoparticles (TiO2 NPs) placental development "human trophoblast-derived cell, HTR8-Svneo" Titanium dioxide nanoparticles (TiO2 NPs) treatment upregulated 31226636 9705 Human hsa-miR-96-5p miRNA angiotensin II (Ang II) "proliferation, migration, and apoptosis of VSMCs" vascular smooth muscle cell (VSMC) angiotensin II (Ang II) treatment miR-96-5p was downregulated in Ang II-induced VSMCs. 32045906 9706 Human hsa-miR-96-5p miRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment miR-96-5p targets FN1 and alleviates TGF-¦Â1-induced fibrosis in HK-2 cells 31810140 9707 Human hsa-miR-98 miRNA cisplatin (DDP) cell death A549 cell cisplatin (DPP) treatment downregulated 21880462 9708 Human hsa-miR-98 miRNA oxidized low density lipoprotein (ox-LDL) apoptosis human umbilical vein ECs (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 28565756 9709 Human hsa-miR-98 miRNA estradiol breast cancer MCF-7 cells Estradiol treatment upregulated 19528081 9710 Human hsa-miR-98 miRNA tamoxifen (TAM) breast cancer MCF-7 breast cancer cells tamoxifen treatment upregulated 30072833 9711 Human hsa-miR-98 miRNA tamoxifen (TAM) breast cancer MCF-7 breast cancer cells tamoxifen treatment upregulated 30072833 9712 Human hsa-miR-98 miRNA TGF-¦Â1 cardiac fibrosis human cardiac fibroblasts (HCFs) TGF-¦Â1 treatment downregulated in a time- and concentration-dependent manner 28251559 9713 Human hsa-miR-98 miRNA cryptosporidium parvum cryptosporidium parvum infection "C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)" cryptosporidium parvum? infection downregulated 20486857 9714 Human hsa-miR-98 miRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" glioblastoma multiforme (GBM) "glioma cell lines (U87, U251, U373 and SHG44)" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29436585 9715 Human hsa-miR-98 miRNA hypoxia inflammation human Aortic Smooth Muscle Cells (hASMCs) Hypoxia treatment downregulated 26045772 9716 Human hsa-miR-98 miRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) brain microvascular endothelial cells (BMVEC) oxygen-glucose deprivation (OGD) treatment downregulated 31601141 9717 Human hsa-miR-98 miRNA aspirin lung cancer A549 and H1299 cell lines aspirin treatment upregulated 30756509 9718 Human hsa-miR-98 miRNA curcumin (Cur) lung cancer lung cancer cell line A549 curcumin treatment upregulated 28587210 9719 Human hsa-miR-98 miRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment ANRIL knockdown inhibited the development of DDP resistance by upregulating miR-98. 32705261 9720 Human hsa-miR-98 miRNA TNF-a and MMP13 osteoarthritis (OA) human OA cartilage and bone TNF-a and MMP13 treatment upregulated 19008124 9721 Human hsa-miR-98 miRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) human synoviocytes (HS) cell line tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 31077735 9722 Human hsa-miR-98-5p miRNA H2O2 acute myocardial infarction (AMI) Human myocardial cell line (AC16) H2O2 treatment downregulated 32888161 9723 Human hsa-miR-98-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33542956 9724 Human hsa-miR-98-5p miRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33249762 9725 Human hsa-miR-98-5p miRNA epigallocatechin-3-gallate (EGCG) non-small cell lung cancer (NSCLC) NCI-H460 cells and another kind of NSCLC cells EGCG treatment upregulated 24712372 9726 Human hsa-miR-98-5p miRNA ¦Á-naphthylisothiocyanate (ANIT) drug-induced liver injury (DILI) upcyte hepatocytes ¦Á-naphthyl isothiocyanate (ANIT) treatment upregulated 31198949 9727 Human hsa-miR-98-5p miRNA oxidized low density lipoprotein (ox-LDL) endothelial cell injury human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "The expression of OIP5-AS1 was upregulated, while miR-98-5p was downregulated in ox-LDL-induced human umbilical vein endothelial cells (HUVECs)." 32990894 9728 Human hsa-miR-98-5p miRNA oxidized low density lipoprotein (ox-LDL) endothelial cell injury human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 33249762 9729 Human hsa-miR-98-5p miRNA temozolomide (TMZ) glioblastoma multiforme (GBM) "human glioma cell lines (U87, U251, LN229, A172)" temozolomide (TMZ) treatment "downregulated FOXD2-AS1 repressed invasion, proliferation, migration and drug resistance of drug-resistant glioma cells while stimulating their apoptosis via increasing miR-98-5p and inhibiting CPEB4 expression." 31770107 9730 Human hsa-miR-98-5p miRNA lauric acid hepatocellular carcinoma (HCC) HepG2 cells lauric acid treatment upregulated 32156243 9731 Human hsa-miR-98-5p miRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HCCLM3 cells; Huh7 cells sorafenib treatment downregulated 32821157 9732 Human hsa-miR-98-5p miRNA ¦Ã- Mangostin (¦Ã-MS) osteoarthritis (OA) SW983 cells ¦Ã- Mangostin (¦Ã-MS) treatment upregulated 32302289 9733 Human hsa-miR-98-5p miRNA osteogenic differentiation medium osteogenesis bone marrow-derived mesenchymal stem cells (BMMSCs) osteogenic-inducing medium [10% FBS; 5 mM L-glycerophosphate; 100 nM dexamethasone (Sigma-Aldrich; Merck KGaA) and 50 mg/ml ascorbic acid (Sigma-Aldrich; Merck KGaA)] treatment downregulated 31555368 9734 Human hsa-miR-98-5p miRNA osteogenic differentiation medium osteogenesis bone marrow-derived mesenchymal stem cells (BMMSCs) and MC3T3-E1 cells osteogenic-inducing medium [10% FBS; 5 mM L-glycerophosphate; 100 nM dexamethasone (Sigma-Aldrich; Merck KGaA) and 50 mg/ml ascorbic acid (Sigma-Aldrich; Merck KGaA)] treatment downregulated 31555368 9735 Human hsa-miR-98-5p miRNA H2O2 ulcerative colitis (UC) Caco-2 cells H2O2 treatment upregulated 33394187 9736 Human hsa-miR-98a-5p miRNA ¦Á-naphthylisothiocyanate (ANIT) drug-induced liver injury (DILI) upcyte hepatocytes ¦Á-naphthyl isothiocyanate (ANIT) treatment upregulated 31198949 9737 Human hsa-miR-99a miRNA benzyl isothiocyanate (BITC) bladder cancer Human bladder cancer cell lines derived from patients (5637 and T24) benzyl isothiocyanate (BITC) treatment upregulated 31587482 9738 Human hsa-miR-99a miRNA advanced glycation end product (AGE) colorectal cancer (CRC) HCT-116 cells advanced glycation end products (AGEs) treatment downregulated 31819515 9739 Human hsa-miR-99a miRNA salidroside (SAL) gastric cancer (GC) GC cell lines (SNU-216 and MGC803) and gastric epithelial cell line GES-1 Salidroside (SAL) treatment upregulated 31432697 9740 Human hsa-miR-99a miRNA hepatitis C virus (HCV) hepatitis C virus (HCV) infection Huh-7 cells hepatitis C virus (HCV) infection Cell-culture-derived HCV (HCVcc) infection caused downregulated of miR-99a in Huh-7 cells. 32605105 9741 Human hsa-miR-99a miRNA lipopolysaccharide (LPS) inflammation HUVECs cells lipopolysaccharide (LPS) treatment downregulated 27403035 9742 Human hsa-miR-99a miRNA paraquat (PQ) neurotoxicity human neural progenitor cells (hNPCs) paraquat (PQ) treatment upregulated 26878281 9743 Human hsa-miR-99a miRNA radiation non-small cell lung cancer (NSCLC) A549 cells radiation treatment miR-99a was significantly upregulated in radiation-sensitive A549 cells compared with radiation-resistant A549 cells 29614485 9744 Human hsa-miR-99a miRNA insulin polycystic ovarian syndrome (PCOS) Granulosa cells (GCs) insulin treatment downregulated 30374732 9745 Human hsa-miR-99a miRNA insulin premature senescence HepG2 cells; HL7702 cells insulin treatment downregulated 23762265 9746 Human hsa-miR-99a miRNA androgen prostate cancer prostate cancer cells androgen treatment downregulated 23503464 9747 Human hsa-miR-99a miRNA mifepristone (MIF) prostate cancer prostate cells Mifepristone treatment upregulated 27340920 9748 Human hsa-miR-99a miRNA curcumin (Cur) retinoblastoma (RB) ?Two Rb cell lines SO-Rb50 and Y79 curcumin treatment upregulated 30526546 9749 Human hsa-miR-99a miRNA bafilomycin A1 hepatocellular carcinoma and ovarian cancer BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell bafilomycin A1 treatment downregulated 26640557 9750 Human hsa-miR-99a* miRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) cancer cell 5-fluorouracil treatment upregulated 23167930 9751 Human hsa-miR-99a* miRNA capecitabine colorectal cancer (CRC) cancer cell capecitabine treatment upregulated 23167930 9752 Human hsa-miR-99a-5p miRNA benzyl isothiocyanate (BITC) bladder cancer "Human BC cell lines RT4, 5637, HT1376, HT1197, T24 and humanureter-sumian-virus-40 transformed immortalized epithelial cell line SV-HUC-1" benzyl isothiocyanate (BITC) treatment upregulated 30942430 9753 Human hsa-miR-99a-5p miRNA cisplatin (DDP) gastric cancer (GC) BGC823 cisplatin (DPP) treatment CircMCTP2 sensitizes GC to CDDP through the upregulation of MTMR3 by sponging miR-99a-5p. 33198772 9754 Human hsa-miR-99a-5p miRNA hormone non-traumatic osteonecrosis of femoral head (ONFH) femoral head hormone treatment downregulated 26298803 9755 Human hsa-miR-99b miRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia injury (CII) SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment The expression of miR-99b was increased in the OGD/R model. 32343508 9756 Human hsa-miR-99b miRNA helicobacter pylori (H. pylori) gastric cancer (GC) gastric cancer tissues; BGC-823 cells Helicobacter pylori treatment microRNA (miR)-99b levels increased in H. pylori-infected gastric cancer tissues and the BGC-823 gastric cancer cell line. 30250606 9757 Human hsa-miR-99b miRNA IL-1¦Â inflammatory response monocytes IL-1¦Â treatment upregulated 30245693 9758 Human hsa-miR-99b miRNA lipopolysaccharide (LPS) inflammatory response monocytes lipopolysaccharide (LPS) treatment upregulated 30245693 9759 Human hsa-miR-99b miRNA TLR2 agonist pam3CSK4 inflammatory response monocytes TLR2 agonist pam3CSK4 treatment upregulated 30245693 9760 Human hsa-miR-99b miRNA lactobacillus casei (L. casei LC01) irritable bowel syndrome with diarrhea (IBS-D) intestinal epithelial cells (IECs) L. casei LC01 treatment upregulated 32807750 9761 Human hsa-miR-99b miRNA nicotine non-small cell lung cancer (NSCLC) A549 and NCI-H460 cells nicotine treatment downregulated 29518612 9762 Human hsa-miR-99b miRNA a moderate-carbohydrate and low glycemic index diet overweight and obese overweight and obese subjects plasma a moderate-carbohydrate and low glycemic index diet downregulated 29233588 9763 Human hsa-miR-99b-5p miRNA p-Coumaric acid (p-CA) autoimmune hepatitis (AIH) SNU-16 cells p-Coumaric acid (p-CA) treatment upregulated 32462517 9764 Human hsa-miR-99b-5p miRNA P. macrocarpa ethyl acetate fraction (PMEAF) breast cancer MDA-MB-231 cells PMEAF treatment downregulated 29154802 9765 Human hsa-miR-99b-5p miRNA particulate matter (PM10) cardiovascular disease (CVD) extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) particulate matter (PM10) treatment downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+) 28899404 9766 Human hsa-miR-99b-5p miRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) SMMC-7721 cells-derived exosomes TGF-¦Â1 treatment upregulated 33194074 9767 Human hsa-miR-99b-5p miRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) neutrophil M.tb infection downregulated 29477867 9768 Human hsa-miR-99b-5p miRNA ultraviolet (UV) irradiation UVB-induced cellular response normal human dermal papilla cells UVB radiation of ¡Ý50 mJ/cm2 treatment upregulated 25069581 9769 Human hsa-miR-9a-3p miRNA methylglyoxal (MGO) ascular tone regulation HEK293 cells methylglyoxal (MGO) treatment upregulated 25354529 9770 Human hsa-miR-AB40 miRNA IL-27 human immunodeficiency virus (HIV)-1 infection macrophages;monocytes IL-27 treatment Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis confirmed that IL-27 dysregulatedthe expression of 16 of the 38 miRNAs. 33525571 9771 Human hsa-miR-B1-3p miRNA polyomavirus BK (BKV) polyomavirus BK (BKV) infection HK-2 cells BKV infection treatment upregulated 24735545 9772 Human hsa-miR-B1-5p miRNA polyomavirus BK (BKV) polyomavirus BK (BKV) infection HK-2 cells BKV infection treatment upregulated 24735545 9773 Human hsa-miR-hz02 miRNA "benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)" miscarriage trophoblast Swan 71 and HTR-8/SVneo cells "BPDE (benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide) treatment" "If trophoblast cells are exposed to BPDE, both miR-hz02 and lnc-HZ02 are upregulated" 33851497 9774 Human hsa-miR-K12-11 miRNA Kaposi¡¯s sarcoma-associated herpesvirus (KSHV) kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection BCBL1cells; JSC-1cells; BJAB cells; Ramous; Loukes ; DG75 cells Kaposi's sarcoma-associated herpesvirus (KSHV) infection upregulated 21221132 9775 Human hsa-miR-SX1 miRNA IL-27 acute liver injury (ALI) human macrophages IL-27?treatment "?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)" 23535375 9776 Human hsa-miR-SX2 miRNA IL-27 acute liver injury (ALI) human macrophages IL-27?treatment "?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)" 23535375 9777 Human hsa-miR-SX3 miRNA IL-27 acute liver injury (ALI) human macrophages IL-27?treatment "?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)" 23535375 9778 Human hsa-miR-SX6 miRNA IL-27 acute liver injury (ALI) human macrophages IL-27?treatment "?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)" 23535375 9779 Human hsa-miR-U86 miRNA human herpesvirus 6A (HHV-6A) human herpesvirus 6A (HHV-6A) infection Jjhan and HSB2 cells totransform HHV-6A-BAC-containing SW102 cells for insertion by homologous recombination treatment upregulated 25520507 9780 Human hsa-miR-UL22A miRNA human cytomegalovirus (HCMV) human cytomegalovirus (HCMV) infection "THP-1 , differentiated THP-1 , human embryo lung fibroblasts" HCMV infection treatment dysregulated 32275696 9781 Human hsa-miR-UL70 miRNA human cytomegalovirus (HCMV) human cytomegalovirus (HCMV) infection "THP-1 , differentiated THP-1 , human embryo lung fibroblasts" HCMV infection treatment dysregulated 32275696 9782 Human hsa-miR-US33 miRNA human cytomegalovirus (HCMV) human cytomegalovirus (HCMV) infection "THP-1 , differentiated THP-1 , human embryo lung fibroblasts" HCMV infection treatment dysregulated 32275696 9783 Human hsa-miR-5703 miRNA TGF-¦Â1 breast cancer MDA-MB231 cells TGF-¦Â1 treatment miR-5703 expression was significantly downregulated at both precursor and mature levels upon TGF-¦Â1-treatment in human breast cancer cells. 34492519 9784 Human hsa-miR-16-2-3p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) peripheral blood SARS-CoV-2 infection "A miRNA¡¯s high-throughput sequencing analysis in peripheral blood of 10 COVID-19 patients and 4 control donors indicated 35 upregulated and 38 downregulated miRNAs, in which changes of miR-16-2-3p is most remarkable in the upregulated list." 33675361 9785 Human hsa-miR-183-5p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) peripheral blood SARS-CoV-2 infection "A miRNA¡¯s high-throughput sequencing analysis in peripheral blood of 10 COVID-19 patients and 4 control donors indicated 35 upregulated and 38 downregulated miRNAs, in which changes of miR-183-5p is the most remarkable in the downregulated list." 33675361 9786 Human hsa-miR-146a-5p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection "transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-146a-5p was consistently downregulated." 33675361 9787 Human hsa-miR-21-5p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection "transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-21-5p was consistently downregulated." 33675361 9788 Human hsa-miR-142-3p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection "transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-142-3p was consistently downregulated." 33675361 9789 Human hsa-miR-3605-3p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection "transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-3605-3p was consistently upregulated." 33675361 9790 Human hsa-miR-15b-5p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection miR-15b-5p was upregulated only in severe COVID-19 patients compared with the healthy donors. 33675361 9791 Human hsa-miR-486-3p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection miR-486-3p was upregulated only in severe COVID-19 patients compared with the healthy donors. 33675361 9792 Human hsa-miR-486-5p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection miR-486-5p was upregulated only in severe COVID-19 patients compared with the healthy donors. 33675361 9793 Human hsa-miR-181a-2-3p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection miR-181a-2-3p was downregulated only in severe COVID-19 patients compared with the healthy donors. 33675361 9794 Human hsa-miR-31-5p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection miR-31-5p was downregulated only in severe COVID-19 patients compared with the healthy donors. 33675361 9795 Human hsa-miR-99a-5p miRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) whole blood SARS-CoV-2 infection miR-99a-5p was downregulated only in severe COVID-19 patients compared with the healthy donors. 33675361